

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview for Request: cder_mpl2p_wp040

Request ID: cder_mpl2p_wp040

Request Description: In this report we described characteristics of patients dispensed montelukast or inhaled corticosteroids (ICS) and evaluated the risk of intentional self-harm in the Sentinel Distributed Database (SDD).

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) module, version 12.0.0, with Propensity Score Analysis module and custom programming.

Data Source: We distributed this request to six Data Partners on December 21, 2022. These six Data Partners are a subset of the SDD. Data from Medicare patients having both fee-for-service medical coverage and Part D drug coverage are included. The study period included data from October 1, 2015 to June 30, 2022. Please see Appendix A for a list of dates of available data for each Data Partner.

Study Design: We identified cohorts of incident montelukast and ICS users among health plan members who were over 10 years of age with asthma (with or without allergic rhinitis) and without chronic obstructive pulmonary disease (COPD). We then conducted a Propensity Score Analysis (PSA) comparing the two treatments using inverse probability of treatment weighting (IPTW) to adjust for confounding. We evaluated the occurrence of intentional self-harm¹ during exposure episodes among these cohorts and estimated hazards ratios and 95% confidence intervals of the risk of intentional self-harm in patients dispensed montelukast compared to patients dispensed ICS. This study used a retrospective active comparator new-user cohort design. This is a Type 2 analysis using the Propensity Score Analysis module in the Query Request Package (QRP) documentation.

Exposures: We defined the exposure of interest, montelukast, and the comparator of interest, ICS, using National Drug Codes (NDCs). Only the first qualifying dispensing of montelukast or ICS (index) in any care setting was included; cohort re-entry was not allowed. We defined new use as no prior use of montelukast, ICS monotherapy, ICS combination therapies, long-acting beta agonists (LABAs), or leukotriene receptor antagonists (LTRAs) in the 183 days prior to the index dispensing. Please see Appendix V for a list of generic and brand names used to define the exposure and comparator medical products in this request. Please see Appendix W for a list of generic and brand names of medical products used to define the washout criteria in this request.

Outcomes of Interest: We defined the outcome of interest as intentional self-harm events¹ using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes. Please see Appendix X for a list of the diagnosis codes used to define the outcomes in this request.

Cohort Eligibility Criteria: We required patients included in the cohorts to be enrolled in health plans with both medical and drug coverage for at least 183 days prior to the index exposure, during which gaps in coverage of up to 45 days were allowed and treated as continuous enrollment. The following age groups were included in the cohort: 10-24, 25-54, and 55+ years. We required evidence of an asthma diagnosis in any care setting in the 183 days prior to and including the index date. We excluded index exposure episodes if there was evidence of a COPD diagnosis in any care setting in the 183 days prior to and including the index date. We additionally excluded index episodes with both the exposure and comparator dispensed on the same day. Inclusion and exclusion criteria were defined using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes, ICD-10-CM codes, and NDCs. Please see Appendix Y for a list of generic and brand names of medical products and Appendix Z for a list of the diagnosis codes used to define inclusion and exclusion criteria in this request.

Overview for Request: cder_mpl2p_wp040

Follow-up: We determined follow-up time based on the length of the exposure episodes. Specifically, we created exposure episodes using days of product supplied per dispensing in outpatient pharmacy dispensing data. We bridged together exposure episodes less than 30 days apart and added 30 days at the end of each exposure episode to create continuous treatment episodes. We censored all exposure episodes upon dispensing of ICS monotherapy, LABAs, ICS combination therapies, or another LTRA, dispensing of an oral corticosteroid, occurrence of an asthma-related hospitalization in the primary position, or a hospitalization or institutional stay unrelated to the outcome. Follow-up began on the day after exposure initiation and continued until the first occurrence of any of the following: 1) outcome occurrence; 2) end of exposure episode; 3) censoring criteria; 4) recorded death; 5) end of available data; 6) end of query period; 7) disenrollment. Censoring criteria were defined using NDC, ICD-9-CM, ICD-10-CM, and Healthcare Common Procedure Coding System (HCPCS) codes. Please see Appendix AA for a list of generic and brand names of medical products and Appendix AB for a list of diagnosis and procedure codes used to define censoring criteria in this request.

Baseline Covariates: We assessed the following characteristics in the 183 days prior to and including the index date: age, year, sex, combined comorbidity score², prior to montelukast Boxed Warning³ (March 2020), following montelukast Boxed Warning, seasonality (winter, spring, summer, fall), allergic rhinitis, past medical history (anxiety, depression, sleep disorder, or substance abuse), past history of drug use (analgesic opiates, antipsychotics, anxiolytics/hypnotics, lithium and other mood stabilizers or antidepressants), and health service utilization intensity (ambulatory, inpatient and emergency encounters overall and for respiratory disorders specifically and dispensings). We assessed psychiatric history in the 183 days prior to and including the index date, which comprised of psychiatric drug dispensings, self-harm encounter⁴ (not including the index date) or encounters for other psychiatric events including psychotherapy in the inpatient, outpatient, and emergency settings. We assessed asthma severity in the 183 days prior to and including the index date based on presence of asthma diagnosis code in inpatient, outpatient or emergency care settings, oral corticosteroid dispensing (not including the index date), use of other asthma medications such as short-acting beta-agonists, anticholinergic agents or phosphodiesterase inhibitors, moderate asthma exacerbation events, or severe asthma exacerbation events. Moderate asthma exacerbation events were defined as the presence of an asthma exacerbation code and oral corticosteroid dispensing within seven days or an asthma diagnosis code and oral corticosteroid dispensing within seven days in the emergency or outpatient settings. Severe asthma exacerbation events were defined as presence of an asthma exacerbation code in any position, asthma diagnosis code in the primary position, or an acute respiratory failure diagnosis in the primary position + asthma diagnosis in any position in the inpatient care setting. Please see Appendix AC for a list of generic and brand names of medical products and Appendices AD and AE for a list of CPT-2, CPT-4, HCPCS, ICD-9-CM, ICD-10-CM, and ICD-10-PCS diagnosis and procedure codes used to define baseline covariates in this request. Please see Appendix AF for evaluation windows used to define covariates. Please see Appendix AG for specifications used to define moderate and severe asthma exacerbation events.

Sensitivity Analyses: We performed the following three sensitivity analyses:

1. Inpatient and Emergency: We assessed intentional self-harm outcomes limited to the inpatient or emergency department care settings for montelukast and ICS users.
2. 0-day Gap and Extension: No montelukast or ICS exposure episodes were bridged together or extended to create continuous treatment episodes.

Overview for Request: cder_mpl2p_wp040

3. 15-day Gap and Extension: We bridged together montelukast and ICS exposure episodes less than 15 days apart and added 15 days at the end of each exposure episode to create continuous treatment episodes

Propensity Score Estimation: We fit a logistic regression model to estimate the propensity score (PS) based on the potential confounders outlined in Appendix AF. After PS estimation and exclusion (i.e., trimming) of patients in non-overlapping regions of the PS distributions, the PS was used to create an average treatment effect in the treated (ATT) weight for each patient.

We initially applied three candidate weight truncation percentile thresholds to deal with potential extreme inverse probability of treatment weights: 0% (no truncation), 2.5%, and 5%. Truncation was operationalized symmetrically, in that weights smaller than the weight at the specified percentile of the weight distribution (2.5% or 5.0%) were re-assigned the value of the weight at the specified percentile (2.5th or 5th), while weights larger than the weight at the specified percentile of the weight distribution (97.5% or 95.0%) were re-assigned the value of the weight at the specified percentile (97.5th or 95.0th). After review of the distribution of inverse probability of treatment (IPT) weights for the three truncation thresholds that was blinded to effect estimates, we selected the 2.5% truncation threshold and applied it to all analyses, as this threshold avoided extreme weights.

Subgroup analyses for effect estimation included sex (male, female), age (10-24, 25-54, >=55 years), psychiatric history (patients with a history of psychiatric disorder, patients without history of psychiatric disorder), and year (2015-2020, 2021-present). Subgroups were formed out of the post-trimming overall population to ensure only those patients contributing to the overall analysis contributed to a subgroup analysis.

Please see Appendix AH for the specifications of parameters used in this request and Appendix AI for a diagram detailing the design of this request.

Limitations: As with all observational studies, this evaluation was limited in its ability to control for all sources of potential bias. Algorithms used to define exposures, outcomes, inclusion and exclusion criteria, and covariates are imperfect and may be misclassified. Therefore, data should be interpreted with this limitation in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinel-system.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (<https://dev.sentinel-system.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse>).

¹Hedegaard H, Schoenbaum M, Claassen C, Crosby A, Holland K, Proescholdbell S. Issues in Developing a Surveillance Case Definition for Nonfatal Suicide Attempt and Intentional Self-harm Using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Coded Data. *Natl Health Stat Report*. 2018;(108):1-19.

²The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol*. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care*. 2017;55(12):1046-1051)

³Clarridge K, Chin S, Eworuke E, Seymour S. A Boxed Warning for Montelukast: The FDA Perspective. *J Allergy Clin Immunol Pract*. 2021 Jul;9(7):2638-41.

⁴Patrick AR, Miller M, Barber CW, Wang PS, Canning CF, Schneeweiss S. Identification of hospitalizations for intentional self-harm when E-codes are incompletely recorded. *Pharmacoepidemiology and Drug Safety*. 2010;19(12):1263-1275. doi:10.1002/pds.2037

Table of Contents

| | |
|-------------------------------|---|
| <u>Glossary (CIDA)</u> | List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in this Report |
| <u>Glossary (PSA)</u> | List of Terms to Define the Propensity Score Analysis (PSA) Found in this Report |
| <u>Table 1a</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022 |
| <u>Table 1b</u> | Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022 |
| <u>Table 1c</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female |
| <u>Table 1d</u> | Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female |
| <u>Table 1e</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male |
| <u>Table 1f</u> | Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male |
| <u>Table 1g</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years |
| <u>Table 1h</u> | Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years |
| <u>Table 1i</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years |
| <u>Table 1j</u> | Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years |
| <u>Table 1k</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years |
| <u>Table 1l</u> | Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years |
| <u>Table 1m</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History |
| <u>Table 1n</u> | Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History |
| <u>Table 1o</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History |
| <u>Table 1p</u> | Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History |
| <u>Table 1q</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning |

Table of Contents

| | |
|-------------------------|--|
| <u>Table 1r</u> | Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning |
| <u>Table 1s</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning |
| <u>Table 1t</u> | Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning |
| <u>Table 1u</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022 |
| <u>Table 1v</u> | Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022 |
| <u>Table 1w</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female |
| <u>Table 1x</u> | Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female |
| <u>Table 1y</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male |
| <u>Table 1z</u> | Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male |
| <u>Table 1aa</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years |
| <u>Table 1ab</u> | Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years |
| <u>Table 1ac</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years |
| <u>Table 1ad</u> | Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years |
| <u>Table 1ae</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years |
| <u>Table 1af</u> | Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years |
| <u>Table 1ag</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History |

Table of Contents

| | |
|-------------------------|--|
| <u>Table 1ah</u> | Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History |
| <u>Table 1ai</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History |
| <u>Table 1aj</u> | Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History |
| <u>Table 1ak</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning |
| <u>Table 1al</u> | Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning |
| <u>Table 1am</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning |
| <u>Table 1an</u> | Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning |
| <u>Table 1ao</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022 |
| <u>Table 1ap</u> | Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022 |
| <u>Table 1aq</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female |
| <u>Table 1ar</u> | Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female |
| <u>Table 1as</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male |
| <u>Table 1at</u> | Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male |
| <u>Table 1au</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years |
| <u>Table 1av</u> | Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years |
| <u>Table 1aw</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years |
| <u>Table 1ax</u> | Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years |

Table of Contents

| | |
|-------------------------|--|
| <u>Table 1ay</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years |
| <u>Table 1az</u> | Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years |
| <u>Table 1ba</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History |
| <u>Table 1bb</u> | Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History |
| <u>Table 1bc</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History |
| <u>Table 1bd</u> | Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History |
| <u>Table 1be</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning |
| <u>Table 1bf</u> | Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning |
| <u>Table 1bg</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning |
| <u>Table 1bh</u> | Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning |
| <u>Table 1bi</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022 |
| <u>Table 1bj</u> | Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022 |
| <u>Table 1bk</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female |
| <u>Table 1bl</u> | Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female |
| <u>Table 1bm</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male |
| <u>Table 1bn</u> | Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male |
| <u>Table 1bo</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years |

Table of Contents

| | |
|-------------------------|---|
| <u>Table 1bp</u> | Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years |
| <u>Table 1bq</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years |
| <u>Table 1br</u> | Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years |
| <u>Table 1bs</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years |
| <u>Table 1bt</u> | Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years |
| <u>Table 1bu</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History |
| <u>Table 1bv</u> | Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History |
| <u>Table 1bw</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History |
| <u>Table 1bx</u> | Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History |
| <u>Table 1by</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning |
| <u>Table 1bz</u> | Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning |
| <u>Table 1ca</u> | Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning |
| <u>Table 1cb</u> | Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning |
| <u>Table 2a</u> | Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type |
| <u>Table 2b</u> | Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Age Group |
| <u>Table 2c</u> | Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Psychiatric History |
| <u>Table 2d</u> | Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Pre-/Post-Boxed Warning |
| <u>Table 2e</u> | Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Sex |

Table of Contents

| | |
|-------------------------|--|
| <u>Table 3a</u> | Effect Estimates for Intentional Self Harm Inpatient and Emergency, Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type |
| <u>Table 3b</u> | Effect Estimates for Intentional Self Harm Inpatient and Emergency, Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Age Group |
| <u>Table 3c</u> | Effect Estimates for Intentional Self Harm Inpatient and Emergency, Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Psychiatric History |
| <u>Table 3d</u> | Effect Estimates for Intentional Self Harm Inpatient and Emergency, Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Pre-/Post-Boxed Warning |
| <u>Table 3e</u> | Effect Estimates for Intentional Self Harm Inpatient and Emergency, Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Sex |
| <u>Table 4a</u> | Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type |
| <u>Table 4b</u> | Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Age Group |
| <u>Table 4c</u> | Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Psychiatric History |
| <u>Table 4d</u> | Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Pre-/Post-Boxed Warning |
| <u>Table 4e</u> | Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Sex |
| <u>Table 5a</u> | Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type |
| <u>Table 5b</u> | Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Age Group |
| <u>Table 5c</u> | Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Psychiatric History |
| <u>Table 5d</u> | Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Pre-/Post-Boxed Warning |
| <u>Table 5e</u> | Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Sex |
| <u>Table 6</u> | Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022 |
| <u>Figure 1a</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022 |
| <u>Figure 1b</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female |

Table of Contents

| | |
|-------------------------|--|
| <u>Figure 1c</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male |
| <u>Figure 1d</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years |
| <u>Figure 1e</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years |
| <u>Figure 1f</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years |
| <u>Figure 1g</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History |
| <u>Figure 1h</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History |
| <u>Figure 1i</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning |
| <u>Figure 1j</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning |
| <u>Figure 2a</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022 |
| <u>Figure 2b</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female |
| <u>Figure 2c</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male |
| <u>Figure 2d</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years |
| <u>Figure 2e</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years |
| <u>Figure 2f</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years |
| <u>Figure 2g</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History |

Table of Contents

| | |
|-------------------------|---|
| <u>Figure 2h</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History |
| <u>Figure 2i</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning |
| <u>Figure 2j</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning |
| <u>Figure 3a</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022 |
| <u>Figure 3b</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female |
| <u>Figure 3c</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male |
| <u>Figure 3d</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years |
| <u>Figure 3e</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years |
| <u>Figure 3f</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years |
| <u>Figure 3g</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History |
| <u>Figure 3h</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History |
| <u>Figure 3i</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning |
| <u>Figure 3j</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning |
| <u>Figure 4a</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022 |
| <u>Figure 4b</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female |

Table of Contents

| | |
|-------------------------|--|
| <u>Figure 4c</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male |
| <u>Figure 4d</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years |
| <u>Figure 4e</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years |
| <u>Figure 4f</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years |
| <u>Figure 4g</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History |
| <u>Figure 4h</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History |
| <u>Figure 4i</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning |
| <u>Figure 4j</u> | Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning |
| <u>Figure 5a</u> | Forest Plot of Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Site-Adjusted Analyses in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022 |
| <u>Figure 5b</u> | Forest Plot of Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Inverse Probability of Treatment Weighted Analyses in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022 |
| <u>Figure 6a</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022 |
| <u>Figure 6b</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022 |
| <u>Figure 6c</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female |
| <u>Figure 6d</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female |
| <u>Figure 6e</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male |

Table of Contents

| | |
|-------------------------|---|
| <u>Figure 6f</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male |
| <u>Figure 6g</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years |
| <u>Figure 6h</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years |
| <u>Figure 6i</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years |
| <u>Figure 6j</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years |
| <u>Figure 6k</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years |
| <u>Figure 6l</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years |
| <u>Figure 6m</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History |
| <u>Figure 6n</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History |
| <u>Figure 6o</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History |
| <u>Figure 6p</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History |
| <u>Figure 6q</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning |
| <u>Figure 6r</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning |

Table of Contents

| | |
|-------------------------|--|
| <u>Figure 6s</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning |
| <u>Figure 6t</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning |
| <u>Figure 7a</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022 |
| <u>Figure 7b</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022 |
| <u>Figure 7c</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female |
| <u>Figure 7d</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female |
| <u>Figure 7e</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male |
| <u>Figure 7f</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male |
| <u>Figure 7g</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years |
| <u>Figure 7h</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years |
| <u>Figure 7i</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years |
| <u>Figure 7j</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years |

Table of Contents

| | |
|-------------------------|--|
| <u>Figure 7k</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years |
| <u>Figure 7l</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years |
| <u>Figure 7m</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History |
| <u>Figure 7n</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History |
| <u>Figure 7o</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History |
| <u>Figure 7p</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History |
| <u>Figure 7q</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning |
| <u>Figure 7r</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning |
| <u>Figure 7s</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning |
| <u>Figure 7t</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning |
| <u>Figure 8a</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022 |
| <u>Figure 8b</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022 |

Table of Contents

| | |
|-------------------------|---|
| <u>Figure 8c</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female |
| <u>Figure 8d</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female |
| <u>Figure 8e</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male |
| <u>Figure 8f</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male |
| <u>Figure 8g</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years |
| <u>Figure 8h</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years |
| <u>Figure 8i</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years |
| <u>Figure 8j</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years |
| <u>Figure 8k</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years |
| <u>Figure 8l</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years |
| <u>Figure 8m</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History |
| <u>Figure 8n</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History |
| <u>Figure 8o</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History |

Table of Contents

| | |
|-------------------------|---|
| <u>Figure 8p</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History |
| <u>Figure 8q</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning |
| <u>Figure 8r</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning |
| <u>Figure 8s</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning |
| <u>Figure 8t</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning |
| <u>Figure 9a</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022 |
| <u>Figure 9b</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022 |
| <u>Figure 9c</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female |
| <u>Figure 9d</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female |
| <u>Figure 9e</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male |
| <u>Figure 9f</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male |
| <u>Figure 9g</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years |
| <u>Figure 9h</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years |

Table of Contents

| | |
|--------------------------|---|
| <u>Figure 9i</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years |
| <u>Figure 9j</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years |
| <u>Figure 9k</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years |
| <u>Figure 9l</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years |
| <u>Figure 9m</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History |
| <u>Figure 9n</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History |
| <u>Figure 9o</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History |
| <u>Figure 9p</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History |
| <u>Figure 9q</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning |
| <u>Figure 9r</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning |
| <u>Figure 9s</u> | Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning |
| <u>Figure 9t</u> | Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning |
| <u>Appendix A</u> | Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (December 21, 2022) |

Table of Contents

| | |
|--------------------------|--|
| <u>Appendix B</u> | Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Data Partner (DP), Weight: Average Treatment Effect in the Treated (ATT) |
| <u>Appendix C</u> | Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Data Partner (DP), Sex, Weight: Average Treatment Effect in the Treated (ATT) |
| <u>Appendix D</u> | Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Data Partner (DP), Age Group, Weight: Average Treatment Effect in the Treated (ATT) |
| <u>Appendix E</u> | Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Data Partner (DP), Psychiatric History, Weight: Average Treatment Effect in the Treated (ATT) |
| <u>Appendix F</u> | Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Data Partner (DP), Pre-/Post-Boxed Warning, Weight: Average Treatment Effect in the Treated (ATT) |
| <u>Appendix G</u> | Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Data Partner (DP), Weight: Average Treatment Effect in the Treated (ATT) |
| <u>Appendix H</u> | Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Data Partner (DP), Sex, Weight: Average Treatment Effect in the Treated (ATT) |
| <u>Appendix I</u> | Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Data Partner (DP), Age Group, Weight: Average Treatment Effect in the Treated (ATT) |
| <u>Appendix J</u> | Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Data Partner (DP), Psychiatric History, Weight: Average Treatment Effect in the Treated (ATT) |
| <u>Appendix K</u> | Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Data Partner (DP), Pre-/Post-Boxed Warning, Weight: Average Treatment Effect in the Treated (ATT) |
| <u>Appendix L</u> | Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Data Partner (DP), Weight: Average Treatment Effect in the Treated (ATT) |
| <u>Appendix M</u> | Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Data Partner (DP), Sex, Weight: Average Treatment Effect in the Treated (ATT) |
| <u>Appendix N</u> | Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Data Partner (DP), Age Group, Weight: Average Treatment Effect in the Treated (ATT) |

Table of Contents

| | |
|---------------------------|---|
| <u>Appendix O</u> | Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Data Partner (DP), Psychiatric History, Weight: Average Treatment Effect in the Treated (ATT) |
| <u>Appendix P</u> | Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Data Partner (DP), Pre-/Post-Boxed Warning, Weight: Average Treatment Effect in the Treated (ATT) |
| <u>Appendix Q</u> | Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Data Partner (DP), Weight: Average Treatment Effect in the Treated (ATT) |
| <u>Appendix R</u> | Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Data Partner (DP), Sex, Weight: Average Treatment Effect in the Treated (ATT) |
| <u>Appendix S</u> | Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Data Partner (DP), Age Group, Weight: Average Treatment Effect in the Treated (ATT) |
| <u>Appendix T</u> | Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Data Partner (DP), Psychiatric History, Weight: Average Treatment Effect in the Treated (ATT) |
| <u>Appendix U</u> | Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Data Partner (DP), Pre-/Post-Boxed Warning, Weight: Average Treatment Effect in the Treated (ATT) |
| <u>Appendix V</u> | List of Generic and Brand Names of Medical Products Used to Define Exposures in this Request |
| <u>Appendix W</u> | List of Generic and Brand Names of Medical Products Used to Define Exposure Incidence Criteria in this Request |
| <u>Appendix X</u> | List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request |
| <u>Appendix Y</u> | List of Generic and Brand Names of Medical Products Used to Define Inclusion Criteria in this Request |
| <u>Appendix Z</u> | List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Inclusion Criteria in this Request |
| <u>Appendix AA</u> | List of Generic and Brand Names of Medical Products Used to Define Exposure Censoring Criteria in this Request |
| <u>Appendix AB</u> | List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Exposure Censoring Criteria in this Request |
| <u>Appendix AC</u> | List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request |
| <u>Appendix AD</u> | List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request |
| <u>Appendix AE</u> | List of Current Procedural Terminology, Fourth Edition (CPT-4) and Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Covariates in this Request |

| Table of Contents | |
|---------------------------|---|
| <u>Appendix AF</u> | Specifications Defining Parameters for Covariates in this Request |
| <u>Appendix AG</u> | Specifications Defining Parameters for Asthma Exacerbation Events in this Request |
| <u>Appendix AH</u> | Specifications Defining Parameters In this Request |
| <u>Appendix AI</u> | Diagram Detailing the Design of this Request |

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Glossary of Terms for Analyses Using Propensity Score Analysis (PSA) Module*

Covariate - requester defined binary variable to include in the propensity score estimation model (e.g., diabetes, heart failure, etc.) during requester-defined lookback period. Requester may also choose to add any of the following categorical, continuous, or count metrics to the propensity score estimation model:

1. Age (continuous)
2. Sex
3. Time period (i.e., monitoring period for sequential analyses)
4. Year of exposure
5. Comorbidity score
6. Medical utilization – number of inpatient stays
7. Medical utilization – number of institutional stays
8. Medical utilization – number of emergency department visits
9. Medical utilization – number of outpatient visits
10. Health care utilization – number of other ambulatory encounters (e.g., telemedicine, email consults)
11. Drug utilization – number of dispensings
12. Drug utilization – number of unique generics dispensed

Covariate Evaluation Window - specified number of days relative to index date to evaluate the occurrence of covariates of interest. Note: members are required to have continuous enrollment during the covariate evaluation window, regardless of the value included in the "Continuous enrollment before exposure" field.

Individual Level Data Return - program may return individual-level, de-identified datasets to the Sentinel Operations Center (SOC). While the datasets contain a single row per patient for each specified analysis, patient identifiers such as a patient ID are not included in the output. Individual-level datasets are returned to the SOC, aggregated, and used to calculate effect estimates via Cox (proportional hazards) regression.

Mahalanobis Distance - provides a measure of balance across all variables while accounting for their correlation.

Matching Caliper - maximum allowed difference in propensity scores between treatment and control patients. Requester may select any caliper (e.g., 0.01, 0.025, and 0.05).

Matching Ratio - patients in exposed and comparator groups are nearest neighbor matched by a 1:1 or 1:n (up to 10) matching ratio.

Matched Conditional and Unconditional Analysis - in a conditional matched analysis, a Cox model, stratified by Data Partner site and matched set, is run on the matched population. This can be done for both the both 1:1 and 1:n matched cohorts. In an unconditional analysis, a Cox model, stratified by Data Partner site only, is run on the matched population. This can be done for the 1:1 matched cohort only.

Propensity Score Stratification - option to stratify propensity scores based on requester-defined percentiles in the unmatched population. In a stratified analysis, a Cox model, stratified by Data Partner site, is run on the stratified population. Note that all patients identified in exposure and comparator cohorts are used in the analysis.

PSM Tool - performs effect estimation by comparing exposure propensity-score matched parallel new user cohorts. Propensity score estimation and matching are conducted within each Sentinel Data Partner site via distributed programming code; data are returned to the SOC, aggregated, and used to calculate effect estimates.

Risk-set Level Data Return - alternative to the patient-level data return approach. In this approach, the PSM tool will produce de-identified, risk-set level datasets instead of or in addition to individual-level output. Whereas each observation in the patient-level datasets represents one patient in the cohort, each observation in the risk set dataset represents one event. Risk sets are created at the Data Partner site, returned to the SOC, aggregated, and used to calculate effect estimates via case-centered logistic regression.

Subgroup Analysis - may be conducted using any requester-defined covariates. Subgroup analyses may be performed in the unmatched and the matched population.

**Glossary of Terms for Analyses Using
Propensity Score Analysis (PSA) Module***

Zero Cell Correction - indicator for whether to screen variables with a zero correction added to each cell in the confounder/outcome 2x2 table. Recommended when the number of exposed outcomes is fewer than 150.

*all terms may not be used in this report

Table 1a. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 752,280 | 100.0% | 923,377 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 44.7 | 15.8 | 37.7 | 16.6 | 6.949 | 0.429 |
| Age | | | | | | |
| 10-24 years | 207,867 | 27.6% | 375,872 | 40.7% | -13.075 | -0.278 |
| 25-54 years | 257,154 | 34.2% | 294,430 | 31.9% | 2.297 | 0.049 |
| ≥ 55 years | 287,259 | 38.2% | 253,075 | 27.4% | 10.778 | 0.231 |
| Sex | | | | | | |
| Female | 497,022 | 66.1% | 568,594 | 61.6% | 4.491 | 0.094 |
| Male | 255,258 | 33.9% | 354,783 | 38.4% | -4.491 | -0.094 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 4,641 | 0.6% | 7,894 | 0.9% | -0.238 | -0.028 |
| Asian | 15,993 | 2.1% | 19,681 | 2.1% | -0.005 | -0.000 |
| Black or African American | 81,721 | 10.9% | 116,767 | 12.6% | -1.783 | -0.055 |
| Multi-racial | 1,913 | 0.3% | 1,968 | 0.2% | 0.041 | 0.009 |
| Native Hawaiian or Other Pacific Islander | 1,348 | 0.2% | 3,235 | 0.4% | -0.171 | -0.033 |
| Unknown | 378,631 | 50.3% | 473,550 | 51.3% | -0.953 | -0.019 |
| White | 268,033 | 35.6% | 300,282 | 32.5% | 3.109 | 0.066 |
| Hispanic origin | | | | | | |
| Yes | 62,019 | 8.2% | 114,481 | 12.4% | -4.154 | -0.137 |
| No | 349,367 | 46.4% | 426,937 | 46.2% | 0.205 | 0.004 |
| Unknown | 340,894 | 45.3% | 381,959 | 41.4% | 3.949 | 0.080 |
| Year | | | | | | |
| 2015 | 29,141 | 3.9% | 46,687 | 5.1% | -1.182 | -0.057 |
| 2016 | 141,992 | 18.9% | 210,011 | 22.7% | -3.869 | -0.095 |
| 2017 | 164,068 | 21.8% | 238,304 | 25.8% | -3.998 | -0.094 |
| 2018 | 156,565 | 20.8% | 202,397 | 21.9% | -1.107 | -0.027 |
| 2019 | 90,783 | 12.1% | 74,740 | 8.1% | 3.974 | 0.132 |
| 2020 | 77,970 | 10.4% | 69,061 | 7.5% | 2.885 | 0.101 |
| 2021 | 69,448 | 9.2% | 61,060 | 6.6% | 2.619 | 0.097 |

Table 1a. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2022 | 22,313 | 3.0% | 21,117 | 2.3% | 0.679 | 0.042 |
| Pre-boxed warning | 597,022 | 79.4% | 785,015 | 85.0% | -5.654 | -0.148 |
| Post-boxed warning | 155,258 | 20.6% | 138,362 | 15.0% | 5.654 | 0.148 |
| Seasonality | | | | | | |
| Winter | 174,459 | 23.2% | 232,656 | 25.2% | -2.006 | -0.047 |
| Spring | 209,611 | 27.9% | 206,659 | 22.4% | 5.483 | 0.127 |
| Summer | 166,779 | 22.2% | 199,054 | 21.6% | 0.613 | 0.015 |
| Autumn | 201,431 | 26.8% | 285,008 | 30.9% | -4.090 | -0.090 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.6 | 1.5 | 1.5 | 1.3 | 0.076 | 0.055 |
| Psychiatric History | 385,520 | 51.2% | 438,981 | 47.5% | 3.706 | 0.074 |
| Psychiatric Drug Dispensings ⁵ | 281,086 | 37.4% | 312,149 | 33.8% | 3.559 | 0.074 |
| Self Harm Encounter ⁵ | 1,394 | 0.2% | 2,455 | 0.3% | -0.081 | -0.017 |
| Encounter for Other Psychiatric Event ⁵ | 320,312 | 42.6% | 369,507 | 40.0% | 2.562 | 0.052 |
| Asthma Emergency Encounter | 76,513 | 10.2% | 110,494 | 12.0% | -1.795 | -0.057 |
| Asthma Inpatient Encounter | 2,253 | 0.3% | 2,905 | 0.3% | -0.015 | -0.003 |
| Asthma Outpatient Encounter | 720,684 | 95.8% | 888,309 | 96.2% | -0.402 | -0.021 |
| Oral Corticosteroid Dispensing | 208,814 | 27.8% | 233,820 | 25.3% | 2.435 | 0.055 |
| Use of Other Asthma Medication | 465,439 | 61.9% | 723,452 | 78.3% | -16.478 | -0.366 |
| Allergic Rhinitis | 324,390 | 43.1% | 214,432 | 23.2% | 19.898 | 0.432 |
| Anxiety | 136,658 | 18.2% | 150,459 | 16.3% | 1.871 | 0.050 |
| Depression | 110,444 | 14.7% | 126,098 | 13.7% | 1.025 | 0.029 |
| Sleep Disorder | 115,514 | 15.4% | 101,044 | 10.9% | 4.412 | 0.131 |
| Substance Abuse | 24,463 | 3.3% | 39,321 | 4.3% | -1.007 | -0.053 |
| Poisoning | 1,319 | 0.2% | 2,470 | 0.3% | -0.092 | -0.020 |
| Suffocation | 30 | 0.0% | 46 | 0.0% | -0.001 | -0.001 |
| Suicide Attempt | 733 | 0.1% | 1,250 | 0.1% | -0.038 | -0.011 |
| Toxicity | 156 | 0.0% | 275 | 0.0% | -0.009 | -0.006 |

Table 1a. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Other Self Harm | 386 | 0.1% | 630 | 0.1% | -0.017 | -0.007 |
| No moderate asthma exacerbations | 636,154 | 84.6% | 779,273 | 84.4% | 0.170 | 0.005 |
| One moderate asthma exacerbation | 102,254 | 13.6% | 128,119 | 13.9% | -0.283 | -0.008 |
| Two or more moderate asthma | 13,872 | 1.8% | 15,985 | 1.7% | 0.113 | 0.009 |
| No severe asthma exacerbations | 746,055 | 99.2% | 914,396 | 99.0% | 0.145 | 0.015 |
| One severe asthma exacerbation | 5,976 | 0.8% | 8,735 | 0.9% | -0.152 | -0.016 |
| Two or more severe asthma exacerbations | 249 | 0.0% | 246 | 0.0% | 0.006 | 0.004 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 149,088 | 19.8% | 157,940 | 17.1% | 2.714 | 0.070 |
| Antipsychotics | 34,679 | 4.6% | 52,338 | 5.7% | -1.058 | -0.048 |
| Anxiolytics Hypnotics | 135,168 | 18.0% | 136,952 | 14.8% | 3.136 | 0.085 |
| Lithium Other Mood Stabilizers | 40,612 | 5.4% | 51,588 | 5.6% | -0.188 | -0.008 |
| Antidepressants | 196,573 | 26.1% | 213,423 | 23.1% | 3.017 | 0.070 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 10.2 | 11.0 | 9.4 | 11.2 | 0.781 | 0.071 |
| Mean number of emergency room encounters | 0.4 | 1.2 | 0.5 | 1.3 | -0.076 | -0.061 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.000 | -0.000 |
| Mean number of other ambulatory encounters | 2.7 | 9.2 | 3.3 | 12.0 | -0.610 | -0.057 |
| Mean number of filled prescriptions | 15.0 | 14.2 | 14.0 | 14.5 | 0.997 | 0.069 |
| Mean number of generics dispensed | 7.8 | 4.9 | 7.0 | 4.6 | 0.803 | 0.169 |
| Mean number of unique drug classes dispensed | 7.4 | 4.4 | 6.7 | 4.2 | 0.655 | 0.153 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.000 | -0.000 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.012 | -0.028 |

Table 1a. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of outpatient visits for respiratory disorders | 2.3 | 3.3 | 1.7 | 2.8 | 0.545 | 0.178 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁴Covariate not included in the propensity score logistic regression model.

Table 1b. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 752,230 | N/A | 724,855 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 44.7 | 15.8 | 44.5 | 16.9 | 0.183 | 0.011 |
| Age | | | | | | |
| 10-24 years | 207,866 | 27.6% | 216,783 | 29.9% | -2.274 | -0.059 |
| 25-54 years | 257,136 | 34.2% | 222,525 | 30.7% | 3.484 | 0.078 |
| ≥ 55 years | 287,228 | 38.2% | 285,548 | 39.4% | -1.210 | -0.033 |
| Sex | | | | | | |
| Female | 496,977 | 66.1% | 475,583 | 65.6% | 0.456 | 0.010 |
| Male | 255,253 | 33.9% | 249,273 | 34.4% | -0.456 | -0.010 |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 4,641 | 0.6% | 4,735 | 0.7% | -0.036 | -0.005 |
| Asian | 15,992 | 2.1% | 13,441 | 1.9% | 0.272 | 0.020 |
| Black or African American | 81,716 | 10.9% | 72,042 | 9.9% | 0.924 | 0.032 |
| Multi-racial | 1,912 | 0.3% | 1,757 | 0.2% | 0.012 | 0.002 |
| Native Hawaiian or Other Pacific Islander | 1,348 | 0.2% | 1,794 | 0.2% | -0.068 | -0.015 |
| Unknown | 378,607 | 50.3% | 368,744 | 50.9% | -0.540 | -0.016 |
| White | 268,014 | 35.6% | 262,343 | 36.2% | -0.563 | -0.015 |
| Hispanic origin | | | | | | |
| Yes | 62,019 | 8.2% | 62,181 | 8.6% | -0.334 | -0.013 |
| No | 349,360 | 46.4% | 332,404 | 45.9% | 0.585 | 0.019 |
| Unknown | 340,851 | 45.3% | 330,270 | 45.6% | -0.251 | -0.010 |
| Year | | | | | | |
| 2015 | 29,140 | 3.9% | 29,519 | 4.1% | -0.199 | -0.010 |
| 2016 | 141,986 | 18.9% | 139,863 | 19.3% | -0.420 | -0.011 |
| 2017 | 164,064 | 21.8% | 159,312 | 22.0% | -0.168 | -0.004 |
| 2018 | 156,558 | 20.8% | 149,324 | 20.6% | 0.212 | 0.005 |
| 2019 | 90,771 | 12.1% | 84,746 | 11.7% | 0.375 | 0.012 |
| 2020 | 77,957 | 10.4% | 74,575 | 10.3% | 0.075 | 0.003 |

Table 1b. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2021 | 69,445 | 9.2% | 66,279 | 9.1% | 0.088 | 0.003 |
| 2022 | 22,309 | 3.0% | 21,236 | 2.9% | 0.036 | 0.002 |
| Pre-boxed warning | 596,990 | 79.4% | 576,339 | 79.5% | -0.148 | -0.004 |
| Post-boxed warning | 155,240 | 20.6% | 148,516 | 20.5% | 0.148 | 0.004 |
| Seasonality | | | | | | |
| Winter | 174,455 | 23.2% | 169,970 | 23.4% | -0.257 | -0.006 |
| Spring | 209,583 | 27.9% | 196,529 | 27.1% | 0.749 | 0.017 |
| Summer | 166,764 | 22.2% | 160,889 | 22.2% | -0.027 | -0.001 |
| Autumn | 201,428 | 26.8% | 197,467 | 27.2% | -0.465 | -0.010 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.6 | 1.5 | 1.6 | 1.5 | 0.000 | 0.000 |
| Psychiatric History | 385,474 | 51.2% | 367,807 | 50.7% | 0.502 | 0.010 |
| Psychiatric Drug Dispensings ⁶ | 281,045 | 37.4% | 267,530 | 36.9% | 0.454 | 0.010 |
| Self Harm Encounter ⁶ | 1,394 | 0.2% | 1,336 | 0.2% | 0.001 | 0.000 |
| Encounter for Other Psychiatric Event ⁶ | 320,270 | 42.6% | 304,849 | 42.1% | 0.520 | 0.011 |
| Asthma Emergency Encounter | 76,496 | 10.2% | 73,303 | 10.1% | 0.057 | 0.002 |
| Asthma Inpatient Encounter | 2,251 | 0.3% | 2,232 | 0.3% | -0.009 | -0.002 |
| Asthma Outpatient Encounter | 720,647 | 95.8% | 696,565 | 96.1% | -0.296 | -0.015 |
| Oral Corticosteroid Dispensing | 208,780 | 27.8% | 198,495 | 27.4% | 0.371 | 0.008 |
| Use of Other Asthma Medication | 465,431 | 61.9% | 462,190 | 63.8% | -1.890 | -0.041 |
| Allergic Rhinitis | 324,343 | 43.1% | 294,367 | 40.6% | 2.507 | 0.051 |
| Anxiety | 136,634 | 18.2% | 129,696 | 17.9% | 0.271 | 0.007 |
| Depression | 110,424 | 14.7% | 105,269 | 14.5% | 0.157 | 0.004 |
| Sleep Disorder | 115,489 | 15.4% | 108,323 | 14.9% | 0.409 | 0.012 |
| Substance Abuse | 24,457 | 3.3% | 23,889 | 3.3% | -0.044 | -0.003 |
| Poisoning | 1,318 | 0.2% | 1,401 | 0.2% | -0.018 | -0.004 |
| Suffocation | 30 | 0.0% | 21 | 0.0% | 0.001 | 0.002 |
| Suicide Attempt | 732 | 0.1% | 721 | 0.1% | -0.002 | -0.001 |

Table 1b. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Toxicity | 156 | 0.0% | 153 | 0.0% | -0.000 | -0.000 |
| Other Self Harm | 386 | 0.1% | 394 | 0.1% | -0.003 | -0.001 |
| No moderate asthma exacerbations | 636,120 | 84.6% | 610,583 | 84.2% | 0.329 | 0.009 |
| One moderate asthma exacerbation | 102,243 | 13.6% | 101,035 | 13.9% | -0.347 | -0.010 |
| Two or more moderate asthma | 13,867 | 1.8% | 13,238 | 1.8% | 0.017 | 0.001 |
| No severe asthma exacerbations | 746,009 | 99.2% | 718,609 | 99.1% | 0.035 | 0.004 |
| One severe asthma exacerbation | 5,972 | 0.8% | 6,007 | 0.8% | -0.035 | -0.004 |
| Two or more severe asthma exacerbations | 249 | 0.0% | 240 | 0.0% | 0.000 | 0.000 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 149,054 | 19.8% | 140,853 | 19.4% | 0.383 | 0.010 |
| Antipsychotics | 34,673 | 4.6% | 33,993 | 4.7% | -0.080 | -0.004 |
| Anxiolytics Hypnotics | 135,137 | 18.0% | 127,968 | 17.7% | 0.311 | 0.008 |
| Lithium Other Mood Stabilizers | 40,602 | 5.4% | 39,421 | 5.4% | -0.041 | -0.002 |
| Antidepressants | 196,544 | 26.1% | 187,126 | 25.8% | 0.312 | 0.007 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 10.2 | 11.0 | 10.2 | 10.5 | -0.029 | -0.003 |
| Mean number of emergency room | 0.4 | 1.2 | 0.4 | 1.2 | -0.003 | -0.002 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.001 | -0.002 |
| Mean number of other ambulatory encounters | 2.7 | 9.2 | 2.8 | 9.7 | -0.153 | -0.016 |
| Mean number of filled prescriptions | 15.0 | 14.2 | 14.9 | 14.1 | 0.048 | 0.003 |
| Mean number of generics dispensed | 7.8 | 4.9 | 7.7 | 4.9 | 0.098 | 0.020 |
| Mean number of unique drug classes dispensed | 7.4 | 4.4 | 7.3 | 4.4 | 0.076 | 0.017 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.001 | -0.004 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.001 | -0.002 |

Table 1b. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of outpatient visits for respiratory disorders | 2.3 | 3.3 | 2.2 | 3.3 | 0.029 | 0.009 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Table 1c. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 496,977 | 100.0% | 568,584 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 47.9 | 15.5 | 41.4 | 16.4 | 6.566 | 0.412 |
| Age | | | | | | |
| 10-24 years | 103,203 | 20.8% | 183,929 | 32.3% | -11.582 | -0.265 |
| 25-54 years | 181,358 | 36.5% | 203,714 | 35.8% | 0.664 | 0.014 |
| ≥ 55 years | 212,416 | 42.7% | 180,941 | 31.8% | 10.919 | 0.227 |
| Sex | | | | | | |
| Female | 496,977 | 100.0% | 568,584 | 100.0% | 0.000 | NaN |
| Male | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 3,088 | 0.6% | 5,021 | 0.9% | -0.262 | -0.030 |
| Asian | 10,098 | 2.0% | 11,303 | 2.0% | 0.044 | 0.003 |
| Black or African American | 55,786 | 11.2% | 73,270 | 12.9% | -1.661 | -0.051 |
| Multi-racial | 1,273 | 0.3% | 1,215 | 0.2% | 0.042 | 0.009 |
| Native Hawaiian or Other Pacific Islander | 849 | 0.2% | 1,892 | 0.3% | -0.162 | -0.032 |
| Unknown | 235,671 | 47.4% | 273,953 | 48.2% | -0.761 | -0.015 |
| White | 190,212 | 38.3% | 201,930 | 35.5% | 2.759 | 0.057 |
| Hispanic origin | | | | | | |
| Yes | 36,808 | 7.4% | 64,770 | 11.4% | -3.985 | -0.137 |
| No | 244,638 | 49.2% | 279,907 | 49.2% | -0.004 | -0.000 |
| Unknown | 215,531 | 43.4% | 223,907 | 39.4% | 3.989 | 0.081 |
| Year | | | | | | |
| 2015 | 18,926 | 3.8% | 28,513 | 5.0% | -1.207 | -0.059 |
| 2016 | 92,749 | 18.7% | 128,071 | 22.5% | -3.862 | -0.096 |
| 2017 | 105,447 | 21.2% | 144,278 | 25.4% | -4.157 | -0.098 |
| 2018 | 101,436 | 20.4% | 122,826 | 21.6% | -1.191 | -0.029 |
| 2019 | 62,186 | 12.5% | 47,616 | 8.4% | 4.138 | 0.136 |

Table 1c. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2020 | 53,781 | 10.8% | 45,012 | 7.9% | 2.905 | 0.100 |
| 2021 | 47,658 | 9.6% | 38,985 | 6.9% | 2.733 | 0.100 |
| 2022 | 14,794 | 3.0% | 13,283 | 2.3% | 0.641 | 0.040 |
| Pre-boxed warning | 390,634 | 78.6% | 479,430 | 84.3% | -5.718 | -0.148 |
| Post-boxed warning | 106,343 | 21.4% | 89,154 | 15.7% | 5.718 | 0.148 |
| Seasonality | | | | | | |
| Winter | 115,698 | 23.3% | 143,922 | 25.3% | -2.032 | -0.047 |
| Spring | 138,899 | 27.9% | 127,256 | 22.4% | 5.568 | 0.129 |
| Summer | 109,776 | 22.1% | 122,372 | 21.5% | 0.567 | 0.014 |
| Autumn | 132,604 | 26.7% | 175,034 | 30.8% | -4.102 | -0.091 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.6 | 1.5 | 1.6 | 1.4 | 0.069 | 0.048 |
| Psychiatric History | 277,016 | 55.7% | 294,831 | 51.9% | 3.887 | 0.078 |
| Psychiatric Drug Dispensings ⁵ | 212,564 | 42.8% | 220,673 | 38.8% | 3.960 | 0.081 |
| Self Harm Encounter ⁵ | 1,054 | 0.2% | 1,866 | 0.3% | -0.116 | -0.022 |
| Encounter for Other Psychiatric Event ⁵ | 226,289 | 45.5% | 243,362 | 42.8% | 2.732 | 0.055 |
| Asthma Emergency Encounter | 53,943 | 10.9% | 71,994 | 12.7% | -1.808 | -0.056 |
| Asthma Inpatient Encounter | 1,704 | 0.3% | 1,862 | 0.3% | 0.015 | 0.003 |
| Asthma Outpatient Encounter | 474,471 | 95.5% | 545,021 | 95.9% | -0.384 | -0.019 |
| Oral Corticosteroid Dispensing | 147,880 | 29.8% | 153,405 | 27.0% | 2.776 | 0.062 |
| Use of Other Asthma Medication | 299,256 | 60.2% | 437,726 | 77.0% | -16.770 | -0.367 |
| Allergic Rhinitis | 213,703 | 43.0% | 128,493 | 22.6% | 20.402 | 0.445 |
| Anxiety | 108,149 | 21.8% | 113,601 | 20.0% | 1.782 | 0.044 |
| Depression | 88,988 | 17.9% | 96,849 | 17.0% | 0.872 | 0.023 |
| Sleep Disorder | 80,287 | 16.2% | 67,006 | 11.8% | 4.370 | 0.126 |
| Substance Abuse | 16,002 | 3.2% | 24,050 | 4.2% | -1.010 | -0.053 |
| Poisoning | 1,042 | 0.2% | 1,917 | 0.3% | -0.127 | -0.024 |

Table 1c. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Suffocation | 13 | 0.0% | 27 | 0.0% | -0.002 | -0.004 |
| Suicide Attempt | 550 | 0.1% | 903 | 0.2% | -0.048 | -0.013 |
| Toxicity | 113 | 0.0% | 201 | 0.0% | -0.013 | -0.007 |
| Other Self Harm | 293 | 0.1% | 469 | 0.1% | -0.024 | -0.009 |
| No moderate asthma exacerbations | 415,652 | 83.6% | 476,141 | 83.7% | -0.105 | -0.003 |
| One moderate asthma exacerbation | 71,216 | 14.3% | 81,838 | 14.4% | -0.063 | -0.002 |
| Two or more moderate asthma exacerbations | 10,109 | 2.0% | 10,605 | 1.9% | 0.169 | 0.012 |
| No severe asthma exacerbations | 492,335 | 99.1% | 562,688 | 99.0% | 0.103 | 0.010 |
| One severe asthma exacerbation | 4,456 | 0.9% | 5,734 | 1.0% | -0.112 | -0.012 |
| Two or more severe asthma exacerbations | 186 | 0.0% | 162 | 0.0% | 0.009 | 0.005 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 114,306 | 23.0% | 117,263 | 20.6% | 2.377 | 0.058 |
| Antipsychotics | 24,875 | 5.0% | 35,212 | 6.2% | -1.188 | -0.052 |
| Anxiolytics Hypnotics | 106,355 | 21.4% | 103,909 | 18.3% | 3.125 | 0.078 |
| Lithium Other Mood Stabilizers | 30,777 | 6.2% | 36,917 | 6.5% | -0.300 | -0.012 |
| Antidepressants | 158,499 | 31.9% | 164,696 | 29.0% | 2.927 | 0.064 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 11.1 | 11.1 | 10.4 | 11.4 | 0.723 | 0.064 |
| Mean number of emergency room encounters | 0.5 | 1.3 | 0.6 | 1.4 | -0.096 | -0.072 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.002 | -0.004 |
| Mean number of other ambulatory encounters | 2.8 | 8.8 | 3.4 | 11.5 | -0.594 | -0.058 |
| Mean number of filled prescriptions | 16.6 | 15.1 | 15.8 | 15.6 | 0.867 | 0.056 |
| Mean number of generics dispensed | 8.5 | 5.1 | 7.8 | 4.9 | 0.758 | 0.151 |
| Mean number of unique drug classes dispensed | 8.1 | 4.6 | 7.4 | 4.5 | 0.609 | 0.135 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | 0.000 | 0.000 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.5 | -0.015 | -0.035 |

Table 1c. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of outpatient visits for respiratory disorders | 2.4 | 3.3 | 1.8 | 2.8 | 0.558 | 0.181 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1d. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 496,923 | N/A | 478,441 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 47.9 | 15.5 | 47.8 | 16.4 | 0.150 | 0.009 |
| Age | | | | | | |
| 10-24 years | 103,202 | 20.8% | 109,538 | 22.9% | -2.126 | -0.058 |
| 25-54 years | 181,342 | 36.5% | 159,269 | 33.3% | 3.204 | 0.071 |
| ≥ 55 years | 212,379 | 42.7% | 209,635 | 43.8% | -1.077 | -0.029 |
| Sex | | | | | | |
| Female | 496,923 | 100.0% | 478,441 | 100.0% | 0.000 | NaN |
| Male | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 3,088 | 0.6% | 3,214 | 0.7% | -0.050 | -0.006 |
| Asian | 10,097 | 2.0% | 8,223 | 1.7% | 0.313 | 0.023 |
| Black or African American | 55,776 | 11.2% | 49,211 | 10.3% | 0.939 | 0.031 |
| Multi-racial | 1,273 | 0.3% | 1,177 | 0.2% | 0.010 | 0.002 |
| Native Hawaiian or Other Pacific Islander | 849 | 0.2% | 1,079 | 0.2% | -0.055 | -0.012 |
| Unknown | 235,653 | 47.4% | 229,044 | 47.9% | -0.451 | -0.014 |
| White | 190,187 | 38.3% | 186,493 | 39.0% | -0.706 | -0.019 |
| Hispanic origin | | | | | | |
| Yes | 36,804 | 7.4% | 36,707 | 7.7% | -0.266 | -0.011 |
| No | 244,604 | 49.2% | 233,045 | 48.7% | 0.515 | 0.017 |
| Unknown | 215,515 | 43.4% | 208,690 | 43.6% | -0.249 | -0.011 |
| Year | | | | | | |
| 2015 | 18,925 | 3.8% | 19,239 | 4.0% | -0.213 | -0.011 |
| 2016 | 92,746 | 18.7% | 91,432 | 19.1% | -0.446 | -0.011 |
| 2017 | 105,439 | 21.2% | 102,312 | 21.4% | -0.166 | -0.004 |
| 2018 | 101,421 | 20.4% | 96,561 | 20.2% | 0.227 | 0.006 |
| 2019 | 62,171 | 12.5% | 57,860 | 12.1% | 0.418 | 0.013 |
| 2020 | 53,773 | 10.8% | 51,475 | 10.8% | 0.062 | 0.002 |

Table 1d. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2021 | 47,654 | 9.6% | 45,440 | 9.5% | 0.092 | 0.003 |
| 2022 | 14,794 | 3.0% | 14,123 | 3.0% | 0.025 | 0.002 |
| Pre-boxed warning | 390,591 | 78.6% | 376,669 | 78.7% | -0.126 | -0.003 |
| Post-boxed warning | 106,332 | 21.4% | 101,772 | 21.3% | 0.126 | 0.003 |
| Seasonality | | | | | | |
| Winter | 115,692 | 23.3% | 112,594 | 23.5% | -0.252 | -0.006 |
| Spring | 138,873 | 27.9% | 130,032 | 27.2% | 0.768 | 0.017 |
| Summer | 109,763 | 22.1% | 105,845 | 22.1% | -0.034 | -0.001 |
| Autumn | 132,595 | 26.7% | 129,969 | 27.2% | -0.482 | -0.011 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.6 | 1.5 | 1.6 | 1.5 | 0.001 | 0.000 |
| Psychiatric History | 276,966 | 55.7% | 264,476 | 55.3% | 0.457 | 0.009 |
| Psychiatric Drug Dispensings ⁶ | 212,518 | 42.8% | 202,446 | 42.3% | 0.453 | 0.009 |
| Self Harm Encounter ⁶ | 1,054 | 0.2% | 1,053 | 0.2% | -0.008 | -0.002 |
| Encounter for Other Psychiatric Event ⁶ | 226,244 | 45.5% | 215,602 | 45.1% | 0.465 | 0.009 |
| Asthma Emergency Encounter | 53,930 | 10.9% | 51,578 | 10.8% | 0.072 | 0.002 |
| Asthma Inpatient Encounter | 1,704 | 0.3% | 1,674 | 0.3% | -0.007 | -0.001 |
| Asthma Outpatient Encounter | 474,432 | 95.5% | 458,361 | 95.8% | -0.329 | -0.016 |
| Oral Corticosteroid Dispensing | 147,848 | 29.8% | 140,654 | 29.4% | 0.354 | 0.008 |
| Use of Other Asthma Medication | 299,248 | 60.2% | 297,403 | 62.2% | -1.941 | -0.041 |
| Allergic Rhinitis | 213,655 | 43.0% | 193,693 | 40.5% | 2.511 | 0.051 |
| Anxiety | 108,119 | 21.8% | 102,739 | 21.5% | 0.284 | 0.007 |
| Depression | 88,965 | 17.9% | 84,925 | 17.8% | 0.153 | 0.004 |
| Sleep Disorder | 80,269 | 16.2% | 75,352 | 15.7% | 0.404 | 0.011 |
| Substance Abuse | 15,996 | 3.2% | 15,525 | 3.2% | -0.026 | -0.001 |
| Poisoning | 1,042 | 0.2% | 1,114 | 0.2% | -0.023 | -0.005 |
| Suffocation | 13 | 0.0% | 12 | 0.0% | 0.000 | 0.000 |
| Suicide Attempt | 550 | 0.1% | 539 | 0.1% | -0.002 | -0.001 |

Table 1d. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Toxicity | 113 | 0.0% | 114 | 0.0% | -0.001 | -0.001 |
| Other Self Harm | 293 | 0.1% | 293 | 0.1% | -0.002 | -0.001 |
| No moderate asthma exacerbations | 415,612 | 83.6% | 398,531 | 83.3% | 0.339 | 0.009 |
| One moderate asthma exacerbation | 71,204 | 14.3% | 70,332 | 14.7% | -0.371 | -0.011 |
| Two or more moderate asthma | 10,107 | 2.0% | 9,578 | 2.0% | 0.032 | 0.002 |
| No severe asthma exacerbations | 492,284 | 99.1% | 473,795 | 99.0% | 0.038 | 0.004 |
| One severe asthma exacerbation | 4,454 | 0.9% | 4,470 | 0.9% | -0.038 | -0.004 |
| Two or more severe asthma exacerbations | 185 | 0.0% | 176 | 0.0% | 0.000 | 0.000 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 114,275 | 23.0% | 108,004 | 22.6% | 0.422 | 0.010 |
| Antipsychotics | 24,872 | 5.0% | 24,356 | 5.1% | -0.085 | -0.004 |
| Anxiolytics Hypnotics | 106,319 | 21.4% | 100,893 | 21.1% | 0.308 | 0.008 |
| Lithium Other Mood Stabilizers | 30,769 | 6.2% | 29,851 | 6.2% | -0.047 | -0.002 |
| Antidepressants | 158,469 | 31.9% | 151,118 | 31.6% | 0.305 | 0.007 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 11.1 | 11.1 | 11.1 | 10.7 | -0.046 | -0.004 |
| Mean number of emergency room | 0.5 | 1.2 | 0.5 | 1.2 | -0.003 | -0.002 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.001 | -0.002 |
| Mean number of other ambulatory encounters | 2.8 | 8.8 | 2.9 | 9.3 | -0.150 | -0.017 |
| Mean number of filled prescriptions | 16.6 | 15.1 | 16.6 | 15.0 | 0.043 | 0.003 |
| Mean number of generics dispensed | 8.5 | 5.1 | 8.4 | 5.2 | 0.098 | 0.019 |
| Mean number of unique drug classes dispensed | 8.1 | 4.6 | 8.0 | 4.6 | 0.074 | 0.016 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.001 | -0.004 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.001 | -0.002 |

Table 1d. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of outpatient visits for respiratory disorders | 2.4 | 3.3 | 2.3 | 3.3 | 0.025 | 0.008 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1e. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 255,253 | 100.0% | 354,773 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 38.3 | 15.9 | 31.9 | 16.2 | 6.433 | 0.401 |
| Age | | | | | | |
| 10-24 years | 104,663 | 41.0% | 191,940 | 54.1% | -13.099 | -0.265 |
| 25-54 years | 75,778 | 29.7% | 90,708 | 25.6% | 4.120 | 0.092 |
| ≥ 55 years | 74,812 | 29.3% | 72,125 | 20.3% | 8.979 | 0.209 |
| Sex | | | | | | |
| Female | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Male | 255,253 | 100.0% | 354,773 | 100.0% | 0.000 | NaN |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 1,553 | 0.6% | 2,873 | 0.8% | -0.201 | -0.024 |
| Asian | 5,894 | 2.3% | 8,378 | 2.4% | -0.052 | -0.003 |
| Black or African American | 25,930 | 10.2% | 43,497 | 12.3% | -2.102 | -0.067 |
| Multi-racial | 639 | 0.3% | 753 | 0.2% | 0.038 | 0.008 |
| Native Hawaiian or Other Pacific Islander | 499 | 0.2% | 1,343 | 0.4% | -0.183 | -0.034 |
| Unknown | 142,936 | 56.0% | 199,583 | 56.3% | -0.259 | -0.005 |
| White | 77,802 | 30.5% | 98,346 | 27.7% | 2.760 | 0.061 |
| Hispanic origin | | | | | | |
| Yes | 25,211 | 9.9% | 49,710 | 14.0% | -4.135 | -0.128 |
| No | 104,722 | 41.0% | 147,025 | 41.4% | -0.415 | -0.008 |
| Unknown | 125,320 | 49.1% | 158,038 | 44.5% | 4.550 | 0.091 |
| Year | | | | | | |
| 2015 | 10,214 | 4.0% | 18,173 | 5.1% | -1.121 | -0.054 |
| 2016 | 49,237 | 19.3% | 81,937 | 23.1% | -3.806 | -0.093 |
| 2017 | 58,617 | 23.0% | 94,019 | 26.5% | -3.537 | -0.082 |
| 2018 | 55,122 | 21.6% | 79,569 | 22.4% | -0.833 | -0.020 |
| 2019 | 28,585 | 11.2% | 27,121 | 7.6% | 3.554 | 0.122 |
| 2020 | 24,176 | 9.5% | 24,048 | 6.8% | 2.693 | 0.099 |

Table 1e. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2021 | 21,787 | 8.5% | 22,073 | 6.2% | 2.314 | 0.089 |
| 2022 | 7,515 | 2.9% | 7,833 | 2.2% | 0.736 | 0.046 |
| Pre-boxed warning | 206,356 | 80.8% | 305,569 | 86.1% | -5.287 | -0.143 |
| Post-boxed warning | 48,897 | 19.2% | 49,204 | 13.9% | 5.287 | 0.143 |
| Seasonality | | | | | | |
| Winter | 58,757 | 23.0% | 88,727 | 25.0% | -1.990 | -0.047 |
| Spring | 70,684 | 27.7% | 79,400 | 22.4% | 5.311 | 0.123 |
| Summer | 56,988 | 22.3% | 76,678 | 21.6% | 0.713 | 0.017 |
| Autumn | 68,824 | 27.0% | 109,968 | 31.0% | -4.034 | -0.089 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.4 | 1.3 | 1.4 | 1.2 | 0.063 | 0.050 |
| Psychiatric History | 108,458 | 42.5% | 144,135 | 40.6% | 1.863 | 0.038 |
| Psychiatric Drug Dispensings ⁵ | 68,481 | 26.8% | 91,463 | 25.8% | 1.048 | 0.024 |
| Self Harm Encounter ⁵ | 340 | 0.1% | 589 | 0.2% | -0.033 | -0.008 |
| Encounter for Other Psychiatric Event ⁵ | 93,981 | 36.8% | 126,131 | 35.6% | 1.266 | 0.026 |
| Asthma Emergency Encounter | 22,553 | 8.8% | 38,496 | 10.9% | -2.015 | -0.068 |
| Asthma Inpatient Encounter | 547 | 0.2% | 1,043 | 0.3% | -0.080 | -0.016 |
| Asthma Outpatient Encounter | 246,176 | 96.4% | 343,269 | 96.8% | -0.313 | -0.017 |
| Oral Corticosteroid Dispensing | 60,900 | 23.9% | 80,408 | 22.7% | 1.194 | 0.028 |
| Use of Other Asthma Medication | 166,175 | 65.1% | 285,712 | 80.5% | -15.432 | -0.352 |
| Allergic Rhinitis | 110,640 | 43.3% | 85,936 | 24.2% | 19.122 | 0.413 |
| Anxiety | 28,485 | 11.2% | 36,854 | 10.4% | 0.771 | 0.025 |
| Depression | 21,436 | 8.4% | 29,241 | 8.2% | 0.156 | 0.006 |
| Sleep Disorder | 35,202 | 13.8% | 34,034 | 9.6% | 4.198 | 0.131 |
| Substance Abuse | 8,455 | 3.3% | 15,267 | 4.3% | -0.991 | -0.052 |
| Poisoning | 276 | 0.1% | 553 | 0.2% | -0.048 | -0.013 |
| Suffocation | 17 | 0.0% | 19 | 0.0% | 0.001 | 0.002 |
| Suicide Attempt | 182 | 0.1% | 347 | 0.1% | -0.027 | -0.009 |

Table 1e. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Toxicity | 43 | 0.0% | 74 | 0.0% | -0.004 | -0.003 |
| Other Self Harm | 93 | 0.0% | 161 | 0.0% | -0.009 | -0.004 |
| No moderate asthma exacerbations | 220,468 | 86.4% | 303,116 | 85.4% | 0.933 | 0.027 |
| One moderate asthma exacerbation | 31,027 | 12.2% | 46,281 | 13.0% | -0.890 | -0.027 |
| Two or more moderate asthma | 3,758 | 1.5% | 5,376 | 1.5% | -0.043 | -0.004 |
| No severe asthma exacerbations | 253,674 | 99.4% | 351,688 | 99.1% | 0.251 | 0.029 |
| One severe asthma exacerbation | 1,516 | 0.6% | 3,001 | 0.8% | -0.252 | -0.030 |
| Two or more severe asthma exacerbations | 63 | 0.0% | 84 | 0.0% | 0.001 | 0.001 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 34,748 | 13.6% | 40,669 | 11.5% | 2.150 | 0.065 |
| Antipsychotics | 9,798 | 3.8% | 17,121 | 4.8% | -0.987 | -0.049 |
| Anxiolytics Hypnotics | 28,782 | 11.3% | 33,036 | 9.3% | 1.964 | 0.065 |
| Lithium Other Mood Stabilizers | 9,825 | 3.8% | 14,665 | 4.1% | -0.285 | -0.015 |
| Antidepressants | 38,045 | 14.9% | 48,716 | 13.7% | 1.173 | 0.034 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 8.4 | 10.5 | 7.8 | 10.7 | 0.563 | 0.053 |
| Mean number of emergency room | 0.4 | 1.0 | 0.4 | 1.2 | -0.060 | -0.053 |
| Mean number of inpatient hospital encounters | 0.1 | 0.3 | 0.1 | 0.4 | -0.001 | -0.003 |
| Mean number of other ambulatory encounters | 2.5 | 9.8 | 3.2 | 12.9 | -0.671 | -0.059 |
| Mean number of filled prescriptions | 11.7 | 11.9 | 11.1 | 12.1 | 0.633 | 0.053 |
| Mean number of generics dispensed | 6.4 | 4.1 | 5.7 | 3.8 | 0.619 | 0.157 |
| Mean number of unique drug classes dispensed | 6.1 | 3.7 | 5.6 | 3.5 | 0.492 | 0.138 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.001 | -0.006 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.010 | -0.025 |

Table 1e. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of outpatient visits for respiratory disorders | 2.1 | 3.2 | 1.6 | 2.8 | 0.494 | 0.164 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1f. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 255,186 | N/A | 246,692 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 38.3 | 15.9 | 38.1 | 17.0 | 0.172 | 0.010 |
| Age | | | | | | |
| 10-24 years | 104,660 | 41.0% | 106,804 | 43.3% | -2.281 | -0.057 |
| 25-54 years | 75,765 | 29.7% | 64,002 | 25.9% | 3.746 | 0.087 |
| ≥ 55 years | 74,761 | 29.3% | 75,886 | 30.8% | -1.465 | -0.043 |
| Sex | | | | | | |
| Female | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Male | 255,186 | 100.0% | 246,692 | 100.0% | 0.000 | NaN |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 1,553 | 0.6% | 1,524 | 0.6% | -0.009 | -0.001 |
| Asian | 5,891 | 2.3% | 5,199 | 2.1% | 0.201 | 0.014 |
| Black or African American | 25,926 | 10.2% | 22,823 | 9.3% | 0.908 | 0.032 |
| Multi-racial | 639 | 0.3% | 587 | 0.2% | 0.013 | 0.003 |
| Native Hawaiian or Other Pacific Islander | 499 | 0.2% | 720 | 0.3% | -0.096 | -0.020 |
| Unknown | 142,900 | 56.0% | 140,031 | 56.8% | -0.765 | -0.022 |
| White | 77,778 | 30.5% | 75,808 | 30.7% | -0.251 | -0.007 |
| Hispanic origin | | | | | | |
| Yes | 25,205 | 9.9% | 25,566 | 10.4% | -0.486 | -0.018 |
| No | 104,695 | 41.0% | 99,266 | 40.2% | 0.788 | 0.024 |
| Unknown | 125,286 | 49.1% | 121,860 | 49.4% | -0.302 | -0.012 |
| Year | | | | | | |
| 2015 | 10,212 | 4.0% | 10,298 | 4.2% | -0.173 | -0.009 |
| 2016 | 49,233 | 19.3% | 48,531 | 19.7% | -0.380 | -0.010 |
| 2017 | 58,610 | 23.0% | 56,999 | 23.1% | -0.138 | -0.003 |
| 2018 | 55,110 | 21.6% | 52,788 | 21.4% | 0.198 | 0.005 |
| 2019 | 28,564 | 11.2% | 26,958 | 10.9% | 0.266 | 0.009 |
| 2020 | 24,164 | 9.5% | 23,129 | 9.4% | 0.094 | 0.003 |

Table 1f. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2021 | 21,782 | 8.5% | 20,873 | 8.5% | 0.075 | 0.003 |
| 2022 | 7,511 | 2.9% | 7,117 | 2.9% | 0.058 | 0.004 |
| Pre-boxed warning | 206,308 | 80.8% | 199,888 | 81.0% | -0.181 | -0.005 |
| Post-boxed warning | 48,878 | 19.2% | 46,804 | 19.0% | 0.181 | 0.005 |
| Seasonality | | | | | | |
| Winter | 58,743 | 23.0% | 57,418 | 23.3% | -0.256 | -0.006 |
| Spring | 70,655 | 27.7% | 66,572 | 27.0% | 0.702 | 0.016 |
| Summer | 56,976 | 22.3% | 55,130 | 22.3% | -0.021 | -0.000 |
| Autumn | 68,812 | 27.0% | 67,572 | 27.4% | -0.426 | -0.010 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.4 | 1.3 | 1.4 | 1.3 | -0.002 | -0.002 |
| Psychiatric History | 108,402 | 42.5% | 103,775 | 42.1% | 0.413 | 0.009 |
| Psychiatric Drug Dispensings ⁶ | 68,438 | 26.8% | 65,555 | 26.6% | 0.245 | 0.006 |
| Self Harm Encounter ⁶ | 340 | 0.1% | 280 | 0.1% | 0.020 | 0.006 |
| Encounter for Other Psychiatric Event ⁶ | 93,930 | 36.8% | 89,511 | 36.3% | 0.524 | 0.011 |
| Asthma Emergency Encounter | 22,545 | 8.8% | 21,797 | 8.8% | -0.001 | -0.000 |
| Asthma Inpatient Encounter | 545 | 0.2% | 554 | 0.2% | -0.011 | -0.002 |
| Asthma Outpatient Encounter | 246,119 | 96.4% | 238,453 | 96.7% | -0.213 | -0.012 |
| Oral Corticosteroid Dispensing | 60,858 | 23.8% | 58,110 | 23.6% | 0.293 | 0.007 |
| Use of Other Asthma Medication | 166,164 | 65.1% | 164,826 | 66.8% | -1.700 | -0.037 |
| Allergic Rhinitis | 110,581 | 43.3% | 100,934 | 40.9% | 2.418 | 0.049 |
| Anxiety | 28,462 | 11.2% | 27,243 | 11.0% | 0.110 | 0.004 |
| Depression | 21,422 | 8.4% | 20,602 | 8.4% | 0.043 | 0.002 |
| Sleep Disorder | 35,166 | 13.8% | 33,002 | 13.4% | 0.403 | 0.012 |
| Substance Abuse | 8,453 | 3.3% | 8,352 | 3.4% | -0.073 | -0.004 |
| Poisoning | 276 | 0.1% | 288 | 0.1% | -0.008 | -0.003 |
| Suffocation | 17 | 0.0% | 8 | 0.0% | 0.003 | 0.005 |
| Suicide Attempt | 181 | 0.1% | 181 | 0.1% | -0.002 | -0.001 |

Table 1f. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Toxicity | 43 | 0.0% | 38 | 0.0% | 0.001 | 0.001 |
| Other Self Harm | 93 | 0.0% | 100 | 0.0% | -0.004 | -0.002 |
| No moderate asthma exacerbations | 220,418 | 86.4% | 212,250 | 86.0% | 0.337 | 0.010 |
| One moderate asthma exacerbation | 31,013 | 12.2% | 30,749 | 12.5% | -0.311 | -0.009 |
| Two or more moderate asthma | 3,755 | 1.5% | 3,693 | 1.5% | -0.026 | -0.002 |
| No severe asthma exacerbations | 253,610 | 99.4% | 245,089 | 99.4% | 0.032 | 0.004 |
| One severe asthma exacerbation | 1,515 | 0.6% | 1,542 | 0.6% | -0.031 | -0.004 |
| Two or more severe asthma exacerbations | 61 | 0.0% | 61 | 0.0% | -0.001 | -0.001 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 34,707 | 13.6% | 33,101 | 13.4% | 0.183 | 0.005 |
| Antipsychotics | 9,789 | 3.8% | 9,658 | 3.9% | -0.079 | -0.004 |
| Anxiolytics Hypnotics | 28,753 | 11.3% | 27,374 | 11.1% | 0.171 | 0.006 |
| Lithium Other Mood Stabilizers | 9,820 | 3.8% | 9,642 | 3.9% | -0.060 | -0.003 |
| Antidepressants | 38,016 | 14.9% | 36,483 | 14.8% | 0.108 | 0.003 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 8.4 | 10.5 | 8.4 | 10.1 | -0.035 | -0.003 |
| Mean number of emergency room | 0.4 | 1.0 | 0.4 | 1.1 | -0.003 | -0.003 |
| Mean number of inpatient hospital encounters | 0.1 | 0.3 | 0.1 | 0.3 | -0.001 | -0.004 |
| Mean number of other ambulatory encounters | 2.5 | 9.8 | 2.6 | 10.5 | -0.163 | -0.016 |
| Mean number of filled prescriptions | 11.7 | 11.8 | 11.7 | 11.7 | -0.017 | -0.001 |
| Mean number of generics dispensed | 6.3 | 4.1 | 6.3 | 4.1 | 0.066 | 0.016 |
| Mean number of unique drug classes dispensed | 6.0 | 3.7 | 6.0 | 3.7 | 0.050 | 0.014 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.001 | -0.006 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.000 | -0.001 |

Table 1f. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of outpatient visits for respiratory disorders | 2.1 | 3.2 | 2.1 | 3.2 | 0.032 | 0.010 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1g. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 207,866 | 100.0% | 375,869 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 15.6 | 4.0 | 15.0 | 3.8 | 0.628 | 0.161 |
| Age | | | | | | |
| 10-24 years | 207,866 | 100.0% | 375,869 | 100.0% | 0.000 | NaN |
| 25-54 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| ≥ 55 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Sex | | | | | | |
| Female | 103,203 | 49.6% | 183,929 | 48.9% | 0.714 | 0.014 |
| Male | 104,663 | 50.4% | 191,940 | 51.1% | -0.714 | -0.014 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 1,875 | 0.9% | 3,665 | 1.0% | -0.073 | -0.008 |
| Asian | 3,222 | 1.6% | 7,781 | 2.1% | -0.520 | -0.039 |
| Black or African American | 30,299 | 14.6% | 58,376 | 15.5% | -0.955 | -0.027 |
| Multi-racial | 448 | 0.2% | 676 | 0.2% | 0.036 | 0.008 |
| Native Hawaiian or Other Pacific Islander | 381 | 0.2% | 1,640 | 0.4% | -0.253 | -0.046 |
| Unknown | 133,758 | 64.3% | 233,458 | 62.1% | 2.237 | 0.046 |
| White | 37,883 | 18.2% | 70,273 | 18.7% | -0.471 | -0.012 |
| Hispanic origin | | | | | | |
| Yes | 36,006 | 17.3% | 75,973 | 20.2% | -2.891 | -0.074 |
| No | 71,480 | 34.4% | 138,107 | 36.7% | -2.356 | -0.049 |
| Unknown | 100,380 | 48.3% | 161,789 | 43.0% | 5.247 | 0.105 |
| Year | | | | | | |
| 2015 | 9,717 | 4.7% | 20,007 | 5.3% | -0.648 | -0.030 |
| 2016 | 48,700 | 23.4% | 95,877 | 25.5% | -2.080 | -0.048 |
| 2017 | 59,942 | 28.8% | 113,849 | 30.3% | -1.453 | -0.032 |
| 2018 | 54,094 | 26.0% | 92,684 | 24.7% | 1.365 | 0.031 |
| 2019 | 13,509 | 6.5% | 18,242 | 4.9% | 1.646 | 0.071 |

Table 1g. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2020 | 9,707 | 4.7% | 14,961 | 4.0% | 0.689 | 0.034 |
| 2021 | 8,746 | 4.2% | 14,425 | 3.8% | 0.370 | 0.019 |
| 2022 | 3,451 | 1.7% | 5,824 | 1.5% | 0.111 | 0.009 |
| Pre-boxed warning | 187,871 | 90.4% | 343,756 | 91.5% | -1.076 | -0.037 |
| Post-boxed warning | 19,995 | 9.6% | 32,113 | 8.5% | 1.076 | 0.037 |
| Seasonality | | | | | | |
| Winter | 43,714 | 21.0% | 89,347 | 23.8% | -2.741 | -0.066 |
| Spring | 54,434 | 26.2% | 78,705 | 20.9% | 5.248 | 0.124 |
| Summer | 50,043 | 24.1% | 84,614 | 22.5% | 1.563 | 0.037 |
| Autumn | 59,675 | 28.7% | 123,203 | 32.8% | -4.070 | -0.088 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.2 | 0.5 | 1.2 | 0.5 | -0.006 | -0.012 |
| Psychiatric History | 68,585 | 33.0% | 123,121 | 32.8% | 0.238 | 0.005 |
| Psychiatric Drug Dispensings ⁵ | 43,114 | 20.7% | 74,269 | 19.8% | 0.982 | 0.024 |
| Self Harm Encounter ⁵ | 550 | 0.3% | 1,164 | 0.3% | -0.045 | -0.008 |
| Encounter for Other Psychiatric Event ⁵ | 60,178 | 29.0% | 109,602 | 29.2% | -0.209 | -0.005 |
| Asthma Emergency Encounter | 24,074 | 11.6% | 47,333 | 12.6% | -1.011 | -0.031 |
| Asthma Inpatient Encounter | 413 | 0.2% | 1,147 | 0.3% | -0.106 | -0.021 |
| Asthma Outpatient Encounter | 199,780 | 96.1% | 363,819 | 96.8% | -0.684 | -0.037 |
| Oral Corticosteroid Dispensing | 42,361 | 20.4% | 78,548 | 20.9% | -0.519 | -0.013 |
| Use of Other Asthma Medication | 156,993 | 75.5% | 323,012 | 85.9% | -10.411 | -0.266 |
| Allergic Rhinitis | 92,341 | 44.4% | 97,740 | 26.0% | 18.420 | 0.393 |
| Anxiety | 20,702 | 10.0% | 36,971 | 9.8% | 0.123 | 0.004 |
| Depression | 15,559 | 7.5% | 27,901 | 7.4% | 0.062 | 0.002 |
| Sleep Disorder | 6,788 | 3.3% | 10,425 | 2.8% | 0.492 | 0.029 |
| Substance Abuse | 2,843 | 1.4% | 6,154 | 1.6% | -0.270 | -0.022 |
| Poisoning | 545 | 0.3% | 1,196 | 0.3% | -0.056 | -0.010 |

Table 1g. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Suffocation | 17 | 0.0% | 28 | 0.0% | 0.001 | 0.001 |
| Suicide Attempt | 288 | 0.1% | 621 | 0.2% | -0.027 | -0.007 |
| Toxicity | 57 | 0.0% | 125 | 0.0% | -0.006 | -0.003 |
| Other Self Harm | 157 | 0.1% | 305 | 0.1% | -0.006 | -0.002 |
| No moderate asthma exacerbations | 181,741 | 87.4% | 322,258 | 85.7% | 1.695 | 0.050 |
| One moderate asthma exacerbation | 23,945 | 11.5% | 48,723 | 13.0% | -1.443 | -0.044 |
| Two or more moderate asthma | 2,180 | 1.0% | 4,888 | 1.3% | -0.252 | -0.023 |
| No severe asthma exacerbations | 206,875 | 99.5% | 372,659 | 99.1% | 0.377 | 0.046 |
| One severe asthma exacerbation | 954 | 0.5% | 3,128 | 0.8% | -0.373 | -0.047 |
| Two or more severe asthma exacerbations | 37 | 0.0% | 82 | 0.0% | -0.004 | -0.003 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 13,031 | 6.3% | 20,608 | 5.5% | 0.786 | 0.033 |
| Antipsychotics | 6,022 | 2.9% | 11,755 | 3.1% | -0.230 | -0.013 |
| Anxiolytics Hypnotics | 11,278 | 5.4% | 17,578 | 4.7% | 0.749 | 0.034 |
| Lithium Other Mood Stabilizers | 4,718 | 2.3% | 9,029 | 2.4% | -0.132 | -0.009 |
| Antidepressants | 21,173 | 10.2% | 35,074 | 9.3% | 0.854 | 0.029 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 6.5 | 8.1 | 6.6 | 8.5 | -0.046 | -0.005 |
| Mean number of emergency room | 0.4 | 1.0 | 0.4 | 1.0 | -0.036 | -0.036 |
| Mean number of inpatient hospital encounters | 0.0 | 0.3 | 0.0 | 0.3 | -0.008 | -0.028 |
| Mean number of other ambulatory encounters | 2.3 | 10.3 | 2.9 | 12.8 | -0.673 | -0.058 |
| Mean number of filled prescriptions | 7.5 | 7.1 | 7.4 | 7.4 | 0.051 | 0.007 |
| Mean number of generics dispensed | 4.9 | 3.1 | 4.7 | 2.9 | 0.256 | 0.084 |
| Mean number of unique drug classes dispensed | 4.8 | 2.8 | 4.6 | 2.7 | 0.153 | 0.055 |

Table 1g. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.1 | 0.0 | 0.2 | -0.006 | -0.038 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.008 | -0.022 |
| Mean number of outpatient visits for respiratory disorders | 1.8 | 2.9 | 1.5 | 2.5 | 0.356 | 0.133 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1h. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 207,822 | N/A | 201,192 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 15.6 | 4.0 | 15.5 | 4.0 | 0.080 | 0.020 |
| Age | | | | | | |
| 10-24 years | 207,822 | 100.0% | 201,192 | 100.0% | 0.000 | NaN |
| 25-54 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| ≥ 55 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Sex | | | | | | |
| Female | 103,172 | 49.6% | 99,420 | 49.4% | 0.229 | 0.005 |
| Male | 104,650 | 50.4% | 101,772 | 50.6% | -0.229 | -0.005 |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 1,875 | 0.9% | 1,742 | 0.9% | 0.036 | 0.004 |
| Asian | 3,222 | 1.6% | 3,945 | 2.0% | -0.411 | -0.031 |
| Black or African American | 30,296 | 14.6% | 27,425 | 13.6% | 0.947 | 0.029 |
| Multi-racial | 448 | 0.2% | 390 | 0.2% | 0.022 | 0.005 |
| Native Hawaiian or Other Pacific Islander | 381 | 0.2% | 763 | 0.4% | -0.196 | -0.037 |
| Unknown | 133,722 | 64.3% | 132,367 | 65.8% | -1.447 | -0.036 |
| White | 37,878 | 18.2% | 34,560 | 17.2% | 1.049 | 0.029 |
| Hispanic origin | | | | | | |
| Yes | 36,005 | 17.3% | 37,492 | 18.6% | -1.310 | -0.037 |
| No | 71,473 | 34.4% | 66,182 | 32.9% | 1.496 | 0.039 |
| Unknown | 100,344 | 48.3% | 97,517 | 48.5% | -0.186 | -0.007 |
| Year | | | | | | |
| 2015 | 9,715 | 4.7% | 9,625 | 4.8% | -0.109 | -0.005 |
| 2016 | 48,695 | 23.4% | 47,580 | 23.6% | -0.218 | -0.005 |
| 2017 | 59,932 | 28.8% | 58,260 | 29.0% | -0.119 | -0.003 |
| 2018 | 54,084 | 26.0% | 51,662 | 25.7% | 0.346 | 0.008 |
| 2019 | 13,500 | 6.5% | 12,790 | 6.4% | 0.139 | 0.006 |
| 2020 | 9,701 | 4.7% | 9,450 | 4.7% | -0.029 | -0.001 |

Table 1h. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2021 | 8,744 | 4.2% | 8,489 | 4.2% | -0.012 | -0.001 |
| 2022 | 3,451 | 1.7% | 3,336 | 1.7% | 0.003 | 0.000 |
| Pre-boxed warning | 187,833 | 90.4% | 181,766 | 90.3% | 0.037 | 0.001 |
| Post-boxed warning | 19,989 | 9.6% | 19,427 | 9.7% | -0.037 | -0.001 |
| Seasonality | | | | | | |
| Winter | 43,709 | 21.0% | 42,880 | 21.3% | -0.281 | -0.007 |
| Spring | 54,405 | 26.2% | 51,246 | 25.5% | 0.708 | 0.016 |
| Summer | 50,037 | 24.1% | 48,372 | 24.0% | 0.034 | 0.001 |
| Autumn | 59,671 | 28.7% | 58,695 | 29.2% | -0.461 | -0.010 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.2 | 0.5 | 1.2 | 0.5 | -0.001 | -0.001 |
| Psychiatric History | 68,549 | 33.0% | 65,949 | 32.8% | 0.206 | 0.004 |
| Psychiatric Drug Dispensings ⁶ | 43,086 | 20.7% | 40,578 | 20.2% | 0.563 | 0.014 |
| Self Harm Encounter ⁶ | 550 | 0.3% | 540 | 0.3% | -0.004 | -0.001 |
| Encounter for Other Psychiatric Event ⁶ | 60,144 | 28.9% | 57,626 | 28.6% | 0.298 | 0.007 |
| Asthma Emergency Encounter | 24,063 | 11.6% | 23,267 | 11.6% | 0.014 | 0.000 |
| Asthma Inpatient Encounter | 413 | 0.2% | 437 | 0.2% | -0.019 | -0.004 |
| Asthma Outpatient Encounter | 199,747 | 96.1% | 193,929 | 96.4% | -0.275 | -0.015 |
| Oral Corticosteroid Dispensing | 42,343 | 20.4% | 41,030 | 20.4% | -0.019 | -0.000 |
| Use of Other Asthma Medication | 156,981 | 75.5% | 155,496 | 77.3% | -1.751 | -0.042 |
| Allergic Rhinitis | 92,301 | 44.4% | 84,939 | 42.2% | 2.196 | 0.045 |
| Anxiety | 20,683 | 10.0% | 19,865 | 9.9% | 0.079 | 0.003 |
| Depression | 15,548 | 7.5% | 14,960 | 7.4% | 0.046 | 0.002 |
| Sleep Disorder | 6,778 | 3.3% | 6,359 | 3.2% | 0.101 | 0.006 |
| Substance Abuse | 2,840 | 1.4% | 2,833 | 1.4% | -0.041 | -0.004 |
| Poisoning | 545 | 0.3% | 597 | 0.3% | -0.034 | -0.007 |
| Suffocation | 17 | 0.0% | 11 | 0.0% | 0.003 | 0.003 |

Table 1h. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Suicide Attempt | 288 | 0.1% | 307 | 0.2% | -0.014 | -0.004 |
| Toxicity | 57 | 0.0% | 62 | 0.0% | -0.003 | -0.002 |
| Other Self Harm | 157 | 0.1% | 154 | 0.1% | -0.001 | -0.000 |
| No moderate asthma exacerbations | 181,701 | 87.4% | 174,396 | 86.7% | 0.750 | 0.022 |
| One moderate asthma exacerbation | 23,942 | 11.5% | 24,287 | 12.1% | -0.551 | -0.017 |
| Two or more moderate asthma | 2,179 | 1.0% | 2,509 | 1.2% | -0.199 | -0.019 |
| No severe asthma exacerbations | 206,832 | 99.5% | 200,111 | 99.5% | 0.061 | 0.009 |
| One severe asthma exacerbation | 954 | 0.5% | 1,040 | 0.5% | -0.058 | -0.008 |
| Two or more severe asthma exacerbations | 36 | 0.0% | 40 | 0.0% | -0.003 | -0.002 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 13,021 | 6.3% | 12,360 | 6.1% | 0.122 | 0.005 |
| Antipsychotics | 6,014 | 2.9% | 5,945 | 3.0% | -0.061 | -0.004 |
| Anxiolytics Hypnotics | 11,265 | 5.4% | 10,555 | 5.2% | 0.174 | 0.008 |
| Lithium Other Mood Stabilizers | 4,711 | 2.3% | 4,602 | 2.3% | -0.020 | -0.001 |
| Antidepressants | 21,153 | 10.2% | 20,142 | 10.0% | 0.167 | 0.006 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 6.5 | 8.1 | 6.6 | 7.8 | -0.006 | -0.001 |
| Mean number of emergency room | 0.4 | 1.0 | 0.4 | 1.0 | -0.002 | -0.002 |
| Mean number of inpatient hospital encounters | 0.0 | 0.3 | 0.0 | 0.3 | -0.002 | -0.007 |
| Mean number of other ambulatory encounters | 2.3 | 10.3 | 2.6 | 11.6 | -0.350 | -0.032 |
| Mean number of filled prescriptions | 7.5 | 7.1 | 7.5 | 7.1 | 0.013 | 0.002 |
| Mean number of generics dispensed | 4.9 | 3.1 | 4.9 | 3.2 | 0.051 | 0.016 |
| Mean number of unique drug classes dispensed | 4.8 | 2.8 | 4.7 | 2.9 | 0.037 | 0.013 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.1 | 0.0 | 0.1 | -0.001 | -0.008 |

Table 1h. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.001 | -0.002 |
| Mean number of outpatient visits for respiratory disorders | 1.8 | 2.9 | 1.8 | 2.8 | 0.043 | 0.015 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1i. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 257,136 | 100.0% | 294,422 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 40.4 | 8.4 | 39.8 | 8.5 | 0.512 | 0.061 |
| Age | | | | | | |
| 10-24 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 25-54 years | 257,136 | 100.0% | 294,422 | 100.0% | 0.000 | NaN |
| ≥ 55 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Sex | | | | | | |
| Female | 181,358 | 70.5% | 203,714 | 69.2% | 1.339 | 0.029 |
| Male | 75,778 | 29.5% | 90,708 | 30.8% | -1.339 | -0.029 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 1,423 | 0.6% | 2,696 | 0.9% | -0.362 | -0.042 |
| Asian | 4,290 | 1.7% | 5,838 | 2.0% | -0.314 | -0.023 |
| Black or African American | 24,388 | 9.5% | 36,234 | 12.3% | -2.822 | -0.091 |
| Multi-racial | 1,158 | 0.5% | 1,019 | 0.3% | 0.104 | 0.017 |
| Native Hawaiian or Other Pacific Islander | 405 | 0.2% | 1,086 | 0.4% | -0.211 | -0.041 |
| Unknown | 171,010 | 66.5% | 167,552 | 56.9% | 9.597 | 0.198 |
| White | 54,462 | 21.2% | 79,997 | 27.2% | -5.991 | -0.140 |
| Hispanic origin | | | | | | |
| Yes | 17,129 | 6.7% | 28,465 | 9.7% | -3.007 | -0.110 |
| No | 74,381 | 28.9% | 116,553 | 39.6% | -10.660 | -0.226 |
| Unknown | 165,626 | 64.4% | 149,404 | 50.7% | 13.667 | 0.279 |
| Year | | | | | | |
| 2015 | 9,809 | 3.8% | 14,029 | 4.8% | -0.950 | -0.047 |
| 2016 | 48,277 | 18.8% | 64,371 | 21.9% | -3.089 | -0.077 |
| 2017 | 55,354 | 21.5% | 75,782 | 25.7% | -4.212 | -0.099 |
| 2018 | 53,238 | 20.7% | 65,902 | 22.4% | -1.679 | -0.041 |
| 2019 | 29,853 | 11.6% | 22,844 | 7.8% | 3.851 | 0.130 |
| 2020 | 28,162 | 11.0% | 23,748 | 8.1% | 2.886 | 0.099 |

Table 1i. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2021 | 23,588 | 9.2% | 19,833 | 6.7% | 2.437 | 0.090 |
| 2022 | 8,855 | 3.4% | 7,913 | 2.7% | 0.756 | 0.044 |
| Pre-boxed warning | 201,267 | 78.3% | 246,921 | 83.9% | -5.594 | -0.143 |
| Post-boxed warning | 55,869 | 21.7% | 47,501 | 16.1% | 5.594 | 0.143 |
| Seasonality | | | | | | |
| Winter | 59,054 | 23.0% | 75,123 | 25.5% | -2.549 | -0.060 |
| Spring | 75,199 | 29.2% | 68,651 | 23.3% | 5.928 | 0.135 |
| Summer | 55,310 | 21.5% | 61,599 | 20.9% | 0.588 | 0.014 |
| Autumn | 67,573 | 26.3% | 89,049 | 30.2% | -3.966 | -0.088 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.4 | 1.1 | 1.5 | 1.2 | -0.053 | -0.046 |
| Psychiatric History | 143,341 | 55.7% | 168,135 | 57.1% | -1.362 | -0.027 |
| Psychiatric Drug Dispensings ⁵ | 107,777 | 41.9% | 126,176 | 42.9% | -0.941 | -0.019 |
| Self Harm Encounter ⁵ | 697 | 0.3% | 1,133 | 0.4% | -0.114 | -0.020 |
| Encounter for Other Psychiatric Event ⁵ | 120,688 | 46.9% | 142,464 | 48.4% | -1.452 | -0.029 |
| Asthma Emergency Encounter | 31,691 | 12.3% | 43,028 | 14.6% | -2.290 | -0.067 |
| Asthma Inpatient Encounter | 937 | 0.4% | 1,019 | 0.3% | 0.018 | 0.003 |
| Asthma Outpatient Encounter | 245,683 | 95.5% | 281,156 | 95.5% | 0.052 | 0.002 |
| Oral Corticosteroid Dispensing | 78,190 | 30.4% | 85,969 | 29.2% | 1.209 | 0.026 |
| Use of Other Asthma Medication | 171,152 | 66.6% | 237,349 | 80.6% | -14.054 | -0.323 |
| Allergic Rhinitis | 109,242 | 42.5% | 59,264 | 20.1% | 22.355 | 0.497 |
| Anxiety | 60,543 | 23.5% | 68,536 | 23.3% | 0.267 | 0.006 |
| Depression | 43,802 | 17.0% | 53,481 | 18.2% | -1.130 | -0.030 |
| Sleep Disorder | 38,542 | 15.0% | 36,500 | 12.4% | 2.592 | 0.075 |
| Substance Abuse | 13,259 | 5.2% | 24,365 | 8.3% | -3.119 | -0.125 |
| Poisoning | 631 | 0.2% | 1,106 | 0.4% | -0.130 | -0.023 |
| Suffocation | 12 | 0.0% | 18 | 0.0% | -0.001 | -0.002 |
| Suicide Attempt | 364 | 0.1% | 556 | 0.2% | -0.047 | -0.012 |

Table 1i. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Toxicity | 68 | 0.0% | 127 | 0.0% | -0.017 | -0.009 |
| Other Self Harm | 193 | 0.1% | 290 | 0.1% | -0.023 | -0.008 |
| No moderate asthma exacerbations | 215,236 | 83.7% | 243,190 | 82.6% | 1.106 | 0.030 |
| One moderate asthma exacerbation | 36,784 | 14.3% | 44,977 | 15.3% | -0.971 | -0.027 |
| Two or more moderate asthma | 5,116 | 2.0% | 6,255 | 2.1% | -0.135 | -0.010 |
| No severe asthma exacerbations | 254,830 | 99.1% | 291,423 | 99.0% | 0.122 | 0.013 |
| One severe asthma exacerbation | 2,180 | 0.8% | 2,893 | 1.0% | -0.135 | -0.014 |
| Two or more severe asthma exacerbations | 126 | 0.0% | 106 | 0.0% | 0.013 | 0.006 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 60,020 | 23.3% | 72,967 | 24.8% | -1.441 | -0.034 |
| Antipsychotics | 17,884 | 7.0% | 28,580 | 9.7% | -2.752 | -0.100 |
| Anxiolytics Hypnotics | 56,405 | 21.9% | 63,986 | 21.7% | 0.203 | 0.005 |
| Lithium Other Mood Stabilizers | 20,505 | 8.0% | 27,553 | 9.4% | -1.384 | -0.049 |
| Antidepressants | 78,747 | 30.6% | 94,171 | 32.0% | -1.360 | -0.029 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 9.6 | 11.2 | 10.1 | 12.5 | -0.445 | -0.037 |
| Mean number of emergency room | 0.6 | 1.5 | 0.7 | 1.8 | -0.158 | -0.095 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.015 | -0.035 |
| Mean number of other ambulatory encounters | 2.6 | 9.4 | 3.6 | 12.4 | -0.938 | -0.085 |
| Mean number of filled prescriptions | 15.7 | 15.1 | 16.7 | 16.5 | -1.055 | -0.067 |
| Mean number of generics dispensed | 7.9 | 5.1 | 7.9 | 5.1 | 0.044 | 0.009 |
| Mean number of unique drug classes dispensed | 7.5 | 4.6 | 7.5 | 4.6 | -0.029 | -0.006 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.3 | -0.006 | -0.024 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.5 | 0.2 | 0.5 | -0.022 | -0.043 |

Table 1i. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of outpatient visits for respiratory disorders | 2.1 | 3.2 | 1.6 | 2.7 | 0.455 | 0.154 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1j. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 257,098 | N/A | 247,509 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 40.3 | 8.4 | 40.4 | 8.5 | -0.002 | -0.000 |
| Age | | | | | | |
| 10-24 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 25-54 years | 257,098 | 100.0% | 247,509 | 100.0% | 0.000 | NaN |
| ≥ 55 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Sex | | | | | | |
| Female | 181,325 | 70.5% | 173,813 | 70.2% | 0.303 | 0.007 |
| Male | 75,773 | 29.5% | 73,697 | 29.8% | -0.303 | -0.007 |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 1,423 | 0.6% | 1,561 | 0.6% | -0.077 | -0.010 |
| Asian | 4,290 | 1.7% | 3,969 | 1.6% | 0.065 | 0.005 |
| Black or African American | 24,380 | 9.5% | 22,652 | 9.2% | 0.331 | 0.012 |
| Multi-racial | 1,158 | 0.5% | 1,153 | 0.5% | -0.016 | -0.002 |
| Native Hawaiian or Other Pacific Islander | 405 | 0.2% | 556 | 0.2% | -0.067 | -0.015 |
| Unknown | 170,992 | 66.5% | 164,596 | 66.5% | 0.008 | 0.000 |
| White | 54,450 | 21.2% | 53,022 | 21.4% | -0.243 | -0.007 |
| Hispanic origin | | | | | | |
| Yes | 17,124 | 6.7% | 16,753 | 6.8% | -0.108 | -0.005 |
| No | 74,363 | 28.9% | 71,058 | 28.7% | 0.215 | 0.008 |
| Unknown | 165,611 | 64.4% | 159,698 | 64.5% | -0.106 | -0.005 |
| Year | | | | | | |
| 2015 | 9,809 | 3.8% | 9,894 | 4.0% | -0.182 | -0.009 |
| 2016 | 48,273 | 18.8% | 47,145 | 19.0% | -0.271 | -0.007 |
| 2017 | 55,347 | 21.5% | 53,421 | 21.6% | -0.056 | -0.001 |
| 2018 | 53,232 | 20.7% | 50,603 | 20.4% | 0.260 | 0.007 |
| 2019 | 29,841 | 11.6% | 27,945 | 11.3% | 0.316 | 0.010 |

Table 1j. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2020 | 28,155 | 11.0% | 27,181 | 11.0% | -0.031 | -0.001 |
| 2021 | 23,586 | 9.2% | 22,778 | 9.2% | -0.029 | -0.001 |
| 2022 | 8,855 | 3.4% | 8,542 | 3.5% | -0.007 | -0.000 |
| Pre-boxed warning | 201,238 | 78.3% | 193,525 | 78.2% | 0.084 | 0.002 |
| Post-boxed warning | 55,860 | 21.7% | 53,984 | 21.8% | -0.084 | -0.002 |
| Seasonality | | | | | | |
| Winter | 59,051 | 23.0% | 57,806 | 23.4% | -0.387 | -0.009 |
| Spring | 75,181 | 29.2% | 70,197 | 28.4% | 0.881 | 0.019 |
| Summer | 55,297 | 21.5% | 53,051 | 21.4% | 0.074 | 0.002 |
| Autumn | 67,569 | 26.3% | 66,456 | 26.8% | -0.568 | -0.013 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.4 | 1.1 | 1.4 | 1.1 | -0.002 | -0.001 |
| Psychiatric History | 143,306 | 55.7% | 136,908 | 55.3% | 0.425 | 0.009 |
| Psychiatric Drug Dispensings ⁶ | 107,748 | 41.9% | 102,582 | 41.4% | 0.463 | 0.010 |
| Self Harm Encounter ⁶ | 697 | 0.3% | 631 | 0.3% | 0.016 | 0.003 |
| Encounter for Other Psychiatric Event ⁶ | 120,657 | 46.9% | 115,308 | 46.6% | 0.343 | 0.007 |
| Asthma Emergency Encounter | 31,673 | 12.3% | 30,138 | 12.2% | 0.143 | 0.004 |
| Asthma Inpatient Encounter | 937 | 0.4% | 908 | 0.4% | -0.003 | -0.000 |
| Asthma Outpatient Encounter | 245,663 | 95.6% | 237,326 | 95.9% | -0.333 | -0.017 |
| Oral Corticosteroid Dispensing | 78,166 | 30.4% | 74,954 | 30.3% | 0.120 | 0.003 |
| Use of Other Asthma Medication | 171,149 | 66.6% | 169,930 | 68.7% | -2.086 | -0.045 |
| Allergic Rhinitis | 109,207 | 42.5% | 99,032 | 40.0% | 2.466 | 0.051 |
| Anxiety | 60,522 | 23.5% | 57,627 | 23.3% | 0.258 | 0.006 |
| Depression | 43,785 | 17.0% | 41,970 | 17.0% | 0.073 | 0.002 |
| Sleep Disorder | 38,525 | 15.0% | 36,165 | 14.6% | 0.373 | 0.011 |
| Substance Abuse | 13,257 | 5.2% | 13,037 | 5.3% | -0.111 | -0.005 |
| Poisoning | 630 | 0.2% | 642 | 0.3% | -0.014 | -0.003 |

Table 1j. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Suffocation | 12 | 0.0% | 9 | 0.0% | 0.001 | 0.002 |
| Suicide Attempt | 364 | 0.1% | 336 | 0.1% | 0.006 | 0.002 |
| Toxicity | 67 | 0.0% | 71 | 0.0% | -0.003 | -0.002 |
| Other Self Harm | 193 | 0.1% | 185 | 0.1% | 0.000 | 0.000 |
| No moderate asthma exacerbations | 215,206 | 83.7% | 205,659 | 83.1% | 0.614 | 0.017 |
| One moderate asthma exacerbation | 36,777 | 14.3% | 36,893 | 14.9% | -0.601 | -0.017 |
| Two or more moderate asthma | 5,115 | 2.0% | 4,957 | 2.0% | -0.013 | -0.001 |
| No severe asthma exacerbations | 254,792 | 99.1% | 245,214 | 99.1% | 0.030 | 0.003 |
| One severe asthma exacerbation | 2,180 | 0.8% | 2,185 | 0.9% | -0.035 | -0.004 |
| Two or more severe asthma exacerbations | 126 | 0.0% | 111 | 0.0% | 0.004 | 0.002 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 59,995 | 23.3% | 56,905 | 23.0% | 0.345 | 0.008 |
| Antipsychotics | 17,876 | 7.0% | 17,399 | 7.0% | -0.077 | -0.003 |
| Anxiolytics Hypnotics | 56,380 | 21.9% | 53,575 | 21.6% | 0.284 | 0.007 |
| Lithium Other Mood Stabilizers | 20,498 | 8.0% | 19,771 | 8.0% | -0.015 | -0.001 |
| Antidepressants | 78,728 | 30.6% | 75,218 | 30.4% | 0.232 | 0.005 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 9.6 | 11.2 | 9.7 | 10.8 | -0.085 | -0.008 |
| Mean number of emergency room | 0.6 | 1.5 | 0.6 | 1.5 | -0.004 | -0.002 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.000 | -0.001 |
| Mean number of other ambulatory encounters | 2.6 | 9.4 | 2.7 | 9.4 | -0.090 | -0.010 |
| Mean number of filled prescriptions | 15.7 | 15.1 | 15.6 | 15.0 | 0.066 | 0.004 |
| Mean number of generics dispensed | 7.9 | 5.1 | 7.8 | 5.2 | 0.093 | 0.018 |
| Mean number of unique drug classes dispensed | 7.5 | 4.5 | 7.4 | 4.6 | 0.072 | 0.016 |

Table 1j. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.001 | -0.003 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.5 | 0.1 | 0.5 | -0.001 | -0.002 |
| Mean number of outpatient visits for respiratory disorders | 2.1 | 3.1 | 2.1 | 3.1 | 0.009 | 0.003 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1k. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 287,228 | 100.0% | 253,066 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 69.6 | 7.3 | 69.0 | 7.5 | 0.535 | 0.072 |
| Age | | | | | | |
| 10-24 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 25-54 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| ≥ 55 years | 287,228 | 100.0% | 253,066 | 100.0% | 0.000 | NaN |
| Sex | | | | | | |
| Female | 212,416 | 74.0% | 180,941 | 71.5% | 2.454 | 0.055 |
| Male | 74,812 | 26.0% | 72,125 | 28.5% | -2.454 | -0.055 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 1,343 | 0.5% | 1,533 | 0.6% | -0.138 | -0.019 |
| Asian | 8,480 | 3.0% | 6,062 | 2.4% | 0.557 | 0.035 |
| Black or African American | 27,029 | 9.4% | 22,157 | 8.8% | 0.655 | 0.023 |
| Multi-racial | 306 | 0.1% | 273 | 0.1% | -0.001 | -0.000 |
| Native Hawaiian or Other Pacific Islander | 562 | 0.2% | 509 | 0.2% | -0.005 | -0.001 |
| Unknown | 73,839 | 25.7% | 72,526 | 28.7% | -2.951 | -0.066 |
| White | 175,669 | 61.2% | 150,006 | 59.3% | 1.885 | 0.039 |
| Hispanic origin | | | | | | |
| Yes | 8,884 | 3.1% | 10,042 | 4.0% | -0.875 | -0.047 |
| No | 203,499 | 70.8% | 172,272 | 68.1% | 2.775 | 0.060 |
| Unknown | 74,845 | 26.1% | 70,752 | 28.0% | -1.900 | -0.043 |
| Year | | | | | | |
| 2015 | 9,614 | 3.3% | 12,650 | 5.0% | -1.652 | -0.083 |
| 2016 | 45,009 | 15.7% | 49,760 | 19.7% | -3.993 | -0.105 |
| 2017 | 48,768 | 17.0% | 48,666 | 19.2% | -2.252 | -0.059 |
| 2018 | 49,226 | 17.1% | 43,809 | 17.3% | -0.173 | -0.005 |

Table 1k. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2019 | 47,409 | 16.5% | 33,651 | 13.3% | 3.208 | 0.090 |
| 2020 | 40,088 | 14.0% | 30,351 | 12.0% | 1.964 | 0.058 |
| 2021 | 37,111 | 12.9% | 26,800 | 10.6% | 2.330 | 0.072 |
| 2022 | 10,003 | 3.5% | 7,379 | 2.9% | 0.567 | 0.032 |
| Pre-boxed warning | 207,852 | 72.4% | 194,322 | 76.8% | -4.422 | -0.102 |
| Post-boxed warning | 79,376 | 27.6% | 58,744 | 23.2% | 4.422 | 0.102 |
| Seasonality | | | | | | |
| Winter | 71,687 | 25.0% | 68,179 | 26.9% | -1.983 | -0.045 |
| Spring | 79,950 | 27.8% | 59,300 | 23.4% | 4.402 | 0.101 |
| Summer | 61,411 | 21.4% | 52,837 | 20.9% | 0.502 | 0.012 |
| Autumn | 74,180 | 25.8% | 72,750 | 28.7% | -2.921 | -0.066 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 2.0 | 2.0 | 2.0 | 2.1 | 0.004 | 0.002 |
| Psychiatric History | 173,548 | 60.4% | 147,710 | 58.4% | 2.054 | 0.042 |
| Psychiatric Drug Dispensings ⁵ | 130,154 | 45.3% | 111,691 | 44.1% | 1.179 | 0.024 |
| Self Harm Encounter ⁵ | 147 | 0.1% | 158 | 0.1% | -0.011 | -0.005 |
| Encounter for Other Psychiatric Event ⁵ | 139,404 | 48.5% | 117,427 | 46.4% | 2.133 | 0.043 |
| Asthma Emergency Encounter | 20,731 | 7.2% | 20,129 | 8.0% | -0.736 | -0.028 |
| Asthma Inpatient Encounter | 901 | 0.3% | 739 | 0.3% | 0.022 | 0.004 |
| Asthma Outpatient Encounter | 275,184 | 95.8% | 243,315 | 96.1% | -0.340 | -0.017 |
| Oral Corticosteroid Dispensing | 88,229 | 30.7% | 69,296 | 27.4% | 3.335 | 0.074 |
| Use of Other Asthma Medication | 137,286 | 47.8% | 163,077 | 64.4% | -16.644 | -0.340 |
| Allergic Rhinitis | 122,760 | 42.7% | 57,425 | 22.7% | 20.048 | 0.437 |
| Anxiety | 55,389 | 19.3% | 44,948 | 17.8% | 1.523 | 0.039 |
| Depression | 51,063 | 17.8% | 44,708 | 17.7% | 0.111 | 0.003 |
| Sleep Disorder | 70,159 | 24.4% | 54,115 | 21.4% | 3.042 | 0.072 |

Table 1k. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Substance Abuse | 8,355 | 2.9% | 8,798 | 3.5% | -0.568 | -0.032 |
| Poisoning | 142 | 0.0% | 168 | 0.1% | -0.017 | -0.007 |
| Suffocation | 1 | 0.0% | 0 | 0.0% | NaN | NaN |
| Suicide Attempt | 80 | 0.0% | 73 | 0.0% | -0.001 | -0.001 |
| Toxicity | 31 | 0.0% | 23 | 0.0% | 0.002 | 0.002 |
| Other Self Harm | 36 | 0.0% | 35 | 0.0% | -0.001 | -0.001 |
| No moderate asthma exacerbations | 239,143 | 83.3% | 213,809 | 84.5% | -1.229 | -0.033 |
| One moderate asthma exacerbation | 41,514 | 14.5% | 34,419 | 13.6% | 0.853 | 0.025 |
| Two or more moderate asthma | 6,571 | 2.3% | 4,838 | 1.9% | 0.376 | 0.026 |
| No severe asthma exacerbations | 284,304 | 99.0% | 250,294 | 98.9% | 0.077 | 0.008 |
| One severe asthma exacerbation | 2,838 | 1.0% | 2,714 | 1.1% | -0.084 | -0.008 |
| Two or more severe asthma exacerbations | 86 | 0.0% | 58 | 0.0% | 0.007 | 0.004 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 76,003 | 26.5% | 64,357 | 25.4% | 1.030 | 0.023 |
| Antipsychotics | 10,767 | 3.7% | 11,998 | 4.7% | -0.992 | -0.049 |
| Anxiolytics Hypnotics | 67,454 | 23.5% | 55,381 | 21.9% | 1.600 | 0.038 |
| Lithium Other Mood Stabilizers | 15,379 | 5.4% | 15,000 | 5.9% | -0.573 | -0.025 |
| Antidepressants | 96,624 | 33.6% | 84,167 | 33.3% | 0.381 | 0.008 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 13.3 | 12.3 | 12.7 | 12.4 | 0.533 | 0.043 |
| Mean number of emergency room | 0.3 | 0.9 | 0.4 | 1.0 | -0.024 | -0.026 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.006 | -0.015 |
| Mean number of other ambulatory encounters | 3.0 | 7.8 | 3.5 | 10.3 | -0.471 | -0.052 |
| Mean number of filled prescriptions | 19.8 | 15.5 | 20.5 | 16.7 | -0.726 | -0.045 |
| Mean number of generics dispensed | 9.7 | 5.1 | 9.3 | 5.0 | 0.368 | 0.073 |

Table 1k. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of unique drug classes dispensed | 9.2 | 4.6 | 9.0 | 4.5 | 0.222 | 0.049 |
| Mean number of inpatient visits for respiratory disorders | 0.1 | 0.3 | 0.1 | 0.3 | -0.006 | -0.019 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.006 | -0.014 |
| Mean number of outpatient visits for respiratory disorders | 2.7 | 3.7 | 2.2 | 3.3 | 0.550 | 0.157 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 11. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 287,144 | N/A | 275,968 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 69.6 | 7.3 | 69.6 | 7.4 | -0.017 | -0.002 |
| Age | | | | | | |
| 10-24 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 25-54 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| ≥ 55 years | 287,144 | 100.0% | 275,968 | 100.0% | 0.000 | NaN |
| Sex | | | | | | |
| Female | 212,348 | 74.0% | 203,283 | 73.7% | 0.290 | 0.007 |
| Male | 74,796 | 26.0% | 72,685 | 26.3% | -0.290 | -0.007 |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 1,343 | 0.5% | 1,425 | 0.5% | -0.048 | -0.007 |
| Asian | 8,475 | 3.0% | 5,678 | 2.1% | 0.894 | 0.058 |
| Black or African American | 27,010 | 9.4% | 21,913 | 7.9% | 1.466 | 0.053 |
| Multi-racial | 305 | 0.1% | 315 | 0.1% | -0.008 | -0.002 |
| Native Hawaiian or Other Pacific Islander | 562 | 0.2% | 481 | 0.2% | 0.021 | 0.005 |
| Unknown | 73,813 | 25.7% | 71,612 | 25.9% | -0.243 | -0.009 |
| White | 175,636 | 61.2% | 174,544 | 63.2% | -2.081 | -0.055 |
| Hispanic origin | | | | | | |
| Yes | 8,876 | 3.1% | 8,067 | 2.9% | 0.168 | 0.010 |
| No | 203,448 | 70.9% | 194,613 | 70.5% | 0.332 | 0.014 |
| Unknown | 74,820 | 26.1% | 73,288 | 26.6% | -0.500 | -0.026 |
| Year | | | | | | |
| 2015 | 9,613 | 3.3% | 9,962 | 3.6% | -0.262 | -0.014 |
| 2016 | 45,006 | 15.7% | 44,874 | 16.3% | -0.587 | -0.016 |
| 2017 | 48,750 | 17.0% | 47,454 | 17.2% | -0.218 | -0.006 |
| 2018 | 49,202 | 17.1% | 46,836 | 17.0% | 0.163 | 0.004 |
| 2019 | 47,386 | 16.5% | 44,022 | 16.0% | 0.551 | 0.015 |
| 2020 | 40,082 | 14.0% | 38,131 | 13.8% | 0.142 | 0.004 |

Table 11. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2021 | 37,105 | 12.9% | 35,213 | 12.8% | 0.162 | 0.005 |
| 2022 | 10,000 | 3.5% | 9,475 | 3.4% | 0.049 | 0.003 |
| Pre-boxed warning | 207,782 | 72.4% | 200,387 | 72.6% | -0.251 | -0.006 |
| Post-boxed warning | 79,362 | 27.6% | 75,581 | 27.4% | 0.251 | 0.006 |
| Seasonality | | | | | | |
| Winter | 71,676 | 25.0% | 69,398 | 25.1% | -0.186 | -0.004 |
| Spring | 79,909 | 27.8% | 74,796 | 27.1% | 0.726 | 0.016 |
| Summer | 61,388 | 21.4% | 59,339 | 21.5% | -0.123 | -0.003 |
| Autumn | 74,171 | 25.8% | 72,435 | 26.2% | -0.417 | -0.010 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 2.0 | 2.0 | 2.0 | 2.0 | 0.000 | 0.000 |
| Psychiatric History | 173,477 | 60.4% | 165,228 | 59.9% | 0.543 | 0.011 |
| Psychiatric Drug Dispensings ⁶ | 130,087 | 45.3% | 124,206 | 45.0% | 0.296 | 0.006 |
| Self Harm Encounter ⁶ | 147 | 0.1% | 131 | 0.0% | 0.004 | 0.002 |
| Encounter for Other Psychiatric Event ⁶ | 139,348 | 48.5% | 132,087 | 47.9% | 0.666 | 0.013 |
| Asthma Emergency Encounter | 20,723 | 7.2% | 19,724 | 7.1% | 0.070 | 0.003 |
| Asthma Inpatient Encounter | 898 | 0.3% | 879 | 0.3% | -0.006 | -0.001 |
| Asthma Outpatient Encounter | 275,111 | 95.8% | 265,254 | 96.1% | -0.308 | -0.016 |
| Oral Corticosteroid Dispensing | 88,179 | 30.7% | 83,212 | 30.2% | 0.556 | 0.012 |
| Use of Other Asthma Medication | 137,269 | 47.8% | 136,575 | 49.5% | -1.684 | -0.034 |
| Allergic Rhinitis | 122,683 | 42.7% | 110,480 | 40.0% | 2.692 | 0.055 |
| Anxiety | 55,351 | 19.3% | 52,304 | 19.0% | 0.323 | 0.008 |
| Depression | 51,035 | 17.8% | 48,396 | 17.5% | 0.236 | 0.006 |
| Sleep Disorder | 70,131 | 24.4% | 66,019 | 23.9% | 0.501 | 0.012 |
| Substance Abuse | 8,347 | 2.9% | 7,886 | 2.9% | 0.049 | 0.003 |
| Poisoning | 142 | 0.0% | 131 | 0.0% | 0.002 | 0.001 |
| Suffocation | 1 | 0.0% | 0 | 0.0% | NaN | NaN |

Table 11. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Suicide Attempt | 80 | 0.0% | 59 | 0.0% | 0.006 | 0.004 |
| Toxicity | 31 | 0.0% | 17 | 0.0% | 0.005 | 0.005 |
| Other Self Harm | 36 | 0.0% | 28 | 0.0% | 0.002 | 0.002 |
| No moderate asthma exacerbations | 239,080 | 83.3% | 230,505 | 83.5% | -0.265 | -0.007 |
| One moderate asthma exacerbation | 41,496 | 14.5% | 39,602 | 14.4% | 0.101 | 0.003 |
| Two or more moderate asthma | 6,568 | 2.3% | 5,861 | 2.1% | 0.164 | 0.011 |
| No severe asthma exacerbations | 284,225 | 99.0% | 273,105 | 99.0% | 0.021 | 0.002 |
| One severe asthma exacerbation | 2,836 | 1.0% | 2,787 | 1.0% | -0.022 | -0.002 |
| Two or more severe asthma exacerbations | 83 | 0.0% | 76 | 0.0% | 0.001 | 0.001 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 75,951 | 26.5% | 71,700 | 26.0% | 0.469 | 0.011 |
| Antipsychotics | 10,759 | 3.7% | 10,510 | 3.8% | -0.062 | -0.003 |
| Anxiolytics Hypnotics | 67,400 | 23.5% | 64,006 | 23.2% | 0.279 | 0.007 |
| Lithium Other Mood Stabilizers | 15,368 | 5.4% | 14,964 | 5.4% | -0.070 | -0.003 |
| Antidepressants | 96,581 | 33.6% | 92,016 | 33.3% | 0.292 | 0.006 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 13.3 | 12.3 | 13.3 | 11.7 | -0.044 | -0.004 |
| Mean number of emergency room | 0.3 | 0.9 | 0.3 | 0.9 | 0.001 | 0.001 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.000 | -0.000 |
| Mean number of other ambulatory encounters | 3.0 | 7.8 | 3.1 | 8.1 | -0.043 | -0.005 |
| Mean number of filled prescriptions | 19.8 | 15.5 | 19.8 | 15.3 | -0.022 | -0.001 |
| Mean number of generics dispensed | 9.7 | 5.1 | 9.6 | 5.2 | 0.092 | 0.018 |
| Mean number of unique drug classes dispensed | 9.2 | 4.6 | 9.1 | 4.6 | 0.070 | 0.015 |
| Mean number of inpatient visits for respiratory disorders | 0.1 | 0.3 | 0.1 | 0.3 | -0.001 | -0.003 |

Table 11. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.000 | -0.001 |
| Mean number of outpatient visits for respiratory disorders | 2.7 | 3.7 | 2.7 | 3.8 | 0.022 | 0.006 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1m. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 366,756 | 100.0% | 484,391 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 39.7 | 15.7 | 32.9 | 15.9 | 6.757 | 0.429 |
| Age | | | | | | |
| 10-24 years | 139,281 | 38.0% | 252,748 | 52.2% | -14.202 | -0.288 |
| 25-54 years | 113,795 | 31.0% | 126,287 | 26.1% | 4.956 | 0.110 |
| ≥ 55 years | 113,680 | 31.0% | 105,356 | 21.8% | 9.246 | 0.211 |
| Sex | | | | | | |
| Female | 219,961 | 60.0% | 273,753 | 56.5% | 3.460 | 0.070 |
| Male | 146,795 | 40.0% | 210,638 | 43.5% | -3.460 | -0.070 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 2,125 | 0.6% | 3,847 | 0.8% | -0.215 | -0.026 |
| Asian | 10,460 | 2.9% | 13,781 | 2.8% | 0.007 | 0.000 |
| Black or African American | 40,995 | 11.2% | 63,077 | 13.0% | -1.844 | -0.057 |
| Multi-racial | 1,061 | 0.3% | 1,120 | 0.2% | 0.058 | 0.011 |
| Native Hawaiian or Other Pacific Islander | 795 | 0.2% | 2,164 | 0.4% | -0.230 | -0.040 |
| Unknown | 213,063 | 58.1% | 282,638 | 58.3% | -0.255 | -0.005 |
| White | 98,257 | 26.8% | 117,764 | 24.3% | 2.479 | 0.057 |
| Hispanic origin | | | | | | |
| Yes | 38,389 | 10.5% | 73,527 | 15.2% | -4.712 | -0.141 |
| No | 141,924 | 38.7% | 189,967 | 39.2% | -0.521 | -0.011 |
| Unknown | 186,443 | 50.8% | 220,897 | 45.6% | 5.233 | 0.105 |
| Year | | | | | | |
| 2015 | 15,456 | 4.2% | 25,241 | 5.2% | -0.997 | -0.047 |
| 2016 | 73,028 | 19.9% | 113,667 | 23.5% | -3.554 | -0.086 |
| 2017 | 84,999 | 23.2% | 130,717 | 27.0% | -3.810 | -0.088 |
| 2018 | 79,850 | 21.8% | 108,392 | 22.4% | -0.605 | -0.015 |
| 2019 | 40,339 | 11.0% | 35,999 | 7.4% | 3.567 | 0.124 |
| 2020 | 34,053 | 9.3% | 32,400 | 6.7% | 2.596 | 0.096 |
| 2021 | 29,079 | 7.9% | 27,760 | 5.7% | 2.198 | 0.087 |

Table 1m. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2022 | 9,952 | 2.7% | 10,215 | 2.1% | 0.605 | 0.039 |
| Pre-boxed warning | 300,131 | 81.8% | 420,266 | 86.8% | -4.928 | -0.136 |
| Post-boxed warning | 66,625 | 18.2% | 64,125 | 13.2% | 4.928 | 0.136 |
| Seasonality | | | | | | |
| Winter | 84,483 | 23.0% | 122,437 | 25.3% | -2.241 | -0.052 |
| Spring | 101,542 | 27.7% | 107,562 | 22.2% | 5.481 | 0.127 |
| Summer | 81,177 | 22.1% | 103,540 | 21.4% | 0.758 | 0.018 |
| Autumn | 99,554 | 27.1% | 150,852 | 31.1% | -3.998 | -0.088 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.2 | 1.0 | 1.1 | 0.8 | 0.030 | 0.033 |
| Psychiatric History | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Psychiatric Drug Dispensings ⁵ | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Self Harm Encounter ⁵ | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Encounter for Other Psychiatric Event ⁵ | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Asthma Emergency Encounter | 29,345 | 8.0% | 48,926 | 10.1% | -2.099 | -0.073 |
| Asthma Inpatient Encounter | 762 | 0.2% | 1,157 | 0.2% | -0.031 | -0.007 |
| Asthma Outpatient Encounter | 356,966 | 97.3% | 472,199 | 97.5% | -0.152 | -0.010 |
| Oral Corticosteroid Dispensing | 86,673 | 23.6% | 108,718 | 22.4% | 1.188 | 0.028 |
| Use of Other Asthma Medication | 240,264 | 65.5% | 387,216 | 79.9% | -14.428 | -0.328 |
| Allergic Rhinitis | 159,611 | 43.5% | 118,967 | 24.6% | 18.960 | 0.408 |
| Anxiety | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Depression | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Sleep Disorder | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Substance Abuse | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Poisoning | 182 | 0.0% | 337 | 0.1% | -0.020 | -0.008 |
| Suffocation | 3 | 0.0% | 6 | 0.0% | -0.000 | -0.001 |
| Suicide Attempt | 95 | 0.0% | 152 | 0.0% | -0.005 | -0.003 |
| Toxicity | 19 | 0.0% | 26 | 0.0% | -0.000 | -0.000 |

Table 1m. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Other Self Harm | 46 | 0.0% | 60 | 0.0% | 0.000 | 0.000 |
| No moderate asthma exacerbations | 315,935 | 86.1% | 412,779 | 85.2% | 0.927 | 0.026 |
| One moderate asthma exacerbation | 45,527 | 12.4% | 64,410 | 13.3% | -0.884 | -0.026 |
| Two or more moderate asthma | 5,294 | 1.4% | 7,202 | 1.5% | -0.043 | -0.004 |
| No severe asthma exacerbations | 365,007 | 99.5% | 481,260 | 99.4% | 0.169 | 0.023 |
| One severe asthma exacerbation | 1,706 | 0.5% | 3,089 | 0.6% | -0.173 | -0.023 |
| Two or more severe asthma exacerbations | 43 | 0.0% | 42 | 0.0% | 0.003 | 0.003 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 38,221 | 10.4% | 42,767 | 8.8% | 1.592 | 0.054 |
| Antipsychotics | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Anxiolytics Hypnotics | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Lithium Other Mood Stabilizers | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Antidepressants | 78 | 0.0% | 129 | 0.0% | -0.005 | -0.003 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 6.7 | 7.3 | 5.9 | 6.6 | 0.797 | 0.114 |
| Mean number of emergency room | 0.3 | 0.7 | 0.3 | 0.8 | -0.053 | -0.072 |
| Mean number of inpatient hospital encounters | 0.0 | 0.2 | 0.0 | 0.2 | -0.000 | -0.001 |
| Mean number of other ambulatory encounters | 1.2 | 4.3 | 1.3 | 5.0 | -0.049 | -0.010 |
| Mean number of filled prescriptions | 9.0 | 8.2 | 8.1 | 7.6 | 0.915 | 0.116 |
| Mean number of generics dispensed | 5.6 | 3.4 | 5.0 | 3.1 | 0.589 | 0.183 |
| Mean number of unique drug classes dispensed | 5.3 | 3.1 | 4.9 | 2.8 | 0.472 | 0.160 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.1 | 0.0 | 0.1 | -0.001 | -0.005 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.3 | 0.1 | 0.3 | -0.013 | -0.038 |
| Mean number of outpatient visits for respiratory disorders | 2.0 | 3.0 | 1.5 | 2.6 | 0.451 | 0.160 |

Table 1m. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--------------------------------------|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1n. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 366,686 | N/A | 354,802 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 39.7 | 15.7 | 39.5 | 16.8 | 0.175 | 0.011 |
| Age | | | | | | |
| 10-24 years | 139,278 | 38.0% | 143,485 | 40.4% | -2.458 | -0.059 |
| 25-54 years | 113,786 | 31.0% | 96,077 | 27.1% | 3.952 | 0.092 |
| ≥ 55 years | 113,622 | 31.0% | 115,240 | 32.5% | -1.494 | -0.046 |
| Sex | | | | | | |
| Female | 219,913 | 60.0% | 211,219 | 59.5% | 0.441 | 0.009 |
| Male | 146,773 | 40.0% | 143,583 | 40.5% | -0.441 | -0.009 |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 2,125 | 0.6% | 2,214 | 0.6% | -0.045 | -0.006 |
| Asian | 10,453 | 2.9% | 8,979 | 2.5% | 0.320 | 0.020 |
| Black or African American | 40,984 | 11.2% | 35,872 | 10.1% | 1.066 | 0.036 |
| Multi-racial | 1,061 | 0.3% | 949 | 0.3% | 0.022 | 0.004 |
| Native Hawaiian or Other Pacific Islander | 794 | 0.2% | 1,175 | 0.3% | -0.115 | -0.022 |
| Unknown | 213,037 | 58.1% | 208,425 | 58.7% | -0.646 | -0.018 |
| White | 98,232 | 26.8% | 97,187 | 27.4% | -0.603 | -0.017 |
| Hispanic origin | | | | | | |
| Yes | 38,379 | 10.5% | 38,852 | 11.0% | -0.484 | -0.017 |
| No | 141,884 | 38.7% | 134,847 | 38.0% | 0.687 | 0.021 |
| Unknown | 186,423 | 50.8% | 181,103 | 51.0% | -0.204 | -0.008 |
| Year | | | | | | |
| 2015 | 15,455 | 4.2% | 15,582 | 4.4% | -0.177 | -0.009 |
| 2016 | 73,020 | 19.9% | 71,971 | 20.3% | -0.371 | -0.009 |
| 2017 | 84,989 | 23.2% | 82,775 | 23.3% | -0.152 | -0.004 |
| 2018 | 79,838 | 21.8% | 76,338 | 21.5% | 0.257 | 0.006 |
| 2019 | 40,321 | 11.0% | 37,962 | 10.7% | 0.297 | 0.010 |
| 2020 | 34,046 | 9.3% | 32,836 | 9.3% | 0.030 | 0.001 |

Table 1n. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2021 | 29,066 | 7.9% | 27,844 | 7.8% | 0.079 | 0.003 |
| 2022 | 9,951 | 2.7% | 9,494 | 2.7% | 0.038 | 0.002 |
| Pre-boxed warning | 300,079 | 81.8% | 290,733 | 81.9% | -0.107 | -0.003 |
| Post-boxed warning | 66,607 | 18.2% | 64,069 | 18.1% | 0.107 | 0.003 |
| Seasonality | | | | | | |
| Winter | 84,467 | 23.0% | 82,701 | 23.3% | -0.274 | -0.007 |
| Spring | 101,513 | 27.7% | 95,640 | 27.0% | 0.728 | 0.016 |
| Summer | 81,163 | 22.1% | 78,589 | 22.2% | -0.016 | -0.000 |
| Autumn | 99,543 | 27.1% | 97,871 | 27.6% | -0.438 | -0.010 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.2 | 1.0 | 1.2 | 1.0 | -0.002 | -0.002 |
| Psychiatric History | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Psychiatric Drug Dispensings ⁶ | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Self Harm Encounter ⁶ | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Encounter for Other Psychiatric Event ⁶ | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Asthma Emergency Encounter | 29,337 | 8.0% | 28,511 | 8.0% | -0.035 | -0.001 |
| Asthma Inpatient Encounter | 760 | 0.2% | 742 | 0.2% | -0.002 | -0.000 |
| Asthma Outpatient Encounter | 356,905 | 97.3% | 345,906 | 97.5% | -0.160 | -0.010 |
| Oral Corticosteroid Dispensing | 86,635 | 23.6% | 82,937 | 23.4% | 0.251 | 0.006 |
| Use of Other Asthma Medication | 240,244 | 65.5% | 238,054 | 67.1% | -1.577 | -0.035 |
| Allergic Rhinitis | 159,549 | 43.5% | 146,303 | 41.2% | 2.276 | 0.046 |
| Anxiety | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Depression | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Sleep Disorder | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Substance Abuse | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Poisoning | 182 | 0.0% | 190 | 0.1% | -0.004 | -0.002 |
| Suffocation | 3 | 0.0% | 3 | 0.0% | -0.000 | -0.000 |
| Suicide Attempt | 95 | 0.0% | 83 | 0.0% | 0.002 | 0.002 |

Table 1n. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Toxicity | 19 | 0.0% | 15 | 0.0% | 0.001 | 0.001 |
| Other Self Harm | 46 | 0.0% | 34 | 0.0% | 0.003 | 0.003 |
| No moderate asthma exacerbations | 315,886 | 86.1% | 303,776 | 85.6% | 0.528 | 0.015 |
| One moderate asthma exacerbation | 45,509 | 12.4% | 45,704 | 12.9% | -0.471 | -0.014 |
| Two or more moderate asthma | 5,291 | 1.4% | 5,323 | 1.5% | -0.057 | -0.005 |
| No severe asthma exacerbations | 364,941 | 99.5% | 353,047 | 99.5% | 0.019 | 0.003 |
| One severe asthma exacerbation | 1,706 | 0.5% | 1,721 | 0.5% | -0.020 | -0.003 |
| Two or more severe asthma exacerbations | 39 | 0.0% | 34 | 0.0% | 0.001 | 0.001 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 38,192 | 10.4% | 36,427 | 10.3% | 0.149 | 0.005 |
| Antipsychotics | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Anxiolytics Hypnotics | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Lithium Other Mood Stabilizers | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Antidepressants | 76 | 0.0% | 69 | 0.0% | 0.001 | 0.001 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 6.7 | 7.3 | 6.7 | 6.9 | -0.001 | -0.000 |
| Mean number of emergency room | 0.3 | 0.7 | 0.3 | 0.7 | -0.001 | -0.001 |
| Mean number of inpatient hospital encounters | 0.0 | 0.2 | 0.0 | 0.2 | -0.000 | -0.001 |
| Mean number of other ambulatory encounters | 1.2 | 4.3 | 1.3 | 4.4 | -0.041 | -0.009 |
| Mean number of filled prescriptions | 9.0 | 8.1 | 8.9 | 7.9 | 0.065 | 0.008 |
| Mean number of generics dispensed | 5.6 | 3.4 | 5.5 | 3.4 | 0.076 | 0.022 |
| Mean number of unique drug classes dispensed | 5.3 | 3.1 | 5.3 | 3.1 | 0.061 | 0.020 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.1 | 0.0 | 0.1 | -0.000 | -0.002 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.3 | 0.1 | 0.3 | -0.000 | -0.001 |

Table 1n. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of outpatient visits for respiratory disorders | 2.0 | 3.0 | 1.9 | 3.0 | 0.026 | 0.009 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1o. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 385,474 | 100.0% | 438,966 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 49.4 | 15.5 | 43.0 | 16.6 | 6.402 | 0.399 |
| Age | | | | | | |
| 10-24 years | 68,585 | 17.8% | 123,121 | 28.0% | -10.256 | -0.246 |
| 25-54 years | 143,341 | 37.2% | 168,135 | 38.3% | -1.117 | -0.023 |
| ≥ 55 years | 173,548 | 45.0% | 147,710 | 33.6% | 11.372 | 0.234 |
| Sex | | | | | | |
| Female | 277,016 | 71.9% | 294,831 | 67.2% | 4.699 | 0.102 |
| Male | 108,458 | 28.1% | 144,135 | 32.8% | -4.699 | -0.102 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 2,516 | 0.7% | 4,047 | 0.9% | -0.269 | -0.030 |
| Asian | 5,532 | 1.4% | 5,900 | 1.3% | 0.091 | 0.008 |
| Black or African American | 40,721 | 10.6% | 53,690 | 12.2% | -1.667 | -0.052 |
| Multi-racial | 851 | 0.2% | 848 | 0.2% | 0.028 | 0.006 |
| Native Hawaiian or Other Pacific Islander | 553 | 0.1% | 1,071 | 0.2% | -0.101 | -0.023 |
| Unknown | 165,544 | 42.9% | 190,898 | 43.5% | -0.543 | -0.011 |
| White | 169,757 | 44.0% | 182,512 | 41.6% | 2.461 | 0.050 |
| Hispanic origin | | | | | | |
| Yes | 23,630 | 6.1% | 40,953 | 9.3% | -3.199 | -0.120 |
| No | 207,436 | 53.8% | 236,965 | 54.0% | -0.169 | -0.003 |
| Unknown | 154,408 | 40.1% | 161,048 | 36.7% | 3.369 | 0.069 |
| Year | | | | | | |
| 2015 | 13,684 | 3.5% | 21,445 | 4.9% | -1.335 | -0.066 |
| 2016 | 68,958 | 17.9% | 96,341 | 21.9% | -4.058 | -0.102 |
| 2017 | 79,065 | 20.5% | 107,580 | 24.5% | -3.996 | -0.096 |
| 2018 | 76,708 | 19.9% | 94,003 | 21.4% | -1.515 | -0.037 |

Table 1o. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2019 | 50,432 | 13.1% | 38,738 | 8.8% | 4.258 | 0.137 |
| 2020 | 43,904 | 11.4% | 36,660 | 8.4% | 3.038 | 0.102 |
| 2021 | 40,366 | 10.5% | 33,298 | 7.6% | 2.886 | 0.101 |
| 2022 | 12,357 | 3.2% | 10,901 | 2.5% | 0.722 | 0.043 |
| Pre-boxed warning | 296,859 | 77.0% | 364,733 | 83.1% | -6.078 | -0.153 |
| Post-boxed warning | 88,615 | 23.0% | 74,233 | 16.9% | 6.078 | 0.153 |
| Seasonality | | | | | | |
| Winter | 89,972 | 23.3% | 110,212 | 25.1% | -1.767 | -0.041 |
| Spring | 108,041 | 28.0% | 99,094 | 22.6% | 5.454 | 0.126 |
| Summer | 85,587 | 22.2% | 95,510 | 21.8% | 0.445 | 0.011 |
| Autumn | 101,874 | 26.4% | 134,150 | 30.6% | -4.132 | -0.092 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.9 | 1.8 | 1.9 | 1.6 | 0.066 | 0.039 |
| Psychiatric History | 385,474 | 100.0% | 438,966 | 100.0% | 0.000 | NaN |
| Psychiatric Drug Dispensings ⁵ | 281,045 | 72.9% | 312,136 | 71.1% | 1.802 | 0.040 |
| Self Harm Encounter ⁵ | 1,394 | 0.4% | 2,455 | 0.6% | -0.198 | -0.029 |
| Encounter for Other Psychiatric Event ⁵ | 320,270 | 83.1% | 369,493 | 84.2% | -1.089 | -0.029 |
| Asthma Emergency Encounter | 47,151 | 12.2% | 61,564 | 14.0% | -1.793 | -0.053 |
| Asthma Inpatient Encounter | 1,489 | 0.4% | 1,748 | 0.4% | -0.012 | -0.002 |
| Asthma Outpatient Encounter | 363,681 | 94.3% | 416,091 | 94.8% | -0.442 | -0.020 |
| Oral Corticosteroid Dispensing | 122,107 | 31.7% | 125,095 | 28.5% | 3.179 | 0.069 |
| Use of Other Asthma Medication | 225,167 | 58.4% | 336,222 | 76.6% | -18.181 | -0.396 |
| Allergic Rhinitis | 164,732 | 42.7% | 95,462 | 21.7% | 20.988 | 0.461 |
| Anxiety | 136,634 | 35.4% | 150,455 | 34.3% | 1.171 | 0.025 |
| Depression | 110,424 | 28.6% | 126,090 | 28.7% | -0.078 | -0.002 |
| Sleep Disorder | 115,489 | 30.0% | 101,040 | 23.0% | 6.943 | 0.158 |
| Substance Abuse | 24,457 | 6.3% | 39,317 | 9.0% | -2.612 | -0.098 |

Table 1o. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Poisoning | 1,136 | 0.3% | 2,133 | 0.5% | -0.191 | -0.031 |
| Suffocation | 27 | 0.0% | 40 | 0.0% | -0.002 | -0.002 |
| Suicide Attempt | 637 | 0.2% | 1,098 | 0.3% | -0.085 | -0.019 |
| Toxicity | 137 | 0.0% | 249 | 0.1% | -0.021 | -0.010 |
| Other Self Harm | 340 | 0.1% | 570 | 0.1% | -0.042 | -0.013 |
| No moderate asthma exacerbations | 320,185 | 83.1% | 366,478 | 83.5% | -0.424 | -0.011 |
| One moderate asthma exacerbation | 56,716 | 14.7% | 63,709 | 14.5% | 0.200 | 0.006 |
| Two or more moderate asthma | 8,573 | 2.2% | 8,779 | 2.0% | 0.224 | 0.016 |
| No severe asthma exacerbations | 381,002 | 98.8% | 433,116 | 98.7% | 0.173 | 0.016 |
| One severe asthma exacerbation | 4,266 | 1.1% | 5,646 | 1.3% | -0.180 | -0.017 |
| Two or more severe asthma exacerbations | 206 | 0.1% | 204 | 0.0% | 0.007 | 0.003 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 110,833 | 28.8% | 115,165 | 26.2% | 2.517 | 0.056 |
| Antipsychotics | 34,673 | 9.0% | 52,333 | 11.9% | -2.927 | -0.096 |
| Anxiolytics Hypnotics | 135,137 | 35.1% | 136,945 | 31.2% | 3.860 | 0.082 |
| Lithium Other Mood Stabilizers | 40,602 | 10.5% | 51,582 | 11.8% | -1.218 | -0.039 |
| Antidepressants | 196,466 | 51.0% | 213,283 | 48.6% | 2.380 | 0.048 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 13.5 | 12.9 | 13.2 | 13.8 | 0.236 | 0.018 |
| Mean number of emergency room | 0.6 | 1.5 | 0.7 | 1.7 | -0.128 | -0.080 |
| Mean number of inpatient hospital encounters | 0.1 | 0.5 | 0.1 | 0.5 | -0.008 | -0.016 |
| Mean number of other ambulatory encounters | 4.1 | 11.8 | 5.5 | 16.2 | -1.452 | -0.102 |
| Mean number of filled prescriptions | 20.6 | 16.8 | 20.5 | 17.8 | 0.183 | 0.011 |
| Mean number of generics dispensed | 9.9 | 5.4 | 9.2 | 5.2 | 0.703 | 0.133 |
| Mean number of unique drug classes dispensed | 9.3 | 4.8 | 8.8 | 4.7 | 0.548 | 0.116 |

Table 1o. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of inpatient visits for respiratory disorders | 0.1 | 0.3 | 0.1 | 0.3 | -0.003 | -0.010 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.5 | 0.2 | 0.5 | -0.016 | -0.033 |
| Mean number of outpatient visits for respiratory disorders | 2.5 | 3.5 | 1.9 | 3.0 | 0.603 | 0.185 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1p. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 385,425 | N/A | 369,811 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 49.4 | 15.5 | 49.3 | 16.4 | 0.138 | 0.009 |
| Age | | | | | | |
| 10-24 years | 68,584 | 17.8% | 72,762 | 19.7% | -1.881 | -0.055 |
| 25-54 years | 143,321 | 37.2% | 127,026 | 34.3% | 2.836 | 0.062 |
| ≥ 55 years | 173,520 | 45.0% | 170,022 | 46.0% | -0.955 | -0.024 |
| Sex | | | | | | |
| Female | 276,972 | 71.9% | 264,456 | 71.5% | 0.350 | 0.008 |
| Male | 108,453 | 28.1% | 105,354 | 28.5% | -0.350 | -0.008 |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 2,516 | 0.7% | 2,519 | 0.7% | -0.028 | -0.003 |
| Asian | 5,530 | 1.4% | 4,531 | 1.2% | 0.210 | 0.018 |
| Black or African American | 40,710 | 10.6% | 36,082 | 9.8% | 0.806 | 0.027 |
| Multi-racial | 851 | 0.2% | 815 | 0.2% | 0.000 | 0.000 |
| Native Hawaiian or Other Pacific Islander | 553 | 0.1% | 626 | 0.2% | -0.026 | -0.007 |
| Unknown | 165,527 | 42.9% | 160,401 | 43.4% | -0.427 | -0.013 |
| White | 169,738 | 44.0% | 164,838 | 44.6% | -0.534 | -0.014 |
| Hispanic origin | | | | | | |
| Yes | 23,627 | 6.1% | 23,383 | 6.3% | -0.193 | -0.008 |
| No | 207,407 | 53.8% | 197,205 | 53.3% | 0.487 | 0.017 |
| Unknown | 154,391 | 40.1% | 149,222 | 40.4% | -0.294 | -0.013 |
| Year | | | | | | |
| 2015 | 13,683 | 3.6% | 13,932 | 3.8% | -0.217 | -0.012 |
| 2016 | 68,954 | 17.9% | 67,869 | 18.4% | -0.462 | -0.012 |
| 2017 | 79,058 | 20.5% | 76,443 | 20.7% | -0.159 | -0.004 |
| 2018 | 76,696 | 19.9% | 72,842 | 19.7% | 0.202 | 0.005 |
| 2019 | 50,418 | 13.1% | 46,756 | 12.6% | 0.438 | 0.013 |

Table 1p. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2020 | 43,897 | 11.4% | 41,723 | 11.3% | 0.107 | 0.003 |
| 2021 | 40,362 | 10.5% | 38,470 | 10.4% | 0.069 | 0.002 |
| 2022 | 12,357 | 3.2% | 11,777 | 3.2% | 0.022 | 0.001 |
| Pre-boxed warning | 296,821 | 77.0% | 285,298 | 77.1% | -0.136 | -0.003 |
| Post-boxed warning | 88,604 | 23.0% | 84,513 | 22.9% | 0.136 | 0.003 |
| Seasonality | | | | | | |
| Winter | 89,966 | 23.3% | 87,281 | 23.6% | -0.259 | -0.006 |
| Spring | 108,014 | 28.0% | 100,760 | 27.2% | 0.778 | 0.017 |
| Summer | 85,578 | 22.2% | 82,227 | 22.2% | -0.031 | -0.001 |
| Autumn | 101,867 | 26.4% | 99,543 | 26.9% | -0.487 | -0.011 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.9 | 1.8 | 1.9 | 1.7 | -0.003 | -0.002 |
| Psychiatric History | 385,425 | 100.0% | 369,811 | 100.0% | 0.000 | NaN |
| Psychiatric Drug Dispensings ⁶ | 281,003 | 72.9% | 269,059 | 72.8% | 0.151 | 0.003 |
| Self Harm Encounter ⁶ | 1,394 | 0.4% | 1,361 | 0.4% | -0.006 | -0.001 |
| Encounter for Other Psychiatric Event ⁶ | 320,225 | 83.1% | 306,597 | 82.9% | 0.177 | 0.005 |
| Asthma Emergency Encounter | 47,138 | 12.2% | 44,814 | 12.1% | 0.112 | 0.003 |
| Asthma Inpatient Encounter | 1,489 | 0.4% | 1,492 | 0.4% | -0.017 | -0.003 |
| Asthma Outpatient Encounter | 363,647 | 94.3% | 350,445 | 94.8% | -0.414 | -0.018 |
| Oral Corticosteroid Dispensing | 122,080 | 31.7% | 115,713 | 31.3% | 0.384 | 0.008 |
| Use of Other Asthma Medication | 225,162 | 58.4% | 223,882 | 60.5% | -2.121 | -0.045 |
| Allergic Rhinitis | 164,688 | 42.7% | 147,826 | 40.0% | 2.755 | 0.056 |
| Anxiety | 136,604 | 35.4% | 130,356 | 35.2% | 0.193 | 0.004 |
| Depression | 110,400 | 28.6% | 105,643 | 28.6% | 0.077 | 0.002 |
| Sleep Disorder | 115,466 | 30.0% | 109,056 | 29.5% | 0.468 | 0.011 |
| Substance Abuse | 24,451 | 6.3% | 23,727 | 6.4% | -0.072 | -0.003 |
| Poisoning | 1,135 | 0.3% | 1,218 | 0.3% | -0.035 | -0.006 |

Table 1p. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Suffocation | 27 | 0.0% | 18 | 0.0% | 0.002 | 0.003 |
| Suicide Attempt | 637 | 0.2% | 644 | 0.2% | -0.009 | -0.002 |
| Toxicity | 136 | 0.0% | 139 | 0.0% | -0.002 | -0.001 |
| Other Self Harm | 340 | 0.1% | 363 | 0.1% | -0.010 | -0.003 |
| No moderate asthma exacerbations | 320,144 | 83.1% | 306,651 | 82.9% | 0.141 | 0.004 |
| One moderate asthma exacerbation | 56,708 | 14.7% | 55,212 | 14.9% | -0.217 | -0.006 |
| Two or more moderate asthma | 8,573 | 2.2% | 7,948 | 2.1% | 0.075 | 0.005 |
| No severe asthma exacerbations | 380,954 | 98.8% | 365,309 | 98.8% | 0.057 | 0.005 |
| One severe asthma exacerbation | 4,265 | 1.1% | 4,301 | 1.2% | -0.056 | -0.005 |
| Two or more severe asthma exacerbations | 206 | 0.1% | 201 | 0.1% | -0.001 | -0.000 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 110,804 | 28.7% | 104,621 | 28.3% | 0.458 | 0.010 |
| Antipsychotics | 34,667 | 9.0% | 33,850 | 9.2% | -0.159 | -0.006 |
| Anxiolytics Hypnotics | 135,104 | 35.1% | 128,691 | 34.8% | 0.254 | 0.005 |
| Lithium Other Mood Stabilizers | 40,594 | 10.5% | 39,455 | 10.7% | -0.137 | -0.004 |
| Antidepressants | 196,435 | 51.0% | 187,926 | 50.8% | 0.149 | 0.003 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 13.5 | 12.9 | 13.6 | 12.4 | -0.101 | -0.008 |
| Mean number of emergency room | 0.6 | 1.5 | 0.6 | 1.5 | -0.005 | -0.003 |
| Mean number of inpatient hospital encounters | 0.1 | 0.5 | 0.1 | 0.5 | -0.002 | -0.003 |
| Mean number of other ambulatory encounters | 4.1 | 11.8 | 4.4 | 12.6 | -0.285 | -0.023 |
| Mean number of filled prescriptions | 20.6 | 16.8 | 20.7 | 16.5 | -0.046 | -0.003 |
| Mean number of generics dispensed | 9.9 | 5.4 | 9.8 | 5.4 | 0.081 | 0.015 |
| Mean number of unique drug classes dispensed | 9.3 | 4.8 | 9.2 | 4.8 | 0.057 | 0.012 |

Table 1p. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of inpatient visits for respiratory disorders | 0.1 | 0.3 | 0.1 | 0.3 | -0.002 | -0.006 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.5 | 0.1 | 0.5 | -0.001 | -0.003 |
| Mean number of outpatient visits for respiratory disorders | 2.5 | 3.5 | 2.5 | 3.5 | 0.026 | 0.007 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1q. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 596,990 | 100.0% | 784,999 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 42.6 | 15.8 | 36.0 | 16.4 | 6.539 | 0.406 |
| Age | | | | | | |
| 10-24 years | 187,871 | 31.5% | 343,756 | 43.8% | -12.321 | -0.256 |
| 25-54 years | 201,267 | 33.7% | 246,921 | 31.5% | 2.259 | 0.048 |
| ≥ 55 years | 207,852 | 34.8% | 194,322 | 24.8% | 10.062 | 0.221 |
| Sex | | | | | | |
| Female | 390,634 | 65.4% | 479,430 | 61.1% | 4.360 | 0.091 |
| Male | 206,356 | 34.6% | 305,569 | 38.9% | -4.360 | -0.091 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 4,135 | 0.7% | 7,518 | 1.0% | -0.265 | -0.029 |
| Asian | 13,699 | 2.3% | 18,066 | 2.3% | -0.007 | -0.000 |
| Black or African American | 71,428 | 12.0% | 109,890 | 14.0% | -2.034 | -0.061 |
| Multi-racial | 1,256 | 0.2% | 1,185 | 0.2% | 0.059 | 0.014 |
| Native Hawaiian or Other Pacific Islander | 1,168 | 0.2% | 3,122 | 0.4% | -0.202 | -0.037 |
| Unknown | 294,656 | 49.4% | 389,087 | 49.6% | -0.208 | -0.004 |
| White | 210,648 | 35.3% | 256,131 | 32.6% | 2.657 | 0.056 |
| Hispanic origin | | | | | | |
| Yes | 58,337 | 9.8% | 111,480 | 14.2% | -4.429 | -0.137 |
| No | 287,383 | 48.1% | 382,024 | 48.7% | -0.527 | -0.011 |
| Unknown | 251,270 | 42.1% | 291,495 | 37.1% | 4.956 | 0.101 |
| Year | | | | | | |
| 2015 | 29,140 | 4.9% | 46,686 | 5.9% | -1.066 | -0.047 |
| 2016 | 141,986 | 23.8% | 210,008 | 26.8% | -2.969 | -0.068 |
| 2017 | 164,064 | 27.5% | 238,297 | 30.4% | -2.874 | -0.063 |
| 2018 | 156,558 | 26.2% | 202,395 | 25.8% | 0.442 | 0.010 |
| 2019 | 90,771 | 15.2% | 74,737 | 9.5% | 5.684 | 0.173 |
| 2020 | 14,471 | 2.4% | 12,876 | 1.6% | 0.784 | 0.056 |

Table 1q. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2021 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2022 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Pre-boxed warning | 596,990 | 100.0% | 784,999 | 100.0% | 0.000 | NaN |
| Post-boxed warning | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Seasonality | | | | | | |
| Winter | 138,406 | 23.2% | 196,454 | 25.0% | -1.842 | -0.043 |
| Spring | 158,758 | 26.6% | 168,462 | 21.5% | 5.133 | 0.120 |
| Summer | 132,488 | 22.2% | 168,714 | 21.5% | 0.700 | 0.017 |
| Autumn | 167,338 | 28.0% | 251,369 | 32.0% | -3.991 | -0.087 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.5 | 1.4 | 1.5 | 1.2 | 0.065 | 0.049 |
| Psychiatric History | 296,859 | 49.7% | 364,733 | 46.5% | 3.263 | 0.065 |
| Psychiatric Drug Dispensings ⁵ | 216,728 | 36.3% | 258,762 | 33.0% | 3.340 | 0.070 |
| Self Harm Encounter ⁵ | 1,227 | 0.2% | 2,239 | 0.3% | -0.080 | -0.016 |
| Encounter for Other Psychiatric Event ⁵ | 244,506 | 41.0% | 305,675 | 38.9% | 2.017 | 0.041 |
| Asthma Emergency Encounter | 64,316 | 10.8% | 98,902 | 12.6% | -1.826 | -0.057 |
| Asthma Inpatient Encounter | 2,005 | 0.3% | 2,707 | 0.3% | -0.009 | -0.002 |
| Asthma Outpatient Encounter | 570,651 | 95.6% | 753,867 | 96.0% | -0.446 | -0.022 |
| Oral Corticosteroid Dispensing | 168,292 | 28.2% | 200,637 | 25.6% | 2.631 | 0.059 |
| Use of Other Asthma Medication | 379,039 | 63.5% | 626,813 | 79.8% | -16.357 | -0.369 |
| Allergic Rhinitis | 255,187 | 42.7% | 178,386 | 22.7% | 20.021 | 0.437 |
| Anxiety | 100,202 | 16.8% | 119,297 | 15.2% | 1.587 | 0.043 |
| Depression | 83,175 | 13.9% | 103,037 | 13.1% | 0.807 | 0.024 |
| Sleep Disorder | 83,138 | 13.9% | 77,669 | 9.9% | 4.032 | 0.125 |
| Substance Abuse | 19,266 | 3.2% | 34,153 | 4.4% | -1.124 | -0.059 |
| Poisoning | 1,163 | 0.2% | 2,286 | 0.3% | -0.096 | -0.020 |
| Suffocation | 24 | 0.0% | 43 | 0.0% | -0.001 | -0.002 |
| Suicide Attempt | 643 | 0.1% | 1,134 | 0.1% | -0.037 | -0.010 |

Table 1q. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Toxicity | 138 | 0.0% | 255 | 0.0% | -0.009 | -0.006 |
| Other Self Harm | 322 | 0.1% | 544 | 0.1% | -0.015 | -0.006 |
| No moderate asthma exacerbations | 500,038 | 83.8% | 657,176 | 83.7% | 0.043 | 0.001 |
| One moderate asthma exacerbation | 85,297 | 14.3% | 113,517 | 14.5% | -0.173 | -0.005 |
| Two or more moderate asthma | 11,655 | 2.0% | 14,306 | 1.8% | 0.130 | 0.010 |
| No severe asthma exacerbations | 591,637 | 99.1% | 776,884 | 99.0% | 0.137 | 0.014 |
| One severe asthma exacerbation | 5,137 | 0.9% | 7,895 | 1.0% | -0.145 | -0.015 |
| Two or more severe asthma exacerbations | 216 | 0.0% | 220 | 0.0% | 0.008 | 0.005 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 121,052 | 20.3% | 137,373 | 17.5% | 2.777 | 0.071 |
| Antipsychotics | 27,907 | 4.7% | 45,143 | 5.8% | -1.076 | -0.048 |
| Anxiolytics Hypnotics | 104,857 | 17.6% | 113,663 | 14.5% | 3.085 | 0.084 |
| Lithium Other Mood Stabilizers | 32,398 | 5.4% | 43,708 | 5.6% | -0.141 | -0.006 |
| Antidepressants | 148,648 | 24.9% | 173,833 | 22.1% | 2.755 | 0.065 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 10.0 | 10.9 | 9.3 | 11.2 | 0.773 | 0.070 |
| Mean number of emergency room | 0.5 | 1.2 | 0.5 | 1.4 | -0.077 | -0.060 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.000 | -0.001 |
| Mean number of other ambulatory encounters | 2.8 | 9.9 | 3.4 | 12.8 | -0.695 | -0.061 |
| Mean number of filled prescriptions | 15.0 | 14.4 | 13.9 | 14.6 | 1.015 | 0.070 |
| Mean number of generics dispensed | 7.8 | 4.9 | 7.0 | 4.6 | 0.793 | 0.167 |
| Mean number of unique drug classes dispensed | 7.3 | 4.4 | 6.7 | 4.2 | 0.639 | 0.149 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.000 | -0.000 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.010 | -0.024 |

Table 1q. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of outpatient visits for respiratory disorders | 2.3 | 3.3 | 1.7 | 2.7 | 0.587 | 0.195 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1r. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 596,938 | 100.0% | 784,981 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 42.6 | 15.8 | 36.0 | 16.4 | 6.538 | 0.406 |
| Age | | | | | | |
| 10-24 years | 187,870 | 31.5% | 343,749 | 43.8% | -12.318 | -0.256 |
| 25-54 years | 201,256 | 33.7% | 246,918 | 31.5% | 2.259 | 0.048 |
| ≥ 55 years | 207,812 | 34.8% | 194,314 | 24.8% | 10.059 | 0.221 |
| Sex | | | | | | |
| Female | 390,591 | 65.4% | 479,420 | 61.1% | 4.358 | 0.090 |
| Male | 206,347 | 34.6% | 305,561 | 38.9% | -4.358 | -0.090 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 4,135 | 0.7% | 7,518 | 1.0% | -0.265 | -0.029 |
| Asian | 13,697 | 2.3% | 18,066 | 2.3% | -0.007 | -0.000 |
| Black or African American | 71,421 | 12.0% | 109,890 | 14.0% | -2.035 | -0.061 |
| Multi-racial | 1,256 | 0.2% | 1,185 | 0.2% | 0.059 | 0.014 |
| Native Hawaiian or Other Pacific Islander | 1,168 | 0.2% | 3,122 | 0.4% | -0.202 | -0.037 |
| Unknown | 294,639 | 49.4% | 389,072 | 49.6% | -0.206 | -0.004 |
| White | 210,622 | 35.3% | 256,128 | 32.6% | 2.655 | 0.056 |
| Hispanic origin | | | | | | |
| Yes | 58,333 | 9.8% | 111,478 | 14.2% | -4.429 | -0.137 |
| No | 287,357 | 48.1% | 382,021 | 48.7% | -0.528 | -0.011 |
| Unknown | 251,248 | 42.1% | 291,482 | 37.1% | 4.957 | 0.101 |
| Year | | | | | | |
| 2015 | 29,139 | 4.9% | 46,685 | 5.9% | -1.066 | -0.047 |
| 2016 | 141,981 | 23.8% | 210,004 | 26.8% | -2.968 | -0.068 |
| 2017 | 164,055 | 27.5% | 238,294 | 30.4% | -2.874 | -0.063 |
| 2018 | 156,542 | 26.2% | 202,391 | 25.8% | 0.441 | 0.010 |
| 2019 | 90,751 | 15.2% | 74,732 | 9.5% | 5.683 | 0.173 |
| 2020 | 14,470 | 2.4% | 12,875 | 1.6% | 0.784 | 0.056 |

Table 1r. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2021 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2022 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Pre-boxed warning | 596,938 | 100.0% | 784,981 | 100.0% | 0.000 | NaN |
| Post-boxed warning | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Seasonality | | | | | | |
| Winter | 138,398 | 23.2% | 196,448 | 25.0% | -1.841 | -0.043 |
| Spring | 158,733 | 26.6% | 168,459 | 21.5% | 5.131 | 0.120 |
| Summer | 132,477 | 22.2% | 168,711 | 21.5% | 0.700 | 0.017 |
| Autumn | 167,330 | 28.0% | 251,363 | 32.0% | -3.990 | -0.087 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.5 | 1.4 | 1.5 | 1.2 | 0.065 | 0.049 |
| Psychiatric History | 296,810 | 49.7% | 364,716 | 46.5% | 3.260 | 0.065 |
| Psychiatric Drug Dispensings ⁵ | 216,681 | 36.3% | 258,748 | 33.0% | 3.336 | 0.070 |
| Self Harm Encounter ⁵ | 1,227 | 0.2% | 2,239 | 0.3% | -0.080 | -0.016 |
| Encounter for Other Psychiatric Event ⁵ | 244,463 | 41.0% | 305,658 | 38.9% | 2.015 | 0.041 |
| Asthma Emergency Encounter | 64,308 | 10.8% | 98,898 | 12.6% | -1.826 | -0.057 |
| Asthma Inpatient Encounter | 2,005 | 0.3% | 2,707 | 0.3% | -0.009 | -0.002 |
| Asthma Outpatient Encounter | 570,610 | 95.6% | 753,851 | 96.0% | -0.445 | -0.022 |
| Oral Corticosteroid Dispensing | 168,261 | 28.2% | 200,630 | 25.6% | 2.629 | 0.059 |
| Use of Other Asthma Medication | 379,029 | 63.5% | 626,803 | 79.8% | -16.354 | -0.369 |
| Allergic Rhinitis | 255,141 | 42.7% | 178,379 | 22.7% | 20.018 | 0.437 |
| Anxiety | 100,168 | 16.8% | 119,285 | 15.2% | 1.584 | 0.043 |
| Depression | 83,153 | 13.9% | 103,031 | 13.1% | 0.805 | 0.024 |
| Sleep Disorder | 83,113 | 13.9% | 77,663 | 9.9% | 4.030 | 0.125 |
| Substance Abuse | 19,262 | 3.2% | 34,149 | 4.4% | -1.123 | -0.059 |
| Poisoning | 1,163 | 0.2% | 2,285 | 0.3% | -0.096 | -0.020 |
| Suffocation | 24 | 0.0% | 43 | 0.0% | -0.001 | -0.002 |
| Suicide Attempt | 643 | 0.1% | 1,133 | 0.1% | -0.037 | -0.010 |

Table 1r. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Toxicity | 138 | 0.0% | 255 | 0.0% | -0.009 | -0.006 |
| Other Self Harm | 322 | 0.1% | 544 | 0.1% | -0.015 | -0.006 |
| No moderate asthma exacerbations | 499,995 | 83.8% | 657,162 | 83.7% | 0.043 | 0.001 |
| One moderate asthma exacerbation | 85,290 | 14.3% | 113,514 | 14.5% | -0.173 | -0.005 |
| Two or more moderate asthma | 11,653 | 2.0% | 14,305 | 1.8% | 0.130 | 0.010 |
| No severe asthma exacerbations | 591,586 | 99.1% | 776,867 | 99.0% | 0.137 | 0.014 |
| One severe asthma exacerbation | 5,136 | 0.9% | 7,894 | 1.0% | -0.145 | -0.015 |
| Two or more severe asthma exacerbations | 216 | 0.0% | 220 | 0.0% | 0.008 | 0.005 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 121,020 | 20.3% | 137,367 | 17.5% | 2.774 | 0.071 |
| Antipsychotics | 27,902 | 4.7% | 45,140 | 5.8% | -1.076 | -0.048 |
| Anxiolytics Hypnotics | 104,817 | 17.6% | 113,653 | 14.5% | 3.081 | 0.084 |
| Lithium Other Mood Stabilizers | 32,391 | 5.4% | 43,706 | 5.6% | -0.142 | -0.006 |
| Antidepressants | 148,615 | 24.9% | 173,821 | 22.1% | 2.753 | 0.065 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 10.0 | 10.9 | 9.3 | 11.2 | 0.773 | 0.070 |
| Mean number of emergency room | 0.5 | 1.2 | 0.5 | 1.4 | -0.077 | -0.060 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.000 | -0.001 |
| Mean number of other ambulatory encounters | 2.8 | 9.9 | 3.4 | 12.8 | -0.695 | -0.061 |
| Mean number of filled prescriptions | 15.0 | 14.4 | 13.9 | 14.6 | 1.013 | 0.070 |
| Mean number of generics dispensed | 7.8 | 4.9 | 7.0 | 4.6 | 0.792 | 0.166 |
| Mean number of unique drug classes dispensed | 7.3 | 4.4 | 6.7 | 4.2 | 0.638 | 0.149 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.000 | -0.000 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.010 | -0.024 |

Table 1r. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of outpatient visits for respiratory disorders | 2.3 | 3.3 | 1.7 | 2.7 | 0.587 | 0.195 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1s. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 155,240 | 100.0% | 138,358 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 52.7 | 15.8 | 47.2 | 17.6 | 5.465 | 0.327 |
| Age | | | | | | |
| 10-24 years | 19,995 | 12.9% | 32,113 | 23.2% | -10.330 | -0.271 |
| 25-54 years | 55,869 | 36.0% | 47,501 | 34.3% | 1.657 | 0.035 |
| ≥ 55 years | 79,376 | 51.1% | 58,744 | 42.5% | 8.673 | 0.174 |
| Sex | | | | | | |
| Female | 106,343 | 68.5% | 89,154 | 64.4% | 4.065 | 0.086 |
| Male | 48,897 | 31.5% | 49,204 | 35.6% | -4.065 | -0.086 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 506 | 0.3% | 376 | 0.3% | 0.054 | 0.010 |
| Asian | 2,293 | 1.5% | 1,615 | 1.2% | 0.310 | 0.027 |
| Black or African American | 10,288 | 6.6% | 6,877 | 5.0% | 1.657 | 0.071 |
| Multi-racial | 656 | 0.4% | 783 | 0.6% | -0.143 | -0.020 |
| Native Hawaiian or Other Pacific Islander | 180 | 0.1% | 113 | 0.1% | 0.034 | 0.011 |
| Unknown | 83,951 | 54.1% | 84,449 | 61.0% | -6.958 | -0.141 |
| White | 57,366 | 37.0% | 44,145 | 31.9% | 5.047 | 0.106 |
| Hispanic origin | | | | | | |
| Yes | 3,682 | 2.4% | 3,000 | 2.2% | 0.204 | 0.014 |
| No | 61,977 | 39.9% | 44,908 | 32.5% | 7.466 | 0.156 |
| Unknown | 89,581 | 57.7% | 90,450 | 65.4% | -7.669 | -0.158 |
| Year | | | | | | |
| 2015 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2016 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2017 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2018 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2019 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2020 | 63,486 | 40.9% | 56,184 | 40.6% | 0.288 | 0.006 |

Table 1s. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2021 | 69,445 | 44.7% | 61,058 | 44.1% | 0.604 | 0.012 |
| 2022 | 22,309 | 14.4% | 21,116 | 15.3% | -0.891 | -0.025 |
| Pre-boxed warning | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Post-boxed warning | 155,240 | 100.0% | 138,358 | 100.0% | 0.000 | NaN |
| Seasonality | | | | | | |
| Winter | 36,049 | 23.2% | 36,195 | 26.2% | -2.939 | -0.068 |
| Spring | 50,825 | 32.7% | 38,194 | 27.6% | 5.134 | 0.112 |
| Summer | 34,276 | 22.1% | 30,336 | 21.9% | 0.154 | 0.004 |
| Autumn | 34,090 | 22.0% | 33,633 | 24.3% | -2.349 | -0.056 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.7 | 1.7 | 1.7 | 1.6 | 0.052 | 0.032 |
| Psychiatric History | 88,615 | 57.1% | 74,233 | 53.7% | 3.430 | 0.069 |
| Psychiatric Drug Dispensings ⁵ | 64,317 | 41.4% | 53,374 | 38.6% | 2.854 | 0.058 |
| Self Harm Encounter ⁵ | 167 | 0.1% | 216 | 0.2% | -0.049 | -0.013 |
| Encounter for Other Psychiatric Event ⁵ | 75,764 | 48.8% | 63,818 | 46.1% | 2.679 | 0.054 |
| Asthma Emergency Encounter | 12,180 | 7.8% | 11,588 | 8.4% | -0.529 | -0.019 |
| Asthma Inpatient Encounter | 246 | 0.2% | 198 | 0.1% | 0.015 | 0.004 |
| Asthma Outpatient Encounter | 149,996 | 96.6% | 134,423 | 97.2% | -0.534 | -0.031 |
| Oral Corticosteroid Dispensing | 40,488 | 26.1% | 33,176 | 24.0% | 2.103 | 0.049 |
| Use of Other Asthma Medication | 86,392 | 55.7% | 96,625 | 69.8% | -14.186 | -0.297 |
| Allergic Rhinitis | 69,156 | 44.5% | 36,043 | 26.1% | 18.497 | 0.395 |
| Anxiety | 36,432 | 23.5% | 31,158 | 22.5% | 0.948 | 0.023 |
| Depression | 27,249 | 17.6% | 23,053 | 16.7% | 0.891 | 0.024 |
| Sleep Disorder | 32,351 | 20.8% | 23,371 | 16.9% | 3.948 | 0.101 |
| Substance Abuse | 5,191 | 3.3% | 5,164 | 3.7% | -0.388 | -0.021 |
| Poisoning | 155 | 0.1% | 184 | 0.1% | -0.033 | -0.010 |
| Suffocation | 6 | 0.0% | 3 | 0.0% | 0.002 | 0.003 |
| Suicide Attempt | 89 | 0.1% | 116 | 0.1% | -0.027 | -0.010 |

Table 1s. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Toxicity | 18 | 0.0% | 20 | 0.0% | -0.003 | -0.003 |
| Other Self Harm | 64 | 0.0% | 86 | 0.1% | -0.021 | -0.009 |
| No moderate asthma exacerbations | 136,082 | 87.7% | 122,081 | 88.2% | -0.576 | -0.018 |
| One moderate asthma exacerbation | 16,946 | 10.9% | 14,602 | 10.6% | 0.362 | 0.012 |
| Two or more moderate asthma | 2,212 | 1.4% | 1,675 | 1.2% | 0.214 | 0.019 |
| No severe asthma exacerbations | 154,372 | 99.4% | 137,492 | 99.4% | 0.067 | 0.009 |
| One severe asthma exacerbation | 835 | 0.5% | 840 | 0.6% | -0.069 | -0.009 |
| Two or more severe asthma exacerbations | 33 | 0.0% | 26 | 0.0% | 0.002 | 0.002 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 28,002 | 18.0% | 20,559 | 14.9% | 3.179 | 0.086 |
| Antipsychotics | 6,766 | 4.4% | 7,190 | 5.2% | -0.838 | -0.039 |
| Anxiolytics Hypnotics | 30,280 | 19.5% | 23,282 | 16.8% | 2.678 | 0.069 |
| Lithium Other Mood Stabilizers | 8,204 | 5.3% | 7,874 | 5.7% | -0.406 | -0.018 |
| Antidepressants | 47,896 | 30.9% | 39,579 | 28.6% | 2.247 | 0.049 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 10.6 | 11.1 | 10.0 | 10.9 | 0.616 | 0.056 |
| Mean number of emergency room | 0.3 | 1.0 | 0.3 | 1.1 | -0.020 | -0.019 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | 0.001 | 0.004 |
| Mean number of other ambulatory encounters | 2.5 | 5.7 | 2.5 | 6.4 | -0.017 | -0.003 |
| Mean number of filled prescriptions | 15.0 | 13.4 | 14.1 | 13.6 | 0.881 | 0.065 |
| Mean number of generics dispensed | 7.9 | 4.8 | 7.1 | 4.5 | 0.801 | 0.172 |
| Mean number of unique drug classes dispensed | 7.5 | 4.4 | 6.8 | 4.1 | 0.673 | 0.158 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.3 | -0.001 | -0.006 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.013 | -0.032 |

Table 1s. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of outpatient visits for respiratory disorders | 2.2 | 3.3 | 1.9 | 3.1 | 0.335 | 0.104 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1t. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 155,203 | N/A | 149,925 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 52.7 | 15.8 | 52.5 | 17.2 | 0.117 | 0.007 |
| Age | | | | | | |
| 10-24 years | 19,993 | 12.9% | 23,727 | 15.8% | -2.944 | -0.089 |
| 25-54 years | 55,855 | 36.0% | 46,864 | 31.3% | 4.730 | 0.109 |
| ≥ 55 years | 79,355 | 51.1% | 79,335 | 52.9% | -1.786 | -0.044 |
| Sex | | | | | | |
| Female | 106,311 | 68.5% | 102,116 | 68.1% | 0.387 | 0.008 |
| Male | 48,892 | 31.5% | 47,809 | 31.9% | -0.387 | -0.008 |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 506 | 0.3% | 408 | 0.3% | 0.054 | 0.010 |
| Asian | 2,292 | 1.5% | 1,813 | 1.2% | 0.267 | 0.023 |
| Black or African American | 10,284 | 6.6% | 8,165 | 5.4% | 1.180 | 0.051 |
| Multi-racial | 656 | 0.4% | 680 | 0.5% | -0.031 | -0.005 |
| Native Hawaiian or Other Pacific Islander | 180 | 0.1% | 145 | 0.1% | 0.020 | 0.006 |
| Unknown | 83,923 | 54.1% | 81,230 | 54.2% | -0.107 | -0.004 |
| White | 57,362 | 37.0% | 57,485 | 38.3% | -1.383 | -0.042 |
| Hispanic origin | | | | | | |
| Yes | 3,680 | 2.4% | 3,192 | 2.1% | 0.242 | 0.016 |
| No | 61,968 | 39.9% | 59,453 | 39.7% | 0.272 | 0.014 |
| Unknown | 89,555 | 57.7% | 87,279 | 58.2% | -0.513 | -0.027 |
| Year | | | | | | |
| 2015 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2016 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2017 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2018 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2019 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2020 | 63,467 | 40.9% | 61,588 | 41.1% | -0.186 | -0.004 |

Table 1t. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2021 | 69,429 | 44.7% | 66,933 | 44.6% | 0.090 | 0.002 |
| 2022 | 22,307 | 14.4% | 21,404 | 14.3% | 0.096 | 0.003 |
| Pre-boxed warning | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Post-boxed warning | 155,203 | 100.0% | 149,925 | 100.0% | 0.000 | NaN |
| Seasonality | | | | | | |
| Winter | 36,046 | 23.2% | 35,423 | 23.6% | -0.402 | -0.009 |
| Spring | 50,801 | 32.7% | 47,793 | 31.9% | 0.854 | 0.018 |
| Summer | 34,269 | 22.1% | 33,280 | 22.2% | -0.118 | -0.003 |
| Autumn | 34,087 | 22.0% | 33,429 | 22.3% | -0.334 | -0.008 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.7 | 1.7 | 1.7 | 1.7 | -0.003 | -0.002 |
| Psychiatric History | 88,583 | 57.1% | 84,848 | 56.6% | 0.482 | 0.010 |
| Psychiatric Drug Dispensings ⁶ | 64,290 | 41.4% | 61,580 | 41.1% | 0.349 | 0.007 |
| Self Harm Encounter ⁶ | 167 | 0.1% | 169 | 0.1% | -0.005 | -0.002 |
| Encounter for Other Psychiatric Event ⁶ | 75,735 | 48.8% | 72,207 | 48.2% | 0.635 | 0.013 |
| Asthma Emergency Encounter | 12,174 | 7.8% | 11,577 | 7.7% | 0.122 | 0.005 |
| Asthma Inpatient Encounter | 246 | 0.2% | 237 | 0.2% | 0.000 | 0.000 |
| Asthma Outpatient Encounter | 149,962 | 96.6% | 145,268 | 96.9% | -0.271 | -0.015 |
| Oral Corticosteroid Dispensing | 40,466 | 26.1% | 38,543 | 25.7% | 0.365 | 0.008 |
| Use of Other Asthma Medication | 86,385 | 55.7% | 85,780 | 57.2% | -1.556 | -0.032 |
| Allergic Rhinitis | 69,121 | 44.5% | 63,056 | 42.1% | 2.478 | 0.050 |
| Anxiety | 36,415 | 23.5% | 34,731 | 23.2% | 0.297 | 0.007 |
| Depression | 27,231 | 17.5% | 26,027 | 17.4% | 0.186 | 0.005 |
| Sleep Disorder | 32,334 | 20.8% | 30,562 | 20.4% | 0.448 | 0.011 |
| Substance Abuse | 5,188 | 3.3% | 4,950 | 3.3% | 0.041 | 0.002 |
| Poisoning | 154 | 0.1% | 161 | 0.1% | -0.008 | -0.002 |
| Suffocation | 6 | 0.0% | 1 | 0.0% | 0.003 | 0.006 |

Table 1t. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Suicide Attempt | 88 | 0.1% | 101 | 0.1% | -0.011 | -0.004 |
| Toxicity | 18 | 0.0% | 19 | 0.0% | -0.001 | -0.001 |
| Other Self Harm | 63 | 0.0% | 66 | 0.0% | -0.003 | -0.002 |
| No moderate asthma exacerbations | 136,053 | 87.7% | 131,618 | 87.8% | -0.128 | -0.004 |
| One moderate asthma exacerbation | 16,938 | 10.9% | 16,339 | 10.9% | 0.015 | 0.000 |
| Two or more moderate asthma | 2,212 | 1.4% | 1,969 | 1.3% | 0.112 | 0.010 |
| No severe asthma exacerbations | 154,336 | 99.4% | 149,061 | 99.4% | 0.018 | 0.002 |
| One severe asthma exacerbation | 834 | 0.5% | 836 | 0.6% | -0.020 | -0.003 |
| Two or more severe asthma exacerbations | 33 | 0.0% | 28 | 0.0% | 0.002 | 0.002 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 27,977 | 18.0% | 26,286 | 17.5% | 0.494 | 0.013 |
| Antipsychotics | 6,762 | 4.4% | 6,703 | 4.5% | -0.114 | -0.006 |
| Anxiolytics Hypnotics | 30,264 | 19.5% | 28,881 | 19.3% | 0.236 | 0.006 |
| Lithium Other Mood Stabilizers | 8,199 | 5.3% | 8,042 | 5.4% | -0.081 | -0.004 |
| Antidepressants | 47,874 | 30.8% | 45,836 | 30.6% | 0.274 | 0.006 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 10.6 | 11.1 | 10.7 | 10.6 | -0.086 | -0.008 |
| Mean number of emergency room | 0.3 | 1.0 | 0.3 | 1.0 | -0.004 | -0.003 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.001 | -0.004 |
| Mean number of other ambulatory encounters | 2.5 | 5.7 | 2.6 | 6.1 | -0.128 | -0.022 |
| Mean number of filled prescriptions | 15.0 | 13.4 | 15.0 | 13.2 | -0.016 | -0.001 |
| Mean number of generics dispensed | 7.9 | 4.8 | 7.8 | 4.9 | 0.074 | 0.015 |
| Mean number of unique drug classes dispensed | 7.5 | 4.4 | 7.5 | 4.4 | 0.062 | 0.014 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.001 | -0.005 |

Table 1t. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|-----------------|---|-------------------------------|---|---------------------|-------------------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.002 | -0.004 |
| Mean number of outpatient visits for respiratory disorders | 2.2 | 3.3 | 2.2 | 3.2 | 0.003 | 0.001 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1u. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 752,307 | 100.0% | 923,409 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 44.7 | 15.8 | 37.7 | 16.6 | 6.949 | 0.429 |
| Age | | | | | | |
| 10-24 years | 207,872 | 27.6% | 375,890 | 40.7% | -13.075 | -0.278 |
| 25-54 years | 257,168 | 34.2% | 294,443 | 31.9% | 2.297 | 0.049 |
| ≥ 55 years | 287,267 | 38.2% | 253,076 | 27.4% | 10.778 | 0.231 |
| Sex | | | | | | |
| Female | 497,043 | 66.1% | 568,619 | 61.6% | 4.491 | 0.094 |
| Male | 255,264 | 33.9% | 354,790 | 38.4% | -4.491 | -0.094 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 4,641 | 0.6% | 7,895 | 0.9% | -0.238 | -0.028 |
| Asian | 15,994 | 2.1% | 19,681 | 2.1% | -0.005 | -0.000 |
| Black or African American | 81,724 | 10.9% | 116,770 | 12.6% | -1.782 | -0.055 |
| Multi-racial | 1,913 | 0.3% | 1,968 | 0.2% | 0.041 | 0.009 |
| Native Hawaiian or Other Pacific Islander | 1,348 | 0.2% | 3,235 | 0.4% | -0.171 | -0.033 |
| Unknown | 378,640 | 50.3% | 473,566 | 51.3% | -0.954 | -0.019 |
| White | 268,047 | 35.6% | 300,294 | 32.5% | 3.110 | 0.066 |
| Hispanic origin | | | | | | |
| Yes | 62,020 | 8.2% | 114,484 | 12.4% | -4.154 | -0.137 |
| No | 349,384 | 46.4% | 426,953 | 46.2% | 0.205 | 0.004 |
| Unknown | 340,903 | 45.3% | 381,972 | 41.4% | 3.949 | 0.080 |
| Year | | | | | | |
| 2015 | 29,142 | 3.9% | 46,689 | 5.1% | -1.182 | -0.057 |
| 2016 | 141,995 | 18.9% | 210,018 | 22.7% | -3.869 | -0.095 |
| 2017 | 164,077 | 21.8% | 238,311 | 25.8% | -3.998 | -0.094 |
| 2018 | 156,569 | 20.8% | 202,401 | 21.9% | -1.107 | -0.027 |
| 2019 | 90,789 | 12.1% | 74,744 | 8.1% | 3.974 | 0.132 |
| 2020 | 77,970 | 10.4% | 69,064 | 7.5% | 2.885 | 0.101 |

Table 1u. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2021 | 69,451 | 9.2% | 61,064 | 6.6% | 2.619 | 0.097 |
| 2022 | 22,314 | 3.0% | 21,118 | 2.3% | 0.679 | 0.042 |
| Pre-boxed warning | 597,045 | 79.4% | 785,041 | 85.0% | -5.654 | -0.148 |
| Post-boxed warning | 155,262 | 20.6% | 138,368 | 15.0% | 5.654 | 0.148 |
| Seasonality | | | | | | |
| Winter | 174,464 | 23.2% | 232,667 | 25.2% | -2.006 | -0.047 |
| Spring | 209,621 | 27.9% | 206,664 | 22.4% | 5.483 | 0.127 |
| Summer | 166,782 | 22.2% | 199,059 | 21.6% | 0.612 | 0.015 |
| Autumn | 201,440 | 26.8% | 285,019 | 30.9% | -4.090 | -0.090 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.6 | 1.5 | 1.5 | 1.3 | 0.076 | 0.055 |
| Psychiatric History | 385,548 | 51.2% | 439,015 | 47.5% | 3.706 | 0.074 |
| Psychiatric Drug Dispensings ⁵ | 281,107 | 37.4% | 312,175 | 33.8% | 3.559 | 0.074 |
| Self Harm Encounter ⁵ | 1,408 | 0.2% | 2,474 | 0.3% | -0.081 | -0.017 |
| Encounter for Other Psychiatric Event ⁵ | 320,340 | 42.6% | 369,541 | 40.0% | 2.562 | 0.052 |
| Asthma Emergency Encounter | 76,522 | 10.2% | 110,499 | 12.0% | -1.795 | -0.057 |
| Asthma Inpatient Encounter | 2,253 | 0.3% | 2,905 | 0.3% | -0.015 | -0.003 |
| Asthma Outpatient Encounter | 720,706 | 95.8% | 888,340 | 96.2% | -0.403 | -0.021 |
| Oral Corticosteroid Dispensing | 208,822 | 27.8% | 233,830 | 25.3% | 2.435 | 0.055 |
| Use of Other Asthma Medication | 465,453 | 61.9% | 723,480 | 78.3% | -16.479 | -0.366 |
| Allergic Rhinitis | 324,404 | 43.1% | 214,435 | 23.2% | 19.899 | 0.432 |
| Anxiety | 136,674 | 18.2% | 150,482 | 16.3% | 1.871 | 0.050 |
| Depression | 110,460 | 14.7% | 126,123 | 13.7% | 1.024 | 0.029 |
| Sleep Disorder | 115,523 | 15.4% | 101,050 | 10.9% | 4.413 | 0.131 |
| Substance Abuse | 24,474 | 3.3% | 39,334 | 4.3% | -1.006 | -0.053 |
| Poisoning | 1,327 | 0.2% | 2,483 | 0.3% | -0.093 | -0.020 |
| Suffocation | 30 | 0.0% | 46 | 0.0% | -0.001 | -0.001 |
| Suicide Attempt | 741 | 0.1% | 1,264 | 0.1% | -0.038 | -0.011 |

Table 1u. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Toxicity | 166 | 0.0% | 279 | 0.0% | -0.008 | -0.005 |
| Other Self Harm | 392 | 0.1% | 638 | 0.1% | -0.017 | -0.007 |
| No moderate asthma exacerbations | 636,177 | 84.6% | 779,303 | 84.4% | 0.169 | 0.005 |
| One moderate asthma exacerbation | 102,258 | 13.6% | 128,121 | 13.9% | -0.282 | -0.008 |
| Two or more moderate asthma | 13,872 | 1.8% | 15,985 | 1.7% | 0.113 | 0.009 |
| No severe asthma exacerbations | 746,082 | 99.2% | 914,428 | 99.0% | 0.145 | 0.015 |
| One severe asthma exacerbation | 5,976 | 0.8% | 8,735 | 0.9% | -0.152 | -0.016 |
| Two or more severe asthma exacerbations | 249 | 0.0% | 246 | 0.0% | 0.006 | 0.004 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 149,096 | 19.8% | 157,947 | 17.1% | 2.714 | 0.070 |
| Antipsychotics | 34,687 | 4.6% | 52,348 | 5.7% | -1.058 | -0.048 |
| Anxiolytics Hypnotics | 135,183 | 18.0% | 136,965 | 14.8% | 3.137 | 0.085 |
| Lithium Other Mood Stabilizers | 40,622 | 5.4% | 51,596 | 5.6% | -0.188 | -0.008 |
| Antidepressants | 196,592 | 26.1% | 213,448 | 23.1% | 3.017 | 0.070 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 10.2 | 11.0 | 9.4 | 11.2 | 0.781 | 0.071 |
| Mean number of emergency room | 0.4 | 1.2 | 0.5 | 1.3 | -0.076 | -0.061 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.000 | -0.000 |
| Mean number of other ambulatory encounters | 2.7 | 9.2 | 3.3 | 12.0 | -0.610 | -0.057 |
| Mean number of filled prescriptions | 15.0 | 14.2 | 14.0 | 14.5 | 0.998 | 0.069 |
| Mean number of generics dispensed | 7.8 | 4.9 | 7.0 | 4.6 | 0.803 | 0.169 |
| Mean number of unique drug classes dispensed | 7.4 | 4.4 | 6.7 | 4.2 | 0.655 | 0.153 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.000 | -0.000 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.012 | -0.029 |

Table 1u. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of outpatient visits for respiratory disorders | 2.3 | 3.3 | 1.7 | 2.8 | 0.545 | 0.178 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Table 1v. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| | Medical Product | | Covariate Balance | | | |
|---|----------------------------------|---|--|---|------------------------|----------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | | |
| Patient Characteristics ^{1,2} | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | Absolute Difference | Standardized Difference |
| Weighted patients | 752,257 | N/A | 724,885 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 44.7 | 15.8 | 44.5 | 16.9 | 0.183 | 0.011 |
| Age | | | | | | |
| 10-24 years | 207,872 | 27.6% | 216,790 | 29.9% | -2.274 | -0.059 |
| 25-54 years | 257,148 | 34.2% | 222,538 | 30.7% | 3.484 | 0.078 |
| ≥ 55 years | 287,237 | 38.2% | 285,557 | 39.4% | -1.210 | -0.033 |
| Sex | | | | | | |
| Female | 496,998 | 66.1% | 475,606 | 65.6% | 0.456 | 0.010 |
| Male | 255,259 | 33.9% | 249,280 | 34.4% | -0.456 | -0.010 |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 4,641 | 0.6% | 4,735 | 0.7% | -0.036 | -0.005 |
| Asian | 15,993 | 2.1% | 13,441 | 1.9% | 0.272 | 0.020 |
| Black or African American | 81,719 | 10.9% | 72,045 | 9.9% | 0.924 | 0.032 |
| Multi-racial | 1,912 | 0.3% | 1,757 | 0.2% | 0.012 | 0.002 |
| Native Hawaiian or Other Pacific Islander | 1,348 | 0.2% | 1,794 | 0.2% | -0.068 | -0.015 |
| Unknown | 378,617 | 50.3% | 368,756 | 50.9% | -0.540 | -0.016 |
| White | 268,027 | 35.6% | 262,357 | 36.2% | -0.563 | -0.015 |
| Hispanic origin | | | | | | |
| Yes | 62,020 | 8.2% | 62,178 | 8.6% | -0.333 | -0.013 |
| No | 349,376 | 46.4% | 332,421 | 45.9% | 0.585 | 0.019 |
| Unknown | 340,861 | 45.3% | 330,287 | 45.6% | -0.252 | -0.010 |
| Year | | | | | | |
| 2015 | 29,141 | 3.9% | 29,520 | 4.1% | -0.199 | -0.010 |
| 2016 | 141,988 | 18.9% | 139,866 | 19.3% | -0.420 | -0.011 |
| 2017 | 164,074 | 21.8% | 159,322 | 22.0% | -0.168 | -0.004 |
| 2018 | 156,561 | 20.8% | 149,333 | 20.6% | 0.211 | 0.005 |
| 2019 | 90,778 | 12.1% | 84,752 | 11.7% | 0.376 | 0.012 |
| 2020 | 77,957 | 10.4% | 74,573 | 10.3% | 0.076 | 0.003 |

Table 1v. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| Patient Characteristics ^{1,2} | Medical Product | | Covariate Balance | | | |
|---|----------------------------------|---|--|---|------------------------|----------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | | |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | Absolute Difference | Standardized Difference |
| 2021 | 69,448 | 9.2% | 66,283 | 9.1% | 0.088 | 0.003 |
| 2022 | 22,310 | 3.0% | 21,236 | 2.9% | 0.036 | 0.002 |
| Pre-boxed warning | 597,013 | 79.4% | 576,364 | 79.5% | -0.148 | -0.004 |
| Post-boxed warning | 155,244 | 20.6% | 148,521 | 20.5% | 0.148 | 0.004 |
| Seasonality | | | | | | |
| Winter | 174,460 | 23.2% | 169,972 | 23.4% | -0.257 | -0.006 |
| Spring | 209,593 | 27.9% | 196,542 | 27.1% | 0.748 | 0.017 |
| Summer | 166,766 | 22.2% | 160,892 | 22.2% | -0.027 | -0.001 |
| Autumn | 201,438 | 26.8% | 197,479 | 27.2% | -0.465 | -0.010 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.6 | 1.5 | 1.6 | 1.5 | 0.000 | 0.000 |
| Psychiatric History | 385,502 | 51.2% | 367,834 | 50.7% | 0.502 | 0.010 |
| Psychiatric Drug Dispensings ⁶ | 281,067 | 37.4% | 267,552 | 36.9% | 0.454 | 0.010 |
| Self Harm Encounter ⁶ | 1,408 | 0.2% | 1,345 | 0.2% | 0.002 | 0.000 |
| Encounter for Other Psychiatric Event ⁶ | 320,298 | 42.6% | 304,874 | 42.1% | 0.520 | 0.011 |
| Asthma Emergency Encounter | 76,506 | 10.2% | 73,311 | 10.1% | 0.057 | 0.002 |
| Asthma Inpatient Encounter | 2,251 | 0.3% | 2,232 | 0.3% | -0.009 | -0.002 |
| Asthma Outpatient Encounter | 720,668 | 95.8% | 696,592 | 96.1% | -0.296 | -0.015 |
| Oral Corticosteroid Dispensing | 208,789 | 27.8% | 198,506 | 27.4% | 0.370 | 0.008 |
| Use of Other Asthma Medication | 465,446 | 61.9% | 462,203 | 63.8% | -1.889 | -0.041 |
| Allergic Rhinitis | 324,357 | 43.1% | 294,382 | 40.6% | 2.507 | 0.051 |
| Anxiety | 136,649 | 18.2% | 129,708 | 17.9% | 0.272 | 0.007 |
| Depression | 110,440 | 14.7% | 105,288 | 14.5% | 0.156 | 0.004 |
| Sleep Disorder | 115,498 | 15.4% | 108,329 | 14.9% | 0.409 | 0.012 |
| Substance Abuse | 24,469 | 3.3% | 23,895 | 3.3% | -0.044 | -0.002 |
| Poisoning | 1,326 | 0.2% | 1,409 | 0.2% | -0.018 | -0.004 |
| Suffocation | 30 | 0.0% | 21 | 0.0% | 0.001 | 0.002 |

Table 1v. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| | Medical Product | | Covariate Balance | | | |
|---|----------------------------------|---|--|---|------------------------|----------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | | |
| Patient Characteristics ^{1,2} | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | Absolute Difference | Standardized Difference |
| Suicide Attempt | 740 | 0.1% | 727 | 0.1% | -0.002 | -0.001 |
| Toxicity | 166 | 0.0% | 154 | 0.0% | 0.001 | 0.001 |
| Other Self Harm | 392 | 0.1% | 398 | 0.1% | -0.003 | -0.001 |
| No moderate asthma exacerbations | 636,142 | 84.6% | 610,605 | 84.2% | 0.330 | 0.009 |
| One moderate asthma exacerbation | 102,248 | 13.6% | 101,036 | 13.9% | -0.346 | -0.010 |
| Two or more moderate asthma | 13,867 | 1.8% | 13,244 | 1.8% | 0.016 | 0.001 |
| No severe asthma exacerbations | 746,036 | 99.2% | 718,638 | 99.1% | 0.035 | 0.004 |
| One severe asthma exacerbation | 5,972 | 0.8% | 6,007 | 0.8% | -0.035 | -0.004 |
| Two or more severe asthma exacerbations | 249 | 0.0% | 240 | 0.0% | 0.000 | 0.000 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 149,061 | 19.8% | 140,864 | 19.4% | 0.383 | 0.010 |
| Antipsychotics | 34,680 | 4.6% | 33,999 | 4.7% | -0.080 | -0.004 |
| Anxiolytics Hypnotics | 135,151 | 18.0% | 127,985 | 17.7% | 0.310 | 0.008 |
| Lithium Other Mood Stabilizers | 40,611 | 5.4% | 39,432 | 5.4% | -0.041 | -0.002 |
| Antidepressants | 196,564 | 26.1% | 187,145 | 25.8% | 0.313 | 0.007 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 10.2 | 11.0 | 10.2 | 10.5 | -0.030 | -0.003 |
| Mean number of emergency room | 0.4 | 1.2 | 0.4 | 1.2 | -0.003 | -0.002 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.001 | -0.002 |
| Mean number of other ambulatory encounters | 2.7 | 9.2 | 2.8 | 9.7 | -0.153 | -0.016 |
| Mean number of filled prescriptions | 15.0 | 14.2 | 14.9 | 14.1 | 0.048 | 0.003 |
| Mean number of generics dispensed | 7.8 | 4.9 | 7.7 | 4.9 | 0.098 | 0.020 |
| Mean number of unique drug classes dispensed | 7.4 | 4.4 | 7.3 | 4.4 | 0.076 | 0.017 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.001 | -0.004 |

Table 1v. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.001 | -0.002 |
| Mean number of outpatient visits for respiratory disorders | 2.3 | 3.3 | 2.2 | 3.3 | 0.029 | 0.009 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

Table 1w. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 496,998 | 100.0% | 568,609 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 47.9 | 15.5 | 41.4 | 16.4 | 6.567 | 0.412 |
| Age | | | | | | |
| 10-24 years | 103,207 | 20.8% | 183,943 | 32.3% | -11.584 | -0.265 |
| 25-54 years | 181,369 | 36.5% | 203,726 | 35.8% | 0.664 | 0.014 |
| ≥ 55 years | 212,422 | 42.7% | 180,940 | 31.8% | 10.920 | 0.227 |
| Sex | | | | | | |
| Female | 496,998 | 100.0% | 568,609 | 100.0% | 0.000 | NaN |
| Male | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 3,088 | 0.6% | 5,022 | 0.9% | -0.262 | -0.030 |
| Asian | 10,099 | 2.0% | 11,303 | 2.0% | 0.044 | 0.003 |
| Black or African American | 55,788 | 11.2% | 73,272 | 12.9% | -1.661 | -0.051 |
| Multi-racial | 1,273 | 0.3% | 1,215 | 0.2% | 0.042 | 0.009 |
| Native Hawaiian or Other Pacific Islander | 849 | 0.2% | 1,892 | 0.3% | -0.162 | -0.032 |
| Unknown | 235,680 | 47.4% | 273,965 | 48.2% | -0.761 | -0.015 |
| White | 190,221 | 38.3% | 201,940 | 35.5% | 2.759 | 0.057 |
| Hispanic origin | | | | | | |
| Yes | 36,809 | 7.4% | 64,770 | 11.4% | -3.985 | -0.137 |
| No | 244,649 | 49.2% | 279,920 | 49.2% | -0.004 | -0.000 |
| Unknown | 215,540 | 43.4% | 223,919 | 39.4% | 3.988 | 0.081 |
| Year | | | | | | |
| 2015 | 18,927 | 3.8% | 28,515 | 5.0% | -1.207 | -0.059 |
| 2016 | 92,752 | 18.7% | 128,076 | 22.5% | -3.862 | -0.096 |
| 2017 | 105,455 | 21.2% | 144,285 | 25.4% | -4.157 | -0.098 |
| 2018 | 101,437 | 20.4% | 122,830 | 21.6% | -1.192 | -0.029 |
| 2019 | 62,191 | 12.5% | 47,618 | 8.4% | 4.139 | 0.136 |
| 2020 | 53,782 | 10.8% | 45,014 | 7.9% | 2.905 | 0.100 |

Table 1w. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2021 | 47,659 | 9.6% | 38,987 | 6.9% | 2.733 | 0.100 |
| 2022 | 14,795 | 3.0% | 13,284 | 2.3% | 0.641 | 0.040 |
| Pre-boxed warning | 390,652 | 78.6% | 479,451 | 84.3% | -5.718 | -0.148 |
| Post-boxed warning | 106,346 | 21.4% | 89,158 | 15.7% | 5.718 | 0.148 |
| Seasonality | | | | | | |
| Winter | 115,700 | 23.3% | 143,931 | 25.3% | -2.033 | -0.047 |
| Spring | 138,906 | 27.9% | 127,260 | 22.4% | 5.568 | 0.129 |
| Summer | 109,779 | 22.1% | 122,376 | 21.5% | 0.566 | 0.014 |
| Autumn | 132,613 | 26.7% | 175,042 | 30.8% | -4.101 | -0.091 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.6 | 1.5 | 1.6 | 1.4 | 0.069 | 0.048 |
| Psychiatric History | 277,038 | 55.7% | 294,856 | 51.9% | 3.887 | 0.078 |
| Psychiatric Drug Dispensings ⁵ | 212,582 | 42.8% | 220,693 | 38.8% | 3.960 | 0.081 |
| Self Harm Encounter ⁵ | 1,066 | 0.2% | 1,883 | 0.3% | -0.117 | -0.022 |
| Encounter for Other Psychiatric Event ⁵ | 226,311 | 45.5% | 243,387 | 42.8% | 2.732 | 0.055 |
| Asthma Emergency Encounter | 53,952 | 10.9% | 71,997 | 12.7% | -1.806 | -0.056 |
| Asthma Inpatient Encounter | 1,704 | 0.3% | 1,862 | 0.3% | 0.015 | 0.003 |
| Asthma Outpatient Encounter | 474,486 | 95.5% | 545,045 | 95.9% | -0.385 | -0.019 |
| Oral Corticosteroid Dispensing | 147,886 | 29.8% | 153,414 | 27.0% | 2.775 | 0.062 |
| Use of Other Asthma Medication | 299,267 | 60.2% | 437,748 | 77.0% | -16.771 | -0.367 |
| Allergic Rhinitis | 213,715 | 43.0% | 128,494 | 22.6% | 20.403 | 0.445 |
| Anxiety | 108,163 | 21.8% | 113,618 | 20.0% | 1.782 | 0.044 |
| Depression | 89,002 | 17.9% | 96,872 | 17.0% | 0.871 | 0.023 |
| Sleep Disorder | 80,294 | 16.2% | 67,008 | 11.8% | 4.371 | 0.126 |
| Substance Abuse | 16,011 | 3.2% | 24,060 | 4.2% | -1.010 | -0.053 |
| Poisoning | 1,048 | 0.2% | 1,927 | 0.3% | -0.128 | -0.024 |
| Suffocation | 13 | 0.0% | 26 | 0.0% | -0.002 | -0.003 |
| Suicide Attempt | 557 | 0.1% | 914 | 0.2% | -0.049 | -0.013 |

Table 1w. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Toxicity | 119 | 0.0% | 204 | 0.0% | -0.012 | -0.007 |
| Other Self Harm | 298 | 0.1% | 474 | 0.1% | -0.023 | -0.009 |
| No moderate asthma exacerbations | 415,669 | 83.6% | 476,164 | 83.7% | -0.106 | -0.003 |
| One moderate asthma exacerbation | 71,220 | 14.3% | 81,838 | 14.4% | -0.063 | -0.002 |
| Two or more moderate asthma | 10,109 | 2.0% | 10,607 | 1.9% | 0.169 | 0.012 |
| No severe asthma exacerbations | 492,356 | 99.1% | 562,713 | 99.0% | 0.103 | 0.010 |
| One severe asthma exacerbation | 4,456 | 0.9% | 5,734 | 1.0% | -0.112 | -0.012 |
| Two or more severe asthma exacerbations | 186 | 0.0% | 162 | 0.0% | 0.009 | 0.005 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 114,312 | 23.0% | 117,270 | 20.6% | 2.376 | 0.058 |
| Antipsychotics | 24,881 | 5.0% | 35,219 | 6.2% | -1.188 | -0.052 |
| Anxiolytics Hypnotics | 106,367 | 21.4% | 103,920 | 18.3% | 3.126 | 0.078 |
| Lithium Other Mood Stabilizers | 30,785 | 6.2% | 36,924 | 6.5% | -0.300 | -0.012 |
| Antidepressants | 158,515 | 31.9% | 164,716 | 29.0% | 2.926 | 0.064 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 11.1 | 11.1 | 10.4 | 11.4 | 0.723 | 0.064 |
| Mean number of emergency room | 0.5 | 1.3 | 0.6 | 1.4 | -0.096 | -0.072 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.002 | -0.004 |
| Mean number of other ambulatory encounters | 2.8 | 8.8 | 3.4 | 11.5 | -0.594 | -0.058 |
| Mean number of filled prescriptions | 16.6 | 15.1 | 15.8 | 15.6 | 0.866 | 0.056 |
| Mean number of generics dispensed | 8.5 | 5.1 | 7.8 | 4.9 | 0.758 | 0.151 |
| Mean number of unique drug classes dispensed | 8.1 | 4.6 | 7.4 | 4.5 | 0.609 | 0.135 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | 0.000 | 0.000 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.5 | -0.015 | -0.035 |

Table 1w. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of outpatient visits for respiratory disorders | 2.4 | 3.3 | 1.8 | 2.8 | 0.558 | 0.181 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1x. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 496,977 | N/A | 478,459 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 47.9 | 15.5 | 47.8 | 16.4 | 0.150 | 0.009 |
| Age | | | | | | |
| 10-24 years | 103,207 | 20.8% | 109,543 | 22.9% | -2.128 | -0.058 |
| 25-54 years | 181,358 | 36.5% | 159,271 | 33.3% | 3.204 | 0.071 |
| ≥ 55 years | 212,412 | 42.7% | 209,645 | 43.8% | -1.076 | -0.029 |
| Sex | | | | | | |
| Female | 496,977 | 100.0% | 478,459 | 100.0% | 0.000 | NaN |
| Male | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 3,087 | 0.6% | 3,214 | 0.7% | -0.051 | -0.006 |
| Asian | 10,098 | 2.0% | 8,223 | 1.7% | 0.313 | 0.023 |
| Black or African American | 55,785 | 11.2% | 49,211 | 10.3% | 0.939 | 0.031 |
| Multi-racial | 1,273 | 0.3% | 1,178 | 0.2% | 0.010 | 0.002 |
| Native Hawaiian or Other Pacific Islander | 849 | 0.2% | 1,079 | 0.2% | -0.055 | -0.012 |
| Unknown | 235,670 | 47.4% | 229,050 | 47.9% | -0.452 | -0.014 |
| White | 190,215 | 38.3% | 186,504 | 39.0% | -0.706 | -0.019 |
| Hispanic origin | | | | | | |
| Yes | 36,806 | 7.4% | 36,709 | 7.7% | -0.266 | -0.011 |
| No | 244,641 | 49.2% | 233,054 | 48.7% | 0.517 | 0.017 |
| Unknown | 215,530 | 43.4% | 208,696 | 43.6% | -0.250 | -0.011 |
| Year | | | | | | |
| 2015 | 18,926 | 3.8% | 19,239 | 4.0% | -0.213 | -0.011 |
| 2016 | 92,748 | 18.7% | 91,434 | 19.1% | -0.448 | -0.011 |
| 2017 | 105,452 | 21.2% | 102,322 | 21.4% | -0.167 | -0.004 |
| 2018 | 101,430 | 20.4% | 96,558 | 20.2% | 0.228 | 0.006 |
| 2019 | 62,188 | 12.5% | 57,864 | 12.1% | 0.419 | 0.013 |

Table 1x. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2020 | 53,780 | 10.8% | 51,477 | 10.8% | 0.063 | 0.002 |
| 2021 | 47,658 | 9.6% | 45,442 | 9.5% | 0.092 | 0.003 |
| 2022 | 14,795 | 3.0% | 14,124 | 3.0% | 0.025 | 0.001 |
| Pre-boxed warning | 390,633 | 78.6% | 376,684 | 78.7% | -0.127 | -0.003 |
| Post-boxed warning | 106,344 | 21.4% | 101,775 | 21.3% | 0.127 | 0.003 |
| Seasonality | | | | | | |
| Winter | 115,697 | 23.3% | 112,599 | 23.5% | -0.254 | -0.006 |
| Spring | 138,900 | 27.9% | 130,037 | 27.2% | 0.771 | 0.017 |
| Summer | 109,772 | 22.1% | 105,848 | 22.1% | -0.035 | -0.001 |
| Autumn | 132,608 | 26.7% | 129,974 | 27.2% | -0.482 | -0.011 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.6 | 1.5 | 1.6 | 1.5 | 0.001 | 0.000 |
| Psychiatric History | 277,018 | 55.7% | 264,494 | 55.3% | 0.460 | 0.009 |
| Psychiatric Drug Dispensings ⁶ | 212,565 | 42.8% | 202,459 | 42.3% | 0.457 | 0.009 |
| Self Harm Encounter ⁶ | 1,066 | 0.2% | 1,059 | 0.2% | -0.007 | -0.001 |
| Encounter for Other Psychiatric Event ⁶ | 226,294 | 45.5% | 215,619 | 45.1% | 0.469 | 0.010 |
| Asthma Emergency Encounter | 53,948 | 10.9% | 51,584 | 10.8% | 0.074 | 0.002 |
| Asthma Inpatient Encounter | 1,704 | 0.3% | 1,674 | 0.3% | -0.007 | -0.001 |
| Asthma Outpatient Encounter | 474,474 | 95.5% | 458,374 | 95.8% | -0.330 | -0.016 |
| Oral Corticosteroid Dispensing | 147,877 | 29.8% | 140,653 | 29.4% | 0.358 | 0.008 |
| Use of Other Asthma Medication | 299,260 | 60.2% | 297,416 | 62.2% | -1.945 | -0.041 |
| Allergic Rhinitis | 213,701 | 43.0% | 193,705 | 40.5% | 2.515 | 0.051 |
| Anxiety | 108,153 | 21.8% | 102,752 | 21.5% | 0.287 | 0.007 |
| Depression | 88,991 | 17.9% | 84,931 | 17.8% | 0.155 | 0.004 |
| Sleep Disorder | 80,286 | 16.2% | 75,362 | 15.8% | 0.404 | 0.011 |
| Substance Abuse | 16,011 | 3.2% | 15,530 | 3.2% | -0.024 | -0.001 |
| Poisoning | 1,047 | 0.2% | 1,118 | 0.2% | -0.023 | -0.005 |

Table 1x. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Suffocation | 13 | 0.0% | 12 | 0.0% | 0.000 | 0.000 |
| Suicide Attempt | 557 | 0.1% | 544 | 0.1% | -0.002 | -0.000 |
| Toxicity | 118 | 0.0% | 115 | 0.0% | -0.000 | -0.000 |
| Other Self Harm | 298 | 0.1% | 295 | 0.1% | -0.002 | -0.001 |
| No moderate asthma exacerbations | 415,650 | 83.6% | 398,551 | 83.3% | 0.337 | 0.009 |
| One moderate asthma exacerbation | 71,218 | 14.3% | 70,330 | 14.7% | -0.369 | -0.010 |
| Two or more moderate asthma | 10,109 | 2.0% | 9,578 | 2.0% | 0.032 | 0.002 |
| No severe asthma exacerbations | 492,338 | 99.1% | 473,813 | 99.0% | 0.038 | 0.004 |
| One severe asthma exacerbation | 4,454 | 0.9% | 4,470 | 0.9% | -0.038 | -0.004 |
| Two or more severe asthma exacerbations | 185 | 0.0% | 176 | 0.0% | 0.000 | 0.000 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 114,299 | 23.0% | 108,005 | 22.6% | 0.425 | 0.010 |
| Antipsychotics | 24,877 | 5.0% | 24,356 | 5.1% | -0.085 | -0.004 |
| Anxiolytics Hypnotics | 106,352 | 21.4% | 100,900 | 21.1% | 0.311 | 0.008 |
| Lithium Other Mood Stabilizers | 30,781 | 6.2% | 29,854 | 6.2% | -0.046 | -0.002 |
| Antidepressants | 158,501 | 31.9% | 151,130 | 31.6% | 0.306 | 0.007 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 11.1 | 11.1 | 11.1 | 10.7 | -0.046 | -0.004 |
| Mean number of emergency room | 0.5 | 1.2 | 0.5 | 1.2 | -0.003 | -0.002 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.001 | -0.002 |
| Mean number of other ambulatory encounters | 2.8 | 8.8 | 2.9 | 9.3 | -0.150 | -0.017 |
| Mean number of filled prescriptions | 16.6 | 15.1 | 16.6 | 15.0 | 0.046 | 0.003 |
| Mean number of generics dispensed | 8.5 | 5.1 | 8.4 | 5.2 | 0.098 | 0.019 |
| Mean number of unique drug classes dispensed | 8.1 | 4.6 | 8.0 | 4.6 | 0.075 | 0.016 |

Table 1x. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.001 | -0.004 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.001 | -0.002 |
| Mean number of outpatient visits for respiratory disorders | 2.4 | 3.3 | 2.3 | 3.3 | 0.025 | 0.008 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1y. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 255,259 | 100.0% | 354,780 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 38.3 | 15.9 | 31.9 | 16.2 | 6.433 | 0.402 |
| Age | | | | | | |
| 10-24 years | 104,665 | 41.0% | 191,944 | 54.1% | -13.099 | -0.265 |
| 25-54 years | 75,779 | 29.7% | 90,710 | 25.6% | 4.119 | 0.092 |
| ≥ 55 years | 74,815 | 29.3% | 72,126 | 20.3% | 8.980 | 0.209 |
| Sex | | | | | | |
| Female | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Male | 255,259 | 100.0% | 354,780 | 100.0% | 0.000 | NaN |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 1,553 | 0.6% | 2,873 | 0.8% | -0.201 | -0.024 |
| Asian | 5,894 | 2.3% | 8,378 | 2.4% | -0.052 | -0.003 |
| Black or African American | 25,931 | 10.2% | 43,498 | 12.3% | -2.102 | -0.067 |
| Multi-racial | 639 | 0.3% | 753 | 0.2% | 0.038 | 0.008 |
| Native Hawaiian or Other Pacific Islander | 499 | 0.2% | 1,343 | 0.4% | -0.183 | -0.034 |
| Unknown | 142,937 | 56.0% | 199,587 | 56.3% | -0.260 | -0.005 |
| White | 77,806 | 30.5% | 98,348 | 27.7% | 2.760 | 0.061 |
| Hispanic origin | | | | | | |
| Yes | 25,211 | 9.9% | 49,711 | 14.0% | -4.135 | -0.128 |
| No | 104,727 | 41.0% | 147,028 | 41.4% | -0.414 | -0.008 |
| Unknown | 125,321 | 49.1% | 158,041 | 44.5% | 4.549 | 0.091 |
| Year | | | | | | |
| 2015 | 10,214 | 4.0% | 18,173 | 5.1% | -1.121 | -0.054 |
| 2016 | 49,236 | 19.3% | 81,939 | 23.1% | -3.807 | -0.093 |

Table 1y. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|------------------------|----------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | | |
| Patient Characteristics ¹ | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | Absolute Difference | Standardized Difference |
| 2017 | 58,619 | 23.0% | 94,019 | 26.5% | -3.536 | -0.082 |
| 2018 | 55,124 | 21.6% | 79,570 | 22.4% | -0.833 | -0.020 |
| 2019 | 28,587 | 11.2% | 27,123 | 7.6% | 3.554 | 0.122 |
| 2020 | 24,175 | 9.5% | 24,048 | 6.8% | 2.692 | 0.099 |
| 2021 | 21,789 | 8.5% | 22,075 | 6.2% | 2.314 | 0.089 |
| 2022 | 7,515 | 2.9% | 7,833 | 2.2% | 0.736 | 0.046 |
| Pre-boxed warning | 206,361 | 80.8% | 305,574 | 86.1% | -5.287 | -0.143 |
| Post-boxed warning | 48,898 | 19.2% | 49,206 | 13.9% | 5.287 | 0.143 |
| Seasonality | | | | | | |
| Winter | 58,760 | 23.0% | 88,727 | 25.0% | -1.989 | -0.047 |
| Spring | 70,687 | 27.7% | 79,402 | 22.4% | 5.312 | 0.123 |
| Summer | 56,987 | 22.3% | 76,679 | 21.6% | 0.712 | 0.017 |
| Autumn | 68,825 | 27.0% | 109,972 | 31.0% | -4.034 | -0.089 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.4 | 1.3 | 1.4 | 1.2 | 0.063 | 0.050 |
| Psychiatric History | 108,464 | 42.5% | 144,144 | 40.6% | 1.863 | 0.038 |
| Psychiatric Drug Dispensings ⁵ | 68,485 | 26.8% | 91,469 | 25.8% | 1.048 | 0.024 |
| Self Harm Encounter ⁵ | 342 | 0.1% | 591 | 0.2% | -0.033 | -0.008 |
| Encounter for Other Psychiatric Event ⁵ | 93,987 | 36.8% | 126,140 | 35.6% | 1.266 | 0.026 |
| Asthma Emergency Encounter | 22,554 | 8.8% | 38,498 | 10.9% | -2.016 | -0.068 |
| Asthma Inpatient Encounter | 547 | 0.2% | 1,043 | 0.3% | -0.080 | -0.016 |
| Asthma Outpatient Encounter | 246,182 | 96.4% | 343,276 | 96.8% | -0.313 | -0.017 |
| Oral Corticosteroid Dispensing | 60,903 | 23.9% | 80,410 | 22.7% | 1.195 | 0.028 |
| Use of Other Asthma Medication | 166,179 | 65.1% | 285,718 | 80.5% | -15.432 | -0.352 |

Table 1y. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| | Medical Product | | Covariate Balance | | | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| Patient Characteristics ¹ | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Allergic Rhinitis | 110,642 | 43.3% | 85,938 | 24.2% | 19.122 | 0.413 |
| Anxiety | 28,486 | 11.2% | 36,859 | 10.4% | 0.770 | 0.025 |
| Depression | 21,438 | 8.4% | 29,245 | 8.2% | 0.155 | 0.006 |
| Sleep Disorder | 35,204 | 13.8% | 34,037 | 9.6% | 4.198 | 0.131 |
| Substance Abuse | 8,458 | 3.3% | 15,269 | 4.3% | -0.990 | -0.052 |
| Poisoning | 278 | 0.1% | 556 | 0.2% | -0.048 | -0.013 |
| Suffocation | 17 | 0.0% | 20 | 0.0% | 0.001 | 0.001 |
| Suicide Attempt | 183 | 0.1% | 350 | 0.1% | -0.027 | -0.009 |
| Toxicity | 47 | 0.0% | 75 | 0.0% | -0.003 | -0.002 |
| Other Self Harm | 94 | 0.0% | 164 | 0.0% | -0.009 | -0.005 |
| No moderate asthma exacerbations | 220,473 | 86.4% | 303,122 | 85.4% | 0.933 | 0.027 |
| One moderate asthma exacerbation | 31,028 | 12.2% | 46,282 | 13.0% | -0.890 | -0.027 |
| Two or more moderate asthma | 3,758 | 1.5% | 5,376 | 1.5% | -0.043 | -0.004 |
| No severe asthma exacerbations | 253,680 | 99.4% | 351,695 | 99.1% | 0.251 | 0.029 |
| One severe asthma exacerbation | 1,516 | 0.6% | 3,001 | 0.8% | -0.252 | -0.030 |
| Two or more severe asthma exacerbations | 63 | 0.0% | 84 | 0.0% | 0.001 | 0.001 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 34,749 | 13.6% | 40,670 | 11.5% | 2.150 | 0.065 |
| Antipsychotics | 9,799 | 3.8% | 17,124 | 4.8% | -0.988 | -0.049 |
| Anxiolytics Hypnotics | 28,784 | 11.3% | 33,039 | 9.3% | 1.964 | 0.065 |
| Lithium Other Mood Stabilizers | 9,826 | 3.8% | 14,667 | 4.1% | -0.285 | -0.015 |
| Antidepressants | 38,049 | 14.9% | 48,721 | 13.7% | 1.173 | 0.034 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 8.4 | 10.5 | 7.8 | 10.7 | 0.563 | 0.053 |
| Mean number of emergency room | 0.4 | 1.0 | 0.4 | 1.2 | -0.060 | -0.054 |

Table 1y. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of inpatient hospital encounters | 0.1 | 0.3 | 0.1 | 0.4 | -0.001 | -0.003 |
| Mean number of other ambulatory encounters | 2.5 | 9.8 | 3.2 | 12.9 | -0.672 | -0.059 |
| Mean number of filled prescriptions | 11.7 | 11.9 | 11.1 | 12.1 | 0.633 | 0.053 |
| Mean number of generics dispensed | 6.4 | 4.1 | 5.7 | 3.8 | 0.619 | 0.157 |
| Mean number of unique drug classes dispensed | 6.1 | 3.7 | 5.6 | 3.5 | 0.492 | 0.138 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.001 | -0.006 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.010 | -0.025 |
| Mean number of outpatient visits for respiratory disorders | 2.1 | 3.2 | 1.6 | 2.8 | 0.494 | 0.164 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1z. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| | Medical Product | | Covariate Balance | | | |
|---|----------------------------------|---|--|---|------------------------|----------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | | |
| Patient Characteristics ^{1,2} | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | Absolute Difference | Standardized Difference |
| Weighted patients | 255,192 | N/A | 246,700 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 38.3 | 15.9 | 38.1 | 17.0 | 0.172 | 0.010 |
| Age | | | | | | |
| 10-24 years | 104,662 | 41.0% | 106,806 | 43.3% | -2.281 | -0.057 |
| 25-54 years | 75,767 | 29.7% | 64,005 | 25.9% | 3.746 | 0.087 |
| ≥ 55 years | 74,763 | 29.3% | 75,890 | 30.8% | -1.465 | -0.043 |
| Sex | | | | | | |
| Female | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Male | 255,192 | 100.0% | 246,700 | 100.0% | 0.000 | NaN |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 1,553 | 0.6% | 1,524 | 0.6% | -0.009 | -0.001 |
| Asian | 5,891 | 2.3% | 5,199 | 2.1% | 0.201 | 0.014 |
| Black or African American | 25,927 | 10.2% | 22,823 | 9.3% | 0.909 | 0.032 |
| Multi-racial | 639 | 0.3% | 587 | 0.2% | 0.013 | 0.003 |
| Native Hawaiian or Other Pacific Islander | 499 | 0.2% | 720 | 0.3% | -0.096 | -0.020 |
| Unknown | 142,902 | 56.0% | 140,031 | 56.8% | -0.764 | -0.021 |
| White | 77,781 | 30.5% | 75,816 | 30.7% | -0.253 | -0.007 |
| Hispanic origin | | | | | | |
| Yes | 25,205 | 9.9% | 25,565 | 10.4% | -0.486 | -0.018 |
| No | 104,699 | 41.0% | 99,274 | 40.2% | 0.787 | 0.024 |
| Unknown | 125,288 | 49.1% | 121,860 | 49.4% | -0.301 | -0.012 |
| Year | | | | | | |
| 2015 | 10,212 | 4.0% | 10,298 | 4.2% | -0.172 | -0.009 |
| 2016 | 49,231 | 19.3% | 48,528 | 19.7% | -0.379 | -0.010 |
| 2017 | 58,611 | 23.0% | 57,003 | 23.1% | -0.139 | -0.003 |
| 2018 | 55,113 | 21.6% | 52,791 | 21.4% | 0.198 | 0.005 |
| 2019 | 28,566 | 11.2% | 26,961 | 10.9% | 0.265 | 0.009 |
| 2020 | 24,163 | 9.5% | 23,128 | 9.4% | 0.094 | 0.003 |

Table 1z. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| Patient Characteristics ^{1,2} | Medical Product | | Covariate Balance | | | |
|---|----------------------------------|---|--|---|------------------------|----------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | | |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | Absolute Difference | Standardized Difference |
| 2021 | 21,785 | 8.5% | 20,875 | 8.5% | 0.075 | 0.003 |
| 2022 | 7,511 | 2.9% | 7,117 | 2.9% | 0.059 | 0.004 |
| Pre-boxed warning | 206,312 | 80.8% | 199,895 | 81.0% | -0.182 | -0.005 |
| Post-boxed warning | 48,880 | 19.2% | 46,805 | 19.0% | 0.182 | 0.005 |
| Seasonality | | | | | | |
| Winter | 58,745 | 23.0% | 57,423 | 23.3% | -0.256 | -0.006 |
| Spring | 70,658 | 27.7% | 66,573 | 27.0% | 0.703 | 0.016 |
| Summer | 56,976 | 22.3% | 55,128 | 22.3% | -0.020 | -0.000 |
| Autumn | 68,813 | 27.0% | 67,576 | 27.4% | -0.427 | -0.010 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.4 | 1.3 | 1.4 | 1.3 | -0.002 | -0.002 |
| Psychiatric History | 108,408 | 42.5% | 103,785 | 42.1% | 0.412 | 0.008 |
| Psychiatric Drug Dispensings ⁶ | 68,441 | 26.8% | 65,564 | 26.6% | 0.243 | 0.006 |
| Self Harm Encounter ⁶ | 342 | 0.1% | 283 | 0.1% | 0.019 | 0.006 |
| Encounter for Other Psychiatric Event ⁶ | 93,936 | 36.8% | 89,519 | 36.3% | 0.523 | 0.011 |
| Asthma Emergency Encounter | 22,547 | 8.8% | 21,802 | 8.8% | -0.002 | -0.000 |
| Asthma Inpatient Encounter | 545 | 0.2% | 554 | 0.2% | -0.011 | -0.002 |
| Asthma Outpatient Encounter | 246,124 | 96.4% | 238,461 | 96.7% | -0.214 | -0.012 |
| Oral Corticosteroid Dispensing | 60,861 | 23.8% | 58,117 | 23.6% | 0.291 | 0.007 |
| Use of Other Asthma Medication | 166,168 | 65.1% | 164,830 | 66.8% | -1.699 | -0.037 |
| Allergic Rhinitis | 110,584 | 43.3% | 100,937 | 40.9% | 2.419 | 0.049 |
| Anxiety | 28,463 | 11.2% | 27,247 | 11.0% | 0.109 | 0.003 |
| Depression | 21,424 | 8.4% | 20,609 | 8.4% | 0.041 | 0.002 |
| Sleep Disorder | 35,169 | 13.8% | 33,004 | 13.4% | 0.403 | 0.012 |
| Substance Abuse | 8,455 | 3.3% | 8,354 | 3.4% | -0.073 | -0.004 |
| Poisoning | 278 | 0.1% | 291 | 0.1% | -0.009 | -0.003 |
| Suffocation | 17 | 0.0% | 9 | 0.0% | 0.003 | 0.004 |

Table 1z. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| Patient Characteristics ^{1,2} | Medical Product | | Covariate Balance | | | |
|---|----------------------------------|---|--|---|------------------------|----------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | | |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | Absolute Difference | Standardized Difference |
| Suicide Attempt | 182 | 0.1% | 183 | 0.1% | -0.003 | -0.001 |
| Toxicity | 47 | 0.0% | 39 | 0.0% | 0.003 | 0.002 |
| Other Self Harm | 94 | 0.0% | 102 | 0.0% | -0.004 | -0.002 |
| No moderate asthma exacerbations | 220,424 | 86.4% | 212,253 | 86.0% | 0.339 | 0.010 |
| One moderate asthma exacerbation | 31,013 | 12.2% | 30,752 | 12.5% | -0.312 | -0.010 |
| Two or more moderate asthma | 3,755 | 1.5% | 3,695 | 1.5% | -0.026 | -0.002 |
| No severe asthma exacerbations | 253,616 | 99.4% | 245,098 | 99.4% | 0.032 | 0.004 |
| One severe asthma exacerbation | 1,515 | 0.6% | 1,542 | 0.6% | -0.031 | -0.004 |
| Two or more severe asthma exacerbations | 61 | 0.0% | 61 | 0.0% | -0.001 | -0.001 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 34,709 | 13.6% | 33,106 | 13.4% | 0.182 | 0.005 |
| Antipsychotics | 9,789 | 3.8% | 9,663 | 3.9% | -0.081 | -0.004 |
| Anxiolytics Hypnotics | 28,754 | 11.3% | 27,380 | 11.1% | 0.169 | 0.005 |
| Lithium Other Mood Stabilizers | 9,820 | 3.8% | 9,644 | 3.9% | -0.061 | -0.003 |
| Antidepressants | 38,019 | 14.9% | 36,491 | 14.8% | 0.106 | 0.003 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 8.4 | 10.5 | 8.4 | 10.1 | -0.036 | -0.003 |
| Mean number of emergency room | 0.4 | 1.0 | 0.4 | 1.1 | -0.003 | -0.003 |
| Mean number of inpatient hospital encounters | 0.1 | 0.3 | 0.1 | 0.3 | -0.001 | -0.004 |
| Mean number of other ambulatory encounters | 2.5 | 9.8 | 2.7 | 10.6 | -0.164 | -0.016 |
| Mean number of filled prescriptions | 11.7 | 11.8 | 11.7 | 11.7 | -0.019 | -0.002 |
| Mean number of generics dispensed | 6.3 | 4.1 | 6.3 | 4.1 | 0.065 | 0.016 |
| Mean number of unique drug classes dispensed | 6.0 | 3.7 | 6.0 | 3.7 | 0.050 | 0.014 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.001 | -0.006 |

Table 1z. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.000 | -0.001 |
| Mean number of outpatient visits for respiratory disorders | 2.1 | 3.2 | 2.1 | 3.2 | 0.031 | 0.010 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1aa. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 207,872 | 100.0% | 375,887 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 15.6 | 4.0 | 15.0 | 3.8 | 0.628 | 0.161 |
| Age | | | | | | |
| 10-24 years | 207,872 | 100.0% | 375,887 | 100.0% | 0.000 | NaN |
| 25-54 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| ≥ 55 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Sex | | | | | | |
| Female | 103,207 | 49.6% | 183,943 | 48.9% | 0.714 | 0.014 |
| Male | 104,665 | 50.4% | 191,944 | 51.1% | -0.714 | -0.014 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 1,875 | 0.9% | 3,666 | 1.0% | -0.073 | -0.008 |
| Asian | 3,223 | 1.6% | 7,781 | 2.1% | -0.520 | -0.039 |
| Black or African American | 30,300 | 14.6% | 58,379 | 15.5% | -0.955 | -0.027 |
| Multi-racial | 448 | 0.2% | 676 | 0.2% | 0.036 | 0.008 |
| Native Hawaiian or Other Pacific Islander | 381 | 0.2% | 1,640 | 0.4% | -0.253 | -0.046 |
| Unknown | 133,761 | 64.3% | 233,470 | 62.1% | 2.236 | 0.046 |
| White | 37,884 | 18.2% | 70,275 | 18.7% | -0.471 | -0.012 |
| Hispanic origin | | | | | | |
| Yes | 36,007 | 17.3% | 75,976 | 20.2% | -2.891 | -0.074 |
| No | 71,482 | 34.4% | 138,113 | 36.7% | -2.356 | -0.049 |
| Unknown | 100,383 | 48.3% | 161,798 | 43.0% | 5.246 | 0.105 |
| Year | | | | | | |
| 2015 | 9,718 | 4.7% | 20,009 | 5.3% | -0.648 | -0.030 |
| 2016 | 48,700 | 23.4% | 95,879 | 25.5% | -2.080 | -0.048 |
| 2017 | 59,946 | 28.8% | 113,853 | 30.3% | -1.451 | -0.032 |
| 2018 | 54,094 | 26.0% | 92,686 | 24.7% | 1.365 | 0.031 |
| 2019 | 13,511 | 6.5% | 18,246 | 4.9% | 1.646 | 0.071 |

Table 1aa. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2020 | 9,706 | 4.7% | 14,962 | 4.0% | 0.689 | 0.034 |
| 2021 | 8,746 | 4.2% | 14,427 | 3.8% | 0.369 | 0.019 |
| 2022 | 3,451 | 1.7% | 5,825 | 1.5% | 0.110 | 0.009 |
| Pre-boxed warning | 187,878 | 90.4% | 343,771 | 91.5% | -1.074 | -0.037 |
| Post-boxed warning | 19,994 | 9.6% | 32,116 | 8.5% | 1.074 | 0.037 |
| Seasonality | | | | | | |
| Winter | 43,717 | 21.0% | 89,354 | 23.8% | -2.741 | -0.066 |
| Spring | 54,434 | 26.2% | 78,707 | 20.9% | 5.247 | 0.124 |
| Summer | 50,043 | 24.1% | 84,617 | 22.5% | 1.563 | 0.037 |
| Autumn | 59,678 | 28.7% | 123,209 | 32.8% | -4.069 | -0.088 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.2 | 0.5 | 1.2 | 0.5 | -0.006 | -0.012 |
| Psychiatric History | 68,592 | 33.0% | 123,140 | 32.8% | 0.237 | 0.005 |
| Psychiatric Drug Dispensings ⁵ | 43,119 | 20.7% | 74,283 | 19.8% | 0.981 | 0.024 |
| Self Harm Encounter ⁵ | 553 | 0.3% | 1,175 | 0.3% | -0.047 | -0.009 |
| Encounter for Other Psychiatric Event ⁵ | 60,185 | 29.0% | 109,621 | 29.2% | -0.210 | -0.005 |
| Asthma Emergency Encounter | 24,077 | 11.6% | 47,337 | 12.6% | -1.011 | -0.031 |
| Asthma Inpatient Encounter | 413 | 0.2% | 1,147 | 0.3% | -0.106 | -0.021 |
| Asthma Outpatient Encounter | 199,785 | 96.1% | 363,837 | 96.8% | -0.685 | -0.037 |
| Oral Corticosteroid Dispensing | 42,363 | 20.4% | 78,553 | 20.9% | -0.519 | -0.013 |
| Use of Other Asthma Medication | 156,997 | 75.5% | 323,028 | 85.9% | -10.412 | -0.266 |
| Allergic Rhinitis | 92,342 | 44.4% | 97,742 | 26.0% | 18.420 | 0.393 |
| Anxiety | 20,705 | 10.0% | 36,986 | 9.8% | 0.121 | 0.004 |
| Depression | 15,563 | 7.5% | 27,916 | 7.4% | 0.060 | 0.002 |
| Sleep Disorder | 6,788 | 3.3% | 10,427 | 2.8% | 0.491 | 0.029 |
| Substance Abuse | 2,845 | 1.4% | 6,159 | 1.6% | -0.270 | -0.022 |
| Poisoning | 547 | 0.3% | 1,204 | 0.3% | -0.057 | -0.011 |

Table 1aa. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|------------------------|----------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | | |
| Patient Characteristics ¹ | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | Absolute Difference | Standardized Difference |
| Suffocation | 17 | 0.0% | 27 | 0.0% | 0.001 | 0.001 |
| Suicide Attempt | 288 | 0.1% | 628 | 0.2% | -0.029 | -0.007 |
| Toxicity | 58 | 0.0% | 126 | 0.0% | -0.006 | -0.003 |
| Other Self Harm | 162 | 0.1% | 312 | 0.1% | -0.005 | -0.002 |
| No moderate asthma exacerbations | 181,745 | 87.4% | 322,274 | 85.7% | 1.694 | 0.050 |
| One moderate asthma exacerbation | 23,947 | 11.5% | 48,725 | 13.0% | -1.443 | -0.044 |
| Two or more moderate asthma | 2,180 | 1.0% | 4,888 | 1.3% | -0.252 | -0.023 |
| No severe asthma exacerbations | 206,881 | 99.5% | 372,677 | 99.1% | 0.377 | 0.046 |
| One severe asthma exacerbation | 954 | 0.5% | 3,128 | 0.8% | -0.373 | -0.047 |
| Two or more severe asthma exacerbations | 37 | 0.0% | 82 | 0.0% | -0.004 | -0.003 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 13,031 | 6.3% | 20,608 | 5.5% | 0.786 | 0.033 |
| Antipsychotics | 6,023 | 2.9% | 11,759 | 3.1% | -0.231 | -0.014 |
| Anxiolytics Hypnotics | 11,280 | 5.4% | 17,583 | 4.7% | 0.749 | 0.034 |
| Lithium Other Mood Stabilizers | 4,719 | 2.3% | 9,032 | 2.4% | -0.133 | -0.009 |
| Antidepressants | 21,178 | 10.2% | 35,087 | 9.3% | 0.854 | 0.029 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 6.5 | 8.1 | 6.6 | 8.5 | -0.045 | -0.005 |
| Mean number of emergency room | 0.4 | 1.0 | 0.4 | 1.0 | -0.036 | -0.036 |
| Mean number of inpatient hospital encounters | 0.0 | 0.3 | 0.0 | 0.3 | -0.008 | -0.028 |
| Mean number of other ambulatory encounters | 2.3 | 10.3 | 2.9 | 12.8 | -0.673 | -0.058 |
| Mean number of filled prescriptions | 7.5 | 7.1 | 7.4 | 7.4 | 0.051 | 0.007 |
| Mean number of generics dispensed | 4.9 | 3.1 | 4.7 | 2.9 | 0.256 | 0.084 |
| Mean number of unique drug classes dispensed | 4.8 | 2.8 | 4.6 | 2.7 | 0.153 | 0.055 |

Table 1aa. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.1 | 0.0 | 0.2 | -0.006 | -0.038 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.008 | -0.022 |
| Mean number of outpatient visits for respiratory disorders | 1.8 | 2.9 | 1.5 | 2.5 | 0.356 | 0.133 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1ab. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 207,831 | N/A | 201,205 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 15.6 | 4.0 | 15.5 | 4.0 | 0.080 | 0.020 |
| Age | | | | | | |
| 10-24 years | 207,831 | 100.0% | 201,205 | 100.0% | 0.000 | NaN |
| 25-54 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| ≥ 55 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Sex | | | | | | |
| Female | 103,178 | 49.6% | 99,427 | 49.4% | 0.229 | 0.005 |
| Male | 104,653 | 50.4% | 101,778 | 50.6% | -0.229 | -0.005 |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 1,875 | 0.9% | 1,743 | 0.9% | 0.036 | 0.004 |
| Asian | 3,223 | 1.6% | 3,945 | 2.0% | -0.410 | -0.031 |
| Black or African American | 30,297 | 14.6% | 27,427 | 13.6% | 0.947 | 0.029 |
| Multi-racial | 448 | 0.2% | 390 | 0.2% | 0.022 | 0.005 |
| Native Hawaiian or Other Pacific Islander | 381 | 0.2% | 763 | 0.4% | -0.196 | -0.037 |
| Unknown | 133,728 | 64.3% | 132,377 | 65.8% | -1.448 | -0.036 |
| White | 37,879 | 18.2% | 34,560 | 17.2% | 1.049 | 0.029 |
| Hispanic origin | | | | | | |
| Yes | 36,006 | 17.3% | 37,493 | 18.6% | -1.309 | -0.037 |
| No | 71,475 | 34.4% | 66,185 | 32.9% | 1.497 | 0.039 |
| Unknown | 100,350 | 48.3% | 97,528 | 48.5% | -0.187 | -0.007 |
| Year | | | | | | |
| 2015 | 9,717 | 4.7% | 9,626 | 4.8% | -0.109 | -0.005 |
| 2016 | 48,695 | 23.4% | 47,581 | 23.6% | -0.218 | -0.005 |
| 2017 | 59,936 | 28.8% | 58,265 | 29.0% | -0.119 | -0.003 |
| 2018 | 54,084 | 26.0% | 51,664 | 25.7% | 0.346 | 0.008 |

Table 1ab. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2019 | 13,504 | 6.5% | 12,792 | 6.4% | 0.140 | 0.006 |
| 2020 | 9,700 | 4.7% | 9,451 | 4.7% | -0.030 | -0.001 |
| 2021 | 8,744 | 4.2% | 8,490 | 4.2% | -0.012 | -0.001 |
| 2022 | 3,451 | 1.7% | 3,336 | 1.7% | 0.003 | 0.000 |
| Pre-boxed warning | 187,843 | 90.4% | 181,777 | 90.3% | 0.039 | 0.001 |
| Post-boxed warning | 19,988 | 9.6% | 19,428 | 9.7% | -0.039 | -0.001 |
| Seasonality | | | | | | |
| Winter | 43,712 | 21.0% | 42,885 | 21.3% | -0.282 | -0.007 |
| Spring | 54,407 | 26.2% | 51,249 | 25.5% | 0.708 | 0.016 |
| Summer | 50,037 | 24.1% | 48,373 | 24.0% | 0.034 | 0.001 |
| Autumn | 59,675 | 28.7% | 58,698 | 29.2% | -0.460 | -0.010 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.2 | 0.5 | 1.2 | 0.5 | -0.001 | -0.001 |
| Psychiatric History | 68,559 | 33.0% | 65,961 | 32.8% | 0.205 | 0.004 |
| Psychiatric Drug Dispensings ⁶ | 43,094 | 20.7% | 40,587 | 20.2% | 0.563 | 0.014 |
| Self Harm Encounter ⁶ | 553 | 0.3% | 545 | 0.3% | -0.005 | -0.001 |
| Encounter for Other Psychiatric Event ⁶ | 60,154 | 28.9% | 57,637 | 28.6% | 0.298 | 0.007 |
| Asthma Emergency Encounter | 24,067 | 11.6% | 23,270 | 11.6% | 0.015 | 0.000 |
| Asthma Inpatient Encounter | 413 | 0.2% | 437 | 0.2% | -0.019 | -0.004 |
| Asthma Outpatient Encounter | 199,754 | 96.1% | 193,941 | 96.4% | -0.276 | -0.015 |
| Oral Corticosteroid Dispensing | 42,345 | 20.4% | 41,037 | 20.4% | -0.021 | -0.001 |
| Use of Other Asthma Medication | 156,987 | 75.5% | 155,504 | 77.3% | -1.750 | -0.042 |
| Allergic Rhinitis | 92,303 | 44.4% | 84,945 | 42.2% | 2.195 | 0.045 |
| Anxiety | 20,688 | 10.0% | 19,870 | 9.9% | 0.079 | 0.003 |
| Depression | 15,553 | 7.5% | 14,965 | 7.4% | 0.046 | 0.002 |
| Sleep Disorder | 6,778 | 3.3% | 6,359 | 3.2% | 0.101 | 0.006 |

Table 1ab. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Substance Abuse | 2,842 | 1.4% | 2,835 | 1.4% | -0.042 | -0.004 |
| Poisoning | 547 | 0.3% | 601 | 0.3% | -0.035 | -0.007 |
| Suffocation | 17 | 0.0% | 10 | 0.0% | 0.003 | 0.004 |
| Suicide Attempt | 288 | 0.1% | 309 | 0.2% | -0.015 | -0.004 |
| Toxicity | 58 | 0.0% | 62 | 0.0% | -0.003 | -0.002 |
| Other Self Harm | 162 | 0.1% | 156 | 0.1% | 0.000 | 0.000 |
| No moderate asthma exacerbations | 181,708 | 87.4% | 174,407 | 86.7% | 0.749 | 0.022 |
| One moderate asthma exacerbation | 23,944 | 11.5% | 24,289 | 12.1% | -0.551 | -0.017 |
| Two or more moderate asthma | 2,179 | 1.0% | 2,509 | 1.2% | -0.199 | -0.019 |
| No severe asthma exacerbations | 206,841 | 99.5% | 200,124 | 99.5% | 0.061 | 0.009 |
| One severe asthma exacerbation | 954 | 0.5% | 1,041 | 0.5% | -0.058 | -0.008 |
| Two or more severe asthma exacerbations | 36 | 0.0% | 40 | 0.0% | -0.003 | -0.002 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 13,022 | 6.3% | 12,363 | 6.1% | 0.121 | 0.005 |
| Antipsychotics | 6,017 | 2.9% | 5,947 | 3.0% | -0.061 | -0.004 |
| Anxiolytics Hypnotics | 11,269 | 5.4% | 10,560 | 5.2% | 0.174 | 0.008 |
| Lithium Other Mood Stabilizers | 4,713 | 2.3% | 4,603 | 2.3% | -0.020 | -0.001 |
| Antidepressants | 21,161 | 10.2% | 20,149 | 10.0% | 0.168 | 0.006 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 6.5 | 8.1 | 6.6 | 7.8 | -0.006 | -0.001 |
| Mean number of emergency room | 0.4 | 1.0 | 0.4 | 1.0 | -0.002 | -0.002 |
| Mean number of inpatient hospital encounters | 0.0 | 0.3 | 0.0 | 0.3 | -0.002 | -0.007 |
| Mean number of other ambulatory encounters | 2.3 | 10.3 | 2.6 | 11.6 | -0.350 | -0.032 |
| Mean number of filled prescriptions | 7.5 | 7.1 | 7.5 | 7.1 | 0.013 | 0.002 |
| Mean number of generics dispensed | 4.9 | 3.1 | 4.9 | 3.2 | 0.051 | 0.016 |

Table 1ab. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of unique drug classes dispensed | 4.8 | 2.8 | 4.7 | 2.9 | 0.037 | 0.013 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.1 | 0.0 | 0.1 | -0.001 | -0.008 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.001 | -0.002 |
| Mean number of outpatient visits for respiratory disorders | 1.8 | 2.9 | 1.8 | 2.8 | 0.042 | 0.015 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1ac. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|---|---|-------------|---|---------------------|-------------------------|
| | Inhaled Corticosteroids (ICS) Sensitivity | | | | Absolute Difference | Standardized Difference |
| | Montelukast Sensitivity Analysis | | Analysis | | | |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 257,148 | 100.0% | 294,436 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 40.4 | 8.4 | 39.8 | 8.5 | 0.512 | 0.061 |
| Age | | | | | | |
| 10-24 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 25-54 years | 257,148 | 100.0% | 294,436 | 100.0% | 0.000 | NaN |
| ≥ 55 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Sex | | | | | | |
| Female | 181,369 | 70.5% | 203,726 | 69.2% | 1.339 | 0.029 |
| Male | 75,779 | 29.5% | 90,710 | 30.8% | -1.339 | -0.029 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 1,423 | 0.6% | 2,696 | 0.9% | -0.362 | -0.042 |
| Asian | 4,290 | 1.7% | 5,838 | 2.0% | -0.314 | -0.023 |
| Black or African American | 24,390 | 9.5% | 36,234 | 12.3% | -2.821 | -0.091 |
| Multi-racial | 1,158 | 0.5% | 1,019 | 0.3% | 0.104 | 0.017 |
| Native Hawaiian or Other Pacific Islander | 405 | 0.2% | 1,086 | 0.4% | -0.211 | -0.041 |
| Unknown | 171,015 | 66.5% | 167,557 | 56.9% | 9.597 | 0.198 |
| White | 54,467 | 21.2% | 80,006 | 27.2% | -5.991 | -0.140 |
| Hispanic origin | | | | | | |
| Yes | 17,129 | 6.7% | 28,464 | 9.7% | -3.006 | -0.110 |
| No | 74,388 | 28.9% | 116,562 | 39.6% | -10.660 | -0.226 |
| Unknown | 165,631 | 64.4% | 149,410 | 50.7% | 13.666 | 0.279 |
| Year | | | | | | |
| 2015 | 9,809 | 3.8% | 14,029 | 4.8% | -0.950 | -0.047 |
| 2016 | 48,279 | 18.8% | 64,375 | 21.9% | -3.089 | -0.077 |
| 2017 | 55,357 | 21.5% | 75,785 | 25.7% | -4.212 | -0.099 |
| 2018 | 53,240 | 20.7% | 65,905 | 22.4% | -1.679 | -0.041 |
| 2019 | 29,855 | 11.6% | 22,845 | 7.8% | 3.851 | 0.130 |

Table 1ac. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2020 | 28,163 | 11.0% | 23,750 | 8.1% | 2.886 | 0.098 |
| 2021 | 23,589 | 9.2% | 19,834 | 6.7% | 2.437 | 0.090 |
| 2022 | 8,856 | 3.4% | 7,913 | 2.7% | 0.756 | 0.044 |
| Pre-boxed warning | 201,276 | 78.3% | 246,933 | 83.9% | -5.594 | -0.143 |
| Post-boxed warning | 55,872 | 21.7% | 47,503 | 16.1% | 5.594 | 0.143 |
| Seasonality | | | | | | |
| Winter | 59,055 | 23.0% | 75,126 | 25.5% | -2.550 | -0.060 |
| Spring | 75,203 | 29.2% | 68,655 | 23.3% | 5.928 | 0.135 |
| Summer | 55,312 | 21.5% | 61,601 | 20.9% | 0.588 | 0.014 |
| Autumn | 67,578 | 26.3% | 89,054 | 30.2% | -3.966 | -0.088 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.4 | 1.1 | 1.5 | 1.2 | -0.053 | -0.046 |
| Psychiatric History | 143,353 | 55.7% | 168,149 | 57.1% | -1.362 | -0.027 |
| Psychiatric Drug Dispensings ⁵ | 107,788 | 41.9% | 126,188 | 42.9% | -0.941 | -0.019 |
| Self Harm Encounter ⁵ | 705 | 0.3% | 1,141 | 0.4% | -0.113 | -0.020 |
| Encounter for Other Psychiatric Event ⁵ | 120,700 | 46.9% | 142,478 | 48.4% | -1.452 | -0.029 |
| Asthma Emergency Encounter | 31,695 | 12.3% | 43,028 | 14.6% | -2.288 | -0.067 |
| Asthma Inpatient Encounter | 937 | 0.4% | 1,019 | 0.3% | 0.018 | 0.003 |
| Asthma Outpatient Encounter | 245,692 | 95.5% | 281,169 | 95.5% | 0.051 | 0.002 |
| Oral Corticosteroid Dispensing | 78,193 | 30.4% | 85,975 | 29.2% | 1.208 | 0.026 |
| Use of Other Asthma Medication | 171,159 | 66.6% | 237,360 | 80.6% | -14.055 | -0.323 |
| Allergic Rhinitis | 109,249 | 42.5% | 59,267 | 20.1% | 22.356 | 0.497 |
| Anxiety | 60,551 | 23.5% | 68,544 | 23.3% | 0.267 | 0.006 |
| Depression | 43,810 | 17.0% | 53,492 | 18.2% | -1.131 | -0.030 |
| Sleep Disorder | 38,545 | 15.0% | 36,504 | 12.4% | 2.591 | 0.075 |
| Substance Abuse | 13,267 | 5.2% | 24,373 | 8.3% | -3.119 | -0.125 |
| Poisoning | 634 | 0.2% | 1,111 | 0.4% | -0.131 | -0.023 |

Table 1ac. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| | Medical Product | | | | Covariate Balance | |
|---|---|---|-------------|---|------------------------|----------------------------|
| | Inhaled Corticosteroids (ICS) Sensitivity | | | | | |
| | Montelukast Sensitivity Analysis | | | Analysis | | |
| Patient Characteristics ¹ | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | Absolute Difference | Standardized Difference |
| Suffocation | 12 | 0.0% | 19 | 0.0% | -0.002 | -0.002 |
| Suicide Attempt | 372 | 0.1% | 562 | 0.2% | -0.046 | -0.011 |
| Toxicity | 72 | 0.0% | 130 | 0.0% | -0.016 | -0.009 |
| Other Self Harm | 194 | 0.1% | 290 | 0.1% | -0.023 | -0.008 |
| No moderate asthma exacerbations | 215,246 | 83.7% | 243,203 | 82.6% | 1.105 | 0.030 |
| One moderate asthma exacerbation | 36,786 | 14.3% | 44,976 | 15.3% | -0.970 | -0.027 |
| Two or more moderate asthma | 5,116 | 2.0% | 6,257 | 2.1% | -0.136 | -0.010 |
| No severe asthma exacerbations | 254,842 | 99.1% | 291,437 | 99.0% | 0.122 | 0.013 |
| One severe asthma exacerbation | 2,180 | 0.8% | 2,893 | 1.0% | -0.135 | -0.014 |
| Two or more severe asthma exacerbations | 126 | 0.0% | 106 | 0.0% | 0.013 | 0.006 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 60,024 | 23.3% | 72,975 | 24.8% | -1.442 | -0.034 |
| Antipsychotics | 17,888 | 7.0% | 28,585 | 9.7% | -2.752 | -0.100 |
| Anxiolytics Hypnotics | 56,414 | 21.9% | 63,995 | 21.7% | 0.204 | 0.005 |
| Lithium Other Mood Stabilizers | 20,512 | 8.0% | 27,559 | 9.4% | -1.383 | -0.049 |
| Antidepressants | 78,757 | 30.6% | 94,183 | 32.0% | -1.360 | -0.029 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 9.6 | 11.2 | 10.1 | 12.5 | -0.446 | -0.038 |
| Mean number of emergency room | 0.6 | 1.5 | 0.7 | 1.8 | -0.158 | -0.096 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.015 | -0.035 |
| Mean number of other ambulatory encounters | 2.6 | 9.4 | 3.6 | 12.4 | -0.938 | -0.085 |
| Mean number of filled prescriptions | 15.7 | 15.1 | 16.7 | 16.5 | -1.058 | -0.067 |
| Mean number of generics dispensed | 7.9 | 5.1 | 7.9 | 5.1 | 0.044 | 0.009 |
| Mean number of unique drug classes dispensed | 7.5 | 4.6 | 7.5 | 4.6 | -0.030 | -0.006 |

Table 1ac. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.3 | -0.006 | -0.024 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.5 | 0.2 | 0.5 | -0.022 | -0.043 |
| Mean number of outpatient visits for respiratory disorders | 2.1 | 3.2 | 1.6 | 2.7 | 0.454 | 0.154 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1ad. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|---|---|-------------|---|---------------------|-------------------------|
| | Inhaled Corticosteroids (ICS) Sensitivity | | | | Absolute Difference | Standardized Difference |
| | Montelukast Sensitivity Analysis | | Analysis | | | |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 257,106 | N/A | 247,528 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 40.3 | 8.4 | 40.4 | 8.5 | -0.002 | -0.000 |
| Age | | | | | | |
| 10-24 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 25-54 years | 257,106 | 100.0% | 247,528 | 100.0% | 0.000 | NaN |
| ≥ 55 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Sex | | | | | | |
| Female | 181,330 | 70.5% | 173,831 | 70.2% | 0.301 | 0.007 |
| Male | 75,776 | 29.5% | 73,698 | 29.8% | -0.301 | -0.007 |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 1,422 | 0.6% | 1,561 | 0.6% | -0.078 | -0.010 |
| Asian | 4,290 | 1.7% | 3,970 | 1.6% | 0.065 | 0.005 |
| Black or African American | 24,383 | 9.5% | 22,654 | 9.2% | 0.332 | 0.012 |
| Multi-racial | 1,158 | 0.5% | 1,153 | 0.5% | -0.016 | -0.002 |
| Native Hawaiian or Other Pacific Islander | 405 | 0.2% | 556 | 0.2% | -0.067 | -0.015 |
| Unknown | 170,995 | 66.5% | 164,605 | 66.5% | 0.008 | 0.000 |
| White | 54,453 | 21.2% | 53,029 | 21.4% | -0.244 | -0.007 |
| Hispanic origin | | | | | | |
| Yes | 17,121 | 6.7% | 16,756 | 6.8% | -0.110 | -0.005 |
| No | 74,368 | 28.9% | 71,067 | 28.7% | 0.214 | 0.008 |
| Unknown | 165,617 | 64.4% | 159,706 | 64.5% | -0.104 | -0.004 |
| Year | | | | | | |
| 2015 | 9,809 | 3.8% | 9,894 | 4.0% | -0.182 | -0.009 |
| 2016 | 48,275 | 18.8% | 47,147 | 19.0% | -0.271 | -0.007 |
| 2017 | 55,349 | 21.5% | 53,426 | 21.6% | -0.056 | -0.001 |
| 2018 | 53,226 | 20.7% | 50,608 | 20.4% | 0.257 | 0.007 |

Table 1ad. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|---|---|-------------|---|---------------------|-------------------------|
| | Inhaled Corticosteroids (ICS) Sensitivity | | | | Absolute Difference | Standardized Difference |
| | Montelukast Sensitivity Analysis | | Analysis | | | |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2019 | 29,846 | 11.6% | 27,950 | 11.3% | 0.317 | 0.010 |
| 2020 | 28,158 | 11.0% | 27,182 | 11.0% | -0.029 | -0.001 |
| 2021 | 23,587 | 9.2% | 22,780 | 9.2% | -0.029 | -0.001 |
| 2022 | 8,856 | 3.4% | 8,542 | 3.5% | -0.007 | -0.000 |
| Pre-boxed warning | 201,241 | 78.3% | 193,542 | 78.2% | 0.082 | 0.002 |
| Post-boxed warning | 55,865 | 21.7% | 53,987 | 21.8% | -0.082 | -0.002 |
| Seasonality | | | | | | |
| Winter | 59,053 | 23.0% | 57,809 | 23.4% | -0.386 | -0.009 |
| Spring | 75,180 | 29.2% | 70,204 | 28.4% | 0.879 | 0.019 |
| Summer | 55,300 | 21.5% | 53,053 | 21.4% | 0.076 | 0.002 |
| Autumn | 67,573 | 26.3% | 66,462 | 26.9% | -0.568 | -0.013 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.4 | 1.1 | 1.4 | 1.1 | -0.002 | -0.001 |
| Psychiatric History | 143,311 | 55.7% | 136,924 | 55.3% | 0.424 | 0.009 |
| Psychiatric Drug Dispensings ⁶ | 107,750 | 41.9% | 102,597 | 41.4% | 0.460 | 0.010 |
| Self Harm Encounter ⁶ | 705 | 0.3% | 634 | 0.3% | 0.018 | 0.003 |
| Encounter for Other Psychiatric Event ⁶ | 120,664 | 46.9% | 115,321 | 46.6% | 0.343 | 0.007 |
| Asthma Emergency Encounter | 31,679 | 12.3% | 30,144 | 12.2% | 0.143 | 0.004 |
| Asthma Inpatient Encounter | 935 | 0.4% | 908 | 0.4% | -0.003 | -0.001 |
| Asthma Outpatient Encounter | 245,669 | 95.6% | 237,342 | 95.9% | -0.333 | -0.017 |
| Oral Corticosteroid Dispensing | 78,162 | 30.4% | 74,963 | 30.3% | 0.116 | 0.003 |
| Use of Other Asthma Medication | 171,156 | 66.6% | 169,941 | 68.7% | -2.085 | -0.045 |
| Allergic Rhinitis | 109,208 | 42.5% | 99,045 | 40.0% | 2.462 | 0.051 |
| Anxiety | 60,528 | 23.5% | 57,637 | 23.3% | 0.257 | 0.006 |
| Depression | 43,790 | 17.0% | 41,980 | 17.0% | 0.072 | 0.002 |
| Sleep Disorder | 38,524 | 15.0% | 36,168 | 14.6% | 0.372 | 0.011 |

Table 1ad. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| | Medical Product | | | | Covariate Balance | |
|---|---|---|-------------|---|------------------------|----------------------------|
| | Inhaled Corticosteroids (ICS) Sensitivity | | | | | |
| | Montelukast Sensitivity Analysis | | | Analysis | | |
| Patient Characteristics ^{1,2} | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | Absolute Difference | Standardized Difference |
| Substance Abuse | 13,266 | 5.2% | 13,043 | 5.3% | -0.110 | -0.005 |
| Poisoning | 632 | 0.2% | 645 | 0.3% | -0.015 | -0.003 |
| Suffocation | 12 | 0.0% | 10 | 0.0% | 0.001 | 0.001 |
| Suicide Attempt | 371 | 0.1% | 339 | 0.1% | 0.007 | 0.002 |
| Toxicity | 71 | 0.0% | 72 | 0.0% | -0.001 | -0.001 |
| Other Self Harm | 194 | 0.1% | 185 | 0.1% | 0.001 | 0.000 |
| No moderate asthma exacerbations | 215,213 | 83.7% | 205,669 | 83.1% | 0.617 | 0.017 |
| One moderate asthma exacerbation | 36,778 | 14.3% | 36,896 | 14.9% | -0.601 | -0.017 |
| Two or more moderate asthma | 5,115 | 2.0% | 4,964 | 2.0% | -0.016 | -0.001 |
| No severe asthma exacerbations | 254,802 | 99.1% | 245,233 | 99.1% | 0.031 | 0.003 |
| One severe asthma exacerbation | 2,179 | 0.8% | 2,185 | 0.9% | -0.035 | -0.004 |
| Two or more severe asthma exacerbations | 125 | 0.0% | 111 | 0.0% | 0.004 | 0.002 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 59,994 | 23.3% | 56,916 | 23.0% | 0.341 | 0.008 |
| Antipsychotics | 17,879 | 7.0% | 17,402 | 7.0% | -0.076 | -0.003 |
| Anxiolytics Hypnotics | 56,380 | 21.9% | 53,586 | 21.6% | 0.280 | 0.007 |
| Lithium Other Mood Stabilizers | 20,503 | 8.0% | 19,779 | 8.0% | -0.016 | -0.001 |
| Antidepressants | 78,731 | 30.6% | 75,231 | 30.4% | 0.229 | 0.005 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 9.6 | 11.2 | 9.7 | 10.8 | -0.084 | -0.008 |
| Mean number of emergency room | 0.6 | 1.5 | 0.6 | 1.5 | -0.003 | -0.002 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.000 | -0.001 |
| Mean number of other ambulatory encounters | 2.6 | 9.4 | 2.7 | 9.4 | -0.090 | -0.010 |
| Mean number of filled prescriptions | 15.7 | 15.1 | 15.6 | 15.0 | 0.065 | 0.004 |
| Mean number of generics dispensed | 7.9 | 5.1 | 7.8 | 5.2 | 0.092 | 0.018 |

Table 1ad. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of unique drug classes dispensed | 7.5 | 4.5 | 7.4 | 4.6 | 0.071 | 0.015 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.001 | -0.003 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.5 | 0.1 | 0.5 | -0.001 | -0.002 |
| Mean number of outpatient visits for respiratory disorders | 2.1 | 3.2 | 2.1 | 3.1 | 0.009 | 0.003 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1ae. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 287,237 | 100.0% | 253,066 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 69.6 | 7.3 | 69.0 | 7.5 | 0.535 | 0.072 |
| Age | | | | | | |
| 10-24 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 25-54 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| ≥ 55 years | 287,237 | 100.0% | 253,066 | 100.0% | 0.000 | NaN |
| Sex | | | | | | |
| Female | 212,422 | 74.0% | 180,940 | 71.5% | 2.454 | 0.055 |
| Male | 74,815 | 26.0% | 72,126 | 28.5% | -2.454 | -0.055 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 1,343 | 0.5% | 1,533 | 0.6% | -0.138 | -0.019 |
| Asian | 8,480 | 3.0% | 6,062 | 2.4% | 0.557 | 0.035 |
| Black or African American | 27,029 | 9.4% | 22,157 | 8.8% | 0.655 | 0.023 |
| Multi-racial | 306 | 0.1% | 273 | 0.1% | -0.001 | -0.000 |
| Native Hawaiian or Other Pacific Islander | 562 | 0.2% | 509 | 0.2% | -0.005 | -0.001 |
| Unknown | 73,841 | 25.7% | 72,525 | 28.7% | -2.951 | -0.066 |
| White | 175,676 | 61.2% | 150,007 | 59.3% | 1.885 | 0.039 |
| Hispanic origin | | | | | | |
| Yes | 8,884 | 3.1% | 10,041 | 4.0% | -0.875 | -0.047 |
| No | 203,506 | 70.8% | 172,273 | 68.1% | 2.775 | 0.060 |
| Unknown | 74,847 | 26.1% | 70,752 | 28.0% | -1.900 | -0.043 |
| Year | | | | | | |
| 2015 | 9,614 | 3.3% | 12,650 | 5.0% | -1.652 | -0.083 |
| 2016 | 45,009 | 15.7% | 49,761 | 19.7% | -3.994 | -0.105 |
| 2017 | 48,771 | 17.0% | 48,666 | 19.2% | -2.251 | -0.058 |
| 2018 | 49,227 | 17.1% | 43,809 | 17.3% | -0.173 | -0.005 |
| 2019 | 47,412 | 16.5% | 33,650 | 13.3% | 3.209 | 0.090 |

Table 1ae. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2020 | 40,088 | 14.0% | 30,350 | 12.0% | 1.964 | 0.058 |
| 2021 | 37,113 | 12.9% | 26,801 | 10.6% | 2.330 | 0.072 |
| 2022 | 10,003 | 3.5% | 7,379 | 2.9% | 0.567 | 0.032 |
| Pre-boxed warning | 207,859 | 72.4% | 194,321 | 76.8% | -4.422 | -0.102 |
| Post-boxed warning | 79,378 | 27.6% | 58,745 | 23.2% | 4.422 | 0.102 |
| Seasonality | | | | | | |
| Winter | 71,688 | 25.0% | 68,178 | 26.9% | -1.983 | -0.045 |
| Spring | 79,956 | 27.8% | 59,300 | 23.4% | 4.404 | 0.101 |
| Summer | 61,411 | 21.4% | 52,837 | 20.9% | 0.501 | 0.012 |
| Autumn | 74,182 | 25.8% | 72,751 | 28.7% | -2.922 | -0.066 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 2.0 | 2.0 | 2.0 | 2.1 | 0.005 | 0.002 |
| Psychiatric History | 173,557 | 60.4% | 147,711 | 58.4% | 2.054 | 0.042 |
| Psychiatric Drug Dispensings ⁵ | 130,160 | 45.3% | 111,691 | 44.1% | 1.179 | 0.024 |
| Self Harm Encounter ⁵ | 150 | 0.1% | 158 | 0.1% | -0.010 | -0.004 |
| Encounter for Other Psychiatric Event ⁵ | 139,413 | 48.5% | 117,428 | 46.4% | 2.134 | 0.043 |
| Asthma Emergency Encounter | 20,734 | 7.2% | 20,130 | 8.0% | -0.736 | -0.028 |
| Asthma Inpatient Encounter | 901 | 0.3% | 739 | 0.3% | 0.022 | 0.004 |
| Asthma Outpatient Encounter | 275,191 | 95.8% | 243,315 | 96.1% | -0.341 | -0.017 |
| Oral Corticosteroid Dispensing | 88,233 | 30.7% | 69,296 | 27.4% | 3.335 | 0.074 |
| Use of Other Asthma Medication | 137,290 | 47.8% | 163,078 | 64.4% | -16.644 | -0.340 |
| Allergic Rhinitis | 122,766 | 42.7% | 57,423 | 22.7% | 20.049 | 0.437 |
| Anxiety | 55,393 | 19.3% | 44,947 | 17.8% | 1.524 | 0.039 |
| Depression | 51,067 | 17.8% | 44,709 | 17.7% | 0.112 | 0.003 |
| Sleep Disorder | 70,165 | 24.4% | 54,114 | 21.4% | 3.044 | 0.072 |
| Substance Abuse | 8,357 | 2.9% | 8,797 | 3.5% | -0.567 | -0.032 |
| Poisoning | 145 | 0.1% | 168 | 0.1% | -0.016 | -0.007 |

Table 1ae. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Suffocation | 1 | 0.0% | 0 | 0.0% | NaN | NaN |
| Suicide Attempt | 80 | 0.0% | 74 | 0.0% | -0.001 | -0.001 |
| Toxicity | 36 | 0.0% | 23 | 0.0% | 0.003 | 0.003 |
| Other Self Harm | 36 | 0.0% | 36 | 0.0% | -0.002 | -0.001 |
| No moderate asthma exacerbations | 239,151 | 83.3% | 213,809 | 84.5% | -1.228 | -0.033 |
| One moderate asthma exacerbation | 41,515 | 14.5% | 34,419 | 13.6% | 0.852 | 0.025 |
| Two or more moderate asthma | 6,571 | 2.3% | 4,838 | 1.9% | 0.376 | 0.026 |
| No severe asthma exacerbations | 284,313 | 99.0% | 250,294 | 98.9% | 0.077 | 0.008 |
| One severe asthma exacerbation | 2,838 | 1.0% | 2,714 | 1.1% | -0.084 | -0.008 |
| Two or more severe asthma exacerbations | 86 | 0.0% | 58 | 0.0% | 0.007 | 0.004 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 76,006 | 26.5% | 64,357 | 25.4% | 1.030 | 0.024 |
| Antipsychotics | 10,769 | 3.7% | 11,999 | 4.7% | -0.992 | -0.049 |
| Anxiolytics Hypnotics | 67,457 | 23.5% | 55,381 | 21.9% | 1.601 | 0.038 |
| Lithium Other Mood Stabilizers | 15,380 | 5.4% | 15,000 | 5.9% | -0.573 | -0.025 |
| Antidepressants | 96,629 | 33.6% | 84,167 | 33.3% | 0.382 | 0.008 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 13.3 | 12.3 | 12.7 | 12.4 | 0.534 | 0.043 |
| Mean number of emergency room | 0.3 | 0.9 | 0.4 | 1.0 | -0.024 | -0.026 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.006 | -0.015 |
| Mean number of other ambulatory encounters | 3.0 | 7.8 | 3.5 | 10.3 | -0.471 | -0.052 |
| Mean number of filled prescriptions | 19.8 | 15.5 | 20.5 | 16.7 | -0.725 | -0.045 |
| Mean number of generics dispensed | 9.7 | 5.1 | 9.3 | 5.0 | 0.369 | 0.073 |
| Mean number of unique drug classes dispensed | 9.2 | 4.6 | 9.0 | 4.5 | 0.223 | 0.049 |

Table 1ae. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of inpatient visits for respiratory disorders | 0.1 | 0.3 | 0.1 | 0.3 | -0.006 | -0.019 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.006 | -0.014 |
| Mean number of outpatient visits for respiratory disorders | 2.7 | 3.7 | 2.2 | 3.3 | 0.550 | 0.157 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1af. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 287,155 | N/A | 275,983 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 69.6 | 7.3 | 69.6 | 7.4 | -0.018 | -0.002 |
| Age | | | | | | |
| 10-24 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 25-54 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| ≥ 55 years | 287,155 | 100.0% | 275,983 | 100.0% | 0.000 | NaN |
| Sex | | | | | | |
| Female | 212,356 | 74.0% | 203,295 | 73.7% | 0.290 | 0.007 |
| Male | 74,799 | 26.0% | 72,688 | 26.3% | -0.290 | -0.007 |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 1,343 | 0.5% | 1,425 | 0.5% | -0.049 | -0.007 |
| Asian | 8,475 | 3.0% | 5,678 | 2.1% | 0.894 | 0.058 |
| Black or African American | 27,010 | 9.4% | 21,916 | 7.9% | 1.465 | 0.053 |
| Multi-racial | 305 | 0.1% | 315 | 0.1% | -0.008 | -0.002 |
| Native Hawaiian or Other Pacific Islander | 562 | 0.2% | 481 | 0.2% | 0.021 | 0.005 |
| Unknown | 73,818 | 25.7% | 71,614 | 25.9% | -0.242 | -0.009 |
| White | 175,642 | 61.2% | 174,555 | 63.2% | -2.082 | -0.055 |
| Hispanic origin | | | | | | |
| Yes | 8,876 | 3.1% | 8,068 | 2.9% | 0.168 | 0.010 |
| No | 203,454 | 70.9% | 194,623 | 70.5% | 0.332 | 0.014 |
| Unknown | 74,825 | 26.1% | 73,292 | 26.6% | -0.499 | -0.026 |
| Year | | | | | | |
| 2015 | 9,613 | 3.3% | 9,962 | 3.6% | -0.262 | -0.014 |
| 2016 | 45,005 | 15.7% | 44,876 | 16.3% | -0.588 | -0.016 |
| 2017 | 48,753 | 17.0% | 47,456 | 17.2% | -0.217 | -0.006 |
| 2018 | 49,204 | 17.1% | 46,839 | 17.0% | 0.163 | 0.004 |
| 2019 | 47,390 | 16.5% | 44,026 | 16.0% | 0.551 | 0.015 |

Table 1af. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2020 | 40,082 | 14.0% | 38,134 | 13.8% | 0.141 | 0.004 |
| 2021 | 37,108 | 12.9% | 35,215 | 12.8% | 0.163 | 0.005 |
| 2022 | 10,000 | 3.5% | 9,476 | 3.4% | 0.049 | 0.003 |
| Pre-boxed warning | 207,790 | 72.4% | 200,400 | 72.6% | -0.251 | -0.006 |
| Post-boxed warning | 79,365 | 27.6% | 75,584 | 27.4% | 0.251 | 0.006 |
| Seasonality | | | | | | |
| Winter | 71,677 | 25.0% | 69,404 | 25.1% | -0.187 | -0.004 |
| Spring | 79,915 | 27.8% | 74,799 | 27.1% | 0.727 | 0.016 |
| Summer | 61,390 | 21.4% | 59,340 | 21.5% | -0.123 | -0.003 |
| Autumn | 74,173 | 25.8% | 72,439 | 26.2% | -0.417 | -0.010 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 2.0 | 2.0 | 2.0 | 2.0 | 0.000 | 0.000 |
| Psychiatric History | 173,488 | 60.4% | 165,240 | 59.9% | 0.543 | 0.011 |
| Psychiatric Drug Dispensings ⁶ | 130,095 | 45.3% | 124,214 | 45.0% | 0.297 | 0.006 |
| Self Harm Encounter ⁶ | 150 | 0.1% | 131 | 0.0% | 0.005 | 0.002 |
| Encounter for Other Psychiatric Event ⁶ | 139,360 | 48.5% | 132,100 | 47.9% | 0.666 | 0.013 |
| Asthma Emergency Encounter | 20,726 | 7.2% | 19,727 | 7.1% | 0.070 | 0.003 |
| Asthma Inpatient Encounter | 898 | 0.3% | 879 | 0.3% | -0.006 | -0.001 |
| Asthma Outpatient Encounter | 275,120 | 95.8% | 265,267 | 96.1% | -0.308 | -0.016 |
| Oral Corticosteroid Dispensing | 88,184 | 30.7% | 83,219 | 30.2% | 0.556 | 0.012 |
| Use of Other Asthma Medication | 137,273 | 47.8% | 136,581 | 49.5% | -1.685 | -0.034 |
| Allergic Rhinitis | 122,692 | 42.7% | 110,490 | 40.0% | 2.692 | 0.055 |
| Anxiety | 55,358 | 19.3% | 52,309 | 19.0% | 0.325 | 0.008 |
| Depression | 51,040 | 17.8% | 48,400 | 17.5% | 0.237 | 0.006 |
| Sleep Disorder | 70,138 | 24.4% | 66,028 | 23.9% | 0.501 | 0.012 |
| Substance Abuse | 8,350 | 2.9% | 7,886 | 2.9% | 0.050 | 0.003 |
| Poisoning | 145 | 0.1% | 131 | 0.0% | 0.003 | 0.001 |

Table 1af. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Suffocation | 1 | 0.0% | 0 | 0.0% | NaN | NaN |
| Suicide Attempt | 80 | 0.0% | 60 | 0.0% | 0.006 | 0.004 |
| Toxicity | 36 | 0.0% | 17 | 0.0% | 0.007 | 0.007 |
| Other Self Harm | 36 | 0.0% | 29 | 0.0% | 0.002 | 0.002 |
| No moderate asthma exacerbations | 239,089 | 83.3% | 230,515 | 83.5% | -0.264 | -0.007 |
| One moderate asthma exacerbation | 41,497 | 14.5% | 39,607 | 14.4% | 0.100 | 0.003 |
| Two or more moderate asthma | 6,569 | 2.3% | 5,862 | 2.1% | 0.164 | 0.011 |
| No severe asthma exacerbations | 284,236 | 99.0% | 273,120 | 99.0% | 0.021 | 0.002 |
| One severe asthma exacerbation | 2,836 | 1.0% | 2,787 | 1.0% | -0.022 | -0.002 |
| Two or more severe asthma exacerbations | 83 | 0.0% | 76 | 0.0% | 0.001 | 0.001 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 75,955 | 26.5% | 71,705 | 26.0% | 0.469 | 0.011 |
| Antipsychotics | 10,761 | 3.7% | 10,511 | 3.8% | -0.061 | -0.003 |
| Anxiolytics Hypnotics | 67,405 | 23.5% | 64,010 | 23.2% | 0.280 | 0.007 |
| Lithium Other Mood Stabilizers | 15,369 | 5.4% | 14,966 | 5.4% | -0.070 | -0.003 |
| Antidepressants | 96,586 | 33.6% | 92,024 | 33.3% | 0.292 | 0.006 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 13.3 | 12.3 | 13.3 | 11.7 | -0.044 | -0.004 |
| Mean number of emergency room | 0.3 | 0.9 | 0.3 | 0.9 | 0.001 | 0.001 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.000 | -0.000 |
| Mean number of other ambulatory encounters | 3.0 | 7.8 | 3.1 | 8.1 | -0.043 | -0.005 |
| Mean number of filled prescriptions | 19.8 | 15.5 | 19.8 | 15.3 | -0.023 | -0.001 |
| Mean number of generics dispensed | 9.7 | 5.1 | 9.6 | 5.2 | 0.092 | 0.018 |
| Mean number of unique drug classes dispensed | 9.2 | 4.6 | 9.1 | 4.6 | 0.070 | 0.015 |

Table 1af. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of inpatient visits for respiratory disorders | 0.1 | 0.3 | 0.1 | 0.3 | -0.001 | -0.003 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.000 | -0.001 |
| Mean number of outpatient visits for respiratory disorders | 2.7 | 3.7 | 2.7 | 3.8 | 0.022 | 0.006 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1ag. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 366,755 | 100.0% | 484,389 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 39.7 | 15.7 | 32.9 | 15.9 | 6.758 | 0.429 |
| Age | | | | | | |
| 10-24 years | 139,280 | 38.0% | 252,747 | 52.2% | -14.202 | -0.288 |
| 25-54 years | 113,795 | 31.0% | 126,287 | 26.1% | 4.956 | 0.110 |
| ≥ 55 years | 113,680 | 31.0% | 105,355 | 21.8% | 9.246 | 0.211 |
| Sex | | | | | | |
| Female | 219,960 | 60.0% | 273,753 | 56.5% | 3.460 | 0.070 |
| Male | 146,795 | 40.0% | 210,636 | 43.5% | -3.460 | -0.070 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 2,125 | 0.6% | 3,847 | 0.8% | -0.215 | -0.026 |
| Asian | 10,459 | 2.9% | 13,781 | 2.8% | 0.007 | 0.000 |
| Black or African American | 40,995 | 11.2% | 63,077 | 13.0% | -1.844 | -0.057 |
| Multi-racial | 1,061 | 0.3% | 1,120 | 0.2% | 0.058 | 0.011 |
| Native Hawaiian or Other Pacific Islander | 795 | 0.2% | 2,164 | 0.4% | -0.230 | -0.040 |
| Unknown | 213,063 | 58.1% | 282,637 | 58.3% | -0.255 | -0.005 |
| White | 98,257 | 26.8% | 117,763 | 24.3% | 2.479 | 0.057 |
| Hispanic origin | | | | | | |
| Yes | 38,389 | 10.5% | 73,527 | 15.2% | -4.712 | -0.141 |
| No | 141,923 | 38.7% | 189,966 | 39.2% | -0.521 | -0.011 |
| Unknown | 186,443 | 50.8% | 220,896 | 45.6% | 5.233 | 0.105 |
| Year | | | | | | |
| 2015 | 15,456 | 4.2% | 25,241 | 5.2% | -0.997 | -0.047 |
| 2016 | 73,028 | 19.9% | 113,667 | 23.5% | -3.554 | -0.086 |
| 2017 | 84,999 | 23.2% | 130,716 | 27.0% | -3.810 | -0.088 |
| 2018 | 79,849 | 21.8% | 108,391 | 22.4% | -0.605 | -0.015 |
| 2019 | 40,339 | 11.0% | 35,999 | 7.4% | 3.567 | 0.124 |
| 2020 | 34,053 | 9.3% | 32,400 | 6.7% | 2.596 | 0.096 |

Table 1ag. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2021 | 29,079 | 7.9% | 27,760 | 5.7% | 2.198 | 0.087 |
| 2022 | 9,952 | 2.7% | 10,215 | 2.1% | 0.605 | 0.039 |
| Pre-boxed warning | 300,130 | 81.8% | 420,264 | 86.8% | -4.928 | -0.136 |
| Post-boxed warning | 66,625 | 18.2% | 64,125 | 13.2% | 4.928 | 0.136 |
| Seasonality | | | | | | |
| Winter | 84,483 | 23.0% | 122,436 | 25.3% | -2.241 | -0.052 |
| Spring | 101,541 | 27.7% | 107,561 | 22.2% | 5.481 | 0.127 |
| Summer | 81,177 | 22.1% | 103,540 | 21.4% | 0.758 | 0.018 |
| Autumn | 99,554 | 27.1% | 150,852 | 31.1% | -3.998 | -0.088 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.2 | 1.0 | 1.1 | 0.8 | 0.030 | 0.033 |
| Psychiatric History | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Psychiatric Drug Dispensings ⁵ | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Self Harm Encounter ⁵ | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Encounter for Other Psychiatric Event ⁵ | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Asthma Emergency Encounter | 29,345 | 8.0% | 48,926 | 10.1% | -2.099 | -0.073 |
| Asthma Inpatient Encounter | 762 | 0.2% | 1,157 | 0.2% | -0.031 | -0.007 |
| Asthma Outpatient Encounter | 356,965 | 97.3% | 472,197 | 97.5% | -0.152 | -0.010 |
| Oral Corticosteroid Dispensing | 86,673 | 23.6% | 108,718 | 22.4% | 1.188 | 0.028 |
| Use of Other Asthma Medication | 240,263 | 65.5% | 387,214 | 79.9% | -14.428 | -0.328 |
| Allergic Rhinitis | 159,610 | 43.5% | 118,966 | 24.6% | 18.960 | 0.408 |
| Anxiety | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Depression | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Sleep Disorder | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Substance Abuse | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Poisoning | 182 | 0.0% | 337 | 0.1% | -0.020 | -0.008 |
| Suffocation | 3 | 0.0% | 6 | 0.0% | -0.000 | -0.001 |
| Suicide Attempt | 95 | 0.0% | 152 | 0.0% | -0.005 | -0.003 |

Table 1ag. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Toxicity | 19 | 0.0% | 26 | 0.0% | -0.000 | -0.000 |
| Other Self Harm | 46 | 0.0% | 60 | 0.0% | 0.000 | 0.000 |
| No moderate asthma exacerbations | 315,934 | 86.1% | 412,777 | 85.2% | 0.927 | 0.026 |
| One moderate asthma exacerbation | 45,527 | 12.4% | 64,410 | 13.3% | -0.884 | -0.026 |
| Two or more moderate asthma | 5,294 | 1.4% | 7,202 | 1.5% | -0.043 | -0.004 |
| No severe asthma exacerbations | 365,006 | 99.5% | 481,258 | 99.4% | 0.169 | 0.023 |
| One severe asthma exacerbation | 1,706 | 0.5% | 3,089 | 0.6% | -0.173 | -0.023 |
| Two or more severe asthma exacerbations | 43 | 0.0% | 42 | 0.0% | 0.003 | 0.003 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 38,221 | 10.4% | 42,767 | 8.8% | 1.592 | 0.054 |
| Antipsychotics | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Anxiolytics Hypnotics | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Lithium Other Mood Stabilizers | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Antidepressants | 78 | 0.0% | 129 | 0.0% | -0.005 | -0.003 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 6.7 | 7.3 | 5.9 | 6.6 | 0.797 | 0.114 |
| Mean number of emergency room | 0.3 | 0.7 | 0.3 | 0.8 | -0.053 | -0.072 |
| Mean number of inpatient hospital encounters | 0.0 | 0.2 | 0.0 | 0.2 | -0.000 | -0.001 |
| Mean number of other ambulatory encounters | 1.2 | 4.3 | 1.3 | 5.0 | -0.049 | -0.010 |
| Mean number of filled prescriptions | 9.0 | 8.2 | 8.1 | 7.6 | 0.915 | 0.116 |
| Mean number of generics dispensed | 5.6 | 3.4 | 5.0 | 3.1 | 0.589 | 0.183 |
| Mean number of unique drug classes dispensed | 5.3 | 3.1 | 4.9 | 2.8 | 0.472 | 0.160 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.1 | 0.0 | 0.1 | -0.001 | -0.005 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.3 | 0.1 | 0.3 | -0.013 | -0.038 |

Table 1ag. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of outpatient visits for respiratory disorders | 2.0 | 3.0 | 1.5 | 2.6 | 0.451 | 0.160 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1ah. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | Covariate Balance | | | |
|---|----------------------------------|---|--|---|------------------------|----------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | | |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | Absolute Difference | Standardized Difference |
| Weighted patients | 366,683 | N/A | 354,806 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 39.7 | 15.7 | 39.5 | 16.8 | 0.174 | 0.011 |
| Age | | | | | | |
| 10-24 years | 139,277 | 38.0% | 143,484 | 40.4% | -2.457 | -0.059 |
| 25-54 years | 113,785 | 31.0% | 96,077 | 27.1% | 3.952 | 0.092 |
| ≥ 55 years | 113,621 | 31.0% | 115,245 | 32.5% | -1.495 | -0.046 |
| Sex | | | | | | |
| Female | 219,910 | 60.0% | 211,223 | 59.5% | 0.441 | 0.009 |
| Male | 146,773 | 40.0% | 143,583 | 40.5% | -0.441 | -0.009 |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 2,124 | 0.6% | 2,214 | 0.6% | -0.045 | -0.006 |
| Asian | 10,452 | 2.9% | 8,979 | 2.5% | 0.320 | 0.020 |
| Black or African American | 40,984 | 11.2% | 35,872 | 10.1% | 1.067 | 0.036 |
| Multi-racial | 1,061 | 0.3% | 949 | 0.3% | 0.022 | 0.004 |
| Native Hawaiian or Other Pacific Islander | 794 | 0.2% | 1,175 | 0.3% | -0.115 | -0.022 |
| Unknown | 213,036 | 58.1% | 208,424 | 58.7% | -0.645 | -0.018 |
| White | 98,232 | 26.8% | 97,191 | 27.4% | -0.604 | -0.017 |
| Hispanic origin | | | | | | |
| Yes | 38,378 | 10.5% | 38,852 | 11.0% | -0.484 | -0.017 |
| No | 141,882 | 38.7% | 134,851 | 38.0% | 0.686 | 0.021 |
| Unknown | 186,423 | 50.8% | 181,103 | 51.0% | -0.203 | -0.008 |
| Year | | | | | | |
| 2015 | 15,453 | 4.2% | 15,582 | 4.4% | -0.178 | -0.009 |
| 2016 | 73,020 | 19.9% | 71,971 | 20.3% | -0.371 | -0.009 |
| 2017 | 84,989 | 23.2% | 82,775 | 23.3% | -0.152 | -0.004 |
| 2018 | 79,837 | 21.8% | 76,338 | 21.5% | 0.257 | 0.006 |
| 2019 | 40,321 | 11.0% | 37,965 | 10.7% | 0.296 | 0.010 |

Table 1ah. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2020 | 34,046 | 9.3% | 32,837 | 9.3% | 0.030 | 0.001 |
| 2021 | 29,066 | 7.9% | 27,844 | 7.8% | 0.079 | 0.003 |
| 2022 | 9,951 | 2.7% | 9,494 | 2.7% | 0.038 | 0.002 |
| Pre-boxed warning | 300,076 | 81.8% | 290,736 | 81.9% | -0.107 | -0.003 |
| Post-boxed warning | 66,607 | 18.2% | 64,070 | 18.1% | 0.107 | 0.003 |
| Seasonality | | | | | | |
| Winter | 84,467 | 23.0% | 82,702 | 23.3% | -0.274 | -0.006 |
| Spring | 101,512 | 27.7% | 95,643 | 27.0% | 0.727 | 0.016 |
| Summer | 81,163 | 22.1% | 78,590 | 22.2% | -0.016 | -0.000 |
| Autumn | 99,541 | 27.1% | 97,871 | 27.6% | -0.438 | -0.010 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.2 | 1.0 | 1.2 | 1.0 | -0.002 | -0.002 |
| Psychiatric History | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Psychiatric Drug Dispensings ⁶ | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Self Harm Encounter ⁶ | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Encounter for Other Psychiatric Event ⁶ | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Asthma Emergency Encounter | 29,336 | 8.0% | 28,511 | 8.0% | -0.035 | -0.001 |
| Asthma Inpatient Encounter | 760 | 0.2% | 742 | 0.2% | -0.002 | -0.000 |
| Asthma Outpatient Encounter | 356,902 | 97.3% | 345,909 | 97.5% | -0.160 | -0.010 |
| Oral Corticosteroid Dispensing | 86,635 | 23.6% | 82,937 | 23.4% | 0.251 | 0.006 |
| Use of Other Asthma Medication | 240,241 | 65.5% | 238,053 | 67.1% | -1.577 | -0.035 |
| Allergic Rhinitis | 159,548 | 43.5% | 146,307 | 41.2% | 2.275 | 0.046 |
| Anxiety | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Depression | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Sleep Disorder | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Substance Abuse | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Poisoning | 182 | 0.0% | 190 | 0.1% | -0.004 | -0.002 |

Table 1ah. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Suffocation | 3 | 0.0% | 3 | 0.0% | -0.000 | -0.000 |
| Suicide Attempt | 95 | 0.0% | 83 | 0.0% | 0.002 | 0.002 |
| Toxicity | 19 | 0.0% | 15 | 0.0% | 0.001 | 0.001 |
| Other Self Harm | 46 | 0.0% | 34 | 0.0% | 0.003 | 0.003 |
| No moderate asthma exacerbations | 315,883 | 86.1% | 303,779 | 85.6% | 0.528 | 0.015 |
| One moderate asthma exacerbation | 45,509 | 12.4% | 45,704 | 12.9% | -0.470 | -0.014 |
| Two or more moderate asthma | 5,291 | 1.4% | 5,323 | 1.5% | -0.057 | -0.005 |
| No severe asthma exacerbations | 364,938 | 99.5% | 353,051 | 99.5% | 0.019 | 0.003 |
| One severe asthma exacerbation | 1,706 | 0.5% | 1,721 | 0.5% | -0.020 | -0.003 |
| Two or more severe asthma exacerbations | 39 | 0.0% | 34 | 0.0% | 0.001 | 0.001 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 38,191 | 10.4% | 36,427 | 10.3% | 0.148 | 0.005 |
| Antipsychotics | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Anxiolytics Hypnotics | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Lithium Other Mood Stabilizers | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Antidepressants | 76 | 0.0% | 69 | 0.0% | 0.001 | 0.001 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 6.7 | 7.3 | 6.7 | 6.9 | -0.001 | -0.000 |
| Mean number of emergency room | 0.3 | 0.7 | 0.3 | 0.7 | -0.001 | -0.001 |
| Mean number of inpatient hospital encounters | 0.0 | 0.2 | 0.0 | 0.2 | -0.000 | -0.001 |
| Mean number of other ambulatory encounters | 1.2 | 4.3 | 1.3 | 4.4 | -0.041 | -0.009 |
| Mean number of filled prescriptions | 9.0 | 8.1 | 8.9 | 7.9 | 0.064 | 0.008 |
| Mean number of generics dispensed | 5.6 | 3.4 | 5.5 | 3.4 | 0.076 | 0.022 |
| Mean number of unique drug classes dispensed | 5.3 | 3.1 | 5.3 | 3.1 | 0.061 | 0.020 |

Table 1ah. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.1 | 0.0 | 0.1 | -0.000 | -0.002 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.3 | 0.1 | 0.3 | -0.000 | -0.001 |
| Mean number of outpatient visits for respiratory disorders | 2.0 | 3.0 | 1.9 | 3.0 | 0.026 | 0.009 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1ai. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 385,502 | 100.0% | 439,000 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 49.4 | 15.5 | 43.0 | 16.6 | 6.402 | 0.399 |
| Age | | | | | | |
| 10-24 years | 68,592 | 17.8% | 123,140 | 28.1% | -10.257 | -0.246 |
| 25-54 years | 143,353 | 37.2% | 168,149 | 38.3% | -1.117 | -0.023 |
| ≥ 55 years | 173,557 | 45.0% | 147,711 | 33.6% | 11.374 | 0.234 |
| Sex | | | | | | |
| Female | 277,038 | 71.9% | 294,856 | 67.2% | 4.699 | 0.102 |
| Male | 108,464 | 28.1% | 144,144 | 32.8% | -4.699 | -0.102 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 2,516 | 0.7% | 4,048 | 0.9% | -0.269 | -0.030 |
| Asian | 5,534 | 1.4% | 5,900 | 1.3% | 0.092 | 0.008 |
| Black or African American | 40,724 | 10.6% | 53,693 | 12.2% | -1.667 | -0.052 |
| Multi-racial | 851 | 0.2% | 848 | 0.2% | 0.028 | 0.006 |
| Native Hawaiian or Other Pacific Islander | 553 | 0.1% | 1,071 | 0.2% | -0.101 | -0.023 |
| Unknown | 165,554 | 42.9% | 190,915 | 43.5% | -0.544 | -0.011 |
| White | 169,770 | 44.0% | 182,525 | 41.6% | 2.461 | 0.050 |
| Hispanic origin | | | | | | |
| Yes | 23,631 | 6.1% | 40,954 | 9.3% | -3.199 | -0.120 |
| No | 207,453 | 53.8% | 236,982 | 54.0% | -0.169 | -0.003 |
| Unknown | 154,418 | 40.1% | 161,064 | 36.7% | 3.368 | 0.069 |
| Year | | | | | | |
| 2015 | 13,685 | 3.5% | 21,447 | 4.9% | -1.336 | -0.066 |
| 2016 | 68,960 | 17.9% | 96,348 | 21.9% | -4.059 | -0.102 |
| 2017 | 79,075 | 20.5% | 107,588 | 24.5% | -3.995 | -0.096 |
| 2018 | 76,712 | 19.9% | 94,009 | 21.4% | -1.515 | -0.037 |
| 2019 | 50,439 | 13.1% | 38,742 | 8.8% | 4.259 | 0.137 |
| 2020 | 43,904 | 11.4% | 36,662 | 8.4% | 3.038 | 0.102 |

Table 1ai. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2021 | 40,369 | 10.5% | 33,302 | 7.6% | 2.886 | 0.101 |
| 2022 | 12,358 | 3.2% | 10,902 | 2.5% | 0.722 | 0.043 |
| Pre-boxed warning | 296,883 | 77.0% | 364,761 | 83.1% | -6.077 | -0.153 |
| Post-boxed warning | 88,619 | 23.0% | 74,239 | 16.9% | 6.077 | 0.153 |
| Seasonality | | | | | | |
| Winter | 89,977 | 23.3% | 110,222 | 25.1% | -1.767 | -0.041 |
| Spring | 108,052 | 28.0% | 99,101 | 22.6% | 5.455 | 0.126 |
| Summer | 85,589 | 22.2% | 95,515 | 21.8% | 0.445 | 0.011 |
| Autumn | 101,884 | 26.4% | 134,162 | 30.6% | -4.132 | -0.092 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.9 | 1.8 | 1.9 | 1.6 | 0.066 | 0.039 |
| Psychiatric History | 385,502 | 100.0% | 439,000 | 100.0% | 0.000 | NaN |
| Psychiatric Drug Dispensings ⁵ | 281,067 | 72.9% | 312,162 | 71.1% | 1.802 | 0.040 |
| Self Harm Encounter ⁵ | 1,408 | 0.4% | 2,474 | 0.6% | -0.198 | -0.029 |
| Encounter for Other Psychiatric Event ⁵ | 320,298 | 83.1% | 369,527 | 84.2% | -1.089 | -0.029 |
| Asthma Emergency Encounter | 47,161 | 12.2% | 61,569 | 14.0% | -1.791 | -0.053 |
| Asthma Inpatient Encounter | 1,489 | 0.4% | 1,748 | 0.4% | -0.012 | -0.002 |
| Asthma Outpatient Encounter | 363,703 | 94.3% | 416,124 | 94.8% | -0.444 | -0.020 |
| Oral Corticosteroid Dispensing | 122,116 | 31.7% | 125,106 | 28.5% | 3.179 | 0.069 |
| Use of Other Asthma Medication | 225,183 | 58.4% | 336,252 | 76.6% | -18.182 | -0.396 |
| Allergic Rhinitis | 164,747 | 42.7% | 95,466 | 21.7% | 20.989 | 0.461 |
| Anxiety | 136,649 | 35.4% | 150,477 | 34.3% | 1.170 | 0.025 |
| Depression | 110,440 | 28.6% | 126,117 | 28.7% | -0.080 | -0.002 |
| Sleep Disorder | 115,498 | 30.0% | 101,045 | 23.0% | 6.943 | 0.158 |
| Substance Abuse | 24,469 | 6.3% | 39,329 | 9.0% | -2.611 | -0.098 |
| Poisoning | 1,144 | 0.3% | 2,146 | 0.5% | -0.192 | -0.031 |
| Suffocation | 27 | 0.0% | 40 | 0.0% | -0.002 | -0.002 |
| Suicide Attempt | 645 | 0.2% | 1,112 | 0.3% | -0.086 | -0.019 |

Table 1ai. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Toxicity | 147 | 0.0% | 253 | 0.1% | -0.019 | -0.009 |
| Other Self Harm | 346 | 0.1% | 578 | 0.1% | -0.042 | -0.013 |
| No moderate asthma exacerbations | 320,208 | 83.1% | 366,509 | 83.5% | -0.425 | -0.011 |
| One moderate asthma exacerbation | 56,721 | 14.7% | 63,710 | 14.5% | 0.201 | 0.006 |
| Two or more moderate asthma | 8,573 | 2.2% | 8,781 | 2.0% | 0.224 | 0.016 |
| No severe asthma exacerbations | 381,030 | 98.8% | 433,150 | 98.7% | 0.173 | 0.016 |
| One severe asthma exacerbation | 4,266 | 1.1% | 5,646 | 1.3% | -0.179 | -0.017 |
| Two or more severe asthma exacerbations | 206 | 0.1% | 204 | 0.0% | 0.007 | 0.003 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 110,840 | 28.8% | 115,173 | 26.2% | 2.517 | 0.056 |
| Antipsychotics | 34,680 | 9.0% | 52,343 | 11.9% | -2.927 | -0.096 |
| Anxiolytics Hypnotics | 135,151 | 35.1% | 136,959 | 31.2% | 3.860 | 0.082 |
| Lithium Other Mood Stabilizers | 40,611 | 10.5% | 51,591 | 11.8% | -1.217 | -0.039 |
| Antidepressants | 196,486 | 51.0% | 213,308 | 48.6% | 2.379 | 0.048 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 13.5 | 12.9 | 13.2 | 13.8 | 0.236 | 0.018 |
| Mean number of emergency room | 0.6 | 1.5 | 0.7 | 1.7 | -0.129 | -0.081 |
| Mean number of inpatient hospital encounters | 0.1 | 0.5 | 0.1 | 0.5 | -0.008 | -0.016 |
| Mean number of other ambulatory encounters | 4.1 | 11.8 | 5.5 | 16.2 | -1.452 | -0.102 |
| Mean number of filled prescriptions | 20.6 | 16.8 | 20.5 | 17.8 | 0.182 | 0.011 |
| Mean number of generics dispensed | 9.9 | 5.4 | 9.2 | 5.2 | 0.703 | 0.133 |
| Mean number of unique drug classes dispensed | 9.3 | 4.8 | 8.8 | 4.7 | 0.548 | 0.116 |
| Mean number of inpatient visits for respiratory disorders | 0.1 | 0.3 | 0.1 | 0.3 | -0.003 | -0.010 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.5 | 0.2 | 0.5 | -0.016 | -0.033 |

Table 1ai. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of outpatient visits for respiratory disorders | 2.5 | 3.5 | 1.9 | 3.0 | 0.603 | 0.185 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1aj. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 385,471 | N/A | 369,831 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 49.4 | 15.5 | 49.3 | 16.4 | 0.140 | 0.009 |
| Age | | | | | | |
| 10-24 years | 68,590 | 17.8% | 72,773 | 19.7% | -1.884 | -0.055 |
| 25-54 years | 143,331 | 37.2% | 127,029 | 34.3% | 2.836 | 0.062 |
| ≥ 55 years | 173,550 | 45.0% | 170,029 | 46.0% | -0.952 | -0.024 |
| Sex | | | | | | |
| Female | 277,011 | 71.9% | 264,469 | 71.5% | 0.352 | 0.008 |
| Male | 108,460 | 28.1% | 105,362 | 28.5% | -0.352 | -0.008 |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 2,515 | 0.7% | 2,519 | 0.7% | -0.029 | -0.004 |
| Asian | 5,534 | 1.4% | 4,531 | 1.2% | 0.210 | 0.018 |
| Black or African American | 40,717 | 10.6% | 36,083 | 9.8% | 0.806 | 0.028 |
| Multi-racial | 851 | 0.2% | 815 | 0.2% | 0.000 | 0.000 |
| Native Hawaiian or Other Pacific Islander | 553 | 0.1% | 626 | 0.2% | -0.026 | -0.007 |
| Unknown | 165,541 | 42.9% | 160,403 | 43.4% | -0.427 | -0.013 |
| White | 169,760 | 44.0% | 164,854 | 44.6% | -0.536 | -0.014 |
| Hispanic origin | | | | | | |
| Yes | 23,626 | 6.1% | 23,386 | 6.3% | -0.194 | -0.008 |
| No | 207,441 | 53.8% | 197,221 | 53.3% | 0.488 | 0.017 |
| Unknown | 154,404 | 40.1% | 149,225 | 40.3% | -0.293 | -0.013 |
| Year | | | | | | |
| 2015 | 13,684 | 3.5% | 13,932 | 3.8% | -0.217 | -0.012 |
| 2016 | 68,958 | 17.9% | 67,869 | 18.4% | -0.462 | -0.012 |
| 2017 | 79,066 | 20.5% | 76,452 | 20.7% | -0.161 | -0.004 |
| 2018 | 76,703 | 19.9% | 72,843 | 19.7% | 0.202 | 0.005 |
| 2019 | 50,434 | 13.1% | 46,764 | 12.6% | 0.439 | 0.013 |

Table 1aj. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2020 | 43,902 | 11.4% | 41,723 | 11.3% | 0.108 | 0.003 |
| 2021 | 40,367 | 10.5% | 38,471 | 10.4% | 0.070 | 0.002 |
| 2022 | 12,357 | 3.2% | 11,777 | 3.2% | 0.021 | 0.001 |
| Pre-boxed warning | 296,856 | 77.0% | 285,318 | 77.1% | -0.137 | -0.003 |
| Post-boxed warning | 88,615 | 23.0% | 84,513 | 22.9% | 0.137 | 0.003 |
| Seasonality | | | | | | |
| Winter | 89,972 | 23.3% | 87,289 | 23.6% | -0.262 | -0.006 |
| Spring | 108,037 | 28.0% | 100,763 | 27.2% | 0.782 | 0.017 |
| Summer | 85,584 | 22.2% | 82,230 | 22.2% | -0.032 | -0.001 |
| Autumn | 101,878 | 26.4% | 99,550 | 26.9% | -0.488 | -0.011 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.9 | 1.8 | 1.9 | 1.7 | -0.003 | -0.002 |
| Psychiatric History | 385,471 | 100.0% | 369,831 | 100.0% | 0.000 | NaN |
| Psychiatric Drug Dispensings ⁶ | 281,040 | 72.9% | 269,075 | 72.8% | 0.152 | 0.003 |
| Self Harm Encounter ⁶ | 1,408 | 0.4% | 1,370 | 0.4% | -0.005 | -0.001 |
| Encounter for Other Psychiatric Event ⁶ | 320,269 | 83.1% | 306,616 | 82.9% | 0.178 | 0.005 |
| Asthma Emergency Encounter | 47,151 | 12.2% | 44,826 | 12.1% | 0.111 | 0.003 |
| Asthma Inpatient Encounter | 1,489 | 0.4% | 1,492 | 0.4% | -0.017 | -0.003 |
| Asthma Outpatient Encounter | 363,688 | 94.3% | 350,456 | 94.8% | -0.412 | -0.018 |
| Oral Corticosteroid Dispensing | 122,100 | 31.7% | 115,716 | 31.3% | 0.387 | 0.008 |
| Use of Other Asthma Medication | 225,178 | 58.4% | 223,897 | 60.5% | -2.124 | -0.045 |
| Allergic Rhinitis | 164,720 | 42.7% | 147,834 | 40.0% | 2.759 | 0.056 |
| Anxiety | 136,633 | 35.4% | 130,370 | 35.3% | 0.195 | 0.004 |
| Depression | 110,424 | 28.6% | 105,652 | 28.6% | 0.079 | 0.002 |
| Sleep Disorder | 115,482 | 30.0% | 109,064 | 29.5% | 0.469 | 0.011 |
| Substance Abuse | 24,467 | 6.3% | 23,738 | 6.4% | -0.071 | -0.003 |
| Poisoning | 1,143 | 0.3% | 1,225 | 0.3% | -0.035 | -0.006 |

Table 1aj. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Suffocation | 27 | 0.0% | 18 | 0.0% | 0.002 | 0.003 |
| Suicide Attempt | 644 | 0.2% | 651 | 0.2% | -0.009 | -0.002 |
| Toxicity | 147 | 0.0% | 140 | 0.0% | 0.000 | 0.000 |
| Other Self Harm | 346 | 0.1% | 368 | 0.1% | -0.010 | -0.003 |
| No moderate asthma exacerbations | 320,180 | 83.1% | 306,670 | 82.9% | 0.140 | 0.004 |
| One moderate asthma exacerbation | 56,718 | 14.7% | 55,213 | 14.9% | -0.215 | -0.006 |
| Two or more moderate asthma | 8,573 | 2.2% | 7,948 | 2.1% | 0.075 | 0.005 |
| No severe asthma exacerbations | 381,000 | 98.8% | 365,329 | 98.8% | 0.057 | 0.005 |
| One severe asthma exacerbation | 4,265 | 1.1% | 4,301 | 1.2% | -0.057 | -0.005 |
| Two or more severe asthma exacerbations | 206 | 0.1% | 201 | 0.1% | -0.001 | -0.000 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 110,820 | 28.7% | 104,623 | 28.3% | 0.460 | 0.010 |
| Antipsychotics | 34,672 | 9.0% | 33,853 | 9.2% | -0.159 | -0.006 |
| Anxiolytics Hypnotics | 135,128 | 35.1% | 128,700 | 34.8% | 0.256 | 0.005 |
| Lithium Other Mood Stabilizers | 40,604 | 10.5% | 39,459 | 10.7% | -0.136 | -0.004 |
| Antidepressants | 196,467 | 51.0% | 187,937 | 50.8% | 0.151 | 0.003 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 13.5 | 12.9 | 13.6 | 12.4 | -0.102 | -0.008 |
| Mean number of emergency room | 0.6 | 1.5 | 0.6 | 1.4 | -0.005 | -0.003 |
| Mean number of inpatient hospital encounters | 0.1 | 0.5 | 0.1 | 0.5 | -0.002 | -0.003 |
| Mean number of other ambulatory encounters | 4.1 | 11.8 | 4.4 | 12.6 | -0.286 | -0.023 |
| Mean number of filled prescriptions | 20.6 | 16.8 | 20.7 | 16.5 | -0.041 | -0.002 |
| Mean number of generics dispensed | 9.9 | 5.4 | 9.8 | 5.4 | 0.081 | 0.015 |
| Mean number of unique drug classes dispensed | 9.3 | 4.8 | 9.2 | 4.8 | 0.057 | 0.012 |

Table 1aj. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of inpatient visits for respiratory disorders | 0.1 | 0.3 | 0.1 | 0.3 | -0.002 | -0.006 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.5 | 0.1 | 0.5 | -0.001 | -0.003 |
| Mean number of outpatient visits for respiratory disorders | 2.5 | 3.5 | 2.5 | 3.5 | 0.026 | 0.007 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1ak. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 597,013 | 100.0% | 785,025 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 42.6 | 15.8 | 36.0 | 16.4 | 6.540 | 0.406 |
| Age | | | | | | |
| 10-24 years | 187,878 | 31.5% | 343,771 | 43.8% | -12.321 | -0.256 |
| 25-54 years | 201,276 | 33.7% | 246,933 | 31.5% | 2.258 | 0.048 |
| ≥ 55 years | 207,859 | 34.8% | 194,321 | 24.8% | 10.063 | 0.221 |
| Sex | | | | | | |
| Female | 390,652 | 65.4% | 479,451 | 61.1% | 4.360 | 0.091 |
| Male | 206,361 | 34.6% | 305,574 | 38.9% | -4.360 | -0.091 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 4,135 | 0.7% | 7,519 | 1.0% | -0.265 | -0.029 |
| Asian | 13,700 | 2.3% | 18,066 | 2.3% | -0.007 | -0.000 |
| Black or African American | 71,432 | 12.0% | 109,892 | 14.0% | -2.034 | -0.061 |
| Multi-racial | 1,256 | 0.2% | 1,185 | 0.2% | 0.059 | 0.014 |
| Native Hawaiian or Other Pacific Islander | 1,168 | 0.2% | 3,122 | 0.4% | -0.202 | -0.037 |
| Unknown | 294,664 | 49.4% | 389,100 | 49.6% | -0.209 | -0.004 |
| White | 210,658 | 35.3% | 256,141 | 32.6% | 2.657 | 0.056 |
| Hispanic origin | | | | | | |
| Yes | 58,338 | 9.8% | 111,481 | 14.2% | -4.429 | -0.137 |
| No | 287,397 | 48.1% | 382,037 | 48.7% | -0.526 | -0.011 |
| Unknown | 251,278 | 42.1% | 291,507 | 37.1% | 4.956 | 0.101 |
| Year | | | | | | |
| 2015 | 29,141 | 4.9% | 46,688 | 5.9% | -1.066 | -0.047 |
| 2016 | 141,988 | 23.8% | 210,015 | 26.8% | -2.970 | -0.068 |
| 2017 | 164,074 | 27.5% | 238,304 | 30.4% | -2.874 | -0.063 |
| 2018 | 156,561 | 26.2% | 202,400 | 25.8% | 0.441 | 0.010 |
| 2019 | 90,778 | 15.2% | 74,741 | 9.5% | 5.685 | 0.173 |
| 2020 | 14,471 | 2.4% | 12,877 | 1.6% | 0.784 | 0.056 |

Table 1ak. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2021 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2022 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Pre-boxed warning | 597,013 | 100.0% | 785,025 | 100.0% | 0.000 | NaN |
| Post-boxed warning | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Seasonality | | | | | | |
| Winter | 138,409 | 23.2% | 196,460 | 25.0% | -1.842 | -0.043 |
| Spring | 158,765 | 26.6% | 168,468 | 21.5% | 5.133 | 0.120 |
| Summer | 132,491 | 22.2% | 168,718 | 21.5% | 0.700 | 0.017 |
| Autumn | 167,348 | 28.0% | 251,379 | 32.0% | -3.991 | -0.087 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.5 | 1.4 | 1.5 | 1.2 | 0.065 | 0.049 |
| Psychiatric History | 296,883 | 49.7% | 364,761 | 46.5% | 3.263 | 0.065 |
| Psychiatric Drug Dispensings ⁵ | 216,746 | 36.3% | 258,783 | 33.0% | 3.340 | 0.070 |
| Self Harm Encounter ⁵ | 1,238 | 0.2% | 2,254 | 0.3% | -0.080 | -0.016 |
| Encounter for Other Psychiatric Event ⁵ | 244,530 | 41.0% | 305,703 | 38.9% | 2.017 | 0.041 |
| Asthma Emergency Encounter | 64,326 | 10.8% | 98,904 | 12.6% | -1.824 | -0.057 |
| Asthma Inpatient Encounter | 2,005 | 0.3% | 2,707 | 0.3% | -0.009 | -0.002 |
| Asthma Outpatient Encounter | 570,669 | 95.6% | 753,892 | 96.0% | -0.447 | -0.022 |
| Oral Corticosteroid Dispensing | 168,300 | 28.2% | 200,647 | 25.6% | 2.631 | 0.059 |
| Use of Other Asthma Medication | 379,053 | 63.5% | 626,836 | 79.8% | -16.358 | -0.369 |
| Allergic Rhinitis | 255,197 | 42.7% | 178,388 | 22.7% | 20.022 | 0.437 |
| Anxiety | 100,214 | 16.8% | 119,313 | 15.2% | 1.587 | 0.043 |
| Depression | 83,188 | 13.9% | 103,058 | 13.1% | 0.806 | 0.024 |
| Sleep Disorder | 83,144 | 13.9% | 77,672 | 9.9% | 4.032 | 0.125 |
| Substance Abuse | 19,275 | 3.2% | 34,163 | 4.4% | -1.123 | -0.059 |
| Poisoning | 1,168 | 0.2% | 2,296 | 0.3% | -0.097 | -0.020 |
| Suffocation | 24 | 0.0% | 43 | 0.0% | -0.001 | -0.002 |
| Suicide Attempt | 649 | 0.1% | 1,145 | 0.1% | -0.037 | -0.010 |

Table 1ak. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Toxicity | 146 | 0.0% | 259 | 0.0% | -0.009 | -0.005 |
| Other Self Harm | 328 | 0.1% | 551 | 0.1% | -0.015 | -0.006 |
| No moderate asthma exacerbations | 500,056 | 83.8% | 657,199 | 83.7% | 0.043 | 0.001 |
| One moderate asthma exacerbation | 85,302 | 14.3% | 113,518 | 14.5% | -0.172 | -0.005 |
| Two or more moderate asthma | 11,655 | 2.0% | 14,308 | 1.8% | 0.130 | 0.010 |
| No severe asthma exacerbations | 591,660 | 99.1% | 776,910 | 99.0% | 0.137 | 0.014 |
| One severe asthma exacerbation | 5,137 | 0.9% | 7,895 | 1.0% | -0.145 | -0.015 |
| Two or more severe asthma exacerbations | 216 | 0.0% | 220 | 0.0% | 0.008 | 0.005 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 121,058 | 20.3% | 137,379 | 17.5% | 2.777 | 0.071 |
| Antipsychotics | 27,913 | 4.7% | 45,150 | 5.8% | -1.076 | -0.048 |
| Anxiolytics Hypnotics | 104,869 | 17.6% | 113,674 | 14.5% | 3.085 | 0.084 |
| Lithium Other Mood Stabilizers | 32,406 | 5.4% | 43,716 | 5.6% | -0.141 | -0.006 |
| Antidepressants | 148,664 | 24.9% | 173,853 | 22.1% | 2.755 | 0.065 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 10.0 | 10.9 | 9.3 | 11.2 | 0.773 | 0.070 |
| Mean number of emergency room | 0.5 | 1.2 | 0.5 | 1.4 | -0.077 | -0.060 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.000 | -0.000 |
| Mean number of other ambulatory encounters | 2.8 | 9.9 | 3.4 | 12.8 | -0.695 | -0.061 |
| Mean number of filled prescriptions | 15.0 | 14.4 | 13.9 | 14.6 | 1.014 | 0.070 |
| Mean number of generics dispensed | 7.8 | 4.9 | 7.0 | 4.6 | 0.793 | 0.167 |
| Mean number of unique drug classes dispensed | 7.3 | 4.4 | 6.7 | 4.2 | 0.639 | 0.149 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.000 | -0.000 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.010 | -0.024 |

Table 1ak. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of outpatient visits for respiratory disorders | 2.3 | 3.3 | 1.7 | 2.7 | 0.587 | 0.194 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1a. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ^{1,2} | Medical Product | | Covariate Balance | | | |
|---|----------------------------------|---|--|---|------------------------|----------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | | |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | Absolute Difference | Standardized Difference |
| Weighted patients | 596,988 | N/A | 575,135 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 42.6 | 15.8 | 42.4 | 16.8 | 0.188 | 0.012 |
| Age | | | | | | |
| 10-24 years | 187,877 | 31.5% | 193,068 | 33.6% | -2.098 | -0.053 |
| 25-54 years | 201,269 | 33.7% | 175,546 | 30.5% | 3.191 | 0.071 |
| ≥ 55 years | 207,842 | 34.8% | 206,521 | 35.9% | -1.093 | -0.031 |
| Sex | | | | | | |
| Female | 390,632 | 65.4% | 373,633 | 65.0% | 0.469 | 0.010 |
| Male | 206,356 | 34.6% | 201,503 | 35.0% | -0.469 | -0.010 |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 4,135 | 0.7% | 4,323 | 0.8% | -0.059 | -0.007 |
| Asian | 13,698 | 2.3% | 11,628 | 2.0% | 0.273 | 0.019 |
| Black or African American | 71,429 | 12.0% | 63,874 | 11.1% | 0.859 | 0.028 |
| Multi-racial | 1,256 | 0.2% | 1,072 | 0.2% | 0.024 | 0.005 |
| Native Hawaiian or Other Pacific Islander | 1,168 | 0.2% | 1,649 | 0.3% | -0.091 | -0.019 |
| Unknown | 294,655 | 49.4% | 287,476 | 50.0% | -0.627 | -0.018 |
| White | 210,647 | 35.3% | 205,114 | 35.7% | -0.379 | -0.010 |
| Hispanic origin | | | | | | |
| Yes | 58,335 | 9.8% | 58,982 | 10.3% | -0.484 | -0.017 |
| No | 287,391 | 48.1% | 273,187 | 47.5% | 0.641 | 0.020 |
| Unknown | 251,262 | 42.1% | 242,967 | 42.2% | -0.157 | -0.006 |
| Year | | | | | | |
| 2015 | 29,140 | 4.9% | 29,442 | 5.1% | -0.238 | -0.011 |
| 2016 | 141,985 | 23.8% | 139,633 | 24.3% | -0.495 | -0.012 |
| 2017 | 164,070 | 27.5% | 159,067 | 27.7% | -0.174 | -0.004 |
| 2018 | 156,553 | 26.2% | 149,036 | 25.9% | 0.311 | 0.007 |
| 2019 | 90,769 | 15.2% | 84,431 | 14.7% | 0.524 | 0.015 |

Table 1a. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2020 | 14,471 | 2.4% | 13,527 | 2.4% | 0.072 | 0.005 |
| 2021 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2022 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Pre-boxed warning | 596,988 | 100.0% | 575,135 | 100.0% | 0.000 | NaN |
| Post-boxed warning | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Seasonality | | | | | | |
| Winter | 138,403 | 23.2% | 134,611 | 23.4% | -0.222 | -0.005 |
| Spring | 158,757 | 26.6% | 148,775 | 25.9% | 0.725 | 0.016 |
| Summer | 132,485 | 22.2% | 127,663 | 22.2% | -0.005 | -0.000 |
| Autumn | 167,343 | 28.0% | 164,086 | 28.5% | -0.499 | -0.011 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.5 | 1.4 | 1.5 | 1.4 | 0.001 | 0.000 |
| Psychiatric History | 296,860 | 49.7% | 283,128 | 49.2% | 0.498 | 0.010 |
| Psychiatric Drug Dispensings ⁶ | 216,723 | 36.3% | 206,061 | 35.8% | 0.474 | 0.010 |
| Self Harm Encounter ⁶ | 1,238 | 0.2% | 1,177 | 0.2% | 0.003 | 0.001 |
| Encounter for Other Psychiatric Event ⁶ | 244,512 | 41.0% | 232,824 | 40.5% | 0.476 | 0.010 |
| Asthma Emergency Encounter | 64,321 | 10.8% | 61,706 | 10.7% | 0.045 | 0.001 |
| Asthma Inpatient Encounter | 2,005 | 0.3% | 1,987 | 0.3% | -0.010 | -0.002 |
| Asthma Outpatient Encounter | 570,651 | 95.6% | 551,518 | 95.9% | -0.305 | -0.015 |
| Oral Corticosteroid Dispensing | 168,285 | 28.2% | 159,917 | 27.8% | 0.384 | 0.009 |
| Use of Other Asthma Medication | 379,046 | 63.5% | 376,392 | 65.4% | -1.951 | -0.042 |
| Allergic Rhinitis | 255,176 | 42.7% | 231,464 | 40.2% | 2.499 | 0.051 |
| Anxiety | 100,202 | 16.8% | 95,059 | 16.5% | 0.256 | 0.007 |
| Depression | 83,179 | 13.9% | 79,329 | 13.8% | 0.140 | 0.004 |
| Sleep Disorder | 83,132 | 13.9% | 77,885 | 13.5% | 0.383 | 0.011 |
| Substance Abuse | 19,274 | 3.2% | 18,971 | 3.3% | -0.070 | -0.004 |
| Poisoning | 1,168 | 0.2% | 1,246 | 0.2% | -0.021 | -0.005 |

Table 1a. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Suffocation | 24 | 0.0% | 20 | 0.0% | 0.001 | 0.001 |
| Suicide Attempt | 649 | 0.1% | 622 | 0.1% | 0.000 | 0.000 |
| Toxicity | 146 | 0.0% | 135 | 0.0% | 0.001 | 0.001 |
| Other Self Harm | 328 | 0.1% | 332 | 0.1% | -0.003 | -0.001 |
| No moderate asthma exacerbations | 500,034 | 83.8% | 479,127 | 83.3% | 0.453 | 0.012 |
| One moderate asthma exacerbation | 85,299 | 14.3% | 84,732 | 14.7% | -0.444 | -0.013 |
| Two or more moderate asthma | 11,655 | 2.0% | 11,276 | 2.0% | -0.008 | -0.001 |
| No severe asthma exacerbations | 591,636 | 99.1% | 569,767 | 99.1% | 0.037 | 0.004 |
| One severe asthma exacerbation | 5,136 | 0.9% | 5,161 | 0.9% | -0.037 | -0.004 |
| Two or more severe asthma exacerbations | 216 | 0.0% | 207 | 0.0% | 0.000 | 0.000 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 121,042 | 20.3% | 114,487 | 19.9% | 0.369 | 0.009 |
| Antipsychotics | 27,909 | 4.7% | 27,316 | 4.7% | -0.075 | -0.004 |
| Anxiolytics Hypnotics | 104,851 | 17.6% | 99,109 | 17.2% | 0.331 | 0.009 |
| Lithium Other Mood Stabilizers | 32,403 | 5.4% | 31,385 | 5.5% | -0.029 | -0.001 |
| Antidepressants | 148,649 | 24.9% | 141,391 | 24.6% | 0.316 | 0.007 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 10.0 | 10.9 | 10.1 | 10.5 | -0.015 | -0.001 |
| Mean number of emergency room | 0.5 | 1.2 | 0.5 | 1.2 | -0.002 | -0.002 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.001 | -0.002 |
| Mean number of other ambulatory encounters | 2.8 | 9.9 | 2.9 | 10.5 | -0.161 | -0.016 |
| Mean number of filled prescriptions | 15.0 | 14.4 | 14.9 | 14.2 | 0.065 | 0.005 |
| Mean number of generics dispensed | 7.8 | 4.9 | 7.7 | 5.0 | 0.105 | 0.021 |
| Mean number of unique drug classes dispensed | 7.3 | 4.4 | 7.3 | 4.4 | 0.080 | 0.018 |

Table 1a. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.001 | -0.004 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.000 | -0.001 |
| Mean number of outpatient visits for respiratory disorders | 2.3 | 3.3 | 2.2 | 3.3 | 0.037 | 0.011 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1am. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 155,244 | 100.0% | 138,364 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 52.7 | 15.8 | 47.2 | 17.6 | 5.466 | 0.327 |
| Age | | | | | | |
| 10-24 years | 19,994 | 12.9% | 32,116 | 23.2% | -10.332 | -0.271 |
| 25-54 years | 55,872 | 36.0% | 47,503 | 34.3% | 1.658 | 0.035 |
| ≥ 55 years | 79,378 | 51.1% | 58,745 | 42.5% | 8.674 | 0.175 |
| Sex | | | | | | |
| Female | 106,346 | 68.5% | 89,158 | 64.4% | 4.065 | 0.086 |
| Male | 48,898 | 31.5% | 49,206 | 35.6% | -4.065 | -0.086 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 506 | 0.3% | 376 | 0.3% | 0.054 | 0.010 |
| Asian | 2,293 | 1.5% | 1,615 | 1.2% | 0.310 | 0.027 |
| Black or African American | 10,287 | 6.6% | 6,878 | 5.0% | 1.655 | 0.071 |
| Multi-racial | 656 | 0.4% | 783 | 0.6% | -0.143 | -0.020 |
| Native Hawaiian or Other Pacific Islander | 180 | 0.1% | 113 | 0.1% | 0.034 | 0.011 |
| Unknown | 83,953 | 54.1% | 84,452 | 61.0% | -6.958 | -0.141 |
| White | 57,369 | 37.0% | 44,147 | 31.9% | 5.048 | 0.106 |
| Hispanic origin | | | | | | |
| Yes | 3,682 | 2.4% | 3,000 | 2.2% | 0.204 | 0.014 |
| No | 61,979 | 39.9% | 44,911 | 32.5% | 7.465 | 0.156 |
| Unknown | 89,583 | 57.7% | 90,453 | 65.4% | -7.669 | -0.158 |
| Year | | | | | | |
| 2015 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2016 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2017 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2018 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2019 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2020 | 63,486 | 40.9% | 56,185 | 40.6% | 0.288 | 0.006 |

Table 1am. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2021 | 69,448 | 44.7% | 61,062 | 44.1% | 0.603 | 0.012 |
| 2022 | 22,310 | 14.4% | 21,117 | 15.3% | -0.891 | -0.025 |
| Pre-boxed warning | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Post-boxed warning | 155,244 | 100.0% | 138,364 | 100.0% | 0.000 | NaN |
| Seasonality | | | | | | |
| Winter | 36,051 | 23.2% | 36,198 | 26.2% | -2.939 | -0.068 |
| Spring | 50,828 | 32.7% | 38,194 | 27.6% | 5.137 | 0.112 |
| Summer | 34,275 | 22.1% | 30,337 | 21.9% | 0.153 | 0.004 |
| Autumn | 34,090 | 22.0% | 33,635 | 24.3% | -2.350 | -0.056 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.7 | 1.7 | 1.7 | 1.6 | 0.052 | 0.032 |
| Psychiatric History | 88,619 | 57.1% | 74,239 | 53.7% | 3.429 | 0.069 |
| Psychiatric Drug Dispensings ⁵ | 64,321 | 41.4% | 53,379 | 38.6% | 2.854 | 0.058 |
| Self Harm Encounter ⁵ | 170 | 0.1% | 220 | 0.2% | -0.049 | -0.014 |
| Encounter for Other Psychiatric Event ⁵ | 75,768 | 48.8% | 63,824 | 46.1% | 2.678 | 0.054 |
| Asthma Emergency Encounter | 12,180 | 7.8% | 11,591 | 8.4% | -0.531 | -0.019 |
| Asthma Inpatient Encounter | 246 | 0.2% | 198 | 0.1% | 0.015 | 0.004 |
| Asthma Outpatient Encounter | 149,999 | 96.6% | 134,429 | 97.2% | -0.535 | -0.031 |
| Oral Corticosteroid Dispensing | 40,489 | 26.1% | 33,177 | 24.0% | 2.103 | 0.049 |
| Use of Other Asthma Medication | 86,393 | 55.6% | 96,630 | 69.8% | -14.188 | -0.297 |
| Allergic Rhinitis | 69,160 | 44.5% | 36,044 | 26.1% | 18.499 | 0.395 |
| Anxiety | 36,435 | 23.5% | 31,164 | 22.5% | 0.946 | 0.022 |
| Depression | 27,252 | 17.6% | 23,059 | 16.7% | 0.889 | 0.024 |
| Sleep Disorder | 32,354 | 20.8% | 23,373 | 16.9% | 3.948 | 0.101 |
| Substance Abuse | 5,194 | 3.3% | 5,166 | 3.7% | -0.388 | -0.021 |
| Poisoning | 158 | 0.1% | 187 | 0.1% | -0.033 | -0.010 |
| Suffocation | 6 | 0.0% | 3 | 0.0% | 0.002 | 0.003 |
| Suicide Attempt | 91 | 0.1% | 119 | 0.1% | -0.027 | -0.010 |

Table 1am. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Toxicity | 20 | 0.0% | 20 | 0.0% | -0.002 | -0.001 |
| Other Self Harm | 64 | 0.0% | 87 | 0.1% | -0.022 | -0.009 |
| No moderate asthma exacerbations | 136,086 | 87.7% | 122,087 | 88.2% | -0.577 | -0.018 |
| One moderate asthma exacerbation | 16,946 | 10.9% | 14,602 | 10.6% | 0.362 | 0.012 |
| Two or more moderate asthma | 2,212 | 1.4% | 1,675 | 1.2% | 0.214 | 0.019 |
| No severe asthma exacerbations | 154,376 | 99.4% | 137,498 | 99.4% | 0.067 | 0.009 |
| One severe asthma exacerbation | 835 | 0.5% | 840 | 0.6% | -0.069 | -0.009 |
| Two or more severe asthma exacerbations | 33 | 0.0% | 26 | 0.0% | 0.002 | 0.002 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 28,003 | 18.0% | 20,561 | 14.9% | 3.178 | 0.086 |
| Antipsychotics | 6,767 | 4.4% | 7,193 | 5.2% | -0.840 | -0.039 |
| Anxiolytics Hypnotics | 30,282 | 19.5% | 23,285 | 16.8% | 2.677 | 0.069 |
| Lithium Other Mood Stabilizers | 8,205 | 5.3% | 7,875 | 5.7% | -0.406 | -0.018 |
| Antidepressants | 47,900 | 30.9% | 39,584 | 28.6% | 2.246 | 0.049 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 10.6 | 11.1 | 10.0 | 10.9 | 0.616 | 0.056 |
| Mean number of emergency room | 0.3 | 1.0 | 0.3 | 1.1 | -0.020 | -0.019 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | 0.001 | 0.004 |
| Mean number of other ambulatory encounters | 2.5 | 5.7 | 2.5 | 6.4 | -0.017 | -0.003 |
| Mean number of filled prescriptions | 15.0 | 13.4 | 14.1 | 13.6 | 0.882 | 0.065 |
| Mean number of generics dispensed | 7.9 | 4.8 | 7.1 | 4.5 | 0.801 | 0.172 |
| Mean number of unique drug classes dispensed | 7.5 | 4.4 | 6.8 | 4.1 | 0.673 | 0.158 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.3 | -0.001 | -0.006 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.013 | -0.032 |

Table 1am. Aggregated Unadjusted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of outpatient visits for respiratory disorders | 2.2 | 3.3 | 1.9 | 3.1 | 0.335 | 0.104 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1an. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 155,205 | N/A | 149,925 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 52.7 | 15.8 | 52.5 | 17.1 | 0.118 | 0.007 |
| Age | | | | | | |
| 10-24 years | 19,992 | 12.9% | 23,728 | 15.8% | -2.946 | -0.089 |
| 25-54 years | 55,857 | 36.0% | 46,865 | 31.3% | 4.730 | 0.109 |
| ≥ 55 years | 79,356 | 51.1% | 79,332 | 52.9% | -1.784 | -0.044 |
| Sex | | | | | | |
| Female | 106,312 | 68.5% | 102,116 | 68.1% | 0.386 | 0.008 |
| Male | 48,893 | 31.5% | 47,809 | 31.9% | -0.386 | -0.008 |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 506 | 0.3% | 408 | 0.3% | 0.054 | 0.010 |
| Asian | 2,292 | 1.5% | 1,813 | 1.2% | 0.267 | 0.023 |
| Black or African American | 10,282 | 6.6% | 8,165 | 5.4% | 1.179 | 0.051 |
| Multi-racial | 656 | 0.4% | 680 | 0.5% | -0.031 | -0.005 |
| Native Hawaiian or Other Pacific Islander | 180 | 0.1% | 145 | 0.1% | 0.020 | 0.006 |
| Unknown | 83,924 | 54.1% | 81,231 | 54.2% | -0.108 | -0.004 |
| White | 57,365 | 37.0% | 57,483 | 38.3% | -1.380 | -0.042 |
| Hispanic origin | | | | | | |
| Yes | 3,680 | 2.4% | 3,192 | 2.1% | 0.242 | 0.016 |
| No | 61,969 | 39.9% | 59,454 | 39.7% | 0.271 | 0.013 |
| Unknown | 89,556 | 57.7% | 87,279 | 58.2% | -0.513 | -0.027 |
| Year | | | | | | |
| 2015 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2016 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2017 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2018 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2019 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |

Table 1an. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2020 | 63,467 | 40.9% | 61,589 | 41.1% | -0.188 | -0.004 |
| 2021 | 69,431 | 44.7% | 66,933 | 44.6% | 0.091 | 0.002 |
| 2022 | 22,307 | 14.4% | 21,403 | 14.3% | 0.097 | 0.003 |
| Pre-boxed warning | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Post-boxed warning | 155,205 | 100.0% | 149,925 | 100.0% | 0.000 | NaN |
| Seasonality | | | | | | |
| Winter | 36,048 | 23.2% | 35,425 | 23.6% | -0.402 | -0.010 |
| Spring | 50,803 | 32.7% | 47,792 | 31.9% | 0.855 | 0.018 |
| Summer | 34,268 | 22.1% | 33,279 | 22.2% | -0.118 | -0.003 |
| Autumn | 34,086 | 22.0% | 33,429 | 22.3% | -0.335 | -0.008 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.7 | 1.7 | 1.7 | 1.7 | -0.003 | -0.002 |
| Psychiatric History | 88,585 | 57.1% | 84,848 | 56.6% | 0.483 | 0.010 |
| Psychiatric Drug Dispensings ⁶ | 64,293 | 41.4% | 61,581 | 41.1% | 0.350 | 0.007 |
| Self Harm Encounter ⁶ | 170 | 0.1% | 172 | 0.1% | -0.005 | -0.002 |
| Encounter for Other Psychiatric Event ⁶ | 75,737 | 48.8% | 72,207 | 48.2% | 0.636 | 0.013 |
| Asthma Emergency Encounter | 12,174 | 7.8% | 11,577 | 7.7% | 0.122 | 0.005 |
| Asthma Inpatient Encounter | 246 | 0.2% | 237 | 0.2% | 0.000 | 0.000 |
| Asthma Outpatient Encounter | 149,963 | 96.6% | 145,268 | 96.9% | -0.271 | -0.015 |
| Oral Corticosteroid Dispensing | 40,466 | 26.1% | 38,543 | 25.7% | 0.364 | 0.008 |
| Use of Other Asthma Medication | 86,384 | 55.7% | 85,781 | 57.2% | -1.558 | -0.032 |
| Allergic Rhinitis | 69,124 | 44.5% | 63,056 | 42.1% | 2.479 | 0.050 |
| Anxiety | 36,417 | 23.5% | 34,729 | 23.2% | 0.300 | 0.007 |
| Depression | 27,234 | 17.5% | 26,027 | 17.4% | 0.187 | 0.005 |
| Sleep Disorder | 32,335 | 20.8% | 30,561 | 20.4% | 0.449 | 0.011 |
| Substance Abuse | 5,191 | 3.3% | 4,952 | 3.3% | 0.042 | 0.002 |
| Poisoning | 157 | 0.1% | 163 | 0.1% | -0.008 | -0.002 |

Table 1an. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Suffocation | 6 | 0.0% | 1 | 0.0% | 0.003 | 0.006 |
| Suicide Attempt | 90 | 0.1% | 103 | 0.1% | -0.011 | -0.004 |
| Toxicity | 20 | 0.0% | 19 | 0.0% | 0.000 | 0.000 |
| Other Self Harm | 63 | 0.0% | 66 | 0.0% | -0.004 | -0.002 |
| No moderate asthma exacerbations | 136,055 | 87.7% | 131,618 | 87.8% | -0.128 | -0.004 |
| One moderate asthma exacerbation | 16,938 | 10.9% | 16,338 | 10.9% | 0.016 | 0.001 |
| Two or more moderate asthma | 2,212 | 1.4% | 1,969 | 1.3% | 0.112 | 0.010 |
| No severe asthma exacerbations | 154,338 | 99.4% | 149,061 | 99.4% | 0.018 | 0.002 |
| One severe asthma exacerbation | 834 | 0.5% | 836 | 0.6% | -0.020 | -0.003 |
| Two or more severe asthma exacerbations | 33 | 0.0% | 28 | 0.0% | 0.002 | 0.002 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 27,977 | 18.0% | 26,286 | 17.5% | 0.493 | 0.013 |
| Antipsychotics | 6,762 | 4.4% | 6,705 | 4.5% | -0.116 | -0.006 |
| Anxiolytics Hypnotics | 30,265 | 19.5% | 28,879 | 19.3% | 0.238 | 0.006 |
| Lithium Other Mood Stabilizers | 8,200 | 5.3% | 8,044 | 5.4% | -0.082 | -0.004 |
| Antidepressants | 47,877 | 30.8% | 45,836 | 30.6% | 0.275 | 0.006 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 10.6 | 11.1 | 10.7 | 10.6 | -0.088 | -0.008 |
| Mean number of emergency room | 0.3 | 1.0 | 0.3 | 1.0 | -0.004 | -0.003 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.001 | -0.004 |
| Mean number of other ambulatory encounters | 2.5 | 5.7 | 2.6 | 6.1 | -0.128 | -0.022 |
| Mean number of filled prescriptions | 15.0 | 13.4 | 15.0 | 13.2 | -0.016 | -0.001 |
| Mean number of generics dispensed | 7.9 | 4.8 | 7.8 | 4.9 | 0.074 | 0.015 |
| Mean number of unique drug classes dispensed | 7.5 | 4.4 | 7.5 | 4.4 | 0.062 | 0.014 |

Table 1an. Aggregated Weighted Characteristics of Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|----------------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast Sensitivity Analysis | | Inhaled Corticosteroids (ICS) Sensitivity Analysis | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.001 | -0.005 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.002 | -0.004 |
| Mean number of outpatient visits for respiratory disorders | 2.2 | 3.3 | 2.2 | 3.2 | 0.003 | 0.001 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1ao. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 752,128 | 100.0% | 923,145 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 44.7 | 15.8 | 37.7 | 16.6 | 6.947 | 0.429 |
| Age | | | | | | |
| 10-24 years | 207,843 | 27.6% | 375,784 | 40.7% | -13.073 | -0.278 |
| 25-54 years | 257,110 | 34.2% | 294,341 | 31.9% | 2.300 | 0.049 |
| ≥ 55 years | 287,175 | 38.2% | 253,020 | 27.4% | 10.773 | 0.231 |
| Sex | | | | | | |
| Female | 496,909 | 66.1% | 568,448 | 61.6% | 4.490 | 0.094 |
| Male | 255,219 | 33.9% | 354,697 | 38.4% | -4.490 | -0.094 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 4,641 | 0.6% | 7,888 | 0.9% | -0.237 | -0.028 |
| Asian | 15,988 | 2.1% | 19,677 | 2.1% | -0.006 | -0.000 |
| Black or African American | 81,707 | 10.9% | 116,745 | 12.6% | -1.783 | -0.055 |
| Multi-racial | 1,912 | 0.3% | 1,968 | 0.2% | 0.041 | 0.008 |
| Native Hawaiian or Other Pacific Islander | 1,348 | 0.2% | 3,235 | 0.4% | -0.171 | -0.033 |
| Unknown | 378,574 | 50.3% | 473,411 | 51.3% | -0.949 | -0.019 |
| White | 267,958 | 35.6% | 300,221 | 32.5% | 3.105 | 0.066 |
| Hispanic origin | | | | | | |
| Yes | 62,009 | 8.2% | 114,454 | 12.4% | -4.154 | -0.137 |
| No | 349,293 | 46.4% | 426,847 | 46.2% | 0.202 | 0.004 |
| Unknown | 340,826 | 45.3% | 381,844 | 41.4% | 3.952 | 0.080 |
| Year | | | | | | |
| 2015 | 29,137 | 3.9% | 46,672 | 5.1% | -1.182 | -0.057 |
| 2016 | 141,971 | 18.9% | 209,935 | 22.7% | -3.865 | -0.095 |
| 2017 | 164,045 | 21.8% | 238,247 | 25.8% | -3.997 | -0.094 |
| 2018 | 156,535 | 20.8% | 202,341 | 21.9% | -1.106 | -0.027 |
| 2019 | 90,758 | 12.1% | 74,729 | 8.1% | 3.972 | 0.132 |
| 2020 | 77,940 | 10.4% | 69,051 | 7.5% | 2.883 | 0.101 |

Table 1ao. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2021 | 69,434 | 9.2% | 61,053 | 6.6% | 2.618 | 0.097 |
| 2022 | 22,308 | 3.0% | 21,117 | 2.3% | 0.678 | 0.042 |
| Pre-boxed warning | 596,913 | 79.4% | 784,799 | 85.0% | -5.650 | -0.148 |
| Post-boxed warning | 155,215 | 20.6% | 138,346 | 15.0% | 5.650 | 0.148 |
| Seasonality | | | | | | |
| Winter | 174,435 | 23.2% | 232,605 | 25.2% | -2.005 | -0.047 |
| Spring | 209,546 | 27.9% | 206,599 | 22.4% | 5.481 | 0.127 |
| Summer | 166,744 | 22.2% | 198,998 | 21.6% | 0.613 | 0.015 |
| Autumn | 201,403 | 26.8% | 284,943 | 30.9% | -4.089 | -0.090 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.6 | 1.5 | 1.5 | 1.3 | 0.076 | 0.054 |
| Psychiatric History | 385,407 | 51.2% | 438,857 | 47.5% | 3.703 | 0.074 |
| Psychiatric Drug Dispensings ⁵ | 280,998 | 37.4% | 312,055 | 33.8% | 3.557 | 0.074 |
| Self Harm Encounter ⁵ | 1,395 | 0.2% | 2,452 | 0.3% | -0.080 | -0.017 |
| Encounter for Other Psychiatric Event ⁵ | 320,209 | 42.6% | 369,403 | 40.0% | 2.558 | 0.052 |
| Asthma Emergency Encounter | 76,474 | 10.2% | 110,448 | 12.0% | -1.797 | -0.057 |
| Asthma Inpatient Encounter | 2,251 | 0.3% | 2,904 | 0.3% | -0.015 | -0.003 |
| Asthma Outpatient Encounter | 720,562 | 95.8% | 888,089 | 96.2% | -0.399 | -0.020 |
| Oral Corticosteroid Dispensing | 208,755 | 27.8% | 233,763 | 25.3% | 2.433 | 0.055 |
| Use of Other Asthma Medication | 465,392 | 61.9% | 723,290 | 78.4% | -16.474 | -0.366 |
| Allergic Rhinitis | 324,308 | 43.1% | 214,382 | 23.2% | 19.896 | 0.432 |
| Anxiety | 136,600 | 18.2% | 150,423 | 16.3% | 1.867 | 0.049 |
| Depression | 110,396 | 14.7% | 126,065 | 13.7% | 1.022 | 0.029 |
| Sleep Disorder | 115,470 | 15.4% | 101,010 | 10.9% | 4.410 | 0.131 |
| Substance Abuse | 24,452 | 3.3% | 39,308 | 4.3% | -1.007 | -0.053 |
| Poisoning | 1,318 | 0.2% | 2,469 | 0.3% | -0.092 | -0.020 |
| Suffocation | 30 | 0.0% | 46 | 0.0% | -0.001 | -0.001 |
| Suicide Attempt | 732 | 0.1% | 1,248 | 0.1% | -0.038 | -0.011 |

Table 1ao. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Toxicity | 156 | 0.0% | 275 | 0.0% | -0.009 | -0.006 |
| Other Self Harm | 386 | 0.1% | 628 | 0.1% | -0.017 | -0.007 |
| No moderate asthma exacerbations | 636,027 | 84.6% | 779,078 | 84.4% | 0.170 | 0.005 |
| One moderate asthma exacerbation | 102,234 | 13.6% | 128,091 | 13.9% | -0.283 | -0.008 |
| Two or more moderate asthma | 13,867 | 1.8% | 15,976 | 1.7% | 0.113 | 0.009 |
| No severe asthma exacerbations | 745,908 | 99.2% | 914,165 | 99.0% | 0.146 | 0.015 |
| One severe asthma exacerbation | 5,971 | 0.8% | 8,734 | 0.9% | -0.152 | -0.016 |
| Two or more severe asthma exacerbations | 249 | 0.0% | 246 | 0.0% | 0.006 | 0.004 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 149,025 | 19.8% | 157,879 | 17.1% | 2.711 | 0.070 |
| Antipsychotics | 34,654 | 4.6% | 52,319 | 5.7% | -1.060 | -0.048 |
| Anxiolytics Hypnotics | 135,110 | 18.0% | 136,903 | 14.8% | 3.134 | 0.085 |
| Lithium Other Mood Stabilizers | 40,585 | 5.4% | 51,566 | 5.6% | -0.190 | -0.008 |
| Antidepressants | 196,515 | 26.1% | 213,357 | 23.1% | 3.016 | 0.070 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 10.2 | 11.0 | 9.4 | 11.2 | 0.782 | 0.071 |
| Mean number of emergency room | 0.4 | 1.2 | 0.5 | 1.3 | -0.076 | -0.061 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.000 | -0.001 |
| Mean number of other ambulatory encounters | 2.7 | 9.2 | 3.3 | 12.0 | -0.611 | -0.057 |
| Mean number of filled prescriptions | 15.0 | 14.2 | 14.0 | 14.5 | 0.997 | 0.069 |
| Mean number of generics dispensed | 7.8 | 4.9 | 7.0 | 4.6 | 0.802 | 0.169 |
| Mean number of unique drug classes dispensed | 7.4 | 4.4 | 6.7 | 4.2 | 0.654 | 0.153 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.000 | -0.000 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.012 | -0.029 |

Table 1ao. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of outpatient visits for respiratory disorders | 2.3 | 3.3 | 1.7 | 2.8 | 0.545 | 0.178 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1ap. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 752,128 | N/A | 724,746 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 44.7 | 15.8 | 44.5 | 16.9 | 0.183 | 0.011 |
| Age | | | | | | |
| 10-24 years | 207,843 | 27.6% | 216,761 | 29.9% | -2.275 | -0.059 |
| 25-54 years | 257,110 | 34.2% | 222,489 | 30.7% | 3.485 | 0.078 |
| ≥ 55 years | 287,175 | 38.2% | 285,496 | 39.4% | -1.211 | -0.033 |
| Sex | | | | | | |
| Female | 496,909 | 66.1% | 475,508 | 65.6% | 0.457 | 0.010 |
| Male | 255,219 | 33.9% | 249,238 | 34.4% | -0.457 | -0.010 |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 4,641 | 0.6% | 4,732 | 0.7% | -0.036 | -0.005 |
| Asian | 15,988 | 2.1% | 13,438 | 1.9% | 0.272 | 0.020 |
| Black or African American | 81,707 | 10.9% | 72,035 | 9.9% | 0.924 | 0.032 |
| Multi-racial | 1,912 | 0.3% | 1,757 | 0.2% | 0.012 | 0.002 |
| Native Hawaiian or Other Pacific Islander | 1,348 | 0.2% | 1,794 | 0.2% | -0.068 | -0.015 |
| Unknown | 378,574 | 50.3% | 368,705 | 50.9% | -0.540 | -0.016 |
| White | 267,958 | 35.6% | 262,285 | 36.2% | -0.563 | -0.015 |
| Hispanic origin | | | | | | |
| Yes | 62,009 | 8.2% | 62,170 | 8.6% | -0.334 | -0.013 |
| No | 349,293 | 46.4% | 332,335 | 45.9% | 0.585 | 0.019 |
| Unknown | 340,826 | 45.3% | 330,241 | 45.6% | -0.252 | -0.010 |
| Year | | | | | | |
| 2015 | 29,137 | 3.9% | 29,516 | 4.1% | -0.199 | -0.010 |
| 2016 | 141,971 | 18.9% | 139,840 | 19.3% | -0.419 | -0.011 |
| 2017 | 164,045 | 21.8% | 159,291 | 22.0% | -0.168 | -0.004 |
| 2018 | 156,535 | 20.8% | 149,297 | 20.6% | 0.212 | 0.005 |
| 2019 | 90,758 | 12.1% | 84,734 | 11.7% | 0.375 | 0.012 |

Table 1ap. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2020 | 77,940 | 10.4% | 74,562 | 10.3% | 0.075 | 0.003 |
| 2021 | 69,434 | 9.2% | 66,271 | 9.1% | 0.088 | 0.003 |
| 2022 | 22,308 | 3.0% | 21,236 | 2.9% | 0.036 | 0.002 |
| Pre-boxed warning | 596,913 | 79.4% | 576,249 | 79.5% | -0.147 | -0.004 |
| Post-boxed warning | 155,215 | 20.6% | 148,497 | 20.5% | 0.147 | 0.004 |
| Seasonality | | | | | | |
| Winter | 174,435 | 23.2% | 169,950 | 23.4% | -0.257 | -0.006 |
| Spring | 209,546 | 27.9% | 196,486 | 27.1% | 0.749 | 0.017 |
| Summer | 166,744 | 22.2% | 160,864 | 22.2% | -0.026 | -0.001 |
| Autumn | 201,403 | 26.8% | 197,446 | 27.2% | -0.466 | -0.011 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.6 | 1.5 | 1.6 | 1.4 | 0.000 | 0.000 |
| Psychiatric History | 385,407 | 51.2% | 367,736 | 50.7% | 0.502 | 0.010 |
| Psychiatric Drug Dispensings ⁶ | 280,998 | 37.4% | 267,475 | 36.9% | 0.454 | 0.010 |
| Self Harm Encounter ⁶ | 1,395 | 0.2% | 1,335 | 0.2% | 0.001 | 0.000 |
| Encounter for Other Psychiatric Event ⁶ | 320,209 | 42.6% | 304,789 | 42.1% | 0.519 | 0.011 |
| Asthma Emergency Encounter | 76,474 | 10.2% | 73,283 | 10.1% | 0.056 | 0.002 |
| Asthma Inpatient Encounter | 2,251 | 0.3% | 2,232 | 0.3% | -0.009 | -0.002 |
| Asthma Outpatient Encounter | 720,562 | 95.8% | 696,471 | 96.1% | -0.296 | -0.015 |
| Oral Corticosteroid Dispensing | 208,755 | 27.8% | 198,470 | 27.4% | 0.370 | 0.008 |
| Use of Other Asthma Medication | 465,392 | 61.9% | 462,152 | 63.8% | -1.891 | -0.041 |
| Allergic Rhinitis | 324,308 | 43.1% | 294,326 | 40.6% | 2.508 | 0.051 |
| Anxiety | 136,600 | 18.2% | 129,663 | 17.9% | 0.271 | 0.007 |
| Depression | 110,396 | 14.7% | 105,243 | 14.5% | 0.156 | 0.004 |
| Sleep Disorder | 115,470 | 15.4% | 108,304 | 14.9% | 0.409 | 0.012 |
| Substance Abuse | 24,452 | 3.3% | 23,883 | 3.3% | -0.044 | -0.002 |
| Poisoning | 1,318 | 0.2% | 1,401 | 0.2% | -0.018 | -0.004 |

Table 1ap. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Suffocation | 30 | 0.0% | 21 | 0.0% | 0.001 | 0.002 |
| Suicide Attempt | 732 | 0.1% | 720 | 0.1% | -0.002 | -0.001 |
| Toxicity | 156 | 0.0% | 153 | 0.0% | -0.000 | -0.000 |
| Other Self Harm | 386 | 0.1% | 393 | 0.1% | -0.003 | -0.001 |
| No moderate asthma exacerbations | 636,027 | 84.6% | 610,492 | 84.2% | 0.328 | 0.009 |
| One moderate asthma exacerbation | 102,234 | 13.6% | 101,019 | 13.9% | -0.346 | -0.010 |
| Two or more moderate asthma | 13,867 | 1.8% | 13,235 | 1.8% | 0.018 | 0.001 |
| No severe asthma exacerbations | 745,908 | 99.2% | 718,500 | 99.1% | 0.035 | 0.004 |
| One severe asthma exacerbation | 5,971 | 0.8% | 6,006 | 0.8% | -0.035 | -0.004 |
| Two or more severe asthma exacerbations | 249 | 0.0% | 240 | 0.0% | 0.000 | 0.000 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 149,025 | 19.8% | 140,818 | 19.4% | 0.384 | 0.010 |
| Antipsychotics | 34,654 | 4.6% | 33,976 | 4.7% | -0.081 | -0.004 |
| Anxiolytics Hypnotics | 135,110 | 18.0% | 127,935 | 17.7% | 0.311 | 0.008 |
| Lithium Other Mood Stabilizers | 40,585 | 5.4% | 39,405 | 5.4% | -0.041 | -0.002 |
| Antidepressants | 196,515 | 26.1% | 187,094 | 25.8% | 0.313 | 0.007 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 10.2 | 11.0 | 10.2 | 10.5 | -0.029 | -0.003 |
| Mean number of emergency room | 0.4 | 1.2 | 0.4 | 1.2 | -0.003 | -0.002 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.001 | -0.002 |
| Mean number of other ambulatory encounters | 2.7 | 9.2 | 2.8 | 9.7 | -0.154 | -0.016 |
| Mean number of filled prescriptions | 15.0 | 14.2 | 14.9 | 14.1 | 0.048 | 0.003 |
| Mean number of generics dispensed | 7.8 | 4.9 | 7.7 | 4.9 | 0.098 | 0.020 |
| Mean number of unique drug classes dispensed | 7.4 | 4.4 | 7.3 | 4.4 | 0.076 | 0.017 |

Table 1ap. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.001 | -0.004 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.001 | -0.002 |
| Mean number of outpatient visits for respiratory disorders | 2.3 | 3.3 | 2.2 | 3.3 | 0.029 | 0.009 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1a. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 496,909 | 100.0% | 568,448 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 47.9 | 15.5 | 41.4 | 16.4 | 6.564 | 0.412 |
| Age | | | | | | |
| 10-24 years | 103,196 | 20.8% | 183,882 | 32.3% | -11.580 | -0.264 |
| 25-54 years | 181,338 | 36.5% | 203,653 | 35.8% | 0.667 | 0.014 |
| ≥ 55 years | 212,375 | 42.7% | 180,913 | 31.8% | 10.913 | 0.227 |
| Sex | | | | | | |
| Female | 496,909 | 100.0% | 568,448 | 100.0% | 0.000 | NaN |
| Male | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 3,088 | 0.6% | 5,016 | 0.9% | -0.261 | -0.030 |
| Asian | 10,096 | 2.0% | 11,303 | 2.0% | 0.043 | 0.003 |
| Black or African American | 55,779 | 11.2% | 73,258 | 12.9% | -1.662 | -0.051 |
| Multi-racial | 1,273 | 0.3% | 1,215 | 0.2% | 0.042 | 0.009 |
| Native Hawaiian or Other Pacific Islander | 849 | 0.2% | 1,892 | 0.3% | -0.162 | -0.032 |
| Unknown | 235,654 | 47.4% | 273,868 | 48.2% | -0.754 | -0.015 |
| White | 190,170 | 38.3% | 201,896 | 35.5% | 2.754 | 0.057 |
| Hispanic origin | | | | | | |
| Yes | 36,805 | 7.4% | 64,752 | 11.4% | -3.984 | -0.137 |
| No | 244,588 | 49.2% | 279,856 | 49.2% | -0.010 | -0.000 |
| Unknown | 215,516 | 43.4% | 223,840 | 39.4% | 3.994 | 0.081 |
| Year | | | | | | |
| 2015 | 18,923 | 3.8% | 28,502 | 5.0% | -1.206 | -0.059 |
| 2016 | 92,738 | 18.7% | 128,025 | 22.5% | -3.859 | -0.096 |
| 2017 | 105,436 | 21.2% | 144,247 | 25.4% | -4.157 | -0.098 |
| 2018 | 101,421 | 20.4% | 122,789 | 21.6% | -1.190 | -0.029 |
| 2019 | 62,176 | 12.5% | 47,613 | 8.4% | 4.137 | 0.136 |
| 2020 | 53,770 | 10.8% | 45,006 | 7.9% | 2.904 | 0.100 |

Table 1a. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2021 | 47,651 | 9.6% | 38,983 | 6.9% | 2.732 | 0.100 |
| 2022 | 14,794 | 3.0% | 13,283 | 2.3% | 0.640 | 0.040 |
| Pre-boxed warning | 390,581 | 78.6% | 479,301 | 84.3% | -5.715 | -0.147 |
| Post-boxed warning | 106,328 | 21.4% | 89,147 | 15.7% | 5.715 | 0.147 |
| Seasonality | | | | | | |
| Winter | 115,679 | 23.3% | 143,890 | 25.3% | -2.033 | -0.047 |
| Spring | 138,875 | 27.9% | 127,222 | 22.4% | 5.567 | 0.129 |
| Summer | 109,769 | 22.1% | 122,339 | 21.5% | 0.569 | 0.014 |
| Autumn | 132,586 | 26.7% | 174,997 | 30.8% | -4.103 | -0.091 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.6 | 1.5 | 1.6 | 1.4 | 0.069 | 0.047 |
| Psychiatric History | 276,966 | 55.7% | 294,761 | 51.9% | 3.884 | 0.078 |
| Psychiatric Drug Dispensings ⁵ | 212,530 | 42.8% | 220,615 | 38.8% | 3.960 | 0.081 |
| Self Harm Encounter ⁵ | 1,054 | 0.2% | 1,863 | 0.3% | -0.116 | -0.022 |
| Encounter for Other Psychiatric Event ⁵ | 226,242 | 45.5% | 243,306 | 42.8% | 2.728 | 0.055 |
| Asthma Emergency Encounter | 53,928 | 10.9% | 71,966 | 12.7% | -1.807 | -0.056 |
| Asthma Inpatient Encounter | 1,704 | 0.3% | 1,861 | 0.3% | 0.016 | 0.003 |
| Asthma Outpatient Encounter | 474,416 | 95.5% | 544,889 | 95.9% | -0.382 | -0.019 |
| Oral Corticosteroid Dispensing | 147,866 | 29.8% | 153,374 | 27.0% | 2.776 | 0.062 |
| Use of Other Asthma Medication | 299,231 | 60.2% | 437,633 | 77.0% | -16.769 | -0.367 |
| Allergic Rhinitis | 213,679 | 43.0% | 128,456 | 22.6% | 20.404 | 0.445 |
| Anxiety | 108,121 | 21.8% | 113,576 | 20.0% | 1.779 | 0.044 |
| Depression | 88,964 | 17.9% | 96,828 | 17.0% | 0.870 | 0.023 |
| Sleep Disorder | 80,271 | 16.2% | 66,986 | 11.8% | 4.370 | 0.126 |
| Substance Abuse | 15,997 | 3.2% | 24,045 | 4.2% | -1.011 | -0.053 |
| Poisoning | 1,042 | 0.2% | 1,916 | 0.3% | -0.127 | -0.024 |
| Suffocation | 13 | 0.0% | 27 | 0.0% | -0.002 | -0.004 |
| Suicide Attempt | 550 | 0.1% | 902 | 0.2% | -0.048 | -0.013 |

Table 1a. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Toxicity | 113 | 0.0% | 201 | 0.0% | -0.013 | -0.007 |
| Other Self Harm | 293 | 0.1% | 467 | 0.1% | -0.023 | -0.009 |
| No moderate asthma exacerbations | 415,587 | 83.6% | 476,028 | 83.7% | -0.107 | -0.003 |
| One moderate asthma exacerbation | 71,213 | 14.3% | 81,819 | 14.4% | -0.062 | -0.002 |
| Two or more moderate asthma | 10,109 | 2.0% | 10,601 | 1.9% | 0.169 | 0.012 |
| No severe asthma exacerbations | 492,268 | 99.1% | 562,553 | 99.0% | 0.103 | 0.010 |
| One severe asthma exacerbation | 4,455 | 0.9% | 5,733 | 1.0% | -0.112 | -0.012 |
| Two or more severe asthma exacerbations | 186 | 0.0% | 162 | 0.0% | 0.009 | 0.005 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 114,288 | 23.0% | 117,228 | 20.6% | 2.377 | 0.058 |
| Antipsychotics | 24,862 | 5.0% | 35,203 | 6.2% | -1.189 | -0.052 |
| Anxiolytics Hypnotics | 106,337 | 21.4% | 103,880 | 18.3% | 3.125 | 0.078 |
| Lithium Other Mood Stabilizers | 30,764 | 6.2% | 36,907 | 6.5% | -0.302 | -0.012 |
| Antidepressants | 158,470 | 31.9% | 164,651 | 29.0% | 2.926 | 0.064 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 11.1 | 11.1 | 10.4 | 11.4 | 0.723 | 0.064 |
| Mean number of emergency room | 0.5 | 1.3 | 0.6 | 1.4 | -0.096 | -0.072 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.002 | -0.004 |
| Mean number of other ambulatory encounters | 2.8 | 8.8 | 3.4 | 11.5 | -0.596 | -0.058 |
| Mean number of filled prescriptions | 16.6 | 15.1 | 15.8 | 15.6 | 0.865 | 0.056 |
| Mean number of generics dispensed | 8.5 | 5.1 | 7.8 | 4.9 | 0.758 | 0.151 |
| Mean number of unique drug classes dispensed | 8.1 | 4.6 | 7.4 | 4.5 | 0.609 | 0.134 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | 0.000 | 0.000 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.5 | -0.015 | -0.035 |

Table 1a. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of outpatient visits for respiratory disorders | 2.4 | 3.3 | 1.8 | 2.8 | 0.558 | 0.181 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1ar. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 496,850 | N/A | 478,373 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 47.9 | 15.5 | 47.8 | 16.4 | 0.149 | 0.009 |
| Age | | | | | | |
| 10-24 years | 103,195 | 20.8% | 109,532 | 22.9% | -2.127 | -0.058 |
| 25-54 years | 181,321 | 36.5% | 159,241 | 33.3% | 3.206 | 0.071 |
| ≥ 55 years | 212,334 | 42.7% | 209,600 | 43.8% | -1.079 | -0.029 |
| Sex | | | | | | |
| Female | 496,850 | 100.0% | 478,373 | 100.0% | 0.000 | NaN |
| Male | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 3,088 | 0.6% | 3,212 | 0.7% | -0.050 | -0.006 |
| Asian | 10,094 | 2.0% | 8,223 | 1.7% | 0.313 | 0.023 |
| Black or African American | 55,769 | 11.2% | 49,208 | 10.3% | 0.938 | 0.031 |
| Multi-racial | 1,273 | 0.3% | 1,178 | 0.2% | 0.010 | 0.002 |
| Native Hawaiian or Other Pacific Islander | 849 | 0.2% | 1,079 | 0.2% | -0.055 | -0.012 |
| Unknown | 235,634 | 47.4% | 229,020 | 47.9% | -0.449 | -0.014 |
| White | 190,143 | 38.3% | 186,453 | 39.0% | -0.707 | -0.019 |
| Hispanic origin | | | | | | |
| Yes | 36,801 | 7.4% | 36,700 | 7.7% | -0.265 | -0.011 |
| No | 244,553 | 49.2% | 232,998 | 48.7% | 0.514 | 0.017 |
| Unknown | 215,496 | 43.4% | 208,675 | 43.6% | -0.249 | -0.011 |
| Year | | | | | | |
| 2015 | 18,922 | 3.8% | 19,235 | 4.0% | -0.213 | -0.011 |
| 2016 | 92,734 | 18.7% | 91,417 | 19.1% | -0.445 | -0.011 |
| 2017 | 105,428 | 21.2% | 102,303 | 21.4% | -0.166 | -0.004 |
| 2018 | 101,405 | 20.4% | 96,540 | 20.2% | 0.229 | 0.006 |
| 2019 | 62,158 | 12.5% | 57,854 | 12.1% | 0.416 | 0.013 |
| 2020 | 53,762 | 10.8% | 51,466 | 10.8% | 0.062 | 0.002 |

Table 1ar. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2021 | 47,647 | 9.6% | 45,435 | 9.5% | 0.092 | 0.003 |
| 2022 | 14,794 | 3.0% | 14,123 | 3.0% | 0.025 | 0.001 |
| Pre-boxed warning | 390,533 | 78.6% | 376,612 | 78.7% | -0.126 | -0.003 |
| Post-boxed warning | 106,317 | 21.4% | 101,762 | 21.3% | 0.126 | 0.003 |
| Seasonality | | | | | | |
| Winter | 115,673 | 23.3% | 112,577 | 23.5% | -0.252 | -0.006 |
| Spring | 138,846 | 27.9% | 130,011 | 27.2% | 0.768 | 0.017 |
| Summer | 109,754 | 22.1% | 105,836 | 22.1% | -0.034 | -0.001 |
| Autumn | 132,577 | 26.7% | 129,950 | 27.2% | -0.481 | -0.011 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.6 | 1.5 | 1.6 | 1.5 | 0.001 | 0.000 |
| Psychiatric History | 276,912 | 55.7% | 264,430 | 55.3% | 0.457 | 0.009 |
| Psychiatric Drug Dispensings ⁶ | 212,481 | 42.8% | 202,408 | 42.3% | 0.454 | 0.009 |
| Self Harm Encounter ⁶ | 1,054 | 0.2% | 1,052 | 0.2% | -0.008 | -0.002 |
| Encounter for Other Psychiatric Event ⁶ | 226,194 | 45.5% | 215,566 | 45.1% | 0.463 | 0.009 |
| Asthma Emergency Encounter | 53,915 | 10.9% | 51,561 | 10.8% | 0.073 | 0.002 |
| Asthma Inpatient Encounter | 1,704 | 0.3% | 1,674 | 0.4% | -0.007 | -0.001 |
| Asthma Outpatient Encounter | 474,373 | 95.5% | 458,307 | 95.8% | -0.329 | -0.016 |
| Oral Corticosteroid Dispensing | 147,832 | 29.8% | 140,639 | 29.4% | 0.354 | 0.008 |
| Use of Other Asthma Medication | 299,223 | 60.2% | 297,384 | 62.2% | -1.942 | -0.041 |
| Allergic Rhinitis | 213,627 | 43.0% | 193,669 | 40.5% | 2.511 | 0.051 |
| Anxiety | 108,089 | 21.8% | 102,718 | 21.5% | 0.283 | 0.007 |
| Depression | 88,940 | 17.9% | 84,908 | 17.7% | 0.151 | 0.004 |
| Sleep Disorder | 80,251 | 16.2% | 75,345 | 15.8% | 0.402 | 0.011 |
| Substance Abuse | 15,991 | 3.2% | 15,524 | 3.2% | -0.027 | -0.002 |
| Poisoning | 1,041 | 0.2% | 1,114 | 0.2% | -0.023 | -0.005 |
| Suffocation | 13 | 0.0% | 12 | 0.0% | 0.000 | 0.000 |
| Suicide Attempt | 550 | 0.1% | 538 | 0.1% | -0.002 | -0.001 |

Table 1ar. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Toxicity | 112 | 0.0% | 114 | 0.0% | -0.001 | -0.001 |
| Other Self Harm | 293 | 0.1% | 292 | 0.1% | -0.002 | -0.001 |
| No moderate asthma exacerbations | 415,543 | 83.6% | 398,478 | 83.3% | 0.337 | 0.009 |
| One moderate asthma exacerbation | 71,200 | 14.3% | 70,320 | 14.7% | -0.369 | -0.010 |
| Two or more moderate asthma | 10,107 | 2.0% | 9,575 | 2.0% | 0.033 | 0.002 |
| No severe asthma exacerbations | 492,212 | 99.1% | 473,727 | 99.0% | 0.038 | 0.004 |
| One severe asthma exacerbation | 4,453 | 0.9% | 4,469 | 0.9% | -0.038 | -0.004 |
| Two or more severe asthma exacerbations | 185 | 0.0% | 176 | 0.0% | 0.000 | 0.000 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 114,254 | 23.0% | 107,984 | 22.6% | 0.423 | 0.010 |
| Antipsychotics | 24,858 | 5.0% | 24,344 | 5.1% | -0.086 | -0.004 |
| Anxiolytics Hypnotics | 106,299 | 21.4% | 100,874 | 21.1% | 0.308 | 0.008 |
| Lithium Other Mood Stabilizers | 30,755 | 6.2% | 29,838 | 6.2% | -0.047 | -0.002 |
| Antidepressants | 158,438 | 31.9% | 151,090 | 31.6% | 0.304 | 0.007 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 11.1 | 11.1 | 11.1 | 10.7 | -0.046 | -0.004 |
| Mean number of emergency room | 0.5 | 1.2 | 0.5 | 1.2 | -0.003 | -0.002 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.001 | -0.002 |
| Mean number of other ambulatory encounters | 2.8 | 8.8 | 2.9 | 9.3 | -0.151 | -0.017 |
| Mean number of filled prescriptions | 16.6 | 15.1 | 16.6 | 15.0 | 0.042 | 0.003 |
| Mean number of generics dispensed | 8.5 | 5.1 | 8.4 | 5.2 | 0.097 | 0.019 |
| Mean number of unique drug classes dispensed | 8.1 | 4.6 | 8.0 | 4.6 | 0.074 | 0.016 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.001 | -0.004 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.001 | -0.002 |

Table 1ar. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of outpatient visits for respiratory disorders | 2.4 | 3.3 | 2.3 | 3.3 | 0.025 | 0.008 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1as. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 255,219 | 100.0% | 354,697 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 38.3 | 15.9 | 31.9 | 16.2 | 6.433 | 0.402 |
| Age | | | | | | |
| 10-24 years | 104,647 | 41.0% | 191,902 | 54.1% | -13.100 | -0.265 |
| 25-54 years | 75,772 | 29.7% | 90,688 | 25.6% | 4.121 | 0.092 |
| ≥ 55 years | 74,800 | 29.3% | 72,107 | 20.3% | 8.979 | 0.209 |
| Sex | | | | | | |
| Female | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Male | 255,219 | 100.0% | 354,697 | 100.0% | 0.000 | NaN |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 1,553 | 0.6% | 2,872 | 0.8% | -0.201 | -0.024 |
| Asian | 5,892 | 2.3% | 8,374 | 2.4% | -0.052 | -0.003 |
| Black or African American | 25,928 | 10.2% | 43,487 | 12.3% | -2.101 | -0.067 |
| Multi-racial | 639 | 0.3% | 753 | 0.2% | 0.038 | 0.008 |
| Native Hawaiian or Other Pacific Islander | 499 | 0.2% | 1,343 | 0.4% | -0.183 | -0.034 |
| Unknown | 142,920 | 56.0% | 199,543 | 56.3% | -0.258 | -0.005 |
| White | 77,788 | 30.5% | 98,325 | 27.7% | 2.758 | 0.061 |
| Hispanic origin | | | | | | |
| Yes | 25,204 | 9.9% | 49,702 | 14.0% | -4.137 | -0.128 |
| No | 104,705 | 41.0% | 146,991 | 41.4% | -0.416 | -0.008 |
| Unknown | 125,310 | 49.1% | 158,004 | 44.5% | 4.553 | 0.091 |
| Year | | | | | | |
| 2015 | 10,214 | 4.0% | 18,170 | 5.1% | -1.121 | -0.054 |
| 2016 | 49,233 | 19.3% | 81,910 | 23.1% | -3.802 | -0.093 |
| 2017 | 58,609 | 23.0% | 94,000 | 26.5% | -3.537 | -0.082 |
| 2018 | 55,114 | 21.6% | 79,552 | 22.4% | -0.833 | -0.020 |
| 2019 | 28,582 | 11.2% | 27,116 | 7.6% | 3.554 | 0.122 |
| 2020 | 24,170 | 9.5% | 24,045 | 6.8% | 2.691 | 0.099 |

Table 1as. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2021 | 21,783 | 8.5% | 22,070 | 6.2% | 2.313 | 0.089 |
| 2022 | 7,514 | 2.9% | 7,834 | 2.2% | 0.735 | 0.046 |
| Pre-boxed warning | 206,332 | 80.8% | 305,498 | 86.1% | -5.284 | -0.143 |
| Post-boxed warning | 48,887 | 19.2% | 49,199 | 13.9% | 5.284 | 0.143 |
| Seasonality | | | | | | |
| Winter | 58,756 | 23.0% | 88,715 | 25.0% | -1.990 | -0.047 |
| Spring | 70,671 | 27.7% | 79,377 | 22.4% | 5.312 | 0.123 |
| Summer | 56,975 | 22.3% | 76,659 | 21.6% | 0.711 | 0.017 |
| Autumn | 68,817 | 27.0% | 109,946 | 31.0% | -4.033 | -0.089 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.4 | 1.3 | 1.4 | 1.2 | 0.063 | 0.050 |
| Psychiatric History | 108,441 | 42.5% | 144,096 | 40.6% | 1.864 | 0.038 |
| Psychiatric Drug Dispensings ⁵ | 68,468 | 26.8% | 91,440 | 25.8% | 1.047 | 0.024 |
| Self Harm Encounter ⁵ | 341 | 0.1% | 589 | 0.2% | -0.032 | -0.008 |
| Encounter for Other Psychiatric Event ⁵ | 93,967 | 36.8% | 126,097 | 35.6% | 1.268 | 0.026 |
| Asthma Emergency Encounter | 22,546 | 8.8% | 38,482 | 10.8% | -2.015 | -0.068 |
| Asthma Inpatient Encounter | 547 | 0.2% | 1,043 | 0.3% | -0.080 | -0.016 |
| Asthma Outpatient Encounter | 246,146 | 96.4% | 343,200 | 96.8% | -0.314 | -0.017 |
| Oral Corticosteroid Dispensing | 60,889 | 23.9% | 80,389 | 22.7% | 1.193 | 0.028 |
| Use of Other Asthma Medication | 166,161 | 65.1% | 285,657 | 80.5% | -15.430 | -0.352 |
| Allergic Rhinitis | 110,629 | 43.3% | 85,926 | 24.2% | 19.122 | 0.413 |
| Anxiety | 28,479 | 11.2% | 36,847 | 10.4% | 0.770 | 0.025 |
| Depression | 21,432 | 8.4% | 29,237 | 8.2% | 0.155 | 0.006 |
| Sleep Disorder | 35,199 | 13.8% | 34,024 | 9.6% | 4.199 | 0.131 |
| Substance Abuse | 8,455 | 3.3% | 15,263 | 4.3% | -0.990 | -0.052 |
| Poisoning | 276 | 0.1% | 553 | 0.2% | -0.048 | -0.013 |
| Suffocation | 17 | 0.0% | 19 | 0.0% | 0.001 | 0.002 |
| Suicide Attempt | 182 | 0.1% | 346 | 0.1% | -0.026 | -0.009 |

Table 1as. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Toxicity | 43 | 0.0% | 74 | 0.0% | -0.004 | -0.003 |
| Other Self Harm | 93 | 0.0% | 161 | 0.0% | -0.009 | -0.004 |
| No moderate asthma exacerbations | 220,440 | 86.4% | 303,050 | 85.4% | 0.934 | 0.027 |
| One moderate asthma exacerbation | 31,021 | 12.2% | 46,272 | 13.0% | -0.891 | -0.027 |
| Two or more moderate asthma | 3,758 | 1.5% | 5,375 | 1.5% | -0.043 | -0.004 |
| No severe asthma exacerbations | 253,640 | 99.4% | 351,612 | 99.1% | 0.251 | 0.029 |
| One severe asthma exacerbation | 1,516 | 0.6% | 3,001 | 0.8% | -0.252 | -0.030 |
| Two or more severe asthma exacerbations | 63 | 0.0% | 84 | 0.0% | 0.001 | 0.001 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 34,737 | 13.6% | 40,651 | 11.5% | 2.150 | 0.065 |
| Antipsychotics | 9,792 | 3.8% | 17,116 | 4.8% | -0.989 | -0.049 |
| Anxiolytics Hypnotics | 28,773 | 11.3% | 33,023 | 9.3% | 1.964 | 0.065 |
| Lithium Other Mood Stabilizers | 9,821 | 3.8% | 14,659 | 4.1% | -0.285 | -0.015 |
| Antidepressants | 38,045 | 14.9% | 48,706 | 13.7% | 1.175 | 0.034 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 8.4 | 10.5 | 7.8 | 10.7 | 0.563 | 0.053 |
| Mean number of emergency room | 0.4 | 1.0 | 0.4 | 1.2 | -0.059 | -0.053 |
| Mean number of inpatient hospital encounters | 0.1 | 0.3 | 0.1 | 0.4 | -0.001 | -0.003 |
| Mean number of other ambulatory encounters | 2.5 | 9.8 | 3.2 | 12.9 | -0.672 | -0.059 |
| Mean number of filled prescriptions | 11.7 | 11.9 | 11.1 | 12.1 | 0.633 | 0.053 |
| Mean number of generics dispensed | 6.4 | 4.1 | 5.7 | 3.8 | 0.619 | 0.157 |
| Mean number of unique drug classes dispensed | 6.1 | 3.7 | 5.6 | 3.5 | 0.492 | 0.138 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.001 | -0.006 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.010 | -0.025 |

Table 1as. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of outpatient visits for respiratory disorders | 2.1 | 3.2 | 1.6 | 2.8 | 0.494 | 0.164 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1at. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 255,153 | N/A | 246,665 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 38.3 | 15.9 | 38.1 | 17.0 | 0.171 | 0.010 |
| Age | | | | | | |
| 10-24 years | 104,644 | 41.0% | 106,788 | 43.3% | -2.280 | -0.057 |
| 25-54 years | 75,759 | 29.7% | 63,999 | 25.9% | 3.746 | 0.087 |
| ≥ 55 years | 74,750 | 29.3% | 75,879 | 30.8% | -1.466 | -0.043 |
| Sex | | | | | | |
| Female | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Male | 255,153 | 100.0% | 246,665 | 100.0% | 0.000 | NaN |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 1,553 | 0.6% | 1,524 | 0.6% | -0.009 | -0.001 |
| Asian | 5,889 | 2.3% | 5,195 | 2.1% | 0.202 | 0.014 |
| Black or African American | 25,924 | 10.2% | 22,819 | 9.3% | 0.909 | 0.032 |
| Multi-racial | 639 | 0.3% | 587 | 0.2% | 0.013 | 0.003 |
| Native Hawaiian or Other Pacific Islander | 499 | 0.2% | 720 | 0.3% | -0.096 | -0.020 |
| Unknown | 142,885 | 56.0% | 140,020 | 56.8% | -0.766 | -0.022 |
| White | 77,764 | 30.5% | 75,800 | 30.7% | -0.253 | -0.007 |
| Hispanic origin | | | | | | |
| Yes | 25,197 | 9.9% | 25,562 | 10.4% | -0.488 | -0.018 |
| No | 104,678 | 41.0% | 99,250 | 40.2% | 0.789 | 0.024 |
| Unknown | 125,278 | 49.1% | 121,854 | 49.4% | -0.301 | -0.012 |
| Year | | | | | | |
| 2015 | 10,212 | 4.0% | 10,298 | 4.2% | -0.172 | -0.009 |
| 2016 | 49,228 | 19.3% | 48,522 | 19.7% | -0.378 | -0.010 |
| 2017 | 58,601 | 23.0% | 56,995 | 23.1% | -0.139 | -0.003 |
| 2018 | 55,103 | 21.6% | 52,780 | 21.4% | 0.199 | 0.005 |
| 2019 | 28,561 | 11.2% | 26,956 | 10.9% | 0.265 | 0.009 |
| 2020 | 24,158 | 9.5% | 23,126 | 9.4% | 0.092 | 0.003 |

Table 1at. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2021 | 21,780 | 8.5% | 20,870 | 8.5% | 0.075 | 0.003 |
| 2022 | 7,510 | 2.9% | 7,117 | 2.9% | 0.058 | 0.003 |
| Pre-boxed warning | 206,283 | 80.8% | 199,866 | 81.0% | -0.180 | -0.005 |
| Post-boxed warning | 48,870 | 19.2% | 46,799 | 19.0% | 0.180 | 0.005 |
| Seasonality | | | | | | |
| Winter | 58,741 | 23.0% | 57,419 | 23.3% | -0.256 | -0.006 |
| Spring | 70,643 | 27.7% | 66,558 | 27.0% | 0.703 | 0.016 |
| Summer | 56,964 | 22.3% | 55,116 | 22.3% | -0.019 | -0.000 |
| Autumn | 68,805 | 27.0% | 67,572 | 27.4% | -0.428 | -0.010 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.4 | 1.3 | 1.4 | 1.3 | -0.002 | -0.002 |
| Psychiatric History | 108,386 | 42.5% | 103,765 | 42.1% | 0.412 | 0.008 |
| Psychiatric Drug Dispensings ⁶ | 68,424 | 26.8% | 65,552 | 26.6% | 0.241 | 0.006 |
| Self Harm Encounter ⁶ | 341 | 0.1% | 280 | 0.1% | 0.020 | 0.006 |
| Encounter for Other Psychiatric Event ⁶ | 93,918 | 36.8% | 89,502 | 36.3% | 0.524 | 0.011 |
| Asthma Emergency Encounter | 22,539 | 8.8% | 21,795 | 8.8% | -0.002 | -0.000 |
| Asthma Inpatient Encounter | 545 | 0.2% | 554 | 0.2% | -0.011 | -0.002 |
| Asthma Outpatient Encounter | 246,089 | 96.4% | 238,431 | 96.7% | -0.214 | -0.012 |
| Oral Corticosteroid Dispensing | 60,847 | 23.8% | 58,106 | 23.6% | 0.290 | 0.007 |
| Use of Other Asthma Medication | 166,150 | 65.1% | 164,813 | 66.8% | -1.699 | -0.037 |
| Allergic Rhinitis | 110,572 | 43.3% | 100,930 | 40.9% | 2.418 | 0.049 |
| Anxiety | 28,457 | 11.2% | 27,241 | 11.0% | 0.109 | 0.004 |
| Depression | 21,419 | 8.4% | 20,605 | 8.4% | 0.041 | 0.002 |
| Sleep Disorder | 35,164 | 13.8% | 33,002 | 13.4% | 0.402 | 0.012 |
| Substance Abuse | 8,452 | 3.3% | 8,352 | 3.4% | -0.074 | -0.004 |
| Poisoning | 276 | 0.1% | 288 | 0.1% | -0.008 | -0.003 |
| Suffocation | 17 | 0.0% | 8 | 0.0% | 0.003 | 0.005 |
| Suicide Attempt | 181 | 0.1% | 180 | 0.1% | -0.002 | -0.001 |

Table 1at. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Toxicity | 43 | 0.0% | 38 | 0.0% | 0.001 | 0.001 |
| Other Self Harm | 93 | 0.0% | 100 | 0.0% | -0.004 | -0.002 |
| No moderate asthma exacerbations | 220,392 | 86.4% | 212,226 | 86.0% | 0.338 | 0.010 |
| One moderate asthma exacerbation | 31,006 | 12.2% | 30,744 | 12.5% | -0.312 | -0.009 |
| Two or more moderate asthma | 3,755 | 1.5% | 3,695 | 1.5% | -0.026 | -0.002 |
| No severe asthma exacerbations | 253,577 | 99.4% | 245,063 | 99.4% | 0.032 | 0.004 |
| One severe asthma exacerbation | 1,515 | 0.6% | 1,541 | 0.6% | -0.031 | -0.004 |
| Two or more severe asthma exacerbations | 61 | 0.0% | 61 | 0.0% | -0.001 | -0.001 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 34,696 | 13.6% | 33,093 | 13.4% | 0.182 | 0.005 |
| Antipsychotics | 9,783 | 3.8% | 9,656 | 3.9% | -0.081 | -0.004 |
| Anxiolytics Hypnotics | 28,743 | 11.3% | 27,368 | 11.1% | 0.170 | 0.005 |
| Lithium Other Mood Stabilizers | 9,816 | 3.8% | 9,639 | 3.9% | -0.060 | -0.003 |
| Antidepressants | 38,016 | 14.9% | 36,490 | 14.8% | 0.106 | 0.003 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 8.4 | 10.5 | 8.4 | 10.1 | -0.035 | -0.003 |
| Mean number of emergency room | 0.4 | 1.0 | 0.4 | 1.1 | -0.003 | -0.003 |
| Mean number of inpatient hospital encounters | 0.1 | 0.3 | 0.1 | 0.3 | -0.001 | -0.004 |
| Mean number of other ambulatory encounters | 2.5 | 9.8 | 2.6 | 10.5 | -0.163 | -0.016 |
| Mean number of filled prescriptions | 11.7 | 11.8 | 11.7 | 11.7 | -0.017 | -0.001 |
| Mean number of generics dispensed | 6.3 | 4.1 | 6.3 | 4.1 | 0.066 | 0.016 |
| Mean number of unique drug classes dispensed | 6.0 | 3.7 | 6.0 | 3.7 | 0.050 | 0.014 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.001 | -0.006 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.000 | -0.001 |

Table 1at. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of outpatient visits for respiratory disorders | 2.1 | 3.2 | 2.1 | 3.2 | 0.031 | 0.010 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1au. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 207,843 | 100.0% | 375,784 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 15.6 | 4.0 | 15.0 | 3.8 | 0.628 | 0.161 |
| Age | | | | | | |
| 10-24 years | 207,843 | 100.0% | 375,784 | 100.0% | 0.000 | NaN |
| 25-54 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| ≥ 55 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Sex | | | | | | |
| Female | 103,196 | 49.7% | 183,882 | 48.9% | 0.718 | 0.014 |
| Male | 104,647 | 50.3% | 191,902 | 51.1% | -0.718 | -0.014 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 1,875 | 0.9% | 3,662 | 1.0% | -0.072 | -0.008 |
| Asian | 3,220 | 1.5% | 7,778 | 2.1% | -0.521 | -0.039 |
| Black or African American | 30,297 | 14.6% | 58,363 | 15.5% | -0.954 | -0.027 |
| Multi-racial | 448 | 0.2% | 676 | 0.2% | 0.036 | 0.008 |
| Native Hawaiian or Other Pacific Islander | 381 | 0.2% | 1,640 | 0.4% | -0.253 | -0.046 |
| Unknown | 133,743 | 64.3% | 233,407 | 62.1% | 2.236 | 0.046 |
| White | 37,879 | 18.2% | 70,258 | 18.7% | -0.472 | -0.012 |
| Hispanic origin | | | | | | |
| Yes | 35,999 | 17.3% | 75,958 | 20.2% | -2.893 | -0.074 |
| No | 71,472 | 34.4% | 138,072 | 36.7% | -2.355 | -0.049 |
| Unknown | 100,372 | 48.3% | 161,754 | 43.0% | 5.248 | 0.105 |
| Year | | | | | | |
| 2015 | 9,716 | 4.7% | 20,002 | 5.3% | -0.648 | -0.030 |
| 2016 | 48,697 | 23.4% | 95,848 | 25.5% | -2.076 | -0.048 |
| 2017 | 59,936 | 28.8% | 113,823 | 30.3% | -1.452 | -0.032 |
| 2018 | 54,086 | 26.0% | 92,660 | 24.7% | 1.365 | 0.031 |
| 2019 | 13,507 | 6.5% | 18,241 | 4.9% | 1.645 | 0.071 |
| 2020 | 9,705 | 4.7% | 14,961 | 4.0% | 0.688 | 0.034 |

Table 1au. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2021 | 8,746 | 4.2% | 14,424 | 3.8% | 0.370 | 0.019 |
| 2022 | 3,450 | 1.7% | 5,825 | 1.6% | 0.110 | 0.009 |
| Pre-boxed warning | 187,851 | 90.4% | 343,671 | 91.5% | -1.073 | -0.037 |
| Post-boxed warning | 19,992 | 9.6% | 32,113 | 8.5% | 1.073 | 0.037 |
| Seasonality | | | | | | |
| Winter | 43,716 | 21.0% | 89,332 | 23.8% | -2.739 | -0.066 |
| Spring | 54,422 | 26.2% | 78,681 | 20.9% | 5.246 | 0.124 |
| Summer | 50,035 | 24.1% | 84,586 | 22.5% | 1.564 | 0.037 |
| Autumn | 59,670 | 28.7% | 123,185 | 32.8% | -4.072 | -0.088 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.2 | 0.5 | 1.2 | 0.5 | -0.006 | -0.012 |
| Psychiatric History | 68,576 | 33.0% | 123,092 | 32.8% | 0.238 | 0.005 |
| Psychiatric Drug Dispensings ⁵ | 43,108 | 20.7% | 74,249 | 19.8% | 0.982 | 0.024 |
| Self Harm Encounter ⁵ | 550 | 0.3% | 1,163 | 0.3% | -0.045 | -0.008 |
| Encounter for Other Psychiatric Event ⁵ | 60,170 | 28.9% | 109,576 | 29.2% | -0.210 | -0.005 |
| Asthma Emergency Encounter | 24,071 | 11.6% | 47,314 | 12.6% | -1.009 | -0.031 |
| Asthma Inpatient Encounter | 413 | 0.2% | 1,147 | 0.3% | -0.107 | -0.021 |
| Asthma Outpatient Encounter | 199,759 | 96.1% | 363,736 | 96.8% | -0.683 | -0.037 |
| Oral Corticosteroid Dispensing | 42,355 | 20.4% | 78,531 | 20.9% | -0.520 | -0.013 |
| Use of Other Asthma Medication | 156,979 | 75.5% | 322,947 | 85.9% | -10.412 | -0.266 |
| Allergic Rhinitis | 92,331 | 44.4% | 97,718 | 26.0% | 18.420 | 0.393 |
| Anxiety | 20,698 | 10.0% | 36,965 | 9.8% | 0.122 | 0.004 |
| Depression | 15,557 | 7.5% | 27,897 | 7.4% | 0.061 | 0.002 |
| Sleep Disorder | 6,788 | 3.3% | 10,421 | 2.8% | 0.493 | 0.029 |
| Substance Abuse | 2,843 | 1.4% | 6,151 | 1.6% | -0.269 | -0.022 |
| Poisoning | 545 | 0.3% | 1,196 | 0.3% | -0.056 | -0.010 |
| Suffocation | 17 | 0.0% | 28 | 0.0% | 0.001 | 0.001 |
| Suicide Attempt | 288 | 0.1% | 621 | 0.2% | -0.027 | -0.007 |

Table 1au. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Toxicity | 57 | 0.0% | 125 | 0.0% | -0.006 | -0.003 |
| Other Self Harm | 157 | 0.1% | 305 | 0.1% | -0.006 | -0.002 |
| No moderate asthma exacerbations | 181,721 | 87.4% | 322,184 | 85.7% | 1.695 | 0.050 |
| One moderate asthma exacerbation | 23,942 | 11.5% | 48,712 | 13.0% | -1.443 | -0.044 |
| Two or more moderate asthma | 2,180 | 1.0% | 4,888 | 1.3% | -0.252 | -0.023 |
| No severe asthma exacerbations | 206,852 | 99.5% | 372,574 | 99.1% | 0.377 | 0.046 |
| One severe asthma exacerbation | 954 | 0.5% | 3,128 | 0.8% | -0.373 | -0.047 |
| Two or more severe asthma exacerbations | 37 | 0.0% | 82 | 0.0% | -0.004 | -0.003 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 13,028 | 6.3% | 20,596 | 5.5% | 0.787 | 0.033 |
| Antipsychotics | 6,021 | 2.9% | 11,754 | 3.1% | -0.231 | -0.014 |
| Anxiolytics Hypnotics | 11,274 | 5.4% | 17,569 | 4.7% | 0.749 | 0.034 |
| Lithium Other Mood Stabilizers | 4,717 | 2.3% | 9,026 | 2.4% | -0.132 | -0.009 |
| Antidepressants | 21,173 | 10.2% | 35,063 | 9.3% | 0.856 | 0.029 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 6.5 | 8.1 | 6.6 | 8.5 | -0.045 | -0.005 |
| Mean number of emergency room | 0.4 | 1.0 | 0.4 | 1.0 | -0.036 | -0.036 |
| Mean number of inpatient hospital encounters | 0.0 | 0.3 | 0.0 | 0.3 | -0.008 | -0.028 |
| Mean number of other ambulatory encounters | 2.3 | 10.3 | 2.9 | 12.8 | -0.674 | -0.058 |
| Mean number of filled prescriptions | 7.5 | 7.1 | 7.4 | 7.4 | 0.051 | 0.007 |
| Mean number of generics dispensed | 4.9 | 3.1 | 4.7 | 2.9 | 0.256 | 0.084 |
| Mean number of unique drug classes dispensed | 4.8 | 2.8 | 4.6 | 2.7 | 0.154 | 0.055 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.1 | 0.0 | 0.2 | -0.006 | -0.038 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.008 | -0.022 |

Table 1au. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of outpatient visits for respiratory disorders | 1.8 | 2.9 | 1.5 | 2.5 | 0.356 | 0.133 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1av. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 207,800 | N/A | 201,178 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 15.6 | 4.0 | 15.5 | 4.0 | 0.080 | 0.020 |
| Age | | | | | | |
| 10-24 years | 207,800 | 100.0% | 201,178 | 100.0% | 0.000 | NaN |
| 25-54 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| ≥ 55 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Sex | | | | | | |
| Female | 103,165 | 49.6% | 99,417 | 49.4% | 0.229 | 0.005 |
| Male | 104,635 | 50.4% | 101,761 | 50.6% | -0.229 | -0.005 |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 1,875 | 0.9% | 1,741 | 0.9% | 0.037 | 0.004 |
| Asian | 3,220 | 1.5% | 3,944 | 2.0% | -0.411 | -0.031 |
| Black or African American | 30,294 | 14.6% | 27,422 | 13.6% | 0.948 | 0.029 |
| Multi-racial | 448 | 0.2% | 390 | 0.2% | 0.022 | 0.005 |
| Native Hawaiian or Other Pacific Islander | 381 | 0.2% | 763 | 0.4% | -0.196 | -0.037 |
| Unknown | 133,708 | 64.3% | 132,364 | 65.8% | -1.450 | -0.036 |
| White | 37,874 | 18.2% | 34,553 | 17.2% | 1.051 | 0.029 |
| Hispanic origin | | | | | | |
| Yes | 35,998 | 17.3% | 37,492 | 18.6% | -1.313 | -0.037 |
| No | 71,465 | 34.4% | 66,172 | 32.9% | 1.499 | 0.039 |
| Unknown | 100,337 | 48.3% | 97,513 | 48.5% | -0.186 | -0.007 |
| Year | | | | | | |
| 2015 | 9,715 | 4.7% | 9,624 | 4.8% | -0.109 | -0.005 |
| 2016 | 48,692 | 23.4% | 47,579 | 23.7% | -0.218 | -0.005 |
| 2017 | 59,926 | 28.8% | 58,256 | 29.0% | -0.119 | -0.003 |
| 2018 | 54,075 | 26.0% | 51,655 | 25.7% | 0.346 | 0.008 |
| 2019 | 13,499 | 6.5% | 12,788 | 6.4% | 0.140 | 0.006 |

Table 1av. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2020 | 9,699 | 4.7% | 9,450 | 4.7% | -0.030 | -0.001 |
| 2021 | 8,744 | 4.2% | 8,489 | 4.2% | -0.012 | -0.001 |
| 2022 | 3,450 | 1.7% | 3,336 | 1.7% | 0.002 | 0.000 |
| Pre-boxed warning | 187,814 | 90.4% | 181,750 | 90.3% | 0.039 | 0.001 |
| Post-boxed warning | 19,986 | 9.6% | 19,427 | 9.7% | -0.039 | -0.001 |
| Seasonality | | | | | | |
| Winter | 43,711 | 21.0% | 42,884 | 21.3% | -0.282 | -0.007 |
| Spring | 54,393 | 26.2% | 51,236 | 25.5% | 0.708 | 0.016 |
| Summer | 50,029 | 24.1% | 48,365 | 24.0% | 0.034 | 0.001 |
| Autumn | 59,667 | 28.7% | 58,692 | 29.2% | -0.461 | -0.010 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.2 | 0.5 | 1.2 | 0.5 | -0.001 | -0.001 |
| Psychiatric History | 68,541 | 33.0% | 65,947 | 32.8% | 0.203 | 0.004 |
| Psychiatric Drug Dispensings ⁶ | 43,081 | 20.7% | 40,578 | 20.2% | 0.562 | 0.014 |
| Self Harm Encounter ⁶ | 550 | 0.3% | 540 | 0.3% | -0.004 | -0.001 |
| Encounter for Other Psychiatric Event ⁶ | 60,137 | 28.9% | 57,623 | 28.6% | 0.297 | 0.007 |
| Asthma Emergency Encounter | 24,061 | 11.6% | 23,264 | 11.6% | 0.015 | 0.000 |
| Asthma Inpatient Encounter | 413 | 0.2% | 437 | 0.2% | -0.019 | -0.004 |
| Asthma Outpatient Encounter | 199,726 | 96.1% | 193,915 | 96.4% | -0.276 | -0.015 |
| Oral Corticosteroid Dispensing | 42,337 | 20.4% | 41,029 | 20.4% | -0.020 | -0.001 |
| Use of Other Asthma Medication | 156,967 | 75.5% | 155,485 | 77.3% | -1.750 | -0.042 |
| Allergic Rhinitis | 92,291 | 44.4% | 84,934 | 42.2% | 2.195 | 0.045 |
| Anxiety | 20,680 | 10.0% | 19,864 | 9.9% | 0.078 | 0.003 |
| Depression | 15,547 | 7.5% | 14,959 | 7.4% | 0.046 | 0.002 |
| Sleep Disorder | 6,777 | 3.3% | 6,361 | 3.2% | 0.099 | 0.006 |
| Substance Abuse | 2,840 | 1.4% | 2,833 | 1.4% | -0.042 | -0.004 |
| Poisoning | 545 | 0.3% | 597 | 0.3% | -0.034 | -0.007 |

Table 1av. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Suffocation | 17 | 0.0% | 11 | 0.0% | 0.003 | 0.003 |
| Suicide Attempt | 288 | 0.1% | 307 | 0.2% | -0.014 | -0.004 |
| Toxicity | 57 | 0.0% | 62 | 0.0% | -0.003 | -0.002 |
| Other Self Harm | 157 | 0.1% | 154 | 0.1% | -0.001 | -0.000 |
| No moderate asthma exacerbations | 181,682 | 87.4% | 174,384 | 86.7% | 0.750 | 0.022 |
| One moderate asthma exacerbation | 23,939 | 11.5% | 24,284 | 12.1% | -0.551 | -0.017 |
| Two or more moderate asthma | 2,179 | 1.0% | 2,509 | 1.2% | -0.199 | -0.019 |
| No severe asthma exacerbations | 206,810 | 99.5% | 200,096 | 99.5% | 0.061 | 0.009 |
| One severe asthma exacerbation | 954 | 0.5% | 1,041 | 0.5% | -0.058 | -0.008 |
| Two or more severe asthma exacerbations | 36 | 0.0% | 40 | 0.0% | -0.003 | -0.002 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 13,019 | 6.3% | 12,361 | 6.1% | 0.121 | 0.005 |
| Antipsychotics | 6,014 | 2.9% | 5,945 | 3.0% | -0.061 | -0.004 |
| Anxiolytics Hypnotics | 11,263 | 5.4% | 10,555 | 5.2% | 0.173 | 0.008 |
| Lithium Other Mood Stabilizers | 4,710 | 2.3% | 4,601 | 2.3% | -0.020 | -0.001 |
| Antidepressants | 21,154 | 10.2% | 20,145 | 10.0% | 0.167 | 0.006 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 6.5 | 8.1 | 6.6 | 7.8 | -0.007 | -0.001 |
| Mean number of emergency room | 0.4 | 1.0 | 0.4 | 1.0 | -0.002 | -0.002 |
| Mean number of inpatient hospital encounters | 0.0 | 0.3 | 0.0 | 0.3 | -0.002 | -0.007 |
| Mean number of other ambulatory encounters | 2.3 | 10.3 | 2.6 | 11.6 | -0.351 | -0.032 |
| Mean number of filled prescriptions | 7.5 | 7.1 | 7.5 | 7.1 | 0.012 | 0.002 |
| Mean number of generics dispensed | 4.9 | 3.1 | 4.9 | 3.2 | 0.051 | 0.016 |
| Mean number of unique drug classes dispensed | 4.8 | 2.8 | 4.7 | 2.9 | 0.037 | 0.013 |

Table 1av. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.1 | 0.0 | 0.1 | -0.001 | -0.008 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.001 | -0.002 |
| Mean number of outpatient visits for respiratory disorders | 1.8 | 2.9 | 1.8 | 2.8 | 0.042 | 0.015 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1aw. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 257,110 | 100.0% | 294,341 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 40.4 | 8.4 | 39.8 | 8.5 | 0.512 | 0.061 |
| Age | | | | | | |
| 10-24 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 25-54 years | 257,110 | 100.0% | 294,341 | 100.0% | 0.000 | NaN |
| ≥ 55 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Sex | | | | | | |
| Female | 181,338 | 70.5% | 203,653 | 69.2% | 1.340 | 0.029 |
| Male | 75,772 | 29.5% | 90,688 | 30.8% | -1.340 | -0.029 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 1,423 | 0.6% | 2,693 | 0.9% | -0.361 | -0.042 |
| Asian | 4,289 | 1.7% | 5,838 | 2.0% | -0.315 | -0.024 |
| Black or African American | 24,385 | 9.5% | 36,232 | 12.3% | -2.825 | -0.091 |
| Multi-racial | 1,158 | 0.5% | 1,019 | 0.3% | 0.104 | 0.017 |
| Native Hawaiian or Other Pacific Islander | 405 | 0.2% | 1,086 | 0.4% | -0.211 | -0.041 |
| Unknown | 170,998 | 66.5% | 167,494 | 56.9% | 9.603 | 0.199 |
| White | 54,452 | 21.2% | 79,979 | 27.2% | -5.994 | -0.140 |
| Hispanic origin | | | | | | |
| Yes | 17,125 | 6.7% | 28,457 | 9.7% | -3.007 | -0.110 |
| No | 74,367 | 28.9% | 116,533 | 39.6% | -10.667 | -0.226 |
| Unknown | 165,618 | 64.4% | 149,351 | 50.7% | 13.674 | 0.279 |
| Year | | | | | | |
| 2015 | 9,809 | 3.8% | 14,025 | 4.8% | -0.950 | -0.047 |
| 2016 | 48,272 | 18.8% | 64,342 | 21.9% | -3.085 | -0.077 |
| 2017 | 55,345 | 21.5% | 75,760 | 25.7% | -4.213 | -0.099 |
| 2018 | 53,229 | 20.7% | 65,883 | 22.4% | -1.680 | -0.041 |
| 2019 | 29,853 | 11.6% | 22,843 | 7.8% | 3.850 | 0.130 |
| 2020 | 28,159 | 11.0% | 23,741 | 8.1% | 2.886 | 0.099 |

Table 1aw. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2021 | 23,587 | 9.2% | 19,834 | 6.7% | 2.435 | 0.090 |
| 2022 | 8,856 | 3.4% | 7,913 | 2.7% | 0.756 | 0.044 |
| Pre-boxed warning | 201,244 | 78.3% | 246,845 | 83.9% | -5.592 | -0.143 |
| Post-boxed warning | 55,866 | 21.7% | 47,496 | 16.1% | 5.592 | 0.143 |
| Seasonality | | | | | | |
| Winter | 59,048 | 23.0% | 75,105 | 25.5% | -2.550 | -0.060 |
| Spring | 75,190 | 29.2% | 68,632 | 23.3% | 5.927 | 0.135 |
| Summer | 55,307 | 21.5% | 61,585 | 20.9% | 0.588 | 0.014 |
| Autumn | 67,565 | 26.3% | 89,019 | 30.2% | -3.965 | -0.088 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.4 | 1.1 | 1.5 | 1.2 | -0.053 | -0.046 |
| Psychiatric History | 143,325 | 55.7% | 168,088 | 57.1% | -1.362 | -0.027 |
| Psychiatric Drug Dispensings ⁵ | 107,765 | 41.9% | 126,142 | 42.9% | -0.942 | -0.019 |
| Self Harm Encounter ⁵ | 698 | 0.3% | 1,131 | 0.4% | -0.113 | -0.020 |
| Encounter for Other Psychiatric Event ⁵ | 120,674 | 46.9% | 142,428 | 48.4% | -1.454 | -0.029 |
| Asthma Emergency Encounter | 31,681 | 12.3% | 43,015 | 14.6% | -2.292 | -0.067 |
| Asthma Inpatient Encounter | 937 | 0.4% | 1,018 | 0.3% | 0.019 | 0.003 |
| Asthma Outpatient Encounter | 245,663 | 95.5% | 281,077 | 95.5% | 0.054 | 0.003 |
| Oral Corticosteroid Dispensing | 78,184 | 30.4% | 85,945 | 29.2% | 1.210 | 0.026 |
| Use of Other Asthma Medication | 171,136 | 66.6% | 237,291 | 80.6% | -14.056 | -0.323 |
| Allergic Rhinitis | 109,228 | 42.5% | 59,245 | 20.1% | 22.355 | 0.497 |
| Anxiety | 60,536 | 23.5% | 68,518 | 23.3% | 0.266 | 0.006 |
| Depression | 43,794 | 17.0% | 53,468 | 18.2% | -1.132 | -0.030 |
| Sleep Disorder | 38,538 | 15.0% | 36,486 | 12.4% | 2.593 | 0.075 |
| Substance Abuse | 13,255 | 5.2% | 24,363 | 8.3% | -3.122 | -0.125 |
| Poisoning | 631 | 0.2% | 1,105 | 0.4% | -0.130 | -0.023 |
| Suffocation | 12 | 0.0% | 18 | 0.0% | -0.001 | -0.002 |
| Suicide Attempt | 364 | 0.1% | 554 | 0.2% | -0.047 | -0.011 |

Table 1aw. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Toxicity | 68 | 0.0% | 127 | 0.0% | -0.017 | -0.009 |
| Other Self Harm | 193 | 0.1% | 288 | 0.1% | -0.023 | -0.008 |
| No moderate asthma exacerbations | 215,213 | 83.7% | 243,125 | 82.6% | 1.105 | 0.030 |
| One moderate asthma exacerbation | 36,781 | 14.3% | 44,964 | 15.3% | -0.971 | -0.027 |
| Two or more moderate asthma | 5,116 | 2.0% | 6,252 | 2.1% | -0.134 | -0.009 |
| No severe asthma exacerbations | 254,804 | 99.1% | 291,343 | 99.0% | 0.122 | 0.012 |
| One severe asthma exacerbation | 2,180 | 0.8% | 2,892 | 1.0% | -0.135 | -0.014 |
| Two or more severe asthma exacerbations | 126 | 0.0% | 106 | 0.0% | 0.013 | 0.006 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 60,012 | 23.3% | 72,943 | 24.8% | -1.441 | -0.034 |
| Antipsychotics | 17,880 | 7.0% | 28,570 | 9.7% | -2.752 | -0.100 |
| Anxiolytics Hypnotics | 56,395 | 21.9% | 63,967 | 21.7% | 0.202 | 0.005 |
| Lithium Other Mood Stabilizers | 20,498 | 8.0% | 27,544 | 9.4% | -1.385 | -0.049 |
| Antidepressants | 78,739 | 30.6% | 94,144 | 32.0% | -1.360 | -0.029 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 9.6 | 11.2 | 10.1 | 12.5 | -0.445 | -0.037 |
| Mean number of emergency room | 0.6 | 1.5 | 0.7 | 1.8 | -0.158 | -0.095 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.015 | -0.035 |
| Mean number of other ambulatory encounters | 2.6 | 9.4 | 3.6 | 12.4 | -0.940 | -0.085 |
| Mean number of filled prescriptions | 15.7 | 15.1 | 16.7 | 16.5 | -1.055 | -0.067 |
| Mean number of generics dispensed | 7.9 | 5.1 | 7.9 | 5.1 | 0.044 | 0.009 |
| Mean number of unique drug classes dispensed | 7.5 | 4.6 | 7.5 | 4.6 | -0.029 | -0.006 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.3 | -0.006 | -0.024 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.5 | 0.2 | 0.5 | -0.022 | -0.043 |

Table 1aw. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of outpatient visits for respiratory disorders | 2.1 | 3.2 | 1.6 | 2.7 | 0.455 | 0.154 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1ax. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 257,075 | N/A | 247,483 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 40.3 | 8.4 | 40.4 | 8.5 | -0.002 | -0.000 |
| Age | | | | | | |
| 10-24 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 25-54 years | 257,075 | 100.0% | 247,483 | 100.0% | 0.000 | NaN |
| ≥ 55 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Sex | | | | | | |
| Female | 181,307 | 70.5% | 173,792 | 70.2% | 0.303 | 0.007 |
| Male | 75,768 | 29.5% | 73,691 | 29.8% | -0.303 | -0.007 |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 1,423 | 0.6% | 1,560 | 0.6% | -0.077 | -0.010 |
| Asian | 4,289 | 1.7% | 3,970 | 1.6% | 0.064 | 0.005 |
| Black or African American | 24,377 | 9.5% | 22,651 | 9.2% | 0.330 | 0.012 |
| Multi-racial | 1,158 | 0.5% | 1,154 | 0.5% | -0.016 | -0.002 |
| Native Hawaiian or Other Pacific Islander | 405 | 0.2% | 556 | 0.2% | -0.067 | -0.015 |
| Unknown | 170,983 | 66.5% | 164,585 | 66.5% | 0.007 | 0.000 |
| White | 54,440 | 21.2% | 53,007 | 21.4% | -0.242 | -0.007 |
| Hispanic origin | | | | | | |
| Yes | 17,120 | 6.7% | 16,748 | 6.8% | -0.108 | -0.005 |
| No | 74,349 | 28.9% | 71,044 | 28.7% | 0.215 | 0.008 |
| Unknown | 165,606 | 64.4% | 159,691 | 64.5% | -0.107 | -0.005 |
| Year | | | | | | |
| 2015 | 9,809 | 3.8% | 9,894 | 4.0% | -0.182 | -0.009 |
| 2016 | 48,269 | 18.8% | 47,132 | 19.0% | -0.268 | -0.007 |
| 2017 | 55,339 | 21.5% | 53,409 | 21.6% | -0.054 | -0.001 |
| 2018 | 53,223 | 20.7% | 50,596 | 20.4% | 0.259 | 0.007 |
| 2019 | 29,841 | 11.6% | 27,949 | 11.3% | 0.314 | 0.010 |

Table 1ax. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2020 | 28,153 | 11.0% | 27,180 | 11.0% | -0.031 | -0.001 |
| 2021 | 23,585 | 9.2% | 22,779 | 9.2% | -0.030 | -0.001 |
| 2022 | 8,856 | 3.4% | 8,543 | 3.5% | -0.007 | -0.000 |
| Pre-boxed warning | 201,217 | 78.3% | 193,498 | 78.2% | 0.085 | 0.002 |
| Post-boxed warning | 55,858 | 21.7% | 53,985 | 21.8% | -0.085 | -0.002 |
| Seasonality | | | | | | |
| Winter | 59,045 | 23.0% | 57,799 | 23.4% | -0.387 | -0.009 |
| Spring | 75,172 | 29.2% | 70,186 | 28.4% | 0.881 | 0.019 |
| Summer | 55,296 | 21.5% | 53,048 | 21.4% | 0.075 | 0.002 |
| Autumn | 67,562 | 26.3% | 66,449 | 26.9% | -0.569 | -0.013 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.4 | 1.1 | 1.4 | 1.1 | -0.002 | -0.001 |
| Psychiatric History | 143,293 | 55.7% | 136,888 | 55.3% | 0.428 | 0.009 |
| Psychiatric Drug Dispensings ⁶ | 107,738 | 41.9% | 102,569 | 41.4% | 0.464 | 0.010 |
| Self Harm Encounter ⁶ | 698 | 0.3% | 630 | 0.3% | 0.017 | 0.003 |
| Encounter for Other Psychiatric Event ⁶ | 120,646 | 46.9% | 115,293 | 46.6% | 0.344 | 0.007 |
| Asthma Emergency Encounter | 31,664 | 12.3% | 30,126 | 12.2% | 0.144 | 0.004 |
| Asthma Inpatient Encounter | 937 | 0.4% | 908 | 0.4% | -0.003 | -0.000 |
| Asthma Outpatient Encounter | 245,643 | 95.6% | 237,307 | 95.9% | -0.335 | -0.017 |
| Oral Corticosteroid Dispensing | 78,161 | 30.4% | 74,948 | 30.3% | 0.120 | 0.003 |
| Use of Other Asthma Medication | 171,134 | 66.6% | 169,918 | 68.7% | -2.089 | -0.045 |
| Allergic Rhinitis | 109,194 | 42.5% | 99,019 | 40.0% | 2.465 | 0.051 |
| Anxiety | 60,518 | 23.5% | 57,615 | 23.3% | 0.260 | 0.006 |
| Depression | 43,779 | 17.0% | 41,962 | 17.0% | 0.074 | 0.002 |
| Sleep Disorder | 38,522 | 15.0% | 36,154 | 14.6% | 0.376 | 0.011 |
| Substance Abuse | 13,254 | 5.2% | 13,031 | 5.3% | -0.110 | -0.005 |
| Poisoning | 631 | 0.2% | 642 | 0.3% | -0.014 | -0.003 |

Table 1ax. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Suffocation | 12 | 0.0% | 9 | 0.0% | 0.001 | 0.002 |
| Suicide Attempt | 364 | 0.1% | 335 | 0.1% | 0.006 | 0.002 |
| Toxicity | 68 | 0.0% | 71 | 0.0% | -0.002 | -0.001 |
| Other Self Harm | 193 | 0.1% | 185 | 0.1% | 0.000 | 0.000 |
| No moderate asthma exacerbations | 215,186 | 83.7% | 205,639 | 83.1% | 0.613 | 0.017 |
| One moderate asthma exacerbation | 36,774 | 14.3% | 36,889 | 14.9% | -0.601 | -0.017 |
| Two or more moderate asthma | 5,115 | 2.0% | 4,955 | 2.0% | -0.013 | -0.001 |
| No severe asthma exacerbations | 254,769 | 99.1% | 245,187 | 99.1% | 0.031 | 0.003 |
| One severe asthma exacerbation | 2,180 | 0.8% | 2,185 | 0.9% | -0.035 | -0.004 |
| Two or more severe asthma exacerbations | 126 | 0.0% | 111 | 0.0% | 0.004 | 0.002 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 59,988 | 23.3% | 56,895 | 23.0% | 0.345 | 0.008 |
| Antipsychotics | 17,874 | 7.0% | 17,397 | 7.0% | -0.077 | -0.003 |
| Anxiolytics Hypnotics | 56,372 | 21.9% | 53,562 | 21.6% | 0.286 | 0.007 |
| Lithium Other Mood Stabilizers | 20,493 | 8.0% | 19,762 | 8.0% | -0.014 | -0.001 |
| Antidepressants | 78,721 | 30.6% | 75,207 | 30.4% | 0.233 | 0.005 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 9.6 | 11.2 | 9.7 | 10.8 | -0.083 | -0.008 |
| Mean number of emergency room | 0.6 | 1.5 | 0.6 | 1.5 | -0.003 | -0.002 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.000 | -0.001 |
| Mean number of other ambulatory encounters | 2.6 | 9.4 | 2.7 | 9.4 | -0.091 | -0.010 |
| Mean number of filled prescriptions | 15.7 | 15.1 | 15.6 | 15.0 | 0.065 | 0.004 |
| Mean number of generics dispensed | 7.9 | 5.1 | 7.8 | 5.2 | 0.094 | 0.018 |
| Mean number of unique drug classes dispensed | 7.5 | 4.5 | 7.4 | 4.6 | 0.072 | 0.016 |

Table 1ax. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.001 | -0.003 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.5 | 0.1 | 0.5 | -0.001 | -0.002 |
| Mean number of outpatient visits for respiratory disorders | 2.1 | 3.2 | 2.1 | 3.1 | 0.010 | 0.003 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1ay. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 287,175 | 100.0% | 253,020 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 69.6 | 7.3 | 69.0 | 7.5 | 0.533 | 0.072 |
| Age | | | | | | |
| 10-24 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 25-54 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| ≥ 55 years | 287,175 | 100.0% | 253,020 | 100.0% | 0.000 | NaN |
| Sex | | | | | | |
| Female | 212,375 | 74.0% | 180,913 | 71.5% | 2.452 | 0.055 |
| Male | 74,800 | 26.0% | 72,107 | 28.5% | -2.452 | -0.055 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 1,343 | 0.5% | 1,533 | 0.6% | -0.138 | -0.019 |
| Asian | 8,479 | 3.0% | 6,061 | 2.4% | 0.557 | 0.035 |
| Black or African American | 27,025 | 9.4% | 22,150 | 8.8% | 0.656 | 0.023 |
| Multi-racial | 306 | 0.1% | 273 | 0.1% | -0.001 | -0.000 |
| Native Hawaiian or Other Pacific Islander | 562 | 0.2% | 509 | 0.2% | -0.005 | -0.001 |
| Unknown | 73,833 | 25.7% | 72,510 | 28.7% | -2.948 | -0.066 |
| White | 175,627 | 61.2% | 149,984 | 59.3% | 1.879 | 0.038 |
| Hispanic origin | | | | | | |
| Yes | 8,885 | 3.1% | 10,039 | 4.0% | -0.874 | -0.047 |
| No | 203,454 | 70.8% | 172,242 | 68.1% | 2.772 | 0.060 |
| Unknown | 74,836 | 26.1% | 70,739 | 28.0% | -1.898 | -0.043 |
| Year | | | | | | |
| 2015 | 9,612 | 3.3% | 12,645 | 5.0% | -1.651 | -0.083 |
| 2016 | 45,002 | 15.7% | 49,745 | 19.7% | -3.990 | -0.105 |
| 2017 | 48,764 | 17.0% | 48,664 | 19.2% | -2.253 | -0.059 |
| 2018 | 49,220 | 17.1% | 43,798 | 17.3% | -0.171 | -0.005 |
| 2019 | 47,398 | 16.5% | 33,645 | 13.3% | 3.208 | 0.090 |
| 2020 | 40,076 | 14.0% | 30,349 | 12.0% | 1.961 | 0.058 |

Table 1ay. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2021 | 37,101 | 12.9% | 26,795 | 10.6% | 2.329 | 0.072 |
| 2022 | 10,002 | 3.5% | 7,379 | 2.9% | 0.567 | 0.032 |
| Pre-boxed warning | 207,818 | 72.4% | 194,283 | 76.8% | -4.419 | -0.102 |
| Post-boxed warning | 79,357 | 27.6% | 58,737 | 23.2% | 4.419 | 0.102 |
| Seasonality | | | | | | |
| Winter | 71,671 | 25.0% | 68,168 | 26.9% | -1.984 | -0.045 |
| Spring | 79,934 | 27.8% | 59,286 | 23.4% | 4.403 | 0.101 |
| Summer | 61,402 | 21.4% | 52,827 | 20.9% | 0.503 | 0.012 |
| Autumn | 74,168 | 25.8% | 72,739 | 28.7% | -2.922 | -0.066 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 2.0 | 2.0 | 2.0 | 2.1 | 0.004 | 0.002 |
| Psychiatric History | 173,506 | 60.4% | 147,677 | 58.4% | 2.052 | 0.042 |
| Psychiatric Drug Dispensings ⁵ | 130,125 | 45.3% | 111,664 | 44.1% | 1.180 | 0.024 |
| Self Harm Encounter ⁵ | 147 | 0.1% | 158 | 0.1% | -0.011 | -0.005 |
| Encounter for Other Psychiatric Event ⁵ | 139,365 | 48.5% | 117,399 | 46.4% | 2.131 | 0.043 |
| Asthma Emergency Encounter | 20,722 | 7.2% | 20,119 | 8.0% | -0.736 | -0.028 |
| Asthma Inpatient Encounter | 901 | 0.3% | 739 | 0.3% | 0.022 | 0.004 |
| Asthma Outpatient Encounter | 275,140 | 95.8% | 243,276 | 96.1% | -0.340 | -0.017 |
| Oral Corticosteroid Dispensing | 88,216 | 30.7% | 69,287 | 27.4% | 3.335 | 0.073 |
| Use of Other Asthma Medication | 137,277 | 47.8% | 163,052 | 64.4% | -16.640 | -0.340 |
| Allergic Rhinitis | 122,749 | 42.7% | 57,419 | 22.7% | 20.050 | 0.437 |
| Anxiety | 55,366 | 19.3% | 44,940 | 17.8% | 1.518 | 0.039 |
| Depression | 51,045 | 17.8% | 44,700 | 17.7% | 0.108 | 0.003 |
| Sleep Disorder | 70,144 | 24.4% | 54,103 | 21.4% | 3.043 | 0.072 |
| Substance Abuse | 8,354 | 2.9% | 8,794 | 3.5% | -0.567 | -0.032 |
| Poisoning | 142 | 0.0% | 168 | 0.1% | -0.017 | -0.007 |
| Suffocation | 1 | 0.0% | 0 | 0.0% | NaN | NaN |
| Suicide Attempt | 80 | 0.0% | 73 | 0.0% | -0.001 | -0.001 |

Table 1ay. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Toxicity | 31 | 0.0% | 23 | 0.0% | 0.002 | 0.002 |
| Other Self Harm | 36 | 0.0% | 35 | 0.0% | -0.001 | -0.001 |
| No moderate asthma exacerbations | 239,093 | 83.3% | 213,769 | 84.5% | -1.230 | -0.033 |
| One moderate asthma exacerbation | 41,511 | 14.5% | 34,415 | 13.6% | 0.853 | 0.025 |
| Two or more moderate asthma | 6,571 | 2.3% | 4,836 | 1.9% | 0.377 | 0.026 |
| No severe asthma exacerbations | 284,252 | 99.0% | 250,248 | 98.9% | 0.078 | 0.008 |
| One severe asthma exacerbation | 2,837 | 1.0% | 2,714 | 1.1% | -0.085 | -0.008 |
| Two or more severe asthma exacerbations | 86 | 0.0% | 58 | 0.0% | 0.007 | 0.004 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 75,985 | 26.5% | 64,340 | 25.4% | 1.031 | 0.024 |
| Antipsychotics | 10,753 | 3.7% | 11,995 | 4.7% | -0.996 | -0.049 |
| Anxiolytics Hypnotics | 67,441 | 23.5% | 55,367 | 21.9% | 1.602 | 0.038 |
| Lithium Other Mood Stabilizers | 15,370 | 5.4% | 14,996 | 5.9% | -0.575 | -0.025 |
| Antidepressants | 96,603 | 33.6% | 84,150 | 33.3% | 0.381 | 0.008 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 13.3 | 12.3 | 12.7 | 12.4 | 0.533 | 0.043 |
| Mean number of emergency room | 0.3 | 0.9 | 0.4 | 1.0 | -0.024 | -0.026 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.006 | -0.015 |
| Mean number of other ambulatory encounters | 3.0 | 7.8 | 3.5 | 10.3 | -0.472 | -0.052 |
| Mean number of filled prescriptions | 19.8 | 15.5 | 20.5 | 16.7 | -0.728 | -0.045 |
| Mean number of generics dispensed | 9.7 | 5.1 | 9.3 | 5.0 | 0.368 | 0.073 |
| Mean number of unique drug classes dispensed | 9.2 | 4.6 | 9.0 | 4.5 | 0.222 | 0.049 |
| Mean number of inpatient visits for respiratory disorders | 0.1 | 0.3 | 0.1 | 0.3 | -0.006 | -0.019 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.006 | -0.014 |

Table 1ay. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of outpatient visits for respiratory disorders | 2.7 | 3.7 | 2.2 | 3.3 | 0.550 | 0.157 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1az. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 287,090 | N/A | 275,915 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 69.6 | 7.3 | 69.6 | 7.4 | -0.017 | -0.002 |
| Age | | | | | | |
| 10-24 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 25-54 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| ≥ 55 years | 287,090 | 100.0% | 275,915 | 100.0% | 0.000 | NaN |
| Sex | | | | | | |
| Female | 212,304 | 74.0% | 203,242 | 73.7% | 0.289 | 0.007 |
| Male | 74,786 | 26.0% | 72,673 | 26.3% | -0.289 | -0.007 |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 1,343 | 0.5% | 1,424 | 0.5% | -0.048 | -0.007 |
| Asian | 8,475 | 3.0% | 5,676 | 2.1% | 0.895 | 0.058 |
| Black or African American | 27,006 | 9.4% | 21,911 | 7.9% | 1.466 | 0.053 |
| Multi-racial | 305 | 0.1% | 315 | 0.1% | -0.008 | -0.002 |
| Native Hawaiian or Other Pacific Islander | 562 | 0.2% | 481 | 0.2% | 0.021 | 0.005 |
| Unknown | 73,807 | 25.7% | 71,596 | 25.9% | -0.240 | -0.009 |
| White | 175,592 | 61.2% | 174,511 | 63.2% | -2.086 | -0.055 |
| Hispanic origin | | | | | | |
| Yes | 8,877 | 3.1% | 8,064 | 2.9% | 0.169 | 0.010 |
| No | 203,402 | 70.8% | 194,574 | 70.5% | 0.330 | 0.014 |
| Unknown | 74,811 | 26.1% | 73,276 | 26.6% | -0.499 | -0.026 |
| Year | | | | | | |
| 2015 | 9,612 | 3.3% | 9,960 | 3.6% | -0.262 | -0.014 |
| 2016 | 44,998 | 15.7% | 44,865 | 16.3% | -0.587 | -0.016 |
| 2017 | 48,745 | 17.0% | 47,452 | 17.2% | -0.219 | -0.006 |
| 2018 | 49,196 | 17.1% | 46,831 | 17.0% | 0.163 | 0.004 |
| 2019 | 47,375 | 16.5% | 44,008 | 15.9% | 0.552 | 0.015 |

Table 1az. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2020 | 40,070 | 14.0% | 38,120 | 13.8% | 0.141 | 0.004 |
| 2021 | 37,095 | 12.9% | 35,204 | 12.8% | 0.162 | 0.005 |
| 2022 | 9,999 | 3.5% | 9,475 | 3.4% | 0.049 | 0.003 |
| Pre-boxed warning | 207,747 | 72.4% | 200,351 | 72.6% | -0.250 | -0.006 |
| Post-boxed warning | 79,343 | 27.6% | 75,564 | 27.4% | 0.250 | 0.006 |
| Seasonality | | | | | | |
| Winter | 71,659 | 25.0% | 69,386 | 25.1% | -0.187 | -0.004 |
| Spring | 79,891 | 27.8% | 74,777 | 27.1% | 0.726 | 0.016 |
| Summer | 61,380 | 21.4% | 59,323 | 21.5% | -0.121 | -0.003 |
| Autumn | 74,160 | 25.8% | 72,428 | 26.3% | -0.418 | -0.010 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 2.0 | 2.0 | 2.0 | 2.0 | 0.000 | 0.000 |
| Psychiatric History | 173,434 | 60.4% | 165,187 | 59.9% | 0.542 | 0.011 |
| Psychiatric Drug Dispensings ⁶ | 130,058 | 45.3% | 124,172 | 45.0% | 0.298 | 0.006 |
| Self Harm Encounter ⁶ | 147 | 0.1% | 131 | 0.0% | 0.004 | 0.002 |
| Encounter for Other Psychiatric Event ⁶ | 139,309 | 48.5% | 132,050 | 47.9% | 0.665 | 0.013 |
| Asthma Emergency Encounter | 20,714 | 7.2% | 19,716 | 7.1% | 0.070 | 0.003 |
| Asthma Inpatient Encounter | 898 | 0.3% | 879 | 0.3% | -0.006 | -0.001 |
| Asthma Outpatient Encounter | 275,066 | 95.8% | 265,210 | 96.1% | -0.308 | -0.016 |
| Oral Corticosteroid Dispensing | 88,165 | 30.7% | 83,204 | 30.2% | 0.554 | 0.012 |
| Use of Other Asthma Medication | 137,259 | 47.8% | 136,570 | 49.5% | -1.687 | -0.034 |
| Allergic Rhinitis | 122,671 | 42.7% | 110,465 | 40.0% | 2.693 | 0.055 |
| Anxiety | 55,328 | 19.3% | 52,285 | 18.9% | 0.322 | 0.008 |
| Depression | 51,017 | 17.8% | 48,381 | 17.5% | 0.236 | 0.006 |
| Sleep Disorder | 70,115 | 24.4% | 66,008 | 23.9% | 0.499 | 0.012 |
| Substance Abuse | 8,346 | 2.9% | 7,885 | 2.9% | 0.049 | 0.003 |
| Poisoning | 142 | 0.0% | 131 | 0.0% | 0.002 | 0.001 |

Table 1az. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Suffocation | 1 | 0.0% | 0 | 0.0% | NaN | NaN |
| Suicide Attempt | 80 | 0.0% | 59 | 0.0% | 0.006 | 0.004 |
| Toxicity | 31 | 0.0% | 17 | 0.0% | 0.005 | 0.005 |
| Other Self Harm | 36 | 0.0% | 28 | 0.0% | 0.002 | 0.002 |
| No moderate asthma exacerbations | 239,030 | 83.3% | 230,457 | 83.5% | -0.265 | -0.007 |
| One moderate asthma exacerbation | 41,492 | 14.5% | 39,599 | 14.4% | 0.101 | 0.003 |
| Two or more moderate asthma | 6,568 | 2.3% | 5,860 | 2.1% | 0.164 | 0.011 |
| No severe asthma exacerbations | 284,172 | 99.0% | 273,053 | 99.0% | 0.021 | 0.002 |
| One severe asthma exacerbation | 2,835 | 1.0% | 2,786 | 1.0% | -0.022 | -0.002 |
| Two or more severe asthma exacerbations | 83 | 0.0% | 76 | 0.0% | 0.001 | 0.001 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 75,932 | 26.4% | 71,681 | 26.0% | 0.469 | 0.011 |
| Antipsychotics | 10,745 | 3.7% | 10,497 | 3.8% | -0.062 | -0.003 |
| Anxiolytics Hypnotics | 67,387 | 23.5% | 63,992 | 23.2% | 0.280 | 0.007 |
| Lithium Other Mood Stabilizers | 15,358 | 5.3% | 14,956 | 5.4% | -0.071 | -0.003 |
| Antidepressants | 96,559 | 33.6% | 91,995 | 33.3% | 0.292 | 0.006 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 13.3 | 12.3 | 13.3 | 11.7 | -0.044 | -0.004 |
| Mean number of emergency room | 0.3 | 0.9 | 0.3 | 0.9 | 0.001 | 0.001 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.000 | -0.000 |
| Mean number of other ambulatory encounters | 3.0 | 7.8 | 3.1 | 8.1 | -0.044 | -0.006 |
| Mean number of filled prescriptions | 19.8 | 15.5 | 19.8 | 15.3 | -0.022 | -0.001 |
| Mean number of generics dispensed | 9.7 | 5.1 | 9.6 | 5.2 | 0.092 | 0.018 |
| Mean number of unique drug classes dispensed | 9.2 | 4.6 | 9.1 | 4.6 | 0.070 | 0.015 |

Table 1az. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of inpatient visits for respiratory disorders | 0.1 | 0.3 | 0.1 | 0.3 | -0.001 | -0.003 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.000 | -0.001 |
| Mean number of outpatient visits for respiratory disorders | 2.7 | 3.7 | 2.7 | 3.8 | 0.022 | 0.006 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1ba. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 366,721 | 100.0% | 484,288 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 39.7 | 15.7 | 32.9 | 15.9 | 6.757 | 0.429 |
| Age | | | | | | |
| 10-24 years | 139,267 | 38.0% | 252,692 | 52.2% | -14.202 | -0.288 |
| 25-54 years | 113,785 | 31.0% | 126,253 | 26.1% | 4.958 | 0.110 |
| ≥ 55 years | 113,669 | 31.0% | 105,343 | 21.8% | 9.244 | 0.211 |
| Sex | | | | | | |
| Female | 219,943 | 60.0% | 273,687 | 56.5% | 3.462 | 0.070 |
| Male | 146,778 | 40.0% | 210,601 | 43.5% | -3.462 | -0.070 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 2,125 | 0.6% | 3,843 | 0.8% | -0.214 | -0.026 |
| Asian | 10,457 | 2.9% | 13,779 | 2.8% | 0.006 | 0.000 |
| Black or African American | 40,994 | 11.2% | 63,063 | 13.0% | -1.843 | -0.057 |
| Multi-racial | 1,061 | 0.3% | 1,120 | 0.2% | 0.058 | 0.011 |
| Native Hawaiian or Other Pacific Islander | 795 | 0.2% | 2,164 | 0.4% | -0.230 | -0.040 |
| Unknown | 213,044 | 58.1% | 282,576 | 58.3% | -0.254 | -0.005 |
| White | 98,245 | 26.8% | 117,743 | 24.3% | 2.478 | 0.057 |
| Hispanic origin | | | | | | |
| Yes | 38,383 | 10.5% | 73,511 | 15.2% | -4.713 | -0.141 |
| No | 141,908 | 38.7% | 189,927 | 39.2% | -0.521 | -0.011 |
| Unknown | 186,430 | 50.8% | 220,850 | 45.6% | 5.234 | 0.105 |
| Year | | | | | | |
| 2015 | 15,454 | 4.2% | 25,233 | 5.2% | -0.996 | -0.047 |
| 2016 | 73,025 | 19.9% | 113,632 | 23.5% | -3.551 | -0.086 |
| 2017 | 84,986 | 23.2% | 130,687 | 27.0% | -3.811 | -0.088 |
| 2018 | 79,845 | 21.8% | 108,367 | 22.4% | -0.604 | -0.015 |
| 2019 | 40,336 | 11.0% | 35,997 | 7.4% | 3.566 | 0.124 |
| 2020 | 34,048 | 9.3% | 32,396 | 6.7% | 2.595 | 0.096 |

Table 1ba. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2021 | 29,076 | 7.9% | 27,760 | 5.7% | 2.197 | 0.087 |
| 2022 | 9,951 | 2.7% | 10,216 | 2.1% | 0.604 | 0.039 |
| Pre-boxed warning | 300,105 | 81.8% | 420,165 | 86.8% | -4.925 | -0.136 |
| Post-boxed warning | 66,616 | 18.2% | 64,123 | 13.2% | 4.925 | 0.136 |
| Seasonality | | | | | | |
| Winter | 84,478 | 23.0% | 122,419 | 25.3% | -2.242 | -0.052 |
| Spring | 101,528 | 27.7% | 107,533 | 22.2% | 5.481 | 0.127 |
| Summer | 81,170 | 22.1% | 103,512 | 21.4% | 0.760 | 0.018 |
| Autumn | 99,545 | 27.1% | 150,824 | 31.1% | -3.999 | -0.088 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.2 | 1.0 | 1.1 | 0.8 | 0.030 | 0.033 |
| Psychiatric History | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Psychiatric Drug Dispensings ⁵ | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Self Harm Encounter ⁵ | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Encounter for Other Psychiatric Event ⁵ | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Asthma Emergency Encounter | 29,342 | 8.0% | 48,904 | 10.1% | -2.097 | -0.073 |
| Asthma Inpatient Encounter | 762 | 0.2% | 1,156 | 0.2% | -0.031 | -0.007 |
| Asthma Outpatient Encounter | 356,933 | 97.3% | 472,098 | 97.5% | -0.152 | -0.010 |
| Oral Corticosteroid Dispensing | 86,664 | 23.6% | 108,696 | 22.4% | 1.188 | 0.028 |
| Use of Other Asthma Medication | 240,247 | 65.5% | 387,145 | 79.9% | -14.429 | -0.328 |
| Allergic Rhinitis | 159,591 | 43.5% | 118,941 | 24.6% | 18.958 | 0.408 |
| Anxiety | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Depression | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Sleep Disorder | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Substance Abuse | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Poisoning | 182 | 0.0% | 337 | 0.1% | -0.020 | -0.008 |
| Suffocation | 3 | 0.0% | 6 | 0.0% | -0.000 | -0.001 |
| Suicide Attempt | 95 | 0.0% | 152 | 0.0% | -0.005 | -0.003 |

Table 1ba. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Toxicity | 19 | 0.0% | 26 | 0.0% | -0.000 | -0.000 |
| Other Self Harm | 46 | 0.0% | 60 | 0.0% | 0.000 | 0.000 |
| No moderate asthma exacerbations | 315,905 | 86.1% | 412,691 | 85.2% | 0.927 | 0.026 |
| One moderate asthma exacerbation | 45,522 | 12.4% | 64,397 | 13.3% | -0.884 | -0.026 |
| Two or more moderate asthma | 5,294 | 1.4% | 7,200 | 1.5% | -0.043 | -0.004 |
| No severe asthma exacerbations | 364,972 | 99.5% | 481,158 | 99.4% | 0.169 | 0.023 |
| One severe asthma exacerbation | 1,706 | 0.5% | 3,088 | 0.6% | -0.172 | -0.023 |
| Two or more severe asthma exacerbations | 43 | 0.0% | 42 | 0.0% | 0.003 | 0.003 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 38,215 | 10.4% | 42,752 | 8.8% | 1.593 | 0.054 |
| Antipsychotics | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Anxiolytics Hypnotics | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Lithium Other Mood Stabilizers | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Antidepressants | 78 | 0.0% | 129 | 0.0% | -0.005 | -0.003 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 6.7 | 7.3 | 5.9 | 6.6 | 0.797 | 0.114 |
| Mean number of emergency room | 0.3 | 0.7 | 0.3 | 0.8 | -0.053 | -0.072 |
| Mean number of inpatient hospital encounters | 0.0 | 0.2 | 0.0 | 0.2 | -0.000 | -0.001 |
| Mean number of other ambulatory encounters | 1.2 | 4.3 | 1.3 | 5.0 | -0.049 | -0.010 |
| Mean number of filled prescriptions | 9.0 | 8.2 | 8.1 | 7.6 | 0.915 | 0.116 |
| Mean number of generics dispensed | 5.6 | 3.4 | 5.0 | 3.1 | 0.589 | 0.183 |
| Mean number of unique drug classes dispensed | 5.3 | 3.1 | 4.9 | 2.8 | 0.472 | 0.160 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.1 | 0.0 | 0.1 | -0.001 | -0.005 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.3 | 0.1 | 0.3 | -0.013 | -0.038 |

Table 1ba. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of outpatient visits for respiratory disorders | 2.0 | 3.0 | 1.5 | 2.6 | 0.451 | 0.160 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1bb. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 366,650 | N/A | 354,769 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 39.7 | 15.7 | 39.5 | 16.8 | 0.174 | 0.011 |
| Age | | | | | | |
| 10-24 years | 139,264 | 38.0% | 143,472 | 40.4% | -2.458 | -0.059 |
| 25-54 years | 113,775 | 31.0% | 96,062 | 27.1% | 3.954 | 0.092 |
| ≥ 55 years | 113,611 | 31.0% | 115,235 | 32.5% | -1.495 | -0.046 |
| Sex | | | | | | |
| Female | 219,893 | 60.0% | 211,202 | 59.5% | 0.441 | 0.009 |
| Male | 146,757 | 40.0% | 143,567 | 40.5% | -0.441 | -0.009 |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 2,125 | 0.6% | 2,212 | 0.6% | -0.044 | -0.006 |
| Asian | 10,450 | 2.9% | 8,979 | 2.5% | 0.319 | 0.020 |
| Black or African American | 40,983 | 11.2% | 35,869 | 10.1% | 1.067 | 0.036 |
| Multi-racial | 1,061 | 0.3% | 950 | 0.3% | 0.022 | 0.004 |
| Native Hawaiian or Other Pacific Islander | 794 | 0.2% | 1,175 | 0.3% | -0.115 | -0.022 |
| Unknown | 213,016 | 58.1% | 208,407 | 58.7% | -0.647 | -0.018 |
| White | 98,221 | 26.8% | 97,177 | 27.4% | -0.603 | -0.017 |
| Hispanic origin | | | | | | |
| Yes | 38,372 | 10.5% | 38,847 | 11.0% | -0.484 | -0.017 |
| No | 141,869 | 38.7% | 134,831 | 38.0% | 0.688 | 0.021 |
| Unknown | 186,409 | 50.8% | 181,091 | 51.0% | -0.204 | -0.008 |
| Year | | | | | | |
| 2015 | 15,451 | 4.2% | 15,580 | 4.4% | -0.178 | -0.009 |
| 2016 | 73,017 | 19.9% | 71,962 | 20.3% | -0.370 | -0.009 |
| 2017 | 84,977 | 23.2% | 82,763 | 23.3% | -0.152 | -0.004 |
| 2018 | 79,833 | 21.8% | 76,330 | 21.5% | 0.258 | 0.006 |
| 2019 | 40,318 | 11.0% | 37,960 | 10.7% | 0.296 | 0.010 |

Table 1bb. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2020 | 34,041 | 9.3% | 32,834 | 9.3% | 0.029 | 0.001 |
| 2021 | 29,063 | 7.9% | 27,846 | 7.8% | 0.078 | 0.003 |
| 2022 | 9,950 | 2.7% | 9,494 | 2.7% | 0.038 | 0.002 |
| Pre-boxed warning | 300,052 | 81.8% | 290,701 | 81.9% | -0.105 | -0.003 |
| Post-boxed warning | 66,598 | 18.2% | 64,068 | 18.1% | 0.105 | 0.003 |
| Seasonality | | | | | | |
| Winter | 84,462 | 23.0% | 82,696 | 23.3% | -0.274 | -0.006 |
| Spring | 101,500 | 27.7% | 95,628 | 27.0% | 0.728 | 0.016 |
| Summer | 81,156 | 22.1% | 78,582 | 22.2% | -0.016 | -0.000 |
| Autumn | 99,532 | 27.1% | 97,863 | 27.6% | -0.439 | -0.010 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.2 | 1.0 | 1.2 | 1.0 | -0.002 | -0.002 |
| Psychiatric History | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Psychiatric Drug Dispensings ⁶ | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Self Harm Encounter ⁶ | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Encounter for Other Psychiatric Event ⁶ | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Asthma Emergency Encounter | 29,333 | 8.0% | 28,507 | 8.0% | -0.035 | -0.001 |
| Asthma Inpatient Encounter | 760 | 0.2% | 742 | 0.2% | -0.002 | -0.000 |
| Asthma Outpatient Encounter | 356,871 | 97.3% | 345,872 | 97.5% | -0.159 | -0.010 |
| Oral Corticosteroid Dispensing | 86,626 | 23.6% | 82,928 | 23.4% | 0.251 | 0.006 |
| Use of Other Asthma Medication | 240,226 | 65.5% | 238,039 | 67.1% | -1.578 | -0.035 |
| Allergic Rhinitis | 159,530 | 43.5% | 146,282 | 41.2% | 2.277 | 0.046 |
| Anxiety | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Depression | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Sleep Disorder | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Substance Abuse | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Poisoning | 182 | 0.0% | 190 | 0.1% | -0.004 | -0.002 |

Table 1bb. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Suffocation | 3 | 0.0% | 3 | 0.0% | -0.000 | -0.000 |
| Suicide Attempt | 95 | 0.0% | 83 | 0.0% | 0.002 | 0.002 |
| Toxicity | 19 | 0.0% | 15 | 0.0% | 0.001 | 0.001 |
| Other Self Harm | 46 | 0.0% | 34 | 0.0% | 0.003 | 0.003 |
| No moderate asthma exacerbations | 315,855 | 86.1% | 303,748 | 85.6% | 0.528 | 0.015 |
| One moderate asthma exacerbation | 45,504 | 12.4% | 45,700 | 12.9% | -0.471 | -0.014 |
| Two or more moderate asthma | 5,291 | 1.4% | 5,322 | 1.5% | -0.057 | -0.005 |
| No severe asthma exacerbations | 364,905 | 99.5% | 353,014 | 99.5% | 0.019 | 0.003 |
| One severe asthma exacerbation | 1,706 | 0.5% | 1,721 | 0.5% | -0.020 | -0.003 |
| Two or more severe asthma exacerbations | 39 | 0.0% | 34 | 0.0% | 0.001 | 0.001 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 38,186 | 10.4% | 36,423 | 10.3% | 0.148 | 0.005 |
| Antipsychotics | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Anxiolytics Hypnotics | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Lithium Other Mood Stabilizers | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Antidepressants | 76 | 0.0% | 69 | 0.0% | 0.001 | 0.001 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 6.7 | 7.3 | 6.7 | 6.9 | -0.001 | -0.000 |
| Mean number of emergency room | 0.3 | 0.7 | 0.3 | 0.7 | -0.001 | -0.001 |
| Mean number of inpatient hospital encounters | 0.0 | 0.2 | 0.0 | 0.2 | -0.000 | -0.001 |
| Mean number of other ambulatory encounters | 1.2 | 4.3 | 1.3 | 4.4 | -0.041 | -0.009 |
| Mean number of filled prescriptions | 9.0 | 8.1 | 8.9 | 7.9 | 0.065 | 0.008 |
| Mean number of generics dispensed | 5.6 | 3.4 | 5.5 | 3.4 | 0.076 | 0.022 |
| Mean number of unique drug classes dispensed | 5.3 | 3.1 | 5.3 | 3.1 | 0.061 | 0.020 |

Table 1bb. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.1 | 0.0 | 0.1 | -0.000 | -0.002 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.3 | 0.1 | 0.3 | -0.000 | -0.001 |
| Mean number of outpatient visits for respiratory disorders | 2.0 | 3.0 | 1.9 | 3.0 | 0.026 | 0.009 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1bc. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 385,407 | 100.0% | 438,857 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 49.4 | 15.5 | 43.0 | 16.6 | 6.400 | 0.398 |
| Age | | | | | | |
| 10-24 years | 68,576 | 17.8% | 123,092 | 28.0% | -10.255 | -0.246 |
| 25-54 years | 143,325 | 37.2% | 168,088 | 38.3% | -1.113 | -0.023 |
| ≥ 55 years | 173,506 | 45.0% | 147,677 | 33.7% | 11.369 | 0.234 |
| Sex | | | | | | |
| Female | 276,966 | 71.9% | 294,761 | 67.2% | 4.698 | 0.102 |
| Male | 108,441 | 28.1% | 144,096 | 32.8% | -4.698 | -0.102 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 2,516 | 0.7% | 4,045 | 0.9% | -0.269 | -0.030 |
| Asian | 5,531 | 1.4% | 5,898 | 1.3% | 0.091 | 0.008 |
| Black or African American | 40,713 | 10.6% | 53,682 | 12.2% | -1.669 | -0.053 |
| Multi-racial | 851 | 0.2% | 848 | 0.2% | 0.028 | 0.006 |
| Native Hawaiian or Other Pacific Islander | 553 | 0.1% | 1,071 | 0.2% | -0.101 | -0.023 |
| Unknown | 165,530 | 42.9% | 190,835 | 43.5% | -0.535 | -0.011 |
| White | 169,713 | 44.0% | 182,478 | 41.6% | 2.454 | 0.050 |
| Hispanic origin | | | | | | |
| Yes | 23,626 | 6.1% | 40,943 | 9.3% | -3.199 | -0.120 |
| No | 207,385 | 53.8% | 236,920 | 54.0% | -0.176 | -0.004 |
| Unknown | 154,396 | 40.1% | 160,994 | 36.7% | 3.376 | 0.069 |
| Year | | | | | | |
| 2015 | 13,683 | 3.6% | 21,439 | 4.9% | -1.335 | -0.066 |
| 2016 | 68,946 | 17.9% | 96,303 | 21.9% | -4.055 | -0.102 |
| 2017 | 79,059 | 20.5% | 107,560 | 24.5% | -3.996 | -0.096 |
| 2018 | 76,690 | 19.9% | 93,974 | 21.4% | -1.515 | -0.037 |
| 2019 | 50,422 | 13.1% | 38,732 | 8.8% | 4.257 | 0.137 |
| 2020 | 43,892 | 11.4% | 36,655 | 8.4% | 3.036 | 0.102 |

Table 1bc. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2021 | 40,358 | 10.5% | 33,293 | 7.6% | 2.885 | 0.101 |
| 2022 | 12,357 | 3.2% | 10,901 | 2.5% | 0.722 | 0.043 |
| Pre-boxed warning | 296,808 | 77.0% | 364,634 | 83.1% | -6.076 | -0.152 |
| Post-boxed warning | 88,599 | 23.0% | 74,223 | 16.9% | 6.076 | 0.152 |
| Seasonality | | | | | | |
| Winter | 89,957 | 23.3% | 110,186 | 25.1% | -1.767 | -0.041 |
| Spring | 108,018 | 28.0% | 99,066 | 22.6% | 5.453 | 0.126 |
| Summer | 85,574 | 22.2% | 95,486 | 21.8% | 0.446 | 0.011 |
| Autumn | 101,858 | 26.4% | 134,119 | 30.6% | -4.132 | -0.092 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.9 | 1.8 | 1.9 | 1.6 | 0.066 | 0.039 |
| Psychiatric History | 385,407 | 100.0% | 438,857 | 100.0% | 0.000 | NaN |
| Psychiatric Drug Dispensings ⁵ | 280,998 | 72.9% | 312,055 | 71.1% | 1.803 | 0.040 |
| Self Harm Encounter ⁵ | 1,395 | 0.4% | 2,452 | 0.6% | -0.197 | -0.029 |
| Encounter for Other Psychiatric Event ⁵ | 320,209 | 83.1% | 369,403 | 84.2% | -1.091 | -0.029 |
| Asthma Emergency Encounter | 47,132 | 12.2% | 61,544 | 14.0% | -1.795 | -0.053 |
| Asthma Inpatient Encounter | 1,489 | 0.4% | 1,748 | 0.4% | -0.012 | -0.002 |
| Asthma Outpatient Encounter | 363,629 | 94.3% | 415,991 | 94.8% | -0.440 | -0.019 |
| Oral Corticosteroid Dispensing | 122,091 | 31.7% | 125,067 | 28.5% | 3.180 | 0.069 |
| Use of Other Asthma Medication | 225,145 | 58.4% | 336,145 | 76.6% | -18.178 | -0.396 |
| Allergic Rhinitis | 164,717 | 42.7% | 95,441 | 21.7% | 20.991 | 0.461 |
| Anxiety | 136,600 | 35.4% | 150,423 | 34.3% | 1.167 | 0.024 |
| Depression | 110,396 | 28.6% | 126,065 | 28.7% | -0.082 | -0.002 |
| Sleep Disorder | 115,470 | 30.0% | 101,010 | 23.0% | 6.944 | 0.158 |
| Substance Abuse | 24,452 | 6.3% | 39,308 | 9.0% | -2.612 | -0.098 |
| Poisoning | 1,136 | 0.3% | 2,132 | 0.5% | -0.191 | -0.031 |
| Suffocation | 27 | 0.0% | 40 | 0.0% | -0.002 | -0.002 |
| Suicide Attempt | 637 | 0.2% | 1,096 | 0.2% | -0.084 | -0.019 |

Table 1bc. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Toxicity | 137 | 0.0% | 249 | 0.1% | -0.021 | -0.010 |
| Other Self Harm | 340 | 0.1% | 568 | 0.1% | -0.041 | -0.012 |
| No moderate asthma exacerbations | 320,122 | 83.1% | 366,387 | 83.5% | -0.426 | -0.011 |
| One moderate asthma exacerbation | 56,712 | 14.7% | 63,694 | 14.5% | 0.201 | 0.006 |
| Two or more moderate asthma | 8,573 | 2.2% | 8,776 | 2.0% | 0.225 | 0.016 |
| No severe asthma exacerbations | 380,936 | 98.8% | 433,007 | 98.7% | 0.173 | 0.016 |
| One severe asthma exacerbation | 4,265 | 1.1% | 5,646 | 1.3% | -0.180 | -0.017 |
| Two or more severe asthma exacerbations | 206 | 0.1% | 204 | 0.0% | 0.007 | 0.003 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 110,810 | 28.8% | 115,127 | 26.2% | 2.518 | 0.056 |
| Antipsychotics | 34,654 | 9.0% | 52,319 | 11.9% | -2.930 | -0.096 |
| Anxiolytics Hypnotics | 135,110 | 35.1% | 136,903 | 31.2% | 3.861 | 0.082 |
| Lithium Other Mood Stabilizers | 40,585 | 10.5% | 51,566 | 11.8% | -1.220 | -0.039 |
| Antidepressants | 196,437 | 51.0% | 213,228 | 48.6% | 2.382 | 0.048 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 13.5 | 12.9 | 13.2 | 13.8 | 0.237 | 0.018 |
| Mean number of emergency room | 0.6 | 1.5 | 0.7 | 1.7 | -0.128 | -0.080 |
| Mean number of inpatient hospital encounters | 0.1 | 0.5 | 0.1 | 0.5 | -0.008 | -0.016 |
| Mean number of other ambulatory encounters | 4.1 | 11.8 | 5.5 | 16.2 | -1.455 | -0.103 |
| Mean number of filled prescriptions | 20.6 | 16.8 | 20.5 | 17.8 | 0.182 | 0.011 |
| Mean number of generics dispensed | 9.9 | 5.4 | 9.2 | 5.2 | 0.703 | 0.133 |
| Mean number of unique drug classes dispensed | 9.3 | 4.8 | 8.8 | 4.7 | 0.547 | 0.116 |
| Mean number of inpatient visits for respiratory disorders | 0.1 | 0.3 | 0.1 | 0.3 | -0.003 | -0.010 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.5 | 0.2 | 0.5 | -0.016 | -0.033 |

Table 1bc. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of outpatient visits for respiratory disorders | 2.5 | 3.5 | 1.9 | 3.0 | 0.604 | 0.185 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1bd. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 385,354 | N/A | 369,740 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 49.4 | 15.5 | 49.3 | 16.4 | 0.138 | 0.009 |
| Age | | | | | | |
| 10-24 years | 68,575 | 17.8% | 72,755 | 19.7% | -1.882 | -0.055 |
| 25-54 years | 143,303 | 37.2% | 127,003 | 34.3% | 2.838 | 0.062 |
| ≥ 55 years | 173,476 | 45.0% | 169,982 | 46.0% | -0.956 | -0.024 |
| Sex | | | | | | |
| Female | 276,918 | 71.9% | 264,399 | 71.5% | 0.351 | 0.008 |
| Male | 108,436 | 28.1% | 105,341 | 28.5% | -0.351 | -0.008 |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 2,516 | 0.7% | 2,518 | 0.7% | -0.028 | -0.003 |
| Asian | 5,530 | 1.4% | 4,528 | 1.2% | 0.210 | 0.018 |
| Black or African American | 40,701 | 10.6% | 36,079 | 9.8% | 0.804 | 0.027 |
| Multi-racial | 851 | 0.2% | 815 | 0.2% | 0.000 | 0.000 |
| Native Hawaiian or Other Pacific Islander | 553 | 0.1% | 626 | 0.2% | -0.026 | -0.007 |
| Unknown | 165,511 | 43.0% | 160,377 | 43.4% | -0.425 | -0.013 |
| White | 169,692 | 44.0% | 164,797 | 44.6% | -0.536 | -0.014 |
| Hispanic origin | | | | | | |
| Yes | 23,623 | 6.1% | 23,377 | 6.3% | -0.192 | -0.008 |
| No | 207,357 | 53.8% | 197,158 | 53.3% | 0.486 | 0.017 |
| Unknown | 154,374 | 40.1% | 149,205 | 40.4% | -0.294 | -0.013 |
| Year | | | | | | |
| 2015 | 13,683 | 3.6% | 13,930 | 3.8% | -0.217 | -0.012 |
| 2016 | 68,943 | 17.9% | 67,853 | 18.4% | -0.461 | -0.012 |
| 2017 | 79,052 | 20.5% | 76,433 | 20.7% | -0.158 | -0.004 |
| 2018 | 76,677 | 19.9% | 72,820 | 19.7% | 0.203 | 0.005 |
| 2019 | 50,404 | 13.1% | 46,752 | 12.6% | 0.435 | 0.013 |

Table 1bd. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2020 | 43,885 | 11.4% | 41,712 | 11.3% | 0.107 | 0.003 |
| 2021 | 40,354 | 10.5% | 38,463 | 10.4% | 0.069 | 0.002 |
| 2022 | 12,356 | 3.2% | 11,777 | 3.2% | 0.021 | 0.001 |
| Pre-boxed warning | 296,767 | 77.0% | 285,241 | 77.1% | -0.135 | -0.003 |
| Post-boxed warning | 88,587 | 23.0% | 84,499 | 22.9% | 0.135 | 0.003 |
| Seasonality | | | | | | |
| Winter | 89,950 | 23.3% | 87,267 | 23.6% | -0.260 | -0.006 |
| Spring | 107,989 | 28.0% | 100,735 | 27.2% | 0.779 | 0.017 |
| Summer | 85,564 | 22.2% | 82,212 | 22.2% | -0.031 | -0.001 |
| Autumn | 101,851 | 26.4% | 99,526 | 26.9% | -0.487 | -0.011 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.9 | 1.8 | 1.9 | 1.7 | -0.003 | -0.002 |
| Psychiatric History | 385,354 | 100.0% | 369,740 | 100.0% | 0.000 | NaN |
| Psychiatric Drug Dispensings ⁶ | 280,953 | 72.9% | 269,005 | 72.8% | 0.153 | 0.003 |
| Self Harm Encounter ⁶ | 1,395 | 0.4% | 1,360 | 0.4% | -0.006 | -0.001 |
| Encounter for Other Psychiatric Event ⁶ | 320,160 | 83.1% | 306,538 | 82.9% | 0.176 | 0.005 |
| Asthma Emergency Encounter | 47,117 | 12.2% | 44,799 | 12.1% | 0.111 | 0.003 |
| Asthma Inpatient Encounter | 1,489 | 0.4% | 1,491 | 0.4% | -0.017 | -0.003 |
| Asthma Outpatient Encounter | 363,593 | 94.4% | 350,387 | 94.8% | -0.413 | -0.018 |
| Oral Corticosteroid Dispensing | 122,060 | 31.7% | 115,693 | 31.3% | 0.384 | 0.008 |
| Use of Other Asthma Medication | 225,140 | 58.4% | 223,863 | 60.5% | -2.122 | -0.045 |
| Allergic Rhinitis | 164,668 | 42.7% | 147,807 | 40.0% | 2.756 | 0.056 |
| Anxiety | 136,568 | 35.4% | 130,326 | 35.2% | 0.192 | 0.004 |
| Depression | 110,371 | 28.6% | 105,618 | 28.6% | 0.076 | 0.002 |
| Sleep Disorder | 115,443 | 30.0% | 109,043 | 29.5% | 0.466 | 0.010 |
| Substance Abuse | 24,446 | 6.3% | 23,727 | 6.4% | -0.073 | -0.003 |
| Poisoning | 1,136 | 0.3% | 1,217 | 0.3% | -0.034 | -0.006 |

Table 1bd. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Suffocation | 27 | 0.0% | 18 | 0.0% | 0.002 | 0.003 |
| Suicide Attempt | 637 | 0.2% | 643 | 0.2% | -0.009 | -0.002 |
| Toxicity | 137 | 0.0% | 139 | 0.0% | -0.002 | -0.001 |
| Other Self Harm | 340 | 0.1% | 363 | 0.1% | -0.010 | -0.003 |
| No moderate asthma exacerbations | 320,078 | 83.1% | 306,598 | 82.9% | 0.138 | 0.004 |
| One moderate asthma exacerbation | 56,703 | 14.7% | 55,197 | 14.9% | -0.214 | -0.006 |
| Two or more moderate asthma | 8,573 | 2.2% | 7,945 | 2.1% | 0.076 | 0.005 |
| No severe asthma exacerbations | 380,884 | 98.8% | 365,239 | 98.8% | 0.057 | 0.005 |
| One severe asthma exacerbation | 4,264 | 1.1% | 4,300 | 1.2% | -0.056 | -0.005 |
| Two or more severe asthma exacerbations | 206 | 0.1% | 201 | 0.1% | -0.001 | -0.000 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 110,779 | 28.7% | 104,591 | 28.3% | 0.460 | 0.010 |
| Antipsychotics | 34,648 | 9.0% | 33,834 | 9.2% | -0.160 | -0.006 |
| Anxiolytics Hypnotics | 135,075 | 35.1% | 128,659 | 34.8% | 0.255 | 0.005 |
| Lithium Other Mood Stabilizers | 40,578 | 10.5% | 39,439 | 10.7% | -0.137 | -0.004 |
| Antidepressants | 196,405 | 51.0% | 187,892 | 50.8% | 0.150 | 0.003 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 13.5 | 12.9 | 13.6 | 12.4 | -0.102 | -0.008 |
| Mean number of emergency room | 0.6 | 1.5 | 0.6 | 1.5 | -0.005 | -0.003 |
| Mean number of inpatient hospital encounters | 0.1 | 0.5 | 0.1 | 0.5 | -0.002 | -0.003 |
| Mean number of other ambulatory encounters | 4.1 | 11.8 | 4.4 | 12.6 | -0.286 | -0.023 |
| Mean number of filled prescriptions | 20.6 | 16.8 | 20.7 | 16.5 | -0.045 | -0.003 |
| Mean number of generics dispensed | 9.9 | 5.4 | 9.8 | 5.4 | 0.081 | 0.015 |
| Mean number of unique drug classes dispensed | 9.3 | 4.8 | 9.2 | 4.8 | 0.057 | 0.012 |

Table 1bd. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of inpatient visits for respiratory disorders | 0.1 | 0.3 | 0.1 | 0.3 | -0.002 | -0.006 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.5 | 0.1 | 0.5 | -0.001 | -0.003 |
| Mean number of outpatient visits for respiratory disorders | 2.5 | 3.5 | 2.5 | 3.5 | 0.026 | 0.007 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1be. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 596,913 | 100.0% | 784,799 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 42.6 | 15.8 | 36.0 | 16.4 | 6.539 | 0.406 |
| Age | | | | | | |
| 10-24 years | 187,851 | 31.5% | 343,671 | 43.8% | -12.321 | -0.256 |
| 25-54 years | 201,244 | 33.7% | 246,845 | 31.5% | 2.261 | 0.048 |
| ≥ 55 years | 207,818 | 34.8% | 194,283 | 24.8% | 10.060 | 0.221 |
| Sex | | | | | | |
| Female | 390,581 | 65.4% | 479,301 | 61.1% | 4.360 | 0.091 |
| Male | 206,332 | 34.6% | 305,498 | 38.9% | -4.360 | -0.091 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 4,135 | 0.7% | 7,512 | 1.0% | -0.264 | -0.029 |
| Asian | 13,695 | 2.3% | 18,063 | 2.3% | -0.007 | -0.000 |
| Black or African American | 71,420 | 12.0% | 109,868 | 14.0% | -2.035 | -0.061 |
| Multi-racial | 1,256 | 0.2% | 1,185 | 0.2% | 0.059 | 0.014 |
| Native Hawaiian or Other Pacific Islander | 1,168 | 0.2% | 3,122 | 0.4% | -0.202 | -0.037 |
| Unknown | 294,631 | 49.4% | 388,969 | 49.6% | -0.204 | -0.004 |
| White | 210,608 | 35.3% | 256,080 | 32.6% | 2.653 | 0.056 |
| Hispanic origin | | | | | | |
| Yes | 58,326 | 9.8% | 111,454 | 14.2% | -4.430 | -0.137 |
| No | 287,332 | 48.1% | 381,944 | 48.7% | -0.531 | -0.011 |
| Unknown | 251,255 | 42.1% | 291,401 | 37.1% | 4.962 | 0.102 |
| Year | | | | | | |
| 2015 | 29,137 | 4.9% | 46,672 | 5.9% | -1.066 | -0.047 |
| 2016 | 141,971 | 23.8% | 209,935 | 26.8% | -2.966 | -0.068 |
| 2017 | 164,045 | 27.5% | 238,247 | 30.4% | -2.875 | -0.063 |
| 2018 | 156,535 | 26.2% | 202,341 | 25.8% | 0.442 | 0.010 |

Table 1be. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2019 | 90,758 | 15.2% | 74,729 | 9.5% | 5.683 | 0.173 |
| 2020 | 14,467 | 2.4% | 12,875 | 1.6% | 0.783 | 0.056 |
| 2021 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2022 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Pre-boxed warning | 596,913 | 100.0% | 784,799 | 100.0% | 0.000 | NaN |
| Post-boxed warning | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Seasonality | | | | | | |
| Winter | 138,386 | 23.2% | 196,414 | 25.0% | -1.844 | -0.043 |
| Spring | 158,733 | 26.6% | 168,408 | 21.5% | 5.134 | 0.120 |
| Summer | 132,477 | 22.2% | 168,663 | 21.5% | 0.702 | 0.017 |
| Autumn | 167,317 | 28.0% | 251,314 | 32.0% | -3.992 | -0.087 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.5 | 1.4 | 1.5 | 1.2 | 0.065 | 0.049 |
| Psychiatric History | 296,808 | 49.7% | 364,634 | 46.5% | 3.262 | 0.065 |
| Psychiatric Drug Dispensings ⁵ | 216,692 | 36.3% | 258,685 | 33.0% | 3.340 | 0.070 |
| Self Harm Encounter ⁵ | 1,227 | 0.2% | 2,236 | 0.3% | -0.079 | -0.016 |
| Encounter for Other Psychiatric Event ⁵ | 244,459 | 41.0% | 305,594 | 38.9% | 2.015 | 0.041 |
| Asthma Emergency Encounter | 64,300 | 10.8% | 98,861 | 12.6% | -1.825 | -0.057 |
| Asthma Inpatient Encounter | 2,005 | 0.3% | 2,706 | 0.3% | -0.009 | -0.002 |
| Asthma Outpatient Encounter | 570,590 | 95.6% | 753,674 | 96.0% | -0.444 | -0.022 |
| Oral Corticosteroid Dispensing | 168,273 | 28.2% | 200,587 | 25.6% | 2.632 | 0.059 |
| Use of Other Asthma Medication | 379,003 | 63.5% | 626,670 | 79.9% | -16.357 | -0.369 |
| Allergic Rhinitis | 255,161 | 42.7% | 178,338 | 22.7% | 20.023 | 0.437 |
| Anxiety | 100,172 | 16.8% | 119,267 | 15.2% | 1.585 | 0.043 |
| Depression | 83,155 | 13.9% | 103,014 | 13.1% | 0.805 | 0.024 |
| Sleep Disorder | 83,128 | 13.9% | 77,643 | 9.9% | 4.033 | 0.125 |

Table 1be. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Substance Abuse | 19,262 | 3.2% | 34,144 | 4.4% | -1.124 | -0.059 |
| Poisoning | 1,163 | 0.2% | 2,285 | 0.3% | -0.096 | -0.020 |
| Suffocation | 24 | 0.0% | 43 | 0.0% | -0.001 | -0.002 |
| Suicide Attempt | 643 | 0.1% | 1,132 | 0.1% | -0.037 | -0.010 |
| Toxicity | 138 | 0.0% | 255 | 0.0% | -0.009 | -0.006 |
| Other Self Harm | 322 | 0.1% | 542 | 0.1% | -0.015 | -0.006 |
| No moderate asthma exacerbations | 499,968 | 83.8% | 657,009 | 83.7% | 0.042 | 0.001 |
| One moderate asthma exacerbation | 85,290 | 14.3% | 113,489 | 14.5% | -0.172 | -0.005 |
| Two or more moderate asthma | 11,655 | 2.0% | 14,301 | 1.8% | 0.130 | 0.010 |
| No severe asthma exacerbations | 591,561 | 99.1% | 776,685 | 99.0% | 0.137 | 0.014 |
| One severe asthma exacerbation | 5,136 | 0.9% | 7,894 | 1.0% | -0.145 | -0.015 |
| Two or more severe asthma exacerbations | 216 | 0.0% | 220 | 0.0% | 0.008 | 0.005 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 121,030 | 20.3% | 137,322 | 17.5% | 2.778 | 0.071 |
| Antipsychotics | 27,894 | 4.7% | 45,129 | 5.8% | -1.077 | -0.048 |
| Anxiolytics Hypnotics | 104,833 | 17.6% | 113,621 | 14.5% | 3.085 | 0.084 |
| Lithium Other Mood Stabilizers | 32,384 | 5.4% | 43,692 | 5.6% | -0.142 | -0.006 |
| Antidepressants | 148,627 | 24.9% | 173,781 | 22.1% | 2.756 | 0.065 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 10.0 | 10.9 | 9.3 | 11.2 | 0.773 | 0.070 |
| Mean number of emergency room | 0.5 | 1.2 | 0.5 | 1.4 | -0.077 | -0.060 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.000 | -0.001 |
| Mean number of other ambulatory encounters | 2.8 | 9.9 | 3.4 | 12.8 | -0.696 | -0.061 |
| Mean number of filled prescriptions | 15.0 | 14.4 | 13.9 | 14.6 | 1.015 | 0.070 |
| Mean number of generics dispensed | 7.8 | 4.9 | 7.0 | 4.6 | 0.793 | 0.167 |

Table 1be. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of unique drug classes dispensed | 7.3 | 4.4 | 6.7 | 4.2 | 0.639 | 0.149 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.000 | -0.000 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.010 | -0.024 |
| Mean number of outpatient visits for respiratory disorders | 2.3 | 3.3 | 1.7 | 2.7 | 0.587 | 0.194 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1bf. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 596,859 | N/A | 575,038 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 42.6 | 15.8 | 42.4 | 16.8 | 0.187 | 0.011 |
| Age | | | | | | |
| 10-24 years | 187,850 | 31.5% | 193,040 | 33.6% | -2.097 | -0.053 |
| 25-54 years | 201,233 | 33.7% | 175,510 | 30.5% | 3.194 | 0.071 |
| ≥ 55 years | 207,776 | 34.8% | 206,489 | 35.9% | -1.097 | -0.031 |
| Sex | | | | | | |
| Female | 390,536 | 65.4% | 373,562 | 65.0% | 0.469 | 0.010 |
| Male | 206,323 | 34.6% | 201,476 | 35.0% | -0.469 | -0.010 |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 4,135 | 0.7% | 4,321 | 0.8% | -0.059 | -0.007 |
| Asian | 13,693 | 2.3% | 11,626 | 2.0% | 0.272 | 0.019 |
| Black or African American | 71,412 | 12.0% | 63,867 | 11.1% | 0.858 | 0.028 |
| Multi-racial | 1,256 | 0.2% | 1,072 | 0.2% | 0.024 | 0.005 |
| Native Hawaiian or Other Pacific Islander | 1,168 | 0.2% | 1,649 | 0.3% | -0.091 | -0.019 |
| Unknown | 294,614 | 49.4% | 287,444 | 50.0% | -0.626 | -0.018 |
| White | 210,581 | 35.3% | 205,060 | 35.7% | -0.379 | -0.010 |
| Hispanic origin | | | | | | |
| Yes | 58,322 | 9.8% | 58,971 | 10.3% | -0.484 | -0.017 |
| No | 287,305 | 48.1% | 273,124 | 47.5% | 0.639 | 0.019 |
| Unknown | 251,232 | 42.1% | 242,943 | 42.2% | -0.156 | -0.006 |
| Year | | | | | | |
| 2015 | 29,136 | 4.9% | 29,439 | 5.1% | -0.238 | -0.011 |
| 2016 | 141,966 | 23.8% | 139,612 | 24.3% | -0.493 | -0.012 |
| 2017 | 164,035 | 27.5% | 159,037 | 27.7% | -0.174 | -0.004 |
| 2018 | 156,518 | 26.2% | 149,011 | 25.9% | 0.310 | 0.007 |
| 2019 | 90,738 | 15.2% | 84,418 | 14.7% | 0.522 | 0.015 |

Table 1bf. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2020 | 14,466 | 2.4% | 13,523 | 2.4% | 0.072 | 0.005 |
| 2021 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2022 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Pre-boxed warning | 596,859 | 100.0% | 575,038 | 100.0% | 0.000 | NaN |
| Post-boxed warning | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Seasonality | | | | | | |
| Winter | 138,376 | 23.2% | 134,590 | 23.4% | -0.221 | -0.005 |
| Spring | 158,708 | 26.6% | 148,742 | 25.9% | 0.724 | 0.016 |
| Summer | 132,466 | 22.2% | 127,647 | 22.2% | -0.004 | -0.000 |
| Autumn | 167,309 | 28.0% | 164,060 | 28.5% | -0.499 | -0.011 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.5 | 1.4 | 1.5 | 1.4 | 0.000 | 0.000 |
| Psychiatric History | 296,757 | 49.7% | 283,058 | 49.2% | 0.496 | 0.010 |
| Psychiatric Drug Dispensings ⁶ | 216,643 | 36.3% | 206,005 | 35.8% | 0.473 | 0.010 |
| Self Harm Encounter ⁶ | 1,227 | 0.2% | 1,169 | 0.2% | 0.002 | 0.000 |
| Encounter for Other Psychiatric Event ⁶ | 244,415 | 41.0% | 232,765 | 40.5% | 0.472 | 0.010 |
| Asthma Emergency Encounter | 64,293 | 10.8% | 61,681 | 10.7% | 0.046 | 0.001 |
| Asthma Inpatient Encounter | 2,005 | 0.3% | 1,987 | 0.3% | -0.010 | -0.002 |
| Asthma Outpatient Encounter | 570,546 | 95.6% | 551,441 | 95.9% | -0.305 | -0.015 |
| Oral Corticosteroid Dispensing | 168,239 | 28.2% | 159,891 | 27.8% | 0.382 | 0.009 |
| Use of Other Asthma Medication | 378,992 | 63.5% | 376,345 | 65.4% | -1.949 | -0.042 |
| Allergic Rhinitis | 255,113 | 42.7% | 231,430 | 40.2% | 2.497 | 0.051 |
| Anxiety | 100,139 | 16.8% | 95,022 | 16.5% | 0.253 | 0.007 |
| Depression | 83,134 | 13.9% | 79,300 | 13.8% | 0.138 | 0.004 |
| Sleep Disorder | 83,102 | 13.9% | 77,872 | 13.5% | 0.381 | 0.011 |
| Substance Abuse | 19,257 | 3.2% | 18,963 | 3.3% | -0.071 | -0.004 |
| Poisoning | 1,163 | 0.2% | 1,240 | 0.2% | -0.021 | -0.005 |

Table 1bf. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Suffocation | 24 | 0.0% | 19 | 0.0% | 0.001 | 0.001 |
| Suicide Attempt | 643 | 0.1% | 616 | 0.1% | 0.001 | 0.000 |
| Toxicity | 138 | 0.0% | 134 | 0.0% | -0.000 | -0.000 |
| Other Self Harm | 322 | 0.1% | 328 | 0.1% | -0.003 | -0.001 |
| No moderate asthma exacerbations | 499,925 | 83.8% | 479,050 | 83.3% | 0.452 | 0.012 |
| One moderate asthma exacerbation | 85,281 | 14.3% | 84,718 | 14.7% | -0.444 | -0.013 |
| Two or more moderate asthma | 11,653 | 2.0% | 11,270 | 2.0% | -0.008 | -0.001 |
| No severe asthma exacerbations | 591,508 | 99.1% | 569,671 | 99.1% | 0.037 | 0.004 |
| One severe asthma exacerbation | 5,135 | 0.9% | 5,160 | 0.9% | -0.037 | -0.004 |
| Two or more severe asthma exacerbations | 216 | 0.0% | 207 | 0.0% | 0.000 | 0.000 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 120,997 | 20.3% | 114,458 | 19.9% | 0.368 | 0.009 |
| Antipsychotics | 27,889 | 4.7% | 27,305 | 4.7% | -0.076 | -0.004 |
| Anxiolytics Hypnotics | 104,793 | 17.6% | 99,075 | 17.2% | 0.328 | 0.009 |
| Lithium Other Mood Stabilizers | 32,377 | 5.4% | 31,368 | 5.5% | -0.030 | -0.001 |
| Antidepressants | 148,594 | 24.9% | 141,354 | 24.6% | 0.314 | 0.007 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 10.0 | 10.9 | 10.1 | 10.5 | -0.015 | -0.001 |
| Mean number of emergency room | 0.5 | 1.2 | 0.5 | 1.2 | -0.003 | -0.002 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.001 | -0.002 |
| Mean number of other ambulatory encounters | 2.8 | 9.9 | 2.9 | 10.5 | -0.162 | -0.016 |
| Mean number of filled prescriptions | 15.0 | 14.4 | 14.9 | 14.2 | 0.063 | 0.004 |
| Mean number of generics dispensed | 7.8 | 4.9 | 7.7 | 5.0 | 0.104 | 0.021 |
| Mean number of unique drug classes dispensed | 7.3 | 4.4 | 7.3 | 4.4 | 0.079 | 0.018 |

Table 1bf. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.001 | -0.004 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.000 | -0.001 |
| Mean number of outpatient visits for respiratory disorders | 2.3 | 3.3 | 2.2 | 3.3 | 0.036 | 0.011 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1bg. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 155,215 | 100.0% | 138,346 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 52.7 | 15.8 | 47.2 | 17.6 | 5.463 | 0.327 |
| Age | | | | | | |
| 10-24 years | 19,992 | 12.9% | 32,113 | 23.2% | -10.332 | -0.271 |
| 25-54 years | 55,866 | 36.0% | 47,496 | 34.3% | 1.661 | 0.035 |
| ≥ 55 years | 79,357 | 51.1% | 58,737 | 42.5% | 8.671 | 0.174 |
| Sex | | | | | | |
| Female | 106,328 | 68.5% | 89,147 | 64.4% | 4.066 | 0.086 |
| Male | 48,887 | 31.5% | 49,199 | 35.6% | -4.066 | -0.086 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 506 | 0.3% | 376 | 0.3% | 0.054 | 0.010 |
| Asian | 2,293 | 1.5% | 1,614 | 1.2% | 0.311 | 0.027 |
| Black or African American | 10,287 | 6.6% | 6,877 | 5.0% | 1.657 | 0.071 |
| Multi-racial | 656 | 0.4% | 783 | 0.6% | -0.143 | -0.020 |
| Native Hawaiian or Other Pacific Islander | 180 | 0.1% | 113 | 0.1% | 0.034 | 0.011 |
| Unknown | 83,943 | 54.1% | 84,442 | 61.0% | -6.955 | -0.141 |
| White | 57,350 | 36.9% | 44,141 | 31.9% | 5.043 | 0.106 |
| Hispanic origin | | | | | | |
| Yes | 3,683 | 2.4% | 3,000 | 2.2% | 0.204 | 0.014 |
| No | 61,961 | 39.9% | 44,903 | 32.5% | 7.462 | 0.156 |
| Unknown | 89,571 | 57.7% | 90,443 | 65.4% | -7.667 | -0.158 |
| Year | | | | | | |
| 2015 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2016 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2017 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2018 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2019 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2020 | 63,473 | 40.9% | 56,176 | 40.6% | 0.288 | 0.006 |

Table 1bg. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2021 | 69,434 | 44.7% | 61,053 | 44.1% | 0.603 | 0.012 |
| 2022 | 22,308 | 14.4% | 21,117 | 15.3% | -0.892 | -0.025 |
| Pre-boxed warning | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Post-boxed warning | 155,215 | 100.0% | 138,346 | 100.0% | 0.000 | NaN |
| Seasonality | | | | | | |
| Winter | 36,049 | 23.2% | 36,191 | 26.2% | -2.935 | -0.068 |
| Spring | 50,813 | 32.7% | 38,191 | 27.6% | 5.132 | 0.112 |
| Summer | 34,267 | 22.1% | 30,335 | 21.9% | 0.150 | 0.004 |
| Autumn | 34,086 | 22.0% | 33,629 | 24.3% | -2.347 | -0.056 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.7 | 1.7 | 1.7 | 1.6 | 0.052 | 0.031 |
| Psychiatric History | 88,599 | 57.1% | 74,223 | 53.7% | 3.431 | 0.069 |
| Psychiatric Drug Dispensings ⁵ | 64,306 | 41.4% | 53,370 | 38.6% | 2.853 | 0.058 |
| Self Harm Encounter ⁵ | 168 | 0.1% | 216 | 0.2% | -0.048 | -0.013 |
| Encounter for Other Psychiatric Event ⁵ | 75,750 | 48.8% | 63,809 | 46.1% | 2.681 | 0.054 |
| Asthma Emergency Encounter | 12,174 | 7.8% | 11,587 | 8.4% | -0.532 | -0.019 |
| Asthma Inpatient Encounter | 246 | 0.2% | 198 | 0.1% | 0.015 | 0.004 |
| Asthma Outpatient Encounter | 149,972 | 96.6% | 134,415 | 97.2% | -0.536 | -0.031 |
| Oral Corticosteroid Dispensing | 40,482 | 26.1% | 33,176 | 24.0% | 2.101 | 0.049 |
| Use of Other Asthma Medication | 86,389 | 55.7% | 96,620 | 69.8% | -14.182 | -0.297 |
| Allergic Rhinitis | 69,147 | 44.5% | 36,044 | 26.1% | 18.496 | 0.394 |
| Anxiety | 36,428 | 23.5% | 31,156 | 22.5% | 0.949 | 0.023 |
| Depression | 27,241 | 17.6% | 23,051 | 16.7% | 0.889 | 0.024 |
| Sleep Disorder | 32,342 | 20.8% | 23,367 | 16.9% | 3.947 | 0.101 |
| Substance Abuse | 5,190 | 3.3% | 5,164 | 3.7% | -0.389 | -0.021 |
| Poisoning | 155 | 0.1% | 184 | 0.1% | -0.033 | -0.010 |
| Suffocation | 6 | 0.0% | 3 | 0.0% | 0.002 | 0.003 |
| Suicide Attempt | 89 | 0.1% | 116 | 0.1% | -0.027 | -0.010 |

Table 1bg. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Toxicity | 18 | 0.0% | 20 | 0.0% | -0.003 | -0.003 |
| Other Self Harm | 64 | 0.0% | 86 | 0.1% | -0.021 | -0.009 |
| No moderate asthma exacerbations | 136,059 | 87.7% | 122,069 | 88.2% | -0.576 | -0.018 |
| One moderate asthma exacerbation | 16,944 | 10.9% | 14,602 | 10.6% | 0.362 | 0.012 |
| Two or more moderate asthma | 2,212 | 1.4% | 1,675 | 1.2% | 0.214 | 0.019 |
| No severe asthma exacerbations | 154,347 | 99.4% | 137,480 | 99.4% | 0.067 | 0.009 |
| One severe asthma exacerbation | 835 | 0.5% | 840 | 0.6% | -0.069 | -0.009 |
| Two or more severe asthma exacerbations | 33 | 0.0% | 26 | 0.0% | 0.002 | 0.002 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 27,995 | 18.0% | 20,557 | 14.9% | 3.177 | 0.086 |
| Antipsychotics | 6,760 | 4.4% | 7,190 | 5.2% | -0.842 | -0.039 |
| Anxiolytics Hypnotics | 30,277 | 19.5% | 23,282 | 16.8% | 2.678 | 0.069 |
| Lithium Other Mood Stabilizers | 8,201 | 5.3% | 7,874 | 5.7% | -0.408 | -0.018 |
| Antidepressants | 47,888 | 30.9% | 39,576 | 28.6% | 2.246 | 0.049 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 10.6 | 11.1 | 10.0 | 10.9 | 0.615 | 0.056 |
| Mean number of emergency room | 0.3 | 1.0 | 0.3 | 1.1 | -0.020 | -0.019 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | 0.001 | 0.004 |
| Mean number of other ambulatory encounters | 2.5 | 5.7 | 2.5 | 6.4 | -0.018 | -0.003 |
| Mean number of filled prescriptions | 15.0 | 13.4 | 14.1 | 13.6 | 0.878 | 0.065 |
| Mean number of generics dispensed | 7.9 | 4.8 | 7.1 | 4.5 | 0.800 | 0.172 |
| Mean number of unique drug classes dispensed | 7.5 | 4.4 | 6.8 | 4.1 | 0.673 | 0.158 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.3 | -0.001 | -0.006 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.013 | -0.032 |

Table 1bg. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of outpatient visits for respiratory disorders | 2.2 | 3.3 | 1.9 | 3.1 | 0.335 | 0.104 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1bh. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 155,180 | N/A | 149,899 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 52.7 | 15.8 | 52.5 | 17.2 | 0.118 | 0.007 |
| Age | | | | | | |
| 10-24 years | 19,991 | 12.9% | 23,727 | 15.8% | -2.946 | -0.089 |
| 25-54 years | 55,852 | 36.0% | 46,864 | 31.3% | 4.728 | 0.108 |
| ≥ 55 years | 79,337 | 51.1% | 79,309 | 52.9% | -1.782 | -0.044 |
| Sex | | | | | | |
| Female | 106,297 | 68.5% | 102,100 | 68.1% | 0.387 | 0.008 |
| Male | 48,883 | 31.5% | 47,799 | 31.9% | -0.387 | -0.008 |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 506 | 0.3% | 407 | 0.3% | 0.054 | 0.010 |
| Asian | 2,292 | 1.5% | 1,811 | 1.2% | 0.269 | 0.023 |
| Black or African American | 10,283 | 6.6% | 8,164 | 5.4% | 1.180 | 0.051 |
| Multi-racial | 656 | 0.4% | 680 | 0.5% | -0.031 | -0.005 |
| Native Hawaiian or Other Pacific Islander | 180 | 0.1% | 145 | 0.1% | 0.020 | 0.006 |
| Unknown | 83,917 | 54.1% | 81,226 | 54.2% | -0.110 | -0.004 |
| White | 57,346 | 37.0% | 57,466 | 38.3% | -1.382 | -0.042 |
| Hispanic origin | | | | | | |
| Yes | 3,681 | 2.4% | 3,192 | 2.1% | 0.242 | 0.017 |
| No | 61,952 | 39.9% | 59,431 | 39.6% | 0.275 | 0.014 |
| Unknown | 89,547 | 57.7% | 87,276 | 58.2% | -0.518 | -0.027 |
| Year | | | | | | |
| 2015 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2016 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2017 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2018 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2019 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |

Table 1bh. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2020 | 63,456 | 40.9% | 61,577 | 41.1% | -0.187 | -0.004 |
| 2021 | 69,419 | 44.7% | 66,918 | 44.6% | 0.093 | 0.002 |
| 2022 | 22,305 | 14.4% | 21,405 | 14.3% | 0.094 | 0.003 |
| Pre-boxed warning | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Post-boxed warning | 155,180 | 100.0% | 149,899 | 100.0% | 0.000 | NaN |
| Seasonality | | | | | | |
| Winter | 36,047 | 23.2% | 35,422 | 23.6% | -0.401 | -0.009 |
| Spring | 50,789 | 32.7% | 47,781 | 31.9% | 0.853 | 0.018 |
| Summer | 34,261 | 22.1% | 33,272 | 22.2% | -0.118 | -0.003 |
| Autumn | 34,083 | 22.0% | 33,425 | 22.3% | -0.334 | -0.008 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.7 | 1.7 | 1.7 | 1.7 | -0.003 | -0.002 |
| Psychiatric History | 88,569 | 57.1% | 84,830 | 56.6% | 0.483 | 0.010 |
| Psychiatric Drug Dispensings ⁶ | 64,279 | 41.4% | 61,570 | 41.1% | 0.348 | 0.007 |
| Self Harm Encounter ⁶ | 168 | 0.1% | 169 | 0.1% | -0.005 | -0.001 |
| Encounter for Other Psychiatric Event ⁶ | 75,723 | 48.8% | 72,190 | 48.2% | 0.638 | 0.013 |
| Asthma Emergency Encounter | 12,169 | 7.8% | 11,570 | 7.7% | 0.124 | 0.005 |
| Asthma Inpatient Encounter | 246 | 0.2% | 237 | 0.2% | 0.000 | 0.000 |
| Asthma Outpatient Encounter | 149,940 | 96.6% | 145,243 | 96.9% | -0.270 | -0.015 |
| Oral Corticosteroid Dispensing | 40,459 | 26.1% | 38,540 | 25.7% | 0.361 | 0.008 |
| Use of Other Asthma Medication | 86,384 | 55.7% | 85,778 | 57.2% | -1.557 | -0.032 |
| Allergic Rhinitis | 69,112 | 44.5% | 63,045 | 42.1% | 2.479 | 0.050 |
| Anxiety | 36,411 | 23.5% | 34,724 | 23.2% | 0.299 | 0.007 |
| Depression | 27,225 | 17.5% | 26,016 | 17.4% | 0.189 | 0.005 |
| Sleep Disorder | 32,325 | 20.8% | 30,550 | 20.4% | 0.450 | 0.011 |
| Substance Abuse | 5,188 | 3.3% | 4,949 | 3.3% | 0.042 | 0.002 |
| Poisoning | 155 | 0.1% | 161 | 0.1% | -0.007 | -0.002 |

Table 1bh. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Suffocation | 6 | 0.0% | 1 | 0.0% | 0.003 | 0.006 |
| Suicide Attempt | 89 | 0.1% | 101 | 0.1% | -0.010 | -0.004 |
| Toxicity | 18 | 0.0% | 19 | 0.0% | -0.001 | -0.001 |
| Other Self Harm | 64 | 0.0% | 66 | 0.0% | -0.003 | -0.001 |
| No moderate asthma exacerbations | 136,032 | 87.7% | 131,595 | 87.8% | -0.128 | -0.004 |
| One moderate asthma exacerbation | 16,936 | 10.9% | 16,336 | 10.9% | 0.016 | 0.001 |
| Two or more moderate asthma | 2,212 | 1.4% | 1,968 | 1.3% | 0.113 | 0.010 |
| No severe asthma exacerbations | 154,313 | 99.4% | 149,035 | 99.4% | 0.018 | 0.002 |
| One severe asthma exacerbation | 834 | 0.5% | 836 | 0.6% | -0.020 | -0.003 |
| Two or more severe asthma exacerbations | 33 | 0.0% | 28 | 0.0% | 0.002 | 0.002 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 27,970 | 18.0% | 26,274 | 17.5% | 0.496 | 0.013 |
| Antipsychotics | 6,756 | 4.4% | 6,700 | 4.5% | -0.116 | -0.006 |
| Anxiolytics Hypnotics | 30,261 | 19.5% | 28,878 | 19.3% | 0.236 | 0.006 |
| Lithium Other Mood Stabilizers | 8,197 | 5.3% | 8,040 | 5.4% | -0.081 | -0.004 |
| Antidepressants | 47,866 | 30.8% | 45,828 | 30.6% | 0.273 | 0.006 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 10.6 | 11.1 | 10.7 | 10.6 | -0.085 | -0.008 |
| Mean number of emergency room | 0.3 | 1.0 | 0.3 | 1.0 | -0.003 | -0.003 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.001 | -0.004 |
| Mean number of other ambulatory encounters | 2.5 | 5.7 | 2.6 | 6.1 | -0.128 | -0.022 |
| Mean number of filled prescriptions | 15.0 | 13.4 | 15.0 | 13.2 | -0.015 | -0.001 |
| Mean number of generics dispensed | 7.9 | 4.8 | 7.8 | 4.9 | 0.075 | 0.015 |
| Mean number of unique drug classes dispensed | 7.5 | 4.4 | 7.5 | 4.4 | 0.062 | 0.014 |

Table 1bh. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 0-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|-----------------------|---|---|---|---------------------|-------------------------|
| | Montelukast 0 Day Gap | | Inhaled Corticosteroids (ICS) 0 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.001 | -0.005 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.002 | -0.004 |
| Mean number of outpatient visits for respiratory disorders | 2.2 | 3.3 | 2.2 | 3.2 | 0.003 | 0.001 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1bi. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 752,280 | 100.0% | 923,377 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 44.7 | 15.8 | 37.7 | 16.6 | 6.949 | 0.429 |
| Age | | | | | | |
| 10-24 years | 207,867 | 27.6% | 375,872 | 40.7% | -13.075 | -0.278 |
| 25-54 years | 257,154 | 34.2% | 294,430 | 31.9% | 2.297 | 0.049 |
| ≥ 55 years | 287,259 | 38.2% | 253,075 | 27.4% | 10.778 | 0.231 |
| Sex | | | | | | |
| Female | 497,022 | 66.1% | 568,594 | 61.6% | 4.491 | 0.094 |
| Male | 255,258 | 33.9% | 354,783 | 38.4% | -4.491 | -0.094 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 4,641 | 0.6% | 7,894 | 0.9% | -0.238 | -0.028 |
| Asian | 15,993 | 2.1% | 19,681 | 2.1% | -0.005 | -0.000 |
| Black or African American | 81,721 | 10.9% | 116,767 | 12.6% | -1.783 | -0.055 |
| Multi-racial | 1,913 | 0.3% | 1,968 | 0.2% | 0.041 | 0.009 |
| Native Hawaiian or Other Pacific Islander | 1,348 | 0.2% | 3,235 | 0.4% | -0.171 | -0.033 |
| Unknown | 378,631 | 50.3% | 473,550 | 51.3% | -0.953 | -0.019 |
| White | 268,033 | 35.6% | 300,282 | 32.5% | 3.109 | 0.066 |
| Hispanic origin | | | | | | |
| Yes | 62,019 | 8.2% | 114,481 | 12.4% | -4.154 | -0.137 |
| No | 349,367 | 46.4% | 426,937 | 46.2% | 0.205 | 0.004 |
| Unknown | 340,894 | 45.3% | 381,959 | 41.4% | 3.949 | 0.080 |
| Year | | | | | | |
| 2015 | 29,141 | 3.9% | 46,687 | 5.1% | -1.182 | -0.057 |
| 2016 | 141,992 | 18.9% | 210,011 | 22.7% | -3.869 | -0.095 |
| 2017 | 164,068 | 21.8% | 238,304 | 25.8% | -3.998 | -0.094 |
| 2018 | 156,565 | 20.8% | 202,397 | 21.9% | -1.107 | -0.027 |
| 2019 | 90,783 | 12.1% | 74,740 | 8.1% | 3.974 | 0.132 |
| 2020 | 77,970 | 10.4% | 69,061 | 7.5% | 2.885 | 0.101 |

Table 1bi. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2021 | 69,448 | 9.2% | 61,060 | 6.6% | 2.619 | 0.097 |
| 2022 | 22,313 | 3.0% | 21,117 | 2.3% | 0.679 | 0.042 |
| Pre-boxed warning | 597,022 | 79.4% | 785,015 | 85.0% | -5.654 | -0.148 |
| Post-boxed warning | 155,258 | 20.6% | 138,362 | 15.0% | 5.654 | 0.148 |
| Seasonality | | | | | | |
| Winter | 174,459 | 23.2% | 232,656 | 25.2% | -2.006 | -0.047 |
| Spring | 209,611 | 27.9% | 206,659 | 22.4% | 5.483 | 0.127 |
| Summer | 166,779 | 22.2% | 199,054 | 21.6% | 0.613 | 0.015 |
| Autumn | 201,431 | 26.8% | 285,008 | 30.9% | -4.090 | -0.090 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.6 | 1.5 | 1.5 | 1.3 | 0.076 | 0.055 |
| Psychiatric History | 385,520 | 51.2% | 438,981 | 47.5% | 3.706 | 0.074 |
| Psychiatric Drug Dispensings ⁵ | 281,086 | 37.4% | 312,149 | 33.8% | 3.559 | 0.074 |
| Self Harm Encounter ⁵ | 1,394 | 0.2% | 2,455 | 0.3% | -0.081 | -0.017 |
| Encounter for Other Psychiatric Event ⁵ | 320,312 | 42.6% | 369,507 | 40.0% | 2.562 | 0.052 |
| Asthma Emergency Encounter | 76,513 | 10.2% | 110,494 | 12.0% | -1.795 | -0.057 |
| Asthma Inpatient Encounter | 2,253 | 0.3% | 2,905 | 0.3% | -0.015 | -0.003 |
| Asthma Outpatient Encounter | 720,684 | 95.8% | 888,309 | 96.2% | -0.402 | -0.021 |
| Oral Corticosteroid Dispensing | 208,814 | 27.8% | 233,820 | 25.3% | 2.435 | 0.055 |
| Use of Other Asthma Medication | 465,439 | 61.9% | 723,452 | 78.3% | -16.478 | -0.366 |
| Allergic Rhinitis | 324,390 | 43.1% | 214,432 | 23.2% | 19.898 | 0.432 |
| Anxiety | 136,658 | 18.2% | 150,459 | 16.3% | 1.871 | 0.050 |
| Depression | 110,444 | 14.7% | 126,098 | 13.7% | 1.025 | 0.029 |
| Sleep Disorder | 115,514 | 15.4% | 101,044 | 10.9% | 4.412 | 0.131 |
| Substance Abuse | 24,463 | 3.3% | 39,321 | 4.3% | -1.007 | -0.053 |
| Poisoning | 1,319 | 0.2% | 2,470 | 0.3% | -0.092 | -0.020 |
| Suffocation | 30 | 0.0% | 46 | 0.0% | -0.001 | -0.001 |
| Suicide Attempt | 733 | 0.1% | 1,250 | 0.1% | -0.038 | -0.011 |

Table 1bi. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Toxicity | 156 | 0.0% | 275 | 0.0% | -0.009 | -0.006 |
| Other Self Harm | 386 | 0.1% | 630 | 0.1% | -0.017 | -0.007 |
| No moderate asthma exacerbations | 636,154 | 84.6% | 779,273 | 84.4% | 0.170 | 0.005 |
| One moderate asthma exacerbation | 102,254 | 13.6% | 128,119 | 13.9% | -0.283 | -0.008 |
| Two or more moderate asthma | 13,872 | 1.8% | 15,985 | 1.7% | 0.113 | 0.009 |
| No severe asthma exacerbations | 746,055 | 99.2% | 914,396 | 99.0% | 0.145 | 0.015 |
| One severe asthma exacerbation | 5,976 | 0.8% | 8,735 | 0.9% | -0.152 | -0.016 |
| Two or more severe asthma exacerbations | 249 | 0.0% | 246 | 0.0% | 0.006 | 0.004 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 149,088 | 19.8% | 157,940 | 17.1% | 2.714 | 0.070 |
| Antipsychotics | 34,679 | 4.6% | 52,338 | 5.7% | -1.058 | -0.048 |
| Anxiolytics Hypnotics | 135,168 | 18.0% | 136,952 | 14.8% | 3.136 | 0.085 |
| Lithium Other Mood Stabilizers | 40,612 | 5.4% | 51,588 | 5.6% | -0.188 | -0.008 |
| Antidepressants | 196,573 | 26.1% | 213,423 | 23.1% | 3.017 | 0.070 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 10.2 | 11.0 | 9.4 | 11.2 | 0.781 | 0.071 |
| Mean number of emergency room | 0.4 | 1.2 | 0.5 | 1.3 | -0.076 | -0.061 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.000 | -0.000 |
| Mean number of other ambulatory encounters | 2.7 | 9.2 | 3.3 | 12.0 | -0.610 | -0.057 |
| Mean number of filled prescriptions | 15.0 | 14.2 | 14.0 | 14.5 | 0.997 | 0.069 |
| Mean number of generics dispensed | 7.8 | 4.9 | 7.0 | 4.6 | 0.803 | 0.169 |
| Mean number of unique drug classes dispensed | 7.4 | 4.4 | 6.7 | 4.2 | 0.655 | 0.153 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.000 | -0.000 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.012 | -0.028 |

Table 1bi. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of outpatient visits for respiratory disorders | 2.3 | 3.3 | 1.7 | 2.8 | 0.545 | 0.178 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1bj. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 752,230 | N/A | 724,855 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 44.7 | 15.8 | 44.5 | 16.9 | 0.183 | 0.011 |
| Age | | | | | | |
| 10-24 years | 207,866 | 27.6% | 216,783 | 29.9% | -2.274 | -0.059 |
| 25-54 years | 257,136 | 34.2% | 222,525 | 30.7% | 3.484 | 0.078 |
| ≥ 55 years | 287,228 | 38.2% | 285,548 | 39.4% | -1.210 | -0.033 |
| Sex | | | | | | |
| Female | 496,977 | 66.1% | 475,583 | 65.6% | 0.456 | 0.010 |
| Male | 255,253 | 33.9% | 249,273 | 34.4% | -0.456 | -0.010 |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 4,641 | 0.6% | 4,735 | 0.7% | -0.036 | -0.005 |
| Asian | 15,992 | 2.1% | 13,441 | 1.9% | 0.272 | 0.020 |
| Black or African American | 81,716 | 10.9% | 72,042 | 9.9% | 0.924 | 0.032 |
| Multi-racial | 1,912 | 0.3% | 1,757 | 0.2% | 0.012 | 0.002 |
| Native Hawaiian or Other Pacific Islander | 1,348 | 0.2% | 1,794 | 0.2% | -0.068 | -0.015 |
| Unknown | 378,607 | 50.3% | 368,744 | 50.9% | -0.540 | -0.016 |
| White | 268,014 | 35.6% | 262,343 | 36.2% | -0.563 | -0.015 |
| Hispanic origin | | | | | | |
| Yes | 62,019 | 8.2% | 62,181 | 8.6% | -0.334 | -0.013 |
| No | 349,360 | 46.4% | 332,404 | 45.9% | 0.585 | 0.019 |
| Unknown | 340,851 | 45.3% | 330,270 | 45.6% | -0.251 | -0.010 |
| Year | | | | | | |
| 2015 | 29,140 | 3.9% | 29,519 | 4.1% | -0.199 | -0.010 |
| 2016 | 141,986 | 18.9% | 139,863 | 19.3% | -0.420 | -0.011 |
| 2017 | 164,064 | 21.8% | 159,312 | 22.0% | -0.168 | -0.004 |
| 2018 | 156,558 | 20.8% | 149,324 | 20.6% | 0.212 | 0.005 |
| 2019 | 90,771 | 12.1% | 84,746 | 11.7% | 0.375 | 0.012 |

Table 1bj. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2020 | 77,957 | 10.4% | 74,575 | 10.3% | 0.075 | 0.003 |
| 2021 | 69,445 | 9.2% | 66,279 | 9.1% | 0.088 | 0.003 |
| 2022 | 22,309 | 3.0% | 21,236 | 2.9% | 0.036 | 0.002 |
| Pre-boxed warning | 596,990 | 79.4% | 576,339 | 79.5% | -0.148 | -0.004 |
| Post-boxed warning | 155,240 | 20.6% | 148,516 | 20.5% | 0.148 | 0.004 |
| Seasonality | | | | | | |
| Winter | 174,455 | 23.2% | 169,970 | 23.4% | -0.257 | -0.006 |
| Spring | 209,583 | 27.9% | 196,529 | 27.1% | 0.749 | 0.017 |
| Summer | 166,764 | 22.2% | 160,889 | 22.2% | -0.027 | -0.001 |
| Autumn | 201,428 | 26.8% | 197,467 | 27.2% | -0.465 | -0.010 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.6 | 1.5 | 1.6 | 1.5 | 0.000 | 0.000 |
| Psychiatric History | 385,474 | 51.2% | 367,807 | 50.7% | 0.502 | 0.010 |
| Psychiatric Drug Dispensings ⁶ | 281,045 | 37.4% | 267,530 | 36.9% | 0.454 | 0.010 |
| Self Harm Encounter ⁶ | 1,394 | 0.2% | 1,336 | 0.2% | 0.001 | 0.000 |
| Encounter for Other Psychiatric Event ⁶ | 320,270 | 42.6% | 304,849 | 42.1% | 0.520 | 0.011 |
| Asthma Emergency Encounter | 76,496 | 10.2% | 73,303 | 10.1% | 0.057 | 0.002 |
| Asthma Inpatient Encounter | 2,251 | 0.3% | 2,232 | 0.3% | -0.009 | -0.002 |
| Asthma Outpatient Encounter | 720,647 | 95.8% | 696,565 | 96.1% | -0.296 | -0.015 |
| Oral Corticosteroid Dispensing | 208,780 | 27.8% | 198,495 | 27.4% | 0.371 | 0.008 |
| Use of Other Asthma Medication | 465,431 | 61.9% | 462,190 | 63.8% | -1.890 | -0.041 |
| Allergic Rhinitis | 324,343 | 43.1% | 294,367 | 40.6% | 2.507 | 0.051 |
| Anxiety | 136,634 | 18.2% | 129,696 | 17.9% | 0.271 | 0.007 |
| Depression | 110,424 | 14.7% | 105,269 | 14.5% | 0.157 | 0.004 |
| Sleep Disorder | 115,489 | 15.4% | 108,323 | 14.9% | 0.409 | 0.012 |
| Substance Abuse | 24,457 | 3.3% | 23,889 | 3.3% | -0.044 | -0.003 |
| Poisoning | 1,318 | 0.2% | 1,401 | 0.2% | -0.018 | -0.004 |

Table 1bj. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Suffocation | 30 | 0.0% | 21 | 0.0% | 0.001 | 0.002 |
| Suicide Attempt | 732 | 0.1% | 721 | 0.1% | -0.002 | -0.001 |
| Toxicity | 156 | 0.0% | 153 | 0.0% | -0.000 | -0.000 |
| Other Self Harm | 386 | 0.1% | 394 | 0.1% | -0.003 | -0.001 |
| No moderate asthma exacerbations | 636,120 | 84.6% | 610,583 | 84.2% | 0.329 | 0.009 |
| One moderate asthma exacerbation | 102,243 | 13.6% | 101,035 | 13.9% | -0.347 | -0.010 |
| Two or more moderate asthma | 13,867 | 1.8% | 13,238 | 1.8% | 0.017 | 0.001 |
| No severe asthma exacerbations | 746,009 | 99.2% | 718,609 | 99.1% | 0.035 | 0.004 |
| One severe asthma exacerbation | 5,972 | 0.8% | 6,007 | 0.8% | -0.035 | -0.004 |
| Two or more severe asthma exacerbations | 249 | 0.0% | 240 | 0.0% | 0.000 | 0.000 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 149,054 | 19.8% | 140,853 | 19.4% | 0.383 | 0.010 |
| Antipsychotics | 34,673 | 4.6% | 33,993 | 4.7% | -0.080 | -0.004 |
| Anxiolytics Hypnotics | 135,137 | 18.0% | 127,968 | 17.7% | 0.311 | 0.008 |
| Lithium Other Mood Stabilizers | 40,602 | 5.4% | 39,421 | 5.4% | -0.041 | -0.002 |
| Antidepressants | 196,544 | 26.1% | 187,126 | 25.8% | 0.312 | 0.007 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 10.2 | 11.0 | 10.2 | 10.5 | -0.029 | -0.003 |
| Mean number of emergency room | 0.4 | 1.2 | 0.4 | 1.2 | -0.003 | -0.002 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.001 | -0.002 |
| Mean number of other ambulatory encounters | 2.7 | 9.2 | 2.8 | 9.7 | -0.153 | -0.016 |
| Mean number of filled prescriptions | 15.0 | 14.2 | 14.9 | 14.1 | 0.048 | 0.003 |
| Mean number of generics dispensed | 7.8 | 4.9 | 7.7 | 4.9 | 0.098 | 0.020 |
| Mean number of unique drug classes dispensed | 7.4 | 4.4 | 7.3 | 4.4 | 0.076 | 0.017 |

Table 1bj. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.001 | -0.004 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.001 | -0.002 |
| Mean number of outpatient visits for respiratory disorders | 2.3 | 3.3 | 2.2 | 3.3 | 0.029 | 0.009 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1bk. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 496,977 | 100.0% | 568,584 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 47.9 | 15.5 | 41.4 | 16.4 | 6.566 | 0.412 |
| Age | | | | | | |
| 10-24 years | 103,203 | 20.8% | 183,929 | 32.3% | -11.582 | -0.265 |
| 25-54 years | 181,358 | 36.5% | 203,714 | 35.8% | 0.664 | 0.014 |
| ≥ 55 years | 212,416 | 42.7% | 180,941 | 31.8% | 10.919 | 0.227 |
| Sex | | | | | | |
| Female | 496,977 | 100.0% | 568,584 | 100.0% | 0.000 | NaN |
| Male | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 3,088 | 0.6% | 5,021 | 0.9% | -0.262 | -0.030 |
| Asian | 10,098 | 2.0% | 11,303 | 2.0% | 0.044 | 0.003 |
| Black or African American | 55,786 | 11.2% | 73,270 | 12.9% | -1.661 | -0.051 |
| Multi-racial | 1,273 | 0.3% | 1,215 | 0.2% | 0.042 | 0.009 |
| Native Hawaiian or Other Pacific Islander | 849 | 0.2% | 1,892 | 0.3% | -0.162 | -0.032 |
| Unknown | 235,671 | 47.4% | 273,953 | 48.2% | -0.761 | -0.015 |
| White | 190,212 | 38.3% | 201,930 | 35.5% | 2.759 | 0.057 |
| Hispanic origin | | | | | | |
| Yes | 36,808 | 7.4% | 64,770 | 11.4% | -3.985 | -0.137 |
| No | 244,638 | 49.2% | 279,907 | 49.2% | -0.004 | -0.000 |
| Unknown | 215,531 | 43.4% | 223,907 | 39.4% | 3.989 | 0.081 |
| Year | | | | | | |
| 2015 | 18,926 | 3.8% | 28,513 | 5.0% | -1.207 | -0.059 |
| 2016 | 92,749 | 18.7% | 128,071 | 22.5% | -3.862 | -0.096 |
| 2017 | 105,447 | 21.2% | 144,278 | 25.4% | -4.157 | -0.098 |
| 2018 | 101,436 | 20.4% | 122,826 | 21.6% | -1.191 | -0.029 |
| 2019 | 62,186 | 12.5% | 47,616 | 8.4% | 4.138 | 0.136 |
| 2020 | 53,781 | 10.8% | 45,012 | 7.9% | 2.905 | 0.100 |

Table 1bk. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2021 | 47,658 | 9.6% | 38,985 | 6.9% | 2.733 | 0.100 |
| 2022 | 14,794 | 3.0% | 13,283 | 2.3% | 0.641 | 0.040 |
| Pre-boxed warning | 390,634 | 78.6% | 479,430 | 84.3% | -5.718 | -0.148 |
| Post-boxed warning | 106,343 | 21.4% | 89,154 | 15.7% | 5.718 | 0.148 |
| Seasonality | | | | | | |
| Winter | 115,698 | 23.3% | 143,922 | 25.3% | -2.032 | -0.047 |
| Spring | 138,899 | 27.9% | 127,256 | 22.4% | 5.568 | 0.129 |
| Summer | 109,776 | 22.1% | 122,372 | 21.5% | 0.567 | 0.014 |
| Autumn | 132,604 | 26.7% | 175,034 | 30.8% | -4.102 | -0.091 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.6 | 1.5 | 1.6 | 1.4 | 0.069 | 0.048 |
| Psychiatric History | 277,016 | 55.7% | 294,831 | 51.9% | 3.887 | 0.078 |
| Psychiatric Drug Dispensings ⁵ | 212,564 | 42.8% | 220,673 | 38.8% | 3.960 | 0.081 |
| Self Harm Encounter ⁵ | 1,054 | 0.2% | 1,866 | 0.3% | -0.116 | -0.022 |
| Encounter for Other Psychiatric Event ⁵ | 226,289 | 45.5% | 243,362 | 42.8% | 2.732 | 0.055 |
| Asthma Emergency Encounter | 53,943 | 10.9% | 71,994 | 12.7% | -1.808 | -0.056 |
| Asthma Inpatient Encounter | 1,704 | 0.3% | 1,862 | 0.3% | 0.015 | 0.003 |
| Asthma Outpatient Encounter | 474,471 | 95.5% | 545,021 | 95.9% | -0.384 | -0.019 |
| Oral Corticosteroid Dispensing | 147,880 | 29.8% | 153,405 | 27.0% | 2.776 | 0.062 |
| Use of Other Asthma Medication | 299,256 | 60.2% | 437,726 | 77.0% | -16.770 | -0.367 |
| Allergic Rhinitis | 213,703 | 43.0% | 128,493 | 22.6% | 20.402 | 0.445 |
| Anxiety | 108,149 | 21.8% | 113,601 | 20.0% | 1.782 | 0.044 |
| Depression | 88,988 | 17.9% | 96,849 | 17.0% | 0.872 | 0.023 |
| Sleep Disorder | 80,287 | 16.2% | 67,006 | 11.8% | 4.370 | 0.126 |
| Substance Abuse | 16,002 | 3.2% | 24,050 | 4.2% | -1.010 | -0.053 |
| Poisoning | 1,042 | 0.2% | 1,917 | 0.3% | -0.127 | -0.024 |
| Suffocation | 13 | 0.0% | 27 | 0.0% | -0.002 | -0.004 |
| Suicide Attempt | 550 | 0.1% | 903 | 0.2% | -0.048 | -0.013 |

Table 1bk. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Toxicity | 113 | 0.0% | 201 | 0.0% | -0.013 | -0.007 |
| Other Self Harm | 293 | 0.1% | 469 | 0.1% | -0.024 | -0.009 |
| No moderate asthma exacerbations | 415,652 | 83.6% | 476,141 | 83.7% | -0.105 | -0.003 |
| One moderate asthma exacerbation | 71,216 | 14.3% | 81,838 | 14.4% | -0.063 | -0.002 |
| Two or more moderate asthma | 10,109 | 2.0% | 10,605 | 1.9% | 0.169 | 0.012 |
| No severe asthma exacerbations | 492,335 | 99.1% | 562,688 | 99.0% | 0.103 | 0.010 |
| One severe asthma exacerbation | 4,456 | 0.9% | 5,734 | 1.0% | -0.112 | -0.012 |
| Two or more severe asthma exacerbations | 186 | 0.0% | 162 | 0.0% | 0.009 | 0.005 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 114,306 | 23.0% | 117,263 | 20.6% | 2.377 | 0.058 |
| Antipsychotics | 24,875 | 5.0% | 35,212 | 6.2% | -1.188 | -0.052 |
| Anxiolytics Hypnotics | 106,355 | 21.4% | 103,909 | 18.3% | 3.125 | 0.078 |
| Lithium Other Mood Stabilizers | 30,777 | 6.2% | 36,917 | 6.5% | -0.300 | -0.012 |
| Antidepressants | 158,499 | 31.9% | 164,696 | 29.0% | 2.927 | 0.064 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 11.1 | 11.1 | 10.4 | 11.4 | 0.723 | 0.064 |
| Mean number of emergency room | 0.5 | 1.3 | 0.6 | 1.4 | -0.096 | -0.072 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.002 | -0.004 |
| Mean number of other ambulatory encounters | 2.8 | 8.8 | 3.4 | 11.5 | -0.594 | -0.058 |
| Mean number of filled prescriptions | 16.6 | 15.1 | 15.8 | 15.6 | 0.867 | 0.056 |
| Mean number of generics dispensed | 8.5 | 5.1 | 7.8 | 4.9 | 0.758 | 0.151 |
| Mean number of unique drug classes dispensed | 8.1 | 4.6 | 7.4 | 4.5 | 0.609 | 0.135 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | 0.000 | 0.000 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.5 | -0.015 | -0.035 |

Table 1bk. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of outpatient visits for respiratory disorders | 2.4 | 3.3 | 1.8 | 2.8 | 0.558 | 0.181 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1b. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 496,923 | N/A | 478,441 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 47.9 | 15.5 | 47.8 | 16.4 | 0.150 | 0.009 |
| Age | | | | | | |
| 10-24 years | 103,202 | 20.8% | 109,538 | 22.9% | -2.126 | -0.058 |
| 25-54 years | 181,342 | 36.5% | 159,269 | 33.3% | 3.204 | 0.071 |
| ≥ 55 years | 212,379 | 42.7% | 209,635 | 43.8% | -1.077 | -0.029 |
| Sex | | | | | | |
| Female | 496,923 | 100.0% | 478,441 | 100.0% | 0.000 | NaN |
| Male | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 3,088 | 0.6% | 3,214 | 0.7% | -0.050 | -0.006 |
| Asian | 10,097 | 2.0% | 8,223 | 1.7% | 0.313 | 0.023 |
| Black or African American | 55,776 | 11.2% | 49,211 | 10.3% | 0.939 | 0.031 |
| Multi-racial | 1,273 | 0.3% | 1,177 | 0.2% | 0.010 | 0.002 |
| Native Hawaiian or Other Pacific Islander | 849 | 0.2% | 1,079 | 0.2% | -0.055 | -0.012 |
| Unknown | 235,653 | 47.4% | 229,044 | 47.9% | -0.451 | -0.014 |
| White | 190,187 | 38.3% | 186,493 | 39.0% | -0.706 | -0.019 |
| Hispanic origin | | | | | | |
| Yes | 36,804 | 7.4% | 36,707 | 7.7% | -0.266 | -0.011 |
| No | 244,604 | 49.2% | 233,045 | 48.7% | 0.515 | 0.017 |
| Unknown | 215,515 | 43.4% | 208,690 | 43.6% | -0.249 | -0.011 |
| Year | | | | | | |
| 2015 | 18,925 | 3.8% | 19,239 | 4.0% | -0.213 | -0.011 |
| 2016 | 92,746 | 18.7% | 91,432 | 19.1% | -0.446 | -0.011 |
| 2017 | 105,439 | 21.2% | 102,312 | 21.4% | -0.166 | -0.004 |
| 2018 | 101,421 | 20.4% | 96,561 | 20.2% | 0.227 | 0.006 |
| 2019 | 62,171 | 12.5% | 57,860 | 12.1% | 0.418 | 0.013 |

Table 1b. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2020 | 53,773 | 10.8% | 51,475 | 10.8% | 0.062 | 0.002 |
| 2021 | 47,654 | 9.6% | 45,440 | 9.5% | 0.092 | 0.003 |
| 2022 | 14,794 | 3.0% | 14,123 | 3.0% | 0.025 | 0.002 |
| Pre-boxed warning | 390,591 | 78.6% | 376,669 | 78.7% | -0.126 | -0.003 |
| Post-boxed warning | 106,332 | 21.4% | 101,772 | 21.3% | 0.126 | 0.003 |
| Seasonality | | | | | | |
| Winter | 115,692 | 23.3% | 112,594 | 23.5% | -0.252 | -0.006 |
| Spring | 138,873 | 27.9% | 130,032 | 27.2% | 0.768 | 0.017 |
| Summer | 109,763 | 22.1% | 105,845 | 22.1% | -0.034 | -0.001 |
| Autumn | 132,595 | 26.7% | 129,969 | 27.2% | -0.482 | -0.011 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.6 | 1.5 | 1.6 | 1.5 | 0.001 | 0.000 |
| Psychiatric History | 276,966 | 55.7% | 264,476 | 55.3% | 0.457 | 0.009 |
| Psychiatric Drug Dispensings ⁶ | 212,518 | 42.8% | 202,446 | 42.3% | 0.453 | 0.009 |
| Self Harm Encounter ⁶ | 1,054 | 0.2% | 1,053 | 0.2% | -0.008 | -0.002 |
| Encounter for Other Psychiatric Event ⁶ | 226,244 | 45.5% | 215,602 | 45.1% | 0.465 | 0.009 |
| Asthma Emergency Encounter | 53,930 | 10.9% | 51,578 | 10.8% | 0.072 | 0.002 |
| Asthma Inpatient Encounter | 1,704 | 0.3% | 1,674 | 0.3% | -0.007 | -0.001 |
| Asthma Outpatient Encounter | 474,432 | 95.5% | 458,361 | 95.8% | -0.329 | -0.016 |
| Oral Corticosteroid Dispensing | 147,848 | 29.8% | 140,654 | 29.4% | 0.354 | 0.008 |
| Use of Other Asthma Medication | 299,248 | 60.2% | 297,403 | 62.2% | -1.941 | -0.041 |
| Allergic Rhinitis | 213,655 | 43.0% | 193,693 | 40.5% | 2.511 | 0.051 |
| Anxiety | 108,119 | 21.8% | 102,739 | 21.5% | 0.284 | 0.007 |
| Depression | 88,965 | 17.9% | 84,925 | 17.8% | 0.153 | 0.004 |
| Sleep Disorder | 80,269 | 16.2% | 75,352 | 15.7% | 0.404 | 0.011 |
| Substance Abuse | 15,996 | 3.2% | 15,525 | 3.2% | -0.026 | -0.001 |
| Poisoning | 1,042 | 0.2% | 1,114 | 0.2% | -0.023 | -0.005 |

Table 1b. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Suffocation | 13 | 0.0% | 12 | 0.0% | 0.000 | 0.000 |
| Suicide Attempt | 550 | 0.1% | 539 | 0.1% | -0.002 | -0.001 |
| Toxicity | 113 | 0.0% | 114 | 0.0% | -0.001 | -0.001 |
| Other Self Harm | 293 | 0.1% | 293 | 0.1% | -0.002 | -0.001 |
| No moderate asthma exacerbations | 415,612 | 83.6% | 398,531 | 83.3% | 0.339 | 0.009 |
| One moderate asthma exacerbation | 71,204 | 14.3% | 70,332 | 14.7% | -0.371 | -0.011 |
| Two or more moderate asthma | 10,107 | 2.0% | 9,578 | 2.0% | 0.032 | 0.002 |
| No severe asthma exacerbations | 492,284 | 99.1% | 473,795 | 99.0% | 0.038 | 0.004 |
| One severe asthma exacerbation | 4,454 | 0.9% | 4,470 | 0.9% | -0.038 | -0.004 |
| Two or more severe asthma exacerbations | 185 | 0.0% | 176 | 0.0% | 0.000 | 0.000 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 114,275 | 23.0% | 108,004 | 22.6% | 0.422 | 0.010 |
| Antipsychotics | 24,872 | 5.0% | 24,356 | 5.1% | -0.085 | -0.004 |
| Anxiolytics Hypnotics | 106,319 | 21.4% | 100,893 | 21.1% | 0.308 | 0.008 |
| Lithium Other Mood Stabilizers | 30,769 | 6.2% | 29,851 | 6.2% | -0.047 | -0.002 |
| Antidepressants | 158,469 | 31.9% | 151,118 | 31.6% | 0.305 | 0.007 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 11.1 | 11.1 | 11.1 | 10.7 | -0.046 | -0.004 |
| Mean number of emergency room | 0.5 | 1.2 | 0.5 | 1.2 | -0.003 | -0.002 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.001 | -0.002 |
| Mean number of other ambulatory encounters | 2.8 | 8.8 | 2.9 | 9.3 | -0.150 | -0.017 |
| Mean number of filled prescriptions | 16.6 | 15.1 | 16.6 | 15.0 | 0.043 | 0.003 |
| Mean number of generics dispensed | 8.5 | 5.1 | 8.4 | 5.2 | 0.098 | 0.019 |
| Mean number of unique drug classes dispensed | 8.1 | 4.6 | 8.0 | 4.6 | 0.074 | 0.016 |

Table 1b1. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.001 | -0.004 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.001 | -0.002 |
| Mean number of outpatient visits for respiratory disorders | 2.4 | 3.3 | 2.3 | 3.3 | 0.025 | 0.008 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1bm. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 255,253 | 100.0% | 354,773 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 38.3 | 15.9 | 31.9 | 16.2 | 6.433 | 0.401 |
| Age | | | | | | |
| 10-24 years | 104,663 | 41.0% | 191,940 | 54.1% | -13.099 | -0.265 |
| 25-54 years | 75,778 | 29.7% | 90,708 | 25.6% | 4.120 | 0.092 |
| ≥ 55 years | 74,812 | 29.3% | 72,125 | 20.3% | 8.979 | 0.209 |
| Sex | | | | | | |
| Female | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Male | 255,253 | 100.0% | 354,773 | 100.0% | 0.000 | NaN |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 1,553 | 0.6% | 2,873 | 0.8% | -0.201 | -0.024 |
| Asian | 5,894 | 2.3% | 8,378 | 2.4% | -0.052 | -0.003 |
| Black or African American | 25,930 | 10.2% | 43,497 | 12.3% | -2.102 | -0.067 |
| Multi-racial | 639 | 0.3% | 753 | 0.2% | 0.038 | 0.008 |
| Native Hawaiian or Other Pacific Islander | 499 | 0.2% | 1,343 | 0.4% | -0.183 | -0.034 |
| Unknown | 142,936 | 56.0% | 199,583 | 56.3% | -0.259 | -0.005 |
| White | 77,802 | 30.5% | 98,346 | 27.7% | 2.760 | 0.061 |
| Hispanic origin | | | | | | |
| Yes | 25,211 | 9.9% | 49,710 | 14.0% | -4.135 | -0.128 |
| No | 104,722 | 41.0% | 147,025 | 41.4% | -0.415 | -0.008 |
| Unknown | 125,320 | 49.1% | 158,038 | 44.5% | 4.550 | 0.091 |
| Year | | | | | | |
| 2015 | 10,214 | 4.0% | 18,173 | 5.1% | -1.121 | -0.054 |
| 2016 | 49,237 | 19.3% | 81,937 | 23.1% | -3.806 | -0.093 |
| 2017 | 58,617 | 23.0% | 94,019 | 26.5% | -3.537 | -0.082 |
| 2018 | 55,122 | 21.6% | 79,569 | 22.4% | -0.833 | -0.020 |

Table 1bm. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2019 | 28,585 | 11.2% | 27,121 | 7.6% | 3.554 | 0.122 |
| 2020 | 24,176 | 9.5% | 24,048 | 6.8% | 2.693 | 0.099 |
| 2021 | 21,787 | 8.5% | 22,073 | 6.2% | 2.314 | 0.089 |
| 2022 | 7,515 | 2.9% | 7,833 | 2.2% | 0.736 | 0.046 |
| Pre-boxed warning | 206,356 | 80.8% | 305,569 | 86.1% | -5.287 | -0.143 |
| Post-boxed warning | 48,897 | 19.2% | 49,204 | 13.9% | 5.287 | 0.143 |
| Seasonality | | | | | | |
| Winter | 58,757 | 23.0% | 88,727 | 25.0% | -1.990 | -0.047 |
| Spring | 70,684 | 27.7% | 79,400 | 22.4% | 5.311 | 0.123 |
| Summer | 56,988 | 22.3% | 76,678 | 21.6% | 0.713 | 0.017 |
| Autumn | 68,824 | 27.0% | 109,968 | 31.0% | -4.034 | -0.089 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.4 | 1.3 | 1.4 | 1.2 | 0.063 | 0.050 |
| Psychiatric History | 108,458 | 42.5% | 144,135 | 40.6% | 1.863 | 0.038 |
| Psychiatric Drug Dispensings ⁵ | 68,481 | 26.8% | 91,463 | 25.8% | 1.048 | 0.024 |
| Self Harm Encounter ⁵ | 340 | 0.1% | 589 | 0.2% | -0.033 | -0.008 |
| Encounter for Other Psychiatric Event ⁵ | 93,981 | 36.8% | 126,131 | 35.6% | 1.266 | 0.026 |
| Asthma Emergency Encounter | 22,553 | 8.8% | 38,496 | 10.9% | -2.015 | -0.068 |
| Asthma Inpatient Encounter | 547 | 0.2% | 1,043 | 0.3% | -0.080 | -0.016 |
| Asthma Outpatient Encounter | 246,176 | 96.4% | 343,269 | 96.8% | -0.313 | -0.017 |
| Oral Corticosteroid Dispensing | 60,900 | 23.9% | 80,408 | 22.7% | 1.194 | 0.028 |
| Use of Other Asthma Medication | 166,175 | 65.1% | 285,712 | 80.5% | -15.432 | -0.352 |
| Allergic Rhinitis | 110,640 | 43.3% | 85,936 | 24.2% | 19.122 | 0.413 |
| Anxiety | 28,485 | 11.2% | 36,854 | 10.4% | 0.771 | 0.025 |
| Depression | 21,436 | 8.4% | 29,241 | 8.2% | 0.156 | 0.006 |
| Sleep Disorder | 35,202 | 13.8% | 34,034 | 9.6% | 4.198 | 0.131 |

Table 1bm. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Substance Abuse | 8,455 | 3.3% | 15,267 | 4.3% | -0.991 | -0.052 |
| Poisoning | 276 | 0.1% | 553 | 0.2% | -0.048 | -0.013 |
| Suffocation | 17 | 0.0% | 19 | 0.0% | 0.001 | 0.002 |
| Suicide Attempt | 182 | 0.1% | 347 | 0.1% | -0.027 | -0.009 |
| Toxicity | 43 | 0.0% | 74 | 0.0% | -0.004 | -0.003 |
| Other Self Harm | 93 | 0.0% | 161 | 0.0% | -0.009 | -0.004 |
| No moderate asthma exacerbations | 220,468 | 86.4% | 303,116 | 85.4% | 0.933 | 0.027 |
| One moderate asthma exacerbation | 31,027 | 12.2% | 46,281 | 13.0% | -0.890 | -0.027 |
| Two or more moderate asthma | 3,758 | 1.5% | 5,376 | 1.5% | -0.043 | -0.004 |
| No severe asthma exacerbations | 253,674 | 99.4% | 351,688 | 99.1% | 0.251 | 0.029 |
| One severe asthma exacerbation | 1,516 | 0.6% | 3,001 | 0.8% | -0.252 | -0.030 |
| Two or more severe asthma exacerbations | 63 | 0.0% | 84 | 0.0% | 0.001 | 0.001 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 34,748 | 13.6% | 40,669 | 11.5% | 2.150 | 0.065 |
| Antipsychotics | 9,798 | 3.8% | 17,121 | 4.8% | -0.987 | -0.049 |
| Anxiolytics Hypnotics | 28,782 | 11.3% | 33,036 | 9.3% | 1.964 | 0.065 |
| Lithium Other Mood Stabilizers | 9,825 | 3.8% | 14,665 | 4.1% | -0.285 | -0.015 |
| Antidepressants | 38,045 | 14.9% | 48,716 | 13.7% | 1.173 | 0.034 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 8.4 | 10.5 | 7.8 | 10.7 | 0.563 | 0.053 |
| Mean number of emergency room | 0.4 | 1.0 | 0.4 | 1.2 | -0.060 | -0.053 |
| Mean number of inpatient hospital encounters | 0.1 | 0.3 | 0.1 | 0.4 | -0.001 | -0.003 |
| Mean number of other ambulatory encounters | 2.5 | 9.8 | 3.2 | 12.9 | -0.671 | -0.059 |
| Mean number of filled prescriptions | 11.7 | 11.9 | 11.1 | 12.1 | 0.633 | 0.053 |
| Mean number of generics dispensed | 6.4 | 4.1 | 5.7 | 3.8 | 0.619 | 0.157 |

Table 1bm. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of unique drug classes dispensed | 6.1 | 3.7 | 5.6 | 3.5 | 0.492 | 0.138 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.001 | -0.006 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.010 | -0.025 |
| Mean number of outpatient visits for respiratory disorders | 2.1 | 3.2 | 1.6 | 2.8 | 0.494 | 0.164 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1bn. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 255,186 | N/A | 246,692 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 38.3 | 15.9 | 38.1 | 17.0 | 0.172 | 0.010 |
| Age | | | | | | |
| 10-24 years | 104,660 | 41.0% | 106,804 | 43.3% | -2.281 | -0.057 |
| 25-54 years | 75,765 | 29.7% | 64,002 | 25.9% | 3.746 | 0.087 |
| ≥ 55 years | 74,761 | 29.3% | 75,886 | 30.8% | -1.465 | -0.043 |
| Sex | | | | | | |
| Female | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Male | 255,186 | 100.0% | 246,692 | 100.0% | 0.000 | NaN |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 1,553 | 0.6% | 1,524 | 0.6% | -0.009 | -0.001 |
| Asian | 5,891 | 2.3% | 5,199 | 2.1% | 0.201 | 0.014 |
| Black or African American | 25,926 | 10.2% | 22,823 | 9.3% | 0.908 | 0.032 |
| Multi-racial | 639 | 0.3% | 587 | 0.2% | 0.013 | 0.003 |
| Native Hawaiian or Other Pacific Islander | 499 | 0.2% | 720 | 0.3% | -0.096 | -0.020 |
| Unknown | 142,900 | 56.0% | 140,031 | 56.8% | -0.765 | -0.022 |
| White | 77,778 | 30.5% | 75,808 | 30.7% | -0.251 | -0.007 |
| Hispanic origin | | | | | | |
| Yes | 25,205 | 9.9% | 25,566 | 10.4% | -0.486 | -0.018 |
| No | 104,695 | 41.0% | 99,266 | 40.2% | 0.788 | 0.024 |
| Unknown | 125,286 | 49.1% | 121,860 | 49.4% | -0.302 | -0.012 |
| Year | | | | | | |
| 2015 | 10,212 | 4.0% | 10,298 | 4.2% | -0.173 | -0.009 |
| 2016 | 49,233 | 19.3% | 48,531 | 19.7% | -0.380 | -0.010 |
| 2017 | 58,610 | 23.0% | 56,999 | 23.1% | -0.138 | -0.003 |
| 2018 | 55,110 | 21.6% | 52,788 | 21.4% | 0.198 | 0.005 |
| 2019 | 28,564 | 11.2% | 26,958 | 10.9% | 0.266 | 0.009 |
| 2020 | 24,164 | 9.5% | 23,129 | 9.4% | 0.094 | 0.003 |

Table 1bn. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2021 | 21,782 | 8.5% | 20,873 | 8.5% | 0.075 | 0.003 |
| 2022 | 7,511 | 2.9% | 7,117 | 2.9% | 0.058 | 0.004 |
| Pre-boxed warning | 206,308 | 80.8% | 199,888 | 81.0% | -0.181 | -0.005 |
| Post-boxed warning | 48,878 | 19.2% | 46,804 | 19.0% | 0.181 | 0.005 |
| Seasonality | | | | | | |
| Winter | 58,743 | 23.0% | 57,418 | 23.3% | -0.256 | -0.006 |
| Spring | 70,655 | 27.7% | 66,572 | 27.0% | 0.702 | 0.016 |
| Summer | 56,976 | 22.3% | 55,130 | 22.3% | -0.021 | -0.000 |
| Autumn | 68,812 | 27.0% | 67,572 | 27.4% | -0.426 | -0.010 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.4 | 1.3 | 1.4 | 1.3 | -0.002 | -0.002 |
| Psychiatric History | 108,402 | 42.5% | 103,775 | 42.1% | 0.413 | 0.009 |
| Psychiatric Drug Dispensings ⁶ | 68,438 | 26.8% | 65,555 | 26.6% | 0.245 | 0.006 |
| Self Harm Encounter ⁶ | 340 | 0.1% | 280 | 0.1% | 0.020 | 0.006 |
| Encounter for Other Psychiatric Event ⁶ | 93,930 | 36.8% | 89,511 | 36.3% | 0.524 | 0.011 |
| Asthma Emergency Encounter | 22,545 | 8.8% | 21,797 | 8.8% | -0.001 | -0.000 |
| Asthma Inpatient Encounter | 545 | 0.2% | 554 | 0.2% | -0.011 | -0.002 |
| Asthma Outpatient Encounter | 246,119 | 96.4% | 238,453 | 96.7% | -0.213 | -0.012 |
| Oral Corticosteroid Dispensing | 60,858 | 23.8% | 58,110 | 23.6% | 0.293 | 0.007 |
| Use of Other Asthma Medication | 166,164 | 65.1% | 164,826 | 66.8% | -1.700 | -0.037 |
| Allergic Rhinitis | 110,581 | 43.3% | 100,934 | 40.9% | 2.418 | 0.049 |
| Anxiety | 28,462 | 11.2% | 27,243 | 11.0% | 0.110 | 0.004 |
| Depression | 21,422 | 8.4% | 20,602 | 8.4% | 0.043 | 0.002 |
| Sleep Disorder | 35,166 | 13.8% | 33,002 | 13.4% | 0.403 | 0.012 |
| Substance Abuse | 8,453 | 3.3% | 8,352 | 3.4% | -0.073 | -0.004 |
| Poisoning | 276 | 0.1% | 288 | 0.1% | -0.008 | -0.003 |
| Suffocation | 17 | 0.0% | 8 | 0.0% | 0.003 | 0.005 |
| Suicide Attempt | 181 | 0.1% | 181 | 0.1% | -0.002 | -0.001 |

Table 1bn. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Toxicity | 43 | 0.0% | 38 | 0.0% | 0.001 | 0.001 |
| Other Self Harm | 93 | 0.0% | 100 | 0.0% | -0.004 | -0.002 |
| No moderate asthma exacerbations | 220,418 | 86.4% | 212,250 | 86.0% | 0.337 | 0.010 |
| One moderate asthma exacerbation | 31,013 | 12.2% | 30,749 | 12.5% | -0.311 | -0.009 |
| Two or more moderate asthma | 3,755 | 1.5% | 3,693 | 1.5% | -0.026 | -0.002 |
| No severe asthma exacerbations | 253,610 | 99.4% | 245,089 | 99.4% | 0.032 | 0.004 |
| One severe asthma exacerbation | 1,515 | 0.6% | 1,542 | 0.6% | -0.031 | -0.004 |
| Two or more severe asthma exacerbations | 61 | 0.0% | 61 | 0.0% | -0.001 | -0.001 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 34,707 | 13.6% | 33,101 | 13.4% | 0.183 | 0.005 |
| Antipsychotics | 9,789 | 3.8% | 9,658 | 3.9% | -0.079 | -0.004 |
| Anxiolytics Hypnotics | 28,753 | 11.3% | 27,374 | 11.1% | 0.171 | 0.006 |
| Lithium Other Mood Stabilizers | 9,820 | 3.8% | 9,642 | 3.9% | -0.060 | -0.003 |
| Antidepressants | 38,016 | 14.9% | 36,483 | 14.8% | 0.108 | 0.003 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 8.4 | 10.5 | 8.4 | 10.1 | -0.035 | -0.003 |
| Mean number of emergency room | 0.4 | 1.0 | 0.4 | 1.1 | -0.003 | -0.003 |
| Mean number of inpatient hospital encounters | 0.1 | 0.3 | 0.1 | 0.3 | -0.001 | -0.004 |
| Mean number of other ambulatory encounters | 2.5 | 9.8 | 2.6 | 10.5 | -0.163 | -0.016 |
| Mean number of filled prescriptions | 11.7 | 11.8 | 11.7 | 11.7 | -0.017 | -0.001 |
| Mean number of generics dispensed | 6.3 | 4.1 | 6.3 | 4.1 | 0.066 | 0.016 |
| Mean number of unique drug classes dispensed | 6.0 | 3.7 | 6.0 | 3.7 | 0.050 | 0.014 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.001 | -0.006 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.000 | -0.001 |

Table 1bn. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of outpatient visits for respiratory disorders | 2.1 | 3.2 | 2.1 | 3.2 | 0.032 | 0.010 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1bo. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 207,866 | 100.0% | 375,869 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 15.6 | 4.0 | 15.0 | 3.8 | 0.628 | 0.161 |
| Age | | | | | | |
| 10-24 years | 207,866 | 100.0% | 375,869 | 100.0% | 0.000 | NaN |
| 25-54 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| ≥ 55 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Sex | | | | | | |
| Female | 103,203 | 49.6% | 183,929 | 48.9% | 0.714 | 0.014 |
| Male | 104,663 | 50.4% | 191,940 | 51.1% | -0.714 | -0.014 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 1,875 | 0.9% | 3,665 | 1.0% | -0.073 | -0.008 |
| Asian | 3,222 | 1.6% | 7,781 | 2.1% | -0.520 | -0.039 |
| Black or African American | 30,299 | 14.6% | 58,376 | 15.5% | -0.955 | -0.027 |
| Multi-racial | 448 | 0.2% | 676 | 0.2% | 0.036 | 0.008 |
| Native Hawaiian or Other Pacific Islander | 381 | 0.2% | 1,640 | 0.4% | -0.253 | -0.046 |
| Unknown | 133,758 | 64.3% | 233,458 | 62.1% | 2.237 | 0.046 |
| White | 37,883 | 18.2% | 70,273 | 18.7% | -0.471 | -0.012 |
| Hispanic origin | | | | | | |
| Yes | 36,006 | 17.3% | 75,973 | 20.2% | -2.891 | -0.074 |
| No | 71,480 | 34.4% | 138,107 | 36.7% | -2.356 | -0.049 |
| Unknown | 100,380 | 48.3% | 161,789 | 43.0% | 5.247 | 0.105 |
| Year | | | | | | |
| 2015 | 9,717 | 4.7% | 20,007 | 5.3% | -0.648 | -0.030 |
| 2016 | 48,700 | 23.4% | 95,877 | 25.5% | -2.080 | -0.048 |
| 2017 | 59,942 | 28.8% | 113,849 | 30.3% | -1.453 | -0.032 |
| 2018 | 54,094 | 26.0% | 92,684 | 24.7% | 1.365 | 0.031 |
| 2019 | 13,509 | 6.5% | 18,242 | 4.9% | 1.646 | 0.071 |
| 2020 | 9,707 | 4.7% | 14,961 | 4.0% | 0.689 | 0.034 |

Table 1bo. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2021 | 8,746 | 4.2% | 14,425 | 3.8% | 0.370 | 0.019 |
| 2022 | 3,451 | 1.7% | 5,824 | 1.5% | 0.111 | 0.009 |
| Pre-boxed warning | 187,871 | 90.4% | 343,756 | 91.5% | -1.076 | -0.037 |
| Post-boxed warning | 19,995 | 9.6% | 32,113 | 8.5% | 1.076 | 0.037 |
| Seasonality | | | | | | |
| Winter | 43,714 | 21.0% | 89,347 | 23.8% | -2.741 | -0.066 |
| Spring | 54,434 | 26.2% | 78,705 | 20.9% | 5.248 | 0.124 |
| Summer | 50,043 | 24.1% | 84,614 | 22.5% | 1.563 | 0.037 |
| Autumn | 59,675 | 28.7% | 123,203 | 32.8% | -4.070 | -0.088 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.2 | 0.5 | 1.2 | 0.5 | -0.006 | -0.012 |
| Psychiatric History | 68,585 | 33.0% | 123,121 | 32.8% | 0.238 | 0.005 |
| Psychiatric Drug Dispensings ⁵ | 43,114 | 20.7% | 74,269 | 19.8% | 0.982 | 0.024 |
| Self Harm Encounter ⁵ | 550 | 0.3% | 1,164 | 0.3% | -0.045 | -0.008 |
| Encounter for Other Psychiatric Event ⁵ | 60,178 | 29.0% | 109,602 | 29.2% | -0.209 | -0.005 |
| Asthma Emergency Encounter | 24,074 | 11.6% | 47,333 | 12.6% | -1.011 | -0.031 |
| Asthma Inpatient Encounter | 413 | 0.2% | 1,147 | 0.3% | -0.106 | -0.021 |
| Asthma Outpatient Encounter | 199,780 | 96.1% | 363,819 | 96.8% | -0.684 | -0.037 |
| Oral Corticosteroid Dispensing | 42,361 | 20.4% | 78,548 | 20.9% | -0.519 | -0.013 |
| Use of Other Asthma Medication | 156,993 | 75.5% | 323,012 | 85.9% | -10.411 | -0.266 |
| Allergic Rhinitis | 92,341 | 44.4% | 97,740 | 26.0% | 18.420 | 0.393 |
| Anxiety | 20,702 | 10.0% | 36,971 | 9.8% | 0.123 | 0.004 |
| Depression | 15,559 | 7.5% | 27,901 | 7.4% | 0.062 | 0.002 |
| Sleep Disorder | 6,788 | 3.3% | 10,425 | 2.8% | 0.492 | 0.029 |
| Substance Abuse | 2,843 | 1.4% | 6,154 | 1.6% | -0.270 | -0.022 |
| Poisoning | 545 | 0.3% | 1,196 | 0.3% | -0.056 | -0.010 |
| Suffocation | 17 | 0.0% | 28 | 0.0% | 0.001 | 0.001 |
| Suicide Attempt | 288 | 0.1% | 621 | 0.2% | -0.027 | -0.007 |

Table 1bo. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Toxicity | 57 | 0.0% | 125 | 0.0% | -0.006 | -0.003 |
| Other Self Harm | 157 | 0.1% | 305 | 0.1% | -0.006 | -0.002 |
| No moderate asthma exacerbations | 181,741 | 87.4% | 322,258 | 85.7% | 1.695 | 0.050 |
| One moderate asthma exacerbation | 23,945 | 11.5% | 48,723 | 13.0% | -1.443 | -0.044 |
| Two or more moderate asthma | 2,180 | 1.0% | 4,888 | 1.3% | -0.252 | -0.023 |
| No severe asthma exacerbations | 206,875 | 99.5% | 372,659 | 99.1% | 0.377 | 0.046 |
| One severe asthma exacerbation | 954 | 0.5% | 3,128 | 0.8% | -0.373 | -0.047 |
| Two or more severe asthma exacerbations | 37 | 0.0% | 82 | 0.0% | -0.004 | -0.003 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 13,031 | 6.3% | 20,608 | 5.5% | 0.786 | 0.033 |
| Antipsychotics | 6,022 | 2.9% | 11,755 | 3.1% | -0.230 | -0.013 |
| Anxiolytics Hypnotics | 11,278 | 5.4% | 17,578 | 4.7% | 0.749 | 0.034 |
| Lithium Other Mood Stabilizers | 4,718 | 2.3% | 9,029 | 2.4% | -0.132 | -0.009 |
| Antidepressants | 21,173 | 10.2% | 35,074 | 9.3% | 0.854 | 0.029 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 6.5 | 8.1 | 6.6 | 8.5 | -0.046 | -0.005 |
| Mean number of emergency room | 0.4 | 1.0 | 0.4 | 1.0 | -0.036 | -0.036 |
| Mean number of inpatient hospital encounters | 0.0 | 0.3 | 0.0 | 0.3 | -0.008 | -0.028 |
| Mean number of other ambulatory encounters | 2.3 | 10.3 | 2.9 | 12.8 | -0.673 | -0.058 |
| Mean number of filled prescriptions | 7.5 | 7.1 | 7.4 | 7.4 | 0.051 | 0.007 |
| Mean number of generics dispensed | 4.9 | 3.1 | 4.7 | 2.9 | 0.256 | 0.084 |
| Mean number of unique drug classes dispensed | 4.8 | 2.8 | 4.6 | 2.7 | 0.153 | 0.055 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.1 | 0.0 | 0.2 | -0.006 | -0.038 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.008 | -0.022 |

Table 1bo. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of outpatient visits for respiratory disorders | 1.8 | 2.9 | 1.5 | 2.5 | 0.356 | 0.133 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1bp. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 207,822 | N/A | 201,192 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 15.6 | 4.0 | 15.5 | 4.0 | 0.080 | 0.020 |
| Age | | | | | | |
| 10-24 years | 207,822 | 100.0% | 201,192 | 100.0% | 0.000 | NaN |
| 25-54 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| ≥ 55 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Sex | | | | | | |
| Female | 103,172 | 49.6% | 99,420 | 49.4% | 0.229 | 0.005 |
| Male | 104,650 | 50.4% | 101,772 | 50.6% | -0.229 | -0.005 |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 1,875 | 0.9% | 1,742 | 0.9% | 0.036 | 0.004 |
| Asian | 3,222 | 1.6% | 3,945 | 2.0% | -0.411 | -0.031 |
| Black or African American | 30,296 | 14.6% | 27,425 | 13.6% | 0.947 | 0.029 |
| Multi-racial | 448 | 0.2% | 390 | 0.2% | 0.022 | 0.005 |
| Native Hawaiian or Other Pacific Islander | 381 | 0.2% | 763 | 0.4% | -0.196 | -0.037 |
| Unknown | 133,722 | 64.3% | 132,367 | 65.8% | -1.447 | -0.036 |
| White | 37,878 | 18.2% | 34,560 | 17.2% | 1.049 | 0.029 |
| Hispanic origin | | | | | | |
| Yes | 36,005 | 17.3% | 37,492 | 18.6% | -1.310 | -0.037 |
| No | 71,473 | 34.4% | 66,182 | 32.9% | 1.496 | 0.039 |
| Unknown | 100,344 | 48.3% | 97,517 | 48.5% | -0.186 | -0.007 |
| Year | | | | | | |
| 2015 | 9,715 | 4.7% | 9,625 | 4.8% | -0.109 | -0.005 |
| 2016 | 48,695 | 23.4% | 47,580 | 23.6% | -0.218 | -0.005 |
| 2017 | 59,932 | 28.8% | 58,260 | 29.0% | -0.119 | -0.003 |
| 2018 | 54,084 | 26.0% | 51,662 | 25.7% | 0.346 | 0.008 |
| 2019 | 13,500 | 6.5% | 12,790 | 6.4% | 0.139 | 0.006 |

Table 1bp. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2020 | 9,701 | 4.7% | 9,450 | 4.7% | -0.029 | -0.001 |
| 2021 | 8,744 | 4.2% | 8,489 | 4.2% | -0.012 | -0.001 |
| 2022 | 3,451 | 1.7% | 3,336 | 1.7% | 0.003 | 0.000 |
| Pre-boxed warning | 187,833 | 90.4% | 181,766 | 90.3% | 0.037 | 0.001 |
| Post-boxed warning | 19,989 | 9.6% | 19,427 | 9.7% | -0.037 | -0.001 |
| Seasonality | | | | | | |
| Winter | 43,709 | 21.0% | 42,880 | 21.3% | -0.281 | -0.007 |
| Spring | 54,405 | 26.2% | 51,246 | 25.5% | 0.708 | 0.016 |
| Summer | 50,037 | 24.1% | 48,372 | 24.0% | 0.034 | 0.001 |
| Autumn | 59,671 | 28.7% | 58,695 | 29.2% | -0.461 | -0.010 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.2 | 0.5 | 1.2 | 0.5 | -0.001 | -0.001 |
| Psychiatric History | 68,549 | 33.0% | 65,949 | 32.8% | 0.206 | 0.004 |
| Psychiatric Drug Dispensings ⁶ | 43,086 | 20.7% | 40,578 | 20.2% | 0.563 | 0.014 |
| Self Harm Encounter ⁶ | 550 | 0.3% | 540 | 0.3% | -0.004 | -0.001 |
| Encounter for Other Psychiatric Event ⁶ | 60,144 | 28.9% | 57,626 | 28.6% | 0.298 | 0.007 |
| Asthma Emergency Encounter | 24,063 | 11.6% | 23,267 | 11.6% | 0.014 | 0.000 |
| Asthma Inpatient Encounter | 413 | 0.2% | 437 | 0.2% | -0.019 | -0.004 |
| Asthma Outpatient Encounter | 199,747 | 96.1% | 193,929 | 96.4% | -0.275 | -0.015 |
| Oral Corticosteroid Dispensing | 42,343 | 20.4% | 41,030 | 20.4% | -0.019 | -0.000 |
| Use of Other Asthma Medication | 156,981 | 75.5% | 155,496 | 77.3% | -1.751 | -0.042 |
| Allergic Rhinitis | 92,301 | 44.4% | 84,939 | 42.2% | 2.196 | 0.045 |
| Anxiety | 20,683 | 10.0% | 19,865 | 9.9% | 0.079 | 0.003 |
| Depression | 15,548 | 7.5% | 14,960 | 7.4% | 0.046 | 0.002 |
| Sleep Disorder | 6,778 | 3.3% | 6,359 | 3.2% | 0.101 | 0.006 |
| Substance Abuse | 2,840 | 1.4% | 2,833 | 1.4% | -0.041 | -0.004 |
| Poisoning | 545 | 0.3% | 597 | 0.3% | -0.034 | -0.007 |

Table 1bp. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Suffocation | 17 | 0.0% | 11 | 0.0% | 0.003 | 0.003 |
| Suicide Attempt | 288 | 0.1% | 307 | 0.2% | -0.014 | -0.004 |
| Toxicity | 57 | 0.0% | 62 | 0.0% | -0.003 | -0.002 |
| Other Self Harm | 157 | 0.1% | 154 | 0.1% | -0.001 | -0.000 |
| No moderate asthma exacerbations | 181,701 | 87.4% | 174,396 | 86.7% | 0.750 | 0.022 |
| One moderate asthma exacerbation | 23,942 | 11.5% | 24,287 | 12.1% | -0.551 | -0.017 |
| Two or more moderate asthma | 2,179 | 1.0% | 2,509 | 1.2% | -0.199 | -0.019 |
| No severe asthma exacerbations | 206,832 | 99.5% | 200,111 | 99.5% | 0.061 | 0.009 |
| One severe asthma exacerbation | 954 | 0.5% | 1,040 | 0.5% | -0.058 | -0.008 |
| Two or more severe asthma exacerbations | 36 | 0.0% | 40 | 0.0% | -0.003 | -0.002 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 13,021 | 6.3% | 12,360 | 6.1% | 0.122 | 0.005 |
| Antipsychotics | 6,014 | 2.9% | 5,945 | 3.0% | -0.061 | -0.004 |
| Anxiolytics Hypnotics | 11,265 | 5.4% | 10,555 | 5.2% | 0.174 | 0.008 |
| Lithium Other Mood Stabilizers | 4,711 | 2.3% | 4,602 | 2.3% | -0.020 | -0.001 |
| Antidepressants | 21,153 | 10.2% | 20,142 | 10.0% | 0.167 | 0.006 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 6.5 | 8.1 | 6.6 | 7.8 | -0.006 | -0.001 |
| Mean number of emergency room | 0.4 | 1.0 | 0.4 | 1.0 | -0.002 | -0.002 |
| Mean number of inpatient hospital encounters | 0.0 | 0.3 | 0.0 | 0.3 | -0.002 | -0.007 |
| Mean number of other ambulatory encounters | 2.3 | 10.3 | 2.6 | 11.6 | -0.350 | -0.032 |
| Mean number of filled prescriptions | 7.5 | 7.1 | 7.5 | 7.1 | 0.013 | 0.002 |
| Mean number of generics dispensed | 4.9 | 3.1 | 4.9 | 3.2 | 0.051 | 0.016 |
| Mean number of unique drug classes dispensed | 4.8 | 2.8 | 4.7 | 2.9 | 0.037 | 0.013 |

Table 1bp. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.1 | 0.0 | 0.1 | -0.001 | -0.008 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.001 | -0.002 |
| Mean number of outpatient visits for respiratory disorders | 1.8 | 2.9 | 1.8 | 2.8 | 0.043 | 0.015 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1bq. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 257,136 | 100.0% | 294,422 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 40.4 | 8.4 | 39.8 | 8.5 | 0.512 | 0.061 |
| Age | | | | | | |
| 10-24 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 25-54 years | 257,136 | 100.0% | 294,422 | 100.0% | 0.000 | NaN |
| ≥ 55 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Sex | | | | | | |
| Female | 181,358 | 70.5% | 203,714 | 69.2% | 1.339 | 0.029 |
| Male | 75,778 | 29.5% | 90,708 | 30.8% | -1.339 | -0.029 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 1,423 | 0.6% | 2,696 | 0.9% | -0.362 | -0.042 |
| Asian | 4,290 | 1.7% | 5,838 | 2.0% | -0.314 | -0.023 |
| Black or African American | 24,388 | 9.5% | 36,234 | 12.3% | -2.822 | -0.091 |
| Multi-racial | 1,158 | 0.5% | 1,019 | 0.3% | 0.104 | 0.017 |
| Native Hawaiian or Other Pacific Islander | 405 | 0.2% | 1,086 | 0.4% | -0.211 | -0.041 |
| Unknown | 171,010 | 66.5% | 167,552 | 56.9% | 9.597 | 0.198 |
| White | 54,462 | 21.2% | 79,997 | 27.2% | -5.991 | -0.140 |
| Hispanic origin | | | | | | |
| Yes | 17,129 | 6.7% | 28,465 | 9.7% | -3.007 | -0.110 |
| No | 74,381 | 28.9% | 116,553 | 39.6% | -10.660 | -0.226 |
| Unknown | 165,626 | 64.4% | 149,404 | 50.7% | 13.667 | 0.279 |
| Year | | | | | | |
| 2015 | 9,809 | 3.8% | 14,029 | 4.8% | -0.950 | -0.047 |
| 2016 | 48,277 | 18.8% | 64,371 | 21.9% | -3.089 | -0.077 |
| 2017 | 55,354 | 21.5% | 75,782 | 25.7% | -4.212 | -0.099 |
| 2018 | 53,238 | 20.7% | 65,902 | 22.4% | -1.679 | -0.041 |
| 2019 | 29,853 | 11.6% | 22,844 | 7.8% | 3.851 | 0.130 |
| 2020 | 28,162 | 11.0% | 23,748 | 8.1% | 2.886 | 0.099 |

Table 1bq. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2021 | 23,588 | 9.2% | 19,833 | 6.7% | 2.437 | 0.090 |
| 2022 | 8,855 | 3.4% | 7,913 | 2.7% | 0.756 | 0.044 |
| Pre-boxed warning | 201,267 | 78.3% | 246,921 | 83.9% | -5.594 | -0.143 |
| Post-boxed warning | 55,869 | 21.7% | 47,501 | 16.1% | 5.594 | 0.143 |
| Seasonality | | | | | | |
| Winter | 59,054 | 23.0% | 75,123 | 25.5% | -2.549 | -0.060 |
| Spring | 75,199 | 29.2% | 68,651 | 23.3% | 5.928 | 0.135 |
| Summer | 55,310 | 21.5% | 61,599 | 20.9% | 0.588 | 0.014 |
| Autumn | 67,573 | 26.3% | 89,049 | 30.2% | -3.966 | -0.088 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.4 | 1.1 | 1.5 | 1.2 | -0.053 | -0.046 |
| Psychiatric History | 143,341 | 55.7% | 168,135 | 57.1% | -1.362 | -0.027 |
| Psychiatric Drug Dispensings ⁵ | 107,777 | 41.9% | 126,176 | 42.9% | -0.941 | -0.019 |
| Self Harm Encounter ⁵ | 697 | 0.3% | 1,133 | 0.4% | -0.114 | -0.020 |
| Encounter for Other Psychiatric Event ⁵ | 120,688 | 46.9% | 142,464 | 48.4% | -1.452 | -0.029 |
| Asthma Emergency Encounter | 31,691 | 12.3% | 43,028 | 14.6% | -2.290 | -0.067 |
| Asthma Inpatient Encounter | 937 | 0.4% | 1,019 | 0.3% | 0.018 | 0.003 |
| Asthma Outpatient Encounter | 245,683 | 95.5% | 281,156 | 95.5% | 0.052 | 0.002 |
| Oral Corticosteroid Dispensing | 78,190 | 30.4% | 85,969 | 29.2% | 1.209 | 0.026 |
| Use of Other Asthma Medication | 171,152 | 66.6% | 237,349 | 80.6% | -14.054 | -0.323 |
| Allergic Rhinitis | 109,242 | 42.5% | 59,264 | 20.1% | 22.355 | 0.497 |
| Anxiety | 60,543 | 23.5% | 68,536 | 23.3% | 0.267 | 0.006 |
| Depression | 43,802 | 17.0% | 53,481 | 18.2% | -1.130 | -0.030 |
| Sleep Disorder | 38,542 | 15.0% | 36,500 | 12.4% | 2.592 | 0.075 |
| Substance Abuse | 13,259 | 5.2% | 24,365 | 8.3% | -3.119 | -0.125 |
| Poisoning | 631 | 0.2% | 1,106 | 0.4% | -0.130 | -0.023 |
| Suffocation | 12 | 0.0% | 18 | 0.0% | -0.001 | -0.002 |
| Suicide Attempt | 364 | 0.1% | 556 | 0.2% | -0.047 | -0.012 |

Table 1bq. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Toxicity | 68 | 0.0% | 127 | 0.0% | -0.017 | -0.009 |
| Other Self Harm | 193 | 0.1% | 290 | 0.1% | -0.023 | -0.008 |
| No moderate asthma exacerbations | 215,236 | 83.7% | 243,190 | 82.6% | 1.106 | 0.030 |
| One moderate asthma exacerbation | 36,784 | 14.3% | 44,977 | 15.3% | -0.971 | -0.027 |
| Two or more moderate asthma | 5,116 | 2.0% | 6,255 | 2.1% | -0.135 | -0.010 |
| No severe asthma exacerbations | 254,830 | 99.1% | 291,423 | 99.0% | 0.122 | 0.013 |
| One severe asthma exacerbation | 2,180 | 0.8% | 2,893 | 1.0% | -0.135 | -0.014 |
| Two or more severe asthma exacerbations | 126 | 0.0% | 106 | 0.0% | 0.013 | 0.006 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 60,020 | 23.3% | 72,967 | 24.8% | -1.441 | -0.034 |
| Antipsychotics | 17,884 | 7.0% | 28,580 | 9.7% | -2.752 | -0.100 |
| Anxiolytics Hypnotics | 56,405 | 21.9% | 63,986 | 21.7% | 0.203 | 0.005 |
| Lithium Other Mood Stabilizers | 20,505 | 8.0% | 27,553 | 9.4% | -1.384 | -0.049 |
| Antidepressants | 78,747 | 30.6% | 94,171 | 32.0% | -1.360 | -0.029 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 9.6 | 11.2 | 10.1 | 12.5 | -0.445 | -0.037 |
| Mean number of emergency room | 0.6 | 1.5 | 0.7 | 1.8 | -0.158 | -0.095 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.015 | -0.035 |
| Mean number of other ambulatory encounters | 2.6 | 9.4 | 3.6 | 12.4 | -0.938 | -0.085 |
| Mean number of filled prescriptions | 15.7 | 15.1 | 16.7 | 16.5 | -1.055 | -0.067 |
| Mean number of generics dispensed | 7.9 | 5.1 | 7.9 | 5.1 | 0.044 | 0.009 |
| Mean number of unique drug classes dispensed | 7.5 | 4.6 | 7.5 | 4.6 | -0.029 | -0.006 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.3 | -0.006 | -0.024 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.5 | 0.2 | 0.5 | -0.022 | -0.043 |

Table 1bq. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of outpatient visits for respiratory disorders | 2.1 | 3.2 | 1.6 | 2.7 | 0.455 | 0.154 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1br. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 257,098 | N/A | 247,509 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 40.3 | 8.4 | 40.4 | 8.5 | -0.002 | -0.000 |
| Age | | | | | | |
| 10-24 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 25-54 years | 257,098 | 100.0% | 247,509 | 100.0% | 0.000 | NaN |
| ≥ 55 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Sex | | | | | | |
| Female | 181,325 | 70.5% | 173,813 | 70.2% | 0.303 | 0.007 |
| Male | 75,773 | 29.5% | 73,697 | 29.8% | -0.303 | -0.007 |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 1,423 | 0.6% | 1,561 | 0.6% | -0.077 | -0.010 |
| Asian | 4,290 | 1.7% | 3,969 | 1.6% | 0.065 | 0.005 |
| Black or African American | 24,380 | 9.5% | 22,652 | 9.2% | 0.331 | 0.012 |
| Multi-racial | 1,158 | 0.5% | 1,153 | 0.5% | -0.016 | -0.002 |
| Native Hawaiian or Other Pacific Islander | 405 | 0.2% | 556 | 0.2% | -0.067 | -0.015 |
| Unknown | 170,992 | 66.5% | 164,596 | 66.5% | 0.008 | 0.000 |
| White | 54,450 | 21.2% | 53,022 | 21.4% | -0.243 | -0.007 |
| Hispanic origin | | | | | | |
| Yes | 17,124 | 6.7% | 16,753 | 6.8% | -0.108 | -0.005 |
| No | 74,363 | 28.9% | 71,058 | 28.7% | 0.215 | 0.008 |
| Unknown | 165,611 | 64.4% | 159,698 | 64.5% | -0.106 | -0.005 |
| Year | | | | | | |
| 2015 | 9,809 | 3.8% | 9,894 | 4.0% | -0.182 | -0.009 |
| 2016 | 48,273 | 18.8% | 47,145 | 19.0% | -0.271 | -0.007 |
| 2017 | 55,347 | 21.5% | 53,421 | 21.6% | -0.056 | -0.001 |
| 2018 | 53,232 | 20.7% | 50,603 | 20.4% | 0.260 | 0.007 |
| 2019 | 29,841 | 11.6% | 27,945 | 11.3% | 0.316 | 0.010 |

Table 1br. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2020 | 28,155 | 11.0% | 27,181 | 11.0% | -0.031 | -0.001 |
| 2021 | 23,586 | 9.2% | 22,778 | 9.2% | -0.029 | -0.001 |
| 2022 | 8,855 | 3.4% | 8,542 | 3.5% | -0.007 | -0.000 |
| Pre-boxed warning | 201,238 | 78.3% | 193,525 | 78.2% | 0.084 | 0.002 |
| Post-boxed warning | 55,860 | 21.7% | 53,984 | 21.8% | -0.084 | -0.002 |
| Seasonality | | | | | | |
| Winter | 59,051 | 23.0% | 57,806 | 23.4% | -0.387 | -0.009 |
| Spring | 75,181 | 29.2% | 70,197 | 28.4% | 0.881 | 0.019 |
| Summer | 55,297 | 21.5% | 53,051 | 21.4% | 0.074 | 0.002 |
| Autumn | 67,569 | 26.3% | 66,456 | 26.8% | -0.568 | -0.013 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.4 | 1.1 | 1.4 | 1.1 | -0.002 | -0.001 |
| Psychiatric History | 143,306 | 55.7% | 136,908 | 55.3% | 0.425 | 0.009 |
| Psychiatric Drug Dispensings ⁶ | 107,748 | 41.9% | 102,582 | 41.4% | 0.463 | 0.010 |
| Self Harm Encounter ⁶ | 697 | 0.3% | 631 | 0.3% | 0.016 | 0.003 |
| Encounter for Other Psychiatric Event ⁶ | 120,657 | 46.9% | 115,308 | 46.6% | 0.343 | 0.007 |
| Asthma Emergency Encounter | 31,673 | 12.3% | 30,138 | 12.2% | 0.143 | 0.004 |
| Asthma Inpatient Encounter | 937 | 0.4% | 908 | 0.4% | -0.003 | -0.000 |
| Asthma Outpatient Encounter | 245,663 | 95.6% | 237,326 | 95.9% | -0.333 | -0.017 |
| Oral Corticosteroid Dispensing | 78,166 | 30.4% | 74,954 | 30.3% | 0.120 | 0.003 |
| Use of Other Asthma Medication | 171,149 | 66.6% | 169,930 | 68.7% | -2.086 | -0.045 |
| Allergic Rhinitis | 109,207 | 42.5% | 99,032 | 40.0% | 2.466 | 0.051 |
| Anxiety | 60,522 | 23.5% | 57,627 | 23.3% | 0.258 | 0.006 |
| Depression | 43,785 | 17.0% | 41,970 | 17.0% | 0.073 | 0.002 |
| Sleep Disorder | 38,525 | 15.0% | 36,165 | 14.6% | 0.373 | 0.011 |
| Substance Abuse | 13,257 | 5.2% | 13,037 | 5.3% | -0.111 | -0.005 |
| Poisoning | 630 | 0.2% | 642 | 0.3% | -0.014 | -0.003 |

Table 1br. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Suffocation | 12 | 0.0% | 9 | 0.0% | 0.001 | 0.002 |
| Suicide Attempt | 364 | 0.1% | 336 | 0.1% | 0.006 | 0.002 |
| Toxicity | 67 | 0.0% | 71 | 0.0% | -0.003 | -0.002 |
| Other Self Harm | 193 | 0.1% | 185 | 0.1% | 0.000 | 0.000 |
| No moderate asthma exacerbations | 215,206 | 83.7% | 205,659 | 83.1% | 0.614 | 0.017 |
| One moderate asthma exacerbation | 36,777 | 14.3% | 36,893 | 14.9% | -0.601 | -0.017 |
| Two or more moderate asthma | 5,115 | 2.0% | 4,957 | 2.0% | -0.013 | -0.001 |
| No severe asthma exacerbations | 254,792 | 99.1% | 245,214 | 99.1% | 0.030 | 0.003 |
| One severe asthma exacerbation | 2,180 | 0.8% | 2,185 | 0.9% | -0.035 | -0.004 |
| Two or more severe asthma exacerbations | 126 | 0.0% | 111 | 0.0% | 0.004 | 0.002 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 59,995 | 23.3% | 56,905 | 23.0% | 0.345 | 0.008 |
| Antipsychotics | 17,876 | 7.0% | 17,399 | 7.0% | -0.077 | -0.003 |
| Anxiolytics Hypnotics | 56,380 | 21.9% | 53,575 | 21.6% | 0.284 | 0.007 |
| Lithium Other Mood Stabilizers | 20,498 | 8.0% | 19,771 | 8.0% | -0.015 | -0.001 |
| Antidepressants | 78,728 | 30.6% | 75,218 | 30.4% | 0.232 | 0.005 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 9.6 | 11.2 | 9.7 | 10.8 | -0.085 | -0.008 |
| Mean number of emergency room | 0.6 | 1.5 | 0.6 | 1.5 | -0.004 | -0.002 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.000 | -0.001 |
| Mean number of other ambulatory encounters | 2.6 | 9.4 | 2.7 | 9.4 | -0.090 | -0.010 |
| Mean number of filled prescriptions | 15.7 | 15.1 | 15.6 | 15.0 | 0.066 | 0.004 |
| Mean number of generics dispensed | 7.9 | 5.1 | 7.8 | 5.2 | 0.093 | 0.018 |
| Mean number of unique drug classes dispensed | 7.5 | 4.5 | 7.4 | 4.6 | 0.072 | 0.016 |

Table 1br. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.001 | -0.003 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.5 | 0.1 | 0.5 | -0.001 | -0.002 |
| Mean number of outpatient visits for respiratory disorders | 2.1 | 3.1 | 2.1 | 3.1 | 0.009 | 0.003 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1bs. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 287,228 | 100.0% | 253,066 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 69.6 | 7.3 | 69.0 | 7.5 | 0.535 | 0.072 |
| Age | | | | | | |
| 10-24 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 25-54 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| ≥ 55 years | 287,228 | 100.0% | 253,066 | 100.0% | 0.000 | NaN |
| Sex | | | | | | |
| Female | 212,416 | 74.0% | 180,941 | 71.5% | 2.454 | 0.055 |
| Male | 74,812 | 26.0% | 72,125 | 28.5% | -2.454 | -0.055 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 1,343 | 0.5% | 1,533 | 0.6% | -0.138 | -0.019 |
| Asian | 8,480 | 3.0% | 6,062 | 2.4% | 0.557 | 0.035 |
| Black or African American | 27,029 | 9.4% | 22,157 | 8.8% | 0.655 | 0.023 |
| Multi-racial | 306 | 0.1% | 273 | 0.1% | -0.001 | -0.000 |
| Native Hawaiian or Other Pacific Islander | 562 | 0.2% | 509 | 0.2% | -0.005 | -0.001 |
| Unknown | 73,839 | 25.7% | 72,526 | 28.7% | -2.951 | -0.066 |
| White | 175,669 | 61.2% | 150,006 | 59.3% | 1.885 | 0.039 |
| Hispanic origin | | | | | | |
| Yes | 8,884 | 3.1% | 10,042 | 4.0% | -0.875 | -0.047 |
| No | 203,499 | 70.8% | 172,272 | 68.1% | 2.775 | 0.060 |
| Unknown | 74,845 | 26.1% | 70,752 | 28.0% | -1.900 | -0.043 |
| Year | | | | | | |
| 2015 | 9,614 | 3.3% | 12,650 | 5.0% | -1.652 | -0.083 |
| 2016 | 45,009 | 15.7% | 49,760 | 19.7% | -3.993 | -0.105 |
| 2017 | 48,768 | 17.0% | 48,666 | 19.2% | -2.252 | -0.059 |
| 2018 | 49,226 | 17.1% | 43,809 | 17.3% | -0.173 | -0.005 |
| 2019 | 47,409 | 16.5% | 33,651 | 13.3% | 3.208 | 0.090 |
| 2020 | 40,088 | 14.0% | 30,351 | 12.0% | 1.964 | 0.058 |

Table 1bs. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2021 | 37,111 | 12.9% | 26,800 | 10.6% | 2.330 | 0.072 |
| 2022 | 10,003 | 3.5% | 7,379 | 2.9% | 0.567 | 0.032 |
| Pre-boxed warning | 207,852 | 72.4% | 194,322 | 76.8% | -4.422 | -0.102 |
| Post-boxed warning | 79,376 | 27.6% | 58,744 | 23.2% | 4.422 | 0.102 |
| Seasonality | | | | | | |
| Winter | 71,687 | 25.0% | 68,179 | 26.9% | -1.983 | -0.045 |
| Spring | 79,950 | 27.8% | 59,300 | 23.4% | 4.402 | 0.101 |
| Summer | 61,411 | 21.4% | 52,837 | 20.9% | 0.502 | 0.012 |
| Autumn | 74,180 | 25.8% | 72,750 | 28.7% | -2.921 | -0.066 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 2.0 | 2.0 | 2.0 | 2.1 | 0.004 | 0.002 |
| Psychiatric History | 173,548 | 60.4% | 147,710 | 58.4% | 2.054 | 0.042 |
| Psychiatric Drug Dispensings ⁵ | 130,154 | 45.3% | 111,691 | 44.1% | 1.179 | 0.024 |
| Self Harm Encounter ⁵ | 147 | 0.1% | 158 | 0.1% | -0.011 | -0.005 |
| Encounter for Other Psychiatric Event ⁵ | 139,404 | 48.5% | 117,427 | 46.4% | 2.133 | 0.043 |
| Asthma Emergency Encounter | 20,731 | 7.2% | 20,129 | 8.0% | -0.736 | -0.028 |
| Asthma Inpatient Encounter | 901 | 0.3% | 739 | 0.3% | 0.022 | 0.004 |
| Asthma Outpatient Encounter | 275,184 | 95.8% | 243,315 | 96.1% | -0.340 | -0.017 |
| Oral Corticosteroid Dispensing | 88,229 | 30.7% | 69,296 | 27.4% | 3.335 | 0.074 |
| Use of Other Asthma Medication | 137,286 | 47.8% | 163,077 | 64.4% | -16.644 | -0.340 |
| Allergic Rhinitis | 122,760 | 42.7% | 57,425 | 22.7% | 20.048 | 0.437 |
| Anxiety | 55,389 | 19.3% | 44,948 | 17.8% | 1.523 | 0.039 |
| Depression | 51,063 | 17.8% | 44,708 | 17.7% | 0.111 | 0.003 |
| Sleep Disorder | 70,159 | 24.4% | 54,115 | 21.4% | 3.042 | 0.072 |
| Substance Abuse | 8,355 | 2.9% | 8,798 | 3.5% | -0.568 | -0.032 |
| Poisoning | 142 | 0.0% | 168 | 0.1% | -0.017 | -0.007 |
| Suffocation | 1 | 0.0% | 0 | 0.0% | NaN | NaN |
| Suicide Attempt | 80 | 0.0% | 73 | 0.0% | -0.001 | -0.001 |

Table 1bs. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Toxicity | 31 | 0.0% | 23 | 0.0% | 0.002 | 0.002 |
| Other Self Harm | 36 | 0.0% | 35 | 0.0% | -0.001 | -0.001 |
| No moderate asthma exacerbations | 239,143 | 83.3% | 213,809 | 84.5% | -1.229 | -0.033 |
| One moderate asthma exacerbation | 41,514 | 14.5% | 34,419 | 13.6% | 0.853 | 0.025 |
| Two or more moderate asthma | 6,571 | 2.3% | 4,838 | 1.9% | 0.376 | 0.026 |
| No severe asthma exacerbations | 284,304 | 99.0% | 250,294 | 98.9% | 0.077 | 0.008 |
| One severe asthma exacerbation | 2,838 | 1.0% | 2,714 | 1.1% | -0.084 | -0.008 |
| Two or more severe asthma exacerbations | 86 | 0.0% | 58 | 0.0% | 0.007 | 0.004 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 76,003 | 26.5% | 64,357 | 25.4% | 1.030 | 0.023 |
| Antipsychotics | 10,767 | 3.7% | 11,998 | 4.7% | -0.992 | -0.049 |
| Anxiolytics Hypnotics | 67,454 | 23.5% | 55,381 | 21.9% | 1.600 | 0.038 |
| Lithium Other Mood Stabilizers | 15,379 | 5.4% | 15,000 | 5.9% | -0.573 | -0.025 |
| Antidepressants | 96,624 | 33.6% | 84,167 | 33.3% | 0.381 | 0.008 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 13.3 | 12.3 | 12.7 | 12.4 | 0.533 | 0.043 |
| Mean number of emergency room | 0.3 | 0.9 | 0.4 | 1.0 | -0.024 | -0.026 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.006 | -0.015 |
| Mean number of other ambulatory encounters | 3.0 | 7.8 | 3.5 | 10.3 | -0.471 | -0.052 |
| Mean number of filled prescriptions | 19.8 | 15.5 | 20.5 | 16.7 | -0.726 | -0.045 |
| Mean number of generics dispensed | 9.7 | 5.1 | 9.3 | 5.0 | 0.368 | 0.073 |
| Mean number of unique drug classes dispensed | 9.2 | 4.6 | 9.0 | 4.5 | 0.222 | 0.049 |
| Mean number of inpatient visits for respiratory disorders | 0.1 | 0.3 | 0.1 | 0.3 | -0.006 | -0.019 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.006 | -0.014 |

Table 1bs. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of outpatient visits for respiratory disorders | 2.7 | 3.7 | 2.2 | 3.3 | 0.550 | 0.157 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1bt. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 287,144 | N/A | 275,968 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 69.6 | 7.3 | 69.6 | 7.4 | -0.017 | -0.002 |
| Age | | | | | | |
| 10-24 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 25-54 years | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| ≥ 55 years | 287,144 | 100.0% | 275,968 | 100.0% | 0.000 | NaN |
| Sex | | | | | | |
| Female | 212,348 | 74.0% | 203,283 | 73.7% | 0.290 | 0.007 |
| Male | 74,796 | 26.0% | 72,685 | 26.3% | -0.290 | -0.007 |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 1,343 | 0.5% | 1,425 | 0.5% | -0.048 | -0.007 |
| Asian | 8,475 | 3.0% | 5,678 | 2.1% | 0.894 | 0.058 |
| Black or African American | 27,010 | 9.4% | 21,913 | 7.9% | 1.466 | 0.053 |
| Multi-racial | 305 | 0.1% | 315 | 0.1% | -0.008 | -0.002 |
| Native Hawaiian or Other Pacific Islander | 562 | 0.2% | 481 | 0.2% | 0.021 | 0.005 |
| Unknown | 73,813 | 25.7% | 71,612 | 25.9% | -0.243 | -0.009 |
| White | 175,636 | 61.2% | 174,544 | 63.2% | -2.081 | -0.055 |
| Hispanic origin | | | | | | |
| Yes | 8,876 | 3.1% | 8,067 | 2.9% | 0.168 | 0.010 |
| No | 203,448 | 70.9% | 194,613 | 70.5% | 0.332 | 0.014 |
| Unknown | 74,820 | 26.1% | 73,288 | 26.6% | -0.500 | -0.026 |
| Year | | | | | | |
| 2015 | 9,613 | 3.3% | 9,962 | 3.6% | -0.262 | -0.014 |
| 2016 | 45,006 | 15.7% | 44,874 | 16.3% | -0.587 | -0.016 |
| 2017 | 48,750 | 17.0% | 47,454 | 17.2% | -0.218 | -0.006 |
| 2018 | 49,202 | 17.1% | 46,836 | 17.0% | 0.163 | 0.004 |
| 2019 | 47,386 | 16.5% | 44,022 | 16.0% | 0.551 | 0.015 |

Table 1bt. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2020 | 40,082 | 14.0% | 38,131 | 13.8% | 0.142 | 0.004 |
| 2021 | 37,105 | 12.9% | 35,213 | 12.8% | 0.162 | 0.005 |
| 2022 | 10,000 | 3.5% | 9,475 | 3.4% | 0.049 | 0.003 |
| Pre-boxed warning | 207,782 | 72.4% | 200,387 | 72.6% | -0.251 | -0.006 |
| Post-boxed warning | 79,362 | 27.6% | 75,581 | 27.4% | 0.251 | 0.006 |
| Seasonality | | | | | | |
| Winter | 71,676 | 25.0% | 69,398 | 25.1% | -0.186 | -0.004 |
| Spring | 79,909 | 27.8% | 74,796 | 27.1% | 0.726 | 0.016 |
| Summer | 61,388 | 21.4% | 59,339 | 21.5% | -0.123 | -0.003 |
| Autumn | 74,171 | 25.8% | 72,435 | 26.2% | -0.417 | -0.010 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 2.0 | 2.0 | 2.0 | 2.0 | 0.000 | 0.000 |
| Psychiatric History | 173,477 | 60.4% | 165,228 | 59.9% | 0.543 | 0.011 |
| Psychiatric Drug Dispensings ⁶ | 130,087 | 45.3% | 124,206 | 45.0% | 0.296 | 0.006 |
| Self Harm Encounter ⁶ | 147 | 0.1% | 131 | 0.0% | 0.004 | 0.002 |
| Encounter for Other Psychiatric Event ⁶ | 139,348 | 48.5% | 132,087 | 47.9% | 0.666 | 0.013 |
| Asthma Emergency Encounter | 20,723 | 7.2% | 19,724 | 7.1% | 0.070 | 0.003 |
| Asthma Inpatient Encounter | 898 | 0.3% | 879 | 0.3% | -0.006 | -0.001 |
| Asthma Outpatient Encounter | 275,111 | 95.8% | 265,254 | 96.1% | -0.308 | -0.016 |
| Oral Corticosteroid Dispensing | 88,179 | 30.7% | 83,212 | 30.2% | 0.556 | 0.012 |
| Use of Other Asthma Medication | 137,269 | 47.8% | 136,575 | 49.5% | -1.684 | -0.034 |
| Allergic Rhinitis | 122,683 | 42.7% | 110,480 | 40.0% | 2.692 | 0.055 |
| Anxiety | 55,351 | 19.3% | 52,304 | 19.0% | 0.323 | 0.008 |
| Depression | 51,035 | 17.8% | 48,396 | 17.5% | 0.236 | 0.006 |
| Sleep Disorder | 70,131 | 24.4% | 66,019 | 23.9% | 0.501 | 0.012 |
| Substance Abuse | 8,347 | 2.9% | 7,886 | 2.9% | 0.049 | 0.003 |
| Poisoning | 142 | 0.0% | 131 | 0.0% | 0.002 | 0.001 |

Table 1bt. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Suffocation | 1 | 0.0% | 0 | 0.0% | NaN | NaN |
| Suicide Attempt | 80 | 0.0% | 59 | 0.0% | 0.006 | 0.004 |
| Toxicity | 31 | 0.0% | 17 | 0.0% | 0.005 | 0.005 |
| Other Self Harm | 36 | 0.0% | 28 | 0.0% | 0.002 | 0.002 |
| No moderate asthma exacerbations | 239,080 | 83.3% | 230,505 | 83.5% | -0.265 | -0.007 |
| One moderate asthma exacerbation | 41,496 | 14.5% | 39,602 | 14.4% | 0.101 | 0.003 |
| Two or more moderate asthma | 6,568 | 2.3% | 5,861 | 2.1% | 0.164 | 0.011 |
| No severe asthma exacerbations | 284,225 | 99.0% | 273,105 | 99.0% | 0.021 | 0.002 |
| One severe asthma exacerbation | 2,836 | 1.0% | 2,787 | 1.0% | -0.022 | -0.002 |
| Two or more severe asthma exacerbations | 83 | 0.0% | 76 | 0.0% | 0.001 | 0.001 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 75,951 | 26.5% | 71,700 | 26.0% | 0.469 | 0.011 |
| Antipsychotics | 10,759 | 3.7% | 10,510 | 3.8% | -0.062 | -0.003 |
| Anxiolytics Hypnotics | 67,400 | 23.5% | 64,006 | 23.2% | 0.279 | 0.007 |
| Lithium Other Mood Stabilizers | 15,368 | 5.4% | 14,964 | 5.4% | -0.070 | -0.003 |
| Antidepressants | 96,581 | 33.6% | 92,016 | 33.3% | 0.292 | 0.006 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 13.3 | 12.3 | 13.3 | 11.7 | -0.044 | -0.004 |
| Mean number of emergency room | 0.3 | 0.9 | 0.3 | 0.9 | 0.001 | 0.001 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.000 | -0.000 |
| Mean number of other ambulatory encounters | 3.0 | 7.8 | 3.1 | 8.1 | -0.043 | -0.005 |
| Mean number of filled prescriptions | 19.8 | 15.5 | 19.8 | 15.3 | -0.022 | -0.001 |
| Mean number of generics dispensed | 9.7 | 5.1 | 9.6 | 5.2 | 0.092 | 0.018 |
| Mean number of unique drug classes dispensed | 9.2 | 4.6 | 9.1 | 4.6 | 0.070 | 0.015 |

Table 1bt. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 Years

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of inpatient visits for respiratory disorders | 0.1 | 0.3 | 0.1 | 0.3 | -0.001 | -0.003 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.000 | -0.001 |
| Mean number of outpatient visits for respiratory disorders | 2.7 | 3.7 | 2.7 | 3.8 | 0.022 | 0.006 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1bu. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 366,756 | 100.0% | 484,391 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 39.7 | 15.7 | 32.9 | 15.9 | 6.757 | 0.429 |
| Age | | | | | | |
| 10-24 years | 139,281 | 38.0% | 252,748 | 52.2% | -14.202 | -0.288 |
| 25-54 years | 113,795 | 31.0% | 126,287 | 26.1% | 4.956 | 0.110 |
| ≥ 55 years | 113,680 | 31.0% | 105,356 | 21.8% | 9.246 | 0.211 |
| Sex | | | | | | |
| Female | 219,961 | 60.0% | 273,753 | 56.5% | 3.460 | 0.070 |
| Male | 146,795 | 40.0% | 210,638 | 43.5% | -3.460 | -0.070 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 2,125 | 0.6% | 3,847 | 0.8% | -0.215 | -0.026 |
| Asian | 10,460 | 2.9% | 13,781 | 2.8% | 0.007 | 0.000 |
| Black or African American | 40,995 | 11.2% | 63,077 | 13.0% | -1.844 | -0.057 |
| Multi-racial | 1,061 | 0.3% | 1,120 | 0.2% | 0.058 | 0.011 |
| Native Hawaiian or Other Pacific Islander | 795 | 0.2% | 2,164 | 0.4% | -0.230 | -0.040 |
| Unknown | 213,063 | 58.1% | 282,638 | 58.3% | -0.255 | -0.005 |
| White | 98,257 | 26.8% | 117,764 | 24.3% | 2.479 | 0.057 |
| Hispanic origin | | | | | | |
| Yes | 38,389 | 10.5% | 73,527 | 15.2% | -4.712 | -0.141 |
| No | 141,924 | 38.7% | 189,967 | 39.2% | -0.521 | -0.011 |
| Unknown | 186,443 | 50.8% | 220,897 | 45.6% | 5.233 | 0.105 |
| Year | | | | | | |
| 2015 | 15,456 | 4.2% | 25,241 | 5.2% | -0.997 | -0.047 |
| 2016 | 73,028 | 19.9% | 113,667 | 23.5% | -3.554 | -0.086 |
| 2017 | 84,999 | 23.2% | 130,717 | 27.0% | -3.810 | -0.088 |
| 2018 | 79,850 | 21.8% | 108,392 | 22.4% | -0.605 | -0.015 |
| 2019 | 40,339 | 11.0% | 35,999 | 7.4% | 3.567 | 0.124 |
| 2020 | 34,053 | 9.3% | 32,400 | 6.7% | 2.596 | 0.096 |

Table 1bu. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2021 | 29,079 | 7.9% | 27,760 | 5.7% | 2.198 | 0.087 |
| 2022 | 9,952 | 2.7% | 10,215 | 2.1% | 0.605 | 0.039 |
| Pre-boxed warning | 300,131 | 81.8% | 420,266 | 86.8% | -4.928 | -0.136 |
| Post-boxed warning | 66,625 | 18.2% | 64,125 | 13.2% | 4.928 | 0.136 |
| Seasonality | | | | | | |
| Winter | 84,483 | 23.0% | 122,437 | 25.3% | -2.241 | -0.052 |
| Spring | 101,542 | 27.7% | 107,562 | 22.2% | 5.481 | 0.127 |
| Summer | 81,177 | 22.1% | 103,540 | 21.4% | 0.758 | 0.018 |
| Autumn | 99,554 | 27.1% | 150,852 | 31.1% | -3.998 | -0.088 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.2 | 1.0 | 1.1 | 0.8 | 0.030 | 0.033 |
| Psychiatric History | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Psychiatric Drug Dispensings ⁵ | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Self Harm Encounter ⁵ | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Encounter for Other Psychiatric Event ⁵ | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Asthma Emergency Encounter | 29,345 | 8.0% | 48,926 | 10.1% | -2.099 | -0.073 |
| Asthma Inpatient Encounter | 762 | 0.2% | 1,157 | 0.2% | -0.031 | -0.007 |
| Asthma Outpatient Encounter | 356,966 | 97.3% | 472,199 | 97.5% | -0.152 | -0.010 |
| Oral Corticosteroid Dispensing | 86,673 | 23.6% | 108,718 | 22.4% | 1.188 | 0.028 |
| Use of Other Asthma Medication | 240,264 | 65.5% | 387,216 | 79.9% | -14.428 | -0.328 |
| Allergic Rhinitis | 159,611 | 43.5% | 118,967 | 24.6% | 18.960 | 0.408 |
| Anxiety | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Depression | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Sleep Disorder | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Substance Abuse | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Poisoning | 182 | 0.0% | 337 | 0.1% | -0.020 | -0.008 |
| Suffocation | 3 | 0.0% | 6 | 0.0% | -0.000 | -0.001 |
| Suicide Attempt | 95 | 0.0% | 152 | 0.0% | -0.005 | -0.003 |

Table 1bu. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Toxicity | 19 | 0.0% | 26 | 0.0% | -0.000 | -0.000 |
| Other Self Harm | 46 | 0.0% | 60 | 0.0% | 0.000 | 0.000 |
| No moderate asthma exacerbations | 315,935 | 86.1% | 412,779 | 85.2% | 0.927 | 0.026 |
| One moderate asthma exacerbation | 45,527 | 12.4% | 64,410 | 13.3% | -0.884 | -0.026 |
| Two or more moderate asthma | 5,294 | 1.4% | 7,202 | 1.5% | -0.043 | -0.004 |
| No severe asthma exacerbations | 365,007 | 99.5% | 481,260 | 99.4% | 0.169 | 0.023 |
| One severe asthma exacerbation | 1,706 | 0.5% | 3,089 | 0.6% | -0.173 | -0.023 |
| Two or more severe asthma exacerbations | 43 | 0.0% | 42 | 0.0% | 0.003 | 0.003 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 38,221 | 10.4% | 42,767 | 8.8% | 1.592 | 0.054 |
| Antipsychotics | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Anxiolytics Hypnotics | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Lithium Other Mood Stabilizers | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Antidepressants | 78 | 0.0% | 129 | 0.0% | -0.005 | -0.003 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 6.7 | 7.3 | 5.9 | 6.6 | 0.797 | 0.114 |
| Mean number of emergency room | 0.3 | 0.7 | 0.3 | 0.8 | -0.053 | -0.072 |
| Mean number of inpatient hospital encounters | 0.0 | 0.2 | 0.0 | 0.2 | -0.000 | -0.001 |
| Mean number of other ambulatory encounters | 1.2 | 4.3 | 1.3 | 5.0 | -0.049 | -0.010 |
| Mean number of filled prescriptions | 9.0 | 8.2 | 8.1 | 7.6 | 0.915 | 0.116 |
| Mean number of generics dispensed | 5.6 | 3.4 | 5.0 | 3.1 | 0.589 | 0.183 |
| Mean number of unique drug classes dispensed | 5.3 | 3.1 | 4.9 | 2.8 | 0.472 | 0.160 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.1 | 0.0 | 0.1 | -0.001 | -0.005 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.3 | 0.1 | 0.3 | -0.013 | -0.038 |

Table 1bu. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of outpatient visits for respiratory disorders | 2.0 | 3.0 | 1.5 | 2.6 | 0.451 | 0.160 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1bv. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 366,686 | N/A | 354,802 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 39.7 | 15.7 | 39.5 | 16.8 | 0.175 | 0.011 |
| Age | | | | | | |
| 10-24 years | 139,278 | 38.0% | 143,485 | 40.4% | -2.458 | -0.059 |
| 25-54 years | 113,786 | 31.0% | 96,077 | 27.1% | 3.952 | 0.092 |
| ≥ 55 years | 113,622 | 31.0% | 115,240 | 32.5% | -1.494 | -0.046 |
| Sex | | | | | | |
| Female | 219,913 | 60.0% | 211,219 | 59.5% | 0.441 | 0.009 |
| Male | 146,773 | 40.0% | 143,583 | 40.5% | -0.441 | -0.009 |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 2,125 | 0.6% | 2,214 | 0.6% | -0.045 | -0.006 |
| Asian | 10,453 | 2.9% | 8,979 | 2.5% | 0.320 | 0.020 |
| Black or African American | 40,984 | 11.2% | 35,872 | 10.1% | 1.066 | 0.036 |
| Multi-racial | 1,061 | 0.3% | 949 | 0.3% | 0.022 | 0.004 |
| Native Hawaiian or Other Pacific Islander | 794 | 0.2% | 1,175 | 0.3% | -0.115 | -0.022 |
| Unknown | 213,037 | 58.1% | 208,425 | 58.7% | -0.646 | -0.018 |
| White | 98,232 | 26.8% | 97,187 | 27.4% | -0.603 | -0.017 |
| Hispanic origin | | | | | | |
| Yes | 38,379 | 10.5% | 38,852 | 11.0% | -0.484 | -0.017 |
| No | 141,884 | 38.7% | 134,847 | 38.0% | 0.687 | 0.021 |
| Unknown | 186,423 | 50.8% | 181,103 | 51.0% | -0.204 | -0.008 |
| Year | | | | | | |
| 2015 | 15,455 | 4.2% | 15,582 | 4.4% | -0.177 | -0.009 |
| 2016 | 73,020 | 19.9% | 71,971 | 20.3% | -0.371 | -0.009 |
| 2017 | 84,989 | 23.2% | 82,775 | 23.3% | -0.152 | -0.004 |
| 2018 | 79,838 | 21.8% | 76,338 | 21.5% | 0.257 | 0.006 |
| 2019 | 40,321 | 11.0% | 37,962 | 10.7% | 0.297 | 0.010 |

Table 1bv. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2020 | 34,046 | 9.3% | 32,836 | 9.3% | 0.030 | 0.001 |
| 2021 | 29,066 | 7.9% | 27,844 | 7.8% | 0.079 | 0.003 |
| 2022 | 9,951 | 2.7% | 9,494 | 2.7% | 0.038 | 0.002 |
| Pre-boxed warning | 300,079 | 81.8% | 290,733 | 81.9% | -0.107 | -0.003 |
| Post-boxed warning | 66,607 | 18.2% | 64,069 | 18.1% | 0.107 | 0.003 |
| Seasonality | | | | | | |
| Winter | 84,467 | 23.0% | 82,701 | 23.3% | -0.274 | -0.007 |
| Spring | 101,513 | 27.7% | 95,640 | 27.0% | 0.728 | 0.016 |
| Summer | 81,163 | 22.1% | 78,589 | 22.2% | -0.016 | -0.000 |
| Autumn | 99,543 | 27.1% | 97,871 | 27.6% | -0.438 | -0.010 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.2 | 1.0 | 1.2 | 1.0 | -0.002 | -0.002 |
| Psychiatric History | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Psychiatric Drug Dispensings ⁶ | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Self Harm Encounter ⁶ | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Encounter for Other Psychiatric Event ⁶ | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Asthma Emergency Encounter | 29,337 | 8.0% | 28,511 | 8.0% | -0.035 | -0.001 |
| Asthma Inpatient Encounter | 760 | 0.2% | 742 | 0.2% | -0.002 | -0.000 |
| Asthma Outpatient Encounter | 356,905 | 97.3% | 345,906 | 97.5% | -0.160 | -0.010 |
| Oral Corticosteroid Dispensing | 86,635 | 23.6% | 82,937 | 23.4% | 0.251 | 0.006 |
| Use of Other Asthma Medication | 240,244 | 65.5% | 238,054 | 67.1% | -1.577 | -0.035 |
| Allergic Rhinitis | 159,549 | 43.5% | 146,303 | 41.2% | 2.276 | 0.046 |
| Anxiety | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Depression | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Sleep Disorder | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Substance Abuse | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Poisoning | 182 | 0.0% | 190 | 0.1% | -0.004 | -0.002 |

Table 1bv. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Suffocation | 3 | 0.0% | 3 | 0.0% | -0.000 | -0.000 |
| Suicide Attempt | 95 | 0.0% | 83 | 0.0% | 0.002 | 0.002 |
| Toxicity | 19 | 0.0% | 15 | 0.0% | 0.001 | 0.001 |
| Other Self Harm | 46 | 0.0% | 34 | 0.0% | 0.003 | 0.003 |
| No moderate asthma exacerbations | 315,886 | 86.1% | 303,776 | 85.6% | 0.528 | 0.015 |
| One moderate asthma exacerbation | 45,509 | 12.4% | 45,704 | 12.9% | -0.471 | -0.014 |
| Two or more moderate asthma | 5,291 | 1.4% | 5,323 | 1.5% | -0.057 | -0.005 |
| No severe asthma exacerbations | 364,941 | 99.5% | 353,047 | 99.5% | 0.019 | 0.003 |
| One severe asthma exacerbation | 1,706 | 0.5% | 1,721 | 0.5% | -0.020 | -0.003 |
| Two or more severe asthma exacerbations | 39 | 0.0% | 34 | 0.0% | 0.001 | 0.001 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 38,192 | 10.4% | 36,427 | 10.3% | 0.149 | 0.005 |
| Antipsychotics | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Anxiolytics Hypnotics | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Lithium Other Mood Stabilizers | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Antidepressants | 76 | 0.0% | 69 | 0.0% | 0.001 | 0.001 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 6.7 | 7.3 | 6.7 | 6.9 | -0.001 | -0.000 |
| Mean number of emergency room | 0.3 | 0.7 | 0.3 | 0.7 | -0.001 | -0.001 |
| Mean number of inpatient hospital encounters | 0.0 | 0.2 | 0.0 | 0.2 | -0.000 | -0.001 |
| Mean number of other ambulatory encounters | 1.2 | 4.3 | 1.3 | 4.4 | -0.041 | -0.009 |
| Mean number of filled prescriptions | 9.0 | 8.1 | 8.9 | 7.9 | 0.065 | 0.008 |
| Mean number of generics dispensed | 5.6 | 3.4 | 5.5 | 3.4 | 0.076 | 0.022 |
| Mean number of unique drug classes dispensed | 5.3 | 3.1 | 5.3 | 3.1 | 0.061 | 0.020 |

Table 1bv. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.1 | 0.0 | 0.1 | -0.000 | -0.002 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.3 | 0.1 | 0.3 | -0.000 | -0.001 |
| Mean number of outpatient visits for respiratory disorders | 2.0 | 3.0 | 1.9 | 3.0 | 0.026 | 0.009 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1bw. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 385,474 | 100.0% | 438,966 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 49.4 | 15.5 | 43.0 | 16.6 | 6.402 | 0.399 |
| Age | | | | | | |
| 10-24 years | 68,585 | 17.8% | 123,121 | 28.0% | -10.256 | -0.246 |
| 25-54 years | 143,341 | 37.2% | 168,135 | 38.3% | -1.117 | -0.023 |
| ≥ 55 years | 173,548 | 45.0% | 147,710 | 33.6% | 11.372 | 0.234 |
| Sex | | | | | | |
| Female | 277,016 | 71.9% | 294,831 | 67.2% | 4.699 | 0.102 |
| Male | 108,458 | 28.1% | 144,135 | 32.8% | -4.699 | -0.102 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 2,516 | 0.7% | 4,047 | 0.9% | -0.269 | -0.030 |
| Asian | 5,532 | 1.4% | 5,900 | 1.3% | 0.091 | 0.008 |
| Black or African American | 40,721 | 10.6% | 53,690 | 12.2% | -1.667 | -0.052 |
| Multi-racial | 851 | 0.2% | 848 | 0.2% | 0.028 | 0.006 |
| Native Hawaiian or Other Pacific Islander | 553 | 0.1% | 1,071 | 0.2% | -0.101 | -0.023 |
| Unknown | 165,544 | 42.9% | 190,898 | 43.5% | -0.543 | -0.011 |
| White | 169,757 | 44.0% | 182,512 | 41.6% | 2.461 | 0.050 |
| Hispanic origin | | | | | | |
| Yes | 23,630 | 6.1% | 40,953 | 9.3% | -3.199 | -0.120 |
| No | 207,436 | 53.8% | 236,965 | 54.0% | -0.169 | -0.003 |
| Unknown | 154,408 | 40.1% | 161,048 | 36.7% | 3.369 | 0.069 |
| Year | | | | | | |
| 2015 | 13,684 | 3.5% | 21,445 | 4.9% | -1.335 | -0.066 |
| 2016 | 68,958 | 17.9% | 96,341 | 21.9% | -4.058 | -0.102 |
| 2017 | 79,065 | 20.5% | 107,580 | 24.5% | -3.996 | -0.096 |
| 2018 | 76,708 | 19.9% | 94,003 | 21.4% | -1.515 | -0.037 |
| 2019 | 50,432 | 13.1% | 38,738 | 8.8% | 4.258 | 0.137 |
| 2020 | 43,904 | 11.4% | 36,660 | 8.4% | 3.038 | 0.102 |

Table 1bw. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2021 | 40,366 | 10.5% | 33,298 | 7.6% | 2.886 | 0.101 |
| 2022 | 12,357 | 3.2% | 10,901 | 2.5% | 0.722 | 0.043 |
| Pre-boxed warning | 296,859 | 77.0% | 364,733 | 83.1% | -6.078 | -0.153 |
| Post-boxed warning | 88,615 | 23.0% | 74,233 | 16.9% | 6.078 | 0.153 |
| Seasonality | | | | | | |
| Winter | 89,972 | 23.3% | 110,212 | 25.1% | -1.767 | -0.041 |
| Spring | 108,041 | 28.0% | 99,094 | 22.6% | 5.454 | 0.126 |
| Summer | 85,587 | 22.2% | 95,510 | 21.8% | 0.445 | 0.011 |
| Autumn | 101,874 | 26.4% | 134,150 | 30.6% | -4.132 | -0.092 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.9 | 1.8 | 1.9 | 1.6 | 0.066 | 0.039 |
| Psychiatric History | 385,474 | 100.0% | 438,966 | 100.0% | 0.000 | NaN |
| Psychiatric Drug Dispensings ⁵ | 281,045 | 72.9% | 312,136 | 71.1% | 1.802 | 0.040 |
| Self Harm Encounter ⁵ | 1,394 | 0.4% | 2,455 | 0.6% | -0.198 | -0.029 |
| Encounter for Other Psychiatric Event ⁵ | 320,270 | 83.1% | 369,493 | 84.2% | -1.089 | -0.029 |
| Asthma Emergency Encounter | 47,151 | 12.2% | 61,564 | 14.0% | -1.793 | -0.053 |
| Asthma Inpatient Encounter | 1,489 | 0.4% | 1,748 | 0.4% | -0.012 | -0.002 |
| Asthma Outpatient Encounter | 363,681 | 94.3% | 416,091 | 94.8% | -0.442 | -0.020 |
| Oral Corticosteroid Dispensing | 122,107 | 31.7% | 125,095 | 28.5% | 3.179 | 0.069 |
| Use of Other Asthma Medication | 225,167 | 58.4% | 336,222 | 76.6% | -18.181 | -0.396 |
| Allergic Rhinitis | 164,732 | 42.7% | 95,462 | 21.7% | 20.988 | 0.461 |
| Anxiety | 136,634 | 35.4% | 150,455 | 34.3% | 1.171 | 0.025 |
| Depression | 110,424 | 28.6% | 126,090 | 28.7% | -0.078 | -0.002 |
| Sleep Disorder | 115,489 | 30.0% | 101,040 | 23.0% | 6.943 | 0.158 |
| Substance Abuse | 24,457 | 6.3% | 39,317 | 9.0% | -2.612 | -0.098 |
| Poisoning | 1,136 | 0.3% | 2,133 | 0.5% | -0.191 | -0.031 |
| Suffocation | 27 | 0.0% | 40 | 0.0% | -0.002 | -0.002 |
| Suicide Attempt | 637 | 0.2% | 1,098 | 0.3% | -0.085 | -0.019 |

Table 1bw. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Toxicity | 137 | 0.0% | 249 | 0.1% | -0.021 | -0.010 |
| Other Self Harm | 340 | 0.1% | 570 | 0.1% | -0.042 | -0.013 |
| No moderate asthma exacerbations | 320,185 | 83.1% | 366,478 | 83.5% | -0.424 | -0.011 |
| One moderate asthma exacerbation | 56,716 | 14.7% | 63,709 | 14.5% | 0.200 | 0.006 |
| Two or more moderate asthma | 8,573 | 2.2% | 8,779 | 2.0% | 0.224 | 0.016 |
| No severe asthma exacerbations | 381,002 | 98.8% | 433,116 | 98.7% | 0.173 | 0.016 |
| One severe asthma exacerbation | 4,266 | 1.1% | 5,646 | 1.3% | -0.180 | -0.017 |
| Two or more severe asthma exacerbations | 206 | 0.1% | 204 | 0.0% | 0.007 | 0.003 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 110,833 | 28.8% | 115,165 | 26.2% | 2.517 | 0.056 |
| Antipsychotics | 34,673 | 9.0% | 52,333 | 11.9% | -2.927 | -0.096 |
| Anxiolytics Hypnotics | 135,137 | 35.1% | 136,945 | 31.2% | 3.860 | 0.082 |
| Lithium Other Mood Stabilizers | 40,602 | 10.5% | 51,582 | 11.8% | -1.218 | -0.039 |
| Antidepressants | 196,466 | 51.0% | 213,283 | 48.6% | 2.380 | 0.048 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 13.5 | 12.9 | 13.2 | 13.8 | 0.236 | 0.018 |
| Mean number of emergency room | 0.6 | 1.5 | 0.7 | 1.7 | -0.128 | -0.080 |
| Mean number of inpatient hospital encounters | 0.1 | 0.5 | 0.1 | 0.5 | -0.008 | -0.016 |
| Mean number of other ambulatory encounters | 4.1 | 11.8 | 5.5 | 16.2 | -1.452 | -0.102 |
| Mean number of filled prescriptions | 20.6 | 16.8 | 20.5 | 17.8 | 0.183 | 0.011 |
| Mean number of generics dispensed | 9.9 | 5.4 | 9.2 | 5.2 | 0.703 | 0.133 |
| Mean number of unique drug classes dispensed | 9.3 | 4.8 | 8.8 | 4.7 | 0.548 | 0.116 |
| Mean number of inpatient visits for respiratory disorders | 0.1 | 0.3 | 0.1 | 0.3 | -0.003 | -0.010 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.5 | 0.2 | 0.5 | -0.016 | -0.033 |

Table 1bw. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of outpatient visits for respiratory disorders | 2.5 | 3.5 | 1.9 | 3.0 | 0.603 | 0.185 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1bx. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 385,425 | N/A | 369,811 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 49.4 | 15.5 | 49.3 | 16.4 | 0.138 | 0.009 |
| Age | | | | | | |
| 10-24 years | 68,584 | 17.8% | 72,762 | 19.7% | -1.881 | -0.055 |
| 25-54 years | 143,321 | 37.2% | 127,026 | 34.3% | 2.836 | 0.062 |
| ≥ 55 years | 173,520 | 45.0% | 170,022 | 46.0% | -0.955 | -0.024 |
| Sex | | | | | | |
| Female | 276,972 | 71.9% | 264,456 | 71.5% | 0.350 | 0.008 |
| Male | 108,453 | 28.1% | 105,354 | 28.5% | -0.350 | -0.008 |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 2,516 | 0.7% | 2,519 | 0.7% | -0.028 | -0.003 |
| Asian | 5,530 | 1.4% | 4,531 | 1.2% | 0.210 | 0.018 |
| Black or African American | 40,710 | 10.6% | 36,082 | 9.8% | 0.806 | 0.027 |
| Multi-racial | 851 | 0.2% | 815 | 0.2% | 0.000 | 0.000 |
| Native Hawaiian or Other Pacific Islander | 553 | 0.1% | 626 | 0.2% | -0.026 | -0.007 |
| Unknown | 165,527 | 42.9% | 160,401 | 43.4% | -0.427 | -0.013 |
| White | 169,738 | 44.0% | 164,838 | 44.6% | -0.534 | -0.014 |
| Hispanic origin | | | | | | |
| Yes | 23,627 | 6.1% | 23,383 | 6.3% | -0.193 | -0.008 |
| No | 207,407 | 53.8% | 197,205 | 53.3% | 0.487 | 0.017 |
| Unknown | 154,391 | 40.1% | 149,222 | 40.4% | -0.294 | -0.013 |
| Year | | | | | | |
| 2015 | 13,683 | 3.6% | 13,932 | 3.8% | -0.217 | -0.012 |
| 2016 | 68,954 | 17.9% | 67,869 | 18.4% | -0.462 | -0.012 |
| 2017 | 79,058 | 20.5% | 76,443 | 20.7% | -0.159 | -0.004 |
| 2018 | 76,696 | 19.9% | 72,842 | 19.7% | 0.202 | 0.005 |
| 2019 | 50,418 | 13.1% | 46,756 | 12.6% | 0.438 | 0.013 |

Table 1bx. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2020 | 43,897 | 11.4% | 41,723 | 11.3% | 0.107 | 0.003 |
| 2021 | 40,362 | 10.5% | 38,470 | 10.4% | 0.069 | 0.002 |
| 2022 | 12,357 | 3.2% | 11,777 | 3.2% | 0.022 | 0.001 |
| Pre-boxed warning | 296,821 | 77.0% | 285,298 | 77.1% | -0.136 | -0.003 |
| Post-boxed warning | 88,604 | 23.0% | 84,513 | 22.9% | 0.136 | 0.003 |
| Seasonality | | | | | | |
| Winter | 89,966 | 23.3% | 87,281 | 23.6% | -0.259 | -0.006 |
| Spring | 108,014 | 28.0% | 100,760 | 27.2% | 0.778 | 0.017 |
| Summer | 85,578 | 22.2% | 82,227 | 22.2% | -0.031 | -0.001 |
| Autumn | 101,867 | 26.4% | 99,543 | 26.9% | -0.487 | -0.011 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.9 | 1.8 | 1.9 | 1.7 | -0.003 | -0.002 |
| Psychiatric History | 385,425 | 100.0% | 369,811 | 100.0% | 0.000 | NaN |
| Psychiatric Drug Dispensings ⁶ | 281,003 | 72.9% | 269,059 | 72.8% | 0.151 | 0.003 |
| Self Harm Encounter ⁶ | 1,394 | 0.4% | 1,361 | 0.4% | -0.006 | -0.001 |
| Encounter for Other Psychiatric Event ⁶ | 320,225 | 83.1% | 306,597 | 82.9% | 0.177 | 0.005 |
| Asthma Emergency Encounter | 47,138 | 12.2% | 44,814 | 12.1% | 0.112 | 0.003 |
| Asthma Inpatient Encounter | 1,489 | 0.4% | 1,492 | 0.4% | -0.017 | -0.003 |
| Asthma Outpatient Encounter | 363,647 | 94.3% | 350,445 | 94.8% | -0.414 | -0.018 |
| Oral Corticosteroid Dispensing | 122,080 | 31.7% | 115,713 | 31.3% | 0.384 | 0.008 |
| Use of Other Asthma Medication | 225,162 | 58.4% | 223,882 | 60.5% | -2.121 | -0.045 |
| Allergic Rhinitis | 164,688 | 42.7% | 147,826 | 40.0% | 2.755 | 0.056 |
| Anxiety | 136,604 | 35.4% | 130,356 | 35.2% | 0.193 | 0.004 |
| Depression | 110,400 | 28.6% | 105,643 | 28.6% | 0.077 | 0.002 |
| Sleep Disorder | 115,466 | 30.0% | 109,056 | 29.5% | 0.468 | 0.011 |
| Substance Abuse | 24,451 | 6.3% | 23,727 | 6.4% | -0.072 | -0.003 |
| Poisoning | 1,135 | 0.3% | 1,218 | 0.3% | -0.035 | -0.006 |

Table 1bx. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Suffocation | 27 | 0.0% | 18 | 0.0% | 0.002 | 0.003 |
| Suicide Attempt | 637 | 0.2% | 644 | 0.2% | -0.009 | -0.002 |
| Toxicity | 136 | 0.0% | 139 | 0.0% | -0.002 | -0.001 |
| Other Self Harm | 340 | 0.1% | 363 | 0.1% | -0.010 | -0.003 |
| No moderate asthma exacerbations | 320,144 | 83.1% | 306,651 | 82.9% | 0.141 | 0.004 |
| One moderate asthma exacerbation | 56,708 | 14.7% | 55,212 | 14.9% | -0.217 | -0.006 |
| Two or more moderate asthma | 8,573 | 2.2% | 7,948 | 2.1% | 0.075 | 0.005 |
| No severe asthma exacerbations | 380,954 | 98.8% | 365,309 | 98.8% | 0.057 | 0.005 |
| One severe asthma exacerbation | 4,265 | 1.1% | 4,301 | 1.2% | -0.056 | -0.005 |
| Two or more severe asthma exacerbations | 206 | 0.1% | 201 | 0.1% | -0.001 | -0.000 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 110,804 | 28.7% | 104,621 | 28.3% | 0.458 | 0.010 |
| Antipsychotics | 34,667 | 9.0% | 33,850 | 9.2% | -0.159 | -0.006 |
| Anxiolytics Hypnotics | 135,104 | 35.1% | 128,691 | 34.8% | 0.254 | 0.005 |
| Lithium Other Mood Stabilizers | 40,594 | 10.5% | 39,455 | 10.7% | -0.137 | -0.004 |
| Antidepressants | 196,435 | 51.0% | 187,926 | 50.8% | 0.149 | 0.003 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 13.5 | 12.9 | 13.6 | 12.4 | -0.101 | -0.008 |
| Mean number of emergency room | 0.6 | 1.5 | 0.6 | 1.5 | -0.005 | -0.003 |
| Mean number of inpatient hospital encounters | 0.1 | 0.5 | 0.1 | 0.5 | -0.002 | -0.003 |
| Mean number of other ambulatory encounters | 4.1 | 11.8 | 4.4 | 12.6 | -0.285 | -0.023 |
| Mean number of filled prescriptions | 20.6 | 16.8 | 20.7 | 16.5 | -0.046 | -0.003 |
| Mean number of generics dispensed | 9.9 | 5.4 | 9.8 | 5.4 | 0.081 | 0.015 |
| Mean number of unique drug classes dispensed | 9.3 | 4.8 | 9.2 | 4.8 | 0.057 | 0.012 |

Table 1bx. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of inpatient visits for respiratory disorders | 0.1 | 0.3 | 0.1 | 0.3 | -0.002 | -0.006 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.5 | 0.1 | 0.5 | -0.001 | -0.003 |
| Mean number of outpatient visits for respiratory disorders | 2.5 | 3.5 | 2.5 | 3.5 | 0.026 | 0.007 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1by. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 596,990 | 100.0% | 784,999 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 42.6 | 15.8 | 36.0 | 16.4 | 6.539 | 0.406 |
| Age | | | | | | |
| 10-24 years | 187,871 | 31.5% | 343,756 | 43.8% | -12.321 | -0.256 |
| 25-54 years | 201,267 | 33.7% | 246,921 | 31.5% | 2.259 | 0.048 |
| ≥ 55 years | 207,852 | 34.8% | 194,322 | 24.8% | 10.062 | 0.221 |
| Sex | | | | | | |
| Female | 390,634 | 65.4% | 479,430 | 61.1% | 4.360 | 0.091 |
| Male | 206,356 | 34.6% | 305,569 | 38.9% | -4.360 | -0.091 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 4,135 | 0.7% | 7,518 | 1.0% | -0.265 | -0.029 |
| Asian | 13,699 | 2.3% | 18,066 | 2.3% | -0.007 | -0.000 |
| Black or African American | 71,428 | 12.0% | 109,890 | 14.0% | -2.034 | -0.061 |
| Multi-racial | 1,256 | 0.2% | 1,185 | 0.2% | 0.059 | 0.014 |
| Native Hawaiian or Other Pacific Islander | 1,168 | 0.2% | 3,122 | 0.4% | -0.202 | -0.037 |
| Unknown | 294,656 | 49.4% | 389,087 | 49.6% | -0.208 | -0.004 |
| White | 210,648 | 35.3% | 256,131 | 32.6% | 2.657 | 0.056 |
| Hispanic origin | | | | | | |
| Yes | 58,337 | 9.8% | 111,480 | 14.2% | -4.429 | -0.137 |
| No | 287,383 | 48.1% | 382,024 | 48.7% | -0.527 | -0.011 |
| Unknown | 251,270 | 42.1% | 291,495 | 37.1% | 4.956 | 0.101 |
| Year | | | | | | |
| 2015 | 29,140 | 4.9% | 46,686 | 5.9% | -1.066 | -0.047 |
| 2016 | 141,986 | 23.8% | 210,008 | 26.8% | -2.969 | -0.068 |
| 2017 | 164,064 | 27.5% | 238,297 | 30.4% | -2.874 | -0.063 |
| 2018 | 156,558 | 26.2% | 202,395 | 25.8% | 0.442 | 0.010 |
| 2019 | 90,771 | 15.2% | 74,737 | 9.5% | 5.684 | 0.173 |
| 2020 | 14,471 | 2.4% | 12,876 | 1.6% | 0.784 | 0.056 |
| 2021 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |

Table 1by. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2022 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Pre-boxed warning | 596,990 | 100.0% | 784,999 | 100.0% | 0.000 | NaN |
| Post-boxed warning | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Seasonality | | | | | | |
| Winter | 138,406 | 23.2% | 196,454 | 25.0% | -1.842 | -0.043 |
| Spring | 158,758 | 26.6% | 168,462 | 21.5% | 5.133 | 0.120 |
| Summer | 132,488 | 22.2% | 168,714 | 21.5% | 0.700 | 0.017 |
| Autumn | 167,338 | 28.0% | 251,369 | 32.0% | -3.991 | -0.087 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.5 | 1.4 | 1.5 | 1.2 | 0.065 | 0.049 |
| Psychiatric History | 296,859 | 49.7% | 364,733 | 46.5% | 3.263 | 0.065 |
| Psychiatric Drug Dispensings ⁵ | 216,728 | 36.3% | 258,762 | 33.0% | 3.340 | 0.070 |
| Self Harm Encounter ⁵ | 1,227 | 0.2% | 2,239 | 0.3% | -0.080 | -0.016 |
| Encounter for Other Psychiatric Event ⁵ | 244,506 | 41.0% | 305,675 | 38.9% | 2.017 | 0.041 |
| Asthma Emergency Encounter | 64,316 | 10.8% | 98,902 | 12.6% | -1.826 | -0.057 |
| Asthma Inpatient Encounter | 2,005 | 0.3% | 2,707 | 0.3% | -0.009 | -0.002 |
| Asthma Outpatient Encounter | 570,651 | 95.6% | 753,867 | 96.0% | -0.446 | -0.022 |
| Oral Corticosteroid Dispensing | 168,292 | 28.2% | 200,637 | 25.6% | 2.631 | 0.059 |
| Use of Other Asthma Medication | 379,039 | 63.5% | 626,813 | 79.8% | -16.357 | -0.369 |
| Allergic Rhinitis | 255,187 | 42.7% | 178,386 | 22.7% | 20.021 | 0.437 |
| Anxiety | 100,202 | 16.8% | 119,297 | 15.2% | 1.587 | 0.043 |
| Depression | 83,175 | 13.9% | 103,037 | 13.1% | 0.807 | 0.024 |
| Sleep Disorder | 83,138 | 13.9% | 77,669 | 9.9% | 4.032 | 0.125 |
| Substance Abuse | 19,266 | 3.2% | 34,153 | 4.4% | -1.124 | -0.059 |
| Poisoning | 1,163 | 0.2% | 2,286 | 0.3% | -0.096 | -0.020 |
| Suffocation | 24 | 0.0% | 43 | 0.0% | -0.001 | -0.002 |
| Suicide Attempt | 643 | 0.1% | 1,134 | 0.1% | -0.037 | -0.010 |
| Toxicity | 138 | 0.0% | 255 | 0.0% | -0.009 | -0.006 |

Table 1by. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Other Self Harm | 322 | 0.1% | 544 | 0.1% | -0.015 | -0.006 |
| No moderate asthma exacerbations | 500,038 | 83.8% | 657,176 | 83.7% | 0.043 | 0.001 |
| One moderate asthma exacerbation | 85,297 | 14.3% | 113,517 | 14.5% | -0.173 | -0.005 |
| Two or more moderate asthma | 11,655 | 2.0% | 14,306 | 1.8% | 0.130 | 0.010 |
| No severe asthma exacerbations | 591,637 | 99.1% | 776,884 | 99.0% | 0.137 | 0.014 |
| One severe asthma exacerbation | 5,137 | 0.9% | 7,895 | 1.0% | -0.145 | -0.015 |
| Two or more severe asthma exacerbations | 216 | 0.0% | 220 | 0.0% | 0.008 | 0.005 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 121,052 | 20.3% | 137,373 | 17.5% | 2.777 | 0.071 |
| Antipsychotics | 27,907 | 4.7% | 45,143 | 5.8% | -1.076 | -0.048 |
| Anxiolytics Hypnotics | 104,857 | 17.6% | 113,663 | 14.5% | 3.085 | 0.084 |
| Lithium Other Mood Stabilizers | 32,398 | 5.4% | 43,708 | 5.6% | -0.141 | -0.006 |
| Antidepressants | 148,648 | 24.9% | 173,833 | 22.1% | 2.755 | 0.065 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 10.0 | 10.9 | 9.3 | 11.2 | 0.773 | 0.070 |
| Mean number of emergency room | 0.5 | 1.2 | 0.5 | 1.4 | -0.077 | -0.060 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.000 | -0.001 |
| Mean number of other ambulatory encounters | 2.8 | 9.9 | 3.4 | 12.8 | -0.695 | -0.061 |
| Mean number of filled prescriptions | 15.0 | 14.4 | 13.9 | 14.6 | 1.015 | 0.070 |
| Mean number of generics dispensed | 7.8 | 4.9 | 7.0 | 4.6 | 0.793 | 0.167 |
| Mean number of unique drug classes dispensed | 7.3 | 4.4 | 6.7 | 4.2 | 0.639 | 0.149 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.000 | -0.000 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.010 | -0.024 |
| Mean number of outpatient visits for respiratory disorders | 2.3 | 3.3 | 1.7 | 2.7 | 0.587 | 0.195 |

Table 1by. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--------------------------------------|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| | | | | | | |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1bz. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ^{1,2} | Medical Product | | Covariate Balance | | | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 596,938 | N/A | 575,113 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 42.6 | 15.8 | 42.4 | 16.8 | 0.187 | 0.011 |
| Age | | | | | | |
| 10-24 years | 187,870 | 31.5% | 193,058 | 33.6% | -2.097 | -0.053 |
| 25-54 years | 201,256 | 33.7% | 175,542 | 30.5% | 3.192 | 0.071 |
| ≥ 55 years | 207,812 | 34.8% | 206,513 | 35.9% | -1.095 | -0.031 |
| Sex | | | | | | |
| Female | 390,591 | 65.4% | 373,616 | 65.0% | 0.469 | 0.010 |
| Male | 206,347 | 34.6% | 201,497 | 35.0% | -0.469 | -0.010 |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 4,135 | 0.7% | 4,323 | 0.8% | -0.059 | -0.007 |
| Asian | 13,697 | 2.3% | 11,627 | 2.0% | 0.273 | 0.019 |
| Black or African American | 71,421 | 12.0% | 63,873 | 11.1% | 0.858 | 0.028 |
| Multi-racial | 1,256 | 0.2% | 1,072 | 0.2% | 0.024 | 0.005 |
| Native Hawaiian or Other Pacific Islander | 1,168 | 0.2% | 1,649 | 0.3% | -0.091 | -0.019 |
| Unknown | 294,639 | 49.4% | 287,470 | 50.0% | -0.627 | -0.018 |
| White | 210,622 | 35.3% | 205,099 | 35.7% | -0.379 | -0.010 |
| Hispanic origin | | | | | | |
| Yes | 58,333 | 9.8% | 58,982 | 10.3% | -0.484 | -0.017 |
| No | 287,357 | 48.1% | 273,172 | 47.5% | 0.640 | 0.019 |
| Unknown | 251,248 | 42.1% | 242,959 | 42.2% | -0.156 | -0.006 |
| Year | | | | | | |
| 2015 | 29,139 | 4.9% | 29,441 | 5.1% | -0.238 | -0.011 |
| 2016 | 141,981 | 23.8% | 139,631 | 24.3% | -0.494 | -0.012 |
| 2017 | 164,055 | 27.5% | 159,054 | 27.7% | -0.173 | -0.004 |
| 2018 | 156,542 | 26.2% | 149,035 | 25.9% | 0.310 | 0.007 |
| 2019 | 90,751 | 15.2% | 84,426 | 14.7% | 0.523 | 0.015 |

Table 1bz. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2020 | 14,470 | 2.4% | 13,525 | 2.4% | 0.072 | 0.005 |
| 2021 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2022 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Pre-boxed warning | 596,938 | 100.0% | 575,113 | 100.0% | 0.000 | NaN |
| Post-boxed warning | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Seasonality | | | | | | |
| Winter | 138,398 | 23.2% | 134,605 | 23.4% | -0.220 | -0.005 |
| Spring | 158,733 | 26.6% | 148,771 | 25.9% | 0.723 | 0.016 |
| Summer | 132,477 | 22.2% | 127,664 | 22.2% | -0.005 | -0.000 |
| Autumn | 167,330 | 28.0% | 164,073 | 28.5% | -0.497 | -0.011 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.5 | 1.4 | 1.5 | 1.4 | 0.001 | 0.000 |
| Psychiatric History | 296,810 | 49.7% | 283,103 | 49.2% | 0.496 | 0.010 |
| Psychiatric Drug Dispensings ⁶ | 216,681 | 36.3% | 206,042 | 35.8% | 0.472 | 0.010 |
| Self Harm Encounter ⁶ | 1,227 | 0.2% | 1,170 | 0.2% | 0.002 | 0.000 |
| Encounter for Other Psychiatric Event ⁶ | 244,463 | 41.0% | 232,800 | 40.5% | 0.474 | 0.010 |
| Asthma Emergency Encounter | 64,308 | 10.8% | 61,696 | 10.7% | 0.045 | 0.001 |
| Asthma Inpatient Encounter | 2,005 | 0.3% | 1,987 | 0.3% | -0.010 | -0.002 |
| Asthma Outpatient Encounter | 570,610 | 95.6% | 551,501 | 95.9% | -0.305 | -0.015 |
| Oral Corticosteroid Dispensing | 168,261 | 28.2% | 159,905 | 27.8% | 0.383 | 0.009 |
| Use of Other Asthma Medication | 379,029 | 63.5% | 376,376 | 65.4% | -1.948 | -0.042 |
| Allergic Rhinitis | 255,141 | 42.7% | 231,456 | 40.2% | 2.496 | 0.051 |
| Anxiety | 100,168 | 16.8% | 95,043 | 16.5% | 0.254 | 0.007 |
| Depression | 83,153 | 13.9% | 79,314 | 13.8% | 0.139 | 0.004 |
| Sleep Disorder | 83,113 | 13.9% | 77,880 | 13.5% | 0.381 | 0.011 |
| Substance Abuse | 19,262 | 3.2% | 18,963 | 3.3% | -0.070 | -0.004 |
| Poisoning | 1,163 | 0.2% | 1,240 | 0.2% | -0.021 | -0.005 |

Table 1bz. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Suffocation | 24 | 0.0% | 19 | 0.0% | 0.001 | 0.001 |
| Suicide Attempt | 643 | 0.1% | 617 | 0.1% | 0.000 | 0.000 |
| Toxicity | 138 | 0.0% | 134 | 0.0% | -0.000 | -0.000 |
| Other Self Harm | 322 | 0.1% | 328 | 0.1% | -0.003 | -0.001 |
| No moderate asthma exacerbations | 499,995 | 83.8% | 479,111 | 83.3% | 0.453 | 0.012 |
| One moderate asthma exacerbation | 85,290 | 14.3% | 84,730 | 14.7% | -0.445 | -0.013 |
| Two or more moderate asthma | 11,653 | 2.0% | 11,272 | 2.0% | -0.008 | -0.001 |
| No severe asthma exacerbations | 591,586 | 99.1% | 569,745 | 99.1% | 0.037 | 0.004 |
| One severe asthma exacerbation | 5,136 | 0.9% | 5,160 | 0.9% | -0.037 | -0.004 |
| Two or more severe asthma exacerbations | 216 | 0.0% | 207 | 0.0% | 0.000 | 0.000 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 121,020 | 20.3% | 114,481 | 19.9% | 0.368 | 0.009 |
| Antipsychotics | 27,902 | 4.7% | 27,317 | 4.7% | -0.076 | -0.004 |
| Anxiolytics Hypnotics | 104,817 | 17.6% | 99,097 | 17.2% | 0.328 | 0.009 |
| Lithium Other Mood Stabilizers | 32,391 | 5.4% | 31,381 | 5.5% | -0.030 | -0.001 |
| Antidepressants | 148,615 | 24.9% | 141,373 | 24.6% | 0.314 | 0.007 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 10.0 | 10.9 | 10.1 | 10.5 | -0.015 | -0.001 |
| Mean number of emergency room | 0.5 | 1.2 | 0.5 | 1.2 | -0.003 | -0.002 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.001 | -0.002 |
| Mean number of other ambulatory encounters | 2.8 | 9.9 | 2.9 | 10.5 | -0.161 | -0.016 |
| Mean number of filled prescriptions | 15.0 | 14.4 | 14.9 | 14.2 | 0.062 | 0.004 |
| Mean number of generics dispensed | 7.8 | 4.9 | 7.7 | 5.0 | 0.104 | 0.021 |
| Mean number of unique drug classes dispensed | 7.3 | 4.4 | 7.3 | 4.4 | 0.079 | 0.018 |

Table 1bz. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.001 | -0.004 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.000 | -0.001 |
| Mean number of outpatient visits for respiratory disorders | 2.3 | 3.3 | 2.2 | 3.3 | 0.037 | 0.011 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1ca. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Unique patients | 155,240 | 100.0% | 138,358 | 100.0% | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 52.7 | 15.8 | 47.2 | 17.6 | 5.465 | 0.327 |
| Age | | | | | | |
| 10-24 years | 19,995 | 12.9% | 32,113 | 23.2% | -10.330 | -0.271 |
| 25-54 years | 55,869 | 36.0% | 47,501 | 34.3% | 1.657 | 0.035 |
| ≥ 55 years | 79,376 | 51.1% | 58,744 | 42.5% | 8.673 | 0.174 |
| Sex | | | | | | |
| Female | 106,343 | 68.5% | 89,154 | 64.4% | 4.065 | 0.086 |
| Male | 48,897 | 31.5% | 49,204 | 35.6% | -4.065 | -0.086 |
| Race ³ | | | | | | |
| American Indian or Alaska Native | 506 | 0.3% | 376 | 0.3% | 0.054 | 0.010 |
| Asian | 2,293 | 1.5% | 1,615 | 1.2% | 0.310 | 0.027 |
| Black or African American | 10,288 | 6.6% | 6,877 | 5.0% | 1.657 | 0.071 |
| Multi-racial | 656 | 0.4% | 783 | 0.6% | -0.143 | -0.020 |
| Native Hawaiian or Other Pacific Islander | 180 | 0.1% | 113 | 0.1% | 0.034 | 0.011 |
| Unknown | 83,951 | 54.1% | 84,449 | 61.0% | -6.958 | -0.141 |
| White | 57,366 | 37.0% | 44,145 | 31.9% | 5.047 | 0.106 |
| Hispanic origin | | | | | | |
| Yes | 3,682 | 2.4% | 3,000 | 2.2% | 0.204 | 0.014 |
| No | 61,977 | 39.9% | 44,908 | 32.5% | 7.466 | 0.156 |
| Unknown | 89,581 | 57.7% | 90,450 | 65.4% | -7.669 | -0.158 |
| Year | | | | | | |
| 2015 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2016 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2017 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2018 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2019 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2020 | 63,486 | 40.9% | 56,184 | 40.6% | 0.288 | 0.006 |

Table 1ca. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| 2021 | 69,445 | 44.7% | 61,058 | 44.1% | 0.604 | 0.012 |
| 2022 | 22,309 | 14.4% | 21,116 | 15.3% | -0.891 | -0.025 |
| Pre-boxed warning | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Post-boxed warning | 155,240 | 100.0% | 138,358 | 100.0% | 0.000 | NaN |
| Seasonality | | | | | | |
| Winter | 36,049 | 23.2% | 36,195 | 26.2% | -2.939 | -0.068 |
| Spring | 50,825 | 32.7% | 38,194 | 27.6% | 5.134 | 0.112 |
| Summer | 34,276 | 22.1% | 30,336 | 21.9% | 0.154 | 0.004 |
| Autumn | 34,090 | 22.0% | 33,633 | 24.3% | -2.349 | -0.056 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁴ | 1.7 | 1.7 | 1.7 | 1.6 | 0.052 | 0.032 |
| Psychiatric History | 88,615 | 57.1% | 74,233 | 53.7% | 3.430 | 0.069 |
| Psychiatric Drug Dispensings ⁵ | 64,317 | 41.4% | 53,374 | 38.6% | 2.854 | 0.058 |
| Self Harm Encounter ⁵ | 167 | 0.1% | 216 | 0.2% | -0.049 | -0.013 |
| Encounter for Other Psychiatric Event ⁵ | 75,764 | 48.8% | 63,818 | 46.1% | 2.679 | 0.054 |
| Asthma Emergency Encounter | 12,180 | 7.8% | 11,588 | 8.4% | -0.529 | -0.019 |
| Asthma Inpatient Encounter | 246 | 0.2% | 198 | 0.1% | 0.015 | 0.004 |
| Asthma Outpatient Encounter | 149,996 | 96.6% | 134,423 | 97.2% | -0.534 | -0.031 |
| Oral Corticosteroid Dispensing | 40,488 | 26.1% | 33,176 | 24.0% | 2.103 | 0.049 |
| Use of Other Asthma Medication | 86,392 | 55.7% | 96,625 | 69.8% | -14.186 | -0.297 |
| Allergic Rhinitis | 69,156 | 44.5% | 36,043 | 26.1% | 18.497 | 0.395 |
| Anxiety | 36,432 | 23.5% | 31,158 | 22.5% | 0.948 | 0.023 |
| Depression | 27,249 | 17.6% | 23,053 | 16.7% | 0.891 | 0.024 |
| Sleep Disorder | 32,351 | 20.8% | 23,371 | 16.9% | 3.948 | 0.101 |
| Substance Abuse | 5,191 | 3.3% | 5,164 | 3.7% | -0.388 | -0.021 |
| Poisoning | 155 | 0.1% | 184 | 0.1% | -0.033 | -0.010 |
| Suffocation | 6 | 0.0% | 3 | 0.0% | 0.002 | 0.003 |
| Suicide Attempt | 89 | 0.1% | 116 | 0.1% | -0.027 | -0.010 |

Table 1ca. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Toxicity | 18 | 0.0% | 20 | 0.0% | -0.003 | -0.003 |
| Other Self Harm | 64 | 0.0% | 86 | 0.1% | -0.021 | -0.009 |
| No moderate asthma exacerbations | 136,082 | 87.7% | 122,081 | 88.2% | -0.576 | -0.018 |
| One moderate asthma exacerbation | 16,946 | 10.9% | 14,602 | 10.6% | 0.362 | 0.012 |
| Two or more moderate asthma | 2,212 | 1.4% | 1,675 | 1.2% | 0.214 | 0.019 |
| No severe asthma exacerbations | 154,372 | 99.4% | 137,492 | 99.4% | 0.067 | 0.009 |
| One severe asthma exacerbation | 835 | 0.5% | 840 | 0.6% | -0.069 | -0.009 |
| Two or more severe asthma exacerbations | 33 | 0.0% | 26 | 0.0% | 0.002 | 0.002 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 28,002 | 18.0% | 20,559 | 14.9% | 3.179 | 0.086 |
| Antipsychotics | 6,766 | 4.4% | 7,190 | 5.2% | -0.838 | -0.039 |
| Anxiolytics Hypnotics | 30,280 | 19.5% | 23,282 | 16.8% | 2.678 | 0.069 |
| Lithium Other Mood Stabilizers | 8,204 | 5.3% | 7,874 | 5.7% | -0.406 | -0.018 |
| Antidepressants | 47,896 | 30.9% | 39,579 | 28.6% | 2.247 | 0.049 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 10.6 | 11.1 | 10.0 | 10.9 | 0.616 | 0.056 |
| Mean number of emergency room | 0.3 | 1.0 | 0.3 | 1.1 | -0.020 | -0.019 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | 0.001 | 0.004 |
| Mean number of other ambulatory encounters | 2.5 | 5.7 | 2.5 | 6.4 | -0.017 | -0.003 |
| Mean number of filled prescriptions | 15.0 | 13.4 | 14.1 | 13.6 | 0.881 | 0.065 |
| Mean number of generics dispensed | 7.9 | 4.8 | 7.1 | 4.5 | 0.801 | 0.172 |
| Mean number of unique drug classes dispensed | 7.5 | 4.4 | 6.8 | 4.1 | 0.673 | 0.158 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.3 | -0.001 | -0.006 |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.013 | -0.032 |

Table 1ca. Aggregated Unadjusted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ¹ | Medical Product | | | | Covariate Balance | |
|--|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ² | Number/Mean | Percent/ Standard Deviation ² | | |
| Mean number of outpatient visits for respiratory disorders | 2.2 | 3.3 | 1.9 | 3.1 | 0.335 | 0.104 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 1cb. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Weighted patients | 155,203 | N/A | 149,925 | N/A | N/A | N/A |
| Demographic Characteristics | | | | | | |
| Age (years) | 52.7 | 15.8 | 52.5 | 17.2 | 0.117 | 0.007 |
| Age | | | | | | |
| 10-24 years | 19,993 | 12.9% | 23,727 | 15.8% | -2.944 | -0.089 |
| 25-54 years | 55,855 | 36.0% | 46,864 | 31.3% | 4.730 | 0.109 |
| ≥ 55 years | 79,355 | 51.1% | 79,335 | 52.9% | -1.786 | -0.044 |
| Sex | | | | | | |
| Female | 106,311 | 68.5% | 102,116 | 68.1% | 0.387 | 0.008 |
| Male | 48,892 | 31.5% | 47,809 | 31.9% | -0.387 | -0.008 |
| Race ⁴ | | | | | | |
| American Indian or Alaska Native | 506 | 0.3% | 408 | 0.3% | 0.054 | 0.010 |
| Asian | 2,292 | 1.5% | 1,813 | 1.2% | 0.267 | 0.023 |
| Black or African American | 10,284 | 6.6% | 8,165 | 5.4% | 1.180 | 0.051 |
| Multi-racial | 656 | 0.4% | 680 | 0.5% | -0.031 | -0.005 |
| Native Hawaiian or Other Pacific Islander | 180 | 0.1% | 145 | 0.1% | 0.020 | 0.006 |
| Unknown | 83,923 | 54.1% | 81,230 | 54.2% | -0.107 | -0.004 |
| White | 57,362 | 37.0% | 57,485 | 38.3% | -1.383 | -0.042 |
| Hispanic origin | | | | | | |
| Yes | 3,680 | 2.4% | 3,192 | 2.1% | 0.242 | 0.016 |
| No | 61,968 | 39.9% | 59,453 | 39.7% | 0.272 | 0.014 |
| Unknown | 89,555 | 57.7% | 87,279 | 58.2% | -0.513 | -0.027 |
| Year | | | | | | |
| 2015 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2016 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2017 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2018 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2019 | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| 2020 | 63,467 | 40.9% | 61,588 | 41.1% | -0.186 | -0.004 |

Table 1cb. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| 2021 | 69,429 | 44.7% | 66,933 | 44.6% | 0.090 | 0.002 |
| 2022 | 22,307 | 14.4% | 21,404 | 14.3% | 0.096 | 0.003 |
| Pre-boxed warning | 0 | 0.0% | 0 | 0.0% | NaN | NaN |
| Post-boxed warning | 155,203 | 100.0% | 149,925 | 100.0% | 0.000 | NaN |
| Seasonality | | | | | | |
| Winter | 36,046 | 23.2% | 35,423 | 23.6% | -0.402 | -0.009 |
| Spring | 50,801 | 32.7% | 47,793 | 31.9% | 0.854 | 0.018 |
| Summer | 34,269 | 22.1% | 33,280 | 22.2% | -0.118 | -0.003 |
| Autumn | 34,087 | 22.0% | 33,429 | 22.3% | -0.334 | -0.008 |
| Health Characteristics | | | | | | |
| Charlson/Elixhauser combined comorbidity score ⁵ | 1.7 | 1.7 | 1.7 | 1.7 | -0.003 | -0.002 |
| Psychiatric History | 88,583 | 57.1% | 84,848 | 56.6% | 0.482 | 0.010 |
| Psychiatric Drug Dispensings ⁶ | 64,290 | 41.4% | 61,580 | 41.1% | 0.349 | 0.007 |
| Self Harm Encounter ⁶ | 167 | 0.1% | 169 | 0.1% | -0.005 | -0.002 |
| Encounter for Other Psychiatric Event ⁶ | 75,735 | 48.8% | 72,207 | 48.2% | 0.635 | 0.013 |
| Asthma Emergency Encounter | 12,174 | 7.8% | 11,577 | 7.7% | 0.122 | 0.005 |
| Asthma Inpatient Encounter | 246 | 0.2% | 237 | 0.2% | 0.000 | 0.000 |
| Asthma Outpatient Encounter | 149,962 | 96.6% | 145,268 | 96.9% | -0.271 | -0.015 |
| Oral Corticosteroid Dispensing | 40,466 | 26.1% | 38,543 | 25.7% | 0.365 | 0.008 |
| Use of Other Asthma Medication | 86,385 | 55.7% | 85,780 | 57.2% | -1.556 | -0.032 |
| Allergic Rhinitis | 69,121 | 44.5% | 63,056 | 42.1% | 2.478 | 0.050 |
| Anxiety | 36,415 | 23.5% | 34,731 | 23.2% | 0.297 | 0.007 |
| Depression | 27,231 | 17.5% | 26,027 | 17.4% | 0.186 | 0.005 |
| Sleep Disorder | 32,334 | 20.8% | 30,562 | 20.4% | 0.448 | 0.011 |
| Substance Abuse | 5,188 | 3.3% | 4,950 | 3.3% | 0.041 | 0.002 |
| Poisoning | 154 | 0.1% | 161 | 0.1% | -0.008 | -0.002 |
| Suffocation | 6 | 0.0% | 1 | 0.0% | 0.003 | 0.006 |

Table 1cb. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|---|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Suicide Attempt | 88 | 0.1% | 101 | 0.1% | -0.011 | -0.004 |
| Toxicity | 18 | 0.0% | 19 | 0.0% | -0.001 | -0.001 |
| Other Self Harm | 63 | 0.0% | 66 | 0.0% | -0.003 | -0.002 |
| No moderate asthma exacerbations | 136,053 | 87.7% | 131,618 | 87.8% | -0.128 | -0.004 |
| One moderate asthma exacerbation | 16,938 | 10.9% | 16,339 | 10.9% | 0.015 | 0.000 |
| Two or more moderate asthma | 2,212 | 1.4% | 1,969 | 1.3% | 0.112 | 0.010 |
| No severe asthma exacerbations | 154,336 | 99.4% | 149,061 | 99.4% | 0.018 | 0.002 |
| One severe asthma exacerbation | 834 | 0.5% | 836 | 0.6% | -0.020 | -0.003 |
| Two or more severe asthma exacerbations | 33 | 0.0% | 28 | 0.0% | 0.002 | 0.002 |
| Medical Product Use | | | | | | |
| Analgesic Opiates | 27,977 | 18.0% | 26,286 | 17.5% | 0.494 | 0.013 |
| Antipsychotics | 6,762 | 4.4% | 6,703 | 4.5% | -0.114 | -0.006 |
| Anxiolytics Hypnotics | 30,264 | 19.5% | 28,881 | 19.3% | 0.236 | 0.006 |
| Lithium Other Mood Stabilizers | 8,199 | 5.3% | 8,042 | 5.4% | -0.081 | -0.004 |
| Antidepressants | 47,874 | 30.8% | 45,836 | 30.6% | 0.274 | 0.006 |
| Health Service Utilization Intensity Metrics | | | | | | |
| Mean number of ambulatory encounters | 10.6 | 11.1 | 10.7 | 10.6 | -0.086 | -0.008 |
| Mean number of emergency room | 0.3 | 1.0 | 0.3 | 1.0 | -0.004 | -0.003 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 | 0.1 | 0.4 | -0.001 | -0.004 |
| Mean number of other ambulatory encounters | 2.5 | 5.7 | 2.6 | 6.1 | -0.128 | -0.022 |
| Mean number of filled prescriptions | 15.0 | 13.4 | 15.0 | 13.2 | -0.016 | -0.001 |
| Mean number of generics dispensed | 7.9 | 4.8 | 7.8 | 4.9 | 0.074 | 0.015 |
| Mean number of unique drug classes dispensed | 7.5 | 4.4 | 7.5 | 4.4 | 0.062 | 0.014 |
| Mean number of inpatient visits for respiratory disorders | 0.0 | 0.2 | 0.0 | 0.2 | -0.001 | -0.005 |

Table 1cb. Aggregated Weighted Characteristics of Intentional Self Harm All Settings, 15-day Gap and Extension (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect in the Treated (ATT), Truncation: 2.5%), in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

| Patient Characteristics ^{1,2} | Medical Product | | | | Covariate Balance | |
|--|------------------------|---|--|---|---------------------|-------------------------|
| | Montelukast 15 Day Gap | | Inhaled Corticosteroids (ICS) 15 Day Gap | | Absolute Difference | Standardized Difference |
| | Number/Mean | Percent/ Standard Deviation ³ | Number/Mean | Percent/ Standard Deviation ³ | | |
| Mean number of emergency department visits for respiratory disorders | 0.1 | 0.4 | 0.1 | 0.4 | -0.002 | -0.004 |
| Mean number of outpatient visits for respiratory disorders | 2.2 | 3.3 | 2.2 | 3.2 | 0.003 | 0.001 |

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are assigned a weight of 1. Reference patients are weighted by their propensity score (PS) divided by 1 minus their PS.

³Value represents standard deviation where no % follows the value.

⁴Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

NaN: Not a Number

Table 2a. Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type

| Medical Product | Number of New Users | Person Years at Risk | Average Person Days at Risk | Average Person Years at Risk | Number of Events | Incidence | | Incidence Rate | | Hazard Ratio (95% Confidence Interval) | Wald P-Value |
|--|---------------------|----------------------|-----------------------------|------------------------------|------------------|-----------------------------|--------------------------|------------------------|-------------------------------------|--|--------------|
| | | | | | | Rate per 1,000 Person Years | Risk per 1,000 New Users | per 1,000 Person Years | Risk Difference per 1,000 New Users | | |
| Site-Adjusted Analysis, Unweighted | | | | | | | | | | | |
| Montelukast | 752,280 | 226,485.37 | 109.96 | 0.30 | 580 | 2.56 | 0.77 | -1.87 | -0.18 | 0.80 (0.71, 0.89) | <0.001 |
| Inhaled Corticosteroids (ICS) | 923,377 | 199,147.33 | 78.77 | 0.22 | 882 | 4.43 | 0.96 | | | | |
| Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed² | | | | | | | | | | | |
| Montelukast | 752,230 | 226,474.30 | 109.97 | 0.30 | 580 | 2.56 | 0.77 | -0.55 | 0.08 | 0.96 (0.85, 1.08) | N/A |
| ICS | 724,855 | 161,239.11 | 81.25 | 0.22 | 501 | 3.11 | 0.69 | | | | |

¹All values in this section are weighted.

²ATT = Average Treatment Effect in the Treated.

Table 2b. Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Age Group

| Medical Product | Number of New Users | Person Years at Risk | Average Person Days at Risk | Average Person Years at Risk | Number of Events | Incidence Rate per 1,000 Person Years | Risk per 1,000 New Users | Incidence Rate Difference per 1,000 Person Years | Risk Difference per 1,000 New Users | Hazard Ratio (95% Confidence Interval) | Wald P-Value |
|--|---------------------|----------------------|-----------------------------|------------------------------|------------------|---------------------------------------|--------------------------|--|-------------------------------------|--|--------------|
| Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 752,280 | 226,485.37 | 109.96 | 0.30 | 580 | 2.56 | 0.77 | -1.87 | -0.18 | 0.80 (0.71, 0.89) | <0.001 |
| Inhaled Corticosteroids (ICS) | 923,377 | 199,147.33 | 78.77 | 0.22 | 882 | 4.43 | 0.96 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 752,230 | 226,474.30 | 109.97 | 0.30 | 580 | 2.56 | 0.77 | -0.55 | 0.08 | 0.96 (0.85, 1.08) | N/A |
| ICS | 724,855 | 161,239.11 | 81.25 | 0.22 | 501 | 3.11 | 0.69 | | | | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension, Age Group: 10-24 year | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 207,866 | 46,264.66 | 81.29 | 0.22 | 242 | 5.23 | 1.16 | -0.70 | 0.01 | 0.92 (0.79, 1.08) | 0.324 |
| ICS | 375,869 | 73,157.11 | 71.09 | 0.19 | 434 | 5.93 | 1.15 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 207,822 | 46,251.66 | 81.29 | 0.22 | 242 | 5.23 | 1.16 | -0.08 | 0.13 | 1.01 (0.85, 1.20) | N/A |
| ICS | 201,192 | 39,326.35 | 71.39 | 0.20 | 209 | 5.32 | 1.04 | | | | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension, Age Group: 25-54 year | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 257,136 | 71,422.18 | 101.45 | 0.28 | 263 | 3.68 | 1.02 | -2.51 | -0.29 | 0.81 (0.69, 0.95) | 0.011 |
| ICS | 294,422 | 62,341.27 | 77.34 | 0.21 | 386 | 6.19 | 1.31 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 257,098 | 71,412.48 | 101.45 | 0.28 | 263 | 3.68 | 1.02 | -0.58 | 0.12 | 0.98 (0.82, 1.17) | N/A |
| ICS | 247,509 | 52,235.88 | 77.08 | 0.21 | 223 | 4.26 | 0.90 | | | | |

Table 2b. Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Age Group

| Medical Product | Number of New Users | Person Years at Risk | Average Person Days at Risk | Average Person Years at Risk | Number of Events | Incidence | Risk per | Incidence | Risk | Hazard Ratio | Wald P-Value |
|--|---------------------|----------------------|-----------------------------|------------------------------|------------------|-----------------------------|-----------------|-----------------------------|--------------------------------|---------------------------|--------------|
| | | | | | | Rate per 1,000 Person Years | 1,000 New Users | Rate per 1,000 Person Years | Difference per 1,000 New Users | (95% Confidence Interval) | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension, Age Group: >= 55 years | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 287,228 | 108,787.46 | 138.34 | 0.38 | 75 | 0.69 | 0.26 | -0.28 | 0.02 | 0.88 (0.61, 1.25) | 0.466 |
| ICS | 253,066 | 63,644.94 | 91.86 | 0.25 | 62 | 0.97 | 0.24 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 287,144 | 108,764.34 | 138.35 | 0.38 | 75 | 0.69 | 0.26 | -0.10 | 0.06 | 0.94 (0.62, 1.41) | N/A |
| ICS | 275,968 | 69,169.37 | 91.55 | 0.25 | 55 | 0.79 | 0.20 | | | | |

¹All values in this section are weighted.

²ATT = Average Treatment Effect in the Treated.

Table 2c. Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Psychiatric History

| Medical Product | Number of New Users | Person Years at Risk | Average Person Days at Risk | Average Person Years at Risk | Number of Events | Incidence | Risk per | Incidence | Risk | Hazard Ratio | Wald P-Value |
|---|---------------------|----------------------|-----------------------------|------------------------------|------------------|-----------------------------|-----------------|-----------------------------|--------------------------------|---------------------------|--------------|
| | | | | | | Rate per 1,000 Person Years | 1,000 New Users | Rate per 1,000 Person Years | Difference per 1,000 New Users | (95% Confidence Interval) | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 752,280 | 226,485.37 | 109.96 | 0.30 | 580 | 2.56 | 0.77 | -1.87 | -0.18 | 0.80 (0.71, 0.89) | <0.001 |
| Inhaled Corticosteroids (ICS) | 923,377 | 199,147.33 | 78.77 | 0.22 | 882 | 4.43 | 0.96 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 752,230 | 226,474.30 | 109.97 | 0.30 | 580 | 2.56 | 0.77 | -0.55 | 0.08 | 0.96 (0.85, 1.08) | N/A |
| ICS | 724,855 | 161,239.11 | 81.25 | 0.22 | 501 | 3.11 | 0.69 | | | | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension, No Psychiatric History | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 366,756 | 103,203.99 | 102.78 | 0.28 | 61 | 0.59 | 0.17 | -0.29 | -0.02 | 1.05 (0.75, 1.47) | 0.763 |
| ICS | 484,391 | 101,856.33 | 76.80 | 0.21 | 90 | 0.88 | 0.19 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 366,686 | 103,179.03 | 102.77 | 0.28 | 61 | 0.59 | 0.17 | -0.07 | 0.02 | 1.06 (0.75, 1.51) | N/A |
| ICS | 354,802 | 77,695.56 | 79.98 | 0.22 | 52 | 0.66 | 0.15 | | | | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension, Psychiatric History | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 385,474 | 123,270.31 | 116.80 | 0.32 | 519 | 4.21 | 1.35 | -3.93 | -0.46 | 0.75 (0.67, 0.85) | <0.001 |
| ICS | 438,966 | 97,286.99 | 80.95 | 0.22 | 792 | 8.14 | 1.80 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 385,425 | 123,258.48 | 116.81 | 0.32 | 519 | 4.21 | 1.35 | -1.20 | 0.13 | 0.93 (0.82, 1.06) | N/A |
| ICS | 369,811 | 83,399.94 | 82.37 | 0.23 | 451 | 5.41 | 1.22 | | | | |

¹All values in this section are weighted.

²ATT = Average Treatment Effect in the Treated.

Table 2d. Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Pre-/Post-Boxed Warning

| Medical Product | Number of New Users | Person Years at Risk | Average Person Days at Risk | Average Person Years at Risk | Number of Events | Incidence | Risk per | Incidence | Risk | Hazard Ratio (95% Confidence Interval) | Wald P-Value |
|---|---------------------|----------------------|-----------------------------|------------------------------|------------------|-----------------------------|-----------------|-----------------------------|--------------------------------|--|--------------|
| | | | | | | Rate per 1,000 Person Years | 1,000 New Users | Rate per 1,000 Person Years | Difference per 1,000 New Users | | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 752,280 | 226,485.37 | 109.96 | 0.30 | 580 | 2.56 | 0.77 | -1.87 | -0.18 | 0.80 (0.71, 0.89) | <0.001 |
| Inhaled Corticosteroids (ICS) | 923,377 | 199,147.33 | 78.77 | 0.22 | 882 | 4.43 | 0.96 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 752,230 | 226,474.30 | 109.97 | 0.30 | 580 | 2.56 | 0.77 | -0.55 | 0.08 | 0.96 (0.85, 1.08) | N/A |
| ICS | 724,855 | 161,239.11 | 81.25 | 0.22 | 501 | 3.11 | 0.69 | | | | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension, Pre-boxed warning | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 596,990 | 179,446.08 | 109.79 | 0.30 | 499 | 2.78 | 0.84 | -1.92 | -0.17 | 0.83 (0.74, 0.93) | 0.001 |
| ICS | 784,999 | 168,065.77 | 78.20 | 0.21 | 790 | 4.70 | 1.01 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 596,938 | 179,434.27 | 109.79 | 0.30 | 499 | 2.78 | 0.84 | -0.54 | 0.10 | 0.99 (0.88, 1.13) | N/A |
| ICS | 575,113 | 126,984.71 | 80.65 | 0.22 | 421 | 3.32 | 0.73 | | | | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension, Post-boxed warning | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 155,240 | 47,028.22 | 110.65 | 0.30 | 81 | 1.72 | 0.52 | -1.24 | -0.14 | 0.61 (0.45, 0.83) | 0.002 |
| ICS | 138,358 | 31,077.55 | 82.04 | 0.22 | 92 | 2.96 | 0.66 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 155,203 | 47,015.74 | 110.65 | 0.30 | 81 | 1.72 | 0.52 | -0.56 | -0.00 | 0.82 (0.59, 1.14) | N/A |
| ICS | 149,925 | 34,318.76 | 83.61 | 0.23 | 79 | 2.29 | 0.52 | | | | |

¹All values in this section are weighted.

²ATT = Average Treatment Effect in the Treated.

Table 2e. Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Sex

| Medical Product | Number of New Users | Person Years at Risk | Average Person Days at Risk | Average Person Years at Risk | Number of Events | Incidence | Risk per | Incidence | Risk | Hazard Ratio (95% Confidence Interval) | Wald P-Value |
|--|---------------------|----------------------|-----------------------------|------------------------------|------------------|-----------------------------|-----------------|-----------------------------|--------------------------------|--|--------------|
| | | | | | | Rate per 1,000 Person Years | 1,000 New Users | Rate per 1,000 Person Years | Difference per 1,000 New Users | | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 752,280 | 226,485.37 | 109.96 | 0.30 | 580 | 2.56 | 0.77 | -1.87 | -0.18 | 0.80 (0.71, 0.89) | <0.001 |
| Inhaled Corticosteroids (ICS) | 923,377 | 199,147.33 | 78.77 | 0.22 | 882 | 4.43 | 0.96 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 752,230 | 226,474.30 | 109.97 | 0.30 | 580 | 2.56 | 0.77 | -0.55 | 0.08 | 0.96 (0.85, 1.08) | N/A |
| ICS | 724,855 | 161,239.11 | 81.25 | 0.22 | 501 | 3.11 | 0.69 | | | | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension, Sex: Female | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 496,977 | 152,007.67 | 111.72 | 0.31 | 442 | 2.91 | 0.89 | -2.45 | -0.27 | 0.78 (0.69, 0.88) | <0.001 |
| ICS | 568,584 | 122,627.97 | 78.77 | 0.22 | 657 | 5.36 | 1.16 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 496,923 | 151,994.22 | 111.72 | 0.31 | 442 | 2.91 | 0.89 | -0.66 | 0.10 | 0.96 (0.84, 1.10) | N/A |
| ICS | 478,441 | 106,150.20 | 81.04 | 0.22 | 379 | 3.57 | 0.79 | | | | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension, Sex: Male | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 255,253 | 74,466.63 | 106.56 | 0.29 | 138 | 1.85 | 0.54 | -1.09 | -0.09 | 0.81 (0.65, 1.01) | 0.057 |
| ICS | 354,773 | 76,515.36 | 78.77 | 0.22 | 225 | 2.94 | 0.63 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 255,186 | 74,451.15 | 106.56 | 0.29 | 138 | 1.85 | 0.54 | -0.34 | 0.05 | 0.95 (0.74, 1.21) | N/A |
| ICS | 246,692 | 55,110.79 | 81.60 | 0.22 | 121 | 2.19 | 0.49 | | | | |

¹All values in this section are weighted.

²ATT = Average Treatment Effect in the Treated.

Table 3a. Effect Estimates for Intentional Self Harm Inpatient and Emergency, Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type

| Medical Product | Number of New Users | Person Years at Risk | Average Person Days at Risk | Average Person Years at Risk | Number of Events | Incidence | Risk per | Incidence | Risk | Hazard Ratio | Wald P-Value |
|--|---------------------|----------------------|-----------------------------|------------------------------|------------------|-----------------------------|-----------------|-----------------------------|--------------------------------|---------------------------|--------------|
| | | | | | | Rate per 1,000 Person Years | 1,000 New Users | Rate per 1,000 Person Years | Difference per 1,000 New Users | (95% Confidence Interval) | |
| Site-Adjusted Analysis, Unweighted | | | | | | | | | | | |
| Montelukast | 752,307 | 226,530.76 | 109.98 | 0.30 | 411 | 1.81 | 0.55 | -1.09 | -0.08 | 0.85 (0.74, 0.97) | 0.013 |
| Inhaled Corticosteroids (ICS) | 923,409 | 199,190.38 | 78.79 | 0.22 | 578 | 2.90 | 0.63 | | | | |
| Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed² | | | | | | | | | | | |
| Montelukast | 752,257 | 226,519.76 | 109.98 | 0.30 | 411 | 1.81 | 0.55 | -0.24 | 0.09 | 1.03 (0.89, 1.18) | N/A |
| ICS | 724,885 | 161,266.46 | 81.26 | 0.22 | 331 | 2.05 | 0.46 | | | | |

¹All values in this section are weighted.

²ATT = Average Treatment Effect in the Treated.

Table 3b. Effect Estimates for Intentional Self Harm Inpatient and Emergency, Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Age Group

| Medical Product | Number of New Users | Person Years at Risk | Average Person Days at Risk | Average Person Years at Risk | Number of Events | Incidence | Risk per | Incidence | Risk | Hazard Ratio | Wald P-Value |
|--|---------------------|----------------------|-----------------------------|------------------------------|------------------|-----------------------------|-----------------|-----------------------------|--------------------------------|---------------------------|--------------|
| | | | | | | Rate per 1,000 Person Years | 1,000 New Users | Rate per 1,000 Person Years | Difference per 1,000 New Users | (95% Confidence Interval) | |
| Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 752,307 | 226,530.76 | 109.98 | 0.30 | 411 | 1.81 | 0.55 | -1.09 | -0.08 | 0.85 (0.74, 0.97) | 0.013 |
| Inhaled Corticosteroids (ICS) | 923,409 | 199,190.38 | 78.79 | 0.22 | 578 | 2.90 | 0.63 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 752,257 | 226,519.76 | 109.98 | 0.30 | 411 | 1.81 | 0.55 | -0.24 | 0.09 | 1.03 (0.89, 1.18) | N/A |
| ICS | 724,885 | 161,266.46 | 81.26 | 0.22 | 331 | 2.05 | 0.46 | | | | |
| Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension, Age Group: 10-24 years | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 207,872 | 46,279.33 | 81.32 | 0.22 | 174 | 3.76 | 0.84 | -0.09 | 0.09 | 1.02 (0.84, 1.23) | 0.878 |
| ICS | 375,887 | 73,175.37 | 71.10 | 0.19 | 282 | 3.85 | 0.75 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 207,831 | 46,266.63 | 81.31 | 0.22 | 174 | 3.76 | 0.84 | 0.18 | 0.14 | 1.07 (0.87, 1.32) | N/A |
| ICS | 201,205 | 39,336.11 | 71.41 | 0.20 | 141 | 3.59 | 0.70 | | | | |
| Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension, Age Group: 25-54 years | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 257,148 | 71,439.98 | 101.47 | 0.28 | 184 | 2.58 | 0.72 | -1.58 | -0.16 | 0.82 (0.68, 1.00) | 0.048 |
| ICS | 294,436 | 62,364.14 | 77.36 | 0.21 | 259 | 4.15 | 0.88 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 257,106 | 71,428.90 | 101.47 | 0.28 | 184 | 2.58 | 0.72 | -0.22 | 0.13 | 1.05 (0.85, 1.29) | N/A |
| ICS | 247,528 | 52,248.40 | 77.10 | 0.21 | 146 | 2.79 | 0.59 | | | | |

Table 3b. Effect Estimates for Intentional Self Harm Inpatient and Emergency, Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Age Group

| Medical Product | Number of New Users | Person Years at Risk | Average Person Days at Risk | Average Person Years at Risk | Number of Events | Incidence | Risk per | Incidence | Risk | Hazard Ratio | Wald P-Value |
|---|---------------------|----------------------|-----------------------------|------------------------------|------------------|-----------------------------|-----------------|-----------------------------|--------------------------------|---------------------------|--------------|
| | | | | | | Rate per 1,000 Person Years | 1,000 New Users | Rate per 1,000 Person Years | Difference per 1,000 New Users | (95% Confidence Interval) | |
| Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension, Age Group: ≥ 55 years | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 287,237 | 108,800.45 | 138.35 | 0.38 | 53 | 0.49 | 0.18 | -0.09 | 0.04 | 1.05 (0.67, 1.64) | 0.824 |
| ICS | 253,066 | 63,647.10 | 91.86 | 0.25 | 37 | 0.58 | 0.15 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 287,155 | 108,777.53 | 138.36 | 0.38 | 53 | 0.49 | 0.18 | 0.01 | 0.07 | 1.08 (0.66, 1.80) | N/A |
| ICS | 275,983 | 69,175.48 | 91.55 | 0.25 | 33 | 0.48 | 0.12 | | | | |

¹All values in this section are weighted.

²ATT = Average Treatment Effect in the Treated.

Table 3c. Effect Estimates for Intentional Self Harm Inpatient and Emergency, Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Psychiatric History

| Medical Product | Number of New Users | Person Years at Risk | Average Person Days at Risk | Average Person Years at Risk | Number of Events | Incidence | Risk per | Incidence | Risk | Hazard Ratio | Wald P-Value |
|--|---------------------|----------------------|-----------------------------|------------------------------|------------------|-----------------------------|-----------------|-----------------------------|--------------------------------|---------------------------|--------------|
| | | | | | | Rate per 1,000 Person Years | 1,000 New Users | Rate per 1,000 Person Years | Difference per 1,000 New Users | (95% Confidence Interval) | |
| Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 752,307 | 226,530.76 | 109.98 | 0.30 | 411 | 1.81 | 0.55 | -1.09 | -0.08 | 0.85 (0.74, 0.97) | 0.013 |
| Inhaled Corticosteroids (ICS) | 923,409 | 199,190.38 | 78.79 | 0.22 | 578 | 2.90 | 0.63 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 752,257 | 226,519.76 | 109.98 | 0.30 | 411 | 1.81 | 0.55 | -0.24 | 0.09 | 1.03 (0.89, 1.18) | N/A |
| ICS | 724,885 | 161,266.46 | 81.26 | 0.22 | 331 | 2.05 | 0.46 | | | | |
| Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension, No Psychiatric History | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 366,755 | 103,205.13 | 102.78 | 0.28 | 43 | 0.42 | 0.12 | -0.12 | 0.00 | 1.25 (0.83, 1.88) | 0.286 |
| ICS | 484,389 | 101,859.30 | 76.81 | 0.21 | 55 | 0.54 | 0.11 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 366,683 | 103,179.86 | 102.78 | 0.28 | 43 | 0.42 | 0.12 | 0.03 | 0.03 | 1.27 (0.81, 1.97) | N/A |
| ICS | 354,806 | 77,699.17 | 79.99 | 0.22 | 30 | 0.39 | 0.09 | | | | |
| Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension, Psychiatric History | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 385,502 | 123,314.63 | 116.84 | 0.32 | 368 | 2.98 | 0.95 | -2.39 | -0.24 | 0.79 (0.69, 0.91) | 0.001 |
| ICS | 439,000 | 97,327.32 | 80.98 | 0.22 | 523 | 5.37 | 1.19 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 385,471 | 123,307.95 | 116.84 | 0.32 | 368 | 2.98 | 0.95 | -0.66 | 0.13 | 0.98 (0.84, 1.13) | N/A |
| ICS | 369,831 | 83,421.76 | 82.39 | 0.23 | 304 | 3.64 | 0.82 | | | | |

¹All values in this section are weighted.

²ATT = Average Treatment Effect in the Treated.

Table 3d. Effect Estimates for Intentional Self Harm Inpatient and Emergency, Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Pre-/Post-Boxed Warning

| Medical Product | Number of New Users | Person Years at Risk | Average Person Days at Risk | Average Person Years at Risk | Number of Events | Incidence | Risk per | Incidence | Risk | Hazard Ratio | Wald P-Value |
|--|---------------------|----------------------|-----------------------------|------------------------------|------------------|-----------------------------|-----------------|-----------------------------|--------------------------------|---------------------------|--------------|
| | | | | | | Rate per 1,000 Person Years | 1,000 New Users | Rate per 1,000 Person Years | Difference per 1,000 New Users | (95% Confidence Interval) | |
| Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 752,307 | 226,530.76 | 109.98 | 0.30 | 411 | 1.81 | 0.55 | -1.09 | -0.08 | 0.85 (0.74, 0.97) | 0.013 |
| Inhaled Corticosteroids (ICS) | 923,409 | 199,190.38 | 78.79 | 0.22 | 578 | 2.90 | 0.63 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 752,257 | 226,519.76 | 109.98 | 0.30 | 411 | 1.81 | 0.55 | -0.24 | 0.09 | 1.03 (0.89, 1.18) | N/A |
| ICS | 724,885 | 161,266.46 | 81.26 | 0.22 | 331 | 2.05 | 0.46 | | | | |
| Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension, Pre-boxed Warning | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 597,013 | 179,483.96 | 109.81 | 0.30 | 352 | 1.96 | 0.59 | -1.07 | -0.06 | 0.89 (0.78, 1.03) | 0.122 |
| ICS | 785,025 | 168,104.47 | 78.21 | 0.21 | 510 | 3.03 | 0.65 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 596,988 | 179,479.40 | 109.81 | 0.30 | 352 | 1.96 | 0.59 | -0.20 | 0.11 | 1.07 (0.92, 1.24) | N/A |
| ICS | 575,135 | 127,005.49 | 80.66 | 0.22 | 275 | 2.16 | 0.48 | | | | |
| Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension, Post-boxed Warning | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 155,244 | 47,035.80 | 110.66 | 0.30 | 59 | 1.25 | 0.38 | -0.93 | -0.11 | 0.60 (0.42, 0.85) | 0.004 |
| ICS | 138,364 | 31,082.15 | 82.05 | 0.22 | 68 | 2.19 | 0.49 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 155,205 | 47,022.97 | 110.66 | 0.30 | 59 | 1.25 | 0.38 | -0.43 | -0.00 | 0.81 (0.55, 1.18) | N/A |
| ICS | 149,925 | 34,322.07 | 83.62 | 0.23 | 58 | 1.68 | 0.38 | | | | |

¹All values in this section are weighted.

²ATT = Average Treatment Effect in the Treated.

Table 3e. Effect Estimates for Intentional Self Harm Inpatient and Emergency, Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Sex

| Medical Product | Number of New Users | Person Years at Risk | Average Person Days at Risk | Average Person Years at Risk | Number of Events | Incidence | Risk per | Incidence | Risk | Hazard Ratio | Wald P-Value |
|---|---------------------|----------------------|-----------------------------|------------------------------|------------------|-----------------------------|-----------------|-----------------------------|--------------------------------|---------------------------|--------------|
| | | | | | | Rate per 1,000 Person Years | 1,000 New Users | Rate per 1,000 Person Years | Difference per 1,000 New Users | (95% Confidence Interval) | |
| Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 752,307 | 226,530.76 | 109.98 | 0.30 | 411 | 1.81 | 0.55 | -1.09 | -0.08 | 0.85 (0.74, 0.97) | 0.013 |
| Inhaled Corticosteroids (ICS) | 923,409 | 199,190.38 | 78.79 | 0.22 | 578 | 2.90 | 0.63 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 752,257 | 226,519.76 | 109.98 | 0.30 | 411 | 1.81 | 0.55 | -0.24 | 0.09 | 1.03 (0.89, 1.18) | N/A |
| ICS | 724,885 | 161,266.46 | 81.26 | 0.22 | 331 | 2.05 | 0.46 | | | | |
| Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension, Sex: Female | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 496,998 | 152,038.52 | 111.73 | 0.31 | 322 | 2.12 | 0.65 | -1.39 | -0.11 | 0.85 (0.73, 0.98) | 0.031 |
| ICS | 568,609 | 122,659.50 | 78.79 | 0.22 | 430 | 3.51 | 0.76 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 496,977 | 152,033.92 | 111.74 | 0.31 | 322 | 2.12 | 0.65 | -0.22 | 0.13 | 1.06 (0.91, 1.24) | N/A |
| ICS | 478,459 | 106,168.54 | 81.05 | 0.22 | 248 | 2.34 | 0.52 | | | | |
| Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension, Sex: Male | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 255,259 | 74,481.24 | 106.58 | 0.29 | 89 | 1.19 | 0.35 | -0.74 | -0.07 | 0.79 (0.60, 1.04) | 0.094 |
| ICS | 354,780 | 76,527.12 | 78.79 | 0.22 | 148 | 1.93 | 0.42 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 255,192 | 74,465.54 | 106.58 | 0.29 | 89 | 1.20 | 0.35 | -0.28 | 0.02 | 0.93 (0.69, 1.27) | N/A |
| ICS | 246,700 | 55,116.96 | 81.60 | 0.22 | 81 | 1.47 | 0.33 | | | | |

¹All values in this section are weighted.

²ATT = Average Treatment Effect in the Treated.

Table 4a. Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type

| Medical Product | Number of New Users | Person Years at Risk | Average Person Days at Risk | Average Person Years at Risk | Number of Events | Incidence | Risk per | Incidence | Risk | Hazard Ratio | Wald P-Value |
|--|---------------------|----------------------|-----------------------------|------------------------------|------------------|-----------------------------|-----------------|-----------------------------|--------------------------------|---------------------------|--------------|
| | | | | | | Rate per 1,000 Person Years | 1,000 New Users | Rate per 1,000 Person Years | Difference per 1,000 New Users | (95% Confidence Interval) | |
| Site-Adjusted Analysis, Unweighted | | | | | | | | | | | |
| Montelukast | 752,176 | 119,963.99 | 58.25 | 0.16 | 325 | 2.71 | 0.43 | -2.21 | -0.12 | 0.76 (0.66, 0.88) | <0.001 |
| Inhaled Corticosteroids (ICS) | 923,166 | 104,173.40 | 41.22 | 0.11 | 512 | 4.91 | 0.55 | | | | |
| Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed² | | | | | | | | | | | |
| Montelukast | 752,128 | 119,956.30 | 58.25 | 0.16 | 325 | 2.71 | 0.43 | -0.76 | 0.02 | 0.91 (0.78, 1.07) | N/A |
| ICS | 724,746 | 85,912.19 | 43.30 | 0.12 | 298 | 3.47 | 0.41 | | | | |

¹All values in this section are weighted.

²ATT = Average Treatment Effect in the Treated.

Table 4b. Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Age Group

| Medical Product | Number of New Users | Person Years at Risk | Average Person Days at Risk | Average Person Years at Risk | Number of Events | Incidence Rate per 1,000 Person Years | Risk per 1,000 New Users | Incidence Rate Difference per 1,000 Person Years | Risk Difference per 1,000 New Users | Hazard Ratio (95% Confidence Interval) | Wald P-Value |
|--|---------------------|----------------------|-----------------------------|------------------------------|------------------|---------------------------------------|--------------------------|--|-------------------------------------|--|--------------|
| Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 752,176 | 119,963.99 | 58.25 | 0.16 | 325 | 2.71 | 0.43 | -2.21 | -0.12 | 0.76 (0.66, 0.88) | <0.001 |
| Inhaled Corticosteroids (ICS) | 923,166 | 104,173.40 | 41.22 | 0.11 | 512 | 4.91 | 0.55 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 752,128 | 119,956.30 | 58.25 | 0.16 | 325 | 2.71 | 0.43 | -0.76 | 0.02 | 0.91 (0.78, 1.07) | N/A |
| ICS | 724,746 | 85,912.19 | 43.30 | 0.12 | 298 | 3.47 | 0.41 | | | | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension, Age Group: 10-24 years | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 207,843 | 22,250.09 | 39.10 | 0.11 | 117 | 5.26 | 0.56 | -1.53 | -0.11 | 0.81 (0.65, 1.01) | 0.067 |
| ICS | 375,784 | 36,989.16 | 35.95 | 0.10 | 251 | 6.79 | 0.67 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 207,800 | 22,242.23 | 39.10 | 0.11 | 117 | 5.26 | 0.56 | -1.12 | -0.07 | 0.87 (0.68, 1.10) | N/A |
| ICS | 201,178 | 19,983.94 | 36.28 | 0.10 | 127 | 6.38 | 0.63 | | | | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension, Age Group: 25-54 years | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 257,110 | 36,509.56 | 51.87 | 0.14 | 164 | 4.49 | 0.64 | -2.38 | -0.13 | 0.88 (0.71, 1.08) | 0.212 |
| ICS | 294,341 | 32,734.57 | 40.62 | 0.11 | 225 | 6.87 | 0.76 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 257,075 | 36,503.19 | 51.86 | 0.14 | 164 | 4.49 | 0.64 | -0.18 | 0.11 | 1.04 (0.83, 1.30) | N/A |
| ICS | 247,483 | 27,704.43 | 40.89 | 0.11 | 130 | 4.68 | 0.52 | | | | |

Table 4b. Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Age Group

| Medical Product | Number of New Users | Person Years at Risk | Average Person Days at Risk | Average Person Years at Risk | Number of Events | Incidence | Risk per | Incidence | Risk | Hazard Ratio | Wald P-Value |
|---|---------------------|----------------------|-----------------------------|------------------------------|------------------|----------------------|-----------------|-----------------------------|--------------------------------|---------------------------|--------------|
| | | | | | | Rate per 1,000 Years | 1,000 New Users | Rate per 1,000 Person Years | Difference per 1,000 New Users | (95% Confidence Interval) | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension, Age Group: ≥ 55 years | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 287,175 | 61,196.65 | 77.83 | 0.21 | 44 | 0.72 | 0.15 | -0.33 | 0.01 | 0.77 (0.48, 1.22) | 0.265 |
| ICS | 253,020 | 34,448.17 | 49.73 | 0.14 | 36 | 1.05 | 0.14 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 287,090 | 61,184.19 | 77.84 | 0.21 | 44 | 0.72 | 0.15 | -0.14 | 0.04 | 0.85 (0.50, 1.44) | N/A |
| ICS | 275,915 | 37,933.12 | 50.22 | 0.14 | 33 | 0.86 | 0.12 | | | | |

¹All values in this section are weighted.

²ATT = Average Treatment Effect in the Treated.

Table 4c. Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Psychiatric History

| Medical Product | Number of New Users | Person Years at Risk | Average Person Days at Risk | Average Person Years at Risk | Number of Events | Incidence | Risk per | Incidence | Risk | Hazard Ratio | Wald P-Value |
|--|---------------------|----------------------|-----------------------------|------------------------------|------------------|-----------------------------|-----------------|-----------------------------|--------------------------------|---------------------------|--------------|
| | | | | | | Rate per 1,000 Person Years | 1,000 New Users | Rate per 1,000 Person Years | Difference per 1,000 New Users | (95% Confidence Interval) | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 752,176 | 119,963.99 | 58.25 | 0.16 | 325 | 2.71 | 0.43 | -2.21 | -0.12 | 0.76 (0.66, 0.88) | <0.001 |
| Inhaled Corticosteroids (ICS) | 923,166 | 104,173.40 | 41.22 | 0.11 | 512 | 4.91 | 0.55 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 752,128 | 119,956.30 | 58.25 | 0.16 | 325 | 2.71 | 0.43 | -0.76 | 0.02 | 0.91 (0.78, 1.07) | N/A |
| ICS | 724,746 | 85,912.19 | 43.30 | 0.12 | 298 | 3.47 | 0.41 | | | | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension, No Psychiatric History | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 366,721 | 53,335.28 | 53.12 | 0.15 | 28 | 0.52 | 0.08 | -0.29 | -0.01 | 1.02 (0.63, 1.67) | 0.928 |
| ICS | 484,288 | 52,903.86 | 39.90 | 0.11 | 43 | 0.81 | 0.09 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 366,650 | 53,320.20 | 53.12 | 0.15 | 28 | 0.53 | 0.08 | -0.13 | 0.00 | 0.97 (0.57, 1.63) | N/A |
| ICS | 354,769 | 40,940.29 | 42.15 | 0.12 | 27 | 0.66 | 0.08 | | | | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension, Psychiatric History | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 385,407 | 66,621.02 | 63.14 | 0.17 | 297 | 4.46 | 0.77 | -4.69 | -0.30 | 0.72 (0.62, 0.84) | <0.001 |
| ICS | 438,857 | 51,268.04 | 42.67 | 0.12 | 469 | 9.15 | 1.07 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 385,354 | 66,612.10 | 63.14 | 0.17 | 297 | 4.46 | 0.77 | -1.68 | 0.02 | 0.87 (0.74, 1.03) | N/A |
| ICS | 369,740 | 44,913.35 | 44.37 | 0.12 | 276 | 6.14 | 0.75 | | | | |

¹All values in this section are weighted.

²ATT = Average Treatment Effect in the Treated.

Table 4d. Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Pre-/Post-Boxed Warning

| Medical Product | Number of New Users | Person Years at Risk | Average Person Days at Risk | Average Person Years at Risk | Number of Events | Incidence | Risk per | Incidence | Risk | Hazard Ratio | Wald P-Value |
|--|---------------------|----------------------|-----------------------------|------------------------------|------------------|-----------------------------|-----------------|-----------------------------|--------------------------------|---------------------------|--------------|
| | | | | | | Rate per 1,000 Person Years | 1,000 New Users | Rate per 1,000 Person Years | Difference per 1,000 New Users | (95% Confidence Interval) | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 752,176 | 119,963.99 | 58.25 | 0.16 | 325 | 2.71 | 0.43 | -2.21 | -0.12 | 0.76 (0.66, 0.88) | <0.001 |
| Inhaled Corticosteroids (ICS) | 923,166 | 104,173.40 | 41.22 | 0.11 | 512 | 4.91 | 0.55 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 752,128 | 119,956.30 | 58.25 | 0.16 | 325 | 2.71 | 0.43 | -0.76 | 0.02 | 0.91 (0.78, 1.07) | N/A |
| ICS | 724,746 | 85,912.19 | 43.30 | 0.12 | 298 | 3.47 | 0.41 | | | | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension, Pre-boxed Warning | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 596,913 | 90,311.75 | 55.26 | 0.15 | 272 | 3.01 | 0.46 | -2.25 | -0.12 | 0.79 (0.67, 0.92) | 0.003 |
| ICS | 784,799 | 86,484.87 | 40.25 | 0.11 | 455 | 5.26 | 0.58 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 596,859 | 90,304.08 | 55.26 | 0.15 | 272 | 3.01 | 0.46 | -0.79 | 0.02 | 0.92 (0.77, 1.09) | N/A |
| ICS | 575,038 | 66,270.07 | 42.09 | 0.12 | 252 | 3.80 | 0.44 | | | | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension, Post-boxed Warning | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 155,215 | 29,644.55 | 69.76 | 0.19 | 53 | 1.79 | 0.34 | -1.43 | -0.07 | 0.64 (0.43, 0.94) | 0.021 |
| ICS | 138,346 | 17,687.02 | 46.70 | 0.13 | 57 | 3.22 | 0.41 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 155,180 | 29,636.13 | 69.76 | 0.19 | 53 | 1.79 | 0.34 | -0.61 | 0.03 | 0.88 (0.58, 1.32) | N/A |
| ICS | 149,899 | 19,699.98 | 48.00 | 0.13 | 47 | 2.39 | 0.31 | | | | |

¹All values in this section are weighted.

²ATT = Average Treatment Effect in the Treated.

Table 4e. Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Sex

| Medical Product | Number of New Users | Person Years at Risk | Average Person Days at Risk | Average Person Years at Risk | Number of Events | Incidence | Risk per | Incidence | Risk | Hazard Ratio | Wald P-Value |
|--|---------------------|----------------------|-----------------------------|------------------------------|------------------|-----------------------------|-----------------|-----------------------------|--------------------------------|---------------------------|--------------|
| | | | | | | Rate per 1,000 Person Years | 1,000 New Users | Rate per 1,000 Person Years | Difference per 1,000 New Users | (95% Confidence Interval) | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 752,176 | 119,963.99 | 58.25 | 0.16 | 325 | 2.71 | 0.43 | -2.21 | -0.12 | 0.76 (0.66, 0.88) | <0.001 |
| Inhaled Corticosteroids (ICS) | 923,166 | 104,173.40 | 41.22 | 0.11 | 512 | 4.91 | 0.55 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 752,128 | 119,956.30 | 58.25 | 0.16 | 325 | 2.71 | 0.43 | -0.76 | 0.02 | 0.91 (0.78, 1.07) | N/A |
| ICS | 724,746 | 85,912.19 | 43.30 | 0.12 | 298 | 3.47 | 0.41 | | | | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension, Sex: Female | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 496,909 | 81,501.14 | 59.91 | 0.16 | 249 | 3.06 | 0.50 | -3.08 | -0.20 | 0.72 (0.61, 0.86) | <0.001 |
| ICS | 568,448 | 64,729.73 | 41.59 | 0.11 | 397 | 6.13 | 0.70 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 496,850 | 81,491.54 | 59.91 | 0.16 | 249 | 3.06 | 0.50 | -1.00 | 0.02 | 0.91 (0.77, 1.09) | N/A |
| ICS | 478,373 | 56,920.79 | 43.46 | 0.12 | 231 | 4.06 | 0.48 | | | | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension, Sex: Male | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 255,219 | 38,455.16 | 55.03 | 0.15 | 76 | 1.98 | 0.30 | -0.94 | -0.03 | 0.85 (0.63, 1.16) | 0.307 |
| ICS | 354,697 | 39,442.17 | 40.62 | 0.11 | 115 | 2.92 | 0.32 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 255,153 | 38,445.29 | 55.03 | 0.15 | 76 | 1.98 | 0.30 | -0.32 | 0.03 | 0.92 (0.64, 1.31) | N/A |
| ICS | 246,665 | 29,005.74 | 42.95 | 0.12 | 66 | 2.29 | 0.27 | | | | |

¹All values in this section are weighted.

²ATT = Average Treatment Effect in the Treated.

Table 5a. Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type

| Medical Product | Number of New Users | Person Years at Risk | Average Person Days at Risk | Average Person Years at Risk | Number of Events | Incidence | Risk per | Incidence | Risk | Hazard Ratio | Wald P-Value |
|--|---------------------|----------------------|-----------------------------|------------------------------|------------------|-----------------------------|-----------------|-----------------------------|--------------------------------|---------------------------|--------------|
| | | | | | | Rate per 1,000 Person Years | 1,000 New Users | Rate per 1,000 Person Years | Difference per 1,000 New Users | (95% Confidence Interval) | |
| Site-Adjusted Analysis, Unweighted | | | | | | | | | | | |
| Montelukast | 752,280 | 186,602.17 | 90.60 | 0.25 | 496 | 2.66 | 0.66 | -1.95 | -0.12 | 0.81 (0.71, 0.91) | <0.001 |
| Inhaled Corticosteroids (ICS) | 923,377 | 155,359.53 | 61.45 | 0.17 | 716 | 4.61 | 0.78 | | | | |
| Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed² | | | | | | | | | | | |
| Montelukast | 752,230 | 186,592.70 | 90.60 | 0.25 | 496 | 2.66 | 0.66 | -0.60 | 0.09 | 0.97 (0.85, 1.10) | N/A |
| ICS | 724,855 | 126,811.70 | 63.90 | 0.17 | 413 | 3.26 | 0.57 | | | | |

¹All values in this section are weighted.

²ATT = Average Treatment Effect in the Treated.

Table 5b. Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Age Group

| Medical Product | Number of New Users | Person Years at Risk | Average Person Days at Risk | Average Person Years at Risk | Number of Events | Incidence | Risk per | Incidence | Risk | Hazard Ratio | Wald P-Value |
|---|---------------------|----------------------|-----------------------------|------------------------------|------------------|-----------------------------|-----------------|-----------------------------|--------------------------------|---------------------------|--------------|
| | | | | | | Rate per 1,000 Person Years | 1,000 New Users | Rate per 1,000 Person Years | Difference per 1,000 New Users | (95% Confidence Interval) | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 752,280 | 186,602.17 | 90.60 | 0.25 | 496 | 2.66 | 0.66 | -1.95 | -0.12 | 0.81 (0.71, 0.91) | <0.001 |
| Inhaled Corticosteroids (ICS) | 923,377 | 155,359.53 | 61.45 | 0.17 | 716 | 4.61 | 0.78 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 752,230 | 186,592.70 | 90.60 | 0.25 | 496 | 2.66 | 0.66 | -0.60 | 0.09 | 0.97 (0.85, 1.10) | N/A |
| ICS | 724,855 | 126,811.70 | 63.90 | 0.17 | 413 | 3.26 | 0.57 | | | | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension, Age Group: 10-24 years | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 207,866 | 35,796.05 | 62.90 | 0.17 | 200 | 5.59 | 0.96 | -0.54 | 0.05 | 0.96 (0.81, 1.15) | 0.666 |
| ICS | 375,869 | 55,841.30 | 54.26 | 0.15 | 342 | 6.12 | 0.91 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 207,822 | 35,786.41 | 62.90 | 0.17 | 200 | 5.59 | 0.96 | 0.04 | 0.13 | 1.05 (0.87, 1.27) | N/A |
| ICS | 201,192 | 30,075.79 | 54.60 | 0.15 | 167 | 5.55 | 0.83 | | | | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension, Age Group: 25-54 years | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 257,136 | 58,225.80 | 82.71 | 0.23 | 230 | 3.95 | 0.89 | -2.64 | -0.20 | 0.82 (0.69, 0.98) | 0.027 |
| ICS | 294,422 | 48,862.35 | 60.62 | 0.17 | 322 | 6.59 | 1.09 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 257,098 | 58,217.17 | 82.71 | 0.23 | 230 | 3.95 | 0.89 | -0.67 | 0.13 | 0.97 (0.80, 1.17) | N/A |
| ICS | 247,509 | 41,047.05 | 60.57 | 0.17 | 190 | 4.62 | 0.77 | | | | |

Table 5b. Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Age Group

| Medical Product | Number of New Users | Person Years at Risk | Average Person Days at Risk | Average Person Years at Risk | Number of Events | Incidence | Risk per | Incidence | Risk | Hazard Ratio | Wald P-Value |
|--|---------------------|----------------------|-----------------------------|------------------------------|------------------|-----------------------------|-----------------|-----------------------------|--------------------------------|---------------------------|--------------|
| | | | | | | Rate per 1,000 Person Years | 1,000 New Users | Rate per 1,000 Person Years | Difference per 1,000 New Users | (95% Confidence Interval) | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension, Age Group: ≥ 55 years | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 287,228 | 92,570.85 | 117.72 | 0.32 | 66 | 0.71 | 0.23 | -0.31 | 0.02 | 0.81 (0.55, 1.19) | 0.279 |
| ICS | 253,066 | 50,652.74 | 73.11 | 0.20 | 52 | 1.03 | 0.21 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 287,144 | 92,553.51 | 117.73 | 0.32 | 66 | 0.71 | 0.23 | -0.12 | 0.06 | 0.89 (0.57, 1.38) | N/A |
| ICS | 275,968 | 55,281.55 | 73.17 | 0.20 | 46 | 0.84 | 0.17 | | | | |

¹All values in this section are weighted.

²ATT = Average Treatment Effect in the Treated.

Table 5c. Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Psychiatric History

| Medical Product | Number of New Users | Person Years at Risk | Average Person Days at Risk | Average Person Years at Risk | Number of Events | Incidence | Risk per | Incidence | Risk | Hazard Ratio | Wald P-Value |
|---|---------------------|----------------------|-----------------------------|------------------------------|------------------|-----------------------------|-----------------|-----------------------------|--------------------------------|---------------------------|--------------|
| | | | | | | Rate per 1,000 Person Years | 1,000 New Users | Rate per 1,000 Person Years | Difference per 1,000 New Users | (95% Confidence Interval) | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 752,280 | 186,602.17 | 90.60 | 0.25 | 496 | 2.66 | 0.66 | -1.95 | -0.12 | 0.81 (0.71, 0.91) | <0.001 |
| Inhaled Corticosteroids (ICS) | 923,377 | 155,359.53 | 61.45 | 0.17 | 716 | 4.61 | 0.78 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 752,230 | 186,592.70 | 90.60 | 0.25 | 496 | 2.66 | 0.66 | -0.60 | 0.09 | 0.97 (0.85, 1.10) | N/A |
| ICS | 724,855 | 126,811.70 | 63.90 | 0.17 | 413 | 3.26 | 0.57 | | | | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension, No Psychiatric History | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 366,756 | 83,544.68 | 83.20 | 0.23 | 51 | 0.61 | 0.14 | -0.19 | 0.01 | 1.24 (0.85, 1.82) | 0.261 |
| ICS | 484,391 | 78,734.27 | 59.37 | 0.16 | 63 | 0.80 | 0.13 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 366,686 | 83,524.01 | 83.20 | 0.23 | 51 | 0.61 | 0.14 | 0.02 | 0.04 | 1.27 (0.85, 1.90) | N/A |
| ICS | 354,802 | 60,501.16 | 62.28 | 0.17 | 35 | 0.59 | 0.10 | | | | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension, Psychiatric History | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 385,474 | 103,048.02 | 97.64 | 0.27 | 445 | 4.32 | 1.15 | -4.20 | -0.33 | 0.75 (0.66, 0.85) | <0.001 |
| ICS | 438,966 | 76,622.12 | 63.75 | 0.17 | 653 | 8.52 | 1.49 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 385,425 | 103,038.14 | 97.64 | 0.27 | 445 | 4.32 | 1.15 | -1.41 | 0.13 | 0.92 (0.81, 1.06) | N/A |
| ICS | 369,811 | 66,201.80 | 65.39 | 0.18 | 379 | 5.72 | 1.02 | | | | |

¹All values in this section are weighted.

²ATT = Average Treatment Effect in the Treated.

Table 5d. Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Pre-/Post-Boxed Warning

| Medical Product | Number of New Users | Person Years at Risk | Average Person Days at Risk | Average Person Years at Risk | Number of Events | Incidence | Risk per | Incidence | Risk | Hazard Ratio | Wald P-Value |
|---|---------------------|----------------------|-----------------------------|------------------------------|------------------|-----------------------------|-----------------|-----------------------------|--------------------------------|---------------------------|--------------|
| | | | | | | Rate per 1,000 Person Years | 1,000 New Users | Rate per 1,000 Person Years | Difference per 1,000 New Users | (95% Confidence Interval) | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 752,280 | 186,602.17 | 90.60 | 0.25 | 496 | 2.66 | 0.66 | -1.95 | -0.12 | 0.81 (0.71, 0.91) | <0.001 |
| Inhaled Corticosteroids (ICS) | 923,377 | 155,359.53 | 61.45 | 0.17 | 716 | 4.61 | 0.78 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 752,230 | 186,592.70 | 90.60 | 0.25 | 496 | 2.66 | 0.66 | -0.60 | 0.09 | 0.97 (0.85, 1.10) | N/A |
| ICS | 724,855 | 126,811.70 | 63.90 | 0.17 | 413 | 3.26 | 0.57 | | | | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension, Pre-boxed Warning | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 596,990 | 145,539.65 | 89.04 | 0.24 | 423 | 2.91 | 0.71 | -1.98 | -0.10 | 0.84 (0.74, 0.96) | 0.009 |
| ICS | 784,999 | 130,001.03 | 60.49 | 0.17 | 635 | 4.88 | 0.81 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 596,938 | 145,530.19 | 89.05 | 0.24 | 423 | 2.91 | 0.71 | -0.58 | 0.11 | 1.00 (0.87, 1.15) | N/A |
| ICS | 575,113 | 98,788.85 | 62.74 | 0.17 | 345 | 3.49 | 0.60 | | | | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension, Post-boxed Warning | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 155,240 | 41,053.05 | 96.59 | 0.26 | 73 | 1.78 | 0.47 | -1.42 | -0.12 | 0.61 (0.44, 0.84) | 0.003 |
| ICS | 138,358 | 25,355.36 | 66.94 | 0.18 | 81 | 3.19 | 0.59 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 155,203 | 41,041.31 | 96.59 | 0.26 | 73 | 1.78 | 0.47 | -0.62 | 0.02 | 0.84 (0.60, 1.18) | N/A |
| ICS | 149,925 | 28,093.17 | 68.44 | 0.19 | 67 | 2.40 | 0.45 | | | | |

¹All values in this section are weighted.

²ATT = Average Treatment Effect in the Treated.

Table 5e. Effect Estimates for Intentional Self Harm All Settings, Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Analysis Type and Sex

| Medical Product | Number of New Users | Person Years at Risk | Average Person Days at Risk | Average Person Years at Risk | Number of Events | Incidence Rate per 1,000 Person Years | Risk per 1,000 New Users | Incidence Rate Difference per 1,000 Person Years | Risk Difference per 1,000 New Users | Hazard Ratio (95% Confidence Interval) | Wald P-Value |
|--|---------------------|----------------------|-----------------------------|------------------------------|------------------|---------------------------------------|--------------------------|--|-------------------------------------|--|--------------|
| Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 752,280 | 186,602.17 | 90.60 | 0.25 | 496 | 2.66 | 0.66 | -1.95 | -0.12 | 0.81 (0.71, 0.91) | <0.001 |
| Inhaled Corticosteroids (ICS) | 923,377 | 155,359.53 | 61.45 | 0.17 | 716 | 4.61 | 0.78 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 752,230 | 186,592.70 | 90.60 | 0.25 | 496 | 2.66 | 0.66 | -0.60 | 0.09 | 0.97 (0.85, 1.10) | N/A |
| ICS | 724,855 | 126,811.70 | 63.90 | 0.17 | 413 | 3.26 | 0.57 | | | | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension, Sex: Female | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 496,977 | 125,994.48 | 92.60 | 0.25 | 377 | 2.99 | 0.76 | -2.56 | -0.18 | 0.79 (0.69, 0.91) | <0.001 |
| ICS | 568,584 | 96,182.25 | 61.79 | 0.17 | 534 | 5.55 | 0.94 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 496,923 | 125,982.94 | 92.60 | 0.25 | 377 | 2.99 | 0.76 | -0.73 | 0.11 | 0.98 (0.85, 1.14) | N/A |
| ICS | 478,441 | 83,815.77 | 63.99 | 0.18 | 312 | 3.72 | 0.65 | | | | |
| Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension, Sex: Male | | | | | | | | | | | |
| <i>Site-Adjusted Analysis, Unweighted</i> | | | | | | | | | | | |
| Montelukast | 255,253 | 60,598.22 | 86.71 | 0.24 | 119 | 1.96 | 0.47 | -1.11 | -0.05 | 0.82 (0.64, 1.04) | 0.101 |
| ICS | 354,773 | 59,174.14 | 60.92 | 0.17 | 182 | 3.08 | 0.51 | | | | |
| <i>Inverse Probability of Treatment Weighted Analysis¹; Weight = ATT, Trimmed²</i> | | | | | | | | | | | |
| Montelukast | 255,186 | 60,585.24 | 86.72 | 0.24 | 119 | 1.96 | 0.47 | -0.38 | 0.06 | 0.94 (0.71, 1.23) | N/A |
| ICS | 246,692 | 43,013.01 | 63.68 | 0.17 | 101 | 2.34 | 0.41 | | | | |

¹All values in this section are weighted.

²ATT = Average Treatment Effect in the Treated.

Table 6. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| | Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension | | | | Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension | | | |
|--|--|-------------|-------------------------------|-------------|---|-------------|-------------|-------------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Montelukast | | ICS | |
| | Remaining | Excluded | Remaining | Excluded | Remaining | Excluded | Remaining | Excluded |
| Members meeting enrollment and demographic requirements | | | | | | | | |
| Enrolled at any point during the query period | 326,966,050 | N/A | 326,966,050 | N/A | 326,966,050 | N/A | 326,966,050 | N/A |
| Had required coverage type (medical and/or drug coverage) | 238,643,511 | 88,322,539 | 238,643,511 | 88,322,539 | 238,643,511 | 88,322,539 | 238,643,511 | 88,322,539 |
| Enrolled during specified age range | 208,424,252 | 30,219,259 | 208,424,252 | 30,219,259 | 208,424,252 | 30,219,259 | 208,424,252 | 30,219,259 |
| Had requestable medical charts | 208,424,252 | 0 | 208,424,252 | 0 | 208,424,252 | 0 | 208,424,252 | 0 |
| Met demographic requirements (sex, race, and Hispanic origin) | 208,341,758 | 82,494 | 208,341,758 | 82,494 | 208,341,758 | 82,494 | 208,341,758 | 82,494 |
| Members with a valid index event | | | | | | | | |
| Had any cohort-defining claim during the query period | 9,937,567 | 198,404,191 | 5,005,983 | 203,335,775 | 9,937,567 | 198,404,191 | 5,005,983 | 203,335,775 |
| Claim recorded during specified age range | 9,567,331 | 370,236 | 4,661,260 | 344,723 | 9,567,331 | 370,236 | 4,661,260 | 344,723 |
| Episode defining index claim recorded during the query period | 8,389,960 | 1,177,371 | 4,286,088 | 375,172 | 8,389,960 | 1,177,371 | 4,286,088 | 375,172 |
| Members with required pre-index history | | | | | | | | |
| Had sufficient pre-index continuous enrollment | 5,937,854 | 2,452,106 | 3,325,118 | 960,970 | 5,937,854 | 2,452,106 | 3,325,118 | 960,970 |
| Met inclusion and exclusion criteria ¹ | 993,959 | 4,943,895 | 1,056,651 | 2,268,467 | 993,959 | 4,943,895 | 1,056,651 | 2,268,467 |
| <i>Evidence of copd_EXC</i> | N/A | 820,930 | N/A | 566,698 | N/A | 820,930 | N/A | 566,698 |
| <i>Evidence of ICS_EXC</i> | N/A | 194,004 | N/A | N/A | N/A | 194,004 | N/A | N/A |
| <i>Evidence of mont_EXC</i> | N/A | N/A | N/A | 211,203 | N/A | N/A | N/A | 211,203 |
| <i>Evidence of non_ICS_wash</i> | N/A | N/A | N/A | 720,166 | N/A | N/A | N/A | 720,166 |

Table 6. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| | Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension | | | | Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension | | | |
|--|--|-----------|-------------------------------|-----------|---|-----------|-----------|-----------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Montelukast | | ICS | |
| | Remaining | Excluded | Remaining | Excluded | Remaining | Excluded | Remaining | Excluded |
| <i>Evidence of non_mont_wash</i> | N/A | 923,690 | N/A | N/A | N/A | 923,690 | N/A | N/A |
| <i>No evidence of asthma_INC</i> | N/A | 4,206,100 | N/A | 1,709,965 | N/A | 4,206,100 | N/A | 1,709,965 |
| Met event incidence criteria | 993,959 | 0 | 1,056,651 | 0 | 993,959 | 0 | 1,056,651 | 0 |
| Members with required post-index follow-up | | | | | | | | |
| Had sufficient post-index continuous enrollment | 993,856 | 103 | 1,056,612 | 39 | 993,856 | 103 | 1,056,612 | 39 |
| Had minimum days' supply on index date | 993,856 | 0 | 1,056,612 | 0 | 993,856 | 0 | 1,056,612 | 0 |
| Had index episode of at least required length | 993,856 | 0 | 1,056,612 | 0 | 993,856 | 0 | 1,056,612 | 0 |
| Had index episode longer than blackout period | 769,703 | 224,153 | 936,277 | 120,335 | 769,703 | ***** | 936,277 | ***** |
| Did not have an event during blackout period | 769,673 | 30 | 936,241 | 36 | 769,702 | ***** | 936,273 | ***** |
| Final cohort | | | | | | | | |
| Number of members | 769,673 | N/A | 936,241 | N/A | 769,702 | N/A | 936,273 | N/A |
| Number of episodes | 769,673 | N/A | 936,241 | N/A | 769,702 | N/A | 936,273 | N/A |
| Members meeting comparative cohort eligibility requirements | | | | | | | | |
| Excluded due to same-day initiation of both exposure groups | 769,781 | 0 | 936,281 | 0 | 769,810 | 0 | 936,313 | 0 |
| Excluded due to prior initiation of other exposure group | 752,280 | 17,501 | 923,377 | 12,904 | 752,307 | 17,503 | 923,409 | 12,904 |
| Excluded due to propensity score trimming | 752,230 | 50 | 923,357 | 20 | 752,257 | 50 | 923,389 | 20 |
| Included in comparative analysis | 752,230 | 0 | 923,357 | 0 | 752,257 | 0 | 923,389 | 0 |

Table 6. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| | Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension | | | | Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension | | | |
|---|--|----------|-------------------------------|----------|---|----------|-----------|----------|
| | Montelukast | | Inhaled Corticosteroids (ICS) | | Montelukast | | ICS | |
| | Remaining | Excluded | Remaining | Excluded | Remaining | Excluded | Remaining | Excluded |
| Additional information | | | | | | | | |
| Number of events in comparative analysis | 580 | N/A | 882 | N/A | 411 | N/A | 578 | N/A |
| Number of patients with a truncated inverse probability of treatment weight | 0 | N/A | 53,276 | N/A | 0 | N/A | 53,278 | N/A |

Table 6. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| | Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension | | | | Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension | | | |
|--|---|-------------|-------------|-------------|--|-------------|-------------|-------------|
| | Montelukast | | ICS | | Montelukast | | ICS | |
| | Remaining | Excluded | Remaining | Excluded | Remaining | Excluded | Remaining | Excluded |
| Members meeting enrollment and demographic requirements | | | | | | | | |
| Enrolled at any point during the query period | 326,966,050 | N/A | 326,966,050 | N/A | 326,966,050 | N/A | 326,966,050 | N/A |
| Had required coverage type (medical and/or drug coverage) | 238,643,511 | 88,322,539 | 238,643,511 | 88,322,539 | 238,643,511 | 88,322,539 | 238,643,511 | 88,322,539 |
| Enrolled during specified age range | 208,424,252 | 30,219,259 | 208,424,252 | 30,219,259 | 208,424,252 | 30,219,259 | 208,424,252 | 30,219,259 |
| Had requestable medical charts | 208,424,252 | 0 | 208,424,252 | 0 | 208,424,252 | 0 | 208,424,252 | 0 |
| Met demographic requirements (sex, race, and Hispanic origin) | 208,341,758 | 82,494 | 208,341,758 | 82,494 | 208,341,758 | 82,494 | 208,341,758 | 82,494 |
| Members with a valid index event | | | | | | | | |
| Had any cohort-defining claim during the query period | 9,937,567 | 198,404,191 | 5,005,983 | 203,335,775 | 9,937,567 | 198,404,191 | 5,005,983 | 203,335,775 |
| Claim recorded during specified age range | 9,567,331 | 370,236 | 4,661,260 | 344,723 | 9,567,331 | 370,236 | 4,661,260 | 344,723 |
| Episode defining index claim recorded during the query period | 8,389,960 | 1,177,371 | 4,286,088 | 375,172 | 8,389,960 | 1,177,371 | 4,286,088 | 375,172 |
| Members with required pre-index history | | | | | | | | |
| Had sufficient pre-index continuous enrollment | 5,937,854 | 2,452,106 | 3,325,118 | 960,970 | 5,937,854 | 2,452,106 | 3,325,118 | 960,970 |
| Met inclusion and exclusion criteria ¹ | 993,959 | 4,943,895 | 1,056,651 | 2,268,467 | 993,959 | 4,943,895 | 1,056,651 | 2,268,467 |
| <i>Evidence of copd_EXC</i> | N/A | 820,930 | N/A | 566,698 | N/A | 820,930 | N/A | 566,698 |
| <i>Evidence of ICS_EXC</i> | N/A | 194,004 | N/A | N/A | N/A | 194,004 | N/A | N/A |
| <i>Evidence of mont_EXC</i> | N/A | N/A | N/A | 211,203 | N/A | N/A | N/A | 211,203 |
| <i>Evidence of non_ICS_wash</i> | N/A | N/A | N/A | 720,166 | N/A | N/A | N/A | 720,166 |
| <i>Evidence of non_mont_wash</i> | N/A | 923,690 | N/A | N/A | N/A | 923,690 | N/A | N/A |
| <i>No evidence of asthma_INC</i> | N/A | 4,206,100 | N/A | 1,709,965 | N/A | 4,206,100 | N/A | 1,709,965 |
| Met event incidence criteria | 993,959 | 0 | 1,056,651 | 0 | 993,959 | 0 | 1,056,651 | 0 |

Table 6. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

| | Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension | | | | Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension | | | |
|---|---|----------|-----------|----------|--|----------|-----------|----------|
| | Montelukast | | ICS | | Montelukast | | ICS | |
| | Remaining | Excluded | Remaining | Excluded | Remaining | Excluded | Remaining | Excluded |
| Members with required post-index follow-up | | | | | | | | |
| Had sufficient post-index continuous enrollment | 993,893 | 66 | 1,056,634 | 17 | 993,870 | 89 | 1,056,621 | 30 |
| Had minimum days' supply on index date | 993,893 | 0 | 1,056,634 | 0 | 993,870 | 0 | 1,056,621 | 0 |
| Had index episode of at least required length | 993,893 | 0 | 1,056,634 | 0 | 993,870 | 0 | 1,056,621 | 0 |
| Had index episode longer than blackout period | 769,632 | 224,261 | 936,087 | 120,547 | 769,719 | 224,151 | 936,287 | 120,334 |
| Did not have an event during blackout period | 769,602 | 30 | 936,051 | 36 | 769,689 | 30 | 936,251 | 36 |
| Final cohort | | | | | | | | |
| Number of members | 769,602 | N/A | 936,051 | N/A | 769,689 | N/A | 936,251 | N/A |
| Number of episodes | 769,602 | N/A | 936,051 | N/A | 769,689 | N/A | 936,251 | N/A |
| Members meeting comparative cohort eligibility requirements | | | | | | | | |
| Excluded due to same-day initiation of both exposure groups | 769,671 | 0 | 936,068 | 0 | 769,781 | 0 | 936,281 | 0 |
| Excluded due to prior initiation of other exposure group | 752,176 | 17,495 | 923,166 | 12,902 | 752,280 | 17,501 | 923,377 | 12,904 |
| Excluded due to propensity score trimming | 752,128 | 48 | 923,145 | 21 | 752,230 | 50 | 923,357 | 20 |
| Included in comparative analysis | 752,128 | 0 | 923,145 | 0 | 752,230 | 0 | 923,357 | 0 |
| Additional information | | | | | | | | |
| Number of events in comparative analysis | 325 | N/A | 512 | N/A | 496 | N/A | 716 | N/A |
| Number of patients with a truncated inverse probability of treatment weight | 0 | N/A | 53,263 | N/A | 0 | N/A | 53,276 | N/A |

¹Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Figure 1a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

Unweighted Propensity Score Distribution Before Trimming




Figure 1a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

Unweighted Propensity Score Distribution After Trimming




Figure 1a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 1b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

Unweighted Propensity Score Distribution Before Trimming




Figure 1b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

Unweighted Propensity Score Distribution After Trimming




Figure 1b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 1c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

Unweighted Propensity Score Distribution Before Trimming




Figure 1c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

Unweighted Propensity Score Distribution After Trimming




Figure 1c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 1d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 years

Unweighted Propensity Score Distribution Before Trimming




Figure 1d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 years

Unweighted Propensity Score Distribution After Trimming




Figure 1d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 1e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 years

Unweighted Propensity Score Distribution Before Trimming




Figure 1e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 years

Unweighted Propensity Score Distribution After Trimming




Figure 1e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 1f. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 years

Unweighted Propensity Score Distribution Before Trimming




Figure 1f. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 years

Unweighted Propensity Score Distribution After Trimming




Figure 1f. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 1g. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

Unweighted Propensity Score Distribution Before Trimming




Figure 1g. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

Unweighted Propensity Score Distribution After Trimming




Figure 1g. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 1h. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

Unweighted Propensity Score Distribution Before Trimming




Figure 1h. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

Unweighted Propensity Score Distribution After Trimming




Figure 1h. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 1i. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

Unweighted Propensity Score Distribution Before Trimming




Figure 1i. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

Unweighted Propensity Score Distribution After Trimming




Figure 1i. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 1j. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

Unweighted Propensity Score Distribution Before Trimming




Figure 1j. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

Unweighted Propensity Score Distribution After Trimming




Figure 1j. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 2a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

Unweighted Propensity Score Distribution Before Trimming




Figure 2a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

Unweighted Propensity Score Distribution After Trimming




Figure 2a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 2b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

Unweighted Propensity Score Distribution Before Trimming




Figure 2b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

Unweighted Propensity Score Distribution After Trimming




Figure 2b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 2c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

Unweighted Propensity Score Distribution Before Trimming




Figure 2c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

Unweighted Propensity Score Distribution After Trimming




Figure 2c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 2d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 years

Unweighted Propensity Score Distribution Before Trimming




Figure 2d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 years

Unweighted Propensity Score Distribution After Trimming




Figure 2d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 2e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 years

Unweighted Propensity Score Distribution Before Trimming




Figure 2e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 years

Unweighted Propensity Score Distribution After Trimming




Figure 2e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 2f. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 years

Unweighted Propensity Score Distribution Before Trimming




Figure 2f. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 years

Unweighted Propensity Score Distribution After Trimming




Figure 2f. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 2g. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

Unweighted Propensity Score Distribution Before Trimming




Figure 2g. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

Unweighted Propensity Score Distribution After Trimming




Figure 2g. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 2h. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

Unweighted Propensity Score Distribution Before Trimming




Figure 2h. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

Unweighted Propensity Score Distribution After Trimming




Figure 2h. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 2i. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

Unweighted Propensity Score Distribution Before Trimming




Figure 2i. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

Unweighted Propensity Score Distribution After Trimming




Figure 2i. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 2j. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

Unweighted Propensity Score Distribution Before Trimming




Figure 2j. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

Unweighted Propensity Score Distribution After Trimming




Figure 2j. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 3a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

Unweighted Propensity Score Distribution Before Trimming




Figure 3a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

Unweighted Propensity Score Distribution After Trimming




Figure 3a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 3b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

Unweighted Propensity Score Distribution Before Trimming




Figure 3b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

Unweighted Propensity Score Distribution After Trimming




Figure 3b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 3c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

Unweighted Propensity Score Distribution Before Trimming




Figure 3c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

Unweighted Propensity Score Distribution After Trimming




Figure 3c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 3d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 years

Unweighted Propensity Score Distribution Before Trimming




Figure 3d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 years

Unweighted Propensity Score Distribution After Trimming




Figure 3d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 3e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 years

Unweighted Propensity Score Distribution Before Trimming




Figure 3e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 years

Unweighted Propensity Score Distribution After Trimming




Figure 3e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 3f. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 years

Unweighted Propensity Score Distribution Before Trimming




Figure 3f. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 years

Unweighted Propensity Score Distribution After Trimming




Figure 3f. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 3g. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

Unweighted Propensity Score Distribution Before Trimming




Figure 3g. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

Unweighted Propensity Score Distribution After Trimming




Figure 3g. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 3h. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

Unweighted Propensity Score Distribution Before Trimming




Figure 3h. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

Unweighted Propensity Score Distribution After Trimming




Figure 3h. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 3i. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

Unweighted Propensity Score Distribution Before Trimming




Figure 3i. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

Unweighted Propensity Score Distribution After Trimming




Figure 3i. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 3j. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

Unweighted Propensity Score Distribution Before Trimming




Figure 3j. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

Unweighted Propensity Score Distribution After Trimming




Figure 3j. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 4a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

Unweighted Propensity Score Distribution Before Trimming




Figure 4a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

Unweighted Propensity Score Distribution After Trimming




Figure 4a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 4b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

Unweighted Propensity Score Distribution Before Trimming




Figure 4b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

Unweighted Propensity Score Distribution After Trimming




Figure 4b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 4c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

Unweighted Propensity Score Distribution Before Trimming




Figure 4c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

Unweighted Propensity Score Distribution After Trimming




Figure 4c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 4d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 years

Unweighted Propensity Score Distribution Before Trimming




Figure 4d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 years

Unweighted Propensity Score Distribution After Trimming




Figure 4d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 4e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 years

Unweighted Propensity Score Distribution Before Trimming




Figure 4e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 years

Unweighted Propensity Score Distribution After Trimming




Figure 4e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 4f. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 years

Unweighted Propensity Score Distribution Before Trimming




Figure 4f. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 years

Unweighted Propensity Score Distribution After Trimming




Figure 4f. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 years

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 4g. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

Unweighted Propensity Score Distribution Before Trimming




Figure 4g. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

Unweighted Propensity Score Distribution After Trimming




Figure 4g. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 4h. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

Unweighted Propensity Score Distribution Before Trimming




Figure 4h. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

Unweighted Propensity Score Distribution After Trimming




Figure 4h. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 4i. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

Unweighted Propensity Score Distribution Before Trimming




Figure 4i. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

Unweighted Propensity Score Distribution After Trimming




Figure 4i. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 4j. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

Unweighted Propensity Score Distribution Before Trimming




Figure 4j. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

Unweighted Propensity Score Distribution After Trimming




Figure 4j. Histograms Depicting Propensity Score Distributions Before and After Adjustment for Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect in the Treated (ATT)




Figure 5a. Forest Plot of Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Site-Adjusted Analyses in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022





Figure 5b. Forest Plot of Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Inverse Probability of Treatment Weighted Analyses in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022



¹Weighted using Average Treatment Effect in the Treated, (ATT)

Figure 6a. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022




Figure 6b. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022




Figure 6c. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female




Figure 6d. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female




Figure 6e. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male




Figure 6f. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male




Figure 6g. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 years




Figure 6h. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 years




Figure 6i. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 years




Figure 6j. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 years




Figure 6k. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 years




Figure 6I. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 years




Figure 6m. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History




Figure 6n. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History




Figure 6o. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History




Figure 6p. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History




Figure 6q. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning




Figure 6r. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning




Figure 6s. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning




Figure 6t. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning




Figure 7a. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022




Figure 7b. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022




Figure 7c. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female




Figure 7d. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm Inpatient and Emergency 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female




Figure 7e. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male




Figure 7f. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male




Figure 7g. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 years




Figure 7h. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 years




Figure 7i. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 years




Figure 7j. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 years




Figure 7k. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 years




Figure 7I. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 years




Figure 7m. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History




Figure 7n. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History




Figure 7o. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History




Figure 7p. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History




Figure 7q. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning




Figure 7r. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning




Figure 7s. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning




Figure 7t. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension from the Weighted Population after Intentional Self Harm Inpatient and Emergency, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning




Figure 8a. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022




Figure 8b. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022




Figure 8c. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female




Figure 8d. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female




Figure 8e. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male




Figure 8f. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male




Figure 8g. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 years




Figure 8h. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 years




Figure 8i. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 years




Figure 8j. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 years




Figure 8k. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 years




Figure 8I. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 years




Figure 8m. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History




Figure 8n. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History




Figure 80. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History




Figure 8p. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History




Figure 8q. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning




Figure 8r. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning




Figure 8s. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning




Figure 8t. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 0-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning




Figure 9a. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022




Figure 9b. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022




Figure 9c. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female




Figure 9d. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Female




Figure 9e. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male




Figure 9f. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Sex: Male




Figure 9g. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 years




Figure 9h. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 10-24 years




Figure 9i. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 years




Figure 9j. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: 25-54 years




Figure 9k. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 years




Figure 9I. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Age Group: ≥ 55 years




Figure 9m. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History




Figure 9n. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, No Psychiatric History




Figure 9o. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History




Figure 9p. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Psychiatric History




Figure 9q. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning




Figure 9r. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Pre-boxed Warning




Figure 9s. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Whole Population in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning





Figure 9t. Aggregated Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among Intentional Self Harm All Settings Truncation Weight = 2.5, 15-day Gap and Extension from the Weighted Population after Intentional Self Harm All Settings 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, Post-boxed Warning



Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (December 21, 2022)

| DP ID | DP Start Date | DP End Date ¹ |
|-------|---------------|--------------------------|
| DP01 | 01/01/2006 | 06/30/2022 |
| DP02 | 01/01/2007 | 01/31/2022 |
| DP03 | 01/01/2008 | 04/30/2022 |
| DP04 | 01/01/2014 | 12/31/2018 |
| DP05 | 01/01/2008 | 06/30/2022 |
| DP06 | 01/01/2010 | 03/31/2022 |

¹End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

**Appendix B. Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm All Settings
Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022,
by Data Partner (DP), Weight: Average Treatment Effect in the Treated (ATT)**

| DP ID | Number of Patients | Minimum | Maximum | Mean | Standard Deviation |
|------------|--------------------|---------|---------|-------|--------------------|
| Aggregated | 1,675,587 | 0.239 | 3.482 | 0.882 | 0.392 |
| DP01 | 289,671 | 0.386 | 2.292 | 0.982 | 0.377 |
| DP02 | 59,948 | 0.594 | 3.482 | 1.206 | 0.581 |
| DP03 | 180,018 | 0.335 | 2.059 | 0.919 | 0.357 |
| DP04 | 593,493 | 0.239 | 1.128 | 0.657 | 0.308 |
| DP05 | 137,116 | 0.337 | 2.290 | 0.961 | 0.388 |
| DP06 | 415,341 | 0.363 | 2.923 | 1.043 | 0.481 |

**Appendix C. Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm All Settings
Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022,
by Data Partner (DP), Sex, Weight: Average Treatment Effect in the Treated (ATT)**

| DP ID | Number of Patients | Minimum | Maximum | Mean | Standard Deviation |
|--------------------|--------------------|---------|---------|-------|--------------------|
| Overall | | | | | |
| Aggregated | 1,675,587 | 0.239 | 3.482 | 0.882 | 0.392 |
| DP01 | 289,671 | 0.386 | 2.292 | 0.982 | 0.377 |
| DP02 | 59,948 | 0.594 | 3.482 | 1.206 | 0.581 |
| DP03 | 180,018 | 0.335 | 2.059 | 0.919 | 0.357 |
| DP04 | 593,493 | 0.239 | 1.128 | 0.657 | 0.308 |
| DP05 | 137,116 | 0.337 | 2.290 | 0.961 | 0.388 |
| DP06 | 415,341 | 0.363 | 2.923 | 1.043 | 0.481 |
| Sex: Female | | | | | |
| Aggregated | 1,065,491 | 0.246 | 3.622 | 0.915 | 0.410 |
| DP01 | 178,881 | 0.422 | 2.461 | 1.019 | 0.399 |
| DP02 | 43,279 | 0.639 | 3.622 | 1.228 | 0.610 |
| DP03 | 107,647 | 0.359 | 2.224 | 0.955 | 0.375 |
| DP04 | 346,420 | 0.246 | 1.167 | 0.666 | 0.309 |
| DP05 | 85,620 | 0.375 | 2.486 | 1.005 | 0.413 |
| DP06 | 303,644 | 0.376 | 2.959 | 1.056 | 0.485 |
| Sex: Male | | | | | |
| Aggregated | 609,940 | 0.218 | 3.192 | 0.823 | 0.362 |
| DP01 | 110,781 | 0.351 | 2.019 | 0.924 | 0.344 |
| DP02 | 16,618 | 0.502 | 3.192 | 1.149 | 0.520 |
| DP03 | 72,342 | 0.312 | 1.818 | 0.868 | 0.333 |
| DP04 | 247,062 | 0.218 | 1.097 | 0.645 | 0.309 |
| DP05 | 51,475 | 0.304 | 1.944 | 0.889 | 0.347 |
| DP06 | 111,662 | 0.332 | 2.830 | 1.009 | 0.469 |

**Appendix D. Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm All Settings
Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022,
by Data Partner (DP), Age Group, Weight: Average Treatment Effect in the Treated (ATT)**

| DP ID | Number of Patients | Minimum | Maximum | Mean | Standard Deviation |
|-------------------------------|--------------------|---------|---------|-------|--------------------|
| Overall | | | | | |
| Aggregated | 1,675,587 | 0.239 | 3.482 | 0.882 | 0.392 |
| DP01 | 289,671 | 0.386 | 2.292 | 0.982 | 0.377 |
| DP02 | 59,948 | 0.594 | 3.482 | 1.206 | 0.581 |
| DP03 | 180,018 | 0.335 | 2.059 | 0.919 | 0.357 |
| DP04 | 593,493 | 0.239 | 1.128 | 0.657 | 0.308 |
| DP05 | 137,116 | 0.337 | 2.290 | 0.961 | 0.388 |
| DP06 | 415,341 | 0.363 | 2.923 | 1.043 | 0.481 |
| Age Group: 10-24 years | | | | | |
| Aggregated | 583,661 | 0.190 | 2.542 | 0.701 | 0.327 |
| DP01 | 96,753 | 0.232 | 1.775 | 0.810 | 0.356 |
| DP02 | 4,828 | 0.257 | 2.542 | 0.955 | 0.438 |
| DP03 | 63,343 | 0.213 | 1.595 | 0.762 | 0.346 |
| DP04 | 374,042 | 0.220 | 1.157 | 0.653 | 0.312 |
| DP05 | 41,441 | 0.190 | 1.535 | 0.737 | 0.348 |
| DP06 | 3,254 | 0.286 | 2.131 | 0.918 | 0.365 |
| Age Group: 25-54 years | | | | | |
| Aggregated | 551,500 | 0.231 | 3.974 | 0.915 | 0.404 |
| DP01 | 129,388 | 0.546 | 2.763 | 1.094 | 0.442 |
| DP02 | 13,478 | 0.744 | 3.974 | 1.301 | 0.703 |
| DP03 | 90,932 | 0.465 | 2.425 | 1.018 | 0.396 |
| DP04 | 187,358 | 0.231 | 1.229 | 0.667 | 0.316 |
| DP05 | 59,642 | 0.499 | 2.656 | 1.058 | 0.432 |
| DP06 | 70,702 | 0.255 | 2.504 | 0.917 | 0.443 |
| Age Group: ≥ 55 years | | | | | |
| Aggregated | 540,190 | 0.195 | 3.633 | 1.042 | 0.465 |
| DP01 | 63,507 | 0.436 | 2.336 | 1.016 | 0.367 |
| DP02 | 41,543 | 0.566 | 3.633 | 1.205 | 0.606 |
| DP03 | 25,703 | 0.423 | 2.159 | 0.967 | 0.345 |
| DP04 | 32,073 | 0.195 | 1.181 | 0.638 | 0.324 |
| DP05 | 36,008 | 0.462 | 2.713 | 1.065 | 0.431 |
| DP06 | 341,356 | 0.400 | 2.962 | 1.069 | 0.483 |

**Appendix E. Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm All Settings
Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30,
2022, by Data Partner (DP), Psychiatric History, Weight: Average Treatment Effect in the Treated (ATT)**

| DP ID | Number of Patients | Minimum | Maximum | Mean | Standard Deviation |
|-------------------------------|--------------------|---------|---------|-------|--------------------|
| Overall | | | | | |
| Aggregated | 1,675,587 | 0.239 | 3.482 | 0.882 | 0.392 |
| DP01 | 289,671 | 0.386 | 2.292 | 0.982 | 0.377 |
| DP02 | 59,948 | 0.594 | 3.482 | 1.206 | 0.581 |
| DP03 | 180,018 | 0.335 | 2.059 | 0.919 | 0.357 |
| DP04 | 593,493 | 0.239 | 1.128 | 0.657 | 0.308 |
| DP05 | 137,116 | 0.337 | 2.290 | 0.961 | 0.388 |
| DP06 | 415,341 | 0.363 | 2.923 | 1.043 | 0.481 |
| No Psychiatric History | | | | | |
| Aggregated | 851,056 | 0.243 | 3.378 | 0.848 | 0.360 |
| DP01 | 162,051 | 0.374 | 2.118 | 0.950 | 0.354 |
| DP02 | 23,613 | 0.574 | 3.378 | 1.189 | 0.556 |
| DP03 | 104,329 | 0.322 | 1.936 | 0.892 | 0.344 |
| DP04 | 342,985 | 0.243 | 1.159 | 0.664 | 0.307 |
| DP05 | 77,304 | 0.327 | 2.151 | 0.932 | 0.369 |
| DP06 | 140,774 | 0.397 | 2.738 | 1.042 | 0.443 |
| Psychiatric History | | | | | |
| Aggregated | 824,376 | 0.225 | 3.650 | 0.916 | 0.428 |
| DP01 | 127,609 | 0.400 | 2.534 | 1.023 | 0.412 |
| DP02 | 36,265 | 0.590 | 3.650 | 1.218 | 0.613 |
| DP03 | 75,672 | 0.347 | 2.261 | 0.958 | 0.382 |
| DP04 | 250,496 | 0.225 | 1.143 | 0.647 | 0.316 |
| DP05 | 59,794 | 0.347 | 2.492 | 0.998 | 0.417 |
| DP06 | 274,540 | 0.343 | 3.028 | 1.043 | 0.502 |

**Appendix F. Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm All Settings
Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30,
2022, by Data Partner (DP), Pre-/Post-Boxed Warning, Weight: Average Treatment Effect in the Treated (ATT)**

| DP ID | Number of Patients | Minimum | Maximum | Mean | Standard Deviation |
|---------------------------|--------------------|---------|---------|-------|--------------------|
| Overall | | | | | |
| Aggregated | 1,675,587 | 0.239 | 3.482 | 0.882 | 0.392 |
| DP01 | 289,671 | 0.386 | 2.292 | 0.982 | 0.377 |
| DP02 | 59,948 | 0.594 | 3.482 | 1.206 | 0.581 |
| DP03 | 180,018 | 0.335 | 2.059 | 0.919 | 0.357 |
| DP04 | 593,493 | 0.239 | 1.128 | 0.657 | 0.308 |
| DP05 | 137,116 | 0.337 | 2.290 | 0.961 | 0.388 |
| DP06 | 415,341 | 0.363 | 2.923 | 1.043 | 0.481 |
| Pre-boxed warning | | | | | |
| Aggregated | 1,381,919 | 0.239 | 3.548 | 0.848 | 0.380 |
| DP01 | 204,552 | 0.377 | 2.299 | 0.975 | 0.381 |
| DP02 | 40,767 | 0.570 | 3.548 | 1.213 | 0.599 |
| DP03 | 131,209 | 0.329 | 2.050 | 0.914 | 0.358 |
| DP04 | 593,489 | 0.239 | 1.128 | 0.657 | 0.308 |
| DP05 | 96,818 | 0.339 | 2.286 | 0.958 | 0.388 |
| DP06 | 315,084 | 0.345 | 2.794 | 1.017 | 0.465 |
| Post-boxed warning | | | | | |
| Aggregated | 293,541 | 0.329 | 3.414 | 1.039 | 0.448 |
| DP01 | 85,095 | 0.399 | 2.320 | 0.999 | 0.377 |
| DP02 | 19,136 | 0.630 | 3.414 | 1.192 | 0.558 |
| DP03 | 48,779 | 0.347 | 2.103 | 0.934 | 0.356 |
| DP05 | 40,281 | 0.329 | 2.328 | 0.967 | 0.394 |
| DP06 | 100,250 | 0.492 | 3.298 | 1.126 | 0.533 |

Appendix G. Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Data Partner (DP), Weight: Average Treatment Effect in the Treated (ATT)

| DP ID | Number of Patients | Minimum | Maximum | Mean | Standard Deviation |
|------------|--------------------|---------|---------|-------|--------------------|
| Aggregated | 1,675,646 | 0.239 | 3.483 | 0.882 | 0.392 |
| DP01 | 289,683 | 0.386 | 2.292 | 0.982 | 0.377 |
| DP02 | 59,952 | 0.594 | 3.483 | 1.206 | 0.581 |
| DP03 | 180,024 | 0.335 | 2.059 | 0.919 | 0.357 |
| DP04 | 593,510 | 0.239 | 1.128 | 0.657 | 0.308 |
| DP05 | 137,119 | 0.337 | 2.291 | 0.961 | 0.388 |
| DP06 | 415,358 | 0.363 | 2.924 | 1.043 | 0.481 |

Appendix H. Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Data Partner (DP), Sex, Weight: Average Treatment Effect in the Treated (ATT)

| DP ID | Number of Patients | Minimum | Maximum | Mean | Standard Deviation |
|--------------------|--------------------|---------|---------|-------|--------------------|
| Overall | | | | | |
| Aggregated | 1,675,646 | 0.239 | 3.483 | 0.882 | 0.392 |
| DP01 | 289,683 | 0.386 | 2.292 | 0.982 | 0.377 |
| DP02 | 59,952 | 0.594 | 3.483 | 1.206 | 0.581 |
| DP03 | 180,024 | 0.335 | 2.059 | 0.919 | 0.357 |
| DP04 | 593,510 | 0.239 | 1.128 | 0.657 | 0.308 |
| DP05 | 137,119 | 0.337 | 2.291 | 0.961 | 0.388 |
| DP06 | 415,358 | 0.363 | 2.924 | 1.043 | 0.481 |
| Sex: Female | | | | | |
| Aggregated | 1,065,561 | 0.245 | 3.616 | 0.915 | 0.410 |
| DP01 | 178,890 | 0.422 | 2.461 | 1.019 | 0.399 |
| DP02 | 43,320 | 0.640 | 3.616 | 1.228 | 0.609 |
| DP03 | 107,656 | 0.359 | 2.223 | 0.955 | 0.375 |
| DP04 | 346,426 | 0.245 | 1.167 | 0.666 | 0.309 |
| DP05 | 85,622 | 0.375 | 2.487 | 1.005 | 0.413 |
| DP06 | 303,647 | 0.376 | 2.960 | 1.056 | 0.486 |
| Sex: Male | | | | | |
| Aggregated | 609,960 | 0.218 | 3.192 | 0.823 | 0.362 |
| DP01 | 110,783 | 0.351 | 2.019 | 0.924 | 0.344 |
| DP02 | 16,618 | 0.502 | 3.192 | 1.149 | 0.520 |
| DP03 | 72,349 | 0.312 | 1.817 | 0.868 | 0.333 |
| DP04 | 247,066 | 0.218 | 1.097 | 0.645 | 0.309 |
| DP05 | 51,475 | 0.304 | 1.944 | 0.889 | 0.347 |
| DP06 | 111,669 | 0.332 | 2.831 | 1.009 | 0.469 |

Appendix I. Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Data Partner (DP), Age Group, Weight: Average Treatment Effect in the Treated (ATT)

| DP ID | Number of Patients | Minimum | Maximum | Mean | Standard Deviation |
|-------------------------------|--------------------|---------|---------|-------|--------------------|
| Overall | | | | | |
| Aggregated | 1,675,646 | 0.239 | 3.483 | 0.882 | 0.392 |
| DP01 | 289,683 | 0.386 | 2.292 | 0.982 | 0.377 |
| DP02 | 59,952 | 0.594 | 3.483 | 1.206 | 0.581 |
| DP03 | 180,024 | 0.335 | 2.059 | 0.919 | 0.357 |
| DP04 | 593,510 | 0.239 | 1.128 | 0.657 | 0.308 |
| DP05 | 137,119 | 0.337 | 2.291 | 0.961 | 0.388 |
| DP06 | 415,358 | 0.363 | 2.924 | 1.043 | 0.481 |
| Age Group: 10-24 years | | | | | |
| Aggregated | 583,695 | 0.190 | 2.539 | 0.701 | 0.327 |
| DP01 | 96,760 | 0.232 | 1.776 | 0.810 | 0.356 |
| DP02 | 4,829 | 0.257 | 2.539 | 0.954 | 0.438 |
| DP03 | 63,352 | 0.213 | 1.595 | 0.762 | 0.346 |
| DP04 | 374,053 | 0.220 | 1.157 | 0.653 | 0.312 |
| DP05 | 41,443 | 0.190 | 1.536 | 0.737 | 0.348 |
| DP06 | 3,258 | 0.284 | 2.134 | 0.918 | 0.366 |
| Age Group: 25-54 years | | | | | |
| Aggregated | 551,511 | 0.231 | 3.967 | 0.915 | 0.404 |
| DP01 | 129,395 | 0.546 | 2.762 | 1.094 | 0.442 |
| DP02 | 13,487 | 0.747 | 3.967 | 1.300 | 0.701 |
| DP03 | 90,935 | 0.465 | 2.426 | 1.018 | 0.396 |
| DP04 | 187,344 | 0.231 | 1.230 | 0.667 | 0.316 |
| DP05 | 59,644 | 0.500 | 2.657 | 1.058 | 0.432 |
| DP06 | 70,706 | 0.255 | 2.508 | 0.917 | 0.443 |
| Age Group: ≥ 55 years | | | | | |
| Aggregated | 540,203 | 0.195 | 3.633 | 1.042 | 0.465 |
| DP01 | 63,507 | 0.436 | 2.336 | 1.016 | 0.367 |
| DP02 | 41,543 | 0.567 | 3.633 | 1.205 | 0.606 |
| DP03 | 25,708 | 0.424 | 2.158 | 0.967 | 0.345 |
| DP04 | 32,073 | 0.195 | 1.181 | 0.638 | 0.324 |
| DP05 | 36,009 | 0.462 | 2.714 | 1.066 | 0.431 |
| DP06 | 341,363 | 0.400 | 2.963 | 1.069 | 0.484 |

Appendix J. Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Data Partner (DP), Psychiatric History, Weight: Average Treatment Effect in the Treated (ATT)

| DP ID | Number of Patients | Minimum | Maximum | Mean | Standard Deviation |
|-------------------------------|--------------------|---------|---------|-------|--------------------|
| Overall | | | | | |
| Aggregated | 1,675,646 | 0.239 | 3.483 | 0.882 | 0.392 |
| DP01 | 289,683 | 0.386 | 2.292 | 0.982 | 0.377 |
| DP02 | 59,952 | 0.594 | 3.483 | 1.206 | 0.581 |
| DP03 | 180,024 | 0.335 | 2.059 | 0.919 | 0.357 |
| DP04 | 593,510 | 0.239 | 1.128 | 0.657 | 0.308 |
| DP05 | 137,119 | 0.337 | 2.291 | 0.961 | 0.388 |
| DP06 | 415,358 | 0.363 | 2.924 | 1.043 | 0.481 |
| No Psychiatric History | | | | | |
| Aggregated | 851,052 | 0.243 | 3.378 | 0.848 | 0.360 |
| DP01 | 162,050 | 0.374 | 2.118 | 0.950 | 0.354 |
| DP02 | 23,613 | 0.574 | 3.378 | 1.189 | 0.556 |
| DP03 | 104,329 | 0.322 | 1.936 | 0.892 | 0.344 |
| DP04 | 342,983 | 0.243 | 1.159 | 0.664 | 0.307 |
| DP05 | 77,304 | 0.327 | 2.151 | 0.932 | 0.369 |
| DP06 | 140,773 | 0.397 | 2.738 | 1.042 | 0.443 |
| Psychiatric History | | | | | |
| Aggregated | 824,449 | 0.225 | 3.645 | 0.916 | 0.428 |
| DP01 | 127,622 | 0.400 | 2.533 | 1.023 | 0.412 |
| DP02 | 36,298 | 0.591 | 3.645 | 1.217 | 0.612 |
| DP03 | 75,688 | 0.347 | 2.259 | 0.957 | 0.381 |
| DP04 | 250,499 | 0.225 | 1.143 | 0.647 | 0.316 |
| DP05 | 59,794 | 0.347 | 2.493 | 0.998 | 0.417 |
| DP06 | 274,548 | 0.343 | 3.028 | 1.043 | 0.502 |

Appendix K. Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm Inpatient and Emergency Truncation Weight = 2.5, 30-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by Data Partner (DP), Pre-/Post-Boxed Warning, Weight: Average Treatment Effect in the Treated (ATT)

| DP ID | Number of Patients | Minimum | Maximum | Mean | Standard Deviation |
|---------------------------|--------------------|---------|---------|-------|--------------------|
| Overall | | | | | |
| Aggregated | 1,675,646 | 0.239 | 3.483 | 0.882 | 0.392 |
| DP01 | 289,683 | 0.386 | 2.292 | 0.982 | 0.377 |
| DP02 | 59,952 | 0.594 | 3.483 | 1.206 | 0.581 |
| DP03 | 180,024 | 0.335 | 2.059 | 0.919 | 0.357 |
| DP04 | 593,510 | 0.239 | 1.128 | 0.657 | 0.308 |
| DP05 | 137,119 | 0.337 | 2.291 | 0.961 | 0.388 |
| DP06 | 415,358 | 0.363 | 2.924 | 1.043 | 0.481 |
| Pre-boxed warning | | | | | |
| Aggregated | 1,381,996 | 0.239 | 3.546 | 0.848 | 0.380 |
| DP01 | 204,559 | 0.378 | 2.298 | 0.975 | 0.381 |
| DP02 | 40,796 | 0.571 | 3.546 | 1.213 | 0.598 |
| DP03 | 131,229 | 0.329 | 2.048 | 0.914 | 0.358 |
| DP04 | 593,505 | 0.239 | 1.129 | 0.657 | 0.308 |
| DP05 | 96,819 | 0.339 | 2.287 | 0.958 | 0.388 |
| DP06 | 315,088 | 0.345 | 2.794 | 1.017 | 0.465 |
| Post-boxed warning | | | | | |
| Aggregated | 293,548 | 0.329 | 3.414 | 1.039 | 0.448 |
| DP01 | 85,099 | 0.398 | 2.320 | 0.999 | 0.377 |
| DP02 | 19,136 | 0.630 | 3.414 | 1.192 | 0.558 |
| DP03 | 48,778 | 0.347 | 2.102 | 0.934 | 0.356 |
| DP05 | 40,281 | 0.329 | 2.328 | 0.967 | 0.394 |
| DP06 | 100,254 | 0.492 | 3.298 | 1.126 | 0.533 |

**Appendix L. Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm All Settings
Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022,
by Data Partner (DP), Weight: Average Treatment Effect in the Treated (ATT)**

| DP ID | Number of Patients | Minimum | Maximum | Mean | Standard Deviation |
|------------|--------------------|---------|---------|-------|--------------------|
| Aggregated | 1,675,273 | 0.239 | 3.482 | 0.882 | 0.392 |
| DP01 | 289,637 | 0.386 | 2.292 | 0.982 | 0.377 |
| DP02 | 59,945 | 0.594 | 3.482 | 1.206 | 0.581 |
| DP03 | 179,971 | 0.335 | 2.060 | 0.920 | 0.357 |
| DP04 | 593,353 | 0.239 | 1.128 | 0.657 | 0.308 |
| DP05 | 137,102 | 0.338 | 2.291 | 0.961 | 0.388 |
| DP06 | 415,265 | 0.363 | 2.923 | 1.043 | 0.481 |

**Appendix M. Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm All Settings
Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022,
by Data Partner (DP), Sex, Weight: Average Treatment Effect in the Treated (ATT)**

| DP ID | Number of Patients | Minimum | Maximum | Mean | Standard Deviation |
|--------------------|--------------------|---------|---------|-------|--------------------|
| Overall | | | | | |
| Aggregated | 1,675,273 | 0.239 | 3.482 | 0.882 | 0.392 |
| DP01 | 289,637 | 0.386 | 2.292 | 0.982 | 0.377 |
| DP02 | 59,945 | 0.594 | 3.482 | 1.206 | 0.581 |
| DP03 | 179,971 | 0.335 | 2.060 | 0.920 | 0.357 |
| DP04 | 593,353 | 0.239 | 1.128 | 0.657 | 0.308 |
| DP05 | 137,102 | 0.338 | 2.291 | 0.961 | 0.388 |
| DP06 | 415,265 | 0.363 | 2.923 | 1.043 | 0.481 |
| Sex: Female | | | | | |
| Aggregated | 1,065,283 | 0.246 | 3.626 | 0.915 | 0.410 |
| DP01 | 178,856 | 0.422 | 2.460 | 1.019 | 0.399 |
| DP02 | 43,279 | 0.638 | 3.626 | 1.229 | 0.610 |
| DP03 | 107,617 | 0.359 | 2.224 | 0.955 | 0.375 |
| DP04 | 346,334 | 0.246 | 1.167 | 0.666 | 0.309 |
| DP05 | 85,608 | 0.375 | 2.488 | 1.005 | 0.413 |
| DP06 | 303,589 | 0.376 | 2.958 | 1.056 | 0.485 |
| Sex: Male | | | | | |
| Aggregated | 609,836 | 0.218 | 3.196 | 0.823 | 0.362 |
| DP01 | 110,772 | 0.351 | 2.019 | 0.924 | 0.344 |
| DP02 | 16,614 | 0.502 | 3.196 | 1.149 | 0.521 |
| DP03 | 72,330 | 0.312 | 1.818 | 0.868 | 0.333 |
| DP04 | 247,007 | 0.218 | 1.097 | 0.645 | 0.309 |
| DP05 | 51,470 | 0.304 | 1.944 | 0.889 | 0.347 |
| DP06 | 111,643 | 0.332 | 2.831 | 1.009 | 0.469 |

**Appendix N. Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm All Settings
Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022, by
Data Partner (DP), Age Group, Weight: Average Treatment Effect in the Treated (ATT)**

| DP ID | Number of Patients | Minimum | Maximum | Mean | Standard Deviation |
|-------------------------------|--------------------|---------|---------|-------|--------------------|
| Overall | | | | | |
| Aggregated | 1,675,273 | 0.239 | 3.482 | 0.882 | 0.392 |
| DP01 | 289,637 | 0.386 | 2.292 | 0.982 | 0.377 |
| DP02 | 59,945 | 0.594 | 3.482 | 1.206 | 0.581 |
| DP03 | 179,971 | 0.335 | 2.060 | 0.920 | 0.357 |
| DP04 | 593,353 | 0.239 | 1.128 | 0.657 | 0.308 |
| DP05 | 137,102 | 0.338 | 2.291 | 0.961 | 0.388 |
| DP06 | 415,265 | 0.363 | 2.923 | 1.043 | 0.481 |
| Age Group: 10-24 years | | | | | |
| Aggregated | 583,562 | 0.190 | 2.542 | 0.701 | 0.327 |
| DP01 | 96,746 | 0.232 | 1.775 | 0.810 | 0.356 |
| DP02 | 4,828 | 0.257 | 2.542 | 0.955 | 0.438 |
| DP03 | 63,331 | 0.213 | 1.595 | 0.762 | 0.346 |
| DP04 | 373,963 | 0.220 | 1.157 | 0.653 | 0.312 |
| DP05 | 41,440 | 0.190 | 1.535 | 0.737 | 0.348 |
| DP06 | 3,254 | 0.286 | 2.131 | 0.918 | 0.365 |
| Age Group: 25-54 years | | | | | |
| Aggregated | 551,396 | 0.231 | 3.974 | 0.915 | 0.404 |
| DP01 | 129,373 | 0.546 | 2.764 | 1.094 | 0.442 |
| DP02 | 13,478 | 0.744 | 3.974 | 1.301 | 0.703 |
| DP03 | 90,907 | 0.465 | 2.427 | 1.018 | 0.396 |
| DP04 | 187,311 | 0.231 | 1.229 | 0.668 | 0.316 |
| DP05 | 59,634 | 0.500 | 2.658 | 1.058 | 0.432 |
| DP06 | 70,693 | 0.255 | 2.503 | 0.917 | 0.443 |
| Age Group: ≥ 55 years | | | | | |
| Aggregated | 540,090 | 0.195 | 3.636 | 1.042 | 0.465 |
| DP01 | 63,495 | 0.436 | 2.335 | 1.016 | 0.367 |
| DP02 | 41,539 | 0.566 | 3.636 | 1.205 | 0.606 |
| DP03 | 25,702 | 0.423 | 2.159 | 0.967 | 0.345 |
| DP04 | 32,063 | 0.195 | 1.180 | 0.638 | 0.324 |
| DP05 | 36,003 | 0.462 | 2.713 | 1.066 | 0.431 |
| DP06 | 341,288 | 0.400 | 2.962 | 1.069 | 0.483 |

**Appendix O. Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm All Settings
Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022,
by Data Partner (DP), Psychiatric History, Weight: Average Treatment Effect in the Treated (ATT)**

| DP ID | Number of Patients | Minimum | Maximum | Mean | Standard Deviation |
|-------------------------------|--------------------|---------|---------|-------|--------------------|
| Overall | | | | | |
| Aggregated | 1,675,273 | 0.239 | 3.482 | 0.882 | 0.392 |
| DP01 | 289,637 | 0.386 | 2.292 | 0.982 | 0.377 |
| DP02 | 59,945 | 0.594 | 3.482 | 1.206 | 0.581 |
| DP03 | 179,971 | 0.335 | 2.060 | 0.920 | 0.357 |
| DP04 | 593,353 | 0.239 | 1.128 | 0.657 | 0.308 |
| DP05 | 137,102 | 0.338 | 2.291 | 0.961 | 0.388 |
| DP06 | 415,265 | 0.363 | 2.923 | 1.043 | 0.481 |
| No Psychiatric History | | | | | |
| Aggregated | 850,917 | 0.243 | 3.378 | 0.848 | 0.360 |
| DP01 | 162,036 | 0.374 | 2.118 | 0.950 | 0.354 |
| DP02 | 23,612 | 0.573 | 3.378 | 1.189 | 0.556 |
| DP03 | 104,302 | 0.322 | 1.936 | 0.892 | 0.344 |
| DP04 | 342,913 | 0.243 | 1.159 | 0.664 | 0.307 |
| DP05 | 77,297 | 0.328 | 2.152 | 0.932 | 0.369 |
| DP06 | 140,757 | 0.397 | 2.738 | 1.042 | 0.443 |
| Psychiatric History | | | | | |
| Aggregated | 824,202 | 0.225 | 3.650 | 0.916 | 0.428 |
| DP01 | 127,590 | 0.400 | 2.534 | 1.023 | 0.412 |
| DP02 | 36,262 | 0.590 | 3.650 | 1.218 | 0.613 |
| DP03 | 75,657 | 0.348 | 2.260 | 0.958 | 0.381 |
| DP04 | 250,427 | 0.225 | 1.143 | 0.647 | 0.316 |
| DP05 | 59,783 | 0.347 | 2.492 | 0.998 | 0.417 |
| DP06 | 274,483 | 0.343 | 3.027 | 1.043 | 0.502 |

**Appendix P. Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm All Settings
Truncation Weight = 2.5, 0-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022,
by Data Partner (DP), Pre-/Post-Boxed Warning, Weight: Average Treatment Effect in the Treated (ATT)**

| DP ID | Number of Patients | Minimum | Maximum | Mean | Standard Deviation |
|---------------------------|--------------------|---------|---------|-------|--------------------|
| Overall | | | | | |
| Aggregated | 1,675,273 | 0.239 | 3.482 | 0.882 | 0.392 |
| DP01 | 289,637 | 0.386 | 2.292 | 0.982 | 0.377 |
| DP02 | 59,945 | 0.594 | 3.482 | 1.206 | 0.581 |
| DP03 | 179,971 | 0.335 | 2.060 | 0.920 | 0.357 |
| DP04 | 593,353 | 0.239 | 1.128 | 0.657 | 0.308 |
| DP05 | 137,102 | 0.338 | 2.291 | 0.961 | 0.388 |
| DP06 | 415,265 | 0.363 | 2.923 | 1.043 | 0.481 |
| Pre-boxed warning | | | | | |
| Aggregated | 1,381,648 | 0.239 | 3.551 | 0.848 | 0.380 |
| DP01 | 204,526 | 0.378 | 2.299 | 0.975 | 0.381 |
| DP02 | 40,765 | 0.570 | 3.551 | 1.213 | 0.599 |
| DP03 | 131,177 | 0.329 | 2.050 | 0.914 | 0.358 |
| DP04 | 593,349 | 0.239 | 1.128 | 0.657 | 0.308 |
| DP05 | 96,804 | 0.339 | 2.286 | 0.958 | 0.388 |
| DP06 | 315,027 | 0.345 | 2.794 | 1.017 | 0.465 |
| Post-boxed warning | | | | | |
| Aggregated | 293,506 | 0.329 | 3.410 | 1.039 | 0.448 |
| DP01 | 85,088 | 0.399 | 2.321 | 0.999 | 0.377 |
| DP02 | 19,134 | 0.630 | 3.410 | 1.192 | 0.557 |
| DP03 | 48,774 | 0.347 | 2.101 | 0.934 | 0.356 |
| DP05 | 40,280 | 0.329 | 2.329 | 0.967 | 0.394 |
| DP06 | 100,230 | 0.492 | 3.297 | 1.126 | 0.533 |

**Appendix Q. Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm All Settings
Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022,
by Data Partner (DP), Weight: Average Treatment Effect in the Treated (ATT)**

| DP ID | Number of Patients | Minimum | Maximum | Mean | Standard Deviation |
|------------|--------------------|---------|---------|-------|--------------------|
| Aggregated | 1,675,587 | 0.239 | 3.482 | 0.882 | 0.392 |
| DP01 | 289,671 | 0.386 | 2.292 | 0.982 | 0.377 |
| DP02 | 59,948 | 0.594 | 3.482 | 1.206 | 0.581 |
| DP03 | 180,018 | 0.335 | 2.059 | 0.919 | 0.357 |
| DP04 | 593,493 | 0.239 | 1.128 | 0.657 | 0.308 |
| DP05 | 137,116 | 0.337 | 2.290 | 0.961 | 0.388 |
| DP06 | 415,341 | 0.363 | 2.923 | 1.043 | 0.481 |

**Appendix R. Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm All Settings
Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30,
2022, by Data Partner (DP), Sex, Weight: Average Treatment Effect in the Treated (ATT)**

| DP ID | Number of Patients | Minimum | Maximum | Mean | Standard Deviation |
|--------------------|--------------------|---------|---------|-------|--------------------|
| Overall | | | | | |
| Aggregated | 1,675,587 | 0.239 | 3.482 | 0.882 | 0.392 |
| DP01 | 289,671 | 0.386 | 2.292 | 0.982 | 0.377 |
| DP02 | 59,948 | 0.594 | 3.482 | 1.206 | 0.581 |
| DP03 | 180,018 | 0.335 | 2.059 | 0.919 | 0.357 |
| DP04 | 593,493 | 0.239 | 1.128 | 0.657 | 0.308 |
| DP05 | 137,116 | 0.337 | 2.290 | 0.961 | 0.388 |
| DP06 | 415,341 | 0.363 | 2.923 | 1.043 | 0.481 |
| Sex: Female | | | | | |
| Aggregated | 1,065,491 | 0.246 | 3.622 | 0.915 | 0.410 |
| DP01 | 178,881 | 0.422 | 2.461 | 1.019 | 0.399 |
| DP02 | 43,279 | 0.639 | 3.622 | 1.228 | 0.610 |
| DP03 | 107,647 | 0.359 | 2.224 | 0.955 | 0.375 |
| DP04 | 346,420 | 0.246 | 1.167 | 0.666 | 0.309 |
| DP05 | 85,620 | 0.375 | 2.486 | 1.005 | 0.413 |
| DP06 | 303,644 | 0.376 | 2.959 | 1.056 | 0.485 |
| Sex: Male | | | | | |
| Aggregated | 609,940 | 0.218 | 3.192 | 0.823 | 0.362 |
| DP01 | 110,781 | 0.351 | 2.019 | 0.924 | 0.344 |
| DP02 | 16,618 | 0.502 | 3.192 | 1.149 | 0.520 |
| DP03 | 72,342 | 0.312 | 1.818 | 0.868 | 0.333 |
| DP04 | 247,062 | 0.218 | 1.097 | 0.645 | 0.309 |
| DP05 | 51,475 | 0.304 | 1.944 | 0.889 | 0.347 |
| DP06 | 111,662 | 0.332 | 2.830 | 1.009 | 0.469 |

**Appendix S. Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm All Settings
Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022,
by Data Partner (DP), Age Group, Weight: Average Treatment Effect in the Treated (ATT)**

| DP ID | Number of Patients | Minimum | Maximum | Mean | Standard Deviation |
|-------------------------------|--------------------|---------|---------|-------|--------------------|
| Overall | | | | | |
| Aggregated | 1,675,587 | 0.239 | 3.482 | 0.882 | 0.392 |
| DP01 | 289,671 | 0.386 | 2.292 | 0.982 | 0.377 |
| DP02 | 59,948 | 0.594 | 3.482 | 1.206 | 0.581 |
| DP03 | 180,018 | 0.335 | 2.059 | 0.919 | 0.357 |
| DP04 | 593,493 | 0.239 | 1.128 | 0.657 | 0.308 |
| DP05 | 137,116 | 0.337 | 2.290 | 0.961 | 0.388 |
| DP06 | 415,341 | 0.363 | 2.923 | 1.043 | 0.481 |
| Age Group: 10-24 years | | | | | |
| Aggregated | 583,661 | 0.190 | 2.542 | 0.701 | 0.327 |
| DP01 | 96,753 | 0.232 | 1.775 | 0.810 | 0.356 |
| DP02 | 4,828 | 0.257 | 2.542 | 0.955 | 0.438 |
| DP03 | 63,343 | 0.213 | 1.595 | 0.762 | 0.346 |
| DP04 | 374,042 | 0.220 | 1.157 | 0.653 | 0.312 |
| DP05 | 41,441 | 0.190 | 1.535 | 0.737 | 0.348 |
| DP06 | 3,254 | 0.286 | 2.131 | 0.918 | 0.365 |
| Age Group: 25-54 years | | | | | |
| Aggregated | 551,500 | 0.231 | 3.974 | 0.915 | 0.404 |
| DP01 | 129,388 | 0.546 | 2.763 | 1.094 | 0.442 |
| DP02 | 13,478 | 0.744 | 3.974 | 1.301 | 0.703 |
| DP03 | 90,932 | 0.465 | 2.425 | 1.018 | 0.396 |
| DP04 | 187,358 | 0.231 | 1.229 | 0.667 | 0.316 |
| DP05 | 59,642 | 0.499 | 2.656 | 1.058 | 0.432 |
| DP06 | 70,702 | 0.255 | 2.504 | 0.917 | 0.443 |
| Age Group: ≥ 55 years | | | | | |
| Aggregated | 540,190 | 0.195 | 3.633 | 1.042 | 0.465 |
| DP01 | 63,507 | 0.436 | 2.336 | 1.016 | 0.367 |
| DP02 | 41,543 | 0.566 | 3.633 | 1.205 | 0.606 |
| DP03 | 25,703 | 0.423 | 2.159 | 0.967 | 0.345 |
| DP04 | 32,073 | 0.195 | 1.181 | 0.638 | 0.324 |
| DP05 | 36,008 | 0.462 | 2.713 | 1.065 | 0.431 |
| DP06 | 341,356 | 0.400 | 2.962 | 1.069 | 0.483 |

**Appendix T. Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm All Settings
Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30, 2022,
by Data Partner (DP), Psychiatric History, Weight: Average Treatment Effect in the Treated (ATT)**

| DP ID | Number of Patients | Minimum | Maximum | Mean | Standard Deviation |
|-------------------------------|--------------------|---------|---------|-------|--------------------|
| Overall | | | | | |
| Aggregated | 1,675,587 | 0.239 | 3.482 | 0.882 | 0.392 |
| DP01 | 289,671 | 0.386 | 2.292 | 0.982 | 0.377 |
| DP02 | 59,948 | 0.594 | 3.482 | 1.206 | 0.581 |
| DP03 | 180,018 | 0.335 | 2.059 | 0.919 | 0.357 |
| DP04 | 593,493 | 0.239 | 1.128 | 0.657 | 0.308 |
| DP05 | 137,116 | 0.337 | 2.290 | 0.961 | 0.388 |
| DP06 | 415,341 | 0.363 | 2.923 | 1.043 | 0.481 |
| No Psychiatric History | | | | | |
| Aggregated | 851,056 | 0.243 | 3.378 | 0.848 | 0.360 |
| DP01 | 162,051 | 0.374 | 2.118 | 0.950 | 0.354 |
| DP02 | 23,613 | 0.574 | 3.378 | 1.189 | 0.556 |
| DP03 | 104,329 | 0.322 | 1.936 | 0.892 | 0.344 |
| DP04 | 342,985 | 0.243 | 1.159 | 0.664 | 0.307 |
| DP05 | 77,304 | 0.327 | 2.151 | 0.932 | 0.369 |
| DP06 | 140,774 | 0.397 | 2.738 | 1.042 | 0.443 |
| Psychiatric History | | | | | |
| Aggregated | 824,376 | 0.225 | 3.650 | 0.916 | 0.428 |
| DP01 | 127,609 | 0.400 | 2.534 | 1.023 | 0.412 |
| DP02 | 36,265 | 0.590 | 3.650 | 1.218 | 0.613 |
| DP03 | 75,672 | 0.347 | 2.261 | 0.958 | 0.382 |
| DP04 | 250,496 | 0.225 | 1.143 | 0.647 | 0.316 |
| DP05 | 59,794 | 0.347 | 2.492 | 0.998 | 0.417 |
| DP06 | 274,540 | 0.343 | 3.028 | 1.043 | 0.502 |

**Appendix U. Distribution of Inverse Probability of Treatment Weights After Trimming for Intentional Self Harm All Settings
Truncation Weight = 2.5, 15-day Gap and Extension in the Sentinel Distributed Database from October 1, 2015 to June 30,
2022, by Data Partner (DP), Pre-/Post-Boxed Warning, Weight: Average Treatment Effect in the Treated (ATT)**

| DP ID | Number of Patients | Minimum | Maximum | Mean | Standard Deviation |
|---------------------------|--------------------|---------|---------|-------|--------------------|
| Overall | | | | | |
| Aggregated | 1,675,587 | 0.239 | 3.482 | 0.882 | 0.392 |
| DP01 | 289,671 | 0.386 | 2.292 | 0.982 | 0.377 |
| DP02 | 59,948 | 0.594 | 3.482 | 1.206 | 0.581 |
| DP03 | 180,018 | 0.335 | 2.059 | 0.919 | 0.357 |
| DP04 | 593,493 | 0.239 | 1.128 | 0.657 | 0.308 |
| DP05 | 137,116 | 0.337 | 2.290 | 0.961 | 0.388 |
| DP06 | 415,341 | 0.363 | 2.923 | 1.043 | 0.481 |
| Pre-boxed warning | | | | | |
| Aggregated | 1,381,919 | 0.239 | 3.548 | 0.848 | 0.380 |
| DP01 | 204,552 | 0.377 | 2.299 | 0.975 | 0.381 |
| DP02 | 40,767 | 0.570 | 3.548 | 1.213 | 0.599 |
| DP03 | 131,209 | 0.329 | 2.050 | 0.914 | 0.358 |
| DP04 | 593,489 | 0.239 | 1.128 | 0.657 | 0.308 |
| DP05 | 96,818 | 0.339 | 2.286 | 0.958 | 0.388 |
| DP06 | 315,084 | 0.345 | 2.794 | 1.017 | 0.465 |
| Post-boxed warning | | | | | |
| Aggregated | 293,541 | 0.329 | 3.414 | 1.039 | 0.448 |
| DP01 | 85,095 | 0.399 | 2.320 | 0.999 | 0.377 |
| DP02 | 19,136 | 0.630 | 3.414 | 1.192 | 0.558 |
| DP03 | 48,779 | 0.347 | 2.103 | 0.934 | 0.356 |
| DP05 | 40,281 | 0.329 | 2.328 | 0.967 | 0.394 |
| DP06 | 100,250 | 0.492 | 3.298 | 1.126 | 0.533 |

Appendix V. List of Generic and Brand Names of Medical Products Used to Define Exposures in this Request

| Generic Name | Brand Name |
|--|---------------------|
| Montelukast | |
| montelukast sodium | Singulair |
| montelukast sodium | montelukast |
| Inhaled Corticosteroids (ICS) Monotherapy | |
| beclomethasone dipropionate | Qvar |
| beclomethasone dipropionate | Qvar RediHaler |
| budesonide | Pulmicort |
| budesonide | Pulmicort Flexhaler |
| budesonide | budesonide |
| ciclesonide | Alvesco |
| flunisolide | Aerospan |
| fluticasone furoate | Arnuity Ellipta |
| fluticasone propionate | ArmonAir Digihaler |
| fluticasone propionate | ArmonAir RespiClick |
| fluticasone propionate | Flovent Diskus |
| fluticasone propionate | Flovent HFA |
| mometasone furoate | Asmanex HFA |
| mometasone furoate | Asmanex Twisthaler |

Appendix W. List of Generic and Brand Names of Medical Products Used to Define Exposure Incidence Criteria in this Request

| Generic Name | Brand Name |
|--|--------------------------------|
| Montelukast | |
| montelukast sodium | Singulair |
| montelukast sodium | montelukast |
| Inhaled Corticosteroids (ICS) Monotherapy | |
| beclomethasone dipropionate | Qvar |
| beclomethasone dipropionate | Qvar RediHaler |
| budesonide | Pulmicort |
| budesonide | Pulmicort Flexhaler |
| budesonide | budesonide |
| ciclesonide | Alvesco |
| flunisolide | Aerospan |
| fluticasone furoate | Arnuity Ellipta |
| fluticasone propionate | ArmonAir Digihaler |
| fluticasone propionate | ArmonAir RespiClick |
| fluticasone propionate | Flovent Diskus |
| fluticasone propionate | Flovent HFA |
| mometasone furoate | Asmanex HFA |
| mometasone furoate | Asmanex Twisthaler |
| Long-Acting Beta-Agonists (LABAs) | |
| acclidinium bromide/formoterol fumarate | Duaklir Pressair |
| arformoterol tartrate | Brovana |
| arformoterol tartrate | arformoterol |
| formoterol fumarate | Foradil Aerolizer |
| formoterol fumarate | Perforomist |
| formoterol fumarate | formoterol fumarate |
| glycopyrrolate/formoterol fumarate | Bevespi Aerosphere |
| indacaterol maleate | Arcapta Neohaler |
| indacaterol maleate/glycopyrrolate | Utibron Neohaler |
| olodaterol HCl | Striverdi Respimat |
| salmeterol xinafoate | Serevent Diskus |
| tiotropium bromide/olodaterol HCl | Stiolto Respimat |
| Inhaled Corticosteroids (ICS) Long-Acting Beta-Agonists (LABAs) | |
| budesonide/formoterol fumarate | Symbicort |
| budesonide/formoterol fumarate | budesonide-formoterol |
| budesonide/glycopyrrolate/formoterol fumarate | Breztri Aerosphere |
| fluticasone furoate/vilanterol trifenate | Breo Ellipta |
| fluticasone propionate/salmeterol xinafoate | Advair Diskus |
| fluticasone propionate/salmeterol xinafoate | Advair HFA |
| fluticasone propionate/salmeterol xinafoate | AirDuo Digihaler |
| fluticasone propionate/salmeterol xinafoate | AirDuo RespiClick |
| fluticasone propionate/salmeterol xinafoate | Wixela Inhub |
| fluticasone propionate/salmeterol xinafoate | fluticasone propion-salmeterol |
| mometasone furoate/formoterol fumarate | Dulera |
| Leukotriene Receptor Antagonists (LTRAs) | |
| zafirlukast | Accolate |
| zafirlukast | zafirlukast |
| zileuton | Zyflo |
| zileuton | Zyflo CR |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------------------------------|--|---------------|-----------|
| Any Intentional Self-Harm | | | |
| T14.91 | Suicide attempt | Diagnosis | ICD-10-CM |
| T14.91XA | Suicide attempt, initial encounter | Diagnosis | ICD-10-CM |
| T14.91XD | Suicide attempt, subsequent encounter | Diagnosis | ICD-10-CM |
| T14.91XS | Suicide attempt, sequela | Diagnosis | ICD-10-CM |
| T36.0X2 | Poisoning by penicillins, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.0X2A | Poisoning by penicillins, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.0X2D | Poisoning by penicillins, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.0X2S | Poisoning by penicillins, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.1X2 | Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.1X2A | Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.1X2D | Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.1X2S | Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.2X2 | Poisoning by chloramphenicol group, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.2X2A | Poisoning by chloramphenicol group, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.2X2D | Poisoning by chloramphenicol group, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.2X2S | Poisoning by chloramphenicol group, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.3X2 | Poisoning by macrolides, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.3X2A | Poisoning by macrolides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.3X2D | Poisoning by macrolides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.3X2S | Poisoning by macrolides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.4X2 | Poisoning by tetracyclines, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.4X2A | Poisoning by tetracyclines, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.4X2D | Poisoning by tetracyclines, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.4X2S | Poisoning by tetracyclines, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.5X2 | Poisoning by aminoglycosides, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.5X2A | Poisoning by aminoglycosides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.5X2D | Poisoning by aminoglycosides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.5X2S | Poisoning by aminoglycosides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.6X2 | Poisoning by rifampicins, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.6X2A | Poisoning by rifampicins, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.6X2D | Poisoning by rifampicins, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.6X2S | Poisoning by rifampicins, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.7X2 | Poisoning by antifungal antibiotics, systemically used, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.7X2A | Poisoning by antifungal antibiotics, systemically used, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.7X2D | Poisoning by antifungal antibiotics, systemically used, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.7X2S | Poisoning by antifungal antibiotics, systemically used, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.8X2 | Poisoning by other systemic antibiotics, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.8X2A | Poisoning by other systemic antibiotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T36.8X2D | Poisoning by other systemic antibiotics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.8X2S | Poisoning by other systemic antibiotics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.92 | Poisoning by unspecified systemic antibiotic, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.92XA | Poisoning by unspecified systemic antibiotic, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.92XD | Poisoning by unspecified systemic antibiotic, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.92XS | Poisoning by unspecified systemic antibiotic, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.0X2 | Poisoning by sulfonamides, intentional self-harm | Diagnosis | ICD-10-CM |
| T37.0X2A | Poisoning by sulfonamides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.0X2D | Poisoning by sulfonamides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.0X2S | Poisoning by sulfonamides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.1X2 | Poisoning by antimycobacterial drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T37.1X2A | Poisoning by antimycobacterial drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.1X2D | Poisoning by antimycobacterial drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.1X2S | Poisoning by antimycobacterial drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.2X2 | Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm | Diagnosis | ICD-10-CM |
| T37.2X2A | Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.2X2D | Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.2X2S | Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.3X2 | Poisoning by other antiprotozoal drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T37.3X2A | Poisoning by other antiprotozoal drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.3X2D | Poisoning by other antiprotozoal drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.3X2S | Poisoning by other antiprotozoal drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.4X2 | Poisoning by anthelmintics, intentional self-harm | Diagnosis | ICD-10-CM |
| T37.4X2A | Poisoning by anthelmintics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.4X2D | Poisoning by anthelmintics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.4X2S | Poisoning by anthelmintics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.5X2 | Poisoning by antiviral drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T37.5X2A | Poisoning by antiviral drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.5X2D | Poisoning by antiviral drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.5X2S | Poisoning by antiviral drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.8X2 | Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm | Diagnosis | ICD-10-CM |
| T37.8X2A | Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.8X2D | Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.8X2S | Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T37.92 | Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm | Diagnosis | ICD-10-CM |
| T37.92XA | Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.92XD | Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.92XS | Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.0X2 | Poisoning by glucocorticoids and synthetic analogues, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.0X2A | Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.0X2D | Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.0X2S | Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.1X2 | Poisoning by thyroid hormones and substitutes, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.1X2A | Poisoning by thyroid hormones and substitutes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.1X2D | Poisoning by thyroid hormones and substitutes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.1X2S | Poisoning by thyroid hormones and substitutes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.2X2 | Poisoning by antithyroid drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.2X2A | Poisoning by antithyroid drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.2X2D | Poisoning by antithyroid drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.2X2S | Poisoning by antithyroid drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.3X2 | Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.3X2A | Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.3X2D | Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.3X2S | Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.4X2 | Poisoning by oral contraceptives, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.4X2A | Poisoning by oral contraceptives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.4X2D | Poisoning by oral contraceptives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.4X2S | Poisoning by oral contraceptives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.5X2 | Poisoning by other estrogens and progestogens, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.5X2A | Poisoning by other estrogens and progestogens, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.5X2D | Poisoning by other estrogens and progestogens, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.5X2S | Poisoning by other estrogens and progestogens, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.6X2 | Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.6X2A | Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T38.6X2D | Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.6X2S | Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.7X2 | Poisoning by androgens and anabolic congeners, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.7X2A | Poisoning by androgens and anabolic congeners, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.7X2D | Poisoning by androgens and anabolic congeners, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.7X2S | Poisoning by androgens and anabolic congeners, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.802 | Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.802A | Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.802D | Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.802S | Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.812 | Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.812A | Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.812D | Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.812S | Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.892 | Poisoning by other hormones and synthetic substitutes, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.892A | Poisoning by other hormones and synthetic substitutes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.892D | Poisoning by other hormones and synthetic substitutes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.892S | Poisoning by other hormones and synthetic substitutes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.902 | Poisoning by unspecified hormone antagonists, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.902A | Poisoning by unspecified hormone antagonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.902D | Poisoning by unspecified hormone antagonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.902S | Poisoning by unspecified hormone antagonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.992 | Poisoning by other hormone antagonists, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.992A | Poisoning by other hormone antagonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.992D | Poisoning by other hormone antagonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.992S | Poisoning by other hormone antagonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.012 | Poisoning by aspirin, intentional self-harm | Diagnosis | ICD-10-CM |
| T39.012A | Poisoning by aspirin, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T39.012D | Poisoning by aspirin, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.012S | Poisoning by aspirin, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.092 | Poisoning by salicylates, intentional self-harm | Diagnosis | ICD-10-CM |
| T39.092A | Poisoning by salicylates, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.092D | Poisoning by salicylates, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.092S | Poisoning by salicylates, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.1X2 | Poisoning by 4-Aminophenol derivatives, intentional self-harm | Diagnosis | ICD-10-CM |
| T39.1X2A | Poisoning by 4-Aminophenol derivatives, intentional self-harm, initial | Diagnosis | ICD-10-CM |
| T39.1X2D | Poisoning by 4-Aminophenol derivatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.1X2S | Poisoning by 4-Aminophenol derivatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.2X2 | Poisoning by pyrazolone derivatives, intentional self-harm | Diagnosis | ICD-10-CM |
| T39.2X2A | Poisoning by pyrazolone derivatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.2X2D | Poisoning by pyrazolone derivatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.2X2S | Poisoning by pyrazolone derivatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.312 | Poisoning by propionic acid derivatives, intentional self-harm | Diagnosis | ICD-10-CM |
| T39.312A | Poisoning by propionic acid derivatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.312D | Poisoning by propionic acid derivatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.312S | Poisoning by propionic acid derivatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.392 | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm | Diagnosis | ICD-10-CM |
| T39.392A | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.392D | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.392S | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.4X2 | Poisoning by antirheumatics, not elsewhere classified, intentional self-harm | Diagnosis | ICD-10-CM |
| T39.4X2A | Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.4X2D | Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.4X2S | Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.8X2 | Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm | Diagnosis | ICD-10-CM |
| T39.8X2A | Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.8X2D | Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.8X2S | Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.92 | Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T39.92XA | Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.92XD | Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.92XS | Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.0X2 | Poisoning by opium, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.0X2A | Poisoning by opium, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.0X2D | Poisoning by opium, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.0X2S | Poisoning by opium, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.1X2 | Poisoning by heroin, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.1X2A | Poisoning by heroin, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.1X2D | Poisoning by heroin, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.1X2S | Poisoning by heroin, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.2X2 | Poisoning by other opioids, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.2X2A | Poisoning by other opioids, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.2X2D | Poisoning by other opioids, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.2X2S | Poisoning by other opioids, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.3X2 | Poisoning by methadone, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.3X2A | Poisoning by methadone, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.3X2D | Poisoning by methadone, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.3X2S | Poisoning by methadone, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.412 | Poisoning by fentanyl or fentanyl analogs, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.412A | Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.412D | Poisoning by fentanyl or fentanyl analogs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.412S | Poisoning by fentanyl or fentanyl analogs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.422 | Poisoning by tramadol, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.422A | Poisoning by tramadol, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.422D | Poisoning by tramadol, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.422S | Poisoning by tramadol, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.492 | Poisoning by other synthetic narcotics, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.492A | Poisoning by other synthetic narcotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.492D | Poisoning by other synthetic narcotics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.492S | Poisoning by other synthetic narcotics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.4X2 | Poisoning by other synthetic narcotics, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.4X2A | Poisoning by other synthetic narcotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.4X2D | Poisoning by other synthetic narcotics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.4X2S | Poisoning by other synthetic narcotics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.5X2 | Poisoning by cocaine, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.5X2A | Poisoning by cocaine, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.5X2D | Poisoning by cocaine, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.5X2S | Poisoning by cocaine, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.602 | Poisoning by unspecified narcotics, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T40.602A | Poisoning by unspecified narcotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.602D | Poisoning by unspecified narcotics, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T40.602S | Poisoning by unspecified narcotics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.692 | Poisoning by other narcotics, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.692A | Poisoning by other narcotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.692D | Poisoning by other narcotics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.692S | Poisoning by other narcotics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.712 | Poisoning by cannabis, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.712A | Poisoning by cannabis, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.712D | Poisoning by cannabis, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.712S | Poisoning by cannabis, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.722 | Poisoning by synthetic cannabinoids, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.722A | Poisoning by synthetic cannabinoids, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.722D | Poisoning by synthetic cannabinoids, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.722S | Poisoning by synthetic cannabinoids, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.7X2 | Poisoning by cannabis (derivatives), intentional self-harm | Diagnosis | ICD-10-CM |
| T40.7X2A | Poisoning by cannabis (derivatives), intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.7X2D | Poisoning by cannabis (derivatives), intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.7X2S | Poisoning by cannabis (derivatives), intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.8X2 | Poisoning by lysergide [LSD], intentional self-harm | Diagnosis | ICD-10-CM |
| T40.8X2A | Poisoning by lysergide [LSD], intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.8X2D | Poisoning by lysergide [LSD], intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.8X2S | Poisoning by lysergide [LSD], intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.902 | Poisoning by unspecified psychodysleptics [hallucinogens], intentional self- | Diagnosis | ICD-10-CM |
| T40.902A | Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.902D | Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.902S | Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.992 | Poisoning by other psychodysleptics [hallucinogens], intentional self-harm | Diagnosis | ICD-10-CM |
| T40.992A | Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.992D | Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.992S | Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.0X2 | Poisoning by inhaled anesthetics, intentional self-harm | Diagnosis | ICD-10-CM |
| T41.0X2A | Poisoning by inhaled anesthetics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.0X2D | Poisoning by inhaled anesthetics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.0X2S | Poisoning by inhaled anesthetics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.1X2 | Poisoning by intravenous anesthetics, intentional self-harm | Diagnosis | ICD-10-CM |
| T41.1X2A | Poisoning by intravenous anesthetics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.1X2D | Poisoning by intravenous anesthetics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T41.1X2S | Poisoning by intravenous anesthetics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.202 | Poisoning by unspecified general anesthetics, intentional self-harm | Diagnosis | ICD-10-CM |
| T41.202A | Poisoning by unspecified general anesthetics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.202D | Poisoning by unspecified general anesthetics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.202S | Poisoning by unspecified general anesthetics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.292 | Poisoning by other general anesthetics, intentional self-harm | Diagnosis | ICD-10-CM |
| T41.292A | Poisoning by other general anesthetics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.292D | Poisoning by other general anesthetics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.292S | Poisoning by other general anesthetics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.3X2 | Poisoning by local anesthetics, intentional self-harm | Diagnosis | ICD-10-CM |
| T41.3X2A | Poisoning by local anesthetics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.3X2D | Poisoning by local anesthetics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.3X2S | Poisoning by local anesthetics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.42 | Poisoning by unspecified anesthetic, intentional self-harm | Diagnosis | ICD-10-CM |
| T41.42XA | Poisoning by unspecified anesthetic, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.42XD | Poisoning by unspecified anesthetic, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.42XS | Poisoning by unspecified anesthetic, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.5X2 | Poisoning by therapeutic gases, intentional self-harm | Diagnosis | ICD-10-CM |
| T41.5X2A | Poisoning by therapeutic gases, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.5X2D | Poisoning by therapeutic gases, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.5X2S | Poisoning by therapeutic gases, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.0X2 | Poisoning by hydantoin derivatives, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.0X2A | Poisoning by hydantoin derivatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.0X2D | Poisoning by hydantoin derivatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.0X2S | Poisoning by hydantoin derivatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.1X2 | Poisoning by iminostilbenes, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.1X2A | Poisoning by iminostilbenes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.1X2D | Poisoning by iminostilbenes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.1X2S | Poisoning by iminostilbenes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.2X2 | Poisoning by succinimides and oxazolidinediones, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.2X2A | Poisoning by succinimides and oxazolidinediones, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.2X2D | Poisoning by succinimides and oxazolidinediones, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.2X2S | Poisoning by succinimides and oxazolidinediones, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.3X2 | Poisoning by barbiturates, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.3X2A | Poisoning by barbiturates, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.3X2D | Poisoning by barbiturates, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.3X2S | Poisoning by barbiturates, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.4X2 | Poisoning by benzodiazepines, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.4X2A | Poisoning by benzodiazepines, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.4X2D | Poisoning by benzodiazepines, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T42.4X2S | Poisoning by benzodiazepines, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.5X2 | Poisoning by mixed antiepileptics, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.5X2A | Poisoning by mixed antiepileptics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.5X2D | Poisoning by mixed antiepileptics, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T42.5X2S | Poisoning by mixed antiepileptics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.6X2 | Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.6X2A | Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.6X2D | Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.6X2S | Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.72 | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.72XA | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.72XD | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.72XS | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.8X2 | Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.8X2A | Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.8X2D | Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.8X2S | Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.012 | Poisoning by tricyclic antidepressants, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.012A | Poisoning by tricyclic antidepressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.012D | Poisoning by tricyclic antidepressants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.012S | Poisoning by tricyclic antidepressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.022 | Poisoning by tetracyclic antidepressants, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.022A | Poisoning by tetracyclic antidepressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.022D | Poisoning by tetracyclic antidepressants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.022S | Poisoning by tetracyclic antidepressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.1X2 | Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.1X2A | Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.1X2D | Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.1X2S | Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T43.202 | Poisoning by unspecified antidepressants, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.202A | Poisoning by unspecified antidepressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.202D | Poisoning by unspecified antidepressants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.202S | Poisoning by unspecified antidepressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.212 | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.212A | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.212D | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.212S | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.222 | Poisoning by selective serotonin reuptake inhibitors, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.222A | Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.222D | Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.222S | Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.292 | Poisoning by other antidepressants, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.292A | Poisoning by other antidepressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.292D | Poisoning by other antidepressants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.292S | Poisoning by other antidepressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.3X2 | Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.3X2A | Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.3X2D | Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.3X2S | Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.4X2 | Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.4X2A | Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.4X2D | Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.4X2S | Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.502 | Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.502A | Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.502D | Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T43.502S | Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.592 | Poisoning by other antipsychotics and neuroleptics, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.592A | Poisoning by other antipsychotics and neuroleptics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.592D | Poisoning by other antipsychotics and neuroleptics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.592S | Poisoning by other antipsychotics and neuroleptics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.602 | Poisoning by unspecified psychostimulants, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.602A | Poisoning by unspecified psychostimulants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.602D | Poisoning by unspecified psychostimulants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.602S | Poisoning by unspecified psychostimulants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.612 | Poisoning by caffeine, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.612A | Poisoning by caffeine, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.612D | Poisoning by caffeine, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.612S | Poisoning by caffeine, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.622 | Poisoning by amphetamines, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.622A | Poisoning by amphetamines, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.622D | Poisoning by amphetamines, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.622S | Poisoning by amphetamines, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.632 | Poisoning by methylphenidate, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.632A | Poisoning by methylphenidate, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.632D | Poisoning by methylphenidate, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.632S | Poisoning by methylphenidate, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.642 | Poisoning by ecstasy, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.642A | Poisoning by ecstasy, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.642D | Poisoning by ecstasy, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.642S | Poisoning by ecstasy, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.692 | Poisoning by other psychostimulants, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.692A | Poisoning by other psychostimulants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.692D | Poisoning by other psychostimulants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.692S | Poisoning by other psychostimulants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.8X2 | Poisoning by other psychotropic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.8X2A | Poisoning by other psychotropic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.8X2D | Poisoning by other psychotropic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.8X2S | Poisoning by other psychotropic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.92 | Poisoning by unspecified psychotropic drug, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.92XA | Poisoning by unspecified psychotropic drug, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.92XD | Poisoning by unspecified psychotropic drug, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.92XS | Poisoning by unspecified psychotropic drug, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T44.0X2 | Poisoning by anticholinesterase agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.0X2A | Poisoning by anticholinesterase agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.0X2D | Poisoning by anticholinesterase agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.0X2S | Poisoning by anticholinesterase agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.1X2 | Poisoning by other parasympathomimetics [cholinergics], intentional self-harm | Diagnosis | ICD-10-CM |
| T44.1X2A | Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.1X2D | Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.1X2S | Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.2X2 | Poisoning by ganglionic blocking drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.2X2A | Poisoning by ganglionic blocking drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.2X2D | Poisoning by ganglionic blocking drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.2X2S | Poisoning by ganglionic blocking drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.3X2 | Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.3X2A | Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.3X2D | Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.3X2S | Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.4X2 | Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.4X2A | Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.4X2D | Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.4X2S | Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.5X2 | Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.5X2A | Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.5X2D | Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.5X2S | Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.6X2 | Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.6X2A | Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.6X2D | Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.6X2S | Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T44.7X2 | Poisoning by beta-adrenoreceptor antagonists, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.7X2A | Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.7X2D | Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.7X2S | Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.8X2 | Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.8X2A | Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.8X2D | Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.8X2S | Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.902 | Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.902A | Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.902D | Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.902S | Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.992 | Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.992A | Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.992D | Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.992S | Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.0X2 | Poisoning by antiallergic and antiemetic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.0X2A | Poisoning by antiallergic and antiemetic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.0X2D | Poisoning by antiallergic and antiemetic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.0X2S | Poisoning by antiallergic and antiemetic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.1X2 | Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.1X2A | Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.1X2D | Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.1X2S | Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.2X2 | Poisoning by vitamins, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.2X2A | Poisoning by vitamins, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.2X2D | Poisoning by vitamins, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T45.2X2S | Poisoning by vitamins, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.3X2 | Poisoning by enzymes, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.3X2A | Poisoning by enzymes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.3X2D | Poisoning by enzymes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.3X2S | Poisoning by enzymes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.4X2 | Poisoning by iron and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.4X2A | Poisoning by iron and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.4X2D | Poisoning by iron and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.4X2S | Poisoning by iron and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.512 | Poisoning by anticoagulants, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.512A | Poisoning by anticoagulants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.512D | Poisoning by anticoagulants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.512S | Poisoning by anticoagulants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.522 | Poisoning by antithrombotic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.522A | Poisoning by antithrombotic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.522D | Poisoning by antithrombotic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.522S | Poisoning by antithrombotic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.602 | Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.602A | Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.602D | Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.602S | Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.612 | Poisoning by thrombolytic drug, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.612A | Poisoning by thrombolytic drug, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.612D | Poisoning by thrombolytic drug, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.612S | Poisoning by thrombolytic drug, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.622 | Poisoning by hemostatic drug, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.622A | Poisoning by hemostatic drug, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.622D | Poisoning by hemostatic drug, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.622S | Poisoning by hemostatic drug, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.692 | Poisoning by other fibrinolysis-affecting drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.692A | Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.692D | Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.692S | Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.7X2 | Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.7X2A | Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.7X2D | Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T45.7X2S | Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.8X2 | Poisoning by other primarily systemic and hematological agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.8X2A | Poisoning by other primarily systemic and hematological agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.8X2D | Poisoning by other primarily systemic and hematological agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.8X2S | Poisoning by other primarily systemic and hematological agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.92 | Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.92XA | Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.92XD | Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.92XS | Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.0X2 | Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.0X2A | Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.0X2D | Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.0X2S | Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.1X2 | Poisoning by calcium-channel blockers, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.1X2A | Poisoning by calcium-channel blockers, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.1X2D | Poisoning by calcium-channel blockers, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.1X2S | Poisoning by calcium-channel blockers, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.2X2 | Poisoning by other antidysrhythmic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.2X2A | Poisoning by other antidysrhythmic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.2X2D | Poisoning by other antidysrhythmic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.2X2S | Poisoning by other antidysrhythmic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.3X2 | Poisoning by coronary vasodilators, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.3X2A | Poisoning by coronary vasodilators, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.3X2D | Poisoning by coronary vasodilators, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.3X2S | Poisoning by coronary vasodilators, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.4X2 | Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.4X2A | Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.4X2D | Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T46.4X2S | Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.5X2 | Poisoning by other antihypertensive drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.5X2A | Poisoning by other antihypertensive drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.5X2D | Poisoning by other antihypertensive drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.5X2S | Poisoning by other antihypertensive drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.6X2 | Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.6X2A | Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.6X2D | Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.6X2S | Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.7X2 | Poisoning by peripheral vasodilators, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.7X2A | Poisoning by peripheral vasodilators, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.7X2D | Poisoning by peripheral vasodilators, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.7X2S | Poisoning by peripheral vasodilators, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.8X2 | Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.8X2A | Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.8X2D | Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.8X2S | Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.902 | Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.902A | Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.902D | Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.902S | Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.992 | Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.992A | Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.992D | Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.992S | Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.0X2 | Poisoning by histamine H2-receptor blockers, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T47.0X2A | Poisoning by histamine H2-receptor blockers, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.0X2D | Poisoning by histamine H2-receptor blockers, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.0X2S | Poisoning by histamine H2-receptor blockers, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.1X2 | Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.1X2A | Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.1X2D | Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.1X2S | Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.2X2 | Poisoning by stimulant laxatives, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.2X2A | Poisoning by stimulant laxatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.2X2D | Poisoning by stimulant laxatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.2X2S | Poisoning by stimulant laxatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.3X2 | Poisoning by saline and osmotic laxatives, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.3X2A | Poisoning by saline and osmotic laxatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.3X2D | Poisoning by saline and osmotic laxatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.3X2S | Poisoning by saline and osmotic laxatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.4X2 | Poisoning by other laxatives, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.4X2A | Poisoning by other laxatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.4X2D | Poisoning by other laxatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.4X2S | Poisoning by other laxatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.5X2 | Poisoning by digestants, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.5X2A | Poisoning by digestants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.5X2D | Poisoning by digestants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.5X2S | Poisoning by digestants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.6X2 | Poisoning by antidiarrheal drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.6X2A | Poisoning by antidiarrheal drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.6X2D | Poisoning by antidiarrheal drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.6X2S | Poisoning by antidiarrheal drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.7X2 | Poisoning by emetics, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.7X2A | Poisoning by emetics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.7X2D | Poisoning by emetics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.7X2S | Poisoning by emetics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.8X2 | Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.8X2A | Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.8X2D | Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.8X2S | Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T47.92 | Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.92XA | Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.92XD | Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.92XS | Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.0X2 | Poisoning by oxytocic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.0X2A | Poisoning by oxytocic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.0X2D | Poisoning by oxytocic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.0X2S | Poisoning by oxytocic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.1X2 | Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm | Diagnosis | ICD-10-CM |
| T48.1X2A | Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.1X2D | Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.1X2S | Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.202 | Poisoning by unspecified drugs acting on muscles, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.202A | Poisoning by unspecified drugs acting on muscles, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.202D | Poisoning by unspecified drugs acting on muscles, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.202S | Poisoning by unspecified drugs acting on muscles, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.292 | Poisoning by other drugs acting on muscles, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.292A | Poisoning by other drugs acting on muscles, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.292D | Poisoning by other drugs acting on muscles, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.292S | Poisoning by other drugs acting on muscles, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.3X2 | Poisoning by antitussives, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.3X2A | Poisoning by antitussives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.3X2D | Poisoning by antitussives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.3X2S | Poisoning by antitussives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.4X2 | Poisoning by expectorants, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.4X2A | Poisoning by expectorants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.4X2D | Poisoning by expectorants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.4X2S | Poisoning by expectorants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.5X2 | Poisoning by other anti-common-cold drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.5X2A | Poisoning by other anti-common-cold drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.5X2D | Poisoning by other anti-common-cold drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.5X2S | Poisoning by other anti-common-cold drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T48.6X2 | Poisoning by antiasthmatics, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.6X2A | Poisoning by antiasthmatics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.6X2D | Poisoning by antiasthmatics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.6X2S | Poisoning by antiasthmatics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.902 | Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.902A | Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.902D | Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.902S | Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.992 | Poisoning by other agents primarily acting on the respiratory system, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.992A | Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.992D | Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.992S | Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.0X2 | Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.0X2A | Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.0X2D | Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.0X2S | Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.1X2 | Poisoning by antipruritics, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.1X2A | Poisoning by antipruritics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.1X2D | Poisoning by antipruritics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.1X2S | Poisoning by antipruritics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.2X2 | Poisoning by local astringents and local detergents, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.2X2A | Poisoning by local astringents and local detergents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.2X2D | Poisoning by local astringents and local detergents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.2X2S | Poisoning by local astringents and local detergents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.3X2 | Poisoning by emollients, demulcents and protectants, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.3X2A | Poisoning by emollients, demulcents and protectants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.3X2D | Poisoning by emollients, demulcents and protectants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.3X2S | Poisoning by emollients, demulcents and protectants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T49.4X2 | Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.4X2A | Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.4X2D | Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.4X2S | Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.5X2 | Poisoning by ophthalmological drugs and preparations, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.5X2A | Poisoning by ophthalmological drugs and preparations, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.5X2D | Poisoning by ophthalmological drugs and preparations, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.5X2S | Poisoning by ophthalmological drugs and preparations, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.6X2 | Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.6X2A | Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.6X2D | Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.6X2S | Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.7X2 | Poisoning by dental drugs, topically applied, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.7X2A | Poisoning by dental drugs, topically applied, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.7X2D | Poisoning by dental drugs, topically applied, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.7X2S | Poisoning by dental drugs, topically applied, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.8X2 | Poisoning by other topical agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.8X2A | Poisoning by other topical agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.8X2D | Poisoning by other topical agents, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T49.8X2S | Poisoning by other topical agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.92 | Poisoning by unspecified topical agent, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.92XA | Poisoning by unspecified topical agent, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.92XD | Poisoning by unspecified topical agent, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.92XS | Poisoning by unspecified topical agent, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.0X2 | Poisoning by mineralocorticoids and their antagonists, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.0X2A | Poisoning by mineralocorticoids and their antagonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.0X2D | Poisoning by mineralocorticoids and their antagonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.0X2S | Poisoning by mineralocorticoids and their antagonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.1X2 | Poisoning by loop [high-ceiling] diuretics, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.1X2A | Poisoning by loop [high-ceiling] diuretics, intentional self-harm, initial | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T50.1X2D | Poisoning by loop [high-ceiling] diuretics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.1X2S | Poisoning by loop [high-ceiling] diuretics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.2X2 | Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.2X2A | Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.2X2D | Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.2X2S | Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.3X2 | Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.3X2A | Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.3X2D | Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.3X2S | Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.4X2 | Poisoning by drugs affecting uric acid metabolism, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.4X2A | Poisoning by drugs affecting uric acid metabolism, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.4X2D | Poisoning by drugs affecting uric acid metabolism, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.4X2S | Poisoning by drugs affecting uric acid metabolism, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.5X2 | Poisoning by appetite depressants, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.5X2A | Poisoning by appetite depressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.5X2D | Poisoning by appetite depressants, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T50.5X2S | Poisoning by appetite depressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.6X2 | Poisoning by antidotes and chelating agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.6X2A | Poisoning by antidotes and chelating agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.6X2D | Poisoning by antidotes and chelating agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.6X2S | Poisoning by antidotes and chelating agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.7X2 | Poisoning by analeptics and opioid receptor antagonists, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.7X2A | Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.7X2D | Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.7X2S | Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.8X2 | Poisoning by diagnostic agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.8X2A | Poisoning by diagnostic agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.8X2D | Poisoning by diagnostic agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.8X2S | Poisoning by diagnostic agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|-------------|--|----------------------|------------------|
| T50.902 | Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.902A | Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.902D | Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.902S | Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.912 | Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.912A | Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.912D | Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.912S | Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.992 | Poisoning by other drugs, medicaments and biological substances, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.992A | Poisoning by other drugs, medicaments and biological substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.992D | Poisoning by other drugs, medicaments and biological substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.992S | Poisoning by other drugs, medicaments and biological substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.A12 | Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.A12A | Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.A12D | Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.A12S | Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.A22 | Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.A22A | Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.A22D | Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.A22S | Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.A92 | Poisoning by other bacterial vaccines, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.A92A | Poisoning by other bacterial vaccines, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.A92D | Poisoning by other bacterial vaccines, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.A92S | Poisoning by other bacterial vaccines, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.B12 | Poisoning by smallpox vaccines, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.B12A | Poisoning by smallpox vaccines, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T50.B12D | Poisoning by smallpox vaccines, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.B12S | Poisoning by smallpox vaccines, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.B92 | Poisoning by other viral vaccines, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.B92A | Poisoning by other viral vaccines, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.B92D | Poisoning by other viral vaccines, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.B92S | Poisoning by other viral vaccines, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.Z12 | Poisoning by immunoglobulin, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.Z12A | Poisoning by immunoglobulin, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.Z12D | Poisoning by immunoglobulin, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.Z12S | Poisoning by immunoglobulin, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.Z92 | Poisoning by other vaccines and biological substances, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.Z92A | Poisoning by other vaccines and biological substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.Z92D | Poisoning by other vaccines and biological substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.Z92S | Poisoning by other vaccines and biological substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T51.0X2 | Toxic effect of ethanol, intentional self-harm | Diagnosis | ICD-10-CM |
| T51.0X2A | Toxic effect of ethanol, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T51.0X2D | Toxic effect of ethanol, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T51.0X2S | Toxic effect of ethanol, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T51.1X2 | Toxic effect of methanol, intentional self-harm | Diagnosis | ICD-10-CM |
| T51.1X2A | Toxic effect of methanol, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T51.1X2D | Toxic effect of methanol, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T51.1X2S | Toxic effect of methanol, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T51.2X2 | Toxic effect of 2-Propanol, intentional self-harm | Diagnosis | ICD-10-CM |
| T51.2X2A | Toxic effect of 2-Propanol, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T51.2X2D | Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T51.2X2S | Toxic effect of 2-Propanol, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T51.3X2 | Toxic effect of fusel oil, intentional self-harm | Diagnosis | ICD-10-CM |
| T51.3X2A | Toxic effect of fusel oil, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T51.3X2D | Toxic effect of fusel oil, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T51.3X2S | Toxic effect of fusel oil, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T51.8X2 | Toxic effect of other alcohols, intentional self-harm | Diagnosis | ICD-10-CM |
| T51.8X2A | Toxic effect of other alcohols, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T51.8X2D | Toxic effect of other alcohols, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T51.8X2S | Toxic effect of other alcohols, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T51.92 | Toxic effect of unspecified alcohol, intentional self-harm | Diagnosis | ICD-10-CM |
| T51.92XA | Toxic effect of unspecified alcohol, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T51.92XD | Toxic effect of unspecified alcohol, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T51.92XS | Toxic effect of unspecified alcohol, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.0X2 | Toxic effect of petroleum products, intentional self-harm | Diagnosis | ICD-10-CM |
| T52.0X2A | Toxic effect of petroleum products, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.0X2D | Toxic effect of petroleum products, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T52.0X2S | Toxic effect of petroleum products, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.1X2 | Toxic effect of benzene, intentional self-harm | Diagnosis | ICD-10-CM |
| T52.1X2A | Toxic effect of benzene, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T52.1X2D | Toxic effect of benzene, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T52.1X2S | Toxic effect of benzene, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.2X2 | Toxic effect of homologues of benzene, intentional self-harm | Diagnosis | ICD-10-CM |
| T52.2X2A | Toxic effect of homologues of benzene, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.2X2D | Toxic effect of homologues of benzene, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T52.2X2S | Toxic effect of homologues of benzene, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.3X2 | Toxic effect of glycols, intentional self-harm | Diagnosis | ICD-10-CM |
| T52.3X2A | Toxic effect of glycols, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.3X2D | Toxic effect of glycols, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T52.3X2S | Toxic effect of glycols, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.4X2 | Toxic effect of ketones, intentional self-harm | Diagnosis | ICD-10-CM |
| T52.4X2A | Toxic effect of ketones, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.4X2D | Toxic effect of ketones, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T52.4X2S | Toxic effect of ketones, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.8X2 | Toxic effect of other organic solvents, intentional self-harm | Diagnosis | ICD-10-CM |
| T52.8X2A | Toxic effect of other organic solvents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.8X2D | Toxic effect of other organic solvents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T52.8X2S | Toxic effect of other organic solvents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.92 | Toxic effect of unspecified organic solvent, intentional self-harm | Diagnosis | ICD-10-CM |
| T52.92XA | Toxic effect of unspecified organic solvent, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.92XD | Toxic effect of unspecified organic solvent, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T52.92XS | Toxic effect of unspecified organic solvent, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.0X2 | Toxic effect of carbon tetrachloride, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.0X2A | Toxic effect of carbon tetrachloride, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.0X2D | Toxic effect of carbon tetrachloride, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.0X2S | Toxic effect of carbon tetrachloride, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.1X2 | Toxic effect of chloroform, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.1X2A | Toxic effect of chloroform, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.1X2D | Toxic effect of chloroform, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.1X2S | Toxic effect of chloroform, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.2X2 | Toxic effect of trichloroethylene, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.2X2A | Toxic effect of trichloroethylene, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.2X2D | Toxic effect of trichloroethylene, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.2X2S | Toxic effect of trichloroethylene, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.3X2 | Toxic effect of tetrachloroethylene, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.3X2A | Toxic effect of tetrachloroethylene, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.3X2D | Toxic effect of tetrachloroethylene, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.3X2S | Toxic effect of tetrachloroethylene, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.4X2 | Toxic effect of dichloromethane, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.4X2A | Toxic effect of dichloromethane, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.4X2D | Toxic effect of dichloromethane, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.4X2S | Toxic effect of dichloromethane, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T53.5X2 | Toxic effect of chlorofluorocarbons, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.5X2A | Toxic effect of chlorofluorocarbons, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.5X2D | Toxic effect of chlorofluorocarbons, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.5X2S | Toxic effect of chlorofluorocarbons, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.6X2 | Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.6X2A | Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.6X2D | Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.6X2S | Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.7X2 | Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.7X2A | Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.7X2D | Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.7X2S | Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.92 | Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.92XA | Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.92XD | Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.92XS | Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T54.0X2 | Toxic effect of phenol and phenol homologues, intentional self-harm | Diagnosis | ICD-10-CM |
| T54.0X2A | Toxic effect of phenol and phenol homologues, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T54.0X2D | Toxic effect of phenol and phenol homologues, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T54.0X2S | Toxic effect of phenol and phenol homologues, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T54.1X2 | Toxic effect of other corrosive organic compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T54.1X2A | Toxic effect of other corrosive organic compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T54.1X2D | Toxic effect of other corrosive organic compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T54.1X2S | Toxic effect of other corrosive organic compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T54.2X2 | Toxic effect of corrosive acids and acid-like substances, intentional self-harm | Diagnosis | ICD-10-CM |
| T54.2X2A | Toxic effect of corrosive acids and acid-like substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T54.2X2D | Toxic effect of corrosive acids and acid-like substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T54.2X2S | Toxic effect of corrosive acids and acid-like substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T54.3X2 | Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm | Diagnosis | ICD-10-CM |
| T54.3X2A | Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T54.3X2D | Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T54.3X2S | Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T54.92 | Toxic effect of unspecified corrosive substance, intentional self-harm | Diagnosis | ICD-10-CM |
| T54.92XA | Toxic effect of unspecified corrosive substance, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T54.92XD | Toxic effect of unspecified corrosive substance, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T54.92XS | Toxic effect of unspecified corrosive substance, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T55.0X2 | Toxic effect of soaps, intentional self-harm | Diagnosis | ICD-10-CM |
| T55.0X2A | Toxic effect of soaps, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T55.0X2D | Toxic effect of soaps, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T55.0X2S | Toxic effect of soaps, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T55.1X2 | Toxic effect of detergents, intentional self-harm | Diagnosis | ICD-10-CM |
| T55.1X2A | Toxic effect of detergents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T55.1X2D | Toxic effect of detergents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T55.1X2S | Toxic effect of detergents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.0X2 | Toxic effect of lead and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.0X2A | Toxic effect of lead and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.0X2D | Toxic effect of lead and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.0X2S | Toxic effect of lead and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.1X2 | Toxic effect of mercury and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.1X2A | Toxic effect of mercury and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.1X2D | Toxic effect of mercury and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.1X2S | Toxic effect of mercury and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.2X2 | Toxic effect of chromium and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.2X2A | Toxic effect of chromium and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.2X2D | Toxic effect of chromium and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.2X2S | Toxic effect of chromium and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.3X2 | Toxic effect of cadmium and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.3X2A | Toxic effect of cadmium and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.3X2D | Toxic effect of cadmium and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.3X2S | Toxic effect of cadmium and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.4X2 | Toxic effect of copper and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T56.4X2A | Toxic effect of copper and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.4X2D | Toxic effect of copper and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.4X2S | Toxic effect of copper and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.5X2 | Toxic effect of zinc and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.5X2A | Toxic effect of zinc and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.5X2D | Toxic effect of zinc and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.5X2S | Toxic effect of zinc and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.6X2 | Toxic effect of tin and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.6X2A | Toxic effect of tin and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.6X2D | Toxic effect of tin and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.6X2S | Toxic effect of tin and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.7X2 | Toxic effect of beryllium and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.7X2A | Toxic effect of beryllium and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.7X2D | Toxic effect of beryllium and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.7X2S | Toxic effect of beryllium and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.812 | Toxic effect of thallium, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.812A | Toxic effect of thallium, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.812D | Toxic effect of thallium, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.812S | Toxic effect of thallium, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.892 | Toxic effect of other metals, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.892A | Toxic effect of other metals, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.892D | Toxic effect of other metals, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.892S | Toxic effect of other metals, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.92 | Toxic effect of unspecified metal, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.92XA | Toxic effect of unspecified metal, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.92XD | Toxic effect of unspecified metal, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.92XS | Toxic effect of unspecified metal, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T57.0X2 | Toxic effect of arsenic and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T57.0X2A | Toxic effect of arsenic and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T57.0X2D | Toxic effect of arsenic and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T57.0X2S | Toxic effect of arsenic and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T57.1X2 | Toxic effect of phosphorus and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T57.1X2A | Toxic effect of phosphorus and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T57.1X2D | Toxic effect of phosphorus and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T57.1X2S | Toxic effect of phosphorus and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T57.2X2 | Toxic effect of manganese and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T57.2X2A | Toxic effect of manganese and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T57.2X2D | Toxic effect of manganese and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T57.2X2S | Toxic effect of manganese and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T57.3X2 | Toxic effect of hydrogen cyanide, intentional self-harm | Diagnosis | ICD-10-CM |
| T57.3X2A | Toxic effect of hydrogen cyanide, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T57.3X2D | Toxic effect of hydrogen cyanide, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T57.3X2S | Toxic effect of hydrogen cyanide, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T57.8X2 | Toxic effect of other specified inorganic substances, intentional self-harm | Diagnosis | ICD-10-CM |
| T57.8X2A | Toxic effect of other specified inorganic substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T57.8X2D | Toxic effect of other specified inorganic substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T57.8X2S | Toxic effect of other specified inorganic substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T57.92 | Toxic effect of unspecified inorganic substance, intentional self-harm | Diagnosis | ICD-10-CM |
| T57.92XA | Toxic effect of unspecified inorganic substance, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T57.92XD | Toxic effect of unspecified inorganic substance, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T57.92XS | Toxic effect of unspecified inorganic substance, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T58.02 | Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm | Diagnosis | ICD-10-CM |
| T58.02XA | Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T58.02XD | Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T58.02XS | Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T58.12 | Toxic effect of carbon monoxide from utility gas, intentional self-harm | Diagnosis | ICD-10-CM |
| T58.12XA | Toxic effect of carbon monoxide from utility gas, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T58.12XD | Toxic effect of carbon monoxide from utility gas, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T58.12XS | Toxic effect of carbon monoxide from utility gas, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T58.2X2 | Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm | Diagnosis | ICD-10-CM |
| T58.2X2A | Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T58.2X2D | Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T58.2X2S | Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T58.8X2 | Toxic effect of carbon monoxide from other source, intentional self-harm | Diagnosis | ICD-10-CM |
| T58.8X2A | Toxic effect of carbon monoxide from other source, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T58.8X2D | Toxic effect of carbon monoxide from other source, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T58.8X2S | Toxic effect of carbon monoxide from other source, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T58.92 | Toxic effect of carbon monoxide from unspecified source, intentional self-harm | Diagnosis | ICD-10-CM |
| T58.92XA | Toxic effect of carbon monoxide from unspecified source, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T58.92XD | Toxic effect of carbon monoxide from unspecified source, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T58.92XS | Toxic effect of carbon monoxide from unspecified source, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.0X2 | Toxic effect of nitrogen oxides, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.0X2A | Toxic effect of nitrogen oxides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.0X2D | Toxic effect of nitrogen oxides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.0X2S | Toxic effect of nitrogen oxides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.1X2 | Toxic effect of sulfur dioxide, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.1X2A | Toxic effect of sulfur dioxide, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.1X2D | Toxic effect of sulfur dioxide, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.1X2S | Toxic effect of sulfur dioxide, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.2X2 | Toxic effect of formaldehyde, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.2X2A | Toxic effect of formaldehyde, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.2X2D | Toxic effect of formaldehyde, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.2X2S | Toxic effect of formaldehyde, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.3X2 | Toxic effect of lacrimogenic gas, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.3X2A | Toxic effect of lacrimogenic gas, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.3X2D | Toxic effect of lacrimogenic gas, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.3X2S | Toxic effect of lacrimogenic gas, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.4X2 | Toxic effect of chlorine gas, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.4X2A | Toxic effect of chlorine gas, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.4X2D | Toxic effect of chlorine gas, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.4X2S | Toxic effect of chlorine gas, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.5X2 | Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.5X2A | Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.5X2D | Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.5X2S | Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.6X2 | Toxic effect of hydrogen sulfide, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.6X2A | Toxic effect of hydrogen sulfide, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.6X2D | Toxic effect of hydrogen sulfide, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.6X2S | Toxic effect of hydrogen sulfide, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.7X2 | Toxic effect of carbon dioxide, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.7X2A | Toxic effect of carbon dioxide, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.7X2D | Toxic effect of carbon dioxide, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.7X2S | Toxic effect of carbon dioxide, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.812 | Toxic effect of smoke, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.812A | Toxic effect of smoke, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T59.812D | Toxic effect of smoke, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.812S | Toxic effect of smoke, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.892 | Toxic effect of other specified gases, fumes and vapors, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.892A | Toxic effect of other specified gases, fumes and vapors, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.892D | Toxic effect of other specified gases, fumes and vapors, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.892S | Toxic effect of other specified gases, fumes and vapors, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.92 | Toxic effect of unspecified gases, fumes and vapors, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.92XA | Toxic effect of unspecified gases, fumes and vapors, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.92XD | Toxic effect of unspecified gases, fumes and vapors, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.92XS | Toxic effect of unspecified gases, fumes and vapors, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.0X2 | Toxic effect of organophosphate and carbamate insecticides, intentional self-harm | Diagnosis | ICD-10-CM |
| T60.0X2A | Toxic effect of organophosphate and carbamate insecticides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.0X2D | Toxic effect of organophosphate and carbamate insecticides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.0X2S | Toxic effect of organophosphate and carbamate insecticides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.1X2 | Toxic effect of halogenated insecticides, intentional self-harm | Diagnosis | ICD-10-CM |
| T60.1X2A | Toxic effect of halogenated insecticides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.1X2D | Toxic effect of halogenated insecticides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.1X2S | Toxic effect of halogenated insecticides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.2X2 | Toxic effect of other insecticides, intentional self-harm | Diagnosis | ICD-10-CM |
| T60.2X2A | Toxic effect of other insecticides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.2X2D | Toxic effect of other insecticides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.2X2S | Toxic effect of other insecticides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.3X2 | Toxic effect of herbicides and fungicides, intentional self-harm | Diagnosis | ICD-10-CM |
| T60.3X2A | Toxic effect of herbicides and fungicides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.3X2D | Toxic effect of herbicides and fungicides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.3X2S | Toxic effect of herbicides and fungicides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.4X2 | Toxic effect of rodenticides, intentional self-harm | Diagnosis | ICD-10-CM |
| T60.4X2A | Toxic effect of rodenticides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.4X2D | Toxic effect of rodenticides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.4X2S | Toxic effect of rodenticides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.8X2 | Toxic effect of other pesticides, intentional self-harm | Diagnosis | ICD-10-CM |
| T60.8X2A | Toxic effect of other pesticides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.8X2D | Toxic effect of other pesticides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.8X2S | Toxic effect of other pesticides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.92 | Toxic effect of unspecified pesticide, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T60.92XA | Toxic effect of unspecified pesticide, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.92XD | Toxic effect of unspecified pesticide, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.92XS | Toxic effect of unspecified pesticide, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T61.02 | Ciguatera fish poisoning, intentional self-harm | Diagnosis | ICD-10-CM |
| T61.02XA | Ciguatera fish poisoning, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T61.02XD | Ciguatera fish poisoning, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T61.02XS | Ciguatera fish poisoning, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T61.12 | Scombroid fish poisoning, intentional self-harm | Diagnosis | ICD-10-CM |
| T61.12XA | Scombroid fish poisoning, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T61.12XD | Scombroid fish poisoning, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T61.12XS | Scombroid fish poisoning, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T61.772 | Other fish poisoning, intentional self-harm | Diagnosis | ICD-10-CM |
| T61.772A | Other fish poisoning, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T61.772D | Other fish poisoning, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T61.772S | Other fish poisoning, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T61.782 | Other shellfish poisoning, intentional self-harm | Diagnosis | ICD-10-CM |
| T61.782A | Other shellfish poisoning, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T61.782D | Other shellfish poisoning, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T61.782S | Other shellfish poisoning, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T61.8X2 | Toxic effect of other seafood, intentional self-harm | Diagnosis | ICD-10-CM |
| T61.8X2A | Toxic effect of other seafood, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T61.8X2D | Toxic effect of other seafood, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T61.8X2S | Toxic effect of other seafood, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T61.92 | Toxic effect of unspecified seafood, intentional self-harm | Diagnosis | ICD-10-CM |
| T61.92XA | Toxic effect of unspecified seafood, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T61.92XD | Toxic effect of unspecified seafood, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T61.92XS | Toxic effect of unspecified seafood, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T62.0X2 | Toxic effect of ingested mushrooms, intentional self-harm | Diagnosis | ICD-10-CM |
| T62.0X2A | Toxic effect of ingested mushrooms, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T62.0X2D | Toxic effect of ingested mushrooms, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T62.0X2S | Toxic effect of ingested mushrooms, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T62.1X2 | Toxic effect of ingested berries, intentional self-harm | Diagnosis | ICD-10-CM |
| T62.1X2A | Toxic effect of ingested berries, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T62.1X2D | Toxic effect of ingested berries, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T62.1X2S | Toxic effect of ingested berries, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T62.2X2 | Toxic effect of other ingested (parts of) plant(s), intentional self-harm | Diagnosis | ICD-10-CM |
| T62.2X2A | Toxic effect of other ingested (parts of) plant(s), intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T62.2X2D | Toxic effect of other ingested (parts of) plant(s), intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T62.2X2S | Toxic effect of other ingested (parts of) plant(s), intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T62.8X2 | Toxic effect of other specified noxious substances eaten as food, intentional self-harm | Diagnosis | ICD-10-CM |
| T62.8X2A | Toxic effect of other specified noxious substances eaten as food, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T62.8X2D | Toxic effect of other specified noxious substances eaten as food, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T62.8X2S | Toxic effect of other specified noxious substances eaten as food, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T62.92 | Toxic effect of unspecified noxious substance eaten as food, intentional self-harm | Diagnosis | ICD-10-CM |
| T62.92XA | Toxic effect of unspecified noxious substance eaten as food, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T62.92XD | Toxic effect of unspecified noxious substance eaten as food, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T62.92XS | Toxic effect of unspecified noxious substance eaten as food, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.002 | Toxic effect of unspecified snake venom, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.002A | Toxic effect of unspecified snake venom, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.002D | Toxic effect of unspecified snake venom, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.002S | Toxic effect of unspecified snake venom, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.012 | Toxic effect of rattlesnake venom, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.012A | Toxic effect of rattlesnake venom, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.012D | Toxic effect of rattlesnake venom, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.012S | Toxic effect of rattlesnake venom, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.022 | Toxic effect of coral snake venom, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.022A | Toxic effect of coral snake venom, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.022D | Toxic effect of coral snake venom, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.022S | Toxic effect of coral snake venom, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.032 | Toxic effect of taipan venom, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.032A | Toxic effect of taipan venom, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.032D | Toxic effect of taipan venom, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.032S | Toxic effect of taipan venom, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.042 | Toxic effect of cobra venom, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.042A | Toxic effect of cobra venom, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.042D | Toxic effect of cobra venom, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.042S | Toxic effect of cobra venom, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.062 | Toxic effect of venom of other North and South American snake, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.062A | Toxic effect of venom of other North and South American snake, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.062D | Toxic effect of venom of other North and South American snake, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.062S | Toxic effect of venom of other North and South American snake, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.072 | Toxic effect of venom of other Australian snake, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.072A | Toxic effect of venom of other Australian snake, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.072D | Toxic effect of venom of other Australian snake, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.072S | Toxic effect of venom of other Australian snake, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T63.082 | Toxic effect of venom of other African and Asian snake, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.082A | Toxic effect of venom of other African and Asian snake, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.082D | Toxic effect of venom of other African and Asian snake, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.082S | Toxic effect of venom of other African and Asian snake, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.092 | Toxic effect of venom of other snake, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.092A | Toxic effect of venom of other snake, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.092D | Toxic effect of venom of other snake, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.092S | Toxic effect of venom of other snake, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.112 | Toxic effect of venom of gila monster, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.112A | Toxic effect of venom of gila monster, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.112D | Toxic effect of venom of gila monster, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.112S | Toxic effect of venom of gila monster, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.122 | Toxic effect of venom of other venomous lizard, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.122A | Toxic effect of venom of other venomous lizard, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.122D | Toxic effect of venom of other venomous lizard, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.122S | Toxic effect of venom of other venomous lizard, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.192 | Toxic effect of venom of other reptiles, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.192A | Toxic effect of venom of other reptiles, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.192D | Toxic effect of venom of other reptiles, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.192S | Toxic effect of venom of other reptiles, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.2X2 | Toxic effect of venom of scorpion, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.2X2A | Toxic effect of venom of scorpion, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.2X2D | Toxic effect of venom of scorpion, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.2X2S | Toxic effect of venom of scorpion, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.302 | Toxic effect of unspecified spider venom, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.302A | Toxic effect of unspecified spider venom, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.302D | Toxic effect of unspecified spider venom, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.302S | Toxic effect of unspecified spider venom, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.312 | Toxic effect of venom of black widow spider, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.312A | Toxic effect of venom of black widow spider, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.312D | Toxic effect of venom of black widow spider, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.312S | Toxic effect of venom of black widow spider, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.322 | Toxic effect of venom of tarantula, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.322A | Toxic effect of venom of tarantula, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.322D | Toxic effect of venom of tarantula, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.322S | Toxic effect of venom of tarantula, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T63.332 | Toxic effect of venom of brown recluse spider, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.332A | Toxic effect of venom of brown recluse spider, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.332D | Toxic effect of venom of brown recluse spider, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.332S | Toxic effect of venom of brown recluse spider, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.392 | Toxic effect of venom of other spider, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.392A | Toxic effect of venom of other spider, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.392D | Toxic effect of venom of other spider, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.392S | Toxic effect of venom of other spider, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.412 | Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.412A | Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.412D | Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.412S | Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.422 | Toxic effect of venom of ants, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.422A | Toxic effect of venom of ants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.422D | Toxic effect of venom of ants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.422S | Toxic effect of venom of ants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.432 | Toxic effect of venom of caterpillars, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.432A | Toxic effect of venom of caterpillars, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.432D | Toxic effect of venom of caterpillars, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.432S | Toxic effect of venom of caterpillars, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.442 | Toxic effect of venom of bees, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.442A | Toxic effect of venom of bees, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.442D | Toxic effect of venom of bees, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.442S | Toxic effect of venom of bees, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.452 | Toxic effect of venom of hornets, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.452A | Toxic effect of venom of hornets, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.452D | Toxic effect of venom of hornets, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.452S | Toxic effect of venom of hornets, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.462 | Toxic effect of venom of wasps, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.462A | Toxic effect of venom of wasps, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.462D | Toxic effect of venom of wasps, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.462S | Toxic effect of venom of wasps, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.482 | Toxic effect of venom of other arthropod, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.482A | Toxic effect of venom of other arthropod, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.482D | Toxic effect of venom of other arthropod, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.482S | Toxic effect of venom of other arthropod, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.512 | Toxic effect of contact with stingray, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T63.512A | Toxic effect of contact with stingray, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.512D | Toxic effect of contact with stingray, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.512S | Toxic effect of contact with stingray, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.592 | Toxic effect of contact with other venomous fish, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.592A | Toxic effect of contact with other venomous fish, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.592D | Toxic effect of contact with other venomous fish, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.592S | Toxic effect of contact with other venomous fish, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.612 | Toxic effect of contact with Portuguese Man-o-war, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.612A | Toxic effect of contact with Portuguese Man-o-war, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.612D | Toxic effect of contact with Portuguese Man-o-war, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.612S | Toxic effect of contact with Portuguese Man-o-war, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.622 | Toxic effect of contact with other jellyfish, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.622A | Toxic effect of contact with other jellyfish, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.622D | Toxic effect of contact with other jellyfish, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.622S | Toxic effect of contact with other jellyfish, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.632 | Toxic effect of contact with sea anemone, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.632A | Toxic effect of contact with sea anemone, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.632D | Toxic effect of contact with sea anemone, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.632S | Toxic effect of contact with sea anemone, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.692 | Toxic effect of contact with other venomous marine animals, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.692A | Toxic effect of contact with other venomous marine animals, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.692D | Toxic effect of contact with other venomous marine animals, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.692S | Toxic effect of contact with other venomous marine animals, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.712 | Toxic effect of contact with venomous marine plant, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.712A | Toxic effect of contact with venomous marine plant, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.712D | Toxic effect of contact with venomous marine plant, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.712S | Toxic effect of contact with venomous marine plant, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.792 | Toxic effect of contact with other venomous plant, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.792A | Toxic effect of contact with other venomous plant, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T63.792D | Toxic effect of contact with other venomous plant, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.792S | Toxic effect of contact with other venomous plant, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.812 | Toxic effect of contact with venomous frog, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.812A | Toxic effect of contact with venomous frog, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.812D | Toxic effect of contact with venomous frog, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.812S | Toxic effect of contact with venomous frog, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.822 | Toxic effect of contact with venomous toad, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.822A | Toxic effect of contact with venomous toad, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.822D | Toxic effect of contact with venomous toad, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.822S | Toxic effect of contact with venomous toad, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.832 | Toxic effect of contact with other venomous amphibian, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.832A | Toxic effect of contact with other venomous amphibian, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.832D | Toxic effect of contact with other venomous amphibian, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.832S | Toxic effect of contact with other venomous amphibian, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.892 | Toxic effect of contact with other venomous animals, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.892A | Toxic effect of contact with other venomous animals, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.892D | Toxic effect of contact with other venomous animals, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.892S | Toxic effect of contact with other venomous animals, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.92 | Toxic effect of contact with unspecified venomous animal, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.92XA | Toxic effect of contact with unspecified venomous animal, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.92XD | Toxic effect of contact with unspecified venomous animal, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.92XS | Toxic effect of contact with unspecified venomous animal, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T64.02 | Toxic effect of aflatoxin, intentional self-harm | Diagnosis | ICD-10-CM |
| T64.02XA | Toxic effect of aflatoxin, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T64.02XD | Toxic effect of aflatoxin, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T64.02XS | Toxic effect of aflatoxin, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T64.82 | Toxic effect of other mycotoxin food contaminants, intentional self-harm | Diagnosis | ICD-10-CM |
| T64.82XA | Toxic effect of other mycotoxin food contaminants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T64.82XD | Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T64.82XS | Toxic effect of other mycotoxin food contaminants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.0X2 | Toxic effect of cyanides, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.0X2A | Toxic effect of cyanides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.0X2D | Toxic effect of cyanides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.0X2S | Toxic effect of cyanides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.1X2 | Toxic effect of strychnine and its salts, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.1X2A | Toxic effect of strychnine and its salts, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.1X2D | Toxic effect of strychnine and its salts, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.1X2S | Toxic effect of strychnine and its salts, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.212 | Toxic effect of chewing tobacco, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.212A | Toxic effect of chewing tobacco, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.212D | Toxic effect of chewing tobacco, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.212S | Toxic effect of chewing tobacco, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.222 | Toxic effect of tobacco cigarettes, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.222A | Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.222D | Toxic effect of tobacco cigarettes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.222S | Toxic effect of tobacco cigarettes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.292 | Toxic effect of other tobacco and nicotine, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.292A | Toxic effect of other tobacco and nicotine, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.292D | Toxic effect of other tobacco and nicotine, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.292S | Toxic effect of other tobacco and nicotine, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.3X2 | Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.3X2A | Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.3X2D | Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.3X2S | Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.4X2 | Toxic effect of carbon disulfide, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.4X2A | Toxic effect of carbon disulfide, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.4X2D | Toxic effect of carbon disulfide, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.4X2S | Toxic effect of carbon disulfide, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.5X2 | Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.5X2A | Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.5X2D | Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.5X2S | Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.6X2 | Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T65.6X2A | Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.6X2D | Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.6X2S | Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.812 | Toxic effect of latex, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.812A | Toxic effect of latex, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.812D | Toxic effect of latex, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.812S | Toxic effect of latex, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.822 | Toxic effect of harmful algae and algae toxins, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.822A | Toxic effect of harmful algae and algae toxins, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.822D | Toxic effect of harmful algae and algae toxins, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.822S | Toxic effect of harmful algae and algae toxins, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.832 | Toxic effect of fiberglass, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.832A | Toxic effect of fiberglass, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.832D | Toxic effect of fiberglass, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.832S | Toxic effect of fiberglass, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.892 | Toxic effect of other specified substances, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.892A | Toxic effect of other specified substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.892D | Toxic effect of other specified substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.892S | Toxic effect of other specified substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.92 | Toxic effect of unspecified substance, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.92XA | Toxic effect of unspecified substance, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.92XD | Toxic effect of unspecified substance, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.92XS | Toxic effect of unspecified substance, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.112 | Asphyxiation due to smothering under pillow, intentional self-harm | Diagnosis | ICD-10-CM |
| T71.112A | Asphyxiation due to smothering under pillow, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.112D | Asphyxiation due to smothering under pillow, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.112S | Asphyxiation due to smothering under pillow, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.122 | Asphyxiation due to plastic bag, intentional self-harm | Diagnosis | ICD-10-CM |
| T71.122A | Asphyxiation due to plastic bag, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.122D | Asphyxiation due to plastic bag, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.122S | Asphyxiation due to plastic bag, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.132 | Asphyxiation due to being trapped in bed linens, intentional self-harm | Diagnosis | ICD-10-CM |
| T71.132A | Asphyxiation due to being trapped in bed linens, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.132D | Asphyxiation due to being trapped in bed linens, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.132S | Asphyxiation due to being trapped in bed linens, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T71.152 | Asphyxiation due to smothering in furniture, intentional self-harm | Diagnosis | ICD-10-CM |
| T71.152A | Asphyxiation due to smothering in furniture, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.152D | Asphyxiation due to smothering in furniture, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.152S | Asphyxiation due to smothering in furniture, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.162 | Asphyxiation due to hanging, intentional self-harm | Diagnosis | ICD-10-CM |
| T71.162A | Asphyxiation due to hanging, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.162D | Asphyxiation due to hanging, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.162S | Asphyxiation due to hanging, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.192 | Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm | Diagnosis | ICD-10-CM |
| T71.192A | Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.192D | Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.192S | Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.222 | Asphyxiation due to being trapped in a car trunk, intentional self-harm | Diagnosis | ICD-10-CM |
| T71.222A | Asphyxiation due to being trapped in a car trunk, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.222D | Asphyxiation due to being trapped in a car trunk, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.222S | Asphyxiation due to being trapped in a car trunk, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.232 | Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm | Diagnosis | ICD-10-CM |
| T71.232A | Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.232D | Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.232S | Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| X71 | Intentional self-harm by drowning and submersion | Diagnosis | ICD-10-CM |
| X71.0 | Intentional self-harm by drowning and submersion while in bathtub | Diagnosis | ICD-10-CM |
| X71.0XXA | Intentional self-harm by drowning and submersion while in bathtub, initial encounter | Diagnosis | ICD-10-CM |
| X71.0XXD | Intentional self-harm by drowning and submersion while in bathtub, subsequent encounter | Diagnosis | ICD-10-CM |
| X71.0XXS | Intentional self-harm by drowning and submersion while in bathtub, sequela | Diagnosis | ICD-10-CM |
| X71.1 | Intentional self-harm by drowning and submersion while in swimming pool | Diagnosis | ICD-10-CM |
| X71.1XXA | Intentional self-harm by drowning and submersion while in swimming pool, initial encounter | Diagnosis | ICD-10-CM |
| X71.1XXD | Intentional self-harm by drowning and submersion while in swimming pool, subsequent encounter | Diagnosis | ICD-10-CM |
| X71.1XXS | Intentional self-harm by drowning and submersion while in swimming pool, sequela | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| X71.2 | Intentional self-harm by drowning and submersion after jump into swimming pool | Diagnosis | ICD-10-CM |
| X71.2XXA | Intentional self-harm by drowning and submersion after jump into swimming pool, initial encounter | Diagnosis | ICD-10-CM |
| X71.2XXD | Intentional self-harm by drowning and submersion after jump into swimming pool, subsequent encounter | Diagnosis | ICD-10-CM |
| X71.2XXS | Intentional self-harm by drowning and submersion after jump into swimming pool, sequela | Diagnosis | ICD-10-CM |
| X71.3 | Intentional self-harm by drowning and submersion in natural water | Diagnosis | ICD-10-CM |
| X71.3XXA | Intentional self-harm by drowning and submersion in natural water, initial encounter | Diagnosis | ICD-10-CM |
| X71.3XXD | Intentional self-harm by drowning and submersion in natural water, subsequent encounter | Diagnosis | ICD-10-CM |
| X71.3XXS | Intentional self-harm by drowning and submersion in natural water, sequela | Diagnosis | ICD-10-CM |
| X71.8 | Other intentional self-harm by drowning and submersion | Diagnosis | ICD-10-CM |
| X71.8XXA | Other intentional self-harm by drowning and submersion, initial encounter | Diagnosis | ICD-10-CM |
| X71.8XXD | Other intentional self-harm by drowning and submersion, subsequent encounter | Diagnosis | ICD-10-CM |
| X71.8XXS | Other intentional self-harm by drowning and submersion, sequela | Diagnosis | ICD-10-CM |
| X71.9 | Intentional self-harm by drowning and submersion, unspecified | Diagnosis | ICD-10-CM |
| X71.9XXA | Intentional self-harm by drowning and submersion, unspecified, initial encounter | Diagnosis | ICD-10-CM |
| X71.9XXD | Intentional self-harm by drowning and submersion, unspecified, subsequent encounter | Diagnosis | ICD-10-CM |
| X71.9XXS | Intentional self-harm by drowning and submersion, unspecified, sequela | Diagnosis | ICD-10-CM |
| X72 | Intentional self-harm by handgun discharge | Diagnosis | ICD-10-CM |
| X72.XXXA | Intentional self-harm by handgun discharge, initial encounter | Diagnosis | ICD-10-CM |
| X72.XXXD | Intentional self-harm by handgun discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X72.XXXS | Intentional self-harm by handgun discharge, sequela | Diagnosis | ICD-10-CM |
| X73 | Intentional self-harm by rifle, shotgun and larger firearm discharge | Diagnosis | ICD-10-CM |
| X73.0 | Intentional self-harm by shotgun discharge | Diagnosis | ICD-10-CM |
| X73.0XXA | Intentional self-harm by shotgun discharge, initial encounter | Diagnosis | ICD-10-CM |
| X73.0XXD | Intentional self-harm by shotgun discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X73.0XXS | Intentional self-harm by shotgun discharge, sequela | Diagnosis | ICD-10-CM |
| X73.1 | Intentional self-harm by hunting rifle discharge | Diagnosis | ICD-10-CM |
| X73.1XXA | Intentional self-harm by hunting rifle discharge, initial encounter | Diagnosis | ICD-10-CM |
| X73.1XXD | Intentional self-harm by hunting rifle discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X73.1XXS | Intentional self-harm by hunting rifle discharge, sequela | Diagnosis | ICD-10-CM |
| X73.2 | Intentional self-harm by machine gun discharge | Diagnosis | ICD-10-CM |
| X73.2XXA | Intentional self-harm by machine gun discharge, initial encounter | Diagnosis | ICD-10-CM |
| X73.2XXD | Intentional self-harm by machine gun discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X73.2XXS | Intentional self-harm by machine gun discharge, sequela | Diagnosis | ICD-10-CM |
| X73.8 | Intentional self-harm by other larger firearm discharge | Diagnosis | ICD-10-CM |
| X73.8XXA | Intentional self-harm by other larger firearm discharge, initial encounter | Diagnosis | ICD-10-CM |
| X73.8XXD | Intentional self-harm by other larger firearm discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X73.8XXS | Intentional self-harm by other larger firearm discharge, sequela | Diagnosis | ICD-10-CM |
| X73.9 | Intentional self-harm by unspecified larger firearm discharge | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| X73.9XXA | Intentional self-harm by unspecified larger firearm discharge, initial encounter | Diagnosis | ICD-10-CM |
| X73.9XXD | Intentional self-harm by unspecified larger firearm discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X73.9XXS | Intentional self-harm by unspecified larger firearm discharge, sequela | Diagnosis | ICD-10-CM |
| X74 | Intentional self-harm by other and unspecified firearm and gun discharge | Diagnosis | ICD-10-CM |
| X74.0 | Intentional self-harm by gas, air or spring-operated guns | Diagnosis | ICD-10-CM |
| X74.01 | Intentional self-harm by airgun | Diagnosis | ICD-10-CM |
| X74.01XA | Intentional self-harm by airgun, initial encounter | Diagnosis | ICD-10-CM |
| X74.01XD | Intentional self-harm by airgun, subsequent encounter | Diagnosis | ICD-10-CM |
| X74.01XS | Intentional self-harm by airgun, sequela | Diagnosis | ICD-10-CM |
| X74.02 | Intentional self-harm by paintball gun | Diagnosis | ICD-10-CM |
| X74.02XA | Intentional self-harm by paintball gun, initial encounter | Diagnosis | ICD-10-CM |
| X74.02XD | Intentional self-harm by paintball gun, subsequent encounter | Diagnosis | ICD-10-CM |
| X74.02XS | Intentional self-harm by paintball gun, sequela | Diagnosis | ICD-10-CM |
| X74.09 | Intentional self-harm by other gas, air or spring-operated gun | Diagnosis | ICD-10-CM |
| X74.09XA | Intentional self-harm by other gas, air or spring-operated gun, initial encounter | Diagnosis | ICD-10-CM |
| X74.09XD | Intentional self-harm by other gas, air or spring-operated gun, subsequent encounter | Diagnosis | ICD-10-CM |
| X74.09XS | Intentional self-harm by other gas, air or spring-operated gun, sequela | Diagnosis | ICD-10-CM |
| X74.8 | Intentional self-harm by other firearm discharge | Diagnosis | ICD-10-CM |
| X74.8XXA | Intentional self-harm by other firearm discharge, initial encounter | Diagnosis | ICD-10-CM |
| X74.8XXD | Intentional self-harm by other firearm discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X74.8XXS | Intentional self-harm by other firearm discharge, sequela | Diagnosis | ICD-10-CM |
| X74.9 | Intentional self-harm by unspecified firearm discharge | Diagnosis | ICD-10-CM |
| X74.9XXA | Intentional self-harm by unspecified firearm discharge, initial encounter | Diagnosis | ICD-10-CM |
| X74.9XXD | Intentional self-harm by unspecified firearm discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X74.9XXS | Intentional self-harm by unspecified firearm discharge, sequela | Diagnosis | ICD-10-CM |
| X75 | Intentional self-harm by explosive material | Diagnosis | ICD-10-CM |
| X75.XXXA | Intentional self-harm by explosive material, initial encounter | Diagnosis | ICD-10-CM |
| X75.XXXD | Intentional self-harm by explosive material, subsequent encounter | Diagnosis | ICD-10-CM |
| X75.XXXS | Intentional self-harm by explosive material, sequela | Diagnosis | ICD-10-CM |
| X76 | Intentional self-harm by smoke, fire and flames | Diagnosis | ICD-10-CM |
| X76.XXXA | Intentional self-harm by smoke, fire and flames, initial encounter | Diagnosis | ICD-10-CM |
| X76.XXXD | Intentional self-harm by smoke, fire and flames, subsequent encounter | Diagnosis | ICD-10-CM |
| X76.XXXS | Intentional self-harm by smoke, fire and flames, sequela | Diagnosis | ICD-10-CM |
| X77 | Intentional self-harm by steam, hot vapors and hot objects | Diagnosis | ICD-10-CM |
| X77.0 | Intentional self-harm by steam or hot vapors | Diagnosis | ICD-10-CM |
| X77.0XXA | Intentional self-harm by steam or hot vapors, initial encounter | Diagnosis | ICD-10-CM |
| X77.0XXD | Intentional self-harm by steam or hot vapors, subsequent encounter | Diagnosis | ICD-10-CM |
| X77.0XXS | Intentional self-harm by steam or hot vapors, sequela | Diagnosis | ICD-10-CM |
| X77.1 | Intentional self-harm by hot tap water | Diagnosis | ICD-10-CM |
| X77.1XXA | Intentional self-harm by hot tap water, initial encounter | Diagnosis | ICD-10-CM |
| X77.1XXD | Intentional self-harm by hot tap water, subsequent encounter | Diagnosis | ICD-10-CM |
| X77.1XXS | Intentional self-harm by hot tap water, sequela | Diagnosis | ICD-10-CM |
| X77.2 | Intentional self-harm by other hot fluids | Diagnosis | ICD-10-CM |
| X77.2XXA | Intentional self-harm by other hot fluids, initial encounter | Diagnosis | ICD-10-CM |
| X77.2XXD | Intentional self-harm by other hot fluids, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| X77.2XXS | Intentional self-harm by other hot fluids, sequela | Diagnosis | ICD-10-CM |
| X77.3 | Intentional self-harm by hot household appliances | Diagnosis | ICD-10-CM |
| X77.3XXA | Intentional self-harm by hot household appliances, initial encounter | Diagnosis | ICD-10-CM |
| X77.3XXD | Intentional self-harm by hot household appliances, subsequent encounter | Diagnosis | ICD-10-CM |
| X77.3XXS | Intentional self-harm by hot household appliances, sequela | Diagnosis | ICD-10-CM |
| X77.8 | Intentional self-harm by other hot objects | Diagnosis | ICD-10-CM |
| X77.8XXA | Intentional self-harm by other hot objects, initial encounter | Diagnosis | ICD-10-CM |
| X77.8XXD | Intentional self-harm by other hot objects, subsequent encounter | Diagnosis | ICD-10-CM |
| X77.8XXS | Intentional self-harm by other hot objects, sequela | Diagnosis | ICD-10-CM |
| X77.9 | Intentional self-harm by unspecified hot objects | Diagnosis | ICD-10-CM |
| X77.9XXA | Intentional self-harm by unspecified hot objects, initial encounter | Diagnosis | ICD-10-CM |
| X77.9XXD | Intentional self-harm by unspecified hot objects, subsequent encounter | Diagnosis | ICD-10-CM |
| X77.9XXS | Intentional self-harm by unspecified hot objects, sequela | Diagnosis | ICD-10-CM |
| X78 | Intentional self-harm by sharp object | Diagnosis | ICD-10-CM |
| X78.0 | Intentional self-harm by sharp glass | Diagnosis | ICD-10-CM |
| X78.0XXA | Intentional self-harm by sharp glass, initial encounter | Diagnosis | ICD-10-CM |
| X78.0XXD | Intentional self-harm by sharp glass, subsequent encounter | Diagnosis | ICD-10-CM |
| X78.0XXS | Intentional self-harm by sharp glass, sequela | Diagnosis | ICD-10-CM |
| X78.1 | Intentional self-harm by knife | Diagnosis | ICD-10-CM |
| X78.1XXA | Intentional self-harm by knife, initial encounter | Diagnosis | ICD-10-CM |
| X78.1XXD | Intentional self-harm by knife, subsequent encounter | Diagnosis | ICD-10-CM |
| X78.1XXS | Intentional self-harm by knife, sequela | Diagnosis | ICD-10-CM |
| X78.2 | Intentional self-harm by sword or dagger | Diagnosis | ICD-10-CM |
| X78.2XXA | Intentional self-harm by sword or dagger, initial encounter | Diagnosis | ICD-10-CM |
| X78.2XXD | Intentional self-harm by sword or dagger, subsequent encounter | Diagnosis | ICD-10-CM |
| X78.2XXS | Intentional self-harm by sword or dagger, sequela | Diagnosis | ICD-10-CM |
| X78.8 | Intentional self-harm by other sharp object | Diagnosis | ICD-10-CM |
| X78.8XXA | Intentional self-harm by other sharp object, initial encounter | Diagnosis | ICD-10-CM |
| X78.8XXD | Intentional self-harm by other sharp object, subsequent encounter | Diagnosis | ICD-10-CM |
| X78.8XXS | Intentional self-harm by other sharp object, sequela | Diagnosis | ICD-10-CM |
| X78.9 | Intentional self-harm by unspecified sharp object | Diagnosis | ICD-10-CM |
| X78.9XXA | Intentional self-harm by unspecified sharp object, initial encounter | Diagnosis | ICD-10-CM |
| X78.9XXD | Intentional self-harm by unspecified sharp object, subsequent encounter | Diagnosis | ICD-10-CM |
| X78.9XXS | Intentional self-harm by unspecified sharp object, sequela | Diagnosis | ICD-10-CM |
| X79 | Intentional self-harm by blunt object | Diagnosis | ICD-10-CM |
| X79.XXXA | Intentional self-harm by blunt object, initial encounter | Diagnosis | ICD-10-CM |
| X79.XXXD | Intentional self-harm by blunt object, subsequent encounter | Diagnosis | ICD-10-CM |
| X79.XXXS | Intentional self-harm by blunt object, sequela | Diagnosis | ICD-10-CM |
| X80 | Intentional self-harm by jumping from a high place | Diagnosis | ICD-10-CM |
| X80.XXXA | Intentional self-harm by jumping from a high place, initial encounter | Diagnosis | ICD-10-CM |
| X80.XXXD | Intentional self-harm by jumping from a high place, subsequent encounter | Diagnosis | ICD-10-CM |
| X80.XXXS | Intentional self-harm by jumping from a high place, sequela | Diagnosis | ICD-10-CM |
| X81 | Intentional self-harm by jumping or lying in front of moving object | Diagnosis | ICD-10-CM |
| X81.0 | Intentional self-harm by jumping or lying in front of motor vehicle | Diagnosis | ICD-10-CM |
| X81.0XXA | Intentional self-harm by jumping or lying in front of motor vehicle, initial encounter | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| X81.0XXD | Intentional self-harm by jumping or lying in front of motor vehicle, subsequent encounter | Diagnosis | ICD-10-CM |
| X81.0XXS | Intentional self-harm by jumping or lying in front of motor vehicle, sequela | Diagnosis | ICD-10-CM |
| X81.1 | Intentional self-harm by jumping or lying in front of (subway) train | Diagnosis | ICD-10-CM |
| X81.1XXA | Intentional self-harm by jumping or lying in front of (subway) train, initial encounter | Diagnosis | ICD-10-CM |
| X81.1XXD | Intentional self-harm by jumping or lying in front of (subway) train, subsequent encounter | Diagnosis | ICD-10-CM |
| X81.1XXS | Intentional self-harm by jumping or lying in front of (subway) train, sequela | Diagnosis | ICD-10-CM |
| X81.8 | Intentional self-harm by jumping or lying in front of other moving object | Diagnosis | ICD-10-CM |
| X81.8XXA | Intentional self-harm by jumping or lying in front of other moving object, initial encounter | Diagnosis | ICD-10-CM |
| X81.8XXD | Intentional self-harm by jumping or lying in front of other moving object, subsequent encounter | Diagnosis | ICD-10-CM |
| X81.8XXS | Intentional self-harm by jumping or lying in front of other moving object, sequela | Diagnosis | ICD-10-CM |
| X82 | Intentional self-harm by crashing of motor vehicle | Diagnosis | ICD-10-CM |
| X82.0 | Intentional collision of motor vehicle with other motor vehicle | Diagnosis | ICD-10-CM |
| X82.0XXA | Intentional collision of motor vehicle with other motor vehicle, initial encounter | Diagnosis | ICD-10-CM |
| X82.0XXD | Intentional collision of motor vehicle with other motor vehicle, subsequent encounter | Diagnosis | ICD-10-CM |
| X82.0XXS | Intentional collision of motor vehicle with other motor vehicle, sequela | Diagnosis | ICD-10-CM |
| X82.1 | Intentional collision of motor vehicle with train | Diagnosis | ICD-10-CM |
| X82.1XXA | Intentional collision of motor vehicle with train, initial encounter | Diagnosis | ICD-10-CM |
| X82.1XXD | Intentional collision of motor vehicle with train, subsequent encounter | Diagnosis | ICD-10-CM |
| X82.1XXS | Intentional collision of motor vehicle with train, sequela | Diagnosis | ICD-10-CM |
| X82.2 | Intentional collision of motor vehicle with tree | Diagnosis | ICD-10-CM |
| X82.2XXA | Intentional collision of motor vehicle with tree, initial encounter | Diagnosis | ICD-10-CM |
| X82.2XXD | Intentional collision of motor vehicle with tree, subsequent encounter | Diagnosis | ICD-10-CM |
| X82.2XXS | Intentional collision of motor vehicle with tree, sequela | Diagnosis | ICD-10-CM |
| X82.8 | Other intentional self-harm by crashing of motor vehicle | Diagnosis | ICD-10-CM |
| X82.8XXA | Other intentional self-harm by crashing of motor vehicle, initial encounter | Diagnosis | ICD-10-CM |
| X82.8XXD | Other intentional self-harm by crashing of motor vehicle, subsequent encounter | Diagnosis | ICD-10-CM |
| X82.8XXS | Other intentional self-harm by crashing of motor vehicle, sequela | Diagnosis | ICD-10-CM |
| X83 | Intentional self-harm by other specified means | Diagnosis | ICD-10-CM |
| X83.0 | Intentional self-harm by crashing of aircraft | Diagnosis | ICD-10-CM |
| X83.0XXA | Intentional self-harm by crashing of aircraft, initial encounter | Diagnosis | ICD-10-CM |
| X83.0XXD | Intentional self-harm by crashing of aircraft, subsequent encounter | Diagnosis | ICD-10-CM |
| X83.0XXS | Intentional self-harm by crashing of aircraft, sequela | Diagnosis | ICD-10-CM |
| X83.1 | Intentional self-harm by electrocution | Diagnosis | ICD-10-CM |
| X83.1XXA | Intentional self-harm by electrocution, initial encounter | Diagnosis | ICD-10-CM |
| X83.1XXD | Intentional self-harm by electrocution, subsequent encounter | Diagnosis | ICD-10-CM |
| X83.1XXS | Intentional self-harm by electrocution, sequela | Diagnosis | ICD-10-CM |
| X83.2 | Intentional self-harm by exposure to extremes of cold | Diagnosis | ICD-10-CM |
| X83.2XXA | Intentional self-harm by exposure to extremes of cold, initial encounter | Diagnosis | ICD-10-CM |
| X83.2XXD | Intentional self-harm by exposure to extremes of cold, subsequent encounter | Diagnosis | ICD-10-CM |
| X83.2XXS | Intentional self-harm by exposure to extremes of cold, sequela | Diagnosis | ICD-10-CM |

Appendix X. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

| Code | Description | Code Category | Code Type |
|-------------|--|----------------------|------------------|
| X83.8 | Intentional self-harm by other specified means | Diagnosis | ICD-10-CM |
| X83.8XXA | Intentional self-harm by other specified means, initial encounter | Diagnosis | ICD-10-CM |
| X83.8XXD | Intentional self-harm by other specified means, subsequent encounter | Diagnosis | ICD-10-CM |
| X83.8XXS | Intentional self-harm by other specified means, sequela | Diagnosis | ICD-10-CM |

Appendix Y. List of Generic and Brand Names of Medical Products Used to Define Inclusion Criteria in this Request

| Generic Name | Brand Name |
|--|---------------------|
| Montelukast | |
| montelukast sodium | Singulair |
| montelukast sodium | montelukast |
| Inhaled Corticosteroids (ICS) Monotherapy | |
| beclomethasone dipropionate | Qvar |
| beclomethasone dipropionate | Qvar RediHaler |
| budesonide | Pulmicort |
| budesonide | Pulmicort Flexhaler |
| budesonide | budesonide |
| ciclesonide | Alvesco |
| flunisolide | Aerospan |
| fluticasone furoate | Arnuity Ellipta |
| fluticasone propionate | ArmonAir Digihaler |
| fluticasone propionate | ArmonAir RespiClick |
| fluticasone propionate | Flovent Diskus |
| fluticasone propionate | Flovent HFA |
| mometasone furoate | Asmanex HFA |
| mometasone furoate | Asmanex Twisthaler |

Appendix Z. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Inclusion Criteria in this Request

| Code | Description | Code Category | Code Type |
|---|--|---------------|-----------|
| Asthma | | | |
| 493.0 | Extrinsic asthma | Diagnosis | ICD-9-CM |
| 493.00 | Extrinsic asthma, unspecified | Diagnosis | ICD-9-CM |
| 493.02 | Extrinsic asthma, with (acute) exacerbation | Diagnosis | ICD-9-CM |
| 493.1 | Intrinsic asthma | Diagnosis | ICD-9-CM |
| 493.10 | Intrinsic asthma, unspecified | Diagnosis | ICD-9-CM |
| 493.12 | Intrinsic asthma, with (acute) exacerbation | Diagnosis | ICD-9-CM |
| 493.20 | Chronic obstructive asthma, unspecified ICD-9-CM | Diagnosis | ICD-9-CM |
| 493.21 | Chronic obstructive asthma with status asthmaticus ICD-9-CM | Diagnosis | ICD-9-CM |
| 493.22 | Chronic obstructive asthma, with (acute) exacerbation ICD-9-CM | Diagnosis | ICD-9-CM |
| 493.8 | Other forms of asthma | Diagnosis | ICD-9-CM |
| 493.82 | Cough variant asthma | Diagnosis | ICD-9-CM |
| 493.9 | Unspecified asthma | Diagnosis | ICD-9-CM |
| 493.90 | Asthma, unspecified, unspecified status | Diagnosis | ICD-9-CM |
| 493.92 | Asthma, unspecified, with (acute) exacerbation | Diagnosis | ICD-9-CM |
| J45 | Asthma | Diagnosis | ICD-10-CM |
| J45.2 | Mild intermittent asthma | Diagnosis | ICD-10-CM |
| J45.20 | Mild intermittent asthma, uncomplicated | Diagnosis | ICD-10-CM |
| J45.21 | Mild intermittent asthma with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J45.3 | Mild persistent asthma | Diagnosis | ICD-10-CM |
| J45.30 | Mild persistent asthma, uncomplicated | Diagnosis | ICD-10-CM |
| J45.31 | Mild persistent asthma with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J45.4 | Moderate persistent asthma | Diagnosis | ICD-10-CM |
| J45.40 | Moderate persistent asthma, uncomplicated | Diagnosis | ICD-10-CM |
| J45.41 | Moderate persistent asthma with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J45.5 | Severe persistent asthma | Diagnosis | ICD-10-CM |
| J45.50 | Severe persistent asthma, uncomplicated | Diagnosis | ICD-10-CM |
| J45.51 | Severe persistent asthma with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J45.9 | Other and unspecified asthma | Diagnosis | ICD-10-CM |
| J45.90 | Unspecified asthma | Diagnosis | ICD-10-CM |
| J45.901 | Unspecified asthma with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J45.909 | Unspecified asthma, uncomplicated | Diagnosis | ICD-10-CM |
| J45.99 | Other asthma | Diagnosis | ICD-10-CM |
| J45.991 | Cough variant asthma | Diagnosis | ICD-10-CM |
| J45.998 | Other asthma | Diagnosis | ICD-10-CM |
| Chronic Obstructive Pulmonary Disease (COPD) | | | |
| 490 | Bronchitis, not specified as acute or chronic | Diagnosis | ICD-9-CM |
| 491 | Chronic bronchitis | Diagnosis | ICD-9-CM |
| 491.0 | Simple chronic bronchitis | Diagnosis | ICD-9-CM |
| 491.1 | Mucopurulent chronic bronchitis | Diagnosis | ICD-9-CM |
| 491.2 | Obstructive chronic bronchitis | Diagnosis | ICD-9-CM |
| 491.20 | Obstructive chronic bronchitis, without exacerbation | Diagnosis | ICD-9-CM |
| 491.21 | Obstructive chronic bronchitis, with (acute) exacerbation | Diagnosis | ICD-9-CM |
| 491.22 | Obstructive chronic bronchitis with acute bronchitis | Diagnosis | ICD-9-CM |
| 491.8 | Other chronic bronchitis | Diagnosis | ICD-9-CM |
| 491.9 | Unspecified chronic bronchitis | Diagnosis | ICD-9-CM |
| 492 | Emphysema | Diagnosis | ICD-9-CM |
| 492.0 | Emphysematous bleb | Diagnosis | ICD-9-CM |

Appendix Z. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Inclusion Criteria in this Request

| Code | Description | Code Category | Code Type |
|-------------|--|----------------------|------------------|
| 492.8 | Other emphysema | Diagnosis | ICD-9-CM |
| 493.2 | Chronic obstructive asthma | Diagnosis | ICD-9-CM |
| 493.20 | Chronic obstructive asthma, unspecified | Diagnosis | ICD-9-CM |
| 493.21 | Chronic obstructive asthma with status asthmaticus | Diagnosis | ICD-9-CM |
| 493.22 | Chronic obstructive asthma, with (acute) exacerbation | Diagnosis | ICD-9-CM |
| 494 | Bronchiectasis | Diagnosis | ICD-9-CM |
| 494.0 | Bronchiectasis without acute exacerbation | Diagnosis | ICD-9-CM |
| 494.1 | Bronchiectasis with acute exacerbation | Diagnosis | ICD-9-CM |
| 496 | Chronic airway obstruction, not elsewhere classified | Diagnosis | ICD-9-CM |
| J41 | Simple and mucopurulent chronic bronchitis | Diagnosis | ICD-10-CM |
| J41.0 | Simple chronic bronchitis | Diagnosis | ICD-10-CM |
| J41.1 | Mucopurulent chronic bronchitis | Diagnosis | ICD-10-CM |
| J41.8 | Mixed simple and mucopurulent chronic bronchitis | Diagnosis | ICD-10-CM |
| J42 | Unspecified chronic bronchitis | Diagnosis | ICD-10-CM |
| J43 | Emphysema | Diagnosis | ICD-10-CM |
| J43.1 | Panlobular emphysema | Diagnosis | ICD-10-CM |
| J43.2 | Centrilobular emphysema | Diagnosis | ICD-10-CM |
| J43.8 | Other emphysema | Diagnosis | ICD-10-CM |
| J43.9 | Emphysema, unspecified | Diagnosis | ICD-10-CM |
| J44 | Other chronic obstructive pulmonary disease | Diagnosis | ICD-10-CM |
| J44.0 | Chronic obstructive pulmonary disease with (acute) lower respiratory infection | Diagnosis | ICD-10-CM |
| J44.1 | Chronic obstructive pulmonary disease with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J44.9 | Chronic obstructive pulmonary disease, unspecified | Diagnosis | ICD-10-CM |

Appendix AA. List of Generic and Brand Names of Medical Products Used to Define Exposure Censoring Criteria in this Request

| Generic Name | Brand Name |
|--|--------------------------------|
| Montelukast | |
| montelukast sodium | Singulair |
| montelukast sodium | montelukast |
| Inhaled Corticosteroids (ICS) Monotherapy | |
| beclomethasone dipropionate | Qvar |
| beclomethasone dipropionate | Qvar RediHaler |
| budesonide | Pulmicort |
| budesonide | Pulmicort Flexhaler |
| budesonide | budesonide |
| ciclesonide | Alvesco |
| flunisolide | Aerospan |
| fluticasone furoate | Arnuity Ellipta |
| fluticasone propionate | ArmonAir Digihaler |
| fluticasone propionate | ArmonAir RespiClick |
| fluticasone propionate | Flovent Diskus |
| fluticasone propionate | Flovent HFA |
| mometasone furoate | Asmanex HFA |
| mometasone furoate | Asmanex Twisthaler |
| Long-Acting Beta-Agonists (LABAs) | |
| acclidinium bromide/formoterol fumarate | Duaklir Pressair |
| arformoterol tartrate | Brovana |
| arformoterol tartrate | arformoterol |
| formoterol fumarate | Foradil Aerolizer |
| formoterol fumarate | Perforomist |
| formoterol fumarate | formoterol fumarate |
| glycopyrrolate/formoterol fumarate | Bevespi Aerosphere |
| indacaterol maleate | Arcapta Neohaler |
| indacaterol maleate/glycopyrrolate | Utibron Neohaler |
| olodaterol HCl | Striverdi Respimat |
| salmeterol xinafoate | Serevent Diskus |
| tiotropium bromide/olodaterol HCl | Stiolto Respimat |
| Inhaled Corticosteroids (ICS) Long-Acting Beta-Agonists (LABAs) | |
| budesonide/formoterol fumarate | Symbicort |
| budesonide/formoterol fumarate | budesonide-formoterol |
| budesonide/glycopyrrolate/formoterol fumarate | Breztri Aerosphere |
| fluticasone furoate/vilanterol trifenate | Breo Ellipta |
| fluticasone propionate/salmeterol xinafoate | Advair Diskus |
| fluticasone propionate/salmeterol xinafoate | Advair HFA |
| fluticasone propionate/salmeterol xinafoate | AirDuo Digihaler |
| fluticasone propionate/salmeterol xinafoate | AirDuo RespiClick |
| fluticasone propionate/salmeterol xinafoate | Wixela Inhub |
| fluticasone propionate/salmeterol xinafoate | fluticasone propion-salmeterol |
| mometasone furoate/formoterol fumarate | Dulera |
| Leukotriene Receptor Antagonists (LTRAs) | |
| zafirlukast | Accolate |
| zafirlukast | zafirlukast |
| zileuton | Zyflo |
| zileuton | Zyflo CR |

Appendix AA. List of Generic and Brand Names of Medical Products Used to Define Exposure Censoring Criteria in this Request

| Generic Name | Brand Name |
|-------------------------------|-------------------------------|
| zileuton | zileuton |
| Oral Corticosteroids | |
| cortisone acetate | cortisone |
| dexamethasone | Decadron |
| dexamethasone | DexPak 10 day |
| dexamethasone | DexPak 13 Day |
| dexamethasone | DexPak 6 Day |
| dexamethasone | Dexabliss |
| dexamethasone | Dexamethasone Intensol |
| dexamethasone | Dxevo |
| dexamethasone | Hemady |
| dexamethasone | HiDex |
| dexamethasone | LoCort |
| dexamethasone | TaperDex |
| dexamethasone | ZCort |
| dexamethasone | ZoDex |
| dexamethasone | ZonaCort |
| dexamethasone | dexamethasone |
| hydrocortisone | Alkindi Sprinkle |
| hydrocortisone | Cortef |
| hydrocortisone | hydrocortisone |
| methylprednisolone | Medrol |
| methylprednisolone | Medrol (Pak) |
| methylprednisolone | Methylpred DP |
| methylprednisolone | methylprednisolone |
| prednisolone | Millipred |
| prednisolone | Millipred DP |
| prednisolone | Prelone |
| prednisolone | prednisolone |
| prednisolone acetate | Flo-Pred |
| prednisolone sodium phosphate | Millipred |
| prednisolone sodium phosphate | Orapred ODT |
| prednisolone sodium phosphate | Pediapred |
| prednisolone sodium phosphate | Veripred 20 |
| prednisolone sodium phosphate | prednisolone sodium phosphate |
| prednisone | Deltasone |
| prednisone | Prednisone Intensol |
| prednisone | Rayos |
| prednisone | prednisone |

Appendix AB. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Exposure Censoring Criteria in this Request

| Code | Description | Code Category | Code Type |
|-----------------------------|--|---------------|-----------|
| Oral Corticosteroids | | | |
| J7506 | Prednisone, oral, per 5 mg | Procedure | HCPCS |
| J7509 | Methylprednisolone, oral, per 4 mg | Procedure | HCPCS |
| J7510 | Prednisolone, oral, per 5 mg | Procedure | HCPCS |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | Procedure | HCPCS |
| J8540 | Dexamethasone, oral, 0.25 mg | Procedure | HCPCS |
| S0173 | Dexamethasone, oral, 4 mg | Procedure | HCPCS |
| Asthma | | | |
| 493.0 | Extrinsic asthma | Diagnosis | ICD-9-CM |
| 493.00 | Extrinsic asthma, unspecified | Diagnosis | ICD-9-CM |
| 493.02 | Extrinsic asthma, with (acute) exacerbation | Diagnosis | ICD-9-CM |
| 493.1 | Intrinsic asthma | Diagnosis | ICD-9-CM |
| 493.10 | Intrinsic asthma, unspecified | Diagnosis | ICD-9-CM |
| 493.12 | Intrinsic asthma, with (acute) exacerbation | Diagnosis | ICD-9-CM |
| 493.20 | Chronic obstructive asthma, unspecified ICD-9-CM | Diagnosis | ICD-9-CM |
| 493.21 | Chronic obstructive asthma with status asthmaticus ICD-9-CM | Diagnosis | ICD-9-CM |
| 493.22 | Chronic obstructive asthma, with (acute) exacerbation ICD-9-CM | Diagnosis | ICD-9-CM |
| 493.8 | Other forms of asthma | Diagnosis | ICD-9-CM |
| 493.82 | Cough variant asthma | Diagnosis | ICD-9-CM |
| 493.9 | Unspecified asthma | Diagnosis | ICD-9-CM |
| 493.90 | Asthma, unspecified, unspecified status | Diagnosis | ICD-9-CM |
| 493.92 | Asthma, unspecified, with (acute) exacerbation | Diagnosis | ICD-9-CM |
| J45 | Asthma | Diagnosis | ICD-10-CM |
| J45.2 | Mild intermittent asthma | Diagnosis | ICD-10-CM |
| J45.20 | Mild intermittent asthma, uncomplicated | Diagnosis | ICD-10-CM |
| J45.21 | Mild intermittent asthma with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J45.3 | Mild persistent asthma | Diagnosis | ICD-10-CM |
| J45.30 | Mild persistent asthma, uncomplicated | Diagnosis | ICD-10-CM |
| J45.31 | Mild persistent asthma with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J45.4 | Moderate persistent asthma | Diagnosis | ICD-10-CM |
| J45.40 | Moderate persistent asthma, uncomplicated | Diagnosis | ICD-10-CM |
| J45.41 | Moderate persistent asthma with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J45.5 | Severe persistent asthma | Diagnosis | ICD-10-CM |
| J45.50 | Severe persistent asthma, uncomplicated | Diagnosis | ICD-10-CM |
| J45.51 | Severe persistent asthma with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J45.9 | Other and unspecified asthma | Diagnosis | ICD-10-CM |
| J45.90 | Unspecified asthma | Diagnosis | ICD-10-CM |
| J45.901 | Unspecified asthma with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J45.909 | Unspecified asthma, uncomplicated | Diagnosis | ICD-10-CM |
| J45.99 | Other asthma | Diagnosis | ICD-10-CM |
| J45.991 | Cough variant asthma | Diagnosis | ICD-10-CM |
| J45.998 | Other asthma | Diagnosis | ICD-10-CM |

Appendix AC. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

| Generic Name | Brand Name |
|--|--------------------------------|
| Psychiatric History | |
| alprazolam | Alprazolam Intensol |
| alprazolam | Xanax |
| alprazolam | Xanax XR |
| alprazolam | alprazolam |
| amitriptyline HCl | amitriptyline |
| amitriptyline HCl/chlordiazepoxide | amitriptyline-chlordiazepoxide |
| amobarbital sodium | Amytal |
| amoxapine | amoxapine |
| aripiprazole | Abilify |
| aripiprazole | Abilify Discmelt |
| aripiprazole | Abilify Maintena |
| aripiprazole | Abilify MyCite |
| aripiprazole | Abilify MyCite Maintenance Kit |
| aripiprazole | Abilify MyCite Starter Kit |
| aripiprazole | aripiprazole |
| aripiprazole lauroxil | Aristada |
| aripiprazole lauroxil, submicronized | Aristada Initio |
| asenapine | Secuado |
| asenapine maleate | Saphris |
| asenapine maleate | Saphris (black cherry) |
| asenapine maleate | asenapine maleate |
| atomoxetine HCl | Strattera |
| atomoxetine HCl | atomoxetine |
| brexanolone | Zulresso |
| brexpiprazole | Rexulti |
| bromelains/melatonin/herbal complex no.233 | MidNite PM |
| bupropion HBr | Aplenzin |
| bupropion HCl | Buproban |
| bupropion HCl | Forfivo XL |
| bupropion HCl | Wellbutrin |
| bupropion HCl | Wellbutrin SR |
| bupropion HCl | Wellbutrin XL |
| bupropion HCl | Zyban |
| bupropion HCl | bupropion HCl |
| bupropion HCl | bupropion HCl (smoking deter) |
| buspirone HCl | buspirone |
| butabarbital sodium | Butisol |
| calcium phosphate/melatonin | calcium-melatonin |
| carbamazepine | Carbatrol |
| carbamazepine | Eptol |
| carbamazepine | Equetro |
| carbamazepine | Tegretol |
| carbamazepine | Tegretol XR |
| carbamazepine | carbamazepine |
| cariprazine HCl | Vraylar |
| chlordiazepoxide HCl | chlordiazepoxide HCl |
| chlordiazepoxide/clidinium bromide | Librax (with clidinium) |
| chlordiazepoxide/clidinium bromide | chlordiazepoxide-clidinium |
| chlorpromazine HCl | chlorpromazine |

Appendix AC. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

| Generic Name | Brand Name |
|--|--------------------------------|
| citalopram hydrobromide | Celexa |
| citalopram hydrobromide | citalopram |
| clomipramine HCl | Anafranil |
| clomipramine HCl | clomipramine |
| clonazepam | Klonopin |
| clonazepam | clonazepam |
| clorazepate dipotassium | Tranxene T-Tab |
| clorazepate dipotassium | clorazepate dipotassium |
| clozapine | Clozaril |
| clozapine | FazaClo |
| clozapine | Versacloz |
| clozapine | clozapine |
| daridorexant HCl | Quviviq |
| desipramine HCl | Norpramin |
| desipramine HCl | desipramine |
| desvenlafaxine | Khedezla |
| desvenlafaxine | desvenlafaxine |
| desvenlafaxine fumarate | desvenlafaxine fumarate |
| desvenlafaxine succinate | Pristiq |
| desvenlafaxine succinate | desvenlafaxine succinate |
| dexmedetomidine HCl | Precedex |
| dexmedetomidine HCl | dexmedetomidine |
| dexmedetomidine HCl in 0.9 % sodium chloride | Precedex in 0.9 % sodium chlor |
| dexmedetomidine HCl in 0.9 % sodium chloride | dexmedetomidine in 0.9 % NaCl |
| dexmedetomidine in 5 % dextrose in water | dexmedetomidine in dextrose 5% |
| dexmethylphenidate HCl | Focalin |
| dexmethylphenidate HCl | Focalin XR |
| dexmethylphenidate HCl | dexmethylphenidate |
| dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate | Adderall |
| dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate | Adderall XR |
| dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate | Mydayis |
| dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate | dextroamphetamine-amphetamine |
| dextroamphetamine sulfate | Dexedrine |
| dextroamphetamine sulfate | Dexedrine Spansule |
| dextroamphetamine sulfate | ProCentra |
| dextroamphetamine sulfate | Zenzedi |
| dextroamphetamine sulfate | dextroamphetamine sulfate |
| diazepam | Diastat |
| diazepam | Diastat AcuDial |
| diazepam | Diazepam Intensol |
| diazepam | Valium |
| diazepam | Valtoco |
| diazepam | diazepam |
| divalproex sodium | Depakote |
| divalproex sodium | Depakote ER |
| divalproex sodium | Depakote Sprinkles |
| divalproex sodium | divalproex |
| doxepin HCl | Silenor |
| doxepin HCl | doxepin |

Appendix AC. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

| Generic Name | Brand Name |
|----------------------------|-------------------------------|
| droperidol | droperidol |
| duloxetine HCl | Cymbalta |
| duloxetine HCl | Drizalma Sprinkle |
| duloxetine HCl | Irenka |
| duloxetine HCl | duloxetine |
| escitalopram oxalate | Lexapro |
| escitalopram oxalate | escitalopram oxalate |
| esketamine HCl | Spravato |
| estazolam | estazolam |
| eszopiclone | Lunesta |
| eszopiclone | eszopiclone |
| ethyl alcohol/herbal drugs | Lydia Pinkham Herbal |
| fluoxetine HCl | Prozac |
| fluoxetine HCl | Prozac Weekly |
| fluoxetine HCl | Sarafem |
| fluoxetine HCl | fluoxetine |
| fluphenazine HCl | fluphenazine HCl |
| fluphenazine decanoate | fluphenazine decanoate |
| flurazepam HCl | flurazepam |
| fluvoxamine maleate | Luvox CR |
| fluvoxamine maleate | fluvoxamine |
| guanfacine HCl | Intuniv ER |
| guanfacine HCl | Tenex |
| guanfacine HCl | guanfacine |
| haloperidol | haloperidol |
| haloperidol decanoate | Haldol Decanoate |
| haloperidol decanoate | haloperidol decanoate |
| haloperidol lactate | Haldol |
| haloperidol lactate | haloperidol lactate |
| hydroxyzine HCl | hydroxyzine HCl |
| hydroxyzine pamoate | Vistaril |
| hydroxyzine pamoate | hydroxyzine pamoate |
| iloperidone | Fanapt |
| imipramine HCl | Tofranil |
| imipramine HCl | imipramine HCl |
| imipramine pamoate | Tofranil-PM |
| imipramine pamoate | imipramine pamoate |
| isocarboxazid | Marplan |
| lamotrigine | Lamictal |
| lamotrigine | Lamictal ODT |
| lamotrigine | Lamictal ODT Starter (Blue) |
| lamotrigine | Lamictal ODT Starter (Green) |
| lamotrigine | Lamictal ODT Starter (Orange) |
| lamotrigine | Lamictal Starter (Blue) Kit |
| lamotrigine | Lamictal Starter (Green) Kit |
| lamotrigine | Lamictal Starter (Orange) Kit |
| lamotrigine | Lamictal XR |
| lamotrigine | Lamictal XR Starter (Blue) |
| lamotrigine | Lamictal XR Starter (Green) |
| lamotrigine | Lamictal XR Starter (Orange) |

Appendix AC. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

| Generic Name | Brand Name |
|---|--------------------------------|
| lamotrigine | Subvenite |
| lamotrigine | Subvenite Starter (Blue) Kit |
| lamotrigine | Subvenite Starter (Green) Kit |
| lamotrigine | Subvenite Starter (Orange) Kit |
| lamotrigine | lamotrigine |
| lemborexant | Dayvigo |
| levomilnacipran HCl | Fetzima |
| lisdexamfetamine dimesylate | Vyvanse |
| lithium carbonate | Lithobid |
| lithium carbonate | lithium carbonate |
| lithium citrate | lithium citrate |
| lorazepam | Ativan |
| lorazepam | Lorazepam Intensol |
| lorazepam | Loreev XR |
| lorazepam | lorazepam |
| lorazepam in 0.9 % sodium chloride | lorazepam in 0.9% sod chloride |
| loxapine | Adasuve |
| loxapine succinate | loxapine succinate |
| lumateperone tosylate | Caplyta |
| lurasidone HCl | Latuda |
| maprotiline HCl | maprotiline |
| melatonin | Children's Sleep (melatonin) |
| melatonin | Meladox |
| melatonin | Melatin |
| melatonin | VitaJoy Melatonin |
| melatonin | melatonin |
| melatonin/5-HTP/valerian/folic acid/dietary combination 28 | Hypnosom |
| melatonin/5-Hydroxytryptophan/tryptophan/B6/magnesium oxide | Somnicin |
| melatonin/GABA/5-HTP/theanine/magnesium citrate,oxide/herbs | Sopordren |
| melatonin/gamma-aminobutyric acid/herbal complex no.183 | Sintralyne-PM |
| melatonin/gamma-aminobutyric acid/valerian | Medi-Doze |
| melatonin/genistein/herbal complex no.233 | Midnite for Menopause |
| melatonin/herbal complex no.184 | Sleep Caps |
| melatonin/herbal complex no.184 | melatonin-herbal complex #184 |
| melatonin/herbal complex no.233 | MidNite |
| melatonin/lemon balm leaf extract | melatonin-lemon balm leaf extr |
| melatonin/pyridoxal phosphate | Melatonin-B6 (pyridoxal phos) |
| melatonin/pyridoxal phosphate | melatonin-pyridoxal phos (B6) |
| melatonin/pyridoxine | Melatonin (with B6) |
| melatonin/pyridoxine | melatonin-pyridoxine (vit B6) |
| melatonin/pyridoxine HCl (vit B6) | Melatonex |
| melatonin/pyridoxine HCl (vit B6) | melatonin-pyridoxine HCl (B6) |
| melatonin/theanine | melatonin-theanine |
| melatonin/tryptophan | Restone |
| melatonin/tryptophan | Wrestone |
| melatonin/tryptophan/valerian/chamomile/niacin/inositol/B6 | Toprophan |
| meprobamate | meprobamate |
| methamphetamine HCl | Desoxyn |

Appendix AC. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

| Generic Name | Brand Name |
|--------------------------------|--------------------------------|
| methamphetamine HCl | methamphetamine |
| methylphenidate | Cotempla XR-ODT |
| methylphenidate | Daytrana |
| methylphenidate HCl | Adhansia XR |
| methylphenidate HCl | Aptensio XR |
| methylphenidate HCl | Concerta |
| methylphenidate HCl | Jornay PM |
| methylphenidate HCl | Metadate CD |
| methylphenidate HCl | Metadate ER |
| methylphenidate HCl | Methylin |
| methylphenidate HCl | QuilliChew ER |
| methylphenidate HCl | Quillivant XR |
| methylphenidate HCl | Relexxii |
| methylphenidate HCl | Ritalin |
| methylphenidate HCl | Ritalin LA |
| methylphenidate HCl | Ritalin SR |
| methylphenidate HCl | methylphenidate HCl |
| midazolam HCl | midazolam |
| milnacipran HCl | Savella |
| mirtazapine | Remeron |
| mirtazapine | Remeron SolTab |
| mirtazapine | mirtazapine |
| molindone HCl | molindone |
| nefazodone HCl | nefazodone |
| nortriptyline HCl | Pamelor |
| nortriptyline HCl | nortriptyline |
| olanzapine | Zyprexa |
| olanzapine | Zyprexa Zydis |
| olanzapine | olanzapine |
| olanzapine pamoate | Zyprexa Relprevv |
| olanzapine/fluoxetine HCl | Symbyax |
| olanzapine/fluoxetine HCl | olanzapine-fluoxetine |
| olanzapine/samidorphane malate | Lybalvi |
| oxazepam | oxazepam |
| oxcarbazepine | Oxtellar XR |
| oxcarbazepine | Trileptal |
| oxcarbazepine | oxcarbazepine |
| paliperidone | Invega |
| paliperidone | paliperidone |
| paliperidone palmitate | Invega Hafyera |
| paliperidone palmitate | Invega Sustenna |
| paliperidone palmitate | Invega Trinza |
| paroxetine HCl | Paxil |
| paroxetine HCl | Paxil CR |
| paroxetine HCl | paroxetine HCl |
| paroxetine mesylate | Brisdelle |
| paroxetine mesylate | Pexeva |
| paroxetine mesylate | paroxetine mesylate(menop.sym) |
| pentobarbital sodium | Nembutal Sodium |
| pentobarbital sodium | pentobarbital sodium |

Appendix AC. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

| Generic Name | Brand Name |
|---|--------------------------------|
| perphenazine | perphenazine |
| perphenazine/amitriptyline HCl | perphenazine-amitriptyline |
| phenelzine sulfate | Nardil |
| phenelzine sulfate | phenelzine |
| phenobarbital | phenobarbital |
| phenobarbital sodium | phenobarbital sodium |
| phenobarbital sodium in 0.9 % sodium chloride | phenobarbital in 0.9 % sod chl |
| pimavanserin tartrate | Nuplazid |
| pimozide | Orap |
| pimozide | pimozide |
| prochlorperazine maleate | Compazine |
| prochlorperazine maleate | prochlorperazine maleate |
| protriptyline HCl | Vivactil |
| protriptyline HCl | protriptyline |
| quazepam | Doral |
| quazepam | quazepam |
| quetiapine fumarate | Seroquel |
| quetiapine fumarate | Seroquel XR |
| quetiapine fumarate | quetiapine |
| ramelteon | Rozerem |
| ramelteon | ramelteon |
| risperidone | Perseris |
| risperidone | Risperdal |
| risperidone | Risperdal M-TAB |
| risperidone | risperidone |
| risperidone microspheres | Risperdal Consta |
| secobarbital sodium | Seconal Sodium |
| selegiline | Emsam |
| serdexmethylphenidate chloride/dexmethylphenidate HCl | Azstarys |
| sertraline HCl | Zoloft |
| sertraline HCl | sertraline |
| suvorexant | Belsomra |
| tasimelteon | Hetlioz |
| tasimelteon | Hetlioz LQ |
| temazepam | Restoril |
| temazepam | temazepam |
| thioridazine HCl | thioridazine |
| thiothixene | thiothixene |
| tranylcypromine sulfate | Parnate |
| tranylcypromine sulfate | tranylcypromine |
| trazodone HCl | Oleptro ER |
| trazodone HCl | trazodone |
| triazolam | Halcion |
| triazolam | triazolam |
| trifluoperazine HCl | trifluoperazine |
| trimipramine maleate | Surmontil |
| trimipramine maleate | trimipramine |
| tryptophan | tryptophan |
| valerian root extract | valerian root extract |
| valerian root extract/hops | valerian root extract-hops |

Appendix AC. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

| Generic Name | Brand Name |
|---|--------------------------------|
| valproic acid | Depakene |
| valproic acid | Stavzor |
| valproic acid | valproic acid |
| valproic acid (as sodium salt) (valproate sodium) | Depacon |
| valproic acid (as sodium salt) (valproate sodium) | Depakene |
| valproic acid (as sodium salt) (valproate sodium) | valproate sodium |
| valproic acid (as sodium salt) (valproate sodium) | valproic acid (as sodium salt) |
| venlafaxine HCl | Effexor XR |
| venlafaxine HCl | venlafaxine |
| vilazodone HCl | Viiibryd |
| vortioxetine hydrobromide | Brintellix |
| vortioxetine hydrobromide | Trintellix |
| zaleplon | Sonata |
| zaleplon | zaleplon |
| ziprasidone HCl | Geodon |
| ziprasidone HCl | ziprasidone HCl |
| ziprasidone mesylate | Geodon |
| ziprasidone mesylate | ziprasidone mesylate |
| zolpidem tartrate | Ambien |
| zolpidem tartrate | Ambien CR |
| zolpidem tartrate | Edluar |
| zolpidem tartrate | Intermezzo |
| zolpidem tartrate | Zolpimist |
| zolpidem tartrate | zolpidem |
| y | |
| alprazolam | Alprazolam Intensol |
| alprazolam | Xanax |
| alprazolam | Xanax XR |
| alprazolam | alprazolam |
| amitriptyline HCl | amitriptyline |
| amitriptyline HCl/chlordiazepoxide | amitriptyline-chlordiazepoxide |
| amobarbital sodium | Amytal |
| amoxapine | amoxapine |
| aripiprazole | Abilify |
| aripiprazole | Abilify Discmelt |
| aripiprazole | Abilify Maintena |
| aripiprazole | Abilify MyCite |
| aripiprazole | Abilify MyCite Maintenance Kit |
| aripiprazole | Abilify MyCite Starter Kit |
| aripiprazole | aripiprazole |
| aripiprazole lauroxil | Aristada |
| aripiprazole lauroxil, submicronized | Aristada Initio |
| asenapine | Secuado |
| asenapine maleate | Saphris |
| asenapine maleate | Saphris (black cherry) |
| asenapine maleate | asenapine maleate |
| atomoxetine HCl | Strattera |
| atomoxetine HCl | atomoxetine |
| brexanolone | Zulresso |
| brexpiprazole | Rexulti |

Appendix AC. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

| Generic Name | Brand Name |
|--|--------------------------------|
| bromelains/melatonin/herbal complex no.233 | MidNite PM |
| bupropion HBr | Aplenzin |
| bupropion HCl | Buproban |
| bupropion HCl | Forfivo XL |
| bupropion HCl | Wellbutrin |
| bupropion HCl | Wellbutrin SR |
| bupropion HCl | Wellbutrin XL |
| bupropion HCl | Zyban |
| bupropion HCl | bupropion HCl |
| bupropion HCl | bupropion HCl (smoking deter) |
| bupirone HCl | bupirone |
| butabarbital sodium | Butisol |
| calcium phosphate/melatonin | calcium-melatonin |
| carbamazepine | Carbatrol |
| carbamazepine | Epitol |
| carbamazepine | Equetro |
| carbamazepine | Tegretol |
| carbamazepine | Tegretol XR |
| carbamazepine | carbamazepine |
| cariprazine HCl | Vraylar |
| chlordiazepoxide HCl | chlordiazepoxide HCl |
| chlordiazepoxide/clidinium bromide | Librax (with clidinium) |
| chlordiazepoxide/clidinium bromide | chlordiazepoxide-clidinium |
| chlorpromazine HCl | chlorpromazine |
| citalopram hydrobromide | Celexa |
| citalopram hydrobromide | citalopram |
| clomipramine HCl | Anafranil |
| clomipramine HCl | clomipramine |
| clonazepam | Klonopin |
| clonazepam | clonazepam |
| clorazepate dipotassium | Tranxene T-Tab |
| clorazepate dipotassium | clorazepate dipotassium |
| clozapine | Clozaril |
| clozapine | FazaClo |
| clozapine | Versacloz |
| clozapine | clozapine |
| daridorexant HCl | Quviviq |
| desipramine HCl | Norpramin |
| desipramine HCl | desipramine |
| desvenlafaxine | Khedezla |
| desvenlafaxine | desvenlafaxine |
| desvenlafaxine fumarate | desvenlafaxine fumarate |
| desvenlafaxine succinate | Pristiq |
| desvenlafaxine succinate | desvenlafaxine succinate |
| dexmedetomidine HCl | Precedex |
| dexmedetomidine HCl | dexmedetomidine |
| dexmedetomidine HCl in 0.9 % sodium chloride | Precedex in 0.9 % sodium chlor |
| dexmedetomidine HCl in 0.9 % sodium chloride | dexmedetomidine in 0.9 % NaCl |
| dexmedetomidine in 5 % dextrose in water | dexmedetomidine in dextrose 5% |
| dexmethylphenidate HCl | Focalin |

Appendix AC. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

| Generic Name | Brand Name |
|--|-------------------------------|
| dexmethylphenidate HCl | Focalin XR |
| dexmethylphenidate HCl | dexmethylphenidate |
| dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate | Adderall |
| dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate | Adderall XR |
| dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate | Mydayis |
| dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate | dextroamphetamine-amphetamine |
| dextroamphetamine sulfate | Dexedrine |
| dextroamphetamine sulfate | Dexedrine Spansule |
| dextroamphetamine sulfate | ProCentra |
| dextroamphetamine sulfate | Zenzedi |
| dextroamphetamine sulfate | dextroamphetamine sulfate |
| diazepam | Diastat |
| diazepam | Diastat AcuDial |
| diazepam | Diazepam Intensol |
| diazepam | Valium |
| diazepam | Valtoco |
| diazepam | diazepam |
| divalproex sodium | Depakote |
| divalproex sodium | Depakote ER |
| divalproex sodium | Depakote Sprinkles |
| divalproex sodium | divalproex |
| doxepin HCl | Silenor |
| doxepin HCl | doxepin |
| droperidol | droperidol |
| duloxetine HCl | Cymbalta |
| duloxetine HCl | Drizalma Sprinkle |
| duloxetine HCl | Irenka |
| duloxetine HCl | duloxetine |
| escitalopram oxalate | Lexapro |
| escitalopram oxalate | escitalopram oxalate |
| esketamine HCl | Spravato |
| estazolam | estazolam |
| eszopiclone | Lunesta |
| eszopiclone | eszopiclone |
| ethyl alcohol/herbal drugs | Lydia Pinkham Herbal |
| fluoxetine HCl | Prozac |
| fluoxetine HCl | Prozac Weekly |
| fluoxetine HCl | Sarafem |
| fluoxetine HCl | fluoxetine |
| fluphenazine HCl | fluphenazine HCl |
| fluphenazine decanoate | fluphenazine decanoate |
| flurazepam HCl | flurazepam |
| fluvoxamine maleate | Luvox CR |
| fluvoxamine maleate | fluvoxamine |
| guanfacine HCl | Intuniv ER |
| guanfacine HCl | Tenex |
| guanfacine HCl | guanfacine |
| haloperidol | haloperidol |
| haloperidol decanoate | Haldol Decanoate |
| haloperidol decanoate | haloperidol decanoate |

Appendix AC. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

| Generic Name | Brand Name |
|--|--------------------------------|
| haloperidol lactate | Haldol |
| haloperidol lactate | haloperidol lactate |
| hydroxyzine HCl | hydroxyzine HCl |
| hydroxyzine pamoate | Vistaril |
| hydroxyzine pamoate | hydroxyzine pamoate |
| iloperidone | Fanapt |
| imipramine HCl | Tofranil |
| imipramine HCl | imipramine HCl |
| imipramine pamoate | Tofranil-PM |
| imipramine pamoate | imipramine pamoate |
| isocarboxazid | Marplan |
| lamotrigine | Lamictal |
| lamotrigine | Lamictal ODT |
| lamotrigine | Lamictal ODT Starter (Blue) |
| lamotrigine | Lamictal ODT Starter (Green) |
| lamotrigine | Lamictal ODT Starter (Orange) |
| lamotrigine | Lamictal Starter (Blue) Kit |
| lamotrigine | Lamictal Starter (Green) Kit |
| lamotrigine | Lamictal Starter (Orange) Kit |
| lamotrigine | Lamictal XR |
| lamotrigine | Lamictal XR Starter (Blue) |
| lamotrigine | Lamictal XR Starter (Green) |
| lamotrigine | Lamictal XR Starter (Orange) |
| lamotrigine | Subvenite |
| lamotrigine | Subvenite Starter (Blue) Kit |
| lamotrigine | Subvenite Starter (Green) Kit |
| lamotrigine | Subvenite Starter (Orange) Kit |
| lamotrigine | lamotrigine |
| lemborexant | Dayvigo |
| levomilnacipran HCl | Fetzima |
| lisdexamfetamine dimesylate | Vyvanse |
| lithium carbonate | Lithobid |
| lithium carbonate | lithium carbonate |
| lithium citrate | lithium citrate |
| lorazepam | Ativan |
| lorazepam | Lorazepam Intensol |
| lorazepam | Loreev XR |
| lorazepam | lorazepam |
| lorazepam in 0.9 % sodium chloride | lorazepam in 0.9% sod chloride |
| loxapine | Adasuve |
| loxapine succinate | loxapine succinate |
| lumateperone tosylate | Caplyta |
| lurasidone HCl | Latuda |
| maprotiline HCl | maprotiline |
| melatonin | Children's Sleep (melatonin) |
| melatonin | Meladox |
| melatonin | Melatin |
| melatonin | VitaJoy Melatonin |
| melatonin | melatonin |
| melatonin/5-HTP/valerian/folic acid/dietary combination 28 | Hypnosom |

Appendix AC. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

| Generic Name | Brand Name |
|---|--------------------------------|
| melatonin/5-Hydroxytryptophan/tryptophan/B6/magnesium oxide | Somnicin |
| melatonin/GABA/5-HTP/theanine/magnesium citrate,oxide/herbs | Sopordren |
| melatonin/gamma-aminobutyric acid/herbal complex no.183 | Sintralyne-PM |
| melatonin/gamma-aminobutyric acid/valerian | Medi-Doze |
| melatonin/genistein/herbal complex no.233 | Midnite for Menopause |
| melatonin/herbal complex no.184 | Sleep Caps |
| melatonin/herbal complex no.184 | melatonin-herbal complex #184 |
| melatonin/herbal complex no.233 | MidNite |
| melatonin/lemon balm leaf extract | melatonin-lemon balm leaf extr |
| melatonin/pyridoxal phosphate | Melatonin-B6 (pyridoxal phos) |
| melatonin/pyridoxal phosphate | melatonin-pyridoxal phos (B6) |
| melatonin/pyridoxine | Melatonin (with B6) |
| melatonin/pyridoxine | melatonin-pyridoxine (vit B6) |
| melatonin/pyridoxine HCl (vit B6) | Melatonex |
| melatonin/pyridoxine HCl (vit B6) | melatonin-pyridoxine HCl (B6) |
| melatonin/theanine | melatonin-theanine |
| melatonin/tryptophan | Restone |
| melatonin/tryptophan | Wrestone |
| melatonin/tryptophan/valerian/chamomile/niacin/inositol/B6 | Toprophan |
| meprobamate | meprobamate |
| methamphetamine HCl | Desoxyn |
| methamphetamine HCl | methamphetamine |
| methylphenidate | Cotempla XR-ODT |
| methylphenidate | Daytrana |
| methylphenidate HCl | Adhansia XR |
| methylphenidate HCl | Aptensio XR |
| methylphenidate HCl | Concerta |
| methylphenidate HCl | Jornay PM |
| methylphenidate HCl | Metadate CD |
| methylphenidate HCl | Metadate ER |
| methylphenidate HCl | Methylin |
| methylphenidate HCl | QuilliChew ER |
| methylphenidate HCl | Quillivant XR |
| methylphenidate HCl | Relexxii |
| methylphenidate HCl | Ritalin |
| methylphenidate HCl | Ritalin LA |
| methylphenidate HCl | Ritalin SR |
| methylphenidate HCl | methylphenidate HCl |
| midazolam HCl | midazolam |
| milnacipran HCl | Savella |
| mirtazapine | Remeron |
| mirtazapine | Remeron SolTab |
| mirtazapine | mirtazapine |
| molindone HCl | molindone |
| nefazodone HCl | nefazodone |
| nortriptyline HCl | Pamelor |
| nortriptyline HCl | nortriptyline |
| olanzapine | Zyprexa |

Appendix AC. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

| Generic Name | Brand Name |
|---|--------------------------------|
| olanzapine | Zyprexa Zydis |
| olanzapine | olanzapine |
| olanzapine pamoate | Zyprexa Relprevv |
| olanzapine/fluoxetine HCl | Symbyax |
| olanzapine/fluoxetine HCl | olanzapine-fluoxetine |
| olanzapine/samidorphane malate | Lybalvi |
| oxazepam | oxazepam |
| oxcarbazepine | Oxtellar XR |
| oxcarbazepine | Trileptal |
| oxcarbazepine | oxcarbazepine |
| paliperidone | Invega |
| paliperidone | paliperidone |
| paliperidone palmitate | Invega Hafyera |
| paliperidone palmitate | Invega Sustenna |
| paliperidone palmitate | Invega Trinza |
| paroxetine HCl | Paxil |
| paroxetine HCl | Paxil CR |
| paroxetine HCl | paroxetine HCl |
| paroxetine mesylate | Brisdelle |
| paroxetine mesylate | Pexeva |
| paroxetine mesylate | paroxetine mesylate(menop.sym) |
| pentobarbital sodium | Nembutal Sodium |
| pentobarbital sodium | pentobarbital sodium |
| perphenazine | perphenazine |
| perphenazine/amitriptyline HCl | perphenazine-amitriptyline |
| phenelzine sulfate | Nardil |
| phenelzine sulfate | phenelzine |
| phenobarbital | phenobarbital |
| phenobarbital sodium | phenobarbital sodium |
| phenobarbital sodium in 0.9 % sodium chloride | phenobarbital in 0.9 % sod chl |
| pimavanserin tartrate | Nuplazid |
| pimozide | Orap |
| pimozide | pimozide |
| prochlorperazine maleate | Compazine |
| prochlorperazine maleate | prochlorperazine maleate |
| protriptyline HCl | Vivactil |
| protriptyline HCl | protriptyline |
| quazepam | Doral |
| quazepam | quazepam |
| quetiapine fumarate | Seroquel |
| quetiapine fumarate | Seroquel XR |
| quetiapine fumarate | quetiapine |
| ramelteon | Rozerem |
| ramelteon | ramelteon |
| risperidone | Perseris |
| risperidone | Risperdal |
| risperidone | Risperdal M-TAB |
| risperidone | risperidone |
| risperidone microspheres | Risperdal Consta |
| secobarbital sodium | Seconal Sodium |

Appendix AC. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

| Generic Name | Brand Name |
|---|--------------------------------|
| selegiline | Emsam |
| serdexmethylphenidate chloride/dexmethylphenidate HCl | Azstarys |
| sertraline HCl | Zoloft |
| sertraline HCl | sertraline |
| suvorexant | Belsomra |
| tasimelteon | Hetlioz |
| tasimelteon | Hetlioz LQ |
| temazepam | Restoril |
| temazepam | temazepam |
| thioridazine HCl | thioridazine |
| thiothixene | thiothixene |
| tranylcypromine sulfate | Parnate |
| tranylcypromine sulfate | tranylcypromine |
| trazodone HCl | Oleptro ER |
| trazodone HCl | trazodone |
| triazolam | Halcion |
| triazolam | triazolam |
| trifluoperazine HCl | trifluoperazine |
| trimipramine maleate | Surmontil |
| trimipramine maleate | trimipramine |
| tryptophan | tryptophan |
| valerian root extract | valerian root extract |
| valerian root extract/hops | valerian root extract-hops |
| valproic acid | Depakene |
| valproic acid | Stavzor |
| valproic acid | valproic acid |
| valproic acid (as sodium salt) (valproate sodium) | Depacon |
| valproic acid (as sodium salt) (valproate sodium) | Depakene |
| valproic acid (as sodium salt) (valproate sodium) | valproate sodium |
| valproic acid (as sodium salt) (valproate sodium) | valproic acid (as sodium salt) |
| venlafaxine HCl | Effexor XR |
| venlafaxine HCl | venlafaxine |
| vilazodone HCl | Viiibryd |
| vortioxetine hydrobromide | Brintellix |
| vortioxetine hydrobromide | Trintellix |
| zaleplon | Sonata |
| zaleplon | zaleplon |
| ziprasidone HCl | Geodon |
| ziprasidone HCl | ziprasidone HCl |
| ziprasidone mesylate | Geodon |
| ziprasidone mesylate | ziprasidone mesylate |
| zolpidem tartrate | Ambien |
| zolpidem tartrate | Ambien CR |
| zolpidem tartrate | Edluar |
| zolpidem tartrate | Intermezzo |
| zolpidem tartrate | Zolpimist |
| zolpidem tartrate | zolpidem |
| Oral Corticosteroid Dispensing | |
| cortisone acetate | cortisone |
| dexamethasone | Decadron |

Appendix AC. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

| Generic Name | Brand Name |
|---------------------------------------|-------------------------------|
| dexamethasone | DexPak 10 day |
| dexamethasone | DexPak 13 Day |
| dexamethasone | DexPak 6 Day |
| dexamethasone | Dexabliss |
| dexamethasone | Dexamethasone Intensol |
| dexamethasone | Dxevo |
| dexamethasone | Hemady |
| dexamethasone | HiDex |
| dexamethasone | LoCort |
| dexamethasone | TaperDex |
| dexamethasone | ZCort |
| dexamethasone | ZoDex |
| dexamethasone | ZonaCort |
| dexamethasone | dexamethasone |
| hydrocortisone | Alkindi Sprinkle |
| hydrocortisone | Cortef |
| hydrocortisone | hydrocortisone |
| methylprednisolone | Medrol |
| methylprednisolone | Medrol (Pak) |
| methylprednisolone | Methylpred DP |
| methylprednisolone | methylprednisolone |
| prednisolone | Millipred |
| prednisolone | Millipred DP |
| prednisolone | Prelone |
| prednisolone | prednisolone |
| prednisolone acetate | Flo-Pred |
| prednisolone sodium phosphate | Millipred |
| prednisolone sodium phosphate | Orapred ODT |
| prednisolone sodium phosphate | Pediapred |
| prednisolone sodium phosphate | Veripred 20 |
| prednisolone sodium phosphate | prednisolone sodium phosphate |
| prednisone | Deltasone |
| prednisone | Prednisone Intensol |
| prednisone | Rayos |
| prednisone | prednisone |
| Other Asthma Medication | |
| albuterol sulfate | ProAir HFA |
| albuterol sulfate | ProAir RespiClick |
| albuterol sulfate | Proair Digihaler |
| albuterol sulfate | Proventil HFA |
| albuterol sulfate | Ventolin HFA |
| albuterol sulfate | Vospire ER |
| albuterol sulfate | albuterol sulfate |
| aminophylline | aminophylline |
| dyphylline | Lufyllin |
| ipratropium bromide/albuterol sulfate | Combivent Respimat |
| ipratropium bromide/albuterol sulfate | ipratropium-albuterol |
| levalbuterol HCl | Xopenex |
| levalbuterol HCl | Xopenex Concentrate |
| levalbuterol HCl | levalbuterol HCl |

Appendix AC. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

| Generic Name | Brand Name |
|---|--------------------------------|
| levalbuterol tartrate | Xopenex HFA |
| levalbuterol tartrate | levalbuterol tartrate |
| metaproterenol sulfate | metaproterenol |
| terbutaline sulfate | terbutaline |
| theophylline anhydrous | Elixophyllin |
| theophylline anhydrous | Theo-24 |
| theophylline anhydrous | Theochron |
| theophylline anhydrous | theophylline |
| tiotropium bromide | Spiriva Respimat |
| tiotropium bromide | Spiriva with HandiHaler |
| tiotropium bromide/olodaterol HCl | Stiolto Respimat |
| Opiates | |
| TRAMADOL HCL/GLUCOSAMINE SULFATE | Synapryn |
| acetaminophen with codeine phosphate | Capital with Codeine |
| acetaminophen with codeine phosphate | Tylenol-Codeine #3 |
| acetaminophen with codeine phosphate | Tylenol-Codeine #4 |
| acetaminophen with codeine phosphate | acetaminophen-codeine |
| acetaminophen/caffeine/dihydrocodeine bitartrate | Dvorah |
| acetaminophen/caffeine/dihydrocodeine bitartrate | Panlor(acetam-caff-dihydrocod) |
| acetaminophen/caffeine/dihydrocodeine bitartrate | Trezix |
| acetaminophen/caffeine/dihydrocodeine bitartrate | acetaminophen-caff-dihydrocod |
| alfentanil HCl | alfentanil |
| aspirin/caffeine/dihydrocodeine bitartrate | Synalgos-DC |
| aspirin/caffeine/dihydrocodeine bitartrate | aspirin-caffeine-dihydrocodein |
| benzhydrocodone HCl/acetaminophen | Apadaz |
| benzhydrocodone HCl/acetaminophen | benzhydrocodone-acetaminophen |
| buprenorphine | Butrans |
| buprenorphine | buprenorphine |
| buprenorphine HCl | Belbuca |
| buprenorphine HCl | Buprenex |
| buprenorphine HCl | Probuphine |
| buprenorphine HCl | buprenorphine HCl |
| butalbital/acetaminophen/caffeine/codeine phosphate | Fioricet with Codeine |
| butalbital/acetaminophen/caffeine/codeine phosphate | butalbital-acetaminop-caf-cod |
| butorphanol tartrate | butorphanol |
| carisoprodol/aspirin/codeine phosphate | carisoprodol-aspirin-codeine |
| codeine phosphate/butalbital/aspirin/caffeine | Ascomp with Codeine |
| codeine phosphate/butalbital/aspirin/caffeine | Butalbital Compound W/Codeine |
| codeine phosphate/butalbital/aspirin/caffeine | Butalbital Compound-Codeine |
| codeine phosphate/butalbital/aspirin/caffeine | Fiorinal-Codeine #3 |
| codeine phosphate/butalbital/aspirin/caffeine | codeine-butalbital-ASA-caff |
| codeine sulfate | codeine sulfate |
| difelikefalin acetate | Korsuva |
| fentanyl | Duragesic |
| fentanyl | Subsys |
| fentanyl | fentanyl |
| fentanyl HCl | Ionsys |
| fentanyl citrate | Abstral |
| fentanyl citrate | Actiq |
| fentanyl citrate | Fentora |

Appendix AC. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

| Generic Name | Brand Name |
|--|--------------------------------|
| fentanyl citrate | Lazanda |
| fentanyl citrate | fentanyl citrate |
| fentanyl citrate in 0.9 % sodium chloride/PF | fentanyl citrate (PF)-0.9%NaCl |
| fentanyl citrate in dextrose 5% in water/PF | fentanyl citrate in D5W (PF) |
| fentanyl citrate/PF | fentanyl citrate (PF) |
| fentanyl citrate/bupivacaine HCl in 0.9 % sodium chloride/PF | fentanyl (PF)-bupivacaine-NaCl |
| fentanyl citrate/ropivacaine HCl/sodium chloride 0.9%/PF | fentanyl-ropivacaine-NaCl (PF) |
| hydrocodone bitartrate | Hysingla ER |
| hydrocodone bitartrate | Zohydro ER |
| hydrocodone bitartrate | hydrocodone bitartrate |
| hydrocodone bitartrate/acetaminophen | Hycet |
| hydrocodone bitartrate/acetaminophen | Lorcet (hydrocodone) |
| hydrocodone bitartrate/acetaminophen | Lorcet HD |
| hydrocodone bitartrate/acetaminophen | Lorcet Plus |
| hydrocodone bitartrate/acetaminophen | Lortab 10-325 |
| hydrocodone bitartrate/acetaminophen | Lortab 5-325 |
| hydrocodone bitartrate/acetaminophen | Lortab 7.5-325 |
| hydrocodone bitartrate/acetaminophen | Lortab Elixir |
| hydrocodone bitartrate/acetaminophen | Norco |
| hydrocodone bitartrate/acetaminophen | Verdrocet |
| hydrocodone bitartrate/acetaminophen | Vicodin |
| hydrocodone bitartrate/acetaminophen | Vicodin ES |
| hydrocodone bitartrate/acetaminophen | Vicodin HP |
| hydrocodone bitartrate/acetaminophen | Xodol 10/300 |
| hydrocodone bitartrate/acetaminophen | Xodol 5/300 |
| hydrocodone bitartrate/acetaminophen | Xodol 7.5/300 |
| hydrocodone bitartrate/acetaminophen | Zamicet |
| hydrocodone bitartrate/acetaminophen | hydrocodone-acetaminophen |
| hydrocodone/ibuprofen | Ibudone |
| hydrocodone/ibuprofen | Reprexain |
| hydrocodone/ibuprofen | Vicoprofen |
| hydrocodone/ibuprofen | Xylon 10 |
| hydrocodone/ibuprofen | hydrocodone-ibuprofen |
| hydromorphone HCl | Dilaudid |
| hydromorphone HCl | Exalgo ER |
| hydromorphone HCl | hydromorphone |
| hydromorphone HCl in 0.9 % sodium chloride | hydromorphone in 0.9 % NaCl |
| hydromorphone HCl in 0.9 % sodium chloride/PF | hydromorphone (PF)-0.9 % NaCl |
| hydromorphone HCl in dextrose 5 %-water/PF | hydromorphone in D5W (PF) |
| hydromorphone HCl in sodium chloride, iso-osmotic/PF | hydromorphone(PF)-NaCl,iso-osm |
| hydromorphone HCl in sterile water/PF | hydromorphone (PF) in water |
| hydromorphone HCl/PF | Dilaudid (PF) |
| hydromorphone HCl/PF | Dilaudid-HP (PF) |
| hydromorphone HCl/PF | hydromorphone (PF) |
| hydromorphone HCl/bupivacaine HCl in 0.9% sodium chloride/PF | hydromorphone-bupiv (PF)-NaCl |
| hydromorphone HCl/ropivacaine in 0.9 % sodium chloride/PF | hydromorph(PF)-ropiv-0.9% NaCl |
| ibuprofen/oxycodone HCl | ibuprofen-oxycodone |
| levorphanol tartrate | levorphanol tartrate |
| meperidine HCl | Demerol |

Appendix AC. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

| Generic Name | Brand Name |
|---|--------------------------------|
| meperidine HCl | meperidine |
| meperidine HCl in 0.9 % sodium chloride | meperidine in 0.9 % NaCl |
| meperidine HCl in 0.9 % sodium chloride/PF | meperidine (PF) in 0.9 % NaCl |
| meperidine HCl/PF | Demerol (PF) |
| meperidine HCl/PF | meperidine (PF) |
| methadone HCl | Diskets |
| methadone HCl | Dolophine |
| methadone HCl | Methadone Intensol |
| methadone HCl | Methadose |
| methadone HCl | methadone |
| methadone hydrochloride in 0.9 % sodium chloride | methadone in 0.9 % sod.chlorid |
| morphine sulfate | Arymo ER |
| morphine sulfate | Avinza |
| morphine sulfate | Kadian |
| morphine sulfate | MS Contin |
| morphine sulfate | MorphaBond ER |
| morphine sulfate | morphine |
| morphine sulfate | morphine concentrate |
| morphine sulfate in 0.9 % sodium chloride | morphine in 0.9 % sodium chlor |
| morphine sulfate in 0.9 % sodium chloride/PF | morphine (PF) in 0.9 % sod chl |
| morphine sulfate in sodium chloride, iso-osmotic/PF | morphine(PF)in iso sod chlorid |
| morphine sulfate liposomal/PF | DepoDur (PF) |
| morphine sulfate/PF | Duramorph (PF) |
| morphine sulfate/PF | Infumorph P/F |
| morphine sulfate/PF | Mitigo (PF) |
| morphine sulfate/PF | morphine (PF) |
| morphine sulfate/dextrose 5 % in water | morphine in dextrose 5 % |
| morphine sulfate/dextrose 5%-water/PF | morphine (PF) in dextrose 5 % |
| morphine sulfate/naltrexone HCl | Embeda |
| nalbuphine HCl | nalbuphine |
| olliceridine fumarate | Olinvyk |
| oxycodone HCl | Oxaydo |
| oxycodone HCl | Oxecta |
| oxycodone HCl | OxyContin |
| oxycodone HCl | Roxicodone |
| oxycodone HCl | RoxyBond |
| oxycodone HCl | oxycodone |
| oxycodone HCl/acetaminophen | Endocet |
| oxycodone HCl/acetaminophen | Nalocet |
| oxycodone HCl/acetaminophen | Percocet |
| oxycodone HCl/acetaminophen | Primlev |
| oxycodone HCl/acetaminophen | Prolate |
| oxycodone HCl/acetaminophen | Roxicet |
| oxycodone HCl/acetaminophen | Xartemis XR |
| oxycodone HCl/acetaminophen | oxycodone-acetaminophen |
| oxycodone HCl/aspirin | Endodan |
| oxycodone HCl/aspirin | Percodan |
| oxycodone HCl/aspirin | oxycodone-aspirin |
| oxycodone myristate | Xtampza ER |
| oxymorphone HCl | Opana |

Appendix AC. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

| Generic Name | Brand Name |
|---|--------------------------------|
| oxymorphone HCl | Opana ER |
| oxymorphone HCl | oxymorphone |
| pentazocine HCl/naloxone HCl | pentazocine-naloxone |
| pentazocine lactate | Talwin |
| sufentanil citrate | Dsuvia |
| sufentanil citrate/bupivacaine HCl/0.9 % sodium chloride/PF | sufentanil-bupivacain-NaCl(PF) |
| tapentadol HCl | Nucynta |
| tapentadol HCl | Nucynta ER |
| tramadol HCl | ConZip |
| tramadol HCl | Qdolo |
| tramadol HCl | Ultram |
| tramadol HCl | Ultram ER |
| tramadol HCl | tramadol |
| tramadol HCl/acetaminophen | Ultracet |
| tramadol HCl/acetaminophen | tramadol-acetaminophen |
| tramadol HCl/celecoxib | Seglentis |
| Antipsychotics | |
| aripiprazole | Abilify |
| aripiprazole | Abilify Discmelt |
| aripiprazole | Abilify Maintena |
| aripiprazole | Abilify MyCite |
| aripiprazole | Abilify MyCite Maintenance Kit |
| aripiprazole | Abilify MyCite Starter Kit |
| aripiprazole | aripiprazole |
| aripiprazole lauroxil | Aristada |
| aripiprazole lauroxil, submicronized | Aristada Initio |
| asenapine | Secuado |
| asenapine maleate | Saphris |
| asenapine maleate | Saphris (black cherry) |
| asenapine maleate | asenapine maleate |
| brexpiprazole | Rexulti |
| cariprazine HCl | Vraylar |
| chlorpromazine HCl | chlorpromazine |
| clozapine | Clozaril |
| clozapine | FazaClo |
| clozapine | Versacloz |
| clozapine | clozapine |
| fluphenazine HCl | fluphenazine HCl |
| fluphenazine decanoate | fluphenazine decanoate |
| haloperidol | haloperidol |
| haloperidol decanoate | Haldol Decanoate |
| haloperidol decanoate | haloperidol decanoate |
| haloperidol lactate | Haldol |
| haloperidol lactate | haloperidol lactate |
| iloperidone | Fanapt |
| loxapine | Adasuve |
| loxapine succinate | loxapine succinate |
| lumateperone tosylate | Caplyta |
| lurasidone HCl | Latuda |
| molindone HCl | molindone |

Appendix AC. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

| Generic Name | Brand Name |
|--|----------------------------|
| olanzapine | Zyprexa |
| olanzapine | Zyprexa Zydis |
| olanzapine | olanzapine |
| olanzapine pamoate | Zyprexa Relprevv |
| olanzapine/fluoxetine HCl | Symbyax |
| olanzapine/fluoxetine HCl | olanzapine-fluoxetine |
| olanzapine/samidorphan malate | Lybalvi |
| paliperidone | Invega |
| paliperidone | paliperidone |
| paliperidone palmitate | Invega Hafyera |
| paliperidone palmitate | Invega Sustenna |
| paliperidone palmitate | Invega Trinza |
| perphenazine | perphenazine |
| perphenazine/amitriptyline HCl | perphenazine-amitriptyline |
| pimavanserin tartrate | Nuplazid |
| pimozide | Orap |
| pimozide | pimozide |
| prochlorperazine maleate | Compazine |
| prochlorperazine maleate | prochlorperazine maleate |
| quetiapine fumarate | Seroquel |
| quetiapine fumarate | Seroquel XR |
| quetiapine fumarate | quetiapine |
| risperidone | Perseris |
| risperidone | Risperdal |
| risperidone | Risperdal M-TAB |
| risperidone | risperidone |
| risperidone microspheres | Risperdal Consta |
| thioridazine HCl | thioridazine |
| thiothixene | thiothixene |
| trifluoperazine HCl | trifluoperazine |
| ziprasidone HCl | Geodon |
| ziprasidone HCl | ziprasidone HCl |
| ziprasidone mesylate | Geodon |
| ziprasidone mesylate | ziprasidone mesylate |
| Anxiolytics and Hypnotics | |
| alprazolam | Alprazolam Intensol |
| alprazolam | Xanax |
| alprazolam | Xanax XR |
| alprazolam | alprazolam |
| amobarbital sodium | Amytal |
| bromelains/melatonin/herbal complex no.233 | MidNite PM |
| bupirone HCl | bupirone |
| butabarbital sodium | Butisol |
| calcium phosphate/melatonin | calcium-melatonin |
| chlordiazepoxide HCl | chlordiazepoxide HCl |
| clonazepam | Klonopin |
| clonazepam | clonazepam |
| clorazepate dipotassium | Tranxene T-Tab |
| clorazepate dipotassium | clorazepate dipotassium |
| daridorexant HCl | Quviviq |

Appendix AC. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

| Generic Name | Brand Name |
|---|--------------------------------|
| dexmedetomidine HCl | Precedex |
| dexmedetomidine HCl | dexmedetomidine |
| dexmedetomidine HCl in 0.9 % sodium chloride | Precedex in 0.9 % sodium chlor |
| dexmedetomidine HCl in 0.9 % sodium chloride | dexmedetomidine in 0.9 % NaCl |
| dexmedetomidine in 5 % dextrose in water | dexmedetomidine in dextrose 5% |
| diazepam | Diazepam Intensol |
| diazepam | Valium |
| diazepam | diazepam |
| doxepin HCl | Silenor |
| doxepin HCl | doxepin |
| estazolam | estazolam |
| eszopiclone | Lunesta |
| eszopiclone | eszopiclone |
| ethyl alcohol/herbal drugs | Lydia Pinkham Herbal |
| flurazepam HCl | flurazepam |
| hydroxyzine HCl | hydroxyzine HCl |
| hydroxyzine pamoate | Vistaril |
| hydroxyzine pamoate | hydroxyzine pamoate |
| lemborexant | Dayvigo |
| lorazepam | Ativan |
| lorazepam | Lorazepam Intensol |
| lorazepam | Loreev XR |
| lorazepam | lorazepam |
| lorazepam in 0.9 % sodium chloride | lorazepam in 0.9% sod chloride |
| melatonin | Children's Sleep (melatonin) |
| melatonin | Meladox |
| melatonin | Melatin |
| melatonin | VitaJoy Melatonin |
| melatonin | melatonin |
| melatonin/5-HTP/valerian/folic acid/dietary combination 28 | Hypnosom |
| melatonin/5-Hydroxytryptophan/tryptophan/B6/magnesium oxide | Somnicin |
| melatonin/GABA/5-HTP/theanine/magnesium citrate,oxide/herbs | Sopordren |
| melatonin/gamma-aminobutyric acid/herbal complex no.183 | Sinralyne-PM |
| melatonin/gamma-aminobutyric acid/valerian | Medi-Doze |
| melatonin/genistein/herbal complex no.233 | Midnite for Menopause |
| melatonin/herbal complex no.184 | Sleep Caps |
| melatonin/herbal complex no.184 | melatonin-herbal complex #184 |
| melatonin/herbal complex no.233 | MidNite |
| melatonin/lemon balm leaf extract | melatonin-lemon balm leaf extr |
| melatonin/pyridoxal phosphate | Melatonin-B6 (pyridoxal phos) |
| melatonin/pyridoxal phosphate | melatonin-pyridoxal phos (B6) |
| melatonin/pyridoxine | Melatonin (with B6) |
| melatonin/pyridoxine | melatonin-pyridoxine (vit B6) |
| melatonin/pyridoxine HCl (vit B6) | Melatonex |
| melatonin/pyridoxine HCl (vit B6) | melatonin-pyridoxine HCl (B6) |
| melatonin/theanine | melatonin-theanine |
| melatonin/tryptophan | Restone |
| melatonin/tryptophan | Wrestone |

Appendix AC. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

| Generic Name | Brand Name |
|--|--------------------------------|
| melatonin/tryptophan/valerian/chamomile/niacin/inositol/B6 | Toprophan |
| meprobamate | meprobamate |
| midazolam HCl | midazolam |
| oxazepam | oxazepam |
| pentobarbital sodium | Nembutal Sodium |
| pentobarbital sodium | pentobarbital sodium |
| phenobarbital | phenobarbital |
| phenobarbital sodium | phenobarbital sodium |
| phenobarbital sodium in 0.9 % sodium chloride | phenobarbital in 0.9 % sod chl |
| quazepam | Doral |
| quazepam | quazepam |
| ramelteon | Rozerem |
| ramelteon | ramelteon |
| secobarbital sodium | Seconal Sodium |
| suvorexant | Belsomra |
| tasimelteon | Hetlioz |
| tasimelteon | Hetlioz LQ |
| temazepam | Restoril |
| temazepam | temazepam |
| triazolam | Halcion |
| triazolam | triazolam |
| tryptophan | tryptophan |
| valerian root extract | valerian root extract |
| valerian root extract/hops | valerian root extract-hops |
| zaleplon | Sonata |
| zaleplon | zaleplon |
| zolpidem tartrate | Ambien |
| zolpidem tartrate | Ambien CR |
| zolpidem tartrate | Edluar |
| zolpidem tartrate | Intermezzo |
| zolpidem tartrate | Zolpimist |
| zolpidem tartrate | zolpidem |
| Lithium and Other Mood Stabilizers | |
| carbamazepine | Carbatrol |
| carbamazepine | Epitol |
| carbamazepine | Equetro |
| carbamazepine | Tegretol |
| carbamazepine | Tegretol XR |
| carbamazepine | carbamazepine |
| clonazepam | Klonopin |
| clonazepam | clonazepam |
| divalproex sodium | Depakote |
| divalproex sodium | Depakote ER |
| divalproex sodium | Depakote Sprinkles |
| divalproex sodium | divalproex |
| lamotrigine | Lamictal |
| lamotrigine | Lamictal ODT |
| lamotrigine | Lamictal ODT Starter (Blue) |
| lamotrigine | Lamictal ODT Starter (Green) |
| lamotrigine | Lamictal ODT Starter (Orange) |

Appendix AC. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

| Generic Name | Brand Name |
|---|--------------------------------|
| lamotrigine | Lamictal Starter (Blue) Kit |
| lamotrigine | Lamictal Starter (Green) Kit |
| lamotrigine | Lamictal Starter (Orange) Kit |
| lamotrigine | Lamictal XR |
| lamotrigine | Lamictal XR Starter (Blue) |
| lamotrigine | Lamictal XR Starter (Green) |
| lamotrigine | Lamictal XR Starter (Orange) |
| lamotrigine | Subvenite |
| lamotrigine | Subvenite Starter (Blue) Kit |
| lamotrigine | Subvenite Starter (Green) Kit |
| lamotrigine | Subvenite Starter (Orange) Kit |
| lamotrigine | lamotrigine |
| lithium carbonate | Lithobid |
| lithium carbonate | lithium carbonate |
| lithium citrate | lithium citrate |
| oxcarbazepine | Oxtellar XR |
| oxcarbazepine | Trileptal |
| oxcarbazepine | oxcarbazepine |
| valproic acid | Depakene |
| valproic acid | Stavzor |
| valproic acid | valproic acid |
| valproic acid (as sodium salt) (valproate sodium) | Depacon |
| valproic acid (as sodium salt) (valproate sodium) | Depakene |
| valproic acid (as sodium salt) (valproate sodium) | valproate sodium |
| valproic acid (as sodium salt) (valproate sodium) | valproic acid (as sodium salt) |
| Antidepressants | |
| amitriptyline HCl | amitriptyline |
| amitriptyline HCl/chlordiazepoxide | amitriptyline-chlordiazepoxide |
| amoxapine | amoxapine |
| brexanolone | Zulresso |
| bupropion HBr | Aplenzin |
| bupropion HCl | Forfivo XL |
| bupropion HCl | Wellbutrin |
| bupropion HCl | Wellbutrin SR |
| bupropion HCl | Wellbutrin XL |
| bupropion HCl | bupropion HCl |
| citalopram hydrobromide | Celexa |
| citalopram hydrobromide | citalopram |
| clomipramine HCl | Anafranil |
| clomipramine HCl | clomipramine |
| desipramine HCl | Norpramin |
| desipramine HCl | desipramine |
| desvenlafaxine | Khedezla |
| desvenlafaxine | desvenlafaxine |
| desvenlafaxine fumarate | desvenlafaxine fumarate |
| desvenlafaxine succinate | Pristiq |
| desvenlafaxine succinate | desvenlafaxine succinate |
| doxepin HCl | Silenor |
| doxepin HCl | doxepin |
| duloxetine HCl | Cymbalta |

Appendix AC. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

| Generic Name | Brand Name |
|--------------------------------|--------------------------------|
| duloxetine HCl | Drizalma Sprinkle |
| duloxetine HCl | Irenka |
| duloxetine HCl | duloxetine |
| escitalopram oxalate | Lexapro |
| escitalopram oxalate | escitalopram oxalate |
| esketamine HCl | Spravato |
| fluoxetine HCl | Prozac |
| fluoxetine HCl | Prozac Weekly |
| fluoxetine HCl | Sarafem |
| fluoxetine HCl | fluoxetine |
| fluvoxamine maleate | Luvox CR |
| fluvoxamine maleate | fluvoxamine |
| imipramine HCl | Tofranil |
| imipramine HCl | imipramine HCl |
| imipramine pamoate | Tofranil-PM |
| imipramine pamoate | imipramine pamoate |
| isocarboxazid | Marplan |
| levomilnacipran HCl | Fetzima |
| maprotiline HCl | maprotiline |
| milnacipran HCl | Savella |
| mirtazapine | Remeron |
| mirtazapine | Remeron SolTab |
| mirtazapine | mirtazapine |
| nefazodone HCl | nefazodone |
| nortriptyline HCl | Pamelor |
| nortriptyline HCl | nortriptyline |
| olanzapine/fluoxetine HCl | Symbyax |
| olanzapine/fluoxetine HCl | olanzapine-fluoxetine |
| paroxetine HCl | Paxil |
| paroxetine HCl | Paxil CR |
| paroxetine HCl | paroxetine HCl |
| paroxetine mesylate | Brisdelle |
| paroxetine mesylate | Pexeva |
| paroxetine mesylate | paroxetine mesylate(menop.sym) |
| perphenazine/amitriptyline HCl | perphenazine-amitriptyline |
| phenelzine sulfate | Nardil |
| phenelzine sulfate | phenelzine |
| protriptyline HCl | Vivactil |
| protriptyline HCl | protriptyline |
| selegiline | Emsam |
| sertraline HCl | Zoloft |
| sertraline HCl | sertraline |
| tranylcypromine sulfate | Parnate |
| tranylcypromine sulfate | tranylcypromine |
| trazodone HCl | Oleptro ER |
| trazodone HCl | trazodone |
| trimipramine maleate | Surmontil |
| trimipramine maleate | trimipramine |
| venlafaxine HCl | Effexor XR |
| venlafaxine HCl | venlafaxine |

Appendix AC. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

| Generic Name | Brand Name |
|---|-------------------------------|
| vilazodone HCl | Viibryd |
| vortioxetine hydrobromide | Brintellix |
| vortioxetine hydrobromide | Trintellix |
| Oral Corticosteroid Dispensing - Component of Asthma Exacerbation Episode | |
| cortisone acetate | cortisone |
| dexamethasone | Decadron |
| dexamethasone | DexPak 10 day |
| dexamethasone | DexPak 13 Day |
| dexamethasone | DexPak 6 Day |
| dexamethasone | Dexabliss |
| dexamethasone | Dexamethasone Intensol |
| dexamethasone | Dxevo |
| dexamethasone | Hemady |
| dexamethasone | HiDex |
| dexamethasone | LoCort |
| dexamethasone | TaperDex |
| dexamethasone | ZCort |
| dexamethasone | ZoDex |
| dexamethasone | ZonaCort |
| dexamethasone | dexamethasone |
| hydrocortisone | Alkindi Sprinkle |
| hydrocortisone | Cortef |
| hydrocortisone | hydrocortisone |
| methylprednisolone | Medrol |
| methylprednisolone | Medrol (Pak) |
| methylprednisolone | Methylpred DP |
| methylprednisolone | methylprednisolone |
| prednisolone | Millipred |
| prednisolone | Millipred DP |
| prednisolone | Prelone |
| prednisolone | prednisolone |
| prednisolone acetate | Flo-Pred |
| prednisolone sodium phosphate | Millipred |
| prednisolone sodium phosphate | Orapred ODT |
| prednisolone sodium phosphate | Pediapred |
| prednisolone sodium phosphate | Veripred 20 |
| prednisolone sodium phosphate | prednisolone sodium phosphate |
| prednisone | Deltasone |
| prednisone | Prednisone Intensol |
| prednisone | Rayos |
| prednisone | prednisone |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------------------------|---|---------------|-----------|
| Psychiatric History | | | |
| 290.0 | Senile dementia, uncomplicated | Diagnosis | ICD-9-CM |
| 290.10 | Presenile dementia, uncomplicated | Diagnosis | ICD-9-CM |
| 290.11 | Presenile dementia with delirium | Diagnosis | ICD-9-CM |
| 290.12 | Presenile dementia with delusional features | Diagnosis | ICD-9-CM |
| 290.13 | Presenile dementia with depressive features | Diagnosis | ICD-9-CM |
| 290.20 | Senile dementia with delusional features | Diagnosis | ICD-9-CM |
| 290.21 | Senile dementia with depressive features | Diagnosis | ICD-9-CM |
| 290.3 | Senile dementia with delirium | Diagnosis | ICD-9-CM |
| 290.40 | Vascular dementia, uncomplicated | Diagnosis | ICD-9-CM |
| 290.41 | Vascular dementia, with delirium | Diagnosis | ICD-9-CM |
| 290.42 | Vascular dementia, with delusions | Diagnosis | ICD-9-CM |
| 290.43 | Vascular dementia, with depressed mood | Diagnosis | ICD-9-CM |
| 290.8 | Other specified senile psychotic conditions | Diagnosis | ICD-9-CM |
| 290.9 | Unspecified senile psychotic condition | Diagnosis | ICD-9-CM |
| 291 | Alcohol-induced mental disorders | Diagnosis | ICD-9-CM |
| 291.0 | Alcohol withdrawal delirium | Diagnosis | ICD-9-CM |
| 291.1 | Alcohol-induced persisting amnesic disorder | Diagnosis | ICD-9-CM |
| 291.2 | Alcohol-induced persisting dementia | Diagnosis | ICD-9-CM |
| 291.3 | Alcohol-induced psychotic disorder with hallucinations | Diagnosis | ICD-9-CM |
| 291.4 | Idiosyncratic alcohol intoxication | Diagnosis | ICD-9-CM |
| 291.5 | Alcohol-induced psychotic disorder with delusions | Diagnosis | ICD-9-CM |
| 291.8 | Other specified alcohol-induced mental disorders | Diagnosis | ICD-9-CM |
| 291.81 | Alcohol withdrawal | Diagnosis | ICD-9-CM |
| 291.82 | Alcohol induced sleep disorders | Diagnosis | ICD-9-CM |
| 291.89 | Other specified alcohol-induced mental disorders | Diagnosis | ICD-9-CM |
| 291.9 | Unspecified alcohol-induced mental disorders | Diagnosis | ICD-9-CM |
| 292 | Drug-induced mental disorders | Diagnosis | ICD-9-CM |
| 292.0 | Drug withdrawal | Diagnosis | ICD-9-CM |
| 292.1 | Drug-induced psychotic disorder | Diagnosis | ICD-9-CM |
| 292.11 | Drug-induced psychotic disorder with delusions | Diagnosis | ICD-9-CM |
| 292.12 | Drug-induced psychotic disorder with hallucinations | Diagnosis | ICD-9-CM |
| 292.2 | Pathological drug intoxication | Diagnosis | ICD-9-CM |
| 292.8 | Other specified drug-induced mental disorders | Diagnosis | ICD-9-CM |
| 292.81 | Drug-induced delirium | Diagnosis | ICD-9-CM |
| 292.82 | Drug-induced persisting dementia | Diagnosis | ICD-9-CM |
| 292.83 | Drug-induced persisting amnesic disorder | Diagnosis | ICD-9-CM |
| 292.84 | Drug-induced mood disorder | Diagnosis | ICD-9-CM |
| 292.85 | Drug induced sleep disorders | Diagnosis | ICD-9-CM |
| 292.89 | Other specified drug-induced mental disorder | Diagnosis | ICD-9-CM |
| 292.9 | Unspecified drug-induced mental disorder | Diagnosis | ICD-9-CM |
| 293 | Transient mental disorders due to conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 293.0 | Delirium due to conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 293.1 | Subacute delirium | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| 293.8 | Other specified transient mental disorders due to conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 293.81 | Psychotic disorder with delusions in conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 293.82 | Psychotic disorder with hallucinations in conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 293.83 | Mood disorder in conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 293.84 | Anxiety disorder in conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 293.89 | Other transient mental disorders due to conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 293.9 | Unspecified transient mental disorder in conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 294 | Persistent mental disorders due to conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 294.0 | Amnestic disorder in conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 294.1 | Dementia in conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 294.10 | Dementia in conditions classified elsewhere without behavioral disturbance | Diagnosis | ICD-9-CM |
| 294.11 | Dementia in conditions classified elsewhere with behavioral disturbance | Diagnosis | ICD-9-CM |
| 294.2 | Dementia, unspecified | Diagnosis | ICD-9-CM |
| 294.20 | Dementia, unspecified, without behavioral disturbance | Diagnosis | ICD-9-CM |
| 294.21 | Dementia, unspecified, with behavioral disturbance | Diagnosis | ICD-9-CM |
| 294.8 | Other persistent mental disorders due to conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 294.9 | Unspecified persistent mental disorders due to conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 295 | Schizophrenic disorders | Diagnosis | ICD-9-CM |
| 295.0 | Simple type schizophrenia | Diagnosis | ICD-9-CM |
| 295.00 | Simple schizophrenia, unspecified condition | Diagnosis | ICD-9-CM |
| 295.01 | Simple schizophrenia, subchronic condition | Diagnosis | ICD-9-CM |
| 295.02 | Simple schizophrenia, chronic condition | Diagnosis | ICD-9-CM |
| 295.03 | Simple schizophrenia, subchronic condition with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.04 | Simple schizophrenia, chronic condition with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.05 | Simple schizophrenia, in remission | Diagnosis | ICD-9-CM |
| 295.1 | Disorganized type schizophrenia | Diagnosis | ICD-9-CM |
| 295.10 | Disorganized schizophrenia, unspecified condition | Diagnosis | ICD-9-CM |
| 295.11 | Disorganized schizophrenia, subchronic condition | Diagnosis | ICD-9-CM |
| 295.12 | Disorganized schizophrenia, chronic condition | Diagnosis | ICD-9-CM |
| 295.13 | Disorganized schizophrenia, subchronic condition with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.14 | Disorganized schizophrenia, chronic condition with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.15 | Disorganized schizophrenia, in remission | Diagnosis | ICD-9-CM |
| 295.2 | Catatonic type schizophrenia | Diagnosis | ICD-9-CM |
| 295.20 | Catatonic schizophrenia, unspecified condition | Diagnosis | ICD-9-CM |
| 295.21 | Catatonic schizophrenia, subchronic condition | Diagnosis | ICD-9-CM |
| 295.22 | Catatonic schizophrenia, chronic condition | Diagnosis | ICD-9-CM |
| 295.23 | Catatonic schizophrenia, subchronic condition with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.24 | Catatonic schizophrenia, chronic condition with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.25 | Catatonic schizophrenia, in remission | Diagnosis | ICD-9-CM |
| 295.3 | Paranoid type schizophrenia | Diagnosis | ICD-9-CM |
| 295.30 | Paranoid schizophrenia, unspecified condition | Diagnosis | ICD-9-CM |
| 295.31 | Paranoid schizophrenia, subchronic condition | Diagnosis | ICD-9-CM |
| 295.32 | Paranoid schizophrenia, chronic condition | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 295.33 | Paranoid schizophrenia, subchronic condition with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.34 | Paranoid schizophrenia, chronic condition with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.35 | Paranoid schizophrenia, in remission | Diagnosis | ICD-9-CM |
| 295.4 | Schizophreniform disorder | Diagnosis | ICD-9-CM |
| 295.40 | Schizophreniform disorder, unspecified | Diagnosis | ICD-9-CM |
| 295.41 | Schizophreniform disorder, subchronic | Diagnosis | ICD-9-CM |
| 295.42 | Schizophreniform disorder, chronic | Diagnosis | ICD-9-CM |
| 295.43 | Schizophreniform disorder, subchronic with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.44 | Schizophreniform disorder, chronic with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.45 | Schizophreniform disorder, in remission | Diagnosis | ICD-9-CM |
| 295.5 | Latent schizophrenia | Diagnosis | ICD-9-CM |
| 295.50 | Latent schizophrenia, unspecified condition | Diagnosis | ICD-9-CM |
| 295.51 | Latent schizophrenia, subchronic condition | Diagnosis | ICD-9-CM |
| 295.52 | Latent schizophrenia, chronic condition | Diagnosis | ICD-9-CM |
| 295.53 | Latent schizophrenia, subchronic condition with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.54 | Latent schizophrenia, chronic condition with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.55 | Latent schizophrenia, in remission | Diagnosis | ICD-9-CM |
| 295.6 | Schizophrenic disorders, residual type | Diagnosis | ICD-9-CM |
| 295.60 | Schizophrenic disorders, residual type, unspecified | Diagnosis | ICD-9-CM |
| 295.61 | Schizophrenic disorders, residual type, subchronic | Diagnosis | ICD-9-CM |
| 295.62 | Schizophrenic disorders, residual type, chronic | Diagnosis | ICD-9-CM |
| 295.63 | Schizophrenic disorders, residual type, subchronic with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.64 | Schizophrenic disorders, residual type, chronic with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.65 | Schizophrenic disorders, residual type, in remission | Diagnosis | ICD-9-CM |
| 295.7 | Schizoaffective disorder | Diagnosis | ICD-9-CM |
| 295.70 | Schizoaffective disorder, unspecified | Diagnosis | ICD-9-CM |
| 295.71 | Schizoaffective disorder, subchronic | Diagnosis | ICD-9-CM |
| 295.72 | Schizoaffective disorder, chronic | Diagnosis | ICD-9-CM |
| 295.73 | Schizoaffective disorder, subchronic with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.74 | Schizoaffective disorder, chronic with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.75 | Schizoaffective disorder, in remission | Diagnosis | ICD-9-CM |
| 295.8 | Other specified types of schizophrenia | Diagnosis | ICD-9-CM |
| 295.80 | Other specified types of schizophrenia, unspecified condition | Diagnosis | ICD-9-CM |
| 295.81 | Other specified types of schizophrenia, subchronic condition | Diagnosis | ICD-9-CM |
| 295.82 | Other specified types of schizophrenia, chronic condition | Diagnosis | ICD-9-CM |
| 295.83 | Other specified types of schizophrenia, subchronic condition with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.84 | Other specified types of schizophrenia, chronic condition with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.85 | Other specified types of schizophrenia, in remission | Diagnosis | ICD-9-CM |
| 295.9 | Unspecified schizophrenia | Diagnosis | ICD-9-CM |
| 295.90 | Unspecified schizophrenia, unspecified condition | Diagnosis | ICD-9-CM |
| 295.91 | Unspecified schizophrenia, subchronic condition | Diagnosis | ICD-9-CM |
| 295.92 | Unspecified schizophrenia, chronic condition | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| 295.93 | Unspecified schizophrenia, subchronic condition with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.94 | Unspecified schizophrenia, chronic condition with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.95 | Unspecified schizophrenia, in remission | Diagnosis | ICD-9-CM |
| 296.0 | Bipolar I disorder, single manic episode | Diagnosis | ICD-9-CM |
| 296.00 | Bipolar I disorder, single manic episode, unspecified | Diagnosis | ICD-9-CM |
| 296.01 | Bipolar I disorder, single manic episode, mild | Diagnosis | ICD-9-CM |
| 296.02 | Bipolar I disorder, single manic episode, moderate | Diagnosis | ICD-9-CM |
| 296.03 | Bipolar I disorder, single manic episode, severe, without mention of psychotic behavior | Diagnosis | ICD-9-CM |
| 296.04 | Bipolar I disorder, single manic episode, severe, specified as with psychotic behavior | Diagnosis | ICD-9-CM |
| 296.05 | Bipolar I disorder, single manic episode, in partial or unspecified remission | Diagnosis | ICD-9-CM |
| 296.06 | Bipolar I disorder, single manic episode, in full remission | Diagnosis | ICD-9-CM |
| 296.1 | Manic disorder, recurrent episode | Diagnosis | ICD-9-CM |
| 296.10 | Manic disorder, recurrent episode, unspecified | Diagnosis | ICD-9-CM |
| 296.11 | Manic disorder, recurrent episode, mild | Diagnosis | ICD-9-CM |
| 296.12 | Manic disorder, recurrent episode, moderate | Diagnosis | ICD-9-CM |
| 296.13 | Manic disorder, recurrent episode, severe, without mention of psychotic behavior | Diagnosis | ICD-9-CM |
| 296.14 | Manic disorder, recurrent episode, severe, specified as with psychotic behavior | Diagnosis | ICD-9-CM |
| 296.15 | Manic disorder, recurrent episode, in partial or unspecified remission | Diagnosis | ICD-9-CM |
| 296.16 | Manic disorder, recurrent episode, in full remission | Diagnosis | ICD-9-CM |
| 296.2 | Major depressive disorder, single episode | Diagnosis | ICD-9-CM |
| 296.20 | Major depressive disorder, single episode, unspecified | Diagnosis | ICD-9-CM |
| 296.21 | Major depressive disorder, single episode, mild | Diagnosis | ICD-9-CM |
| 296.22 | Major depressive disorder, single episode, moderate | Diagnosis | ICD-9-CM |
| 296.23 | Major depressive disorder, single episode, severe, without mention of psychotic behavior | Diagnosis | ICD-9-CM |
| 296.24 | Major depressive disorder, single episode, severe, specified as with psychotic behavior | Diagnosis | ICD-9-CM |
| 296.25 | Major depressive disorder, single episode, in partial or unspecified remission | Diagnosis | ICD-9-CM |
| 296.26 | Major depressive disorder, single episode in full remission | Diagnosis | ICD-9-CM |
| 296.3 | Major depressive disorder, recurrent episode | Diagnosis | ICD-9-CM |
| 296.30 | Major depressive disorder, recurrent episode, unspecified | Diagnosis | ICD-9-CM |
| 296.31 | Major depressive disorder, recurrent episode, mild | Diagnosis | ICD-9-CM |
| 296.32 | Major depressive disorder, recurrent episode, moderate | Diagnosis | ICD-9-CM |
| 296.33 | Major depressive disorder, recurrent episode, severe, without mention of psychotic behavior | Diagnosis | ICD-9-CM |
| 296.34 | Major depressive disorder, recurrent episode, severe, specified as with psychotic behavior | Diagnosis | ICD-9-CM |
| 296.35 | Major depressive disorder, recurrent episode, in partial or unspecified | Diagnosis | ICD-9-CM |
| 296.36 | Major depressive disorder, recurrent episode, in full remission | Diagnosis | ICD-9-CM |
| 296.4 | Bipolar I disorder, most recent episode (or current) manic | Diagnosis | ICD-9-CM |
| 296.40 | Bipolar I disorder, most recent episode (or current) manic, unspecified | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| 296.41 | Bipolar I disorder, most recent episode (or current) manic, mild | Diagnosis | ICD-9-CM |
| 296.42 | Bipolar I disorder, most recent episode (or current) manic, moderate | Diagnosis | ICD-9-CM |
| 296.43 | Bipolar I disorder, most recent episode (or current) manic, severe, without mention of psychotic behavior | Diagnosis | ICD-9-CM |
| 296.44 | Bipolar I disorder, most recent episode (or current) manic, severe, specified as with psychotic behavior | Diagnosis | ICD-9-CM |
| 296.45 | Bipolar I disorder, most recent episode (or current) manic, in partial or unspecified remission | Diagnosis | ICD-9-CM |
| 296.46 | Bipolar I disorder, most recent episode (or current) manic, in full remission | Diagnosis | ICD-9-CM |
| 296.5 | Bipolar I disorder, most recent episode (or current), depressed | Diagnosis | ICD-9-CM |
| 296.50 | Bipolar I disorder, most recent episode (or current) depressed, unspecified | Diagnosis | ICD-9-CM |
| 296.51 | Bipolar I disorder, most recent episode (or current) depressed, mild | Diagnosis | ICD-9-CM |
| 296.52 | Bipolar I disorder, most recent episode (or current) depressed, moderate | Diagnosis | ICD-9-CM |
| 296.53 | Bipolar I disorder, most recent episode (or current) depressed, severe, without mention of psychotic behavior | Diagnosis | ICD-9-CM |
| 296.54 | Bipolar I disorder, most recent episode (or current) depressed, severe, specified as with psychotic behavior | Diagnosis | ICD-9-CM |
| 296.55 | Bipolar I disorder, most recent episode (or current) depressed, in partial or unspecified remission | Diagnosis | ICD-9-CM |
| 296.56 | Bipolar I disorder, most recent episode (or current) depressed, in full remission | Diagnosis | ICD-9-CM |
| 296.6 | Bipolar I disorder, most recent episode (or current), mixed | Diagnosis | ICD-9-CM |
| 296.60 | Bipolar I disorder, most recent episode (or current) mixed, unspecified | Diagnosis | ICD-9-CM |
| 296.61 | Bipolar I disorder, most recent episode (or current) mixed, mild | Diagnosis | ICD-9-CM |
| 296.62 | Bipolar I disorder, most recent episode (or current) mixed, moderate | Diagnosis | ICD-9-CM |
| 296.63 | Bipolar I disorder, most recent episode (or current) mixed, severe, without mention of psychotic behavior | Diagnosis | ICD-9-CM |
| 296.64 | Bipolar I disorder, most recent episode (or current) mixed, severe, specified as with psychotic behavior | Diagnosis | ICD-9-CM |
| 296.65 | Bipolar I disorder, most recent episode (or current) mixed, in partial or unspecified remission | Diagnosis | ICD-9-CM |
| 296.66 | Bipolar I disorder, most recent episode (or current) mixed, in full remission | Diagnosis | ICD-9-CM |
| 296.7 | Bipolar I disorder, most recent episode (or current) unspecified | Diagnosis | ICD-9-CM |
| 296.8 | Other and unspecified bipolar disorders | Diagnosis | ICD-9-CM |
| 296.80 | Bipolar disorder, unspecified | Diagnosis | ICD-9-CM |
| 296.81 | Atypical manic disorder | Diagnosis | ICD-9-CM |
| 296.82 | Atypical depressive disorder | Diagnosis | ICD-9-CM |
| 296.89 | Other and unspecified bipolar disorders | Diagnosis | ICD-9-CM |
| 296.90 | Unspecified episodic mood disorder | Diagnosis | ICD-9-CM |
| 296.99 | Other specified episodic mood disorder | Diagnosis | ICD-9-CM |
| 297 | Delusional disorders | Diagnosis | ICD-9-CM |
| 297.0 | Paranoid state, simple | Diagnosis | ICD-9-CM |
| 297.1 | Delusional disorder | Diagnosis | ICD-9-CM |
| 297.2 | Paraphrenia | Diagnosis | ICD-9-CM |
| 297.3 | Shared psychotic disorder | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 297.8 | Other specified paranoid states | Diagnosis | ICD-9-CM |
| 297.9 | Unspecified paranoid state | Diagnosis | ICD-9-CM |
| 298 | Other nonorganic psychoses | Diagnosis | ICD-9-CM |
| 298.0 | Depressive type psychosis | Diagnosis | ICD-9-CM |
| 298.1 | Excitative type psychosis | Diagnosis | ICD-9-CM |
| 298.2 | Reactive confusion | Diagnosis | ICD-9-CM |
| 298.3 | Acute paranoid reaction | Diagnosis | ICD-9-CM |
| 298.4 | Psychogenic paranoid psychosis | Diagnosis | ICD-9-CM |
| 298.8 | Other and unspecified reactive psychosis | Diagnosis | ICD-9-CM |
| 298.9 | Unspecified psychosis | Diagnosis | ICD-9-CM |
| 299 | Pervasive developmental disorders | Diagnosis | ICD-9-CM |
| 299.0 | Autistic disorder | Diagnosis | ICD-9-CM |
| 299.00 | Autistic disorder, current or active state | Diagnosis | ICD-9-CM |
| 299.01 | Autistic disorder, residual state | Diagnosis | ICD-9-CM |
| 299.1 | Childhood disintegrative disorder | Diagnosis | ICD-9-CM |
| 299.10 | Childhood disintegrative disorder, current or active state | Diagnosis | ICD-9-CM |
| 299.11 | Childhood disintegrative disorder, residual state | Diagnosis | ICD-9-CM |
| 299.8 | Other specified pervasive developmental disorders | Diagnosis | ICD-9-CM |
| 299.80 | Other specified pervasive developmental disorders, current or active state | Diagnosis | ICD-9-CM |
| 299.81 | Other specified pervasive developmental disorders, residual state | Diagnosis | ICD-9-CM |
| 299.9 | Unspecified pervasive developmental disorder | Diagnosis | ICD-9-CM |
| 299.90 | Unspecified pervasive developmental disorder, current or active state | Diagnosis | ICD-9-CM |
| 299.91 | Unspecified pervasive developmental disorder, residual state | Diagnosis | ICD-9-CM |
| 300.0 | Anxiety states | Diagnosis | ICD-9-CM |
| 300.00 | Anxiety state, unspecified | Diagnosis | ICD-9-CM |
| 300.01 | Panic disorder without agoraphobia | Diagnosis | ICD-9-CM |
| 300.02 | Generalized anxiety disorder | Diagnosis | ICD-9-CM |
| 300.09 | Other anxiety states | Diagnosis | ICD-9-CM |
| 300.1 | Dissociative, conversion and factitious disorders | Diagnosis | ICD-9-CM |
| 300.10 | Hysteria, unspecified | Diagnosis | ICD-9-CM |
| 300.11 | Conversion disorder | Diagnosis | ICD-9-CM |
| 300.12 | Dissociative amnesia | Diagnosis | ICD-9-CM |
| 300.13 | Dissociative fugue | Diagnosis | ICD-9-CM |
| 300.14 | Dissociative identity disorder | Diagnosis | ICD-9-CM |
| 300.15 | Dissociative disorder or reaction, unspecified | Diagnosis | ICD-9-CM |
| 300.16 | Factitious disorder with predominantly psychological signs and symptoms | Diagnosis | ICD-9-CM |
| 300.19 | Other and unspecified factitious illness | Diagnosis | ICD-9-CM |
| 300.2 | Phobic disorders | Diagnosis | ICD-9-CM |
| 300.20 | Phobia, unspecified | Diagnosis | ICD-9-CM |
| 300.21 | Agoraphobia with panic disorder | Diagnosis | ICD-9-CM |
| 300.22 | Agoraphobia without mention of panic attacks | Diagnosis | ICD-9-CM |
| 300.23 | Social phobia | Diagnosis | ICD-9-CM |
| 300.29 | Other isolated or specific phobias | Diagnosis | ICD-9-CM |
| 300.3 | Obsessive-compulsive disorders | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| 300.4 | Dysthymic disorder | Diagnosis | ICD-9-CM |
| 300.5 | Neurasthenia | Diagnosis | ICD-9-CM |
| 300.6 | Depersonalization disorder | Diagnosis | ICD-9-CM |
| 300.7 | Hypochondriasis | Diagnosis | ICD-9-CM |
| 300.8 | Somatoform disorders | Diagnosis | ICD-9-CM |
| 300.81 | Somatization disorder | Diagnosis | ICD-9-CM |
| 300.82 | Undifferentiated somatoform disorder | Diagnosis | ICD-9-CM |
| 300.89 | Other somatoform disorders | Diagnosis | ICD-9-CM |
| 300.9 | Unspecified nonpsychotic mental disorder | Diagnosis | ICD-9-CM |
| 301 | Personality disorders | Diagnosis | ICD-9-CM |
| 301.0 | Paranoid personality disorder | Diagnosis | ICD-9-CM |
| 301.1 | Affective personality disorder | Diagnosis | ICD-9-CM |
| 301.10 | Affective personality disorder, unspecified | Diagnosis | ICD-9-CM |
| 301.11 | Chronic hypomanic personality disorder | Diagnosis | ICD-9-CM |
| 301.12 | Chronic depressive personality disorder | Diagnosis | ICD-9-CM |
| 301.13 | Cyclothymic disorder | Diagnosis | ICD-9-CM |
| 301.2 | Schizoid personality disorder | Diagnosis | ICD-9-CM |
| 301.20 | Schizoid personality disorder, unspecified | Diagnosis | ICD-9-CM |
| 301.21 | Introverted personality | Diagnosis | ICD-9-CM |
| 301.22 | Schizotypal personality disorder | Diagnosis | ICD-9-CM |
| 301.3 | Explosive personality disorder | Diagnosis | ICD-9-CM |
| 301.4 | Obsessive-compulsive personality disorder | Diagnosis | ICD-9-CM |
| 301.5 | Histrionic personality disorder | Diagnosis | ICD-9-CM |
| 301.50 | Histrionic personality disorder, unspecified | Diagnosis | ICD-9-CM |
| 301.51 | Chronic factitious illness with physical symptoms | Diagnosis | ICD-9-CM |
| 301.59 | Other histrionic personality disorder | Diagnosis | ICD-9-CM |
| 301.6 | Dependent personality disorder | Diagnosis | ICD-9-CM |
| 301.7 | Antisocial personality disorder | Diagnosis | ICD-9-CM |
| 301.8 | Other personality disorders | Diagnosis | ICD-9-CM |
| 301.81 | Narcissistic personality disorder | Diagnosis | ICD-9-CM |
| 301.82 | Avoidant personality disorder | Diagnosis | ICD-9-CM |
| 301.83 | Borderline personality disorder | Diagnosis | ICD-9-CM |
| 301.84 | Passive-aggressive personality | Diagnosis | ICD-9-CM |
| 301.89 | Other personality disorder | Diagnosis | ICD-9-CM |
| 301.9 | Unspecified personality disorder | Diagnosis | ICD-9-CM |
| 302 | Sexual and gender identity disorders | Diagnosis | ICD-9-CM |
| 302.0 | Ego-dystonic sexual orientation | Diagnosis | ICD-9-CM |
| 302.1 | Zoophilia | Diagnosis | ICD-9-CM |
| 302.2 | Pedophilia | Diagnosis | ICD-9-CM |
| 302.3 | Transvestic fetishism | Diagnosis | ICD-9-CM |
| 302.4 | Exhibitionism | Diagnosis | ICD-9-CM |
| 302.5 | Trans-sexualism | Diagnosis | ICD-9-CM |
| 302.50 | Trans-sexualism with unspecified sexual history | Diagnosis | ICD-9-CM |
| 302.51 | Trans-sexualism with asexual history | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| 302.52 | Trans-sexualism with homosexual history | Diagnosis | ICD-9-CM |
| 302.53 | Trans-sexualism with heterosexual history | Diagnosis | ICD-9-CM |
| 302.6 | Gender identity disorder in children | Diagnosis | ICD-9-CM |
| 302.7 | Psychosexual dysfunction | Diagnosis | ICD-9-CM |
| 302.70 | Psychosexual dysfunction, unspecified | Diagnosis | ICD-9-CM |
| 302.71 | Hypoactive sexual desire disorder | Diagnosis | ICD-9-CM |
| 302.72 | Psychosexual dysfunction with inhibited sexual excitement | Diagnosis | ICD-9-CM |
| 302.73 | Female orgasmic disorder | Diagnosis | ICD-9-CM |
| 302.74 | Male orgasmic disorder | Diagnosis | ICD-9-CM |
| 302.75 | Premature ejaculation | Diagnosis | ICD-9-CM |
| 302.76 | Dyspareunia, psychogenic | Diagnosis | ICD-9-CM |
| 302.79 | Psychosexual dysfunction with other specified psychosexual dysfunctions | Diagnosis | ICD-9-CM |
| 302.8 | Other specified psychosexual disorders | Diagnosis | ICD-9-CM |
| 302.81 | Fetishism | Diagnosis | ICD-9-CM |
| 302.82 | Voyeurism | Diagnosis | ICD-9-CM |
| 302.83 | Sexual masochism | Diagnosis | ICD-9-CM |
| 302.84 | Sexual sadism | Diagnosis | ICD-9-CM |
| 302.85 | Gender identity disorder in adolescents or adults | Diagnosis | ICD-9-CM |
| 302.89 | Other specified psychosexual disorder | Diagnosis | ICD-9-CM |
| 302.9 | Unspecified psychosexual disorder | Diagnosis | ICD-9-CM |
| 303 | Alcohol dependence syndrome | Diagnosis | ICD-9-CM |
| 303.0 | Acute alcoholic intoxication | Diagnosis | ICD-9-CM |
| 303.00 | Acute alcoholic intoxication, unspecified | Diagnosis | ICD-9-CM |
| 303.01 | Acute alcoholic intoxication, continuous | Diagnosis | ICD-9-CM |
| 303.02 | Acute alcoholic intoxication, episodic | Diagnosis | ICD-9-CM |
| 303.03 | Acute alcoholic intoxication, in remission | Diagnosis | ICD-9-CM |
| 303.9 | Other and unspecified alcohol dependence | Diagnosis | ICD-9-CM |
| 303.90 | Other and unspecified alcohol dependence, unspecified | Diagnosis | ICD-9-CM |
| 303.91 | Other and unspecified alcohol dependence, continuous | Diagnosis | ICD-9-CM |
| 303.92 | Other and unspecified alcohol dependence, episodic | Diagnosis | ICD-9-CM |
| 303.93 | Other and unspecified alcohol dependence, in remission | Diagnosis | ICD-9-CM |
| 304 | Drug dependence | Diagnosis | ICD-9-CM |
| 304.0 | Opioid type dependence | Diagnosis | ICD-9-CM |
| 304.00 | Opioid type dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.01 | Opioid type dependence, continuous | Diagnosis | ICD-9-CM |
| 304.02 | Opioid type dependence, episodic | Diagnosis | ICD-9-CM |
| 304.03 | Opioid type dependence, in remission | Diagnosis | ICD-9-CM |
| 304.1 | Sedative, hypnotic or anxiolytic dependence | Diagnosis | ICD-9-CM |
| 304.10 | Sedative, hypnotic or anxiolytic dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.11 | Sedative, hypnotic or anxiolytic dependence, continuous | Diagnosis | ICD-9-CM |
| 304.12 | Sedative, hypnotic or anxiolytic dependence, episodic | Diagnosis | ICD-9-CM |
| 304.13 | Sedative, hypnotic or anxiolytic dependence, in remission | Diagnosis | ICD-9-CM |
| 304.2 | Cocaine dependence | Diagnosis | ICD-9-CM |
| 304.20 | Cocaine dependence, unspecified | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| 304.21 | Cocaine dependence, continuous | Diagnosis | ICD-9-CM |
| 304.22 | Cocaine dependence, episodic | Diagnosis | ICD-9-CM |
| 304.23 | Cocaine dependence, in remission | Diagnosis | ICD-9-CM |
| 304.3 | Cannabis dependence | Diagnosis | ICD-9-CM |
| 304.30 | Cannabis dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.31 | Cannabis dependence, continuous | Diagnosis | ICD-9-CM |
| 304.32 | Cannabis dependence, episodic | Diagnosis | ICD-9-CM |
| 304.33 | Cannabis dependence, in remission | Diagnosis | ICD-9-CM |
| 304.4 | Amphetamine and other psychostimulant dependence | Diagnosis | ICD-9-CM |
| 304.40 | Amphetamine and other psychostimulant dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.41 | Amphetamine and other psychostimulant dependence, continuous | Diagnosis | ICD-9-CM |
| 304.42 | Amphetamine and other psychostimulant dependence, episodic | Diagnosis | ICD-9-CM |
| 304.43 | Amphetamine and other psychostimulant dependence, in remission | Diagnosis | ICD-9-CM |
| 304.5 | Hallucinogen dependence | Diagnosis | ICD-9-CM |
| 304.50 | Hallucinogen dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.51 | Hallucinogen dependence, continuous | Diagnosis | ICD-9-CM |
| 304.52 | Hallucinogen dependence, episodic | Diagnosis | ICD-9-CM |
| 304.53 | Hallucinogen dependence, in remission | Diagnosis | ICD-9-CM |
| 304.6 | Other specified drug dependence | Diagnosis | ICD-9-CM |
| 304.60 | Other specified drug dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.61 | Other specified drug dependence, continuous | Diagnosis | ICD-9-CM |
| 304.62 | Other specified drug dependence, episodic | Diagnosis | ICD-9-CM |
| 304.63 | Other specified drug dependence, in remission | Diagnosis | ICD-9-CM |
| 304.7 | Combinations of opioid type drug with any other drug dependence | Diagnosis | ICD-9-CM |
| 304.70 | Combinations of opioid type drug with any other drug dependence, | Diagnosis | ICD-9-CM |
| 304.71 | Combinations of opioid type drug with any other drug dependence, | Diagnosis | ICD-9-CM |
| 304.72 | Combinations of opioid type drug with any other drug dependence, episodic | Diagnosis | ICD-9-CM |
| 304.73 | Combinations of opioid type drug with any other drug dependence, in | Diagnosis | ICD-9-CM |
| 304.8 | Combinations of drug dependence excluding opioid type drug | Diagnosis | ICD-9-CM |
| 304.80 | Combinations of drug dependence excluding opioid type drug, unspecified | Diagnosis | ICD-9-CM |
| 304.81 | Combinations of drug dependence excluding opioid type drug, continuous | Diagnosis | ICD-9-CM |
| 304.82 | Combinations of drug dependence excluding opioid type drug, episodic | Diagnosis | ICD-9-CM |
| 304.83 | Combinations of drug dependence excluding opioid type drug, in remission | Diagnosis | ICD-9-CM |
| 304.9 | Unspecified drug dependence | Diagnosis | ICD-9-CM |
| 304.90 | Unspecified drug dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.91 | Unspecified drug dependence, continuous | Diagnosis | ICD-9-CM |
| 304.92 | Unspecified drug dependence, episodic | Diagnosis | ICD-9-CM |
| 304.93 | Unspecified drug dependence, in remission | Diagnosis | ICD-9-CM |
| 305 | Nondependent abuse of drugs | Diagnosis | ICD-9-CM |
| 305.0 | Nondependent alcohol abuse | Diagnosis | ICD-9-CM |
| 305.00 | Nondependent alcohol abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.01 | Nondependent alcohol abuse, continuous | Diagnosis | ICD-9-CM |
| 305.02 | Nondependent alcohol abuse, episodic | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 305.03 | Nondependent alcohol abuse, in remission | Diagnosis | ICD-9-CM |
| 305.1 | Nondependent tobacco use disorder | Diagnosis | ICD-9-CM |
| 305.2 | Nondependent cannabis abuse | Diagnosis | ICD-9-CM |
| 305.20 | Nondependent cannabis abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.21 | Nondependent cannabis abuse, continuous | Diagnosis | ICD-9-CM |
| 305.22 | Nondependent cannabis abuse, episodic | Diagnosis | ICD-9-CM |
| 305.23 | Nondependent cannabis abuse, in remission | Diagnosis | ICD-9-CM |
| 305.3 | Nondependent hallucinogen abuse | Diagnosis | ICD-9-CM |
| 305.30 | Nondependent hallucinogen abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.31 | Nondependent hallucinogen abuse, continuous | Diagnosis | ICD-9-CM |
| 305.32 | Nondependent hallucinogen abuse, episodic | Diagnosis | ICD-9-CM |
| 305.33 | Nondependent hallucinogen abuse, in remission | Diagnosis | ICD-9-CM |
| 305.4 | Nondependent sedative, hypnotic or anxiolytic abuse | Diagnosis | ICD-9-CM |
| 305.40 | Nondependent sedative, hypnotic or anxiolytic abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.41 | Nondependent sedative hypnotic or anxiolytic abuse, continuous | Diagnosis | ICD-9-CM |
| 305.42 | Nondependent sedative, hypnotic or anxiolytic abuse, episodic | Diagnosis | ICD-9-CM |
| 305.43 | Nondependent sedative, hypnotic or anxiolytic abuse, in remission | Diagnosis | ICD-9-CM |
| 305.5 | Nondependent opioid abuse | Diagnosis | ICD-9-CM |
| 305.50 | Nondependent opioid abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.51 | Nondependent opioid abuse, continuous | Diagnosis | ICD-9-CM |
| 305.52 | Nondependent opioid abuse, episodic | Diagnosis | ICD-9-CM |
| 305.53 | Nondependent opioid abuse, in remission | Diagnosis | ICD-9-CM |
| 305.6 | Nondependent cocaine abuse | Diagnosis | ICD-9-CM |
| 305.60 | Nondependent cocaine abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.61 | Nondependent cocaine abuse, continuous | Diagnosis | ICD-9-CM |
| 305.62 | Nondependent cocaine abuse, episodic | Diagnosis | ICD-9-CM |
| 305.63 | Nondependent cocaine abuse, in remission | Diagnosis | ICD-9-CM |
| 305.7 | Nondependent amphetamine or related acting sympathomimetic abuse | Diagnosis | ICD-9-CM |
| 305.70 | Nondependent amphetamine or related acting sympathomimetic abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.71 | Nondependent amphetamine or related acting sympathomimetic abuse, continuous | Diagnosis | ICD-9-CM |
| 305.72 | Nondependent amphetamine or related acting sympathomimetic abuse, episodic | Diagnosis | ICD-9-CM |
| 305.73 | Nondependent amphetamine or related acting sympathomimetic abuse, in remission | Diagnosis | ICD-9-CM |
| 305.8 | Nondependent antidepressant type abuse | Diagnosis | ICD-9-CM |
| 305.80 | Nondependent antidepressant type abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.81 | Nondependent antidepressant type abuse, continuous | Diagnosis | ICD-9-CM |
| 305.82 | Nondependent antidepressant type abuse, episodic | Diagnosis | ICD-9-CM |
| 305.83 | Nondependent antidepressant type abuse, in remission | Diagnosis | ICD-9-CM |
| 305.9 | Other, mixed, or unspecified nondependent drug abuse | Diagnosis | ICD-9-CM |
| 305.90 | Other, mixed, or unspecified nondependent drug abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.91 | Other, mixed, or unspecified nondependent drug abuse, continuous | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 305.92 | Other, mixed, or unspecified nondependent drug abuse, episodic | Diagnosis | ICD-9-CM |
| 305.93 | Other, mixed, or unspecified nondependent drug abuse, in remission | Diagnosis | ICD-9-CM |
| 306 | Physiological malfunction arising from mental factors | Diagnosis | ICD-9-CM |
| 306.0 | Musculoskeletal malfunction arising from mental factors | Diagnosis | ICD-9-CM |
| 306.1 | Respiratory malfunction arising from mental factors | Diagnosis | ICD-9-CM |
| 306.2 | Cardiovascular malfunction arising from mental factors | Diagnosis | ICD-9-CM |
| 306.3 | Skin malfunction arising from mental factors | Diagnosis | ICD-9-CM |
| 306.4 | Gastrointestinal malfunction arising from mental factors | Diagnosis | ICD-9-CM |
| 306.5 | Genitourinary malfunctions arising from mental factors | Diagnosis | ICD-9-CM |
| 306.50 | Psychogenic genitourinary malfunction, unspecified | Diagnosis | ICD-9-CM |
| 306.51 | Psychogenic vaginismus | Diagnosis | ICD-9-CM |
| 306.52 | Psychogenic dysmenorrhea | Diagnosis | ICD-9-CM |
| 306.53 | Psychogenic dysuria | Diagnosis | ICD-9-CM |
| 306.59 | Other genitourinary malfunction arising from mental factors | Diagnosis | ICD-9-CM |
| 306.6 | Endocrine malfunction arising from mental factors | Diagnosis | ICD-9-CM |
| 306.7 | Malfunction of organs of special sense arising from mental factors | Diagnosis | ICD-9-CM |
| 306.8 | Other specified psychophysiological malfunction | Diagnosis | ICD-9-CM |
| 306.9 | Unspecified psychophysiological malfunction | Diagnosis | ICD-9-CM |
| 307 | Special symptoms or syndromes, not elsewhere classified | Diagnosis | ICD-9-CM |
| 307.0 | Adult onset fluency disorder | Diagnosis | ICD-9-CM |
| 307.1 | Anorexia nervosa | Diagnosis | ICD-9-CM |
| 307.2 | Tics | Diagnosis | ICD-9-CM |
| 307.20 | Tic disorder, unspecified | Diagnosis | ICD-9-CM |
| 307.21 | Transient tic disorder | Diagnosis | ICD-9-CM |
| 307.22 | Chronic motor or vocal tic disorder | Diagnosis | ICD-9-CM |
| 307.23 | Tourette's disorder | Diagnosis | ICD-9-CM |
| 307.3 | Stereotypic movement disorder | Diagnosis | ICD-9-CM |
| 307.4 | Specific disorders of sleep of nonorganic origin | Diagnosis | ICD-9-CM |
| 307.40 | Nonorganic sleep disorder, unspecified | Diagnosis | ICD-9-CM |
| 307.41 | Transient disorder of initiating or maintaining sleep | Diagnosis | ICD-9-CM |
| 307.42 | Persistent disorder of initiating or maintaining sleep | Diagnosis | ICD-9-CM |
| 307.43 | Transient disorder of initiating or maintaining wakefulness | Diagnosis | ICD-9-CM |
| 307.44 | Persistent disorder of initiating or maintaining wakefulness | Diagnosis | ICD-9-CM |
| 307.45 | Circadian rhythm sleep disorder of nonorganic origin | Diagnosis | ICD-9-CM |
| 307.46 | Sleep arousal disorder | Diagnosis | ICD-9-CM |
| 307.47 | Other dysfunctions of sleep stages or arousal from sleep | Diagnosis | ICD-9-CM |
| 307.48 | Repetitive intrusions of sleep | Diagnosis | ICD-9-CM |
| 307.49 | Other specific disorder of sleep of nonorganic origin | Diagnosis | ICD-9-CM |
| 307.5 | Other and unspecified disorders of eating | Diagnosis | ICD-9-CM |
| 307.50 | Eating disorder, unspecified | Diagnosis | ICD-9-CM |
| 307.51 | Bulimia nervosa | Diagnosis | ICD-9-CM |
| 307.52 | Pica | Diagnosis | ICD-9-CM |
| 307.53 | Rumination disorder | Diagnosis | ICD-9-CM |
| 307.54 | Psychogenic vomiting | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 307.59 | Other disorder of eating | Diagnosis | ICD-9-CM |
| 307.6 | Enuresis | Diagnosis | ICD-9-CM |
| 307.7 | Encopresis | Diagnosis | ICD-9-CM |
| 307.8 | Pain disorders related to psychological factors | Diagnosis | ICD-9-CM |
| 307.80 | Psychogenic pain, site unspecified | Diagnosis | ICD-9-CM |
| 307.81 | Tension headache | Diagnosis | ICD-9-CM |
| 307.89 | Other pain disorder related to psychological factors | Diagnosis | ICD-9-CM |
| 307.9 | Other and unspecified special symptom or syndrome, not elsewhere classified | Diagnosis | ICD-9-CM |
| 308 | Acute reaction to stress | Diagnosis | ICD-9-CM |
| 308.0 | Predominant disturbance of emotions | Diagnosis | ICD-9-CM |
| 308.1 | Predominant disturbance of consciousness as reaction to stress | Diagnosis | ICD-9-CM |
| 308.2 | Predominant psychomotor disturbance as reaction to stress | Diagnosis | ICD-9-CM |
| 308.3 | Other acute reactions to stress | Diagnosis | ICD-9-CM |
| 308.4 | Mixed disorders as reaction to stress | Diagnosis | ICD-9-CM |
| 308.9 | Unspecified acute reaction to stress | Diagnosis | ICD-9-CM |
| 309.0 | Adjustment disorder with depressed mood | Diagnosis | ICD-9-CM |
| 309.1 | Prolonged depressive reaction as adjustment reaction | Diagnosis | ICD-9-CM |
| 309.2 | Predominant disturbance of other emotions as adjustment reaction | Diagnosis | ICD-9-CM |
| 309.21 | Separation anxiety disorder | Diagnosis | ICD-9-CM |
| 309.22 | Emancipation disorder of adolescence and early adult life | Diagnosis | ICD-9-CM |
| 309.23 | Specific academic or work inhibition as adjustment reaction | Diagnosis | ICD-9-CM |
| 309.24 | Adjustment disorder with anxiety | Diagnosis | ICD-9-CM |
| 309.28 | Adjustment disorder with mixed anxiety and depressed mood | Diagnosis | ICD-9-CM |
| 309.29 | Other adjustment reaction with predominant disturbance of other emotions | Diagnosis | ICD-9-CM |
| 309.3 | Adjustment disorder with disturbance of conduct | Diagnosis | ICD-9-CM |
| 309.4 | Adjustment disorder with mixed disturbance of emotions and conduct | Diagnosis | ICD-9-CM |
| 309.8 | Other specified adjustment reactions | Diagnosis | ICD-9-CM |
| 309.81 | Posttraumatic stress disorder | Diagnosis | ICD-9-CM |
| 309.82 | Adjustment reaction with physical symptoms | Diagnosis | ICD-9-CM |
| 309.83 | Adjustment reaction with withdrawal | Diagnosis | ICD-9-CM |
| 309.89 | Other specified adjustment reaction | Diagnosis | ICD-9-CM |
| 309.9 | Unspecified adjustment reaction | Diagnosis | ICD-9-CM |
| 310 | Specific nonpsychotic mental disorders due to brain damage | Diagnosis | ICD-9-CM |
| 310.0 | Frontal lobe syndrome | Diagnosis | ICD-9-CM |
| 310.1 | Personality change due to conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 310.2 | Postconcussion syndrome | Diagnosis | ICD-9-CM |
| 310.8 | Other specified nonpsychotic mental disorder following organic brain damage | Diagnosis | ICD-9-CM |
| 310.81 | Pseudobulbar affect | Diagnosis | ICD-9-CM |
| 310.89 | Other specified nonpsychotic mental disorders following organic brain damage | Diagnosis | ICD-9-CM |
| 310.9 | Unspecified nonpsychotic mental disorder following organic brain damage | Diagnosis | ICD-9-CM |
| 311 | Depressive disorder, not elsewhere classified | Diagnosis | ICD-9-CM |
| 312 | Disturbance of conduct, not elsewhere classified | Diagnosis | ICD-9-CM |
| 312.0 | Undersocialized conduct disorder, aggressive type | Diagnosis | ICD-9-CM |
| 312.00 | Undersocialized conduct disorder, aggressive type, unspecified | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 312.01 | Undersocialized conduct disorder, aggressive type, mild | Diagnosis | ICD-9-CM |
| 312.02 | Undersocialized conduct disorder, aggressive type, moderate | Diagnosis | ICD-9-CM |
| 312.03 | Undersocialized conduct disorder, aggressive type, severe | Diagnosis | ICD-9-CM |
| 312.1 | Undersocialized conduct disorder, unaggressive type | Diagnosis | ICD-9-CM |
| 312.10 | Undersocialized conduct disorder, unaggressive type, unspecified | Diagnosis | ICD-9-CM |
| 312.11 | Undersocialized conduct disorder, unaggressive type, mild | Diagnosis | ICD-9-CM |
| 312.12 | Undersocialized conduct disorder, unaggressive type, moderate | Diagnosis | ICD-9-CM |
| 312.13 | Undersocialized conduct disorder, unaggressive type, severe | Diagnosis | ICD-9-CM |
| 312.2 | Socialized conduct disorder | Diagnosis | ICD-9-CM |
| 312.20 | Socialized conduct disorder, unspecified | Diagnosis | ICD-9-CM |
| 312.21 | Socialized conduct disorder, mild | Diagnosis | ICD-9-CM |
| 312.22 | Socialized conduct disorder, moderate | Diagnosis | ICD-9-CM |
| 312.23 | Socialized conduct disorder, severe | Diagnosis | ICD-9-CM |
| 312.3 | Disorders of impulse control, not elsewhere classified | Diagnosis | ICD-9-CM |
| 312.30 | Impulse control disorder, unspecified | Diagnosis | ICD-9-CM |
| 312.31 | Pathological gambling | Diagnosis | ICD-9-CM |
| 312.32 | Kleptomania | Diagnosis | ICD-9-CM |
| 312.33 | Pyromania | Diagnosis | ICD-9-CM |
| 312.34 | Intermittent explosive disorder | Diagnosis | ICD-9-CM |
| 312.35 | Isolated explosive disorder | Diagnosis | ICD-9-CM |
| 312.39 | Other disorder of impulse control | Diagnosis | ICD-9-CM |
| 312.4 | Mixed disturbance of conduct and emotions | Diagnosis | ICD-9-CM |
| 312.8 | Other specified disturbances of conduct, not elsewhere classified | Diagnosis | ICD-9-CM |
| 312.81 | Conduct disorder, childhood onset type | Diagnosis | ICD-9-CM |
| 312.82 | Conduct disorder, adolescent onset type | Diagnosis | ICD-9-CM |
| 312.89 | Other specified disturbance of conduct, not elsewhere classified | Diagnosis | ICD-9-CM |
| 312.9 | Unspecified disturbance of conduct | Diagnosis | ICD-9-CM |
| 313 | Disturbance of emotions specific to childhood and adolescence | Diagnosis | ICD-9-CM |
| 313.0 | Overanxious disorder specific to childhood and adolescence | Diagnosis | ICD-9-CM |
| 313.1 | Misery and unhappiness disorder specific to childhood and adolescence | Diagnosis | ICD-9-CM |
| 313.2 | Sensitivity, shyness, and social withdrawal disorder specific to childhood and adolescence | Diagnosis | ICD-9-CM |
| 313.21 | Shyness disorder of childhood | Diagnosis | ICD-9-CM |
| 313.22 | Introverted disorder of childhood | Diagnosis | ICD-9-CM |
| 313.23 | Selective mutism | Diagnosis | ICD-9-CM |
| 313.3 | Relationship problems specific to childhood and adolescence | Diagnosis | ICD-9-CM |
| 313.8 | Other or mixed emotional disturbances of childhood or adolescence | Diagnosis | ICD-9-CM |
| 313.81 | Oppositional defiant disorder | Diagnosis | ICD-9-CM |
| 313.82 | Identity disorder of childhood or adolescence | Diagnosis | ICD-9-CM |
| 313.83 | Academic underachievement disorder of childhood or adolescence | Diagnosis | ICD-9-CM |
| 313.89 | Other emotional disturbance of childhood or adolescence | Diagnosis | ICD-9-CM |
| 313.9 | Unspecified emotional disturbance of childhood or adolescence | Diagnosis | ICD-9-CM |
| 314 | Hyperkinetic syndrome of childhood | Diagnosis | ICD-9-CM |
| 314.0 | Attention deficit disorder of childhood | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 314.00 | Attention deficit disorder of childhood without mention of hyperactivity | Diagnosis | ICD-9-CM |
| 314.01 | Attention deficit disorder of childhood with hyperactivity | Diagnosis | ICD-9-CM |
| 314.1 | Hyperkinesis of childhood with developmental delay | Diagnosis | ICD-9-CM |
| 314.2 | Hyperkinetic conduct disorder of childhood | Diagnosis | ICD-9-CM |
| 314.8 | Other specified manifestations of hyperkinetic syndrome of childhood | Diagnosis | ICD-9-CM |
| 314.9 | Unspecified hyperkinetic syndrome of childhood | Diagnosis | ICD-9-CM |
| 315 | Specific delays in development | Diagnosis | ICD-9-CM |
| 315.0 | Specific developmental reading disorder | Diagnosis | ICD-9-CM |
| 315.00 | Developmental reading disorder, unspecified | Diagnosis | ICD-9-CM |
| 315.01 | Alexia | Diagnosis | ICD-9-CM |
| 315.02 | Developmental dyslexia | Diagnosis | ICD-9-CM |
| 315.09 | Other specific developmental reading disorder | Diagnosis | ICD-9-CM |
| 315.1 | Mathematics disorder | Diagnosis | ICD-9-CM |
| 315.2 | Other specific developmental learning difficulties | Diagnosis | ICD-9-CM |
| 315.3 | Developmental speech or language disorder | Diagnosis | ICD-9-CM |
| 315.31 | Expressive language disorder | Diagnosis | ICD-9-CM |
| 315.32 | Mixed receptive-expressive language disorder | Diagnosis | ICD-9-CM |
| 315.34 | Speech and language developmental delay due to hearing loss | Diagnosis | ICD-9-CM |
| 315.35 | Childhood onset fluency disorder | Diagnosis | ICD-9-CM |
| 315.39 | Other developmental speech or language disorder | Diagnosis | ICD-9-CM |
| 315.4 | Developmental coordination disorder | Diagnosis | ICD-9-CM |
| 315.5 | Mixed development disorder | Diagnosis | ICD-9-CM |
| 315.8 | Other specified delay in development | Diagnosis | ICD-9-CM |
| 315.9 | Unspecified delay in development | Diagnosis | ICD-9-CM |
| 316 | Psychic factors associated with diseases classified elsewhere | Diagnosis | ICD-9-CM |
| 317 | Mild intellectual disabilities | Diagnosis | ICD-9-CM |
| 318.0 | Moderate intellectual disabilities | Diagnosis | ICD-9-CM |
| 318.1 | Severe intellectual disabilities | Diagnosis | ICD-9-CM |
| 318.2 | Profound intellectual disabilities | Diagnosis | ICD-9-CM |
| 319 | Unspecified intellectual disabilities | Diagnosis | ICD-9-CM |
| 327 | Organic sleep disorders | Diagnosis | ICD-9-CM |
| 327.0 | Organic disorders of initiating and maintaining sleep [Organic insomnia] | Diagnosis | ICD-9-CM |
| 327.00 | Organic insomnia, unspecified | Diagnosis | ICD-9-CM |
| 327.01 | Insomnia due to medical condition classified elsewhere | Diagnosis | ICD-9-CM |
| 327.02 | Insomnia due to mental disorder | Diagnosis | ICD-9-CM |
| 327.09 | Other organic insomnia | Diagnosis | ICD-9-CM |
| 327.1 | Organic disorders of excessive somnolence [Organic hypersomnia] | Diagnosis | ICD-9-CM |
| 327.10 | Organic hypersomnia, unspecified | Diagnosis | ICD-9-CM |
| 327.11 | Idiopathic hypersomnia with long sleep time | Diagnosis | ICD-9-CM |
| 327.12 | Idiopathic hypersomnia without long sleep time | Diagnosis | ICD-9-CM |
| 327.13 | Recurrent hypersomnia | Diagnosis | ICD-9-CM |
| 327.14 | Hypersomnia due to medical condition classified elsewhere | Diagnosis | ICD-9-CM |
| 327.15 | Hypersomnia due to mental disorder | Diagnosis | ICD-9-CM |
| 327.19 | Other organic hypersomnia | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 327.2 | Organic sleep apnea | Diagnosis | ICD-9-CM |
| 327.20 | Organic sleep apnea, unspecified | Diagnosis | ICD-9-CM |
| 327.21 | Primary central sleep apnea | Diagnosis | ICD-9-CM |
| 327.23 | Obstructive sleep apnea (adult) (pediatric) | Diagnosis | ICD-9-CM |
| 327.24 | Idiopathic sleep related nonobstructive alveolar hypoventilation | Diagnosis | ICD-9-CM |
| 327.25 | Congenital central alveolar hypoventilation syndrome | Diagnosis | ICD-9-CM |
| 327.26 | Sleep related hypoventilation/hypoxemia in conditions classifiable elsewhere | Diagnosis | ICD-9-CM |
| 327.27 | Central sleep apnea in conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 327.29 | Other organic sleep apnea | Diagnosis | ICD-9-CM |
| 327.3 | Circadian rhythm sleep disorder | Diagnosis | ICD-9-CM |
| 327.30 | Circadian rhythm sleep disorder, unspecified | Diagnosis | ICD-9-CM |
| 327.31 | Circadian rhythm sleep disorder, delayed sleep phase type | Diagnosis | ICD-9-CM |
| 327.32 | Circadian rhythm sleep disorder, advanced sleep phase type | Diagnosis | ICD-9-CM |
| 327.33 | Circadian rhythm sleep disorder, irregular sleep-wake type | Diagnosis | ICD-9-CM |
| 327.34 | Circadian rhythm sleep disorder, free-running type | Diagnosis | ICD-9-CM |
| 327.35 | Circadian rhythm sleep disorder, jet lag type | Diagnosis | ICD-9-CM |
| 327.36 | Circadian rhythm sleep disorder, shift work type | Diagnosis | ICD-9-CM |
| 327.37 | Circadian rhythm sleep disorder in conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 327.39 | Other circadian rhythm sleep disorder | Diagnosis | ICD-9-CM |
| 327.4 | Organic parasomnia | Diagnosis | ICD-9-CM |
| 327.40 | Organic parasomnia, unspecified | Diagnosis | ICD-9-CM |
| 327.41 | Confusional arousals | Diagnosis | ICD-9-CM |
| 327.42 | REM sleep behavior disorder | Diagnosis | ICD-9-CM |
| 327.43 | Recurrent isolated sleep paralysis | Diagnosis | ICD-9-CM |
| 327.44 | Parasomnia in conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 327.49 | Other organic parasomnia | Diagnosis | ICD-9-CM |
| 327.5 | Organic sleep related movement disorders | Diagnosis | ICD-9-CM |
| 327.51 | Periodic limb movement disorder | Diagnosis | ICD-9-CM |
| 327.52 | Sleep related leg cramps | Diagnosis | ICD-9-CM |
| 327.53 | Sleep related bruxism | Diagnosis | ICD-9-CM |
| 327.59 | Other organic sleep related movement disorders | Diagnosis | ICD-9-CM |
| 327.8 | Other organic sleep disorders | Diagnosis | ICD-9-CM |
| 330 | Cerebral degenerations usually manifest in childhood | Diagnosis | ICD-9-CM |
| 330.0 | Leukodystrophy | Diagnosis | ICD-9-CM |
| 330.1 | Cerebral lipidoses | Diagnosis | ICD-9-CM |
| 330.2 | Cerebral degeneration in generalized lipidoses | Diagnosis | ICD-9-CM |
| 330.3 | Cerebral degeneration of childhood in other diseases classified elsewhere | Diagnosis | ICD-9-CM |
| 330.8 | Other specified cerebral degenerations in childhood | Diagnosis | ICD-9-CM |
| 330.9 | Unspecified cerebral degeneration in childhood | Diagnosis | ICD-9-CM |
| 331 | Other cerebral degenerations | Diagnosis | ICD-9-CM |
| 331.0 | Alzheimer's disease | Diagnosis | ICD-9-CM |
| 331.1 | Frontotemporal dementia | Diagnosis | ICD-9-CM |
| 331.11 | Pick's disease | Diagnosis | ICD-9-CM |
| 331.19 | Other frontotemporal dementia | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| 331.2 | Senile degeneration of brain | Diagnosis | ICD-9-CM |
| 331.3 | Communicating hydrocephalus | Diagnosis | ICD-9-CM |
| 331.4 | Obstructive hydrocephalus | Diagnosis | ICD-9-CM |
| 331.5 | Idiopathic normal pressure hydrocephalus [INPH] | Diagnosis | ICD-9-CM |
| 331.6 | Corticobasal degeneration | Diagnosis | ICD-9-CM |
| 331.7 | Cerebral degeneration in diseases classified elsewhere | Diagnosis | ICD-9-CM |
| 331.8 | Other cerebral degeneration | Diagnosis | ICD-9-CM |
| 331.81 | Reye's syndrome | Diagnosis | ICD-9-CM |
| 331.82 | Dementia with Lewy bodies | Diagnosis | ICD-9-CM |
| 331.83 | Mild cognitive impairment, so stated | Diagnosis | ICD-9-CM |
| 331.89 | Other cerebral degeneration | Diagnosis | ICD-9-CM |
| 331.9 | Unspecified cerebral degeneration | Diagnosis | ICD-9-CM |
| 333.99 | Other extrapyramidal disease and abnormal movement disorder | Diagnosis | ICD-9-CM |
| 347 | Cataplexy and narcolepsy | Diagnosis | ICD-9-CM |
| 347.0 | Narcolepsy | Diagnosis | ICD-9-CM |
| 347.00 | Narcolepsy, without cataplexy | Diagnosis | ICD-9-CM |
| 347.01 | Narcolepsy, with cataplexy | Diagnosis | ICD-9-CM |
| 347.1 | Narcolepsy in conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 347.10 | Narcolepsy in conditions classified elsewhere, without cataplexy | Diagnosis | ICD-9-CM |
| 347.11 | Narcolepsy in conditions classified elsewhere, with cataplexy | Diagnosis | ICD-9-CM |
| 348.3 | Encephalopathy, not elsewhere classified | Diagnosis | ICD-9-CM |
| 348.30 | Encephalopathy, unspecified | Diagnosis | ICD-9-CM |
| 348.31 | Metabolic encephalopathy | Diagnosis | ICD-9-CM |
| 348.39 | Other encephalopathy | Diagnosis | ICD-9-CM |
| 357.5 | Alcoholic polyneuropathy | Diagnosis | ICD-9-CM |
| 425.5 | Alcoholic cardiomyopathy | Diagnosis | ICD-9-CM |
| 4320F | Patient counseled regarding psychosocial and pharmacologic treatment options for alcohol dependence (SUD) | Procedure | CPT-2 |
| 535.3 | Alcoholic gastritis | Diagnosis | ICD-9-CM |
| 535.30 | Alcoholic gastritis without mention of hemorrhage | Diagnosis | ICD-9-CM |
| 535.31 | Alcoholic gastritis with hemorrhage | Diagnosis | ICD-9-CM |
| 571.0 | Alcoholic fatty liver | Diagnosis | ICD-9-CM |
| 571.1 | Acute alcoholic hepatitis | Diagnosis | ICD-9-CM |
| 571.2 | Alcoholic cirrhosis of liver | Diagnosis | ICD-9-CM |
| 571.3 | Unspecified alcoholic liver damage | Diagnosis | ICD-9-CM |
| 61885 | Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to a single electrode | Procedure | CPT-4 |
| 61886 | Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to 2 or more electrode | Procedure | CPT-4 |
| 61888 | Revision or removal of cranial neurostimulator pulse generator or receiver | Procedure | CPT-4 |
| 625.4 | Premenstrual tension syndromes | Diagnosis | ICD-9-CM |
| 64553 | Percutaneous implantation of neurostimulator electrode array; cranial nerve | Procedure | CPT-4 |
| 64568 | Open implantation of cranial nerve (eg, vagus nerve) neurostimulator electrode array and pulse generator | Procedure | CPT-4 |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 64569 | Revision or replacement of cranial nerve (eg, vagus nerve) neurostimulator electrode array, including connection to existing pulse generator | Procedure | CPT-4 |
| 64570 | Removal of cranial nerve (eg, vagus nerve) neurostimulator electrode array and pulse generator | Procedure | CPT-4 |
| 64585 | Revision or removal of peripheral neurostimulator electrode array | Procedure | CPT-4 |
| 648.30 | Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, unspecified as to episode of care | Diagnosis | ICD-9-CM |
| 648.31 | Maternal drug dependence, with delivery | Diagnosis | ICD-9-CM |
| 648.32 | Maternal drug dependence, with delivery, with current postpartum complication | Diagnosis | ICD-9-CM |
| 648.33 | Maternal drug dependence, antepartum | Diagnosis | ICD-9-CM |
| 648.34 | Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, postpartum condition or complication | Diagnosis | ICD-9-CM |
| 648.40 | Maternal mental disorders, complicating pregnancy, childbirth, or the puerperium, unspecified as to episode of care | Diagnosis | ICD-9-CM |
| 648.41 | Maternal mental disorders, with delivery | Diagnosis | ICD-9-CM |
| 648.42 | Maternal mental disorders, with delivery, with current postpartum complication | Diagnosis | ICD-9-CM |
| 648.43 | Maternal mental disorders, antepartum | Diagnosis | ICD-9-CM |
| 648.44 | Maternal mental disorders complicating pregnancy, childbirth, or the puerperium, postpartum condition or complication | Diagnosis | ICD-9-CM |
| 655.50 | Suspected damage to fetus from drugs, affecting management of mother, unspecified as to episode of care | Diagnosis | ICD-9-CM |
| 655.51 | Suspected damage to fetus from drugs, affecting management of mother, delivered | Diagnosis | ICD-9-CM |
| 655.53 | Suspected damage to fetus from drugs, affecting management of mother, antepartum | Diagnosis | ICD-9-CM |
| 760.71 | Noxious influences affecting fetus or newborn via placenta or breast milk, alcohol | Diagnosis | ICD-9-CM |
| 760.72 | Noxious influences affecting fetus or newborn via placenta or breast milk, narcotics | Diagnosis | ICD-9-CM |
| 760.73 | Noxious influences affecting fetus or newborn via placenta or breast milk, hallucinogenic agents | Diagnosis | ICD-9-CM |
| 760.75 | Noxious influences affecting fetus or newborn via placenta or breast milk, cocaine | Diagnosis | ICD-9-CM |
| 779.5 | Drug withdrawal syndrome in newborn | Diagnosis | ICD-9-CM |
| 780.1 | Hallucinations | Diagnosis | ICD-9-CM |
| 780.5 | Sleep disturbances | Diagnosis | ICD-9-CM |
| 780.50 | Unspecified sleep disturbance | Diagnosis | ICD-9-CM |
| 780.51 | Insomnia with sleep apnea, unspecified | Diagnosis | ICD-9-CM |
| 780.52 | Insomnia, unspecified | Diagnosis | ICD-9-CM |
| 780.53 | Hypersomnia with sleep apnea, unspecified | Diagnosis | ICD-9-CM |
| 780.54 | Hypersomnia, unspecified | Diagnosis | ICD-9-CM |
| 780.55 | Disruption of 24 hour sleep wake cycle, unspecified | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|---|---------------|------------|
| 780.56 | Dysfunctions associated with sleep stages or arousal from sleep | Diagnosis | ICD-9-CM |
| 780.57 | Unspecified sleep apnea | Diagnosis | ICD-9-CM |
| 780.58 | Sleep related movement disorder, unspecified | Diagnosis | ICD-9-CM |
| 780.59 | Other sleep disturbances | Diagnosis | ICD-9-CM |
| 881 | Open wound of elbow, forearm, and wrist | Diagnosis | ICD-9-CM |
| 8E0ZXY5 | Meditation | Procedure | ICD-10-PCS |
| 90810 | Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an office or outpatient facility, approximately 20 to 30 minutes face-to-face with the patient; | Procedure | CPT-4 |
| 90811 | Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an office or outpatient facility, approximately 20 to 30 minutes face-to-face with the patient; with medical evaluation and management services | Procedure | CPT-4 |
| 90812 | Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an office or outpatient facility, approximately 45 to 50 minutes face-to-face with the patient; | Procedure | CPT-4 |
| 90813 | Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an office or outpatient facility, approximately 45 to 50 minutes face-to-face with the patient; with medical evaluation and management services | Procedure | CPT-4 |
| 90814 | Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an office or outpatient facility, approximately 75 to 80 minutes face-to-face with the patient; | Procedure | CPT-4 |
| 90815 | Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an office or outpatient facility, approximately 75 to 80 minutes face-to-face with the patient; with medical evaluation and management services | Procedure | CPT-4 |
| 90823 | Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an inpatient hospital, partial hospital or residential care setting, approximately 20 to 30 minutes face-to-face with the patient; | Procedure | CPT-4 |
| 90824 | Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an inpatient hospital, partial hospital or residential care setting, approximately 20 to 30 minutes face-to-face with the patient; with medical evaluation and management services | Procedure | CPT-4 |
| 90826 | Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an inpatient hospital, partial hospital or residential care setting, approximately 45 to 50 minutes face-to-face with the patient; | Procedure | CPT-4 |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|-------|---|---------------|-----------|
| 90827 | Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an inpatient hospital, partial hospital or residential care setting, approximately 45 to 50 minutes face-to-face with the patient; with medical evaluation and management services | Procedure | CPT-4 |
| 90828 | Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an inpatient hospital, partial hospital or residential care setting, approximately 75 to 80 minutes face-to-face with the patient; | Procedure | CPT-4 |
| 90829 | Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an inpatient hospital, partial hospital or residential care setting, approximately 75 to 80 minutes face-to-face with the patient; with medical evaluation and management services | Procedure | CPT-4 |
| 90832 | Psychotherapy, 30 minutes with patient | Procedure | CPT-4 |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an evaluation and management service (List separately in addition to the code for primary procedure) | Procedure | CPT-4 |
| 90834 | Psychotherapy, 45 minutes with patient | Procedure | CPT-4 |
| 90836 | Psychotherapy, 45 minutes with patient when performed with an evaluation and management service (List separately in addition to the code for primary procedure) | Procedure | CPT-4 |
| 90837 | Psychotherapy, 60 minutes with patient | Procedure | CPT-4 |
| 90838 | Psychotherapy, 60 minutes with patient when performed with an evaluation and management service (List separately in addition to the code for primary procedure) | Procedure | CPT-4 |
| 90839 | Psychotherapy for crisis; first 60 minutes | Procedure | CPT-4 |
| 90840 | Psychotherapy for crisis; each additional 30 minutes (List separately in addition to code for primary service) | Procedure | CPT-4 |
| 90845 | Psychoanalysis | Procedure | CPT-4 |
| 90853 | Group psychotherapy (other than of a multiple-family group) | Procedure | CPT-4 |
| 90857 | Interactive group psychotherapy | Procedure | CPT-4 |
| 90867 | Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; initial, including cortical mapping, motor threshold determination, delivery and management | Procedure | CPT-4 |
| 90868 | Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent delivery and management, per session | Procedure | CPT-4 |
| 90869 | Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent motor threshold re-determination with delivery and management | Procedure | CPT-4 |
| 90870 | Electroconvulsive therapy (includes necessary monitoring) | Procedure | CPT-4 |
| 90871 | Electroconvulsive therapy (includes necessary monitoring); multiple seizures, per day | Procedure | CPT-4 |
| 94.31 | Psychoanalysis | Procedure | ICD-9-CM |
| 94.32 | Hypnotherapy | Procedure | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|-------|---|---------------|-----------|
| 94.33 | Behavior therapy | Procedure | ICD-9-CM |
| 94.35 | Crisis intervention | Procedure | ICD-9-CM |
| 94.36 | Play psychotherapy | Procedure | ICD-9-CM |
| 94.37 | Exploratory verbal psychotherapy | Procedure | ICD-9-CM |
| 94.38 | Supportive verbal psychotherapy | Procedure | ICD-9-CM |
| 94.39 | Other individual psychotherapy | Procedure | ICD-9-CM |
| 94.43 | Psychodrama | Procedure | ICD-9-CM |
| 94.44 | Other group therapy | Procedure | ICD-9-CM |
| 94.46 | Alcoholism counseling | Procedure | ICD-9-CM |
| 94.53 | Referral for alcoholism rehabilitation | Procedure | ICD-9-CM |
| 94.6 | Alcohol and drug rehabilitation and detoxification | Procedure | ICD-9-CM |
| 94.61 | Alcohol rehabilitation | Procedure | ICD-9-CM |
| 94.62 | Alcohol detoxification | Procedure | ICD-9-CM |
| 94.63 | Alcohol rehabilitation and detoxification | Procedure | ICD-9-CM |
| 94.67 | Combined alcohol and drug rehabilitation | Procedure | ICD-9-CM |
| 94.68 | Combined alcohol and drug detoxification | Procedure | ICD-9-CM |
| 94.69 | Combined alcohol and drug rehabilitation and detoxification | Procedure | ICD-9-CM |
| 95970 | Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain, cranial nerve, spinal cord, peripheral nerve, or sacral nerve, neurostimulator pulse generator/transmitter, without | Procedure | CPT-4 |
| 95971 | Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with simple spinal cord or peripheral nerve (eg, sacral nerve) neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional | Procedure | CPT-4 |
| 95974 | Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); complex cranial nerve neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming, with or without nerve interface testing, first hour | Procedure | CPT-4 |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|-------|--|---------------|-----------|
| 95975 | Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); complex cranial nerve neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming, each additional 30 minutes after first hour (List separately in addition to code for primary procedure) | Procedure | CPT-4 |
| 960 | Poisoning by antibiotics | Diagnosis | ICD-9-CM |
| 960.0 | Poisoning by penicillins | Diagnosis | ICD-9-CM |
| 960.1 | Poisoning by antifungal antibiotics | Diagnosis | ICD-9-CM |
| 960.2 | Poisoning by chloramphenicol group | Diagnosis | ICD-9-CM |
| 960.3 | Poisoning by erythromycin and other macrolides | Diagnosis | ICD-9-CM |
| 960.4 | Poisoning by tetracycline group | Diagnosis | ICD-9-CM |
| 960.5 | Poisoning of cephalosporin group | Diagnosis | ICD-9-CM |
| 960.6 | Poisoning of antimycobacterial antibiotics | Diagnosis | ICD-9-CM |
| 960.7 | Poisoning by antineoplastic antibiotics | Diagnosis | ICD-9-CM |
| 960.8 | Poisoning by other specified antibiotics | Diagnosis | ICD-9-CM |
| 960.9 | Poisoning by unspecified antibiotic | Diagnosis | ICD-9-CM |
| 961 | Poisoning by other anti-infectives | Diagnosis | ICD-9-CM |
| 961.0 | Poisoning by sulfonamides | Diagnosis | ICD-9-CM |
| 961.1 | Poisoning by arsenical anti-infectives | Diagnosis | ICD-9-CM |
| 961.2 | Poisoning by heavy metal anti-infectives | Diagnosis | ICD-9-CM |
| 961.3 | Poisoning by quinoline and hydroxyquinoline derivatives | Diagnosis | ICD-9-CM |
| 961.4 | Poisoning by antimalarials and drugs acting on other blood protozoa | Diagnosis | ICD-9-CM |
| 961.5 | Poisoning by other antiprotozoal drugs | Diagnosis | ICD-9-CM |
| 961.6 | Poisoning by anthelmintics | Diagnosis | ICD-9-CM |
| 961.7 | Poisoning by antiviral drugs | Diagnosis | ICD-9-CM |
| 961.8 | Poisoning by other antimycobacterial drugs | Diagnosis | ICD-9-CM |
| 961.9 | Poisoning by other and unspecified anti-infectives | Diagnosis | ICD-9-CM |
| 962 | Poisoning by hormones and synthetic substitutes | Diagnosis | ICD-9-CM |
| 962.0 | Poisoning by adrenal cortical steroids | Diagnosis | ICD-9-CM |
| 962.1 | Poisoning by androgens and anabolic congeners | Diagnosis | ICD-9-CM |
| 962.2 | Poisoning by ovarian hormones and synthetic substitutes | Diagnosis | ICD-9-CM |
| 962.3 | Poisoning by insulins and antidiabetic agents | Diagnosis | ICD-9-CM |
| 962.4 | Poisoning by anterior pituitary hormones | Diagnosis | ICD-9-CM |
| 962.5 | Poisoning by posterior pituitary hormones | Diagnosis | ICD-9-CM |
| 962.6 | Poisoning by parathyroid and parathyroid derivatives | Diagnosis | ICD-9-CM |
| 962.7 | Poisoning by thyroid and thyroid derivatives | Diagnosis | ICD-9-CM |
| 962.8 | Poisoning by antithyroid agents | Diagnosis | ICD-9-CM |
| 962.9 | Poisoning by other and unspecified hormones and synthetic substitutes | Diagnosis | ICD-9-CM |
| 963 | Poisoning by primarily systemic agents | Diagnosis | ICD-9-CM |
| 963.0 | Poisoning by antiallergic and antiemetic drugs | Diagnosis | ICD-9-CM |
| 963.1 | Poisoning by antineoplastic and immunosuppressive drugs | Diagnosis | ICD-9-CM |
| 963.2 | Poisoning by acidifying agents | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 963.3 | Poisoning by alkalizing agents | Diagnosis | ICD-9-CM |
| 963.4 | Poisoning by enzymes, not elsewhere classified | Diagnosis | ICD-9-CM |
| 963.5 | Poisoning by vitamins, not elsewhere classified | Diagnosis | ICD-9-CM |
| 963.8 | Poisoning by other specified systemic agents | Diagnosis | ICD-9-CM |
| 963.9 | Poisoning by unspecified systemic agent | Diagnosis | ICD-9-CM |
| 964 | Poisoning by agents primarily affecting blood constituents | Diagnosis | ICD-9-CM |
| 964.0 | Poisoning by iron and its compounds | Diagnosis | ICD-9-CM |
| 964.1 | Poisoning by liver preparations and other antianemic agents | Diagnosis | ICD-9-CM |
| 964.2 | Poisoning by anticoagulants | Diagnosis | ICD-9-CM |
| 964.3 | Poisoning by vitamin K (phytonadione) | Diagnosis | ICD-9-CM |
| 964.4 | Poisoning by fibrinolysis-affecting drugs | Diagnosis | ICD-9-CM |
| 964.5 | Poisoning by anticoagulant antagonists and other coagulants | Diagnosis | ICD-9-CM |
| 964.6 | Poisoning by gamma globulin | Diagnosis | ICD-9-CM |
| 964.7 | Poisoning by natural blood and blood products | Diagnosis | ICD-9-CM |
| 964.8 | Poisoning by other specified agents affecting blood constituents | Diagnosis | ICD-9-CM |
| 964.9 | Poisoning by unspecified agent affecting blood constituents | Diagnosis | ICD-9-CM |
| 965 | Poisoning by analgesics, antipyretics, and antirheumatics | Diagnosis | ICD-9-CM |
| 965.0 | Poisoning by opiates and related narcotics | Diagnosis | ICD-9-CM |
| 965.00 | Poisoning by opium (alkaloids), unspecified | Diagnosis | ICD-9-CM |
| 965.01 | Poisoning by heroin | Diagnosis | ICD-9-CM |
| 965.02 | Poisoning by methadone | Diagnosis | ICD-9-CM |
| 965.09 | Poisoning by opiates and related narcotics, other | Diagnosis | ICD-9-CM |
| 965.1 | Poisoning by salicylates | Diagnosis | ICD-9-CM |
| 965.4 | Poisoning by aromatic analgesics, not elsewhere classified | Diagnosis | ICD-9-CM |
| 965.5 | Poisoning by pyrazole derivatives | Diagnosis | ICD-9-CM |
| 965.6 | Poisoning by antirheumatics (antiphlogistics) | Diagnosis | ICD-9-CM |
| 965.61 | Poisoning by propionic acid derivatives | Diagnosis | ICD-9-CM |
| 965.69 | Poisoning by other antirheumatics | Diagnosis | ICD-9-CM |
| 965.7 | Poisoning by other non-narcotic analgesics | Diagnosis | ICD-9-CM |
| 965.8 | Poisoning by other specified analgesics and antipyretics | Diagnosis | ICD-9-CM |
| 965.9 | Poisoning by unspecified analgesic and antipyretic | Diagnosis | ICD-9-CM |
| 966 | Poisoning by anticonvulsants and anti-Parkinsonism drugs | Diagnosis | ICD-9-CM |
| 966.0 | Poisoning by oxazolidine derivatives | Diagnosis | ICD-9-CM |
| 966.1 | Poisoning by hydantoin derivatives | Diagnosis | ICD-9-CM |
| 966.2 | Poisoning by succinimides | Diagnosis | ICD-9-CM |
| 966.3 | Poisoning by other and unspecified anticonvulsants | Diagnosis | ICD-9-CM |
| 966.4 | Poisoning by anti-Parkinsonism drugs | Diagnosis | ICD-9-CM |
| 967 | Poisoning by sedatives and hypnotics | Diagnosis | ICD-9-CM |
| 967.0 | Poisoning by barbiturates | Diagnosis | ICD-9-CM |
| 967.1 | Poisoning by chloral hydrate group | Diagnosis | ICD-9-CM |
| 967.2 | Poisoning by paraldehyde | Diagnosis | ICD-9-CM |
| 967.3 | Poisoning by bromine compounds | Diagnosis | ICD-9-CM |
| 967.4 | Poisoning by methaqualone compounds | Diagnosis | ICD-9-CM |
| 967.5 | Poisoning by glutethimide group | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| 967.6 | Poisoning by mixed sedatives, not elsewhere classified | Diagnosis | ICD-9-CM |
| 967.8 | Poisoning by other sedatives and hypnotics | Diagnosis | ICD-9-CM |
| 967.9 | Poisoning by unspecified sedative or hypnotic | Diagnosis | ICD-9-CM |
| 968 | Poisoning by other central nervous system depressants and anesthetics | Diagnosis | ICD-9-CM |
| 968.0 | Poisoning by central nervous system muscle-tone depressants | Diagnosis | ICD-9-CM |
| 968.1 | Poisoning by halothane | Diagnosis | ICD-9-CM |
| 968.2 | Poisoning by other gaseous anesthetics | Diagnosis | ICD-9-CM |
| 968.3 | Poisoning by intravenous anesthetics | Diagnosis | ICD-9-CM |
| 968.4 | Poisoning by other and unspecified general anesthetics | Diagnosis | ICD-9-CM |
| 968.5 | Poisoning by other central nervous system depressants and anesthetics, Surface (topical) and infiltration anesthetics | Diagnosis | ICD-9-CM |
| 968.6 | Poisoning by peripheral nerve- and plexus-blocking anesthetics | Diagnosis | ICD-9-CM |
| 968.7 | Poisoning by spinal anesthetics | Diagnosis | ICD-9-CM |
| 968.9 | Poisoning by other and unspecified local anesthetics | Diagnosis | ICD-9-CM |
| 969 | Poisoning by psychotropic agents | Diagnosis | ICD-9-CM |
| 969.0 | Poisoning by antidepressants | Diagnosis | ICD-9-CM |
| 969.00 | Poisoning by antidepressant, unspecified | Diagnosis | ICD-9-CM |
| 969.01 | Poisoning by monoamine oxidase inhibitors | Diagnosis | ICD-9-CM |
| 969.02 | Poisoning by selective serotonin and norepinephrine reuptake inhibitors | Diagnosis | ICD-9-CM |
| 969.03 | Poisoning by selective serotonin reuptake inhibitors | Diagnosis | ICD-9-CM |
| 969.04 | Poisoning by tetracyclic antidepressants | Diagnosis | ICD-9-CM |
| 969.05 | Poisoning by tricyclic antidepressants | Diagnosis | ICD-9-CM |
| 969.09 | Poisoning by other antidepressants | Diagnosis | ICD-9-CM |
| 969.1 | Poisoning by phenothiazine-based tranquilizers | Diagnosis | ICD-9-CM |
| 969.2 | Poisoning by butyrophenone-based tranquilizers | Diagnosis | ICD-9-CM |
| 969.3 | Poisoning by other antipsychotics, neuroleptics, and major tranquilizers | Diagnosis | ICD-9-CM |
| 969.4 | Poisoning by benzodiazepine-based tranquilizers | Diagnosis | ICD-9-CM |
| 969.5 | Poisoning by other tranquilizers | Diagnosis | ICD-9-CM |
| 969.6 | Poisoning by psychodysleptics (hallucinogens) | Diagnosis | ICD-9-CM |
| 969.7 | Poisoning by psychostimulants | Diagnosis | ICD-9-CM |
| 969.70 | Poisoning by psychostimulant, unspecified | Diagnosis | ICD-9-CM |
| 969.71 | Poisoning by caffeine | Diagnosis | ICD-9-CM |
| 969.72 | Poisoning by amphetamines | Diagnosis | ICD-9-CM |
| 969.73 | Poisoning by methylphenidate | Diagnosis | ICD-9-CM |
| 969.79 | Poisoning by other psychostimulants | Diagnosis | ICD-9-CM |
| 969.8 | Poisoning by other specified psychotropic agents | Diagnosis | ICD-9-CM |
| 969.9 | Poisoning by unspecified psychotropic agent | Diagnosis | ICD-9-CM |
| 970 | Poisoning by central nervous system stimulants | Diagnosis | ICD-9-CM |
| 970.0 | Poisoning by analeptics | Diagnosis | ICD-9-CM |
| 970.1 | Poisoning by opiate antagonists | Diagnosis | ICD-9-CM |
| 970.8 | Poisoning by other specified central nervous system stimulants | Diagnosis | ICD-9-CM |
| 970.9 | Poisoning by unspecified central nervous system stimulant | Diagnosis | ICD-9-CM |
| 971 | Poisoning by drugs primarily affecting the autonomic nervous system | Diagnosis | ICD-9-CM |
| 971.0 | Poisoning by parasympathomimetics (cholinergics) | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|-------|--|---------------|-----------|
| 971.1 | Poisoning by parasympatholytics (anticholinergics and antimuscarinics) and spasmolytics | Diagnosis | ICD-9-CM |
| 971.2 | Poisoning by sympathomimetics (adrenergics) | Diagnosis | ICD-9-CM |
| 971.3 | Poisoning by sympatholytics (antiadrenergics) | Diagnosis | ICD-9-CM |
| 971.9 | Poisoning by unspecified drug primarily affecting autonomic nervous system | Diagnosis | ICD-9-CM |
| 972 | Poisoning by agents primarily affecting the cardiovascular system | Diagnosis | ICD-9-CM |
| 972.0 | Poisoning by cardiac rhythm regulators | Diagnosis | ICD-9-CM |
| 972.1 | Poisoning by cardiotonic glycosides and drugs of similar action | Diagnosis | ICD-9-CM |
| 972.2 | Poisoning by antilipemic and antiarteriosclerotic drugs | Diagnosis | ICD-9-CM |
| 972.3 | Poisoning by ganglion-blocking agents | Diagnosis | ICD-9-CM |
| 972.4 | Poisoning by coronary vasodilators | Diagnosis | ICD-9-CM |
| 972.5 | Poisoning by other vasodilators | Diagnosis | ICD-9-CM |
| 972.6 | Poisoning by other antihypertensive agents | Diagnosis | ICD-9-CM |
| 972.7 | Poisoning by antivaricose drugs, including sclerosing agents | Diagnosis | ICD-9-CM |
| 972.8 | Poisoning by capillary-active drugs | Diagnosis | ICD-9-CM |
| 972.9 | Poisoning by other and unspecified agents primarily affecting the cardiovascular system | Diagnosis | ICD-9-CM |
| 973 | Poisoning by agents primarily affecting the gastrointestinal system | Diagnosis | ICD-9-CM |
| 973.0 | Poisoning by antacids and antigastric secretion drugs | Diagnosis | ICD-9-CM |
| 973.1 | Poisoning by irritant cathartics | Diagnosis | ICD-9-CM |
| 973.2 | Poisoning by emollient cathartics | Diagnosis | ICD-9-CM |
| 973.3 | Poisoning by other cathartics, including intestinal atonia drugs | Diagnosis | ICD-9-CM |
| 973.4 | Poisoning by digestants | Diagnosis | ICD-9-CM |
| 973.5 | Poisoning by antidiarrheal drugs | Diagnosis | ICD-9-CM |
| 973.6 | Poisoning by emetics | Diagnosis | ICD-9-CM |
| 973.8 | Poisoning by other specified agents primarily affecting the gastrointestinal system | Diagnosis | ICD-9-CM |
| 973.9 | Poisoning by unspecified agent primarily affecting the gastrointestinal system | Diagnosis | ICD-9-CM |
| 974 | Poisoning by water, mineral, and uric acid metabolism drugs | Diagnosis | ICD-9-CM |
| 974.0 | Poisoning by mercurial diuretics | Diagnosis | ICD-9-CM |
| 974.1 | Poisoning by purine derivative diuretics | Diagnosis | ICD-9-CM |
| 974.2 | Poisoning by carbonic acid anhydrase inhibitors | Diagnosis | ICD-9-CM |
| 974.3 | Poisoning by saluretics | Diagnosis | ICD-9-CM |
| 974.4 | Poisoning by other diuretics | Diagnosis | ICD-9-CM |
| 974.5 | Poisoning by electrolytic, caloric, and water-balance agents | Diagnosis | ICD-9-CM |
| 974.6 | Poisoning by other mineral salts, not elsewhere classified | Diagnosis | ICD-9-CM |
| 974.7 | Poisoning by uric acid metabolism drugs | Diagnosis | ICD-9-CM |
| 975 | Poisoning by agents primarily acting on the smooth and skeletal muscles and respiratory system | Diagnosis | ICD-9-CM |
| 975.0 | Poisoning by oxytocic agents | Diagnosis | ICD-9-CM |
| 975.1 | Poisoning by smooth muscle relaxants | Diagnosis | ICD-9-CM |
| 975.2 | Poisoning by skeletal muscle relaxants | Diagnosis | ICD-9-CM |
| 975.3 | Poisoning by other and unspecified drugs acting on muscles | Diagnosis | ICD-9-CM |
| 975.4 | Poisoning by antitussives | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|-------|--|---------------|-----------|
| 975.5 | Poisoning by expectorants | Diagnosis | ICD-9-CM |
| 975.6 | Poisoning by anti-common cold drugs | Diagnosis | ICD-9-CM |
| 975.7 | Poisoning by antiasthmatics | Diagnosis | ICD-9-CM |
| 975.8 | Poisoning by other and unspecified respiratory drugs | Diagnosis | ICD-9-CM |
| 976 | Poisoning by agents primarily affecting skin and mucous membrane, ophthalmological, otorhinolaryngological, and dental drugs | Diagnosis | ICD-9-CM |
| 976.0 | Poisoning by local anti-infectives and anti-inflammatory drugs | Diagnosis | ICD-9-CM |
| 976.1 | Poisoning by antipruritics | Diagnosis | ICD-9-CM |
| 976.2 | Poisoning by local astringents and local detergents | Diagnosis | ICD-9-CM |
| 976.3 | Poisoning by emollients, demulcents, and protectants | Diagnosis | ICD-9-CM |
| 976.4 | Poisoning by keratolytics, keratoplastics, other hair treatment drugs and preparations | Diagnosis | ICD-9-CM |
| 976.5 | Poisoning by eye anti-infectives and other eye drugs | Diagnosis | ICD-9-CM |
| 976.6 | Poisoning by anti-infectives and other drugs and preparations for ear, nose, and throat | Diagnosis | ICD-9-CM |
| 976.7 | Poisoning by dental drugs topically applied | Diagnosis | ICD-9-CM |
| 976.8 | Poisoning by other agents primarily affecting skin and mucous membrane | Diagnosis | ICD-9-CM |
| 976.9 | Poisoning by unspecified agent primarily affecting skin and mucous membrane | Diagnosis | ICD-9-CM |
| 977 | Poisoning by other and unspecified drugs and medicinal substances | Diagnosis | ICD-9-CM |
| 977.0 | Poisoning by dietetics | Diagnosis | ICD-9-CM |
| 977.1 | Poisoning by lipotropic drugs | Diagnosis | ICD-9-CM |
| 977.2 | Poisoning by antidotes and chelating agents, not elsewhere classified | Diagnosis | ICD-9-CM |
| 977.3 | Poisoning by alcohol deterrents | Diagnosis | ICD-9-CM |
| 977.4 | Poisoning by pharmaceutical excipients | Diagnosis | ICD-9-CM |
| 977.8 | Poisoning by other specified drugs and medicinal substances | Diagnosis | ICD-9-CM |
| 977.9 | Poisoning by unspecified drug or medicinal substance | Diagnosis | ICD-9-CM |
| 978 | Poisoning by bacterial vaccines | Diagnosis | ICD-9-CM |
| 978.0 | Poisoning by BCG vaccine | Diagnosis | ICD-9-CM |
| 978.1 | Poisoning by typhoid and paratyphoid vaccine | Diagnosis | ICD-9-CM |
| 978.2 | Poisoning by cholera vaccine | Diagnosis | ICD-9-CM |
| 978.3 | Poisoning by plague vaccine | Diagnosis | ICD-9-CM |
| 978.4 | Poisoning by tetanus vaccine | Diagnosis | ICD-9-CM |
| 978.5 | Poisoning by diphtheria vaccine | Diagnosis | ICD-9-CM |
| 978.6 | Poisoning by pertussis vaccine, including combinations with pertussis component | Diagnosis | ICD-9-CM |
| 978.8 | Poisoning by other and unspecified bacterial vaccines | Diagnosis | ICD-9-CM |
| 978.9 | Poisoning by mixed bacterial vaccines, except combinations with pertussis component | Diagnosis | ICD-9-CM |
| 979 | Poisoning by other vaccines and biological substances | Diagnosis | ICD-9-CM |
| 979.0 | Poisoning by smallpox vaccine | Diagnosis | ICD-9-CM |
| 979.1 | Poisoning by rabies vaccine | Diagnosis | ICD-9-CM |
| 979.2 | Poisoning by typhus vaccine | Diagnosis | ICD-9-CM |
| 979.3 | Poisoning by yellow fever vaccine | Diagnosis | ICD-9-CM |
| 979.4 | Poisoning by measles vaccine | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|-------|---|---------------|-----------|
| 979.5 | Poisoning by poliomyelitis vaccine | Diagnosis | ICD-9-CM |
| 979.6 | Poisoning by other and unspecified viral and rickettsial vaccines | Diagnosis | ICD-9-CM |
| 979.7 | Poisoning by mixed viral-rickettsial and bacterial vaccines, except combinations with pertussis component | Diagnosis | ICD-9-CM |
| 979.9 | Poisoning by other and unspecified vaccines and biological substances | Diagnosis | ICD-9-CM |
| 980 | Toxic effect of alcohol | Diagnosis | ICD-9-CM |
| 980.0 | Toxic effect of ethyl alcohol | Diagnosis | ICD-9-CM |
| 980.1 | Toxic effect of methyl alcohol | Diagnosis | ICD-9-CM |
| 980.2 | Toxic effect of isopropyl alcohol | Diagnosis | ICD-9-CM |
| 980.3 | Toxic effect of fusel oil | Diagnosis | ICD-9-CM |
| 980.8 | Toxic effect of other specified alcohols | Diagnosis | ICD-9-CM |
| 980.9 | Toxic effect of unspecified alcohol | Diagnosis | ICD-9-CM |
| 981 | Toxic effect of petroleum products | Diagnosis | ICD-9-CM |
| 982 | Toxic effect of solvents other than petroleum-based | Diagnosis | ICD-9-CM |
| 982.0 | Toxic effect of benzene and homologues | Diagnosis | ICD-9-CM |
| 982.1 | Toxic effect of carbon tetrachloride | Diagnosis | ICD-9-CM |
| 982.2 | Toxic effect of carbon disulfide | Diagnosis | ICD-9-CM |
| 982.3 | Toxic effect of other chlorinated hydrocarbon solvents | Diagnosis | ICD-9-CM |
| 982.4 | Toxic effect of nitroglycol | Diagnosis | ICD-9-CM |
| 982.8 | Toxic effect of other nonpetroleum-based solvents | Diagnosis | ICD-9-CM |
| 983 | Toxic effect of corrosive aromatics, acids, and caustic alkalis | Diagnosis | ICD-9-CM |
| 983.0 | Toxic effect of corrosive aromatics | Diagnosis | ICD-9-CM |
| 983.1 | Toxic effect of acids | Diagnosis | ICD-9-CM |
| 983.2 | Toxic effect of caustic alkalis | Diagnosis | ICD-9-CM |
| 983.9 | Toxic effect of caustic, unspecified | Diagnosis | ICD-9-CM |
| 984 | Toxic effect of lead and its compounds (including fumes) | Diagnosis | ICD-9-CM |
| 984.0 | Toxic effect of inorganic lead compounds | Diagnosis | ICD-9-CM |
| 984.1 | Toxic effect of organic lead compounds | Diagnosis | ICD-9-CM |
| 984.8 | Toxic effect of other lead compounds | Diagnosis | ICD-9-CM |
| 984.9 | Toxic effect of unspecified lead compound | Diagnosis | ICD-9-CM |
| 985 | Toxic effect of other metals | Diagnosis | ICD-9-CM |
| 985.0 | Toxic effect of mercury and its compounds | Diagnosis | ICD-9-CM |
| 985.1 | Toxic effect of arsenic and its compounds | Diagnosis | ICD-9-CM |
| 985.2 | Toxic effect of manganese and its compounds | Diagnosis | ICD-9-CM |
| 985.3 | Toxic effect of beryllium and its compounds | Diagnosis | ICD-9-CM |
| 985.4 | Toxic effect of antimony and its compounds | Diagnosis | ICD-9-CM |
| 985.5 | Toxic effect of cadmium and its compounds | Diagnosis | ICD-9-CM |
| 985.6 | Toxic effect of chromium | Diagnosis | ICD-9-CM |
| 985.8 | Toxic effect of other specified metals | Diagnosis | ICD-9-CM |
| 985.9 | Toxic effect of unspecified metal | Diagnosis | ICD-9-CM |
| 986 | Toxic effect of carbon monoxide | Diagnosis | ICD-9-CM |
| 987 | Toxic effect of other gases, fumes, or vapors | Diagnosis | ICD-9-CM |
| 987.0 | Toxic effect of liquefied petroleum gases | Diagnosis | ICD-9-CM |
| 987.1 | Toxic effect of other hydrocarbon gas | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 987.2 | Toxic effect of nitrogen oxides | Diagnosis | ICD-9-CM |
| 987.3 | Toxic effect of sulfur dioxide | Diagnosis | ICD-9-CM |
| 987.4 | Toxic effect of freon | Diagnosis | ICD-9-CM |
| 987.5 | Toxic effect of lacrimogenic gas | Diagnosis | ICD-9-CM |
| 987.6 | Toxic effect of chlorine gas | Diagnosis | ICD-9-CM |
| 987.7 | Toxic effect of hydrocyanic acid gas | Diagnosis | ICD-9-CM |
| 987.8 | Toxic effect of other specified gases, fumes, or vapors | Diagnosis | ICD-9-CM |
| 987.9 | Toxic effect of unspecified gas, fume, or vapor | Diagnosis | ICD-9-CM |
| 988 | Toxic effect of noxious substances eaten as food | Diagnosis | ICD-9-CM |
| 988.0 | Toxic effect of fish and shellfish | Diagnosis | ICD-9-CM |
| 988.1 | Toxic effect of mushrooms | Diagnosis | ICD-9-CM |
| 988.2 | Toxic effect of berries and other plants | Diagnosis | ICD-9-CM |
| 988.8 | Toxic effect of other specified noxious substances | Diagnosis | ICD-9-CM |
| 988.9 | Toxic effect of unspecified noxious substance | Diagnosis | ICD-9-CM |
| 989 | Toxic effect of other substances, chiefly nonmedicinal as to source | Diagnosis | ICD-9-CM |
| 989.0 | Toxic effect of hydrocyanic acid and cyanides | Diagnosis | ICD-9-CM |
| 989.1 | Toxic effect of strychnine and salts | Diagnosis | ICD-9-CM |
| 989.2 | Toxic effect of chlorinated hydrocarbons | Diagnosis | ICD-9-CM |
| 989.3 | Toxic effect of organophosphate and carbamate | Diagnosis | ICD-9-CM |
| 989.4 | Toxic effect of other pesticides, not elsewhere classified | Diagnosis | ICD-9-CM |
| 989.5 | Toxic effect of venom | Diagnosis | ICD-9-CM |
| 989.6 | Toxic effect of soaps and detergents | Diagnosis | ICD-9-CM |
| 989.7 | Toxic effect of aflatoxin and other mycotoxin (food contaminants) | Diagnosis | ICD-9-CM |
| 989.8 | Toxic effect of other substances, chiefly nonmedicinal as to source | Diagnosis | ICD-9-CM |
| 989.81 | Toxic effect of asbestos | Diagnosis | ICD-9-CM |
| 989.82 | Toxic effect of latex | Diagnosis | ICD-9-CM |
| 989.83 | Toxic effect of silicone | Diagnosis | ICD-9-CM |
| 989.84 | Toxic effect of tobacco | Diagnosis | ICD-9-CM |
| 989.89 | Toxic effect of other substances | Diagnosis | ICD-9-CM |
| 989.9 | Toxic effect of unspecified substance, chiefly nonmedicinal as to source | Diagnosis | ICD-9-CM |
| 994.7 | Asphyxiation and strangulation | Diagnosis | ICD-9-CM |
| C9035 | Injection, aripiprazole lauroxil (Aristada Initio), 1 mg | Procedure | HCPCS |
| C9037 | Injection, risperidone (Perseris), 0.5 mg | Procedure | HCPCS |
| C9125 | Injection, risperidone, per 12.5 mg | Procedure | HCPCS |
| C9204 | Injection, ziprasidone mesylate injection, per 20 mg | Procedure | HCPCS |
| C9255 | Injection, paliperidone palmitate, 1 mg | Procedure | HCPCS |
| C9470 | Injection, aripiprazole lauroxil, 1 mg | Procedure | HCPCS |
| C9497 | Loxapine, inhalation powder, 10 mg | Procedure | HCPCS |
| E75.00 | GM2 gangliosidosis, unspecified | Diagnosis | ICD-10-CM |
| E75.01 | Sandhoff disease | Diagnosis | ICD-10-CM |
| E75.02 | Tay-Sachs disease | Diagnosis | ICD-10-CM |
| E75.09 | Other GM2 gangliosidosis | Diagnosis | ICD-10-CM |
| E75.10 | Unspecified gangliosidosis | Diagnosis | ICD-10-CM |
| E75.11 | Mucopolipidosis IV | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| E75.19 | Other gangliosidosis | Diagnosis | ICD-10-CM |
| E75.23 | Krabbe disease | Diagnosis | ICD-10-CM |
| E75.25 | Metachromatic leukodystrophy | Diagnosis | ICD-10-CM |
| E75.29 | Other sphingolipidosis | Diagnosis | ICD-10-CM |
| E75.4 | Neuronal ceroid lipofuscinosis | Diagnosis | ICD-10-CM |
| E950 | Suicide and self-inflicted poisoning by solid or liquid substances | Diagnosis | ICD-9-CM |
| E950.0 | Suicide and self-inflicted poisoning by analgesics, antipyretics, and antirheumatics | Diagnosis | ICD-9-CM |
| E950.1 | Suicide and self-inflicted poisoning by barbiturates | Diagnosis | ICD-9-CM |
| E950.2 | Suicide and self-inflicted poisoning by other sedatives and hypnotics | Diagnosis | ICD-9-CM |
| E950.3 | Suicide and self-inflicted poisoning by tranquilizers and other psychotropic agents | Diagnosis | ICD-9-CM |
| E950.4 | Suicide and self-inflicted poisoning by other specified drugs and medicinal substances | Diagnosis | ICD-9-CM |
| E950.5 | Suicide and self-inflicted poisoning by unspecified drug or medicinal substance | Diagnosis | ICD-9-CM |
| E950.6 | Suicide and self-inflicted poisoning by agricultural and horticultural chemical and pharmaceutical preparations other than plant foods and fertilizers | Diagnosis | ICD-9-CM |
| E950.7 | Suicide and self-inflicted poisoning by corrosive and caustic substances | Diagnosis | ICD-9-CM |
| E950.8 | Suicide and self-inflicted poisoning by arsenic and its compounds | Diagnosis | ICD-9-CM |
| E950.9 | Suicide and self-inflicted poisoning by other and unspecified solid and liquid substances | Diagnosis | ICD-9-CM |
| E951 | Suicide and self-inflicted poisoning by gases in domestic use | Diagnosis | ICD-9-CM |
| E951.0 | Suicide and self-inflicted poisoning by gas distributed by pipeline | Diagnosis | ICD-9-CM |
| E951.1 | Suicide and self-inflicted poisoning by liquefied petroleum gas distributed in mobile containers | Diagnosis | ICD-9-CM |
| E951.8 | Suicide and self-inflicted poisoning by other utility gas | Diagnosis | ICD-9-CM |
| E952 | Suicide and self-inflicted poisoning by other gases and vapors | Diagnosis | ICD-9-CM |
| E952.0 | Suicide and self-inflicted poisoning by motor vehicle exhaust gas | Diagnosis | ICD-9-CM |
| E952.1 | Suicide and self-inflicted poisoning by other carbon monoxide | Diagnosis | ICD-9-CM |
| E952.8 | Suicide and self-inflicted poisoning by other specified gases and vapors | Diagnosis | ICD-9-CM |
| E952.9 | Suicide and self-inflicted poisoning by unspecified gases and vapors | Diagnosis | ICD-9-CM |
| E953 | Suicide and self-inflicted injury by hanging strangulation and suffocation | Diagnosis | ICD-9-CM |
| E953.0 | Suicide and self-inflicted injury by hanging | Diagnosis | ICD-9-CM |
| E953.1 | Suicide and self-inflicted injury by suffocation by plastic bag | Diagnosis | ICD-9-CM |
| E953.8 | Suicide and self-inflicted injury by other specified means | Diagnosis | ICD-9-CM |
| E953.9 | Suicide and self-inflicted injury by unspecified means | Diagnosis | ICD-9-CM |
| E954 | Suicide and self-inflicted injury by submersion (drowning) | Diagnosis | ICD-9-CM |
| E954 | Suicide and self-inflicted injury by submersion [drowning] | Diagnosis | ICD-9-CM |
| E955 | Suicide and self-inflicted injury by firearms air guns and explosives | Diagnosis | ICD-9-CM |
| E955.0 | Suicide and self-inflicted injury by handgun | Diagnosis | ICD-9-CM |
| E955.1 | Suicide and self-inflicted injury by shotgun | Diagnosis | ICD-9-CM |
| E955.2 | Suicide and self-inflicted injury by hunting rifle | Diagnosis | ICD-9-CM |
| E955.3 | Suicide and self-inflicted injury by military firearms | Diagnosis | ICD-9-CM |
| E955.4 | Suicide and self-inflicted injury by other and unspecified firearm | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| E955.5 | Suicide and self-inflicted injury by explosives | Diagnosis | ICD-9-CM |
| E955.6 | Suicide and self-inflicted injury by air gun | Diagnosis | ICD-9-CM |
| E955.7 | Suicide and self-inflicted injury by paintball gun | Diagnosis | ICD-9-CM |
| E955.9 | Suicide and self-inflicted injury by firearms and explosives, unspecified | Diagnosis | ICD-9-CM |
| E956 | Suicide and self-inflicted injury by cutting and piercing instrument | Diagnosis | ICD-9-CM |
| E957 | Suicide and self-inflicted injuries by jumping from high place | Diagnosis | ICD-9-CM |
| E957.0 | Suicide and self-inflicted injuries by jumping from residential premises | Diagnosis | ICD-9-CM |
| E957.1 | Suicide and self-inflicted injuries by jumping from other man-made structures | Diagnosis | ICD-9-CM |
| E957.2 | Suicide and self-inflicted injuries by jumping from natural sites | Diagnosis | ICD-9-CM |
| E957.9 | Suicide and self-inflicted injuries by jumping from unspecified site | Diagnosis | ICD-9-CM |
| E958 | Suicide and self-inflicted injury by other and unspecified means | Diagnosis | ICD-9-CM |
| E958.0 | Suicide and self-inflicted injury by jumping or lying before moving object | Diagnosis | ICD-9-CM |
| E958.1 | Suicide and self-inflicted injury by burns, fire | Diagnosis | ICD-9-CM |
| E958.2 | Suicide and self-inflicted injury by scald | Diagnosis | ICD-9-CM |
| E958.3 | Suicide and self-inflicted injury by extremes of cold | Diagnosis | ICD-9-CM |
| E958.4 | Suicide and self-inflicted injury by electrocution | Diagnosis | ICD-9-CM |
| E958.5 | Suicide and self-inflicted injury by crashing of motor vehicle | Diagnosis | ICD-9-CM |
| E958.6 | Suicide and self-inflicted injury by crashing of aircraft | Diagnosis | ICD-9-CM |
| E958.7 | Suicide and self-inflicted injury by caustic substances, except poisoning | Diagnosis | ICD-9-CM |
| E958.8 | Suicide and self-inflicted injury by other specified means | Diagnosis | ICD-9-CM |
| E958.9 | Suicide and self-inflicted injury by unspecified means | Diagnosis | ICD-9-CM |
| E959 | Late effects of self-inflicted injury | Diagnosis | ICD-9-CM |
| F01 | Vascular dementia | Diagnosis | ICD-10-CM |
| F01.5 | Vascular dementia | Diagnosis | ICD-10-CM |
| F01.50 | Vascular dementia without behavioral disturbance | Diagnosis | ICD-10-CM |
| F01.51 | Vascular dementia with behavioral disturbance | Diagnosis | ICD-10-CM |
| F02 | Dementia in other diseases classified elsewhere | Diagnosis | ICD-10-CM |
| F02.8 | Dementia in other diseases classified elsewhere | Diagnosis | ICD-10-CM |
| F02.80 | Dementia in other diseases classified elsewhere without behavioral | Diagnosis | ICD-10-CM |
| F02.81 | Dementia in other diseases classified elsewhere with behavioral disturbance | Diagnosis | ICD-10-CM |
| F03 | Unspecified dementia | Diagnosis | ICD-10-CM |
| F03.9 | Unspecified dementia | Diagnosis | ICD-10-CM |
| F03.90 | Unspecified dementia without behavioral disturbance | Diagnosis | ICD-10-CM |
| F03.91 | Unspecified dementia with behavioral disturbance | Diagnosis | ICD-10-CM |
| F04 | Amnestic disorder due to known physiological condition | Diagnosis | ICD-10-CM |
| F05 | Delirium due to known physiological condition | Diagnosis | ICD-10-CM |
| F06 | Other mental disorders due to known physiological condition | Diagnosis | ICD-10-CM |
| F06.0 | Psychotic disorder with hallucinations due to known physiological condition | Diagnosis | ICD-10-CM |
| F06.1 | Catatonic disorder due to known physiological condition | Diagnosis | ICD-10-CM |
| F06.2 | Psychotic disorder with delusions due to known physiological condition | Diagnosis | ICD-10-CM |
| F06.3 | Mood disorder due to known physiological condition | Diagnosis | ICD-10-CM |
| F06.30 | Mood disorder due to known physiological condition, unspecified | Diagnosis | ICD-10-CM |
| F06.31 | Mood disorder due to known physiological condition with depressive features | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| F06.32 | Mood disorder due to known physiological condition with major depressive-like episode | Diagnosis | ICD-10-CM |
| F06.33 | Mood disorder due to known physiological condition with manic features | Diagnosis | ICD-10-CM |
| F06.34 | Mood disorder due to known physiological condition with mixed features | Diagnosis | ICD-10-CM |
| F06.4 | Anxiety disorder due to known physiological condition | Diagnosis | ICD-10-CM |
| F06.8 | Other specified mental disorders due to known physiological condition | Diagnosis | ICD-10-CM |
| F07 | Personality and behavioral disorders due to known physiological condition | Diagnosis | ICD-10-CM |
| F07.0 | Personality change due to known physiological condition | Diagnosis | ICD-10-CM |
| F07.8 | Other personality and behavioral disorders due to known physiological condition | Diagnosis | ICD-10-CM |
| F07.81 | Postconcussional syndrome | Diagnosis | ICD-10-CM |
| F07.89 | Other personality and behavioral disorders due to known physiological condition | Diagnosis | ICD-10-CM |
| F07.9 | Unspecified personality and behavioral disorder due to known physiological condition | Diagnosis | ICD-10-CM |
| F09 | Unspecified mental disorder due to known physiological condition | Diagnosis | ICD-10-CM |
| F10 | Alcohol related disorders | Diagnosis | ICD-10-CM |
| F10.1 | Alcohol abuse | Diagnosis | ICD-10-CM |
| F10.10 | Alcohol abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F10.11 | Alcohol abuse, in remission | Diagnosis | ICD-10-CM |
| F10.12 | Alcohol abuse with intoxication | Diagnosis | ICD-10-CM |
| F10.120 | Alcohol abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F10.121 | Alcohol abuse with intoxication delirium | Diagnosis | ICD-10-CM |
| F10.129 | Alcohol abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F10.14 | Alcohol abuse with alcohol-induced mood disorder | Diagnosis | ICD-10-CM |
| F10.15 | Alcohol abuse with alcohol-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F10.150 | Alcohol abuse with alcohol-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F10.151 | Alcohol abuse with alcohol-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F10.159 | Alcohol abuse with alcohol-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F10.18 | Alcohol abuse with other alcohol-induced disorders | Diagnosis | ICD-10-CM |
| F10.180 | Alcohol abuse with alcohol-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F10.181 | Alcohol abuse with alcohol-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F10.182 | Alcohol abuse with alcohol-induced sleep disorder | Diagnosis | ICD-10-CM |
| F10.188 | Alcohol abuse with other alcohol-induced disorder | Diagnosis | ICD-10-CM |
| F10.19 | Alcohol abuse with unspecified alcohol-induced disorder | Diagnosis | ICD-10-CM |
| F10.2 | Alcohol dependence | Diagnosis | ICD-10-CM |
| F10.20 | Alcohol dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F10.21 | Alcohol dependence, in remission | Diagnosis | ICD-10-CM |
| F10.22 | Alcohol dependence with intoxication | Diagnosis | ICD-10-CM |
| F10.220 | Alcohol dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F10.221 | Alcohol dependence with intoxication delirium | Diagnosis | ICD-10-CM |
| F10.229 | Alcohol dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F10.23 | Alcohol dependence with withdrawal | Diagnosis | ICD-10-CM |
| F10.230 | Alcohol dependence with withdrawal, uncomplicated | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F10.231 | Alcohol dependence with withdrawal delirium | Diagnosis | ICD-10-CM |
| F10.232 | Alcohol dependence with withdrawal with perceptual disturbance | Diagnosis | ICD-10-CM |
| F10.239 | Alcohol dependence with withdrawal, unspecified | Diagnosis | ICD-10-CM |
| F10.24 | Alcohol dependence with alcohol-induced mood disorder | Diagnosis | ICD-10-CM |
| F10.25 | Alcohol dependence with alcohol-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F10.250 | Alcohol dependence with alcohol-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F10.251 | Alcohol dependence with alcohol-induced psychotic disorder with | Diagnosis | ICD-10-CM |
| F10.259 | Alcohol dependence with alcohol-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F10.26 | Alcohol dependence with alcohol-induced persisting amnesic disorder | Diagnosis | ICD-10-CM |
| F10.27 | Alcohol dependence with alcohol-induced persisting dementia | Diagnosis | ICD-10-CM |
| F10.28 | Alcohol dependence with other alcohol-induced disorders | Diagnosis | ICD-10-CM |
| F10.280 | Alcohol dependence with alcohol-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F10.281 | Alcohol dependence with alcohol-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F10.282 | Alcohol dependence with alcohol-induced sleep disorder | Diagnosis | ICD-10-CM |
| F10.288 | Alcohol dependence with other alcohol-induced disorder | Diagnosis | ICD-10-CM |
| F10.29 | Alcohol dependence with unspecified alcohol-induced disorder | Diagnosis | ICD-10-CM |
| F10.9 | Alcohol use, unspecified | Diagnosis | ICD-10-CM |
| F10.92 | Alcohol use, unspecified with intoxication | Diagnosis | ICD-10-CM |
| F10.920 | Alcohol use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F10.921 | Alcohol use, unspecified with intoxication delirium | Diagnosis | ICD-10-CM |
| F10.929 | Alcohol use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F10.94 | Alcohol use, unspecified with alcohol-induced mood disorder | Diagnosis | ICD-10-CM |
| F10.95 | Alcohol use, unspecified with alcohol-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F10.950 | Alcohol use, unspecified with alcohol-induced psychotic disorder with | Diagnosis | ICD-10-CM |
| F10.951 | Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F10.959 | Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F10.96 | Alcohol use, unspecified with alcohol-induced persisting amnesic disorder | Diagnosis | ICD-10-CM |
| F10.97 | Alcohol use, unspecified with alcohol-induced persisting dementia | Diagnosis | ICD-10-CM |
| F10.98 | Alcohol use, unspecified with other alcohol-induced disorders | Diagnosis | ICD-10-CM |
| F10.980 | Alcohol use, unspecified with alcohol-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F10.981 | Alcohol use, unspecified with alcohol-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F10.982 | Alcohol use, unspecified with alcohol-induced sleep disorder | Diagnosis | ICD-10-CM |
| F10.988 | Alcohol use, unspecified with other alcohol-induced disorder | Diagnosis | ICD-10-CM |
| F10.99 | Alcohol use, unspecified with unspecified alcohol-induced disorder | Diagnosis | ICD-10-CM |
| F11 | Opioid related disorders | Diagnosis | ICD-10-CM |
| F11.1 | Opioid abuse | Diagnosis | ICD-10-CM |
| F11.10 | Opioid abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F11.11 | Opioid abuse, in remission | Diagnosis | ICD-10-CM |
| F11.12 | Opioid abuse with intoxication | Diagnosis | ICD-10-CM |
| F11.120 | Opioid abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F11.121 | Opioid abuse with intoxication delirium | Diagnosis | ICD-10-CM |
| F11.122 | Opioid abuse with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F11.129 | Opioid abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F11.14 | Opioid abuse with opioid-induced mood disorder | Diagnosis | ICD-10-CM |
| F11.15 | Opioid abuse with opioid-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F11.150 | Opioid abuse with opioid-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F11.151 | Opioid abuse with opioid-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F11.159 | Opioid abuse with opioid-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F11.18 | Opioid abuse with other opioid-induced disorder | Diagnosis | ICD-10-CM |
| F11.181 | Opioid abuse with opioid-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F11.182 | Opioid abuse with opioid-induced sleep disorder | Diagnosis | ICD-10-CM |
| F11.188 | Opioid abuse with other opioid-induced disorder | Diagnosis | ICD-10-CM |
| F11.19 | Opioid abuse with unspecified opioid-induced disorder | Diagnosis | ICD-10-CM |
| F11.2 | Opioid dependence | Diagnosis | ICD-10-CM |
| F11.20 | Opioid dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F11.21 | Opioid dependence, in remission | Diagnosis | ICD-10-CM |
| F11.22 | Opioid dependence with intoxication | Diagnosis | ICD-10-CM |
| F11.220 | Opioid dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F11.221 | Opioid dependence with intoxication delirium | Diagnosis | ICD-10-CM |
| F11.222 | Opioid dependence with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F11.229 | Opioid dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F11.23 | Opioid dependence with withdrawal | Diagnosis | ICD-10-CM |
| F11.24 | Opioid dependence with opioid-induced mood disorder | Diagnosis | ICD-10-CM |
| F11.25 | Opioid dependence with opioid-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F11.250 | Opioid dependence with opioid-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F11.251 | Opioid dependence with opioid-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F11.259 | Opioid dependence with opioid-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F11.28 | Opioid dependence with other opioid-induced disorder | Diagnosis | ICD-10-CM |
| F11.281 | Opioid dependence with opioid-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F11.282 | Opioid dependence with opioid-induced sleep disorder | Diagnosis | ICD-10-CM |
| F11.288 | Opioid dependence with other opioid-induced disorder | Diagnosis | ICD-10-CM |
| F11.29 | Opioid dependence with unspecified opioid-induced disorder | Diagnosis | ICD-10-CM |
| F11.9 | Opioid use, unspecified | Diagnosis | ICD-10-CM |
| F11.90 | Opioid use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F11.92 | Opioid use, unspecified with intoxication | Diagnosis | ICD-10-CM |
| F11.920 | Opioid use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F11.921 | Opioid use, unspecified with intoxication delirium | Diagnosis | ICD-10-CM |
| F11.922 | Opioid use, unspecified with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F11.929 | Opioid use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F11.93 | Opioid use, unspecified with withdrawal | Diagnosis | ICD-10-CM |
| F11.94 | Opioid use, unspecified with opioid-induced mood disorder | Diagnosis | ICD-10-CM |
| F11.95 | Opioid use, unspecified with opioid-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F11.950 | Opioid use, unspecified with opioid-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F11.951 | Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F11.959 | Opioid use, unspecified with opioid-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F11.98 | Opioid use, unspecified with other specified opioid-induced disorder | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| F11.981 | Opioid use, unspecified with opioid-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F11.982 | Opioid use, unspecified with opioid-induced sleep disorder | Diagnosis | ICD-10-CM |
| F11.988 | Opioid use, unspecified with other opioid-induced disorder | Diagnosis | ICD-10-CM |
| F11.99 | Opioid use, unspecified with unspecified opioid-induced disorder | Diagnosis | ICD-10-CM |
| F12 | Cannabis related disorders | Diagnosis | ICD-10-CM |
| F12.1 | Cannabis abuse | Diagnosis | ICD-10-CM |
| F12.10 | Cannabis abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F12.11 | Cannabis abuse, in remission | Diagnosis | ICD-10-CM |
| F12.12 | Cannabis abuse with intoxication | Diagnosis | ICD-10-CM |
| F12.120 | Cannabis abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F12.121 | Cannabis abuse with intoxication delirium | Diagnosis | ICD-10-CM |
| F12.122 | Cannabis abuse with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F12.129 | Cannabis abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F12.15 | Cannabis abuse with psychotic disorder | Diagnosis | ICD-10-CM |
| F12.150 | Cannabis abuse with psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F12.151 | Cannabis abuse with psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F12.159 | Cannabis abuse with psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F12.18 | Cannabis abuse with other cannabis-induced disorder | Diagnosis | ICD-10-CM |
| F12.180 | Cannabis abuse with cannabis-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F12.188 | Cannabis abuse with other cannabis-induced disorder | Diagnosis | ICD-10-CM |
| F12.19 | Cannabis abuse with unspecified cannabis-induced disorder | Diagnosis | ICD-10-CM |
| F12.2 | Cannabis dependence | Diagnosis | ICD-10-CM |
| F12.20 | Cannabis dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F12.21 | Cannabis dependence, in remission | Diagnosis | ICD-10-CM |
| F12.22 | Cannabis dependence with intoxication | Diagnosis | ICD-10-CM |
| F12.220 | Cannabis dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F12.221 | Cannabis dependence with intoxication delirium | Diagnosis | ICD-10-CM |
| F12.222 | Cannabis dependence with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F12.229 | Cannabis dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F12.23 | Cannabis dependence with withdrawal | Diagnosis | ICD-10-CM |
| F12.25 | Cannabis dependence with psychotic disorder | Diagnosis | ICD-10-CM |
| F12.250 | Cannabis dependence with psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F12.251 | Cannabis dependence with psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F12.259 | Cannabis dependence with psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F12.28 | Cannabis dependence with other cannabis-induced disorder | Diagnosis | ICD-10-CM |
| F12.280 | Cannabis dependence with cannabis-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F12.288 | Cannabis dependence with other cannabis-induced disorder | Diagnosis | ICD-10-CM |
| F12.29 | Cannabis dependence with unspecified cannabis-induced disorder | Diagnosis | ICD-10-CM |
| F12.9 | Cannabis use, unspecified | Diagnosis | ICD-10-CM |
| F12.90 | Cannabis use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F12.92 | Cannabis use, unspecified with intoxication | Diagnosis | ICD-10-CM |
| F12.920 | Cannabis use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F12.921 | Cannabis use, unspecified with intoxication delirium | Diagnosis | ICD-10-CM |
| F12.922 | Cannabis use, unspecified with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| F12.929 | Cannabis use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F12.93 | Cannabis use, unspecified with withdrawal | Diagnosis | ICD-10-CM |
| F12.95 | Cannabis use, unspecified with psychotic disorder | Diagnosis | ICD-10-CM |
| F12.950 | Cannabis use, unspecified with psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F12.951 | Cannabis use, unspecified with psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F12.959 | Cannabis use, unspecified with psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F12.98 | Cannabis use, unspecified with other cannabis-induced disorder | Diagnosis | ICD-10-CM |
| F12.980 | Cannabis use, unspecified with anxiety disorder | Diagnosis | ICD-10-CM |
| F12.988 | Cannabis use, unspecified with other cannabis-induced disorder | Diagnosis | ICD-10-CM |
| F12.99 | Cannabis use, unspecified with unspecified cannabis-induced disorder | Diagnosis | ICD-10-CM |
| F13 | Sedative, hypnotic, or anxiolytic related disorders | Diagnosis | ICD-10-CM |
| F13.1 | Sedative, hypnotic or anxiolytic-related abuse | Diagnosis | ICD-10-CM |
| F13.10 | Sedative, hypnotic or anxiolytic abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F13.11 | Sedative, hypnotic or anxiolytic abuse, in remission | Diagnosis | ICD-10-CM |
| F13.12 | Sedative, hypnotic or anxiolytic abuse with intoxication | Diagnosis | ICD-10-CM |
| F13.120 | Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F13.121 | Sedative, hypnotic or anxiolytic abuse with intoxication delirium | Diagnosis | ICD-10-CM |
| F13.129 | Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F13.14 | Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood disorder | Diagnosis | ICD-10-CM |
| F13.15 | Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F13.150 | Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F13.151 | Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F13.159 | Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F13.18 | Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorders | Diagnosis | ICD-10-CM |
| F13.180 | Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F13.181 | Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F13.182 | Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep disorder | Diagnosis | ICD-10-CM |
| F13.188 | Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorder | Diagnosis | ICD-10-CM |
| F13.19 | Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolytic-induced disorder | Diagnosis | ICD-10-CM |
| F13.2 | Sedative, hypnotic or anxiolytic-related dependence | Diagnosis | ICD-10-CM |
| F13.20 | Sedative, hypnotic or anxiolytic dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F13.21 | Sedative, hypnotic or anxiolytic dependence, in remission | Diagnosis | ICD-10-CM |
| F13.22 | Sedative, hypnotic or anxiolytic dependence with intoxication | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F13.220 | Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F13.221 | Sedative, hypnotic or anxiolytic dependence with intoxication delirium | Diagnosis | ICD-10-CM |
| F13.229 | Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F13.23 | Sedative, hypnotic or anxiolytic dependence with withdrawal | Diagnosis | ICD-10-CM |
| F13.230 | Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated | Diagnosis | ICD-10-CM |
| F13.231 | Sedative, hypnotic or anxiolytic dependence with withdrawal delirium | Diagnosis | ICD-10-CM |
| F13.232 | Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbance | Diagnosis | ICD-10-CM |
| F13.239 | Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified | Diagnosis | ICD-10-CM |
| F13.24 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced mood disorder | Diagnosis | ICD-10-CM |
| F13.25 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F13.250 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F13.251 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F13.259 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F13.26 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting amnesic disorder | Diagnosis | ICD-10-CM |
| F13.27 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting dementia | Diagnosis | ICD-10-CM |
| F13.28 | Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorders | Diagnosis | ICD-10-CM |
| F13.280 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F13.281 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F13.282 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sleep disorder | Diagnosis | ICD-10-CM |
| F13.288 | Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorder | Diagnosis | ICD-10-CM |
| F13.29 | Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or anxiolytic-induced disorder | Diagnosis | ICD-10-CM |
| F13.9 | Sedative, hypnotic or anxiolytic-related use, unspecified | Diagnosis | ICD-10-CM |
| F13.90 | Sedative, hypnotic, or anxiolytic use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F13.92 | Sedative, hypnotic or anxiolytic use, unspecified with intoxication | Diagnosis | ICD-10-CM |
| F13.920 | Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F13.921 | Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium | Diagnosis | ICD-10-CM |
| F13.929 | Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F13.93 | Sedative, hypnotic or anxiolytic use, unspecified with withdrawal | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F13.930 | Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated | Diagnosis | ICD-10-CM |
| F13.931 | Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium | Diagnosis | ICD-10-CM |
| F13.932 | Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual disturbances | Diagnosis | ICD-10-CM |
| F13.939 | Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, unspecified | Diagnosis | ICD-10-CM |
| F13.94 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced mood disorder | Diagnosis | ICD-10-CM |
| F13.95 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F13.950 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F13.951 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F13.959 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F13.96 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting amnesic disorder | Diagnosis | ICD-10-CM |
| F13.97 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia | Diagnosis | ICD-10-CM |
| F13.98 | Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorders | Diagnosis | ICD-10-CM |
| F13.980 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F13.981 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F13.982 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sleep disorder | Diagnosis | ICD-10-CM |
| F13.988 | Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorder | Diagnosis | ICD-10-CM |
| F13.99 | Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic or anxiolytic-induced disorder | Diagnosis | ICD-10-CM |
| F14 | Cocaine related disorders | Diagnosis | ICD-10-CM |
| F14.1 | Cocaine abuse | Diagnosis | ICD-10-CM |
| F14.10 | Cocaine abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F14.11 | Cocaine abuse, in remission | Diagnosis | ICD-10-CM |
| F14.12 | Cocaine abuse with intoxication | Diagnosis | ICD-10-CM |
| F14.120 | Cocaine abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F14.121 | Cocaine abuse with intoxication with delirium | Diagnosis | ICD-10-CM |
| F14.122 | Cocaine abuse with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F14.129 | Cocaine abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F14.14 | Cocaine abuse with cocaine-induced mood disorder | Diagnosis | ICD-10-CM |
| F14.15 | Cocaine abuse with cocaine-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F14.150 | Cocaine abuse with cocaine-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F14.151 | Cocaine abuse with cocaine-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F14.159 | Cocaine abuse with cocaine-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F14.18 | Cocaine abuse with other cocaine-induced disorder | Diagnosis | ICD-10-CM |
| F14.180 | Cocaine abuse with cocaine-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F14.181 | Cocaine abuse with cocaine-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F14.182 | Cocaine abuse with cocaine-induced sleep disorder | Diagnosis | ICD-10-CM |
| F14.188 | Cocaine abuse with other cocaine-induced disorder | Diagnosis | ICD-10-CM |
| F14.19 | Cocaine abuse with unspecified cocaine-induced disorder | Diagnosis | ICD-10-CM |
| F14.2 | Cocaine dependence | Diagnosis | ICD-10-CM |
| F14.20 | Cocaine dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F14.21 | Cocaine dependence, in remission | Diagnosis | ICD-10-CM |
| F14.22 | Cocaine dependence with intoxication | Diagnosis | ICD-10-CM |
| F14.220 | Cocaine dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F14.221 | Cocaine dependence with intoxication delirium | Diagnosis | ICD-10-CM |
| F14.222 | Cocaine dependence with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F14.229 | Cocaine dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F14.23 | Cocaine dependence with withdrawal | Diagnosis | ICD-10-CM |
| F14.24 | Cocaine dependence with cocaine-induced mood disorder | Diagnosis | ICD-10-CM |
| F14.25 | Cocaine dependence with cocaine-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F14.250 | Cocaine dependence with cocaine-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F14.251 | Cocaine dependence with cocaine-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F14.259 | Cocaine dependence with cocaine-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F14.28 | Cocaine dependence with other cocaine-induced disorder | Diagnosis | ICD-10-CM |
| F14.280 | Cocaine dependence with cocaine-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F14.281 | Cocaine dependence with cocaine-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F14.282 | Cocaine dependence with cocaine-induced sleep disorder | Diagnosis | ICD-10-CM |
| F14.288 | Cocaine dependence with other cocaine-induced disorder | Diagnosis | ICD-10-CM |
| F14.29 | Cocaine dependence with unspecified cocaine-induced disorder | Diagnosis | ICD-10-CM |
| F14.9 | Cocaine use, unspecified | Diagnosis | ICD-10-CM |
| F14.90 | Cocaine use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F14.92 | Cocaine use, unspecified with intoxication | Diagnosis | ICD-10-CM |
| F14.920 | Cocaine use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F14.921 | Cocaine use, unspecified with intoxication delirium | Diagnosis | ICD-10-CM |
| F14.922 | Cocaine use, unspecified with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F14.929 | Cocaine use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F14.94 | Cocaine use, unspecified with cocaine-induced mood disorder | Diagnosis | ICD-10-CM |
| F14.95 | Cocaine use, unspecified with cocaine-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F14.950 | Cocaine use, unspecified with cocaine-induced psychotic disorder with | Diagnosis | ICD-10-CM |
| F14.951 | Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F14.959 | Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F14.98 | Cocaine use, unspecified with other specified cocaine-induced disorder | Diagnosis | ICD-10-CM |
| F14.980 | Cocaine use, unspecified with cocaine-induced anxiety disorder | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F14.981 | Cocaine use, unspecified with cocaine-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F14.982 | Cocaine use, unspecified with cocaine-induced sleep disorder | Diagnosis | ICD-10-CM |
| F14.988 | Cocaine use, unspecified with other cocaine-induced disorder | Diagnosis | ICD-10-CM |
| F14.99 | Cocaine use, unspecified with unspecified cocaine-induced disorder | Diagnosis | ICD-10-CM |
| F15 | Other stimulant related disorders | Diagnosis | ICD-10-CM |
| F15.1 | Other stimulant abuse | Diagnosis | ICD-10-CM |
| F15.10 | Other stimulant abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F15.11 | Other stimulant abuse, in remission | Diagnosis | ICD-10-CM |
| F15.12 | Other stimulant abuse with intoxication | Diagnosis | ICD-10-CM |
| F15.120 | Other stimulant abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F15.121 | Other stimulant abuse with intoxication delirium | Diagnosis | ICD-10-CM |
| F15.122 | Other stimulant abuse with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F15.129 | Other stimulant abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F15.14 | Other stimulant abuse with stimulant-induced mood disorder | Diagnosis | ICD-10-CM |
| F15.15 | Other stimulant abuse with stimulant-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F15.150 | Other stimulant abuse with stimulant-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F15.151 | Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F15.159 | Other stimulant abuse with stimulant-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F15.18 | Other stimulant abuse with other stimulant-induced disorder | Diagnosis | ICD-10-CM |
| F15.180 | Other stimulant abuse with stimulant-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F15.181 | Other stimulant abuse with stimulant-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F15.182 | Other stimulant abuse with stimulant-induced sleep disorder | Diagnosis | ICD-10-CM |
| F15.188 | Other stimulant abuse with other stimulant-induced disorder | Diagnosis | ICD-10-CM |
| F15.19 | Other stimulant abuse with unspecified stimulant-induced disorder | Diagnosis | ICD-10-CM |
| F15.2 | Other stimulant dependence | Diagnosis | ICD-10-CM |
| F15.20 | Other stimulant dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F15.21 | Other stimulant dependence, in remission | Diagnosis | ICD-10-CM |
| F15.22 | Other stimulant dependence with intoxication | Diagnosis | ICD-10-CM |
| F15.220 | Other stimulant dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F15.221 | Other stimulant dependence with intoxication delirium | Diagnosis | ICD-10-CM |
| F15.222 | Other stimulant dependence with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F15.229 | Other stimulant dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F15.23 | Other stimulant dependence with withdrawal | Diagnosis | ICD-10-CM |
| F15.24 | Other stimulant dependence with stimulant-induced mood disorder | Diagnosis | ICD-10-CM |
| F15.25 | Other stimulant dependence with stimulant-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F15.250 | Other stimulant dependence with stimulant-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F15.251 | Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F15.259 | Other stimulant dependence with stimulant-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F15.28 | Other stimulant dependence with other stimulant-induced disorder | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F15.280 | Other stimulant dependence with stimulant-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F15.281 | Other stimulant dependence with stimulant-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F15.282 | Other stimulant dependence with stimulant-induced sleep disorder | Diagnosis | ICD-10-CM |
| F15.288 | Other stimulant dependence with other stimulant-induced disorder | Diagnosis | ICD-10-CM |
| F15.29 | Other stimulant dependence with unspecified stimulant-induced disorder | Diagnosis | ICD-10-CM |
| F15.9 | Other stimulant use, unspecified | Diagnosis | ICD-10-CM |
| F15.90 | Other stimulant use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F15.92 | Other stimulant use, unspecified with intoxication | Diagnosis | ICD-10-CM |
| F15.920 | Other stimulant use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F15.921 | Other stimulant use, unspecified with intoxication delirium | Diagnosis | ICD-10-CM |
| F15.922 | Other stimulant use, unspecified with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F15.929 | Other stimulant use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F15.93 | Other stimulant use, unspecified with withdrawal | Diagnosis | ICD-10-CM |
| F15.94 | Other stimulant use, unspecified with stimulant-induced mood disorder | Diagnosis | ICD-10-CM |
| F15.95 | Other stimulant use, unspecified with stimulant-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F15.950 | Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F15.951 | Other stimulant use, unspecified with stimulant-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F15.959 | Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F15.98 | Other stimulant use, unspecified with other stimulant-induced disorder | Diagnosis | ICD-10-CM |
| F15.980 | Other stimulant use, unspecified with stimulant-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F15.981 | Other stimulant use, unspecified with stimulant-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F15.982 | Other stimulant use, unspecified with stimulant-induced sleep disorder | Diagnosis | ICD-10-CM |
| F15.988 | Other stimulant use, unspecified with other stimulant-induced disorder | Diagnosis | ICD-10-CM |
| F15.99 | Other stimulant use, unspecified with unspecified stimulant-induced disorder | Diagnosis | ICD-10-CM |
| F16 | Hallucinogen related disorders | Diagnosis | ICD-10-CM |
| F16.1 | Hallucinogen abuse | Diagnosis | ICD-10-CM |
| F16.10 | Hallucinogen abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F16.11 | Hallucinogen abuse, in remission | Diagnosis | ICD-10-CM |
| F16.12 | Hallucinogen abuse with intoxication | Diagnosis | ICD-10-CM |
| F16.120 | Hallucinogen abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F16.121 | Hallucinogen abuse with intoxication with delirium | Diagnosis | ICD-10-CM |
| F16.122 | Hallucinogen abuse with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F16.129 | Hallucinogen abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F16.14 | Hallucinogen abuse with hallucinogen-induced mood disorder | Diagnosis | ICD-10-CM |
| F16.15 | Hallucinogen abuse with hallucinogen-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F16.150 | Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F16.151 | Hallucinogen abuse with hallucinogen-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F16.159 | Hallucinogen abuse with hallucinogen-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F16.18 | Hallucinogen abuse with other hallucinogen-induced disorder | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F16.180 | Hallucinogen abuse with hallucinogen-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F16.183 | Hallucinogen abuse with hallucinogen persisting perception disorder (flashbacks) | Diagnosis | ICD-10-CM |
| F16.188 | Hallucinogen abuse with other hallucinogen-induced disorder | Diagnosis | ICD-10-CM |
| F16.19 | Hallucinogen abuse with unspecified hallucinogen-induced disorder | Diagnosis | ICD-10-CM |
| F16.2 | Hallucinogen dependence | Diagnosis | ICD-10-CM |
| F16.20 | Hallucinogen dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F16.21 | Hallucinogen dependence, in remission | Diagnosis | ICD-10-CM |
| F16.22 | Hallucinogen dependence with intoxication | Diagnosis | ICD-10-CM |
| F16.220 | Hallucinogen dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F16.221 | Hallucinogen dependence with intoxication with delirium | Diagnosis | ICD-10-CM |
| F16.229 | Hallucinogen dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F16.24 | Hallucinogen dependence with hallucinogen-induced mood disorder | Diagnosis | ICD-10-CM |
| F16.25 | Hallucinogen dependence with hallucinogen-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F16.250 | Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F16.251 | Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F16.259 | Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F16.28 | Hallucinogen dependence with other hallucinogen-induced disorder | Diagnosis | ICD-10-CM |
| F16.280 | Hallucinogen dependence with hallucinogen-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F16.283 | Hallucinogen dependence with hallucinogen persisting perception disorder (flashbacks) | Diagnosis | ICD-10-CM |
| F16.288 | Hallucinogen dependence with other hallucinogen-induced disorder | Diagnosis | ICD-10-CM |
| F16.29 | Hallucinogen dependence with unspecified hallucinogen-induced disorder | Diagnosis | ICD-10-CM |
| F16.9 | Hallucinogen use, unspecified | Diagnosis | ICD-10-CM |
| F16.90 | Hallucinogen use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F16.92 | Hallucinogen use, unspecified with intoxication | Diagnosis | ICD-10-CM |
| F16.920 | Hallucinogen use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F16.921 | Hallucinogen use, unspecified with intoxication with delirium | Diagnosis | ICD-10-CM |
| F16.929 | Hallucinogen use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F16.94 | Hallucinogen use, unspecified with hallucinogen-induced mood disorder | Diagnosis | ICD-10-CM |
| F16.95 | Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F16.950 | Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F16.951 | Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F16.959 | Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F16.98 | Hallucinogen use, unspecified with other specified hallucinogen-induced disorder | Diagnosis | ICD-10-CM |
| F16.980 | Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| F16.983 | Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks) | Diagnosis | ICD-10-CM |
| F16.988 | Hallucinogen use, unspecified with other hallucinogen-induced disorder | Diagnosis | ICD-10-CM |
| F16.99 | Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder | Diagnosis | ICD-10-CM |
| F17 | Nicotine dependence | Diagnosis | ICD-10-CM |
| F17.2 | Nicotine dependence | Diagnosis | ICD-10-CM |
| F17.20 | Nicotine dependence, unspecified | Diagnosis | ICD-10-CM |
| F17.200 | Nicotine dependence, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F17.201 | Nicotine dependence, unspecified, in remission | Diagnosis | ICD-10-CM |
| F17.203 | Nicotine dependence unspecified, with withdrawal | Diagnosis | ICD-10-CM |
| F17.208 | Nicotine dependence, unspecified, with other nicotine-induced disorders | Diagnosis | ICD-10-CM |
| F17.209 | Nicotine dependence, unspecified, with unspecified nicotine-induced disorders | Diagnosis | ICD-10-CM |
| F17.21 | Nicotine dependence, cigarettes | Diagnosis | ICD-10-CM |
| F17.210 | Nicotine dependence, cigarettes, uncomplicated | Diagnosis | ICD-10-CM |
| F17.211 | Nicotine dependence, cigarettes, in remission | Diagnosis | ICD-10-CM |
| F17.213 | Nicotine dependence, cigarettes, with withdrawal | Diagnosis | ICD-10-CM |
| F17.218 | Nicotine dependence, cigarettes, with other nicotine-induced disorders | Diagnosis | ICD-10-CM |
| F17.219 | Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders | Diagnosis | ICD-10-CM |
| F17.22 | Nicotine dependence, chewing tobacco | Diagnosis | ICD-10-CM |
| F17.220 | Nicotine dependence, chewing tobacco, uncomplicated | Diagnosis | ICD-10-CM |
| F17.221 | Nicotine dependence, chewing tobacco, in remission | Diagnosis | ICD-10-CM |
| F17.223 | Nicotine dependence, chewing tobacco, with withdrawal | Diagnosis | ICD-10-CM |
| F17.228 | Nicotine dependence, chewing tobacco, with other nicotine-induced disorders | Diagnosis | ICD-10-CM |
| F17.229 | Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders | Diagnosis | ICD-10-CM |
| F17.29 | Nicotine dependence, other tobacco product | Diagnosis | ICD-10-CM |
| F17.290 | Nicotine dependence, other tobacco product, uncomplicated | Diagnosis | ICD-10-CM |
| F17.291 | Nicotine dependence, other tobacco product, in remission | Diagnosis | ICD-10-CM |
| F17.293 | Nicotine dependence, other tobacco product, with withdrawal | Diagnosis | ICD-10-CM |
| F17.298 | Nicotine dependence, other tobacco product, with other nicotine-induced disorders | Diagnosis | ICD-10-CM |
| F17.299 | Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders | Diagnosis | ICD-10-CM |
| F18 | Inhalant related disorders | Diagnosis | ICD-10-CM |
| F18.1 | Inhalant abuse | Diagnosis | ICD-10-CM |
| F18.10 | Inhalant abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F18.11 | Inhalant abuse, in remission | Diagnosis | ICD-10-CM |
| F18.12 | Inhalant abuse with intoxication | Diagnosis | ICD-10-CM |
| F18.120 | Inhalant abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F18.121 | Inhalant abuse with intoxication delirium | Diagnosis | ICD-10-CM |
| F18.129 | Inhalant abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F18.14 | Inhalant abuse with inhalant-induced mood disorder | Diagnosis | ICD-10-CM |
| F18.15 | Inhalant abuse with inhalant-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F18.150 | Inhalant abuse with inhalant-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F18.151 | Inhalant abuse with inhalant-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F18.159 | Inhalant abuse with inhalant-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F18.17 | Inhalant abuse with inhalant-induced dementia | Diagnosis | ICD-10-CM |
| F18.18 | Inhalant abuse with other inhalant-induced disorders | Diagnosis | ICD-10-CM |
| F18.180 | Inhalant abuse with inhalant-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F18.188 | Inhalant abuse with other inhalant-induced disorder | Diagnosis | ICD-10-CM |
| F18.19 | Inhalant abuse with unspecified inhalant-induced disorder | Diagnosis | ICD-10-CM |
| F18.2 | Inhalant dependence | Diagnosis | ICD-10-CM |
| F18.20 | Inhalant dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F18.21 | Inhalant dependence, in remission | Diagnosis | ICD-10-CM |
| F18.22 | Inhalant dependence with intoxication | Diagnosis | ICD-10-CM |
| F18.220 | Inhalant dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F18.221 | Inhalant dependence with intoxication delirium | Diagnosis | ICD-10-CM |
| F18.229 | Inhalant dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F18.24 | Inhalant dependence with inhalant-induced mood disorder | Diagnosis | ICD-10-CM |
| F18.25 | Inhalant dependence with inhalant-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F18.250 | Inhalant dependence with inhalant-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F18.251 | Inhalant dependence with inhalant-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F18.259 | Inhalant dependence with inhalant-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F18.27 | Inhalant dependence with inhalant-induced dementia | Diagnosis | ICD-10-CM |
| F18.28 | Inhalant dependence with other inhalant-induced disorders | Diagnosis | ICD-10-CM |
| F18.280 | Inhalant dependence with inhalant-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F18.288 | Inhalant dependence with other inhalant-induced disorder | Diagnosis | ICD-10-CM |
| F18.29 | Inhalant dependence with unspecified inhalant-induced disorder | Diagnosis | ICD-10-CM |
| F18.9 | Inhalant use, unspecified | Diagnosis | ICD-10-CM |
| F18.90 | Inhalant use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F18.92 | Inhalant use, unspecified with intoxication | Diagnosis | ICD-10-CM |
| F18.920 | Inhalant use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F18.921 | Inhalant use, unspecified with intoxication with delirium | Diagnosis | ICD-10-CM |
| F18.929 | Inhalant use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F18.94 | Inhalant use, unspecified with inhalant-induced mood disorder | Diagnosis | ICD-10-CM |
| F18.95 | Inhalant use, unspecified with inhalant-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F18.950 | Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F18.951 | Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F18.959 | Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F18.97 | Inhalant use, unspecified with inhalant-induced persisting dementia | Diagnosis | ICD-10-CM |
| F18.98 | Inhalant use, unspecified with other inhalant-induced disorders | Diagnosis | ICD-10-CM |
| F18.980 | Inhalant use, unspecified with inhalant-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F18.988 | Inhalant use, unspecified with other inhalant-induced disorder | Diagnosis | ICD-10-CM |
| F18.99 | Inhalant use, unspecified with unspecified inhalant-induced disorder | Diagnosis | ICD-10-CM |
| F19 | Other psychoactive substance related disorders | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| F19.1 | Other psychoactive substance abuse | Diagnosis | ICD-10-CM |
| F19.10 | Other psychoactive substance abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F19.11 | Other psychoactive substance abuse, in remission | Diagnosis | ICD-10-CM |
| F19.12 | Other psychoactive substance abuse with intoxication | Diagnosis | ICD-10-CM |
| F19.120 | Other psychoactive substance abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F19.121 | Other psychoactive substance abuse with intoxication delirium | Diagnosis | ICD-10-CM |
| F19.122 | Other psychoactive substance abuse with intoxication with perceptual disturbances | Diagnosis | ICD-10-CM |
| F19.129 | Other psychoactive substance abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F19.14 | Other psychoactive substance abuse with psychoactive substance-induced mood disorder | Diagnosis | ICD-10-CM |
| F19.15 | Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F19.150 | Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F19.151 | Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F19.159 | Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F19.16 | Other psychoactive substance abuse with psychoactive substance-induced persisting amnestic disorder | Diagnosis | ICD-10-CM |
| F19.17 | Other psychoactive substance abuse with psychoactive substance-induced persisting dementia | Diagnosis | ICD-10-CM |
| F19.18 | Other psychoactive substance abuse with other psychoactive substance-induced disorders | Diagnosis | ICD-10-CM |
| F19.180 | Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F19.181 | Other psychoactive substance abuse with psychoactive substance-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F19.182 | Other psychoactive substance abuse with psychoactive substance-induced sleep disorder | Diagnosis | ICD-10-CM |
| F19.188 | Other psychoactive substance abuse with other psychoactive substance-induced disorder | Diagnosis | ICD-10-CM |
| F19.19 | Other psychoactive substance abuse with unspecified psychoactive substance-induced disorder | Diagnosis | ICD-10-CM |
| F19.2 | Other psychoactive substance dependence | Diagnosis | ICD-10-CM |
| F19.20 | Other psychoactive substance dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F19.21 | Other psychoactive substance dependence, in remission | Diagnosis | ICD-10-CM |
| F19.22 | Other psychoactive substance dependence with intoxication | Diagnosis | ICD-10-CM |
| F19.220 | Other psychoactive substance dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F19.221 | Other psychoactive substance dependence with intoxication delirium | Diagnosis | ICD-10-CM |
| F19.222 | Other psychoactive substance dependence with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F19.229 | Other psychoactive substance dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F19.23 | Other psychoactive substance dependence with withdrawal | Diagnosis | ICD-10-CM |
| F19.230 | Other psychoactive substance dependence with withdrawal, uncomplicated | Diagnosis | ICD-10-CM |
| F19.231 | Other psychoactive substance dependence with withdrawal delirium | Diagnosis | ICD-10-CM |
| F19.232 | Other psychoactive substance dependence with withdrawal with perceptual disturbance | Diagnosis | ICD-10-CM |
| F19.239 | Other psychoactive substance dependence with withdrawal, unspecified | Diagnosis | ICD-10-CM |
| F19.24 | Other psychoactive substance dependence with psychoactive substance-induced mood disorder | Diagnosis | ICD-10-CM |
| F19.25 | Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F19.250 | Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F19.251 | Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F19.259 | Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F19.26 | Other psychoactive substance dependence with psychoactive substance-induced persisting amnesic disorder | Diagnosis | ICD-10-CM |
| F19.27 | Other psychoactive substance dependence with psychoactive substance-induced persisting dementia | Diagnosis | ICD-10-CM |
| F19.28 | Other psychoactive substance dependence with other psychoactive substance-induced disorders | Diagnosis | ICD-10-CM |
| F19.280 | Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F19.281 | Other psychoactive substance dependence with psychoactive substance-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F19.282 | Other psychoactive substance dependence with psychoactive substance-induced sleep disorder | Diagnosis | ICD-10-CM |
| F19.288 | Other psychoactive substance dependence with other psychoactive substance-induced disorder | Diagnosis | ICD-10-CM |
| F19.29 | Other psychoactive substance dependence with unspecified psychoactive substance-induced disorder | Diagnosis | ICD-10-CM |
| F19.9 | Other psychoactive substance use, unspecified | Diagnosis | ICD-10-CM |
| F19.90 | Other psychoactive substance use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F19.92 | Other psychoactive substance use, unspecified with intoxication | Diagnosis | ICD-10-CM |
| F19.920 | Other psychoactive substance use, unspecified with intoxication, | Diagnosis | ICD-10-CM |
| F19.921 | Other psychoactive substance use, unspecified with intoxication with delirium | Diagnosis | ICD-10-CM |
| F19.922 | Other psychoactive substance use, unspecified with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F19.929 | Other psychoactive substance use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F19.93 | Other psychoactive substance use, unspecified with withdrawal | Diagnosis | ICD-10-CM |
| F19.930 | Other psychoactive substance use, unspecified with withdrawal, | Diagnosis | ICD-10-CM |
| F19.931 | Other psychoactive substance use, unspecified with withdrawal delirium | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F19.932 | Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance | Diagnosis | ICD-10-CM |
| F19.939 | Other psychoactive substance use, unspecified with withdrawal, unspecified | Diagnosis | ICD-10-CM |
| F19.94 | Other psychoactive substance use, unspecified with psychoactive substance-induced mood disorder | Diagnosis | ICD-10-CM |
| F19.95 | Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F19.950 | Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F19.951 | Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F19.959 | Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F19.96 | Other psychoactive substance use, unspecified with psychoactive substance-induced persisting amnestic disorder | Diagnosis | ICD-10-CM |
| F19.97 | Other psychoactive substance use, unspecified with psychoactive substance-induced persisting dementia | Diagnosis | ICD-10-CM |
| F19.98 | Other psychoactive substance use, unspecified with other psychoactive substance-induced disorders | Diagnosis | ICD-10-CM |
| F19.980 | Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F19.981 | Other psychoactive substance use, unspecified with psychoactive substance-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F19.982 | Other psychoactive substance use, unspecified with psychoactive substance-induced sleep disorder | Diagnosis | ICD-10-CM |
| F19.988 | Other psychoactive substance use, unspecified with other psychoactive substance-induced disorder | Diagnosis | ICD-10-CM |
| F19.99 | Other psychoactive substance use, unspecified with unspecified psychoactive substance-induced disorder | Diagnosis | ICD-10-CM |
| F20 | Schizophrenia | Diagnosis | ICD-10-CM |
| F20.0 | Paranoid schizophrenia | Diagnosis | ICD-10-CM |
| F20.1 | Disorganized schizophrenia | Diagnosis | ICD-10-CM |
| F20.2 | Catatonic schizophrenia | Diagnosis | ICD-10-CM |
| F20.3 | Undifferentiated schizophrenia | Diagnosis | ICD-10-CM |
| F20.5 | Residual schizophrenia | Diagnosis | ICD-10-CM |
| F20.8 | Other schizophrenia | Diagnosis | ICD-10-CM |
| F20.81 | Schizophreniform disorder | Diagnosis | ICD-10-CM |
| F20.89 | Other schizophrenia | Diagnosis | ICD-10-CM |
| F20.9 | Schizophrenia, unspecified | Diagnosis | ICD-10-CM |
| F21 | Schizotypal disorder | Diagnosis | ICD-10-CM |
| F22 | Delusional disorders | Diagnosis | ICD-10-CM |
| F23 | Brief psychotic disorder | Diagnosis | ICD-10-CM |
| F24 | Shared psychotic disorder | Diagnosis | ICD-10-CM |
| F25 | Schizoaffective disorders | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| F25.0 | Schizoaffective disorder, bipolar type | Diagnosis | ICD-10-CM |
| F25.1 | Schizoaffective disorder, depressive type | Diagnosis | ICD-10-CM |
| F25.8 | Other schizoaffective disorders | Diagnosis | ICD-10-CM |
| F25.9 | Schizoaffective disorder, unspecified | Diagnosis | ICD-10-CM |
| F28 | Other psychotic disorder not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F29 | Unspecified psychosis not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F30 | Manic episode | Diagnosis | ICD-10-CM |
| F30.1 | Manic episode without psychotic symptoms | Diagnosis | ICD-10-CM |
| F30.10 | Manic episode without psychotic symptoms, unspecified | Diagnosis | ICD-10-CM |
| F30.11 | Manic episode without psychotic symptoms, mild | Diagnosis | ICD-10-CM |
| F30.12 | Manic episode without psychotic symptoms, moderate | Diagnosis | ICD-10-CM |
| F30.13 | Manic episode, severe, without psychotic symptoms | Diagnosis | ICD-10-CM |
| F30.2 | Manic episode, severe with psychotic symptoms | Diagnosis | ICD-10-CM |
| F30.3 | Manic episode in partial remission | Diagnosis | ICD-10-CM |
| F30.4 | Manic episode in full remission | Diagnosis | ICD-10-CM |
| F30.8 | Other manic episodes | Diagnosis | ICD-10-CM |
| F30.9 | Manic episode, unspecified | Diagnosis | ICD-10-CM |
| F31 | Bipolar disorder | Diagnosis | ICD-10-CM |
| F31.0 | Bipolar disorder, current episode hypomanic | Diagnosis | ICD-10-CM |
| F31.1 | Bipolar disorder, current episode manic without psychotic features | Diagnosis | ICD-10-CM |
| F31.10 | Bipolar disorder, current episode manic without psychotic features, | Diagnosis | ICD-10-CM |
| F31.11 | Bipolar disorder, current episode manic without psychotic features, mild | Diagnosis | ICD-10-CM |
| F31.12 | Bipolar disorder, current episode manic without psychotic features, moderate | Diagnosis | ICD-10-CM |
| F31.13 | Bipolar disorder, current episode manic without psychotic features, severe | Diagnosis | ICD-10-CM |
| F31.2 | Bipolar disorder, current episode manic severe with psychotic features | Diagnosis | ICD-10-CM |
| F31.3 | Bipolar disorder, current episode depressed, mild or moderate severity | Diagnosis | ICD-10-CM |
| F31.30 | Bipolar disorder, current episode depressed, mild or moderate severity, unspecified | Diagnosis | ICD-10-CM |
| F31.31 | Bipolar disorder, current episode depressed, mild | Diagnosis | ICD-10-CM |
| F31.32 | Bipolar disorder, current episode depressed, moderate | Diagnosis | ICD-10-CM |
| F31.4 | Bipolar disorder, current episode depressed, severe, without psychotic | Diagnosis | ICD-10-CM |
| F31.5 | Bipolar disorder, current episode depressed, severe, with psychotic features | Diagnosis | ICD-10-CM |
| F31.6 | Bipolar disorder, current episode mixed | Diagnosis | ICD-10-CM |
| F31.60 | Bipolar disorder, current episode mixed, unspecified | Diagnosis | ICD-10-CM |
| F31.61 | Bipolar disorder, current episode mixed, mild | Diagnosis | ICD-10-CM |
| F31.62 | Bipolar disorder, current episode mixed, moderate | Diagnosis | ICD-10-CM |
| F31.63 | Bipolar disorder, current episode mixed, severe, without psychotic features | Diagnosis | ICD-10-CM |
| F31.64 | Bipolar disorder, current episode mixed, severe, with psychotic features | Diagnosis | ICD-10-CM |
| F31.7 | Bipolar disorder, currently in remission | Diagnosis | ICD-10-CM |
| F31.70 | Bipolar disorder, currently in remission, most recent episode unspecified | Diagnosis | ICD-10-CM |
| F31.71 | Bipolar disorder, in partial remission, most recent episode hypomanic | Diagnosis | ICD-10-CM |
| F31.72 | Bipolar disorder, in full remission, most recent episode hypomanic | Diagnosis | ICD-10-CM |
| F31.73 | Bipolar disorder, in partial remission, most recent episode manic | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| F31.74 | Bipolar disorder, in full remission, most recent episode manic | Diagnosis | ICD-10-CM |
| F31.75 | Bipolar disorder, in partial remission, most recent episode depressed | Diagnosis | ICD-10-CM |
| F31.76 | Bipolar disorder, in full remission, most recent episode depressed | Diagnosis | ICD-10-CM |
| F31.77 | Bipolar disorder, in partial remission, most recent episode mixed | Diagnosis | ICD-10-CM |
| F31.78 | Bipolar disorder, in full remission, most recent episode mixed | Diagnosis | ICD-10-CM |
| F31.8 | Other bipolar disorders | Diagnosis | ICD-10-CM |
| F31.81 | Bipolar II disorder | Diagnosis | ICD-10-CM |
| F31.89 | Other bipolar disorder | Diagnosis | ICD-10-CM |
| F31.9 | Bipolar disorder, unspecified | Diagnosis | ICD-10-CM |
| F32 | Depressive episode | Diagnosis | ICD-10-CM |
| F32.0 | Major depressive disorder, single episode, mild | Diagnosis | ICD-10-CM |
| F32.1 | Major depressive disorder, single episode, moderate | Diagnosis | ICD-10-CM |
| F32.2 | Major depressive disorder, single episode, severe without psychotic features | Diagnosis | ICD-10-CM |
| F32.3 | Major depressive disorder, single episode, severe with psychotic features | Diagnosis | ICD-10-CM |
| F32.4 | Major depressive disorder, single episode, in partial remission | Diagnosis | ICD-10-CM |
| F32.5 | Major depressive disorder, single episode, in full remission | Diagnosis | ICD-10-CM |
| F32.8 | Other depressive episodes | Diagnosis | ICD-10-CM |
| F32.81 | Premenstrual dysphoric disorder | Diagnosis | ICD-10-CM |
| F32.89 | Other specified depressive episodes | Diagnosis | ICD-10-CM |
| F32.9 | Major depressive disorder, single episode, unspecified | Diagnosis | ICD-10-CM |
| F33 | Major depressive disorder, recurrent | Diagnosis | ICD-10-CM |
| F33.0 | Major depressive disorder, recurrent, mild | Diagnosis | ICD-10-CM |
| F33.1 | Major depressive disorder, recurrent, moderate | Diagnosis | ICD-10-CM |
| F33.2 | Major depressive disorder, recurrent severe without psychotic features | Diagnosis | ICD-10-CM |
| F33.3 | Major depressive disorder, recurrent, severe with psychotic symptoms | Diagnosis | ICD-10-CM |
| F33.4 | Major depressive disorder, recurrent, in remission | Diagnosis | ICD-10-CM |
| F33.40 | Major depressive disorder, recurrent, in remission, unspecified | Diagnosis | ICD-10-CM |
| F33.41 | Major depressive disorder, recurrent, in partial remission | Diagnosis | ICD-10-CM |
| F33.42 | Major depressive disorder, recurrent, in full remission | Diagnosis | ICD-10-CM |
| F33.8 | Other recurrent depressive disorders | Diagnosis | ICD-10-CM |
| F33.9 | Major depressive disorder, recurrent, unspecified | Diagnosis | ICD-10-CM |
| F34 | Persistent mood [affective] disorders | Diagnosis | ICD-10-CM |
| F34.0 | Cyclothymic disorder | Diagnosis | ICD-10-CM |
| F34.1 | Dysthymic disorder | Diagnosis | ICD-10-CM |
| F34.8 | Other persistent mood [affective] disorders | Diagnosis | ICD-10-CM |
| F34.81 | Disruptive mood dysregulation disorder | Diagnosis | ICD-10-CM |
| F34.89 | Other specified persistent mood disorders | Diagnosis | ICD-10-CM |
| F34.9 | Persistent mood [affective] disorder, unspecified | Diagnosis | ICD-10-CM |
| F39 | Unspecified mood [affective] disorder | Diagnosis | ICD-10-CM |
| F40 | Phobic anxiety disorders | Diagnosis | ICD-10-CM |
| F40.0 | Agoraphobia | Diagnosis | ICD-10-CM |
| F40.00 | Agoraphobia, unspecified | Diagnosis | ICD-10-CM |
| F40.01 | Agoraphobia with panic disorder | Diagnosis | ICD-10-CM |
| F40.02 | Agoraphobia without panic disorder | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| F40.1 | Social phobias | Diagnosis | ICD-10-CM |
| F40.10 | Social phobia, unspecified | Diagnosis | ICD-10-CM |
| F40.11 | Social phobia, generalized | Diagnosis | ICD-10-CM |
| F40.2 | Specific (isolated) phobias | Diagnosis | ICD-10-CM |
| F40.21 | Animal type phobia | Diagnosis | ICD-10-CM |
| F40.210 | Arachnophobia | Diagnosis | ICD-10-CM |
| F40.218 | Other animal type phobia | Diagnosis | ICD-10-CM |
| F40.22 | Natural environment type phobia | Diagnosis | ICD-10-CM |
| F40.220 | Fear of thunderstorms | Diagnosis | ICD-10-CM |
| F40.228 | Other natural environment type phobia | Diagnosis | ICD-10-CM |
| F40.23 | Blood, injection, injury type phobia | Diagnosis | ICD-10-CM |
| F40.230 | Fear of blood | Diagnosis | ICD-10-CM |
| F40.231 | Fear of injections and transfusions | Diagnosis | ICD-10-CM |
| F40.232 | Fear of other medical care | Diagnosis | ICD-10-CM |
| F40.233 | Fear of injury | Diagnosis | ICD-10-CM |
| F40.24 | Situational type phobia | Diagnosis | ICD-10-CM |
| F40.240 | Claustrophobia | Diagnosis | ICD-10-CM |
| F40.241 | Acrophobia | Diagnosis | ICD-10-CM |
| F40.242 | Fear of bridges | Diagnosis | ICD-10-CM |
| F40.243 | Fear of flying | Diagnosis | ICD-10-CM |
| F40.248 | Other situational type phobia | Diagnosis | ICD-10-CM |
| F40.29 | Other specified phobia | Diagnosis | ICD-10-CM |
| F40.290 | Androphobia | Diagnosis | ICD-10-CM |
| F40.291 | Gynephobia | Diagnosis | ICD-10-CM |
| F40.298 | Other specified phobia | Diagnosis | ICD-10-CM |
| F40.8 | Other phobic anxiety disorders | Diagnosis | ICD-10-CM |
| F40.9 | Phobic anxiety disorder, unspecified | Diagnosis | ICD-10-CM |
| F41 | Other anxiety disorders | Diagnosis | ICD-10-CM |
| F41.0 | Panic disorder [episodic paroxysmal anxiety] | Diagnosis | ICD-10-CM |
| F41.1 | Generalized anxiety disorder | Diagnosis | ICD-10-CM |
| F41.3 | Other mixed anxiety disorders | Diagnosis | ICD-10-CM |
| F41.8 | Other specified anxiety disorders | Diagnosis | ICD-10-CM |
| F41.9 | Anxiety disorder, unspecified | Diagnosis | ICD-10-CM |
| F42 | Obsessive-compulsive disorder | Diagnosis | ICD-10-CM |
| F42.2 | Mixed obsessional thoughts and acts | Diagnosis | ICD-10-CM |
| F42.3 | Hoarding disorder | Diagnosis | ICD-10-CM |
| F42.4 | Excoriation (skin-picking) disorder | Diagnosis | ICD-10-CM |
| F42.8 | Other obsessive-compulsive disorder | Diagnosis | ICD-10-CM |
| F42.9 | Obsessive-compulsive disorder, unspecified | Diagnosis | ICD-10-CM |
| F43 | Reaction to severe stress, and adjustment disorders | Diagnosis | ICD-10-CM |
| F43.0 | Acute stress reaction | Diagnosis | ICD-10-CM |
| F43.1 | Post-traumatic stress disorder (PTSD) | Diagnosis | ICD-10-CM |
| F43.10 | Post-traumatic stress disorder, unspecified | Diagnosis | ICD-10-CM |
| F43.11 | Post-traumatic stress disorder, acute | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| F43.12 | Post-traumatic stress disorder, chronic | Diagnosis | ICD-10-CM |
| F43.2 | Adjustment disorders | Diagnosis | ICD-10-CM |
| F43.20 | Adjustment disorder, unspecified | Diagnosis | ICD-10-CM |
| F43.21 | Adjustment disorder with depressed mood | Diagnosis | ICD-10-CM |
| F43.22 | Adjustment disorder with anxiety | Diagnosis | ICD-10-CM |
| F43.23 | Adjustment disorder with mixed anxiety and depressed mood | Diagnosis | ICD-10-CM |
| F43.24 | Adjustment disorder with disturbance of conduct | Diagnosis | ICD-10-CM |
| F43.25 | Adjustment disorder with mixed disturbance of emotions and conduct | Diagnosis | ICD-10-CM |
| F43.29 | Adjustment disorder with other symptoms | Diagnosis | ICD-10-CM |
| F43.8 | Other reactions to severe stress | Diagnosis | ICD-10-CM |
| F43.9 | Reaction to severe stress, unspecified | Diagnosis | ICD-10-CM |
| F44 | Dissociative and conversion disorders | Diagnosis | ICD-10-CM |
| F44.0 | Dissociative amnesia | Diagnosis | ICD-10-CM |
| F44.1 | Dissociative fugue | Diagnosis | ICD-10-CM |
| F44.2 | Dissociative stupor | Diagnosis | ICD-10-CM |
| F44.4 | Conversion disorder with motor symptom or deficit | Diagnosis | ICD-10-CM |
| F44.5 | Conversion disorder with seizures or convulsions | Diagnosis | ICD-10-CM |
| F44.6 | Conversion disorder with sensory symptom or deficit | Diagnosis | ICD-10-CM |
| F44.7 | Conversion disorder with mixed symptom presentation | Diagnosis | ICD-10-CM |
| F44.8 | Other dissociative and conversion disorders | Diagnosis | ICD-10-CM |
| F44.81 | Dissociative identity disorder | Diagnosis | ICD-10-CM |
| F44.89 | Other dissociative and conversion disorders | Diagnosis | ICD-10-CM |
| F44.9 | Dissociative and conversion disorder, unspecified | Diagnosis | ICD-10-CM |
| F45 | Somatoform disorders | Diagnosis | ICD-10-CM |
| F45.0 | Somatization disorder | Diagnosis | ICD-10-CM |
| F45.1 | Undifferentiated somatoform disorder | Diagnosis | ICD-10-CM |
| F45.2 | Hypochondriacal disorders | Diagnosis | ICD-10-CM |
| F45.20 | Hypochondriacal disorder, unspecified | Diagnosis | ICD-10-CM |
| F45.21 | Hypochondriasis | Diagnosis | ICD-10-CM |
| F45.22 | Body dysmorphic disorder | Diagnosis | ICD-10-CM |
| F45.29 | Other hypochondriacal disorders | Diagnosis | ICD-10-CM |
| F45.4 | Pain disorders related to psychological factors | Diagnosis | ICD-10-CM |
| F45.41 | Pain disorder exclusively related to psychological factors | Diagnosis | ICD-10-CM |
| F45.42 | Pain disorder with related psychological factors | Diagnosis | ICD-10-CM |
| F45.8 | Other somatoform disorders | Diagnosis | ICD-10-CM |
| F45.9 | Somatoform disorder, unspecified | Diagnosis | ICD-10-CM |
| F48 | Other nonpsychotic mental disorders | Diagnosis | ICD-10-CM |
| F48.1 | Depersonalization-derealization syndrome | Diagnosis | ICD-10-CM |
| F48.2 | Pseudobulbar affect | Diagnosis | ICD-10-CM |
| F48.8 | Other specified nonpsychotic mental disorders | Diagnosis | ICD-10-CM |
| F48.9 | Nonpsychotic mental disorder, unspecified | Diagnosis | ICD-10-CM |
| F50 | Eating disorders | Diagnosis | ICD-10-CM |
| F50.0 | Anorexia nervosa | Diagnosis | ICD-10-CM |
| F50.00 | Anorexia nervosa, unspecified | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| F50.01 | Anorexia nervosa, restricting type | Diagnosis | ICD-10-CM |
| F50.02 | Anorexia nervosa, binge eating/purging type | Diagnosis | ICD-10-CM |
| F50.2 | Bulimia nervosa | Diagnosis | ICD-10-CM |
| F50.8 | Other eating disorders | Diagnosis | ICD-10-CM |
| F50.81 | Binge eating disorder | Diagnosis | ICD-10-CM |
| F50.82 | Avoidant/restrictive food intake disorder | Diagnosis | ICD-10-CM |
| F50.89 | Other specified eating disorder | Diagnosis | ICD-10-CM |
| F50.9 | Eating disorder, unspecified | Diagnosis | ICD-10-CM |
| F51 | Sleep disorders not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F51.0 | Insomnia not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F51.01 | Primary insomnia | Diagnosis | ICD-10-CM |
| F51.02 | Adjustment insomnia | Diagnosis | ICD-10-CM |
| F51.03 | Paradoxical insomnia | Diagnosis | ICD-10-CM |
| F51.04 | Psychophysiologic insomnia | Diagnosis | ICD-10-CM |
| F51.05 | Insomnia due to other mental disorder | Diagnosis | ICD-10-CM |
| F51.09 | Other insomnia not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F51.1 | Hypersomnia not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F51.11 | Primary hypersomnia | Diagnosis | ICD-10-CM |
| F51.12 | Insufficient sleep syndrome | Diagnosis | ICD-10-CM |
| F51.13 | Hypersomnia due to other mental disorder | Diagnosis | ICD-10-CM |
| F51.19 | Other hypersomnia not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F51.3 | Sleepwalking [somnambulism] | Diagnosis | ICD-10-CM |
| F51.4 | Sleep terrors [night terrors] | Diagnosis | ICD-10-CM |
| F51.5 | Nightmare disorder | Diagnosis | ICD-10-CM |
| F51.8 | Other sleep disorders not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F51.9 | Sleep disorder not due to a substance or known physiological condition, unspecified | Diagnosis | ICD-10-CM |
| F52 | Sexual dysfunction not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F52.0 | Hypoactive sexual desire disorder | Diagnosis | ICD-10-CM |
| F52.1 | Sexual aversion disorder | Diagnosis | ICD-10-CM |
| F52.2 | Sexual arousal disorders | Diagnosis | ICD-10-CM |
| F52.21 | Male erectile disorder | Diagnosis | ICD-10-CM |
| F52.22 | Female sexual arousal disorder | Diagnosis | ICD-10-CM |
| F52.3 | Orgasmic disorder | Diagnosis | ICD-10-CM |
| F52.31 | Female orgasmic disorder | Diagnosis | ICD-10-CM |
| F52.32 | Male orgasmic disorder | Diagnosis | ICD-10-CM |
| F52.4 | Premature ejaculation | Diagnosis | ICD-10-CM |
| F52.5 | Vaginismus not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F52.6 | Dyspareunia not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F52.8 | Other sexual dysfunction not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F52.9 | Unspecified sexual dysfunction not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| F53 | Mental and behavioral disorders associated with the puerperium, not elsewhere classified | Diagnosis | ICD-10-CM |
| F53.0 | Postpartum depression | Diagnosis | ICD-10-CM |
| F53.1 | Puerperal psychosis | Diagnosis | ICD-10-CM |
| F54 | Psychological and behavioral factors associated with disorders or diseases classified elsewhere | Diagnosis | ICD-10-CM |
| F55.0 | Abuse of antacids | Diagnosis | ICD-10-CM |
| F55.1 | Abuse of herbal or folk remedies | Diagnosis | ICD-10-CM |
| F55.2 | Abuse of laxatives | Diagnosis | ICD-10-CM |
| F55.3 | Abuse of steroids or hormones | Diagnosis | ICD-10-CM |
| F55.4 | Abuse of vitamins | Diagnosis | ICD-10-CM |
| F55.8 | Abuse of other non-psychoactive substances | Diagnosis | ICD-10-CM |
| F59 | Unspecified behavioral syndromes associated with physiological disturbances and physical factors | Diagnosis | ICD-10-CM |
| F60 | Specific personality disorders | Diagnosis | ICD-10-CM |
| F60.0 | Paranoid personality disorder | Diagnosis | ICD-10-CM |
| F60.1 | Schizoid personality disorder | Diagnosis | ICD-10-CM |
| F60.2 | Antisocial personality disorder | Diagnosis | ICD-10-CM |
| F60.3 | Borderline personality disorder | Diagnosis | ICD-10-CM |
| F60.4 | Histrionic personality disorder | Diagnosis | ICD-10-CM |
| F60.5 | Obsessive-compulsive personality disorder | Diagnosis | ICD-10-CM |
| F60.6 | Avoidant personality disorder | Diagnosis | ICD-10-CM |
| F60.7 | Dependent personality disorder | Diagnosis | ICD-10-CM |
| F60.8 | Other specific personality disorders | Diagnosis | ICD-10-CM |
| F60.81 | Narcissistic personality disorder | Diagnosis | ICD-10-CM |
| F60.89 | Other specific personality disorders | Diagnosis | ICD-10-CM |
| F60.9 | Personality disorder, unspecified | Diagnosis | ICD-10-CM |
| F63 | Impulse disorders | Diagnosis | ICD-10-CM |
| F63.0 | Pathological gambling | Diagnosis | ICD-10-CM |
| F63.1 | Pyromania | Diagnosis | ICD-10-CM |
| F63.2 | Kleptomania | Diagnosis | ICD-10-CM |
| F63.3 | Trichotillomania | Diagnosis | ICD-10-CM |
| F63.8 | Other impulse disorders | Diagnosis | ICD-10-CM |
| F63.81 | Intermittent explosive disorder | Diagnosis | ICD-10-CM |
| F63.89 | Other impulse disorders | Diagnosis | ICD-10-CM |
| F63.9 | Impulse disorder, unspecified | Diagnosis | ICD-10-CM |
| F64 | Gender identity disorders | Diagnosis | ICD-10-CM |
| F64.0 | Transsexualism | Diagnosis | ICD-10-CM |
| F64.1 | Dual role transvestism | Diagnosis | ICD-10-CM |
| F64.2 | Gender identity disorder of childhood | Diagnosis | ICD-10-CM |
| F64.8 | Other gender identity disorders | Diagnosis | ICD-10-CM |
| F64.9 | Gender identity disorder, unspecified | Diagnosis | ICD-10-CM |
| F65 | Paraphilias | Diagnosis | ICD-10-CM |
| F65.0 | Fetishism | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| F65.1 | Transvestic fetishism | Diagnosis | ICD-10-CM |
| F65.2 | Exhibitionism | Diagnosis | ICD-10-CM |
| F65.3 | Voyeurism | Diagnosis | ICD-10-CM |
| F65.4 | Pedophilia | Diagnosis | ICD-10-CM |
| F65.5 | Sadomasochism | Diagnosis | ICD-10-CM |
| F65.50 | Sadomasochism, unspecified | Diagnosis | ICD-10-CM |
| F65.51 | Sexual masochism | Diagnosis | ICD-10-CM |
| F65.52 | Sexual sadism | Diagnosis | ICD-10-CM |
| F65.8 | Other paraphilias | Diagnosis | ICD-10-CM |
| F65.81 | Frotteurism | Diagnosis | ICD-10-CM |
| F65.89 | Other paraphilias | Diagnosis | ICD-10-CM |
| F65.9 | Paraphilia, unspecified | Diagnosis | ICD-10-CM |
| F66 | Other sexual disorders | Diagnosis | ICD-10-CM |
| F68 | Other disorders of adult personality and behavior | Diagnosis | ICD-10-CM |
| F68.1 | Factitious disorder imposed on self | Diagnosis | ICD-10-CM |
| F68.10 | Factitious disorder imposed on self, unspecified | Diagnosis | ICD-10-CM |
| F68.11 | Factitious disorder imposed on self, with predominantly psychological signs and symptoms | Diagnosis | ICD-10-CM |
| F68.12 | Factitious disorder imposed on self, with predominantly physical signs and symptoms | Diagnosis | ICD-10-CM |
| F68.13 | Factitious disorder imposed on self, with combined psychological and physical signs and symptoms | Diagnosis | ICD-10-CM |
| F68.8 | Other specified disorders of adult personality and behavior | Diagnosis | ICD-10-CM |
| F68.A | Factitious disorder imposed on another | Diagnosis | ICD-10-CM |
| F69 | Unspecified disorder of adult personality and behavior | Diagnosis | ICD-10-CM |
| F70 | Mild intellectual disabilities | Diagnosis | ICD-10-CM |
| F71 | Moderate intellectual disabilities | Diagnosis | ICD-10-CM |
| F72 | Severe intellectual disabilities | Diagnosis | ICD-10-CM |
| F73 | Profound intellectual disabilities | Diagnosis | ICD-10-CM |
| F78 | Other intellectual disabilities | Diagnosis | ICD-10-CM |
| F79 | Unspecified intellectual disabilities | Diagnosis | ICD-10-CM |
| F80 | Specific developmental disorders of speech and language | Diagnosis | ICD-10-CM |
| F80.0 | Phonological disorder | Diagnosis | ICD-10-CM |
| F80.1 | Expressive language disorder | Diagnosis | ICD-10-CM |
| F80.2 | Mixed receptive-expressive language disorder | Diagnosis | ICD-10-CM |
| F80.4 | Speech and language development delay due to hearing loss | Diagnosis | ICD-10-CM |
| F80.8 | Other developmental disorders of speech and language | Diagnosis | ICD-10-CM |
| F80.81 | Childhood onset fluency disorder | Diagnosis | ICD-10-CM |
| F80.82 | Social pragmatic communication disorder | Diagnosis | ICD-10-CM |
| F80.89 | Other developmental disorders of speech and language | Diagnosis | ICD-10-CM |
| F80.9 | Developmental disorder of speech and language, unspecified | Diagnosis | ICD-10-CM |
| F81 | Specific developmental disorders of scholastic skills | Diagnosis | ICD-10-CM |
| F81.0 | Specific reading disorder | Diagnosis | ICD-10-CM |
| F81.2 | Mathematics disorder | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| F81.8 | Other developmental disorders of scholastic skills | Diagnosis | ICD-10-CM |
| F81.81 | Disorder of written expression | Diagnosis | ICD-10-CM |
| F81.89 | Other developmental disorders of scholastic skills | Diagnosis | ICD-10-CM |
| F81.9 | Developmental disorder of scholastic skills, unspecified | Diagnosis | ICD-10-CM |
| F82 | Specific developmental disorder of motor function | Diagnosis | ICD-10-CM |
| F84 | Pervasive developmental disorders | Diagnosis | ICD-10-CM |
| F84.0 | Autistic disorder | Diagnosis | ICD-10-CM |
| F84.2 | Rett's syndrome | Diagnosis | ICD-10-CM |
| F84.3 | Other childhood disintegrative disorder | Diagnosis | ICD-10-CM |
| F84.5 | Asperger's syndrome | Diagnosis | ICD-10-CM |
| F84.8 | Other pervasive developmental disorders | Diagnosis | ICD-10-CM |
| F84.9 | Pervasive developmental disorder, unspecified | Diagnosis | ICD-10-CM |
| F88 | Other disorders of psychological development | Diagnosis | ICD-10-CM |
| F89 | Unspecified disorder of psychological development | Diagnosis | ICD-10-CM |
| F90 | Attention-deficit hyperactivity disorders | Diagnosis | ICD-10-CM |
| F90.0 | Attention-deficit hyperactivity disorder, predominantly inattentive type | Diagnosis | ICD-10-CM |
| F90.1 | Attention-deficit hyperactivity disorder, predominantly hyperactive type | Diagnosis | ICD-10-CM |
| F90.2 | Attention-deficit hyperactivity disorder, combined type | Diagnosis | ICD-10-CM |
| F90.8 | Attention-deficit hyperactivity disorder, other type | Diagnosis | ICD-10-CM |
| F90.9 | Attention-deficit hyperactivity disorder, unspecified type | Diagnosis | ICD-10-CM |
| F91 | Conduct disorders | Diagnosis | ICD-10-CM |
| F91.0 | Conduct disorder confined to family context | Diagnosis | ICD-10-CM |
| F91.1 | Conduct disorder, childhood-onset type | Diagnosis | ICD-10-CM |
| F91.2 | Conduct disorder, adolescent-onset type | Diagnosis | ICD-10-CM |
| F91.3 | Oppositional defiant disorder | Diagnosis | ICD-10-CM |
| F91.8 | Other conduct disorders | Diagnosis | ICD-10-CM |
| F91.9 | Conduct disorder, unspecified | Diagnosis | ICD-10-CM |
| F93 | Emotional disorders with onset specific to childhood | Diagnosis | ICD-10-CM |
| F93.0 | Separation anxiety disorder of childhood | Diagnosis | ICD-10-CM |
| F93.8 | Other childhood emotional disorders | Diagnosis | ICD-10-CM |
| F93.9 | Childhood emotional disorder, unspecified | Diagnosis | ICD-10-CM |
| F94 | Disorders of social functioning with onset specific to childhood and | Diagnosis | ICD-10-CM |
| F94.0 | Selective mutism | Diagnosis | ICD-10-CM |
| F94.1 | Reactive attachment disorder of childhood | Diagnosis | ICD-10-CM |
| F94.2 | Disinhibited attachment disorder of childhood | Diagnosis | ICD-10-CM |
| F94.8 | Other childhood disorders of social functioning | Diagnosis | ICD-10-CM |
| F94.9 | Childhood disorder of social functioning, unspecified | Diagnosis | ICD-10-CM |
| F95 | Tic disorder | Diagnosis | ICD-10-CM |
| F95.0 | Transient tic disorder | Diagnosis | ICD-10-CM |
| F95.1 | Chronic motor or vocal tic disorder | Diagnosis | ICD-10-CM |
| F95.2 | Tourette's disorder | Diagnosis | ICD-10-CM |
| F95.8 | Other tic disorders | Diagnosis | ICD-10-CM |
| F95.9 | Tic disorder, unspecified | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F98 | Other behavioral and emotional disorders with onset usually occurring in childhood and adolescence | Diagnosis | ICD-10-CM |
| F98.0 | Enuresis not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F98.1 | Encopresis not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F98.2 | Other feeding disorders of infancy and childhood | Diagnosis | ICD-10-CM |
| F98.21 | Rumination disorder of infancy | Diagnosis | ICD-10-CM |
| F98.29 | Other feeding disorders of infancy and early childhood | Diagnosis | ICD-10-CM |
| F98.3 | Pica of infancy and childhood | Diagnosis | ICD-10-CM |
| F98.4 | Stereotyped movement disorders | Diagnosis | ICD-10-CM |
| F98.5 | Adult onset fluency disorder | Diagnosis | ICD-10-CM |
| F98.8 | Other specified behavioral and emotional disorders with onset usually occurring in childhood and adolescence | Diagnosis | ICD-10-CM |
| F98.9 | Unspecified behavioral and emotional disorders with onset usually occurring in childhood and adolescence | Diagnosis | ICD-10-CM |
| F99 | Mental disorder, not otherwise specified | Diagnosis | ICD-10-CM |
| G13.2 | Systemic atrophy primarily affecting the central nervous system in myxedema | Diagnosis | ICD-10-CM |
| G13.8 | Systemic atrophy primarily affecting central nervous system in other diseases classified elsewhere | Diagnosis | ICD-10-CM |
| G25.70 | Drug induced movement disorder, unspecified | Diagnosis | ICD-10-CM |
| G25.71 | Drug induced akathisia | Diagnosis | ICD-10-CM |
| G25.79 | Other drug induced movement disorders | Diagnosis | ICD-10-CM |
| G25.89 | Other specified extrapyramidal and movement disorders | Diagnosis | ICD-10-CM |
| G25.9 | Extrapyramidal and movement disorder, unspecified | Diagnosis | ICD-10-CM |
| G26 | Extrapyramidal and movement disorders in diseases classified elsewhere | Diagnosis | ICD-10-CM |
| G30.0 | Alzheimer's disease with early onset | Diagnosis | ICD-10-CM |
| G30.1 | Alzheimer's disease with late onset | Diagnosis | ICD-10-CM |
| G30.8 | Other Alzheimer's disease | Diagnosis | ICD-10-CM |
| G30.9 | Alzheimer's disease, unspecified | Diagnosis | ICD-10-CM |
| G31.01 | Pick's disease | Diagnosis | ICD-10-CM |
| G31.09 | Other frontotemporal dementia | Diagnosis | ICD-10-CM |
| G31.1 | Senile degeneration of brain, not elsewhere classified | Diagnosis | ICD-10-CM |
| G31.2 | Degeneration of nervous system due to alcohol | Diagnosis | ICD-10-CM |
| G31.81 | Alpers disease | Diagnosis | ICD-10-CM |
| G31.82 | Leigh's disease | Diagnosis | ICD-10-CM |
| G31.83 | Dementia with Lewy bodies | Diagnosis | ICD-10-CM |
| G31.84 | Mild cognitive impairment, so stated | Diagnosis | ICD-10-CM |
| G31.85 | Corticobasal degeneration | Diagnosis | ICD-10-CM |
| G31.89 | Other specified degenerative diseases of nervous system | Diagnosis | ICD-10-CM |
| G31.9 | Degenerative disease of nervous system, unspecified | Diagnosis | ICD-10-CM |
| G44.209 | Tension-type headache, unspecified, not intractable | Diagnosis | ICD-10-CM |
| G47 | Sleep disorders | Diagnosis | ICD-10-CM |
| G47.0 | Insomnia | Diagnosis | ICD-10-CM |
| G47.00 | Insomnia, unspecified | Diagnosis | ICD-10-CM |
| G47.01 | Insomnia due to medical condition | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| G47.09 | Other insomnia | Diagnosis | ICD-10-CM |
| G47.1 | Hypersomnia | Diagnosis | ICD-10-CM |
| G47.10 | Hypersomnia, unspecified | Diagnosis | ICD-10-CM |
| G47.11 | Idiopathic hypersomnia with long sleep time | Diagnosis | ICD-10-CM |
| G47.12 | Idiopathic hypersomnia without long sleep time | Diagnosis | ICD-10-CM |
| G47.13 | Recurrent hypersomnia | Diagnosis | ICD-10-CM |
| G47.14 | Hypersomnia due to medical condition | Diagnosis | ICD-10-CM |
| G47.19 | Other hypersomnia | Diagnosis | ICD-10-CM |
| G47.2 | Circadian rhythm sleep disorders | Diagnosis | ICD-10-CM |
| G47.20 | Circadian rhythm sleep disorder, unspecified type | Diagnosis | ICD-10-CM |
| G47.21 | Circadian rhythm sleep disorder, delayed sleep phase type | Diagnosis | ICD-10-CM |
| G47.22 | Circadian rhythm sleep disorder, advanced sleep phase type | Diagnosis | ICD-10-CM |
| G47.23 | Circadian rhythm sleep disorder, irregular sleep wake type | Diagnosis | ICD-10-CM |
| G47.24 | Circadian rhythm sleep disorder, free running type | Diagnosis | ICD-10-CM |
| G47.25 | Circadian rhythm sleep disorder, jet lag type | Diagnosis | ICD-10-CM |
| G47.26 | Circadian rhythm sleep disorder, shift work type | Diagnosis | ICD-10-CM |
| G47.27 | Circadian rhythm sleep disorder in conditions classified elsewhere | Diagnosis | ICD-10-CM |
| G47.29 | Other circadian rhythm sleep disorder | Diagnosis | ICD-10-CM |
| G47.3 | Sleep apnea | Diagnosis | ICD-10-CM |
| G47.30 | Sleep apnea, unspecified | Diagnosis | ICD-10-CM |
| G47.31 | Primary central sleep apnea | Diagnosis | ICD-10-CM |
| G47.33 | Obstructive sleep apnea (adult) (pediatric) | Diagnosis | ICD-10-CM |
| G47.34 | Idiopathic sleep related nonobstructive alveolar hypoventilation | Diagnosis | ICD-10-CM |
| G47.35 | Congenital central alveolar hypoventilation syndrome | Diagnosis | ICD-10-CM |
| G47.36 | Sleep related hypoventilation in conditions classified elsewhere | Diagnosis | ICD-10-CM |
| G47.37 | Central sleep apnea in conditions classified elsewhere | Diagnosis | ICD-10-CM |
| G47.39 | Other sleep apnea | Diagnosis | ICD-10-CM |
| G47.4 | Narcolepsy and cataplexy | Diagnosis | ICD-10-CM |
| G47.41 | Narcolepsy | Diagnosis | ICD-10-CM |
| G47.411 | Narcolepsy with cataplexy | Diagnosis | ICD-10-CM |
| G47.419 | Narcolepsy without cataplexy | Diagnosis | ICD-10-CM |
| G47.42 | Narcolepsy in conditions classified elsewhere | Diagnosis | ICD-10-CM |
| G47.421 | Narcolepsy in conditions classified elsewhere with cataplexy | Diagnosis | ICD-10-CM |
| G47.429 | Narcolepsy in conditions classified elsewhere without cataplexy | Diagnosis | ICD-10-CM |
| G47.5 | Parasomnia | Diagnosis | ICD-10-CM |
| G47.50 | Parasomnia, unspecified | Diagnosis | ICD-10-CM |
| G47.51 | Confusional arousals | Diagnosis | ICD-10-CM |
| G47.52 | REM sleep behavior disorder | Diagnosis | ICD-10-CM |
| G47.53 | Recurrent isolated sleep paralysis | Diagnosis | ICD-10-CM |
| G47.54 | Parasomnia in conditions classified elsewhere | Diagnosis | ICD-10-CM |
| G47.59 | Other parasomnia | Diagnosis | ICD-10-CM |
| G47.6 | Sleep related movement disorders | Diagnosis | ICD-10-CM |
| G47.61 | Periodic limb movement disorder | Diagnosis | ICD-10-CM |
| G47.62 | Sleep related leg cramps | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|------------|
| G47.63 | Sleep related bruxism | Diagnosis | ICD-10-CM |
| G47.69 | Other sleep related movement disorders | Diagnosis | ICD-10-CM |
| G47.8 | Other sleep disorders | Diagnosis | ICD-10-CM |
| G47.9 | Sleep disorder, unspecified | Diagnosis | ICD-10-CM |
| G62.1 | Alcoholic polyneuropathy | Diagnosis | ICD-10-CM |
| G91.0 | Communicating hydrocephalus | Diagnosis | ICD-10-CM |
| G91.1 | Obstructive hydrocephalus | Diagnosis | ICD-10-CM |
| G91.2 | (Idiopathic) normal pressure hydrocephalus | Diagnosis | ICD-10-CM |
| G91.3 | Post-traumatic hydrocephalus, unspecified | Diagnosis | ICD-10-CM |
| G91.4 | Hydrocephalus in diseases classified elsewhere | Diagnosis | ICD-10-CM |
| G91.8 | Other hydrocephalus | Diagnosis | ICD-10-CM |
| G91.9 | Hydrocephalus, unspecified | Diagnosis | ICD-10-CM |
| G93.40 | Encephalopathy, unspecified | Diagnosis | ICD-10-CM |
| G93.41 | Metabolic encephalopathy | Diagnosis | ICD-10-CM |
| G93.49 | Other encephalopathy | Diagnosis | ICD-10-CM |
| G93.7 | Reye's syndrome | Diagnosis | ICD-10-CM |
| G93.89 | Other specified disorders of brain | Diagnosis | ICD-10-CM |
| G93.9 | Disorder of brain, unspecified | Diagnosis | ICD-10-CM |
| G94 | Other disorders of brain in diseases classified elsewhere | Diagnosis | ICD-10-CM |
| GZ2ZZZZ | Crisis Intervention | Procedure | ICD-10-PCS |
| GZ50ZZZ | Individual Psychotherapy, Interactive | Procedure | ICD-10-PCS |
| GZ51ZZZ | Individual Psychotherapy, Behavioral | Procedure | ICD-10-PCS |
| GZ52ZZZ | Individual Psychotherapy, Cognitive | Procedure | ICD-10-PCS |
| GZ53ZZZ | Individual Psychotherapy, Interpersonal | Procedure | ICD-10-PCS |
| GZ54ZZZ | Individual Psychotherapy, Psychoanalysis | Procedure | ICD-10-PCS |
| GZ55ZZZ | Individual Psychotherapy, Psychodynamic | Procedure | ICD-10-PCS |
| GZ56ZZZ | Individual Psychotherapy, Supportive | Procedure | ICD-10-PCS |
| GZ58ZZZ | Individual Psychotherapy, Cognitive-Behavioral | Procedure | ICD-10-PCS |
| GZC9ZZZ | Biofeedback | Procedure | ICD-10-PCS |
| GZFZZZZ | Hypnosis | Procedure | ICD-10-PCS |
| GZHZZZZ | Group Psychotherapy | Procedure | ICD-10-PCS |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | Procedure | HCPCS |
| H0007 | Alcohol and/or drug services; crisis intervention (outpatient) | Procedure | HCPCS |
| H0008 | Alcohol and/or drug services; subacute detoxification (hospital inpatient) | Procedure | HCPCS |
| H0010 | Alcohol and/or drug services; subacute detoxification (residential addiction program inpatient) | Procedure | HCPCS |
| H0011 | Alcohol and/or drug services; acute detoxification (residential addiction program inpatient) | Procedure | HCPCS |
| H0012 | Alcohol and/or drug services; subacute detoxification (residential addiction program outpatient) | Procedure | HCPCS |
| H0013 | Alcohol and/or drug services; acute detoxification (residential addiction program outpatient) | Procedure | HCPCS |
| H0014 | Alcohol and/or drug services; ambulatory detoxification | Procedure | HCPCS |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|---|---------------|------------|
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | Procedure | HCPCS |
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | Procedure | HCPCS |
| H0022 | Alcohol and/or drug intervention service (planned facilitation) | Procedure | HCPCS |
| H2035 | Alcohol and/or other drug treatment program, per hour | Procedure | HCPCS |
| H2036 | Alcohol and/or other drug treatment program, per diem | Procedure | HCPCS |
| H93.25 | Central auditory processing disorder | Diagnosis | ICD-10-CM |
| HZ2ZZZZ | Detoxification Services for Substance Abuse Treatment | Procedure | ICD-10-PCS |
| HZ30ZZZ | Individual Counseling for Substance Abuse Treatment, Cognitive | Procedure | ICD-10-PCS |
| HZ31ZZZ | Individual Counseling for Substance Abuse Treatment, Behavioral | Procedure | ICD-10-PCS |
| HZ32ZZZ | Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral | Procedure | ICD-10-PCS |
| HZ33ZZZ | Individual Counseling for Substance Abuse Treatment, 12-Step | Procedure | ICD-10-PCS |
| HZ34ZZZ | Individual Counseling for Substance Abuse Treatment, Interpersonal | Procedure | ICD-10-PCS |
| HZ35ZZZ | Individual Counseling for Substance Abuse Treatment, Vocational | Procedure | ICD-10-PCS |
| HZ36ZZZ | Individual Counseling for Substance Abuse Treatment, Psychoeducation | Procedure | ICD-10-PCS |
| HZ37ZZZ | Individual Counseling for Substance Abuse Treatment, Motivational Enhancement | Procedure | ICD-10-PCS |
| HZ38ZZZ | Individual Counseling for Substance Abuse Treatment, Confrontational | Procedure | ICD-10-PCS |
| HZ39ZZZ | Individual Counseling for Substance Abuse Treatment, Continuing Care | Procedure | ICD-10-PCS |
| HZ3BZZZ | Individual Counseling for Substance Abuse Treatment, Spiritual | Procedure | ICD-10-PCS |
| HZ40ZZZ | Group Counseling for Substance Abuse Treatment, Cognitive | Procedure | ICD-10-PCS |
| HZ41ZZZ | Group Counseling for Substance Abuse Treatment, Behavioral | Procedure | ICD-10-PCS |
| HZ42ZZZ | Group Counseling for Substance Abuse Treatment, Cognitive-Behavioral | Procedure | ICD-10-PCS |
| HZ43ZZZ | Group Counseling for Substance Abuse Treatment, 12-Step | Procedure | ICD-10-PCS |
| HZ44ZZZ | Group Counseling for Substance Abuse Treatment, Interpersonal | Procedure | ICD-10-PCS |
| HZ45ZZZ | Group Counseling for Substance Abuse Treatment, Vocational | Procedure | ICD-10-PCS |
| HZ46ZZZ | Group Counseling for Substance Abuse Treatment, Psychoeducation | Procedure | ICD-10-PCS |
| HZ47ZZZ | Group Counseling for Substance Abuse Treatment, Motivational Enhancement | Procedure | ICD-10-PCS |
| HZ48ZZZ | Group Counseling for Substance Abuse Treatment, Confrontational | Procedure | ICD-10-PCS |
| HZ49ZZZ | Group Counseling for Substance Abuse Treatment, Continuing Care | Procedure | ICD-10-PCS |
| HZ4BZZZ | Group Counseling for Substance Abuse Treatment, Spiritual | Procedure | ICD-10-PCS |
| HZ50ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Cognitive | Procedure | ICD-10-PCS |
| HZ51ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Behavioral | Procedure | ICD-10-PCS |
| HZ52ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Cognitive-Behavioral | Procedure | ICD-10-PCS |
| HZ53ZZZ | Individual Psychotherapy for Substance Abuse Treatment, 12-Step | Procedure | ICD-10-PCS |
| HZ54ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Interpersonal | Procedure | ICD-10-PCS |
| HZ55ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Interactive | Procedure | ICD-10-PCS |
| HZ56ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Psychoeducation | Procedure | ICD-10-PCS |
| HZ57ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Motivational Enhancement | Procedure | ICD-10-PCS |
| HZ58ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Confrontational | Procedure | ICD-10-PCS |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|------------|
| HZ59ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Supportive | Procedure | ICD-10-PCS |
| HZ5BZZZ | Individual Psychotherapy for Substance Abuse Treatment, Psychoanalysis | Procedure | ICD-10-PCS |
| HZ5CZZZ | Individual Psychotherapy for Substance Abuse Treatment, Psychodynamic | Procedure | ICD-10-PCS |
| HZ5DZZZ | Individual Psychotherapy for Substance Abuse Treatment, Psychophysiological | Procedure | ICD-10-PCS |
| HZ63ZZZ | Family Counseling for Substance Abuse Treatment | Procedure | ICD-10-PCS |
| HZ83ZZZ | Medication Management for Substance Abuse Treatment, Antabuse | Procedure | ICD-10-PCS |
| HZ86ZZZ | Medication Management for Substance Abuse Treatment, Clonidine | Procedure | ICD-10-PCS |
| HZ88ZZZ | Medication Management for Substance Abuse Treatment, Psychiatric Medication | Procedure | ICD-10-PCS |
| HZ89ZZZ | Medication Management for Substance Abuse Treatment, Other Replacement Medication | Procedure | ICD-10-PCS |
| HZ93ZZZ | Pharmacotherapy for Substance Abuse Treatment, Antabuse | Procedure | ICD-10-PCS |
| HZ96ZZZ | Pharmacotherapy for Substance Abuse Treatment, Clonidine | Procedure | ICD-10-PCS |
| HZ98ZZZ | Pharmacotherapy for Substance Abuse Treatment, Psychiatric Medication | Procedure | ICD-10-PCS |
| HZ99ZZZ | Pharmacotherapy for Substance Abuse Treatment, Other Replacement Medication | Procedure | ICD-10-PCS |
| I42.6 | Alcoholic cardiomyopathy | Diagnosis | ICD-10-CM |
| I67.83 | Posterior reversible encephalopathy syndrome | Diagnosis | ICD-10-CM |
| J0400 | Injection, aripiprazole, intramuscular, 0.25 mg | Procedure | HCPCS |
| J0401 | Injection, aripiprazole, extended release, 1 mg | Procedure | HCPCS |
| J0570 | Buprenorphine implant, 74.2 mg | Procedure | HCPCS |
| J0571 | Buprenorphine, oral, 1 mg | Procedure | HCPCS |
| J0572 | Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine | Procedure | HCPCS |
| J0573 | Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg buprenorphine | Procedure | HCPCS |
| J0574 | Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine | Procedure | HCPCS |
| J0575 | Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine | Procedure | HCPCS |
| J0592 | Injection, buprenorphine HCl, 0.1 mg | Procedure | HCPCS |
| J1230 | Injection, methadone HCl, up to 10 mg | Procedure | HCPCS |
| J1320 | Injection, amitriptyline HCl, up to 20 mg | Procedure | HCPCS |
| J1630 | Injection, haloperidol, up to 5 mg | Procedure | HCPCS |
| J1631 | Injection, haloperidol decanoate, per 50 mg | Procedure | HCPCS |
| J1790 | Injection, droperidol, up to 5 mg | Procedure | HCPCS |
| J1810 | Injection, droperidol and fentanyl citrate, up to 2 ml ampule | Procedure | HCPCS |
| J1942 | Injection, aripiprazole lauroxil, 1 mg | Procedure | HCPCS |
| J1990 | Injection, chlordiazepoxide HCl, up to 100 mg | Procedure | HCPCS |
| J2060 | Injection, lorazepam, 2 mg | Procedure | HCPCS |
| J2062 | Loxapine for inhalation, 1 mg | Procedure | HCPCS |
| J2212 | Injection, methylnaltrexone, 0.1 mg | Procedure | HCPCS |
| J2315 | Injection, naltrexone, depot form, 1 mg | Procedure | HCPCS |
| J2330 | Injection, thiothixene, up to 4 mg | Procedure | HCPCS |
| J2358 | Injection, olanzapine, long-acting, 1 mg | Procedure | HCPCS |
| J2426 | Injection, paliperidone palmitate extended release, 1 mg | Procedure | HCPCS |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| J2515 | Injection, pentobarbital sodium, per 50 mg | Procedure | HCPCS |
| J2680 | Injection, fluphenazine decanoate, up to 25 mg | Procedure | HCPCS |
| J2794 | Injection, risperidone (RISPERDAL CONSTA), 0.5 mg | Procedure | HCPCS |
| J3230 | Injection, chlorpromazine HCl, up to 50 mg | Procedure | HCPCS |
| J3270 | Injection, imipramine hcl, up to 25 mg | Procedure | HCPCS |
| J3310 | Injection, perphenazine, up to 5 mg | Procedure | HCPCS |
| J3360 | Injection, diazepam, up to 5 mg | Procedure | HCPCS |
| J3486 | Injection, ziprasidone mesylate, 10 mg | Procedure | HCPCS |
| K29.2 | Alcoholic gastritis | Diagnosis | ICD-10-CM |
| K29.20 | Alcoholic gastritis without bleeding | Diagnosis | ICD-10-CM |
| K29.21 | Alcoholic gastritis with bleeding | Diagnosis | ICD-10-CM |
| K70.0 | Alcoholic fatty liver | Diagnosis | ICD-10-CM |
| K70.10 | Alcoholic hepatitis without ascites | Diagnosis | ICD-10-CM |
| K70.11 | Alcoholic hepatitis with ascites | Diagnosis | ICD-10-CM |
| K70.2 | Alcoholic fibrosis and sclerosis of liver | Diagnosis | ICD-10-CM |
| K70.30 | Alcoholic cirrhosis of liver without ascites | Diagnosis | ICD-10-CM |
| K70.31 | Alcoholic cirrhosis of liver with ascites | Diagnosis | ICD-10-CM |
| K70.40 | Alcoholic hepatic failure without coma | Diagnosis | ICD-10-CM |
| K70.41 | Alcoholic hepatic failure with coma | Diagnosis | ICD-10-CM |
| K70.9 | Alcoholic liver disease, unspecified | Diagnosis | ICD-10-CM |
| L8679 | Implantable neurostimulator, pulse generator, any type | Procedure | HCPCS |
| L8680 | Implantable neurostimulator electrode, each | Procedure | HCPCS |
| L8681 | Patient programmer (external) for use with implantable programmable neurostimulator pulse generator, replacement only | Procedure | HCPCS |
| L8682 | Implantable neurostimulator radiofrequency receiver | Procedure | HCPCS |
| L8683 | Radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receiver | Procedure | HCPCS |
| L8685 | Implantable neurostimulator pulse generator, single array, rechargeable, includes extension | Procedure | HCPCS |
| L8686 | Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension | Procedure | HCPCS |
| L8687 | Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension | Procedure | HCPCS |
| L8688 | Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension | Procedure | HCPCS |
| L8689 | External recharging system for battery (internal) for use with implantable neurostimulator, replacement only | Procedure | HCPCS |
| M1A.10X0 | Lead-induced chronic gout, unspecified site, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.10X1 | Lead-induced chronic gout, unspecified site, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1110 | Lead-induced chronic gout, right shoulder, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1111 | Lead-induced chronic gout, right shoulder, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1120 | Lead-induced chronic gout, left shoulder, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1121 | Lead-induced chronic gout, left shoulder, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1190 | Lead-induced chronic gout, unspecified shoulder, without tophus (tophi) | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| M1A.1191 | Lead-induced chronic gout, unspecified shoulder, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1210 | Lead-induced chronic gout, right elbow, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1211 | Lead-induced chronic gout, right elbow, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1220 | Lead-induced chronic gout, left elbow, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1221 | Lead-induced chronic gout, left elbow, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1290 | Lead-induced chronic gout, unspecified elbow, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1291 | Lead-induced chronic gout, unspecified elbow, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1310 | Lead-induced chronic gout, right wrist, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1311 | Lead-induced chronic gout, right wrist, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1320 | Lead-induced chronic gout, left wrist, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1321 | Lead-induced chronic gout, left wrist, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1390 | Lead-induced chronic gout, unspecified wrist, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1391 | Lead-induced chronic gout, unspecified wrist, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1410 | Lead-induced chronic gout, right hand, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1411 | Lead-induced chronic gout, right hand, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1420 | Lead-induced chronic gout, left hand, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1421 | Lead-induced chronic gout, left hand, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1490 | Lead-induced chronic gout, unspecified hand, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1491 | Lead-induced chronic gout, unspecified hand, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1510 | Lead-induced chronic gout, right hip, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1511 | Lead-induced chronic gout, right hip, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1520 | Lead-induced chronic gout, left hip, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1521 | Lead-induced chronic gout, left hip, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1590 | Lead-induced chronic gout, unspecified hip, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1591 | Lead-induced chronic gout, unspecified hip, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1610 | Lead-induced chronic gout, right knee, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1611 | Lead-induced chronic gout, right knee, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1620 | Lead-induced chronic gout, left knee, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1621 | Lead-induced chronic gout, left knee, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1690 | Lead-induced chronic gout, unspecified knee, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1691 | Lead-induced chronic gout, unspecified knee, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1710 | Lead-induced chronic gout, right ankle and foot, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1711 | Lead-induced chronic gout, right ankle and foot, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1720 | Lead-induced chronic gout, left ankle and foot, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1721 | Lead-induced chronic gout, left ankle and foot, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1790 | Lead-induced chronic gout, unspecified ankle and foot, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1791 | Lead-induced chronic gout, unspecified ankle and foot, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.18X0 | Lead-induced chronic gout, vertebrae, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.18X1 | Lead-induced chronic gout, vertebrae, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.19X0 | Lead-induced chronic gout, multiple sites, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.19X1 | Lead-induced chronic gout, multiple sites, with tophus (tophi) | Diagnosis | ICD-10-CM |
| O35.5XX0 | Maternal care for (suspected) damage to fetus by drugs, not applicable or unspecified | Diagnosis | ICD-10-CM |
| O35.5XX1 | Maternal care for (suspected) damage to fetus by drugs, fetus 1 | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| O35.5XX2 | Maternal care for (suspected) damage to fetus by drugs, fetus 2 | Diagnosis | ICD-10-CM |
| O35.5XX3 | Maternal care for (suspected) damage to fetus by drugs, fetus 3 | Diagnosis | ICD-10-CM |
| O35.5XX4 | Maternal care for (suspected) damage to fetus by drugs, fetus 4 | Diagnosis | ICD-10-CM |
| O35.5XX5 | Maternal care for (suspected) damage to fetus by drugs, fetus 5 | Diagnosis | ICD-10-CM |
| O35.5XX9 | Maternal care for (suspected) damage to fetus by drugs, other fetus | Diagnosis | ICD-10-CM |
| O90.6 | Postpartum mood disturbance | Diagnosis | ICD-10-CM |
| O99.310 | Alcohol use complicating pregnancy, unspecified trimester | Diagnosis | ICD-10-CM |
| O99.311 | Alcohol use complicating pregnancy, first trimester | Diagnosis | ICD-10-CM |
| O99.312 | Alcohol use complicating pregnancy, second trimester | Diagnosis | ICD-10-CM |
| O99.313 | Alcohol use complicating pregnancy, third trimester | Diagnosis | ICD-10-CM |
| O99.314 | Alcohol use complicating childbirth | Diagnosis | ICD-10-CM |
| O99.315 | Alcohol use complicating the puerperium | Diagnosis | ICD-10-CM |
| O99.320 | Drug use complicating pregnancy, unspecified trimester | Diagnosis | ICD-10-CM |
| O99.321 | Drug use complicating pregnancy, first trimester | Diagnosis | ICD-10-CM |
| O99.322 | Drug use complicating pregnancy, second trimester | Diagnosis | ICD-10-CM |
| O99.323 | Drug use complicating pregnancy, third trimester | Diagnosis | ICD-10-CM |
| O99.324 | Drug use complicating childbirth | Diagnosis | ICD-10-CM |
| O99.325 | Drug use complicating the puerperium | Diagnosis | ICD-10-CM |
| Q9991 | Injection, buprenorphine extended-release (Sublocade), less than or equal to 100 mg | Procedure | HCPCS |
| Q9992 | Injection, buprenorphine extended-release (Sublocade), greater than 100 mg | Procedure | HCPCS |
| R37 | Sexual dysfunction, unspecified | Diagnosis | ICD-10-CM |
| R44.0 | Auditory hallucinations | Diagnosis | ICD-10-CM |
| R44.2 | Other hallucinations | Diagnosis | ICD-10-CM |
| R44.3 | Hallucinations, unspecified | Diagnosis | ICD-10-CM |
| R45.1 | Restlessness and agitation | Diagnosis | ICD-10-CM |
| R45.2 | Unhappiness | Diagnosis | ICD-10-CM |
| R45.3 | Demoralization and apathy | Diagnosis | ICD-10-CM |
| R45.4 | Irritability and anger | Diagnosis | ICD-10-CM |
| R45.5 | Hostility | Diagnosis | ICD-10-CM |
| R45.6 | Violent behavior | Diagnosis | ICD-10-CM |
| R45.7 | State of emotional shock and stress, unspecified | Diagnosis | ICD-10-CM |
| R45.81 | Low self-esteem | Diagnosis | ICD-10-CM |
| R45.82 | Worries | Diagnosis | ICD-10-CM |
| R45.83 | Excessive crying of child, adolescent or adult | Diagnosis | ICD-10-CM |
| R45.84 | Anhedonia | Diagnosis | ICD-10-CM |
| R45.850 | Homicidal ideations | Diagnosis | ICD-10-CM |
| R45.851 | Suicidal ideations | Diagnosis | ICD-10-CM |
| R45.86 | Emotional lability | Diagnosis | ICD-10-CM |
| R45.89 | Other symptoms and signs involving emotional state | Diagnosis | ICD-10-CM |
| R46.0 | Very low level of personal hygiene | Diagnosis | ICD-10-CM |
| R46.1 | Bizarre personal appearance | Diagnosis | ICD-10-CM |
| R46.2 | Strange and inexplicable behavior | Diagnosis | ICD-10-CM |
| R46.3 | Overactivity | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| R46.4 | Slowness and poor responsiveness | Diagnosis | ICD-10-CM |
| R46.5 | Suspiciousness and marked evasiveness | Diagnosis | ICD-10-CM |
| R46.6 | Undue concern and preoccupation with stressful events | Diagnosis | ICD-10-CM |
| R46.7 | Verbosity and circumstantial detail obscuring reason for contact | Diagnosis | ICD-10-CM |
| R46.81 | Obsessive-compulsive behavior | Diagnosis | ICD-10-CM |
| R46.89 | Other symptoms and signs involving appearance and behavior | Diagnosis | ICD-10-CM |
| R48.0 | Dyslexia and alexia | Diagnosis | ICD-10-CM |
| S0109 | Methadone, oral, 5 mg | Procedure | HCPCS |
| S0136 | Clozapine, 25 mg | Procedure | HCPCS |
| S0160 | Dextroamphetamine sulfate, 5 mg | Procedure | HCPCS |
| S0163 | Injection, risperidone, long acting, 12.5 mg | Procedure | HCPCS |
| S0166 | Injection, olanzapine, 2.5 mg | Procedure | HCPCS |
| T1006 | Alcohol and/or substance abuse services, family/couple counseling | Procedure | HCPCS |
| T1007 | Alcohol and/or substance abuse services, treatment plan development and/or modification | Procedure | HCPCS |
| T1008 | Day treatment for individual alcohol and/or substance abuse services | Procedure | HCPCS |
| T1010 | Meals for individuals receiving alcohol and/or substance abuse services (when meals not included in the program) | Procedure | HCPCS |
| T1012 | Alcohol and/or substance abuse services, skills development | Procedure | HCPCS |
| T14.91 | Suicide attempt | Diagnosis | ICD-10-CM |
| T14.91XA | Suicide attempt, initial encounter | Diagnosis | ICD-10-CM |
| T14.91XD | Suicide attempt, subsequent encounter | Diagnosis | ICD-10-CM |
| T14.91XS | Suicide attempt, sequela | Diagnosis | ICD-10-CM |
| T36.0X1A | Poisoning by penicillins, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T36.0X2 | Poisoning by penicillins, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.0X2A | Poisoning by penicillins, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.0X2D | Poisoning by penicillins, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.0X2S | Poisoning by penicillins, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.0X3A | Poisoning by penicillins, assault, initial encounter | Diagnosis | ICD-10-CM |
| T36.0X4A | Poisoning by penicillins, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T36.1X1A | Poisoning by cephalosporins and other beta-lactam antibiotics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T36.1X2 | Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.1X2A | Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.1X2D | Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.1X2S | Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.1X3A | Poisoning by cephalosporins and other beta-lactam antibiotics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T36.1X4A | Poisoning by cephalosporins and other beta-lactam antibiotics, undetermined, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T36.2X1A | Poisoning by chloramphenicol group, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T36.2X2 | Poisoning by chloramphenicol group, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.2X2A | Poisoning by chloramphenicol group, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.2X2D | Poisoning by chloramphenicol group, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.2X2S | Poisoning by chloramphenicol group, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.2X3A | Poisoning by chloramphenicol group, assault, initial encounter | Diagnosis | ICD-10-CM |
| T36.2X4A | Poisoning by chloramphenicol group, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T36.3X1A | Poisoning by macrolides, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T36.3X2 | Poisoning by macrolides, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.3X2A | Poisoning by macrolides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.3X2D | Poisoning by macrolides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.3X2S | Poisoning by macrolides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.3X3A | Poisoning by macrolides, assault, initial encounter | Diagnosis | ICD-10-CM |
| T36.3X4A | Poisoning by macrolides, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T36.4X1A | Poisoning by tetracyclines, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T36.4X2 | Poisoning by tetracyclines, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.4X2A | Poisoning by tetracyclines, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.4X2D | Poisoning by tetracyclines, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.4X2S | Poisoning by tetracyclines, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.4X3A | Poisoning by tetracyclines, assault, initial encounter | Diagnosis | ICD-10-CM |
| T36.4X4A | Poisoning by tetracyclines, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T36.5X1A | Poisoning by aminoglycosides, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T36.5X2 | Poisoning by aminoglycosides, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.5X2A | Poisoning by aminoglycosides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.5X2D | Poisoning by aminoglycosides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.5X2S | Poisoning by aminoglycosides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.5X3A | Poisoning by aminoglycosides, assault, initial encounter | Diagnosis | ICD-10-CM |
| T36.5X4A | Poisoning by aminoglycosides, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T36.6X1A | Poisoning by rifampicins, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T36.6X2 | Poisoning by rifampicins, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.6X2A | Poisoning by rifampicins, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.6X2D | Poisoning by rifampicins, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.6X2S | Poisoning by rifampicins, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.6X3A | Poisoning by rifampicins, assault, initial encounter | Diagnosis | ICD-10-CM |
| T36.6X4A | Poisoning by rifampicins, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T36.7X1A | Poisoning by antifungal antibiotics, systemically used, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T36.7X2 | Poisoning by antifungal antibiotics, systemically used, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.7X2A | Poisoning by antifungal antibiotics, systemically used, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.7X2D | Poisoning by antifungal antibiotics, systemically used, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T36.7X2S | Poisoning by antifungal antibiotics, systemically used, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.7X3A | Poisoning by antifungal antibiotics, systemically used, assault, initial encounter | Diagnosis | ICD-10-CM |
| T36.7X4A | Poisoning by antifungal antibiotics, systemically used, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T36.8X1A | Poisoning by other systemic antibiotics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T36.8X2 | Poisoning by other systemic antibiotics, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.8X2A | Poisoning by other systemic antibiotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.8X2D | Poisoning by other systemic antibiotics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.8X2S | Poisoning by other systemic antibiotics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.8X3A | Poisoning by other systemic antibiotics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T36.8X4A | Poisoning by other systemic antibiotics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T36.91XA | Poisoning by unspecified systemic antibiotic, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T36.92 | Poisoning by unspecified systemic antibiotic, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.92XA | Poisoning by unspecified systemic antibiotic, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.92XD | Poisoning by unspecified systemic antibiotic, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.92XS | Poisoning by unspecified systemic antibiotic, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.93XA | Poisoning by unspecified systemic antibiotic, assault, initial encounter | Diagnosis | ICD-10-CM |
| T36.94XA | Poisoning by unspecified systemic antibiotic, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T37.0X1A | Poisoning by sulfonamides, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T37.0X2 | Poisoning by sulfonamides, intentional self-harm | Diagnosis | ICD-10-CM |
| T37.0X2A | Poisoning by sulfonamides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.0X2D | Poisoning by sulfonamides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.0X2S | Poisoning by sulfonamides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.0X3A | Poisoning by sulfonamides, assault, initial encounter | Diagnosis | ICD-10-CM |
| T37.0X4A | Poisoning by sulfonamides, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T37.1X1A | Poisoning by antimycobacterial drugs, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T37.1X2 | Poisoning by antimycobacterial drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T37.1X2A | Poisoning by antimycobacterial drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.1X2D | Poisoning by antimycobacterial drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.1X2S | Poisoning by antimycobacterial drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.1X3A | Poisoning by antimycobacterial drugs, assault, initial encounter | Diagnosis | ICD-10-CM |
| T37.1X4A | Poisoning by antimycobacterial drugs, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T37.2X1A | Poisoning by antimalarials and drugs acting on other blood protozoa, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T37.2X2 | Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T37.2X2A | Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.2X2D | Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.2X2S | Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.2X3A | Poisoning by antimalarials and drugs acting on other blood protozoa, assault, initial encounter | Diagnosis | ICD-10-CM |
| T37.2X4A | Poisoning by antimalarials and drugs acting on other blood protozoa, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T37.3X1A | Poisoning by other antiprotozoal drugs, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T37.3X2 | Poisoning by other antiprotozoal drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T37.3X2A | Poisoning by other antiprotozoal drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.3X2D | Poisoning by other antiprotozoal drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.3X2S | Poisoning by other antiprotozoal drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.3X3A | Poisoning by other antiprotozoal drugs, assault, initial encounter | Diagnosis | ICD-10-CM |
| T37.3X4A | Poisoning by other antiprotozoal drugs, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T37.4X1A | Poisoning by anthelmintics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T37.4X2 | Poisoning by anthelmintics, intentional self-harm | Diagnosis | ICD-10-CM |
| T37.4X2A | Poisoning by anthelmintics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.4X2D | Poisoning by anthelmintics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.4X2S | Poisoning by anthelmintics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.4X3A | Poisoning by anthelmintics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T37.4X4A | Poisoning by anthelmintics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T37.5X1A | Poisoning by antiviral drugs, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T37.5X2 | Poisoning by antiviral drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T37.5X2A | Poisoning by antiviral drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.5X2D | Poisoning by antiviral drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.5X2S | Poisoning by antiviral drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.5X3A | Poisoning by antiviral drugs, assault, initial encounter | Diagnosis | ICD-10-CM |
| T37.5X4A | Poisoning by antiviral drugs, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T37.8X1A | Poisoning by other specified systemic anti-infectives and antiparasitics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T37.8X2 | Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm | Diagnosis | ICD-10-CM |
| T37.8X2A | Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.8X2D | Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.8X2S | Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T37.8X3A | Poisoning by other specified systemic anti-infectives and antiparasitics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T37.8X4A | Poisoning by other specified systemic anti-infectives and antiparasitics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T37.91XA | Poisoning by unspecified systemic anti-infective and antiparasitics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T37.92 | Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm | Diagnosis | ICD-10-CM |
| T37.92XA | Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.92XD | Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.92XS | Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.93XA | Poisoning by unspecified systemic anti-infective and antiparasitics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T37.94XA | Poisoning by unspecified systemic anti-infective and antiparasitics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T38.0X1A | Poisoning by glucocorticoids and synthetic analogues, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T38.0X2 | Poisoning by glucocorticoids and synthetic analogues, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.0X2A | Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.0X2D | Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.0X2S | Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.0X3A | Poisoning by glucocorticoids and synthetic analogues, assault, initial encounter | Diagnosis | ICD-10-CM |
| T38.0X4A | Poisoning by glucocorticoids and synthetic analogues, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T38.1X1A | Poisoning by thyroid hormones and substitutes, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T38.1X2 | Poisoning by thyroid hormones and substitutes, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.1X2A | Poisoning by thyroid hormones and substitutes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.1X2D | Poisoning by thyroid hormones and substitutes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.1X2S | Poisoning by thyroid hormones and substitutes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.1X3A | Poisoning by thyroid hormones and substitutes, assault, initial encounter | Diagnosis | ICD-10-CM |
| T38.1X4A | Poisoning by thyroid hormones and substitutes, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T38.2X1A | Poisoning by antithyroid drugs, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T38.2X2 | Poisoning by antithyroid drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.2X2A | Poisoning by antithyroid drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T38.2X2D | Poisoning by antithyroid drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.2X2S | Poisoning by antithyroid drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.2X3A | Poisoning by antithyroid drugs, assault, initial encounter | Diagnosis | ICD-10-CM |
| T38.2X4A | Poisoning by antithyroid drugs, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T38.3X1A | Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T38.3X2 | Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.3X2A | Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.3X2D | Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.3X2S | Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.3X3A | Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, assault, initial encounter | Diagnosis | ICD-10-CM |
| T38.3X4A | Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T38.4X1A | Poisoning by oral contraceptives, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T38.4X2 | Poisoning by oral contraceptives, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.4X2A | Poisoning by oral contraceptives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.4X2D | Poisoning by oral contraceptives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.4X2S | Poisoning by oral contraceptives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.4X3A | Poisoning by oral contraceptives, assault, initial encounter | Diagnosis | ICD-10-CM |
| T38.4X4A | Poisoning by oral contraceptives, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T38.5X1A | Poisoning by other estrogens and progestogens, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T38.5X2 | Poisoning by other estrogens and progestogens, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.5X2A | Poisoning by other estrogens and progestogens, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.5X2D | Poisoning by other estrogens and progestogens, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.5X2S | Poisoning by other estrogens and progestogens, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.5X3A | Poisoning by other estrogens and progestogens, assault, initial encounter | Diagnosis | ICD-10-CM |
| T38.5X4A | Poisoning by other estrogens and progestogens, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T38.6X1A | Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T38.6X2 | Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.6X2A | Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.6X2D | Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T38.6X2S | Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.6X3A | Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, assault, initial encounter | Diagnosis | ICD-10-CM |
| T38.6X4A | Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T38.7X1A | Poisoning by androgens and anabolic congeners, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T38.7X2 | Poisoning by androgens and anabolic congeners, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.7X2A | Poisoning by androgens and anabolic congeners, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.7X2D | Poisoning by androgens and anabolic congeners, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.7X2S | Poisoning by androgens and anabolic congeners, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.7X3A | Poisoning by androgens and anabolic congeners, assault, initial encounter | Diagnosis | ICD-10-CM |
| T38.7X4A | Poisoning by androgens and anabolic congeners, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T38.801A | Poisoning by unspecified hormones and synthetic substitutes, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T38.802 | Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.802A | Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.802D | Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.802S | Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.803A | Poisoning by unspecified hormones and synthetic substitutes, assault, initial encounter | Diagnosis | ICD-10-CM |
| T38.804A | Poisoning by unspecified hormones and synthetic substitutes, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T38.811A | Poisoning by anterior pituitary [adenohypophyseal] hormones, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T38.812 | Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.812A | Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.812D | Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.812S | Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.813A | Poisoning by anterior pituitary [adenohypophyseal] hormones, assault, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T38.814A | Poisoning by anterior pituitary [adenohypophyseal] hormones, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T38.891A | Poisoning by other hormones and synthetic substitutes, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T38.892 | Poisoning by other hormones and synthetic substitutes, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.892A | Poisoning by other hormones and synthetic substitutes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.892D | Poisoning by other hormones and synthetic substitutes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.892S | Poisoning by other hormones and synthetic substitutes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.893A | Poisoning by other hormones and synthetic substitutes, assault, initial encounter | Diagnosis | ICD-10-CM |
| T38.894A | Poisoning by other hormones and synthetic substitutes, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T38.901A | Poisoning by unspecified hormone antagonists, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T38.902 | Poisoning by unspecified hormone antagonists, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.902A | Poisoning by unspecified hormone antagonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.902D | Poisoning by unspecified hormone antagonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.902S | Poisoning by unspecified hormone antagonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.903A | Poisoning by unspecified hormone antagonists, assault, initial encounter | Diagnosis | ICD-10-CM |
| T38.904A | Poisoning by unspecified hormone antagonists, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T38.991A | Poisoning by other hormone antagonists, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T38.992 | Poisoning by other hormone antagonists, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.992A | Poisoning by other hormone antagonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.992D | Poisoning by other hormone antagonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.992S | Poisoning by other hormone antagonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.993A | Poisoning by other hormone antagonists, assault, initial encounter | Diagnosis | ICD-10-CM |
| T38.994A | Poisoning by other hormone antagonists, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T39.011A | Poisoning by aspirin, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T39.012 | Poisoning by aspirin, intentional self-harm | Diagnosis | ICD-10-CM |
| T39.012A | Poisoning by aspirin, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.012D | Poisoning by aspirin, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.012S | Poisoning by aspirin, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.013A | Poisoning by aspirin, assault, initial encounter | Diagnosis | ICD-10-CM |
| T39.014A | Poisoning by aspirin, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T39.091A | Poisoning by salicylates, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T39.092 | Poisoning by salicylates, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T39.092A | Poisoning by salicylates, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.092D | Poisoning by salicylates, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.092S | Poisoning by salicylates, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.093A | Poisoning by salicylates, assault, initial encounter | Diagnosis | ICD-10-CM |
| T39.094A | Poisoning by salicylates, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T39.1X1A | Poisoning by 4-Aminophenol derivatives, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T39.1X2 | Poisoning by 4-Aminophenol derivatives, intentional self-harm | Diagnosis | ICD-10-CM |
| T39.1X2A | Poisoning by 4-Aminophenol derivatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.1X2D | Poisoning by 4-Aminophenol derivatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.1X2S | Poisoning by 4-Aminophenol derivatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.1X3A | Poisoning by 4-Aminophenol derivatives, assault, initial encounter | Diagnosis | ICD-10-CM |
| T39.1X4A | Poisoning by 4-Aminophenol derivatives, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T39.2X1A | Poisoning by pyrazolone derivatives, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T39.2X2 | Poisoning by pyrazolone derivatives, intentional self-harm | Diagnosis | ICD-10-CM |
| T39.2X2A | Poisoning by pyrazolone derivatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.2X2D | Poisoning by pyrazolone derivatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.2X2S | Poisoning by pyrazolone derivatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.2X3A | Poisoning by pyrazolone derivatives, assault, initial encounter | Diagnosis | ICD-10-CM |
| T39.2X4A | Poisoning by pyrazolone derivatives, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T39.311A | Poisoning by propionic acid derivatives, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T39.312 | Poisoning by propionic acid derivatives, intentional self-harm | Diagnosis | ICD-10-CM |
| T39.312A | Poisoning by propionic acid derivatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.312D | Poisoning by propionic acid derivatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.312S | Poisoning by propionic acid derivatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.313A | Poisoning by propionic acid derivatives, assault, initial encounter | Diagnosis | ICD-10-CM |
| T39.314A | Poisoning by propionic acid derivatives, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T39.391A | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T39.392 | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm | Diagnosis | ICD-10-CM |
| T39.392A | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.392D | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.392S | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.393A | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], assault, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T39.394A | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T39.4X1A | Poisoning by antirheumatics, not elsewhere classified, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T39.4X2 | Poisoning by antirheumatics, not elsewhere classified, intentional self-harm | Diagnosis | ICD-10-CM |
| T39.4X2A | Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.4X2D | Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.4X2S | Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.4X3A | Poisoning by antirheumatics, not elsewhere classified, assault, initial | Diagnosis | ICD-10-CM |
| T39.4X4A | Poisoning by antirheumatics, not elsewhere classified, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T39.8X1A | Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T39.8X2 | Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm | Diagnosis | ICD-10-CM |
| T39.8X2A | Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.8X2D | Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.8X2S | Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.8X3A | Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, assault, initial encounter | Diagnosis | ICD-10-CM |
| T39.8X4A | Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T39.91XA | Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T39.92 | Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm | Diagnosis | ICD-10-CM |
| T39.92XA | Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.92XD | Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.92XS | Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.93XA | Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, assault, initial encounter | Diagnosis | ICD-10-CM |
| T39.94XA | Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.0X1A | Poisoning by opium, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.0X1D | Poisoning by opium, accidental (unintentional), subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T40.0X1S | Poisoning by opium, accidental (unintentional), sequela | Diagnosis | ICD-10-CM |
| T40.0X2 | Poisoning by opium, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.0X2A | Poisoning by opium, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.0X2D | Poisoning by opium, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.0X2S | Poisoning by opium, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.0X3A | Poisoning by opium, assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.0X3D | Poisoning by opium, assault, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.0X3S | Poisoning by opium, assault, sequela | Diagnosis | ICD-10-CM |
| T40.0X4A | Poisoning by opium, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.0X4D | Poisoning by opium, undetermined, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.0X4S | Poisoning by opium, undetermined, sequela | Diagnosis | ICD-10-CM |
| T40.0X5A | Adverse effect of opium, initial encounter | Diagnosis | ICD-10-CM |
| T40.0X5D | Adverse effect of opium, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.0X5S | Adverse effect of opium, sequela | Diagnosis | ICD-10-CM |
| T40.0X6A | Underdosing of opium, initial encounter | Diagnosis | ICD-10-CM |
| T40.0X6D | Underdosing of opium, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.0X6S | Underdosing of opium, sequela | Diagnosis | ICD-10-CM |
| T40.1X1A | Poisoning by heroin, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.1X1D | Poisoning by heroin, accidental (unintentional), subsequent encounter | Diagnosis | ICD-10-CM |
| T40.1X1S | Poisoning by heroin, accidental (unintentional), sequela | Diagnosis | ICD-10-CM |
| T40.1X2 | Poisoning by heroin, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.1X2A | Poisoning by heroin, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.1X2D | Poisoning by heroin, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.1X2S | Poisoning by heroin, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.1X3A | Poisoning by heroin, assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.1X3D | Poisoning by heroin, assault, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.1X3S | Poisoning by heroin, assault, sequela | Diagnosis | ICD-10-CM |
| T40.1X4A | Poisoning by heroin, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.1X4D | Poisoning by heroin, undetermined, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.1X4S | Poisoning by heroin, undetermined, sequela | Diagnosis | ICD-10-CM |
| T40.1X5A | Adverse effect of heroin, initial encounter | Diagnosis | ICD-10-CM |
| T40.1X5D | Adverse effect of heroin, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.1X5S | Adverse effect of heroin, sequela | Diagnosis | ICD-10-CM |
| T40.2X1A | Poisoning by other opioids, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.2X2 | Poisoning by other opioids, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.2X2A | Poisoning by other opioids, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.2X2D | Poisoning by other opioids, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.2X2S | Poisoning by other opioids, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.2X3A | Poisoning by other opioids, assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.2X4A | Poisoning by other opioids, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.3X1A | Poisoning by methadone, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.3X2 | Poisoning by methadone, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.3X2A | Poisoning by methadone, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.3X2D | Poisoning by methadone, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T40.3X2S | Poisoning by methadone, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.3X3A | Poisoning by methadone, assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.3X4A | Poisoning by methadone, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.412 | Poisoning by fentanyl or fentanyl analogs, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.412A | Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.412D | Poisoning by fentanyl or fentanyl analogs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.412S | Poisoning by fentanyl or fentanyl analogs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.422 | Poisoning by tramadol, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.422A | Poisoning by tramadol, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.422D | Poisoning by tramadol, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.422S | Poisoning by tramadol, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.492 | Poisoning by other synthetic narcotics, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.492A | Poisoning by other synthetic narcotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.492D | Poisoning by other synthetic narcotics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.492S | Poisoning by other synthetic narcotics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.4X1A | Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.4X2 | Poisoning by other synthetic narcotics, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.4X2A | Poisoning by other synthetic narcotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.4X2D | Poisoning by other synthetic narcotics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.4X2S | Poisoning by other synthetic narcotics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.4X3A | Poisoning by other synthetic narcotics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.4X4A | Poisoning by other synthetic narcotics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.5X1A | Poisoning by cocaine, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.5X1D | Poisoning by cocaine, accidental (unintentional), subsequent encounter | Diagnosis | ICD-10-CM |
| T40.5X1S | Poisoning by cocaine, accidental (unintentional), sequela | Diagnosis | ICD-10-CM |
| T40.5X2 | Poisoning by cocaine, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.5X2A | Poisoning by cocaine, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.5X2D | Poisoning by cocaine, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.5X2S | Poisoning by cocaine, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.5X3A | Poisoning by cocaine, assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.5X3D | Poisoning by cocaine, assault, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.5X3S | Poisoning by cocaine, assault, sequela | Diagnosis | ICD-10-CM |
| T40.5X4A | Poisoning by cocaine, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.5X4D | Poisoning by cocaine, undetermined, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.5X4S | Poisoning by cocaine, undetermined, sequela | Diagnosis | ICD-10-CM |
| T40.5X5A | Adverse effect of cocaine, initial encounter | Diagnosis | ICD-10-CM |
| T40.5X5D | Adverse effect of cocaine, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.5X5S | Adverse effect of cocaine, sequela | Diagnosis | ICD-10-CM |
| T40.5X6A | Underdosing of cocaine, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T40.5X6D | Underdosing of cocaine, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.5X6S | Underdosing of cocaine, sequela | Diagnosis | ICD-10-CM |
| T40.601A | Poisoning by unspecified narcotics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.602 | Poisoning by unspecified narcotics, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.602A | Poisoning by unspecified narcotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.602D | Poisoning by unspecified narcotics, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T40.602S | Poisoning by unspecified narcotics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.603A | Poisoning by unspecified narcotics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.604A | Poisoning by unspecified narcotics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.691A | Poisoning by other narcotics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.692 | Poisoning by other narcotics, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.692A | Poisoning by other narcotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.692D | Poisoning by other narcotics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.692S | Poisoning by other narcotics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.693A | Poisoning by other narcotics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.694A | Poisoning by other narcotics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.712 | Poisoning by cannabis, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.712A | Poisoning by cannabis, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.712D | Poisoning by cannabis, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.712S | Poisoning by cannabis, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.722 | Poisoning by synthetic cannabinoids, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.722A | Poisoning by synthetic cannabinoids, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.722D | Poisoning by synthetic cannabinoids, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.722S | Poisoning by synthetic cannabinoids, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.7X1A | Poisoning by cannabis (derivatives), accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.7X1D | Poisoning by cannabis (derivatives), accidental (unintentional), subsequent encounter | Diagnosis | ICD-10-CM |
| T40.7X1S | Poisoning by cannabis (derivatives), accidental (unintentional), sequela | Diagnosis | ICD-10-CM |
| T40.7X2 | Poisoning by cannabis (derivatives), intentional self-harm | Diagnosis | ICD-10-CM |
| T40.7X2A | Poisoning by cannabis (derivatives), intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.7X2D | Poisoning by cannabis (derivatives), intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.7X2S | Poisoning by cannabis (derivatives), intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.7X3A | Poisoning by cannabis (derivatives), assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.7X3D | Poisoning by cannabis (derivatives), assault, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.7X3S | Poisoning by cannabis (derivatives), assault, sequela | Diagnosis | ICD-10-CM |
| T40.7X4A | Poisoning by cannabis (derivatives), undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.7X4D | Poisoning by cannabis (derivatives), undetermined, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.7X4S | Poisoning by cannabis (derivatives), undetermined, sequela | Diagnosis | ICD-10-CM |
| T40.7X5A | Adverse effect of cannabis (derivatives), initial encounter | Diagnosis | ICD-10-CM |
| T40.7X5D | Adverse effect of cannabis (derivatives), subsequent encounter | Diagnosis | ICD-10-CM |
| T40.7X5S | Adverse effect of cannabis (derivatives), sequela | Diagnosis | ICD-10-CM |
| T40.7X6A | Underdosing of cannabis (derivatives), initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T40.7X6D | Underdosing of cannabis (derivatives), subsequent encounter | Diagnosis | ICD-10-CM |
| T40.7X6S | Underdosing of cannabis (derivatives), sequela | Diagnosis | ICD-10-CM |
| T40.8X1A | Poisoning by lysergide [LSD], accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.8X1D | Poisoning by lysergide [LSD], accidental (unintentional), subsequent encounter | Diagnosis | ICD-10-CM |
| T40.8X1S | Poisoning by lysergide [LSD], accidental (unintentional), sequela | Diagnosis | ICD-10-CM |
| T40.8X2 | Poisoning by lysergide [LSD], intentional self-harm | Diagnosis | ICD-10-CM |
| T40.8X2A | Poisoning by lysergide [LSD], intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.8X2D | Poisoning by lysergide [LSD], intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.8X2S | Poisoning by lysergide [LSD], intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.8X3A | Poisoning by lysergide [LSD], assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.8X3D | Poisoning by lysergide [LSD], assault, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.8X3S | Poisoning by lysergide [LSD], assault, sequela | Diagnosis | ICD-10-CM |
| T40.8X4A | Poisoning by lysergide [LSD], undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.8X4D | Poisoning by lysergide [LSD], undetermined, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.8X4S | Poisoning by lysergide [LSD], undetermined, sequela | Diagnosis | ICD-10-CM |
| T40.8X5A | Adverse effect of lysergide [LSD], initial encounter | Diagnosis | ICD-10-CM |
| T40.8X5D | Adverse effect of lysergide [LSD], subsequent encounter | Diagnosis | ICD-10-CM |
| T40.8X5S | Adverse effect of lysergide [LSD], sequela | Diagnosis | ICD-10-CM |
| T40.901A | Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.901D | Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), subsequent encounter | Diagnosis | ICD-10-CM |
| T40.901S | Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), sequela | Diagnosis | ICD-10-CM |
| T40.902 | Poisoning by unspecified psychodysleptics [hallucinogens], intentional self- | Diagnosis | ICD-10-CM |
| T40.902A | Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.902D | Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.902S | Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.903A | Poisoning by unspecified psychodysleptics [hallucinogens], assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.903D | Poisoning by unspecified psychodysleptics [hallucinogens], assault, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.903S | Poisoning by unspecified psychodysleptics [hallucinogens], assault, sequela | Diagnosis | ICD-10-CM |
| T40.904A | Poisoning by unspecified psychodysleptics [hallucinogens], undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.904D | Poisoning by unspecified psychodysleptics [hallucinogens], undetermined, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.904S | Poisoning by unspecified psychodysleptics [hallucinogens], undetermined, sequela | Diagnosis | ICD-10-CM |
| T40.905A | Adverse effect of unspecified psychodysleptics [hallucinogens], initial | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T40.905D | Adverse effect of unspecified psychodysleptics [hallucinogens], subsequent encounter | Diagnosis | ICD-10-CM |
| T40.905S | Adverse effect of unspecified psychodysleptics [hallucinogens], sequela | Diagnosis | ICD-10-CM |
| T40.906A | Underdosing of unspecified psychodysleptics [hallucinogens], initial encounter | Diagnosis | ICD-10-CM |
| T40.906D | Underdosing of unspecified psychodysleptics [hallucinogens], subsequent encounter | Diagnosis | ICD-10-CM |
| T40.906S | Underdosing of unspecified psychodysleptics [hallucinogens], sequela | Diagnosis | ICD-10-CM |
| T40.991A | Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.991D | Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), subsequent encounter | Diagnosis | ICD-10-CM |
| T40.991S | Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), sequela | Diagnosis | ICD-10-CM |
| T40.992 | Poisoning by other psychodysleptics [hallucinogens], intentional self-harm | Diagnosis | ICD-10-CM |
| T40.992A | Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.992D | Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.992S | Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.993A | Poisoning by other psychodysleptics [hallucinogens], assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.993D | Poisoning by other psychodysleptics [hallucinogens], assault, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.993S | Poisoning by other psychodysleptics [hallucinogens], assault, sequela | Diagnosis | ICD-10-CM |
| T40.994A | Poisoning by other psychodysleptics [hallucinogens], undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.994D | Poisoning by other psychodysleptics [hallucinogens], undetermined, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.994S | Poisoning by other psychodysleptics [hallucinogens], undetermined, sequela | Diagnosis | ICD-10-CM |
| T40.995A | Adverse effect of other psychodysleptics [hallucinogens], initial encounter | Diagnosis | ICD-10-CM |
| T40.995D | Adverse effect of other psychodysleptics [hallucinogens], subsequent | Diagnosis | ICD-10-CM |
| T40.995S | Adverse effect of other psychodysleptics [hallucinogens], sequela | Diagnosis | ICD-10-CM |
| T40.996A | Underdosing of other psychodysleptics [hallucinogens], initial encounter | Diagnosis | ICD-10-CM |
| T40.996D | Underdosing of other psychodysleptics [hallucinogens], subsequent encounter | Diagnosis | ICD-10-CM |
| T40.996S | Underdosing of other psychodysleptics [hallucinogens], sequela | Diagnosis | ICD-10-CM |
| T41.0X1A | Poisoning by inhaled anesthetics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T41.0X2 | Poisoning by inhaled anesthetics, intentional self-harm | Diagnosis | ICD-10-CM |
| T41.0X2A | Poisoning by inhaled anesthetics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.0X2D | Poisoning by inhaled anesthetics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.0X2S | Poisoning by inhaled anesthetics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.0X3A | Poisoning by inhaled anesthetics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T41.0X4A | Poisoning by inhaled anesthetics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T41.1X1A | Poisoning by intravenous anesthetics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T41.1X2 | Poisoning by intravenous anesthetics, intentional self-harm | Diagnosis | ICD-10-CM |
| T41.1X2A | Poisoning by intravenous anesthetics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.1X2D | Poisoning by intravenous anesthetics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.1X2S | Poisoning by intravenous anesthetics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.1X3A | Poisoning by intravenous anesthetics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T41.1X4A | Poisoning by intravenous anesthetics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T41.201A | Poisoning by unspecified general anesthetics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T41.202 | Poisoning by unspecified general anesthetics, intentional self-harm | Diagnosis | ICD-10-CM |
| T41.202A | Poisoning by unspecified general anesthetics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.202D | Poisoning by unspecified general anesthetics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.202S | Poisoning by unspecified general anesthetics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.203A | Poisoning by unspecified general anesthetics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T41.204A | Poisoning by unspecified general anesthetics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T41.291A | Poisoning by other general anesthetics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T41.292 | Poisoning by other general anesthetics, intentional self-harm | Diagnosis | ICD-10-CM |
| T41.292A | Poisoning by other general anesthetics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.292D | Poisoning by other general anesthetics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.292S | Poisoning by other general anesthetics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.293A | Poisoning by other general anesthetics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T41.294A | Poisoning by other general anesthetics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T41.3X1A | Poisoning by local anesthetics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T41.3X2 | Poisoning by local anesthetics, intentional self-harm | Diagnosis | ICD-10-CM |
| T41.3X2A | Poisoning by local anesthetics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.3X2D | Poisoning by local anesthetics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.3X2S | Poisoning by local anesthetics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.3X3A | Poisoning by local anesthetics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T41.3X4A | Poisoning by local anesthetics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T41.41XA | Poisoning by unspecified anesthetic, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T41.42 | Poisoning by unspecified anesthetic, intentional self-harm | Diagnosis | ICD-10-CM |
| T41.42XA | Poisoning by unspecified anesthetic, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.42XD | Poisoning by unspecified anesthetic, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.42XS | Poisoning by unspecified anesthetic, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.43XA | Poisoning by unspecified anesthetic, assault, initial encounter | Diagnosis | ICD-10-CM |
| T41.44XA | Poisoning by unspecified anesthetic, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T41.5X2 | Poisoning by therapeutic gases, intentional self-harm | Diagnosis | ICD-10-CM |
| T41.5X2A | Poisoning by therapeutic gases, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.5X2D | Poisoning by therapeutic gases, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T41.5X2S | Poisoning by therapeutic gases, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.0X1A | Poisoning by hydantoin derivatives, accidental (unintentional), initial | Diagnosis | ICD-10-CM |
| T42.0X2 | Poisoning by hydantoin derivatives, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.0X2A | Poisoning by hydantoin derivatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.0X2D | Poisoning by hydantoin derivatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.0X2S | Poisoning by hydantoin derivatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.0X3A | Poisoning by hydantoin derivatives, assault, initial encounter | Diagnosis | ICD-10-CM |
| T42.0X4A | Poisoning by hydantoin derivatives, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T42.1X1A | Poisoning by iminostilbenes, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T42.1X2 | Poisoning by iminostilbenes, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.1X2A | Poisoning by iminostilbenes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.1X2D | Poisoning by iminostilbenes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.1X2S | Poisoning by iminostilbenes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.1X3A | Poisoning by iminostilbenes, assault, initial encounter | Diagnosis | ICD-10-CM |
| T42.1X4A | Poisoning by iminostilbenes, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T42.2X1A | Poisoning by succinimides and oxazolidinediones, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T42.2X2 | Poisoning by succinimides and oxazolidinediones, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.2X2A | Poisoning by succinimides and oxazolidinediones, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.2X2D | Poisoning by succinimides and oxazolidinediones, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.2X2S | Poisoning by succinimides and oxazolidinediones, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.2X3A | Poisoning by succinimides and oxazolidinediones, assault, initial encounter | Diagnosis | ICD-10-CM |
| T42.2X4A | Poisoning by succinimides and oxazolidinediones, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T42.3X1A | Poisoning by barbiturates, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T42.3X2 | Poisoning by barbiturates, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.3X2A | Poisoning by barbiturates, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.3X2D | Poisoning by barbiturates, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.3X2S | Poisoning by barbiturates, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.3X3A | Poisoning by barbiturates, assault, initial encounter | Diagnosis | ICD-10-CM |
| T42.3X4A | Poisoning by barbiturates, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T42.4X1A | Poisoning by benzodiazepines, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T42.4X2 | Poisoning by benzodiazepines, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.4X2A | Poisoning by benzodiazepines, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.4X2D | Poisoning by benzodiazepines, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.4X2S | Poisoning by benzodiazepines, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.4X3A | Poisoning by benzodiazepines, assault, initial encounter | Diagnosis | ICD-10-CM |
| T42.4X4A | Poisoning by benzodiazepines, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T42.5X1A | Poisoning by mixed antiepileptics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T42.5X2 | Poisoning by mixed antiepileptics, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.5X2A | Poisoning by mixed antiepileptics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T42.5X2D | Poisoning by mixed antiepileptics, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T42.5X2S | Poisoning by mixed antiepileptics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.5X3A | Poisoning by mixed antiepileptics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T42.5X4A | Poisoning by mixed antiepileptics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T42.6X1A | Poisoning by other antiepileptic and sedative-hypnotic drugs, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T42.6X2 | Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.6X2A | Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.6X2D | Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.6X2S | Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.6X3A | Poisoning by other antiepileptic and sedative-hypnotic drugs, assault, initial encounter | Diagnosis | ICD-10-CM |
| T42.6X4A | Poisoning by other antiepileptic and sedative-hypnotic drugs, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T42.71XA | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T42.72 | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.72XA | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.72XD | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.72XS | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.73XA | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, assault, initial encounter | Diagnosis | ICD-10-CM |
| T42.74XA | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T42.8X1A | Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T42.8X2 | Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.8X2A | Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.8X2D | Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.8X2S | Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.8X3A | Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, assault, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T42.8X4A | Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T43.011A | Poisoning by tricyclic antidepressants, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.012 | Poisoning by tricyclic antidepressants, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.012A | Poisoning by tricyclic antidepressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.012D | Poisoning by tricyclic antidepressants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.012S | Poisoning by tricyclic antidepressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.013A | Poisoning by tricyclic antidepressants, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.014A | Poisoning by tricyclic antidepressants, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T43.021A | Poisoning by tetracyclic antidepressants, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.022 | Poisoning by tetracyclic antidepressants, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.022A | Poisoning by tetracyclic antidepressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.022D | Poisoning by tetracyclic antidepressants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.022S | Poisoning by tetracyclic antidepressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.023A | Poisoning by tetracyclic antidepressants, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.024A | Poisoning by tetracyclic antidepressants, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T43.1X1A | Poisoning by monoamine-oxidase-inhibitor antidepressants, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.1X2 | Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.1X2A | Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.1X2D | Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.1X2S | Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.1X3A | Poisoning by monoamine-oxidase-inhibitor antidepressants, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.1X4A | Poisoning by monoamine-oxidase-inhibitor antidepressants, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T43.201A | Poisoning by unspecified antidepressants, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.202 | Poisoning by unspecified antidepressants, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.202A | Poisoning by unspecified antidepressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.202D | Poisoning by unspecified antidepressants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.202S | Poisoning by unspecified antidepressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.203A | Poisoning by unspecified antidepressants, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.204A | Poisoning by unspecified antidepressants, undetermined, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T43.211A | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.212 | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.212A | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.212D | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.212S | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.213A | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.214A | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T43.221A | Poisoning by selective serotonin reuptake inhibitors, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.222 | Poisoning by selective serotonin reuptake inhibitors, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.222A | Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.222D | Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.222S | Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.223A | Poisoning by selective serotonin reuptake inhibitors, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.224A | Poisoning by selective serotonin reuptake inhibitors, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T43.291A | Poisoning by other antidepressants, accidental (unintentional), initial | Diagnosis | ICD-10-CM |
| T43.292 | Poisoning by other antidepressants, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.292A | Poisoning by other antidepressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.292D | Poisoning by other antidepressants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.292S | Poisoning by other antidepressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.293A | Poisoning by other antidepressants, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.294A | Poisoning by other antidepressants, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T43.3X1A | Poisoning by phenothiazine antipsychotics and neuroleptics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.3X2 | Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.3X2A | Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.3X2D | Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.3X2S | Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T43.3X3A | Poisoning by phenothiazine antipsychotics and neuroleptics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.3X4A | Poisoning by phenothiazine antipsychotics and neuroleptics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T43.4X1A | Poisoning by butyrophenone and thiothixene neuroleptics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.4X2 | Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.4X2A | Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.4X2D | Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.4X2S | Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.4X3A | Poisoning by butyrophenone and thiothixene neuroleptics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.4X4A | Poisoning by butyrophenone and thiothixene neuroleptics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T43.501A | Poisoning by unspecified antipsychotics and neuroleptics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.502 | Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.502A | Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.502D | Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.502S | Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.503A | Poisoning by unspecified antipsychotics and neuroleptics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.504A | Poisoning by unspecified antipsychotics and neuroleptics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T43.591A | Poisoning by other antipsychotics and neuroleptics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.592 | Poisoning by other antipsychotics and neuroleptics, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.592A | Poisoning by other antipsychotics and neuroleptics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.592D | Poisoning by other antipsychotics and neuroleptics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.592S | Poisoning by other antipsychotics and neuroleptics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.593A | Poisoning by other antipsychotics and neuroleptics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.594A | Poisoning by other antipsychotics and neuroleptics, undetermined, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T43.601A | Poisoning by unspecified psychostimulants, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.602 | Poisoning by unspecified psychostimulants, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.602A | Poisoning by unspecified psychostimulants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.602D | Poisoning by unspecified psychostimulants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.602S | Poisoning by unspecified psychostimulants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.603A | Poisoning by unspecified psychostimulants, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.604A | Poisoning by unspecified psychostimulants, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T43.611A | Poisoning by caffeine, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.612 | Poisoning by caffeine, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.612A | Poisoning by caffeine, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.612D | Poisoning by caffeine, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.612S | Poisoning by caffeine, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.613A | Poisoning by caffeine, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.614A | Poisoning by caffeine, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T43.621A | Poisoning by amphetamines, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.622 | Poisoning by amphetamines, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.622A | Poisoning by amphetamines, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.622D | Poisoning by amphetamines, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.622S | Poisoning by amphetamines, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.623A | Poisoning by amphetamines, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.624A | Poisoning by amphetamines, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T43.631A | Poisoning by methylphenidate, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.632 | Poisoning by methylphenidate, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.632A | Poisoning by methylphenidate, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.632D | Poisoning by methylphenidate, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.632S | Poisoning by methylphenidate, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.633A | Poisoning by methylphenidate, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.634A | Poisoning by methylphenidate, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T43.642 | Poisoning by ecstasy, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.642A | Poisoning by ecstasy, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.642D | Poisoning by ecstasy, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.642S | Poisoning by ecstasy, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.691A | Poisoning by other psychostimulants, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.692 | Poisoning by other psychostimulants, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.692A | Poisoning by other psychostimulants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.692D | Poisoning by other psychostimulants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.692S | Poisoning by other psychostimulants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.693A | Poisoning by other psychostimulants, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.694A | Poisoning by other psychostimulants, undetermined, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T43.8X1A | Poisoning by other psychotropic drugs, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.8X2 | Poisoning by other psychotropic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.8X2A | Poisoning by other psychotropic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.8X2D | Poisoning by other psychotropic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.8X2S | Poisoning by other psychotropic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.8X3A | Poisoning by other psychotropic drugs, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.8X4A | Poisoning by other psychotropic drugs, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T43.91XA | Poisoning by unspecified psychotropic drug, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.92 | Poisoning by unspecified psychotropic drug, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.92XA | Poisoning by unspecified psychotropic drug, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.92XD | Poisoning by unspecified psychotropic drug, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.92XS | Poisoning by unspecified psychotropic drug, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.93XA | Poisoning by unspecified psychotropic drug, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.94XA | Poisoning by unspecified psychotropic drug, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T44.0X2 | Poisoning by anticholinesterase agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.0X2A | Poisoning by anticholinesterase agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.0X2D | Poisoning by anticholinesterase agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.0X2S | Poisoning by anticholinesterase agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.1X2 | Poisoning by other parasympathomimetics [cholinergics], intentional self-harm | Diagnosis | ICD-10-CM |
| T44.1X2A | Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.1X2D | Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.1X2S | Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.2X2 | Poisoning by ganglionic blocking drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.2X2A | Poisoning by ganglionic blocking drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.2X2D | Poisoning by ganglionic blocking drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.2X2S | Poisoning by ganglionic blocking drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.3X2 | Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.3X2A | Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.3X2D | Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.3X2S | Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T44.4X2 | Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.4X2A | Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.4X2D | Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.4X2S | Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.5X2 | Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.5X2A | Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.5X2D | Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.5X2S | Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.6X2 | Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.6X2A | Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.6X2D | Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.6X2S | Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.7X2 | Poisoning by beta-adrenoreceptor antagonists, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.7X2A | Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.7X2D | Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.7X2S | Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.8X2 | Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.8X2A | Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.8X2D | Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.8X2S | Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.902 | Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.902A | Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.902D | Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.902S | Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T44.992 | Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.992A | Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.992D | Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.992S | Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.0X1A | Poisoning by antiallergic and antiemetic drugs, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T45.0X2 | Poisoning by antiallergic and antiemetic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.0X2A | Poisoning by antiallergic and antiemetic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.0X2D | Poisoning by antiallergic and antiemetic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.0X2S | Poisoning by antiallergic and antiemetic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.0X3A | Poisoning by antiallergic and antiemetic drugs, assault, initial encounter | Diagnosis | ICD-10-CM |
| T45.0X4A | Poisoning by antiallergic and antiemetic drugs, undetermined, initial | Diagnosis | ICD-10-CM |
| T45.1X1A | Poisoning by antineoplastic and immunosuppressive drugs, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T45.1X2 | Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.1X2A | Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.1X2D | Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.1X2S | Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.1X3A | Poisoning by antineoplastic and immunosuppressive drugs, assault, initial encounter | Diagnosis | ICD-10-CM |
| T45.1X4A | Poisoning by antineoplastic and immunosuppressive drugs, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T45.2X1A | Poisoning by vitamins, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T45.2X2 | Poisoning by vitamins, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.2X2A | Poisoning by vitamins, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.2X2D | Poisoning by vitamins, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.2X2S | Poisoning by vitamins, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.2X3A | Poisoning by vitamins, assault, initial encounter | Diagnosis | ICD-10-CM |
| T45.2X4A | Poisoning by vitamins, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T45.3X1A | Poisoning by enzymes, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T45.3X2 | Poisoning by enzymes, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.3X2A | Poisoning by enzymes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.3X2D | Poisoning by enzymes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.3X2S | Poisoning by enzymes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T45.3X3A | Poisoning by enzymes, assault, initial encounter | Diagnosis | ICD-10-CM |
| T45.3X4A | Poisoning by enzymes, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T45.4X1A | Poisoning by iron and its compounds, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T45.4X2 | Poisoning by iron and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.4X2A | Poisoning by iron and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.4X2D | Poisoning by iron and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.4X2S | Poisoning by iron and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.4X3A | Poisoning by iron and its compounds, assault, initial encounter | Diagnosis | ICD-10-CM |
| T45.4X4A | Poisoning by iron and its compounds, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T45.511A | Poisoning by anticoagulants, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T45.512 | Poisoning by anticoagulants, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.512A | Poisoning by anticoagulants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.512D | Poisoning by anticoagulants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.512S | Poisoning by anticoagulants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.513A | Poisoning by anticoagulants, assault, initial encounter | Diagnosis | ICD-10-CM |
| T45.514A | Poisoning by anticoagulants, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T45.521A | Poisoning by antithrombotic drugs, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T45.522 | Poisoning by antithrombotic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.522A | Poisoning by antithrombotic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.522D | Poisoning by antithrombotic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.522S | Poisoning by antithrombotic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.523A | Poisoning by antithrombotic drugs, assault, initial encounter | Diagnosis | ICD-10-CM |
| T45.524A | Poisoning by antithrombotic drugs, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T45.601A | Poisoning by unspecified fibrinolysis-affecting drugs, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T45.602 | Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.602A | Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.602D | Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.602S | Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.603A | Poisoning by unspecified fibrinolysis-affecting drugs, assault, initial encounter | Diagnosis | ICD-10-CM |
| T45.604A | Poisoning by unspecified fibrinolysis-affecting drugs, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T45.611A | Poisoning by thrombolytic drug, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T45.612 | Poisoning by thrombolytic drug, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.612A | Poisoning by thrombolytic drug, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.612D | Poisoning by thrombolytic drug, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.612S | Poisoning by thrombolytic drug, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.613A | Poisoning by thrombolytic drug, assault, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T45.614A | Poisoning by thrombolytic drug, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T45.621A | Poisoning by hemostatic drug, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T45.622 | Poisoning by hemostatic drug, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.622A | Poisoning by hemostatic drug, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.622D | Poisoning by hemostatic drug, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.622S | Poisoning by hemostatic drug, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.623A | Poisoning by hemostatic drug, assault, initial encounter | Diagnosis | ICD-10-CM |
| T45.624A | Poisoning by hemostatic drug, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T45.691A | Poisoning by other fibrinolysis-affecting drugs, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T45.692 | Poisoning by other fibrinolysis-affecting drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.692A | Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.692D | Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.692S | Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.693A | Poisoning by other fibrinolysis-affecting drugs, assault, initial encounter | Diagnosis | ICD-10-CM |
| T45.694A | Poisoning by other fibrinolysis-affecting drugs, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T45.7X1A | Poisoning by anticoagulant antagonists, vitamin K and other coagulants, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T45.7X2 | Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.7X2A | Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.7X2D | Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.7X2S | Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.7X3A | Poisoning by anticoagulant antagonists, vitamin K and other coagulants, assault, initial encounter | Diagnosis | ICD-10-CM |
| T45.7X4A | Poisoning by anticoagulant antagonists, vitamin K and other coagulants, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T45.8X1A | Poisoning by other primarily systemic and hematological agents, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T45.8X2 | Poisoning by other primarily systemic and hematological agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.8X2A | Poisoning by other primarily systemic and hematological agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.8X2D | Poisoning by other primarily systemic and hematological agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.8X2S | Poisoning by other primarily systemic and hematological agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.8X3A | Poisoning by other primarily systemic and hematological agents, assault, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T45.8X4A | Poisoning by other primarily systemic and hematological agents, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T45.91XA | Poisoning by unspecified primarily systemic and hematological agent, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T45.92 | Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.92XA | Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.92XD | Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.92XS | Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.93XA | Poisoning by unspecified primarily systemic and hematological agent, assault, initial encounter | Diagnosis | ICD-10-CM |
| T45.94XA | Poisoning by unspecified primarily systemic and hematological agent, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T46.0X2 | Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.0X2A | Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.0X2D | Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.0X2S | Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.1X2 | Poisoning by calcium-channel blockers, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.1X2A | Poisoning by calcium-channel blockers, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.1X2D | Poisoning by calcium-channel blockers, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.1X2S | Poisoning by calcium-channel blockers, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.2X2 | Poisoning by other antidysrhythmic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.2X2A | Poisoning by other antidysrhythmic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.2X2D | Poisoning by other antidysrhythmic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.2X2S | Poisoning by other antidysrhythmic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.3X2 | Poisoning by coronary vasodilators, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.3X2A | Poisoning by coronary vasodilators, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.3X2D | Poisoning by coronary vasodilators, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.3X2S | Poisoning by coronary vasodilators, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.4X2 | Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.4X2A | Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T46.4X2D | Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.4X2S | Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.5X2 | Poisoning by other antihypertensive drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.5X2A | Poisoning by other antihypertensive drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.5X2D | Poisoning by other antihypertensive drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.5X2S | Poisoning by other antihypertensive drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.6X2 | Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.6X2A | Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.6X2D | Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.6X2S | Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.7X2 | Poisoning by peripheral vasodilators, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.7X2A | Poisoning by peripheral vasodilators, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.7X2D | Poisoning by peripheral vasodilators, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.7X2S | Poisoning by peripheral vasodilators, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.8X2 | Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.8X2A | Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.8X2D | Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.8X2S | Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.902 | Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.902A | Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.902D | Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.902S | Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.992 | Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.992A | Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T46.992D | Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.992S | Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.0X2 | Poisoning by histamine H2-receptor blockers, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.0X2A | Poisoning by histamine H2-receptor blockers, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.0X2D | Poisoning by histamine H2-receptor blockers, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.0X2S | Poisoning by histamine H2-receptor blockers, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.1X2 | Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.1X2A | Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.1X2D | Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.1X2S | Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.2X2 | Poisoning by stimulant laxatives, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.2X2A | Poisoning by stimulant laxatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.2X2D | Poisoning by stimulant laxatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.2X2S | Poisoning by stimulant laxatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.3X2 | Poisoning by saline and osmotic laxatives, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.3X2A | Poisoning by saline and osmotic laxatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.3X2D | Poisoning by saline and osmotic laxatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.3X2S | Poisoning by saline and osmotic laxatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.4X2 | Poisoning by other laxatives, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.4X2A | Poisoning by other laxatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.4X2D | Poisoning by other laxatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.4X2S | Poisoning by other laxatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.5X2 | Poisoning by digestants, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.5X2A | Poisoning by digestants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.5X2D | Poisoning by digestants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.5X2S | Poisoning by digestants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.6X2 | Poisoning by antidiarrheal drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.6X2A | Poisoning by antidiarrheal drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.6X2D | Poisoning by antidiarrheal drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.6X2S | Poisoning by antidiarrheal drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.7X2 | Poisoning by emetics, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.7X2A | Poisoning by emetics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.7X2D | Poisoning by emetics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.7X2S | Poisoning by emetics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T47.8X2 | Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.8X2A | Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.8X2D | Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.8X2S | Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.92 | Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.92XA | Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.92XD | Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.92XS | Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.0X2 | Poisoning by oxytotoxic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.0X2A | Poisoning by oxytotoxic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.0X2D | Poisoning by oxytotoxic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.0X2S | Poisoning by oxytotoxic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.1X2 | Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm | Diagnosis | ICD-10-CM |
| T48.1X2A | Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.1X2D | Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.1X2S | Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.202 | Poisoning by unspecified drugs acting on muscles, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.202A | Poisoning by unspecified drugs acting on muscles, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.202D | Poisoning by unspecified drugs acting on muscles, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.202S | Poisoning by unspecified drugs acting on muscles, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.292 | Poisoning by other drugs acting on muscles, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.292A | Poisoning by other drugs acting on muscles, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.292D | Poisoning by other drugs acting on muscles, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.292S | Poisoning by other drugs acting on muscles, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.3X2 | Poisoning by antitussives, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.3X2A | Poisoning by antitussives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.3X2D | Poisoning by antitussives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T48.3X2S | Poisoning by antitussives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.4X2 | Poisoning by expectorants, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.4X2A | Poisoning by expectorants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.4X2D | Poisoning by expectorants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.4X2S | Poisoning by expectorants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.5X2 | Poisoning by other anti-common-cold drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.5X2A | Poisoning by other anti-common-cold drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.5X2D | Poisoning by other anti-common-cold drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.5X2S | Poisoning by other anti-common-cold drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.6X2 | Poisoning by antiasthmatics, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.6X2A | Poisoning by antiasthmatics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.6X2D | Poisoning by antiasthmatics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.6X2S | Poisoning by antiasthmatics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.902 | Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.902A | Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.902D | Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.902S | Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.992 | Poisoning by other agents primarily acting on the respiratory system, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.992A | Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.992D | Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.992S | Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.0X2 | Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.0X2A | Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.0X2D | Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.0X2S | Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.1X2 | Poisoning by antipruritics, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.1X2A | Poisoning by antipruritics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.1X2D | Poisoning by antipruritics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.1X2S | Poisoning by antipruritics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.2X2 | Poisoning by local astringents and local detergents, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T49.2X2A | Poisoning by local astringents and local detergents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.2X2D | Poisoning by local astringents and local detergents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.2X2S | Poisoning by local astringents and local detergents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.3X2 | Poisoning by emollients, demulcents and protectants, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.3X2A | Poisoning by emollients, demulcents and protectants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.3X2D | Poisoning by emollients, demulcents and protectants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.3X2S | Poisoning by emollients, demulcents and protectants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.4X2 | Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.4X2A | Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.4X2D | Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.4X2S | Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.5X2 | Poisoning by ophthalmological drugs and preparations, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.5X2A | Poisoning by ophthalmological drugs and preparations, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.5X2D | Poisoning by ophthalmological drugs and preparations, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.5X2S | Poisoning by ophthalmological drugs and preparations, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.6X2 | Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.6X2A | Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.6X2D | Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.6X2S | Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.7X2 | Poisoning by dental drugs, topically applied, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.7X2A | Poisoning by dental drugs, topically applied, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.7X2D | Poisoning by dental drugs, topically applied, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.7X2S | Poisoning by dental drugs, topically applied, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.8X2 | Poisoning by other topical agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.8X2A | Poisoning by other topical agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T49.8X2D | Poisoning by other topical agents, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T49.8X2S | Poisoning by other topical agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.92 | Poisoning by unspecified topical agent, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.92XA | Poisoning by unspecified topical agent, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.92XD | Poisoning by unspecified topical agent, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.92XS | Poisoning by unspecified topical agent, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.0X1A | Poisoning by mineralocorticoids and their antagonists, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T50.0X2 | Poisoning by mineralocorticoids and their antagonists, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.0X2A | Poisoning by mineralocorticoids and their antagonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.0X2D | Poisoning by mineralocorticoids and their antagonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.0X2S | Poisoning by mineralocorticoids and their antagonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.0X3A | Poisoning by mineralocorticoids and their antagonists, assault, initial | Diagnosis | ICD-10-CM |
| T50.0X4A | Poisoning by mineralocorticoids and their antagonists, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T50.1X2 | Poisoning by loop [high-ceiling] diuretics, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.1X2A | Poisoning by loop [high-ceiling] diuretics, intentional self-harm, initial | Diagnosis | ICD-10-CM |
| T50.1X2D | Poisoning by loop [high-ceiling] diuretics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.1X2S | Poisoning by loop [high-ceiling] diuretics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.2X2 | Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.2X2A | Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.2X2D | Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.2X2S | Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.3X2 | Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.3X2A | Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.3X2D | Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.3X2S | Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.4X2 | Poisoning by drugs affecting uric acid metabolism, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.4X2A | Poisoning by drugs affecting uric acid metabolism, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T50.4X2D | Poisoning by drugs affecting uric acid metabolism, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.4X2S | Poisoning by drugs affecting uric acid metabolism, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.5X2 | Poisoning by appetite depressants, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.5X2A | Poisoning by appetite depressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.5X2D | Poisoning by appetite depressants, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T50.5X2S | Poisoning by appetite depressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.6X2 | Poisoning by antidotes and chelating agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.6X2A | Poisoning by antidotes and chelating agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.6X2D | Poisoning by antidotes and chelating agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.6X2S | Poisoning by antidotes and chelating agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.7X2 | Poisoning by analeptics and opioid receptor antagonists, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.7X2A | Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.7X2D | Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.7X2S | Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.8X2 | Poisoning by diagnostic agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.8X2A | Poisoning by diagnostic agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.8X2D | Poisoning by diagnostic agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.8X2S | Poisoning by diagnostic agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.902 | Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.902A | Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.902D | Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.902S | Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.912 | Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.912A | Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.912D | Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.912S | Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.992 | Poisoning by other drugs, medicaments and biological substances, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T50.992A | Poisoning by other drugs, medicaments and biological substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.992D | Poisoning by other drugs, medicaments and biological substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.992S | Poisoning by other drugs, medicaments and biological substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.A12 | Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.A12A | Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.A12D | Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.A12S | Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.A22 | Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.A22A | Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.A22D | Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.A22S | Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.A92 | Poisoning by other bacterial vaccines, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.A92A | Poisoning by other bacterial vaccines, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.A92D | Poisoning by other bacterial vaccines, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.A92S | Poisoning by other bacterial vaccines, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.B12 | Poisoning by smallpox vaccines, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.B12A | Poisoning by smallpox vaccines, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.B12D | Poisoning by smallpox vaccines, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.B12S | Poisoning by smallpox vaccines, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.B92 | Poisoning by other viral vaccines, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.B92A | Poisoning by other viral vaccines, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.B92D | Poisoning by other viral vaccines, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.B92S | Poisoning by other viral vaccines, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.Z11A | Poisoning by immunoglobulin, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T50.Z12 | Poisoning by immunoglobulin, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.Z12A | Poisoning by immunoglobulin, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.Z12D | Poisoning by immunoglobulin, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.Z12S | Poisoning by immunoglobulin, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.Z13A | Poisoning by immunoglobulin, assault, initial encounter | Diagnosis | ICD-10-CM |
| T50.Z14A | Poisoning by immunoglobulin, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T50.Z92 | Poisoning by other vaccines and biological substances, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T50.Z92A | Poisoning by other vaccines and biological substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.Z92D | Poisoning by other vaccines and biological substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.Z92S | Poisoning by other vaccines and biological substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T51.0X1A | Toxic effect of ethanol, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T51.0X2 | Toxic effect of ethanol, intentional self-harm | Diagnosis | ICD-10-CM |
| T51.0X2A | Toxic effect of ethanol, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T51.0X2D | Toxic effect of ethanol, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T51.0X2S | Toxic effect of ethanol, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T51.0X3A | Toxic effect of ethanol, assault, initial encounter | Diagnosis | ICD-10-CM |
| T51.0X4A | Toxic effect of ethanol, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T51.1X1A | Toxic effect of methanol, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T51.1X2 | Toxic effect of methanol, intentional self-harm | Diagnosis | ICD-10-CM |
| T51.1X2A | Toxic effect of methanol, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T51.1X2D | Toxic effect of methanol, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T51.1X2S | Toxic effect of methanol, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T51.1X3A | Toxic effect of methanol, assault, initial encounter | Diagnosis | ICD-10-CM |
| T51.1X4A | Toxic effect of methanol, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T51.2X1A | Toxic effect of 2-Propanol, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T51.2X2 | Toxic effect of 2-Propanol, intentional self-harm | Diagnosis | ICD-10-CM |
| T51.2X2A | Toxic effect of 2-Propanol, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T51.2X2D | Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T51.2X2S | Toxic effect of 2-Propanol, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T51.2X3A | Toxic effect of 2-Propanol, assault, initial encounter | Diagnosis | ICD-10-CM |
| T51.2X4A | Toxic effect of 2-Propanol, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T51.3X1A | Toxic effect of fusel oil, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T51.3X2 | Toxic effect of fusel oil, intentional self-harm | Diagnosis | ICD-10-CM |
| T51.3X2A | Toxic effect of fusel oil, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T51.3X2D | Toxic effect of fusel oil, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T51.3X2S | Toxic effect of fusel oil, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T51.3X3A | Toxic effect of fusel oil, assault, initial encounter | Diagnosis | ICD-10-CM |
| T51.3X4A | Toxic effect of fusel oil, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T51.8X1A | Toxic effect of other alcohols, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T51.8X2 | Toxic effect of other alcohols, intentional self-harm | Diagnosis | ICD-10-CM |
| T51.8X2A | Toxic effect of other alcohols, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T51.8X2D | Toxic effect of other alcohols, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T51.8X2S | Toxic effect of other alcohols, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T51.8X3A | Toxic effect of other alcohols, assault, initial encounter | Diagnosis | ICD-10-CM |
| T51.8X4A | Toxic effect of other alcohols, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T51.91XA | Toxic effect of unspecified alcohol, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T51.92 | Toxic effect of unspecified alcohol, intentional self-harm | Diagnosis | ICD-10-CM |
| T51.92XA | Toxic effect of unspecified alcohol, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T51.92XD | Toxic effect of unspecified alcohol, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T51.92XS | Toxic effect of unspecified alcohol, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T51.93XA | Toxic effect of unspecified alcohol, assault, initial encounter | Diagnosis | ICD-10-CM |
| T51.94XA | Toxic effect of unspecified alcohol, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T52.0X1A | Toxic effect of petroleum products, accidental (unintentional), initial | Diagnosis | ICD-10-CM |
| T52.0X2 | Toxic effect of petroleum products, intentional self-harm | Diagnosis | ICD-10-CM |
| T52.0X2A | Toxic effect of petroleum products, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.0X2D | Toxic effect of petroleum products, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T52.0X2S | Toxic effect of petroleum products, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.0X3A | Toxic effect of petroleum products, assault, initial encounter | Diagnosis | ICD-10-CM |
| T52.0X4A | Toxic effect of petroleum products, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T52.1X1A | Toxic effect of benzene, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T52.1X2 | Toxic effect of benzene, intentional self-harm | Diagnosis | ICD-10-CM |
| T52.1X2A | Toxic effect of benzene, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.1X2D | Toxic effect of benzene, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T52.1X2S | Toxic effect of benzene, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.1X3A | Toxic effect of benzene, assault, initial encounter | Diagnosis | ICD-10-CM |
| T52.1X4A | Toxic effect of benzene, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T52.2X1A | Toxic effect of homologues of benzene, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T52.2X2 | Toxic effect of homologues of benzene, intentional self-harm | Diagnosis | ICD-10-CM |
| T52.2X2A | Toxic effect of homologues of benzene, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.2X2D | Toxic effect of homologues of benzene, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T52.2X2S | Toxic effect of homologues of benzene, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.2X3A | Toxic effect of homologues of benzene, assault, initial encounter | Diagnosis | ICD-10-CM |
| T52.2X4A | Toxic effect of homologues of benzene, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T52.3X1A | Toxic effect of glycols, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T52.3X2 | Toxic effect of glycols, intentional self-harm | Diagnosis | ICD-10-CM |
| T52.3X2A | Toxic effect of glycols, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.3X2D | Toxic effect of glycols, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T52.3X2S | Toxic effect of glycols, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.3X3A | Toxic effect of glycols, assault, initial encounter | Diagnosis | ICD-10-CM |
| T52.3X4A | Toxic effect of glycols, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T52.4X1A | Toxic effect of ketones, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T52.4X2 | Toxic effect of ketones, intentional self-harm | Diagnosis | ICD-10-CM |
| T52.4X2A | Toxic effect of ketones, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.4X2D | Toxic effect of ketones, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T52.4X2S | Toxic effect of ketones, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.4X3A | Toxic effect of ketones, assault, initial encounter | Diagnosis | ICD-10-CM |
| T52.4X4A | Toxic effect of ketones, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T52.8X1A | Toxic effect of other organic solvents, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T52.8X2 | Toxic effect of other organic solvents, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T52.8X2A | Toxic effect of other organic solvents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.8X2D | Toxic effect of other organic solvents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T52.8X2S | Toxic effect of other organic solvents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.8X3A | Toxic effect of other organic solvents, assault, initial encounter | Diagnosis | ICD-10-CM |
| T52.8X4A | Toxic effect of other organic solvents, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T52.91XA | Toxic effect of unspecified organic solvent, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T52.92 | Toxic effect of unspecified organic solvent, intentional self-harm | Diagnosis | ICD-10-CM |
| T52.92XA | Toxic effect of unspecified organic solvent, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.92XD | Toxic effect of unspecified organic solvent, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T52.92XS | Toxic effect of unspecified organic solvent, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.93XA | Toxic effect of unspecified organic solvent, assault, initial encounter | Diagnosis | ICD-10-CM |
| T52.94XA | Toxic effect of unspecified organic solvent, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T53.0X1A | Toxic effect of carbon tetrachloride, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T53.0X2 | Toxic effect of carbon tetrachloride, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.0X2A | Toxic effect of carbon tetrachloride, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.0X2D | Toxic effect of carbon tetrachloride, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.0X2S | Toxic effect of carbon tetrachloride, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.0X3A | Toxic effect of carbon tetrachloride, assault, initial encounter | Diagnosis | ICD-10-CM |
| T53.0X4A | Toxic effect of carbon tetrachloride, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T53.1X1A | Toxic effect of chloroform, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T53.1X2 | Toxic effect of chloroform, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.1X2A | Toxic effect of chloroform, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.1X2D | Toxic effect of chloroform, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.1X2S | Toxic effect of chloroform, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.1X3A | Toxic effect of chloroform, assault, initial encounter | Diagnosis | ICD-10-CM |
| T53.1X4A | Toxic effect of chloroform, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T53.2X1A | Toxic effect of trichloroethylene, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T53.2X2 | Toxic effect of trichloroethylene, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.2X2A | Toxic effect of trichloroethylene, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.2X2D | Toxic effect of trichloroethylene, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.2X2S | Toxic effect of trichloroethylene, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.2X3A | Toxic effect of trichloroethylene, assault, initial encounter | Diagnosis | ICD-10-CM |
| T53.2X4A | Toxic effect of trichloroethylene, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T53.3X1A | Toxic effect of tetrachloroethylene, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T53.3X2 | Toxic effect of tetrachloroethylene, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.3X2A | Toxic effect of tetrachloroethylene, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.3X2D | Toxic effect of tetrachloroethylene, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.3X2S | Toxic effect of tetrachloroethylene, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.3X3A | Toxic effect of tetrachloroethylene, assault, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T53.3X4A | Toxic effect of tetrachloroethylene, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T53.4X1A | Toxic effect of dichloromethane, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T53.4X2 | Toxic effect of dichloromethane, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.4X2A | Toxic effect of dichloromethane, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.4X2D | Toxic effect of dichloromethane, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.4X2S | Toxic effect of dichloromethane, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.4X3A | Toxic effect of dichloromethane, assault, initial encounter | Diagnosis | ICD-10-CM |
| T53.4X4A | Toxic effect of dichloromethane, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T53.5X1A | Toxic effect of chlorofluorocarbons, accidental (unintentional), initial | Diagnosis | ICD-10-CM |
| T53.5X2 | Toxic effect of chlorofluorocarbons, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.5X2A | Toxic effect of chlorofluorocarbons, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.5X2D | Toxic effect of chlorofluorocarbons, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.5X2S | Toxic effect of chlorofluorocarbons, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.5X3A | Toxic effect of chlorofluorocarbons, assault, initial encounter | Diagnosis | ICD-10-CM |
| T53.5X4A | Toxic effect of chlorofluorocarbons, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T53.6X1A | Toxic effect of other halogen derivatives of aliphatic hydrocarbons, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T53.6X2 | Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.6X2A | Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.6X2D | Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.6X2S | Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.6X3A | Toxic effect of other halogen derivatives of aliphatic hydrocarbons, assault, initial encounter | Diagnosis | ICD-10-CM |
| T53.6X4A | Toxic effect of other halogen derivatives of aliphatic hydrocarbons, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T53.7X1A | Toxic effect of other halogen derivatives of aromatic hydrocarbons, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T53.7X2 | Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.7X2A | Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.7X2D | Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.7X2S | Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.7X3A | Toxic effect of other halogen derivatives of aromatic hydrocarbons, assault, initial encounter | Diagnosis | ICD-10-CM |
| T53.7X4A | Toxic effect of other halogen derivatives of aromatic hydrocarbons, undetermined, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T53.91XA | Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T53.92 | Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.92XA | Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.92XD | Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.92XS | Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.93XA | Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, assault, initial encounter | Diagnosis | ICD-10-CM |
| T53.94XA | Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T54.0X1A | Toxic effect of phenol and phenol homologues, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T54.0X2 | Toxic effect of phenol and phenol homologues, intentional self-harm | Diagnosis | ICD-10-CM |
| T54.0X2A | Toxic effect of phenol and phenol homologues, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T54.0X2D | Toxic effect of phenol and phenol homologues, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T54.0X2S | Toxic effect of phenol and phenol homologues, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T54.0X3A | Toxic effect of phenol and phenol homologues, assault, initial encounter | Diagnosis | ICD-10-CM |
| T54.0X4A | Toxic effect of phenol and phenol homologues, undetermined, initial | Diagnosis | ICD-10-CM |
| T54.1X1A | Toxic effect of other corrosive organic compounds, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T54.1X2 | Toxic effect of other corrosive organic compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T54.1X2A | Toxic effect of other corrosive organic compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T54.1X2D | Toxic effect of other corrosive organic compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T54.1X2S | Toxic effect of other corrosive organic compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T54.1X3A | Toxic effect of other corrosive organic compounds, assault, initial encounter | Diagnosis | ICD-10-CM |
| T54.1X4A | Toxic effect of other corrosive organic compounds, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T54.2X1A | Toxic effect of corrosive acids and acid-like substances, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T54.2X2 | Toxic effect of corrosive acids and acid-like substances, intentional self-harm | Diagnosis | ICD-10-CM |
| T54.2X2A | Toxic effect of corrosive acids and acid-like substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T54.2X2D | Toxic effect of corrosive acids and acid-like substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T54.2X2S | Toxic effect of corrosive acids and acid-like substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T54.2X3A | Toxic effect of corrosive acids and acid-like substances, assault, initial | Diagnosis | ICD-10-CM |
| T54.2X4A | Toxic effect of corrosive acids and acid-like substances, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T54.3X1A | Toxic effect of corrosive alkalis and alkali-like substances, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T54.3X2 | Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm | Diagnosis | ICD-10-CM |
| T54.3X2A | Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T54.3X2D | Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T54.3X2S | Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T54.3X3A | Toxic effect of corrosive alkalis and alkali-like substances, assault, initial encounter | Diagnosis | ICD-10-CM |
| T54.3X4A | Toxic effect of corrosive alkalis and alkali-like substances, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T54.91XA | Toxic effect of unspecified corrosive substance, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T54.92 | Toxic effect of unspecified corrosive substance, intentional self-harm | Diagnosis | ICD-10-CM |
| T54.92XA | Toxic effect of unspecified corrosive substance, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T54.92XD | Toxic effect of unspecified corrosive substance, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T54.92XS | Toxic effect of unspecified corrosive substance, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T54.93XA | Toxic effect of unspecified corrosive substance, assault, initial encounter | Diagnosis | ICD-10-CM |
| T54.94XA | Toxic effect of unspecified corrosive substance, undetermined, initial | Diagnosis | ICD-10-CM |
| T55.0X1A | Toxic effect of soaps, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T55.0X2 | Toxic effect of soaps, intentional self-harm | Diagnosis | ICD-10-CM |
| T55.0X2A | Toxic effect of soaps, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T55.0X2D | Toxic effect of soaps, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T55.0X2S | Toxic effect of soaps, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T55.0X3A | Toxic effect of soaps, assault, initial encounter | Diagnosis | ICD-10-CM |
| T55.0X4A | Toxic effect of soaps, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T55.1X1A | Toxic effect of detergents, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T55.1X2 | Toxic effect of detergents, intentional self-harm | Diagnosis | ICD-10-CM |
| T55.1X2A | Toxic effect of detergents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T55.1X2D | Toxic effect of detergents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T55.1X2S | Toxic effect of detergents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T55.1X3A | Toxic effect of detergents, assault, initial encounter | Diagnosis | ICD-10-CM |
| T55.1X4A | Toxic effect of detergents, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T56.0X1A | Toxic effect of lead and its compounds, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T56.0X2 | Toxic effect of lead and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.0X2A | Toxic effect of lead and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.0X2D | Toxic effect of lead and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.0X2S | Toxic effect of lead and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.0X3A | Toxic effect of lead and its compounds, assault, initial encounter | Diagnosis | ICD-10-CM |
| T56.0X4A | Toxic effect of lead and its compounds, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T56.1X1A | Toxic effect of mercury and its compounds, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T56.1X2 | Toxic effect of mercury and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.1X2A | Toxic effect of mercury and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.1X2D | Toxic effect of mercury and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.1X2S | Toxic effect of mercury and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.1X3A | Toxic effect of mercury and its compounds, assault, initial encounter | Diagnosis | ICD-10-CM |
| T56.1X4A | Toxic effect of mercury and its compounds, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T56.2X1A | Toxic effect of chromium and its compounds, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T56.2X2 | Toxic effect of chromium and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.2X2A | Toxic effect of chromium and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.2X2D | Toxic effect of chromium and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.2X2S | Toxic effect of chromium and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.2X3A | Toxic effect of chromium and its compounds, assault, initial encounter | Diagnosis | ICD-10-CM |
| T56.2X4A | Toxic effect of chromium and its compounds, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T56.3X1A | Toxic effect of cadmium and its compounds, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T56.3X2 | Toxic effect of cadmium and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.3X2A | Toxic effect of cadmium and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.3X2D | Toxic effect of cadmium and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.3X2S | Toxic effect of cadmium and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.3X3A | Toxic effect of cadmium and its compounds, assault, initial encounter | Diagnosis | ICD-10-CM |
| T56.3X4A | Toxic effect of cadmium and its compounds, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T56.4X1A | Toxic effect of copper and its compounds, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T56.4X2 | Toxic effect of copper and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.4X2A | Toxic effect of copper and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.4X2D | Toxic effect of copper and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T56.4X2S | Toxic effect of copper and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.4X3A | Toxic effect of copper and its compounds, assault, initial encounter | Diagnosis | ICD-10-CM |
| T56.4X4A | Toxic effect of copper and its compounds, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T56.5X1A | Toxic effect of zinc and its compounds, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T56.5X2 | Toxic effect of zinc and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.5X2A | Toxic effect of zinc and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.5X2D | Toxic effect of zinc and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.5X2S | Toxic effect of zinc and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.5X3A | Toxic effect of zinc and its compounds, assault, initial encounter | Diagnosis | ICD-10-CM |
| T56.5X4A | Toxic effect of zinc and its compounds, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T56.6X1A | Toxic effect of tin and its compounds, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T56.6X2 | Toxic effect of tin and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.6X2A | Toxic effect of tin and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.6X2D | Toxic effect of tin and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.6X2S | Toxic effect of tin and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.6X3A | Toxic effect of tin and its compounds, assault, initial encounter | Diagnosis | ICD-10-CM |
| T56.6X4A | Toxic effect of tin and its compounds, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T56.7X1A | Toxic effect of beryllium and its compounds, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T56.7X2 | Toxic effect of beryllium and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.7X2A | Toxic effect of beryllium and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.7X2D | Toxic effect of beryllium and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.7X2S | Toxic effect of beryllium and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.7X3A | Toxic effect of beryllium and its compounds, assault, initial encounter | Diagnosis | ICD-10-CM |
| T56.7X4A | Toxic effect of beryllium and its compounds, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T56.811A | Toxic effect of thallium, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T56.812 | Toxic effect of thallium, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.812A | Toxic effect of thallium, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.812D | Toxic effect of thallium, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.812S | Toxic effect of thallium, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.813A | Toxic effect of thallium, assault, initial encounter | Diagnosis | ICD-10-CM |
| T56.814A | Toxic effect of thallium, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T56.891A | Toxic effect of other metals, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T56.892 | Toxic effect of other metals, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.892A | Toxic effect of other metals, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.892D | Toxic effect of other metals, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.892S | Toxic effect of other metals, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.893A | Toxic effect of other metals, assault, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T56.894A | Toxic effect of other metals, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T56.91XA | Toxic effect of unspecified metal, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T56.92 | Toxic effect of unspecified metal, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.92XA | Toxic effect of unspecified metal, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.92XD | Toxic effect of unspecified metal, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.92XS | Toxic effect of unspecified metal, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.93XA | Toxic effect of unspecified metal, assault, initial encounter | Diagnosis | ICD-10-CM |
| T56.94XA | Toxic effect of unspecified metal, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T57.0X1A | Toxic effect of arsenic and its compounds, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T57.0X2 | Toxic effect of arsenic and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T57.0X2A | Toxic effect of arsenic and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T57.0X2D | Toxic effect of arsenic and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T57.0X2S | Toxic effect of arsenic and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T57.0X3A | Toxic effect of arsenic and its compounds, assault, initial encounter | Diagnosis | ICD-10-CM |
| T57.0X4A | Toxic effect of arsenic and its compounds, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T57.1X1A | Toxic effect of phosphorus and its compounds, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T57.1X2 | Toxic effect of phosphorus and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T57.1X2A | Toxic effect of phosphorus and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T57.1X2D | Toxic effect of phosphorus and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T57.1X2S | Toxic effect of phosphorus and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T57.1X3A | Toxic effect of phosphorus and its compounds, assault, initial encounter | Diagnosis | ICD-10-CM |
| T57.1X4A | Toxic effect of phosphorus and its compounds, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T57.2X1A | Toxic effect of manganese and its compounds, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T57.2X2 | Toxic effect of manganese and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T57.2X2A | Toxic effect of manganese and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T57.2X2D | Toxic effect of manganese and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T57.2X2S | Toxic effect of manganese and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T57.2X3A | Toxic effect of manganese and its compounds, assault, initial encounter | Diagnosis | ICD-10-CM |
| T57.2X4A | Toxic effect of manganese and its compounds, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T57.3X1A | Toxic effect of hydrogen cyanide, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T57.3X2 | Toxic effect of hydrogen cyanide, intentional self-harm | Diagnosis | ICD-10-CM |
| T57.3X2A | Toxic effect of hydrogen cyanide, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T57.3X2D | Toxic effect of hydrogen cyanide, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T57.3X2S | Toxic effect of hydrogen cyanide, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T57.3X3A | Toxic effect of hydrogen cyanide, assault, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T57.3X4A | Toxic effect of hydrogen cyanide, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T57.8X1A | Toxic effect of other specified inorganic substances, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T57.8X2 | Toxic effect of other specified inorganic substances, intentional self-harm | Diagnosis | ICD-10-CM |
| T57.8X2A | Toxic effect of other specified inorganic substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T57.8X2D | Toxic effect of other specified inorganic substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T57.8X2S | Toxic effect of other specified inorganic substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T57.8X3A | Toxic effect of other specified inorganic substances, assault, initial encounter | Diagnosis | ICD-10-CM |
| T57.8X4A | Toxic effect of other specified inorganic substances, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T57.91XA | Toxic effect of unspecified inorganic substance, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T57.92 | Toxic effect of unspecified inorganic substance, intentional self-harm | Diagnosis | ICD-10-CM |
| T57.92XA | Toxic effect of unspecified inorganic substance, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T57.92XD | Toxic effect of unspecified inorganic substance, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T57.92XS | Toxic effect of unspecified inorganic substance, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T57.93XA | Toxic effect of unspecified inorganic substance, assault, initial encounter | Diagnosis | ICD-10-CM |
| T57.94XA | Toxic effect of unspecified inorganic substance, undetermined, initial | Diagnosis | ICD-10-CM |
| T58.01XA | Toxic effect of carbon monoxide from motor vehicle exhaust, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T58.02 | Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm | Diagnosis | ICD-10-CM |
| T58.02XA | Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T58.02XD | Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T58.02XS | Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T58.03XA | Toxic effect of carbon monoxide from motor vehicle exhaust, assault, initial encounter | Diagnosis | ICD-10-CM |
| T58.04XA | Toxic effect of carbon monoxide from motor vehicle exhaust, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T58.11XA | Toxic effect of carbon monoxide from utility gas, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T58.12 | Toxic effect of carbon monoxide from utility gas, intentional self-harm | Diagnosis | ICD-10-CM |
| T58.12XA | Toxic effect of carbon monoxide from utility gas, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T58.12XD | Toxic effect of carbon monoxide from utility gas, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T58.12XS | Toxic effect of carbon monoxide from utility gas, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T58.13XA | Toxic effect of carbon monoxide from utility gas, assault, initial encounter | Diagnosis | ICD-10-CM |
| T58.14XA | Toxic effect of carbon monoxide from utility gas, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T58.2X1A | Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T58.2X2 | Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm | Diagnosis | ICD-10-CM |
| T58.2X2A | Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T58.2X2D | Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T58.2X2S | Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T58.2X3A | Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, assault, initial encounter | Diagnosis | ICD-10-CM |
| T58.2X4A | Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T58.8X1A | Toxic effect of carbon monoxide from other source, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T58.8X2 | Toxic effect of carbon monoxide from other source, intentional self-harm | Diagnosis | ICD-10-CM |
| T58.8X2A | Toxic effect of carbon monoxide from other source, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T58.8X2D | Toxic effect of carbon monoxide from other source, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T58.8X2S | Toxic effect of carbon monoxide from other source, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T58.8X3A | Toxic effect of carbon monoxide from other source, assault, initial encounter | Diagnosis | ICD-10-CM |
| T58.8X4A | Toxic effect of carbon monoxide from other source, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T58.91XA | Toxic effect of carbon monoxide from unspecified source, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T58.92 | Toxic effect of carbon monoxide from unspecified source, intentional self-harm | Diagnosis | ICD-10-CM |
| T58.92XA | Toxic effect of carbon monoxide from unspecified source, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T58.92XD | Toxic effect of carbon monoxide from unspecified source, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T58.92XS | Toxic effect of carbon monoxide from unspecified source, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T58.93XA | Toxic effect of carbon monoxide from unspecified source, assault, initial encounter | Diagnosis | ICD-10-CM |
| T58.94XA | Toxic effect of carbon monoxide from unspecified source, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T59.0X1A | Toxic effect of nitrogen oxides, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T59.0X2 | Toxic effect of nitrogen oxides, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.0X2A | Toxic effect of nitrogen oxides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.0X2D | Toxic effect of nitrogen oxides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.0X2S | Toxic effect of nitrogen oxides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.0X3A | Toxic effect of nitrogen oxides, assault, initial encounter | Diagnosis | ICD-10-CM |
| T59.0X4A | Toxic effect of nitrogen oxides, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T59.1X1A | Toxic effect of sulfur dioxide, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T59.1X2 | Toxic effect of sulfur dioxide, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.1X2A | Toxic effect of sulfur dioxide, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.1X2D | Toxic effect of sulfur dioxide, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.1X2S | Toxic effect of sulfur dioxide, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.1X3A | Toxic effect of sulfur dioxide, assault, initial encounter | Diagnosis | ICD-10-CM |
| T59.1X4A | Toxic effect of sulfur dioxide, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T59.2X1A | Toxic effect of formaldehyde, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T59.2X2 | Toxic effect of formaldehyde, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.2X2A | Toxic effect of formaldehyde, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.2X2D | Toxic effect of formaldehyde, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.2X2S | Toxic effect of formaldehyde, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.2X3A | Toxic effect of formaldehyde, assault, initial encounter | Diagnosis | ICD-10-CM |
| T59.2X4A | Toxic effect of formaldehyde, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T59.3X1A | Toxic effect of lacrimogenic gas, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T59.3X2 | Toxic effect of lacrimogenic gas, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.3X2A | Toxic effect of lacrimogenic gas, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.3X2D | Toxic effect of lacrimogenic gas, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.3X2S | Toxic effect of lacrimogenic gas, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.3X3A | Toxic effect of lacrimogenic gas, assault, initial encounter | Diagnosis | ICD-10-CM |
| T59.3X4A | Toxic effect of lacrimogenic gas, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T59.4X1A | Toxic effect of chlorine gas, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T59.4X2 | Toxic effect of chlorine gas, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.4X2A | Toxic effect of chlorine gas, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.4X2D | Toxic effect of chlorine gas, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.4X2S | Toxic effect of chlorine gas, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.4X3A | Toxic effect of chlorine gas, assault, initial encounter | Diagnosis | ICD-10-CM |
| T59.4X4A | Toxic effect of chlorine gas, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T59.5X1A | Toxic effect of fluorine gas and hydrogen fluoride, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T59.5X2 | Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.5X2A | Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.5X2D | Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.5X2S | Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.5X3A | Toxic effect of fluorine gas and hydrogen fluoride, assault, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T59.5X4A | Toxic effect of fluorine gas and hydrogen fluoride, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T59.6X1A | Toxic effect of hydrogen sulfide, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T59.6X2 | Toxic effect of hydrogen sulfide, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.6X2A | Toxic effect of hydrogen sulfide, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.6X2D | Toxic effect of hydrogen sulfide, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.6X2S | Toxic effect of hydrogen sulfide, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.6X3A | Toxic effect of hydrogen sulfide, assault, initial encounter | Diagnosis | ICD-10-CM |
| T59.6X4A | Toxic effect of hydrogen sulfide, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T59.7X1A | Toxic effect of carbon dioxide, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T59.7X2 | Toxic effect of carbon dioxide, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.7X2A | Toxic effect of carbon dioxide, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.7X2D | Toxic effect of carbon dioxide, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.7X2S | Toxic effect of carbon dioxide, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.7X3A | Toxic effect of carbon dioxide, assault, initial encounter | Diagnosis | ICD-10-CM |
| T59.7X4A | Toxic effect of carbon dioxide, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T59.811A | Toxic effect of smoke, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T59.812 | Toxic effect of smoke, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.812A | Toxic effect of smoke, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.812D | Toxic effect of smoke, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.812S | Toxic effect of smoke, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.813A | Toxic effect of smoke, assault, initial encounter | Diagnosis | ICD-10-CM |
| T59.814A | Toxic effect of smoke, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T59.891A | Toxic effect of other specified gases, fumes and vapors, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T59.892 | Toxic effect of other specified gases, fumes and vapors, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.892A | Toxic effect of other specified gases, fumes and vapors, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.892D | Toxic effect of other specified gases, fumes and vapors, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.892S | Toxic effect of other specified gases, fumes and vapors, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.893A | Toxic effect of other specified gases, fumes and vapors, assault, initial | Diagnosis | ICD-10-CM |
| T59.894A | Toxic effect of other specified gases, fumes and vapors, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T59.91XA | Toxic effect of unspecified gases, fumes and vapors, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T59.92 | Toxic effect of unspecified gases, fumes and vapors, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.92XA | Toxic effect of unspecified gases, fumes and vapors, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.92XD | Toxic effect of unspecified gases, fumes and vapors, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.92XS | Toxic effect of unspecified gases, fumes and vapors, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T59.93XA | Toxic effect of unspecified gases, fumes and vapors, assault, initial encounter | Diagnosis | ICD-10-CM |
| T59.94XA | Toxic effect of unspecified gases, fumes and vapors, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T60.0X1A | Toxic effect of organophosphate and carbamate insecticides, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T60.0X2 | Toxic effect of organophosphate and carbamate insecticides, intentional self-harm | Diagnosis | ICD-10-CM |
| T60.0X2A | Toxic effect of organophosphate and carbamate insecticides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.0X2D | Toxic effect of organophosphate and carbamate insecticides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.0X2S | Toxic effect of organophosphate and carbamate insecticides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.0X3A | Toxic effect of organophosphate and carbamate insecticides, assault, initial encounter | Diagnosis | ICD-10-CM |
| T60.0X4A | Toxic effect of organophosphate and carbamate insecticides, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T60.1X1A | Toxic effect of halogenated insecticides, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T60.1X2 | Toxic effect of halogenated insecticides, intentional self-harm | Diagnosis | ICD-10-CM |
| T60.1X2A | Toxic effect of halogenated insecticides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.1X2D | Toxic effect of halogenated insecticides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.1X2S | Toxic effect of halogenated insecticides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.1X3A | Toxic effect of halogenated insecticides, assault, initial encounter | Diagnosis | ICD-10-CM |
| T60.1X4A | Toxic effect of halogenated insecticides, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T60.2X1A | Toxic effect of other insecticides, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T60.2X2 | Toxic effect of other insecticides, intentional self-harm | Diagnosis | ICD-10-CM |
| T60.2X2A | Toxic effect of other insecticides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.2X2D | Toxic effect of other insecticides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.2X2S | Toxic effect of other insecticides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.2X3A | Toxic effect of other insecticides, assault, initial encounter | Diagnosis | ICD-10-CM |
| T60.2X4A | Toxic effect of other insecticides, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T60.3X1A | Toxic effect of herbicides and fungicides, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T60.3X2 | Toxic effect of herbicides and fungicides, intentional self-harm | Diagnosis | ICD-10-CM |
| T60.3X2A | Toxic effect of herbicides and fungicides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.3X2D | Toxic effect of herbicides and fungicides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.3X2S | Toxic effect of herbicides and fungicides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.3X3A | Toxic effect of herbicides and fungicides, assault, initial encounter | Diagnosis | ICD-10-CM |
| T60.3X4A | Toxic effect of herbicides and fungicides, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T60.4X1A | Toxic effect of rodenticides, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T60.4X2 | Toxic effect of rodenticides, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T60.4X2A | Toxic effect of rodenticides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.4X2D | Toxic effect of rodenticides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.4X2S | Toxic effect of rodenticides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.4X3A | Toxic effect of rodenticides, assault, initial encounter | Diagnosis | ICD-10-CM |
| T60.4X4A | Toxic effect of rodenticides, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T60.8X1A | Toxic effect of other pesticides, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T60.8X2 | Toxic effect of other pesticides, intentional self-harm | Diagnosis | ICD-10-CM |
| T60.8X2A | Toxic effect of other pesticides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.8X2D | Toxic effect of other pesticides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.8X2S | Toxic effect of other pesticides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.8X3A | Toxic effect of other pesticides, assault, initial encounter | Diagnosis | ICD-10-CM |
| T60.8X4A | Toxic effect of other pesticides, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T60.91XA | Toxic effect of unspecified pesticide, accidental (unintentional), initial | Diagnosis | ICD-10-CM |
| T60.92 | Toxic effect of unspecified pesticide, intentional self-harm | Diagnosis | ICD-10-CM |
| T60.92XA | Toxic effect of unspecified pesticide, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.92XD | Toxic effect of unspecified pesticide, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.92XS | Toxic effect of unspecified pesticide, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.93XA | Toxic effect of unspecified pesticide, assault, initial encounter | Diagnosis | ICD-10-CM |
| T60.94XA | Toxic effect of unspecified pesticide, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T61.01XA | Ciguatera fish poisoning, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T61.02 | Ciguatera fish poisoning, intentional self-harm | Diagnosis | ICD-10-CM |
| T61.02XA | Ciguatera fish poisoning, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T61.02XD | Ciguatera fish poisoning, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T61.02XS | Ciguatera fish poisoning, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T61.03XA | Ciguatera fish poisoning, assault, initial encounter | Diagnosis | ICD-10-CM |
| T61.04XA | Ciguatera fish poisoning, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T61.11XA | Scombroid fish poisoning, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T61.12 | Scombroid fish poisoning, intentional self-harm | Diagnosis | ICD-10-CM |
| T61.12XA | Scombroid fish poisoning, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T61.12XD | Scombroid fish poisoning, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T61.12XS | Scombroid fish poisoning, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T61.13XA | Scombroid fish poisoning, assault, initial encounter | Diagnosis | ICD-10-CM |
| T61.14XA | Scombroid fish poisoning, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T61.771A | Other fish poisoning, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T61.772 | Other fish poisoning, intentional self-harm | Diagnosis | ICD-10-CM |
| T61.772A | Other fish poisoning, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T61.772D | Other fish poisoning, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T61.772S | Other fish poisoning, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T61.773A | Other fish poisoning, assault, initial encounter | Diagnosis | ICD-10-CM |
| T61.774A | Other fish poisoning, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T61.781A | Other shellfish poisoning, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T61.782 | Other shellfish poisoning, intentional self-harm | Diagnosis | ICD-10-CM |
| T61.782A | Other shellfish poisoning, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T61.782D | Other shellfish poisoning, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T61.782S | Other shellfish poisoning, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T61.783A | Other shellfish poisoning, assault, initial encounter | Diagnosis | ICD-10-CM |
| T61.784A | Other shellfish poisoning, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T61.8X1A | Toxic effect of other seafood, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T61.8X2 | Toxic effect of other seafood, intentional self-harm | Diagnosis | ICD-10-CM |
| T61.8X2A | Toxic effect of other seafood, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T61.8X2D | Toxic effect of other seafood, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T61.8X2S | Toxic effect of other seafood, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T61.8X3A | Toxic effect of other seafood, assault, initial encounter | Diagnosis | ICD-10-CM |
| T61.8X4A | Toxic effect of other seafood, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T61.91XA | Toxic effect of unspecified seafood, accidental (unintentional), initial | Diagnosis | ICD-10-CM |
| T61.92 | Toxic effect of unspecified seafood, intentional self-harm | Diagnosis | ICD-10-CM |
| T61.92XA | Toxic effect of unspecified seafood, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T61.92XD | Toxic effect of unspecified seafood, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T61.92XS | Toxic effect of unspecified seafood, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T61.93XA | Toxic effect of unspecified seafood, assault, initial encounter | Diagnosis | ICD-10-CM |
| T61.94XA | Toxic effect of unspecified seafood, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T62.0X1A | Toxic effect of ingested mushrooms, accidental (unintentional), initial | Diagnosis | ICD-10-CM |
| T62.0X2 | Toxic effect of ingested mushrooms, intentional self-harm | Diagnosis | ICD-10-CM |
| T62.0X2A | Toxic effect of ingested mushrooms, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T62.0X2D | Toxic effect of ingested mushrooms, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T62.0X2S | Toxic effect of ingested mushrooms, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T62.0X3A | Toxic effect of ingested mushrooms, assault, initial encounter | Diagnosis | ICD-10-CM |
| T62.0X4A | Toxic effect of ingested mushrooms, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T62.1X1A | Toxic effect of ingested berries, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T62.1X2 | Toxic effect of ingested berries, intentional self-harm | Diagnosis | ICD-10-CM |
| T62.1X2A | Toxic effect of ingested berries, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T62.1X2D | Toxic effect of ingested berries, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T62.1X2S | Toxic effect of ingested berries, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T62.1X3A | Toxic effect of ingested berries, assault, initial encounter | Diagnosis | ICD-10-CM |
| T62.1X4A | Toxic effect of ingested berries, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T62.2X1A | Toxic effect of other ingested (parts of) plant(s), accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T62.2X2 | Toxic effect of other ingested (parts of) plant(s), intentional self-harm | Diagnosis | ICD-10-CM |
| T62.2X2A | Toxic effect of other ingested (parts of) plant(s), intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T62.2X2D | Toxic effect of other ingested (parts of) plant(s), intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T62.2X2S | Toxic effect of other ingested (parts of) plant(s), intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T62.2X3A | Toxic effect of other ingested (parts of) plant(s), assault, initial encounter | Diagnosis | ICD-10-CM |
| T62.2X4A | Toxic effect of other ingested (parts of) plant(s), undetermined, initial | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|-------------|---|----------------------|------------------|
| T62.8X1A | Toxic effect of other specified noxious substances eaten as food, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T62.8X2 | Toxic effect of other specified noxious substances eaten as food, intentional self-harm | Diagnosis | ICD-10-CM |
| T62.8X2A | Toxic effect of other specified noxious substances eaten as food, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T62.8X2D | Toxic effect of other specified noxious substances eaten as food, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T62.8X2S | Toxic effect of other specified noxious substances eaten as food, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T62.8X3A | Toxic effect of other specified noxious substances eaten as food, assault, initial encounter | Diagnosis | ICD-10-CM |
| T62.8X4A | Toxic effect of other specified noxious substances eaten as food, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T62.91XA | Toxic effect of unspecified noxious substance eaten as food, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T62.92 | Toxic effect of unspecified noxious substance eaten as food, intentional self-harm | Diagnosis | ICD-10-CM |
| T62.92XA | Toxic effect of unspecified noxious substance eaten as food, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T62.92XD | Toxic effect of unspecified noxious substance eaten as food, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T62.92XS | Toxic effect of unspecified noxious substance eaten as food, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T62.93XA | Toxic effect of unspecified noxious substance eaten as food, assault, initial encounter | Diagnosis | ICD-10-CM |
| T62.94XA | Toxic effect of unspecified noxious substance eaten as food, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.001A | Toxic effect of unspecified snake venom, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.002 | Toxic effect of unspecified snake venom, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.002A | Toxic effect of unspecified snake venom, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.002D | Toxic effect of unspecified snake venom, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.002S | Toxic effect of unspecified snake venom, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.003A | Toxic effect of unspecified snake venom, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.004A | Toxic effect of unspecified snake venom, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.011A | Toxic effect of rattlesnake venom, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.012 | Toxic effect of rattlesnake venom, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.012A | Toxic effect of rattlesnake venom, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.012D | Toxic effect of rattlesnake venom, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.012S | Toxic effect of rattlesnake venom, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.013A | Toxic effect of rattlesnake venom, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.014A | Toxic effect of rattlesnake venom, undetermined, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T63.021A | Toxic effect of coral snake venom, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.022 | Toxic effect of coral snake venom, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.022A | Toxic effect of coral snake venom, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.022D | Toxic effect of coral snake venom, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T63.022S | Toxic effect of coral snake venom, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.023A | Toxic effect of coral snake venom, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.024A | Toxic effect of coral snake venom, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.031A | Toxic effect of taipan venom, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.032 | Toxic effect of taipan venom, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.032A | Toxic effect of taipan venom, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.032D | Toxic effect of taipan venom, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.032S | Toxic effect of taipan venom, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.033A | Toxic effect of taipan venom, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.034A | Toxic effect of taipan venom, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.041A | Toxic effect of cobra venom, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.042 | Toxic effect of cobra venom, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.042A | Toxic effect of cobra venom, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.042D | Toxic effect of cobra venom, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.042S | Toxic effect of cobra venom, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.043A | Toxic effect of cobra venom, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.044A | Toxic effect of cobra venom, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.061A | Toxic effect of venom of other North and South American snake, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.062 | Toxic effect of venom of other North and South American snake, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.062A | Toxic effect of venom of other North and South American snake, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.062D | Toxic effect of venom of other North and South American snake, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.062S | Toxic effect of venom of other North and South American snake, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.063A | Toxic effect of venom of other North and South American snake, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.064A | Toxic effect of venom of other North and South American snake, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.071A | Toxic effect of venom of other Australian snake, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.072 | Toxic effect of venom of other Australian snake, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.072A | Toxic effect of venom of other Australian snake, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.072D | Toxic effect of venom of other Australian snake, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.072S | Toxic effect of venom of other Australian snake, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.073A | Toxic effect of venom of other Australian snake, assault, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T63.074A | Toxic effect of venom of other Australian snake, undetermined, initial | Diagnosis | ICD-10-CM |
| T63.081A | Toxic effect of venom of other African and Asian snake, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.082 | Toxic effect of venom of other African and Asian snake, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.082A | Toxic effect of venom of other African and Asian snake, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.082D | Toxic effect of venom of other African and Asian snake, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.082S | Toxic effect of venom of other African and Asian snake, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.083A | Toxic effect of venom of other African and Asian snake, assault, initial | Diagnosis | ICD-10-CM |
| T63.084A | Toxic effect of venom of other African and Asian snake, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.091A | Toxic effect of venom of other snake, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.092 | Toxic effect of venom of other snake, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.092A | Toxic effect of venom of other snake, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.092D | Toxic effect of venom of other snake, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.092S | Toxic effect of venom of other snake, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.093A | Toxic effect of venom of other snake, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.094A | Toxic effect of venom of other snake, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.111A | Toxic effect of venom of gila monster, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.112 | Toxic effect of venom of gila monster, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.112A | Toxic effect of venom of gila monster, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.112D | Toxic effect of venom of gila monster, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.112S | Toxic effect of venom of gila monster, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.113A | Toxic effect of venom of gila monster, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.114A | Toxic effect of venom of gila monster, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.121A | Toxic effect of venom of other venomous lizard, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.122 | Toxic effect of venom of other venomous lizard, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.122A | Toxic effect of venom of other venomous lizard, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.122D | Toxic effect of venom of other venomous lizard, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.122S | Toxic effect of venom of other venomous lizard, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.123A | Toxic effect of venom of other venomous lizard, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.124A | Toxic effect of venom of other venomous lizard, undetermined, initial | Diagnosis | ICD-10-CM |
| T63.191A | Toxic effect of venom of other reptiles, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.192 | Toxic effect of venom of other reptiles, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T63.192A | Toxic effect of venom of other reptiles, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.192D | Toxic effect of venom of other reptiles, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.192S | Toxic effect of venom of other reptiles, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.193A | Toxic effect of venom of other reptiles, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.194A | Toxic effect of venom of other reptiles, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.2X1A | Toxic effect of venom of scorpion, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.2X2 | Toxic effect of venom of scorpion, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.2X2A | Toxic effect of venom of scorpion, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.2X2D | Toxic effect of venom of scorpion, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.2X2S | Toxic effect of venom of scorpion, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.2X3A | Toxic effect of venom of scorpion, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.2X4A | Toxic effect of venom of scorpion, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.301A | Toxic effect of unspecified spider venom, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.302 | Toxic effect of unspecified spider venom, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.302A | Toxic effect of unspecified spider venom, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.302D | Toxic effect of unspecified spider venom, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.302S | Toxic effect of unspecified spider venom, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.303A | Toxic effect of unspecified spider venom, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.304A | Toxic effect of unspecified spider venom, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.311A | Toxic effect of venom of black widow spider, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.312 | Toxic effect of venom of black widow spider, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.312A | Toxic effect of venom of black widow spider, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.312D | Toxic effect of venom of black widow spider, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.312S | Toxic effect of venom of black widow spider, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.313A | Toxic effect of venom of black widow spider, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.314A | Toxic effect of venom of black widow spider, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.321A | Toxic effect of venom of tarantula, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.322 | Toxic effect of venom of tarantula, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.322A | Toxic effect of venom of tarantula, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.322D | Toxic effect of venom of tarantula, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.322S | Toxic effect of venom of tarantula, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.323A | Toxic effect of venom of tarantula, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.324A | Toxic effect of venom of tarantula, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.331A | Toxic effect of venom of brown recluse spider, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.332 | Toxic effect of venom of brown recluse spider, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.332A | Toxic effect of venom of brown recluse spider, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T63.332D | Toxic effect of venom of brown recluse spider, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.332S | Toxic effect of venom of brown recluse spider, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.333A | Toxic effect of venom of brown recluse spider, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.334A | Toxic effect of venom of brown recluse spider, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.391A | Toxic effect of venom of other spider, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.392 | Toxic effect of venom of other spider, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.392A | Toxic effect of venom of other spider, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.392D | Toxic effect of venom of other spider, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.392S | Toxic effect of venom of other spider, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.393A | Toxic effect of venom of other spider, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.394A | Toxic effect of venom of other spider, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.411A | Toxic effect of venom of centipedes and venomous millipedes, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.412 | Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.412A | Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.412D | Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.412S | Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.413A | Toxic effect of venom of centipedes and venomous millipedes, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.414A | Toxic effect of venom of centipedes and venomous millipedes, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.421A | Toxic effect of venom of ants, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.422 | Toxic effect of venom of ants, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.422A | Toxic effect of venom of ants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.422D | Toxic effect of venom of ants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.422S | Toxic effect of venom of ants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.423A | Toxic effect of venom of ants, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.424A | Toxic effect of venom of ants, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.431A | Toxic effect of venom of caterpillars, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.432 | Toxic effect of venom of caterpillars, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.432A | Toxic effect of venom of caterpillars, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.432D | Toxic effect of venom of caterpillars, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.432S | Toxic effect of venom of caterpillars, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.433A | Toxic effect of venom of caterpillars, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.434A | Toxic effect of venom of caterpillars, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.441A | Toxic effect of venom of bees, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T63.442 | Toxic effect of venom of bees, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.442A | Toxic effect of venom of bees, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.442D | Toxic effect of venom of bees, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.442S | Toxic effect of venom of bees, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.443A | Toxic effect of venom of bees, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.444A | Toxic effect of venom of bees, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.451A | Toxic effect of venom of hornets, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.452 | Toxic effect of venom of hornets, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.452A | Toxic effect of venom of hornets, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.452D | Toxic effect of venom of hornets, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.452S | Toxic effect of venom of hornets, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.453A | Toxic effect of venom of hornets, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.454A | Toxic effect of venom of hornets, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.461A | Toxic effect of venom of wasps, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.462 | Toxic effect of venom of wasps, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.462A | Toxic effect of venom of wasps, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.462D | Toxic effect of venom of wasps, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.462S | Toxic effect of venom of wasps, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.463A | Toxic effect of venom of wasps, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.464A | Toxic effect of venom of wasps, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.481A | Toxic effect of venom of other arthropod, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.482 | Toxic effect of venom of other arthropod, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.482A | Toxic effect of venom of other arthropod, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.482D | Toxic effect of venom of other arthropod, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.482S | Toxic effect of venom of other arthropod, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.483A | Toxic effect of venom of other arthropod, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.484A | Toxic effect of venom of other arthropod, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.511A | Toxic effect of contact with stingray, accidental (unintentional), initial | Diagnosis | ICD-10-CM |
| T63.512 | Toxic effect of contact with stingray, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.512A | Toxic effect of contact with stingray, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.512D | Toxic effect of contact with stingray, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.512S | Toxic effect of contact with stingray, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.513A | Toxic effect of contact with stingray, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.514A | Toxic effect of contact with stingray, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.591A | Toxic effect of contact with other venomous fish, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.592 | Toxic effect of contact with other venomous fish, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.592A | Toxic effect of contact with other venomous fish, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T63.592D | Toxic effect of contact with other venomous fish, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.592S | Toxic effect of contact with other venomous fish, intentional self-harm, | Diagnosis | ICD-10-CM |
| T63.593A | Toxic effect of contact with other venomous fish, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.594A | Toxic effect of contact with other venomous fish, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.611A | Toxic effect of contact with Portuguese Man-o-war, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.612 | Toxic effect of contact with Portuguese Man-o-war, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.612A | Toxic effect of contact with Portuguese Man-o-war, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.612D | Toxic effect of contact with Portuguese Man-o-war, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.612S | Toxic effect of contact with Portuguese Man-o-war, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.613A | Toxic effect of contact with Portuguese Man-o-war, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.614A | Toxic effect of contact with Portuguese Man-o-war, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.621A | Toxic effect of contact with other jellyfish, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.622 | Toxic effect of contact with other jellyfish, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.622A | Toxic effect of contact with other jellyfish, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.622D | Toxic effect of contact with other jellyfish, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.622S | Toxic effect of contact with other jellyfish, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.623A | Toxic effect of contact with other jellyfish, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.624A | Toxic effect of contact with other jellyfish, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.631A | Toxic effect of contact with sea anemone, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.632 | Toxic effect of contact with sea anemone, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.632A | Toxic effect of contact with sea anemone, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.632D | Toxic effect of contact with sea anemone, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.632S | Toxic effect of contact with sea anemone, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.633A | Toxic effect of contact with sea anemone, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.634A | Toxic effect of contact with sea anemone, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.691A | Toxic effect of contact with other venomous marine animals, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.692 | Toxic effect of contact with other venomous marine animals, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.692A | Toxic effect of contact with other venomous marine animals, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T63.692D | Toxic effect of contact with other venomous marine animals, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.692S | Toxic effect of contact with other venomous marine animals, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.693A | Toxic effect of contact with other venomous marine animals, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.694A | Toxic effect of contact with other venomous marine animals, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.711A | Toxic effect of contact with venomous marine plant, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.712 | Toxic effect of contact with venomous marine plant, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.712A | Toxic effect of contact with venomous marine plant, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.712D | Toxic effect of contact with venomous marine plant, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.712S | Toxic effect of contact with venomous marine plant, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.713A | Toxic effect of contact with venomous marine plant, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.714A | Toxic effect of contact with venomous marine plant, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.791A | Toxic effect of contact with other venomous plant, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.792 | Toxic effect of contact with other venomous plant, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.792A | Toxic effect of contact with other venomous plant, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.792D | Toxic effect of contact with other venomous plant, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.792S | Toxic effect of contact with other venomous plant, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.793A | Toxic effect of contact with other venomous plant, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.794A | Toxic effect of contact with other venomous plant, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.811A | Toxic effect of contact with venomous frog, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.812 | Toxic effect of contact with venomous frog, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.812A | Toxic effect of contact with venomous frog, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.812D | Toxic effect of contact with venomous frog, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.812S | Toxic effect of contact with venomous frog, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.813A | Toxic effect of contact with venomous frog, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.814A | Toxic effect of contact with venomous frog, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.821A | Toxic effect of contact with venomous toad, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T63.822 | Toxic effect of contact with venomous toad, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.822A | Toxic effect of contact with venomous toad, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.822D | Toxic effect of contact with venomous toad, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.822S | Toxic effect of contact with venomous toad, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.823A | Toxic effect of contact with venomous toad, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.824A | Toxic effect of contact with venomous toad, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.831A | Toxic effect of contact with other venomous amphibian, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.832 | Toxic effect of contact with other venomous amphibian, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.832A | Toxic effect of contact with other venomous amphibian, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.832D | Toxic effect of contact with other venomous amphibian, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.832S | Toxic effect of contact with other venomous amphibian, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.833A | Toxic effect of contact with other venomous amphibian, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.834A | Toxic effect of contact with other venomous amphibian, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.891A | Toxic effect of contact with other venomous animals, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.892 | Toxic effect of contact with other venomous animals, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.892A | Toxic effect of contact with other venomous animals, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.892D | Toxic effect of contact with other venomous animals, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.892S | Toxic effect of contact with other venomous animals, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.893A | Toxic effect of contact with other venomous animals, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.894A | Toxic effect of contact with other venomous animals, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.91XA | Toxic effect of contact with unspecified venomous animal, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.92 | Toxic effect of contact with unspecified venomous animal, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.92XA | Toxic effect of contact with unspecified venomous animal, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.92XD | Toxic effect of contact with unspecified venomous animal, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.92XS | Toxic effect of contact with unspecified venomous animal, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.93XA | Toxic effect of contact with unspecified venomous animal, assault, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T63.94XA | Toxic effect of contact with unspecified venomous animal, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T64.01XA | Toxic effect of aflatoxin, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T64.02 | Toxic effect of aflatoxin, intentional self-harm | Diagnosis | ICD-10-CM |
| T64.02XA | Toxic effect of aflatoxin, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T64.02XD | Toxic effect of aflatoxin, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T64.02XS | Toxic effect of aflatoxin, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T64.03XA | Toxic effect of aflatoxin, assault, initial encounter | Diagnosis | ICD-10-CM |
| T64.04XA | Toxic effect of aflatoxin, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T64.81XA | Toxic effect of other mycotoxin food contaminants, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T64.82 | Toxic effect of other mycotoxin food contaminants, intentional self-harm | Diagnosis | ICD-10-CM |
| T64.82XA | Toxic effect of other mycotoxin food contaminants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T64.82XD | Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T64.82XS | Toxic effect of other mycotoxin food contaminants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T64.83XA | Toxic effect of other mycotoxin food contaminants, assault, initial encounter | Diagnosis | ICD-10-CM |
| T64.84XA | Toxic effect of other mycotoxin food contaminants, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T65.0X1A | Toxic effect of cyanides, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T65.0X2 | Toxic effect of cyanides, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.0X2A | Toxic effect of cyanides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.0X2D | Toxic effect of cyanides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.0X2S | Toxic effect of cyanides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.0X3A | Toxic effect of cyanides, assault, initial encounter | Diagnosis | ICD-10-CM |
| T65.0X4A | Toxic effect of cyanides, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T65.1X1A | Toxic effect of strychnine and its salts, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T65.1X2 | Toxic effect of strychnine and its salts, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.1X2A | Toxic effect of strychnine and its salts, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.1X2D | Toxic effect of strychnine and its salts, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.1X2S | Toxic effect of strychnine and its salts, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.1X3A | Toxic effect of strychnine and its salts, assault, initial encounter | Diagnosis | ICD-10-CM |
| T65.1X4A | Toxic effect of strychnine and its salts, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T65.211A | Toxic effect of chewing tobacco, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T65.212 | Toxic effect of chewing tobacco, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.212A | Toxic effect of chewing tobacco, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.212D | Toxic effect of chewing tobacco, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.212S | Toxic effect of chewing tobacco, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.213A | Toxic effect of chewing tobacco, assault, initial encounter | Diagnosis | ICD-10-CM |
| T65.214A | Toxic effect of chewing tobacco, undetermined, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T65.221A | Toxic effect of tobacco cigarettes, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T65.222 | Toxic effect of tobacco cigarettes, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.222A | Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.222D | Toxic effect of tobacco cigarettes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.222S | Toxic effect of tobacco cigarettes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.223A | Toxic effect of tobacco cigarettes, assault, initial encounter | Diagnosis | ICD-10-CM |
| T65.224A | Toxic effect of tobacco cigarettes, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T65.291A | Toxic effect of other tobacco and nicotine, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T65.292 | Toxic effect of other tobacco and nicotine, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.292A | Toxic effect of other tobacco and nicotine, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.292D | Toxic effect of other tobacco and nicotine, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.292S | Toxic effect of other tobacco and nicotine, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.293A | Toxic effect of other tobacco and nicotine, assault, initial encounter | Diagnosis | ICD-10-CM |
| T65.294A | Toxic effect of other tobacco and nicotine, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T65.3X1A | Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T65.3X2 | Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.3X2A | Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.3X2D | Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.3X2S | Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.3X3A | Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, assault, initial encounter | Diagnosis | ICD-10-CM |
| T65.3X4A | Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T65.4X1A | Toxic effect of carbon disulfide, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T65.4X2 | Toxic effect of carbon disulfide, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.4X2A | Toxic effect of carbon disulfide, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.4X2D | Toxic effect of carbon disulfide, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.4X2S | Toxic effect of carbon disulfide, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.4X3A | Toxic effect of carbon disulfide, assault, initial encounter | Diagnosis | ICD-10-CM |
| T65.4X4A | Toxic effect of carbon disulfide, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T65.5X1A | Toxic effect of nitroglycerin and other nitric acids and esters, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T65.5X2 | Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.5X2A | Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T65.5X2D | Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.5X2S | Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.5X3A | Toxic effect of nitroglycerin and other nitric acids and esters, assault, initial encounter | Diagnosis | ICD-10-CM |
| T65.5X4A | Toxic effect of nitroglycerin and other nitric acids and esters, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T65.6X1A | Toxic effect of paints and dyes, not elsewhere classified, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T65.6X2 | Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.6X2A | Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.6X2D | Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.6X2S | Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.6X3A | Toxic effect of paints and dyes, not elsewhere classified, assault, initial encounter | Diagnosis | ICD-10-CM |
| T65.6X4A | Toxic effect of paints and dyes, not elsewhere classified, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T65.811A | Toxic effect of latex, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T65.812 | Toxic effect of latex, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.812A | Toxic effect of latex, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.812D | Toxic effect of latex, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.812S | Toxic effect of latex, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.813A | Toxic effect of latex, assault, initial encounter | Diagnosis | ICD-10-CM |
| T65.814A | Toxic effect of latex, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T65.821A | Toxic effect of harmful algae and algae toxins, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T65.822 | Toxic effect of harmful algae and algae toxins, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.822A | Toxic effect of harmful algae and algae toxins, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.822D | Toxic effect of harmful algae and algae toxins, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.822S | Toxic effect of harmful algae and algae toxins, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.823A | Toxic effect of harmful algae and algae toxins, assault, initial encounter | Diagnosis | ICD-10-CM |
| T65.824A | Toxic effect of harmful algae and algae toxins, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T65.831A | Toxic effect of fiberglass, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T65.832 | Toxic effect of fiberglass, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.832A | Toxic effect of fiberglass, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.832D | Toxic effect of fiberglass, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.832S | Toxic effect of fiberglass, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.833A | Toxic effect of fiberglass, assault, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T65.834A | Toxic effect of fiberglass, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T65.891A | Toxic effect of other specified substances, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T65.892 | Toxic effect of other specified substances, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.892A | Toxic effect of other specified substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.892D | Toxic effect of other specified substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.892S | Toxic effect of other specified substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.893A | Toxic effect of other specified substances, assault, initial encounter | Diagnosis | ICD-10-CM |
| T65.894A | Toxic effect of other specified substances, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T65.91XA | Toxic effect of unspecified substance, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T65.92 | Toxic effect of unspecified substance, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.92XA | Toxic effect of unspecified substance, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.92XD | Toxic effect of unspecified substance, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.92XS | Toxic effect of unspecified substance, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.93XA | Toxic effect of unspecified substance, assault, initial encounter | Diagnosis | ICD-10-CM |
| T65.94XA | Toxic effect of unspecified substance, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T71.111A | Asphyxiation due to smothering under pillow, accidental, initial encounter | Diagnosis | ICD-10-CM |
| T71.112 | Asphyxiation due to smothering under pillow, intentional self-harm | Diagnosis | ICD-10-CM |
| T71.112A | Asphyxiation due to smothering under pillow, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.112D | Asphyxiation due to smothering under pillow, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.112S | Asphyxiation due to smothering under pillow, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.113A | Asphyxiation due to smothering under pillow, assault, initial encounter | Diagnosis | ICD-10-CM |
| T71.114A | Asphyxiation due to smothering under pillow, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T71.121A | Asphyxiation due to plastic bag, accidental, initial encounter | Diagnosis | ICD-10-CM |
| T71.122 | Asphyxiation due to plastic bag, intentional self-harm | Diagnosis | ICD-10-CM |
| T71.122A | Asphyxiation due to plastic bag, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.122D | Asphyxiation due to plastic bag, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.122S | Asphyxiation due to plastic bag, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.123A | Asphyxiation due to plastic bag, assault, initial encounter | Diagnosis | ICD-10-CM |
| T71.124A | Asphyxiation due to plastic bag, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T71.131A | Asphyxiation due to being trapped in bed linens, accidental, initial encounter | Diagnosis | ICD-10-CM |
| T71.132 | Asphyxiation due to being trapped in bed linens, intentional self-harm | Diagnosis | ICD-10-CM |
| T71.132A | Asphyxiation due to being trapped in bed linens, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.132D | Asphyxiation due to being trapped in bed linens, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.132S | Asphyxiation due to being trapped in bed linens, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.133A | Asphyxiation due to being trapped in bed linens, assault, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T71.134A | Asphyxiation due to being trapped in bed linens, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T71.141A | Asphyxiation due to smothering under another person's body (in bed), accidental, initial encounter | Diagnosis | ICD-10-CM |
| T71.143A | Asphyxiation due to smothering under another person's body (in bed), assault, initial encounter | Diagnosis | ICD-10-CM |
| T71.144A | Asphyxiation due to smothering under another person's body (in bed), undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T71.151A | Asphyxiation due to smothering in furniture, accidental, initial encounter | Diagnosis | ICD-10-CM |
| T71.152 | Asphyxiation due to smothering in furniture, intentional self-harm | Diagnosis | ICD-10-CM |
| T71.152A | Asphyxiation due to smothering in furniture, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.152D | Asphyxiation due to smothering in furniture, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.152S | Asphyxiation due to smothering in furniture, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.153A | Asphyxiation due to smothering in furniture, assault, initial encounter | Diagnosis | ICD-10-CM |
| T71.154A | Asphyxiation due to smothering in furniture, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T71.161A | Asphyxiation due to hanging, accidental, initial encounter | Diagnosis | ICD-10-CM |
| T71.162 | Asphyxiation due to hanging, intentional self-harm | Diagnosis | ICD-10-CM |
| T71.162A | Asphyxiation due to hanging, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.162D | Asphyxiation due to hanging, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.162S | Asphyxiation due to hanging, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.163A | Asphyxiation due to hanging, assault, initial encounter | Diagnosis | ICD-10-CM |
| T71.164A | Asphyxiation due to hanging, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T71.191A | Asphyxiation due to mechanical threat to breathing due to other causes, accidental, initial encounter | Diagnosis | ICD-10-CM |
| T71.192 | Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm | Diagnosis | ICD-10-CM |
| T71.192A | Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.192D | Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.192S | Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.193A | Asphyxiation due to mechanical threat to breathing due to other causes, assault, initial encounter | Diagnosis | ICD-10-CM |
| T71.194A | Asphyxiation due to mechanical threat to breathing due to other causes, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T71.20XA | Asphyxiation due to systemic oxygen deficiency due to low oxygen content in ambient air due to unspecified cause, initial encounter | Diagnosis | ICD-10-CM |
| T71.21XA | Asphyxiation due to cave-in or falling earth, initial encounter | Diagnosis | ICD-10-CM |
| T71.221A | Asphyxiation due to being trapped in a car trunk, accidental, initial encounter | Diagnosis | ICD-10-CM |
| T71.222 | Asphyxiation due to being trapped in a car trunk, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T71.222A | Asphyxiation due to being trapped in a car trunk, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.222D | Asphyxiation due to being trapped in a car trunk, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.222S | Asphyxiation due to being trapped in a car trunk, intentional self-harm, | Diagnosis | ICD-10-CM |
| T71.223A | Asphyxiation due to being trapped in a car trunk, assault, initial encounter | Diagnosis | ICD-10-CM |
| T71.224A | Asphyxiation due to being trapped in a car trunk, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T71.231A | Asphyxiation due to being trapped in a (discarded) refrigerator, accidental, initial encounter | Diagnosis | ICD-10-CM |
| T71.232 | Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm | Diagnosis | ICD-10-CM |
| T71.232A | Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.232D | Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.232S | Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.233A | Asphyxiation due to being trapped in a (discarded) refrigerator, assault, initial encounter | Diagnosis | ICD-10-CM |
| T71.234A | Asphyxiation due to being trapped in a (discarded) refrigerator, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T71.29XA | Asphyxiation due to being trapped in other low oxygen environment, initial encounter | Diagnosis | ICD-10-CM |
| T71.9XXA | Asphyxiation due to unspecified cause, initial encounter | Diagnosis | ICD-10-CM |
| T78.1XXA | Other adverse food reactions, not elsewhere classified, initial encounter | Diagnosis | ICD-10-CM |
| V40.0 | Problems with learning | Diagnosis | ICD-9-CM |
| V40.2 | Other mental problems | Diagnosis | ICD-9-CM |
| V40.3 | Other behavioral problems | Diagnosis | ICD-9-CM |
| V40.31 | Wandering in diseases classified elsewhere | Diagnosis | ICD-9-CM |
| V40.39 | Other specified behavioral problem | Diagnosis | ICD-9-CM |
| V40.9 | Unspecified mental or behavioral problem | Diagnosis | ICD-9-CM |
| V41.7 | Problems with sexual function | Diagnosis | ICD-9-CM |
| V62.84 | Suicidal ideation | Diagnosis | ICD-9-CM |
| V65.42 | Counseling on substance use and abuse | Diagnosis | ICD-9-CM |
| V67.3 | Psychotherapy and other treatment for mental disorder follow-up examination | Diagnosis | ICD-9-CM |
| X71 | Intentional self-harm by drowning and submersion | Diagnosis | ICD-10-CM |
| X71.0 | Intentional self-harm by drowning and submersion while in bathtub | Diagnosis | ICD-10-CM |
| X71.0XXA | Intentional self-harm by drowning and submersion while in bathtub, initial encounter | Diagnosis | ICD-10-CM |
| X71.0XXD | Intentional self-harm by drowning and submersion while in bathtub, subsequent encounter | Diagnosis | ICD-10-CM |
| X71.0XXS | Intentional self-harm by drowning and submersion while in bathtub, sequela | Diagnosis | ICD-10-CM |
| X71.1 | Intentional self-harm by drowning and submersion while in swimming pool | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| X71.1XXA | Intentional self-harm by drowning and submersion while in swimming pool, initial encounter | Diagnosis | ICD-10-CM |
| X71.1XXD | Intentional self-harm by drowning and submersion while in swimming pool, subsequent encounter | Diagnosis | ICD-10-CM |
| X71.1XXS | Intentional self-harm by drowning and submersion while in swimming pool, sequela | Diagnosis | ICD-10-CM |
| X71.2 | Intentional self-harm by drowning and submersion after jump into swimming pool | Diagnosis | ICD-10-CM |
| X71.2XXA | Intentional self-harm by drowning and submersion after jump into swimming pool, initial encounter | Diagnosis | ICD-10-CM |
| X71.2XXD | Intentional self-harm by drowning and submersion after jump into swimming pool, subsequent encounter | Diagnosis | ICD-10-CM |
| X71.2XXS | Intentional self-harm by drowning and submersion after jump into swimming pool, sequela | Diagnosis | ICD-10-CM |
| X71.3 | Intentional self-harm by drowning and submersion in natural water | Diagnosis | ICD-10-CM |
| X71.3XXA | Intentional self-harm by drowning and submersion in natural water, initial encounter | Diagnosis | ICD-10-CM |
| X71.3XXD | Intentional self-harm by drowning and submersion in natural water, subsequent encounter | Diagnosis | ICD-10-CM |
| X71.3XXS | Intentional self-harm by drowning and submersion in natural water, sequela | Diagnosis | ICD-10-CM |
| X71.8 | Other intentional self-harm by drowning and submersion | Diagnosis | ICD-10-CM |
| X71.8XXA | Other intentional self-harm by drowning and submersion, initial encounter | Diagnosis | ICD-10-CM |
| X71.8XXD | Other intentional self-harm by drowning and submersion, subsequent encounter | Diagnosis | ICD-10-CM |
| X71.8XXS | Other intentional self-harm by drowning and submersion, sequela | Diagnosis | ICD-10-CM |
| X71.9 | Intentional self-harm by drowning and submersion, unspecified | Diagnosis | ICD-10-CM |
| X71.9XXA | Intentional self-harm by drowning and submersion, unspecified, initial encounter | Diagnosis | ICD-10-CM |
| X71.9XXD | Intentional self-harm by drowning and submersion, unspecified, subsequent encounter | Diagnosis | ICD-10-CM |
| X71.9XXS | Intentional self-harm by drowning and submersion, unspecified, sequela | Diagnosis | ICD-10-CM |
| X72 | Intentional self-harm by handgun discharge | Diagnosis | ICD-10-CM |
| X72.XXXA | Intentional self-harm by handgun discharge, initial encounter | Diagnosis | ICD-10-CM |
| X72.XXXD | Intentional self-harm by handgun discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X72.XXXS | Intentional self-harm by handgun discharge, sequela | Diagnosis | ICD-10-CM |
| X73 | Intentional self-harm by rifle, shotgun and larger firearm discharge | Diagnosis | ICD-10-CM |
| X73.0 | Intentional self-harm by shotgun discharge | Diagnosis | ICD-10-CM |
| X73.0XXA | Intentional self-harm by shotgun discharge, initial encounter | Diagnosis | ICD-10-CM |
| X73.0XXD | Intentional self-harm by shotgun discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X73.0XXS | Intentional self-harm by shotgun discharge, sequela | Diagnosis | ICD-10-CM |
| X73.1 | Intentional self-harm by hunting rifle discharge | Diagnosis | ICD-10-CM |
| X73.1XXA | Intentional self-harm by hunting rifle discharge, initial encounter | Diagnosis | ICD-10-CM |
| X73.1XXD | Intentional self-harm by hunting rifle discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X73.1XXS | Intentional self-harm by hunting rifle discharge, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| X73.2 | Intentional self-harm by machine gun discharge | Diagnosis | ICD-10-CM |
| X73.2XXA | Intentional self-harm by machine gun discharge, initial encounter | Diagnosis | ICD-10-CM |
| X73.2XXD | Intentional self-harm by machine gun discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X73.2XXS | Intentional self-harm by machine gun discharge, sequela | Diagnosis | ICD-10-CM |
| X73.8 | Intentional self-harm by other larger firearm discharge | Diagnosis | ICD-10-CM |
| X73.8XXA | Intentional self-harm by other larger firearm discharge, initial encounter | Diagnosis | ICD-10-CM |
| X73.8XXD | Intentional self-harm by other larger firearm discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X73.8XXS | Intentional self-harm by other larger firearm discharge, sequela | Diagnosis | ICD-10-CM |
| X73.9 | Intentional self-harm by unspecified larger firearm discharge | Diagnosis | ICD-10-CM |
| X73.9XXA | Intentional self-harm by unspecified larger firearm discharge, initial encounter | Diagnosis | ICD-10-CM |
| X73.9XXD | Intentional self-harm by unspecified larger firearm discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X73.9XXS | Intentional self-harm by unspecified larger firearm discharge, sequela | Diagnosis | ICD-10-CM |
| X74 | Intentional self-harm by other and unspecified firearm and gun discharge | Diagnosis | ICD-10-CM |
| X74.0 | Intentional self-harm by gas, air or spring-operated guns | Diagnosis | ICD-10-CM |
| X74.01 | Intentional self-harm by airgun | Diagnosis | ICD-10-CM |
| X74.01XA | Intentional self-harm by airgun, initial encounter | Diagnosis | ICD-10-CM |
| X74.01XD | Intentional self-harm by airgun, subsequent encounter | Diagnosis | ICD-10-CM |
| X74.01XS | Intentional self-harm by airgun, sequela | Diagnosis | ICD-10-CM |
| X74.02 | Intentional self-harm by paintball gun | Diagnosis | ICD-10-CM |
| X74.02XA | Intentional self-harm by paintball gun, initial encounter | Diagnosis | ICD-10-CM |
| X74.02XD | Intentional self-harm by paintball gun, subsequent encounter | Diagnosis | ICD-10-CM |
| X74.02XS | Intentional self-harm by paintball gun, sequela | Diagnosis | ICD-10-CM |
| X74.09 | Intentional self-harm by other gas, air or spring-operated gun | Diagnosis | ICD-10-CM |
| X74.09XA | Intentional self-harm by other gas, air or spring-operated gun, initial encounter | Diagnosis | ICD-10-CM |
| X74.09XD | Intentional self-harm by other gas, air or spring-operated gun, subsequent encounter | Diagnosis | ICD-10-CM |
| X74.09XS | Intentional self-harm by other gas, air or spring-operated gun, sequela | Diagnosis | ICD-10-CM |
| X74.8 | Intentional self-harm by other firearm discharge | Diagnosis | ICD-10-CM |
| X74.8XXA | Intentional self-harm by other firearm discharge, initial encounter | Diagnosis | ICD-10-CM |
| X74.8XXD | Intentional self-harm by other firearm discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X74.8XXS | Intentional self-harm by other firearm discharge, sequela | Diagnosis | ICD-10-CM |
| X74.9 | Intentional self-harm by unspecified firearm discharge | Diagnosis | ICD-10-CM |
| X74.9XXA | Intentional self-harm by unspecified firearm discharge, initial encounter | Diagnosis | ICD-10-CM |
| X74.9XXD | Intentional self-harm by unspecified firearm discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X74.9XXS | Intentional self-harm by unspecified firearm discharge, sequela | Diagnosis | ICD-10-CM |
| X75 | Intentional self-harm by explosive material | Diagnosis | ICD-10-CM |
| X75.XXXA | Intentional self-harm by explosive material, initial encounter | Diagnosis | ICD-10-CM |
| X75.XXXD | Intentional self-harm by explosive material, subsequent encounter | Diagnosis | ICD-10-CM |
| X75.XXXS | Intentional self-harm by explosive material, sequela | Diagnosis | ICD-10-CM |
| X76 | Intentional self-harm by smoke, fire and flames | Diagnosis | ICD-10-CM |
| X76.XXXA | Intentional self-harm by smoke, fire and flames, initial encounter | Diagnosis | ICD-10-CM |
| X76.XXXD | Intentional self-harm by smoke, fire and flames, subsequent encounter | Diagnosis | ICD-10-CM |
| X76.XXXS | Intentional self-harm by smoke, fire and flames, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| X77 | Intentional self-harm by steam, hot vapors and hot objects | Diagnosis | ICD-10-CM |
| X77.0 | Intentional self-harm by steam or hot vapors | Diagnosis | ICD-10-CM |
| X77.0XXA | Intentional self-harm by steam or hot vapors, initial encounter | Diagnosis | ICD-10-CM |
| X77.0XXD | Intentional self-harm by steam or hot vapors, subsequent encounter | Diagnosis | ICD-10-CM |
| X77.0XXS | Intentional self-harm by steam or hot vapors, sequela | Diagnosis | ICD-10-CM |
| X77.1 | Intentional self-harm by hot tap water | Diagnosis | ICD-10-CM |
| X77.1XXA | Intentional self-harm by hot tap water, initial encounter | Diagnosis | ICD-10-CM |
| X77.1XXD | Intentional self-harm by hot tap water, subsequent encounter | Diagnosis | ICD-10-CM |
| X77.1XXS | Intentional self-harm by hot tap water, sequela | Diagnosis | ICD-10-CM |
| X77.2 | Intentional self-harm by other hot fluids | Diagnosis | ICD-10-CM |
| X77.2XXA | Intentional self-harm by other hot fluids, initial encounter | Diagnosis | ICD-10-CM |
| X77.2XXD | Intentional self-harm by other hot fluids, subsequent encounter | Diagnosis | ICD-10-CM |
| X77.2XXS | Intentional self-harm by other hot fluids, sequela | Diagnosis | ICD-10-CM |
| X77.3 | Intentional self-harm by hot household appliances | Diagnosis | ICD-10-CM |
| X77.3XXA | Intentional self-harm by hot household appliances, initial encounter | Diagnosis | ICD-10-CM |
| X77.3XXD | Intentional self-harm by hot household appliances, subsequent encounter | Diagnosis | ICD-10-CM |
| X77.3XXS | Intentional self-harm by hot household appliances, sequela | Diagnosis | ICD-10-CM |
| X77.8 | Intentional self-harm by other hot objects | Diagnosis | ICD-10-CM |
| X77.8XXA | Intentional self-harm by other hot objects, initial encounter | Diagnosis | ICD-10-CM |
| X77.8XXD | Intentional self-harm by other hot objects, subsequent encounter | Diagnosis | ICD-10-CM |
| X77.8XXS | Intentional self-harm by other hot objects, sequela | Diagnosis | ICD-10-CM |
| X77.9 | Intentional self-harm by unspecified hot objects | Diagnosis | ICD-10-CM |
| X77.9XXA | Intentional self-harm by unspecified hot objects, initial encounter | Diagnosis | ICD-10-CM |
| X77.9XXD | Intentional self-harm by unspecified hot objects, subsequent encounter | Diagnosis | ICD-10-CM |
| X77.9XXS | Intentional self-harm by unspecified hot objects, sequela | Diagnosis | ICD-10-CM |
| X78 | Intentional self-harm by sharp object | Diagnosis | ICD-10-CM |
| X78.0 | Intentional self-harm by sharp glass | Diagnosis | ICD-10-CM |
| X78.0XXA | Intentional self-harm by sharp glass, initial encounter | Diagnosis | ICD-10-CM |
| X78.0XXD | Intentional self-harm by sharp glass, subsequent encounter | Diagnosis | ICD-10-CM |
| X78.0XXS | Intentional self-harm by sharp glass, sequela | Diagnosis | ICD-10-CM |
| X78.1 | Intentional self-harm by knife | Diagnosis | ICD-10-CM |
| X78.1XXA | Intentional self-harm by knife, initial encounter | Diagnosis | ICD-10-CM |
| X78.1XXD | Intentional self-harm by knife, subsequent encounter | Diagnosis | ICD-10-CM |
| X78.1XXS | Intentional self-harm by knife, sequela | Diagnosis | ICD-10-CM |
| X78.2 | Intentional self-harm by sword or dagger | Diagnosis | ICD-10-CM |
| X78.2XXA | Intentional self-harm by sword or dagger, initial encounter | Diagnosis | ICD-10-CM |
| X78.2XXD | Intentional self-harm by sword or dagger, subsequent encounter | Diagnosis | ICD-10-CM |
| X78.2XXS | Intentional self-harm by sword or dagger, sequela | Diagnosis | ICD-10-CM |
| X78.8 | Intentional self-harm by other sharp object | Diagnosis | ICD-10-CM |
| X78.8XXA | Intentional self-harm by other sharp object, initial encounter | Diagnosis | ICD-10-CM |
| X78.8XXD | Intentional self-harm by other sharp object, subsequent encounter | Diagnosis | ICD-10-CM |
| X78.8XXS | Intentional self-harm by other sharp object, sequela | Diagnosis | ICD-10-CM |
| X78.9 | Intentional self-harm by unspecified sharp object | Diagnosis | ICD-10-CM |
| X78.9XXA | Intentional self-harm by unspecified sharp object, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| X78.9XXD | Intentional self-harm by unspecified sharp object, subsequent encounter | Diagnosis | ICD-10-CM |
| X78.9XXS | Intentional self-harm by unspecified sharp object, sequela | Diagnosis | ICD-10-CM |
| X79 | Intentional self-harm by blunt object | Diagnosis | ICD-10-CM |
| X79.XXXA | Intentional self-harm by blunt object, initial encounter | Diagnosis | ICD-10-CM |
| X79.XXXD | Intentional self-harm by blunt object, subsequent encounter | Diagnosis | ICD-10-CM |
| X79.XXXS | Intentional self-harm by blunt object, sequela | Diagnosis | ICD-10-CM |
| X80 | Intentional self-harm by jumping from a high place | Diagnosis | ICD-10-CM |
| X80.XXXA | Intentional self-harm by jumping from a high place, initial encounter | Diagnosis | ICD-10-CM |
| X80.XXXD | Intentional self-harm by jumping from a high place, subsequent encounter | Diagnosis | ICD-10-CM |
| X80.XXXS | Intentional self-harm by jumping from a high place, sequela | Diagnosis | ICD-10-CM |
| X81 | Intentional self-harm by jumping or lying in front of moving object | Diagnosis | ICD-10-CM |
| X81.0 | Intentional self-harm by jumping or lying in front of motor vehicle | Diagnosis | ICD-10-CM |
| X81.0XXA | Intentional self-harm by jumping or lying in front of motor vehicle, initial encounter | Diagnosis | ICD-10-CM |
| X81.0XXD | Intentional self-harm by jumping or lying in front of motor vehicle, subsequent encounter | Diagnosis | ICD-10-CM |
| X81.0XXS | Intentional self-harm by jumping or lying in front of motor vehicle, sequela | Diagnosis | ICD-10-CM |
| X81.1 | Intentional self-harm by jumping or lying in front of (subway) train | Diagnosis | ICD-10-CM |
| X81.1XXA | Intentional self-harm by jumping or lying in front of (subway) train, initial encounter | Diagnosis | ICD-10-CM |
| X81.1XXD | Intentional self-harm by jumping or lying in front of (subway) train, subsequent encounter | Diagnosis | ICD-10-CM |
| X81.1XXS | Intentional self-harm by jumping or lying in front of (subway) train, sequela | Diagnosis | ICD-10-CM |
| X81.8 | Intentional self-harm by jumping or lying in front of other moving object | Diagnosis | ICD-10-CM |
| X81.8XXA | Intentional self-harm by jumping or lying in front of other moving object, initial encounter | Diagnosis | ICD-10-CM |
| X81.8XXD | Intentional self-harm by jumping or lying in front of other moving object, subsequent encounter | Diagnosis | ICD-10-CM |
| X81.8XXS | Intentional self-harm by jumping or lying in front of other moving object, sequela | Diagnosis | ICD-10-CM |
| X82 | Intentional self-harm by crashing of motor vehicle | Diagnosis | ICD-10-CM |
| X82.0 | Intentional collision of motor vehicle with other motor vehicle | Diagnosis | ICD-10-CM |
| X82.0XXA | Intentional collision of motor vehicle with other motor vehicle, initial encounter | Diagnosis | ICD-10-CM |
| X82.0XXD | Intentional collision of motor vehicle with other motor vehicle, subsequent encounter | Diagnosis | ICD-10-CM |
| X82.0XXS | Intentional collision of motor vehicle with other motor vehicle, sequela | Diagnosis | ICD-10-CM |
| X82.1 | Intentional collision of motor vehicle with train | Diagnosis | ICD-10-CM |
| X82.1XXA | Intentional collision of motor vehicle with train, initial encounter | Diagnosis | ICD-10-CM |
| X82.1XXD | Intentional collision of motor vehicle with train, subsequent encounter | Diagnosis | ICD-10-CM |
| X82.1XXS | Intentional collision of motor vehicle with train, sequela | Diagnosis | ICD-10-CM |
| X82.2 | Intentional collision of motor vehicle with tree | Diagnosis | ICD-10-CM |
| X82.2XXA | Intentional collision of motor vehicle with tree, initial encounter | Diagnosis | ICD-10-CM |
| X82.2XXD | Intentional collision of motor vehicle with tree, subsequent encounter | Diagnosis | ICD-10-CM |
| X82.2XXS | Intentional collision of motor vehicle with tree, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|-----------------------------|---|---------------|-----------|
| X82.8 | Other intentional self-harm by crashing of motor vehicle | Diagnosis | ICD-10-CM |
| X82.8XXA | Other intentional self-harm by crashing of motor vehicle, initial encounter | Diagnosis | ICD-10-CM |
| X82.8XXD | Other intentional self-harm by crashing of motor vehicle, subsequent | Diagnosis | ICD-10-CM |
| X82.8XXS | Other intentional self-harm by crashing of motor vehicle, sequela | Diagnosis | ICD-10-CM |
| X83 | Intentional self-harm by other specified means | Diagnosis | ICD-10-CM |
| X83.0 | Intentional self-harm by crashing of aircraft | Diagnosis | ICD-10-CM |
| X83.0XXA | Intentional self-harm by crashing of aircraft, initial encounter | Diagnosis | ICD-10-CM |
| X83.0XXD | Intentional self-harm by crashing of aircraft, subsequent encounter | Diagnosis | ICD-10-CM |
| X83.0XXS | Intentional self-harm by crashing of aircraft, sequela | Diagnosis | ICD-10-CM |
| X83.1 | Intentional self-harm by electrocution | Diagnosis | ICD-10-CM |
| X83.1XXA | Intentional self-harm by electrocution, initial encounter | Diagnosis | ICD-10-CM |
| X83.1XXD | Intentional self-harm by electrocution, subsequent encounter | Diagnosis | ICD-10-CM |
| X83.1XXS | Intentional self-harm by electrocution, sequela | Diagnosis | ICD-10-CM |
| X83.2 | Intentional self-harm by exposure to extremes of cold | Diagnosis | ICD-10-CM |
| X83.2XXA | Intentional self-harm by exposure to extremes of cold, initial encounter | Diagnosis | ICD-10-CM |
| X83.2XXD | Intentional self-harm by exposure to extremes of cold, subsequent encounter | Diagnosis | ICD-10-CM |
| X83.2XXS | Intentional self-harm by exposure to extremes of cold, sequela | Diagnosis | ICD-10-CM |
| X83.8 | Intentional self-harm by other specified means | Diagnosis | ICD-10-CM |
| X83.8XXA | Intentional self-harm by other specified means, initial encounter | Diagnosis | ICD-10-CM |
| X83.8XXD | Intentional self-harm by other specified means, subsequent encounter | Diagnosis | ICD-10-CM |
| X83.8XXS | Intentional self-harm by other specified means, sequela | Diagnosis | ICD-10-CM |
| Z87.890 | Personal history of sex reassignment | Diagnosis | ICD-10-CM |
| Z91.5 | Personal history of self-harm | Diagnosis | ICD-10-CM |
| Z91.83 | Wandering in diseases classified elsewhere | Diagnosis | ICD-10-CM |
| Psychiatric Drug Dispensing | | | |
| C9035 | Injection, aripiprazole lauroxil (Aristada Initio), 1 mg | Procedure | HCPCS |
| C9037 | Injection, risperidone (Perseris), 0.5 mg | Procedure | HCPCS |
| C9125 | Injection, risperidone, per 12.5 mg | Procedure | HCPCS |
| C9204 | Injection, ziprasidone mesylate injection, per 20 mg | Procedure | HCPCS |
| C9255 | Injection, paliperidone palmitate, 1 mg | Procedure | HCPCS |
| C9470 | Injection, aripiprazole lauroxil, 1 mg | Procedure | HCPCS |
| C9497 | Loxapine, inhalation powder, 10 mg | Procedure | HCPCS |
| J0400 | Injection, aripiprazole, intramuscular, 0.25 mg | Procedure | HCPCS |
| J0401 | Injection, aripiprazole, extended release, 1 mg | Procedure | HCPCS |
| J1320 | Injection, amitriptyline HCl, up to 20 mg | Procedure | HCPCS |
| J1630 | Injection, haloperidol, up to 5 mg | Procedure | HCPCS |
| J1631 | Injection, haloperidol decanoate, per 50 mg | Procedure | HCPCS |
| J1790 | Injection, droperidol, up to 5 mg | Procedure | HCPCS |
| J1810 | Injection, droperidol and fentanyl citrate, up to 2 ml ampule | Procedure | HCPCS |
| J1942 | Injection, aripiprazole lauroxil, 1 mg | Procedure | HCPCS |
| J1990 | Injection, chlordiazepoxide HCl, up to 100 mg | Procedure | HCPCS |
| J2060 | Injection, lorazepam, 2 mg | Procedure | HCPCS |
| J2062 | Loxapine for inhalation, 1 mg | Procedure | HCPCS |
| J2330 | Injection, thiothixene, up to 4 mg | Procedure | HCPCS |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------------------|--|---------------|-----------|
| J2358 | Injection, olanzapine, long-acting, 1 mg | Procedure | HCPCS |
| J2426 | Injection, paliperidone palmitate extended release, 1 mg | Procedure | HCPCS |
| J2515 | Injection, pentobarbital sodium, per 50 mg | Procedure | HCPCS |
| J2680 | Injection, fluphenazine decanoate, up to 25 mg | Procedure | HCPCS |
| J2794 | Injection, risperidone (RISPERDAL CONSTA), 0.5 mg | Procedure | HCPCS |
| J3230 | Injection, chlorpromazine HCl, up to 50 mg | Procedure | HCPCS |
| J3270 | Injection, imipramine hcl, up to 25 mg | Procedure | HCPCS |
| J3310 | Injection, perphenazine, up to 5 mg | Procedure | HCPCS |
| J3360 | Injection, diazepam, up to 5 mg | Procedure | HCPCS |
| J3486 | Injection, ziprasidone mesylate, 10 mg | Procedure | HCPCS |
| S0136 | Clozapine, 25 mg | Procedure | HCPCS |
| S0160 | Dextroamphetamine sulfate, 5 mg | Procedure | HCPCS |
| S0163 | Injection, risperidone, long acting, 12.5 mg | Procedure | HCPCS |
| S0166 | Injection, olanzapine, 2.5 mg | Procedure | HCPCS |
| Self-Harm Encounter | | | |
| 293.83 | Mood disorder in conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 296.0 | Bipolar I disorder, single manic episode | Diagnosis | ICD-9-CM |
| 296.00 | Bipolar I disorder, single manic episode, unspecified | Diagnosis | ICD-9-CM |
| 296.01 | Bipolar I disorder, single manic episode, mild | Diagnosis | ICD-9-CM |
| 296.02 | Bipolar I disorder, single manic episode, moderate | Diagnosis | ICD-9-CM |
| 296.03 | Bipolar I disorder, single manic episode, severe, without mention of psychotic behavior | Diagnosis | ICD-9-CM |
| 296.04 | Bipolar I disorder, single manic episode, severe, specified as with psychotic behavior | Diagnosis | ICD-9-CM |
| 296.05 | Bipolar I disorder, single manic episode, in partial or unspecified remission | Diagnosis | ICD-9-CM |
| 296.06 | Bipolar I disorder, single manic episode, in full remission | Diagnosis | ICD-9-CM |
| 296.1 | Manic disorder, recurrent episode | Diagnosis | ICD-9-CM |
| 296.10 | Manic disorder, recurrent episode, unspecified | Diagnosis | ICD-9-CM |
| 296.11 | Manic disorder, recurrent episode, mild | Diagnosis | ICD-9-CM |
| 296.12 | Manic disorder, recurrent episode, moderate | Diagnosis | ICD-9-CM |
| 296.13 | Manic disorder, recurrent episode, severe, without mention of psychotic behavior | Diagnosis | ICD-9-CM |
| 296.14 | Manic disorder, recurrent episode, severe, specified as with psychotic behavior | Diagnosis | ICD-9-CM |
| 296.15 | Manic disorder, recurrent episode, in partial or unspecified remission | Diagnosis | ICD-9-CM |
| 296.16 | Manic disorder, recurrent episode, in full remission | Diagnosis | ICD-9-CM |
| 296.2 | Major depressive disorder, single episode | Diagnosis | ICD-9-CM |
| 296.20 | Major depressive disorder, single episode, unspecified | Diagnosis | ICD-9-CM |
| 296.21 | Major depressive disorder, single episode, mild | Diagnosis | ICD-9-CM |
| 296.22 | Major depressive disorder, single episode, moderate | Diagnosis | ICD-9-CM |
| 296.23 | Major depressive disorder, single episode, severe, without mention of psychotic behavior | Diagnosis | ICD-9-CM |
| 296.24 | Major depressive disorder, single episode, severe, specified as with psychotic behavior | Diagnosis | ICD-9-CM |
| 296.25 | Major depressive disorder, single episode, in partial or unspecified remission | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| 296.26 | Major depressive disorder, single episode in full remission | Diagnosis | ICD-9-CM |
| 296.3 | Major depressive disorder, recurrent episode | Diagnosis | ICD-9-CM |
| 296.30 | Major depressive disorder, recurrent episode, unspecified | Diagnosis | ICD-9-CM |
| 296.31 | Major depressive disorder, recurrent episode, mild | Diagnosis | ICD-9-CM |
| 296.32 | Major depressive disorder, recurrent episode, moderate | Diagnosis | ICD-9-CM |
| 296.33 | Major depressive disorder, recurrent episode, severe, without mention of psychotic behavior | Diagnosis | ICD-9-CM |
| 296.34 | Major depressive disorder, recurrent episode, severe, specified as with psychotic behavior | Diagnosis | ICD-9-CM |
| 296.35 | Major depressive disorder, recurrent episode, in partial or unspecified | Diagnosis | ICD-9-CM |
| 296.36 | Major depressive disorder, recurrent episode, in full remission | Diagnosis | ICD-9-CM |
| 296.4 | Bipolar I disorder, most recent episode (or current) manic | Diagnosis | ICD-9-CM |
| 296.40 | Bipolar I disorder, most recent episode (or current) manic, unspecified | Diagnosis | ICD-9-CM |
| 296.41 | Bipolar I disorder, most recent episode (or current) manic, mild | Diagnosis | ICD-9-CM |
| 296.42 | Bipolar I disorder, most recent episode (or current) manic, moderate | Diagnosis | ICD-9-CM |
| 296.43 | Bipolar I disorder, most recent episode (or current) manic, severe, without mention of psychotic behavior | Diagnosis | ICD-9-CM |
| 296.44 | Bipolar I disorder, most recent episode (or current) manic, severe, specified as with psychotic behavior | Diagnosis | ICD-9-CM |
| 296.45 | Bipolar I disorder, most recent episode (or current) manic, in partial or unspecified remission | Diagnosis | ICD-9-CM |
| 296.46 | Bipolar I disorder, most recent episode (or current) manic, in full remission | Diagnosis | ICD-9-CM |
| 296.5 | Bipolar I disorder, most recent episode (or current), depressed | Diagnosis | ICD-9-CM |
| 296.50 | Bipolar I disorder, most recent episode (or current) depressed, unspecified | Diagnosis | ICD-9-CM |
| 296.51 | Bipolar I disorder, most recent episode (or current) depressed, mild | Diagnosis | ICD-9-CM |
| 296.52 | Bipolar I disorder, most recent episode (or current) depressed, moderate | Diagnosis | ICD-9-CM |
| 296.53 | Bipolar I disorder, most recent episode (or current) depressed, severe, without mention of psychotic behavior | Diagnosis | ICD-9-CM |
| 296.54 | Bipolar I disorder, most recent episode (or current) depressed, severe, specified as with psychotic behavior | Diagnosis | ICD-9-CM |
| 296.55 | Bipolar I disorder, most recent episode (or current) depressed, in partial or unspecified remission | Diagnosis | ICD-9-CM |
| 296.56 | Bipolar I disorder, most recent episode (or current) depressed, in full remission | Diagnosis | ICD-9-CM |
| 296.6 | Bipolar I disorder, most recent episode (or current), mixed | Diagnosis | ICD-9-CM |
| 296.60 | Bipolar I disorder, most recent episode (or current) mixed, unspecified | Diagnosis | ICD-9-CM |
| 296.61 | Bipolar I disorder, most recent episode (or current) mixed, mild | Diagnosis | ICD-9-CM |
| 296.62 | Bipolar I disorder, most recent episode (or current) mixed, moderate | Diagnosis | ICD-9-CM |
| 296.63 | Bipolar I disorder, most recent episode (or current) mixed, severe, without mention of psychotic behavior | Diagnosis | ICD-9-CM |
| 296.64 | Bipolar I disorder, most recent episode (or current) mixed, severe, specified as with psychotic behavior | Diagnosis | ICD-9-CM |
| 296.65 | Bipolar I disorder, most recent episode (or current) mixed, in partial or unspecified remission | Diagnosis | ICD-9-CM |
| 296.66 | Bipolar I disorder, most recent episode (or current) mixed, in full remission | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 296.7 | Bipolar I disorder, most recent episode (or current) unspecified | Diagnosis | ICD-9-CM |
| 296.8 | Other and unspecified bipolar disorders | Diagnosis | ICD-9-CM |
| 296.80 | Bipolar disorder, unspecified | Diagnosis | ICD-9-CM |
| 296.81 | Atypical manic disorder | Diagnosis | ICD-9-CM |
| 296.82 | Atypical depressive disorder | Diagnosis | ICD-9-CM |
| 296.89 | Other and unspecified bipolar disorders | Diagnosis | ICD-9-CM |
| 296.90 | Unspecified episodic mood disorder | Diagnosis | ICD-9-CM |
| 296.99 | Other specified episodic mood disorder | Diagnosis | ICD-9-CM |
| 298.0 | Depressive type psychosis | Diagnosis | ICD-9-CM |
| 300.4 | Dysthymic disorder | Diagnosis | ICD-9-CM |
| 300.9 | Unspecified nonpsychotic mental disorder | Diagnosis | ICD-9-CM |
| 301.0 | Paranoid personality disorder | Diagnosis | ICD-9-CM |
| 301.1 | Affective personality disorder | Diagnosis | ICD-9-CM |
| 301.10 | Affective personality disorder, unspecified | Diagnosis | ICD-9-CM |
| 301.11 | Chronic hypomanic personality disorder | Diagnosis | ICD-9-CM |
| 301.12 | Chronic depressive personality disorder | Diagnosis | ICD-9-CM |
| 301.13 | Cyclothymic disorder | Diagnosis | ICD-9-CM |
| 301.2 | Schizoid personality disorder | Diagnosis | ICD-9-CM |
| 301.20 | Schizoid personality disorder, unspecified | Diagnosis | ICD-9-CM |
| 301.21 | Introverted personality | Diagnosis | ICD-9-CM |
| 301.22 | Schizotypal personality disorder | Diagnosis | ICD-9-CM |
| 301.3 | Explosive personality disorder | Diagnosis | ICD-9-CM |
| 301.4 | Obsessive-compulsive personality disorder | Diagnosis | ICD-9-CM |
| 301.5 | Histrionic personality disorder | Diagnosis | ICD-9-CM |
| 301.50 | Histrionic personality disorder, unspecified | Diagnosis | ICD-9-CM |
| 301.51 | Chronic factitious illness with physical symptoms | Diagnosis | ICD-9-CM |
| 301.59 | Other histrionic personality disorder | Diagnosis | ICD-9-CM |
| 301.6 | Dependent personality disorder | Diagnosis | ICD-9-CM |
| 301.7 | Antisocial personality disorder | Diagnosis | ICD-9-CM |
| 301.8 | Other personality disorders | Diagnosis | ICD-9-CM |
| 301.81 | Narcissistic personality disorder | Diagnosis | ICD-9-CM |
| 301.82 | Avoidant personality disorder | Diagnosis | ICD-9-CM |
| 301.83 | Borderline personality disorder | Diagnosis | ICD-9-CM |
| 301.84 | Passive-aggressive personality | Diagnosis | ICD-9-CM |
| 301.89 | Other personality disorder | Diagnosis | ICD-9-CM |
| 301.9 | Unspecified personality disorder | Diagnosis | ICD-9-CM |
| 309.0 | Adjustment disorder with depressed mood | Diagnosis | ICD-9-CM |
| 309.1 | Prolonged depressive reaction as adjustment reaction | Diagnosis | ICD-9-CM |
| 309.2 | Predominant disturbance of other emotions as adjustment reaction | Diagnosis | ICD-9-CM |
| 309.21 | Separation anxiety disorder | Diagnosis | ICD-9-CM |
| 309.22 | Emancipation disorder of adolescence and early adult life | Diagnosis | ICD-9-CM |
| 309.23 | Specific academic or work inhibition as adjustment reaction | Diagnosis | ICD-9-CM |
| 309.24 | Adjustment disorder with anxiety | Diagnosis | ICD-9-CM |
| 309.28 | Adjustment disorder with mixed anxiety and depressed mood | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 309.29 | Other adjustment reaction with predominant disturbance of other emotions | Diagnosis | ICD-9-CM |
| 309.3 | Adjustment disorder with disturbance of conduct | Diagnosis | ICD-9-CM |
| 309.4 | Adjustment disorder with mixed disturbance of emotions and conduct | Diagnosis | ICD-9-CM |
| 309.8 | Other specified adjustment reactions | Diagnosis | ICD-9-CM |
| 309.81 | Posttraumatic stress disorder | Diagnosis | ICD-9-CM |
| 309.82 | Adjustment reaction with physical symptoms | Diagnosis | ICD-9-CM |
| 309.83 | Adjustment reaction with withdrawal | Diagnosis | ICD-9-CM |
| 309.89 | Other specified adjustment reaction | Diagnosis | ICD-9-CM |
| 309.9 | Unspecified adjustment reaction | Diagnosis | ICD-9-CM |
| 311 | Depressive disorder, not elsewhere classified | Diagnosis | ICD-9-CM |
| 881 | Open wound of elbow, forearm, and wrist | Diagnosis | ICD-9-CM |
| 960 | Poisoning by antibiotics | Diagnosis | ICD-9-CM |
| 960.0 | Poisoning by penicillins | Diagnosis | ICD-9-CM |
| 960.1 | Poisoning by antifungal antibiotics | Diagnosis | ICD-9-CM |
| 960.2 | Poisoning by chloramphenicol group | Diagnosis | ICD-9-CM |
| 960.3 | Poisoning by erythromycin and other macrolides | Diagnosis | ICD-9-CM |
| 960.4 | Poisoning by tetracycline group | Diagnosis | ICD-9-CM |
| 960.5 | Poisoning of cephalosporin group | Diagnosis | ICD-9-CM |
| 960.6 | Poisoning of antimycobacterial antibiotics | Diagnosis | ICD-9-CM |
| 960.7 | Poisoning by antineoplastic antibiotics | Diagnosis | ICD-9-CM |
| 960.8 | Poisoning by other specified antibiotics | Diagnosis | ICD-9-CM |
| 960.9 | Poisoning by unspecified antibiotic | Diagnosis | ICD-9-CM |
| 961 | Poisoning by other anti-infectives | Diagnosis | ICD-9-CM |
| 961.0 | Poisoning by sulfonamides | Diagnosis | ICD-9-CM |
| 961.1 | Poisoning by arsenical anti-infectives | Diagnosis | ICD-9-CM |
| 961.2 | Poisoning by heavy metal anti-infectives | Diagnosis | ICD-9-CM |
| 961.3 | Poisoning by quinoline and hydroxyquinoline derivatives | Diagnosis | ICD-9-CM |
| 961.4 | Poisoning by antimalarials and drugs acting on other blood protozoa | Diagnosis | ICD-9-CM |
| 961.5 | Poisoning by other antiprotozoal drugs | Diagnosis | ICD-9-CM |
| 961.6 | Poisoning by anthelmintics | Diagnosis | ICD-9-CM |
| 961.7 | Poisoning by antiviral drugs | Diagnosis | ICD-9-CM |
| 961.8 | Poisoning by other antimycobacterial drugs | Diagnosis | ICD-9-CM |
| 961.9 | Poisoning by other and unspecified anti-infectives | Diagnosis | ICD-9-CM |
| 962 | Poisoning by hormones and synthetic substitutes | Diagnosis | ICD-9-CM |
| 962.0 | Poisoning by adrenal cortical steroids | Diagnosis | ICD-9-CM |
| 962.1 | Poisoning by androgens and anabolic congeners | Diagnosis | ICD-9-CM |
| 962.2 | Poisoning by ovarian hormones and synthetic substitutes | Diagnosis | ICD-9-CM |
| 962.3 | Poisoning by insulins and antidiabetic agents | Diagnosis | ICD-9-CM |
| 962.4 | Poisoning by anterior pituitary hormones | Diagnosis | ICD-9-CM |
| 962.5 | Poisoning by posterior pituitary hormones | Diagnosis | ICD-9-CM |
| 962.6 | Poisoning by parathyroid and parathyroid derivatives | Diagnosis | ICD-9-CM |
| 962.7 | Poisoning by thyroid and thyroid derivatives | Diagnosis | ICD-9-CM |
| 962.8 | Poisoning by antithyroid agents | Diagnosis | ICD-9-CM |
| 962.9 | Poisoning by other and unspecified hormones and synthetic substitutes | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 963 | Poisoning by primarily systemic agents | Diagnosis | ICD-9-CM |
| 963.0 | Poisoning by antiallergic and antiemetic drugs | Diagnosis | ICD-9-CM |
| 963.1 | Poisoning by antineoplastic and immunosuppressive drugs | Diagnosis | ICD-9-CM |
| 963.2 | Poisoning by acidifying agents | Diagnosis | ICD-9-CM |
| 963.3 | Poisoning by alkalinizing agents | Diagnosis | ICD-9-CM |
| 963.4 | Poisoning by enzymes, not elsewhere classified | Diagnosis | ICD-9-CM |
| 963.5 | Poisoning by vitamins, not elsewhere classified | Diagnosis | ICD-9-CM |
| 963.8 | Poisoning by other specified systemic agents | Diagnosis | ICD-9-CM |
| 963.9 | Poisoning by unspecified systemic agent | Diagnosis | ICD-9-CM |
| 964 | Poisoning by agents primarily affecting blood constituents | Diagnosis | ICD-9-CM |
| 964.0 | Poisoning by iron and its compounds | Diagnosis | ICD-9-CM |
| 964.1 | Poisoning by liver preparations and other antianemic agents | Diagnosis | ICD-9-CM |
| 964.2 | Poisoning by anticoagulants | Diagnosis | ICD-9-CM |
| 964.3 | Poisoning by vitamin K (phytonadione) | Diagnosis | ICD-9-CM |
| 964.4 | Poisoning by fibrinolysis-affecting drugs | Diagnosis | ICD-9-CM |
| 964.5 | Poisoning by anticoagulant antagonists and other coagulants | Diagnosis | ICD-9-CM |
| 964.6 | Poisoning by gamma globulin | Diagnosis | ICD-9-CM |
| 964.7 | Poisoning by natural blood and blood products | Diagnosis | ICD-9-CM |
| 964.8 | Poisoning by other specified agents affecting blood constituents | Diagnosis | ICD-9-CM |
| 964.9 | Poisoning by unspecified agent affecting blood constituents | Diagnosis | ICD-9-CM |
| 965 | Poisoning by analgesics, antipyretics, and antirheumatics | Diagnosis | ICD-9-CM |
| 965.0 | Poisoning by opiates and related narcotics | Diagnosis | ICD-9-CM |
| 965.00 | Poisoning by opium (alkaloids), unspecified | Diagnosis | ICD-9-CM |
| 965.01 | Poisoning by heroin | Diagnosis | ICD-9-CM |
| 965.02 | Poisoning by methadone | Diagnosis | ICD-9-CM |
| 965.09 | Poisoning by opiates and related narcotics, other | Diagnosis | ICD-9-CM |
| 965.1 | Poisoning by salicylates | Diagnosis | ICD-9-CM |
| 965.4 | Poisoning by aromatic analgesics, not elsewhere classified | Diagnosis | ICD-9-CM |
| 965.5 | Poisoning by pyrazole derivatives | Diagnosis | ICD-9-CM |
| 965.6 | Poisoning by antirheumatics (antiphlogistics) | Diagnosis | ICD-9-CM |
| 965.61 | Poisoning by propionic acid derivatives | Diagnosis | ICD-9-CM |
| 965.69 | Poisoning by other antirheumatics | Diagnosis | ICD-9-CM |
| 965.7 | Poisoning by other non-narcotic analgesics | Diagnosis | ICD-9-CM |
| 965.8 | Poisoning by other specified analgesics and antipyretics | Diagnosis | ICD-9-CM |
| 965.9 | Poisoning by unspecified analgesic and antipyretic | Diagnosis | ICD-9-CM |
| 966 | Poisoning by anticonvulsants and anti-Parkinsonism drugs | Diagnosis | ICD-9-CM |
| 966.0 | Poisoning by oxazolidine derivatives | Diagnosis | ICD-9-CM |
| 966.1 | Poisoning by hydantoin derivatives | Diagnosis | ICD-9-CM |
| 966.2 | Poisoning by succinimides | Diagnosis | ICD-9-CM |
| 966.3 | Poisoning by other and unspecified anticonvulsants | Diagnosis | ICD-9-CM |
| 966.4 | Poisoning by anti-Parkinsonism drugs | Diagnosis | ICD-9-CM |
| 967 | Poisoning by sedatives and hypnotics | Diagnosis | ICD-9-CM |
| 967.0 | Poisoning by barbiturates | Diagnosis | ICD-9-CM |
| 967.1 | Poisoning by chloral hydrate group | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| 967.2 | Poisoning by paraldehyde | Diagnosis | ICD-9-CM |
| 967.3 | Poisoning by bromine compounds | Diagnosis | ICD-9-CM |
| 967.4 | Poisoning by methaqualone compounds | Diagnosis | ICD-9-CM |
| 967.5 | Poisoning by glutethimide group | Diagnosis | ICD-9-CM |
| 967.6 | Poisoning by mixed sedatives, not elsewhere classified | Diagnosis | ICD-9-CM |
| 967.8 | Poisoning by other sedatives and hypnotics | Diagnosis | ICD-9-CM |
| 967.9 | Poisoning by unspecified sedative or hypnotic | Diagnosis | ICD-9-CM |
| 968 | Poisoning by other central nervous system depressants and anesthetics | Diagnosis | ICD-9-CM |
| 968.0 | Poisoning by central nervous system muscle-tone depressants | Diagnosis | ICD-9-CM |
| 968.1 | Poisoning by halothane | Diagnosis | ICD-9-CM |
| 968.2 | Poisoning by other gaseous anesthetics | Diagnosis | ICD-9-CM |
| 968.3 | Poisoning by intravenous anesthetics | Diagnosis | ICD-9-CM |
| 968.4 | Poisoning by other and unspecified general anesthetics | Diagnosis | ICD-9-CM |
| 968.5 | Poisoning by other central nervous system depressants and anesthetics, Surface (topical) and infiltration anesthetics | Diagnosis | ICD-9-CM |
| 968.6 | Poisoning by peripheral nerve- and plexus-blocking anesthetics | Diagnosis | ICD-9-CM |
| 968.7 | Poisoning by spinal anesthetics | Diagnosis | ICD-9-CM |
| 968.9 | Poisoning by other and unspecified local anesthetics | Diagnosis | ICD-9-CM |
| 969 | Poisoning by psychotropic agents | Diagnosis | ICD-9-CM |
| 969.0 | Poisoning by antidepressants | Diagnosis | ICD-9-CM |
| 969.00 | Poisoning by antidepressant, unspecified | Diagnosis | ICD-9-CM |
| 969.01 | Poisoning by monoamine oxidase inhibitors | Diagnosis | ICD-9-CM |
| 969.02 | Poisoning by selective serotonin and norepinephrine reuptake inhibitors | Diagnosis | ICD-9-CM |
| 969.03 | Poisoning by selective serotonin reuptake inhibitors | Diagnosis | ICD-9-CM |
| 969.04 | Poisoning by tetracyclic antidepressants | Diagnosis | ICD-9-CM |
| 969.05 | Poisoning by tricyclic antidepressants | Diagnosis | ICD-9-CM |
| 969.09 | Poisoning by other antidepressants | Diagnosis | ICD-9-CM |
| 969.1 | Poisoning by phenothiazine-based tranquilizers | Diagnosis | ICD-9-CM |
| 969.2 | Poisoning by butyrophenone-based tranquilizers | Diagnosis | ICD-9-CM |
| 969.3 | Poisoning by other antipsychotics, neuroleptics, and major tranquilizers | Diagnosis | ICD-9-CM |
| 969.4 | Poisoning by benzodiazepine-based tranquilizers | Diagnosis | ICD-9-CM |
| 969.5 | Poisoning by other tranquilizers | Diagnosis | ICD-9-CM |
| 969.6 | Poisoning by psychodysleptics (hallucinogens) | Diagnosis | ICD-9-CM |
| 969.7 | Poisoning by psychostimulants | Diagnosis | ICD-9-CM |
| 969.70 | Poisoning by psychostimulant, unspecified | Diagnosis | ICD-9-CM |
| 969.71 | Poisoning by caffeine | Diagnosis | ICD-9-CM |
| 969.72 | Poisoning by amphetamines | Diagnosis | ICD-9-CM |
| 969.73 | Poisoning by methylphenidate | Diagnosis | ICD-9-CM |
| 969.79 | Poisoning by other psychostimulants | Diagnosis | ICD-9-CM |
| 969.8 | Poisoning by other specified psychotropic agents | Diagnosis | ICD-9-CM |
| 969.9 | Poisoning by unspecified psychotropic agent | Diagnosis | ICD-9-CM |
| 970 | Poisoning by central nervous system stimulants | Diagnosis | ICD-9-CM |
| 970.0 | Poisoning by analeptics | Diagnosis | ICD-9-CM |
| 970.1 | Poisoning by opiate antagonists | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|-------|--|---------------|-----------|
| 970.8 | Poisoning by other specified central nervous system stimulants | Diagnosis | ICD-9-CM |
| 970.9 | Poisoning by unspecified central nervous system stimulant | Diagnosis | ICD-9-CM |
| 971 | Poisoning by drugs primarily affecting the autonomic nervous system | Diagnosis | ICD-9-CM |
| 971.0 | Poisoning by parasympathomimetics (cholinergics) | Diagnosis | ICD-9-CM |
| 971.1 | Poisoning by parasympatholytics (anticholinergics and antimuscarinics) and spasmolytics | Diagnosis | ICD-9-CM |
| 971.2 | Poisoning by sympathomimetics (adrenergics) | Diagnosis | ICD-9-CM |
| 971.3 | Poisoning by sympatholytics (antiadrenergics) | Diagnosis | ICD-9-CM |
| 971.9 | Poisoning by unspecified drug primarily affecting autonomic nervous system | Diagnosis | ICD-9-CM |
| 972 | Poisoning by agents primarily affecting the cardiovascular system | Diagnosis | ICD-9-CM |
| 972.0 | Poisoning by cardiac rhythm regulators | Diagnosis | ICD-9-CM |
| 972.1 | Poisoning by cardiotonic glycosides and drugs of similar action | Diagnosis | ICD-9-CM |
| 972.2 | Poisoning by antilipemic and antiarteriosclerotic drugs | Diagnosis | ICD-9-CM |
| 972.3 | Poisoning by ganglion-blocking agents | Diagnosis | ICD-9-CM |
| 972.4 | Poisoning by coronary vasodilators | Diagnosis | ICD-9-CM |
| 972.5 | Poisoning by other vasodilators | Diagnosis | ICD-9-CM |
| 972.6 | Poisoning by other antihypertensive agents | Diagnosis | ICD-9-CM |
| 972.7 | Poisoning by antivaricose drugs, including sclerosing agents | Diagnosis | ICD-9-CM |
| 972.8 | Poisoning by capillary-active drugs | Diagnosis | ICD-9-CM |
| 972.9 | Poisoning by other and unspecified agents primarily affecting the cardiovascular system | Diagnosis | ICD-9-CM |
| 973 | Poisoning by agents primarily affecting the gastrointestinal system | Diagnosis | ICD-9-CM |
| 973.0 | Poisoning by antacids and antigastric secretion drugs | Diagnosis | ICD-9-CM |
| 973.1 | Poisoning by irritant cathartics | Diagnosis | ICD-9-CM |
| 973.2 | Poisoning by emollient cathartics | Diagnosis | ICD-9-CM |
| 973.3 | Poisoning by other cathartics, including intestinal atonia drugs | Diagnosis | ICD-9-CM |
| 973.4 | Poisoning by digestants | Diagnosis | ICD-9-CM |
| 973.5 | Poisoning by antidiarrheal drugs | Diagnosis | ICD-9-CM |
| 973.6 | Poisoning by emetics | Diagnosis | ICD-9-CM |
| 973.8 | Poisoning by other specified agents primarily affecting the gastrointestinal system | Diagnosis | ICD-9-CM |
| 973.9 | Poisoning by unspecified agent primarily affecting the gastrointestinal system | Diagnosis | ICD-9-CM |
| 974 | Poisoning by water, mineral, and uric acid metabolism drugs | Diagnosis | ICD-9-CM |
| 974.0 | Poisoning by mercurial diuretics | Diagnosis | ICD-9-CM |
| 974.1 | Poisoning by purine derivative diuretics | Diagnosis | ICD-9-CM |
| 974.2 | Poisoning by carbonic acid anhydrase inhibitors | Diagnosis | ICD-9-CM |
| 974.3 | Poisoning by saluretics | Diagnosis | ICD-9-CM |
| 974.4 | Poisoning by other diuretics | Diagnosis | ICD-9-CM |
| 974.5 | Poisoning by electrolytic, caloric, and water-balance agents | Diagnosis | ICD-9-CM |
| 974.6 | Poisoning by other mineral salts, not elsewhere classified | Diagnosis | ICD-9-CM |
| 974.7 | Poisoning by uric acid metabolism drugs | Diagnosis | ICD-9-CM |
| 975 | Poisoning by agents primarily acting on the smooth and skeletal muscles and respiratory system | Diagnosis | ICD-9-CM |
| 975.0 | Poisoning by oxytocic agents | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|-------|--|---------------|-----------|
| 975.1 | Poisoning by smooth muscle relaxants | Diagnosis | ICD-9-CM |
| 975.2 | Poisoning by skeletal muscle relaxants | Diagnosis | ICD-9-CM |
| 975.3 | Poisoning by other and unspecified drugs acting on muscles | Diagnosis | ICD-9-CM |
| 975.4 | Poisoning by antitussives | Diagnosis | ICD-9-CM |
| 975.5 | Poisoning by expectorants | Diagnosis | ICD-9-CM |
| 975.6 | Poisoning by anti-common cold drugs | Diagnosis | ICD-9-CM |
| 975.7 | Poisoning by antiasthmatics | Diagnosis | ICD-9-CM |
| 975.8 | Poisoning by other and unspecified respiratory drugs | Diagnosis | ICD-9-CM |
| 976 | Poisoning by agents primarily affecting skin and mucous membrane, ophthalmological, otorhinolaryngological, and dental drugs | Diagnosis | ICD-9-CM |
| 976.0 | Poisoning by local anti-infectives and anti-inflammatory drugs | Diagnosis | ICD-9-CM |
| 976.1 | Poisoning by antipruritics | Diagnosis | ICD-9-CM |
| 976.2 | Poisoning by local astringents and local detergents | Diagnosis | ICD-9-CM |
| 976.3 | Poisoning by emollients, demulcents, and protectants | Diagnosis | ICD-9-CM |
| 976.4 | Poisoning by keratolytics, keratoplastics, other hair treatment drugs and preparations | Diagnosis | ICD-9-CM |
| 976.5 | Poisoning by eye anti-infectives and other eye drugs | Diagnosis | ICD-9-CM |
| 976.6 | Poisoning by anti-infectives and other drugs and preparations for ear, nose, and throat | Diagnosis | ICD-9-CM |
| 976.7 | Poisoning by dental drugs topically applied | Diagnosis | ICD-9-CM |
| 976.8 | Poisoning by other agents primarily affecting skin and mucous membrane | Diagnosis | ICD-9-CM |
| 976.9 | Poisoning by unspecified agent primarily affecting skin and mucous membrane | Diagnosis | ICD-9-CM |
| 977 | Poisoning by other and unspecified drugs and medicinal substances | Diagnosis | ICD-9-CM |
| 977.0 | Poisoning by dietetics | Diagnosis | ICD-9-CM |
| 977.1 | Poisoning by lipotropic drugs | Diagnosis | ICD-9-CM |
| 977.2 | Poisoning by antidotes and chelating agents, not elsewhere classified | Diagnosis | ICD-9-CM |
| 977.3 | Poisoning by alcohol deterrents | Diagnosis | ICD-9-CM |
| 977.4 | Poisoning by pharmaceutical excipients | Diagnosis | ICD-9-CM |
| 977.8 | Poisoning by other specified drugs and medicinal substances | Diagnosis | ICD-9-CM |
| 977.9 | Poisoning by unspecified drug or medicinal substance | Diagnosis | ICD-9-CM |
| 978 | Poisoning by bacterial vaccines | Diagnosis | ICD-9-CM |
| 978.0 | Poisoning by BCG vaccine | Diagnosis | ICD-9-CM |
| 978.1 | Poisoning by typhoid and paratyphoid vaccine | Diagnosis | ICD-9-CM |
| 978.2 | Poisoning by cholera vaccine | Diagnosis | ICD-9-CM |
| 978.3 | Poisoning by plague vaccine | Diagnosis | ICD-9-CM |
| 978.4 | Poisoning by tetanus vaccine | Diagnosis | ICD-9-CM |
| 978.5 | Poisoning by diphtheria vaccine | Diagnosis | ICD-9-CM |
| 978.6 | Poisoning by pertussis vaccine, including combinations with pertussis component | Diagnosis | ICD-9-CM |
| 978.8 | Poisoning by other and unspecified bacterial vaccines | Diagnosis | ICD-9-CM |
| 978.9 | Poisoning by mixed bacterial vaccines, except combinations with pertussis component | Diagnosis | ICD-9-CM |
| 979 | Poisoning by other vaccines and biological substances | Diagnosis | ICD-9-CM |
| 979.0 | Poisoning by smallpox vaccine | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|-------|---|---------------|-----------|
| 979.1 | Poisoning by rabies vaccine | Diagnosis | ICD-9-CM |
| 979.2 | Poisoning by typhus vaccine | Diagnosis | ICD-9-CM |
| 979.3 | Poisoning by yellow fever vaccine | Diagnosis | ICD-9-CM |
| 979.4 | Poisoning by measles vaccine | Diagnosis | ICD-9-CM |
| 979.5 | Poisoning by poliomyelitis vaccine | Diagnosis | ICD-9-CM |
| 979.6 | Poisoning by other and unspecified viral and rickettsial vaccines | Diagnosis | ICD-9-CM |
| 979.7 | Poisoning by mixed viral-rickettsial and bacterial vaccines, except combinations with pertussis component | Diagnosis | ICD-9-CM |
| 979.9 | Poisoning by other and unspecified vaccines and biological substances | Diagnosis | ICD-9-CM |
| 980 | Toxic effect of alcohol | Diagnosis | ICD-9-CM |
| 980.0 | Toxic effect of ethyl alcohol | Diagnosis | ICD-9-CM |
| 980.1 | Toxic effect of methyl alcohol | Diagnosis | ICD-9-CM |
| 980.2 | Toxic effect of isopropyl alcohol | Diagnosis | ICD-9-CM |
| 980.3 | Toxic effect of fusel oil | Diagnosis | ICD-9-CM |
| 980.8 | Toxic effect of other specified alcohols | Diagnosis | ICD-9-CM |
| 980.9 | Toxic effect of unspecified alcohol | Diagnosis | ICD-9-CM |
| 981 | Toxic effect of petroleum products | Diagnosis | ICD-9-CM |
| 982 | Toxic effect of solvents other than petroleum-based | Diagnosis | ICD-9-CM |
| 982.0 | Toxic effect of benzene and homologues | Diagnosis | ICD-9-CM |
| 982.1 | Toxic effect of carbon tetrachloride | Diagnosis | ICD-9-CM |
| 982.2 | Toxic effect of carbon disulfide | Diagnosis | ICD-9-CM |
| 982.3 | Toxic effect of other chlorinated hydrocarbon solvents | Diagnosis | ICD-9-CM |
| 982.4 | Toxic effect of nitroglycol | Diagnosis | ICD-9-CM |
| 982.8 | Toxic effect of other nonpetroleum-based solvents | Diagnosis | ICD-9-CM |
| 983 | Toxic effect of corrosive aromatics, acids, and caustic alkalis | Diagnosis | ICD-9-CM |
| 983.0 | Toxic effect of corrosive aromatics | Diagnosis | ICD-9-CM |
| 983.1 | Toxic effect of acids | Diagnosis | ICD-9-CM |
| 983.2 | Toxic effect of caustic alkalis | Diagnosis | ICD-9-CM |
| 983.9 | Toxic effect of caustic, unspecified | Diagnosis | ICD-9-CM |
| 984 | Toxic effect of lead and its compounds (including fumes) | Diagnosis | ICD-9-CM |
| 984.0 | Toxic effect of inorganic lead compounds | Diagnosis | ICD-9-CM |
| 984.1 | Toxic effect of organic lead compounds | Diagnosis | ICD-9-CM |
| 984.8 | Toxic effect of other lead compounds | Diagnosis | ICD-9-CM |
| 984.9 | Toxic effect of unspecified lead compound | Diagnosis | ICD-9-CM |
| 985 | Toxic effect of other metals | Diagnosis | ICD-9-CM |
| 985.0 | Toxic effect of mercury and its compounds | Diagnosis | ICD-9-CM |
| 985.1 | Toxic effect of arsenic and its compounds | Diagnosis | ICD-9-CM |
| 985.2 | Toxic effect of manganese and its compounds | Diagnosis | ICD-9-CM |
| 985.3 | Toxic effect of beryllium and its compounds | Diagnosis | ICD-9-CM |
| 985.4 | Toxic effect of antimony and its compounds | Diagnosis | ICD-9-CM |
| 985.5 | Toxic effect of cadmium and its compounds | Diagnosis | ICD-9-CM |
| 985.6 | Toxic effect of chromium | Diagnosis | ICD-9-CM |
| 985.8 | Toxic effect of other specified metal | Diagnosis | ICD-9-CM |
| 985.9 | Toxic effect of unspecified metal | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 986 | Toxic effect of carbon monoxide | Diagnosis | ICD-9-CM |
| 987 | Toxic effect of other gases, fumes, or vapors | Diagnosis | ICD-9-CM |
| 987.0 | Toxic effect of liquefied petroleum gases | Diagnosis | ICD-9-CM |
| 987.1 | Toxic effect of other hydrocarbon gas | Diagnosis | ICD-9-CM |
| 987.2 | Toxic effect of nitrogen oxides | Diagnosis | ICD-9-CM |
| 987.3 | Toxic effect of sulfur dioxide | Diagnosis | ICD-9-CM |
| 987.4 | Toxic effect of freon | Diagnosis | ICD-9-CM |
| 987.5 | Toxic effect of lacrimogenic gas | Diagnosis | ICD-9-CM |
| 987.6 | Toxic effect of chlorine gas | Diagnosis | ICD-9-CM |
| 987.7 | Toxic effect of hydrocyanic acid gas | Diagnosis | ICD-9-CM |
| 987.8 | Toxic effect of other specified gases, fumes, or vapors | Diagnosis | ICD-9-CM |
| 987.9 | Toxic effect of unspecified gas, fume, or vapor | Diagnosis | ICD-9-CM |
| 988 | Toxic effect of noxious substances eaten as food | Diagnosis | ICD-9-CM |
| 988.0 | Toxic effect of fish and shellfish | Diagnosis | ICD-9-CM |
| 988.1 | Toxic effect of mushrooms | Diagnosis | ICD-9-CM |
| 988.2 | Toxic effect of berries and other plants | Diagnosis | ICD-9-CM |
| 988.8 | Toxic effect of other specified noxious substances | Diagnosis | ICD-9-CM |
| 988.9 | Toxic effect of unspecified noxious substance | Diagnosis | ICD-9-CM |
| 989 | Toxic effect of other substances, chiefly nonmedicinal as to source | Diagnosis | ICD-9-CM |
| 989.0 | Toxic effect of hydrocyanic acid and cyanides | Diagnosis | ICD-9-CM |
| 989.1 | Toxic effect of strychnine and salts | Diagnosis | ICD-9-CM |
| 989.2 | Toxic effect of chlorinated hydrocarbons | Diagnosis | ICD-9-CM |
| 989.3 | Toxic effect of organophosphate and carbamate | Diagnosis | ICD-9-CM |
| 989.4 | Toxic effect of other pesticides, not elsewhere classified | Diagnosis | ICD-9-CM |
| 989.5 | Toxic effect of venom | Diagnosis | ICD-9-CM |
| 989.6 | Toxic effect of soaps and detergents | Diagnosis | ICD-9-CM |
| 989.7 | Toxic effect of aflatoxin and other mycotoxin (food contaminants) | Diagnosis | ICD-9-CM |
| 989.8 | Toxic effect of other substances, chiefly nonmedicinal as to source | Diagnosis | ICD-9-CM |
| 989.81 | Toxic effect of asbestos | Diagnosis | ICD-9-CM |
| 989.82 | Toxic effect of latex | Diagnosis | ICD-9-CM |
| 989.83 | Toxic effect of silicone | Diagnosis | ICD-9-CM |
| 989.84 | Toxic effect of tobacco | Diagnosis | ICD-9-CM |
| 989.89 | Toxic effect of other substances | Diagnosis | ICD-9-CM |
| 989.9 | Toxic effect of unspecified substance, chiefly nonmedicinal as to source | Diagnosis | ICD-9-CM |
| 994.7 | Asphyxiation and strangulation | Diagnosis | ICD-9-CM |
| E950 | Suicide and self-inflicted poisoning by solid or liquid substances | Diagnosis | ICD-9-CM |
| E951 | Suicide and self-inflicted poisoning by gases in domestic use | Diagnosis | ICD-9-CM |
| E952 | Suicide and self-inflicted poisoning by other gases and vapors | Diagnosis | ICD-9-CM |
| E953 | Suicide and self-inflicted injury by hanging strangulation and suffocation | Diagnosis | ICD-9-CM |
| E954 | Suicide and self-inflicted injury by submersion [drowning] | Diagnosis | ICD-9-CM |
| E955 | Suicide and self-inflicted injury by firearms air guns and explosives | Diagnosis | ICD-9-CM |
| E956 | Suicide and self-inflicted injury by cutting and piercing instrument | Diagnosis | ICD-9-CM |
| E957 | Suicide and self-inflicted injuries by jumping from high place | Diagnosis | ICD-9-CM |
| E958 | Suicide and self-inflicted injury by other and unspecified means | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T14.91 | Suicide attempt | Diagnosis | ICD-10-CM |
| T14.91XA | Suicide attempt, initial encounter | Diagnosis | ICD-10-CM |
| T14.91XD | Suicide attempt, subsequent encounter | Diagnosis | ICD-10-CM |
| T14.91XS | Suicide attempt, sequela | Diagnosis | ICD-10-CM |
| T36.0X2 | Poisoning by penicillins, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.0X2A | Poisoning by penicillins, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.0X2D | Poisoning by penicillins, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.0X2S | Poisoning by penicillins, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.1X2 | Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.1X2A | Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.1X2D | Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.1X2S | Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.2X2 | Poisoning by chloramphenicol group, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.2X2A | Poisoning by chloramphenicol group, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.2X2D | Poisoning by chloramphenicol group, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.2X2S | Poisoning by chloramphenicol group, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.3X2 | Poisoning by macrolides, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.3X2A | Poisoning by macrolides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.3X2D | Poisoning by macrolides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.3X2S | Poisoning by macrolides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.4X2 | Poisoning by tetracyclines, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.4X2A | Poisoning by tetracyclines, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.4X2D | Poisoning by tetracyclines, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.4X2S | Poisoning by tetracyclines, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.5X2 | Poisoning by aminoglycosides, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.5X2A | Poisoning by aminoglycosides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.5X2D | Poisoning by aminoglycosides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.5X2S | Poisoning by aminoglycosides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.6X2 | Poisoning by rifampicins, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.6X2A | Poisoning by rifampicins, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.6X2D | Poisoning by rifampicins, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.6X2S | Poisoning by rifampicins, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.7X2 | Poisoning by antifungal antibiotics, systemically used, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.7X2A | Poisoning by antifungal antibiotics, systemically used, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.7X2D | Poisoning by antifungal antibiotics, systemically used, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.7X2S | Poisoning by antifungal antibiotics, systemically used, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T36.8X2 | Poisoning by other systemic antibiotics, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.8X2A | Poisoning by other systemic antibiotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.8X2D | Poisoning by other systemic antibiotics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.8X2S | Poisoning by other systemic antibiotics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.92 | Poisoning by unspecified systemic antibiotic, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.92XA | Poisoning by unspecified systemic antibiotic, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.92XD | Poisoning by unspecified systemic antibiotic, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.92XS | Poisoning by unspecified systemic antibiotic, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.0X2 | Poisoning by sulfonamides, intentional self-harm | Diagnosis | ICD-10-CM |
| T37.0X2A | Poisoning by sulfonamides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.0X2D | Poisoning by sulfonamides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.0X2S | Poisoning by sulfonamides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.1X2 | Poisoning by antimycobacterial drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T37.1X2A | Poisoning by antimycobacterial drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.1X2D | Poisoning by antimycobacterial drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.1X2S | Poisoning by antimycobacterial drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.2X2 | Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm | Diagnosis | ICD-10-CM |
| T37.2X2A | Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.2X2D | Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.2X2S | Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.3X2 | Poisoning by other antiprotozoal drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T37.3X2A | Poisoning by other antiprotozoal drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.3X2D | Poisoning by other antiprotozoal drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.3X2S | Poisoning by other antiprotozoal drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.4X2 | Poisoning by anthelmintics, intentional self-harm | Diagnosis | ICD-10-CM |
| T37.4X2A | Poisoning by anthelmintics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.4X2D | Poisoning by anthelmintics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.4X2S | Poisoning by anthelmintics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.5X2 | Poisoning by antiviral drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T37.5X2A | Poisoning by antiviral drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.5X2D | Poisoning by antiviral drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.5X2S | Poisoning by antiviral drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.8X2 | Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T37.8X2A | Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.8X2D | Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.8X2S | Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.92 | Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm | Diagnosis | ICD-10-CM |
| T37.92XA | Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.92XD | Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.92XS | Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.0X2 | Poisoning by glucocorticoids and synthetic analogues, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.0X2A | Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.0X2D | Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.0X2S | Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.1X2 | Poisoning by thyroid hormones and substitutes, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.1X2A | Poisoning by thyroid hormones and substitutes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.1X2D | Poisoning by thyroid hormones and substitutes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.1X2S | Poisoning by thyroid hormones and substitutes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.2X2 | Poisoning by antithyroid drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.2X2A | Poisoning by antithyroid drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.2X2D | Poisoning by antithyroid drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.2X2S | Poisoning by antithyroid drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.3X2 | Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.3X2A | Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.3X2D | Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.3X2S | Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.4X2 | Poisoning by oral contraceptives, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.4X2A | Poisoning by oral contraceptives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.4X2D | Poisoning by oral contraceptives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.4X2S | Poisoning by oral contraceptives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.5X2 | Poisoning by other estrogens and progestogens, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T38.5X2A | Poisoning by other estrogens and progestogens, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.5X2D | Poisoning by other estrogens and progestogens, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.5X2S | Poisoning by other estrogens and progestogens, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.6X2 | Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.6X2A | Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.6X2D | Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.6X2S | Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.7X2 | Poisoning by androgens and anabolic congeners, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.7X2A | Poisoning by androgens and anabolic congeners, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.7X2D | Poisoning by androgens and anabolic congeners, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.7X2S | Poisoning by androgens and anabolic congeners, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.802 | Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.802A | Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.802D | Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.802S | Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.812 | Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.812A | Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.812D | Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.812S | Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.892 | Poisoning by other hormones and synthetic substitutes, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.892A | Poisoning by other hormones and synthetic substitutes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.892D | Poisoning by other hormones and synthetic substitutes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.892S | Poisoning by other hormones and synthetic substitutes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.902 | Poisoning by unspecified hormone antagonists, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T38.902A | Poisoning by unspecified hormone antagonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.902D | Poisoning by unspecified hormone antagonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.902S | Poisoning by unspecified hormone antagonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.992 | Poisoning by other hormone antagonists, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.992A | Poisoning by other hormone antagonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.992D | Poisoning by other hormone antagonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.992S | Poisoning by other hormone antagonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.012 | Poisoning by aspirin, intentional self-harm | Diagnosis | ICD-10-CM |
| T39.012A | Poisoning by aspirin, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.012D | Poisoning by aspirin, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.012S | Poisoning by aspirin, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.092 | Poisoning by salicylates, intentional self-harm | Diagnosis | ICD-10-CM |
| T39.092A | Poisoning by salicylates, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.092D | Poisoning by salicylates, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.092S | Poisoning by salicylates, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.1X2 | Poisoning by 4-Aminophenol derivatives, intentional self-harm | Diagnosis | ICD-10-CM |
| T39.1X2A | Poisoning by 4-Aminophenol derivatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.1X2D | Poisoning by 4-Aminophenol derivatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.1X2S | Poisoning by 4-Aminophenol derivatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.2X2 | Poisoning by pyrazolone derivatives, intentional self-harm | Diagnosis | ICD-10-CM |
| T39.2X2A | Poisoning by pyrazolone derivatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.2X2D | Poisoning by pyrazolone derivatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.2X2S | Poisoning by pyrazolone derivatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.312 | Poisoning by propionic acid derivatives, intentional self-harm | Diagnosis | ICD-10-CM |
| T39.312A | Poisoning by propionic acid derivatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.312D | Poisoning by propionic acid derivatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.312S | Poisoning by propionic acid derivatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.392 | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm | Diagnosis | ICD-10-CM |
| T39.392A | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.392D | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.392S | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.4X2 | Poisoning by antirheumatics, not elsewhere classified, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T39.4X2A | Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.4X2D | Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.4X2S | Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.8X2 | Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm | Diagnosis | ICD-10-CM |
| T39.8X2A | Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.8X2D | Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.8X2S | Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.92 | Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm | Diagnosis | ICD-10-CM |
| T39.92XA | Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.92XD | Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.92XS | Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.0X2 | Poisoning by opium, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.0X2A | Poisoning by opium, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.0X2D | Poisoning by opium, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.0X2S | Poisoning by opium, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.1X2 | Poisoning by heroin, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.1X2A | Poisoning by heroin, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.1X2D | Poisoning by heroin, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.1X2S | Poisoning by heroin, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.2X2 | Poisoning by other opioids, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.2X2A | Poisoning by other opioids, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.2X2D | Poisoning by other opioids, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.2X2S | Poisoning by other opioids, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.3X2 | Poisoning by methadone, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.3X2A | Poisoning by methadone, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.3X2D | Poisoning by methadone, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.3X2S | Poisoning by methadone, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.412 | Poisoning by fentanyl or fentanyl analogs, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.412A | Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.412D | Poisoning by fentanyl or fentanyl analogs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.412S | Poisoning by fentanyl or fentanyl analogs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T40.422 | Poisoning by tramadol, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.422A | Poisoning by tramadol, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.422D | Poisoning by tramadol, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.422S | Poisoning by tramadol, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.492 | Poisoning by other synthetic narcotics, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.492A | Poisoning by other synthetic narcotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.492D | Poisoning by other synthetic narcotics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.492S | Poisoning by other synthetic narcotics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.4X2 | Poisoning by other synthetic narcotics, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.4X2A | Poisoning by other synthetic narcotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.4X2D | Poisoning by other synthetic narcotics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.4X2S | Poisoning by other synthetic narcotics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.5X2 | Poisoning by cocaine, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.5X2A | Poisoning by cocaine, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.5X2D | Poisoning by cocaine, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.5X2S | Poisoning by cocaine, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.602 | Poisoning by unspecified narcotics, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.602A | Poisoning by unspecified narcotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.602D | Poisoning by unspecified narcotics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.602S | Poisoning by unspecified narcotics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.692 | Poisoning by other narcotics, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.692A | Poisoning by other narcotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.692D | Poisoning by other narcotics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.692S | Poisoning by other narcotics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.712 | Poisoning by cannabis, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.712A | Poisoning by cannabis, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.712D | Poisoning by cannabis, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.712S | Poisoning by cannabis, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.722 | Poisoning by synthetic cannabinoids, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.722A | Poisoning by synthetic cannabinoids, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.722D | Poisoning by synthetic cannabinoids, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.722S | Poisoning by synthetic cannabinoids, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.7X2 | Poisoning by cannabis (derivatives), intentional self-harm | Diagnosis | ICD-10-CM |
| T40.7X2A | Poisoning by cannabis (derivatives), intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.7X2D | Poisoning by cannabis (derivatives), intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.7X2S | Poisoning by cannabis (derivatives), intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.8X2 | Poisoning by lysergide [LSD], intentional self-harm | Diagnosis | ICD-10-CM |
| T40.8X2A | Poisoning by lysergide [LSD], intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.8X2D | Poisoning by lysergide [LSD], intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.8X2S | Poisoning by lysergide [LSD], intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T40.902 | Poisoning by unspecified psychodysleptics [hallucinogens], intentional self- | Diagnosis | ICD-10-CM |
| T40.902A | Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.902D | Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.902S | Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.992 | Poisoning by other psychodysleptics [hallucinogens], intentional self-harm | Diagnosis | ICD-10-CM |
| T40.992A | Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.992D | Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.992S | Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.0X2 | Poisoning by inhaled anesthetics, intentional self-harm | Diagnosis | ICD-10-CM |
| T41.0X2A | Poisoning by inhaled anesthetics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.0X2D | Poisoning by inhaled anesthetics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.0X2S | Poisoning by inhaled anesthetics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.1X2 | Poisoning by intravenous anesthetics, intentional self-harm | Diagnosis | ICD-10-CM |
| T41.1X2A | Poisoning by intravenous anesthetics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.1X2D | Poisoning by intravenous anesthetics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.1X2S | Poisoning by intravenous anesthetics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.202 | Poisoning by unspecified general anesthetics, intentional self-harm | Diagnosis | ICD-10-CM |
| T41.202A | Poisoning by unspecified general anesthetics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.202D | Poisoning by unspecified general anesthetics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.202S | Poisoning by unspecified general anesthetics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.292 | Poisoning by other general anesthetics, intentional self-harm | Diagnosis | ICD-10-CM |
| T41.292A | Poisoning by other general anesthetics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.292D | Poisoning by other general anesthetics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.292S | Poisoning by other general anesthetics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.3X2 | Poisoning by local anesthetics, intentional self-harm | Diagnosis | ICD-10-CM |
| T41.3X2A | Poisoning by local anesthetics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.3X2D | Poisoning by local anesthetics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.3X2S | Poisoning by local anesthetics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.42 | Poisoning by unspecified anesthetic, intentional self-harm | Diagnosis | ICD-10-CM |
| T41.42XA | Poisoning by unspecified anesthetic, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.42XD | Poisoning by unspecified anesthetic, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.42XS | Poisoning by unspecified anesthetic, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.5X2 | Poisoning by therapeutic gases, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T41.5X2A | Poisoning by therapeutic gases, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.5X2D | Poisoning by therapeutic gases, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.5X2S | Poisoning by therapeutic gases, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.0X2 | Poisoning by hydantoin derivatives, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.0X2A | Poisoning by hydantoin derivatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.0X2D | Poisoning by hydantoin derivatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.0X2S | Poisoning by hydantoin derivatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.1X2 | Poisoning by iminostilbenes, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.1X2A | Poisoning by iminostilbenes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.1X2D | Poisoning by iminostilbenes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.1X2S | Poisoning by iminostilbenes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.2X2 | Poisoning by succinimides and oxazolidinediones, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.2X2A | Poisoning by succinimides and oxazolidinediones, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.2X2D | Poisoning by succinimides and oxazolidinediones, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.2X2S | Poisoning by succinimides and oxazolidinediones, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.3X2 | Poisoning by barbiturates, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.3X2A | Poisoning by barbiturates, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.3X2D | Poisoning by barbiturates, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.3X2S | Poisoning by barbiturates, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.4X2 | Poisoning by benzodiazepines, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.4X2A | Poisoning by benzodiazepines, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.4X2D | Poisoning by benzodiazepines, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.4X2S | Poisoning by benzodiazepines, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.5X2 | Poisoning by mixed antiepileptics, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.5X2A | Poisoning by mixed antiepileptics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.5X2D | Poisoning by mixed antiepileptics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.5X2S | Poisoning by mixed antiepileptics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.6X2 | Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.6X2A | Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.6X2D | Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.6X2S | Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.72 | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.72XA | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.72XD | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T42.72XS | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.8X2 | Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.8X2A | Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.8X2D | Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.8X2S | Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.012 | Poisoning by tricyclic antidepressants, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.012A | Poisoning by tricyclic antidepressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.012D | Poisoning by tricyclic antidepressants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.012S | Poisoning by tricyclic antidepressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.022 | Poisoning by tetracyclic antidepressants, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.022A | Poisoning by tetracyclic antidepressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.022D | Poisoning by tetracyclic antidepressants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.022S | Poisoning by tetracyclic antidepressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.1X2 | Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.1X2A | Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.1X2D | Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.1X2S | Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.202 | Poisoning by unspecified antidepressants, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.202A | Poisoning by unspecified antidepressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.202D | Poisoning by unspecified antidepressants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.202S | Poisoning by unspecified antidepressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.212 | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.212A | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.212D | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.212S | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.222 | Poisoning by selective serotonin reuptake inhibitors, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T43.222A | Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.222D | Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.222S | Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.292 | Poisoning by other antidepressants, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.292A | Poisoning by other antidepressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.292D | Poisoning by other antidepressants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.292S | Poisoning by other antidepressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.3X2 | Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.3X2A | Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.3X2D | Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.3X2S | Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.4X2 | Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.4X2A | Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.4X2D | Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.4X2S | Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.502 | Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.502A | Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.502D | Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.502S | Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.592 | Poisoning by other antipsychotics and neuroleptics, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.592A | Poisoning by other antipsychotics and neuroleptics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.592D | Poisoning by other antipsychotics and neuroleptics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.592S | Poisoning by other antipsychotics and neuroleptics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.602 | Poisoning by unspecified psychostimulants, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.602A | Poisoning by unspecified psychostimulants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T43.602D | Poisoning by unspecified psychostimulants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.602S | Poisoning by unspecified psychostimulants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.612 | Poisoning by caffeine, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.612A | Poisoning by caffeine, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.612D | Poisoning by caffeine, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.612S | Poisoning by caffeine, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.622 | Poisoning by amphetamines, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.622A | Poisoning by amphetamines, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.622D | Poisoning by amphetamines, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.622S | Poisoning by amphetamines, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.632 | Poisoning by methylphenidate, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.632A | Poisoning by methylphenidate, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.632D | Poisoning by methylphenidate, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.632S | Poisoning by methylphenidate, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.642 | Poisoning by ecstasy, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.642A | Poisoning by ecstasy, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.642D | Poisoning by ecstasy, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.642S | Poisoning by ecstasy, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.692 | Poisoning by other psychostimulants, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.692A | Poisoning by other psychostimulants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.692D | Poisoning by other psychostimulants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.692S | Poisoning by other psychostimulants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.8X2 | Poisoning by other psychotropic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.8X2A | Poisoning by other psychotropic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.8X2D | Poisoning by other psychotropic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.8X2S | Poisoning by other psychotropic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.92 | Poisoning by unspecified psychotropic drug, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.92XA | Poisoning by unspecified psychotropic drug, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.92XD | Poisoning by unspecified psychotropic drug, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.92XS | Poisoning by unspecified psychotropic drug, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.0X2 | Poisoning by anticholinesterase agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.0X2A | Poisoning by anticholinesterase agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.0X2D | Poisoning by anticholinesterase agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.0X2S | Poisoning by anticholinesterase agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.1X2 | Poisoning by other parasympathomimetics [cholinergics], intentional self-harm | Diagnosis | ICD-10-CM |
| T44.1X2A | Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T44.1X2D | Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.1X2S | Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.2X2 | Poisoning by ganglionic blocking drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.2X2A | Poisoning by ganglionic blocking drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.2X2D | Poisoning by ganglionic blocking drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.2X2S | Poisoning by ganglionic blocking drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.3X2 | Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.3X2A | Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.3X2D | Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.3X2S | Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.4X2 | Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.4X2A | Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.4X2D | Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.4X2S | Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.5X2 | Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.5X2A | Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.5X2D | Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.5X2S | Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.6X2 | Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.6X2A | Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.6X2D | Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.6X2S | Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.7X2 | Poisoning by beta-adrenoreceptor antagonists, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.7X2A | Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.7X2D | Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T44.7X2S | Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.8X2 | Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.8X2A | Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.8X2D | Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.8X2S | Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.902 | Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.902A | Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.902D | Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.902S | Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.992 | Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.992A | Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.992D | Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.992S | Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.0X2 | Poisoning by antiallergic and antiemetic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.0X2A | Poisoning by antiallergic and antiemetic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.0X2D | Poisoning by antiallergic and antiemetic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.0X2S | Poisoning by antiallergic and antiemetic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.1X2 | Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.1X2A | Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.1X2D | Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.1X2S | Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.2X2 | Poisoning by vitamins, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.2X2A | Poisoning by vitamins, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.2X2D | Poisoning by vitamins, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.2X2S | Poisoning by vitamins, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.3X2 | Poisoning by enzymes, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T45.3X2A | Poisoning by enzymes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.3X2D | Poisoning by enzymes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.3X2S | Poisoning by enzymes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.4X2 | Poisoning by iron and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.4X2A | Poisoning by iron and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.4X2D | Poisoning by iron and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.4X2S | Poisoning by iron and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.512 | Poisoning by anticoagulants, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.512A | Poisoning by anticoagulants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.512D | Poisoning by anticoagulants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.512S | Poisoning by anticoagulants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.522 | Poisoning by antithrombotic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.522A | Poisoning by antithrombotic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.522D | Poisoning by antithrombotic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.522S | Poisoning by antithrombotic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.602 | Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.602A | Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.602D | Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.602S | Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.612 | Poisoning by thrombolytic drug, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.612A | Poisoning by thrombolytic drug, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.612D | Poisoning by thrombolytic drug, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.612S | Poisoning by thrombolytic drug, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.622 | Poisoning by hemostatic drug, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.622A | Poisoning by hemostatic drug, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.622D | Poisoning by hemostatic drug, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.622S | Poisoning by hemostatic drug, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.692 | Poisoning by other fibrinolysis-affecting drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.692A | Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.692D | Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.692S | Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.7X2 | Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.7X2A | Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.7X2D | Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T45.7X2S | Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.8X2 | Poisoning by other primarily systemic and hematological agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.8X2A | Poisoning by other primarily systemic and hematological agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.8X2D | Poisoning by other primarily systemic and hematological agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.8X2S | Poisoning by other primarily systemic and hematological agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.92 | Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.92XA | Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.92XD | Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.92XS | Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.0X2 | Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.0X2A | Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.0X2D | Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.0X2S | Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.1X2 | Poisoning by calcium-channel blockers, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.1X2A | Poisoning by calcium-channel blockers, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.1X2D | Poisoning by calcium-channel blockers, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.1X2S | Poisoning by calcium-channel blockers, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.2X2 | Poisoning by other antidysrhythmic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.2X2A | Poisoning by other antidysrhythmic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.2X2D | Poisoning by other antidysrhythmic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.2X2S | Poisoning by other antidysrhythmic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.3X2 | Poisoning by coronary vasodilators, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.3X2A | Poisoning by coronary vasodilators, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.3X2D | Poisoning by coronary vasodilators, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.3X2S | Poisoning by coronary vasodilators, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.4X2 | Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T46.4X2A | Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.4X2D | Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.4X2S | Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.5X2 | Poisoning by other antihypertensive drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.5X2A | Poisoning by other antihypertensive drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.5X2D | Poisoning by other antihypertensive drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.5X2S | Poisoning by other antihypertensive drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.6X2 | Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.6X2A | Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.6X2D | Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.6X2S | Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.7X2 | Poisoning by peripheral vasodilators, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.7X2A | Poisoning by peripheral vasodilators, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.7X2D | Poisoning by peripheral vasodilators, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.7X2S | Poisoning by peripheral vasodilators, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.8X2 | Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.8X2A | Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.8X2D | Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.8X2S | Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.902 | Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.902A | Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.902D | Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.902S | Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.992 | Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T46.992A | Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.992D | Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.992S | Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.0X2 | Poisoning by histamine H2-receptor blockers, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.0X2A | Poisoning by histamine H2-receptor blockers, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.0X2D | Poisoning by histamine H2-receptor blockers, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.0X2S | Poisoning by histamine H2-receptor blockers, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.1X2 | Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.1X2A | Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.1X2D | Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.1X2S | Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.2X2 | Poisoning by stimulant laxatives, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.2X2A | Poisoning by stimulant laxatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.2X2D | Poisoning by stimulant laxatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.2X2S | Poisoning by stimulant laxatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.3X2 | Poisoning by saline and osmotic laxatives, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.3X2A | Poisoning by saline and osmotic laxatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.3X2D | Poisoning by saline and osmotic laxatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.3X2S | Poisoning by saline and osmotic laxatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.4X2 | Poisoning by other laxatives, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.4X2A | Poisoning by other laxatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.4X2D | Poisoning by other laxatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.4X2S | Poisoning by other laxatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.5X2 | Poisoning by digestants, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.5X2A | Poisoning by digestants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.5X2D | Poisoning by digestants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.5X2S | Poisoning by digestants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.6X2 | Poisoning by antidiarrheal drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.6X2A | Poisoning by antidiarrheal drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.6X2D | Poisoning by antidiarrheal drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.6X2S | Poisoning by antidiarrheal drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.7X2 | Poisoning by emetics, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.7X2A | Poisoning by emetics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T47.7X2D | Poisoning by emetics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.7X2S | Poisoning by emetics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.8X2 | Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.8X2A | Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.8X2D | Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.8X2S | Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.92 | Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.92XA | Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.92XD | Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.92XS | Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.0X2 | Poisoning by oxytotoxic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.0X2A | Poisoning by oxytotoxic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.0X2D | Poisoning by oxytotoxic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.0X2S | Poisoning by oxytotoxic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.1X2 | Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm | Diagnosis | ICD-10-CM |
| T48.1X2A | Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.1X2D | Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.1X2S | Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.202 | Poisoning by unspecified drugs acting on muscles, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.202A | Poisoning by unspecified drugs acting on muscles, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.202D | Poisoning by unspecified drugs acting on muscles, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.202S | Poisoning by unspecified drugs acting on muscles, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.292 | Poisoning by other drugs acting on muscles, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.292A | Poisoning by other drugs acting on muscles, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.292D | Poisoning by other drugs acting on muscles, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.292S | Poisoning by other drugs acting on muscles, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.3X2 | Poisoning by antitussives, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T48.3X2A | Poisoning by antitussives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.3X2D | Poisoning by antitussives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.3X2S | Poisoning by antitussives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.4X2 | Poisoning by expectorants, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.4X2A | Poisoning by expectorants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.4X2D | Poisoning by expectorants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.4X2S | Poisoning by expectorants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.5X2 | Poisoning by other anti-common-cold drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.5X2A | Poisoning by other anti-common-cold drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.5X2D | Poisoning by other anti-common-cold drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.5X2S | Poisoning by other anti-common-cold drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.6X2 | Poisoning by antiasthmatics, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.6X2A | Poisoning by antiasthmatics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.6X2D | Poisoning by antiasthmatics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.6X2S | Poisoning by antiasthmatics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.902 | Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.902A | Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.902D | Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.902S | Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.992 | Poisoning by other agents primarily acting on the respiratory system, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.992A | Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.992D | Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.992S | Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.0X2 | Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.0X2A | Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.0X2D | Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.0X2S | Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.1X2 | Poisoning by antipruritics, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.1X2A | Poisoning by antipruritics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.1X2D | Poisoning by antipruritics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T49.1X2S | Poisoning by antipruritics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.2X2 | Poisoning by local astringents and local detergents, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.2X2A | Poisoning by local astringents and local detergents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.2X2D | Poisoning by local astringents and local detergents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.2X2S | Poisoning by local astringents and local detergents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.3X2 | Poisoning by emollients, demulcents and protectants, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.3X2A | Poisoning by emollients, demulcents and protectants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.3X2D | Poisoning by emollients, demulcents and protectants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.3X2S | Poisoning by emollients, demulcents and protectants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.4X2 | Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.4X2A | Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.4X2D | Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.4X2S | Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.5X2 | Poisoning by ophthalmological drugs and preparations, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.5X2A | Poisoning by ophthalmological drugs and preparations, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.5X2D | Poisoning by ophthalmological drugs and preparations, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.5X2S | Poisoning by ophthalmological drugs and preparations, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.6X2 | Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.6X2A | Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.6X2D | Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.6X2S | Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.7X2 | Poisoning by dental drugs, topically applied, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.7X2A | Poisoning by dental drugs, topically applied, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.7X2D | Poisoning by dental drugs, topically applied, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.7X2S | Poisoning by dental drugs, topically applied, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T49.8X2 | Poisoning by other topical agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.8X2A | Poisoning by other topical agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.8X2D | Poisoning by other topical agents, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T49.8X2S | Poisoning by other topical agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.92 | Poisoning by unspecified topical agent, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.92XA | Poisoning by unspecified topical agent, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.92XD | Poisoning by unspecified topical agent, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.92XS | Poisoning by unspecified topical agent, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.0X2 | Poisoning by mineralocorticoids and their antagonists, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.0X2A | Poisoning by mineralocorticoids and their antagonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.0X2D | Poisoning by mineralocorticoids and their antagonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.0X2S | Poisoning by mineralocorticoids and their antagonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.1X2 | Poisoning by loop [high-ceiling] diuretics, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.1X2A | Poisoning by loop [high-ceiling] diuretics, intentional self-harm, initial | Diagnosis | ICD-10-CM |
| T50.1X2D | Poisoning by loop [high-ceiling] diuretics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.1X2S | Poisoning by loop [high-ceiling] diuretics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.2X2 | Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.2X2A | Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.2X2D | Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.2X2S | Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.3X2 | Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.3X2A | Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.3X2D | Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.3X2S | Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.4X2 | Poisoning by drugs affecting uric acid metabolism, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.4X2A | Poisoning by drugs affecting uric acid metabolism, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.4X2D | Poisoning by drugs affecting uric acid metabolism, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.4X2S | Poisoning by drugs affecting uric acid metabolism, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T50.5X2 | Poisoning by appetite depressants, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.5X2A | Poisoning by appetite depressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.5X2D | Poisoning by appetite depressants, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T50.5X2S | Poisoning by appetite depressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.6X2 | Poisoning by antidotes and chelating agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.6X2A | Poisoning by antidotes and chelating agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.6X2D | Poisoning by antidotes and chelating agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.6X2S | Poisoning by antidotes and chelating agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.7X2 | Poisoning by analeptics and opioid receptor antagonists, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.7X2A | Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.7X2D | Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.7X2S | Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.8X2 | Poisoning by diagnostic agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.8X2A | Poisoning by diagnostic agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.8X2D | Poisoning by diagnostic agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.8X2S | Poisoning by diagnostic agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.902 | Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.902A | Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.902D | Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.902S | Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.912 | Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.912A | Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.912D | Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.912S | Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.992 | Poisoning by other drugs, medicaments and biological substances, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.992A | Poisoning by other drugs, medicaments and biological substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.992D | Poisoning by other drugs, medicaments and biological substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T50.992S | Poisoning by other drugs, medicaments and biological substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.A12 | Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.A12A | Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.A12D | Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.A12S | Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.A22 | Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.A22A | Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.A22D | Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.A22S | Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.A92 | Poisoning by other bacterial vaccines, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.A92A | Poisoning by other bacterial vaccines, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.A92D | Poisoning by other bacterial vaccines, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.A92S | Poisoning by other bacterial vaccines, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.B12 | Poisoning by smallpox vaccines, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.B12A | Poisoning by smallpox vaccines, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.B12D | Poisoning by smallpox vaccines, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.B12S | Poisoning by smallpox vaccines, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.B92 | Poisoning by other viral vaccines, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.B92A | Poisoning by other viral vaccines, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.B92D | Poisoning by other viral vaccines, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.B92S | Poisoning by other viral vaccines, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.Z12 | Poisoning by immunoglobulin, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.Z12A | Poisoning by immunoglobulin, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.Z12D | Poisoning by immunoglobulin, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.Z12S | Poisoning by immunoglobulin, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.Z92 | Poisoning by other vaccines and biological substances, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.Z92A | Poisoning by other vaccines and biological substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.Z92D | Poisoning by other vaccines and biological substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.Z92S | Poisoning by other vaccines and biological substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T51.0X2 | Toxic effect of ethanol, intentional self-harm | Diagnosis | ICD-10-CM |
| T51.0X2A | Toxic effect of ethanol, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T51.0X2D | Toxic effect of ethanol, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T51.0X2S | Toxic effect of ethanol, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T51.1X2 | Toxic effect of methanol, intentional self-harm | Diagnosis | ICD-10-CM |
| T51.1X2A | Toxic effect of methanol, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T51.1X2D | Toxic effect of methanol, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T51.1X2S | Toxic effect of methanol, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T51.2X2 | Toxic effect of 2-Propanol, intentional self-harm | Diagnosis | ICD-10-CM |
| T51.2X2A | Toxic effect of 2-Propanol, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T51.2X2D | Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T51.2X2S | Toxic effect of 2-Propanol, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T51.3X2 | Toxic effect of fusel oil, intentional self-harm | Diagnosis | ICD-10-CM |
| T51.3X2A | Toxic effect of fusel oil, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T51.3X2D | Toxic effect of fusel oil, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T51.3X2S | Toxic effect of fusel oil, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T51.8X2 | Toxic effect of other alcohols, intentional self-harm | Diagnosis | ICD-10-CM |
| T51.8X2A | Toxic effect of other alcohols, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T51.8X2D | Toxic effect of other alcohols, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T51.8X2S | Toxic effect of other alcohols, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T51.92 | Toxic effect of unspecified alcohol, intentional self-harm | Diagnosis | ICD-10-CM |
| T51.92XA | Toxic effect of unspecified alcohol, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T51.92XD | Toxic effect of unspecified alcohol, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T51.92XS | Toxic effect of unspecified alcohol, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.0X2 | Toxic effect of petroleum products, intentional self-harm | Diagnosis | ICD-10-CM |
| T52.0X2A | Toxic effect of petroleum products, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.0X2D | Toxic effect of petroleum products, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T52.0X2S | Toxic effect of petroleum products, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.1X2 | Toxic effect of benzene, intentional self-harm | Diagnosis | ICD-10-CM |
| T52.1X2A | Toxic effect of benzene, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.1X2D | Toxic effect of benzene, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T52.1X2S | Toxic effect of benzene, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.2X2 | Toxic effect of homologues of benzene, intentional self-harm | Diagnosis | ICD-10-CM |
| T52.2X2A | Toxic effect of homologues of benzene, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.2X2D | Toxic effect of homologues of benzene, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T52.2X2S | Toxic effect of homologues of benzene, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.3X2 | Toxic effect of glycols, intentional self-harm | Diagnosis | ICD-10-CM |
| T52.3X2A | Toxic effect of glycols, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.3X2D | Toxic effect of glycols, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T52.3X2S | Toxic effect of glycols, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.4X2 | Toxic effect of ketones, intentional self-harm | Diagnosis | ICD-10-CM |
| T52.4X2A | Toxic effect of ketones, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.4X2D | Toxic effect of ketones, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T52.4X2S | Toxic effect of ketones, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.8X2 | Toxic effect of other organic solvents, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T52.8X2A | Toxic effect of other organic solvents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.8X2D | Toxic effect of other organic solvents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T52.8X2S | Toxic effect of other organic solvents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.92 | Toxic effect of unspecified organic solvent, intentional self-harm | Diagnosis | ICD-10-CM |
| T52.92XA | Toxic effect of unspecified organic solvent, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.92XD | Toxic effect of unspecified organic solvent, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T52.92XS | Toxic effect of unspecified organic solvent, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.0X2 | Toxic effect of carbon tetrachloride, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.0X2A | Toxic effect of carbon tetrachloride, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.0X2D | Toxic effect of carbon tetrachloride, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.0X2S | Toxic effect of carbon tetrachloride, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.1X2 | Toxic effect of chloroform, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.1X2A | Toxic effect of chloroform, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.1X2D | Toxic effect of chloroform, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.1X2S | Toxic effect of chloroform, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.2X2 | Toxic effect of trichloroethylene, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.2X2A | Toxic effect of trichloroethylene, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.2X2D | Toxic effect of trichloroethylene, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.2X2S | Toxic effect of trichloroethylene, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.3X2 | Toxic effect of tetrachloroethylene, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.3X2A | Toxic effect of tetrachloroethylene, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.3X2D | Toxic effect of tetrachloroethylene, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.3X2S | Toxic effect of tetrachloroethylene, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.4X2 | Toxic effect of dichloromethane, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.4X2A | Toxic effect of dichloromethane, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.4X2D | Toxic effect of dichloromethane, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.4X2S | Toxic effect of dichloromethane, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.5X2 | Toxic effect of chlorofluorocarbons, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.5X2A | Toxic effect of chlorofluorocarbons, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.5X2D | Toxic effect of chlorofluorocarbons, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.5X2S | Toxic effect of chlorofluorocarbons, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.6X2 | Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.6X2A | Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.6X2D | Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.6X2S | Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T53.7X2 | Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.7X2A | Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.7X2D | Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.7X2S | Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.92 | Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.92XA | Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.92XD | Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.92XS | Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T54.0X2 | Toxic effect of phenol and phenol homologues, intentional self-harm | Diagnosis | ICD-10-CM |
| T54.0X2A | Toxic effect of phenol and phenol homologues, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T54.0X2D | Toxic effect of phenol and phenol homologues, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T54.0X2S | Toxic effect of phenol and phenol homologues, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T54.1X2 | Toxic effect of other corrosive organic compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T54.1X2A | Toxic effect of other corrosive organic compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T54.1X2D | Toxic effect of other corrosive organic compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T54.1X2S | Toxic effect of other corrosive organic compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T54.2X2 | Toxic effect of corrosive acids and acid-like substances, intentional self-harm | Diagnosis | ICD-10-CM |
| T54.2X2A | Toxic effect of corrosive acids and acid-like substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T54.2X2D | Toxic effect of corrosive acids and acid-like substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T54.2X2S | Toxic effect of corrosive acids and acid-like substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T54.3X2 | Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm | Diagnosis | ICD-10-CM |
| T54.3X2A | Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T54.3X2D | Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T54.3X2S | Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T54.92 | Toxic effect of unspecified corrosive substance, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T54.92XA | Toxic effect of unspecified corrosive substance, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T54.92XD | Toxic effect of unspecified corrosive substance, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T54.92XS | Toxic effect of unspecified corrosive substance, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T55.0X2 | Toxic effect of soaps, intentional self-harm | Diagnosis | ICD-10-CM |
| T55.0X2A | Toxic effect of soaps, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T55.0X2D | Toxic effect of soaps, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T55.0X2S | Toxic effect of soaps, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T55.1X2 | Toxic effect of detergents, intentional self-harm | Diagnosis | ICD-10-CM |
| T55.1X2A | Toxic effect of detergents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T55.1X2D | Toxic effect of detergents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T55.1X2S | Toxic effect of detergents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.0X2 | Toxic effect of lead and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.0X2A | Toxic effect of lead and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.0X2D | Toxic effect of lead and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.0X2S | Toxic effect of lead and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.1X2 | Toxic effect of mercury and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.1X2A | Toxic effect of mercury and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.1X2D | Toxic effect of mercury and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.1X2S | Toxic effect of mercury and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.2X2 | Toxic effect of chromium and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.2X2A | Toxic effect of chromium and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.2X2D | Toxic effect of chromium and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.2X2S | Toxic effect of chromium and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.3X2 | Toxic effect of cadmium and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.3X2A | Toxic effect of cadmium and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.3X2D | Toxic effect of cadmium and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.3X2S | Toxic effect of cadmium and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.4X2 | Toxic effect of copper and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.4X2A | Toxic effect of copper and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.4X2D | Toxic effect of copper and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.4X2S | Toxic effect of copper and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.5X2 | Toxic effect of zinc and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.5X2A | Toxic effect of zinc and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T56.5X2D | Toxic effect of zinc and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.5X2S | Toxic effect of zinc and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.6X2 | Toxic effect of tin and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.6X2A | Toxic effect of tin and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.6X2D | Toxic effect of tin and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.6X2S | Toxic effect of tin and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.7X2 | Toxic effect of beryllium and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.7X2A | Toxic effect of beryllium and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.7X2D | Toxic effect of beryllium and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.7X2S | Toxic effect of beryllium and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.812 | Toxic effect of thallium, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.812A | Toxic effect of thallium, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.812D | Toxic effect of thallium, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.812S | Toxic effect of thallium, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.892 | Toxic effect of other metals, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.892A | Toxic effect of other metals, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.892D | Toxic effect of other metals, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.892S | Toxic effect of other metals, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.92 | Toxic effect of unspecified metal, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.92XA | Toxic effect of unspecified metal, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.92XD | Toxic effect of unspecified metal, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.92XS | Toxic effect of unspecified metal, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T57.0X2 | Toxic effect of arsenic and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T57.0X2A | Toxic effect of arsenic and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T57.0X2D | Toxic effect of arsenic and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T57.0X2S | Toxic effect of arsenic and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T57.1X2 | Toxic effect of phosphorus and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T57.1X2A | Toxic effect of phosphorus and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T57.1X2D | Toxic effect of phosphorus and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T57.1X2S | Toxic effect of phosphorus and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T57.2X2 | Toxic effect of manganese and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T57.2X2A | Toxic effect of manganese and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T57.2X2D | Toxic effect of manganese and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T57.2X2S | Toxic effect of manganese and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T57.3X2 | Toxic effect of hydrogen cyanide, intentional self-harm | Diagnosis | ICD-10-CM |
| T57.3X2A | Toxic effect of hydrogen cyanide, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T57.3X2D | Toxic effect of hydrogen cyanide, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T57.3X2S | Toxic effect of hydrogen cyanide, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T57.8X2 | Toxic effect of other specified inorganic substances, intentional self-harm | Diagnosis | ICD-10-CM |
| T57.8X2A | Toxic effect of other specified inorganic substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T57.8X2D | Toxic effect of other specified inorganic substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T57.8X2S | Toxic effect of other specified inorganic substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T57.92 | Toxic effect of unspecified inorganic substance, intentional self-harm | Diagnosis | ICD-10-CM |
| T57.92XA | Toxic effect of unspecified inorganic substance, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T57.92XD | Toxic effect of unspecified inorganic substance, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T57.92XS | Toxic effect of unspecified inorganic substance, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T58.02 | Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm | Diagnosis | ICD-10-CM |
| T58.02XA | Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T58.02XD | Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T58.02XS | Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T58.12 | Toxic effect of carbon monoxide from utility gas, intentional self-harm | Diagnosis | ICD-10-CM |
| T58.12XA | Toxic effect of carbon monoxide from utility gas, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T58.12XD | Toxic effect of carbon monoxide from utility gas, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T58.12XS | Toxic effect of carbon monoxide from utility gas, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T58.2X2 | Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm | Diagnosis | ICD-10-CM |
| T58.2X2A | Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T58.2X2D | Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T58.2X2S | Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T58.8X2 | Toxic effect of carbon monoxide from other source, intentional self-harm | Diagnosis | ICD-10-CM |
| T58.8X2A | Toxic effect of carbon monoxide from other source, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T58.8X2D | Toxic effect of carbon monoxide from other source, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T58.8X2S | Toxic effect of carbon monoxide from other source, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T58.92 | Toxic effect of carbon monoxide from unspecified source, intentional self-harm | Diagnosis | ICD-10-CM |
| T58.92XA | Toxic effect of carbon monoxide from unspecified source, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T58.92XD | Toxic effect of carbon monoxide from unspecified source, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T58.92XS | Toxic effect of carbon monoxide from unspecified source, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.0X2 | Toxic effect of nitrogen oxides, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.0X2A | Toxic effect of nitrogen oxides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.0X2D | Toxic effect of nitrogen oxides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.0X2S | Toxic effect of nitrogen oxides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.1X2 | Toxic effect of sulfur dioxide, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.1X2A | Toxic effect of sulfur dioxide, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.1X2D | Toxic effect of sulfur dioxide, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.1X2S | Toxic effect of sulfur dioxide, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.2X2 | Toxic effect of formaldehyde, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.2X2A | Toxic effect of formaldehyde, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.2X2D | Toxic effect of formaldehyde, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.2X2S | Toxic effect of formaldehyde, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.3X2 | Toxic effect of lacrimogenic gas, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.3X2A | Toxic effect of lacrimogenic gas, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.3X2D | Toxic effect of lacrimogenic gas, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.3X2S | Toxic effect of lacrimogenic gas, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.4X2 | Toxic effect of chlorine gas, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.4X2A | Toxic effect of chlorine gas, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.4X2D | Toxic effect of chlorine gas, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.4X2S | Toxic effect of chlorine gas, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.5X2 | Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.5X2A | Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.5X2D | Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.5X2S | Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.6X2 | Toxic effect of hydrogen sulfide, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.6X2A | Toxic effect of hydrogen sulfide, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.6X2D | Toxic effect of hydrogen sulfide, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.6X2S | Toxic effect of hydrogen sulfide, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.7X2 | Toxic effect of carbon dioxide, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.7X2A | Toxic effect of carbon dioxide, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.7X2D | Toxic effect of carbon dioxide, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.7X2S | Toxic effect of carbon dioxide, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.812 | Toxic effect of smoke, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T59.812A | Toxic effect of smoke, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.812D | Toxic effect of smoke, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.812S | Toxic effect of smoke, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.892 | Toxic effect of other specified gases, fumes and vapors, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.892A | Toxic effect of other specified gases, fumes and vapors, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.892D | Toxic effect of other specified gases, fumes and vapors, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.892S | Toxic effect of other specified gases, fumes and vapors, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.92 | Toxic effect of unspecified gases, fumes and vapors, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.92XA | Toxic effect of unspecified gases, fumes and vapors, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.92XD | Toxic effect of unspecified gases, fumes and vapors, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.92XS | Toxic effect of unspecified gases, fumes and vapors, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.0X2 | Toxic effect of organophosphate and carbamate insecticides, intentional self-harm | Diagnosis | ICD-10-CM |
| T60.0X2A | Toxic effect of organophosphate and carbamate insecticides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.0X2D | Toxic effect of organophosphate and carbamate insecticides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.0X2S | Toxic effect of organophosphate and carbamate insecticides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.1X2 | Toxic effect of halogenated insecticides, intentional self-harm | Diagnosis | ICD-10-CM |
| T60.1X2A | Toxic effect of halogenated insecticides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.1X2D | Toxic effect of halogenated insecticides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.1X2S | Toxic effect of halogenated insecticides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.2X2 | Toxic effect of other insecticides, intentional self-harm | Diagnosis | ICD-10-CM |
| T60.2X2A | Toxic effect of other insecticides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.2X2D | Toxic effect of other insecticides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.2X2S | Toxic effect of other insecticides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.3X2 | Toxic effect of herbicides and fungicides, intentional self-harm | Diagnosis | ICD-10-CM |
| T60.3X2A | Toxic effect of herbicides and fungicides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.3X2D | Toxic effect of herbicides and fungicides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.3X2S | Toxic effect of herbicides and fungicides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.4X2 | Toxic effect of rodenticides, intentional self-harm | Diagnosis | ICD-10-CM |
| T60.4X2A | Toxic effect of rodenticides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.4X2D | Toxic effect of rodenticides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.4X2S | Toxic effect of rodenticides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.8X2 | Toxic effect of other pesticides, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T60.8X2A | Toxic effect of other pesticides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.8X2D | Toxic effect of other pesticides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.8X2S | Toxic effect of other pesticides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.92 | Toxic effect of unspecified pesticide, intentional self-harm | Diagnosis | ICD-10-CM |
| T60.92XA | Toxic effect of unspecified pesticide, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.92XD | Toxic effect of unspecified pesticide, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.92XS | Toxic effect of unspecified pesticide, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T61.02 | Ciguatera fish poisoning, intentional self-harm | Diagnosis | ICD-10-CM |
| T61.02XA | Ciguatera fish poisoning, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T61.02XD | Ciguatera fish poisoning, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T61.02XS | Ciguatera fish poisoning, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T61.12 | Scombroid fish poisoning, intentional self-harm | Diagnosis | ICD-10-CM |
| T61.12XA | Scombroid fish poisoning, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T61.12XD | Scombroid fish poisoning, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T61.12XS | Scombroid fish poisoning, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T61.772 | Other fish poisoning, intentional self-harm | Diagnosis | ICD-10-CM |
| T61.772A | Other fish poisoning, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T61.772D | Other fish poisoning, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T61.772S | Other fish poisoning, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T61.782 | Other shellfish poisoning, intentional self-harm | Diagnosis | ICD-10-CM |
| T61.782A | Other shellfish poisoning, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T61.782D | Other shellfish poisoning, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T61.782S | Other shellfish poisoning, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T61.8X2 | Toxic effect of other seafood, intentional self-harm | Diagnosis | ICD-10-CM |
| T61.8X2A | Toxic effect of other seafood, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T61.8X2D | Toxic effect of other seafood, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T61.8X2S | Toxic effect of other seafood, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T61.92 | Toxic effect of unspecified seafood, intentional self-harm | Diagnosis | ICD-10-CM |
| T61.92XA | Toxic effect of unspecified seafood, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T61.92XD | Toxic effect of unspecified seafood, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T61.92XS | Toxic effect of unspecified seafood, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T62.0X2 | Toxic effect of ingested mushrooms, intentional self-harm | Diagnosis | ICD-10-CM |
| T62.0X2A | Toxic effect of ingested mushrooms, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T62.0X2D | Toxic effect of ingested mushrooms, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T62.0X2S | Toxic effect of ingested mushrooms, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T62.1X2 | Toxic effect of ingested berries, intentional self-harm | Diagnosis | ICD-10-CM |
| T62.1X2A | Toxic effect of ingested berries, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T62.1X2D | Toxic effect of ingested berries, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T62.1X2S | Toxic effect of ingested berries, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T62.2X2 | Toxic effect of other ingested (parts of) plant(s), intentional self-harm | Diagnosis | ICD-10-CM |
| T62.2X2A | Toxic effect of other ingested (parts of) plant(s), intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T62.2X2D | Toxic effect of other ingested (parts of) plant(s), intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T62.2X2S | Toxic effect of other ingested (parts of) plant(s), intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T62.8X2 | Toxic effect of other specified noxious substances eaten as food, intentional self-harm | Diagnosis | ICD-10-CM |
| T62.8X2A | Toxic effect of other specified noxious substances eaten as food, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T62.8X2D | Toxic effect of other specified noxious substances eaten as food, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T62.8X2S | Toxic effect of other specified noxious substances eaten as food, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T62.92 | Toxic effect of unspecified noxious substance eaten as food, intentional self-harm | Diagnosis | ICD-10-CM |
| T62.92XA | Toxic effect of unspecified noxious substance eaten as food, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T62.92XD | Toxic effect of unspecified noxious substance eaten as food, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T62.92XS | Toxic effect of unspecified noxious substance eaten as food, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.002 | Toxic effect of unspecified snake venom, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.002A | Toxic effect of unspecified snake venom, intentional self-harm, initial | Diagnosis | ICD-10-CM |
| T63.002D | Toxic effect of unspecified snake venom, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.002S | Toxic effect of unspecified snake venom, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.012 | Toxic effect of rattlesnake venom, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.012A | Toxic effect of rattlesnake venom, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.012D | Toxic effect of rattlesnake venom, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T63.012S | Toxic effect of rattlesnake venom, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.022 | Toxic effect of coral snake venom, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.022A | Toxic effect of coral snake venom, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.022D | Toxic effect of coral snake venom, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T63.022S | Toxic effect of coral snake venom, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.032 | Toxic effect of taipan venom, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.032A | Toxic effect of taipan venom, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.032D | Toxic effect of taipan venom, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.032S | Toxic effect of taipan venom, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.042 | Toxic effect of cobra venom, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.042A | Toxic effect of cobra venom, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.042D | Toxic effect of cobra venom, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.042S | Toxic effect of cobra venom, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.062 | Toxic effect of venom of other North and South American snake, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.062A | Toxic effect of venom of other North and South American snake, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T63.062D | Toxic effect of venom of other North and South American snake, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.062S | Toxic effect of venom of other North and South American snake, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.072 | Toxic effect of venom of other Australian snake, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.072A | Toxic effect of venom of other Australian snake, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.072D | Toxic effect of venom of other Australian snake, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.072S | Toxic effect of venom of other Australian snake, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.082 | Toxic effect of venom of other African and Asian snake, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.082A | Toxic effect of venom of other African and Asian snake, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.082D | Toxic effect of venom of other African and Asian snake, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.082S | Toxic effect of venom of other African and Asian snake, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.092 | Toxic effect of venom of other snake, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.092A | Toxic effect of venom of other snake, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.092D | Toxic effect of venom of other snake, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.092S | Toxic effect of venom of other snake, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.112 | Toxic effect of venom of gila monster, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.112A | Toxic effect of venom of gila monster, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.112D | Toxic effect of venom of gila monster, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.112S | Toxic effect of venom of gila monster, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.122 | Toxic effect of venom of other venomous lizard, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.122A | Toxic effect of venom of other venomous lizard, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.122D | Toxic effect of venom of other venomous lizard, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.122S | Toxic effect of venom of other venomous lizard, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.192 | Toxic effect of venom of other reptiles, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.192A | Toxic effect of venom of other reptiles, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.192D | Toxic effect of venom of other reptiles, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.192S | Toxic effect of venom of other reptiles, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.2X2 | Toxic effect of venom of scorpion, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.2X2A | Toxic effect of venom of scorpion, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.2X2D | Toxic effect of venom of scorpion, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.2X2S | Toxic effect of venom of scorpion, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.302 | Toxic effect of unspecified spider venom, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.302A | Toxic effect of unspecified spider venom, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T63.302D | Toxic effect of unspecified spider venom, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.302S | Toxic effect of unspecified spider venom, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.312 | Toxic effect of venom of black widow spider, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.312A | Toxic effect of venom of black widow spider, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.312D | Toxic effect of venom of black widow spider, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.312S | Toxic effect of venom of black widow spider, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.322 | Toxic effect of venom of tarantula, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.322A | Toxic effect of venom of tarantula, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.322D | Toxic effect of venom of tarantula, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.322S | Toxic effect of venom of tarantula, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.332 | Toxic effect of venom of brown recluse spider, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.332A | Toxic effect of venom of brown recluse spider, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.332D | Toxic effect of venom of brown recluse spider, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.332S | Toxic effect of venom of brown recluse spider, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.392 | Toxic effect of venom of other spider, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.392A | Toxic effect of venom of other spider, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.392D | Toxic effect of venom of other spider, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.392S | Toxic effect of venom of other spider, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.412 | Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.412A | Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.412D | Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.412S | Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.422 | Toxic effect of venom of ants, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.422A | Toxic effect of venom of ants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.422D | Toxic effect of venom of ants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.422S | Toxic effect of venom of ants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.432 | Toxic effect of venom of caterpillars, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.432A | Toxic effect of venom of caterpillars, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.432D | Toxic effect of venom of caterpillars, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.432S | Toxic effect of venom of caterpillars, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.442 | Toxic effect of venom of bees, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.442A | Toxic effect of venom of bees, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.442D | Toxic effect of venom of bees, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T63.442S | Toxic effect of venom of bees, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.452 | Toxic effect of venom of hornets, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.452A | Toxic effect of venom of hornets, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.452D | Toxic effect of venom of hornets, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.452S | Toxic effect of venom of hornets, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.462 | Toxic effect of venom of wasps, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.462A | Toxic effect of venom of wasps, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.462D | Toxic effect of venom of wasps, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.462S | Toxic effect of venom of wasps, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.482 | Toxic effect of venom of other arthropod, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.482A | Toxic effect of venom of other arthropod, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.482D | Toxic effect of venom of other arthropod, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.482S | Toxic effect of venom of other arthropod, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.512 | Toxic effect of contact with stingray, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.512A | Toxic effect of contact with stingray, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.512D | Toxic effect of contact with stingray, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.512S | Toxic effect of contact with stingray, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.592 | Toxic effect of contact with other venomous fish, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.592A | Toxic effect of contact with other venomous fish, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.592D | Toxic effect of contact with other venomous fish, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.592S | Toxic effect of contact with other venomous fish, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.612 | Toxic effect of contact with Portuguese Man-o-war, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.612A | Toxic effect of contact with Portuguese Man-o-war, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.612D | Toxic effect of contact with Portuguese Man-o-war, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.612S | Toxic effect of contact with Portuguese Man-o-war, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.622 | Toxic effect of contact with other jellyfish, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.622A | Toxic effect of contact with other jellyfish, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.622D | Toxic effect of contact with other jellyfish, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.622S | Toxic effect of contact with other jellyfish, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.632 | Toxic effect of contact with sea anemone, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.632A | Toxic effect of contact with sea anemone, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.632D | Toxic effect of contact with sea anemone, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T63.632S | Toxic effect of contact with sea anemone, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.692 | Toxic effect of contact with other venomous marine animals, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.692A | Toxic effect of contact with other venomous marine animals, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.692D | Toxic effect of contact with other venomous marine animals, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.692S | Toxic effect of contact with other venomous marine animals, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.712 | Toxic effect of contact with venomous marine plant, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.712A | Toxic effect of contact with venomous marine plant, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.712D | Toxic effect of contact with venomous marine plant, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.712S | Toxic effect of contact with venomous marine plant, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.792 | Toxic effect of contact with other venomous plant, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.792A | Toxic effect of contact with other venomous plant, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.792D | Toxic effect of contact with other venomous plant, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.792S | Toxic effect of contact with other venomous plant, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.812 | Toxic effect of contact with venomous frog, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.812A | Toxic effect of contact with venomous frog, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.812D | Toxic effect of contact with venomous frog, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.812S | Toxic effect of contact with venomous frog, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.822 | Toxic effect of contact with venomous toad, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.822A | Toxic effect of contact with venomous toad, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.822D | Toxic effect of contact with venomous toad, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.822S | Toxic effect of contact with venomous toad, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.832 | Toxic effect of contact with other venomous amphibian, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.832A | Toxic effect of contact with other venomous amphibian, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.832D | Toxic effect of contact with other venomous amphibian, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.832S | Toxic effect of contact with other venomous amphibian, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.892 | Toxic effect of contact with other venomous animals, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T63.892A | Toxic effect of contact with other venomous animals, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.892D | Toxic effect of contact with other venomous animals, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.892S | Toxic effect of contact with other venomous animals, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.92 | Toxic effect of contact with unspecified venomous animal, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.92XA | Toxic effect of contact with unspecified venomous animal, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.92XD | Toxic effect of contact with unspecified venomous animal, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.92XS | Toxic effect of contact with unspecified venomous animal, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T64.02 | Toxic effect of aflatoxin, intentional self-harm | Diagnosis | ICD-10-CM |
| T64.02XA | Toxic effect of aflatoxin, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T64.02XD | Toxic effect of aflatoxin, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T64.02XS | Toxic effect of aflatoxin, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T64.82 | Toxic effect of other mycotoxin food contaminants, intentional self-harm | Diagnosis | ICD-10-CM |
| T64.82XA | Toxic effect of other mycotoxin food contaminants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T64.82XD | Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T64.82XS | Toxic effect of other mycotoxin food contaminants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.0X2 | Toxic effect of cyanides, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.0X2A | Toxic effect of cyanides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.0X2D | Toxic effect of cyanides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.0X2S | Toxic effect of cyanides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.1X2 | Toxic effect of strychnine and its salts, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.1X2A | Toxic effect of strychnine and its salts, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.1X2D | Toxic effect of strychnine and its salts, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.1X2S | Toxic effect of strychnine and its salts, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.212 | Toxic effect of chewing tobacco, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.212A | Toxic effect of chewing tobacco, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.212D | Toxic effect of chewing tobacco, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.212S | Toxic effect of chewing tobacco, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.222 | Toxic effect of tobacco cigarettes, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.222A | Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.222D | Toxic effect of tobacco cigarettes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.222S | Toxic effect of tobacco cigarettes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.292 | Toxic effect of other tobacco and nicotine, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.292A | Toxic effect of other tobacco and nicotine, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T65.292D | Toxic effect of other tobacco and nicotine, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.292S | Toxic effect of other tobacco and nicotine, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.3X2 | Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.3X2A | Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.3X2D | Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.3X2S | Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.4X2 | Toxic effect of carbon disulfide, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.4X2A | Toxic effect of carbon disulfide, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.4X2D | Toxic effect of carbon disulfide, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.4X2S | Toxic effect of carbon disulfide, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.5X2 | Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.5X2A | Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.5X2D | Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.5X2S | Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.6X2 | Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.6X2A | Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.6X2D | Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.6X2S | Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.812 | Toxic effect of latex, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.812A | Toxic effect of latex, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.812D | Toxic effect of latex, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.812S | Toxic effect of latex, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.822 | Toxic effect of harmful algae and algae toxins, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.822A | Toxic effect of harmful algae and algae toxins, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.822D | Toxic effect of harmful algae and algae toxins, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.822S | Toxic effect of harmful algae and algae toxins, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.832 | Toxic effect of fiberglass, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.832A | Toxic effect of fiberglass, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.832D | Toxic effect of fiberglass, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.832S | Toxic effect of fiberglass, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T65.892 | Toxic effect of other specified substances, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.892A | Toxic effect of other specified substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.892D | Toxic effect of other specified substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.892S | Toxic effect of other specified substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.92 | Toxic effect of unspecified substance, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.92XA | Toxic effect of unspecified substance, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.92XD | Toxic effect of unspecified substance, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.92XS | Toxic effect of unspecified substance, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.112 | Asphyxiation due to smothering under pillow, intentional self-harm | Diagnosis | ICD-10-CM |
| T71.112A | Asphyxiation due to smothering under pillow, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.112D | Asphyxiation due to smothering under pillow, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.112S | Asphyxiation due to smothering under pillow, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.122 | Asphyxiation due to plastic bag, intentional self-harm | Diagnosis | ICD-10-CM |
| T71.122A | Asphyxiation due to plastic bag, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.122D | Asphyxiation due to plastic bag, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.122S | Asphyxiation due to plastic bag, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.132 | Asphyxiation due to being trapped in bed linens, intentional self-harm | Diagnosis | ICD-10-CM |
| T71.132A | Asphyxiation due to being trapped in bed linens, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.132D | Asphyxiation due to being trapped in bed linens, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.132S | Asphyxiation due to being trapped in bed linens, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.152 | Asphyxiation due to smothering in furniture, intentional self-harm | Diagnosis | ICD-10-CM |
| T71.152A | Asphyxiation due to smothering in furniture, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.152D | Asphyxiation due to smothering in furniture, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.152S | Asphyxiation due to smothering in furniture, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.162 | Asphyxiation due to hanging, intentional self-harm | Diagnosis | ICD-10-CM |
| T71.162A | Asphyxiation due to hanging, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.162D | Asphyxiation due to hanging, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.162S | Asphyxiation due to hanging, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.192 | Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm | Diagnosis | ICD-10-CM |
| T71.192A | Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.192D | Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T71.192S | Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.222 | Asphyxiation due to being trapped in a car trunk, intentional self-harm | Diagnosis | ICD-10-CM |
| T71.222A | Asphyxiation due to being trapped in a car trunk, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.222D | Asphyxiation due to being trapped in a car trunk, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.222S | Asphyxiation due to being trapped in a car trunk, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.232 | Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm | Diagnosis | ICD-10-CM |
| T71.232A | Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.232D | Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.232S | Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| X71 | Intentional self-harm by drowning and submersion | Diagnosis | ICD-10-CM |
| X71.0 | Intentional self-harm by drowning and submersion while in bathtub | Diagnosis | ICD-10-CM |
| X71.0XXA | Intentional self-harm by drowning and submersion while in bathtub, initial encounter | Diagnosis | ICD-10-CM |
| X71.0XXD | Intentional self-harm by drowning and submersion while in bathtub, subsequent encounter | Diagnosis | ICD-10-CM |
| X71.0XXS | Intentional self-harm by drowning and submersion while in bathtub, sequela | Diagnosis | ICD-10-CM |
| X71.1 | Intentional self-harm by drowning and submersion while in swimming pool | Diagnosis | ICD-10-CM |
| X71.1XXA | Intentional self-harm by drowning and submersion while in swimming pool, initial encounter | Diagnosis | ICD-10-CM |
| X71.1XXD | Intentional self-harm by drowning and submersion while in swimming pool, subsequent encounter | Diagnosis | ICD-10-CM |
| X71.1XXS | Intentional self-harm by drowning and submersion while in swimming pool, sequela | Diagnosis | ICD-10-CM |
| X71.2 | Intentional self-harm by drowning and submersion after jump into swimming pool | Diagnosis | ICD-10-CM |
| X71.2XXA | Intentional self-harm by drowning and submersion after jump into swimming pool, initial encounter | Diagnosis | ICD-10-CM |
| X71.2XXD | Intentional self-harm by drowning and submersion after jump into swimming pool, subsequent encounter | Diagnosis | ICD-10-CM |
| X71.2XXS | Intentional self-harm by drowning and submersion after jump into swimming pool, sequela | Diagnosis | ICD-10-CM |
| X71.3 | Intentional self-harm by drowning and submersion in natural water | Diagnosis | ICD-10-CM |
| X71.3XXA | Intentional self-harm by drowning and submersion in natural water, initial encounter | Diagnosis | ICD-10-CM |
| X71.3XXD | Intentional self-harm by drowning and submersion in natural water, subsequent encounter | Diagnosis | ICD-10-CM |
| X71.3XXS | Intentional self-harm by drowning and submersion in natural water, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| X71.8 | Other intentional self-harm by drowning and submersion | Diagnosis | ICD-10-CM |
| X71.8XXA | Other intentional self-harm by drowning and submersion, initial encounter | Diagnosis | ICD-10-CM |
| X71.8XXD | Other intentional self-harm by drowning and submersion, subsequent encounter | Diagnosis | ICD-10-CM |
| X71.8XXS | Other intentional self-harm by drowning and submersion, sequela | Diagnosis | ICD-10-CM |
| X71.9 | Intentional self-harm by drowning and submersion, unspecified | Diagnosis | ICD-10-CM |
| X71.9XXA | Intentional self-harm by drowning and submersion, unspecified, initial encounter | Diagnosis | ICD-10-CM |
| X71.9XXD | Intentional self-harm by drowning and submersion, unspecified, subsequent encounter | Diagnosis | ICD-10-CM |
| X71.9XXS | Intentional self-harm by drowning and submersion, unspecified, sequela | Diagnosis | ICD-10-CM |
| X72 | Intentional self-harm by handgun discharge | Diagnosis | ICD-10-CM |
| X72.XXXA | Intentional self-harm by handgun discharge, initial encounter | Diagnosis | ICD-10-CM |
| X72.XXXD | Intentional self-harm by handgun discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X72.XXXS | Intentional self-harm by handgun discharge, sequela | Diagnosis | ICD-10-CM |
| X73 | Intentional self-harm by rifle, shotgun and larger firearm discharge | Diagnosis | ICD-10-CM |
| X73.0 | Intentional self-harm by shotgun discharge | Diagnosis | ICD-10-CM |
| X73.0XXA | Intentional self-harm by shotgun discharge, initial encounter | Diagnosis | ICD-10-CM |
| X73.0XXD | Intentional self-harm by shotgun discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X73.0XXS | Intentional self-harm by shotgun discharge, sequela | Diagnosis | ICD-10-CM |
| X73.1 | Intentional self-harm by hunting rifle discharge | Diagnosis | ICD-10-CM |
| X73.1XXA | Intentional self-harm by hunting rifle discharge, initial encounter | Diagnosis | ICD-10-CM |
| X73.1XXD | Intentional self-harm by hunting rifle discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X73.1XXS | Intentional self-harm by hunting rifle discharge, sequela | Diagnosis | ICD-10-CM |
| X73.2 | Intentional self-harm by machine gun discharge | Diagnosis | ICD-10-CM |
| X73.2XXA | Intentional self-harm by machine gun discharge, initial encounter | Diagnosis | ICD-10-CM |
| X73.2XXD | Intentional self-harm by machine gun discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X73.2XXS | Intentional self-harm by machine gun discharge, sequela | Diagnosis | ICD-10-CM |
| X73.8 | Intentional self-harm by other larger firearm discharge | Diagnosis | ICD-10-CM |
| X73.8XXA | Intentional self-harm by other larger firearm discharge, initial encounter | Diagnosis | ICD-10-CM |
| X73.8XXD | Intentional self-harm by other larger firearm discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X73.8XXS | Intentional self-harm by other larger firearm discharge, sequela | Diagnosis | ICD-10-CM |
| X73.9 | Intentional self-harm by unspecified larger firearm discharge | Diagnosis | ICD-10-CM |
| X73.9XXA | Intentional self-harm by unspecified larger firearm discharge, initial encounter | Diagnosis | ICD-10-CM |
| X73.9XXD | Intentional self-harm by unspecified larger firearm discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X73.9XXS | Intentional self-harm by unspecified larger firearm discharge, sequela | Diagnosis | ICD-10-CM |
| X74 | Intentional self-harm by other and unspecified firearm and gun discharge | Diagnosis | ICD-10-CM |
| X74.0 | Intentional self-harm by gas, air or spring-operated guns | Diagnosis | ICD-10-CM |
| X74.01 | Intentional self-harm by airgun | Diagnosis | ICD-10-CM |
| X74.01XA | Intentional self-harm by airgun, initial encounter | Diagnosis | ICD-10-CM |
| X74.01XD | Intentional self-harm by airgun, subsequent encounter | Diagnosis | ICD-10-CM |
| X74.01XS | Intentional self-harm by airgun, sequela | Diagnosis | ICD-10-CM |
| X74.02 | Intentional self-harm by paintball gun | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| X74.02XA | Intentional self-harm by paintball gun, initial encounter | Diagnosis | ICD-10-CM |
| X74.02XD | Intentional self-harm by paintball gun, subsequent encounter | Diagnosis | ICD-10-CM |
| X74.02XS | Intentional self-harm by paintball gun, sequela | Diagnosis | ICD-10-CM |
| X74.09 | Intentional self-harm by other gas, air or spring-operated gun | Diagnosis | ICD-10-CM |
| X74.09XA | Intentional self-harm by other gas, air or spring-operated gun, initial encounter | Diagnosis | ICD-10-CM |
| X74.09XD | Intentional self-harm by other gas, air or spring-operated gun, subsequent encounter | Diagnosis | ICD-10-CM |
| X74.09XS | Intentional self-harm by other gas, air or spring-operated gun, sequela | Diagnosis | ICD-10-CM |
| X74.8 | Intentional self-harm by other firearm discharge | Diagnosis | ICD-10-CM |
| X74.8XXA | Intentional self-harm by other firearm discharge, initial encounter | Diagnosis | ICD-10-CM |
| X74.8XXD | Intentional self-harm by other firearm discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X74.8XXS | Intentional self-harm by other firearm discharge, sequela | Diagnosis | ICD-10-CM |
| X74.9 | Intentional self-harm by unspecified firearm discharge | Diagnosis | ICD-10-CM |
| X74.9XXA | Intentional self-harm by unspecified firearm discharge, initial encounter | Diagnosis | ICD-10-CM |
| X74.9XXD | Intentional self-harm by unspecified firearm discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X74.9XXS | Intentional self-harm by unspecified firearm discharge, sequela | Diagnosis | ICD-10-CM |
| X75 | Intentional self-harm by explosive material | Diagnosis | ICD-10-CM |
| X75.XXXA | Intentional self-harm by explosive material, initial encounter | Diagnosis | ICD-10-CM |
| X75.XXXD | Intentional self-harm by explosive material, subsequent encounter | Diagnosis | ICD-10-CM |
| X75.XXXS | Intentional self-harm by explosive material, sequela | Diagnosis | ICD-10-CM |
| X76 | Intentional self-harm by smoke, fire and flames | Diagnosis | ICD-10-CM |
| X76.XXXA | Intentional self-harm by smoke, fire and flames, initial encounter | Diagnosis | ICD-10-CM |
| X76.XXXD | Intentional self-harm by smoke, fire and flames, subsequent encounter | Diagnosis | ICD-10-CM |
| X76.XXXS | Intentional self-harm by smoke, fire and flames, sequela | Diagnosis | ICD-10-CM |
| X77 | Intentional self-harm by steam, hot vapors and hot objects | Diagnosis | ICD-10-CM |
| X77.0 | Intentional self-harm by steam or hot vapors | Diagnosis | ICD-10-CM |
| X77.0XXA | Intentional self-harm by steam or hot vapors, initial encounter | Diagnosis | ICD-10-CM |
| X77.0XXD | Intentional self-harm by steam or hot vapors, subsequent encounter | Diagnosis | ICD-10-CM |
| X77.0XXS | Intentional self-harm by steam or hot vapors, sequela | Diagnosis | ICD-10-CM |
| X77.1 | Intentional self-harm by hot tap water | Diagnosis | ICD-10-CM |
| X77.1XXA | Intentional self-harm by hot tap water, initial encounter | Diagnosis | ICD-10-CM |
| X77.1XXD | Intentional self-harm by hot tap water, subsequent encounter | Diagnosis | ICD-10-CM |
| X77.1XXS | Intentional self-harm by hot tap water, sequela | Diagnosis | ICD-10-CM |
| X77.2 | Intentional self-harm by other hot fluids | Diagnosis | ICD-10-CM |
| X77.2XXA | Intentional self-harm by other hot fluids, initial encounter | Diagnosis | ICD-10-CM |
| X77.2XXD | Intentional self-harm by other hot fluids, subsequent encounter | Diagnosis | ICD-10-CM |
| X77.2XXS | Intentional self-harm by other hot fluids, sequela | Diagnosis | ICD-10-CM |
| X77.3 | Intentional self-harm by hot household appliances | Diagnosis | ICD-10-CM |
| X77.3XXA | Intentional self-harm by hot household appliances, initial encounter | Diagnosis | ICD-10-CM |
| X77.3XXD | Intentional self-harm by hot household appliances, subsequent encounter | Diagnosis | ICD-10-CM |
| X77.3XXS | Intentional self-harm by hot household appliances, sequela | Diagnosis | ICD-10-CM |
| X77.8 | Intentional self-harm by other hot objects | Diagnosis | ICD-10-CM |
| X77.8XXA | Intentional self-harm by other hot objects, initial encounter | Diagnosis | ICD-10-CM |
| X77.8XXD | Intentional self-harm by other hot objects, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| X77.8XXS | Intentional self-harm by other hot objects, sequela | Diagnosis | ICD-10-CM |
| X77.9 | Intentional self-harm by unspecified hot objects | Diagnosis | ICD-10-CM |
| X77.9XXA | Intentional self-harm by unspecified hot objects, initial encounter | Diagnosis | ICD-10-CM |
| X77.9XXD | Intentional self-harm by unspecified hot objects, subsequent encounter | Diagnosis | ICD-10-CM |
| X77.9XXS | Intentional self-harm by unspecified hot objects, sequela | Diagnosis | ICD-10-CM |
| X78 | Intentional self-harm by sharp object | Diagnosis | ICD-10-CM |
| X78.0 | Intentional self-harm by sharp glass | Diagnosis | ICD-10-CM |
| X78.0XXA | Intentional self-harm by sharp glass, initial encounter | Diagnosis | ICD-10-CM |
| X78.0XXD | Intentional self-harm by sharp glass, subsequent encounter | Diagnosis | ICD-10-CM |
| X78.0XXS | Intentional self-harm by sharp glass, sequela | Diagnosis | ICD-10-CM |
| X78.1 | Intentional self-harm by knife | Diagnosis | ICD-10-CM |
| X78.1XXA | Intentional self-harm by knife, initial encounter | Diagnosis | ICD-10-CM |
| X78.1XXD | Intentional self-harm by knife, subsequent encounter | Diagnosis | ICD-10-CM |
| X78.1XXS | Intentional self-harm by knife, sequela | Diagnosis | ICD-10-CM |
| X78.2 | Intentional self-harm by sword or dagger | Diagnosis | ICD-10-CM |
| X78.2XXA | Intentional self-harm by sword or dagger, initial encounter | Diagnosis | ICD-10-CM |
| X78.2XXD | Intentional self-harm by sword or dagger, subsequent encounter | Diagnosis | ICD-10-CM |
| X78.2XXS | Intentional self-harm by sword or dagger, sequela | Diagnosis | ICD-10-CM |
| X78.8 | Intentional self-harm by other sharp object | Diagnosis | ICD-10-CM |
| X78.8XXA | Intentional self-harm by other sharp object, initial encounter | Diagnosis | ICD-10-CM |
| X78.8XXD | Intentional self-harm by other sharp object, subsequent encounter | Diagnosis | ICD-10-CM |
| X78.8XXS | Intentional self-harm by other sharp object, sequela | Diagnosis | ICD-10-CM |
| X78.9 | Intentional self-harm by unspecified sharp object | Diagnosis | ICD-10-CM |
| X78.9XXA | Intentional self-harm by unspecified sharp object, initial encounter | Diagnosis | ICD-10-CM |
| X78.9XXD | Intentional self-harm by unspecified sharp object, subsequent encounter | Diagnosis | ICD-10-CM |
| X78.9XXS | Intentional self-harm by unspecified sharp object, sequela | Diagnosis | ICD-10-CM |
| X79 | Intentional self-harm by blunt object | Diagnosis | ICD-10-CM |
| X79.XXXA | Intentional self-harm by blunt object, initial encounter | Diagnosis | ICD-10-CM |
| X79.XXXD | Intentional self-harm by blunt object, subsequent encounter | Diagnosis | ICD-10-CM |
| X79.XXXS | Intentional self-harm by blunt object, sequela | Diagnosis | ICD-10-CM |
| X80 | Intentional self-harm by jumping from a high place | Diagnosis | ICD-10-CM |
| X80.XXXA | Intentional self-harm by jumping from a high place, initial encounter | Diagnosis | ICD-10-CM |
| X80.XXXD | Intentional self-harm by jumping from a high place, subsequent encounter | Diagnosis | ICD-10-CM |
| X80.XXXS | Intentional self-harm by jumping from a high place, sequela | Diagnosis | ICD-10-CM |
| X81 | Intentional self-harm by jumping or lying in front of moving object | Diagnosis | ICD-10-CM |
| X81.0 | Intentional self-harm by jumping or lying in front of motor vehicle | Diagnosis | ICD-10-CM |
| X81.0XXA | Intentional self-harm by jumping or lying in front of motor vehicle, initial encounter | Diagnosis | ICD-10-CM |
| X81.0XXD | Intentional self-harm by jumping or lying in front of motor vehicle, subsequent encounter | Diagnosis | ICD-10-CM |
| X81.0XXS | Intentional self-harm by jumping or lying in front of motor vehicle, sequela | Diagnosis | ICD-10-CM |
| X81.1 | Intentional self-harm by jumping or lying in front of (subway) train | Diagnosis | ICD-10-CM |
| X81.1XXA | Intentional self-harm by jumping or lying in front of (subway) train, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| X81.1XXD | Intentional self-harm by jumping or lying in front of (subway) train, subsequent encounter | Diagnosis | ICD-10-CM |
| X81.1XXS | Intentional self-harm by jumping or lying in front of (subway) train, sequela | Diagnosis | ICD-10-CM |
| X81.8 | Intentional self-harm by jumping or lying in front of other moving object | Diagnosis | ICD-10-CM |
| X81.8XXA | Intentional self-harm by jumping or lying in front of other moving object, initial encounter | Diagnosis | ICD-10-CM |
| X81.8XXD | Intentional self-harm by jumping or lying in front of other moving object, subsequent encounter | Diagnosis | ICD-10-CM |
| X81.8XXS | Intentional self-harm by jumping or lying in front of other moving object, sequela | Diagnosis | ICD-10-CM |
| X82 | Intentional self-harm by crashing of motor vehicle | Diagnosis | ICD-10-CM |
| X82.0 | Intentional collision of motor vehicle with other motor vehicle | Diagnosis | ICD-10-CM |
| X82.0XXA | Intentional collision of motor vehicle with other motor vehicle, initial | Diagnosis | ICD-10-CM |
| X82.0XXD | Intentional collision of motor vehicle with other motor vehicle, subsequent encounter | Diagnosis | ICD-10-CM |
| X82.0XXS | Intentional collision of motor vehicle with other motor vehicle, sequela | Diagnosis | ICD-10-CM |
| X82.1 | Intentional collision of motor vehicle with train | Diagnosis | ICD-10-CM |
| X82.1XXA | Intentional collision of motor vehicle with train, initial encounter | Diagnosis | ICD-10-CM |
| X82.1XXD | Intentional collision of motor vehicle with train, subsequent encounter | Diagnosis | ICD-10-CM |
| X82.1XXS | Intentional collision of motor vehicle with train, sequela | Diagnosis | ICD-10-CM |
| X82.2 | Intentional collision of motor vehicle with tree | Diagnosis | ICD-10-CM |
| X82.2XXA | Intentional collision of motor vehicle with tree, initial encounter | Diagnosis | ICD-10-CM |
| X82.2XXD | Intentional collision of motor vehicle with tree, subsequent encounter | Diagnosis | ICD-10-CM |
| X82.2XXS | Intentional collision of motor vehicle with tree, sequela | Diagnosis | ICD-10-CM |
| X82.8 | Other intentional self-harm by crashing of motor vehicle | Diagnosis | ICD-10-CM |
| X82.8XXA | Other intentional self-harm by crashing of motor vehicle, initial encounter | Diagnosis | ICD-10-CM |
| X82.8XXD | Other intentional self-harm by crashing of motor vehicle, subsequent | Diagnosis | ICD-10-CM |
| X82.8XXS | Other intentional self-harm by crashing of motor vehicle, sequela | Diagnosis | ICD-10-CM |
| X83 | Intentional self-harm by other specified means | Diagnosis | ICD-10-CM |
| X83.0 | Intentional self-harm by crashing of aircraft | Diagnosis | ICD-10-CM |
| X83.0XXA | Intentional self-harm by crashing of aircraft, initial encounter | Diagnosis | ICD-10-CM |
| X83.0XXD | Intentional self-harm by crashing of aircraft, subsequent encounter | Diagnosis | ICD-10-CM |
| X83.0XXS | Intentional self-harm by crashing of aircraft, sequela | Diagnosis | ICD-10-CM |
| X83.1 | Intentional self-harm by electrocution | Diagnosis | ICD-10-CM |
| X83.1XXA | Intentional self-harm by electrocution, initial encounter | Diagnosis | ICD-10-CM |
| X83.1XXD | Intentional self-harm by electrocution, subsequent encounter | Diagnosis | ICD-10-CM |
| X83.1XXS | Intentional self-harm by electrocution, sequela | Diagnosis | ICD-10-CM |
| X83.2 | Intentional self-harm by exposure to extremes of cold | Diagnosis | ICD-10-CM |
| X83.2XXA | Intentional self-harm by exposure to extremes of cold, initial encounter | Diagnosis | ICD-10-CM |
| X83.2XXD | Intentional self-harm by exposure to extremes of cold, subsequent encounter | Diagnosis | ICD-10-CM |
| X83.2XXS | Intentional self-harm by exposure to extremes of cold, sequela | Diagnosis | ICD-10-CM |
| X83.8 | Intentional self-harm by other specified means | Diagnosis | ICD-10-CM |
| X83.8XXA | Intentional self-harm by other specified means, initial encounter | Diagnosis | ICD-10-CM |
| X83.8XXD | Intentional self-harm by other specified means, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--|---|---------------|-----------|
| X83.8XXS | Intentional self-harm by other specified means, sequela | Diagnosis | ICD-10-CM |
| Encounter for Other Psychiatric Event | | | |
| 290.0 | Senile dementia, uncomplicated | Diagnosis | ICD-9-CM |
| 290.10 | Presenile dementia, uncomplicated | Diagnosis | ICD-9-CM |
| 290.11 | Presenile dementia with delirium | Diagnosis | ICD-9-CM |
| 290.12 | Presenile dementia with delusional features | Diagnosis | ICD-9-CM |
| 290.13 | Presenile dementia with depressive features | Diagnosis | ICD-9-CM |
| 290.20 | Senile dementia with delusional features | Diagnosis | ICD-9-CM |
| 290.21 | Senile dementia with depressive features | Diagnosis | ICD-9-CM |
| 290.3 | Senile dementia with delirium | Diagnosis | ICD-9-CM |
| 290.40 | Vascular dementia, uncomplicated | Diagnosis | ICD-9-CM |
| 290.41 | Vascular dementia, with delirium | Diagnosis | ICD-9-CM |
| 290.42 | Vascular dementia, with delusions | Diagnosis | ICD-9-CM |
| 290.43 | Vascular dementia, with depressed mood | Diagnosis | ICD-9-CM |
| 290.8 | Other specified senile psychotic conditions | Diagnosis | ICD-9-CM |
| 290.9 | Unspecified senile psychotic condition | Diagnosis | ICD-9-CM |
| 291 | Alcohol-induced mental disorders | Diagnosis | ICD-9-CM |
| 291.0 | Alcohol withdrawal delirium | Diagnosis | ICD-9-CM |
| 291.1 | Alcohol-induced persisting amnestic disorder | Diagnosis | ICD-9-CM |
| 291.2 | Alcohol-induced persisting dementia | Diagnosis | ICD-9-CM |
| 291.3 | Alcohol-induced psychotic disorder with hallucinations | Diagnosis | ICD-9-CM |
| 291.4 | Idiosyncratic alcohol intoxication | Diagnosis | ICD-9-CM |
| 291.5 | Alcohol-induced psychotic disorder with delusions | Diagnosis | ICD-9-CM |
| 291.8 | Other specified alcohol-induced mental disorders | Diagnosis | ICD-9-CM |
| 291.81 | Alcohol withdrawal | Diagnosis | ICD-9-CM |
| 291.82 | Alcohol induced sleep disorders | Diagnosis | ICD-9-CM |
| 291.89 | Other specified alcohol-induced mental disorders | Diagnosis | ICD-9-CM |
| 291.9 | Unspecified alcohol-induced mental disorders | Diagnosis | ICD-9-CM |
| 292 | Drug-induced mental disorders | Diagnosis | ICD-9-CM |
| 292.0 | Drug withdrawal | Diagnosis | ICD-9-CM |
| 292.1 | Drug-induced psychotic disorder | Diagnosis | ICD-9-CM |
| 292.11 | Drug-induced psychotic disorder with delusions | Diagnosis | ICD-9-CM |
| 292.12 | Drug-induced psychotic disorder with hallucinations | Diagnosis | ICD-9-CM |
| 292.2 | Pathological drug intoxication | Diagnosis | ICD-9-CM |
| 292.8 | Other specified drug-induced mental disorders | Diagnosis | ICD-9-CM |
| 292.81 | Drug-induced delirium | Diagnosis | ICD-9-CM |
| 292.82 | Drug-induced persisting dementia | Diagnosis | ICD-9-CM |
| 292.83 | Drug-induced persisting amnestic disorder | Diagnosis | ICD-9-CM |
| 292.84 | Drug-induced mood disorder | Diagnosis | ICD-9-CM |
| 292.85 | Drug induced sleep disorders | Diagnosis | ICD-9-CM |
| 292.89 | Other specified drug-induced mental disorder | Diagnosis | ICD-9-CM |
| 292.9 | Unspecified drug-induced mental disorder | Diagnosis | ICD-9-CM |
| 293 | Transient mental disorders due to conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 293.0 | Delirium due to conditions classified elsewhere | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| 293.1 | Subacute delirium | Diagnosis | ICD-9-CM |
| 293.8 | Other specified transient mental disorders due to conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 293.81 | Psychotic disorder with delusions in conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 293.82 | Psychotic disorder with hallucinations in conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 293.83 | Mood disorder in conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 293.84 | Anxiety disorder in conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 293.89 | Other transient mental disorders due to conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 293.9 | Unspecified transient mental disorder in conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 294 | Persistent mental disorders due to conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 294.0 | Amnestic disorder in conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 294.1 | Dementia in conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 294.10 | Dementia in conditions classified elsewhere without behavioral disturbance | Diagnosis | ICD-9-CM |
| 294.11 | Dementia in conditions classified elsewhere with behavioral disturbance | Diagnosis | ICD-9-CM |
| 294.2 | Dementia, unspecified | Diagnosis | ICD-9-CM |
| 294.20 | Dementia, unspecified, without behavioral disturbance | Diagnosis | ICD-9-CM |
| 294.21 | Dementia, unspecified, with behavioral disturbance | Diagnosis | ICD-9-CM |
| 294.8 | Other persistent mental disorders due to conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 294.9 | Unspecified persistent mental disorders due to conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 295 | Schizophrenic disorders | Diagnosis | ICD-9-CM |
| 295.0 | Simple type schizophrenia | Diagnosis | ICD-9-CM |
| 295.00 | Simple schizophrenia, unspecified condition | Diagnosis | ICD-9-CM |
| 295.01 | Simple schizophrenia, subchronic condition | Diagnosis | ICD-9-CM |
| 295.02 | Simple schizophrenia, chronic condition | Diagnosis | ICD-9-CM |
| 295.03 | Simple schizophrenia, subchronic condition with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.04 | Simple schizophrenia, chronic condition with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.05 | Simple schizophrenia, in remission | Diagnosis | ICD-9-CM |
| 295.1 | Disorganized type schizophrenia | Diagnosis | ICD-9-CM |
| 295.10 | Disorganized schizophrenia, unspecified condition | Diagnosis | ICD-9-CM |
| 295.11 | Disorganized schizophrenia, subchronic condition | Diagnosis | ICD-9-CM |
| 295.12 | Disorganized schizophrenia, chronic condition | Diagnosis | ICD-9-CM |
| 295.13 | Disorganized schizophrenia, subchronic condition with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.14 | Disorganized schizophrenia, chronic condition with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.15 | Disorganized schizophrenia, in remission | Diagnosis | ICD-9-CM |
| 295.2 | Catatonic type schizophrenia | Diagnosis | ICD-9-CM |
| 295.20 | Catatonic schizophrenia, unspecified condition | Diagnosis | ICD-9-CM |
| 295.21 | Catatonic schizophrenia, subchronic condition | Diagnosis | ICD-9-CM |
| 295.22 | Catatonic schizophrenia, chronic condition | Diagnosis | ICD-9-CM |
| 295.23 | Catatonic schizophrenia, subchronic condition with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.24 | Catatonic schizophrenia, chronic condition with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.25 | Catatonic schizophrenia, in remission | Diagnosis | ICD-9-CM |
| 295.3 | Paranoid type schizophrenia | Diagnosis | ICD-9-CM |
| 295.30 | Paranoid schizophrenia, unspecified condition | Diagnosis | ICD-9-CM |
| 295.31 | Paranoid schizophrenia, subchronic condition | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 295.32 | Paranoid schizophrenia, chronic condition | Diagnosis | ICD-9-CM |
| 295.33 | Paranoid schizophrenia, subchronic condition with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.34 | Paranoid schizophrenia, chronic condition with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.35 | Paranoid schizophrenia, in remission | Diagnosis | ICD-9-CM |
| 295.4 | Schizophreniform disorder | Diagnosis | ICD-9-CM |
| 295.40 | Schizophreniform disorder, unspecified | Diagnosis | ICD-9-CM |
| 295.41 | Schizophreniform disorder, subchronic | Diagnosis | ICD-9-CM |
| 295.42 | Schizophreniform disorder, chronic | Diagnosis | ICD-9-CM |
| 295.43 | Schizophreniform disorder, subchronic with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.44 | Schizophreniform disorder, chronic with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.45 | Schizophreniform disorder, in remission | Diagnosis | ICD-9-CM |
| 295.5 | Latent schizophrenia | Diagnosis | ICD-9-CM |
| 295.50 | Latent schizophrenia, unspecified condition | Diagnosis | ICD-9-CM |
| 295.51 | Latent schizophrenia, subchronic condition | Diagnosis | ICD-9-CM |
| 295.52 | Latent schizophrenia, chronic condition | Diagnosis | ICD-9-CM |
| 295.53 | Latent schizophrenia, subchronic condition with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.54 | Latent schizophrenia, chronic condition with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.55 | Latent schizophrenia, in remission | Diagnosis | ICD-9-CM |
| 295.6 | Schizophrenic disorders, residual type | Diagnosis | ICD-9-CM |
| 295.60 | Schizophrenic disorders, residual type, unspecified | Diagnosis | ICD-9-CM |
| 295.61 | Schizophrenic disorders, residual type, subchronic | Diagnosis | ICD-9-CM |
| 295.62 | Schizophrenic disorders, residual type, chronic | Diagnosis | ICD-9-CM |
| 295.63 | Schizophrenic disorders, residual type, subchronic with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.64 | Schizophrenic disorders, residual type, chronic with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.65 | Schizophrenic disorders, residual type, in remission | Diagnosis | ICD-9-CM |
| 295.7 | Schizoaffective disorder | Diagnosis | ICD-9-CM |
| 295.70 | Schizoaffective disorder, unspecified | Diagnosis | ICD-9-CM |
| 295.71 | Schizoaffective disorder, subchronic | Diagnosis | ICD-9-CM |
| 295.72 | Schizoaffective disorder, chronic | Diagnosis | ICD-9-CM |
| 295.73 | Schizoaffective disorder, subchronic with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.74 | Schizoaffective disorder, chronic with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.75 | Schizoaffective disorder, in remission | Diagnosis | ICD-9-CM |
| 295.8 | Other specified types of schizophrenia | Diagnosis | ICD-9-CM |
| 295.80 | Other specified types of schizophrenia, unspecified condition | Diagnosis | ICD-9-CM |
| 295.81 | Other specified types of schizophrenia, subchronic condition | Diagnosis | ICD-9-CM |
| 295.82 | Other specified types of schizophrenia, chronic condition | Diagnosis | ICD-9-CM |
| 295.83 | Other specified types of schizophrenia, subchronic condition with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.84 | Other specified types of schizophrenia, chronic condition with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.85 | Other specified types of schizophrenia, in remission | Diagnosis | ICD-9-CM |
| 295.9 | Unspecified schizophrenia | Diagnosis | ICD-9-CM |
| 295.90 | Unspecified schizophrenia, unspecified condition | Diagnosis | ICD-9-CM |
| 295.91 | Unspecified schizophrenia, subchronic condition | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| 295.92 | Unspecified schizophrenia, chronic condition | Diagnosis | ICD-9-CM |
| 295.93 | Unspecified schizophrenia, subchronic condition with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.94 | Unspecified schizophrenia, chronic condition with acute exacerbation | Diagnosis | ICD-9-CM |
| 295.95 | Unspecified schizophrenia, in remission | Diagnosis | ICD-9-CM |
| 296.0 | Bipolar I disorder, single manic episode | Diagnosis | ICD-9-CM |
| 296.00 | Bipolar I disorder, single manic episode, unspecified | Diagnosis | ICD-9-CM |
| 296.01 | Bipolar I disorder, single manic episode, mild | Diagnosis | ICD-9-CM |
| 296.02 | Bipolar I disorder, single manic episode, moderate | Diagnosis | ICD-9-CM |
| 296.03 | Bipolar I disorder, single manic episode, severe, without mention of psychotic behavior | Diagnosis | ICD-9-CM |
| 296.04 | Bipolar I disorder, single manic episode, severe, specified as with psychotic behavior | Diagnosis | ICD-9-CM |
| 296.05 | Bipolar I disorder, single manic episode, in partial or unspecified remission | Diagnosis | ICD-9-CM |
| 296.06 | Bipolar I disorder, single manic episode, in full remission | Diagnosis | ICD-9-CM |
| 296.1 | Manic disorder, recurrent episode | Diagnosis | ICD-9-CM |
| 296.10 | Manic disorder, recurrent episode, unspecified | Diagnosis | ICD-9-CM |
| 296.11 | Manic disorder, recurrent episode, mild | Diagnosis | ICD-9-CM |
| 296.12 | Manic disorder, recurrent episode, moderate | Diagnosis | ICD-9-CM |
| 296.13 | Manic disorder, recurrent episode, severe, without mention of psychotic behavior | Diagnosis | ICD-9-CM |
| 296.14 | Manic disorder, recurrent episode, severe, specified as with psychotic behavior | Diagnosis | ICD-9-CM |
| 296.15 | Manic disorder, recurrent episode, in partial or unspecified remission | Diagnosis | ICD-9-CM |
| 296.16 | Manic disorder, recurrent episode, in full remission | Diagnosis | ICD-9-CM |
| 296.2 | Major depressive disorder, single episode | Diagnosis | ICD-9-CM |
| 296.20 | Major depressive disorder, single episode, unspecified | Diagnosis | ICD-9-CM |
| 296.21 | Major depressive disorder, single episode, mild | Diagnosis | ICD-9-CM |
| 296.22 | Major depressive disorder, single episode, moderate | Diagnosis | ICD-9-CM |
| 296.23 | Major depressive disorder, single episode, severe, without mention of psychotic behavior | Diagnosis | ICD-9-CM |
| 296.24 | Major depressive disorder, single episode, severe, specified as with psychotic behavior | Diagnosis | ICD-9-CM |
| 296.25 | Major depressive disorder, single episode, in partial or unspecified remission | Diagnosis | ICD-9-CM |
| 296.26 | Major depressive disorder, single episode in full remission | Diagnosis | ICD-9-CM |
| 296.3 | Major depressive disorder, recurrent episode | Diagnosis | ICD-9-CM |
| 296.30 | Major depressive disorder, recurrent episode, unspecified | Diagnosis | ICD-9-CM |
| 296.31 | Major depressive disorder, recurrent episode, mild | Diagnosis | ICD-9-CM |
| 296.32 | Major depressive disorder, recurrent episode, moderate | Diagnosis | ICD-9-CM |
| 296.33 | Major depressive disorder, recurrent episode, severe, without mention of psychotic behavior | Diagnosis | ICD-9-CM |
| 296.34 | Major depressive disorder, recurrent episode, severe, specified as with psychotic behavior | Diagnosis | ICD-9-CM |
| 296.35 | Major depressive disorder, recurrent episode, in partial or unspecified | Diagnosis | ICD-9-CM |
| 296.36 | Major depressive disorder, recurrent episode, in full remission | Diagnosis | ICD-9-CM |
| 296.4 | Bipolar I disorder, most recent episode (or current) manic | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| 296.40 | Bipolar I disorder, most recent episode (or current) manic, unspecified | Diagnosis | ICD-9-CM |
| 296.41 | Bipolar I disorder, most recent episode (or current) manic, mild | Diagnosis | ICD-9-CM |
| 296.42 | Bipolar I disorder, most recent episode (or current) manic, moderate | Diagnosis | ICD-9-CM |
| 296.43 | Bipolar I disorder, most recent episode (or current) manic, severe, without mention of psychotic behavior | Diagnosis | ICD-9-CM |
| 296.44 | Bipolar I disorder, most recent episode (or current) manic, severe, specified as with psychotic behavior | Diagnosis | ICD-9-CM |
| 296.45 | Bipolar I disorder, most recent episode (or current) manic, in partial or unspecified remission | Diagnosis | ICD-9-CM |
| 296.46 | Bipolar I disorder, most recent episode (or current) manic, in full remission | Diagnosis | ICD-9-CM |
| 296.5 | Bipolar I disorder, most recent episode (or current), depressed | Diagnosis | ICD-9-CM |
| 296.50 | Bipolar I disorder, most recent episode (or current) depressed, unspecified | Diagnosis | ICD-9-CM |
| 296.51 | Bipolar I disorder, most recent episode (or current) depressed, mild | Diagnosis | ICD-9-CM |
| 296.52 | Bipolar I disorder, most recent episode (or current) depressed, moderate | Diagnosis | ICD-9-CM |
| 296.53 | Bipolar I disorder, most recent episode (or current) depressed, severe, without mention of psychotic behavior | Diagnosis | ICD-9-CM |
| 296.54 | Bipolar I disorder, most recent episode (or current) depressed, severe, specified as with psychotic behavior | Diagnosis | ICD-9-CM |
| 296.55 | Bipolar I disorder, most recent episode (or current) depressed, in partial or unspecified remission | Diagnosis | ICD-9-CM |
| 296.56 | Bipolar I disorder, most recent episode (or current) depressed, in full remission | Diagnosis | ICD-9-CM |
| 296.6 | Bipolar I disorder, most recent episode (or current), mixed | Diagnosis | ICD-9-CM |
| 296.60 | Bipolar I disorder, most recent episode (or current) mixed, unspecified | Diagnosis | ICD-9-CM |
| 296.61 | Bipolar I disorder, most recent episode (or current) mixed, mild | Diagnosis | ICD-9-CM |
| 296.62 | Bipolar I disorder, most recent episode (or current) mixed, moderate | Diagnosis | ICD-9-CM |
| 296.63 | Bipolar I disorder, most recent episode (or current) mixed, severe, without mention of psychotic behavior | Diagnosis | ICD-9-CM |
| 296.64 | Bipolar I disorder, most recent episode (or current) mixed, severe, specified as with psychotic behavior | Diagnosis | ICD-9-CM |
| 296.65 | Bipolar I disorder, most recent episode (or current) mixed, in partial or unspecified remission | Diagnosis | ICD-9-CM |
| 296.66 | Bipolar I disorder, most recent episode (or current) mixed, in full remission | Diagnosis | ICD-9-CM |
| 296.7 | Bipolar I disorder, most recent episode (or current) unspecified | Diagnosis | ICD-9-CM |
| 296.8 | Other and unspecified bipolar disorders | Diagnosis | ICD-9-CM |
| 296.80 | Bipolar disorder, unspecified | Diagnosis | ICD-9-CM |
| 296.81 | Atypical manic disorder | Diagnosis | ICD-9-CM |
| 296.82 | Atypical depressive disorder | Diagnosis | ICD-9-CM |
| 296.89 | Other and unspecified bipolar disorders | Diagnosis | ICD-9-CM |
| 296.90 | Unspecified episodic mood disorder | Diagnosis | ICD-9-CM |
| 296.99 | Other specified episodic mood disorder | Diagnosis | ICD-9-CM |
| 297 | Delusional disorders | Diagnosis | ICD-9-CM |
| 297.0 | Paranoid state, simple | Diagnosis | ICD-9-CM |
| 297.1 | Delusional disorder | Diagnosis | ICD-9-CM |
| 297.2 | Paraphrenia | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 297.3 | Shared psychotic disorder | Diagnosis | ICD-9-CM |
| 297.8 | Other specified paranoid states | Diagnosis | ICD-9-CM |
| 297.9 | Unspecified paranoid state | Diagnosis | ICD-9-CM |
| 298 | Other nonorganic psychoses | Diagnosis | ICD-9-CM |
| 298.0 | Depressive type psychosis | Diagnosis | ICD-9-CM |
| 298.1 | Excitatory type psychosis | Diagnosis | ICD-9-CM |
| 298.2 | Reactive confusion | Diagnosis | ICD-9-CM |
| 298.3 | Acute paranoid reaction | Diagnosis | ICD-9-CM |
| 298.4 | Psychogenic paranoid psychosis | Diagnosis | ICD-9-CM |
| 298.8 | Other and unspecified reactive psychosis | Diagnosis | ICD-9-CM |
| 298.9 | Unspecified psychosis | Diagnosis | ICD-9-CM |
| 299 | Pervasive developmental disorders | Diagnosis | ICD-9-CM |
| 299.0 | Autistic disorder | Diagnosis | ICD-9-CM |
| 299.00 | Autistic disorder, current or active state | Diagnosis | ICD-9-CM |
| 299.01 | Autistic disorder, residual state | Diagnosis | ICD-9-CM |
| 299.1 | Childhood disintegrative disorder | Diagnosis | ICD-9-CM |
| 299.10 | Childhood disintegrative disorder, current or active state | Diagnosis | ICD-9-CM |
| 299.11 | Childhood disintegrative disorder, residual state | Diagnosis | ICD-9-CM |
| 299.8 | Other specified pervasive developmental disorders | Diagnosis | ICD-9-CM |
| 299.80 | Other specified pervasive developmental disorders, current or active state | Diagnosis | ICD-9-CM |
| 299.81 | Other specified pervasive developmental disorders, residual state | Diagnosis | ICD-9-CM |
| 299.9 | Unspecified pervasive developmental disorder | Diagnosis | ICD-9-CM |
| 299.90 | Unspecified pervasive developmental disorder, current or active state | Diagnosis | ICD-9-CM |
| 299.91 | Unspecified pervasive developmental disorder, residual state | Diagnosis | ICD-9-CM |
| 300.0 | Anxiety states | Diagnosis | ICD-9-CM |
| 300.00 | Anxiety state, unspecified | Diagnosis | ICD-9-CM |
| 300.01 | Panic disorder without agoraphobia | Diagnosis | ICD-9-CM |
| 300.02 | Generalized anxiety disorder | Diagnosis | ICD-9-CM |
| 300.09 | Other anxiety states | Diagnosis | ICD-9-CM |
| 300.1 | Dissociative, conversion and factitious disorders | Diagnosis | ICD-9-CM |
| 300.10 | Hysteria, unspecified | Diagnosis | ICD-9-CM |
| 300.11 | Conversion disorder | Diagnosis | ICD-9-CM |
| 300.12 | Dissociative amnesia | Diagnosis | ICD-9-CM |
| 300.13 | Dissociative fugue | Diagnosis | ICD-9-CM |
| 300.14 | Dissociative identity disorder | Diagnosis | ICD-9-CM |
| 300.15 | Dissociative disorder or reaction, unspecified | Diagnosis | ICD-9-CM |
| 300.16 | Factitious disorder with predominantly psychological signs and symptoms | Diagnosis | ICD-9-CM |
| 300.19 | Other and unspecified factitious illness | Diagnosis | ICD-9-CM |
| 300.2 | Phobic disorders | Diagnosis | ICD-9-CM |
| 300.20 | Phobia, unspecified | Diagnosis | ICD-9-CM |
| 300.21 | Agoraphobia with panic disorder | Diagnosis | ICD-9-CM |
| 300.22 | Agoraphobia without mention of panic attacks | Diagnosis | ICD-9-CM |
| 300.23 | Social phobia | Diagnosis | ICD-9-CM |
| 300.29 | Other isolated or specific phobias | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| 300.3 | Obsessive-compulsive disorders | Diagnosis | ICD-9-CM |
| 300.4 | Dysthymic disorder | Diagnosis | ICD-9-CM |
| 300.5 | Neurasthenia | Diagnosis | ICD-9-CM |
| 300.6 | Depersonalization disorder | Diagnosis | ICD-9-CM |
| 300.7 | Hypochondriasis | Diagnosis | ICD-9-CM |
| 300.8 | Somatoform disorders | Diagnosis | ICD-9-CM |
| 300.81 | Somatization disorder | Diagnosis | ICD-9-CM |
| 300.82 | Undifferentiated somatoform disorder | Diagnosis | ICD-9-CM |
| 300.89 | Other somatoform disorders | Diagnosis | ICD-9-CM |
| 300.9 | Unspecified nonpsychotic mental disorder | Diagnosis | ICD-9-CM |
| 301 | Personality disorders | Diagnosis | ICD-9-CM |
| 301.0 | Paranoid personality disorder | Diagnosis | ICD-9-CM |
| 301.1 | Affective personality disorder | Diagnosis | ICD-9-CM |
| 301.10 | Affective personality disorder, unspecified | Diagnosis | ICD-9-CM |
| 301.11 | Chronic hypomanic personality disorder | Diagnosis | ICD-9-CM |
| 301.12 | Chronic depressive personality disorder | Diagnosis | ICD-9-CM |
| 301.13 | Cyclothymic disorder | Diagnosis | ICD-9-CM |
| 301.2 | Schizoid personality disorder | Diagnosis | ICD-9-CM |
| 301.20 | Schizoid personality disorder, unspecified | Diagnosis | ICD-9-CM |
| 301.21 | Introverted personality | Diagnosis | ICD-9-CM |
| 301.22 | Schizotypal personality disorder | Diagnosis | ICD-9-CM |
| 301.3 | Explosive personality disorder | Diagnosis | ICD-9-CM |
| 301.4 | Obsessive-compulsive personality disorder | Diagnosis | ICD-9-CM |
| 301.5 | Histrionic personality disorder | Diagnosis | ICD-9-CM |
| 301.50 | Histrionic personality disorder, unspecified | Diagnosis | ICD-9-CM |
| 301.51 | Chronic factitious illness with physical symptoms | Diagnosis | ICD-9-CM |
| 301.59 | Other histrionic personality disorder | Diagnosis | ICD-9-CM |
| 301.6 | Dependent personality disorder | Diagnosis | ICD-9-CM |
| 301.7 | Antisocial personality disorder | Diagnosis | ICD-9-CM |
| 301.8 | Other personality disorders | Diagnosis | ICD-9-CM |
| 301.81 | Narcissistic personality disorder | Diagnosis | ICD-9-CM |
| 301.82 | Avoidant personality disorder | Diagnosis | ICD-9-CM |
| 301.83 | Borderline personality disorder | Diagnosis | ICD-9-CM |
| 301.84 | Passive-aggressive personality | Diagnosis | ICD-9-CM |
| 301.89 | Other personality disorder | Diagnosis | ICD-9-CM |
| 301.9 | Unspecified personality disorder | Diagnosis | ICD-9-CM |
| 302 | Sexual and gender identity disorders | Diagnosis | ICD-9-CM |
| 302.0 | Ego-dystonic sexual orientation | Diagnosis | ICD-9-CM |
| 302.1 | Zoophilia | Diagnosis | ICD-9-CM |
| 302.2 | Pedophilia | Diagnosis | ICD-9-CM |
| 302.3 | Transvestic fetishism | Diagnosis | ICD-9-CM |
| 302.4 | Exhibitionism | Diagnosis | ICD-9-CM |
| 302.5 | Trans-sexualism | Diagnosis | ICD-9-CM |
| 302.50 | Trans-sexualism with unspecified sexual history | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| 302.51 | Trans-sexualism with asexual history | Diagnosis | ICD-9-CM |
| 302.52 | Trans-sexualism with homosexual history | Diagnosis | ICD-9-CM |
| 302.53 | Trans-sexualism with heterosexual history | Diagnosis | ICD-9-CM |
| 302.6 | Gender identity disorder in children | Diagnosis | ICD-9-CM |
| 302.7 | Psychosexual dysfunction | Diagnosis | ICD-9-CM |
| 302.70 | Psychosexual dysfunction, unspecified | Diagnosis | ICD-9-CM |
| 302.71 | Hypoactive sexual desire disorder | Diagnosis | ICD-9-CM |
| 302.72 | Psychosexual dysfunction with inhibited sexual excitement | Diagnosis | ICD-9-CM |
| 302.73 | Female orgasmic disorder | Diagnosis | ICD-9-CM |
| 302.74 | Male orgasmic disorder | Diagnosis | ICD-9-CM |
| 302.75 | Premature ejaculation | Diagnosis | ICD-9-CM |
| 302.76 | Dyspareunia, psychogenic | Diagnosis | ICD-9-CM |
| 302.79 | Psychosexual dysfunction with other specified psychosexual dysfunctions | Diagnosis | ICD-9-CM |
| 302.8 | Other specified psychosexual disorders | Diagnosis | ICD-9-CM |
| 302.81 | Fetishism | Diagnosis | ICD-9-CM |
| 302.82 | Voyeurism | Diagnosis | ICD-9-CM |
| 302.83 | Sexual masochism | Diagnosis | ICD-9-CM |
| 302.84 | Sexual sadism | Diagnosis | ICD-9-CM |
| 302.85 | Gender identity disorder in adolescents or adults | Diagnosis | ICD-9-CM |
| 302.89 | Other specified psychosexual disorder | Diagnosis | ICD-9-CM |
| 302.9 | Unspecified psychosexual disorder | Diagnosis | ICD-9-CM |
| 303 | Alcohol dependence syndrome | Diagnosis | ICD-9-CM |
| 303.0 | Acute alcoholic intoxication | Diagnosis | ICD-9-CM |
| 303.00 | Acute alcoholic intoxication, unspecified | Diagnosis | ICD-9-CM |
| 303.01 | Acute alcoholic intoxication, continuous | Diagnosis | ICD-9-CM |
| 303.02 | Acute alcoholic intoxication, episodic | Diagnosis | ICD-9-CM |
| 303.03 | Acute alcoholic intoxication, in remission | Diagnosis | ICD-9-CM |
| 303.9 | Other and unspecified alcohol dependence | Diagnosis | ICD-9-CM |
| 303.90 | Other and unspecified alcohol dependence, unspecified | Diagnosis | ICD-9-CM |
| 303.91 | Other and unspecified alcohol dependence, continuous | Diagnosis | ICD-9-CM |
| 303.92 | Other and unspecified alcohol dependence, episodic | Diagnosis | ICD-9-CM |
| 303.93 | Other and unspecified alcohol dependence, in remission | Diagnosis | ICD-9-CM |
| 304 | Drug dependence | Diagnosis | ICD-9-CM |
| 304.0 | Opioid type dependence | Diagnosis | ICD-9-CM |
| 304.00 | Opioid type dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.01 | Opioid type dependence, continuous | Diagnosis | ICD-9-CM |
| 304.02 | Opioid type dependence, episodic | Diagnosis | ICD-9-CM |
| 304.03 | Opioid type dependence, in remission | Diagnosis | ICD-9-CM |
| 304.1 | Sedative, hypnotic or anxiolytic dependence | Diagnosis | ICD-9-CM |
| 304.10 | Sedative, hypnotic or anxiolytic dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.11 | Sedative, hypnotic or anxiolytic dependence, continuous | Diagnosis | ICD-9-CM |
| 304.12 | Sedative, hypnotic or anxiolytic dependence, episodic | Diagnosis | ICD-9-CM |
| 304.13 | Sedative, hypnotic or anxiolytic dependence, in remission | Diagnosis | ICD-9-CM |
| 304.2 | Cocaine dependence | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| 304.20 | Cocaine dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.21 | Cocaine dependence, continuous | Diagnosis | ICD-9-CM |
| 304.22 | Cocaine dependence, episodic | Diagnosis | ICD-9-CM |
| 304.23 | Cocaine dependence, in remission | Diagnosis | ICD-9-CM |
| 304.3 | Cannabis dependence | Diagnosis | ICD-9-CM |
| 304.30 | Cannabis dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.31 | Cannabis dependence, continuous | Diagnosis | ICD-9-CM |
| 304.32 | Cannabis dependence, episodic | Diagnosis | ICD-9-CM |
| 304.33 | Cannabis dependence, in remission | Diagnosis | ICD-9-CM |
| 304.4 | Amphetamine and other psychostimulant dependence | Diagnosis | ICD-9-CM |
| 304.40 | Amphetamine and other psychostimulant dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.41 | Amphetamine and other psychostimulant dependence, continuous | Diagnosis | ICD-9-CM |
| 304.42 | Amphetamine and other psychostimulant dependence, episodic | Diagnosis | ICD-9-CM |
| 304.43 | Amphetamine and other psychostimulant dependence, in remission | Diagnosis | ICD-9-CM |
| 304.5 | Hallucinogen dependence | Diagnosis | ICD-9-CM |
| 304.50 | Hallucinogen dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.51 | Hallucinogen dependence, continuous | Diagnosis | ICD-9-CM |
| 304.52 | Hallucinogen dependence, episodic | Diagnosis | ICD-9-CM |
| 304.53 | Hallucinogen dependence, in remission | Diagnosis | ICD-9-CM |
| 304.6 | Other specified drug dependence | Diagnosis | ICD-9-CM |
| 304.60 | Other specified drug dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.61 | Other specified drug dependence, continuous | Diagnosis | ICD-9-CM |
| 304.62 | Other specified drug dependence, episodic | Diagnosis | ICD-9-CM |
| 304.63 | Other specified drug dependence, in remission | Diagnosis | ICD-9-CM |
| 304.7 | Combinations of opioid type drug with any other drug dependence | Diagnosis | ICD-9-CM |
| 304.70 | Combinations of opioid type drug with any other drug dependence, | Diagnosis | ICD-9-CM |
| 304.71 | Combinations of opioid type drug with any other drug dependence, | Diagnosis | ICD-9-CM |
| 304.72 | Combinations of opioid type drug with any other drug dependence, episodic | Diagnosis | ICD-9-CM |
| 304.73 | Combinations of opioid type drug with any other drug dependence, in | Diagnosis | ICD-9-CM |
| 304.8 | Combinations of drug dependence excluding opioid type drug | Diagnosis | ICD-9-CM |
| 304.80 | Combinations of drug dependence excluding opioid type drug, unspecified | Diagnosis | ICD-9-CM |
| 304.81 | Combinations of drug dependence excluding opioid type drug, continuous | Diagnosis | ICD-9-CM |
| 304.82 | Combinations of drug dependence excluding opioid type drug, episodic | Diagnosis | ICD-9-CM |
| 304.83 | Combinations of drug dependence excluding opioid type drug, in remission | Diagnosis | ICD-9-CM |
| 304.9 | Unspecified drug dependence | Diagnosis | ICD-9-CM |
| 304.90 | Unspecified drug dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.91 | Unspecified drug dependence, continuous | Diagnosis | ICD-9-CM |
| 304.92 | Unspecified drug dependence, episodic | Diagnosis | ICD-9-CM |
| 304.93 | Unspecified drug dependence, in remission | Diagnosis | ICD-9-CM |
| 305 | Nondependent abuse of drugs | Diagnosis | ICD-9-CM |
| 305.0 | Nondependent alcohol abuse | Diagnosis | ICD-9-CM |
| 305.00 | Nondependent alcohol abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.01 | Nondependent alcohol abuse, continuous | Diagnosis | ICD-9-CM |
| 305.02 | Nondependent alcohol abuse, episodic | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 305.03 | Nondependent alcohol abuse, in remission | Diagnosis | ICD-9-CM |
| 305.1 | Nondependent tobacco use disorder | Diagnosis | ICD-9-CM |
| 305.2 | Nondependent cannabis abuse | Diagnosis | ICD-9-CM |
| 305.20 | Nondependent cannabis abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.21 | Nondependent cannabis abuse, continuous | Diagnosis | ICD-9-CM |
| 305.22 | Nondependent cannabis abuse, episodic | Diagnosis | ICD-9-CM |
| 305.23 | Nondependent cannabis abuse, in remission | Diagnosis | ICD-9-CM |
| 305.3 | Nondependent hallucinogen abuse | Diagnosis | ICD-9-CM |
| 305.30 | Nondependent hallucinogen abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.31 | Nondependent hallucinogen abuse, continuous | Diagnosis | ICD-9-CM |
| 305.32 | Nondependent hallucinogen abuse, episodic | Diagnosis | ICD-9-CM |
| 305.33 | Nondependent hallucinogen abuse, in remission | Diagnosis | ICD-9-CM |
| 305.4 | Nondependent sedative, hypnotic or anxiolytic abuse | Diagnosis | ICD-9-CM |
| 305.40 | Nondependent sedative, hypnotic or anxiolytic abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.41 | Nondependent sedative hypnotic or anxiolytic abuse, continuous | Diagnosis | ICD-9-CM |
| 305.42 | Nondependent sedative, hypnotic or anxiolytic abuse, episodic | Diagnosis | ICD-9-CM |
| 305.43 | Nondependent sedative, hypnotic or anxiolytic abuse, in remission | Diagnosis | ICD-9-CM |
| 305.5 | Nondependent opioid abuse | Diagnosis | ICD-9-CM |
| 305.50 | Nondependent opioid abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.51 | Nondependent opioid abuse, continuous | Diagnosis | ICD-9-CM |
| 305.52 | Nondependent opioid abuse, episodic | Diagnosis | ICD-9-CM |
| 305.53 | Nondependent opioid abuse, in remission | Diagnosis | ICD-9-CM |
| 305.6 | Nondependent cocaine abuse | Diagnosis | ICD-9-CM |
| 305.60 | Nondependent cocaine abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.61 | Nondependent cocaine abuse, continuous | Diagnosis | ICD-9-CM |
| 305.62 | Nondependent cocaine abuse, episodic | Diagnosis | ICD-9-CM |
| 305.63 | Nondependent cocaine abuse, in remission | Diagnosis | ICD-9-CM |
| 305.7 | Nondependent amphetamine or related acting sympathomimetic abuse | Diagnosis | ICD-9-CM |
| 305.70 | Nondependent amphetamine or related acting sympathomimetic abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.71 | Nondependent amphetamine or related acting sympathomimetic abuse, continuous | Diagnosis | ICD-9-CM |
| 305.72 | Nondependent amphetamine or related acting sympathomimetic abuse, episodic | Diagnosis | ICD-9-CM |
| 305.73 | Nondependent amphetamine or related acting sympathomimetic abuse, in remission | Diagnosis | ICD-9-CM |
| 305.8 | Nondependent antidepressant type abuse | Diagnosis | ICD-9-CM |
| 305.80 | Nondependent antidepressant type abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.81 | Nondependent antidepressant type abuse, continuous | Diagnosis | ICD-9-CM |
| 305.82 | Nondependent antidepressant type abuse, episodic | Diagnosis | ICD-9-CM |
| 305.83 | Nondependent antidepressant type abuse, in remission | Diagnosis | ICD-9-CM |
| 305.9 | Other, mixed, or unspecified nondependent drug abuse | Diagnosis | ICD-9-CM |
| 305.90 | Other, mixed, or unspecified nondependent drug abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.91 | Other, mixed, or unspecified nondependent drug abuse, continuous | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 305.92 | Other, mixed, or unspecified nondependent drug abuse, episodic | Diagnosis | ICD-9-CM |
| 305.93 | Other, mixed, or unspecified nondependent drug abuse, in remission | Diagnosis | ICD-9-CM |
| 306 | Physiological malfunction arising from mental factors | Diagnosis | ICD-9-CM |
| 306.0 | Musculoskeletal malfunction arising from mental factors | Diagnosis | ICD-9-CM |
| 306.1 | Respiratory malfunction arising from mental factors | Diagnosis | ICD-9-CM |
| 306.2 | Cardiovascular malfunction arising from mental factors | Diagnosis | ICD-9-CM |
| 306.3 | Skin malfunction arising from mental factors | Diagnosis | ICD-9-CM |
| 306.4 | Gastrointestinal malfunction arising from mental factors | Diagnosis | ICD-9-CM |
| 306.5 | Genitourinary malfunctions arising from mental factors | Diagnosis | ICD-9-CM |
| 306.50 | Psychogenic genitourinary malfunction, unspecified | Diagnosis | ICD-9-CM |
| 306.51 | Psychogenic vaginismus | Diagnosis | ICD-9-CM |
| 306.52 | Psychogenic dysmenorrhea | Diagnosis | ICD-9-CM |
| 306.53 | Psychogenic dysuria | Diagnosis | ICD-9-CM |
| 306.59 | Other genitourinary malfunction arising from mental factors | Diagnosis | ICD-9-CM |
| 306.6 | Endocrine malfunction arising from mental factors | Diagnosis | ICD-9-CM |
| 306.7 | Malfunction of organs of special sense arising from mental factors | Diagnosis | ICD-9-CM |
| 306.8 | Other specified psychophysiological malfunction | Diagnosis | ICD-9-CM |
| 306.9 | Unspecified psychophysiological malfunction | Diagnosis | ICD-9-CM |
| 307 | Special symptoms or syndromes, not elsewhere classified | Diagnosis | ICD-9-CM |
| 307.0 | Adult onset fluency disorder | Diagnosis | ICD-9-CM |
| 307.1 | Anorexia nervosa | Diagnosis | ICD-9-CM |
| 307.2 | Tics | Diagnosis | ICD-9-CM |
| 307.20 | Tic disorder, unspecified | Diagnosis | ICD-9-CM |
| 307.21 | Transient tic disorder | Diagnosis | ICD-9-CM |
| 307.22 | Chronic motor or vocal tic disorder | Diagnosis | ICD-9-CM |
| 307.23 | Tourette's disorder | Diagnosis | ICD-9-CM |
| 307.3 | Stereotypic movement disorder | Diagnosis | ICD-9-CM |
| 307.4 | Specific disorders of sleep of nonorganic origin | Diagnosis | ICD-9-CM |
| 307.40 | Nonorganic sleep disorder, unspecified | Diagnosis | ICD-9-CM |
| 307.41 | Transient disorder of initiating or maintaining sleep | Diagnosis | ICD-9-CM |
| 307.42 | Persistent disorder of initiating or maintaining sleep | Diagnosis | ICD-9-CM |
| 307.43 | Transient disorder of initiating or maintaining wakefulness | Diagnosis | ICD-9-CM |
| 307.44 | Persistent disorder of initiating or maintaining wakefulness | Diagnosis | ICD-9-CM |
| 307.45 | Circadian rhythm sleep disorder of nonorganic origin | Diagnosis | ICD-9-CM |
| 307.46 | Sleep arousal disorder | Diagnosis | ICD-9-CM |
| 307.47 | Other dysfunctions of sleep stages or arousal from sleep | Diagnosis | ICD-9-CM |
| 307.48 | Repetitive intrusions of sleep | Diagnosis | ICD-9-CM |
| 307.49 | Other specific disorder of sleep of nonorganic origin | Diagnosis | ICD-9-CM |
| 307.5 | Other and unspecified disorders of eating | Diagnosis | ICD-9-CM |
| 307.50 | Eating disorder, unspecified | Diagnosis | ICD-9-CM |
| 307.51 | Bulimia nervosa | Diagnosis | ICD-9-CM |
| 307.52 | Pica | Diagnosis | ICD-9-CM |
| 307.53 | Rumination disorder | Diagnosis | ICD-9-CM |
| 307.54 | Psychogenic vomiting | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 307.59 | Other disorder of eating | Diagnosis | ICD-9-CM |
| 307.6 | Enuresis | Diagnosis | ICD-9-CM |
| 307.7 | Encopresis | Diagnosis | ICD-9-CM |
| 307.8 | Pain disorders related to psychological factors | Diagnosis | ICD-9-CM |
| 307.80 | Psychogenic pain, site unspecified | Diagnosis | ICD-9-CM |
| 307.81 | Tension headache | Diagnosis | ICD-9-CM |
| 307.89 | Other pain disorder related to psychological factors | Diagnosis | ICD-9-CM |
| 307.9 | Other and unspecified special symptom or syndrome, not elsewhere classified | Diagnosis | ICD-9-CM |
| 308 | Acute reaction to stress | Diagnosis | ICD-9-CM |
| 308.0 | Predominant disturbance of emotions | Diagnosis | ICD-9-CM |
| 308.1 | Predominant disturbance of consciousness as reaction to stress | Diagnosis | ICD-9-CM |
| 308.2 | Predominant psychomotor disturbance as reaction to stress | Diagnosis | ICD-9-CM |
| 308.3 | Other acute reactions to stress | Diagnosis | ICD-9-CM |
| 308.4 | Mixed disorders as reaction to stress | Diagnosis | ICD-9-CM |
| 308.9 | Unspecified acute reaction to stress | Diagnosis | ICD-9-CM |
| 309.0 | Adjustment disorder with depressed mood | Diagnosis | ICD-9-CM |
| 309.1 | Prolonged depressive reaction as adjustment reaction | Diagnosis | ICD-9-CM |
| 309.2 | Predominant disturbance of other emotions as adjustment reaction | Diagnosis | ICD-9-CM |
| 309.21 | Separation anxiety disorder | Diagnosis | ICD-9-CM |
| 309.22 | Emancipation disorder of adolescence and early adult life | Diagnosis | ICD-9-CM |
| 309.23 | Specific academic or work inhibition as adjustment reaction | Diagnosis | ICD-9-CM |
| 309.24 | Adjustment disorder with anxiety | Diagnosis | ICD-9-CM |
| 309.28 | Adjustment disorder with mixed anxiety and depressed mood | Diagnosis | ICD-9-CM |
| 309.29 | Other adjustment reaction with predominant disturbance of other emotions | Diagnosis | ICD-9-CM |
| 309.3 | Adjustment disorder with disturbance of conduct | Diagnosis | ICD-9-CM |
| 309.4 | Adjustment disorder with mixed disturbance of emotions and conduct | Diagnosis | ICD-9-CM |
| 309.8 | Other specified adjustment reactions | Diagnosis | ICD-9-CM |
| 309.81 | Posttraumatic stress disorder | Diagnosis | ICD-9-CM |
| 309.82 | Adjustment reaction with physical symptoms | Diagnosis | ICD-9-CM |
| 309.83 | Adjustment reaction with withdrawal | Diagnosis | ICD-9-CM |
| 309.89 | Other specified adjustment reaction | Diagnosis | ICD-9-CM |
| 309.9 | Unspecified adjustment reaction | Diagnosis | ICD-9-CM |
| 310 | Specific nonpsychotic mental disorders due to brain damage | Diagnosis | ICD-9-CM |
| 310.0 | Frontal lobe syndrome | Diagnosis | ICD-9-CM |
| 310.1 | Personality change due to conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 310.2 | Postconcussion syndrome | Diagnosis | ICD-9-CM |
| 310.8 | Other specified nonpsychotic mental disorder following organic brain damage | Diagnosis | ICD-9-CM |
| 310.81 | Pseudobulbar affect | Diagnosis | ICD-9-CM |
| 310.89 | Other specified nonpsychotic mental disorders following organic brain damage | Diagnosis | ICD-9-CM |
| 310.9 | Unspecified nonpsychotic mental disorder following organic brain damage | Diagnosis | ICD-9-CM |
| 311 | Depressive disorder, not elsewhere classified | Diagnosis | ICD-9-CM |
| 312 | Disturbance of conduct, not elsewhere classified | Diagnosis | ICD-9-CM |
| 312.0 | Undersocialized conduct disorder, aggressive type | Diagnosis | ICD-9-CM |
| 312.00 | Undersocialized conduct disorder, aggressive type, unspecified | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 312.01 | Undersocialized conduct disorder, aggressive type, mild | Diagnosis | ICD-9-CM |
| 312.02 | Undersocialized conduct disorder, aggressive type, moderate | Diagnosis | ICD-9-CM |
| 312.03 | Undersocialized conduct disorder, aggressive type, severe | Diagnosis | ICD-9-CM |
| 312.1 | Undersocialized conduct disorder, unaggressive type | Diagnosis | ICD-9-CM |
| 312.10 | Undersocialized conduct disorder, unaggressive type, unspecified | Diagnosis | ICD-9-CM |
| 312.11 | Undersocialized conduct disorder, unaggressive type, mild | Diagnosis | ICD-9-CM |
| 312.12 | Undersocialized conduct disorder, unaggressive type, moderate | Diagnosis | ICD-9-CM |
| 312.13 | Undersocialized conduct disorder, unaggressive type, severe | Diagnosis | ICD-9-CM |
| 312.2 | Socialized conduct disorder | Diagnosis | ICD-9-CM |
| 312.20 | Socialized conduct disorder, unspecified | Diagnosis | ICD-9-CM |
| 312.21 | Socialized conduct disorder, mild | Diagnosis | ICD-9-CM |
| 312.22 | Socialized conduct disorder, moderate | Diagnosis | ICD-9-CM |
| 312.23 | Socialized conduct disorder, severe | Diagnosis | ICD-9-CM |
| 312.3 | Disorders of impulse control, not elsewhere classified | Diagnosis | ICD-9-CM |
| 312.30 | Impulse control disorder, unspecified | Diagnosis | ICD-9-CM |
| 312.31 | Pathological gambling | Diagnosis | ICD-9-CM |
| 312.32 | Kleptomania | Diagnosis | ICD-9-CM |
| 312.33 | Pyromania | Diagnosis | ICD-9-CM |
| 312.34 | Intermittent explosive disorder | Diagnosis | ICD-9-CM |
| 312.35 | Isolated explosive disorder | Diagnosis | ICD-9-CM |
| 312.39 | Other disorder of impulse control | Diagnosis | ICD-9-CM |
| 312.4 | Mixed disturbance of conduct and emotions | Diagnosis | ICD-9-CM |
| 312.8 | Other specified disturbances of conduct, not elsewhere classified | Diagnosis | ICD-9-CM |
| 312.81 | Conduct disorder, childhood onset type | Diagnosis | ICD-9-CM |
| 312.82 | Conduct disorder, adolescent onset type | Diagnosis | ICD-9-CM |
| 312.89 | Other specified disturbance of conduct, not elsewhere classified | Diagnosis | ICD-9-CM |
| 312.9 | Unspecified disturbance of conduct | Diagnosis | ICD-9-CM |
| 313 | Disturbance of emotions specific to childhood and adolescence | Diagnosis | ICD-9-CM |
| 313.0 | Overanxious disorder specific to childhood and adolescence | Diagnosis | ICD-9-CM |
| 313.1 | Misery and unhappiness disorder specific to childhood and adolescence | Diagnosis | ICD-9-CM |
| 313.2 | Sensitivity, shyness, and social withdrawal disorder specific to childhood and adolescence | Diagnosis | ICD-9-CM |
| 313.21 | Shyness disorder of childhood | Diagnosis | ICD-9-CM |
| 313.22 | Introverted disorder of childhood | Diagnosis | ICD-9-CM |
| 313.23 | Selective mutism | Diagnosis | ICD-9-CM |
| 313.3 | Relationship problems specific to childhood and adolescence | Diagnosis | ICD-9-CM |
| 313.8 | Other or mixed emotional disturbances of childhood or adolescence | Diagnosis | ICD-9-CM |
| 313.81 | Oppositional defiant disorder | Diagnosis | ICD-9-CM |
| 313.82 | Identity disorder of childhood or adolescence | Diagnosis | ICD-9-CM |
| 313.83 | Academic underachievement disorder of childhood or adolescence | Diagnosis | ICD-9-CM |
| 313.89 | Other emotional disturbance of childhood or adolescence | Diagnosis | ICD-9-CM |
| 313.9 | Unspecified emotional disturbance of childhood or adolescence | Diagnosis | ICD-9-CM |
| 314 | Hyperkinetic syndrome of childhood | Diagnosis | ICD-9-CM |
| 314.0 | Attention deficit disorder of childhood | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 314.00 | Attention deficit disorder of childhood without mention of hyperactivity | Diagnosis | ICD-9-CM |
| 314.01 | Attention deficit disorder of childhood with hyperactivity | Diagnosis | ICD-9-CM |
| 314.1 | Hyperkinesis of childhood with developmental delay | Diagnosis | ICD-9-CM |
| 314.2 | Hyperkinetic conduct disorder of childhood | Diagnosis | ICD-9-CM |
| 314.8 | Other specified manifestations of hyperkinetic syndrome of childhood | Diagnosis | ICD-9-CM |
| 314.9 | Unspecified hyperkinetic syndrome of childhood | Diagnosis | ICD-9-CM |
| 315 | Specific delays in development | Diagnosis | ICD-9-CM |
| 315.0 | Specific developmental reading disorder | Diagnosis | ICD-9-CM |
| 315.00 | Developmental reading disorder, unspecified | Diagnosis | ICD-9-CM |
| 315.01 | Alexia | Diagnosis | ICD-9-CM |
| 315.02 | Developmental dyslexia | Diagnosis | ICD-9-CM |
| 315.09 | Other specific developmental reading disorder | Diagnosis | ICD-9-CM |
| 315.1 | Mathematics disorder | Diagnosis | ICD-9-CM |
| 315.2 | Other specific developmental learning difficulties | Diagnosis | ICD-9-CM |
| 315.3 | Developmental speech or language disorder | Diagnosis | ICD-9-CM |
| 315.31 | Expressive language disorder | Diagnosis | ICD-9-CM |
| 315.32 | Mixed receptive-expressive language disorder | Diagnosis | ICD-9-CM |
| 315.34 | Speech and language developmental delay due to hearing loss | Diagnosis | ICD-9-CM |
| 315.35 | Childhood onset fluency disorder | Diagnosis | ICD-9-CM |
| 315.39 | Other developmental speech or language disorder | Diagnosis | ICD-9-CM |
| 315.4 | Developmental coordination disorder | Diagnosis | ICD-9-CM |
| 315.5 | Mixed development disorder | Diagnosis | ICD-9-CM |
| 315.8 | Other specified delay in development | Diagnosis | ICD-9-CM |
| 315.9 | Unspecified delay in development | Diagnosis | ICD-9-CM |
| 316 | Psychic factors associated with diseases classified elsewhere | Diagnosis | ICD-9-CM |
| 317 | Mild intellectual disabilities | Diagnosis | ICD-9-CM |
| 318.0 | Moderate intellectual disabilities | Diagnosis | ICD-9-CM |
| 318.1 | Severe intellectual disabilities | Diagnosis | ICD-9-CM |
| 318.2 | Profound intellectual disabilities | Diagnosis | ICD-9-CM |
| 319 | Unspecified intellectual disabilities | Diagnosis | ICD-9-CM |
| 327 | Organic sleep disorders | Diagnosis | ICD-9-CM |
| 327.0 | Organic disorders of initiating and maintaining sleep [Organic insomnia] | Diagnosis | ICD-9-CM |
| 327.00 | Organic insomnia, unspecified | Diagnosis | ICD-9-CM |
| 327.01 | Insomnia due to medical condition classified elsewhere | Diagnosis | ICD-9-CM |
| 327.02 | Insomnia due to mental disorder | Diagnosis | ICD-9-CM |
| 327.09 | Other organic insomnia | Diagnosis | ICD-9-CM |
| 327.1 | Organic disorders of excessive somnolence [Organic hypersomnia] | Diagnosis | ICD-9-CM |
| 327.10 | Organic hypersomnia, unspecified | Diagnosis | ICD-9-CM |
| 327.11 | Idiopathic hypersomnia with long sleep time | Diagnosis | ICD-9-CM |
| 327.12 | Idiopathic hypersomnia without long sleep time | Diagnosis | ICD-9-CM |
| 327.13 | Recurrent hypersomnia | Diagnosis | ICD-9-CM |
| 327.14 | Hypersomnia due to medical condition classified elsewhere | Diagnosis | ICD-9-CM |
| 327.15 | Hypersomnia due to mental disorder | Diagnosis | ICD-9-CM |
| 327.19 | Other organic hypersomnia | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 327.2 | Organic sleep apnea | Diagnosis | ICD-9-CM |
| 327.20 | Organic sleep apnea, unspecified | Diagnosis | ICD-9-CM |
| 327.21 | Primary central sleep apnea | Diagnosis | ICD-9-CM |
| 327.23 | Obstructive sleep apnea (adult) (pediatric) | Diagnosis | ICD-9-CM |
| 327.24 | Idiopathic sleep related nonobstructive alveolar hypoventilation | Diagnosis | ICD-9-CM |
| 327.25 | Congenital central alveolar hypoventilation syndrome | Diagnosis | ICD-9-CM |
| 327.26 | Sleep related hypoventilation/hypoxemia in conditions classifiable elsewhere | Diagnosis | ICD-9-CM |
| 327.27 | Central sleep apnea in conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 327.29 | Other organic sleep apnea | Diagnosis | ICD-9-CM |
| 327.3 | Circadian rhythm sleep disorder | Diagnosis | ICD-9-CM |
| 327.30 | Circadian rhythm sleep disorder, unspecified | Diagnosis | ICD-9-CM |
| 327.31 | Circadian rhythm sleep disorder, delayed sleep phase type | Diagnosis | ICD-9-CM |
| 327.32 | Circadian rhythm sleep disorder, advanced sleep phase type | Diagnosis | ICD-9-CM |
| 327.33 | Circadian rhythm sleep disorder, irregular sleep-wake type | Diagnosis | ICD-9-CM |
| 327.34 | Circadian rhythm sleep disorder, free-running type | Diagnosis | ICD-9-CM |
| 327.35 | Circadian rhythm sleep disorder, jet lag type | Diagnosis | ICD-9-CM |
| 327.36 | Circadian rhythm sleep disorder, shift work type | Diagnosis | ICD-9-CM |
| 327.37 | Circadian rhythm sleep disorder in conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 327.39 | Other circadian rhythm sleep disorder | Diagnosis | ICD-9-CM |
| 327.4 | Organic parasomnia | Diagnosis | ICD-9-CM |
| 327.40 | Organic parasomnia, unspecified | Diagnosis | ICD-9-CM |
| 327.41 | Confusional arousals | Diagnosis | ICD-9-CM |
| 327.42 | REM sleep behavior disorder | Diagnosis | ICD-9-CM |
| 327.43 | Recurrent isolated sleep paralysis | Diagnosis | ICD-9-CM |
| 327.44 | Parasomnia in conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 327.49 | Other organic parasomnia | Diagnosis | ICD-9-CM |
| 327.5 | Organic sleep related movement disorders | Diagnosis | ICD-9-CM |
| 327.51 | Periodic limb movement disorder | Diagnosis | ICD-9-CM |
| 327.52 | Sleep related leg cramps | Diagnosis | ICD-9-CM |
| 327.53 | Sleep related bruxism | Diagnosis | ICD-9-CM |
| 327.59 | Other organic sleep related movement disorders | Diagnosis | ICD-9-CM |
| 327.8 | Other organic sleep disorders | Diagnosis | ICD-9-CM |
| 330 | Cerebral degenerations usually manifest in childhood | Diagnosis | ICD-9-CM |
| 330.0 | Leukodystrophy | Diagnosis | ICD-9-CM |
| 330.1 | Cerebral lipidoses | Diagnosis | ICD-9-CM |
| 330.2 | Cerebral degeneration in generalized lipidoses | Diagnosis | ICD-9-CM |
| 330.3 | Cerebral degeneration of childhood in other diseases classified elsewhere | Diagnosis | ICD-9-CM |
| 330.8 | Other specified cerebral degenerations in childhood | Diagnosis | ICD-9-CM |
| 330.9 | Unspecified cerebral degeneration in childhood | Diagnosis | ICD-9-CM |
| 331 | Other cerebral degenerations | Diagnosis | ICD-9-CM |
| 331.0 | Alzheimer's disease | Diagnosis | ICD-9-CM |
| 331.1 | Frontotemporal dementia | Diagnosis | ICD-9-CM |
| 331.11 | Pick's disease | Diagnosis | ICD-9-CM |
| 331.19 | Other frontotemporal dementia | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| 331.2 | Senile degeneration of brain | Diagnosis | ICD-9-CM |
| 331.3 | Communicating hydrocephalus | Diagnosis | ICD-9-CM |
| 331.4 | Obstructive hydrocephalus | Diagnosis | ICD-9-CM |
| 331.5 | Idiopathic normal pressure hydrocephalus [INPH] | Diagnosis | ICD-9-CM |
| 331.6 | Corticobasal degeneration | Diagnosis | ICD-9-CM |
| 331.7 | Cerebral degeneration in diseases classified elsewhere | Diagnosis | ICD-9-CM |
| 331.8 | Other cerebral degeneration | Diagnosis | ICD-9-CM |
| 331.81 | Reye's syndrome | Diagnosis | ICD-9-CM |
| 331.82 | Dementia with Lewy bodies | Diagnosis | ICD-9-CM |
| 331.83 | Mild cognitive impairment, so stated | Diagnosis | ICD-9-CM |
| 331.89 | Other cerebral degeneration | Diagnosis | ICD-9-CM |
| 331.9 | Unspecified cerebral degeneration | Diagnosis | ICD-9-CM |
| 333.99 | Other extrapyramidal disease and abnormal movement disorder | Diagnosis | ICD-9-CM |
| 347 | Cataplexy and narcolepsy | Diagnosis | ICD-9-CM |
| 347.0 | Narcolepsy | Diagnosis | ICD-9-CM |
| 347.00 | Narcolepsy, without cataplexy | Diagnosis | ICD-9-CM |
| 347.01 | Narcolepsy, with cataplexy | Diagnosis | ICD-9-CM |
| 347.1 | Narcolepsy in conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 347.10 | Narcolepsy in conditions classified elsewhere, without cataplexy | Diagnosis | ICD-9-CM |
| 347.11 | Narcolepsy in conditions classified elsewhere, with cataplexy | Diagnosis | ICD-9-CM |
| 348.3 | Encephalopathy, not elsewhere classified | Diagnosis | ICD-9-CM |
| 348.30 | Encephalopathy, unspecified | Diagnosis | ICD-9-CM |
| 348.31 | Metabolic encephalopathy | Diagnosis | ICD-9-CM |
| 348.39 | Other encephalopathy | Diagnosis | ICD-9-CM |
| 357.5 | Alcoholic polyneuropathy | Diagnosis | ICD-9-CM |
| 425.5 | Alcoholic cardiomyopathy | Diagnosis | ICD-9-CM |
| 4320F | Patient counseled regarding psychosocial and pharmacologic treatment options for alcohol dependence (SUD) | Procedure | CPT-2 |
| 535.3 | Alcoholic gastritis | Diagnosis | ICD-9-CM |
| 535.30 | Alcoholic gastritis without mention of hemorrhage | Diagnosis | ICD-9-CM |
| 535.31 | Alcoholic gastritis with hemorrhage | Diagnosis | ICD-9-CM |
| 571.0 | Alcoholic fatty liver | Diagnosis | ICD-9-CM |
| 571.1 | Acute alcoholic hepatitis | Diagnosis | ICD-9-CM |
| 571.2 | Alcoholic cirrhosis of liver | Diagnosis | ICD-9-CM |
| 571.3 | Unspecified alcoholic liver damage | Diagnosis | ICD-9-CM |
| 61885 | Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to a single electrode | Procedure | CPT-4 |
| 61886 | Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to 2 or more electrode | Procedure | CPT-4 |
| 61888 | Revision or removal of cranial neurostimulator pulse generator or receiver | Procedure | CPT-4 |
| 625.4 | Premenstrual tension syndromes | Diagnosis | ICD-9-CM |
| 64553 | Percutaneous implantation of neurostimulator electrode array; cranial nerve | Procedure | CPT-4 |
| 64568 | Open implantation of cranial nerve (eg, vagus nerve) neurostimulator electrode array and pulse generator | Procedure | CPT-4 |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 64569 | Revision or replacement of cranial nerve (eg, vagus nerve) neurostimulator electrode array, including connection to existing pulse generator | Procedure | CPT-4 |
| 64570 | Removal of cranial nerve (eg, vagus nerve) neurostimulator electrode array and pulse generator | Procedure | CPT-4 |
| 64585 | Revision or removal of peripheral neurostimulator electrode array | Procedure | CPT-4 |
| 648.30 | Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, unspecified as to episode of care | Diagnosis | ICD-9-CM |
| 648.31 | Maternal drug dependence, with delivery | Diagnosis | ICD-9-CM |
| 648.32 | Maternal drug dependence, with delivery, with current postpartum complication | Diagnosis | ICD-9-CM |
| 648.33 | Maternal drug dependence, antepartum | Diagnosis | ICD-9-CM |
| 648.34 | Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, postpartum condition or complication | Diagnosis | ICD-9-CM |
| 648.40 | Maternal mental disorders, complicating pregnancy, childbirth, or the puerperium, unspecified as to episode of care | Diagnosis | ICD-9-CM |
| 648.41 | Maternal mental disorders, with delivery | Diagnosis | ICD-9-CM |
| 648.42 | Maternal mental disorders, with delivery, with current postpartum complication | Diagnosis | ICD-9-CM |
| 648.43 | Maternal mental disorders, antepartum | Diagnosis | ICD-9-CM |
| 648.44 | Maternal mental disorders complicating pregnancy, childbirth, or the puerperium, postpartum condition or complication | Diagnosis | ICD-9-CM |
| 655.50 | Suspected damage to fetus from drugs, affecting management of mother, unspecified as to episode of care | Diagnosis | ICD-9-CM |
| 655.51 | Suspected damage to fetus from drugs, affecting management of mother, delivered | Diagnosis | ICD-9-CM |
| 655.53 | Suspected damage to fetus from drugs, affecting management of mother, antepartum | Diagnosis | ICD-9-CM |
| 760.71 | Noxious influences affecting fetus or newborn via placenta or breast milk, alcohol | Diagnosis | ICD-9-CM |
| 760.72 | Noxious influences affecting fetus or newborn via placenta or breast milk, narcotics | Diagnosis | ICD-9-CM |
| 760.73 | Noxious influences affecting fetus or newborn via placenta or breast milk, hallucinogenic agents | Diagnosis | ICD-9-CM |
| 760.75 | Noxious influences affecting fetus or newborn via placenta or breast milk, cocaine | Diagnosis | ICD-9-CM |
| 779.5 | Drug withdrawal syndrome in newborn | Diagnosis | ICD-9-CM |
| 780.1 | Hallucinations | Diagnosis | ICD-9-CM |
| 780.5 | Sleep disturbances | Diagnosis | ICD-9-CM |
| 780.50 | Unspecified sleep disturbance | Diagnosis | ICD-9-CM |
| 780.51 | Insomnia with sleep apnea, unspecified | Diagnosis | ICD-9-CM |
| 780.52 | Insomnia, unspecified | Diagnosis | ICD-9-CM |
| 780.53 | Hypersomnia with sleep apnea, unspecified | Diagnosis | ICD-9-CM |
| 780.54 | Hypersomnia, unspecified | Diagnosis | ICD-9-CM |
| 780.55 | Disruption of 24 hour sleep wake cycle, unspecified | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|---|---------------|------------|
| 780.56 | Dysfunctions associated with sleep stages or arousal from sleep | Diagnosis | ICD-9-CM |
| 780.57 | Unspecified sleep apnea | Diagnosis | ICD-9-CM |
| 780.58 | Sleep related movement disorder, unspecified | Diagnosis | ICD-9-CM |
| 780.59 | Other sleep disturbances | Diagnosis | ICD-9-CM |
| 881 | Open wound of elbow, forearm, and wrist | Diagnosis | ICD-9-CM |
| 8E0ZXY5 | Meditation | Procedure | ICD-10-PCS |
| 90810 | Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an office or outpatient facility, approximately 20 to 30 minutes face-to-face with the patient; | Procedure | CPT-4 |
| 90811 | Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an office or outpatient facility, approximately 20 to 30 minutes face-to-face with the patient; with medical evaluation and management services | Procedure | CPT-4 |
| 90812 | Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an office or outpatient facility, approximately 45 to 50 minutes face-to-face with the patient; | Procedure | CPT-4 |
| 90813 | Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an office or outpatient facility, approximately 45 to 50 minutes face-to-face with the patient; with medical evaluation and management services | Procedure | CPT-4 |
| 90814 | Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an office or outpatient facility, approximately 75 to 80 minutes face-to-face with the patient; | Procedure | CPT-4 |
| 90815 | Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an office or outpatient facility, approximately 75 to 80 minutes face-to-face with the patient; with medical evaluation and management services | Procedure | CPT-4 |
| 90823 | Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an inpatient hospital, partial hospital or residential care setting, approximately 20 to 30 minutes face-to-face with the patient; | Procedure | CPT-4 |
| 90824 | Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an inpatient hospital, partial hospital or residential care setting, approximately 20 to 30 minutes face-to-face with the patient; with medical evaluation and management services | Procedure | CPT-4 |
| 90826 | Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an inpatient hospital, partial hospital or residential care setting, approximately 45 to 50 minutes face-to-face with the patient; | Procedure | CPT-4 |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|-------|---|---------------|-----------|
| 90827 | Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an inpatient hospital, partial hospital or residential care setting, approximately 45 to 50 minutes face-to-face with the patient; with medical evaluation and management services | Procedure | CPT-4 |
| 90828 | Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an inpatient hospital, partial hospital or residential care setting, approximately 75 to 80 minutes face-to-face with the patient; | Procedure | CPT-4 |
| 90829 | Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an inpatient hospital, partial hospital or residential care setting, approximately 75 to 80 minutes face-to-face with the patient; with medical evaluation and management services | Procedure | CPT-4 |
| 90832 | Psychotherapy, 30 minutes with patient | Procedure | CPT-4 |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an evaluation and management service (List separately in addition to the code for primary procedure) | Procedure | CPT-4 |
| 90834 | Psychotherapy, 45 minutes with patient | Procedure | CPT-4 |
| 90836 | Psychotherapy, 45 minutes with patient when performed with an evaluation and management service (List separately in addition to the code for primary procedure) | Procedure | CPT-4 |
| 90837 | Psychotherapy, 60 minutes with patient | Procedure | CPT-4 |
| 90838 | Psychotherapy, 60 minutes with patient when performed with an evaluation and management service (List separately in addition to the code for primary procedure) | Procedure | CPT-4 |
| 90839 | Psychotherapy for crisis; first 60 minutes | Procedure | CPT-4 |
| 90840 | Psychotherapy for crisis; each additional 30 minutes (List separately in addition to code for primary service) | Procedure | CPT-4 |
| 90845 | Psychoanalysis | Procedure | CPT-4 |
| 90853 | Group psychotherapy (other than of a multiple-family group) | Procedure | CPT-4 |
| 90857 | Interactive group psychotherapy | Procedure | CPT-4 |
| 90867 | Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; initial, including cortical mapping, motor threshold determination, delivery and management | Procedure | CPT-4 |
| 90868 | Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent delivery and management, per session | Procedure | CPT-4 |
| 90869 | Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent motor threshold re-determination with delivery and management | Procedure | CPT-4 |
| 90870 | Electroconvulsive therapy (includes necessary monitoring) | Procedure | CPT-4 |
| 90871 | Electroconvulsive therapy (includes necessary monitoring); multiple seizures, per day | Procedure | CPT-4 |
| 94.31 | Psychoanalysis | Procedure | ICD-9-CM |
| 94.32 | Hypnotherapy | Procedure | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|-------|---|---------------|-----------|
| 94.33 | Behavior therapy | Procedure | ICD-9-CM |
| 94.35 | Crisis intervention | Procedure | ICD-9-CM |
| 94.36 | Play psychotherapy | Procedure | ICD-9-CM |
| 94.37 | Exploratory verbal psychotherapy | Procedure | ICD-9-CM |
| 94.38 | Supportive verbal psychotherapy | Procedure | ICD-9-CM |
| 94.39 | Other individual psychotherapy | Procedure | ICD-9-CM |
| 94.43 | Psychodrama | Procedure | ICD-9-CM |
| 94.44 | Other group therapy | Procedure | ICD-9-CM |
| 94.46 | Alcoholism counseling | Procedure | ICD-9-CM |
| 94.53 | Referral for alcoholism rehabilitation | Procedure | ICD-9-CM |
| 94.6 | Alcohol and drug rehabilitation and detoxification | Procedure | ICD-9-CM |
| 94.61 | Alcohol rehabilitation | Procedure | ICD-9-CM |
| 94.62 | Alcohol detoxification | Procedure | ICD-9-CM |
| 94.63 | Alcohol rehabilitation and detoxification | Procedure | ICD-9-CM |
| 94.67 | Combined alcohol and drug rehabilitation | Procedure | ICD-9-CM |
| 94.68 | Combined alcohol and drug detoxification | Procedure | ICD-9-CM |
| 94.69 | Combined alcohol and drug rehabilitation and detoxification | Procedure | ICD-9-CM |
| 95970 | Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain, cranial nerve, spinal cord, peripheral nerve, or sacral nerve, neurostimulator pulse generator/transmitter, without | Procedure | CPT-4 |
| 95971 | Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with simple spinal cord or peripheral nerve (eg, sacral nerve) neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional | Procedure | CPT-4 |
| 95974 | Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); complex cranial nerve neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming, with or without nerve interface testing, first hour | Procedure | CPT-4 |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|-------|--|---------------|-----------|
| 95975 | Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); complex cranial nerve neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming, each additional 30 minutes after first hour (List separately in addition to code for primary procedure) | Procedure | CPT-4 |
| 960 | Poisoning by antibiotics | Diagnosis | ICD-9-CM |
| 960.0 | Poisoning by penicillins | Diagnosis | ICD-9-CM |
| 960.1 | Poisoning by antifungal antibiotics | Diagnosis | ICD-9-CM |
| 960.2 | Poisoning by chloramphenicol group | Diagnosis | ICD-9-CM |
| 960.3 | Poisoning by erythromycin and other macrolides | Diagnosis | ICD-9-CM |
| 960.4 | Poisoning by tetracycline group | Diagnosis | ICD-9-CM |
| 960.5 | Poisoning of cephalosporin group | Diagnosis | ICD-9-CM |
| 960.6 | Poisoning of antimycobacterial antibiotics | Diagnosis | ICD-9-CM |
| 960.7 | Poisoning by antineoplastic antibiotics | Diagnosis | ICD-9-CM |
| 960.8 | Poisoning by other specified antibiotics | Diagnosis | ICD-9-CM |
| 960.9 | Poisoning by unspecified antibiotic | Diagnosis | ICD-9-CM |
| 961 | Poisoning by other anti-infectives | Diagnosis | ICD-9-CM |
| 961.0 | Poisoning by sulfonamides | Diagnosis | ICD-9-CM |
| 961.1 | Poisoning by arsenical anti-infectives | Diagnosis | ICD-9-CM |
| 961.2 | Poisoning by heavy metal anti-infectives | Diagnosis | ICD-9-CM |
| 961.3 | Poisoning by quinoline and hydroxyquinoline derivatives | Diagnosis | ICD-9-CM |
| 961.4 | Poisoning by antimalarials and drugs acting on other blood protozoa | Diagnosis | ICD-9-CM |
| 961.5 | Poisoning by other antiprotozoal drugs | Diagnosis | ICD-9-CM |
| 961.6 | Poisoning by anthelmintics | Diagnosis | ICD-9-CM |
| 961.7 | Poisoning by antiviral drugs | Diagnosis | ICD-9-CM |
| 961.8 | Poisoning by other antimycobacterial drugs | Diagnosis | ICD-9-CM |
| 961.9 | Poisoning by other and unspecified anti-infectives | Diagnosis | ICD-9-CM |
| 962 | Poisoning by hormones and synthetic substitutes | Diagnosis | ICD-9-CM |
| 962.0 | Poisoning by adrenal cortical steroids | Diagnosis | ICD-9-CM |
| 962.1 | Poisoning by androgens and anabolic congeners | Diagnosis | ICD-9-CM |
| 962.2 | Poisoning by ovarian hormones and synthetic substitutes | Diagnosis | ICD-9-CM |
| 962.3 | Poisoning by insulins and antidiabetic agents | Diagnosis | ICD-9-CM |
| 962.4 | Poisoning by anterior pituitary hormones | Diagnosis | ICD-9-CM |
| 962.5 | Poisoning by posterior pituitary hormones | Diagnosis | ICD-9-CM |
| 962.6 | Poisoning by parathyroid and parathyroid derivatives | Diagnosis | ICD-9-CM |
| 962.7 | Poisoning by thyroid and thyroid derivatives | Diagnosis | ICD-9-CM |
| 962.8 | Poisoning by antithyroid agents | Diagnosis | ICD-9-CM |
| 962.9 | Poisoning by other and unspecified hormones and synthetic substitutes | Diagnosis | ICD-9-CM |
| 963 | Poisoning by primarily systemic agents | Diagnosis | ICD-9-CM |
| 963.0 | Poisoning by antiallergic and antiemetic drugs | Diagnosis | ICD-9-CM |
| 963.1 | Poisoning by antineoplastic and immunosuppressive drugs | Diagnosis | ICD-9-CM |
| 963.2 | Poisoning by acidifying agents | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 963.3 | Poisoning by alkalizing agents | Diagnosis | ICD-9-CM |
| 963.4 | Poisoning by enzymes, not elsewhere classified | Diagnosis | ICD-9-CM |
| 963.5 | Poisoning by vitamins, not elsewhere classified | Diagnosis | ICD-9-CM |
| 963.8 | Poisoning by other specified systemic agents | Diagnosis | ICD-9-CM |
| 963.9 | Poisoning by unspecified systemic agent | Diagnosis | ICD-9-CM |
| 964 | Poisoning by agents primarily affecting blood constituents | Diagnosis | ICD-9-CM |
| 964.0 | Poisoning by iron and its compounds | Diagnosis | ICD-9-CM |
| 964.1 | Poisoning by liver preparations and other antianemic agents | Diagnosis | ICD-9-CM |
| 964.2 | Poisoning by anticoagulants | Diagnosis | ICD-9-CM |
| 964.3 | Poisoning by vitamin K (phytonadione) | Diagnosis | ICD-9-CM |
| 964.4 | Poisoning by fibrinolysis-affecting drugs | Diagnosis | ICD-9-CM |
| 964.5 | Poisoning by anticoagulant antagonists and other coagulants | Diagnosis | ICD-9-CM |
| 964.6 | Poisoning by gamma globulin | Diagnosis | ICD-9-CM |
| 964.7 | Poisoning by natural blood and blood products | Diagnosis | ICD-9-CM |
| 964.8 | Poisoning by other specified agents affecting blood constituents | Diagnosis | ICD-9-CM |
| 964.9 | Poisoning by unspecified agent affecting blood constituents | Diagnosis | ICD-9-CM |
| 965 | Poisoning by analgesics, antipyretics, and antirheumatics | Diagnosis | ICD-9-CM |
| 965.0 | Poisoning by opiates and related narcotics | Diagnosis | ICD-9-CM |
| 965.00 | Poisoning by opium (alkaloids), unspecified | Diagnosis | ICD-9-CM |
| 965.01 | Poisoning by heroin | Diagnosis | ICD-9-CM |
| 965.02 | Poisoning by methadone | Diagnosis | ICD-9-CM |
| 965.09 | Poisoning by opiates and related narcotics, other | Diagnosis | ICD-9-CM |
| 965.1 | Poisoning by salicylates | Diagnosis | ICD-9-CM |
| 965.4 | Poisoning by aromatic analgesics, not elsewhere classified | Diagnosis | ICD-9-CM |
| 965.5 | Poisoning by pyrazole derivatives | Diagnosis | ICD-9-CM |
| 965.6 | Poisoning by antirheumatics (antiphlogistics) | Diagnosis | ICD-9-CM |
| 965.61 | Poisoning by propionic acid derivatives | Diagnosis | ICD-9-CM |
| 965.69 | Poisoning by other antirheumatics | Diagnosis | ICD-9-CM |
| 965.7 | Poisoning by other non-narcotic analgesics | Diagnosis | ICD-9-CM |
| 965.8 | Poisoning by other specified analgesics and antipyretics | Diagnosis | ICD-9-CM |
| 965.9 | Poisoning by unspecified analgesic and antipyretic | Diagnosis | ICD-9-CM |
| 966 | Poisoning by anticonvulsants and anti-Parkinsonism drugs | Diagnosis | ICD-9-CM |
| 966.0 | Poisoning by oxazolidine derivatives | Diagnosis | ICD-9-CM |
| 966.1 | Poisoning by hydantoin derivatives | Diagnosis | ICD-9-CM |
| 966.2 | Poisoning by succinimides | Diagnosis | ICD-9-CM |
| 966.3 | Poisoning by other and unspecified anticonvulsants | Diagnosis | ICD-9-CM |
| 966.4 | Poisoning by anti-Parkinsonism drugs | Diagnosis | ICD-9-CM |
| 967 | Poisoning by sedatives and hypnotics | Diagnosis | ICD-9-CM |
| 967.0 | Poisoning by barbiturates | Diagnosis | ICD-9-CM |
| 967.1 | Poisoning by chloral hydrate group | Diagnosis | ICD-9-CM |
| 967.2 | Poisoning by paraldehyde | Diagnosis | ICD-9-CM |
| 967.3 | Poisoning by bromine compounds | Diagnosis | ICD-9-CM |
| 967.4 | Poisoning by methaqualone compounds | Diagnosis | ICD-9-CM |
| 967.5 | Poisoning by glutethimide group | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| 967.6 | Poisoning by mixed sedatives, not elsewhere classified | Diagnosis | ICD-9-CM |
| 967.8 | Poisoning by other sedatives and hypnotics | Diagnosis | ICD-9-CM |
| 967.9 | Poisoning by unspecified sedative or hypnotic | Diagnosis | ICD-9-CM |
| 968 | Poisoning by other central nervous system depressants and anesthetics | Diagnosis | ICD-9-CM |
| 968.0 | Poisoning by central nervous system muscle-tone depressants | Diagnosis | ICD-9-CM |
| 968.1 | Poisoning by halothane | Diagnosis | ICD-9-CM |
| 968.2 | Poisoning by other gaseous anesthetics | Diagnosis | ICD-9-CM |
| 968.3 | Poisoning by intravenous anesthetics | Diagnosis | ICD-9-CM |
| 968.4 | Poisoning by other and unspecified general anesthetics | Diagnosis | ICD-9-CM |
| 968.5 | Poisoning by other central nervous system depressants and anesthetics, Surface (topical) and infiltration anesthetics | Diagnosis | ICD-9-CM |
| 968.6 | Poisoning by peripheral nerve- and plexus-blocking anesthetics | Diagnosis | ICD-9-CM |
| 968.7 | Poisoning by spinal anesthetics | Diagnosis | ICD-9-CM |
| 968.9 | Poisoning by other and unspecified local anesthetics | Diagnosis | ICD-9-CM |
| 969 | Poisoning by psychotropic agents | Diagnosis | ICD-9-CM |
| 969.0 | Poisoning by antidepressants | Diagnosis | ICD-9-CM |
| 969.00 | Poisoning by antidepressant, unspecified | Diagnosis | ICD-9-CM |
| 969.01 | Poisoning by monoamine oxidase inhibitors | Diagnosis | ICD-9-CM |
| 969.02 | Poisoning by selective serotonin and norepinephrine reuptake inhibitors | Diagnosis | ICD-9-CM |
| 969.03 | Poisoning by selective serotonin reuptake inhibitors | Diagnosis | ICD-9-CM |
| 969.04 | Poisoning by tetracyclic antidepressants | Diagnosis | ICD-9-CM |
| 969.05 | Poisoning by tricyclic antidepressants | Diagnosis | ICD-9-CM |
| 969.09 | Poisoning by other antidepressants | Diagnosis | ICD-9-CM |
| 969.1 | Poisoning by phenothiazine-based tranquilizers | Diagnosis | ICD-9-CM |
| 969.2 | Poisoning by butyrophenone-based tranquilizers | Diagnosis | ICD-9-CM |
| 969.3 | Poisoning by other antipsychotics, neuroleptics, and major tranquilizers | Diagnosis | ICD-9-CM |
| 969.4 | Poisoning by benzodiazepine-based tranquilizers | Diagnosis | ICD-9-CM |
| 969.5 | Poisoning by other tranquilizers | Diagnosis | ICD-9-CM |
| 969.6 | Poisoning by psychodysleptics (hallucinogens) | Diagnosis | ICD-9-CM |
| 969.7 | Poisoning by psychostimulants | Diagnosis | ICD-9-CM |
| 969.70 | Poisoning by psychostimulant, unspecified | Diagnosis | ICD-9-CM |
| 969.71 | Poisoning by caffeine | Diagnosis | ICD-9-CM |
| 969.72 | Poisoning by amphetamines | Diagnosis | ICD-9-CM |
| 969.73 | Poisoning by methylphenidate | Diagnosis | ICD-9-CM |
| 969.79 | Poisoning by other psychostimulants | Diagnosis | ICD-9-CM |
| 969.8 | Poisoning by other specified psychotropic agents | Diagnosis | ICD-9-CM |
| 969.9 | Poisoning by unspecified psychotropic agent | Diagnosis | ICD-9-CM |
| 980 | Toxic effect of alcohol | Diagnosis | ICD-9-CM |
| 980.0 | Toxic effect of ethyl alcohol | Diagnosis | ICD-9-CM |
| 980.1 | Toxic effect of methyl alcohol | Diagnosis | ICD-9-CM |
| 980.2 | Toxic effect of isopropyl alcohol | Diagnosis | ICD-9-CM |
| 980.3 | Toxic effect of fusel oil | Diagnosis | ICD-9-CM |
| 980.8 | Toxic effect of other specified alcohols | Diagnosis | ICD-9-CM |
| 980.9 | Toxic effect of unspecified alcohol | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|-------|---|---------------|-----------|
| 981 | Toxic effect of petroleum products | Diagnosis | ICD-9-CM |
| 982 | Toxic effect of solvents other than petroleum-based | Diagnosis | ICD-9-CM |
| 982.0 | Toxic effect of benzene and homologues | Diagnosis | ICD-9-CM |
| 982.1 | Toxic effect of carbon tetrachloride | Diagnosis | ICD-9-CM |
| 982.2 | Toxic effect of carbon disulfide | Diagnosis | ICD-9-CM |
| 982.3 | Toxic effect of other chlorinated hydrocarbon solvents | Diagnosis | ICD-9-CM |
| 982.4 | Toxic effect of nitroglycol | Diagnosis | ICD-9-CM |
| 982.8 | Toxic effect of other nonpetroleum-based solvents | Diagnosis | ICD-9-CM |
| 983 | Toxic effect of corrosive aromatics, acids, and caustic alkalis | Diagnosis | ICD-9-CM |
| 983.0 | Toxic effect of corrosive aromatics | Diagnosis | ICD-9-CM |
| 983.1 | Toxic effect of acids | Diagnosis | ICD-9-CM |
| 983.2 | Toxic effect of caustic alkalis | Diagnosis | ICD-9-CM |
| 983.9 | Toxic effect of caustic, unspecified | Diagnosis | ICD-9-CM |
| 984 | Toxic effect of lead and its compounds (including fumes) | Diagnosis | ICD-9-CM |
| 984.0 | Toxic effect of inorganic lead compounds | Diagnosis | ICD-9-CM |
| 984.1 | Toxic effect of organic lead compounds | Diagnosis | ICD-9-CM |
| 984.8 | Toxic effect of other lead compounds | Diagnosis | ICD-9-CM |
| 984.9 | Toxic effect of unspecified lead compound | Diagnosis | ICD-9-CM |
| 985 | Toxic effect of other metals | Diagnosis | ICD-9-CM |
| 985.0 | Toxic effect of mercury and its compounds | Diagnosis | ICD-9-CM |
| 985.1 | Toxic effect of arsenic and its compounds | Diagnosis | ICD-9-CM |
| 985.2 | Toxic effect of manganese and its compounds | Diagnosis | ICD-9-CM |
| 985.3 | Toxic effect of beryllium and its compounds | Diagnosis | ICD-9-CM |
| 985.4 | Toxic effect of antimony and its compounds | Diagnosis | ICD-9-CM |
| 985.5 | Toxic effect of cadmium and its compounds | Diagnosis | ICD-9-CM |
| 985.6 | Toxic effect of chromium | Diagnosis | ICD-9-CM |
| 985.8 | Toxic effect of other specified metals | Diagnosis | ICD-9-CM |
| 985.9 | Toxic effect of unspecified metal | Diagnosis | ICD-9-CM |
| 986 | Toxic effect of carbon monoxide | Diagnosis | ICD-9-CM |
| 987 | Toxic effect of other gases, fumes, or vapors | Diagnosis | ICD-9-CM |
| 987.0 | Toxic effect of liquefied petroleum gases | Diagnosis | ICD-9-CM |
| 987.1 | Toxic effect of other hydrocarbon gas | Diagnosis | ICD-9-CM |
| 987.2 | Toxic effect of nitrogen oxides | Diagnosis | ICD-9-CM |
| 987.3 | Toxic effect of sulfur dioxide | Diagnosis | ICD-9-CM |
| 987.4 | Toxic effect of freon | Diagnosis | ICD-9-CM |
| 987.5 | Toxic effect of lacrimogenic gas | Diagnosis | ICD-9-CM |
| 987.6 | Toxic effect of chlorine gas | Diagnosis | ICD-9-CM |
| 987.7 | Toxic effect of hydrocyanic acid gas | Diagnosis | ICD-9-CM |
| 987.8 | Toxic effect of other specified gases, fumes, or vapors | Diagnosis | ICD-9-CM |
| 987.9 | Toxic effect of unspecified gas, fume, or vapor | Diagnosis | ICD-9-CM |
| 988 | Toxic effect of noxious substances eaten as food | Diagnosis | ICD-9-CM |
| 988.0 | Toxic effect of fish and shellfish | Diagnosis | ICD-9-CM |
| 988.1 | Toxic effect of mushrooms | Diagnosis | ICD-9-CM |
| 988.2 | Toxic effect of berries and other plants | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 988.8 | Toxic effect of other specified noxious substances | Diagnosis | ICD-9-CM |
| 988.9 | Toxic effect of unspecified noxious substance | Diagnosis | ICD-9-CM |
| 989 | Toxic effect of other substances, chiefly nonmedicinal as to source | Diagnosis | ICD-9-CM |
| 989.0 | Toxic effect of hydrocyanic acid and cyanides | Diagnosis | ICD-9-CM |
| 989.1 | Toxic effect of strychnine and salts | Diagnosis | ICD-9-CM |
| 989.2 | Toxic effect of chlorinated hydrocarbons | Diagnosis | ICD-9-CM |
| 989.3 | Toxic effect of organophosphate and carbamate | Diagnosis | ICD-9-CM |
| 989.4 | Toxic effect of other pesticides, not elsewhere classified | Diagnosis | ICD-9-CM |
| 989.5 | Toxic effect of venom | Diagnosis | ICD-9-CM |
| 989.6 | Toxic effect of soaps and detergents | Diagnosis | ICD-9-CM |
| 989.7 | Toxic effect of aflatoxin and other mycotoxin (food contaminants) | Diagnosis | ICD-9-CM |
| 989.8 | Toxic effect of other substances, chiefly nonmedicinal as to source | Diagnosis | ICD-9-CM |
| 989.81 | Toxic effect of asbestos | Diagnosis | ICD-9-CM |
| 989.82 | Toxic effect of latex | Diagnosis | ICD-9-CM |
| 989.83 | Toxic effect of silicone | Diagnosis | ICD-9-CM |
| 989.84 | Toxic effect of tobacco | Diagnosis | ICD-9-CM |
| 989.89 | Toxic effect of other substances | Diagnosis | ICD-9-CM |
| 989.9 | Toxic effect of unspecified substance, chiefly nonmedicinal as to source | Diagnosis | ICD-9-CM |
| 994.7 | Asphyxiation and strangulation | Diagnosis | ICD-9-CM |
| E75.00 | GM2 gangliosidosis, unspecified | Diagnosis | ICD-10-CM |
| E75.01 | Sandhoff disease | Diagnosis | ICD-10-CM |
| E75.02 | Tay-Sachs disease | Diagnosis | ICD-10-CM |
| E75.09 | Other GM2 gangliosidosis | Diagnosis | ICD-10-CM |
| E75.10 | Unspecified gangliosidosis | Diagnosis | ICD-10-CM |
| E75.11 | Mucopolidosis IV | Diagnosis | ICD-10-CM |
| E75.19 | Other gangliosidosis | Diagnosis | ICD-10-CM |
| E75.23 | Krabbe disease | Diagnosis | ICD-10-CM |
| E75.25 | Metachromatic leukodystrophy | Diagnosis | ICD-10-CM |
| E75.29 | Other sphingolipidosis | Diagnosis | ICD-10-CM |
| E75.4 | Neuronal ceroid lipofuscinosis | Diagnosis | ICD-10-CM |
| E950.0 | Suicide and self-inflicted poisoning by analgesics, antipyretics, and antirheumatics | Diagnosis | ICD-9-CM |
| E950.1 | Suicide and self-inflicted poisoning by barbiturates | Diagnosis | ICD-9-CM |
| E950.2 | Suicide and self-inflicted poisoning by other sedatives and hypnotics | Diagnosis | ICD-9-CM |
| E950.3 | Suicide and self-inflicted poisoning by tranquilizers and other psychotropic agents | Diagnosis | ICD-9-CM |
| E950.4 | Suicide and self-inflicted poisoning by other specified drugs and medicinal substances | Diagnosis | ICD-9-CM |
| E950.5 | Suicide and self-inflicted poisoning by unspecified drug or medicinal substance | Diagnosis | ICD-9-CM |
| E950.6 | Suicide and self-inflicted poisoning by agricultural and horticultural chemical and pharmaceutical preparations other than plant foods and fertilizers | Diagnosis | ICD-9-CM |
| E950.7 | Suicide and self-inflicted poisoning by corrosive and caustic substances | Diagnosis | ICD-9-CM |
| E950.8 | Suicide and self-inflicted poisoning by arsenic and its compounds | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| E950.9 | Suicide and self-inflicted poisoning by other and unspecified solid and liquid substances | Diagnosis | ICD-9-CM |
| E951.0 | Suicide and self-inflicted poisoning by gas distributed by pipeline | Diagnosis | ICD-9-CM |
| E951.1 | Suicide and self-inflicted poisoning by liquefied petroleum gas distributed in mobile containers | Diagnosis | ICD-9-CM |
| E951.8 | Suicide and self-inflicted poisoning by other utility gas | Diagnosis | ICD-9-CM |
| E952.0 | Suicide and self-inflicted poisoning by motor vehicle exhaust gas | Diagnosis | ICD-9-CM |
| E952.1 | Suicide and self-inflicted poisoning by other carbon monoxide | Diagnosis | ICD-9-CM |
| E952.8 | Suicide and self-inflicted poisoning by other specified gases and vapors | Diagnosis | ICD-9-CM |
| E952.9 | Suicide and self-inflicted poisoning by unspecified gases and vapors | Diagnosis | ICD-9-CM |
| E953.0 | Suicide and self-inflicted injury by hanging | Diagnosis | ICD-9-CM |
| E953.1 | Suicide and self-inflicted injury by suffocation by plastic bag | Diagnosis | ICD-9-CM |
| E953.8 | Suicide and self-inflicted injury by other specified means | Diagnosis | ICD-9-CM |
| E953.9 | Suicide and self-inflicted injury by unspecified means | Diagnosis | ICD-9-CM |
| E954 | Suicide and self-inflicted injury by submersion (drowning) | Diagnosis | ICD-9-CM |
| E955.0 | Suicide and self-inflicted injury by handgun | Diagnosis | ICD-9-CM |
| E955.1 | Suicide and self-inflicted injury by shotgun | Diagnosis | ICD-9-CM |
| E955.2 | Suicide and self-inflicted injury by hunting rifle | Diagnosis | ICD-9-CM |
| E955.3 | Suicide and self-inflicted injury by military firearms | Diagnosis | ICD-9-CM |
| E955.4 | Suicide and self-inflicted injury by other and unspecified firearm | Diagnosis | ICD-9-CM |
| E955.5 | Suicide and self-inflicted injury by explosives | Diagnosis | ICD-9-CM |
| E955.6 | Suicide and self-inflicted injury by air gun | Diagnosis | ICD-9-CM |
| E955.7 | Suicide and self-inflicted injury by paintball gun | Diagnosis | ICD-9-CM |
| E955.9 | Suicide and self-inflicted injury by firearms and explosives, unspecified | Diagnosis | ICD-9-CM |
| E956 | Suicide and self-inflicted injury by cutting and piercing instrument | Diagnosis | ICD-9-CM |
| E957.0 | Suicide and self-inflicted injuries by jumping from residential premises | Diagnosis | ICD-9-CM |
| E957.1 | Suicide and self-inflicted injuries by jumping from other man-made structures | Diagnosis | ICD-9-CM |
| E957.2 | Suicide and self-inflicted injuries by jumping from natural sites | Diagnosis | ICD-9-CM |
| E957.9 | Suicide and self-inflicted injuries by jumping from unspecified site | Diagnosis | ICD-9-CM |
| E958.0 | Suicide and self-inflicted injury by jumping or lying before moving object | Diagnosis | ICD-9-CM |
| E958.1 | Suicide and self-inflicted injury by burns, fire | Diagnosis | ICD-9-CM |
| E958.2 | Suicide and self-inflicted injury by scald | Diagnosis | ICD-9-CM |
| E958.3 | Suicide and self-inflicted injury by extremes of cold | Diagnosis | ICD-9-CM |
| E958.4 | Suicide and self-inflicted injury by electrocution | Diagnosis | ICD-9-CM |
| E958.5 | Suicide and self-inflicted injury by crashing of motor vehicle | Diagnosis | ICD-9-CM |
| E958.6 | Suicide and self-inflicted injury by crashing of aircraft | Diagnosis | ICD-9-CM |
| E958.7 | Suicide and self-inflicted injury by caustic substances, except poisoning | Diagnosis | ICD-9-CM |
| E958.8 | Suicide and self-inflicted injury by other specified means | Diagnosis | ICD-9-CM |
| E958.9 | Suicide and self-inflicted injury by unspecified means | Diagnosis | ICD-9-CM |
| E959 | Late effects of self-inflicted injury | Diagnosis | ICD-9-CM |
| F01 | Vascular dementia | Diagnosis | ICD-10-CM |
| F01.5 | Vascular dementia | Diagnosis | ICD-10-CM |
| F01.50 | Vascular dementia without behavioral disturbance | Diagnosis | ICD-10-CM |
| F01.51 | Vascular dementia with behavioral disturbance | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| F02 | Dementia in other diseases classified elsewhere | Diagnosis | ICD-10-CM |
| F02.8 | Dementia in other diseases classified elsewhere | Diagnosis | ICD-10-CM |
| F02.80 | Dementia in other diseases classified elsewhere without behavioral | Diagnosis | ICD-10-CM |
| F02.81 | Dementia in other diseases classified elsewhere with behavioral disturbance | Diagnosis | ICD-10-CM |
| F03 | Unspecified dementia | Diagnosis | ICD-10-CM |
| F03.9 | Unspecified dementia | Diagnosis | ICD-10-CM |
| F03.90 | Unspecified dementia without behavioral disturbance | Diagnosis | ICD-10-CM |
| F03.91 | Unspecified dementia with behavioral disturbance | Diagnosis | ICD-10-CM |
| F04 | Amnestic disorder due to known physiological condition | Diagnosis | ICD-10-CM |
| F05 | Delirium due to known physiological condition | Diagnosis | ICD-10-CM |
| F06 | Other mental disorders due to known physiological condition | Diagnosis | ICD-10-CM |
| F06.0 | Psychotic disorder with hallucinations due to known physiological condition | Diagnosis | ICD-10-CM |
| F06.1 | Catatonic disorder due to known physiological condition | Diagnosis | ICD-10-CM |
| F06.2 | Psychotic disorder with delusions due to known physiological condition | Diagnosis | ICD-10-CM |
| F06.3 | Mood disorder due to known physiological condition | Diagnosis | ICD-10-CM |
| F06.30 | Mood disorder due to known physiological condition, unspecified | Diagnosis | ICD-10-CM |
| F06.31 | Mood disorder due to known physiological condition with depressive features | Diagnosis | ICD-10-CM |
| F06.32 | Mood disorder due to known physiological condition with major depressive-like episode | Diagnosis | ICD-10-CM |
| F06.33 | Mood disorder due to known physiological condition with manic features | Diagnosis | ICD-10-CM |
| F06.34 | Mood disorder due to known physiological condition with mixed features | Diagnosis | ICD-10-CM |
| F06.4 | Anxiety disorder due to known physiological condition | Diagnosis | ICD-10-CM |
| F06.8 | Other specified mental disorders due to known physiological condition | Diagnosis | ICD-10-CM |
| F07 | Personality and behavioral disorders due to known physiological condition | Diagnosis | ICD-10-CM |
| F07.0 | Personality change due to known physiological condition | Diagnosis | ICD-10-CM |
| F07.8 | Other personality and behavioral disorders due to known physiological condition | Diagnosis | ICD-10-CM |
| F07.81 | Postconcussional syndrome | Diagnosis | ICD-10-CM |
| F07.89 | Other personality and behavioral disorders due to known physiological condition | Diagnosis | ICD-10-CM |
| F07.9 | Unspecified personality and behavioral disorder due to known physiological condition | Diagnosis | ICD-10-CM |
| F09 | Unspecified mental disorder due to known physiological condition | Diagnosis | ICD-10-CM |
| F10 | Alcohol related disorders | Diagnosis | ICD-10-CM |
| F10.1 | Alcohol abuse | Diagnosis | ICD-10-CM |
| F10.10 | Alcohol abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F10.11 | Alcohol abuse, in remission | Diagnosis | ICD-10-CM |
| F10.12 | Alcohol abuse with intoxication | Diagnosis | ICD-10-CM |
| F10.120 | Alcohol abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F10.121 | Alcohol abuse with intoxication delirium | Diagnosis | ICD-10-CM |
| F10.129 | Alcohol abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F10.14 | Alcohol abuse with alcohol-induced mood disorder | Diagnosis | ICD-10-CM |
| F10.15 | Alcohol abuse with alcohol-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F10.150 | Alcohol abuse with alcohol-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F10.151 | Alcohol abuse with alcohol-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F10.159 | Alcohol abuse with alcohol-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F10.18 | Alcohol abuse with other alcohol-induced disorders | Diagnosis | ICD-10-CM |
| F10.180 | Alcohol abuse with alcohol-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F10.181 | Alcohol abuse with alcohol-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F10.182 | Alcohol abuse with alcohol-induced sleep disorder | Diagnosis | ICD-10-CM |
| F10.188 | Alcohol abuse with other alcohol-induced disorder | Diagnosis | ICD-10-CM |
| F10.19 | Alcohol abuse with unspecified alcohol-induced disorder | Diagnosis | ICD-10-CM |
| F10.2 | Alcohol dependence | Diagnosis | ICD-10-CM |
| F10.20 | Alcohol dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F10.21 | Alcohol dependence, in remission | Diagnosis | ICD-10-CM |
| F10.22 | Alcohol dependence with intoxication | Diagnosis | ICD-10-CM |
| F10.220 | Alcohol dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F10.221 | Alcohol dependence with intoxication delirium | Diagnosis | ICD-10-CM |
| F10.229 | Alcohol dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F10.23 | Alcohol dependence with withdrawal | Diagnosis | ICD-10-CM |
| F10.230 | Alcohol dependence with withdrawal, uncomplicated | Diagnosis | ICD-10-CM |
| F10.231 | Alcohol dependence with withdrawal delirium | Diagnosis | ICD-10-CM |
| F10.232 | Alcohol dependence with withdrawal with perceptual disturbance | Diagnosis | ICD-10-CM |
| F10.239 | Alcohol dependence with withdrawal, unspecified | Diagnosis | ICD-10-CM |
| F10.24 | Alcohol dependence with alcohol-induced mood disorder | Diagnosis | ICD-10-CM |
| F10.25 | Alcohol dependence with alcohol-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F10.250 | Alcohol dependence with alcohol-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F10.251 | Alcohol dependence with alcohol-induced psychotic disorder with | Diagnosis | ICD-10-CM |
| F10.259 | Alcohol dependence with alcohol-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F10.26 | Alcohol dependence with alcohol-induced persisting amnestic disorder | Diagnosis | ICD-10-CM |
| F10.27 | Alcohol dependence with alcohol-induced persisting dementia | Diagnosis | ICD-10-CM |
| F10.28 | Alcohol dependence with other alcohol-induced disorders | Diagnosis | ICD-10-CM |
| F10.280 | Alcohol dependence with alcohol-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F10.281 | Alcohol dependence with alcohol-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F10.282 | Alcohol dependence with alcohol-induced sleep disorder | Diagnosis | ICD-10-CM |
| F10.288 | Alcohol dependence with other alcohol-induced disorder | Diagnosis | ICD-10-CM |
| F10.29 | Alcohol dependence with unspecified alcohol-induced disorder | Diagnosis | ICD-10-CM |
| F10.9 | Alcohol use, unspecified | Diagnosis | ICD-10-CM |
| F10.92 | Alcohol use, unspecified with intoxication | Diagnosis | ICD-10-CM |
| F10.920 | Alcohol use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F10.921 | Alcohol use, unspecified with intoxication delirium | Diagnosis | ICD-10-CM |
| F10.929 | Alcohol use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F10.94 | Alcohol use, unspecified with alcohol-induced mood disorder | Diagnosis | ICD-10-CM |
| F10.95 | Alcohol use, unspecified with alcohol-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F10.950 | Alcohol use, unspecified with alcohol-induced psychotic disorder with | Diagnosis | ICD-10-CM |
| F10.951 | Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F10.959 | Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F10.96 | Alcohol use, unspecified with alcohol-induced persisting amnestic disorder | Diagnosis | ICD-10-CM |
| F10.97 | Alcohol use, unspecified with alcohol-induced persisting dementia | Diagnosis | ICD-10-CM |
| F10.98 | Alcohol use, unspecified with other alcohol-induced disorders | Diagnosis | ICD-10-CM |
| F10.980 | Alcohol use, unspecified with alcohol-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F10.981 | Alcohol use, unspecified with alcohol-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F10.982 | Alcohol use, unspecified with alcohol-induced sleep disorder | Diagnosis | ICD-10-CM |
| F10.988 | Alcohol use, unspecified with other alcohol-induced disorder | Diagnosis | ICD-10-CM |
| F10.99 | Alcohol use, unspecified with unspecified alcohol-induced disorder | Diagnosis | ICD-10-CM |
| F11 | Opioid related disorders | Diagnosis | ICD-10-CM |
| F11.1 | Opioid abuse | Diagnosis | ICD-10-CM |
| F11.10 | Opioid abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F11.11 | Opioid abuse, in remission | Diagnosis | ICD-10-CM |
| F11.12 | Opioid abuse with intoxication | Diagnosis | ICD-10-CM |
| F11.120 | Opioid abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F11.121 | Opioid abuse with intoxication delirium | Diagnosis | ICD-10-CM |
| F11.122 | Opioid abuse with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F11.129 | Opioid abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F11.14 | Opioid abuse with opioid-induced mood disorder | Diagnosis | ICD-10-CM |
| F11.15 | Opioid abuse with opioid-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F11.150 | Opioid abuse with opioid-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F11.151 | Opioid abuse with opioid-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F11.159 | Opioid abuse with opioid-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F11.18 | Opioid abuse with other opioid-induced disorder | Diagnosis | ICD-10-CM |
| F11.181 | Opioid abuse with opioid-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F11.182 | Opioid abuse with opioid-induced sleep disorder | Diagnosis | ICD-10-CM |
| F11.188 | Opioid abuse with other opioid-induced disorder | Diagnosis | ICD-10-CM |
| F11.19 | Opioid abuse with unspecified opioid-induced disorder | Diagnosis | ICD-10-CM |
| F11.2 | Opioid dependence | Diagnosis | ICD-10-CM |
| F11.20 | Opioid dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F11.21 | Opioid dependence, in remission | Diagnosis | ICD-10-CM |
| F11.22 | Opioid dependence with intoxication | Diagnosis | ICD-10-CM |
| F11.220 | Opioid dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F11.221 | Opioid dependence with intoxication delirium | Diagnosis | ICD-10-CM |
| F11.222 | Opioid dependence with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F11.229 | Opioid dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F11.23 | Opioid dependence with withdrawal | Diagnosis | ICD-10-CM |
| F11.24 | Opioid dependence with opioid-induced mood disorder | Diagnosis | ICD-10-CM |
| F11.25 | Opioid dependence with opioid-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F11.250 | Opioid dependence with opioid-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F11.251 | Opioid dependence with opioid-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F11.259 | Opioid dependence with opioid-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F11.28 | Opioid dependence with other opioid-induced disorder | Diagnosis | ICD-10-CM |
| F11.281 | Opioid dependence with opioid-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F11.282 | Opioid dependence with opioid-induced sleep disorder | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F11.288 | Opioid dependence with other opioid-induced disorder | Diagnosis | ICD-10-CM |
| F11.29 | Opioid dependence with unspecified opioid-induced disorder | Diagnosis | ICD-10-CM |
| F11.9 | Opioid use, unspecified | Diagnosis | ICD-10-CM |
| F11.90 | Opioid use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F11.92 | Opioid use, unspecified with intoxication | Diagnosis | ICD-10-CM |
| F11.920 | Opioid use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F11.921 | Opioid use, unspecified with intoxication delirium | Diagnosis | ICD-10-CM |
| F11.922 | Opioid use, unspecified with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F11.929 | Opioid use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F11.93 | Opioid use, unspecified with withdrawal | Diagnosis | ICD-10-CM |
| F11.94 | Opioid use, unspecified with opioid-induced mood disorder | Diagnosis | ICD-10-CM |
| F11.95 | Opioid use, unspecified with opioid-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F11.950 | Opioid use, unspecified with opioid-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F11.951 | Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F11.959 | Opioid use, unspecified with opioid-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F11.98 | Opioid use, unspecified with other specified opioid-induced disorder | Diagnosis | ICD-10-CM |
| F11.981 | Opioid use, unspecified with opioid-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F11.982 | Opioid use, unspecified with opioid-induced sleep disorder | Diagnosis | ICD-10-CM |
| F11.988 | Opioid use, unspecified with other opioid-induced disorder | Diagnosis | ICD-10-CM |
| F11.99 | Opioid use, unspecified with unspecified opioid-induced disorder | Diagnosis | ICD-10-CM |
| F12 | Cannabis related disorders | Diagnosis | ICD-10-CM |
| F12.1 | Cannabis abuse | Diagnosis | ICD-10-CM |
| F12.10 | Cannabis abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F12.11 | Cannabis abuse, in remission | Diagnosis | ICD-10-CM |
| F12.12 | Cannabis abuse with intoxication | Diagnosis | ICD-10-CM |
| F12.120 | Cannabis abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F12.121 | Cannabis abuse with intoxication delirium | Diagnosis | ICD-10-CM |
| F12.122 | Cannabis abuse with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F12.129 | Cannabis abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F12.15 | Cannabis abuse with psychotic disorder | Diagnosis | ICD-10-CM |
| F12.150 | Cannabis abuse with psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F12.151 | Cannabis abuse with psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F12.159 | Cannabis abuse with psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F12.18 | Cannabis abuse with other cannabis-induced disorder | Diagnosis | ICD-10-CM |
| F12.180 | Cannabis abuse with cannabis-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F12.188 | Cannabis abuse with other cannabis-induced disorder | Diagnosis | ICD-10-CM |
| F12.19 | Cannabis abuse with unspecified cannabis-induced disorder | Diagnosis | ICD-10-CM |
| F12.2 | Cannabis dependence | Diagnosis | ICD-10-CM |
| F12.20 | Cannabis dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F12.21 | Cannabis dependence, in remission | Diagnosis | ICD-10-CM |
| F12.22 | Cannabis dependence with intoxication | Diagnosis | ICD-10-CM |
| F12.220 | Cannabis dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F12.221 | Cannabis dependence with intoxication delirium | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| F12.222 | Cannabis dependence with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F12.229 | Cannabis dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F12.23 | Cannabis dependence with withdrawal | Diagnosis | ICD-10-CM |
| F12.25 | Cannabis dependence with psychotic disorder | Diagnosis | ICD-10-CM |
| F12.250 | Cannabis dependence with psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F12.251 | Cannabis dependence with psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F12.259 | Cannabis dependence with psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F12.28 | Cannabis dependence with other cannabis-induced disorder | Diagnosis | ICD-10-CM |
| F12.280 | Cannabis dependence with cannabis-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F12.288 | Cannabis dependence with other cannabis-induced disorder | Diagnosis | ICD-10-CM |
| F12.29 | Cannabis dependence with unspecified cannabis-induced disorder | Diagnosis | ICD-10-CM |
| F12.9 | Cannabis use, unspecified | Diagnosis | ICD-10-CM |
| F12.90 | Cannabis use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F12.92 | Cannabis use, unspecified with intoxication | Diagnosis | ICD-10-CM |
| F12.920 | Cannabis use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F12.921 | Cannabis use, unspecified with intoxication delirium | Diagnosis | ICD-10-CM |
| F12.922 | Cannabis use, unspecified with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F12.929 | Cannabis use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F12.93 | Cannabis use, unspecified with withdrawal | Diagnosis | ICD-10-CM |
| F12.95 | Cannabis use, unspecified with psychotic disorder | Diagnosis | ICD-10-CM |
| F12.950 | Cannabis use, unspecified with psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F12.951 | Cannabis use, unspecified with psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F12.959 | Cannabis use, unspecified with psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F12.98 | Cannabis use, unspecified with other cannabis-induced disorder | Diagnosis | ICD-10-CM |
| F12.980 | Cannabis use, unspecified with anxiety disorder | Diagnosis | ICD-10-CM |
| F12.988 | Cannabis use, unspecified with other cannabis-induced disorder | Diagnosis | ICD-10-CM |
| F12.99 | Cannabis use, unspecified with unspecified cannabis-induced disorder | Diagnosis | ICD-10-CM |
| F13 | Sedative, hypnotic, or anxiolytic related disorders | Diagnosis | ICD-10-CM |
| F13.1 | Sedative, hypnotic or anxiolytic-related abuse | Diagnosis | ICD-10-CM |
| F13.10 | Sedative, hypnotic or anxiolytic abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F13.11 | Sedative, hypnotic or anxiolytic abuse, in remission | Diagnosis | ICD-10-CM |
| F13.12 | Sedative, hypnotic or anxiolytic abuse with intoxication | Diagnosis | ICD-10-CM |
| F13.120 | Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F13.121 | Sedative, hypnotic or anxiolytic abuse with intoxication delirium | Diagnosis | ICD-10-CM |
| F13.129 | Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F13.14 | Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood disorder | Diagnosis | ICD-10-CM |
| F13.15 | Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F13.150 | Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F13.151 | Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F13.159 | Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F13.18 | Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorders | Diagnosis | ICD-10-CM |
| F13.180 | Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F13.181 | Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F13.182 | Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep disorder | Diagnosis | ICD-10-CM |
| F13.188 | Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorder | Diagnosis | ICD-10-CM |
| F13.19 | Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolytic-induced disorder | Diagnosis | ICD-10-CM |
| F13.2 | Sedative, hypnotic or anxiolytic-related dependence | Diagnosis | ICD-10-CM |
| F13.20 | Sedative, hypnotic or anxiolytic dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F13.21 | Sedative, hypnotic or anxiolytic dependence, in remission | Diagnosis | ICD-10-CM |
| F13.22 | Sedative, hypnotic or anxiolytic dependence with intoxication | Diagnosis | ICD-10-CM |
| F13.220 | Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F13.221 | Sedative, hypnotic or anxiolytic dependence with intoxication delirium | Diagnosis | ICD-10-CM |
| F13.229 | Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F13.23 | Sedative, hypnotic or anxiolytic dependence with withdrawal | Diagnosis | ICD-10-CM |
| F13.230 | Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated | Diagnosis | ICD-10-CM |
| F13.231 | Sedative, hypnotic or anxiolytic dependence with withdrawal delirium | Diagnosis | ICD-10-CM |
| F13.232 | Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbance | Diagnosis | ICD-10-CM |
| F13.239 | Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified | Diagnosis | ICD-10-CM |
| F13.24 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced mood disorder | Diagnosis | ICD-10-CM |
| F13.25 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F13.250 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F13.251 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F13.259 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F13.26 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting amnesic disorder | Diagnosis | ICD-10-CM |
| F13.27 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting dementia | Diagnosis | ICD-10-CM |
| F13.28 | Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorders | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F13.280 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F13.281 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F13.282 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sleep disorder | Diagnosis | ICD-10-CM |
| F13.288 | Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorder | Diagnosis | ICD-10-CM |
| F13.29 | Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or anxiolytic-induced disorder | Diagnosis | ICD-10-CM |
| F13.9 | Sedative, hypnotic or anxiolytic-related use, unspecified | Diagnosis | ICD-10-CM |
| F13.90 | Sedative, hypnotic, or anxiolytic use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F13.92 | Sedative, hypnotic or anxiolytic use, unspecified with intoxication | Diagnosis | ICD-10-CM |
| F13.920 | Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F13.921 | Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium | Diagnosis | ICD-10-CM |
| F13.929 | Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F13.93 | Sedative, hypnotic or anxiolytic use, unspecified with withdrawal | Diagnosis | ICD-10-CM |
| F13.930 | Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated | Diagnosis | ICD-10-CM |
| F13.931 | Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium | Diagnosis | ICD-10-CM |
| F13.932 | Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual disturbances | Diagnosis | ICD-10-CM |
| F13.939 | Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, unspecified | Diagnosis | ICD-10-CM |
| F13.94 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced mood disorder | Diagnosis | ICD-10-CM |
| F13.95 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F13.950 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F13.951 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F13.959 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F13.96 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting amnesic disorder | Diagnosis | ICD-10-CM |
| F13.97 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia | Diagnosis | ICD-10-CM |
| F13.98 | Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorders | Diagnosis | ICD-10-CM |
| F13.980 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F13.981 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sexual dysfunction | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F13.982 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sleep disorder | Diagnosis | ICD-10-CM |
| F13.988 | Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorder | Diagnosis | ICD-10-CM |
| F13.99 | Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic or anxiolytic-induced disorder | Diagnosis | ICD-10-CM |
| F14 | Cocaine related disorders | Diagnosis | ICD-10-CM |
| F14.1 | Cocaine abuse | Diagnosis | ICD-10-CM |
| F14.10 | Cocaine abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F14.11 | Cocaine abuse, in remission | Diagnosis | ICD-10-CM |
| F14.12 | Cocaine abuse with intoxication | Diagnosis | ICD-10-CM |
| F14.120 | Cocaine abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F14.121 | Cocaine abuse with intoxication with delirium | Diagnosis | ICD-10-CM |
| F14.122 | Cocaine abuse with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F14.129 | Cocaine abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F14.14 | Cocaine abuse with cocaine-induced mood disorder | Diagnosis | ICD-10-CM |
| F14.15 | Cocaine abuse with cocaine-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F14.150 | Cocaine abuse with cocaine-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F14.151 | Cocaine abuse with cocaine-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F14.159 | Cocaine abuse with cocaine-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F14.18 | Cocaine abuse with other cocaine-induced disorder | Diagnosis | ICD-10-CM |
| F14.180 | Cocaine abuse with cocaine-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F14.181 | Cocaine abuse with cocaine-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F14.182 | Cocaine abuse with cocaine-induced sleep disorder | Diagnosis | ICD-10-CM |
| F14.188 | Cocaine abuse with other cocaine-induced disorder | Diagnosis | ICD-10-CM |
| F14.19 | Cocaine abuse with unspecified cocaine-induced disorder | Diagnosis | ICD-10-CM |
| F14.2 | Cocaine dependence | Diagnosis | ICD-10-CM |
| F14.20 | Cocaine dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F14.21 | Cocaine dependence, in remission | Diagnosis | ICD-10-CM |
| F14.22 | Cocaine dependence with intoxication | Diagnosis | ICD-10-CM |
| F14.220 | Cocaine dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F14.221 | Cocaine dependence with intoxication delirium | Diagnosis | ICD-10-CM |
| F14.222 | Cocaine dependence with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F14.229 | Cocaine dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F14.23 | Cocaine dependence with withdrawal | Diagnosis | ICD-10-CM |
| F14.24 | Cocaine dependence with cocaine-induced mood disorder | Diagnosis | ICD-10-CM |
| F14.25 | Cocaine dependence with cocaine-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F14.250 | Cocaine dependence with cocaine-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F14.251 | Cocaine dependence with cocaine-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F14.259 | Cocaine dependence with cocaine-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F14.28 | Cocaine dependence with other cocaine-induced disorder | Diagnosis | ICD-10-CM |
| F14.280 | Cocaine dependence with cocaine-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F14.281 | Cocaine dependence with cocaine-induced sexual dysfunction | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F14.282 | Cocaine dependence with cocaine-induced sleep disorder | Diagnosis | ICD-10-CM |
| F14.288 | Cocaine dependence with other cocaine-induced disorder | Diagnosis | ICD-10-CM |
| F14.29 | Cocaine dependence with unspecified cocaine-induced disorder | Diagnosis | ICD-10-CM |
| F14.9 | Cocaine use, unspecified | Diagnosis | ICD-10-CM |
| F14.90 | Cocaine use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F14.92 | Cocaine use, unspecified with intoxication | Diagnosis | ICD-10-CM |
| F14.920 | Cocaine use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F14.921 | Cocaine use, unspecified with intoxication delirium | Diagnosis | ICD-10-CM |
| F14.922 | Cocaine use, unspecified with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F14.929 | Cocaine use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F14.94 | Cocaine use, unspecified with cocaine-induced mood disorder | Diagnosis | ICD-10-CM |
| F14.95 | Cocaine use, unspecified with cocaine-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F14.950 | Cocaine use, unspecified with cocaine-induced psychotic disorder with | Diagnosis | ICD-10-CM |
| F14.951 | Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F14.959 | Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F14.98 | Cocaine use, unspecified with other specified cocaine-induced disorder | Diagnosis | ICD-10-CM |
| F14.980 | Cocaine use, unspecified with cocaine-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F14.981 | Cocaine use, unspecified with cocaine-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F14.982 | Cocaine use, unspecified with cocaine-induced sleep disorder | Diagnosis | ICD-10-CM |
| F14.988 | Cocaine use, unspecified with other cocaine-induced disorder | Diagnosis | ICD-10-CM |
| F14.99 | Cocaine use, unspecified with unspecified cocaine-induced disorder | Diagnosis | ICD-10-CM |
| F15 | Other stimulant related disorders | Diagnosis | ICD-10-CM |
| F15.1 | Other stimulant abuse | Diagnosis | ICD-10-CM |
| F15.10 | Other stimulant abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F15.11 | Other stimulant abuse, in remission | Diagnosis | ICD-10-CM |
| F15.12 | Other stimulant abuse with intoxication | Diagnosis | ICD-10-CM |
| F15.120 | Other stimulant abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F15.121 | Other stimulant abuse with intoxication delirium | Diagnosis | ICD-10-CM |
| F15.122 | Other stimulant abuse with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F15.129 | Other stimulant abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F15.14 | Other stimulant abuse with stimulant-induced mood disorder | Diagnosis | ICD-10-CM |
| F15.15 | Other stimulant abuse with stimulant-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F15.150 | Other stimulant abuse with stimulant-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F15.151 | Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F15.159 | Other stimulant abuse with stimulant-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F15.18 | Other stimulant abuse with other stimulant-induced disorder | Diagnosis | ICD-10-CM |
| F15.180 | Other stimulant abuse with stimulant-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F15.181 | Other stimulant abuse with stimulant-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F15.182 | Other stimulant abuse with stimulant-induced sleep disorder | Diagnosis | ICD-10-CM |
| F15.188 | Other stimulant abuse with other stimulant-induced disorder | Diagnosis | ICD-10-CM |
| F15.19 | Other stimulant abuse with unspecified stimulant-induced disorder | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F15.2 | Other stimulant dependence | Diagnosis | ICD-10-CM |
| F15.20 | Other stimulant dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F15.21 | Other stimulant dependence, in remission | Diagnosis | ICD-10-CM |
| F15.22 | Other stimulant dependence with intoxication | Diagnosis | ICD-10-CM |
| F15.220 | Other stimulant dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F15.221 | Other stimulant dependence with intoxication delirium | Diagnosis | ICD-10-CM |
| F15.222 | Other stimulant dependence with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F15.229 | Other stimulant dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F15.23 | Other stimulant dependence with withdrawal | Diagnosis | ICD-10-CM |
| F15.24 | Other stimulant dependence with stimulant-induced mood disorder | Diagnosis | ICD-10-CM |
| F15.25 | Other stimulant dependence with stimulant-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F15.250 | Other stimulant dependence with stimulant-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F15.251 | Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F15.259 | Other stimulant dependence with stimulant-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F15.28 | Other stimulant dependence with other stimulant-induced disorder | Diagnosis | ICD-10-CM |
| F15.280 | Other stimulant dependence with stimulant-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F15.281 | Other stimulant dependence with stimulant-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F15.282 | Other stimulant dependence with stimulant-induced sleep disorder | Diagnosis | ICD-10-CM |
| F15.288 | Other stimulant dependence with other stimulant-induced disorder | Diagnosis | ICD-10-CM |
| F15.29 | Other stimulant dependence with unspecified stimulant-induced disorder | Diagnosis | ICD-10-CM |
| F15.9 | Other stimulant use, unspecified | Diagnosis | ICD-10-CM |
| F15.90 | Other stimulant use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F15.92 | Other stimulant use, unspecified with intoxication | Diagnosis | ICD-10-CM |
| F15.920 | Other stimulant use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F15.921 | Other stimulant use, unspecified with intoxication delirium | Diagnosis | ICD-10-CM |
| F15.922 | Other stimulant use, unspecified with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F15.929 | Other stimulant use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F15.93 | Other stimulant use, unspecified with withdrawal | Diagnosis | ICD-10-CM |
| F15.94 | Other stimulant use, unspecified with stimulant-induced mood disorder | Diagnosis | ICD-10-CM |
| F15.95 | Other stimulant use, unspecified with stimulant-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F15.950 | Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F15.951 | Other stimulant use, unspecified with stimulant-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F15.959 | Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F15.98 | Other stimulant use, unspecified with other stimulant-induced disorder | Diagnosis | ICD-10-CM |
| F15.980 | Other stimulant use, unspecified with stimulant-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F15.981 | Other stimulant use, unspecified with stimulant-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F15.982 | Other stimulant use, unspecified with stimulant-induced sleep disorder | Diagnosis | ICD-10-CM |
| F15.988 | Other stimulant use, unspecified with other stimulant-induced disorder | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F15.99 | Other stimulant use, unspecified with unspecified stimulant-induced disorder | Diagnosis | ICD-10-CM |
| F16 | Hallucinogen related disorders | Diagnosis | ICD-10-CM |
| F16.1 | Hallucinogen abuse | Diagnosis | ICD-10-CM |
| F16.10 | Hallucinogen abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F16.11 | Hallucinogen abuse, in remission | Diagnosis | ICD-10-CM |
| F16.12 | Hallucinogen abuse with intoxication | Diagnosis | ICD-10-CM |
| F16.120 | Hallucinogen abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F16.121 | Hallucinogen abuse with intoxication with delirium | Diagnosis | ICD-10-CM |
| F16.122 | Hallucinogen abuse with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F16.129 | Hallucinogen abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F16.14 | Hallucinogen abuse with hallucinogen-induced mood disorder | Diagnosis | ICD-10-CM |
| F16.15 | Hallucinogen abuse with hallucinogen-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F16.150 | Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F16.151 | Hallucinogen abuse with hallucinogen-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F16.159 | Hallucinogen abuse with hallucinogen-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F16.18 | Hallucinogen abuse with other hallucinogen-induced disorder | Diagnosis | ICD-10-CM |
| F16.180 | Hallucinogen abuse with hallucinogen-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F16.183 | Hallucinogen abuse with hallucinogen persisting perception disorder (flashbacks) | Diagnosis | ICD-10-CM |
| F16.188 | Hallucinogen abuse with other hallucinogen-induced disorder | Diagnosis | ICD-10-CM |
| F16.19 | Hallucinogen abuse with unspecified hallucinogen-induced disorder | Diagnosis | ICD-10-CM |
| F16.2 | Hallucinogen dependence | Diagnosis | ICD-10-CM |
| F16.20 | Hallucinogen dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F16.21 | Hallucinogen dependence, in remission | Diagnosis | ICD-10-CM |
| F16.22 | Hallucinogen dependence with intoxication | Diagnosis | ICD-10-CM |
| F16.220 | Hallucinogen dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F16.221 | Hallucinogen dependence with intoxication with delirium | Diagnosis | ICD-10-CM |
| F16.229 | Hallucinogen dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F16.24 | Hallucinogen dependence with hallucinogen-induced mood disorder | Diagnosis | ICD-10-CM |
| F16.25 | Hallucinogen dependence with hallucinogen-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F16.250 | Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F16.251 | Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F16.259 | Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F16.28 | Hallucinogen dependence with other hallucinogen-induced disorder | Diagnosis | ICD-10-CM |
| F16.280 | Hallucinogen dependence with hallucinogen-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F16.283 | Hallucinogen dependence with hallucinogen persisting perception disorder (flashbacks) | Diagnosis | ICD-10-CM |
| F16.288 | Hallucinogen dependence with other hallucinogen-induced disorder | Diagnosis | ICD-10-CM |
| F16.29 | Hallucinogen dependence with unspecified hallucinogen-induced disorder | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F16.9 | Hallucinogen use, unspecified | Diagnosis | ICD-10-CM |
| F16.90 | Hallucinogen use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F16.92 | Hallucinogen use, unspecified with intoxication | Diagnosis | ICD-10-CM |
| F16.920 | Hallucinogen use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F16.921 | Hallucinogen use, unspecified with intoxication with delirium | Diagnosis | ICD-10-CM |
| F16.929 | Hallucinogen use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F16.94 | Hallucinogen use, unspecified with hallucinogen-induced mood disorder | Diagnosis | ICD-10-CM |
| F16.95 | Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F16.950 | Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F16.951 | Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F16.959 | Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F16.98 | Hallucinogen use, unspecified with other specified hallucinogen-induced disorder | Diagnosis | ICD-10-CM |
| F16.980 | Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F16.983 | Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks) | Diagnosis | ICD-10-CM |
| F16.988 | Hallucinogen use, unspecified with other hallucinogen-induced disorder | Diagnosis | ICD-10-CM |
| F16.99 | Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder | Diagnosis | ICD-10-CM |
| F17 | Nicotine dependence | Diagnosis | ICD-10-CM |
| F17.2 | Nicotine dependence | Diagnosis | ICD-10-CM |
| F17.20 | Nicotine dependence, unspecified | Diagnosis | ICD-10-CM |
| F17.200 | Nicotine dependence, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F17.201 | Nicotine dependence, unspecified, in remission | Diagnosis | ICD-10-CM |
| F17.203 | Nicotine dependence unspecified, with withdrawal | Diagnosis | ICD-10-CM |
| F17.208 | Nicotine dependence, unspecified, with other nicotine-induced disorders | Diagnosis | ICD-10-CM |
| F17.209 | Nicotine dependence, unspecified, with unspecified nicotine-induced disorders | Diagnosis | ICD-10-CM |
| F17.21 | Nicotine dependence, cigarettes | Diagnosis | ICD-10-CM |
| F17.210 | Nicotine dependence, cigarettes, uncomplicated | Diagnosis | ICD-10-CM |
| F17.211 | Nicotine dependence, cigarettes, in remission | Diagnosis | ICD-10-CM |
| F17.213 | Nicotine dependence, cigarettes, with withdrawal | Diagnosis | ICD-10-CM |
| F17.218 | Nicotine dependence, cigarettes, with other nicotine-induced disorders | Diagnosis | ICD-10-CM |
| F17.219 | Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders | Diagnosis | ICD-10-CM |
| F17.22 | Nicotine dependence, chewing tobacco | Diagnosis | ICD-10-CM |
| F17.220 | Nicotine dependence, chewing tobacco, uncomplicated | Diagnosis | ICD-10-CM |
| F17.221 | Nicotine dependence, chewing tobacco, in remission | Diagnosis | ICD-10-CM |
| F17.223 | Nicotine dependence, chewing tobacco, with withdrawal | Diagnosis | ICD-10-CM |
| F17.228 | Nicotine dependence, chewing tobacco, with other nicotine-induced disorders | Diagnosis | ICD-10-CM |
| F17.229 | Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders | Diagnosis | ICD-10-CM |
| F17.29 | Nicotine dependence, other tobacco product | Diagnosis | ICD-10-CM |
| F17.290 | Nicotine dependence, other tobacco product, uncomplicated | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| F17.291 | Nicotine dependence, other tobacco product, in remission | Diagnosis | ICD-10-CM |
| F17.293 | Nicotine dependence, other tobacco product, with withdrawal | Diagnosis | ICD-10-CM |
| F17.298 | Nicotine dependence, other tobacco product, with other nicotine-induced disorders | Diagnosis | ICD-10-CM |
| F17.299 | Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders | Diagnosis | ICD-10-CM |
| F18 | Inhalant related disorders | Diagnosis | ICD-10-CM |
| F18.1 | Inhalant abuse | Diagnosis | ICD-10-CM |
| F18.10 | Inhalant abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F18.11 | Inhalant abuse, in remission | Diagnosis | ICD-10-CM |
| F18.12 | Inhalant abuse with intoxication | Diagnosis | ICD-10-CM |
| F18.120 | Inhalant abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F18.121 | Inhalant abuse with intoxication delirium | Diagnosis | ICD-10-CM |
| F18.129 | Inhalant abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F18.14 | Inhalant abuse with inhalant-induced mood disorder | Diagnosis | ICD-10-CM |
| F18.15 | Inhalant abuse with inhalant-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F18.150 | Inhalant abuse with inhalant-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F18.151 | Inhalant abuse with inhalant-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F18.159 | Inhalant abuse with inhalant-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F18.17 | Inhalant abuse with inhalant-induced dementia | Diagnosis | ICD-10-CM |
| F18.18 | Inhalant abuse with other inhalant-induced disorders | Diagnosis | ICD-10-CM |
| F18.180 | Inhalant abuse with inhalant-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F18.188 | Inhalant abuse with other inhalant-induced disorder | Diagnosis | ICD-10-CM |
| F18.19 | Inhalant abuse with unspecified inhalant-induced disorder | Diagnosis | ICD-10-CM |
| F18.2 | Inhalant dependence | Diagnosis | ICD-10-CM |
| F18.20 | Inhalant dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F18.21 | Inhalant dependence, in remission | Diagnosis | ICD-10-CM |
| F18.22 | Inhalant dependence with intoxication | Diagnosis | ICD-10-CM |
| F18.220 | Inhalant dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F18.221 | Inhalant dependence with intoxication delirium | Diagnosis | ICD-10-CM |
| F18.229 | Inhalant dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F18.24 | Inhalant dependence with inhalant-induced mood disorder | Diagnosis | ICD-10-CM |
| F18.25 | Inhalant dependence with inhalant-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F18.250 | Inhalant dependence with inhalant-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F18.251 | Inhalant dependence with inhalant-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F18.259 | Inhalant dependence with inhalant-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F18.27 | Inhalant dependence with inhalant-induced dementia | Diagnosis | ICD-10-CM |
| F18.28 | Inhalant dependence with other inhalant-induced disorders | Diagnosis | ICD-10-CM |
| F18.280 | Inhalant dependence with inhalant-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F18.288 | Inhalant dependence with other inhalant-induced disorder | Diagnosis | ICD-10-CM |
| F18.29 | Inhalant dependence with unspecified inhalant-induced disorder | Diagnosis | ICD-10-CM |
| F18.9 | Inhalant use, unspecified | Diagnosis | ICD-10-CM |
| F18.90 | Inhalant use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| F18.92 | Inhalant use, unspecified with intoxication | Diagnosis | ICD-10-CM |
| F18.920 | Inhalant use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F18.921 | Inhalant use, unspecified with intoxication with delirium | Diagnosis | ICD-10-CM |
| F18.929 | Inhalant use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F18.94 | Inhalant use, unspecified with inhalant-induced mood disorder | Diagnosis | ICD-10-CM |
| F18.95 | Inhalant use, unspecified with inhalant-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F18.950 | Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F18.951 | Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F18.959 | Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F18.97 | Inhalant use, unspecified with inhalant-induced persisting dementia | Diagnosis | ICD-10-CM |
| F18.98 | Inhalant use, unspecified with other inhalant-induced disorders | Diagnosis | ICD-10-CM |
| F18.980 | Inhalant use, unspecified with inhalant-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F18.988 | Inhalant use, unspecified with other inhalant-induced disorder | Diagnosis | ICD-10-CM |
| F18.99 | Inhalant use, unspecified with unspecified inhalant-induced disorder | Diagnosis | ICD-10-CM |
| F19 | Other psychoactive substance related disorders | Diagnosis | ICD-10-CM |
| F19.1 | Other psychoactive substance abuse | Diagnosis | ICD-10-CM |
| F19.10 | Other psychoactive substance abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F19.11 | Other psychoactive substance abuse, in remission | Diagnosis | ICD-10-CM |
| F19.12 | Other psychoactive substance abuse with intoxication | Diagnosis | ICD-10-CM |
| F19.120 | Other psychoactive substance abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F19.121 | Other psychoactive substance abuse with intoxication delirium | Diagnosis | ICD-10-CM |
| F19.122 | Other psychoactive substance abuse with intoxication with perceptual disturbances | Diagnosis | ICD-10-CM |
| F19.129 | Other psychoactive substance abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F19.14 | Other psychoactive substance abuse with psychoactive substance-induced mood disorder | Diagnosis | ICD-10-CM |
| F19.15 | Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F19.150 | Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F19.151 | Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F19.159 | Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F19.16 | Other psychoactive substance abuse with psychoactive substance-induced persisting amnesic disorder | Diagnosis | ICD-10-CM |
| F19.17 | Other psychoactive substance abuse with psychoactive substance-induced persisting dementia | Diagnosis | ICD-10-CM |
| F19.18 | Other psychoactive substance abuse with other psychoactive substance-induced disorders | Diagnosis | ICD-10-CM |
| F19.180 | Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F19.181 | Other psychoactive substance abuse with psychoactive substance-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F19.182 | Other psychoactive substance abuse with psychoactive substance-induced sleep disorder | Diagnosis | ICD-10-CM |
| F19.188 | Other psychoactive substance abuse with other psychoactive substance-induced disorder | Diagnosis | ICD-10-CM |
| F19.19 | Other psychoactive substance abuse with unspecified psychoactive substance-induced disorder | Diagnosis | ICD-10-CM |
| F19.2 | Other psychoactive substance dependence | Diagnosis | ICD-10-CM |
| F19.20 | Other psychoactive substance dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F19.21 | Other psychoactive substance dependence, in remission | Diagnosis | ICD-10-CM |
| F19.22 | Other psychoactive substance dependence with intoxication | Diagnosis | ICD-10-CM |
| F19.220 | Other psychoactive substance dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F19.221 | Other psychoactive substance dependence with intoxication delirium | Diagnosis | ICD-10-CM |
| F19.222 | Other psychoactive substance dependence with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F19.229 | Other psychoactive substance dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F19.23 | Other psychoactive substance dependence with withdrawal | Diagnosis | ICD-10-CM |
| F19.230 | Other psychoactive substance dependence with withdrawal, uncomplicated | Diagnosis | ICD-10-CM |
| F19.231 | Other psychoactive substance dependence with withdrawal delirium | Diagnosis | ICD-10-CM |
| F19.232 | Other psychoactive substance dependence with withdrawal with perceptual disturbance | Diagnosis | ICD-10-CM |
| F19.239 | Other psychoactive substance dependence with withdrawal, unspecified | Diagnosis | ICD-10-CM |
| F19.24 | Other psychoactive substance dependence with psychoactive substance-induced mood disorder | Diagnosis | ICD-10-CM |
| F19.25 | Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F19.250 | Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F19.251 | Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F19.259 | Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F19.26 | Other psychoactive substance dependence with psychoactive substance-induced persisting amnesic disorder | Diagnosis | ICD-10-CM |
| F19.27 | Other psychoactive substance dependence with psychoactive substance-induced persisting dementia | Diagnosis | ICD-10-CM |
| F19.28 | Other psychoactive substance dependence with other psychoactive substance-induced disorders | Diagnosis | ICD-10-CM |
| F19.280 | Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F19.281 | Other psychoactive substance dependence with psychoactive substance-induced sexual dysfunction | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F19.282 | Other psychoactive substance dependence with psychoactive substance-induced sleep disorder | Diagnosis | ICD-10-CM |
| F19.288 | Other psychoactive substance dependence with other psychoactive substance-induced disorder | Diagnosis | ICD-10-CM |
| F19.29 | Other psychoactive substance dependence with unspecified psychoactive substance-induced disorder | Diagnosis | ICD-10-CM |
| F19.9 | Other psychoactive substance use, unspecified | Diagnosis | ICD-10-CM |
| F19.90 | Other psychoactive substance use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F19.92 | Other psychoactive substance use, unspecified with intoxication | Diagnosis | ICD-10-CM |
| F19.920 | Other psychoactive substance use, unspecified with intoxication, | Diagnosis | ICD-10-CM |
| F19.921 | Other psychoactive substance use, unspecified with intoxication with delirium | Diagnosis | ICD-10-CM |
| F19.922 | Other psychoactive substance use, unspecified with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F19.929 | Other psychoactive substance use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F19.93 | Other psychoactive substance use, unspecified with withdrawal | Diagnosis | ICD-10-CM |
| F19.930 | Other psychoactive substance use, unspecified with withdrawal, | Diagnosis | ICD-10-CM |
| F19.931 | Other psychoactive substance use, unspecified with withdrawal delirium | Diagnosis | ICD-10-CM |
| F19.932 | Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance | Diagnosis | ICD-10-CM |
| F19.939 | Other psychoactive substance use, unspecified with withdrawal, unspecified | Diagnosis | ICD-10-CM |
| F19.94 | Other psychoactive substance use, unspecified with psychoactive substance-induced mood disorder | Diagnosis | ICD-10-CM |
| F19.95 | Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder | Diagnosis | ICD-10-CM |
| F19.950 | Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F19.951 | Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F19.959 | Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F19.96 | Other psychoactive substance use, unspecified with psychoactive substance-induced persisting amnesic disorder | Diagnosis | ICD-10-CM |
| F19.97 | Other psychoactive substance use, unspecified with psychoactive substance-induced persisting dementia | Diagnosis | ICD-10-CM |
| F19.98 | Other psychoactive substance use, unspecified with other psychoactive substance-induced disorders | Diagnosis | ICD-10-CM |
| F19.980 | Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F19.981 | Other psychoactive substance use, unspecified with psychoactive substance-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F19.982 | Other psychoactive substance use, unspecified with psychoactive substance-induced sleep disorder | Diagnosis | ICD-10-CM |
| F19.988 | Other psychoactive substance use, unspecified with other psychoactive substance-induced disorder | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| F19.99 | Other psychoactive substance use, unspecified with unspecified psychoactive substance-induced disorder | Diagnosis | ICD-10-CM |
| F20 | Schizophrenia | Diagnosis | ICD-10-CM |
| F20.0 | Paranoid schizophrenia | Diagnosis | ICD-10-CM |
| F20.1 | Disorganized schizophrenia | Diagnosis | ICD-10-CM |
| F20.2 | Catatonic schizophrenia | Diagnosis | ICD-10-CM |
| F20.3 | Undifferentiated schizophrenia | Diagnosis | ICD-10-CM |
| F20.5 | Residual schizophrenia | Diagnosis | ICD-10-CM |
| F20.8 | Other schizophrenia | Diagnosis | ICD-10-CM |
| F20.81 | Schizophreniform disorder | Diagnosis | ICD-10-CM |
| F20.89 | Other schizophrenia | Diagnosis | ICD-10-CM |
| F20.9 | Schizophrenia, unspecified | Diagnosis | ICD-10-CM |
| F21 | Schizotypal disorder | Diagnosis | ICD-10-CM |
| F22 | Delusional disorders | Diagnosis | ICD-10-CM |
| F23 | Brief psychotic disorder | Diagnosis | ICD-10-CM |
| F24 | Shared psychotic disorder | Diagnosis | ICD-10-CM |
| F25 | Schizoaffective disorders | Diagnosis | ICD-10-CM |
| F25.0 | Schizoaffective disorder, bipolar type | Diagnosis | ICD-10-CM |
| F25.1 | Schizoaffective disorder, depressive type | Diagnosis | ICD-10-CM |
| F25.8 | Other schizoaffective disorders | Diagnosis | ICD-10-CM |
| F25.9 | Schizoaffective disorder, unspecified | Diagnosis | ICD-10-CM |
| F28 | Other psychotic disorder not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F29 | Unspecified psychosis not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F30 | Manic episode | Diagnosis | ICD-10-CM |
| F30.1 | Manic episode without psychotic symptoms | Diagnosis | ICD-10-CM |
| F30.10 | Manic episode without psychotic symptoms, unspecified | Diagnosis | ICD-10-CM |
| F30.11 | Manic episode without psychotic symptoms, mild | Diagnosis | ICD-10-CM |
| F30.12 | Manic episode without psychotic symptoms, moderate | Diagnosis | ICD-10-CM |
| F30.13 | Manic episode, severe, without psychotic symptoms | Diagnosis | ICD-10-CM |
| F30.2 | Manic episode, severe with psychotic symptoms | Diagnosis | ICD-10-CM |
| F30.3 | Manic episode in partial remission | Diagnosis | ICD-10-CM |
| F30.4 | Manic episode in full remission | Diagnosis | ICD-10-CM |
| F30.8 | Other manic episodes | Diagnosis | ICD-10-CM |
| F30.9 | Manic episode, unspecified | Diagnosis | ICD-10-CM |
| F31 | Bipolar disorder | Diagnosis | ICD-10-CM |
| F31.0 | Bipolar disorder, current episode hypomanic | Diagnosis | ICD-10-CM |
| F31.1 | Bipolar disorder, current episode manic without psychotic features | Diagnosis | ICD-10-CM |
| F31.10 | Bipolar disorder, current episode manic without psychotic features, | Diagnosis | ICD-10-CM |
| F31.11 | Bipolar disorder, current episode manic without psychotic features, mild | Diagnosis | ICD-10-CM |
| F31.12 | Bipolar disorder, current episode manic without psychotic features, moderate | Diagnosis | ICD-10-CM |
| F31.13 | Bipolar disorder, current episode manic without psychotic features, severe | Diagnosis | ICD-10-CM |
| F31.2 | Bipolar disorder, current episode manic severe with psychotic features | Diagnosis | ICD-10-CM |
| F31.3 | Bipolar disorder, current episode depressed, mild or moderate severity | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| F31.30 | Bipolar disorder, current episode depressed, mild or moderate severity, unspecified | Diagnosis | ICD-10-CM |
| F31.31 | Bipolar disorder, current episode depressed, mild | Diagnosis | ICD-10-CM |
| F31.32 | Bipolar disorder, current episode depressed, moderate | Diagnosis | ICD-10-CM |
| F31.4 | Bipolar disorder, current episode depressed, severe, without psychotic | Diagnosis | ICD-10-CM |
| F31.5 | Bipolar disorder, current episode depressed, severe, with psychotic features | Diagnosis | ICD-10-CM |
| F31.6 | Bipolar disorder, current episode mixed | Diagnosis | ICD-10-CM |
| F31.60 | Bipolar disorder, current episode mixed, unspecified | Diagnosis | ICD-10-CM |
| F31.61 | Bipolar disorder, current episode mixed, mild | Diagnosis | ICD-10-CM |
| F31.62 | Bipolar disorder, current episode mixed, moderate | Diagnosis | ICD-10-CM |
| F31.63 | Bipolar disorder, current episode mixed, severe, without psychotic features | Diagnosis | ICD-10-CM |
| F31.64 | Bipolar disorder, current episode mixed, severe, with psychotic features | Diagnosis | ICD-10-CM |
| F31.7 | Bipolar disorder, currently in remission | Diagnosis | ICD-10-CM |
| F31.70 | Bipolar disorder, currently in remission, most recent episode unspecified | Diagnosis | ICD-10-CM |
| F31.71 | Bipolar disorder, in partial remission, most recent episode hypomanic | Diagnosis | ICD-10-CM |
| F31.72 | Bipolar disorder, in full remission, most recent episode hypomanic | Diagnosis | ICD-10-CM |
| F31.73 | Bipolar disorder, in partial remission, most recent episode manic | Diagnosis | ICD-10-CM |
| F31.74 | Bipolar disorder, in full remission, most recent episode manic | Diagnosis | ICD-10-CM |
| F31.75 | Bipolar disorder, in partial remission, most recent episode depressed | Diagnosis | ICD-10-CM |
| F31.76 | Bipolar disorder, in full remission, most recent episode depressed | Diagnosis | ICD-10-CM |
| F31.77 | Bipolar disorder, in partial remission, most recent episode mixed | Diagnosis | ICD-10-CM |
| F31.78 | Bipolar disorder, in full remission, most recent episode mixed | Diagnosis | ICD-10-CM |
| F31.8 | Other bipolar disorders | Diagnosis | ICD-10-CM |
| F31.81 | Bipolar II disorder | Diagnosis | ICD-10-CM |
| F31.89 | Other bipolar disorder | Diagnosis | ICD-10-CM |
| F31.9 | Bipolar disorder, unspecified | Diagnosis | ICD-10-CM |
| F32 | Depressive episode | Diagnosis | ICD-10-CM |
| F32.0 | Major depressive disorder, single episode, mild | Diagnosis | ICD-10-CM |
| F32.1 | Major depressive disorder, single episode, moderate | Diagnosis | ICD-10-CM |
| F32.2 | Major depressive disorder, single episode, severe without psychotic features | Diagnosis | ICD-10-CM |
| F32.3 | Major depressive disorder, single episode, severe with psychotic features | Diagnosis | ICD-10-CM |
| F32.4 | Major depressive disorder, single episode, in partial remission | Diagnosis | ICD-10-CM |
| F32.5 | Major depressive disorder, single episode, in full remission | Diagnosis | ICD-10-CM |
| F32.8 | Other depressive episodes | Diagnosis | ICD-10-CM |
| F32.81 | Premenstrual dysphoric disorder | Diagnosis | ICD-10-CM |
| F32.89 | Other specified depressive episodes | Diagnosis | ICD-10-CM |
| F32.9 | Major depressive disorder, single episode, unspecified | Diagnosis | ICD-10-CM |
| F33 | Major depressive disorder, recurrent | Diagnosis | ICD-10-CM |
| F33.0 | Major depressive disorder, recurrent, mild | Diagnosis | ICD-10-CM |
| F33.1 | Major depressive disorder, recurrent, moderate | Diagnosis | ICD-10-CM |
| F33.2 | Major depressive disorder, recurrent severe without psychotic features | Diagnosis | ICD-10-CM |
| F33.3 | Major depressive disorder, recurrent, severe with psychotic symptoms | Diagnosis | ICD-10-CM |
| F33.4 | Major depressive disorder, recurrent, in remission | Diagnosis | ICD-10-CM |
| F33.40 | Major depressive disorder, recurrent, in remission, unspecified | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F33.41 | Major depressive disorder, recurrent, in partial remission | Diagnosis | ICD-10-CM |
| F33.42 | Major depressive disorder, recurrent, in full remission | Diagnosis | ICD-10-CM |
| F33.8 | Other recurrent depressive disorders | Diagnosis | ICD-10-CM |
| F33.9 | Major depressive disorder, recurrent, unspecified | Diagnosis | ICD-10-CM |
| F34 | Persistent mood [affective] disorders | Diagnosis | ICD-10-CM |
| F34.0 | Cyclothymic disorder | Diagnosis | ICD-10-CM |
| F34.1 | Dysthymic disorder | Diagnosis | ICD-10-CM |
| F34.8 | Other persistent mood [affective] disorders | Diagnosis | ICD-10-CM |
| F34.81 | Disruptive mood dysregulation disorder | Diagnosis | ICD-10-CM |
| F34.89 | Other specified persistent mood disorders | Diagnosis | ICD-10-CM |
| F34.9 | Persistent mood [affective] disorder, unspecified | Diagnosis | ICD-10-CM |
| F39 | Unspecified mood [affective] disorder | Diagnosis | ICD-10-CM |
| F40 | Phobic anxiety disorders | Diagnosis | ICD-10-CM |
| F40.0 | Agoraphobia | Diagnosis | ICD-10-CM |
| F40.00 | Agoraphobia, unspecified | Diagnosis | ICD-10-CM |
| F40.01 | Agoraphobia with panic disorder | Diagnosis | ICD-10-CM |
| F40.02 | Agoraphobia without panic disorder | Diagnosis | ICD-10-CM |
| F40.1 | Social phobias | Diagnosis | ICD-10-CM |
| F40.10 | Social phobia, unspecified | Diagnosis | ICD-10-CM |
| F40.11 | Social phobia, generalized | Diagnosis | ICD-10-CM |
| F40.2 | Specific (isolated) phobias | Diagnosis | ICD-10-CM |
| F40.21 | Animal type phobia | Diagnosis | ICD-10-CM |
| F40.210 | Arachnophobia | Diagnosis | ICD-10-CM |
| F40.218 | Other animal type phobia | Diagnosis | ICD-10-CM |
| F40.22 | Natural environment type phobia | Diagnosis | ICD-10-CM |
| F40.220 | Fear of thunderstorms | Diagnosis | ICD-10-CM |
| F40.228 | Other natural environment type phobia | Diagnosis | ICD-10-CM |
| F40.23 | Blood, injection, injury type phobia | Diagnosis | ICD-10-CM |
| F40.230 | Fear of blood | Diagnosis | ICD-10-CM |
| F40.231 | Fear of injections and transfusions | Diagnosis | ICD-10-CM |
| F40.232 | Fear of other medical care | Diagnosis | ICD-10-CM |
| F40.233 | Fear of injury | Diagnosis | ICD-10-CM |
| F40.24 | Situational type phobia | Diagnosis | ICD-10-CM |
| F40.240 | Claustrophobia | Diagnosis | ICD-10-CM |
| F40.241 | Acrophobia | Diagnosis | ICD-10-CM |
| F40.242 | Fear of bridges | Diagnosis | ICD-10-CM |
| F40.243 | Fear of flying | Diagnosis | ICD-10-CM |
| F40.248 | Other situational type phobia | Diagnosis | ICD-10-CM |
| F40.29 | Other specified phobia | Diagnosis | ICD-10-CM |
| F40.290 | Androphobia | Diagnosis | ICD-10-CM |
| F40.291 | Gynephobia | Diagnosis | ICD-10-CM |
| F40.298 | Other specified phobia | Diagnosis | ICD-10-CM |
| F40.8 | Other phobic anxiety disorders | Diagnosis | ICD-10-CM |
| F40.9 | Phobic anxiety disorder, unspecified | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| F41 | Other anxiety disorders | Diagnosis | ICD-10-CM |
| F41.0 | Panic disorder [episodic paroxysmal anxiety] | Diagnosis | ICD-10-CM |
| F41.1 | Generalized anxiety disorder | Diagnosis | ICD-10-CM |
| F41.3 | Other mixed anxiety disorders | Diagnosis | ICD-10-CM |
| F41.8 | Other specified anxiety disorders | Diagnosis | ICD-10-CM |
| F41.9 | Anxiety disorder, unspecified | Diagnosis | ICD-10-CM |
| F42 | Obsessive-compulsive disorder | Diagnosis | ICD-10-CM |
| F42.2 | Mixed obsessional thoughts and acts | Diagnosis | ICD-10-CM |
| F42.3 | Hoarding disorder | Diagnosis | ICD-10-CM |
| F42.4 | Excoriation (skin-picking) disorder | Diagnosis | ICD-10-CM |
| F42.8 | Other obsessive-compulsive disorder | Diagnosis | ICD-10-CM |
| F42.9 | Obsessive-compulsive disorder, unspecified | Diagnosis | ICD-10-CM |
| F43 | Reaction to severe stress, and adjustment disorders | Diagnosis | ICD-10-CM |
| F43.0 | Acute stress reaction | Diagnosis | ICD-10-CM |
| F43.1 | Post-traumatic stress disorder (PTSD) | Diagnosis | ICD-10-CM |
| F43.10 | Post-traumatic stress disorder, unspecified | Diagnosis | ICD-10-CM |
| F43.11 | Post-traumatic stress disorder, acute | Diagnosis | ICD-10-CM |
| F43.12 | Post-traumatic stress disorder, chronic | Diagnosis | ICD-10-CM |
| F43.2 | Adjustment disorders | Diagnosis | ICD-10-CM |
| F43.20 | Adjustment disorder, unspecified | Diagnosis | ICD-10-CM |
| F43.21 | Adjustment disorder with depressed mood | Diagnosis | ICD-10-CM |
| F43.22 | Adjustment disorder with anxiety | Diagnosis | ICD-10-CM |
| F43.23 | Adjustment disorder with mixed anxiety and depressed mood | Diagnosis | ICD-10-CM |
| F43.24 | Adjustment disorder with disturbance of conduct | Diagnosis | ICD-10-CM |
| F43.25 | Adjustment disorder with mixed disturbance of emotions and conduct | Diagnosis | ICD-10-CM |
| F43.29 | Adjustment disorder with other symptoms | Diagnosis | ICD-10-CM |
| F43.8 | Other reactions to severe stress | Diagnosis | ICD-10-CM |
| F43.9 | Reaction to severe stress, unspecified | Diagnosis | ICD-10-CM |
| F44 | Dissociative and conversion disorders | Diagnosis | ICD-10-CM |
| F44.0 | Dissociative amnesia | Diagnosis | ICD-10-CM |
| F44.1 | Dissociative fugue | Diagnosis | ICD-10-CM |
| F44.2 | Dissociative stupor | Diagnosis | ICD-10-CM |
| F44.4 | Conversion disorder with motor symptom or deficit | Diagnosis | ICD-10-CM |
| F44.5 | Conversion disorder with seizures or convulsions | Diagnosis | ICD-10-CM |
| F44.6 | Conversion disorder with sensory symptom or deficit | Diagnosis | ICD-10-CM |
| F44.7 | Conversion disorder with mixed symptom presentation | Diagnosis | ICD-10-CM |
| F44.8 | Other dissociative and conversion disorders | Diagnosis | ICD-10-CM |
| F44.81 | Dissociative identity disorder | Diagnosis | ICD-10-CM |
| F44.89 | Other dissociative and conversion disorders | Diagnosis | ICD-10-CM |
| F44.9 | Dissociative and conversion disorder, unspecified | Diagnosis | ICD-10-CM |
| F45 | Somatoform disorders | Diagnosis | ICD-10-CM |
| F45.0 | Somatization disorder | Diagnosis | ICD-10-CM |
| F45.1 | Undifferentiated somatoform disorder | Diagnosis | ICD-10-CM |
| F45.2 | Hypochondriacal disorders | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| F45.20 | Hypochondriacal disorder, unspecified | Diagnosis | ICD-10-CM |
| F45.21 | Hypochondriasis | Diagnosis | ICD-10-CM |
| F45.22 | Body dysmorphic disorder | Diagnosis | ICD-10-CM |
| F45.29 | Other hypochondriacal disorders | Diagnosis | ICD-10-CM |
| F45.4 | Pain disorders related to psychological factors | Diagnosis | ICD-10-CM |
| F45.41 | Pain disorder exclusively related to psychological factors | Diagnosis | ICD-10-CM |
| F45.42 | Pain disorder with related psychological factors | Diagnosis | ICD-10-CM |
| F45.8 | Other somatoform disorders | Diagnosis | ICD-10-CM |
| F45.9 | Somatoform disorder, unspecified | Diagnosis | ICD-10-CM |
| F48 | Other nonpsychotic mental disorders | Diagnosis | ICD-10-CM |
| F48.1 | Depersonalization-derealization syndrome | Diagnosis | ICD-10-CM |
| F48.2 | Pseudobulbar affect | Diagnosis | ICD-10-CM |
| F48.8 | Other specified nonpsychotic mental disorders | Diagnosis | ICD-10-CM |
| F48.9 | Nonpsychotic mental disorder, unspecified | Diagnosis | ICD-10-CM |
| F50 | Eating disorders | Diagnosis | ICD-10-CM |
| F50.0 | Anorexia nervosa | Diagnosis | ICD-10-CM |
| F50.00 | Anorexia nervosa, unspecified | Diagnosis | ICD-10-CM |
| F50.01 | Anorexia nervosa, restricting type | Diagnosis | ICD-10-CM |
| F50.02 | Anorexia nervosa, binge eating/purging type | Diagnosis | ICD-10-CM |
| F50.2 | Bulimia nervosa | Diagnosis | ICD-10-CM |
| F50.8 | Other eating disorders | Diagnosis | ICD-10-CM |
| F50.81 | Binge eating disorder | Diagnosis | ICD-10-CM |
| F50.82 | Avoidant/restrictive food intake disorder | Diagnosis | ICD-10-CM |
| F50.89 | Other specified eating disorder | Diagnosis | ICD-10-CM |
| F50.9 | Eating disorder, unspecified | Diagnosis | ICD-10-CM |
| F51 | Sleep disorders not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F51.0 | Insomnia not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F51.01 | Primary insomnia | Diagnosis | ICD-10-CM |
| F51.02 | Adjustment insomnia | Diagnosis | ICD-10-CM |
| F51.03 | Paradoxical insomnia | Diagnosis | ICD-10-CM |
| F51.04 | Psychophysiologic insomnia | Diagnosis | ICD-10-CM |
| F51.05 | Insomnia due to other mental disorder | Diagnosis | ICD-10-CM |
| F51.09 | Other insomnia not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F51.1 | Hypersomnia not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F51.11 | Primary hypersomnia | Diagnosis | ICD-10-CM |
| F51.12 | Insufficient sleep syndrome | Diagnosis | ICD-10-CM |
| F51.13 | Hypersomnia due to other mental disorder | Diagnosis | ICD-10-CM |
| F51.19 | Other hypersomnia not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F51.3 | Sleepwalking [somnambulism] | Diagnosis | ICD-10-CM |
| F51.4 | Sleep terrors [night terrors] | Diagnosis | ICD-10-CM |
| F51.5 | Nightmare disorder | Diagnosis | ICD-10-CM |
| F51.8 | Other sleep disorders not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F51.9 | Sleep disorder not due to a substance or known physiological condition, unspecified | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| F52 | Sexual dysfunction not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F52.0 | Hypoactive sexual desire disorder | Diagnosis | ICD-10-CM |
| F52.1 | Sexual aversion disorder | Diagnosis | ICD-10-CM |
| F52.2 | Sexual arousal disorders | Diagnosis | ICD-10-CM |
| F52.21 | Male erectile disorder | Diagnosis | ICD-10-CM |
| F52.22 | Female sexual arousal disorder | Diagnosis | ICD-10-CM |
| F52.3 | Orgasmic disorder | Diagnosis | ICD-10-CM |
| F52.31 | Female orgasmic disorder | Diagnosis | ICD-10-CM |
| F52.32 | Male orgasmic disorder | Diagnosis | ICD-10-CM |
| F52.4 | Premature ejaculation | Diagnosis | ICD-10-CM |
| F52.5 | Vaginismus not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F52.6 | Dyspareunia not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F52.8 | Other sexual dysfunction not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F52.9 | Unspecified sexual dysfunction not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F53 | Mental and behavioral disorders associated with the puerperium, not elsewhere classified | Diagnosis | ICD-10-CM |
| F53.0 | Postpartum depression | Diagnosis | ICD-10-CM |
| F53.1 | Puerperal psychosis | Diagnosis | ICD-10-CM |
| F54 | Psychological and behavioral factors associated with disorders or diseases classified elsewhere | Diagnosis | ICD-10-CM |
| F55.0 | Abuse of antacids | Diagnosis | ICD-10-CM |
| F55.1 | Abuse of herbal or folk remedies | Diagnosis | ICD-10-CM |
| F55.2 | Abuse of laxatives | Diagnosis | ICD-10-CM |
| F55.3 | Abuse of steroids or hormones | Diagnosis | ICD-10-CM |
| F55.4 | Abuse of vitamins | Diagnosis | ICD-10-CM |
| F55.8 | Abuse of other non-psychoactive substances | Diagnosis | ICD-10-CM |
| F59 | Unspecified behavioral syndromes associated with physiological disturbances and physical factors | Diagnosis | ICD-10-CM |
| F60 | Specific personality disorders | Diagnosis | ICD-10-CM |
| F60.0 | Paranoid personality disorder | Diagnosis | ICD-10-CM |
| F60.1 | Schizoid personality disorder | Diagnosis | ICD-10-CM |
| F60.2 | Antisocial personality disorder | Diagnosis | ICD-10-CM |
| F60.3 | Borderline personality disorder | Diagnosis | ICD-10-CM |
| F60.4 | Histrionic personality disorder | Diagnosis | ICD-10-CM |
| F60.5 | Obsessive-compulsive personality disorder | Diagnosis | ICD-10-CM |
| F60.6 | Avoidant personality disorder | Diagnosis | ICD-10-CM |
| F60.7 | Dependent personality disorder | Diagnosis | ICD-10-CM |
| F60.8 | Other specific personality disorders | Diagnosis | ICD-10-CM |
| F60.81 | Narcissistic personality disorder | Diagnosis | ICD-10-CM |
| F60.89 | Other specific personality disorders | Diagnosis | ICD-10-CM |
| F60.9 | Personality disorder, unspecified | Diagnosis | ICD-10-CM |
| F63 | Impulse disorders | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| F63.0 | Pathological gambling | Diagnosis | ICD-10-CM |
| F63.1 | Pyromania | Diagnosis | ICD-10-CM |
| F63.2 | Kleptomania | Diagnosis | ICD-10-CM |
| F63.3 | Trichotillomania | Diagnosis | ICD-10-CM |
| F63.8 | Other impulse disorders | Diagnosis | ICD-10-CM |
| F63.81 | Intermittent explosive disorder | Diagnosis | ICD-10-CM |
| F63.89 | Other impulse disorders | Diagnosis | ICD-10-CM |
| F63.9 | Impulse disorder, unspecified | Diagnosis | ICD-10-CM |
| F64 | Gender identity disorders | Diagnosis | ICD-10-CM |
| F64.0 | Transsexualism | Diagnosis | ICD-10-CM |
| F64.1 | Dual role transvestism | Diagnosis | ICD-10-CM |
| F64.2 | Gender identity disorder of childhood | Diagnosis | ICD-10-CM |
| F64.8 | Other gender identity disorders | Diagnosis | ICD-10-CM |
| F64.9 | Gender identity disorder, unspecified | Diagnosis | ICD-10-CM |
| F65 | Paraphilias | Diagnosis | ICD-10-CM |
| F65.0 | Fetishism | Diagnosis | ICD-10-CM |
| F65.1 | Transvestic fetishism | Diagnosis | ICD-10-CM |
| F65.2 | Exhibitionism | Diagnosis | ICD-10-CM |
| F65.3 | Voyeurism | Diagnosis | ICD-10-CM |
| F65.4 | Pedophilia | Diagnosis | ICD-10-CM |
| F65.5 | Sadomasochism | Diagnosis | ICD-10-CM |
| F65.50 | Sadomasochism, unspecified | Diagnosis | ICD-10-CM |
| F65.51 | Sexual masochism | Diagnosis | ICD-10-CM |
| F65.52 | Sexual sadism | Diagnosis | ICD-10-CM |
| F65.8 | Other paraphilias | Diagnosis | ICD-10-CM |
| F65.81 | Frotteurism | Diagnosis | ICD-10-CM |
| F65.89 | Other paraphilias | Diagnosis | ICD-10-CM |
| F65.9 | Paraphilia, unspecified | Diagnosis | ICD-10-CM |
| F66 | Other sexual disorders | Diagnosis | ICD-10-CM |
| F68 | Other disorders of adult personality and behavior | Diagnosis | ICD-10-CM |
| F68.1 | Factitious disorder imposed on self | Diagnosis | ICD-10-CM |
| F68.10 | Factitious disorder imposed on self, unspecified | Diagnosis | ICD-10-CM |
| F68.11 | Factitious disorder imposed on self, with predominantly psychological signs and symptoms | Diagnosis | ICD-10-CM |
| F68.12 | Factitious disorder imposed on self, with predominantly physical signs and symptoms | Diagnosis | ICD-10-CM |
| F68.13 | Factitious disorder imposed on self, with combined psychological and physical signs and symptoms | Diagnosis | ICD-10-CM |
| F68.8 | Other specified disorders of adult personality and behavior | Diagnosis | ICD-10-CM |
| F68.A | Factitious disorder imposed on another | Diagnosis | ICD-10-CM |
| F69 | Unspecified disorder of adult personality and behavior | Diagnosis | ICD-10-CM |
| F70 | Mild intellectual disabilities | Diagnosis | ICD-10-CM |
| F71 | Moderate intellectual disabilities | Diagnosis | ICD-10-CM |
| F72 | Severe intellectual disabilities | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| F73 | Profound intellectual disabilities | Diagnosis | ICD-10-CM |
| F78 | Other intellectual disabilities | Diagnosis | ICD-10-CM |
| F79 | Unspecified intellectual disabilities | Diagnosis | ICD-10-CM |
| F80 | Specific developmental disorders of speech and language | Diagnosis | ICD-10-CM |
| F80.0 | Phonological disorder | Diagnosis | ICD-10-CM |
| F80.1 | Expressive language disorder | Diagnosis | ICD-10-CM |
| F80.2 | Mixed receptive-expressive language disorder | Diagnosis | ICD-10-CM |
| F80.4 | Speech and language development delay due to hearing loss | Diagnosis | ICD-10-CM |
| F80.8 | Other developmental disorders of speech and language | Diagnosis | ICD-10-CM |
| F80.81 | Childhood onset fluency disorder | Diagnosis | ICD-10-CM |
| F80.82 | Social pragmatic communication disorder | Diagnosis | ICD-10-CM |
| F80.89 | Other developmental disorders of speech and language | Diagnosis | ICD-10-CM |
| F80.9 | Developmental disorder of speech and language, unspecified | Diagnosis | ICD-10-CM |
| F81 | Specific developmental disorders of scholastic skills | Diagnosis | ICD-10-CM |
| F81.0 | Specific reading disorder | Diagnosis | ICD-10-CM |
| F81.2 | Mathematics disorder | Diagnosis | ICD-10-CM |
| F81.8 | Other developmental disorders of scholastic skills | Diagnosis | ICD-10-CM |
| F81.81 | Disorder of written expression | Diagnosis | ICD-10-CM |
| F81.89 | Other developmental disorders of scholastic skills | Diagnosis | ICD-10-CM |
| F81.9 | Developmental disorder of scholastic skills, unspecified | Diagnosis | ICD-10-CM |
| F82 | Specific developmental disorder of motor function | Diagnosis | ICD-10-CM |
| F84 | Pervasive developmental disorders | Diagnosis | ICD-10-CM |
| F84.0 | Autistic disorder | Diagnosis | ICD-10-CM |
| F84.2 | Rett's syndrome | Diagnosis | ICD-10-CM |
| F84.3 | Other childhood disintegrative disorder | Diagnosis | ICD-10-CM |
| F84.5 | Asperger's syndrome | Diagnosis | ICD-10-CM |
| F84.8 | Other pervasive developmental disorders | Diagnosis | ICD-10-CM |
| F84.9 | Pervasive developmental disorder, unspecified | Diagnosis | ICD-10-CM |
| F88 | Other disorders of psychological development | Diagnosis | ICD-10-CM |
| F89 | Unspecified disorder of psychological development | Diagnosis | ICD-10-CM |
| F90 | Attention-deficit hyperactivity disorders | Diagnosis | ICD-10-CM |
| F90.0 | Attention-deficit hyperactivity disorder, predominantly inattentive type | Diagnosis | ICD-10-CM |
| F90.1 | Attention-deficit hyperactivity disorder, predominantly hyperactive type | Diagnosis | ICD-10-CM |
| F90.2 | Attention-deficit hyperactivity disorder, combined type | Diagnosis | ICD-10-CM |
| F90.8 | Attention-deficit hyperactivity disorder, other type | Diagnosis | ICD-10-CM |
| F90.9 | Attention-deficit hyperactivity disorder, unspecified type | Diagnosis | ICD-10-CM |
| F91 | Conduct disorders | Diagnosis | ICD-10-CM |
| F91.0 | Conduct disorder confined to family context | Diagnosis | ICD-10-CM |
| F91.1 | Conduct disorder, childhood-onset type | Diagnosis | ICD-10-CM |
| F91.2 | Conduct disorder, adolescent-onset type | Diagnosis | ICD-10-CM |
| F91.3 | Oppositional defiant disorder | Diagnosis | ICD-10-CM |
| F91.8 | Other conduct disorders | Diagnosis | ICD-10-CM |
| F91.9 | Conduct disorder, unspecified | Diagnosis | ICD-10-CM |
| F93 | Emotional disorders with onset specific to childhood | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| F93.0 | Separation anxiety disorder of childhood | Diagnosis | ICD-10-CM |
| F93.8 | Other childhood emotional disorders | Diagnosis | ICD-10-CM |
| F93.9 | Childhood emotional disorder, unspecified | Diagnosis | ICD-10-CM |
| F94 | Disorders of social functioning with onset specific to childhood and | Diagnosis | ICD-10-CM |
| F94.0 | Selective mutism | Diagnosis | ICD-10-CM |
| F94.1 | Reactive attachment disorder of childhood | Diagnosis | ICD-10-CM |
| F94.2 | Disinhibited attachment disorder of childhood | Diagnosis | ICD-10-CM |
| F94.8 | Other childhood disorders of social functioning | Diagnosis | ICD-10-CM |
| F94.9 | Childhood disorder of social functioning, unspecified | Diagnosis | ICD-10-CM |
| F95 | Tic disorder | Diagnosis | ICD-10-CM |
| F95.0 | Transient tic disorder | Diagnosis | ICD-10-CM |
| F95.1 | Chronic motor or vocal tic disorder | Diagnosis | ICD-10-CM |
| F95.2 | Tourette's disorder | Diagnosis | ICD-10-CM |
| F95.8 | Other tic disorders | Diagnosis | ICD-10-CM |
| F95.9 | Tic disorder, unspecified | Diagnosis | ICD-10-CM |
| F98 | Other behavioral and emotional disorders with onset usually occurring in childhood and adolescence | Diagnosis | ICD-10-CM |
| F98.0 | Enuresis not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F98.1 | Encopresis not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F98.2 | Other feeding disorders of infancy and childhood | Diagnosis | ICD-10-CM |
| F98.21 | Rumination disorder of infancy | Diagnosis | ICD-10-CM |
| F98.29 | Other feeding disorders of infancy and early childhood | Diagnosis | ICD-10-CM |
| F98.3 | Pica of infancy and childhood | Diagnosis | ICD-10-CM |
| F98.4 | Stereotyped movement disorders | Diagnosis | ICD-10-CM |
| F98.5 | Adult onset fluency disorder | Diagnosis | ICD-10-CM |
| F98.8 | Other specified behavioral and emotional disorders with onset usually occurring in childhood and adolescence | Diagnosis | ICD-10-CM |
| F98.9 | Unspecified behavioral and emotional disorders with onset usually occurring in childhood and adolescence | Diagnosis | ICD-10-CM |
| F99 | Mental disorder, not otherwise specified | Diagnosis | ICD-10-CM |
| G13.2 | Systemic atrophy primarily affecting the central nervous system in myxedema | Diagnosis | ICD-10-CM |
| G13.8 | Systemic atrophy primarily affecting central nervous system in other diseases classified elsewhere | Diagnosis | ICD-10-CM |
| G25.70 | Drug induced movement disorder, unspecified | Diagnosis | ICD-10-CM |
| G25.71 | Drug induced akathisia | Diagnosis | ICD-10-CM |
| G25.79 | Other drug induced movement disorders | Diagnosis | ICD-10-CM |
| G25.89 | Other specified extrapyramidal and movement disorders | Diagnosis | ICD-10-CM |
| G25.9 | Extrapyramidal and movement disorder, unspecified | Diagnosis | ICD-10-CM |
| G26 | Extrapyramidal and movement disorders in diseases classified elsewhere | Diagnosis | ICD-10-CM |
| G30.0 | Alzheimer's disease with early onset | Diagnosis | ICD-10-CM |
| G30.1 | Alzheimer's disease with late onset | Diagnosis | ICD-10-CM |
| G30.8 | Other Alzheimer's disease | Diagnosis | ICD-10-CM |
| G30.9 | Alzheimer's disease, unspecified | Diagnosis | ICD-10-CM |
| G31.01 | Pick's disease | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| G31.09 | Other frontotemporal dementia | Diagnosis | ICD-10-CM |
| G31.1 | Senile degeneration of brain, not elsewhere classified | Diagnosis | ICD-10-CM |
| G31.2 | Degeneration of nervous system due to alcohol | Diagnosis | ICD-10-CM |
| G31.81 | Alpers disease | Diagnosis | ICD-10-CM |
| G31.82 | Leigh's disease | Diagnosis | ICD-10-CM |
| G31.83 | Dementia with Lewy bodies | Diagnosis | ICD-10-CM |
| G31.84 | Mild cognitive impairment, so stated | Diagnosis | ICD-10-CM |
| G31.85 | Corticobasal degeneration | Diagnosis | ICD-10-CM |
| G31.89 | Other specified degenerative diseases of nervous system | Diagnosis | ICD-10-CM |
| G31.9 | Degenerative disease of nervous system, unspecified | Diagnosis | ICD-10-CM |
| G44.209 | Tension-type headache, unspecified, not intractable | Diagnosis | ICD-10-CM |
| G47 | Sleep disorders | Diagnosis | ICD-10-CM |
| G47.0 | Insomnia | Diagnosis | ICD-10-CM |
| G47.00 | Insomnia, unspecified | Diagnosis | ICD-10-CM |
| G47.01 | Insomnia due to medical condition | Diagnosis | ICD-10-CM |
| G47.09 | Other insomnia | Diagnosis | ICD-10-CM |
| G47.1 | Hypersomnia | Diagnosis | ICD-10-CM |
| G47.10 | Hypersomnia, unspecified | Diagnosis | ICD-10-CM |
| G47.11 | Idiopathic hypersomnia with long sleep time | Diagnosis | ICD-10-CM |
| G47.12 | Idiopathic hypersomnia without long sleep time | Diagnosis | ICD-10-CM |
| G47.13 | Recurrent hypersomnia | Diagnosis | ICD-10-CM |
| G47.14 | Hypersomnia due to medical condition | Diagnosis | ICD-10-CM |
| G47.19 | Other hypersomnia | Diagnosis | ICD-10-CM |
| G47.2 | Circadian rhythm sleep disorders | Diagnosis | ICD-10-CM |
| G47.20 | Circadian rhythm sleep disorder, unspecified type | Diagnosis | ICD-10-CM |
| G47.21 | Circadian rhythm sleep disorder, delayed sleep phase type | Diagnosis | ICD-10-CM |
| G47.22 | Circadian rhythm sleep disorder, advanced sleep phase type | Diagnosis | ICD-10-CM |
| G47.23 | Circadian rhythm sleep disorder, irregular sleep wake type | Diagnosis | ICD-10-CM |
| G47.24 | Circadian rhythm sleep disorder, free running type | Diagnosis | ICD-10-CM |
| G47.25 | Circadian rhythm sleep disorder, jet lag type | Diagnosis | ICD-10-CM |
| G47.26 | Circadian rhythm sleep disorder, shift work type | Diagnosis | ICD-10-CM |
| G47.27 | Circadian rhythm sleep disorder in conditions classified elsewhere | Diagnosis | ICD-10-CM |
| G47.29 | Other circadian rhythm sleep disorder | Diagnosis | ICD-10-CM |
| G47.3 | Sleep apnea | Diagnosis | ICD-10-CM |
| G47.30 | Sleep apnea, unspecified | Diagnosis | ICD-10-CM |
| G47.31 | Primary central sleep apnea | Diagnosis | ICD-10-CM |
| G47.33 | Obstructive sleep apnea (adult) (pediatric) | Diagnosis | ICD-10-CM |
| G47.34 | Idiopathic sleep related nonobstructive alveolar hypoventilation | Diagnosis | ICD-10-CM |
| G47.35 | Congenital central alveolar hypoventilation syndrome | Diagnosis | ICD-10-CM |
| G47.36 | Sleep related hypoventilation in conditions classified elsewhere | Diagnosis | ICD-10-CM |
| G47.37 | Central sleep apnea in conditions classified elsewhere | Diagnosis | ICD-10-CM |
| G47.39 | Other sleep apnea | Diagnosis | ICD-10-CM |
| G47.4 | Narcolepsy and cataplexy | Diagnosis | ICD-10-CM |
| G47.41 | Narcolepsy | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|---|---------------|------------|
| G47.411 | Narcolepsy with cataplexy | Diagnosis | ICD-10-CM |
| G47.419 | Narcolepsy without cataplexy | Diagnosis | ICD-10-CM |
| G47.42 | Narcolepsy in conditions classified elsewhere | Diagnosis | ICD-10-CM |
| G47.421 | Narcolepsy in conditions classified elsewhere with cataplexy | Diagnosis | ICD-10-CM |
| G47.429 | Narcolepsy in conditions classified elsewhere without cataplexy | Diagnosis | ICD-10-CM |
| G47.5 | Parasomnia | Diagnosis | ICD-10-CM |
| G47.50 | Parasomnia, unspecified | Diagnosis | ICD-10-CM |
| G47.51 | Confusional arousals | Diagnosis | ICD-10-CM |
| G47.52 | REM sleep behavior disorder | Diagnosis | ICD-10-CM |
| G47.53 | Recurrent isolated sleep paralysis | Diagnosis | ICD-10-CM |
| G47.54 | Parasomnia in conditions classified elsewhere | Diagnosis | ICD-10-CM |
| G47.59 | Other parasomnia | Diagnosis | ICD-10-CM |
| G47.6 | Sleep related movement disorders | Diagnosis | ICD-10-CM |
| G47.61 | Periodic limb movement disorder | Diagnosis | ICD-10-CM |
| G47.62 | Sleep related leg cramps | Diagnosis | ICD-10-CM |
| G47.63 | Sleep related bruxism | Diagnosis | ICD-10-CM |
| G47.69 | Other sleep related movement disorders | Diagnosis | ICD-10-CM |
| G47.8 | Other sleep disorders | Diagnosis | ICD-10-CM |
| G47.9 | Sleep disorder, unspecified | Diagnosis | ICD-10-CM |
| G62.1 | Alcoholic polyneuropathy | Diagnosis | ICD-10-CM |
| G91.0 | Communicating hydrocephalus | Diagnosis | ICD-10-CM |
| G91.1 | Obstructive hydrocephalus | Diagnosis | ICD-10-CM |
| G91.2 | (Idiopathic) normal pressure hydrocephalus | Diagnosis | ICD-10-CM |
| G91.3 | Post-traumatic hydrocephalus, unspecified | Diagnosis | ICD-10-CM |
| G91.4 | Hydrocephalus in diseases classified elsewhere | Diagnosis | ICD-10-CM |
| G91.8 | Other hydrocephalus | Diagnosis | ICD-10-CM |
| G91.9 | Hydrocephalus, unspecified | Diagnosis | ICD-10-CM |
| G93.40 | Encephalopathy, unspecified | Diagnosis | ICD-10-CM |
| G93.41 | Metabolic encephalopathy | Diagnosis | ICD-10-CM |
| G93.49 | Other encephalopathy | Diagnosis | ICD-10-CM |
| G93.7 | Reye's syndrome | Diagnosis | ICD-10-CM |
| G93.89 | Other specified disorders of brain | Diagnosis | ICD-10-CM |
| G93.9 | Disorder of brain, unspecified | Diagnosis | ICD-10-CM |
| G94 | Other disorders of brain in diseases classified elsewhere | Diagnosis | ICD-10-CM |
| GZ2ZZZZ | Crisis Intervention | Procedure | ICD-10-PCS |
| GZ50ZZZ | Individual Psychotherapy, Interactive | Procedure | ICD-10-PCS |
| GZ51ZZZ | Individual Psychotherapy, Behavioral | Procedure | ICD-10-PCS |
| GZ52ZZZ | Individual Psychotherapy, Cognitive | Procedure | ICD-10-PCS |
| GZ53ZZZ | Individual Psychotherapy, Interpersonal | Procedure | ICD-10-PCS |
| GZ54ZZZ | Individual Psychotherapy, Psychoanalysis | Procedure | ICD-10-PCS |
| GZ55ZZZ | Individual Psychotherapy, Psychodynamic | Procedure | ICD-10-PCS |
| GZ56ZZZ | Individual Psychotherapy, Supportive | Procedure | ICD-10-PCS |
| GZ58ZZZ | Individual Psychotherapy, Cognitive-Behavioral | Procedure | ICD-10-PCS |
| GZC9ZZZ | Biofeedback | Procedure | ICD-10-PCS |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|------------|
| GZFZZZ | Hypnosis | Procedure | ICD-10-PCS |
| GZHZZZ | Group Psychotherapy | Procedure | ICD-10-PCS |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | Procedure | HCPCS |
| H0007 | Alcohol and/or drug services; crisis intervention (outpatient) | Procedure | HCPCS |
| H0008 | Alcohol and/or drug services; subacute detoxification (hospital inpatient) | Procedure | HCPCS |
| H0010 | Alcohol and/or drug services; subacute detoxification (residential addiction program inpatient) | Procedure | HCPCS |
| H0011 | Alcohol and/or drug services; acute detoxification (residential addiction program inpatient) | Procedure | HCPCS |
| H0012 | Alcohol and/or drug services; subacute detoxification (residential addiction program outpatient) | Procedure | HCPCS |
| H0013 | Alcohol and/or drug services; acute detoxification (residential addiction program outpatient) | Procedure | HCPCS |
| H0014 | Alcohol and/or drug services; ambulatory detoxification | Procedure | HCPCS |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | Procedure | HCPCS |
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | Procedure | HCPCS |
| H0022 | Alcohol and/or drug intervention service (planned facilitation) | Procedure | HCPCS |
| H2035 | Alcohol and/or other drug treatment program, per hour | Procedure | HCPCS |
| H2036 | Alcohol and/or other drug treatment program, per diem | Procedure | HCPCS |
| H93.25 | Central auditory processing disorder | Diagnosis | ICD-10-CM |
| HZ2ZZZ | Detoxification Services for Substance Abuse Treatment | Procedure | ICD-10-PCS |
| HZ30ZZ | Individual Counseling for Substance Abuse Treatment, Cognitive | Procedure | ICD-10-PCS |
| HZ31ZZ | Individual Counseling for Substance Abuse Treatment, Behavioral | Procedure | ICD-10-PCS |
| HZ32ZZ | Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral | Procedure | ICD-10-PCS |
| HZ33ZZ | Individual Counseling for Substance Abuse Treatment, 12-Step | Procedure | ICD-10-PCS |
| HZ34ZZ | Individual Counseling for Substance Abuse Treatment, Interpersonal | Procedure | ICD-10-PCS |
| HZ35ZZ | Individual Counseling for Substance Abuse Treatment, Vocational | Procedure | ICD-10-PCS |
| HZ36ZZ | Individual Counseling for Substance Abuse Treatment, Psychoeducation | Procedure | ICD-10-PCS |
| HZ37ZZ | Individual Counseling for Substance Abuse Treatment, Motivational Enhancement | Procedure | ICD-10-PCS |
| HZ38ZZ | Individual Counseling for Substance Abuse Treatment, Confrontational | Procedure | ICD-10-PCS |
| HZ39ZZ | Individual Counseling for Substance Abuse Treatment, Continuing Care | Procedure | ICD-10-PCS |
| HZ3BZZ | Individual Counseling for Substance Abuse Treatment, Spiritual | Procedure | ICD-10-PCS |
| HZ40ZZ | Group Counseling for Substance Abuse Treatment, Cognitive | Procedure | ICD-10-PCS |
| HZ41ZZ | Group Counseling for Substance Abuse Treatment, Behavioral | Procedure | ICD-10-PCS |
| HZ42ZZ | Group Counseling for Substance Abuse Treatment, Cognitive-Behavioral | Procedure | ICD-10-PCS |
| HZ43ZZ | Group Counseling for Substance Abuse Treatment, 12-Step | Procedure | ICD-10-PCS |
| HZ44ZZ | Group Counseling for Substance Abuse Treatment, Interpersonal | Procedure | ICD-10-PCS |
| HZ45ZZ | Group Counseling for Substance Abuse Treatment, Vocational | Procedure | ICD-10-PCS |
| HZ46ZZ | Group Counseling for Substance Abuse Treatment, Psychoeducation | Procedure | ICD-10-PCS |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|------------|
| HZ47ZZZ | Group Counseling for Substance Abuse Treatment, Motivational Enhancement | Procedure | ICD-10-PCS |
| HZ48ZZZ | Group Counseling for Substance Abuse Treatment, Confrontational | Procedure | ICD-10-PCS |
| HZ49ZZZ | Group Counseling for Substance Abuse Treatment, Continuing Care | Procedure | ICD-10-PCS |
| HZ4BZZZ | Group Counseling for Substance Abuse Treatment, Spiritual | Procedure | ICD-10-PCS |
| HZ50ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Cognitive | Procedure | ICD-10-PCS |
| HZ51ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Behavioral | Procedure | ICD-10-PCS |
| HZ52ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Cognitive-Behavioral | Procedure | ICD-10-PCS |
| HZ53ZZZ | Individual Psychotherapy for Substance Abuse Treatment, 12-Step | Procedure | ICD-10-PCS |
| HZ54ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Interpersonal | Procedure | ICD-10-PCS |
| HZ55ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Interactive | Procedure | ICD-10-PCS |
| HZ56ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Psychoeducation | Procedure | ICD-10-PCS |
| HZ57ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Motivational Enhancement | Procedure | ICD-10-PCS |
| HZ58ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Confrontational | Procedure | ICD-10-PCS |
| HZ59ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Supportive | Procedure | ICD-10-PCS |
| HZ5BZZZ | Individual Psychotherapy for Substance Abuse Treatment, Psychoanalysis | Procedure | ICD-10-PCS |
| HZ5CZZZ | Individual Psychotherapy for Substance Abuse Treatment, Psychodynamic | Procedure | ICD-10-PCS |
| HZ5DZZZ | Individual Psychotherapy for Substance Abuse Treatment, Psychophysiological | Procedure | ICD-10-PCS |
| HZ63ZZZ | Family Counseling for Substance Abuse Treatment | Procedure | ICD-10-PCS |
| HZ83ZZZ | Medication Management for Substance Abuse Treatment, Antabuse | Procedure | ICD-10-PCS |
| HZ86ZZZ | Medication Management for Substance Abuse Treatment, Clonidine | Procedure | ICD-10-PCS |
| HZ88ZZZ | Medication Management for Substance Abuse Treatment, Psychiatric Medication | Procedure | ICD-10-PCS |
| HZ89ZZZ | Medication Management for Substance Abuse Treatment, Other Replacement Medication | Procedure | ICD-10-PCS |
| HZ93ZZZ | Pharmacotherapy for Substance Abuse Treatment, Antabuse | Procedure | ICD-10-PCS |
| HZ96ZZZ | Pharmacotherapy for Substance Abuse Treatment, Clonidine | Procedure | ICD-10-PCS |
| HZ98ZZZ | Pharmacotherapy for Substance Abuse Treatment, Psychiatric Medication | Procedure | ICD-10-PCS |
| HZ99ZZZ | Pharmacotherapy for Substance Abuse Treatment, Other Replacement Medication | Procedure | ICD-10-PCS |
| I42.6 | Alcoholic cardiomyopathy | Diagnosis | ICD-10-CM |
| I67.83 | Posterior reversible encephalopathy syndrome | Diagnosis | ICD-10-CM |
| J0570 | Buprenorphine implant, 74.2 mg | Procedure | HCPCS |
| J0571 | Buprenorphine, oral, 1 mg | Procedure | HCPCS |
| J0572 | Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine | Procedure | HCPCS |
| J0573 | Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg buprenorphine | Procedure | HCPCS |
| J0574 | Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine | Procedure | HCPCS |
| J0575 | Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine | Procedure | HCPCS |
| J0592 | Injection, buprenorphine HCl, 0.1 mg | Procedure | HCPCS |
| J1230 | Injection, methadone HCl, up to 10 mg | Procedure | HCPCS |
| J2212 | Injection, methyl naltrexone, 0.1 mg | Procedure | HCPCS |
| J2315 | Injection, naltrexone, depot form, 1 mg | Procedure | HCPCS |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| K29.2 | Alcoholic gastritis | Diagnosis | ICD-10-CM |
| K29.20 | Alcoholic gastritis without bleeding | Diagnosis | ICD-10-CM |
| K29.21 | Alcoholic gastritis with bleeding | Diagnosis | ICD-10-CM |
| K70.0 | Alcoholic fatty liver | Diagnosis | ICD-10-CM |
| K70.10 | Alcoholic hepatitis without ascites | Diagnosis | ICD-10-CM |
| K70.11 | Alcoholic hepatitis with ascites | Diagnosis | ICD-10-CM |
| K70.2 | Alcoholic fibrosis and sclerosis of liver | Diagnosis | ICD-10-CM |
| K70.30 | Alcoholic cirrhosis of liver without ascites | Diagnosis | ICD-10-CM |
| K70.31 | Alcoholic cirrhosis of liver with ascites | Diagnosis | ICD-10-CM |
| K70.40 | Alcoholic hepatic failure without coma | Diagnosis | ICD-10-CM |
| K70.41 | Alcoholic hepatic failure with coma | Diagnosis | ICD-10-CM |
| K70.9 | Alcoholic liver disease, unspecified | Diagnosis | ICD-10-CM |
| L8679 | Implantable neurostimulator, pulse generator, any type | Procedure | HCPCS |
| L8680 | Implantable neurostimulator electrode, each | Procedure | HCPCS |
| L8681 | Patient programmer (external) for use with implantable programmable neurostimulator pulse generator, replacement only | Procedure | HCPCS |
| L8682 | Implantable neurostimulator radiofrequency receiver | Procedure | HCPCS |
| L8683 | Radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receiver | Procedure | HCPCS |
| L8685 | Implantable neurostimulator pulse generator, single array, rechargeable, includes extension | Procedure | HCPCS |
| L8686 | Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension | Procedure | HCPCS |
| L8687 | Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension | Procedure | HCPCS |
| L8688 | Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension | Procedure | HCPCS |
| L8689 | External recharging system for battery (internal) for use with implantable neurostimulator, replacement only | Procedure | HCPCS |
| M1A.10X0 | Lead-induced chronic gout, unspecified site, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.10X1 | Lead-induced chronic gout, unspecified site, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1110 | Lead-induced chronic gout, right shoulder, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1111 | Lead-induced chronic gout, right shoulder, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1120 | Lead-induced chronic gout, left shoulder, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1121 | Lead-induced chronic gout, left shoulder, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1190 | Lead-induced chronic gout, unspecified shoulder, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1191 | Lead-induced chronic gout, unspecified shoulder, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1210 | Lead-induced chronic gout, right elbow, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1211 | Lead-induced chronic gout, right elbow, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1220 | Lead-induced chronic gout, left elbow, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1221 | Lead-induced chronic gout, left elbow, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1290 | Lead-induced chronic gout, unspecified elbow, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1291 | Lead-induced chronic gout, unspecified elbow, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1310 | Lead-induced chronic gout, right wrist, without tophus (tophi) | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| M1A.1311 | Lead-induced chronic gout, right wrist, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1320 | Lead-induced chronic gout, left wrist, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1321 | Lead-induced chronic gout, left wrist, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1390 | Lead-induced chronic gout, unspecified wrist, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1391 | Lead-induced chronic gout, unspecified wrist, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1410 | Lead-induced chronic gout, right hand, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1411 | Lead-induced chronic gout, right hand, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1420 | Lead-induced chronic gout, left hand, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1421 | Lead-induced chronic gout, left hand, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1490 | Lead-induced chronic gout, unspecified hand, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1491 | Lead-induced chronic gout, unspecified hand, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1510 | Lead-induced chronic gout, right hip, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1511 | Lead-induced chronic gout, right hip, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1520 | Lead-induced chronic gout, left hip, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1521 | Lead-induced chronic gout, left hip, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1590 | Lead-induced chronic gout, unspecified hip, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1591 | Lead-induced chronic gout, unspecified hip, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1610 | Lead-induced chronic gout, right knee, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1611 | Lead-induced chronic gout, right knee, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1620 | Lead-induced chronic gout, left knee, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1621 | Lead-induced chronic gout, left knee, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1690 | Lead-induced chronic gout, unspecified knee, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1691 | Lead-induced chronic gout, unspecified knee, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1710 | Lead-induced chronic gout, right ankle and foot, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1711 | Lead-induced chronic gout, right ankle and foot, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1720 | Lead-induced chronic gout, left ankle and foot, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1721 | Lead-induced chronic gout, left ankle and foot, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1790 | Lead-induced chronic gout, unspecified ankle and foot, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.1791 | Lead-induced chronic gout, unspecified ankle and foot, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.18X0 | Lead-induced chronic gout, vertebrae, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.18X1 | Lead-induced chronic gout, vertebrae, with tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.19X0 | Lead-induced chronic gout, multiple sites, without tophus (tophi) | Diagnosis | ICD-10-CM |
| M1A.19X1 | Lead-induced chronic gout, multiple sites, with tophus (tophi) | Diagnosis | ICD-10-CM |
| O35.5XX0 | Maternal care for (suspected) damage to fetus by drugs, not applicable or unspecified | Diagnosis | ICD-10-CM |
| O35.5XX1 | Maternal care for (suspected) damage to fetus by drugs, fetus 1 | Diagnosis | ICD-10-CM |
| O35.5XX2 | Maternal care for (suspected) damage to fetus by drugs, fetus 2 | Diagnosis | ICD-10-CM |
| O35.5XX3 | Maternal care for (suspected) damage to fetus by drugs, fetus 3 | Diagnosis | ICD-10-CM |
| O35.5XX4 | Maternal care for (suspected) damage to fetus by drugs, fetus 4 | Diagnosis | ICD-10-CM |
| O35.5XX5 | Maternal care for (suspected) damage to fetus by drugs, fetus 5 | Diagnosis | ICD-10-CM |
| O35.5XX9 | Maternal care for (suspected) damage to fetus by drugs, other fetus | Diagnosis | ICD-10-CM |
| O90.6 | Postpartum mood disturbance | Diagnosis | ICD-10-CM |
| O99.310 | Alcohol use complicating pregnancy, unspecified trimester | Diagnosis | ICD-10-CM |
| O99.311 | Alcohol use complicating pregnancy, first trimester | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| O99.312 | Alcohol use complicating pregnancy, second trimester | Diagnosis | ICD-10-CM |
| O99.313 | Alcohol use complicating pregnancy, third trimester | Diagnosis | ICD-10-CM |
| O99.314 | Alcohol use complicating childbirth | Diagnosis | ICD-10-CM |
| O99.315 | Alcohol use complicating the puerperium | Diagnosis | ICD-10-CM |
| O99.320 | Drug use complicating pregnancy, unspecified trimester | Diagnosis | ICD-10-CM |
| O99.321 | Drug use complicating pregnancy, first trimester | Diagnosis | ICD-10-CM |
| O99.322 | Drug use complicating pregnancy, second trimester | Diagnosis | ICD-10-CM |
| O99.323 | Drug use complicating pregnancy, third trimester | Diagnosis | ICD-10-CM |
| O99.324 | Drug use complicating childbirth | Diagnosis | ICD-10-CM |
| O99.325 | Drug use complicating the puerperium | Diagnosis | ICD-10-CM |
| Q9991 | Injection, buprenorphine extended-release (Sublocade), less than or equal to 100 mg | Procedure | HCPCS |
| Q9992 | Injection, buprenorphine extended-release (Sublocade), greater than 100 mg | Procedure | HCPCS |
| R37 | Sexual dysfunction, unspecified | Diagnosis | ICD-10-CM |
| R44.0 | Auditory hallucinations | Diagnosis | ICD-10-CM |
| R44.2 | Other hallucinations | Diagnosis | ICD-10-CM |
| R44.3 | Hallucinations, unspecified | Diagnosis | ICD-10-CM |
| R45.1 | Restlessness and agitation | Diagnosis | ICD-10-CM |
| R45.2 | Unhappiness | Diagnosis | ICD-10-CM |
| R45.3 | Demoralization and apathy | Diagnosis | ICD-10-CM |
| R45.4 | Irritability and anger | Diagnosis | ICD-10-CM |
| R45.5 | Hostility | Diagnosis | ICD-10-CM |
| R45.6 | Violent behavior | Diagnosis | ICD-10-CM |
| R45.7 | State of emotional shock and stress, unspecified | Diagnosis | ICD-10-CM |
| R45.81 | Low self-esteem | Diagnosis | ICD-10-CM |
| R45.82 | Worries | Diagnosis | ICD-10-CM |
| R45.83 | Excessive crying of child, adolescent or adult | Diagnosis | ICD-10-CM |
| R45.84 | Anhedonia | Diagnosis | ICD-10-CM |
| R45.850 | Homicidal ideations | Diagnosis | ICD-10-CM |
| R45.851 | Suicidal ideations | Diagnosis | ICD-10-CM |
| R45.86 | Emotional lability | Diagnosis | ICD-10-CM |
| R45.89 | Other symptoms and signs involving emotional state | Diagnosis | ICD-10-CM |
| R46.0 | Very low level of personal hygiene | Diagnosis | ICD-10-CM |
| R46.1 | Bizarre personal appearance | Diagnosis | ICD-10-CM |
| R46.2 | Strange and inexplicable behavior | Diagnosis | ICD-10-CM |
| R46.3 | Overactivity | Diagnosis | ICD-10-CM |
| R46.4 | Slowness and poor responsiveness | Diagnosis | ICD-10-CM |
| R46.5 | Suspiciousness and marked evasiveness | Diagnosis | ICD-10-CM |
| R46.6 | Undue concern and preoccupation with stressful events | Diagnosis | ICD-10-CM |
| R46.7 | Verbosity and circumstantial detail obscuring reason for contact | Diagnosis | ICD-10-CM |
| R46.81 | Obsessive-compulsive behavior | Diagnosis | ICD-10-CM |
| R46.89 | Other symptoms and signs involving appearance and behavior | Diagnosis | ICD-10-CM |
| R48.0 | Dyslexia and alexia | Diagnosis | ICD-10-CM |
| S0109 | Methadone, oral, 5 mg | Procedure | HCPCS |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T1006 | Alcohol and/or substance abuse services, family/couple counseling | Procedure | HCPCS |
| T1007 | Alcohol and/or substance abuse services, treatment plan development and/or modification | Procedure | HCPCS |
| T1008 | Day treatment for individual alcohol and/or substance abuse services | Procedure | HCPCS |
| T1010 | Meals for individuals receiving alcohol and/or substance abuse services (when meals not included in the program) | Procedure | HCPCS |
| T1012 | Alcohol and/or substance abuse services, skills development | Procedure | HCPCS |
| T14.91 | Suicide attempt | Diagnosis | ICD-10-CM |
| T14.91XA | Suicide attempt, initial encounter | Diagnosis | ICD-10-CM |
| T14.91XD | Suicide attempt, subsequent encounter | Diagnosis | ICD-10-CM |
| T14.91XS | Suicide attempt, sequela | Diagnosis | ICD-10-CM |
| T36.0X1A | Poisoning by penicillins, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T36.0X2A | Poisoning by penicillins, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.0X2D | Poisoning by penicillins, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.0X2S | Poisoning by penicillins, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.0X3A | Poisoning by penicillins, assault, initial encounter | Diagnosis | ICD-10-CM |
| T36.0X4A | Poisoning by penicillins, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T36.1X1A | Poisoning by cephalosporins and other beta-lactam antibiotics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T36.1X2A | Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.1X2D | Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.1X2S | Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.1X3A | Poisoning by cephalosporins and other beta-lactam antibiotics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T36.1X4A | Poisoning by cephalosporins and other beta-lactam antibiotics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T36.2X1A | Poisoning by chloramphenicol group, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T36.2X2A | Poisoning by chloramphenicol group, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.2X2D | Poisoning by chloramphenicol group, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.2X2S | Poisoning by chloramphenicol group, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.2X3A | Poisoning by chloramphenicol group, assault, initial encounter | Diagnosis | ICD-10-CM |
| T36.2X4A | Poisoning by chloramphenicol group, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T36.3X1A | Poisoning by macrolides, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T36.3X2A | Poisoning by macrolides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.3X2D | Poisoning by macrolides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.3X2S | Poisoning by macrolides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.3X3A | Poisoning by macrolides, assault, initial encounter | Diagnosis | ICD-10-CM |
| T36.3X4A | Poisoning by macrolides, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T36.4X1A | Poisoning by tetracyclines, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T36.4X2A | Poisoning by tetracyclines, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.4X2D | Poisoning by tetracyclines, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.4X2S | Poisoning by tetracyclines, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.4X3A | Poisoning by tetracyclines, assault, initial encounter | Diagnosis | ICD-10-CM |
| T36.4X4A | Poisoning by tetracyclines, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T36.5X1A | Poisoning by aminoglycosides, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T36.5X2A | Poisoning by aminoglycosides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.5X2D | Poisoning by aminoglycosides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.5X2S | Poisoning by aminoglycosides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.5X3A | Poisoning by aminoglycosides, assault, initial encounter | Diagnosis | ICD-10-CM |
| T36.5X4A | Poisoning by aminoglycosides, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T36.6X1A | Poisoning by rifampicins, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T36.6X2A | Poisoning by rifampicins, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.6X2D | Poisoning by rifampicins, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.6X2S | Poisoning by rifampicins, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.6X3A | Poisoning by rifampicins, assault, initial encounter | Diagnosis | ICD-10-CM |
| T36.6X4A | Poisoning by rifampicins, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T36.7X1A | Poisoning by antifungal antibiotics, systemically used, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T36.7X2A | Poisoning by antifungal antibiotics, systemically used, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.7X2D | Poisoning by antifungal antibiotics, systemically used, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.7X2S | Poisoning by antifungal antibiotics, systemically used, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.7X3A | Poisoning by antifungal antibiotics, systemically used, assault, initial encounter | Diagnosis | ICD-10-CM |
| T36.7X4A | Poisoning by antifungal antibiotics, systemically used, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T36.8X1A | Poisoning by other systemic antibiotics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T36.8X2A | Poisoning by other systemic antibiotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.8X2D | Poisoning by other systemic antibiotics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.8X2S | Poisoning by other systemic antibiotics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.8X3A | Poisoning by other systemic antibiotics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T36.8X4A | Poisoning by other systemic antibiotics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T36.91XA | Poisoning by unspecified systemic antibiotic, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T36.92XA | Poisoning by unspecified systemic antibiotic, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.92XD | Poisoning by unspecified systemic antibiotic, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.92XS | Poisoning by unspecified systemic antibiotic, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.93XA | Poisoning by unspecified systemic antibiotic, assault, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T36.94XA | Poisoning by unspecified systemic antibiotic, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T37.0X1A | Poisoning by sulfonamides, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T37.0X2A | Poisoning by sulfonamides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.0X2D | Poisoning by sulfonamides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.0X2S | Poisoning by sulfonamides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.0X3A | Poisoning by sulfonamides, assault, initial encounter | Diagnosis | ICD-10-CM |
| T37.0X4A | Poisoning by sulfonamides, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T37.1X1A | Poisoning by antimycobacterial drugs, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T37.1X2A | Poisoning by antimycobacterial drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.1X2D | Poisoning by antimycobacterial drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.1X2S | Poisoning by antimycobacterial drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.1X3A | Poisoning by antimycobacterial drugs, assault, initial encounter | Diagnosis | ICD-10-CM |
| T37.1X4A | Poisoning by antimycobacterial drugs, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T37.2X1A | Poisoning by antimalarials and drugs acting on other blood protozoa, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T37.2X2A | Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.2X2D | Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.2X2S | Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.2X3A | Poisoning by antimalarials and drugs acting on other blood protozoa, assault, initial encounter | Diagnosis | ICD-10-CM |
| T37.2X4A | Poisoning by antimalarials and drugs acting on other blood protozoa, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T37.3X1A | Poisoning by other antiprotozoal drugs, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T37.3X2A | Poisoning by other antiprotozoal drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.3X2D | Poisoning by other antiprotozoal drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.3X2S | Poisoning by other antiprotozoal drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.3X3A | Poisoning by other antiprotozoal drugs, assault, initial encounter | Diagnosis | ICD-10-CM |
| T37.3X4A | Poisoning by other antiprotozoal drugs, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T37.4X1A | Poisoning by anthelmintics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T37.4X2A | Poisoning by anthelmintics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.4X2D | Poisoning by anthelmintics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.4X2S | Poisoning by anthelmintics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.4X3A | Poisoning by anthelmintics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T37.4X4A | Poisoning by anthelmintics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T37.5X1A | Poisoning by antiviral drugs, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T37.5X2A | Poisoning by antiviral drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.5X2D | Poisoning by antiviral drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T37.5X2S | Poisoning by antiviral drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.5X3A | Poisoning by antiviral drugs, assault, initial encounter | Diagnosis | ICD-10-CM |
| T37.5X4A | Poisoning by antiviral drugs, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T37.8X1A | Poisoning by other specified systemic anti-infectives and antiparasitics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T37.8X2A | Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.8X2D | Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.8X2S | Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.8X3A | Poisoning by other specified systemic anti-infectives and antiparasitics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T37.8X4A | Poisoning by other specified systemic anti-infectives and antiparasitics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T37.91XA | Poisoning by unspecified systemic anti-infective and antiparasitics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T37.92XA | Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.92XD | Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.92XS | Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.93XA | Poisoning by unspecified systemic anti-infective and antiparasitics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T37.94XA | Poisoning by unspecified systemic anti-infective and antiparasitics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T38.0X1A | Poisoning by glucocorticoids and synthetic analogues, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T38.0X2A | Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.0X2D | Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.0X2S | Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.0X3A | Poisoning by glucocorticoids and synthetic analogues, assault, initial encounter | Diagnosis | ICD-10-CM |
| T38.0X4A | Poisoning by glucocorticoids and synthetic analogues, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T38.1X1A | Poisoning by thyroid hormones and substitutes, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T38.1X2A | Poisoning by thyroid hormones and substitutes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.1X2D | Poisoning by thyroid hormones and substitutes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T38.1X2S | Poisoning by thyroid hormones and substitutes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.1X3A | Poisoning by thyroid hormones and substitutes, assault, initial encounter | Diagnosis | ICD-10-CM |
| T38.1X4A | Poisoning by thyroid hormones and substitutes, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T38.2X1A | Poisoning by antithyroid drugs, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T38.2X2A | Poisoning by antithyroid drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.2X2D | Poisoning by antithyroid drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.2X2S | Poisoning by antithyroid drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.2X3A | Poisoning by antithyroid drugs, assault, initial encounter | Diagnosis | ICD-10-CM |
| T38.2X4A | Poisoning by antithyroid drugs, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T38.3X1A | Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T38.3X2A | Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.3X2D | Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.3X2S | Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.3X3A | Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, assault, initial encounter | Diagnosis | ICD-10-CM |
| T38.3X4A | Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T38.4X1A | Poisoning by oral contraceptives, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T38.4X2A | Poisoning by oral contraceptives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.4X2D | Poisoning by oral contraceptives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.4X2S | Poisoning by oral contraceptives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.4X3A | Poisoning by oral contraceptives, assault, initial encounter | Diagnosis | ICD-10-CM |
| T38.4X4A | Poisoning by oral contraceptives, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T38.5X1A | Poisoning by other estrogens and progestogens, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T38.5X2A | Poisoning by other estrogens and progestogens, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.5X2D | Poisoning by other estrogens and progestogens, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.5X2S | Poisoning by other estrogens and progestogens, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.5X3A | Poisoning by other estrogens and progestogens, assault, initial encounter | Diagnosis | ICD-10-CM |
| T38.5X4A | Poisoning by other estrogens and progestogens, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T38.6X1A | Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T38.6X2A | Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.6X2D | Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T38.6X2S | Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.6X3A | Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, assault, initial encounter | Diagnosis | ICD-10-CM |
| T38.6X4A | Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T38.7X1A | Poisoning by androgens and anabolic congeners, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T38.7X2A | Poisoning by androgens and anabolic congeners, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.7X2D | Poisoning by androgens and anabolic congeners, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.7X2S | Poisoning by androgens and anabolic congeners, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.7X3A | Poisoning by androgens and anabolic congeners, assault, initial encounter | Diagnosis | ICD-10-CM |
| T38.7X4A | Poisoning by androgens and anabolic congeners, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T38.801A | Poisoning by unspecified hormones and synthetic substitutes, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T38.802A | Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.802D | Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.802S | Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.803A | Poisoning by unspecified hormones and synthetic substitutes, assault, initial encounter | Diagnosis | ICD-10-CM |
| T38.804A | Poisoning by unspecified hormones and synthetic substitutes, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T38.811A | Poisoning by anterior pituitary [adenohypophyseal] hormones, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T38.812A | Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.812D | Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.812S | Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.813A | Poisoning by anterior pituitary [adenohypophyseal] hormones, assault, initial encounter | Diagnosis | ICD-10-CM |
| T38.814A | Poisoning by anterior pituitary [adenohypophyseal] hormones, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T38.891A | Poisoning by other hormones and synthetic substitutes, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T38.892A | Poisoning by other hormones and synthetic substitutes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T38.892D | Poisoning by other hormones and synthetic substitutes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.892S | Poisoning by other hormones and synthetic substitutes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.893A | Poisoning by other hormones and synthetic substitutes, assault, initial encounter | Diagnosis | ICD-10-CM |
| T38.894A | Poisoning by other hormones and synthetic substitutes, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T38.901A | Poisoning by unspecified hormone antagonists, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T38.902A | Poisoning by unspecified hormone antagonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.902D | Poisoning by unspecified hormone antagonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.902S | Poisoning by unspecified hormone antagonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.903A | Poisoning by unspecified hormone antagonists, assault, initial encounter | Diagnosis | ICD-10-CM |
| T38.904A | Poisoning by unspecified hormone antagonists, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T38.991A | Poisoning by other hormone antagonists, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T38.992A | Poisoning by other hormone antagonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.992D | Poisoning by other hormone antagonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.992S | Poisoning by other hormone antagonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.993A | Poisoning by other hormone antagonists, assault, initial encounter | Diagnosis | ICD-10-CM |
| T38.994A | Poisoning by other hormone antagonists, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T39.011A | Poisoning by aspirin, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T39.012A | Poisoning by aspirin, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.012D | Poisoning by aspirin, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.012S | Poisoning by aspirin, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.013A | Poisoning by aspirin, assault, initial encounter | Diagnosis | ICD-10-CM |
| T39.014A | Poisoning by aspirin, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T39.091A | Poisoning by salicylates, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T39.092A | Poisoning by salicylates, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.092D | Poisoning by salicylates, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.092S | Poisoning by salicylates, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.093A | Poisoning by salicylates, assault, initial encounter | Diagnosis | ICD-10-CM |
| T39.094A | Poisoning by salicylates, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T39.1X1A | Poisoning by 4-Aminophenol derivatives, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T39.1X2A | Poisoning by 4-Aminophenol derivatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.1X2D | Poisoning by 4-Aminophenol derivatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.1X2S | Poisoning by 4-Aminophenol derivatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T39.1X3A | Poisoning by 4-Aminophenol derivatives, assault, initial encounter | Diagnosis | ICD-10-CM |
| T39.1X4A | Poisoning by 4-Aminophenol derivatives, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T39.2X1A | Poisoning by pyrazolone derivatives, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T39.2X2A | Poisoning by pyrazolone derivatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.2X2D | Poisoning by pyrazolone derivatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.2X2S | Poisoning by pyrazolone derivatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.2X3A | Poisoning by pyrazolone derivatives, assault, initial encounter | Diagnosis | ICD-10-CM |
| T39.2X4A | Poisoning by pyrazolone derivatives, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T39.311A | Poisoning by propionic acid derivatives, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T39.312A | Poisoning by propionic acid derivatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.312D | Poisoning by propionic acid derivatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.312S | Poisoning by propionic acid derivatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.313A | Poisoning by propionic acid derivatives, assault, initial encounter | Diagnosis | ICD-10-CM |
| T39.314A | Poisoning by propionic acid derivatives, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T39.391A | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T39.392A | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.392D | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.392S | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.393A | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], assault, initial encounter | Diagnosis | ICD-10-CM |
| T39.394A | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T39.4X1A | Poisoning by antirheumatics, not elsewhere classified, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T39.4X2A | Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.4X2D | Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.4X2S | Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.4X3A | Poisoning by antirheumatics, not elsewhere classified, assault, initial encounter | Diagnosis | ICD-10-CM |
| T39.4X4A | Poisoning by antirheumatics, not elsewhere classified, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T39.8X1A | Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|-------------|---|----------------------|------------------|
| T39.8X2A | Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.8X2D | Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.8X2S | Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.8X3A | Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, assault, initial encounter | Diagnosis | ICD-10-CM |
| T39.8X4A | Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T39.91XA | Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T39.92XA | Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.92XD | Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.92XS | Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.93XA | Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, assault, initial encounter | Diagnosis | ICD-10-CM |
| T39.94XA | Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.0X1A | Poisoning by opium, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.0X1D | Poisoning by opium, accidental (unintentional), subsequent encounter | Diagnosis | ICD-10-CM |
| T40.0X1S | Poisoning by opium, accidental (unintentional), sequela | Diagnosis | ICD-10-CM |
| T40.0X2A | Poisoning by opium, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.0X2D | Poisoning by opium, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.0X2S | Poisoning by opium, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.0X3A | Poisoning by opium, assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.0X3D | Poisoning by opium, assault, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.0X3S | Poisoning by opium, assault, sequela | Diagnosis | ICD-10-CM |
| T40.0X4A | Poisoning by opium, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.0X4D | Poisoning by opium, undetermined, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.0X4S | Poisoning by opium, undetermined, sequela | Diagnosis | ICD-10-CM |
| T40.0X5A | Adverse effect of opium, initial encounter | Diagnosis | ICD-10-CM |
| T40.0X5D | Adverse effect of opium, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.0X5S | Adverse effect of opium, sequela | Diagnosis | ICD-10-CM |
| T40.0X6A | Underdosing of opium, initial encounter | Diagnosis | ICD-10-CM |
| T40.0X6D | Underdosing of opium, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.0X6S | Underdosing of opium, sequela | Diagnosis | ICD-10-CM |
| T40.1X1A | Poisoning by heroin, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.1X1D | Poisoning by heroin, accidental (unintentional), subsequent encounter | Diagnosis | ICD-10-CM |
| T40.1X1S | Poisoning by heroin, accidental (unintentional), sequela | Diagnosis | ICD-10-CM |
| T40.1X2A | Poisoning by heroin, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T40.1X2D | Poisoning by heroin, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.1X2S | Poisoning by heroin, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.1X3A | Poisoning by heroin, assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.1X3D | Poisoning by heroin, assault, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.1X3S | Poisoning by heroin, assault, sequela | Diagnosis | ICD-10-CM |
| T40.1X4A | Poisoning by heroin, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.1X4D | Poisoning by heroin, undetermined, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.1X4S | Poisoning by heroin, undetermined, sequela | Diagnosis | ICD-10-CM |
| T40.1X5A | Adverse effect of heroin, initial encounter | Diagnosis | ICD-10-CM |
| T40.1X5D | Adverse effect of heroin, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.1X5S | Adverse effect of heroin, sequela | Diagnosis | ICD-10-CM |
| T40.2X1A | Poisoning by other opioids, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.2X2A | Poisoning by other opioids, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.2X2D | Poisoning by other opioids, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.2X2S | Poisoning by other opioids, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.2X3A | Poisoning by other opioids, assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.2X4A | Poisoning by other opioids, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.3X1A | Poisoning by methadone, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.3X2A | Poisoning by methadone, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.3X2D | Poisoning by methadone, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.3X2S | Poisoning by methadone, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.3X3A | Poisoning by methadone, assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.3X4A | Poisoning by methadone, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.4X1A | Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.4X2A | Poisoning by other synthetic narcotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.4X2D | Poisoning by other synthetic narcotics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.4X2S | Poisoning by other synthetic narcotics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.4X3A | Poisoning by other synthetic narcotics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.4X4A | Poisoning by other synthetic narcotics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.5X1A | Poisoning by cocaine, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.5X1D | Poisoning by cocaine, accidental (unintentional), subsequent encounter | Diagnosis | ICD-10-CM |
| T40.5X1S | Poisoning by cocaine, accidental (unintentional), sequela | Diagnosis | ICD-10-CM |
| T40.5X2A | Poisoning by cocaine, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.5X2D | Poisoning by cocaine, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.5X2S | Poisoning by cocaine, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.5X3A | Poisoning by cocaine, assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.5X3D | Poisoning by cocaine, assault, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.5X3S | Poisoning by cocaine, assault, sequela | Diagnosis | ICD-10-CM |
| T40.5X4A | Poisoning by cocaine, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.5X4D | Poisoning by cocaine, undetermined, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.5X4S | Poisoning by cocaine, undetermined, sequela | Diagnosis | ICD-10-CM |
| T40.5X5A | Adverse effect of cocaine, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T40.5X5D | Adverse effect of cocaine, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.5X5S | Adverse effect of cocaine, sequela | Diagnosis | ICD-10-CM |
| T40.5X6A | Underdosing of cocaine, initial encounter | Diagnosis | ICD-10-CM |
| T40.5X6D | Underdosing of cocaine, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.5X6S | Underdosing of cocaine, sequela | Diagnosis | ICD-10-CM |
| T40.601A | Poisoning by unspecified narcotics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.602A | Poisoning by unspecified narcotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.602D | Poisoning by unspecified narcotics, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T40.602S | Poisoning by unspecified narcotics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.603A | Poisoning by unspecified narcotics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.604A | Poisoning by unspecified narcotics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.691A | Poisoning by other narcotics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.692A | Poisoning by other narcotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.692D | Poisoning by other narcotics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.692S | Poisoning by other narcotics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.693A | Poisoning by other narcotics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.694A | Poisoning by other narcotics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.7X1A | Poisoning by cannabis (derivatives), accidental (unintentional), initial | Diagnosis | ICD-10-CM |
| T40.7X1D | Poisoning by cannabis (derivatives), accidental (unintentional), subsequent encounter | Diagnosis | ICD-10-CM |
| T40.7X1S | Poisoning by cannabis (derivatives), accidental (unintentional), sequela | Diagnosis | ICD-10-CM |
| T40.7X2A | Poisoning by cannabis (derivatives), intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.7X2D | Poisoning by cannabis (derivatives), intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.7X2S | Poisoning by cannabis (derivatives), intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.7X3A | Poisoning by cannabis (derivatives), assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.7X3D | Poisoning by cannabis (derivatives), assault, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.7X3S | Poisoning by cannabis (derivatives), assault, sequela | Diagnosis | ICD-10-CM |
| T40.7X4A | Poisoning by cannabis (derivatives), undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.7X4D | Poisoning by cannabis (derivatives), undetermined, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.7X4S | Poisoning by cannabis (derivatives), undetermined, sequela | Diagnosis | ICD-10-CM |
| T40.7X5A | Adverse effect of cannabis (derivatives), initial encounter | Diagnosis | ICD-10-CM |
| T40.7X5D | Adverse effect of cannabis (derivatives), subsequent encounter | Diagnosis | ICD-10-CM |
| T40.7X5S | Adverse effect of cannabis (derivatives), sequela | Diagnosis | ICD-10-CM |
| T40.7X6A | Underdosing of cannabis (derivatives), initial encounter | Diagnosis | ICD-10-CM |
| T40.7X6D | Underdosing of cannabis (derivatives), subsequent encounter | Diagnosis | ICD-10-CM |
| T40.7X6S | Underdosing of cannabis (derivatives), sequela | Diagnosis | ICD-10-CM |
| T40.8X1A | Poisoning by lysergide [LSD], accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.8X1D | Poisoning by lysergide [LSD], accidental (unintentional), subsequent encounter | Diagnosis | ICD-10-CM |
| T40.8X1S | Poisoning by lysergide [LSD], accidental (unintentional), sequela | Diagnosis | ICD-10-CM |
| T40.8X2A | Poisoning by lysergide [LSD], intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.8X2D | Poisoning by lysergide [LSD], intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.8X2S | Poisoning by lysergide [LSD], intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.8X3A | Poisoning by lysergide [LSD], assault, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T40.8X3D | Poisoning by lysergide [LSD], assault, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.8X3S | Poisoning by lysergide [LSD], assault, sequela | Diagnosis | ICD-10-CM |
| T40.8X4A | Poisoning by lysergide [LSD], undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.8X4D | Poisoning by lysergide [LSD], undetermined, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.8X4S | Poisoning by lysergide [LSD], undetermined, sequela | Diagnosis | ICD-10-CM |
| T40.8X5A | Adverse effect of lysergide [LSD], initial encounter | Diagnosis | ICD-10-CM |
| T40.8X5D | Adverse effect of lysergide [LSD], subsequent encounter | Diagnosis | ICD-10-CM |
| T40.8X5S | Adverse effect of lysergide [LSD], sequela | Diagnosis | ICD-10-CM |
| T40.901A | Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.901D | Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), subsequent encounter | Diagnosis | ICD-10-CM |
| T40.901S | Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), sequela | Diagnosis | ICD-10-CM |
| T40.902A | Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.902D | Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.902S | Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.903A | Poisoning by unspecified psychodysleptics [hallucinogens], assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.903D | Poisoning by unspecified psychodysleptics [hallucinogens], assault, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.903S | Poisoning by unspecified psychodysleptics [hallucinogens], assault, sequela | Diagnosis | ICD-10-CM |
| T40.904A | Poisoning by unspecified psychodysleptics [hallucinogens], undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.904D | Poisoning by unspecified psychodysleptics [hallucinogens], undetermined, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.904S | Poisoning by unspecified psychodysleptics [hallucinogens], undetermined, sequela | Diagnosis | ICD-10-CM |
| T40.905A | Adverse effect of unspecified psychodysleptics [hallucinogens], initial encounter | Diagnosis | ICD-10-CM |
| T40.905D | Adverse effect of unspecified psychodysleptics [hallucinogens], subsequent encounter | Diagnosis | ICD-10-CM |
| T40.905S | Adverse effect of unspecified psychodysleptics [hallucinogens], sequela | Diagnosis | ICD-10-CM |
| T40.906A | Underdosing of unspecified psychodysleptics [hallucinogens], initial encounter | Diagnosis | ICD-10-CM |
| T40.906D | Underdosing of unspecified psychodysleptics [hallucinogens], subsequent encounter | Diagnosis | ICD-10-CM |
| T40.906S | Underdosing of unspecified psychodysleptics [hallucinogens], sequela | Diagnosis | ICD-10-CM |
| T40.991A | Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.991D | Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T40.991S | Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), sequela | Diagnosis | ICD-10-CM |
| T40.992A | Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.992D | Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.992S | Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.993A | Poisoning by other psychodysleptics [hallucinogens], assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.993D | Poisoning by other psychodysleptics [hallucinogens], assault, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.993S | Poisoning by other psychodysleptics [hallucinogens], assault, sequela | Diagnosis | ICD-10-CM |
| T40.994A | Poisoning by other psychodysleptics [hallucinogens], undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.994D | Poisoning by other psychodysleptics [hallucinogens], undetermined, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.994S | Poisoning by other psychodysleptics [hallucinogens], undetermined, sequela | Diagnosis | ICD-10-CM |
| T40.995A | Adverse effect of other psychodysleptics [hallucinogens], initial encounter | Diagnosis | ICD-10-CM |
| T40.995D | Adverse effect of other psychodysleptics [hallucinogens], subsequent | Diagnosis | ICD-10-CM |
| T40.995S | Adverse effect of other psychodysleptics [hallucinogens], sequela | Diagnosis | ICD-10-CM |
| T40.996A | Underdosing of other psychodysleptics [hallucinogens], initial encounter | Diagnosis | ICD-10-CM |
| T40.996D | Underdosing of other psychodysleptics [hallucinogens], subsequent encounter | Diagnosis | ICD-10-CM |
| T40.996S | Underdosing of other psychodysleptics [hallucinogens], sequela | Diagnosis | ICD-10-CM |
| T41.0X1A | Poisoning by inhaled anesthetics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T41.0X2A | Poisoning by inhaled anesthetics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.0X2D | Poisoning by inhaled anesthetics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.0X2S | Poisoning by inhaled anesthetics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.0X3A | Poisoning by inhaled anesthetics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T41.0X4A | Poisoning by inhaled anesthetics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T41.1X1A | Poisoning by intravenous anesthetics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T41.1X2A | Poisoning by intravenous anesthetics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.1X2D | Poisoning by intravenous anesthetics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.1X2S | Poisoning by intravenous anesthetics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.1X3A | Poisoning by intravenous anesthetics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T41.1X4A | Poisoning by intravenous anesthetics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T41.201A | Poisoning by unspecified general anesthetics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T41.202A | Poisoning by unspecified general anesthetics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.202D | Poisoning by unspecified general anesthetics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.202S | Poisoning by unspecified general anesthetics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T41.203A | Poisoning by unspecified general anesthetics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T41.204A | Poisoning by unspecified general anesthetics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T41.291A | Poisoning by other general anesthetics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T41.292A | Poisoning by other general anesthetics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.292D | Poisoning by other general anesthetics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.292S | Poisoning by other general anesthetics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.293A | Poisoning by other general anesthetics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T41.294A | Poisoning by other general anesthetics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T41.3X1A | Poisoning by local anesthetics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T41.3X2A | Poisoning by local anesthetics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.3X2D | Poisoning by local anesthetics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.3X2S | Poisoning by local anesthetics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.3X3A | Poisoning by local anesthetics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T41.3X4A | Poisoning by local anesthetics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T41.41XA | Poisoning by unspecified anesthetic, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T41.42XA | Poisoning by unspecified anesthetic, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.42XD | Poisoning by unspecified anesthetic, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.42XS | Poisoning by unspecified anesthetic, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.43XA | Poisoning by unspecified anesthetic, assault, initial encounter | Diagnosis | ICD-10-CM |
| T41.44XA | Poisoning by unspecified anesthetic, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T41.5X2A | Poisoning by therapeutic gases, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.5X2D | Poisoning by therapeutic gases, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.5X2S | Poisoning by therapeutic gases, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.0X1A | Poisoning by hydantoin derivatives, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T42.0X2A | Poisoning by hydantoin derivatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.0X2D | Poisoning by hydantoin derivatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.0X2S | Poisoning by hydantoin derivatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.0X3A | Poisoning by hydantoin derivatives, assault, initial encounter | Diagnosis | ICD-10-CM |
| T42.0X4A | Poisoning by hydantoin derivatives, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T42.1X1A | Poisoning by iminostilbenes, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T42.1X2A | Poisoning by iminostilbenes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.1X2D | Poisoning by iminostilbenes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.1X2S | Poisoning by iminostilbenes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.1X3A | Poisoning by iminostilbenes, assault, initial encounter | Diagnosis | ICD-10-CM |
| T42.1X4A | Poisoning by iminostilbenes, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T42.2X1A | Poisoning by succinimides and oxazolidinediones, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T42.2X2A | Poisoning by succinimides and oxazolidinediones, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T42.2X2D | Poisoning by succinimides and oxazolidinediones, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.2X2S | Poisoning by succinimides and oxazolidinediones, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.2X3A | Poisoning by succinimides and oxazolidinediones, assault, initial encounter | Diagnosis | ICD-10-CM |
| T42.2X4A | Poisoning by succinimides and oxazolidinediones, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T42.3X1A | Poisoning by barbiturates, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T42.3X2A | Poisoning by barbiturates, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.3X2D | Poisoning by barbiturates, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.3X2S | Poisoning by barbiturates, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.3X3A | Poisoning by barbiturates, assault, initial encounter | Diagnosis | ICD-10-CM |
| T42.3X4A | Poisoning by barbiturates, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T42.4X1A | Poisoning by benzodiazepines, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T42.4X2A | Poisoning by benzodiazepines, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.4X2D | Poisoning by benzodiazepines, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.4X2S | Poisoning by benzodiazepines, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.4X3A | Poisoning by benzodiazepines, assault, initial encounter | Diagnosis | ICD-10-CM |
| T42.4X4A | Poisoning by benzodiazepines, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T42.5X1A | Poisoning by mixed antiepileptics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T42.5X2A | Poisoning by mixed antiepileptics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.5X2D | Poisoning by mixed antiepileptics, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T42.5X2S | Poisoning by mixed antiepileptics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.5X3A | Poisoning by mixed antiepileptics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T42.5X4A | Poisoning by mixed antiepileptics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T42.6X1A | Poisoning by other antiepileptic and sedative-hypnotic drugs, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T42.6X2A | Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.6X2D | Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.6X2S | Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.6X3A | Poisoning by other antiepileptic and sedative-hypnotic drugs, assault, initial encounter | Diagnosis | ICD-10-CM |
| T42.6X4A | Poisoning by other antiepileptic and sedative-hypnotic drugs, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T42.71XA | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T42.72XA | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.72XD | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.72XS | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T42.73XA | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, assault, initial encounter | Diagnosis | ICD-10-CM |
| T42.74XA | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T42.8X1A | Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T42.8X2A | Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.8X2D | Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.8X2S | Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.8X3A | Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, assault, initial encounter | Diagnosis | ICD-10-CM |
| T42.8X4A | Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T43.011A | Poisoning by tricyclic antidepressants, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.012A | Poisoning by tricyclic antidepressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.012D | Poisoning by tricyclic antidepressants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.012S | Poisoning by tricyclic antidepressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.013A | Poisoning by tricyclic antidepressants, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.014A | Poisoning by tricyclic antidepressants, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T43.021A | Poisoning by tetracyclic antidepressants, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.022A | Poisoning by tetracyclic antidepressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.022D | Poisoning by tetracyclic antidepressants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.022S | Poisoning by tetracyclic antidepressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.023A | Poisoning by tetracyclic antidepressants, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.024A | Poisoning by tetracyclic antidepressants, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T43.1X1A | Poisoning by monoamine-oxidase-inhibitor antidepressants, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.1X2A | Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.1X2D | Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.1X2S | Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.1X3A | Poisoning by monoamine-oxidase-inhibitor antidepressants, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.1X4A | Poisoning by monoamine-oxidase-inhibitor antidepressants, undetermined, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T43.201A | Poisoning by unspecified antidepressants, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.202A | Poisoning by unspecified antidepressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.202D | Poisoning by unspecified antidepressants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.202S | Poisoning by unspecified antidepressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.203A | Poisoning by unspecified antidepressants, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.204A | Poisoning by unspecified antidepressants, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T43.211A | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.212A | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.212D | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.212S | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.213A | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.214A | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T43.221A | Poisoning by selective serotonin reuptake inhibitors, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.222A | Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.222D | Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.222S | Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.223A | Poisoning by selective serotonin reuptake inhibitors, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.224A | Poisoning by selective serotonin reuptake inhibitors, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T43.291A | Poisoning by other antidepressants, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.292A | Poisoning by other antidepressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.292D | Poisoning by other antidepressants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.292S | Poisoning by other antidepressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.293A | Poisoning by other antidepressants, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.294A | Poisoning by other antidepressants, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T43.3X1A | Poisoning by phenothiazine antipsychotics and neuroleptics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.3X2A | Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T43.3X2D | Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.3X2S | Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.3X3A | Poisoning by phenothiazine antipsychotics and neuroleptics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.3X4A | Poisoning by phenothiazine antipsychotics and neuroleptics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T43.4X1A | Poisoning by butyrophenone and thiothixene neuroleptics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.4X2A | Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.4X2D | Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.4X2S | Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.4X3A | Poisoning by butyrophenone and thiothixene neuroleptics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.4X4A | Poisoning by butyrophenone and thiothixene neuroleptics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T43.501A | Poisoning by unspecified antipsychotics and neuroleptics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.502A | Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.502D | Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.502S | Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.503A | Poisoning by unspecified antipsychotics and neuroleptics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.504A | Poisoning by unspecified antipsychotics and neuroleptics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T43.591A | Poisoning by other antipsychotics and neuroleptics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.592A | Poisoning by other antipsychotics and neuroleptics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.592D | Poisoning by other antipsychotics and neuroleptics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.592S | Poisoning by other antipsychotics and neuroleptics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.593A | Poisoning by other antipsychotics and neuroleptics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.594A | Poisoning by other antipsychotics and neuroleptics, undetermined, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T43.601A | Poisoning by unspecified psychostimulants, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.602A | Poisoning by unspecified psychostimulants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.602D | Poisoning by unspecified psychostimulants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.602S | Poisoning by unspecified psychostimulants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.603A | Poisoning by unspecified psychostimulants, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.604A | Poisoning by unspecified psychostimulants, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T43.611A | Poisoning by caffeine, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.612A | Poisoning by caffeine, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.612D | Poisoning by caffeine, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.612S | Poisoning by caffeine, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.613A | Poisoning by caffeine, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.614A | Poisoning by caffeine, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T43.621A | Poisoning by amphetamines, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.622A | Poisoning by amphetamines, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.622D | Poisoning by amphetamines, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.622S | Poisoning by amphetamines, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.623A | Poisoning by amphetamines, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.624A | Poisoning by amphetamines, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T43.631A | Poisoning by methylphenidate, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.632A | Poisoning by methylphenidate, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.632D | Poisoning by methylphenidate, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.632S | Poisoning by methylphenidate, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.633A | Poisoning by methylphenidate, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.634A | Poisoning by methylphenidate, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T43.691A | Poisoning by other psychostimulants, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.692A | Poisoning by other psychostimulants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.692D | Poisoning by other psychostimulants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.692S | Poisoning by other psychostimulants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.693A | Poisoning by other psychostimulants, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.694A | Poisoning by other psychostimulants, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T43.8X1A | Poisoning by other psychotropic drugs, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.8X2A | Poisoning by other psychotropic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.8X2D | Poisoning by other psychotropic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.8X2S | Poisoning by other psychotropic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.8X3A | Poisoning by other psychotropic drugs, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.8X4A | Poisoning by other psychotropic drugs, undetermined, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T43.91XA | Poisoning by unspecified psychotropic drug, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T43.92XA | Poisoning by unspecified psychotropic drug, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.92XD | Poisoning by unspecified psychotropic drug, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.92XS | Poisoning by unspecified psychotropic drug, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.93XA | Poisoning by unspecified psychotropic drug, assault, initial encounter | Diagnosis | ICD-10-CM |
| T43.94XA | Poisoning by unspecified psychotropic drug, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T44.0X2A | Poisoning by anticholinesterase agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.0X2D | Poisoning by anticholinesterase agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.0X2S | Poisoning by anticholinesterase agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.1X2A | Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.1X2D | Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.1X2S | Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.2X2A | Poisoning by ganglionic blocking drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.2X2D | Poisoning by ganglionic blocking drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.2X2S | Poisoning by ganglionic blocking drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.3X2A | Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.3X2D | Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.3X2S | Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.4X2A | Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.4X2D | Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.4X2S | Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.5X2A | Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.5X2D | Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.5X2S | Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.6X2A | Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T44.6X2D | Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.6X2S | Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.7X2A | Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.7X2D | Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.7X2S | Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.8X2A | Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.8X2D | Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.8X2S | Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.902A | Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.902D | Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.902S | Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.992A | Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.992D | Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.992S | Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.0X1A | Poisoning by antiallergic and antiemetic drugs, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T45.0X2A | Poisoning by antiallergic and antiemetic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.0X2D | Poisoning by antiallergic and antiemetic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.0X2S | Poisoning by antiallergic and antiemetic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.0X3A | Poisoning by antiallergic and antiemetic drugs, assault, initial encounter | Diagnosis | ICD-10-CM |
| T45.0X4A | Poisoning by antiallergic and antiemetic drugs, undetermined, initial | Diagnosis | ICD-10-CM |
| T45.1X1A | Poisoning by antineoplastic and immunosuppressive drugs, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T45.1X2A | Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.1X2D | Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.1X2S | Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T45.1X3A | Poisoning by antineoplastic and immunosuppressive drugs, assault, initial encounter | Diagnosis | ICD-10-CM |
| T45.1X4A | Poisoning by antineoplastic and immunosuppressive drugs, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T45.2X1A | Poisoning by vitamins, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T45.2X2A | Poisoning by vitamins, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.2X2D | Poisoning by vitamins, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.2X2S | Poisoning by vitamins, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.2X3A | Poisoning by vitamins, assault, initial encounter | Diagnosis | ICD-10-CM |
| T45.2X4A | Poisoning by vitamins, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T45.3X1A | Poisoning by enzymes, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T45.3X2A | Poisoning by enzymes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.3X2D | Poisoning by enzymes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.3X2S | Poisoning by enzymes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.3X3A | Poisoning by enzymes, assault, initial encounter | Diagnosis | ICD-10-CM |
| T45.3X4A | Poisoning by enzymes, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T45.4X1A | Poisoning by iron and its compounds, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T45.4X2A | Poisoning by iron and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.4X2D | Poisoning by iron and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.4X2S | Poisoning by iron and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.4X3A | Poisoning by iron and its compounds, assault, initial encounter | Diagnosis | ICD-10-CM |
| T45.4X4A | Poisoning by iron and its compounds, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T45.511A | Poisoning by anticoagulants, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T45.512A | Poisoning by anticoagulants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.512D | Poisoning by anticoagulants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.512S | Poisoning by anticoagulants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.513A | Poisoning by anticoagulants, assault, initial encounter | Diagnosis | ICD-10-CM |
| T45.514A | Poisoning by anticoagulants, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T45.521A | Poisoning by antithrombotic drugs, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T45.522A | Poisoning by antithrombotic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.522D | Poisoning by antithrombotic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.522S | Poisoning by antithrombotic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.523A | Poisoning by antithrombotic drugs, assault, initial encounter | Diagnosis | ICD-10-CM |
| T45.524A | Poisoning by antithrombotic drugs, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T45.601A | Poisoning by unspecified fibrinolysis-affecting drugs, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T45.602A | Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.602D | Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T45.602S | Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.603A | Poisoning by unspecified fibrinolysis-affecting drugs, assault, initial encounter | Diagnosis | ICD-10-CM |
| T45.604A | Poisoning by unspecified fibrinolysis-affecting drugs, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T45.611A | Poisoning by thrombolytic drug, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T45.612A | Poisoning by thrombolytic drug, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.612D | Poisoning by thrombolytic drug, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.612S | Poisoning by thrombolytic drug, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.613A | Poisoning by thrombolytic drug, assault, initial encounter | Diagnosis | ICD-10-CM |
| T45.614A | Poisoning by thrombolytic drug, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T45.621A | Poisoning by hemostatic drug, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T45.622A | Poisoning by hemostatic drug, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.622D | Poisoning by hemostatic drug, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.622S | Poisoning by hemostatic drug, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.623A | Poisoning by hemostatic drug, assault, initial encounter | Diagnosis | ICD-10-CM |
| T45.624A | Poisoning by hemostatic drug, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T45.691A | Poisoning by other fibrinolysis-affecting drugs, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T45.692A | Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.692D | Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.692S | Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.693A | Poisoning by other fibrinolysis-affecting drugs, assault, initial encounter | Diagnosis | ICD-10-CM |
| T45.694A | Poisoning by other fibrinolysis-affecting drugs, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T45.7X1A | Poisoning by anticoagulant antagonists, vitamin K and other coagulants, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T45.7X2A | Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.7X2D | Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.7X2S | Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.7X3A | Poisoning by anticoagulant antagonists, vitamin K and other coagulants, assault, initial encounter | Diagnosis | ICD-10-CM |
| T45.7X4A | Poisoning by anticoagulant antagonists, vitamin K and other coagulants, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T45.8X1A | Poisoning by other primarily systemic and hematological agents, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T45.8X2A | Poisoning by other primarily systemic and hematological agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.8X2D | Poisoning by other primarily systemic and hematological agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T45.8X2S | Poisoning by other primarily systemic and hematological agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.8X3A | Poisoning by other primarily systemic and hematological agents, assault, initial encounter | Diagnosis | ICD-10-CM |
| T45.8X4A | Poisoning by other primarily systemic and hematological agents, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T45.91XA | Poisoning by unspecified primarily systemic and hematological agent, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T45.92XA | Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.92XD | Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.92XS | Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.93XA | Poisoning by unspecified primarily systemic and hematological agent, assault, initial encounter | Diagnosis | ICD-10-CM |
| T45.94XA | Poisoning by unspecified primarily systemic and hematological agent, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T46.0X2A | Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.0X2D | Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.0X2S | Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.1X2A | Poisoning by calcium-channel blockers, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.1X2D | Poisoning by calcium-channel blockers, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.1X2S | Poisoning by calcium-channel blockers, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.2X2A | Poisoning by other antidysrhythmic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.2X2D | Poisoning by other antidysrhythmic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.2X2S | Poisoning by other antidysrhythmic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.3X2A | Poisoning by coronary vasodilators, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.3X2D | Poisoning by coronary vasodilators, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.3X2S | Poisoning by coronary vasodilators, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.4X2A | Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.4X2D | Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.4X2S | Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T46.5X2A | Poisoning by other antihypertensive drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.5X2D | Poisoning by other antihypertensive drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.5X2S | Poisoning by other antihypertensive drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.6X2A | Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.6X2D | Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.6X2S | Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.7X2A | Poisoning by peripheral vasodilators, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.7X2D | Poisoning by peripheral vasodilators, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.7X2S | Poisoning by peripheral vasodilators, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.8X2A | Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.8X2D | Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.8X2S | Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.902A | Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.902D | Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.902S | Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.992A | Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.992D | Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.992S | Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.0X2A | Poisoning by histamine H2-receptor blockers, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.0X2D | Poisoning by histamine H2-receptor blockers, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.0X2S | Poisoning by histamine H2-receptor blockers, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.1X2A | Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.1X2D | Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.1X2S | Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T47.2X2A | Poisoning by stimulant laxatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.2X2D | Poisoning by stimulant laxatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.2X2S | Poisoning by stimulant laxatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.3X2A | Poisoning by saline and osmotic laxatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.3X2D | Poisoning by saline and osmotic laxatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.3X2S | Poisoning by saline and osmotic laxatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.4X2A | Poisoning by other laxatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.4X2D | Poisoning by other laxatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.4X2S | Poisoning by other laxatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.5X2A | Poisoning by digestants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.5X2D | Poisoning by digestants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.5X2S | Poisoning by digestants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.6X2A | Poisoning by antidiarrheal drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.6X2D | Poisoning by antidiarrheal drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.6X2S | Poisoning by antidiarrheal drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.7X2A | Poisoning by emetics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.7X2D | Poisoning by emetics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.7X2S | Poisoning by emetics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.8X2A | Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.8X2D | Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.8X2S | Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.92XA | Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.92XD | Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.92XS | Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.0X2A | Poisoning by oxytotic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.0X2D | Poisoning by oxytotic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.0X2S | Poisoning by oxytotic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.1X2A | Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.1X2D | Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.1X2S | Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.202A | Poisoning by unspecified drugs acting on muscles, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T48.202D | Poisoning by unspecified drugs acting on muscles, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.202S | Poisoning by unspecified drugs acting on muscles, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.292A | Poisoning by other drugs acting on muscles, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.292D | Poisoning by other drugs acting on muscles, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.292S | Poisoning by other drugs acting on muscles, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.3X2A | Poisoning by antitussives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.3X2D | Poisoning by antitussives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.3X2S | Poisoning by antitussives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.4X2A | Poisoning by expectorants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.4X2D | Poisoning by expectorants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.4X2S | Poisoning by expectorants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.5X2A | Poisoning by other anti-common-cold drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.5X2D | Poisoning by other anti-common-cold drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.5X2S | Poisoning by other anti-common-cold drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.6X2A | Poisoning by antiasthmatics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.6X2D | Poisoning by antiasthmatics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.6X2S | Poisoning by antiasthmatics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.902A | Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.902D | Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.902S | Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.992A | Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.992D | Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.992S | Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.0X2A | Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.0X2D | Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.0X2S | Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.1X2A | Poisoning by antipruritics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.1X2D | Poisoning by antipruritics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.1X2S | Poisoning by antipruritics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T49.2X2A | Poisoning by local astringents and local detergents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.2X2D | Poisoning by local astringents and local detergents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.2X2S | Poisoning by local astringents and local detergents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.3X2A | Poisoning by emollients, demulcents and protectants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.3X2D | Poisoning by emollients, demulcents and protectants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.3X2S | Poisoning by emollients, demulcents and protectants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.4X2A | Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.4X2D | Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.4X2S | Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.5X2A | Poisoning by ophthalmological drugs and preparations, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.5X2D | Poisoning by ophthalmological drugs and preparations, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.5X2S | Poisoning by ophthalmological drugs and preparations, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.6X2A | Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.6X2D | Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.6X2S | Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.7X2A | Poisoning by dental drugs, topically applied, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.7X2D | Poisoning by dental drugs, topically applied, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.7X2S | Poisoning by dental drugs, topically applied, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.8X2A | Poisoning by other topical agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.8X2D | Poisoning by other topical agents, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T49.8X2S | Poisoning by other topical agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.92XA | Poisoning by unspecified topical agent, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.92XD | Poisoning by unspecified topical agent, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.92XS | Poisoning by unspecified topical agent, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.0X1A | Poisoning by mineralocorticoids and their antagonists, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T50.0X2A | Poisoning by mineralocorticoids and their antagonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.0X2D | Poisoning by mineralocorticoids and their antagonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.0X2S | Poisoning by mineralocorticoids and their antagonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.0X3A | Poisoning by mineralocorticoids and their antagonists, assault, initial | Diagnosis | ICD-10-CM |
| T50.0X4A | Poisoning by mineralocorticoids and their antagonists, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T50.1X2A | Poisoning by loop [high-ceiling] diuretics, intentional self-harm, initial | Diagnosis | ICD-10-CM |
| T50.1X2D | Poisoning by loop [high-ceiling] diuretics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.1X2S | Poisoning by loop [high-ceiling] diuretics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.2X2A | Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.2X2D | Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.2X2S | Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.3X2A | Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.3X2D | Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.3X2S | Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.4X2A | Poisoning by drugs affecting uric acid metabolism, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.4X2D | Poisoning by drugs affecting uric acid metabolism, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.4X2S | Poisoning by drugs affecting uric acid metabolism, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.5X2A | Poisoning by appetite depressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.5X2D | Poisoning by appetite depressants, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T50.5X2S | Poisoning by appetite depressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.6X2A | Poisoning by antidotes and chelating agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.6X2D | Poisoning by antidotes and chelating agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.6X2S | Poisoning by antidotes and chelating agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.7X2A | Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.7X2D | Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T50.7X2S | Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.8X2A | Poisoning by diagnostic agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.8X2D | Poisoning by diagnostic agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.8X2S | Poisoning by diagnostic agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.902A | Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.902D | Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.902S | Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.992A | Poisoning by other drugs, medicaments and biological substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.992D | Poisoning by other drugs, medicaments and biological substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.992S | Poisoning by other drugs, medicaments and biological substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.A12A | Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.A12D | Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.A12S | Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.A22A | Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.A22D | Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.A22S | Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.A92A | Poisoning by other bacterial vaccines, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.A92D | Poisoning by other bacterial vaccines, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.A92S | Poisoning by other bacterial vaccines, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.B12A | Poisoning by smallpox vaccines, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.B12D | Poisoning by smallpox vaccines, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.B12S | Poisoning by smallpox vaccines, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.B92A | Poisoning by other viral vaccines, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.B92D | Poisoning by other viral vaccines, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.B92S | Poisoning by other viral vaccines, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.Z11A | Poisoning by immunoglobulin, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T50.Z12A | Poisoning by immunoglobulin, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.Z12D | Poisoning by immunoglobulin, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.Z12S | Poisoning by immunoglobulin, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.Z13A | Poisoning by immunoglobulin, assault, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T50.Z14A | Poisoning by immunoglobulin, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T50.Z92A | Poisoning by other vaccines and biological substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.Z92D | Poisoning by other vaccines and biological substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.Z92S | Poisoning by other vaccines and biological substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T51.0X1A | Toxic effect of ethanol, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T51.0X2A | Toxic effect of ethanol, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T51.0X2D | Toxic effect of ethanol, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T51.0X2S | Toxic effect of ethanol, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T51.0X3A | Toxic effect of ethanol, assault, initial encounter | Diagnosis | ICD-10-CM |
| T51.0X4A | Toxic effect of ethanol, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T51.1X1A | Toxic effect of methanol, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T51.1X2A | Toxic effect of methanol, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T51.1X2D | Toxic effect of methanol, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T51.1X2S | Toxic effect of methanol, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T51.1X3A | Toxic effect of methanol, assault, initial encounter | Diagnosis | ICD-10-CM |
| T51.1X4A | Toxic effect of methanol, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T51.2X1A | Toxic effect of 2-Propanol, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T51.2X2A | Toxic effect of 2-Propanol, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T51.2X2D | Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T51.2X2S | Toxic effect of 2-Propanol, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T51.2X3A | Toxic effect of 2-Propanol, assault, initial encounter | Diagnosis | ICD-10-CM |
| T51.2X4A | Toxic effect of 2-Propanol, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T51.3X1A | Toxic effect of fusel oil, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T51.3X2A | Toxic effect of fusel oil, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T51.3X2D | Toxic effect of fusel oil, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T51.3X2S | Toxic effect of fusel oil, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T51.3X3A | Toxic effect of fusel oil, assault, initial encounter | Diagnosis | ICD-10-CM |
| T51.3X4A | Toxic effect of fusel oil, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T51.8X1A | Toxic effect of other alcohols, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T51.8X2A | Toxic effect of other alcohols, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T51.8X2D | Toxic effect of other alcohols, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T51.8X2S | Toxic effect of other alcohols, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T51.8X3A | Toxic effect of other alcohols, assault, initial encounter | Diagnosis | ICD-10-CM |
| T51.8X4A | Toxic effect of other alcohols, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T51.91XA | Toxic effect of unspecified alcohol, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T51.92XA | Toxic effect of unspecified alcohol, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T51.92XD | Toxic effect of unspecified alcohol, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T51.92XS | Toxic effect of unspecified alcohol, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T51.93XA | Toxic effect of unspecified alcohol, assault, initial encounter | Diagnosis | ICD-10-CM |
| T51.94XA | Toxic effect of unspecified alcohol, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T52.0X1A | Toxic effect of petroleum products, accidental (unintentional), initial | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T52.0X2A | Toxic effect of petroleum products, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.0X2D | Toxic effect of petroleum products, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T52.0X2S | Toxic effect of petroleum products, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.0X3A | Toxic effect of petroleum products, assault, initial encounter | Diagnosis | ICD-10-CM |
| T52.0X4A | Toxic effect of petroleum products, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T52.1X1A | Toxic effect of benzene, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T52.1X2A | Toxic effect of benzene, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.1X2D | Toxic effect of benzene, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T52.1X2S | Toxic effect of benzene, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.1X3A | Toxic effect of benzene, assault, initial encounter | Diagnosis | ICD-10-CM |
| T52.1X4A | Toxic effect of benzene, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T52.2X1A | Toxic effect of homologues of benzene, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T52.2X2A | Toxic effect of homologues of benzene, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.2X2D | Toxic effect of homologues of benzene, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T52.2X2S | Toxic effect of homologues of benzene, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.2X3A | Toxic effect of homologues of benzene, assault, initial encounter | Diagnosis | ICD-10-CM |
| T52.2X4A | Toxic effect of homologues of benzene, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T52.3X1A | Toxic effect of glycols, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T52.3X2A | Toxic effect of glycols, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.3X2D | Toxic effect of glycols, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T52.3X2S | Toxic effect of glycols, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.3X3A | Toxic effect of glycols, assault, initial encounter | Diagnosis | ICD-10-CM |
| T52.3X4A | Toxic effect of glycols, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T52.4X1A | Toxic effect of ketones, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T52.4X2A | Toxic effect of ketones, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.4X2D | Toxic effect of ketones, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T52.4X2S | Toxic effect of ketones, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.4X3A | Toxic effect of ketones, assault, initial encounter | Diagnosis | ICD-10-CM |
| T52.4X4A | Toxic effect of ketones, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T52.8X1A | Toxic effect of other organic solvents, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T52.8X2A | Toxic effect of other organic solvents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.8X2D | Toxic effect of other organic solvents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T52.8X2S | Toxic effect of other organic solvents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.8X3A | Toxic effect of other organic solvents, assault, initial encounter | Diagnosis | ICD-10-CM |
| T52.8X4A | Toxic effect of other organic solvents, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T52.91XA | Toxic effect of unspecified organic solvent, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T52.92XA | Toxic effect of unspecified organic solvent, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T52.92XD | Toxic effect of unspecified organic solvent, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T52.92XS | Toxic effect of unspecified organic solvent, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.93XA | Toxic effect of unspecified organic solvent, assault, initial encounter | Diagnosis | ICD-10-CM |
| T52.94XA | Toxic effect of unspecified organic solvent, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T53.0X1A | Toxic effect of carbon tetrachloride, accidental (unintentional), initial | Diagnosis | ICD-10-CM |
| T53.0X2A | Toxic effect of carbon tetrachloride, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.0X2D | Toxic effect of carbon tetrachloride, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.0X2S | Toxic effect of carbon tetrachloride, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.0X3A | Toxic effect of carbon tetrachloride, assault, initial encounter | Diagnosis | ICD-10-CM |
| T53.0X4A | Toxic effect of carbon tetrachloride, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T53.1X1A | Toxic effect of chloroform, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T53.1X2A | Toxic effect of chloroform, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.1X2D | Toxic effect of chloroform, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.1X2S | Toxic effect of chloroform, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.1X3A | Toxic effect of chloroform, assault, initial encounter | Diagnosis | ICD-10-CM |
| T53.1X4A | Toxic effect of chloroform, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T53.2X1A | Toxic effect of trichloroethylene, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T53.2X2A | Toxic effect of trichloroethylene, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.2X2D | Toxic effect of trichloroethylene, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.2X2S | Toxic effect of trichloroethylene, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.2X3A | Toxic effect of trichloroethylene, assault, initial encounter | Diagnosis | ICD-10-CM |
| T53.2X4A | Toxic effect of trichloroethylene, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T53.3X1A | Toxic effect of tetrachloroethylene, accidental (unintentional), initial | Diagnosis | ICD-10-CM |
| T53.3X2A | Toxic effect of tetrachloroethylene, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.3X2D | Toxic effect of tetrachloroethylene, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T53.3X2S | Toxic effect of tetrachloroethylene, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.3X3A | Toxic effect of tetrachloroethylene, assault, initial encounter | Diagnosis | ICD-10-CM |
| T53.3X4A | Toxic effect of tetrachloroethylene, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T53.4X1A | Toxic effect of dichloromethane, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T53.4X2A | Toxic effect of dichloromethane, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.4X2D | Toxic effect of dichloromethane, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.4X2S | Toxic effect of dichloromethane, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.4X3A | Toxic effect of dichloromethane, assault, initial encounter | Diagnosis | ICD-10-CM |
| T53.4X4A | Toxic effect of dichloromethane, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T53.5X1A | Toxic effect of chlorofluorocarbons, accidental (unintentional), initial | Diagnosis | ICD-10-CM |
| T53.5X2A | Toxic effect of chlorofluorocarbons, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.5X2D | Toxic effect of chlorofluorocarbons, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.5X2S | Toxic effect of chlorofluorocarbons, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.5X3A | Toxic effect of chlorofluorocarbons, assault, initial encounter | Diagnosis | ICD-10-CM |
| T53.5X4A | Toxic effect of chlorofluorocarbons, undetermined, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T53.6X1A | Toxic effect of other halogen derivatives of aliphatic hydrocarbons, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T53.6X2A | Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.6X2D | Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.6X2S | Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.6X3A | Toxic effect of other halogen derivatives of aliphatic hydrocarbons, assault, initial encounter | Diagnosis | ICD-10-CM |
| T53.6X4A | Toxic effect of other halogen derivatives of aliphatic hydrocarbons, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T53.7X1A | Toxic effect of other halogen derivatives of aromatic hydrocarbons, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T53.7X2A | Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.7X2D | Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.7X2S | Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.7X3A | Toxic effect of other halogen derivatives of aromatic hydrocarbons, assault, initial encounter | Diagnosis | ICD-10-CM |
| T53.7X4A | Toxic effect of other halogen derivatives of aromatic hydrocarbons, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T53.91XA | Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T53.92XA | Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.92XD | Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.92XS | Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.93XA | Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, assault, initial encounter | Diagnosis | ICD-10-CM |
| T53.94XA | Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T54.0X1A | Toxic effect of phenol and phenol homologues, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T54.0X2A | Toxic effect of phenol and phenol homologues, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T54.0X2D | Toxic effect of phenol and phenol homologues, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T54.0X2S | Toxic effect of phenol and phenol homologues, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T54.0X3A | Toxic effect of phenol and phenol homologues, assault, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T54.0X4A | Toxic effect of phenol and phenol homologues, undetermined, initial | Diagnosis | ICD-10-CM |
| T54.1X1A | Toxic effect of other corrosive organic compounds, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T54.1X2A | Toxic effect of other corrosive organic compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T54.1X2D | Toxic effect of other corrosive organic compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T54.1X2S | Toxic effect of other corrosive organic compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T54.1X3A | Toxic effect of other corrosive organic compounds, assault, initial encounter | Diagnosis | ICD-10-CM |
| T54.1X4A | Toxic effect of other corrosive organic compounds, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T54.2X1A | Toxic effect of corrosive acids and acid-like substances, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T54.2X2A | Toxic effect of corrosive acids and acid-like substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T54.2X2D | Toxic effect of corrosive acids and acid-like substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T54.2X2S | Toxic effect of corrosive acids and acid-like substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T54.2X3A | Toxic effect of corrosive acids and acid-like substances, assault, initial | Diagnosis | ICD-10-CM |
| T54.2X4A | Toxic effect of corrosive acids and acid-like substances, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T54.3X1A | Toxic effect of corrosive alkalis and alkali-like substances, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T54.3X2A | Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T54.3X2D | Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T54.3X2S | Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T54.3X3A | Toxic effect of corrosive alkalis and alkali-like substances, assault, initial encounter | Diagnosis | ICD-10-CM |
| T54.3X4A | Toxic effect of corrosive alkalis and alkali-like substances, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T54.91XA | Toxic effect of unspecified corrosive substance, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T54.92XA | Toxic effect of unspecified corrosive substance, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T54.92XD | Toxic effect of unspecified corrosive substance, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T54.92XS | Toxic effect of unspecified corrosive substance, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T54.93XA | Toxic effect of unspecified corrosive substance, assault, initial encounter | Diagnosis | ICD-10-CM |
| T54.94XA | Toxic effect of unspecified corrosive substance, undetermined, initial | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T55.0X1A | Toxic effect of soaps, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T55.0X2A | Toxic effect of soaps, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T55.0X2D | Toxic effect of soaps, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T55.0X2S | Toxic effect of soaps, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T55.0X3A | Toxic effect of soaps, assault, initial encounter | Diagnosis | ICD-10-CM |
| T55.0X4A | Toxic effect of soaps, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T55.1X1A | Toxic effect of detergents, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T55.1X2A | Toxic effect of detergents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T55.1X2D | Toxic effect of detergents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T55.1X2S | Toxic effect of detergents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T55.1X3A | Toxic effect of detergents, assault, initial encounter | Diagnosis | ICD-10-CM |
| T55.1X4A | Toxic effect of detergents, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T56.0X1A | Toxic effect of lead and its compounds, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T56.0X2A | Toxic effect of lead and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.0X2D | Toxic effect of lead and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.0X2S | Toxic effect of lead and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.0X3A | Toxic effect of lead and its compounds, assault, initial encounter | Diagnosis | ICD-10-CM |
| T56.0X4A | Toxic effect of lead and its compounds, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T56.1X1A | Toxic effect of mercury and its compounds, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T56.1X2A | Toxic effect of mercury and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.1X2D | Toxic effect of mercury and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.1X2S | Toxic effect of mercury and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.1X3A | Toxic effect of mercury and its compounds, assault, initial encounter | Diagnosis | ICD-10-CM |
| T56.1X4A | Toxic effect of mercury and its compounds, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T56.2X1A | Toxic effect of chromium and its compounds, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T56.2X2A | Toxic effect of chromium and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.2X2D | Toxic effect of chromium and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.2X2S | Toxic effect of chromium and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.2X3A | Toxic effect of chromium and its compounds, assault, initial encounter | Diagnosis | ICD-10-CM |
| T56.2X4A | Toxic effect of chromium and its compounds, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T56.3X1A | Toxic effect of cadmium and its compounds, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T56.3X2A | Toxic effect of cadmium and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.3X2D | Toxic effect of cadmium and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T56.3X2S | Toxic effect of cadmium and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.3X3A | Toxic effect of cadmium and its compounds, assault, initial encounter | Diagnosis | ICD-10-CM |
| T56.3X4A | Toxic effect of cadmium and its compounds, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T56.4X1A | Toxic effect of copper and its compounds, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T56.4X2A | Toxic effect of copper and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.4X2D | Toxic effect of copper and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.4X2S | Toxic effect of copper and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.4X3A | Toxic effect of copper and its compounds, assault, initial encounter | Diagnosis | ICD-10-CM |
| T56.4X4A | Toxic effect of copper and its compounds, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T56.5X1A | Toxic effect of zinc and its compounds, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T56.5X2A | Toxic effect of zinc and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.5X2D | Toxic effect of zinc and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.5X2S | Toxic effect of zinc and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.5X3A | Toxic effect of zinc and its compounds, assault, initial encounter | Diagnosis | ICD-10-CM |
| T56.5X4A | Toxic effect of zinc and its compounds, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T56.6X1A | Toxic effect of tin and its compounds, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T56.6X2A | Toxic effect of tin and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.6X2D | Toxic effect of tin and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.6X2S | Toxic effect of tin and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.6X3A | Toxic effect of tin and its compounds, assault, initial encounter | Diagnosis | ICD-10-CM |
| T56.6X4A | Toxic effect of tin and its compounds, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T56.7X1A | Toxic effect of beryllium and its compounds, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T56.7X2A | Toxic effect of beryllium and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.7X2D | Toxic effect of beryllium and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.7X2S | Toxic effect of beryllium and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.7X3A | Toxic effect of beryllium and its compounds, assault, initial encounter | Diagnosis | ICD-10-CM |
| T56.7X4A | Toxic effect of beryllium and its compounds, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T56.811A | Toxic effect of thallium, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T56.812A | Toxic effect of thallium, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.812D | Toxic effect of thallium, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.812S | Toxic effect of thallium, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.813A | Toxic effect of thallium, assault, initial encounter | Diagnosis | ICD-10-CM |
| T56.814A | Toxic effect of thallium, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T56.891A | Toxic effect of other metals, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T56.892A | Toxic effect of other metals, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.892D | Toxic effect of other metals, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.892S | Toxic effect of other metals, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.893A | Toxic effect of other metals, assault, initial encounter | Diagnosis | ICD-10-CM |
| T56.894A | Toxic effect of other metals, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T56.91XA | Toxic effect of unspecified metal, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T56.92XA | Toxic effect of unspecified metal, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.92XD | Toxic effect of unspecified metal, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.92XS | Toxic effect of unspecified metal, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.93XA | Toxic effect of unspecified metal, assault, initial encounter | Diagnosis | ICD-10-CM |
| T56.94XA | Toxic effect of unspecified metal, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T57.0X1A | Toxic effect of arsenic and its compounds, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T57.0X2A | Toxic effect of arsenic and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T57.0X2D | Toxic effect of arsenic and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T57.0X2S | Toxic effect of arsenic and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T57.0X3A | Toxic effect of arsenic and its compounds, assault, initial encounter | Diagnosis | ICD-10-CM |
| T57.0X4A | Toxic effect of arsenic and its compounds, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T57.1X1A | Toxic effect of phosphorus and its compounds, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T57.1X2A | Toxic effect of phosphorus and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T57.1X2D | Toxic effect of phosphorus and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T57.1X2S | Toxic effect of phosphorus and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T57.1X3A | Toxic effect of phosphorus and its compounds, assault, initial encounter | Diagnosis | ICD-10-CM |
| T57.1X4A | Toxic effect of phosphorus and its compounds, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T57.2X1A | Toxic effect of manganese and its compounds, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T57.2X2A | Toxic effect of manganese and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T57.2X2D | Toxic effect of manganese and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T57.2X2S | Toxic effect of manganese and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T57.2X3A | Toxic effect of manganese and its compounds, assault, initial encounter | Diagnosis | ICD-10-CM |
| T57.2X4A | Toxic effect of manganese and its compounds, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T57.3X1A | Toxic effect of hydrogen cyanide, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T57.3X2A | Toxic effect of hydrogen cyanide, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T57.3X2D | Toxic effect of hydrogen cyanide, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T57.3X2S | Toxic effect of hydrogen cyanide, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T57.3X3A | Toxic effect of hydrogen cyanide, assault, initial encounter | Diagnosis | ICD-10-CM |
| T57.3X4A | Toxic effect of hydrogen cyanide, undetermined, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T57.8X1A | Toxic effect of other specified inorganic substances, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T57.8X2A | Toxic effect of other specified inorganic substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T57.8X2D | Toxic effect of other specified inorganic substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T57.8X2S | Toxic effect of other specified inorganic substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T57.8X3A | Toxic effect of other specified inorganic substances, assault, initial encounter | Diagnosis | ICD-10-CM |
| T57.8X4A | Toxic effect of other specified inorganic substances, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T57.91XA | Toxic effect of unspecified inorganic substance, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T57.92XA | Toxic effect of unspecified inorganic substance, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T57.92XD | Toxic effect of unspecified inorganic substance, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T57.92XS | Toxic effect of unspecified inorganic substance, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T57.93XA | Toxic effect of unspecified inorganic substance, assault, initial encounter | Diagnosis | ICD-10-CM |
| T57.94XA | Toxic effect of unspecified inorganic substance, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T58.01XA | Toxic effect of carbon monoxide from motor vehicle exhaust, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T58.02XA | Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T58.02XD | Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T58.02XS | Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T58.03XA | Toxic effect of carbon monoxide from motor vehicle exhaust, assault, initial encounter | Diagnosis | ICD-10-CM |
| T58.04XA | Toxic effect of carbon monoxide from motor vehicle exhaust, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T58.11XA | Toxic effect of carbon monoxide from utility gas, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T58.12XA | Toxic effect of carbon monoxide from utility gas, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T58.12XD | Toxic effect of carbon monoxide from utility gas, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T58.12XS | Toxic effect of carbon monoxide from utility gas, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T58.13XA | Toxic effect of carbon monoxide from utility gas, assault, initial encounter | Diagnosis | ICD-10-CM |
| T58.14XA | Toxic effect of carbon monoxide from utility gas, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T58.2X1A | Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T58.2X2A | Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T58.2X2D | Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T58.2X2S | Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T58.2X3A | Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, assault, initial encounter | Diagnosis | ICD-10-CM |
| T58.2X4A | Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T58.8X1A | Toxic effect of carbon monoxide from other source, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T58.8X2A | Toxic effect of carbon monoxide from other source, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T58.8X2D | Toxic effect of carbon monoxide from other source, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T58.8X2S | Toxic effect of carbon monoxide from other source, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T58.8X3A | Toxic effect of carbon monoxide from other source, assault, initial encounter | Diagnosis | ICD-10-CM |
| T58.8X4A | Toxic effect of carbon monoxide from other source, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T58.91XA | Toxic effect of carbon monoxide from unspecified source, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T58.92XA | Toxic effect of carbon monoxide from unspecified source, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T58.92XD | Toxic effect of carbon monoxide from unspecified source, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T58.92XS | Toxic effect of carbon monoxide from unspecified source, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T58.93XA | Toxic effect of carbon monoxide from unspecified source, assault, initial encounter | Diagnosis | ICD-10-CM |
| T58.94XA | Toxic effect of carbon monoxide from unspecified source, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T59.0X1A | Toxic effect of nitrogen oxides, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T59.0X2A | Toxic effect of nitrogen oxides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.0X2D | Toxic effect of nitrogen oxides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.0X2S | Toxic effect of nitrogen oxides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.0X3A | Toxic effect of nitrogen oxides, assault, initial encounter | Diagnosis | ICD-10-CM |
| T59.0X4A | Toxic effect of nitrogen oxides, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T59.1X1A | Toxic effect of sulfur dioxide, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T59.1X2A | Toxic effect of sulfur dioxide, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.1X2D | Toxic effect of sulfur dioxide, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.1X2S | Toxic effect of sulfur dioxide, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.1X3A | Toxic effect of sulfur dioxide, assault, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T59.1X4A | Toxic effect of sulfur dioxide, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T59.2X1A | Toxic effect of formaldehyde, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T59.2X2A | Toxic effect of formaldehyde, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.2X2D | Toxic effect of formaldehyde, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.2X2S | Toxic effect of formaldehyde, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.2X3A | Toxic effect of formaldehyde, assault, initial encounter | Diagnosis | ICD-10-CM |
| T59.2X4A | Toxic effect of formaldehyde, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T59.3X1A | Toxic effect of lacrimogenic gas, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T59.3X2A | Toxic effect of lacrimogenic gas, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.3X2D | Toxic effect of lacrimogenic gas, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.3X2S | Toxic effect of lacrimogenic gas, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.3X3A | Toxic effect of lacrimogenic gas, assault, initial encounter | Diagnosis | ICD-10-CM |
| T59.3X4A | Toxic effect of lacrimogenic gas, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T59.4X1A | Toxic effect of chlorine gas, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T59.4X2A | Toxic effect of chlorine gas, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.4X2D | Toxic effect of chlorine gas, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.4X2S | Toxic effect of chlorine gas, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.4X3A | Toxic effect of chlorine gas, assault, initial encounter | Diagnosis | ICD-10-CM |
| T59.4X4A | Toxic effect of chlorine gas, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T59.5X1A | Toxic effect of fluorine gas and hydrogen fluoride, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T59.5X2A | Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.5X2D | Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.5X2S | Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.5X3A | Toxic effect of fluorine gas and hydrogen fluoride, assault, initial encounter | Diagnosis | ICD-10-CM |
| T59.5X4A | Toxic effect of fluorine gas and hydrogen fluoride, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T59.6X1A | Toxic effect of hydrogen sulfide, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T59.6X2A | Toxic effect of hydrogen sulfide, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.6X2D | Toxic effect of hydrogen sulfide, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.6X2S | Toxic effect of hydrogen sulfide, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.6X3A | Toxic effect of hydrogen sulfide, assault, initial encounter | Diagnosis | ICD-10-CM |
| T59.6X4A | Toxic effect of hydrogen sulfide, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T59.7X1A | Toxic effect of carbon dioxide, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T59.7X2A | Toxic effect of carbon dioxide, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.7X2D | Toxic effect of carbon dioxide, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.7X2S | Toxic effect of carbon dioxide, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.7X3A | Toxic effect of carbon dioxide, assault, initial encounter | Diagnosis | ICD-10-CM |
| T59.7X4A | Toxic effect of carbon dioxide, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T59.811A | Toxic effect of smoke, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T59.812A | Toxic effect of smoke, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.812D | Toxic effect of smoke, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T59.812S | Toxic effect of smoke, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.813A | Toxic effect of smoke, assault, initial encounter | Diagnosis | ICD-10-CM |
| T59.814A | Toxic effect of smoke, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T59.891A | Toxic effect of other specified gases, fumes and vapors, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T59.892A | Toxic effect of other specified gases, fumes and vapors, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.892D | Toxic effect of other specified gases, fumes and vapors, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.892S | Toxic effect of other specified gases, fumes and vapors, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.893A | Toxic effect of other specified gases, fumes and vapors, assault, initial | Diagnosis | ICD-10-CM |
| T59.894A | Toxic effect of other specified gases, fumes and vapors, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T59.91XA | Toxic effect of unspecified gases, fumes and vapors, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T59.92XA | Toxic effect of unspecified gases, fumes and vapors, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.92XD | Toxic effect of unspecified gases, fumes and vapors, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.92XS | Toxic effect of unspecified gases, fumes and vapors, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.93XA | Toxic effect of unspecified gases, fumes and vapors, assault, initial encounter | Diagnosis | ICD-10-CM |
| T59.94XA | Toxic effect of unspecified gases, fumes and vapors, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T60.0X1A | Toxic effect of organophosphate and carbamate insecticides, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T60.0X2A | Toxic effect of organophosphate and carbamate insecticides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.0X2D | Toxic effect of organophosphate and carbamate insecticides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.0X2S | Toxic effect of organophosphate and carbamate insecticides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.0X3A | Toxic effect of organophosphate and carbamate insecticides, assault, initial encounter | Diagnosis | ICD-10-CM |
| T60.0X4A | Toxic effect of organophosphate and carbamate insecticides, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T60.1X1A | Toxic effect of halogenated insecticides, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T60.1X2A | Toxic effect of halogenated insecticides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.1X2D | Toxic effect of halogenated insecticides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.1X2S | Toxic effect of halogenated insecticides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.1X3A | Toxic effect of halogenated insecticides, assault, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T60.1X4A | Toxic effect of halogenated insecticides, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T60.2X1A | Toxic effect of other insecticides, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T60.2X2A | Toxic effect of other insecticides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.2X2D | Toxic effect of other insecticides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.2X2S | Toxic effect of other insecticides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.2X3A | Toxic effect of other insecticides, assault, initial encounter | Diagnosis | ICD-10-CM |
| T60.2X4A | Toxic effect of other insecticides, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T60.3X1A | Toxic effect of herbicides and fungicides, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T60.3X2A | Toxic effect of herbicides and fungicides, intentional self-harm, initial | Diagnosis | ICD-10-CM |
| T60.3X2D | Toxic effect of herbicides and fungicides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.3X2S | Toxic effect of herbicides and fungicides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.3X3A | Toxic effect of herbicides and fungicides, assault, initial encounter | Diagnosis | ICD-10-CM |
| T60.3X4A | Toxic effect of herbicides and fungicides, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T60.4X1A | Toxic effect of rodenticides, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T60.4X2A | Toxic effect of rodenticides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.4X2D | Toxic effect of rodenticides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.4X2S | Toxic effect of rodenticides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.4X3A | Toxic effect of rodenticides, assault, initial encounter | Diagnosis | ICD-10-CM |
| T60.4X4A | Toxic effect of rodenticides, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T60.8X1A | Toxic effect of other pesticides, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T60.8X2A | Toxic effect of other pesticides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.8X2D | Toxic effect of other pesticides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.8X2S | Toxic effect of other pesticides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.8X3A | Toxic effect of other pesticides, assault, initial encounter | Diagnosis | ICD-10-CM |
| T60.8X4A | Toxic effect of other pesticides, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T60.91XA | Toxic effect of unspecified pesticide, accidental (unintentional), initial | Diagnosis | ICD-10-CM |
| T60.92XA | Toxic effect of unspecified pesticide, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.92XD | Toxic effect of unspecified pesticide, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.92XS | Toxic effect of unspecified pesticide, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.93XA | Toxic effect of unspecified pesticide, assault, initial encounter | Diagnosis | ICD-10-CM |
| T60.94XA | Toxic effect of unspecified pesticide, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T61.01XA | Ciguatera fish poisoning, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T61.02XA | Ciguatera fish poisoning, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T61.02XD | Ciguatera fish poisoning, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T61.02XS | Ciguatera fish poisoning, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T61.03XA | Ciguatera fish poisoning, assault, initial encounter | Diagnosis | ICD-10-CM |
| T61.04XA | Ciguatera fish poisoning, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T61.11XA | Scombroid fish poisoning, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T61.12XA | Scombroid fish poisoning, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T61.12XD | Scombroid fish poisoning, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T61.12XS | Scombroid fish poisoning, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T61.13XA | Scombroid fish poisoning, assault, initial encounter | Diagnosis | ICD-10-CM |
| T61.14XA | Scombroid fish poisoning, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T61.771A | Other fish poisoning, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T61.772A | Other fish poisoning, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T61.772D | Other fish poisoning, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T61.772S | Other fish poisoning, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T61.773A | Other fish poisoning, assault, initial encounter | Diagnosis | ICD-10-CM |
| T61.774A | Other fish poisoning, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T61.781A | Other shellfish poisoning, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T61.782A | Other shellfish poisoning, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T61.782D | Other shellfish poisoning, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T61.782S | Other shellfish poisoning, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T61.783A | Other shellfish poisoning, assault, initial encounter | Diagnosis | ICD-10-CM |
| T61.784A | Other shellfish poisoning, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T61.8X1A | Toxic effect of other seafood, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T61.8X2A | Toxic effect of other seafood, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T61.8X2D | Toxic effect of other seafood, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T61.8X2S | Toxic effect of other seafood, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T61.8X3A | Toxic effect of other seafood, assault, initial encounter | Diagnosis | ICD-10-CM |
| T61.8X4A | Toxic effect of other seafood, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T61.91XA | Toxic effect of unspecified seafood, accidental (unintentional), initial | Diagnosis | ICD-10-CM |
| T61.92XA | Toxic effect of unspecified seafood, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T61.92XD | Toxic effect of unspecified seafood, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T61.92XS | Toxic effect of unspecified seafood, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T61.93XA | Toxic effect of unspecified seafood, assault, initial encounter | Diagnosis | ICD-10-CM |
| T61.94XA | Toxic effect of unspecified seafood, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T62.0X1A | Toxic effect of ingested mushrooms, accidental (unintentional), initial | Diagnosis | ICD-10-CM |
| T62.0X2A | Toxic effect of ingested mushrooms, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T62.0X2D | Toxic effect of ingested mushrooms, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T62.0X2S | Toxic effect of ingested mushrooms, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T62.0X3A | Toxic effect of ingested mushrooms, assault, initial encounter | Diagnosis | ICD-10-CM |
| T62.0X4A | Toxic effect of ingested mushrooms, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T62.1X1A | Toxic effect of ingested berries, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T62.1X2A | Toxic effect of ingested berries, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T62.1X2D | Toxic effect of ingested berries, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T62.1X2S | Toxic effect of ingested berries, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T62.1X3A | Toxic effect of ingested berries, assault, initial encounter | Diagnosis | ICD-10-CM |
| T62.1X4A | Toxic effect of ingested berries, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T62.2X1A | Toxic effect of other ingested (parts of) plant(s), accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T62.2X2A | Toxic effect of other ingested (parts of) plant(s), intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T62.2X2D | Toxic effect of other ingested (parts of) plant(s), intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T62.2X2S | Toxic effect of other ingested (parts of) plant(s), intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T62.2X3A | Toxic effect of other ingested (parts of) plant(s), assault, initial encounter | Diagnosis | ICD-10-CM |
| T62.2X4A | Toxic effect of other ingested (parts of) plant(s), undetermined, initial | Diagnosis | ICD-10-CM |
| T62.8X1A | Toxic effect of other specified noxious substances eaten as food, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T62.8X2A | Toxic effect of other specified noxious substances eaten as food, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T62.8X2D | Toxic effect of other specified noxious substances eaten as food, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T62.8X2S | Toxic effect of other specified noxious substances eaten as food, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T62.8X3A | Toxic effect of other specified noxious substances eaten as food, assault, initial encounter | Diagnosis | ICD-10-CM |
| T62.8X4A | Toxic effect of other specified noxious substances eaten as food, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T62.91XA | Toxic effect of unspecified noxious substance eaten as food, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T62.92XA | Toxic effect of unspecified noxious substance eaten as food, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T62.92XD | Toxic effect of unspecified noxious substance eaten as food, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T62.92XS | Toxic effect of unspecified noxious substance eaten as food, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T62.93XA | Toxic effect of unspecified noxious substance eaten as food, assault, initial encounter | Diagnosis | ICD-10-CM |
| T62.94XA | Toxic effect of unspecified noxious substance eaten as food, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.001A | Toxic effect of unspecified snake venom, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.002A | Toxic effect of unspecified snake venom, intentional self-harm, initial | Diagnosis | ICD-10-CM |
| T63.002D | Toxic effect of unspecified snake venom, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.002S | Toxic effect of unspecified snake venom, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.003A | Toxic effect of unspecified snake venom, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.004A | Toxic effect of unspecified snake venom, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.011A | Toxic effect of rattlesnake venom, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.012A | Toxic effect of rattlesnake venom, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.012D | Toxic effect of rattlesnake venom, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T63.012S | Toxic effect of rattlesnake venom, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.013A | Toxic effect of rattlesnake venom, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.014A | Toxic effect of rattlesnake venom, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.021A | Toxic effect of coral snake venom, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T63.022A | Toxic effect of coral snake venom, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.022D | Toxic effect of coral snake venom, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T63.022S | Toxic effect of coral snake venom, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.023A | Toxic effect of coral snake venom, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.024A | Toxic effect of coral snake venom, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.031A | Toxic effect of taipan venom, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.032A | Toxic effect of taipan venom, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.032D | Toxic effect of taipan venom, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.032S | Toxic effect of taipan venom, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.033A | Toxic effect of taipan venom, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.034A | Toxic effect of taipan venom, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.041A | Toxic effect of cobra venom, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.042A | Toxic effect of cobra venom, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.042D | Toxic effect of cobra venom, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.042S | Toxic effect of cobra venom, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.043A | Toxic effect of cobra venom, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.044A | Toxic effect of cobra venom, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.061A | Toxic effect of venom of other North and South American snake, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.062A | Toxic effect of venom of other North and South American snake, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.062D | Toxic effect of venom of other North and South American snake, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.062S | Toxic effect of venom of other North and South American snake, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.063A | Toxic effect of venom of other North and South American snake, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.064A | Toxic effect of venom of other North and South American snake, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.071A | Toxic effect of venom of other Australian snake, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.072A | Toxic effect of venom of other Australian snake, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.072D | Toxic effect of venom of other Australian snake, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.072S | Toxic effect of venom of other Australian snake, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.073A | Toxic effect of venom of other Australian snake, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.074A | Toxic effect of venom of other Australian snake, undetermined, initial | Diagnosis | ICD-10-CM |
| T63.081A | Toxic effect of venom of other African and Asian snake, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.082A | Toxic effect of venom of other African and Asian snake, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.082D | Toxic effect of venom of other African and Asian snake, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T63.082S | Toxic effect of venom of other African and Asian snake, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.083A | Toxic effect of venom of other African and Asian snake, assault, initial | Diagnosis | ICD-10-CM |
| T63.084A | Toxic effect of venom of other African and Asian snake, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.091A | Toxic effect of venom of other snake, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.092A | Toxic effect of venom of other snake, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.092D | Toxic effect of venom of other snake, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.092S | Toxic effect of venom of other snake, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.093A | Toxic effect of venom of other snake, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.094A | Toxic effect of venom of other snake, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.111A | Toxic effect of venom of gila monster, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.112A | Toxic effect of venom of gila monster, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.112D | Toxic effect of venom of gila monster, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.112S | Toxic effect of venom of gila monster, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.113A | Toxic effect of venom of gila monster, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.114A | Toxic effect of venom of gila monster, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.121A | Toxic effect of venom of other venomous lizard, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.122A | Toxic effect of venom of other venomous lizard, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.122D | Toxic effect of venom of other venomous lizard, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.122S | Toxic effect of venom of other venomous lizard, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.123A | Toxic effect of venom of other venomous lizard, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.124A | Toxic effect of venom of other venomous lizard, undetermined, initial | Diagnosis | ICD-10-CM |
| T63.191A | Toxic effect of venom of other reptiles, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.192A | Toxic effect of venom of other reptiles, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.192D | Toxic effect of venom of other reptiles, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.192S | Toxic effect of venom of other reptiles, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.193A | Toxic effect of venom of other reptiles, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.194A | Toxic effect of venom of other reptiles, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.2X1A | Toxic effect of venom of scorpion, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.2X2A | Toxic effect of venom of scorpion, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.2X2D | Toxic effect of venom of scorpion, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T63.2X2S | Toxic effect of venom of scorpion, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.2X3A | Toxic effect of venom of scorpion, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.2X4A | Toxic effect of venom of scorpion, undetermined, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T63.301A | Toxic effect of unspecified spider venom, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.302A | Toxic effect of unspecified spider venom, intentional self-harm, initial | Diagnosis | ICD-10-CM |
| T63.302D | Toxic effect of unspecified spider venom, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.302S | Toxic effect of unspecified spider venom, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.303A | Toxic effect of unspecified spider venom, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.304A | Toxic effect of unspecified spider venom, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.311A | Toxic effect of venom of black widow spider, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.312A | Toxic effect of venom of black widow spider, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.312D | Toxic effect of venom of black widow spider, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.312S | Toxic effect of venom of black widow spider, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.313A | Toxic effect of venom of black widow spider, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.314A | Toxic effect of venom of black widow spider, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.321A | Toxic effect of venom of tarantula, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.322A | Toxic effect of venom of tarantula, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.322D | Toxic effect of venom of tarantula, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T63.322S | Toxic effect of venom of tarantula, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.323A | Toxic effect of venom of tarantula, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.324A | Toxic effect of venom of tarantula, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.331A | Toxic effect of venom of brown recluse spider, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.332A | Toxic effect of venom of brown recluse spider, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.332D | Toxic effect of venom of brown recluse spider, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.332S | Toxic effect of venom of brown recluse spider, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.333A | Toxic effect of venom of brown recluse spider, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.334A | Toxic effect of venom of brown recluse spider, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.391A | Toxic effect of venom of other spider, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.392A | Toxic effect of venom of other spider, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.392D | Toxic effect of venom of other spider, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.392S | Toxic effect of venom of other spider, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.393A | Toxic effect of venom of other spider, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.394A | Toxic effect of venom of other spider, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.411A | Toxic effect of venom of centipedes and venomous millipedes, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.412A | Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T63.412D | Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.412S | Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.413A | Toxic effect of venom of centipedes and venomous millipedes, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.414A | Toxic effect of venom of centipedes and venomous millipedes, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.421A | Toxic effect of venom of ants, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.422A | Toxic effect of venom of ants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.422D | Toxic effect of venom of ants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.422S | Toxic effect of venom of ants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.423A | Toxic effect of venom of ants, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.424A | Toxic effect of venom of ants, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.431A | Toxic effect of venom of caterpillars, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.432A | Toxic effect of venom of caterpillars, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.432D | Toxic effect of venom of caterpillars, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.432S | Toxic effect of venom of caterpillars, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.433A | Toxic effect of venom of caterpillars, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.434A | Toxic effect of venom of caterpillars, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.441A | Toxic effect of venom of bees, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.442A | Toxic effect of venom of bees, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.442D | Toxic effect of venom of bees, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.442S | Toxic effect of venom of bees, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.443A | Toxic effect of venom of bees, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.444A | Toxic effect of venom of bees, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.451A | Toxic effect of venom of hornets, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.452A | Toxic effect of venom of hornets, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.452D | Toxic effect of venom of hornets, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.452S | Toxic effect of venom of hornets, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.453A | Toxic effect of venom of hornets, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.454A | Toxic effect of venom of hornets, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.461A | Toxic effect of venom of wasps, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.462A | Toxic effect of venom of wasps, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.462D | Toxic effect of venom of wasps, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.462S | Toxic effect of venom of wasps, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.463A | Toxic effect of venom of wasps, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.464A | Toxic effect of venom of wasps, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.481A | Toxic effect of venom of other arthropod, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.482A | Toxic effect of venom of other arthropod, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T63.482D | Toxic effect of venom of other arthropod, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.482S | Toxic effect of venom of other arthropod, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.483A | Toxic effect of venom of other arthropod, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.484A | Toxic effect of venom of other arthropod, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.511A | Toxic effect of contact with stingray, accidental (unintentional), initial | Diagnosis | ICD-10-CM |
| T63.512A | Toxic effect of contact with stingray, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.512D | Toxic effect of contact with stingray, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.512S | Toxic effect of contact with stingray, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.513A | Toxic effect of contact with stingray, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.514A | Toxic effect of contact with stingray, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.591A | Toxic effect of contact with other venomous fish, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.592A | Toxic effect of contact with other venomous fish, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.592D | Toxic effect of contact with other venomous fish, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.592S | Toxic effect of contact with other venomous fish, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.593A | Toxic effect of contact with other venomous fish, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.594A | Toxic effect of contact with other venomous fish, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.611A | Toxic effect of contact with Portuguese Man-o-war, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.612A | Toxic effect of contact with Portuguese Man-o-war, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.612D | Toxic effect of contact with Portuguese Man-o-war, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.612S | Toxic effect of contact with Portuguese Man-o-war, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.613A | Toxic effect of contact with Portuguese Man-o-war, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.614A | Toxic effect of contact with Portuguese Man-o-war, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.621A | Toxic effect of contact with other jellyfish, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.622A | Toxic effect of contact with other jellyfish, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.622D | Toxic effect of contact with other jellyfish, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.622S | Toxic effect of contact with other jellyfish, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.623A | Toxic effect of contact with other jellyfish, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.624A | Toxic effect of contact with other jellyfish, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.631A | Toxic effect of contact with sea anemone, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T63.632A | Toxic effect of contact with sea anemone, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.632D | Toxic effect of contact with sea anemone, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.632S | Toxic effect of contact with sea anemone, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.633A | Toxic effect of contact with sea anemone, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.634A | Toxic effect of contact with sea anemone, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.691A | Toxic effect of contact with other venomous marine animals, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.692A | Toxic effect of contact with other venomous marine animals, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.692D | Toxic effect of contact with other venomous marine animals, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.692S | Toxic effect of contact with other venomous marine animals, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.693A | Toxic effect of contact with other venomous marine animals, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.694A | Toxic effect of contact with other venomous marine animals, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.711A | Toxic effect of contact with venomous marine plant, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.712A | Toxic effect of contact with venomous marine plant, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.712D | Toxic effect of contact with venomous marine plant, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.712S | Toxic effect of contact with venomous marine plant, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.713A | Toxic effect of contact with venomous marine plant, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.714A | Toxic effect of contact with venomous marine plant, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.791A | Toxic effect of contact with other venomous plant, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.792A | Toxic effect of contact with other venomous plant, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.792D | Toxic effect of contact with other venomous plant, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.792S | Toxic effect of contact with other venomous plant, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.793A | Toxic effect of contact with other venomous plant, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.794A | Toxic effect of contact with other venomous plant, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.811A | Toxic effect of contact with venomous frog, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T63.812A | Toxic effect of contact with venomous frog, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.812D | Toxic effect of contact with venomous frog, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.812S | Toxic effect of contact with venomous frog, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.813A | Toxic effect of contact with venomous frog, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.814A | Toxic effect of contact with venomous frog, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.821A | Toxic effect of contact with venomous toad, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.822A | Toxic effect of contact with venomous toad, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.822D | Toxic effect of contact with venomous toad, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.822S | Toxic effect of contact with venomous toad, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.823A | Toxic effect of contact with venomous toad, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.824A | Toxic effect of contact with venomous toad, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.831A | Toxic effect of contact with other venomous amphibian, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.832A | Toxic effect of contact with other venomous amphibian, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.832D | Toxic effect of contact with other venomous amphibian, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.832S | Toxic effect of contact with other venomous amphibian, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.833A | Toxic effect of contact with other venomous amphibian, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.834A | Toxic effect of contact with other venomous amphibian, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.891A | Toxic effect of contact with other venomous animals, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.892A | Toxic effect of contact with other venomous animals, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.892D | Toxic effect of contact with other venomous animals, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.892S | Toxic effect of contact with other venomous animals, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.893A | Toxic effect of contact with other venomous animals, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.894A | Toxic effect of contact with other venomous animals, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T63.91XA | Toxic effect of contact with unspecified venomous animal, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T63.92XA | Toxic effect of contact with unspecified venomous animal, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T63.92XD | Toxic effect of contact with unspecified venomous animal, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.92XS | Toxic effect of contact with unspecified venomous animal, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.93XA | Toxic effect of contact with unspecified venomous animal, assault, initial encounter | Diagnosis | ICD-10-CM |
| T63.94XA | Toxic effect of contact with unspecified venomous animal, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T64.01XA | Toxic effect of aflatoxin, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T64.02XA | Toxic effect of aflatoxin, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T64.02XD | Toxic effect of aflatoxin, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T64.02XS | Toxic effect of aflatoxin, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T64.03XA | Toxic effect of aflatoxin, assault, initial encounter | Diagnosis | ICD-10-CM |
| T64.04XA | Toxic effect of aflatoxin, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T64.81XA | Toxic effect of other mycotoxin food contaminants, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T64.82XA | Toxic effect of other mycotoxin food contaminants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T64.82XD | Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T64.82XS | Toxic effect of other mycotoxin food contaminants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T64.83XA | Toxic effect of other mycotoxin food contaminants, assault, initial encounter | Diagnosis | ICD-10-CM |
| T64.84XA | Toxic effect of other mycotoxin food contaminants, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T65.0X1A | Toxic effect of cyanides, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T65.0X2A | Toxic effect of cyanides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.0X2D | Toxic effect of cyanides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.0X2S | Toxic effect of cyanides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.0X3A | Toxic effect of cyanides, assault, initial encounter | Diagnosis | ICD-10-CM |
| T65.0X4A | Toxic effect of cyanides, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T65.1X1A | Toxic effect of strychnine and its salts, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T65.1X2A | Toxic effect of strychnine and its salts, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.1X2D | Toxic effect of strychnine and its salts, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.1X2S | Toxic effect of strychnine and its salts, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.1X3A | Toxic effect of strychnine and its salts, assault, initial encounter | Diagnosis | ICD-10-CM |
| T65.1X4A | Toxic effect of strychnine and its salts, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T65.211A | Toxic effect of chewing tobacco, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T65.212A | Toxic effect of chewing tobacco, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.212D | Toxic effect of chewing tobacco, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.212S | Toxic effect of chewing tobacco, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.213A | Toxic effect of chewing tobacco, assault, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T65.214A | Toxic effect of chewing tobacco, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T65.221A | Toxic effect of tobacco cigarettes, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T65.222A | Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.222D | Toxic effect of tobacco cigarettes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.222S | Toxic effect of tobacco cigarettes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.223A | Toxic effect of tobacco cigarettes, assault, initial encounter | Diagnosis | ICD-10-CM |
| T65.224A | Toxic effect of tobacco cigarettes, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T65.291A | Toxic effect of other tobacco and nicotine, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T65.292A | Toxic effect of other tobacco and nicotine, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.292D | Toxic effect of other tobacco and nicotine, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.292S | Toxic effect of other tobacco and nicotine, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.293A | Toxic effect of other tobacco and nicotine, assault, initial encounter | Diagnosis | ICD-10-CM |
| T65.294A | Toxic effect of other tobacco and nicotine, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T65.3X1A | Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T65.3X2A | Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.3X2D | Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.3X2S | Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.3X3A | Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, assault, initial encounter | Diagnosis | ICD-10-CM |
| T65.3X4A | Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T65.4X1A | Toxic effect of carbon disulfide, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T65.4X2A | Toxic effect of carbon disulfide, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.4X2D | Toxic effect of carbon disulfide, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.4X2S | Toxic effect of carbon disulfide, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.4X3A | Toxic effect of carbon disulfide, assault, initial encounter | Diagnosis | ICD-10-CM |
| T65.4X4A | Toxic effect of carbon disulfide, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T65.5X1A | Toxic effect of nitroglycerin and other nitric acids and esters, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T65.5X2A | Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.5X2D | Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.5X2S | Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.5X3A | Toxic effect of nitroglycerin and other nitric acids and esters, assault, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T65.5X4A | Toxic effect of nitroglycerin and other nitric acids and esters, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T65.6X1A | Toxic effect of paints and dyes, not elsewhere classified, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T65.6X2A | Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.6X2D | Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.6X2S | Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.6X3A | Toxic effect of paints and dyes, not elsewhere classified, assault, initial encounter | Diagnosis | ICD-10-CM |
| T65.6X4A | Toxic effect of paints and dyes, not elsewhere classified, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T65.811A | Toxic effect of latex, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T65.812A | Toxic effect of latex, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.812D | Toxic effect of latex, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.812S | Toxic effect of latex, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.813A | Toxic effect of latex, assault, initial encounter | Diagnosis | ICD-10-CM |
| T65.814A | Toxic effect of latex, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T65.821A | Toxic effect of harmful algae and algae toxins, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T65.822A | Toxic effect of harmful algae and algae toxins, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.822D | Toxic effect of harmful algae and algae toxins, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.822S | Toxic effect of harmful algae and algae toxins, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.823A | Toxic effect of harmful algae and algae toxins, assault, initial encounter | Diagnosis | ICD-10-CM |
| T65.824A | Toxic effect of harmful algae and algae toxins, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T65.831A | Toxic effect of fiberglass, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T65.832A | Toxic effect of fiberglass, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.832D | Toxic effect of fiberglass, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.832S | Toxic effect of fiberglass, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.833A | Toxic effect of fiberglass, assault, initial encounter | Diagnosis | ICD-10-CM |
| T65.834A | Toxic effect of fiberglass, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T65.891A | Toxic effect of other specified substances, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T65.892A | Toxic effect of other specified substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.892D | Toxic effect of other specified substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.892S | Toxic effect of other specified substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.893A | Toxic effect of other specified substances, assault, initial encounter | Diagnosis | ICD-10-CM |
| T65.894A | Toxic effect of other specified substances, undetermined, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T65.91XA | Toxic effect of unspecified substance, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T65.92XA | Toxic effect of unspecified substance, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.92XD | Toxic effect of unspecified substance, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.92XS | Toxic effect of unspecified substance, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.93XA | Toxic effect of unspecified substance, assault, initial encounter | Diagnosis | ICD-10-CM |
| T65.94XA | Toxic effect of unspecified substance, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T71.111A | Asphyxiation due to smothering under pillow, accidental, initial encounter | Diagnosis | ICD-10-CM |
| T71.112A | Asphyxiation due to smothering under pillow, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.112D | Asphyxiation due to smothering under pillow, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.112S | Asphyxiation due to smothering under pillow, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.113A | Asphyxiation due to smothering under pillow, assault, initial encounter | Diagnosis | ICD-10-CM |
| T71.114A | Asphyxiation due to smothering under pillow, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T71.121A | Asphyxiation due to plastic bag, accidental, initial encounter | Diagnosis | ICD-10-CM |
| T71.122A | Asphyxiation due to plastic bag, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.122D | Asphyxiation due to plastic bag, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.122S | Asphyxiation due to plastic bag, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.123A | Asphyxiation due to plastic bag, assault, initial encounter | Diagnosis | ICD-10-CM |
| T71.124A | Asphyxiation due to plastic bag, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T71.131A | Asphyxiation due to being trapped in bed linens, accidental, initial encounter | Diagnosis | ICD-10-CM |
| T71.132A | Asphyxiation due to being trapped in bed linens, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.132D | Asphyxiation due to being trapped in bed linens, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.132S | Asphyxiation due to being trapped in bed linens, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.133A | Asphyxiation due to being trapped in bed linens, assault, initial encounter | Diagnosis | ICD-10-CM |
| T71.134A | Asphyxiation due to being trapped in bed linens, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T71.141A | Asphyxiation due to smothering under another person's body (in bed), accidental, initial encounter | Diagnosis | ICD-10-CM |
| T71.143A | Asphyxiation due to smothering under another person's body (in bed), assault, initial encounter | Diagnosis | ICD-10-CM |
| T71.144A | Asphyxiation due to smothering under another person's body (in bed), undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T71.151A | Asphyxiation due to smothering in furniture, accidental, initial encounter | Diagnosis | ICD-10-CM |
| T71.152A | Asphyxiation due to smothering in furniture, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.152D | Asphyxiation due to smothering in furniture, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.152S | Asphyxiation due to smothering in furniture, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.153A | Asphyxiation due to smothering in furniture, assault, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T71.154A | Asphyxiation due to smothering in furniture, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T71.161A | Asphyxiation due to hanging, accidental, initial encounter | Diagnosis | ICD-10-CM |
| T71.162A | Asphyxiation due to hanging, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.162D | Asphyxiation due to hanging, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.162S | Asphyxiation due to hanging, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.163A | Asphyxiation due to hanging, assault, initial encounter | Diagnosis | ICD-10-CM |
| T71.164A | Asphyxiation due to hanging, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T71.191A | Asphyxiation due to mechanical threat to breathing due to other causes, accidental, initial encounter | Diagnosis | ICD-10-CM |
| T71.192A | Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.192D | Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.192S | Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.193A | Asphyxiation due to mechanical threat to breathing due to other causes, assault, initial encounter | Diagnosis | ICD-10-CM |
| T71.194A | Asphyxiation due to mechanical threat to breathing due to other causes, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T71.20XA | Asphyxiation due to systemic oxygen deficiency due to low oxygen content in ambient air due to unspecified cause, initial encounter | Diagnosis | ICD-10-CM |
| T71.21XA | Asphyxiation due to cave-in or falling earth, initial encounter | Diagnosis | ICD-10-CM |
| T71.221A | Asphyxiation due to being trapped in a car trunk, accidental, initial encounter | Diagnosis | ICD-10-CM |
| T71.222A | Asphyxiation due to being trapped in a car trunk, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.222D | Asphyxiation due to being trapped in a car trunk, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.222S | Asphyxiation due to being trapped in a car trunk, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.223A | Asphyxiation due to being trapped in a car trunk, assault, initial encounter | Diagnosis | ICD-10-CM |
| T71.224A | Asphyxiation due to being trapped in a car trunk, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T71.231A | Asphyxiation due to being trapped in a (discarded) refrigerator, accidental, initial encounter | Diagnosis | ICD-10-CM |
| T71.232A | Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.232D | Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.232S | Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.233A | Asphyxiation due to being trapped in a (discarded) refrigerator, assault, initial encounter | Diagnosis | ICD-10-CM |
| T71.234A | Asphyxiation due to being trapped in a (discarded) refrigerator, undetermined, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T71.29XA | Asphyxiation due to being trapped in other low oxygen environment, initial encounter | Diagnosis | ICD-10-CM |
| T71.9XXA | Asphyxiation due to unspecified cause, initial encounter | Diagnosis | ICD-10-CM |
| T78.1XXA | Other adverse food reactions, not elsewhere classified, initial encounter | Diagnosis | ICD-10-CM |
| V40.0 | Problems with learning | Diagnosis | ICD-9-CM |
| V40.2 | Other mental problems | Diagnosis | ICD-9-CM |
| V40.3 | Other behavioral problems | Diagnosis | ICD-9-CM |
| V40.31 | Wandering in diseases classified elsewhere | Diagnosis | ICD-9-CM |
| V40.39 | Other specified behavioral problem | Diagnosis | ICD-9-CM |
| V40.9 | Unspecified mental or behavioral problem | Diagnosis | ICD-9-CM |
| V41.7 | Problems with sexual function | Diagnosis | ICD-9-CM |
| V62.84 | Suicidal ideation | Diagnosis | ICD-9-CM |
| V65.42 | Counseling on substance use and abuse | Diagnosis | ICD-9-CM |
| V67.3 | Psychotherapy and other treatment for mental disorder follow-up examination | Diagnosis | ICD-9-CM |
| X71.0XXA | Intentional self-harm by drowning and submersion while in bathtub, initial encounter | Diagnosis | ICD-10-CM |
| X71.0XXD | Intentional self-harm by drowning and submersion while in bathtub, subsequent encounter | Diagnosis | ICD-10-CM |
| X71.0XXS | Intentional self-harm by drowning and submersion while in bathtub, sequela | Diagnosis | ICD-10-CM |
| X71.1XXA | Intentional self-harm by drowning and submersion while in swimming pool, initial encounter | Diagnosis | ICD-10-CM |
| X71.1XXD | Intentional self-harm by drowning and submersion while in swimming pool, subsequent encounter | Diagnosis | ICD-10-CM |
| X71.1XXS | Intentional self-harm by drowning and submersion while in swimming pool, sequela | Diagnosis | ICD-10-CM |
| X71.2XXA | Intentional self-harm by drowning and submersion after jump into swimming pool, initial encounter | Diagnosis | ICD-10-CM |
| X71.2XXD | Intentional self-harm by drowning and submersion after jump into swimming pool, subsequent encounter | Diagnosis | ICD-10-CM |
| X71.2XXS | Intentional self-harm by drowning and submersion after jump into swimming pool, sequela | Diagnosis | ICD-10-CM |
| X71.3XXA | Intentional self-harm by drowning and submersion in natural water, initial encounter | Diagnosis | ICD-10-CM |
| X71.3XXD | Intentional self-harm by drowning and submersion in natural water, subsequent encounter | Diagnosis | ICD-10-CM |
| X71.3XXS | Intentional self-harm by drowning and submersion in natural water, sequela | Diagnosis | ICD-10-CM |
| X71.8XXA | Other intentional self-harm by drowning and submersion, initial encounter | Diagnosis | ICD-10-CM |
| X71.8XXD | Other intentional self-harm by drowning and submersion, subsequent encounter | Diagnosis | ICD-10-CM |
| X71.8XXS | Other intentional self-harm by drowning and submersion, sequela | Diagnosis | ICD-10-CM |
| X71.9XXA | Intentional self-harm by drowning and submersion, unspecified, initial encounter | Diagnosis | ICD-10-CM |
| X71.9XXD | Intentional self-harm by drowning and submersion, unspecified, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| X71.9XXS | Intentional self-harm by drowning and submersion, unspecified, sequela | Diagnosis | ICD-10-CM |
| X72.XXXA | Intentional self-harm by handgun discharge, initial encounter | Diagnosis | ICD-10-CM |
| X72.XXXD | Intentional self-harm by handgun discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X72.XXXS | Intentional self-harm by handgun discharge, sequela | Diagnosis | ICD-10-CM |
| X73.0XXA | Intentional self-harm by shotgun discharge, initial encounter | Diagnosis | ICD-10-CM |
| X73.0XXD | Intentional self-harm by shotgun discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X73.0XXS | Intentional self-harm by shotgun discharge, sequela | Diagnosis | ICD-10-CM |
| X73.1XXA | Intentional self-harm by hunting rifle discharge, initial encounter | Diagnosis | ICD-10-CM |
| X73.1XXD | Intentional self-harm by hunting rifle discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X73.1XXS | Intentional self-harm by hunting rifle discharge, sequela | Diagnosis | ICD-10-CM |
| X73.2XXA | Intentional self-harm by machine gun discharge, initial encounter | Diagnosis | ICD-10-CM |
| X73.2XXD | Intentional self-harm by machine gun discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X73.2XXS | Intentional self-harm by machine gun discharge, sequela | Diagnosis | ICD-10-CM |
| X73.8XXA | Intentional self-harm by other larger firearm discharge, initial encounter | Diagnosis | ICD-10-CM |
| X73.8XXD | Intentional self-harm by other larger firearm discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X73.8XXS | Intentional self-harm by other larger firearm discharge, sequela | Diagnosis | ICD-10-CM |
| X73.9XXA | Intentional self-harm by unspecified larger firearm discharge, initial encounter | Diagnosis | ICD-10-CM |
| X73.9XXD | Intentional self-harm by unspecified larger firearm discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X73.9XXS | Intentional self-harm by unspecified larger firearm discharge, sequela | Diagnosis | ICD-10-CM |
| X74.01XA | Intentional self-harm by airgun, initial encounter | Diagnosis | ICD-10-CM |
| X74.01XD | Intentional self-harm by airgun, subsequent encounter | Diagnosis | ICD-10-CM |
| X74.01XS | Intentional self-harm by airgun, sequela | Diagnosis | ICD-10-CM |
| X74.02XA | Intentional self-harm by paintball gun, initial encounter | Diagnosis | ICD-10-CM |
| X74.02XD | Intentional self-harm by paintball gun, subsequent encounter | Diagnosis | ICD-10-CM |
| X74.02XS | Intentional self-harm by paintball gun, sequela | Diagnosis | ICD-10-CM |
| X74.09XA | Intentional self-harm by other gas, air or spring-operated gun, initial encounter | Diagnosis | ICD-10-CM |
| X74.09XD | Intentional self-harm by other gas, air or spring-operated gun, subsequent encounter | Diagnosis | ICD-10-CM |
| X74.09XS | Intentional self-harm by other gas, air or spring-operated gun, sequela | Diagnosis | ICD-10-CM |
| X74.8XXA | Intentional self-harm by other firearm discharge, initial encounter | Diagnosis | ICD-10-CM |
| X74.8XXD | Intentional self-harm by other firearm discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X74.8XXS | Intentional self-harm by other firearm discharge, sequela | Diagnosis | ICD-10-CM |
| X74.9XXA | Intentional self-harm by unspecified firearm discharge, initial encounter | Diagnosis | ICD-10-CM |
| X74.9XXD | Intentional self-harm by unspecified firearm discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X74.9XXS | Intentional self-harm by unspecified firearm discharge, sequela | Diagnosis | ICD-10-CM |
| X75.XXXA | Intentional self-harm by explosive material, initial encounter | Diagnosis | ICD-10-CM |
| X75.XXXD | Intentional self-harm by explosive material, subsequent encounter | Diagnosis | ICD-10-CM |
| X75.XXXS | Intentional self-harm by explosive material, sequela | Diagnosis | ICD-10-CM |
| X76.XXXA | Intentional self-harm by smoke, fire and flames, initial encounter | Diagnosis | ICD-10-CM |
| X76.XXXD | Intentional self-harm by smoke, fire and flames, subsequent encounter | Diagnosis | ICD-10-CM |
| X76.XXXS | Intentional self-harm by smoke, fire and flames, sequela | Diagnosis | ICD-10-CM |
| X77.0XXA | Intentional self-harm by steam or hot vapors, initial encounter | Diagnosis | ICD-10-CM |
| X77.0XXD | Intentional self-harm by steam or hot vapors, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| X77.0XXS | Intentional self-harm by steam or hot vapors, sequela | Diagnosis | ICD-10-CM |
| X77.1XXA | Intentional self-harm by hot tap water, initial encounter | Diagnosis | ICD-10-CM |
| X77.1XXD | Intentional self-harm by hot tap water, subsequent encounter | Diagnosis | ICD-10-CM |
| X77.1XXS | Intentional self-harm by hot tap water, sequela | Diagnosis | ICD-10-CM |
| X77.2XXA | Intentional self-harm by other hot fluids, initial encounter | Diagnosis | ICD-10-CM |
| X77.2XXD | Intentional self-harm by other hot fluids, subsequent encounter | Diagnosis | ICD-10-CM |
| X77.2XXS | Intentional self-harm by other hot fluids, sequela | Diagnosis | ICD-10-CM |
| X77.3XXA | Intentional self-harm by hot household appliances, initial encounter | Diagnosis | ICD-10-CM |
| X77.3XXD | Intentional self-harm by hot household appliances, subsequent encounter | Diagnosis | ICD-10-CM |
| X77.3XXS | Intentional self-harm by hot household appliances, sequela | Diagnosis | ICD-10-CM |
| X77.8XXA | Intentional self-harm by other hot objects, initial encounter | Diagnosis | ICD-10-CM |
| X77.8XXD | Intentional self-harm by other hot objects, subsequent encounter | Diagnosis | ICD-10-CM |
| X77.8XXS | Intentional self-harm by other hot objects, sequela | Diagnosis | ICD-10-CM |
| X77.9XXA | Intentional self-harm by unspecified hot objects, initial encounter | Diagnosis | ICD-10-CM |
| X77.9XXD | Intentional self-harm by unspecified hot objects, subsequent encounter | Diagnosis | ICD-10-CM |
| X77.9XXS | Intentional self-harm by unspecified hot objects, sequela | Diagnosis | ICD-10-CM |
| X78.0XXA | Intentional self-harm by sharp glass, initial encounter | Diagnosis | ICD-10-CM |
| X78.0XXD | Intentional self-harm by sharp glass, subsequent encounter | Diagnosis | ICD-10-CM |
| X78.0XXS | Intentional self-harm by sharp glass, sequela | Diagnosis | ICD-10-CM |
| X78.1XXA | Intentional self-harm by knife, initial encounter | Diagnosis | ICD-10-CM |
| X78.1XXD | Intentional self-harm by knife, subsequent encounter | Diagnosis | ICD-10-CM |
| X78.1XXS | Intentional self-harm by knife, sequela | Diagnosis | ICD-10-CM |
| X78.2XXA | Intentional self-harm by sword or dagger, initial encounter | Diagnosis | ICD-10-CM |
| X78.2XXD | Intentional self-harm by sword or dagger, subsequent encounter | Diagnosis | ICD-10-CM |
| X78.2XXS | Intentional self-harm by sword or dagger, sequela | Diagnosis | ICD-10-CM |
| X78.8XXA | Intentional self-harm by other sharp object, initial encounter | Diagnosis | ICD-10-CM |
| X78.8XXD | Intentional self-harm by other sharp object, subsequent encounter | Diagnosis | ICD-10-CM |
| X78.8XXS | Intentional self-harm by other sharp object, sequela | Diagnosis | ICD-10-CM |
| X78.9XXA | Intentional self-harm by unspecified sharp object, initial encounter | Diagnosis | ICD-10-CM |
| X78.9XXD | Intentional self-harm by unspecified sharp object, subsequent encounter | Diagnosis | ICD-10-CM |
| X78.9XXS | Intentional self-harm by unspecified sharp object, sequela | Diagnosis | ICD-10-CM |
| X79.XXXA | Intentional self-harm by blunt object, initial encounter | Diagnosis | ICD-10-CM |
| X79.XXXD | Intentional self-harm by blunt object, subsequent encounter | Diagnosis | ICD-10-CM |
| X79.XXXS | Intentional self-harm by blunt object, sequela | Diagnosis | ICD-10-CM |
| X80.XXXA | Intentional self-harm by jumping from a high place, initial encounter | Diagnosis | ICD-10-CM |
| X80.XXXD | Intentional self-harm by jumping from a high place, subsequent encounter | Diagnosis | ICD-10-CM |
| X80.XXXS | Intentional self-harm by jumping from a high place, sequela | Diagnosis | ICD-10-CM |
| X81.0XXA | Intentional self-harm by jumping or lying in front of motor vehicle, initial encounter | Diagnosis | ICD-10-CM |
| X81.0XXD | Intentional self-harm by jumping or lying in front of motor vehicle, subsequent encounter | Diagnosis | ICD-10-CM |
| X81.0XXS | Intentional self-harm by jumping or lying in front of motor vehicle, sequela | Diagnosis | ICD-10-CM |
| X81.1XXA | Intentional self-harm by jumping or lying in front of (subway) train, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|-------------------------|---|---------------|-----------|
| X81.1XXD | Intentional self-harm by jumping or lying in front of (subway) train, subsequent encounter | Diagnosis | ICD-10-CM |
| X81.1XXS | Intentional self-harm by jumping or lying in front of (subway) train, sequela | Diagnosis | ICD-10-CM |
| X81.8XXA | Intentional self-harm by jumping or lying in front of other moving object, initial encounter | Diagnosis | ICD-10-CM |
| X81.8XXD | Intentional self-harm by jumping or lying in front of other moving object, subsequent encounter | Diagnosis | ICD-10-CM |
| X81.8XXS | Intentional self-harm by jumping or lying in front of other moving object, sequela | Diagnosis | ICD-10-CM |
| X82.0XXA | Intentional collision of motor vehicle with other motor vehicle, initial encounter | Diagnosis | ICD-10-CM |
| X82.0XXD | Intentional collision of motor vehicle with other motor vehicle, subsequent encounter | Diagnosis | ICD-10-CM |
| X82.0XXS | Intentional collision of motor vehicle with other motor vehicle, sequela | Diagnosis | ICD-10-CM |
| X82.1XXA | Intentional collision of motor vehicle with train, initial encounter | Diagnosis | ICD-10-CM |
| X82.1XXD | Intentional collision of motor vehicle with train, subsequent encounter | Diagnosis | ICD-10-CM |
| X82.1XXS | Intentional collision of motor vehicle with train, sequela | Diagnosis | ICD-10-CM |
| X82.2XXA | Intentional collision of motor vehicle with tree, initial encounter | Diagnosis | ICD-10-CM |
| X82.2XXD | Intentional collision of motor vehicle with tree, subsequent encounter | Diagnosis | ICD-10-CM |
| X82.2XXS | Intentional collision of motor vehicle with tree, sequela | Diagnosis | ICD-10-CM |
| X82.8XXA | Other intentional self-harm by crashing of motor vehicle, initial encounter | Diagnosis | ICD-10-CM |
| X82.8XXD | Other intentional self-harm by crashing of motor vehicle, subsequent encounter | Diagnosis | ICD-10-CM |
| X82.8XXS | Other intentional self-harm by crashing of motor vehicle, sequela | Diagnosis | ICD-10-CM |
| X83.0XXA | Intentional self-harm by crashing of aircraft, initial encounter | Diagnosis | ICD-10-CM |
| X83.0XXD | Intentional self-harm by crashing of aircraft, subsequent encounter | Diagnosis | ICD-10-CM |
| X83.0XXS | Intentional self-harm by crashing of aircraft, sequela | Diagnosis | ICD-10-CM |
| X83.1XXA | Intentional self-harm by electrocution, initial encounter | Diagnosis | ICD-10-CM |
| X83.1XXD | Intentional self-harm by electrocution, subsequent encounter | Diagnosis | ICD-10-CM |
| X83.1XXS | Intentional self-harm by electrocution, sequela | Diagnosis | ICD-10-CM |
| X83.2XXA | Intentional self-harm by exposure to extremes of cold, initial encounter | Diagnosis | ICD-10-CM |
| X83.2XXD | Intentional self-harm by exposure to extremes of cold, subsequent encounter | Diagnosis | ICD-10-CM |
| X83.2XXS | Intentional self-harm by exposure to extremes of cold, sequela | Diagnosis | ICD-10-CM |
| X83.8XXA | Intentional self-harm by other specified means, initial encounter | Diagnosis | ICD-10-CM |
| X83.8XXD | Intentional self-harm by other specified means, subsequent encounter | Diagnosis | ICD-10-CM |
| X83.8XXS | Intentional self-harm by other specified means, sequela | Diagnosis | ICD-10-CM |
| Z87.890 | Personal history of sex reassignment | Diagnosis | ICD-10-CM |
| Z91.5 | Personal history of self-harm | Diagnosis | ICD-10-CM |
| Z91.83 | Wandering in diseases classified elsewhere | Diagnosis | ICD-10-CM |
| Asthma Encounter | | | |
| 493.0 | Extrinsic asthma | Diagnosis | ICD-9-CM |
| 493.00 | Extrinsic asthma, unspecified | Diagnosis | ICD-9-CM |
| 493.02 | Extrinsic asthma, with (acute) exacerbation | Diagnosis | ICD-9-CM |
| 493.1 | Intrinsic asthma | Diagnosis | ICD-9-CM |
| 493.10 | Intrinsic asthma, unspecified | Diagnosis | ICD-9-CM |
| 493.12 | Intrinsic asthma, with (acute) exacerbation | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------------------------|--|---------------|-----------|
| 493.20 | Chronic obstructive asthma, unspecified ICD-9-CM | Diagnosis | ICD-9-CM |
| 493.21 | Chronic obstructive asthma with status asthmaticus ICD-9-CM | Diagnosis | ICD-9-CM |
| 493.22 | Chronic obstructive asthma, with (acute) exacerbation ICD-9-CM | Diagnosis | ICD-9-CM |
| 493.8 | Other forms of asthma | Diagnosis | ICD-9-CM |
| 493.82 | Cough variant asthma | Diagnosis | ICD-9-CM |
| 493.9 | Unspecified asthma | Diagnosis | ICD-9-CM |
| 493.90 | Asthma, unspecified, unspecified status | Diagnosis | ICD-9-CM |
| 493.92 | Asthma, unspecified, with (acute) exacerbation | Diagnosis | ICD-9-CM |
| J45 | Asthma | Diagnosis | ICD-10-CM |
| J45.2 | Mild intermittent asthma | Diagnosis | ICD-10-CM |
| J45.20 | Mild intermittent asthma, uncomplicated | Diagnosis | ICD-10-CM |
| J45.21 | Mild intermittent asthma with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J45.3 | Mild persistent asthma | Diagnosis | ICD-10-CM |
| J45.30 | Mild persistent asthma, uncomplicated | Diagnosis | ICD-10-CM |
| J45.31 | Mild persistent asthma with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J45.4 | Moderate persistent asthma | Diagnosis | ICD-10-CM |
| J45.40 | Moderate persistent asthma, uncomplicated | Diagnosis | ICD-10-CM |
| J45.41 | Moderate persistent asthma with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J45.5 | Severe persistent asthma | Diagnosis | ICD-10-CM |
| J45.50 | Severe persistent asthma, uncomplicated | Diagnosis | ICD-10-CM |
| J45.51 | Severe persistent asthma with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J45.9 | Other and unspecified asthma | Diagnosis | ICD-10-CM |
| J45.90 | Unspecified asthma | Diagnosis | ICD-10-CM |
| J45.901 | Unspecified asthma with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J45.909 | Unspecified asthma, uncomplicated | Diagnosis | ICD-10-CM |
| J45.99 | Other asthma | Diagnosis | ICD-10-CM |
| J45.991 | Cough variant asthma | Diagnosis | ICD-10-CM |
| J45.998 | Other asthma | Diagnosis | ICD-10-CM |
| Allergic Rhinitis | | | |
| 472.0 | Chronic rhinitis | Diagnosis | ICD-9-CM |
| 477 | Allergic rhinitis | Diagnosis | ICD-9-CM |
| 477.0 | Allergic rhinitis due to pollen | Diagnosis | ICD-9-CM |
| 477.1 | Allergic rhinitis, due to food | Diagnosis | ICD-9-CM |
| 477.2 | Allergic rhinitis due to animal (cat) (dog) hair and dander | Diagnosis | ICD-9-CM |
| 477.8 | Allergic rhinitis due to other allergen | Diagnosis | ICD-9-CM |
| 477.9 | Allergic rhinitis, cause unspecified | Diagnosis | ICD-9-CM |
| J30 | Vasomotor and allergic rhinitis | Diagnosis | ICD-10-CM |
| J30.0 | Vasomotor rhinitis | Diagnosis | ICD-10-CM |
| J30.1 | Allergic rhinitis due to pollen | Diagnosis | ICD-10-CM |
| J30.2 | Other seasonal allergic rhinitis | Diagnosis | ICD-10-CM |
| J30.5 | Allergic rhinitis due to food | Diagnosis | ICD-10-CM |
| J30.8 | Other allergic rhinitis | Diagnosis | ICD-10-CM |
| J30.81 | Allergic rhinitis due to animal (cat) (dog) hair and dander | Diagnosis | ICD-10-CM |
| J30.89 | Other allergic rhinitis | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------------|---|---------------|-----------|
| J30.9 | Allergic rhinitis, unspecified | Diagnosis | ICD-10-CM |
| Anxiety | | | |
| 293.84 | Anxiety disorder in conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 300.0 | Anxiety states | Diagnosis | ICD-9-CM |
| 300.00 | Anxiety state, unspecified | Diagnosis | ICD-9-CM |
| 300.01 | Panic disorder without agoraphobia | Diagnosis | ICD-9-CM |
| 300.02 | Generalized anxiety disorder | Diagnosis | ICD-9-CM |
| 300.09 | Other anxiety states | Diagnosis | ICD-9-CM |
| 300.10 | Hysteria, unspecified | Diagnosis | ICD-9-CM |
| 300.2 | Phobic disorders | Diagnosis | ICD-9-CM |
| 300.20 | Phobia, unspecified | Diagnosis | ICD-9-CM |
| 300.21 | Agoraphobia with panic disorder | Diagnosis | ICD-9-CM |
| 300.22 | Agoraphobia without mention of panic attacks | Diagnosis | ICD-9-CM |
| 300.23 | Social phobia | Diagnosis | ICD-9-CM |
| 300.29 | Other isolated or specific phobias | Diagnosis | ICD-9-CM |
| 300.3 | Obsessive-compulsive disorders | Diagnosis | ICD-9-CM |
| 300.5 | Neurasthenia | Diagnosis | ICD-9-CM |
| 300.89 | Other somatoform disorders | Diagnosis | ICD-9-CM |
| 300.9 | Unspecified nonpsychotic mental disorder | Diagnosis | ICD-9-CM |
| 308.0 | Predominant disturbance of emotions | Diagnosis | ICD-9-CM |
| 308.1 | Predominant disturbance of consciousness as reaction to stress | Diagnosis | ICD-9-CM |
| 308.2 | Predominant psychomotor disturbance as reaction to stress | Diagnosis | ICD-9-CM |
| 308.3 | Other acute reactions to stress | Diagnosis | ICD-9-CM |
| 308.4 | Mixed disorders as reaction to stress | Diagnosis | ICD-9-CM |
| 308.9 | Unspecified acute reaction to stress | Diagnosis | ICD-9-CM |
| 309.81 | Posttraumatic stress disorder | Diagnosis | ICD-9-CM |
| 313.0 | Overanxious disorder specific to childhood and adolescence | Diagnosis | ICD-9-CM |
| 313.1 | Misery and unhappiness disorder specific to childhood and adolescence | Diagnosis | ICD-9-CM |
| 313.21 | Shyness disorder of childhood | Diagnosis | ICD-9-CM |
| 313.22 | Introverted disorder of childhood | Diagnosis | ICD-9-CM |
| 313.3 | Relationship problems specific to childhood and adolescence | Diagnosis | ICD-9-CM |
| 313.82 | Identity disorder of childhood or adolescence | Diagnosis | ICD-9-CM |
| 313.83 | Academic underachievement disorder of childhood or adolescence | Diagnosis | ICD-9-CM |
| F06.4 | Anxiety disorder due to known physiological condition | Diagnosis | ICD-10-CM |
| F40.00 | Agoraphobia, unspecified | Diagnosis | ICD-10-CM |
| F40.01 | Agoraphobia with panic disorder | Diagnosis | ICD-10-CM |
| F40.02 | Agoraphobia without panic disorder | Diagnosis | ICD-10-CM |
| F40.10 | Social phobia, unspecified | Diagnosis | ICD-10-CM |
| F40.11 | Social phobia, generalized | Diagnosis | ICD-10-CM |
| F40.210 | Arachnophobia | Diagnosis | ICD-10-CM |
| F40.218 | Other animal type phobia | Diagnosis | ICD-10-CM |
| F40.220 | Fear of thunderstorms | Diagnosis | ICD-10-CM |
| F40.228 | Other natural environment type phobia | Diagnosis | ICD-10-CM |
| F40.230 | Fear of blood | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|-------------------|--|---------------|-----------|
| F40.231 | Fear of injections and transfusions | Diagnosis | ICD-10-CM |
| F40.232 | Fear of other medical care | Diagnosis | ICD-10-CM |
| F40.233 | Fear of injury | Diagnosis | ICD-10-CM |
| F40.240 | Claustrophobia | Diagnosis | ICD-10-CM |
| F40.241 | Acrophobia | Diagnosis | ICD-10-CM |
| F40.242 | Fear of bridges | Diagnosis | ICD-10-CM |
| F40.243 | Fear of flying | Diagnosis | ICD-10-CM |
| F40.248 | Other situational type phobia | Diagnosis | ICD-10-CM |
| F40.290 | Androphobia | Diagnosis | ICD-10-CM |
| F40.291 | Gynephobia | Diagnosis | ICD-10-CM |
| F40.298 | Other specified phobia | Diagnosis | ICD-10-CM |
| F40.8 | Other phobic anxiety disorders | Diagnosis | ICD-10-CM |
| F40.9 | Phobic anxiety disorder, unspecified | Diagnosis | ICD-10-CM |
| F41.0 | Panic disorder [episodic paroxysmal anxiety] | Diagnosis | ICD-10-CM |
| F41.1 | Generalized anxiety disorder | Diagnosis | ICD-10-CM |
| F41.3 | Other mixed anxiety disorders | Diagnosis | ICD-10-CM |
| F41.8 | Other specified anxiety disorders | Diagnosis | ICD-10-CM |
| F41.9 | Anxiety disorder, unspecified | Diagnosis | ICD-10-CM |
| F42 | Obsessive-compulsive disorder | Diagnosis | ICD-10-CM |
| F42.2 | Mixed obsessional thoughts and acts | Diagnosis | ICD-10-CM |
| F42.3 | Hoarding disorder | Diagnosis | ICD-10-CM |
| F42.4 | Excoriation (skin-picking) disorder | Diagnosis | ICD-10-CM |
| F42.8 | Other obsessive-compulsive disorder | Diagnosis | ICD-10-CM |
| F42.9 | Obsessive-compulsive disorder, unspecified | Diagnosis | ICD-10-CM |
| F43.0 | Acute stress reaction | Diagnosis | ICD-10-CM |
| F43.10 | Post-traumatic stress disorder, unspecified | Diagnosis | ICD-10-CM |
| F43.11 | Post-traumatic stress disorder, acute | Diagnosis | ICD-10-CM |
| F43.12 | Post-traumatic stress disorder, chronic | Diagnosis | ICD-10-CM |
| F44.9 | Dissociative and conversion disorder, unspecified | Diagnosis | ICD-10-CM |
| F45.8 | Other somatoform disorders | Diagnosis | ICD-10-CM |
| F48.8 | Other specified nonpsychotic mental disorders | Diagnosis | ICD-10-CM |
| F48.9 | Nonpsychotic mental disorder, unspecified | Diagnosis | ICD-10-CM |
| F93.8 | Other childhood emotional disorders | Diagnosis | ICD-10-CM |
| F99 | Mental disorder, not otherwise specified | Diagnosis | ICD-10-CM |
| R45.2 | Unhappiness | Diagnosis | ICD-10-CM |
| R45.5 | Hostility | Diagnosis | ICD-10-CM |
| R45.6 | Violent behavior | Diagnosis | ICD-10-CM |
| R45.7 | State of emotional shock and stress, unspecified | Diagnosis | ICD-10-CM |
| Depression | | | |
| 296.2 | Major depressive disorder, single episode | Diagnosis | ICD-9-CM |
| 296.20 | Major depressive disorder, single episode, unspecified | Diagnosis | ICD-9-CM |
| 296.21 | Major depressive disorder, single episode, mild | Diagnosis | ICD-9-CM |
| 296.22 | Major depressive disorder, single episode, moderate | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|-----------------------|---|---------------|-----------|
| 296.23 | Major depressive disorder, single episode, severe, without mention of psychotic behavior | Diagnosis | ICD-9-CM |
| 296.24 | Major depressive disorder, single episode, severe, specified as with psychotic behavior | Diagnosis | ICD-9-CM |
| 296.25 | Major depressive disorder, single episode, in partial or unspecified remission | Diagnosis | ICD-9-CM |
| 296.26 | Major depressive disorder, single episode in full remission | Diagnosis | ICD-9-CM |
| 296.3 | Major depressive disorder, recurrent episode | Diagnosis | ICD-9-CM |
| 296.30 | Major depressive disorder, recurrent episode, unspecified | Diagnosis | ICD-9-CM |
| 296.31 | Major depressive disorder, recurrent episode, mild | Diagnosis | ICD-9-CM |
| 296.32 | Major depressive disorder, recurrent episode, moderate | Diagnosis | ICD-9-CM |
| 296.33 | Major depressive disorder, recurrent episode, severe, without mention of psychotic behavior | Diagnosis | ICD-9-CM |
| 296.34 | Major depressive disorder, recurrent episode, severe, specified as with psychotic behavior | Diagnosis | ICD-9-CM |
| 296.35 | Major depressive disorder, recurrent episode, in partial or unspecified | Diagnosis | ICD-9-CM |
| 296.36 | Major depressive disorder, recurrent episode, in full remission | Diagnosis | ICD-9-CM |
| 296.90 | Unspecified episodic mood disorder | Diagnosis | ICD-9-CM |
| 300.4 | Dysthymic disorder | Diagnosis | ICD-9-CM |
| 309.0 | Adjustment disorder with depressed mood | Diagnosis | ICD-9-CM |
| 309.1 | Prolonged depressive reaction as adjustment reaction | Diagnosis | ICD-9-CM |
| 311 | Depressive disorder, not elsewhere classified | Diagnosis | ICD-9-CM |
| F32.0 | Major depressive disorder, single episode, mild | Diagnosis | ICD-10-CM |
| F32.1 | Major depressive disorder, single episode, moderate | Diagnosis | ICD-10-CM |
| F32.2 | Major depressive disorder, single episode, severe without psychotic features | Diagnosis | ICD-10-CM |
| F32.3 | Major depressive disorder, single episode, severe with psychotic features | Diagnosis | ICD-10-CM |
| F32.4 | Major depressive disorder, single episode, in partial remission | Diagnosis | ICD-10-CM |
| F32.5 | Major depressive disorder, single episode, in full remission | Diagnosis | ICD-10-CM |
| F32.9 | Major depressive disorder, single episode, unspecified | Diagnosis | ICD-10-CM |
| F33.0 | Major depressive disorder, recurrent, mild | Diagnosis | ICD-10-CM |
| F33.1 | Major depressive disorder, recurrent, moderate | Diagnosis | ICD-10-CM |
| F33.2 | Major depressive disorder, recurrent severe without psychotic features | Diagnosis | ICD-10-CM |
| F33.3 | Major depressive disorder, recurrent, severe with psychotic symptoms | Diagnosis | ICD-10-CM |
| F33.40 | Major depressive disorder, recurrent, in remission, unspecified | Diagnosis | ICD-10-CM |
| F33.41 | Major depressive disorder, recurrent, in partial remission | Diagnosis | ICD-10-CM |
| F33.42 | Major depressive disorder, recurrent, in full remission | Diagnosis | ICD-10-CM |
| F33.9 | Major depressive disorder, recurrent, unspecified | Diagnosis | ICD-10-CM |
| F34.1 | Dysthymic disorder | Diagnosis | ICD-10-CM |
| F39 | Unspecified mood [affective] disorder | Diagnosis | ICD-10-CM |
| F43.21 | Adjustment disorder with depressed mood | Diagnosis | ICD-10-CM |
| Sleep Disorder | | | |
| 307.4 | Specific disorders of sleep of nonorganic origin | Diagnosis | ICD-9-CM |
| 307.40 | Nonorganic sleep disorder, unspecified | Diagnosis | ICD-9-CM |
| 307.41 | Transient disorder of initiating or maintaining sleep | Diagnosis | ICD-9-CM |
| 307.42 | Persistent disorder of initiating or maintaining sleep | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 307.43 | Transient disorder of initiating or maintaining wakefulness | Diagnosis | ICD-9-CM |
| 307.44 | Persistent disorder of initiating or maintaining wakefulness | Diagnosis | ICD-9-CM |
| 307.45 | Circadian rhythm sleep disorder of nonorganic origin | Diagnosis | ICD-9-CM |
| 307.46 | Sleep arousal disorder | Diagnosis | ICD-9-CM |
| 307.47 | Other dysfunctions of sleep stages or arousal from sleep | Diagnosis | ICD-9-CM |
| 307.48 | Repetitive intrusions of sleep | Diagnosis | ICD-9-CM |
| 307.49 | Other specific disorder of sleep of nonorganic origin | Diagnosis | ICD-9-CM |
| 327 | Organic sleep disorders | Diagnosis | ICD-9-CM |
| 327.0 | Organic disorders of initiating and maintaining sleep [Organic insomnia] | Diagnosis | ICD-9-CM |
| 327.00 | Organic insomnia, unspecified | Diagnosis | ICD-9-CM |
| 327.01 | Insomnia due to medical condition classified elsewhere | Diagnosis | ICD-9-CM |
| 327.02 | Insomnia due to mental disorder | Diagnosis | ICD-9-CM |
| 327.09 | Other organic insomnia | Diagnosis | ICD-9-CM |
| 327.1 | Organic disorders of excessive somnolence [Organic hypersomnia] | Diagnosis | ICD-9-CM |
| 327.10 | Organic hypersomnia, unspecified | Diagnosis | ICD-9-CM |
| 327.11 | Idiopathic hypersomnia with long sleep time | Diagnosis | ICD-9-CM |
| 327.12 | Idiopathic hypersomnia without long sleep time | Diagnosis | ICD-9-CM |
| 327.13 | Recurrent hypersomnia | Diagnosis | ICD-9-CM |
| 327.14 | Hypersomnia due to medical condition classified elsewhere | Diagnosis | ICD-9-CM |
| 327.15 | Hypersomnia due to mental disorder | Diagnosis | ICD-9-CM |
| 327.19 | Other organic hypersomnia | Diagnosis | ICD-9-CM |
| 327.2 | Organic sleep apnea | Diagnosis | ICD-9-CM |
| 327.20 | Organic sleep apnea, unspecified | Diagnosis | ICD-9-CM |
| 327.21 | Primary central sleep apnea | Diagnosis | ICD-9-CM |
| 327.23 | Obstructive sleep apnea (adult) (pediatric) | Diagnosis | ICD-9-CM |
| 327.24 | Idiopathic sleep related nonobstructive alveolar hypoventilation | Diagnosis | ICD-9-CM |
| 327.25 | Congenital central alveolar hypoventilation syndrome | Diagnosis | ICD-9-CM |
| 327.26 | Sleep related hypoventilation/hypoxemia in conditions classifiable elsewhere | Diagnosis | ICD-9-CM |
| 327.27 | Central sleep apnea in conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 327.29 | Other organic sleep apnea | Diagnosis | ICD-9-CM |
| 327.3 | Circadian rhythm sleep disorder | Diagnosis | ICD-9-CM |
| 327.30 | Circadian rhythm sleep disorder, unspecified | Diagnosis | ICD-9-CM |
| 327.31 | Circadian rhythm sleep disorder, delayed sleep phase type | Diagnosis | ICD-9-CM |
| 327.32 | Circadian rhythm sleep disorder, advanced sleep phase type | Diagnosis | ICD-9-CM |
| 327.33 | Circadian rhythm sleep disorder, irregular sleep-wake type | Diagnosis | ICD-9-CM |
| 327.34 | Circadian rhythm sleep disorder, free-running type | Diagnosis | ICD-9-CM |
| 327.35 | Circadian rhythm sleep disorder, jet lag type | Diagnosis | ICD-9-CM |
| 327.36 | Circadian rhythm sleep disorder, shift work type | Diagnosis | ICD-9-CM |
| 327.37 | Circadian rhythm sleep disorder in conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 327.39 | Other circadian rhythm sleep disorder | Diagnosis | ICD-9-CM |
| 327.4 | Organic parasomnia | Diagnosis | ICD-9-CM |
| 327.40 | Organic parasomnia, unspecified | Diagnosis | ICD-9-CM |
| 327.41 | Confusional arousals | Diagnosis | ICD-9-CM |
| 327.42 | REM sleep behavior disorder | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| 327.43 | Recurrent isolated sleep paralysis | Diagnosis | ICD-9-CM |
| 327.44 | Parasomnia in conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 327.49 | Other organic parasomnia | Diagnosis | ICD-9-CM |
| 327.5 | Organic sleep related movement disorders | Diagnosis | ICD-9-CM |
| 327.51 | Periodic limb movement disorder | Diagnosis | ICD-9-CM |
| 327.52 | Sleep related leg cramps | Diagnosis | ICD-9-CM |
| 327.53 | Sleep related bruxism | Diagnosis | ICD-9-CM |
| 327.59 | Other organic sleep related movement disorders | Diagnosis | ICD-9-CM |
| 327.8 | Other organic sleep disorders | Diagnosis | ICD-9-CM |
| 347 | Cataplexy and narcolepsy | Diagnosis | ICD-9-CM |
| 347.0 | Narcolepsy | Diagnosis | ICD-9-CM |
| 347.00 | Narcolepsy, without cataplexy | Diagnosis | ICD-9-CM |
| 347.01 | Narcolepsy, with cataplexy | Diagnosis | ICD-9-CM |
| 347.1 | Narcolepsy in conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 347.10 | Narcolepsy in conditions classified elsewhere, without cataplexy | Diagnosis | ICD-9-CM |
| 347.11 | Narcolepsy in conditions classified elsewhere, with cataplexy | Diagnosis | ICD-9-CM |
| 780.5 | Sleep disturbances | Diagnosis | ICD-9-CM |
| 780.50 | Unspecified sleep disturbance | Diagnosis | ICD-9-CM |
| 780.51 | Insomnia with sleep apnea, unspecified | Diagnosis | ICD-9-CM |
| 780.52 | Insomnia, unspecified | Diagnosis | ICD-9-CM |
| 780.53 | Hypersomnia with sleep apnea, unspecified | Diagnosis | ICD-9-CM |
| 780.54 | Hypersomnia, unspecified | Diagnosis | ICD-9-CM |
| 780.55 | Disruption of 24 hour sleep wake cycle, unspecified | Diagnosis | ICD-9-CM |
| 780.56 | Dysfunctions associated with sleep stages or arousal from sleep | Diagnosis | ICD-9-CM |
| 780.57 | Unspecified sleep apnea | Diagnosis | ICD-9-CM |
| 780.58 | Sleep related movement disorder, unspecified | Diagnosis | ICD-9-CM |
| 780.59 | Other sleep disturbances | Diagnosis | ICD-9-CM |
| F51 | Sleep disorders not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F51.0 | Insomnia not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F51.01 | Primary insomnia | Diagnosis | ICD-10-CM |
| F51.02 | Adjustment insomnia | Diagnosis | ICD-10-CM |
| F51.03 | Paradoxical insomnia | Diagnosis | ICD-10-CM |
| F51.04 | Psychophysiologic insomnia | Diagnosis | ICD-10-CM |
| F51.05 | Insomnia due to other mental disorder | Diagnosis | ICD-10-CM |
| F51.09 | Other insomnia not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F51.1 | Hypersomnia not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F51.11 | Primary hypersomnia | Diagnosis | ICD-10-CM |
| F51.12 | Insufficient sleep syndrome | Diagnosis | ICD-10-CM |
| F51.13 | Hypersomnia due to other mental disorder | Diagnosis | ICD-10-CM |
| F51.19 | Other hypersomnia not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |
| F51.3 | Sleepwalking [somnambulism] | Diagnosis | ICD-10-CM |
| F51.4 | Sleep terrors [night terrors] | Diagnosis | ICD-10-CM |
| F51.5 | Nightmare disorder | Diagnosis | ICD-10-CM |
| F51.8 | Other sleep disorders not due to a substance or known physiological condition | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| F51.9 | Sleep disorder not due to a substance or known physiological condition, unspecified | Diagnosis | ICD-10-CM |
| G47 | Sleep disorders | Diagnosis | ICD-10-CM |
| G47.0 | Insomnia | Diagnosis | ICD-10-CM |
| G47.00 | Insomnia, unspecified | Diagnosis | ICD-10-CM |
| G47.01 | Insomnia due to medical condition | Diagnosis | ICD-10-CM |
| G47.09 | Other insomnia | Diagnosis | ICD-10-CM |
| G47.1 | Hypersomnia | Diagnosis | ICD-10-CM |
| G47.10 | Hypersomnia, unspecified | Diagnosis | ICD-10-CM |
| G47.11 | Idiopathic hypersomnia with long sleep time | Diagnosis | ICD-10-CM |
| G47.12 | Idiopathic hypersomnia without long sleep time | Diagnosis | ICD-10-CM |
| G47.13 | Recurrent hypersomnia | Diagnosis | ICD-10-CM |
| G47.14 | Hypersomnia due to medical condition | Diagnosis | ICD-10-CM |
| G47.19 | Other hypersomnia | Diagnosis | ICD-10-CM |
| G47.2 | Circadian rhythm sleep disorders | Diagnosis | ICD-10-CM |
| G47.20 | Circadian rhythm sleep disorder, unspecified type | Diagnosis | ICD-10-CM |
| G47.21 | Circadian rhythm sleep disorder, delayed sleep phase type | Diagnosis | ICD-10-CM |
| G47.22 | Circadian rhythm sleep disorder, advanced sleep phase type | Diagnosis | ICD-10-CM |
| G47.23 | Circadian rhythm sleep disorder, irregular sleep wake type | Diagnosis | ICD-10-CM |
| G47.24 | Circadian rhythm sleep disorder, free running type | Diagnosis | ICD-10-CM |
| G47.25 | Circadian rhythm sleep disorder, jet lag type | Diagnosis | ICD-10-CM |
| G47.26 | Circadian rhythm sleep disorder, shift work type | Diagnosis | ICD-10-CM |
| G47.27 | Circadian rhythm sleep disorder in conditions classified elsewhere | Diagnosis | ICD-10-CM |
| G47.29 | Other circadian rhythm sleep disorder | Diagnosis | ICD-10-CM |
| G47.3 | Sleep apnea | Diagnosis | ICD-10-CM |
| G47.30 | Sleep apnea, unspecified | Diagnosis | ICD-10-CM |
| G47.31 | Primary central sleep apnea | Diagnosis | ICD-10-CM |
| G47.33 | Obstructive sleep apnea (adult) (pediatric) | Diagnosis | ICD-10-CM |
| G47.34 | Idiopathic sleep related nonobstructive alveolar hypoventilation | Diagnosis | ICD-10-CM |
| G47.35 | Congenital central alveolar hypoventilation syndrome | Diagnosis | ICD-10-CM |
| G47.36 | Sleep related hypoventilation in conditions classified elsewhere | Diagnosis | ICD-10-CM |
| G47.37 | Central sleep apnea in conditions classified elsewhere | Diagnosis | ICD-10-CM |
| G47.39 | Other sleep apnea | Diagnosis | ICD-10-CM |
| G47.4 | Narcolepsy and cataplexy | Diagnosis | ICD-10-CM |
| G47.41 | Narcolepsy | Diagnosis | ICD-10-CM |
| G47.411 | Narcolepsy with cataplexy | Diagnosis | ICD-10-CM |
| G47.419 | Narcolepsy without cataplexy | Diagnosis | ICD-10-CM |
| G47.42 | Narcolepsy in conditions classified elsewhere | Diagnosis | ICD-10-CM |
| G47.421 | Narcolepsy in conditions classified elsewhere with cataplexy | Diagnosis | ICD-10-CM |
| G47.429 | Narcolepsy in conditions classified elsewhere without cataplexy | Diagnosis | ICD-10-CM |
| G47.5 | Parasomnia | Diagnosis | ICD-10-CM |
| G47.50 | Parasomnia, unspecified | Diagnosis | ICD-10-CM |
| G47.51 | Confusional arousals | Diagnosis | ICD-10-CM |
| G47.52 | REM sleep behavior disorder | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------------------------------|--|---------------|-----------|
| G47.53 | Recurrent isolated sleep paralysis | Diagnosis | ICD-10-CM |
| G47.54 | Parasomnia in conditions classified elsewhere | Diagnosis | ICD-10-CM |
| G47.59 | Other parasomnia | Diagnosis | ICD-10-CM |
| G47.6 | Sleep related movement disorders | Diagnosis | ICD-10-CM |
| G47.61 | Periodic limb movement disorder | Diagnosis | ICD-10-CM |
| G47.62 | Sleep related leg cramps | Diagnosis | ICD-10-CM |
| G47.63 | Sleep related bruxism | Diagnosis | ICD-10-CM |
| G47.69 | Other sleep related movement disorders | Diagnosis | ICD-10-CM |
| G47.8 | Other sleep disorders | Diagnosis | ICD-10-CM |
| G47.9 | Sleep disorder, unspecified | Diagnosis | ICD-10-CM |
| Substance Abuse Disorder | | | |
| 291 | Alcohol-induced mental disorders | Diagnosis | ICD-9-CM |
| 291.0 | Alcohol withdrawal delirium | Diagnosis | ICD-9-CM |
| 291.1 | Alcohol-induced persisting amnestic disorder | Diagnosis | ICD-9-CM |
| 291.2 | Alcohol-induced persisting dementia | Diagnosis | ICD-9-CM |
| 291.3 | Alcohol-induced psychotic disorder with hallucinations | Diagnosis | ICD-9-CM |
| 291.4 | Idiosyncratic alcohol intoxication | Diagnosis | ICD-9-CM |
| 291.5 | Alcohol-induced psychotic disorder with delusions | Diagnosis | ICD-9-CM |
| 291.8 | Other specified alcohol-induced mental disorders | Diagnosis | ICD-9-CM |
| 291.81 | Alcohol withdrawal | Diagnosis | ICD-9-CM |
| 291.82 | Alcohol induced sleep disorders | Diagnosis | ICD-9-CM |
| 291.89 | Other specified alcohol-induced mental disorders | Diagnosis | ICD-9-CM |
| 291.9 | Unspecified alcohol-induced mental disorders | Diagnosis | ICD-9-CM |
| 292 | Drug-induced mental disorders | Diagnosis | ICD-9-CM |
| 292.0 | Drug withdrawal | Diagnosis | ICD-9-CM |
| 292.1 | Drug-induced psychotic disorder | Diagnosis | ICD-9-CM |
| 292.11 | Drug-induced psychotic disorder with delusions | Diagnosis | ICD-9-CM |
| 292.12 | Drug-induced psychotic disorder with hallucinations | Diagnosis | ICD-9-CM |
| 292.2 | Pathological drug intoxication | Diagnosis | ICD-9-CM |
| 292.8 | Other specified drug-induced mental disorders | Diagnosis | ICD-9-CM |
| 292.81 | Drug-induced delirium | Diagnosis | ICD-9-CM |
| 292.82 | Drug-induced persisting dementia | Diagnosis | ICD-9-CM |
| 292.83 | Drug-induced persisting amnestic disorder | Diagnosis | ICD-9-CM |
| 292.84 | Drug-induced mood disorder | Diagnosis | ICD-9-CM |
| 292.85 | Drug induced sleep disorders | Diagnosis | ICD-9-CM |
| 292.89 | Other specified drug-induced mental disorder | Diagnosis | ICD-9-CM |
| 292.9 | Unspecified drug-induced mental disorder | Diagnosis | ICD-9-CM |
| 303 | Alcohol dependence syndrome | Diagnosis | ICD-9-CM |
| 303.0 | Acute alcoholic intoxication | Diagnosis | ICD-9-CM |
| 303.00 | Acute alcoholic intoxication, unspecified | Diagnosis | ICD-9-CM |
| 303.01 | Acute alcoholic intoxication, continuous | Diagnosis | ICD-9-CM |
| 303.02 | Acute alcoholic intoxication, episodic | Diagnosis | ICD-9-CM |
| 303.03 | Acute alcoholic intoxication, in remission | Diagnosis | ICD-9-CM |
| 303.9 | Other and unspecified alcohol dependence | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| 303.90 | Other and unspecified alcohol dependence, unspecified | Diagnosis | ICD-9-CM |
| 303.91 | Other and unspecified alcohol dependence, continuous | Diagnosis | ICD-9-CM |
| 303.92 | Other and unspecified alcohol dependence, episodic | Diagnosis | ICD-9-CM |
| 303.93 | Other and unspecified alcohol dependence, in remission | Diagnosis | ICD-9-CM |
| 304 | Drug dependence | Diagnosis | ICD-9-CM |
| 304.0 | Opioid type dependence | Diagnosis | ICD-9-CM |
| 304.00 | Opioid type dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.01 | Opioid type dependence, continuous | Diagnosis | ICD-9-CM |
| 304.02 | Opioid type dependence, episodic | Diagnosis | ICD-9-CM |
| 304.03 | Opioid type dependence, in remission | Diagnosis | ICD-9-CM |
| 304.1 | Sedative, hypnotic or anxiolytic dependence | Diagnosis | ICD-9-CM |
| 304.10 | Sedative, hypnotic or anxiolytic dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.11 | Sedative, hypnotic or anxiolytic dependence, continuous | Diagnosis | ICD-9-CM |
| 304.12 | Sedative, hypnotic or anxiolytic dependence, episodic | Diagnosis | ICD-9-CM |
| 304.13 | Sedative, hypnotic or anxiolytic dependence, in remission | Diagnosis | ICD-9-CM |
| 304.2 | Cocaine dependence | Diagnosis | ICD-9-CM |
| 304.20 | Cocaine dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.21 | Cocaine dependence, continuous | Diagnosis | ICD-9-CM |
| 304.22 | Cocaine dependence, episodic | Diagnosis | ICD-9-CM |
| 304.23 | Cocaine dependence, in remission | Diagnosis | ICD-9-CM |
| 304.3 | Cannabis dependence | Diagnosis | ICD-9-CM |
| 304.30 | Cannabis dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.31 | Cannabis dependence, continuous | Diagnosis | ICD-9-CM |
| 304.32 | Cannabis dependence, episodic | Diagnosis | ICD-9-CM |
| 304.33 | Cannabis dependence, in remission | Diagnosis | ICD-9-CM |
| 304.4 | Amphetamine and other psychostimulant dependence | Diagnosis | ICD-9-CM |
| 304.40 | Amphetamine and other psychostimulant dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.41 | Amphetamine and other psychostimulant dependence, continuous | Diagnosis | ICD-9-CM |
| 304.42 | Amphetamine and other psychostimulant dependence, episodic | Diagnosis | ICD-9-CM |
| 304.43 | Amphetamine and other psychostimulant dependence, in remission | Diagnosis | ICD-9-CM |
| 304.5 | Hallucinogen dependence | Diagnosis | ICD-9-CM |
| 304.50 | Hallucinogen dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.51 | Hallucinogen dependence, continuous | Diagnosis | ICD-9-CM |
| 304.52 | Hallucinogen dependence, episodic | Diagnosis | ICD-9-CM |
| 304.53 | Hallucinogen dependence, in remission | Diagnosis | ICD-9-CM |
| 304.6 | Other specified drug dependence | Diagnosis | ICD-9-CM |
| 304.60 | Other specified drug dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.61 | Other specified drug dependence, continuous | Diagnosis | ICD-9-CM |
| 304.62 | Other specified drug dependence, episodic | Diagnosis | ICD-9-CM |
| 304.63 | Other specified drug dependence, in remission | Diagnosis | ICD-9-CM |
| 304.7 | Combinations of opioid type drug with any other drug dependence | Diagnosis | ICD-9-CM |
| 304.70 | Combinations of opioid type drug with any other drug dependence, | Diagnosis | ICD-9-CM |
| 304.71 | Combinations of opioid type drug with any other drug dependence, | Diagnosis | ICD-9-CM |
| 304.72 | Combinations of opioid type drug with any other drug dependence, episodic | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 304.73 | Combinations of opioid type drug with any other drug dependence, in | Diagnosis | ICD-9-CM |
| 304.8 | Combinations of drug dependence excluding opioid type drug | Diagnosis | ICD-9-CM |
| 304.80 | Combinations of drug dependence excluding opioid type drug, unspecified | Diagnosis | ICD-9-CM |
| 304.81 | Combinations of drug dependence excluding opioid type drug, continuous | Diagnosis | ICD-9-CM |
| 304.82 | Combinations of drug dependence excluding opioid type drug, episodic | Diagnosis | ICD-9-CM |
| 304.83 | Combinations of drug dependence excluding opioid type drug, in remission | Diagnosis | ICD-9-CM |
| 304.9 | Unspecified drug dependence | Diagnosis | ICD-9-CM |
| 304.90 | Unspecified drug dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.91 | Unspecified drug dependence, continuous | Diagnosis | ICD-9-CM |
| 304.92 | Unspecified drug dependence, episodic | Diagnosis | ICD-9-CM |
| 304.93 | Unspecified drug dependence, in remission | Diagnosis | ICD-9-CM |
| 305 | Nondependent abuse of drugs | Diagnosis | ICD-9-CM |
| 305.0 | Nondependent alcohol abuse | Diagnosis | ICD-9-CM |
| 305.00 | Nondependent alcohol abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.01 | Nondependent alcohol abuse, continuous | Diagnosis | ICD-9-CM |
| 305.02 | Nondependent alcohol abuse, episodic | Diagnosis | ICD-9-CM |
| 305.03 | Nondependent alcohol abuse, in remission | Diagnosis | ICD-9-CM |
| 305.2 | Nondependent cannabis abuse | Diagnosis | ICD-9-CM |
| 305.20 | Nondependent cannabis abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.21 | Nondependent cannabis abuse, continuous | Diagnosis | ICD-9-CM |
| 305.22 | Nondependent cannabis abuse, episodic | Diagnosis | ICD-9-CM |
| 305.23 | Nondependent cannabis abuse, in remission | Diagnosis | ICD-9-CM |
| 305.3 | Nondependent hallucinogen abuse | Diagnosis | ICD-9-CM |
| 305.30 | Nondependent hallucinogen abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.31 | Nondependent hallucinogen abuse, continuous | Diagnosis | ICD-9-CM |
| 305.32 | Nondependent hallucinogen abuse, episodic | Diagnosis | ICD-9-CM |
| 305.33 | Nondependent hallucinogen abuse, in remission | Diagnosis | ICD-9-CM |
| 305.4 | Nondependent sedative, hypnotic or anxiolytic abuse | Diagnosis | ICD-9-CM |
| 305.40 | Nondependent sedative, hypnotic or anxiolytic abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.41 | Nondependent sedative hypnotic or anxiolytic abuse, continuous | Diagnosis | ICD-9-CM |
| 305.42 | Nondependent sedative, hypnotic or anxiolytic abuse, episodic | Diagnosis | ICD-9-CM |
| 305.43 | Nondependent sedative, hypnotic or anxiolytic abuse, in remission | Diagnosis | ICD-9-CM |
| 305.5 | Nondependent opioid abuse | Diagnosis | ICD-9-CM |
| 305.50 | Nondependent opioid abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.51 | Nondependent opioid abuse, continuous | Diagnosis | ICD-9-CM |
| 305.52 | Nondependent opioid abuse, episodic | Diagnosis | ICD-9-CM |
| 305.53 | Nondependent opioid abuse, in remission | Diagnosis | ICD-9-CM |
| 305.6 | Nondependent cocaine abuse | Diagnosis | ICD-9-CM |
| 305.60 | Nondependent cocaine abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.61 | Nondependent cocaine abuse, continuous | Diagnosis | ICD-9-CM |
| 305.62 | Nondependent cocaine abuse, episodic | Diagnosis | ICD-9-CM |
| 305.63 | Nondependent cocaine abuse, in remission | Diagnosis | ICD-9-CM |
| 305.7 | Nondependent amphetamine or related acting sympathomimetic abuse | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 305.70 | Nondependent amphetamine or related acting sympathomimetic abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.71 | Nondependent amphetamine or related acting sympathomimetic abuse, continuous | Diagnosis | ICD-9-CM |
| 305.72 | Nondependent amphetamine or related acting sympathomimetic abuse, episodic | Diagnosis | ICD-9-CM |
| 305.73 | Nondependent amphetamine or related acting sympathomimetic abuse, in remission | Diagnosis | ICD-9-CM |
| 305.8 | Nondependent antidepressant type abuse | Diagnosis | ICD-9-CM |
| 305.80 | Nondependent antidepressant type abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.81 | Nondependent antidepressant type abuse, continuous | Diagnosis | ICD-9-CM |
| 305.82 | Nondependent antidepressant type abuse, episodic | Diagnosis | ICD-9-CM |
| 305.83 | Nondependent antidepressant type abuse, in remission | Diagnosis | ICD-9-CM |
| 305.9 | Other, mixed, or unspecified nondependent drug abuse | Diagnosis | ICD-9-CM |
| 305.90 | Other, mixed, or unspecified nondependent drug abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.91 | Other, mixed, or unspecified nondependent drug abuse, continuous | Diagnosis | ICD-9-CM |
| 305.92 | Other, mixed, or unspecified nondependent drug abuse, episodic | Diagnosis | ICD-9-CM |
| 305.93 | Other, mixed, or unspecified nondependent drug abuse, in remission | Diagnosis | ICD-9-CM |
| 357.5 | Alcoholic polyneuropathy | Diagnosis | ICD-9-CM |
| 425.5 | Alcoholic cardiomyopathy | Diagnosis | ICD-9-CM |
| 4320F | Patient counseled regarding psychosocial and pharmacologic treatment options for alcohol dependence (SUD) | Procedure | CPT-2 |
| 535.3 | Alcoholic gastritis | Diagnosis | ICD-9-CM |
| 535.30 | Alcoholic gastritis without mention of hemorrhage | Diagnosis | ICD-9-CM |
| 535.31 | Alcoholic gastritis with hemorrhage | Diagnosis | ICD-9-CM |
| 571.0 | Alcoholic fatty liver | Diagnosis | ICD-9-CM |
| 571.1 | Acute alcoholic hepatitis | Diagnosis | ICD-9-CM |
| 571.2 | Alcoholic cirrhosis of liver | Diagnosis | ICD-9-CM |
| 571.3 | Unspecified alcoholic liver damage | Diagnosis | ICD-9-CM |
| 648.30 | Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, unspecified as to episode of care | Diagnosis | ICD-9-CM |
| 648.31 | Maternal drug dependence, with delivery | Diagnosis | ICD-9-CM |
| 648.32 | Maternal drug dependence, with delivery, with current postpartum complication | Diagnosis | ICD-9-CM |
| 648.33 | Maternal drug dependence, antepartum | Diagnosis | ICD-9-CM |
| 648.34 | Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, postpartum condition or complication | Diagnosis | ICD-9-CM |
| 655.50 | Suspected damage to fetus from drugs, affecting management of mother, unspecified as to episode of care | Diagnosis | ICD-9-CM |
| 655.51 | Suspected damage to fetus from drugs, affecting management of mother, delivered | Diagnosis | ICD-9-CM |
| 655.53 | Suspected damage to fetus from drugs, affecting management of mother, antepartum | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| 760.71 | Noxious influences affecting fetus or newborn via placenta or breast milk, alcohol | Diagnosis | ICD-9-CM |
| 760.72 | Noxious influences affecting fetus or newborn via placenta or breast milk, narcotics | Diagnosis | ICD-9-CM |
| 760.73 | Noxious influences affecting fetus or newborn via placenta or breast milk, hallucinogenic agents | Diagnosis | ICD-9-CM |
| 760.75 | Noxious influences affecting fetus or newborn via placenta or breast milk, cocaine | Diagnosis | ICD-9-CM |
| 779.5 | Drug withdrawal syndrome in newborn | Diagnosis | ICD-9-CM |
| 94.46 | Alcoholism counseling | Procedure | ICD-9-CM |
| 94.53 | Referral for alcoholism rehabilitation | Procedure | ICD-9-CM |
| 94.6 | Alcohol and drug rehabilitation and detoxification | Procedure | ICD-9-CM |
| 94.61 | Alcohol rehabilitation | Procedure | ICD-9-CM |
| 94.62 | Alcohol detoxification | Procedure | ICD-9-CM |
| 94.63 | Alcohol rehabilitation and detoxification | Procedure | ICD-9-CM |
| 94.67 | Combined alcohol and drug rehabilitation | Procedure | ICD-9-CM |
| 94.68 | Combined alcohol and drug detoxification | Procedure | ICD-9-CM |
| 94.69 | Combined alcohol and drug rehabilitation and detoxification | Procedure | ICD-9-CM |
| 965.00 | Poisoning by opium (alkaloids), unspecified | Diagnosis | ICD-9-CM |
| 965.01 | Poisoning by heroin | Diagnosis | ICD-9-CM |
| 965.02 | Poisoning by methadone | Diagnosis | ICD-9-CM |
| 965.09 | Poisoning by opiates and related narcotics, other | Diagnosis | ICD-9-CM |
| 980.0 | Toxic effect of ethyl alcohol | Diagnosis | ICD-9-CM |
| F10.10 | Alcohol abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F10.11 | Alcohol abuse, in remission | Diagnosis | ICD-10-CM |
| F10.120 | Alcohol abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F10.121 | Alcohol abuse with intoxication delirium | Diagnosis | ICD-10-CM |
| F10.129 | Alcohol abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F10.14 | Alcohol abuse with alcohol-induced mood disorder | Diagnosis | ICD-10-CM |
| F10.150 | Alcohol abuse with alcohol-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F10.151 | Alcohol abuse with alcohol-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F10.159 | Alcohol abuse with alcohol-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F10.180 | Alcohol abuse with alcohol-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F10.181 | Alcohol abuse with alcohol-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F10.182 | Alcohol abuse with alcohol-induced sleep disorder | Diagnosis | ICD-10-CM |
| F10.188 | Alcohol abuse with other alcohol-induced disorder | Diagnosis | ICD-10-CM |
| F10.19 | Alcohol abuse with unspecified alcohol-induced disorder | Diagnosis | ICD-10-CM |
| F10.20 | Alcohol dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F10.21 | Alcohol dependence, in remission | Diagnosis | ICD-10-CM |
| F10.220 | Alcohol dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F10.221 | Alcohol dependence with intoxication delirium | Diagnosis | ICD-10-CM |
| F10.229 | Alcohol dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F10.230 | Alcohol dependence with withdrawal, uncomplicated | Diagnosis | ICD-10-CM |
| F10.231 | Alcohol dependence with withdrawal delirium | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F10.232 | Alcohol dependence with withdrawal with perceptual disturbance | Diagnosis | ICD-10-CM |
| F10.239 | Alcohol dependence with withdrawal, unspecified | Diagnosis | ICD-10-CM |
| F10.24 | Alcohol dependence with alcohol-induced mood disorder | Diagnosis | ICD-10-CM |
| F10.250 | Alcohol dependence with alcohol-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F10.251 | Alcohol dependence with alcohol-induced psychotic disorder with | Diagnosis | ICD-10-CM |
| F10.259 | Alcohol dependence with alcohol-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F10.26 | Alcohol dependence with alcohol-induced persisting amnestic disorder | Diagnosis | ICD-10-CM |
| F10.27 | Alcohol dependence with alcohol-induced persisting dementia | Diagnosis | ICD-10-CM |
| F10.280 | Alcohol dependence with alcohol-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F10.281 | Alcohol dependence with alcohol-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F10.282 | Alcohol dependence with alcohol-induced sleep disorder | Diagnosis | ICD-10-CM |
| F10.288 | Alcohol dependence with other alcohol-induced disorder | Diagnosis | ICD-10-CM |
| F10.29 | Alcohol dependence with unspecified alcohol-induced disorder | Diagnosis | ICD-10-CM |
| F10.920 | Alcohol use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F10.921 | Alcohol use, unspecified with intoxication delirium | Diagnosis | ICD-10-CM |
| F10.929 | Alcohol use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F10.94 | Alcohol use, unspecified with alcohol-induced mood disorder | Diagnosis | ICD-10-CM |
| F10.950 | Alcohol use, unspecified with alcohol-induced psychotic disorder with | Diagnosis | ICD-10-CM |
| F10.951 | Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F10.959 | Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F10.96 | Alcohol use, unspecified with alcohol-induced persisting amnestic disorder | Diagnosis | ICD-10-CM |
| F10.97 | Alcohol use, unspecified with alcohol-induced persisting dementia | Diagnosis | ICD-10-CM |
| F10.980 | Alcohol use, unspecified with alcohol-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F10.981 | Alcohol use, unspecified with alcohol-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F10.982 | Alcohol use, unspecified with alcohol-induced sleep disorder | Diagnosis | ICD-10-CM |
| F10.988 | Alcohol use, unspecified with other alcohol-induced disorder | Diagnosis | ICD-10-CM |
| F10.99 | Alcohol use, unspecified with unspecified alcohol-induced disorder | Diagnosis | ICD-10-CM |
| F11.10 | Opioid abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F11.11 | Opioid abuse, in remission | Diagnosis | ICD-10-CM |
| F11.120 | Opioid abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F11.121 | Opioid abuse with intoxication delirium | Diagnosis | ICD-10-CM |
| F11.122 | Opioid abuse with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F11.129 | Opioid abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F11.14 | Opioid abuse with opioid-induced mood disorder | Diagnosis | ICD-10-CM |
| F11.150 | Opioid abuse with opioid-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F11.151 | Opioid abuse with opioid-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F11.159 | Opioid abuse with opioid-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F11.181 | Opioid abuse with opioid-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F11.182 | Opioid abuse with opioid-induced sleep disorder | Diagnosis | ICD-10-CM |
| F11.188 | Opioid abuse with other opioid-induced disorder | Diagnosis | ICD-10-CM |
| F11.19 | Opioid abuse with unspecified opioid-induced disorder | Diagnosis | ICD-10-CM |
| F11.20 | Opioid dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F11.21 | Opioid dependence, in remission | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F11.220 | Opioid dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F11.221 | Opioid dependence with intoxication delirium | Diagnosis | ICD-10-CM |
| F11.222 | Opioid dependence with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F11.229 | Opioid dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F11.23 | Opioid dependence with withdrawal | Diagnosis | ICD-10-CM |
| F11.24 | Opioid dependence with opioid-induced mood disorder | Diagnosis | ICD-10-CM |
| F11.250 | Opioid dependence with opioid-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F11.251 | Opioid dependence with opioid-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F11.259 | Opioid dependence with opioid-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F11.281 | Opioid dependence with opioid-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F11.282 | Opioid dependence with opioid-induced sleep disorder | Diagnosis | ICD-10-CM |
| F11.288 | Opioid dependence with other opioid-induced disorder | Diagnosis | ICD-10-CM |
| F11.29 | Opioid dependence with unspecified opioid-induced disorder | Diagnosis | ICD-10-CM |
| F11.90 | Opioid use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F11.920 | Opioid use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F11.921 | Opioid use, unspecified with intoxication delirium | Diagnosis | ICD-10-CM |
| F11.922 | Opioid use, unspecified with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F11.929 | Opioid use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F11.93 | Opioid use, unspecified with withdrawal | Diagnosis | ICD-10-CM |
| F11.94 | Opioid use, unspecified with opioid-induced mood disorder | Diagnosis | ICD-10-CM |
| F11.950 | Opioid use, unspecified with opioid-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F11.951 | Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F11.959 | Opioid use, unspecified with opioid-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F11.981 | Opioid use, unspecified with opioid-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F11.982 | Opioid use, unspecified with opioid-induced sleep disorder | Diagnosis | ICD-10-CM |
| F11.988 | Opioid use, unspecified with other opioid-induced disorder | Diagnosis | ICD-10-CM |
| F11.99 | Opioid use, unspecified with unspecified opioid-induced disorder | Diagnosis | ICD-10-CM |
| F12.10 | Cannabis abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F12.11 | Cannabis abuse, in remission | Diagnosis | ICD-10-CM |
| F12.120 | Cannabis abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F12.121 | Cannabis abuse with intoxication delirium | Diagnosis | ICD-10-CM |
| F12.122 | Cannabis abuse with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F12.129 | Cannabis abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F12.150 | Cannabis abuse with psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F12.151 | Cannabis abuse with psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F12.159 | Cannabis abuse with psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F12.180 | Cannabis abuse with cannabis-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F12.188 | Cannabis abuse with other cannabis-induced disorder | Diagnosis | ICD-10-CM |
| F12.19 | Cannabis abuse with unspecified cannabis-induced disorder | Diagnosis | ICD-10-CM |
| F12.20 | Cannabis dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F12.21 | Cannabis dependence, in remission | Diagnosis | ICD-10-CM |
| F12.220 | Cannabis dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F12.221 | Cannabis dependence with intoxication delirium | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| F12.222 | Cannabis dependence with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F12.229 | Cannabis dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F12.23 | Cannabis dependence with withdrawal | Diagnosis | ICD-10-CM |
| F12.250 | Cannabis dependence with psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F12.251 | Cannabis dependence with psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F12.259 | Cannabis dependence with psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F12.280 | Cannabis dependence with cannabis-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F12.288 | Cannabis dependence with other cannabis-induced disorder | Diagnosis | ICD-10-CM |
| F12.29 | Cannabis dependence with unspecified cannabis-induced disorder | Diagnosis | ICD-10-CM |
| F12.90 | Cannabis use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F12.920 | Cannabis use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F12.921 | Cannabis use, unspecified with intoxication delirium | Diagnosis | ICD-10-CM |
| F12.922 | Cannabis use, unspecified with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F12.929 | Cannabis use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F12.93 | Cannabis use, unspecified with withdrawal | Diagnosis | ICD-10-CM |
| F12.950 | Cannabis use, unspecified with psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F12.951 | Cannabis use, unspecified with psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F12.959 | Cannabis use, unspecified with psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F12.980 | Cannabis use, unspecified with anxiety disorder | Diagnosis | ICD-10-CM |
| F12.988 | Cannabis use, unspecified with other cannabis-induced disorder | Diagnosis | ICD-10-CM |
| F12.99 | Cannabis use, unspecified with unspecified cannabis-induced disorder | Diagnosis | ICD-10-CM |
| F13.10 | Sedative, hypnotic or anxiolytic abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F13.11 | Sedative, hypnotic or anxiolytic abuse, in remission | Diagnosis | ICD-10-CM |
| F13.120 | Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F13.121 | Sedative, hypnotic or anxiolytic abuse with intoxication delirium | Diagnosis | ICD-10-CM |
| F13.129 | Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F13.14 | Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood disorder | Diagnosis | ICD-10-CM |
| F13.150 | Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F13.151 | Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F13.159 | Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F13.180 | Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F13.181 | Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F13.182 | Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep disorder | Diagnosis | ICD-10-CM |
| F13.188 | Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorder | Diagnosis | ICD-10-CM |
| F13.19 | Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolytic-induced disorder | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F13.20 | Sedative, hypnotic or anxiolytic dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F13.21 | Sedative, hypnotic or anxiolytic dependence, in remission | Diagnosis | ICD-10-CM |
| F13.220 | Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F13.221 | Sedative, hypnotic or anxiolytic dependence with intoxication delirium | Diagnosis | ICD-10-CM |
| F13.229 | Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F13.230 | Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated | Diagnosis | ICD-10-CM |
| F13.231 | Sedative, hypnotic or anxiolytic dependence with withdrawal delirium | Diagnosis | ICD-10-CM |
| F13.232 | Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbance | Diagnosis | ICD-10-CM |
| F13.239 | Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified | Diagnosis | ICD-10-CM |
| F13.24 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced mood disorder | Diagnosis | ICD-10-CM |
| F13.250 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F13.251 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F13.259 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F13.26 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting amnesic disorder | Diagnosis | ICD-10-CM |
| F13.27 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting dementia | Diagnosis | ICD-10-CM |
| F13.280 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F13.281 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F13.282 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sleep disorder | Diagnosis | ICD-10-CM |
| F13.288 | Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorder | Diagnosis | ICD-10-CM |
| F13.29 | Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or anxiolytic-induced disorder | Diagnosis | ICD-10-CM |
| F13.90 | Sedative, hypnotic, or anxiolytic use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F13.920 | Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F13.921 | Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium | Diagnosis | ICD-10-CM |
| F13.929 | Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F13.930 | Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated | Diagnosis | ICD-10-CM |
| F13.931 | Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium | Diagnosis | ICD-10-CM |
| F13.932 | Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual disturbances | Diagnosis | ICD-10-CM |
| F13.939 | Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, unspecified | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F13.94 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced mood disorder | Diagnosis | ICD-10-CM |
| F13.950 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F13.951 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F13.959 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F13.96 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting amnestic disorder | Diagnosis | ICD-10-CM |
| F13.97 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia | Diagnosis | ICD-10-CM |
| F13.980 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F13.981 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F13.982 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sleep disorder | Diagnosis | ICD-10-CM |
| F13.988 | Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorder | Diagnosis | ICD-10-CM |
| F13.99 | Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic or anxiolytic-induced disorder | Diagnosis | ICD-10-CM |
| F14.10 | Cocaine abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F14.11 | Cocaine abuse, in remission | Diagnosis | ICD-10-CM |
| F14.120 | Cocaine abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F14.121 | Cocaine abuse with intoxication with delirium | Diagnosis | ICD-10-CM |
| F14.122 | Cocaine abuse with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F14.129 | Cocaine abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F14.14 | Cocaine abuse with cocaine-induced mood disorder | Diagnosis | ICD-10-CM |
| F14.150 | Cocaine abuse with cocaine-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F14.151 | Cocaine abuse with cocaine-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F14.159 | Cocaine abuse with cocaine-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F14.180 | Cocaine abuse with cocaine-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F14.181 | Cocaine abuse with cocaine-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F14.182 | Cocaine abuse with cocaine-induced sleep disorder | Diagnosis | ICD-10-CM |
| F14.188 | Cocaine abuse with other cocaine-induced disorder | Diagnosis | ICD-10-CM |
| F14.19 | Cocaine abuse with unspecified cocaine-induced disorder | Diagnosis | ICD-10-CM |
| F14.20 | Cocaine dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F14.21 | Cocaine dependence, in remission | Diagnosis | ICD-10-CM |
| F14.220 | Cocaine dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F14.221 | Cocaine dependence with intoxication delirium | Diagnosis | ICD-10-CM |
| F14.222 | Cocaine dependence with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F14.229 | Cocaine dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F14.23 | Cocaine dependence with withdrawal | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F14.24 | Cocaine dependence with cocaine-induced mood disorder | Diagnosis | ICD-10-CM |
| F14.250 | Cocaine dependence with cocaine-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F14.251 | Cocaine dependence with cocaine-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F14.259 | Cocaine dependence with cocaine-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F14.280 | Cocaine dependence with cocaine-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F14.281 | Cocaine dependence with cocaine-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F14.282 | Cocaine dependence with cocaine-induced sleep disorder | Diagnosis | ICD-10-CM |
| F14.288 | Cocaine dependence with other cocaine-induced disorder | Diagnosis | ICD-10-CM |
| F14.29 | Cocaine dependence with unspecified cocaine-induced disorder | Diagnosis | ICD-10-CM |
| F14.90 | Cocaine use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F14.920 | Cocaine use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F14.921 | Cocaine use, unspecified with intoxication delirium | Diagnosis | ICD-10-CM |
| F14.922 | Cocaine use, unspecified with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F14.929 | Cocaine use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F14.94 | Cocaine use, unspecified with cocaine-induced mood disorder | Diagnosis | ICD-10-CM |
| F14.950 | Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F14.951 | Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F14.959 | Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F14.980 | Cocaine use, unspecified with cocaine-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F14.981 | Cocaine use, unspecified with cocaine-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F14.982 | Cocaine use, unspecified with cocaine-induced sleep disorder | Diagnosis | ICD-10-CM |
| F14.988 | Cocaine use, unspecified with other cocaine-induced disorder | Diagnosis | ICD-10-CM |
| F14.99 | Cocaine use, unspecified with unspecified cocaine-induced disorder | Diagnosis | ICD-10-CM |
| F15.10 | Other stimulant abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F15.11 | Other stimulant abuse, in remission | Diagnosis | ICD-10-CM |
| F15.120 | Other stimulant abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F15.121 | Other stimulant abuse with intoxication delirium | Diagnosis | ICD-10-CM |
| F15.122 | Other stimulant abuse with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F15.129 | Other stimulant abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F15.14 | Other stimulant abuse with stimulant-induced mood disorder | Diagnosis | ICD-10-CM |
| F15.150 | Other stimulant abuse with stimulant-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F15.151 | Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F15.159 | Other stimulant abuse with stimulant-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F15.180 | Other stimulant abuse with stimulant-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F15.181 | Other stimulant abuse with stimulant-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F15.182 | Other stimulant abuse with stimulant-induced sleep disorder | Diagnosis | ICD-10-CM |
| F15.188 | Other stimulant abuse with other stimulant-induced disorder | Diagnosis | ICD-10-CM |
| F15.19 | Other stimulant abuse with unspecified stimulant-induced disorder | Diagnosis | ICD-10-CM |
| F15.20 | Other stimulant dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F15.21 | Other stimulant dependence, in remission | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F15.220 | Other stimulant dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F15.221 | Other stimulant dependence with intoxication delirium | Diagnosis | ICD-10-CM |
| F15.222 | Other stimulant dependence with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F15.229 | Other stimulant dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F15.23 | Other stimulant dependence with withdrawal | Diagnosis | ICD-10-CM |
| F15.24 | Other stimulant dependence with stimulant-induced mood disorder | Diagnosis | ICD-10-CM |
| F15.250 | Other stimulant dependence with stimulant-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F15.251 | Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F15.259 | Other stimulant dependence with stimulant-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F15.280 | Other stimulant dependence with stimulant-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F15.281 | Other stimulant dependence with stimulant-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F15.282 | Other stimulant dependence with stimulant-induced sleep disorder | Diagnosis | ICD-10-CM |
| F15.288 | Other stimulant dependence with other stimulant-induced disorder | Diagnosis | ICD-10-CM |
| F15.29 | Other stimulant dependence with unspecified stimulant-induced disorder | Diagnosis | ICD-10-CM |
| F15.90 | Other stimulant use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F15.920 | Other stimulant use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F15.921 | Other stimulant use, unspecified with intoxication delirium | Diagnosis | ICD-10-CM |
| F15.922 | Other stimulant use, unspecified with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F15.929 | Other stimulant use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F15.93 | Other stimulant use, unspecified with withdrawal | Diagnosis | ICD-10-CM |
| F15.94 | Other stimulant use, unspecified with stimulant-induced mood disorder | Diagnosis | ICD-10-CM |
| F15.950 | Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F15.951 | Other stimulant use, unspecified with stimulant-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F15.959 | Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F15.980 | Other stimulant use, unspecified with stimulant-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F15.981 | Other stimulant use, unspecified with stimulant-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F15.982 | Other stimulant use, unspecified with stimulant-induced sleep disorder | Diagnosis | ICD-10-CM |
| F15.988 | Other stimulant use, unspecified with other stimulant-induced disorder | Diagnosis | ICD-10-CM |
| F15.99 | Other stimulant use, unspecified with unspecified stimulant-induced disorder | Diagnosis | ICD-10-CM |
| F16.10 | Hallucinogen abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F16.11 | Hallucinogen abuse, in remission | Diagnosis | ICD-10-CM |
| F16.120 | Hallucinogen abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F16.121 | Hallucinogen abuse with intoxication with delirium | Diagnosis | ICD-10-CM |
| F16.122 | Hallucinogen abuse with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F16.129 | Hallucinogen abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F16.14 | Hallucinogen abuse with hallucinogen-induced mood disorder | Diagnosis | ICD-10-CM |
| F16.150 | Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F16.151 | Hallucinogen abuse with hallucinogen-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F16.159 | Hallucinogen abuse with hallucinogen-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F16.180 | Hallucinogen abuse with hallucinogen-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F16.183 | Hallucinogen abuse with hallucinogen persisting perception disorder (flashbacks) | Diagnosis | ICD-10-CM |
| F16.188 | Hallucinogen abuse with other hallucinogen-induced disorder | Diagnosis | ICD-10-CM |
| F16.19 | Hallucinogen abuse with unspecified hallucinogen-induced disorder | Diagnosis | ICD-10-CM |
| F16.20 | Hallucinogen dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F16.21 | Hallucinogen dependence, in remission | Diagnosis | ICD-10-CM |
| F16.220 | Hallucinogen dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F16.221 | Hallucinogen dependence with intoxication with delirium | Diagnosis | ICD-10-CM |
| F16.229 | Hallucinogen dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F16.24 | Hallucinogen dependence with hallucinogen-induced mood disorder | Diagnosis | ICD-10-CM |
| F16.250 | Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F16.251 | Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F16.259 | Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F16.280 | Hallucinogen dependence with hallucinogen-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F16.283 | Hallucinogen dependence with hallucinogen persisting perception disorder (flashbacks) | Diagnosis | ICD-10-CM |
| F16.288 | Hallucinogen dependence with other hallucinogen-induced disorder | Diagnosis | ICD-10-CM |
| F16.29 | Hallucinogen dependence with unspecified hallucinogen-induced disorder | Diagnosis | ICD-10-CM |
| F16.90 | Hallucinogen use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F16.920 | Hallucinogen use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F16.921 | Hallucinogen use, unspecified with intoxication with delirium | Diagnosis | ICD-10-CM |
| F16.929 | Hallucinogen use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F16.94 | Hallucinogen use, unspecified with hallucinogen-induced mood disorder | Diagnosis | ICD-10-CM |
| F16.950 | Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F16.951 | Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F16.959 | Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F16.980 | Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F16.983 | Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks) | Diagnosis | ICD-10-CM |
| F16.988 | Hallucinogen use, unspecified with other hallucinogen-induced disorder | Diagnosis | ICD-10-CM |
| F16.99 | Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder | Diagnosis | ICD-10-CM |
| F17.203 | Nicotine dependence unspecified, with withdrawal | Diagnosis | ICD-10-CM |
| F17.208 | Nicotine dependence, unspecified, with other nicotine-induced disorders | Diagnosis | ICD-10-CM |
| F17.209 | Nicotine dependence, unspecified, with unspecified nicotine-induced disorders | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| F17.213 | Nicotine dependence, cigarettes, with withdrawal | Diagnosis | ICD-10-CM |
| F17.218 | Nicotine dependence, cigarettes, with other nicotine-induced disorders | Diagnosis | ICD-10-CM |
| F17.219 | Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders | Diagnosis | ICD-10-CM |
| F17.223 | Nicotine dependence, chewing tobacco, with withdrawal | Diagnosis | ICD-10-CM |
| F17.228 | Nicotine dependence, chewing tobacco, with other nicotine-induced disorders | Diagnosis | ICD-10-CM |
| F17.229 | Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders | Diagnosis | ICD-10-CM |
| F17.293 | Nicotine dependence, other tobacco product, with withdrawal | Diagnosis | ICD-10-CM |
| F17.298 | Nicotine dependence, other tobacco product, with other nicotine-induced disorders | Diagnosis | ICD-10-CM |
| F17.299 | Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders | Diagnosis | ICD-10-CM |
| F18.10 | Inhalant abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F18.11 | Inhalant abuse, in remission | Diagnosis | ICD-10-CM |
| F18.120 | Inhalant abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F18.121 | Inhalant abuse with intoxication delirium | Diagnosis | ICD-10-CM |
| F18.129 | Inhalant abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F18.14 | Inhalant abuse with inhalant-induced mood disorder | Diagnosis | ICD-10-CM |
| F18.150 | Inhalant abuse with inhalant-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F18.151 | Inhalant abuse with inhalant-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F18.159 | Inhalant abuse with inhalant-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F18.17 | Inhalant abuse with inhalant-induced dementia | Diagnosis | ICD-10-CM |
| F18.180 | Inhalant abuse with inhalant-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F18.188 | Inhalant abuse with other inhalant-induced disorder | Diagnosis | ICD-10-CM |
| F18.19 | Inhalant abuse with unspecified inhalant-induced disorder | Diagnosis | ICD-10-CM |
| F18.20 | Inhalant dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F18.21 | Inhalant dependence, in remission | Diagnosis | ICD-10-CM |
| F18.220 | Inhalant dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F18.221 | Inhalant dependence with intoxication delirium | Diagnosis | ICD-10-CM |
| F18.229 | Inhalant dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F18.24 | Inhalant dependence with inhalant-induced mood disorder | Diagnosis | ICD-10-CM |
| F18.250 | Inhalant dependence with inhalant-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F18.251 | Inhalant dependence with inhalant-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F18.259 | Inhalant dependence with inhalant-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F18.27 | Inhalant dependence with inhalant-induced dementia | Diagnosis | ICD-10-CM |
| F18.280 | Inhalant dependence with inhalant-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F18.288 | Inhalant dependence with other inhalant-induced disorder | Diagnosis | ICD-10-CM |
| F18.29 | Inhalant dependence with unspecified inhalant-induced disorder | Diagnosis | ICD-10-CM |
| F18.90 | Inhalant use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F18.920 | Inhalant use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F18.921 | Inhalant use, unspecified with intoxication with delirium | Diagnosis | ICD-10-CM |
| F18.929 | Inhalant use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F18.94 | Inhalant use, unspecified with inhalant-induced mood disorder | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| F18.950 | Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F18.951 | Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F18.959 | Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F18.97 | Inhalant use, unspecified with inhalant-induced persisting dementia | Diagnosis | ICD-10-CM |
| F18.980 | Inhalant use, unspecified with inhalant-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F18.988 | Inhalant use, unspecified with other inhalant-induced disorder | Diagnosis | ICD-10-CM |
| F18.99 | Inhalant use, unspecified with unspecified inhalant-induced disorder | Diagnosis | ICD-10-CM |
| F19.10 | Other psychoactive substance abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F19.11 | Other psychoactive substance abuse, in remission | Diagnosis | ICD-10-CM |
| F19.120 | Other psychoactive substance abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F19.121 | Other psychoactive substance abuse with intoxication delirium | Diagnosis | ICD-10-CM |
| F19.122 | Other psychoactive substance abuse with intoxication with perceptual disturbances | Diagnosis | ICD-10-CM |
| F19.129 | Other psychoactive substance abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F19.14 | Other psychoactive substance abuse with psychoactive substance-induced mood disorder | Diagnosis | ICD-10-CM |
| F19.150 | Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F19.151 | Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F19.159 | Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F19.16 | Other psychoactive substance abuse with psychoactive substance-induced persisting amnestic disorder | Diagnosis | ICD-10-CM |
| F19.17 | Other psychoactive substance abuse with psychoactive substance-induced persisting dementia | Diagnosis | ICD-10-CM |
| F19.180 | Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F19.181 | Other psychoactive substance abuse with psychoactive substance-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F19.182 | Other psychoactive substance abuse with psychoactive substance-induced sleep disorder | Diagnosis | ICD-10-CM |
| F19.188 | Other psychoactive substance abuse with other psychoactive substance-induced disorder | Diagnosis | ICD-10-CM |
| F19.19 | Other psychoactive substance abuse with unspecified psychoactive substance-induced disorder | Diagnosis | ICD-10-CM |
| F19.20 | Other psychoactive substance dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F19.21 | Other psychoactive substance dependence, in remission | Diagnosis | ICD-10-CM |
| F19.220 | Other psychoactive substance dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F19.221 | Other psychoactive substance dependence with intoxication delirium | Diagnosis | ICD-10-CM |
| F19.222 | Other psychoactive substance dependence with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| F19.229 | Other psychoactive substance dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F19.230 | Other psychoactive substance dependence with withdrawal, uncomplicated | Diagnosis | ICD-10-CM |
| F19.231 | Other psychoactive substance dependence with withdrawal delirium | Diagnosis | ICD-10-CM |
| F19.232 | Other psychoactive substance dependence with withdrawal with perceptual disturbance | Diagnosis | ICD-10-CM |
| F19.239 | Other psychoactive substance dependence with withdrawal, unspecified | Diagnosis | ICD-10-CM |
| F19.24 | Other psychoactive substance dependence with psychoactive substance-induced mood disorder | Diagnosis | ICD-10-CM |
| F19.250 | Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F19.251 | Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F19.259 | Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F19.26 | Other psychoactive substance dependence with psychoactive substance-induced persisting amnestic disorder | Diagnosis | ICD-10-CM |
| F19.27 | Other psychoactive substance dependence with psychoactive substance-induced persisting dementia | Diagnosis | ICD-10-CM |
| F19.280 | Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F19.281 | Other psychoactive substance dependence with psychoactive substance-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F19.282 | Other psychoactive substance dependence with psychoactive substance-induced sleep disorder | Diagnosis | ICD-10-CM |
| F19.288 | Other psychoactive substance dependence with other psychoactive substance-induced disorder | Diagnosis | ICD-10-CM |
| F19.29 | Other psychoactive substance dependence with unspecified psychoactive substance-induced disorder | Diagnosis | ICD-10-CM |
| F19.90 | Other psychoactive substance use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F19.920 | Other psychoactive substance use, unspecified with intoxication, | Diagnosis | ICD-10-CM |
| F19.921 | Other psychoactive substance use, unspecified with intoxication with delirium | Diagnosis | ICD-10-CM |
| F19.922 | Other psychoactive substance use, unspecified with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F19.929 | Other psychoactive substance use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F19.930 | Other psychoactive substance use, unspecified with withdrawal, | Diagnosis | ICD-10-CM |
| F19.931 | Other psychoactive substance use, unspecified with withdrawal delirium | Diagnosis | ICD-10-CM |
| F19.932 | Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance | Diagnosis | ICD-10-CM |
| F19.939 | Other psychoactive substance use, unspecified with withdrawal, unspecified | Diagnosis | ICD-10-CM |
| F19.94 | Other psychoactive substance use, unspecified with psychoactive substance-induced mood disorder | Diagnosis | ICD-10-CM |
| F19.950 | Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| F19.951 | Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F19.959 | Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F19.96 | Other psychoactive substance use, unspecified with psychoactive substance-induced persisting amnestic disorder | Diagnosis | ICD-10-CM |
| F19.97 | Other psychoactive substance use, unspecified with psychoactive substance-induced persisting dementia | Diagnosis | ICD-10-CM |
| F19.980 | Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F19.981 | Other psychoactive substance use, unspecified with psychoactive substance-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F19.982 | Other psychoactive substance use, unspecified with psychoactive substance-induced sleep disorder | Diagnosis | ICD-10-CM |
| F19.988 | Other psychoactive substance use, unspecified with other psychoactive substance-induced disorder | Diagnosis | ICD-10-CM |
| F19.99 | Other psychoactive substance use, unspecified with unspecified psychoactive substance-induced disorder | Diagnosis | ICD-10-CM |
| F55.0 | Abuse of antacids | Diagnosis | ICD-10-CM |
| F55.1 | Abuse of herbal or folk remedies | Diagnosis | ICD-10-CM |
| F55.2 | Abuse of laxatives | Diagnosis | ICD-10-CM |
| F55.3 | Abuse of steroids or hormones | Diagnosis | ICD-10-CM |
| F55.4 | Abuse of vitamins | Diagnosis | ICD-10-CM |
| F55.8 | Abuse of other non-psychoactive substances | Diagnosis | ICD-10-CM |
| G62.1 | Alcoholic polyneuropathy | Diagnosis | ICD-10-CM |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | Procedure | HCPCS |
| H0007 | Alcohol and/or drug services; crisis intervention (outpatient) | Procedure | HCPCS |
| H0008 | Alcohol and/or drug services; subacute detoxification (hospital inpatient) | Procedure | HCPCS |
| H0010 | Alcohol and/or drug services; subacute detoxification (residential addiction program inpatient) | Procedure | HCPCS |
| H0011 | Alcohol and/or drug services; acute detoxification (residential addiction program inpatient) | Procedure | HCPCS |
| H0012 | Alcohol and/or drug services; subacute detoxification (residential addiction program outpatient) | Procedure | HCPCS |
| H0013 | Alcohol and/or drug services; acute detoxification (residential addiction program outpatient) | Procedure | HCPCS |
| H0014 | Alcohol and/or drug services; ambulatory detoxification | Procedure | HCPCS |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | Procedure | HCPCS |
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | Procedure | HCPCS |
| H0022 | Alcohol and/or drug intervention service (planned facilitation) | Procedure | HCPCS |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|------------|
| H2035 | Alcohol and/or other drug treatment program, per hour | Procedure | HCPCS |
| H2036 | Alcohol and/or other drug treatment program, per diem | Procedure | HCPCS |
| HZ2ZZZZ | Detoxification Services for Substance Abuse Treatment | Procedure | ICD-10-PCS |
| HZ30ZZZ | Individual Counseling for Substance Abuse Treatment, Cognitive | Procedure | ICD-10-PCS |
| HZ31ZZZ | Individual Counseling for Substance Abuse Treatment, Behavioral | Procedure | ICD-10-PCS |
| HZ32ZZZ | Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral | Procedure | ICD-10-PCS |
| HZ33ZZZ | Individual Counseling for Substance Abuse Treatment, 12-Step | Procedure | ICD-10-PCS |
| HZ34ZZZ | Individual Counseling for Substance Abuse Treatment, Interpersonal | Procedure | ICD-10-PCS |
| HZ35ZZZ | Individual Counseling for Substance Abuse Treatment, Vocational | Procedure | ICD-10-PCS |
| HZ36ZZZ | Individual Counseling for Substance Abuse Treatment, Psychoeducation | Procedure | ICD-10-PCS |
| HZ37ZZZ | Individual Counseling for Substance Abuse Treatment, Motivational Enhancement | Procedure | ICD-10-PCS |
| HZ38ZZZ | Individual Counseling for Substance Abuse Treatment, Confrontational | Procedure | ICD-10-PCS |
| HZ39ZZZ | Individual Counseling for Substance Abuse Treatment, Continuing Care | Procedure | ICD-10-PCS |
| HZ3BZZZ | Individual Counseling for Substance Abuse Treatment, Spiritual | Procedure | ICD-10-PCS |
| HZ40ZZZ | Group Counseling for Substance Abuse Treatment, Cognitive | Procedure | ICD-10-PCS |
| HZ41ZZZ | Group Counseling for Substance Abuse Treatment, Behavioral | Procedure | ICD-10-PCS |
| HZ42ZZZ | Group Counseling for Substance Abuse Treatment, Cognitive-Behavioral | Procedure | ICD-10-PCS |
| HZ43ZZZ | Group Counseling for Substance Abuse Treatment, 12-Step | Procedure | ICD-10-PCS |
| HZ44ZZZ | Group Counseling for Substance Abuse Treatment, Interpersonal | Procedure | ICD-10-PCS |
| HZ45ZZZ | Group Counseling for Substance Abuse Treatment, Vocational | Procedure | ICD-10-PCS |
| HZ46ZZZ | Group Counseling for Substance Abuse Treatment, Psychoeducation | Procedure | ICD-10-PCS |
| HZ47ZZZ | Group Counseling for Substance Abuse Treatment, Motivational Enhancement | Procedure | ICD-10-PCS |
| HZ48ZZZ | Group Counseling for Substance Abuse Treatment, Confrontational | Procedure | ICD-10-PCS |
| HZ49ZZZ | Group Counseling for Substance Abuse Treatment, Continuing Care | Procedure | ICD-10-PCS |
| HZ4BZZZ | Group Counseling for Substance Abuse Treatment, Spiritual | Procedure | ICD-10-PCS |
| HZ50ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Cognitive | Procedure | ICD-10-PCS |
| HZ51ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Behavioral | Procedure | ICD-10-PCS |
| HZ52ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Cognitive-Behavioral | Procedure | ICD-10-PCS |
| HZ53ZZZ | Individual Psychotherapy for Substance Abuse Treatment, 12-Step | Procedure | ICD-10-PCS |
| HZ54ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Interpersonal | Procedure | ICD-10-PCS |
| HZ55ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Interactive | Procedure | ICD-10-PCS |
| HZ56ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Psychoeducation | Procedure | ICD-10-PCS |
| HZ57ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Motivational Enhancement | Procedure | ICD-10-PCS |
| HZ58ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Confrontational | Procedure | ICD-10-PCS |
| HZ59ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Supportive | Procedure | ICD-10-PCS |
| HZ5BZZZ | Individual Psychotherapy for Substance Abuse Treatment, Psychoanalysis | Procedure | ICD-10-PCS |
| HZ5CZZZ | Individual Psychotherapy for Substance Abuse Treatment, Psychodynamic | Procedure | ICD-10-PCS |
| HZ5DZZZ | Individual Psychotherapy for Substance Abuse Treatment, Psychophysiological | Procedure | ICD-10-PCS |
| HZ63ZZZ | Family Counseling for Substance Abuse Treatment | Procedure | ICD-10-PCS |
| HZ83ZZZ | Medication Management for Substance Abuse Treatment, Antabuse | Procedure | ICD-10-PCS |
| HZ86ZZZ | Medication Management for Substance Abuse Treatment, Clonidine | Procedure | ICD-10-PCS |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|------------|
| HZ88ZZZ | Medication Management for Substance Abuse Treatment, Psychiatric Medication | Procedure | ICD-10-PCS |
| HZ89ZZZ | Medication Management for Substance Abuse Treatment, Other Replacement Medication | Procedure | ICD-10-PCS |
| HZ93ZZZ | Pharmacotherapy for Substance Abuse Treatment, Antabuse | Procedure | ICD-10-PCS |
| HZ96ZZZ | Pharmacotherapy for Substance Abuse Treatment, Clonidine | Procedure | ICD-10-PCS |
| HZ98ZZZ | Pharmacotherapy for Substance Abuse Treatment, Psychiatric Medication | Procedure | ICD-10-PCS |
| HZ99ZZZ | Pharmacotherapy for Substance Abuse Treatment, Other Replacement Medication | Procedure | ICD-10-PCS |
| I42.6 | Alcoholic cardiomyopathy | Diagnosis | ICD-10-CM |
| J0570 | Buprenorphine implant, 74.2 mg | Procedure | HCPCS |
| J0571 | Buprenorphine, oral, 1 mg | Procedure | HCPCS |
| J0572 | Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine | Procedure | HCPCS |
| J0573 | Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg buprenorphine | Procedure | HCPCS |
| J0574 | Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine | Procedure | HCPCS |
| J0575 | Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine | Procedure | HCPCS |
| J0592 | Injection, buprenorphine HCl, 0.1 mg | Procedure | HCPCS |
| J1230 | Injection, methadone HCl, up to 10 mg | Procedure | HCPCS |
| J2212 | Injection, methylnaltrexone, 0.1 mg | Procedure | HCPCS |
| J2315 | Injection, naltrexone, depot form, 1 mg | Procedure | HCPCS |
| K29.2 | Alcoholic gastritis | Diagnosis | ICD-10-CM |
| K29.20 | Alcoholic gastritis without bleeding | Diagnosis | ICD-10-CM |
| K29.21 | Alcoholic gastritis with bleeding | Diagnosis | ICD-10-CM |
| K70.0 | Alcoholic fatty liver | Diagnosis | ICD-10-CM |
| K70.10 | Alcoholic hepatitis without ascites | Diagnosis | ICD-10-CM |
| K70.11 | Alcoholic hepatitis with ascites | Diagnosis | ICD-10-CM |
| K70.2 | Alcoholic fibrosis and sclerosis of liver | Diagnosis | ICD-10-CM |
| K70.30 | Alcoholic cirrhosis of liver without ascites | Diagnosis | ICD-10-CM |
| K70.31 | Alcoholic cirrhosis of liver with ascites | Diagnosis | ICD-10-CM |
| K70.40 | Alcoholic hepatic failure without coma | Diagnosis | ICD-10-CM |
| K70.41 | Alcoholic hepatic failure with coma | Diagnosis | ICD-10-CM |
| K70.9 | Alcoholic liver disease, unspecified | Diagnosis | ICD-10-CM |
| O35.5XX0 | Maternal care for (suspected) damage to fetus by drugs, not applicable or unspecified | Diagnosis | ICD-10-CM |
| O35.5XX1 | Maternal care for (suspected) damage to fetus by drugs, fetus 1 | Diagnosis | ICD-10-CM |
| O35.5XX2 | Maternal care for (suspected) damage to fetus by drugs, fetus 2 | Diagnosis | ICD-10-CM |
| O35.5XX3 | Maternal care for (suspected) damage to fetus by drugs, fetus 3 | Diagnosis | ICD-10-CM |
| O35.5XX4 | Maternal care for (suspected) damage to fetus by drugs, fetus 4 | Diagnosis | ICD-10-CM |
| O35.5XX5 | Maternal care for (suspected) damage to fetus by drugs, fetus 5 | Diagnosis | ICD-10-CM |
| O35.5XX9 | Maternal care for (suspected) damage to fetus by drugs, other fetus | Diagnosis | ICD-10-CM |
| O99.310 | Alcohol use complicating pregnancy, unspecified trimester | Diagnosis | ICD-10-CM |
| O99.311 | Alcohol use complicating pregnancy, first trimester | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| O99.312 | Alcohol use complicating pregnancy, second trimester | Diagnosis | ICD-10-CM |
| O99.313 | Alcohol use complicating pregnancy, third trimester | Diagnosis | ICD-10-CM |
| O99.314 | Alcohol use complicating childbirth | Diagnosis | ICD-10-CM |
| O99.315 | Alcohol use complicating the puerperium | Diagnosis | ICD-10-CM |
| O99.320 | Drug use complicating pregnancy, unspecified trimester | Diagnosis | ICD-10-CM |
| O99.321 | Drug use complicating pregnancy, first trimester | Diagnosis | ICD-10-CM |
| O99.322 | Drug use complicating pregnancy, second trimester | Diagnosis | ICD-10-CM |
| O99.323 | Drug use complicating pregnancy, third trimester | Diagnosis | ICD-10-CM |
| O99.324 | Drug use complicating childbirth | Diagnosis | ICD-10-CM |
| O99.325 | Drug use complicating the puerperium | Diagnosis | ICD-10-CM |
| Q9991 | Injection, buprenorphine extended-release (Sublocade), less than or equal to 100 mg | Procedure | HCPCS |
| Q9992 | Injection, buprenorphine extended-release (Sublocade), greater than 100 mg | Procedure | HCPCS |
| S0109 | Methadone, oral, 5 mg | Procedure | HCPCS |
| T1006 | Alcohol and/or substance abuse services, family/couple counseling | Procedure | HCPCS |
| T1007 | Alcohol and/or substance abuse services, treatment plan development and/or modification | Procedure | HCPCS |
| T1008 | Day treatment for individual alcohol and/or substance abuse services | Procedure | HCPCS |
| T1010 | Meals for individuals receiving alcohol and/or substance abuse services (when meals not included in the program) | Procedure | HCPCS |
| T1012 | Alcohol and/or substance abuse services, skills development | Procedure | HCPCS |
| T40.0X1A | Poisoning by opium, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.0X1D | Poisoning by opium, accidental (unintentional), subsequent encounter | Diagnosis | ICD-10-CM |
| T40.0X1S | Poisoning by opium, accidental (unintentional), sequela | Diagnosis | ICD-10-CM |
| T40.0X3A | Poisoning by opium, assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.0X3D | Poisoning by opium, assault, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.0X3S | Poisoning by opium, assault, sequela | Diagnosis | ICD-10-CM |
| T40.0X4A | Poisoning by opium, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.0X4D | Poisoning by opium, undetermined, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.0X4S | Poisoning by opium, undetermined, sequela | Diagnosis | ICD-10-CM |
| T40.0X5A | Adverse effect of opium, initial encounter | Diagnosis | ICD-10-CM |
| T40.0X5D | Adverse effect of opium, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.0X5S | Adverse effect of opium, sequela | Diagnosis | ICD-10-CM |
| T40.0X6A | Underdosing of opium, initial encounter | Diagnosis | ICD-10-CM |
| T40.0X6D | Underdosing of opium, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.0X6S | Underdosing of opium, sequela | Diagnosis | ICD-10-CM |
| T40.1X1A | Poisoning by heroin, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.1X1D | Poisoning by heroin, accidental (unintentional), subsequent encounter | Diagnosis | ICD-10-CM |
| T40.1X1S | Poisoning by heroin, accidental (unintentional), sequela | Diagnosis | ICD-10-CM |
| T40.1X3A | Poisoning by heroin, assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.1X3D | Poisoning by heroin, assault, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.1X3S | Poisoning by heroin, assault, sequela | Diagnosis | ICD-10-CM |
| T40.1X4A | Poisoning by heroin, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.1X4D | Poisoning by heroin, undetermined, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T40.1X4S | Poisoning by heroin, undetermined, sequela | Diagnosis | ICD-10-CM |
| T40.1X5A | Adverse effect of heroin, initial encounter | Diagnosis | ICD-10-CM |
| T40.1X5D | Adverse effect of heroin, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.1X5S | Adverse effect of heroin, sequela | Diagnosis | ICD-10-CM |
| T40.5X1A | Poisoning by cocaine, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.5X1D | Poisoning by cocaine, accidental (unintentional), subsequent encounter | Diagnosis | ICD-10-CM |
| T40.5X1S | Poisoning by cocaine, accidental (unintentional), sequela | Diagnosis | ICD-10-CM |
| T40.5X3A | Poisoning by cocaine, assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.5X3D | Poisoning by cocaine, assault, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.5X3S | Poisoning by cocaine, assault, sequela | Diagnosis | ICD-10-CM |
| T40.5X4A | Poisoning by cocaine, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.5X4D | Poisoning by cocaine, undetermined, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.5X4S | Poisoning by cocaine, undetermined, sequela | Diagnosis | ICD-10-CM |
| T40.5X5A | Adverse effect of cocaine, initial encounter | Diagnosis | ICD-10-CM |
| T40.5X5D | Adverse effect of cocaine, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.5X5S | Adverse effect of cocaine, sequela | Diagnosis | ICD-10-CM |
| T40.5X6A | Underdosing of cocaine, initial encounter | Diagnosis | ICD-10-CM |
| T40.5X6D | Underdosing of cocaine, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.5X6S | Underdosing of cocaine, sequela | Diagnosis | ICD-10-CM |
| T40.7X1A | Poisoning by cannabis (derivatives), accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.7X1D | Poisoning by cannabis (derivatives), accidental (unintentional), subsequent encounter | Diagnosis | ICD-10-CM |
| T40.7X1S | Poisoning by cannabis (derivatives), accidental (unintentional), sequela | Diagnosis | ICD-10-CM |
| T40.7X3A | Poisoning by cannabis (derivatives), assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.7X3D | Poisoning by cannabis (derivatives), assault, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.7X3S | Poisoning by cannabis (derivatives), assault, sequela | Diagnosis | ICD-10-CM |
| T40.7X4A | Poisoning by cannabis (derivatives), undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.7X4D | Poisoning by cannabis (derivatives), undetermined, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.7X4S | Poisoning by cannabis (derivatives), undetermined, sequela | Diagnosis | ICD-10-CM |
| T40.7X5A | Adverse effect of cannabis (derivatives), initial encounter | Diagnosis | ICD-10-CM |
| T40.7X5D | Adverse effect of cannabis (derivatives), subsequent encounter | Diagnosis | ICD-10-CM |
| T40.7X5S | Adverse effect of cannabis (derivatives), sequela | Diagnosis | ICD-10-CM |
| T40.7X6A | Underdosing of cannabis (derivatives), initial encounter | Diagnosis | ICD-10-CM |
| T40.7X6D | Underdosing of cannabis (derivatives), subsequent encounter | Diagnosis | ICD-10-CM |
| T40.7X6S | Underdosing of cannabis (derivatives), sequela | Diagnosis | ICD-10-CM |
| T40.8X1A | Poisoning by lysergide [LSD], accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.8X1D | Poisoning by lysergide [LSD], accidental (unintentional), subsequent encounter | Diagnosis | ICD-10-CM |
| T40.8X1S | Poisoning by lysergide [LSD], accidental (unintentional), sequela | Diagnosis | ICD-10-CM |
| T40.8X3A | Poisoning by lysergide [LSD], assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.8X3D | Poisoning by lysergide [LSD], assault, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.8X3S | Poisoning by lysergide [LSD], assault, sequela | Diagnosis | ICD-10-CM |
| T40.8X4A | Poisoning by lysergide [LSD], undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.8X4D | Poisoning by lysergide [LSD], undetermined, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.8X4S | Poisoning by lysergide [LSD], undetermined, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T40.8X5A | Adverse effect of lysergide [LSD], initial encounter | Diagnosis | ICD-10-CM |
| T40.8X5D | Adverse effect of lysergide [LSD], subsequent encounter | Diagnosis | ICD-10-CM |
| T40.8X5S | Adverse effect of lysergide [LSD], sequela | Diagnosis | ICD-10-CM |
| T40.901A | Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.901D | Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), subsequent encounter | Diagnosis | ICD-10-CM |
| T40.901S | Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), sequela | Diagnosis | ICD-10-CM |
| T40.903A | Poisoning by unspecified psychodysleptics [hallucinogens], assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.903D | Poisoning by unspecified psychodysleptics [hallucinogens], assault, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.903S | Poisoning by unspecified psychodysleptics [hallucinogens], assault, sequela | Diagnosis | ICD-10-CM |
| T40.904A | Poisoning by unspecified psychodysleptics [hallucinogens], undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.904D | Poisoning by unspecified psychodysleptics [hallucinogens], undetermined, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.904S | Poisoning by unspecified psychodysleptics [hallucinogens], undetermined, sequela | Diagnosis | ICD-10-CM |
| T40.905A | Adverse effect of unspecified psychodysleptics [hallucinogens], initial encounter | Diagnosis | ICD-10-CM |
| T40.905D | Adverse effect of unspecified psychodysleptics [hallucinogens], subsequent encounter | Diagnosis | ICD-10-CM |
| T40.905S | Adverse effect of unspecified psychodysleptics [hallucinogens], sequela | Diagnosis | ICD-10-CM |
| T40.906A | Underdosing of unspecified psychodysleptics [hallucinogens], initial encounter | Diagnosis | ICD-10-CM |
| T40.906D | Underdosing of unspecified psychodysleptics [hallucinogens], subsequent encounter | Diagnosis | ICD-10-CM |
| T40.906S | Underdosing of unspecified psychodysleptics [hallucinogens], sequela | Diagnosis | ICD-10-CM |
| T40.991A | Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.991D | Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), subsequent encounter | Diagnosis | ICD-10-CM |
| T40.991S | Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), sequela | Diagnosis | ICD-10-CM |
| T40.993A | Poisoning by other psychodysleptics [hallucinogens], assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.993D | Poisoning by other psychodysleptics [hallucinogens], assault, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.993S | Poisoning by other psychodysleptics [hallucinogens], assault, sequela | Diagnosis | ICD-10-CM |
| T40.994A | Poisoning by other psychodysleptics [hallucinogens], undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.994D | Poisoning by other psychodysleptics [hallucinogens], undetermined, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.994S | Poisoning by other psychodysleptics [hallucinogens], undetermined, sequela | Diagnosis | ICD-10-CM |
| T40.995A | Adverse effect of other psychodysleptics [hallucinogens], initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------------------------------|--|---------------|-----------|
| T40.995D | Adverse effect of other psychodysleptics [hallucinogens], subsequent | Diagnosis | ICD-10-CM |
| T40.995S | Adverse effect of other psychodysleptics [hallucinogens], sequela | Diagnosis | ICD-10-CM |
| T40.996A | Underdosing of other psychodysleptics [hallucinogens], initial encounter | Diagnosis | ICD-10-CM |
| T40.996D | Underdosing of other psychodysleptics [hallucinogens], subsequent encounter | Diagnosis | ICD-10-CM |
| T40.996S | Underdosing of other psychodysleptics [hallucinogens], sequela | Diagnosis | ICD-10-CM |
| V65.42 | Counseling on substance use and abuse | Diagnosis | ICD-9-CM |
| Visits for Respiratory Disorders | | | |
| 003.22 | Salmonella pneumonia | Diagnosis | ICD-9-CM |
| 020.3 | Primary pneumonic plague | Diagnosis | ICD-9-CM |
| 020.4 | Secondary pneumonic plague | Diagnosis | ICD-9-CM |
| 020.5 | Pneumonic plague, unspecified | Diagnosis | ICD-9-CM |
| 021.2 | Pulmonary tularemia | Diagnosis | ICD-9-CM |
| 022.1 | Pulmonary anthrax | Diagnosis | ICD-9-CM |
| 031.0 | Pulmonary diseases due to other mycobacteria | Diagnosis | ICD-9-CM |
| 032.0 | Faucial diphtheria | Diagnosis | ICD-9-CM |
| 032.1 | Nasopharyngeal diphtheria | Diagnosis | ICD-9-CM |
| 032.2 | Anterior nasal diphtheria | Diagnosis | ICD-9-CM |
| 032.3 | Laryngeal diphtheria | Diagnosis | ICD-9-CM |
| 034.0 | Streptococcal sore throat | Diagnosis | ICD-9-CM |
| 039.1 | Pulmonary actinomycotic infection | Diagnosis | ICD-9-CM |
| 052.1 | Varicella (hemorrhagic) pneumonitis | Diagnosis | ICD-9-CM |
| 055.1 | Postmeasles pneumonia | Diagnosis | ICD-9-CM |
| 073.0 | Ornithosis with pneumonia | Diagnosis | ICD-9-CM |
| 083.0 | Q fever | Diagnosis | ICD-9-CM |
| 112.4 | Candidiasis of lung | Diagnosis | ICD-9-CM |
| 114.0 | Primary coccidioidomycosis (pulmonary) | Diagnosis | ICD-9-CM |
| 114.4 | Chronic pulmonary coccidioidomycosis | Diagnosis | ICD-9-CM |
| 114.5 | Unspecified pulmonary coccidioidomycosis | Diagnosis | ICD-9-CM |
| 115.05 | Histoplasma capsulatum pneumonia | Diagnosis | ICD-9-CM |
| 115.15 | Histoplasma duboisii pneumonia | Diagnosis | ICD-9-CM |
| 115.95 | Unspecified Histoplasmosis pneumonia | Diagnosis | ICD-9-CM |
| 122 | Echinococcosis | Diagnosis | ICD-9-CM |
| 122.1 | Echinococcus granulosus infection of lung | Diagnosis | ICD-9-CM |
| 130.4 | Pneumonitis due to toxoplasmosis | Diagnosis | ICD-9-CM |
| 136.3 | Pneumocystosis | Diagnosis | ICD-9-CM |
| 277.02 | Cystic fibrosis with pulmonary manifestations | Diagnosis | ICD-9-CM |
| 277.03 | Cystic fibrosis with gastrointestinal manifestations | Diagnosis | ICD-9-CM |
| 277.09 | Cystic fibrosis with other manifestations | Diagnosis | ICD-9-CM |
| 327.24 | Idiopathic sleep related nonobstructive alveolar hypoventilation | Diagnosis | ICD-9-CM |
| 327.26 | Sleep related hypoventilation/hypoxemia in conditions classifiable elsewhere | Diagnosis | ICD-9-CM |
| 327.29 | Other organic sleep apnea | Diagnosis | ICD-9-CM |
| 460 | Acute nasopharyngitis (common cold) | Diagnosis | ICD-9-CM |
| 461.0 | Acute maxillary sinusitis | Diagnosis | ICD-9-CM |
| 461.1 | Acute frontal sinusitis | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 461.2 | Acute ethmoidal sinusitis | Diagnosis | ICD-9-CM |
| 461.3 | Acute sphenoidal sinusitis | Diagnosis | ICD-9-CM |
| 461.8 | Other acute sinusitis | Diagnosis | ICD-9-CM |
| 461.9 | Acute sinusitis, unspecified | Diagnosis | ICD-9-CM |
| 462 | Acute pharyngitis | Diagnosis | ICD-9-CM |
| 463 | Acute tonsillitis | Diagnosis | ICD-9-CM |
| 464.0 | Acute laryngitis | Diagnosis | ICD-9-CM |
| 464.00 | Acute laryngitis, without mention of obstruction | Diagnosis | ICD-9-CM |
| 464.01 | Acute laryngitis, with obstruction | Diagnosis | ICD-9-CM |
| 464.10 | Acute tracheitis without mention of obstruction | Diagnosis | ICD-9-CM |
| 464.11 | Acute tracheitis with obstruction | Diagnosis | ICD-9-CM |
| 464.20 | Acute laryngotracheitis without mention of obstruction | Diagnosis | ICD-9-CM |
| 464.21 | Acute laryngotracheitis with obstruction | Diagnosis | ICD-9-CM |
| 464.30 | Acute epiglottitis without mention of obstruction | Diagnosis | ICD-9-CM |
| 464.31 | Acute epiglottitis with obstruction | Diagnosis | ICD-9-CM |
| 464.4 | Croup | Diagnosis | ICD-9-CM |
| 464.50 | Unspecified supraglottis, without mention of obstruction | Diagnosis | ICD-9-CM |
| 464.51 | Unspecified supraglottis, with obstruction | Diagnosis | ICD-9-CM |
| 465.0 | Acute laryngopharyngitis | Diagnosis | ICD-9-CM |
| 465.8 | Acute upper respiratory infections of other multiple sites | Diagnosis | ICD-9-CM |
| 465.9 | Acute upper respiratory infections of unspecified site | Diagnosis | ICD-9-CM |
| 466.0 | Acute bronchitis | Diagnosis | ICD-9-CM |
| 466.1 | Acute bronchiolitis | Diagnosis | ICD-9-CM |
| 466.11 | Acute bronchiolitis due to respiratory syncytial virus (RSV) | Diagnosis | ICD-9-CM |
| 466.19 | Acute bronchiolitis due to other infectious organisms | Diagnosis | ICD-9-CM |
| 470 | Deviated nasal septum | Diagnosis | ICD-9-CM |
| 471.0 | Polyp of nasal cavity | Diagnosis | ICD-9-CM |
| 471.1 | Polypoid sinus degeneration | Diagnosis | ICD-9-CM |
| 471.8 | Other polyp of sinus | Diagnosis | ICD-9-CM |
| 471.9 | Unspecified nasal polyp | Diagnosis | ICD-9-CM |
| 472.0 | Chronic rhinitis | Diagnosis | ICD-9-CM |
| 472.1 | Chronic pharyngitis | Diagnosis | ICD-9-CM |
| 472.2 | Chronic nasopharyngitis | Diagnosis | ICD-9-CM |
| 473.0 | Chronic maxillary sinusitis | Diagnosis | ICD-9-CM |
| 473.1 | Chronic frontal sinusitis | Diagnosis | ICD-9-CM |
| 473.2 | Chronic ethmoidal sinusitis | Diagnosis | ICD-9-CM |
| 473.3 | Chronic sphenoidal sinusitis | Diagnosis | ICD-9-CM |
| 473.8 | Other chronic sinusitis | Diagnosis | ICD-9-CM |
| 473.9 | Unspecified sinusitis (chronic) | Diagnosis | ICD-9-CM |
| 474.0 | Chronic tonsillitis and adenoiditis | Diagnosis | ICD-9-CM |
| 474.00 | Chronic tonsillitis | Diagnosis | ICD-9-CM |
| 474.01 | Chronic adenoiditis | Diagnosis | ICD-9-CM |
| 474.02 | Chronic tonsillitis and adenoiditis | Diagnosis | ICD-9-CM |
| 474.10 | Hypertrophy of tonsil with adenoids | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| 474.11 | Hypertrophy of tonsils alone | Diagnosis | ICD-9-CM |
| 474.12 | Hypertrophy of adenoids alone | Diagnosis | ICD-9-CM |
| 474.2 | Adenoid vegetations | Diagnosis | ICD-9-CM |
| 474.8 | Other chronic disease of tonsils and adenoids | Diagnosis | ICD-9-CM |
| 474.9 | Unspecified chronic disease of tonsils and adenoids | Diagnosis | ICD-9-CM |
| 475 | Peritonsillar abscess | Diagnosis | ICD-9-CM |
| 476.0 | Chronic laryngitis | Diagnosis | ICD-9-CM |
| 476.1 | Chronic laryngotracheitis | Diagnosis | ICD-9-CM |
| 477.0 | Allergic rhinitis due to pollen | Diagnosis | ICD-9-CM |
| 477.2 | Allergic rhinitis due to animal (cat) (dog) hair and dander | Diagnosis | ICD-9-CM |
| 477.8 | Allergic rhinitis due to other allergen | Diagnosis | ICD-9-CM |
| 477.9 | Allergic rhinitis, cause unspecified | Diagnosis | ICD-9-CM |
| 478.0 | Hypertrophy of nasal turbinates | Diagnosis | ICD-9-CM |
| 478.1 | Other diseases of nasal cavity and sinuses | Diagnosis | ICD-9-CM |
| 478.11 | Nasal mucositis (ulcerative) | Diagnosis | ICD-9-CM |
| 478.19 | Other diseases of nasal cavity and sinuses | Diagnosis | ICD-9-CM |
| 478.20 | Unspecified disease of pharynx | Diagnosis | ICD-9-CM |
| 478.21 | Cellulitis of pharynx or nasopharynx | Diagnosis | ICD-9-CM |
| 478.22 | Parapharyngeal abscess | Diagnosis | ICD-9-CM |
| 478.24 | Retropharyngeal abscess | Diagnosis | ICD-9-CM |
| 478.25 | Edema of pharynx or nasopharynx | Diagnosis | ICD-9-CM |
| 478.26 | Cyst of pharynx or nasopharynx | Diagnosis | ICD-9-CM |
| 478.29 | Other disease of pharynx or nasopharynx | Diagnosis | ICD-9-CM |
| 478.30 | Unspecified paralysis of vocal cords or larynx | Diagnosis | ICD-9-CM |
| 478.31 | Unilateral partial paralysis of vocal cords or larynx | Diagnosis | ICD-9-CM |
| 478.32 | Unilateral complete paralysis of vocal cords or larynx | Diagnosis | ICD-9-CM |
| 478.33 | Bilateral partial paralysis of vocal cords or larynx | Diagnosis | ICD-9-CM |
| 478.34 | Bilateral complete paralysis of vocal cords or larynx | Diagnosis | ICD-9-CM |
| 478.4 | Polyp of vocal cord or larynx | Diagnosis | ICD-9-CM |
| 478.5 | Other diseases of vocal cords | Diagnosis | ICD-9-CM |
| 478.6 | Edema of larynx | Diagnosis | ICD-9-CM |
| 478.70 | Unspecified disease of larynx | Diagnosis | ICD-9-CM |
| 478.71 | Cellulitis and perichondritis of larynx | Diagnosis | ICD-9-CM |
| 478.74 | Stenosis of larynx | Diagnosis | ICD-9-CM |
| 478.75 | Laryngeal spasm | Diagnosis | ICD-9-CM |
| 478.79 | Other diseases of larynx | Diagnosis | ICD-9-CM |
| 478.8 | Upper respiratory tract hypersensitivity reaction, site unspecified | Diagnosis | ICD-9-CM |
| 478.9 | Other and unspecified diseases of upper respiratory tract | Diagnosis | ICD-9-CM |
| 480.0 | Pneumonia due to adenovirus | Diagnosis | ICD-9-CM |
| 480.1 | Pneumonia due to respiratory syncytial virus | Diagnosis | ICD-9-CM |
| 480.2 | Pneumonia due to parainfluenza virus | Diagnosis | ICD-9-CM |
| 480.3 | Pneumonia due to SARS-associated coronavirus | Diagnosis | ICD-9-CM |
| 480.8 | Pneumonia due to other virus not elsewhere classified | Diagnosis | ICD-9-CM |
| 480.9 | Unspecified viral pneumonia | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| 481 | Pneumococcal pneumonia (streptococcus pneumoniae pneumonia) | Diagnosis | ICD-9-CM |
| 482.0 | Pneumonia due to Klebsiella pneumoniae | Diagnosis | ICD-9-CM |
| 482.1 | Pneumonia due to Pseudomonas | Diagnosis | ICD-9-CM |
| 482.2 | Pneumonia due to Hemophilus influenzae (H. influenzae) | Diagnosis | ICD-9-CM |
| 482.3 | Pneumonia due to Streptococcus | Diagnosis | ICD-9-CM |
| 482.30 | Pneumonia due to unspecified Streptococcus | Diagnosis | ICD-9-CM |
| 482.31 | Pneumonia due to Streptococcus, group A | Diagnosis | ICD-9-CM |
| 482.32 | Pneumonia due to Streptococcus, group B | Diagnosis | ICD-9-CM |
| 482.39 | Pneumonia due to other Streptococcus | Diagnosis | ICD-9-CM |
| 482.4 | Pneumonia due to Staphylococcus | Diagnosis | ICD-9-CM |
| 482.40 | Pneumonia due to Staphylococcus, unspecified | Diagnosis | ICD-9-CM |
| 482.41 | Methicillin susceptible pneumonia due to Staphylococcus aureus | Diagnosis | ICD-9-CM |
| 482.42 | Methicillin resistant pneumonia due to Staphylococcus aureus | Diagnosis | ICD-9-CM |
| 482.49 | Other Staphylococcus pneumonia | Diagnosis | ICD-9-CM |
| 482.8 | Pneumonia due to other specified bacteria | Diagnosis | ICD-9-CM |
| 482.81 | Pneumonia due to anaerobes | Diagnosis | ICD-9-CM |
| 482.82 | Pneumonia due to Escherichia coli (E. coli) | Diagnosis | ICD-9-CM |
| 482.83 | Pneumonia due to other gram-negative bacteria | Diagnosis | ICD-9-CM |
| 482.84 | Legionnaires' disease | Diagnosis | ICD-9-CM |
| 482.89 | Pneumonia due to other specified bacteria | Diagnosis | ICD-9-CM |
| 482.9 | Unspecified bacterial pneumonia | Diagnosis | ICD-9-CM |
| 483 | Pneumonia due to other specified organism | Diagnosis | ICD-9-CM |
| 483.0 | Pneumonia due to Mycoplasma pneumoniae | Diagnosis | ICD-9-CM |
| 483.1 | Pneumonia due to Chlamydia | Diagnosis | ICD-9-CM |
| 483.8 | Pneumonia due to other specified organism | Diagnosis | ICD-9-CM |
| 484.1 | Pneumonia in cytomegalic inclusion disease | Diagnosis | ICD-9-CM |
| 484.3 | Pneumonia in whooping cough | Diagnosis | ICD-9-CM |
| 484.5 | Pneumonia in anthrax | Diagnosis | ICD-9-CM |
| 484.6 | Pneumonia in aspergillosis | Diagnosis | ICD-9-CM |
| 484.7 | Pneumonia in other systemic mycoses | Diagnosis | ICD-9-CM |
| 484.8 | Pneumonia in other infectious diseases classified elsewhere | Diagnosis | ICD-9-CM |
| 485 | Bronchopneumonia, organism unspecified | Diagnosis | ICD-9-CM |
| 486 | Pneumonia, organism unspecified | Diagnosis | ICD-9-CM |
| 487.0 | Influenza with pneumonia | Diagnosis | ICD-9-CM |
| 487.1 | Influenza with other respiratory manifestations | Diagnosis | ICD-9-CM |
| 487.8 | Influenza with other manifestations | Diagnosis | ICD-9-CM |
| 488 | Influenza due to certain identified influenza viruses | Diagnosis | ICD-9-CM |
| 488.0 | Influenza due to identified avian influenza virus | Diagnosis | ICD-9-CM |
| 488.01 | Influenza due to identified avian influenza virus with pneumonia | Diagnosis | ICD-9-CM |
| 488.02 | Influenza due to identified avian influenza virus with other respiratory manifestations | Diagnosis | ICD-9-CM |
| 488.09 | Influenza due to identified avian influenza virus with other manifestations | Diagnosis | ICD-9-CM |
| 488.1 | Influenza due to identified 2009 H1N1 influenza virus | Diagnosis | ICD-9-CM |
| 488.11 | Influenza due to identified 2009 H1N1 influenza virus with pneumonia | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| 488.12 | Influenza due to identified 2009 H1N1 influenza virus with other respiratory manifestations | Diagnosis | ICD-9-CM |
| 488.19 | Influenza due to identified 2009 H1N1 influenza virus with other | Diagnosis | ICD-9-CM |
| 488.81 | Influenza due to identified novel influenza A virus with pneumonia | Diagnosis | ICD-9-CM |
| 488.82 | Influenza due to identified novel influenza A virus with other respiratory manifestations | Diagnosis | ICD-9-CM |
| 488.89 | Influenza due to identified novel influenza A virus with other manifestations | Diagnosis | ICD-9-CM |
| 490 | Bronchitis, not specified as acute or chronic | Diagnosis | ICD-9-CM |
| 491.0 | Simple chronic bronchitis | Diagnosis | ICD-9-CM |
| 491.1 | Mucopurulent chronic bronchitis | Diagnosis | ICD-9-CM |
| 491.8 | Other chronic bronchitis | Diagnosis | ICD-9-CM |
| 491.9 | Unspecified chronic bronchitis | Diagnosis | ICD-9-CM |
| 492.0 | Emphysematous bleb | Diagnosis | ICD-9-CM |
| 492.8 | Other emphysema | Diagnosis | ICD-9-CM |
| 494.0 | Bronchiectasis without acute exacerbation | Diagnosis | ICD-9-CM |
| 494.1 | Bronchiectasis with acute exacerbation | Diagnosis | ICD-9-CM |
| 495.0 | Farmers' lung | Diagnosis | ICD-9-CM |
| 495.1 | Bagassosis | Diagnosis | ICD-9-CM |
| 495.2 | Bird-fanciers' lung | Diagnosis | ICD-9-CM |
| 495.3 | Suberosis | Diagnosis | ICD-9-CM |
| 495.4 | Malt workers' lung | Diagnosis | ICD-9-CM |
| 495.5 | Mushroom workers' lung | Diagnosis | ICD-9-CM |
| 495.6 | Maple bark-strippers' lung | Diagnosis | ICD-9-CM |
| 495.7 | Ventilation pneumonitis | Diagnosis | ICD-9-CM |
| 495.8 | Other specified allergic alveolitis and pneumonitis | Diagnosis | ICD-9-CM |
| 495.9 | Unspecified allergic alveolitis and pneumonitis | Diagnosis | ICD-9-CM |
| 496 | Chronic airway obstruction, not elsewhere classified | Diagnosis | ICD-9-CM |
| 500 | Coal workers' pneumoconiosis | Diagnosis | ICD-9-CM |
| 501 | Asbestosis | Diagnosis | ICD-9-CM |
| 502 | Pneumoconiosis due to other silica or silicates | Diagnosis | ICD-9-CM |
| 503 | Pneumoconiosis due to other inorganic dust | Diagnosis | ICD-9-CM |
| 504 | Pneumonopathy due to inhalation of other dust | Diagnosis | ICD-9-CM |
| 505 | Unspecified pneumoconiosis | Diagnosis | ICD-9-CM |
| 506.0 | Bronchitis and pneumonitis due to fumes and vapors | Diagnosis | ICD-9-CM |
| 506.1 | Acute pulmonary edema due to fumes and vapors | Diagnosis | ICD-9-CM |
| 506.2 | Upper respiratory inflammation due to fumes and vapors | Diagnosis | ICD-9-CM |
| 506.3 | Other acute and subacute respiratory conditions due to fumes and vapors | Diagnosis | ICD-9-CM |
| 506.4 | Chronic respiratory conditions due to fumes and vapors | Diagnosis | ICD-9-CM |
| 506.9 | Unspecified respiratory conditions due to fumes and vapors | Diagnosis | ICD-9-CM |
| 507.0 | Pneumonitis due to inhalation of food or vomitus | Diagnosis | ICD-9-CM |
| 507.1 | Pneumonitis due to inhalation of oils and essences | Diagnosis | ICD-9-CM |
| 507.8 | Pneumonitis due to other solids and liquids | Diagnosis | ICD-9-CM |
| 508.0 | Acute pulmonary manifestations due to radiation | Diagnosis | ICD-9-CM |
| 508.1 | Chronic and other pulmonary manifestations due to radiation | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| 508.2 | Respiratory conditions due to smoke inhalation | Diagnosis | ICD-9-CM |
| 508.8 | Respiratory conditions due to other specified external agents | Diagnosis | ICD-9-CM |
| 508.9 | Respiratory conditions due to unspecified external agent | Diagnosis | ICD-9-CM |
| 510.0 | Empyema with fistula | Diagnosis | ICD-9-CM |
| 510.9 | Empyema without mention of fistula | Diagnosis | ICD-9-CM |
| 511.0 | Pleurisy without mention of effusion or current tuberculosis | Diagnosis | ICD-9-CM |
| 511.1 | Pleurisy with effusion, with mention of bacterial cause other than tuberculosis | Diagnosis | ICD-9-CM |
| 511.8 | Other specified forms of pleural effusion, except tuberculous | Diagnosis | ICD-9-CM |
| 511.89 | Other specified forms of effusion, except tuberculous | Diagnosis | ICD-9-CM |
| 511.9 | Unspecified pleural effusion | Diagnosis | ICD-9-CM |
| 512.0 | Spontaneous tension pneumothorax | Diagnosis | ICD-9-CM |
| 512.8 | Other pneumothorax and air leak | Diagnosis | ICD-9-CM |
| 512.81 | Primary spontaneous pneumothorax | Diagnosis | ICD-9-CM |
| 512.82 | Secondary spontaneous pneumothorax | Diagnosis | ICD-9-CM |
| 512.83 | Chronic pneumothorax | Diagnosis | ICD-9-CM |
| 512.84 | Other air leak | Diagnosis | ICD-9-CM |
| 512.89 | Other pneumothorax | Diagnosis | ICD-9-CM |
| 513.0 | Abscess of lung | Diagnosis | ICD-9-CM |
| 513.1 | Abscess of mediastinum | Diagnosis | ICD-9-CM |
| 514 | Pulmonary congestion and hypostasis | Diagnosis | ICD-9-CM |
| 515 | Postinflammatory pulmonary fibrosis | Diagnosis | ICD-9-CM |
| 516.0 | Pulmonary alveolar proteinosis | Diagnosis | ICD-9-CM |
| 516.1 | Idiopathic pulmonary hemosiderosis | Diagnosis | ICD-9-CM |
| 516.2 | Pulmonary alveolar microlithiasis | Diagnosis | ICD-9-CM |
| 516.3 | Idiopathic interstitial pneumonia | Diagnosis | ICD-9-CM |
| 516.30 | Idiopathic interstitial pneumonia, not otherwise specified | Diagnosis | ICD-9-CM |
| 516.31 | Idiopathic pulmonary fibrosis | Diagnosis | ICD-9-CM |
| 516.32 | Idiopathic non-specific interstitial pneumonitis | Diagnosis | ICD-9-CM |
| 516.33 | Acute interstitial pneumonitis | Diagnosis | ICD-9-CM |
| 516.34 | Respiratory bronchiolitis interstitial lung disease | Diagnosis | ICD-9-CM |
| 516.35 | Idiopathic lymphoid interstitial pneumonia | Diagnosis | ICD-9-CM |
| 516.36 | Cryptogenic organizing pneumonia | Diagnosis | ICD-9-CM |
| 516.37 | Desquamative interstitial pneumonia | Diagnosis | ICD-9-CM |
| 516.4 | Lymphangioleiomyomatosis | Diagnosis | ICD-9-CM |
| 516.5 | Adult pulmonary Langerhans cell histiocytosis | Diagnosis | ICD-9-CM |
| 516.61 | Neuroendocrine cell hyperplasia of infancy | Diagnosis | ICD-9-CM |
| 516.62 | Pulmonary interstitial glycogenosis | Diagnosis | ICD-9-CM |
| 516.63 | Surfactant mutations of the lung | Diagnosis | ICD-9-CM |
| 516.64 | Alveolar capillary dysplasia with vein misalignment | Diagnosis | ICD-9-CM |
| 516.69 | Other interstitial lung diseases of childhood | Diagnosis | ICD-9-CM |
| 516.8 | Other specified alveolar and parietoalveolar pneumonopathies | Diagnosis | ICD-9-CM |
| 516.9 | Unspecified alveolar and parietoalveolar pneumonopathy | Diagnosis | ICD-9-CM |
| 517.1 | Rheumatic pneumonia | Diagnosis | ICD-9-CM |
| 517.2 | Lung involvement in systemic sclerosis | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| 517.3 | Acute chest syndrome | Diagnosis | ICD-9-CM |
| 517.8 | Lung involvement in other diseases classified elsewhere | Diagnosis | ICD-9-CM |
| 518.0 | Pulmonary collapse | Diagnosis | ICD-9-CM |
| 518.1 | Interstitial emphysema | Diagnosis | ICD-9-CM |
| 518.2 | Compensatory emphysema | Diagnosis | ICD-9-CM |
| 518.3 | Pulmonary eosinophilia | Diagnosis | ICD-9-CM |
| 518.4 | Unspecified acute edema of lung | Diagnosis | ICD-9-CM |
| 518.5 | Pulmonary insufficiency following trauma and surgery | Diagnosis | ICD-9-CM |
| 518.51 | Acute respiratory failure following trauma and surgery | Diagnosis | ICD-9-CM |
| 518.52 | Other pulmonary insufficiency, not elsewhere classified, following trauma and surgery | Diagnosis | ICD-9-CM |
| 518.53 | Acute and chronic respiratory failure following trauma and surgery | Diagnosis | ICD-9-CM |
| 518.6 | Allergic bronchopulmonary aspergillosis | Diagnosis | ICD-9-CM |
| 518.81 | Acute respiratory failure | Diagnosis | ICD-9-CM |
| 518.82 | Other pulmonary insufficiency, not elsewhere classified | Diagnosis | ICD-9-CM |
| 518.83 | Chronic respiratory failure | Diagnosis | ICD-9-CM |
| 518.84 | Acute and chronic respiratory failure | Diagnosis | ICD-9-CM |
| 518.89 | Other diseases of lung, not elsewhere classified | Diagnosis | ICD-9-CM |
| 519.1 | Other diseases of trachea and bronchus, not elsewhere classified | Diagnosis | ICD-9-CM |
| 519.11 | Acute bronchospasm | Diagnosis | ICD-9-CM |
| 519.19 | Other diseases of trachea and bronchus | Diagnosis | ICD-9-CM |
| 519.2 | Mediastinitis | Diagnosis | ICD-9-CM |
| 519.3 | Other diseases of mediastinum, not elsewhere classified | Diagnosis | ICD-9-CM |
| 519.4 | Disorders of diaphragm | Diagnosis | ICD-9-CM |
| 519.8 | Other diseases of respiratory system, not elsewhere classified | Diagnosis | ICD-9-CM |
| 519.9 | Unspecified disease of respiratory system | Diagnosis | ICD-9-CM |
| 770.7 | Chronic respiratory disease arising in the perinatal period | Diagnosis | ICD-9-CM |
| 782.5 | Cyanosis | Diagnosis | ICD-9-CM |
| 784.1 | Throat pain | Diagnosis | ICD-9-CM |
| 784.40 | Voice and resonance disorder, unspecified | Diagnosis | ICD-9-CM |
| 784.41 | Aphonia | Diagnosis | ICD-9-CM |
| 784.42 | Dysphonia | Diagnosis | ICD-9-CM |
| 784.43 | Hypernasality | Diagnosis | ICD-9-CM |
| 784.44 | Hyponasality | Diagnosis | ICD-9-CM |
| 784.49 | Other voice and resonance disorders | Diagnosis | ICD-9-CM |
| 784.7 | Epistaxis | Diagnosis | ICD-9-CM |
| 784.8 | Hemorrhage from throat | Diagnosis | ICD-9-CM |
| 784.9 | Other symptoms involving head and neck | Diagnosis | ICD-9-CM |
| 784.91 | Postnasal drip | Diagnosis | ICD-9-CM |
| 784.99 | Other symptoms involving head and neck | Diagnosis | ICD-9-CM |
| 786.00 | Unspecified respiratory abnormality | Diagnosis | ICD-9-CM |
| 786.01 | Hyperventilation | Diagnosis | ICD-9-CM |
| 786.02 | Orthopnea | Diagnosis | ICD-9-CM |
| 786.03 | Apnea | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| 786.04 | Cheyne-Stokes respiration | Diagnosis | ICD-9-CM |
| 786.05 | Shortness of breath | Diagnosis | ICD-9-CM |
| 786.06 | Tachypnea | Diagnosis | ICD-9-CM |
| 786.07 | Wheezing | Diagnosis | ICD-9-CM |
| 786.09 | Other dyspnea and respiratory abnormalities | Diagnosis | ICD-9-CM |
| 786.1 | Stridor | Diagnosis | ICD-9-CM |
| 786.2 | Cough | Diagnosis | ICD-9-CM |
| 786.3 | Hemoptysis | Diagnosis | ICD-9-CM |
| 786.30 | Hemoptysis, unspecified | Diagnosis | ICD-9-CM |
| 786.31 | Acute idiopathic pulmonary hemorrhage in infants [AIPHI] | Diagnosis | ICD-9-CM |
| 786.39 | Other hemoptysis | Diagnosis | ICD-9-CM |
| 786.4 | Abnormal sputum | Diagnosis | ICD-9-CM |
| 786.52 | Painful respiration | Diagnosis | ICD-9-CM |
| 786.6 | Swelling, mass, or lump in chest | Diagnosis | ICD-9-CM |
| 786.7 | Abnormal chest sounds | Diagnosis | ICD-9-CM |
| 786.8 | Hiccough | Diagnosis | ICD-9-CM |
| 786.9 | Other symptoms involving respiratory system and chest | Diagnosis | ICD-9-CM |
| 793.1 | Nonspecific (abnormal) findings on radiological and other examination of body structure, lung field | Diagnosis | ICD-9-CM |
| 793.11 | Solitary pulmonary nodule | Diagnosis | ICD-9-CM |
| 793.19 | Other nonspecific abnormal finding of lung field | Diagnosis | ICD-9-CM |
| 794.2 | Nonspecific abnormal results of pulmonary system function study | Diagnosis | ICD-9-CM |
| 799.1 | Respiratory arrest | Diagnosis | ICD-9-CM |
| A02.22 | Salmonella pneumonia | Diagnosis | ICD-10-CM |
| A20.2 | Pneumonic plague | Diagnosis | ICD-10-CM |
| A21.2 | Pulmonary tularemia | Diagnosis | ICD-10-CM |
| A22.1 | Pulmonary anthrax | Diagnosis | ICD-10-CM |
| A31.0 | Pulmonary mycobacterial infection | Diagnosis | ICD-10-CM |
| A36.0 | Pharyngeal diphtheria | Diagnosis | ICD-10-CM |
| A36.1 | Nasopharyngeal diphtheria | Diagnosis | ICD-10-CM |
| A36.2 | Laryngeal diphtheria | Diagnosis | ICD-10-CM |
| A36.89 | Other diphtheritic complications | Diagnosis | ICD-10-CM |
| A37.01 | Whooping cough due to Bordetella pertussis with pneumonia | Diagnosis | ICD-10-CM |
| A37.11 | Whooping cough due to Bordetella parapertussis with pneumonia | Diagnosis | ICD-10-CM |
| A37.81 | Whooping cough due to other Bordetella species with pneumonia | Diagnosis | ICD-10-CM |
| A37.91 | Whooping cough, unspecified species with pneumonia | Diagnosis | ICD-10-CM |
| A42.0 | Pulmonary actinomycosis | Diagnosis | ICD-10-CM |
| A43.0 | Pulmonary nocardiosis | Diagnosis | ICD-10-CM |
| A48.1 | Legionnaires' disease | Diagnosis | ICD-10-CM |
| A59.00 | Urogenital trichomoniasis, unspecified | Diagnosis | ICD-10-CM |
| A59.01 | Trichomonal vulvovaginitis | Diagnosis | ICD-10-CM |
| A59.02 | Trichomonal prostatitis | Diagnosis | ICD-10-CM |
| A59.03 | Trichomonal cystitis and urethritis | Diagnosis | ICD-10-CM |
| A59.09 | Other urogenital trichomoniasis | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| A59.8 | Trichomoniasis of other sites | Diagnosis | ICD-10-CM |
| A59.9 | Trichomoniasis, unspecified | Diagnosis | ICD-10-CM |
| A70 | Chlamydia psittaci infections | Diagnosis | ICD-10-CM |
| A78 | Q fever | Diagnosis | ICD-10-CM |
| B01.2 | Varicella pneumonia | Diagnosis | ICD-10-CM |
| B05.2 | Measles complicated by pneumonia | Diagnosis | ICD-10-CM |
| B25.0 | Cytomegaloviral pneumonitis | Diagnosis | ICD-10-CM |
| B37.1 | Pulmonary candidiasis | Diagnosis | ICD-10-CM |
| B38.0 | Acute pulmonary coccidioidomycosis | Diagnosis | ICD-10-CM |
| B38.1 | Chronic pulmonary coccidioidomycosis | Diagnosis | ICD-10-CM |
| B38.2 | Pulmonary coccidioidomycosis, unspecified | Diagnosis | ICD-10-CM |
| B39.0 | Acute pulmonary histoplasmosis capsulati | Diagnosis | ICD-10-CM |
| B39.1 | Chronic pulmonary histoplasmosis capsulati | Diagnosis | ICD-10-CM |
| B39.2 | Pulmonary histoplasmosis capsulati, unspecified | Diagnosis | ICD-10-CM |
| B39.5 | Histoplasmosis duboisii | Diagnosis | ICD-10-CM |
| B39.9 | Histoplasmosis, unspecified | Diagnosis | ICD-10-CM |
| B44.0 | Invasive pulmonary aspergillosis | Diagnosis | ICD-10-CM |
| B44.81 | Allergic bronchopulmonary aspergillosis | Diagnosis | ICD-10-CM |
| B58.00 | Toxoplasma oculopathy, unspecified | Diagnosis | ICD-10-CM |
| B58.01 | Toxoplasma chorioretinitis | Diagnosis | ICD-10-CM |
| B58.09 | Other toxoplasma oculopathy | Diagnosis | ICD-10-CM |
| B58.1 | Toxoplasma hepatitis | Diagnosis | ICD-10-CM |
| B58.2 | Toxoplasma meningoencephalitis | Diagnosis | ICD-10-CM |
| B58.3 | Pulmonary toxoplasmosis | Diagnosis | ICD-10-CM |
| B58.81 | Toxoplasma myocarditis | Diagnosis | ICD-10-CM |
| B58.82 | Toxoplasma myositis | Diagnosis | ICD-10-CM |
| B58.83 | Toxoplasma tubulo-interstitial nephropathy | Diagnosis | ICD-10-CM |
| B58.89 | Toxoplasmosis with other organ involvement | Diagnosis | ICD-10-CM |
| B58.9 | Toxoplasmosis, unspecified | Diagnosis | ICD-10-CM |
| B59 | Pneumocystosis | Diagnosis | ICD-10-CM |
| B67.0 | Echinococcus granulosus infection of liver | Diagnosis | ICD-10-CM |
| B67.1 | Echinococcus granulosus infection of lung | Diagnosis | ICD-10-CM |
| B67.2 | Echinococcus granulosus infection of bone | Diagnosis | ICD-10-CM |
| B67.31 | Echinococcus granulosus infection, thyroid gland | Diagnosis | ICD-10-CM |
| B67.32 | Echinococcus granulosus infection, multiple sites | Diagnosis | ICD-10-CM |
| B67.39 | Echinococcus granulosus infection, other sites | Diagnosis | ICD-10-CM |
| B67.4 | Echinococcus granulosus infection, unspecified | Diagnosis | ICD-10-CM |
| B67.5 | Echinococcus multilocularis infection of liver | Diagnosis | ICD-10-CM |
| B67.61 | Echinococcus multilocularis infection, multiple sites | Diagnosis | ICD-10-CM |
| B67.69 | Echinococcus multilocularis infection, other sites | Diagnosis | ICD-10-CM |
| B67.7 | Echinococcus multilocularis infection, unspecified | Diagnosis | ICD-10-CM |
| B67.8 | Echinococcosis, unspecified, of liver | Diagnosis | ICD-10-CM |
| B67.90 | Echinococcosis, unspecified | Diagnosis | ICD-10-CM |
| B67.99 | Other echinococcosis | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| B68.0 | Taenia solium taeniasis | Diagnosis | ICD-10-CM |
| B68.1 | Taenia saginata taeniasis | Diagnosis | ICD-10-CM |
| B68.9 | Taeniasis, unspecified | Diagnosis | ICD-10-CM |
| B69.0 | Cysticercosis of central nervous system | Diagnosis | ICD-10-CM |
| B69.1 | Cysticercosis of eye | Diagnosis | ICD-10-CM |
| B69.81 | Myositis in cysticercosis | Diagnosis | ICD-10-CM |
| B69.89 | Cysticercosis of other sites | Diagnosis | ICD-10-CM |
| B69.9 | Cysticercosis, unspecified | Diagnosis | ICD-10-CM |
| B70.0 | Diphyllobothriasis | Diagnosis | ICD-10-CM |
| B70.1 | Sparganosis | Diagnosis | ICD-10-CM |
| B71.0 | Hymenolepiasis | Diagnosis | ICD-10-CM |
| B71.1 | Dipylidiasis | Diagnosis | ICD-10-CM |
| B71.8 | Other specified cestode infections | Diagnosis | ICD-10-CM |
| B71.9 | Cestode infection, unspecified | Diagnosis | ICD-10-CM |
| B72 | Dracunculiasis | Diagnosis | ICD-10-CM |
| B73.00 | Onchocerciasis with eye involvement, unspecified | Diagnosis | ICD-10-CM |
| B73.01 | Onchocerciasis with endophthalmitis | Diagnosis | ICD-10-CM |
| B73.02 | Onchocerciasis with glaucoma | Diagnosis | ICD-10-CM |
| B73.09 | Onchocerciasis with other eye involvement | Diagnosis | ICD-10-CM |
| B73.1 | Onchocerciasis without eye disease | Diagnosis | ICD-10-CM |
| B74.0 | Filariasis due to Wuchereria bancrofti | Diagnosis | ICD-10-CM |
| B74.1 | Filariasis due to Brugia malayi | Diagnosis | ICD-10-CM |
| B74.2 | Filariasis due to Brugia timori | Diagnosis | ICD-10-CM |
| B74.3 | Loiasis | Diagnosis | ICD-10-CM |
| B74.4 | Mansonelliasis | Diagnosis | ICD-10-CM |
| B74.8 | Other filariases | Diagnosis | ICD-10-CM |
| B74.9 | Filariasis, unspecified | Diagnosis | ICD-10-CM |
| B75 | Trichinellosis | Diagnosis | ICD-10-CM |
| B76.0 | Ancylostomiasis | Diagnosis | ICD-10-CM |
| B76.1 | Necatoriasis | Diagnosis | ICD-10-CM |
| B76.8 | Other hookworm diseases | Diagnosis | ICD-10-CM |
| B76.9 | Hookworm disease, unspecified | Diagnosis | ICD-10-CM |
| B77.0 | Ascariasis with intestinal complications | Diagnosis | ICD-10-CM |
| B77.81 | Ascariasis pneumonia | Diagnosis | ICD-10-CM |
| B77.89 | Ascariasis with other complications | Diagnosis | ICD-10-CM |
| B77.9 | Ascariasis, unspecified | Diagnosis | ICD-10-CM |
| B78.0 | Intestinal strongyloidiasis | Diagnosis | ICD-10-CM |
| B78.7 | Disseminated strongyloidiasis | Diagnosis | ICD-10-CM |
| B78.9 | Strongyloidiasis, unspecified | Diagnosis | ICD-10-CM |
| B79 | Trichuriasis | Diagnosis | ICD-10-CM |
| B80 | Enterobiasis | Diagnosis | ICD-10-CM |
| B81.0 | Anisakiasis | Diagnosis | ICD-10-CM |
| B81.1 | Intestinal capillariasis | Diagnosis | ICD-10-CM |
| B81.2 | Trichostrongyliasis | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| B81.3 | Intestinal angiostrongyliasis | Diagnosis | ICD-10-CM |
| B81.4 | Mixed intestinal helminthiases | Diagnosis | ICD-10-CM |
| B81.8 | Other specified intestinal helminthiases | Diagnosis | ICD-10-CM |
| B82.0 | Intestinal helminthiasis, unspecified | Diagnosis | ICD-10-CM |
| B82.9 | Intestinal parasitism, unspecified | Diagnosis | ICD-10-CM |
| B83.0 | Visceral larva migrans | Diagnosis | ICD-10-CM |
| B83.1 | Gnathostomiasis | Diagnosis | ICD-10-CM |
| B83.2 | Angiostrongyliasis due to <i>Parastrongylus cantonensis</i> | Diagnosis | ICD-10-CM |
| B83.3 | Syngamiasis | Diagnosis | ICD-10-CM |
| B83.4 | Internal hirudiniasis | Diagnosis | ICD-10-CM |
| B83.8 | Other specified helminthiases | Diagnosis | ICD-10-CM |
| B83.9 | Helminthiasis, unspecified | Diagnosis | ICD-10-CM |
| B85.0 | Pediculosis due to <i>Pediculus humanus capitis</i> | Diagnosis | ICD-10-CM |
| B85.1 | Pediculosis due to <i>Pediculus humanus corporis</i> | Diagnosis | ICD-10-CM |
| B85.2 | Pediculosis, unspecified | Diagnosis | ICD-10-CM |
| B85.3 | Phthiriasis | Diagnosis | ICD-10-CM |
| B85.4 | Mixed pediculosis and phthiriasis | Diagnosis | ICD-10-CM |
| B86 | Scabies | Diagnosis | ICD-10-CM |
| B87.0 | Cutaneous myiasis | Diagnosis | ICD-10-CM |
| B87.1 | Wound myiasis | Diagnosis | ICD-10-CM |
| B87.2 | Ocular myiasis | Diagnosis | ICD-10-CM |
| B87.3 | Nasopharyngeal myiasis | Diagnosis | ICD-10-CM |
| B87.4 | Aural myiasis | Diagnosis | ICD-10-CM |
| B87.81 | Genitourinary myiasis | Diagnosis | ICD-10-CM |
| B87.82 | Intestinal myiasis | Diagnosis | ICD-10-CM |
| B87.89 | Myiasis of other sites | Diagnosis | ICD-10-CM |
| B87.9 | Myiasis, unspecified | Diagnosis | ICD-10-CM |
| B88.0 | Other acariasis | Diagnosis | ICD-10-CM |
| B88.1 | Tungiasis [sandflea infestation] | Diagnosis | ICD-10-CM |
| B88.2 | Other arthropod infestations | Diagnosis | ICD-10-CM |
| B88.3 | External hirudiniasis | Diagnosis | ICD-10-CM |
| B88.8 | Other specified infestations | Diagnosis | ICD-10-CM |
| B88.9 | Infestation, unspecified | Diagnosis | ICD-10-CM |
| D57.01 | Hb-SS disease with acute chest syndrome | Diagnosis | ICD-10-CM |
| D57.211 | Sickle-cell/Hb-C disease with acute chest syndrome | Diagnosis | ICD-10-CM |
| D57.411 | Sickle-cell thalassemia, unspecified, with acute chest syndrome | Diagnosis | ICD-10-CM |
| D57.811 | Other sickle-cell disorders with acute chest syndrome | Diagnosis | ICD-10-CM |
| E84.0 | Cystic fibrosis with pulmonary manifestations | Diagnosis | ICD-10-CM |
| E84.1 | Cystic fibrosis with intestinal manifestations | Diagnosis | ICD-10-CM |
| E84.19 | Cystic fibrosis with other intestinal manifestations | Diagnosis | ICD-10-CM |
| E84.8 | Cystic fibrosis with other manifestations | Diagnosis | ICD-10-CM |
| G47.34 | Idiopathic sleep related nonobstructive alveolar hypoventilation | Diagnosis | ICD-10-CM |
| G47.36 | Sleep related hypoventilation in conditions classified elsewhere | Diagnosis | ICD-10-CM |
| G47.39 | Other sleep apnea | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| J00 | Acute nasopharyngitis [common cold] | Diagnosis | ICD-10-CM |
| J01.00 | Acute maxillary sinusitis, unspecified | Diagnosis | ICD-10-CM |
| J01.01 | Acute recurrent maxillary sinusitis | Diagnosis | ICD-10-CM |
| J01.10 | Acute frontal sinusitis, unspecified | Diagnosis | ICD-10-CM |
| J01.11 | Acute recurrent frontal sinusitis | Diagnosis | ICD-10-CM |
| J01.20 | Acute ethmoidal sinusitis, unspecified | Diagnosis | ICD-10-CM |
| J01.21 | Acute recurrent ethmoidal sinusitis | Diagnosis | ICD-10-CM |
| J01.30 | Acute sphenoidal sinusitis, unspecified | Diagnosis | ICD-10-CM |
| J01.31 | Acute recurrent sphenoidal sinusitis | Diagnosis | ICD-10-CM |
| J01.40 | Acute pansinusitis, unspecified | Diagnosis | ICD-10-CM |
| J01.41 | Acute recurrent pansinusitis | Diagnosis | ICD-10-CM |
| J01.80 | Other acute sinusitis | Diagnosis | ICD-10-CM |
| J01.81 | Other acute recurrent sinusitis | Diagnosis | ICD-10-CM |
| J01.90 | Acute sinusitis, unspecified | Diagnosis | ICD-10-CM |
| J01.91 | Acute recurrent sinusitis, unspecified | Diagnosis | ICD-10-CM |
| J02.0 | Streptococcal pharyngitis | Diagnosis | ICD-10-CM |
| J02.8 | Acute pharyngitis due to other specified organisms | Diagnosis | ICD-10-CM |
| J02.9 | Acute pharyngitis, unspecified | Diagnosis | ICD-10-CM |
| J03.00 | Acute streptococcal tonsillitis, unspecified | Diagnosis | ICD-10-CM |
| J03.01 | Acute recurrent streptococcal tonsillitis | Diagnosis | ICD-10-CM |
| J03.80 | Acute tonsillitis due to other specified organisms | Diagnosis | ICD-10-CM |
| J03.81 | Acute recurrent tonsillitis due to other specified organisms | Diagnosis | ICD-10-CM |
| J03.90 | Acute tonsillitis, unspecified | Diagnosis | ICD-10-CM |
| J03.91 | Acute recurrent tonsillitis, unspecified | Diagnosis | ICD-10-CM |
| J04.0 | Acute laryngitis | Diagnosis | ICD-10-CM |
| J04.10 | Acute tracheitis without obstruction | Diagnosis | ICD-10-CM |
| J04.11 | Acute tracheitis with obstruction | Diagnosis | ICD-10-CM |
| J04.2 | Acute laryngotracheitis | Diagnosis | ICD-10-CM |
| J04.30 | Supraglottitis, unspecified, without obstruction | Diagnosis | ICD-10-CM |
| J04.31 | Supraglottitis, unspecified, with obstruction | Diagnosis | ICD-10-CM |
| J05.0 | Acute obstructive laryngitis [croup] | Diagnosis | ICD-10-CM |
| J05.10 | Acute epiglottitis without obstruction | Diagnosis | ICD-10-CM |
| J05.11 | Acute epiglottitis with obstruction | Diagnosis | ICD-10-CM |
| J06.0 | Acute laryngopharyngitis | Diagnosis | ICD-10-CM |
| J06.9 | Acute upper respiratory infection, unspecified | Diagnosis | ICD-10-CM |
| J09.X1 | Influenza due to identified novel influenza A virus with pneumonia | Diagnosis | ICD-10-CM |
| J09.X2 | Influenza due to identified novel influenza A virus with other respiratory manifestations | Diagnosis | ICD-10-CM |
| J09.X3 | Influenza due to identified novel influenza A virus with gastrointestinal manifestations | Diagnosis | ICD-10-CM |
| J09.X9 | Influenza due to identified novel influenza A virus with other manifestations | Diagnosis | ICD-10-CM |
| J10.00 | Influenza due to other identified influenza virus with unspecified type of pneumonia | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| J10.01 | Influenza due to other identified influenza virus with the same other identified influenza virus pneumonia | Diagnosis | ICD-10-CM |
| J10.08 | Influenza due to other identified influenza virus with other specified | Diagnosis | ICD-10-CM |
| J10.1 | Influenza due to other identified influenza virus with other respiratory manifestations | Diagnosis | ICD-10-CM |
| J10.2 | Influenza due to other identified influenza virus with gastrointestinal manifestations | Diagnosis | ICD-10-CM |
| J10.81 | Influenza due to other identified influenza virus with encephalopathy | Diagnosis | ICD-10-CM |
| J10.82 | Influenza due to other identified influenza virus with myocarditis | Diagnosis | ICD-10-CM |
| J10.83 | Influenza due to other identified influenza virus with otitis media | Diagnosis | ICD-10-CM |
| J10.89 | Influenza due to other identified influenza virus with other manifestations | Diagnosis | ICD-10-CM |
| J11.00 | Influenza due to unidentified influenza virus with unspecified type of pneumonia | Diagnosis | ICD-10-CM |
| J11.08 | Influenza due to unidentified influenza virus with specified pneumonia | Diagnosis | ICD-10-CM |
| J11.1 | Influenza due to unidentified influenza virus with other respiratory manifestations | Diagnosis | ICD-10-CM |
| J11.2 | Influenza due to unidentified influenza virus with gastrointestinal manifestations | Diagnosis | ICD-10-CM |
| J11.81 | Influenza due to unidentified influenza virus with encephalopathy | Diagnosis | ICD-10-CM |
| J11.82 | Influenza due to unidentified influenza virus with myocarditis | Diagnosis | ICD-10-CM |
| J11.83 | Influenza due to unidentified influenza virus with otitis media | Diagnosis | ICD-10-CM |
| J11.89 | Influenza due to unidentified influenza virus with other manifestations | Diagnosis | ICD-10-CM |
| J12.0 | Adenoviral pneumonia | Diagnosis | ICD-10-CM |
| J12.1 | Respiratory syncytial virus pneumonia | Diagnosis | ICD-10-CM |
| J12.2 | Parainfluenza virus pneumonia | Diagnosis | ICD-10-CM |
| J12.3 | Human metapneumovirus pneumonia | Diagnosis | ICD-10-CM |
| J12.81 | Pneumonia due to SARS-associated coronavirus | Diagnosis | ICD-10-CM |
| J12.89 | Other viral pneumonia | Diagnosis | ICD-10-CM |
| J12.9 | Viral pneumonia, unspecified | Diagnosis | ICD-10-CM |
| J13 | Pneumonia due to Streptococcus pneumoniae | Diagnosis | ICD-10-CM |
| J14 | Pneumonia due to Hemophilus influenzae | Diagnosis | ICD-10-CM |
| J15.0 | Pneumonia due to Klebsiella pneumoniae | Diagnosis | ICD-10-CM |
| J15.1 | Pneumonia due to Pseudomonas | Diagnosis | ICD-10-CM |
| J15.20 | Pneumonia due to staphylococcus, unspecified | Diagnosis | ICD-10-CM |
| J15.211 | Pneumonia due to Methicillin susceptible Staphylococcus aureus | Diagnosis | ICD-10-CM |
| J15.212 | Pneumonia due to Methicillin resistant Staphylococcus aureus | Diagnosis | ICD-10-CM |
| J15.29 | Pneumonia due to other staphylococcus | Diagnosis | ICD-10-CM |
| J15.3 | Pneumonia due to streptococcus, group B | Diagnosis | ICD-10-CM |
| J15.4 | Pneumonia due to other streptococci | Diagnosis | ICD-10-CM |
| J15.5 | Pneumonia due to Escherichia coli | Diagnosis | ICD-10-CM |
| J15.6 | Pneumonia due to other Gram-negative bacteria | Diagnosis | ICD-10-CM |
| J15.7 | Pneumonia due to Mycoplasma pneumoniae | Diagnosis | ICD-10-CM |
| J15.8 | Pneumonia due to other specified bacteria | Diagnosis | ICD-10-CM |
| J15.9 | Unspecified bacterial pneumonia | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| J16.0 | Chlamydial pneumonia | Diagnosis | ICD-10-CM |
| J16.8 | Pneumonia due to other specified infectious organisms | Diagnosis | ICD-10-CM |
| J17 | Pneumonia in diseases classified elsewhere | Diagnosis | ICD-10-CM |
| J18.0 | Bronchopneumonia, unspecified organism | Diagnosis | ICD-10-CM |
| J18.1 | Lobar pneumonia, unspecified organism | Diagnosis | ICD-10-CM |
| J18.2 | Hypostatic pneumonia, unspecified organism | Diagnosis | ICD-10-CM |
| J18.8 | Other pneumonia, unspecified organism | Diagnosis | ICD-10-CM |
| J18.9 | Pneumonia, unspecified organism | Diagnosis | ICD-10-CM |
| J20.0 | Acute bronchitis due to Mycoplasma pneumoniae | Diagnosis | ICD-10-CM |
| J20.1 | Acute bronchitis due to Hemophilus influenzae | Diagnosis | ICD-10-CM |
| J20.2 | Acute bronchitis due to streptococcus | Diagnosis | ICD-10-CM |
| J20.3 | Acute bronchitis due to coxsackievirus | Diagnosis | ICD-10-CM |
| J20.4 | Acute bronchitis due to parainfluenza virus | Diagnosis | ICD-10-CM |
| J20.5 | Acute bronchitis due to respiratory syncytial virus | Diagnosis | ICD-10-CM |
| J20.6 | Acute bronchitis due to rhinovirus | Diagnosis | ICD-10-CM |
| J20.7 | Acute bronchitis due to echovirus | Diagnosis | ICD-10-CM |
| J20.8 | Acute bronchitis due to other specified organisms | Diagnosis | ICD-10-CM |
| J20.9 | Acute bronchitis, unspecified | Diagnosis | ICD-10-CM |
| J21.0 | Acute bronchiolitis due to respiratory syncytial virus | Diagnosis | ICD-10-CM |
| J21.1 | Acute bronchiolitis due to human metapneumovirus | Diagnosis | ICD-10-CM |
| J21.8 | Acute bronchiolitis due to other specified organisms | Diagnosis | ICD-10-CM |
| J21.9 | Acute bronchiolitis, unspecified | Diagnosis | ICD-10-CM |
| J22 | Unspecified acute lower respiratory infection | Diagnosis | ICD-10-CM |
| J30.0 | Vasomotor rhinitis | Diagnosis | ICD-10-CM |
| J30.1 | Allergic rhinitis due to pollen | Diagnosis | ICD-10-CM |
| J30.2 | Other seasonal allergic rhinitis | Diagnosis | ICD-10-CM |
| J30.81 | Allergic rhinitis due to animal (cat) (dog) hair and dander | Diagnosis | ICD-10-CM |
| J30.89 | Other allergic rhinitis | Diagnosis | ICD-10-CM |
| J30.9 | Allergic rhinitis, unspecified | Diagnosis | ICD-10-CM |
| J31.0 | Chronic rhinitis | Diagnosis | ICD-10-CM |
| J31.1 | Chronic nasopharyngitis | Diagnosis | ICD-10-CM |
| J31.2 | Chronic pharyngitis | Diagnosis | ICD-10-CM |
| J32.0 | Chronic maxillary sinusitis | Diagnosis | ICD-10-CM |
| J32.1 | Chronic frontal sinusitis | Diagnosis | ICD-10-CM |
| J32.2 | Chronic ethmoidal sinusitis | Diagnosis | ICD-10-CM |
| J32.3 | Chronic sphenoidal sinusitis | Diagnosis | ICD-10-CM |
| J32.4 | Chronic pansinusitis | Diagnosis | ICD-10-CM |
| J32.8 | Other chronic sinusitis | Diagnosis | ICD-10-CM |
| J32.9 | Chronic sinusitis, unspecified | Diagnosis | ICD-10-CM |
| J33.0 | Polyp of nasal cavity | Diagnosis | ICD-10-CM |
| J33.1 | Polypoid sinus degeneration | Diagnosis | ICD-10-CM |
| J33.8 | Other polyp of sinus | Diagnosis | ICD-10-CM |
| J33.9 | Nasal polyp, unspecified | Diagnosis | ICD-10-CM |
| J34.0 | Abscess, furuncle and carbuncle of nose | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| J34.1 | Cyst and mucocele of nose and nasal sinus | Diagnosis | ICD-10-CM |
| J34.2 | Deviated nasal septum | Diagnosis | ICD-10-CM |
| J34.3 | Hypertrophy of nasal turbinates | Diagnosis | ICD-10-CM |
| J34.81 | Nasal mucositis (ulcerative) | Diagnosis | ICD-10-CM |
| J34.89 | Other specified disorders of nose and nasal sinuses | Diagnosis | ICD-10-CM |
| J34.9 | Unspecified disorder of nose and nasal sinuses | Diagnosis | ICD-10-CM |
| J35.01 | Chronic tonsillitis | Diagnosis | ICD-10-CM |
| J35.02 | Chronic adenoiditis | Diagnosis | ICD-10-CM |
| J35.03 | Chronic tonsillitis and adenoiditis | Diagnosis | ICD-10-CM |
| J35.1 | Hypertrophy of tonsils | Diagnosis | ICD-10-CM |
| J35.2 | Hypertrophy of adenoids | Diagnosis | ICD-10-CM |
| J35.3 | Hypertrophy of tonsils with hypertrophy of adenoids | Diagnosis | ICD-10-CM |
| J35.8 | Other chronic diseases of tonsils and adenoids | Diagnosis | ICD-10-CM |
| J35.9 | Chronic disease of tonsils and adenoids, unspecified | Diagnosis | ICD-10-CM |
| J36 | Peritonsillar abscess | Diagnosis | ICD-10-CM |
| J37.0 | Chronic laryngitis | Diagnosis | ICD-10-CM |
| J37.1 | Chronic laryngotracheitis | Diagnosis | ICD-10-CM |
| J38.00 | Paralysis of vocal cords and larynx, unspecified | Diagnosis | ICD-10-CM |
| J38.01 | Paralysis of vocal cords and larynx, unilateral | Diagnosis | ICD-10-CM |
| J38.02 | Paralysis of vocal cords and larynx, bilateral | Diagnosis | ICD-10-CM |
| J38.1 | Polyp of vocal cord and larynx | Diagnosis | ICD-10-CM |
| J38.2 | Nodules of vocal cords | Diagnosis | ICD-10-CM |
| J38.3 | Other diseases of vocal cords | Diagnosis | ICD-10-CM |
| J38.4 | Edema of larynx | Diagnosis | ICD-10-CM |
| J38.5 | Laryngeal spasm | Diagnosis | ICD-10-CM |
| J38.6 | Stenosis of larynx | Diagnosis | ICD-10-CM |
| J38.7 | Other diseases of larynx | Diagnosis | ICD-10-CM |
| J39.0 | Retropharyngeal and parapharyngeal abscess | Diagnosis | ICD-10-CM |
| J39.1 | Other abscess of pharynx | Diagnosis | ICD-10-CM |
| J39.2 | Other diseases of pharynx | Diagnosis | ICD-10-CM |
| J39.3 | Upper respiratory tract hypersensitivity reaction, site unspecified | Diagnosis | ICD-10-CM |
| J39.8 | Other specified diseases of upper respiratory tract | Diagnosis | ICD-10-CM |
| J39.9 | Disease of upper respiratory tract, unspecified | Diagnosis | ICD-10-CM |
| J40 | Bronchitis, not specified as acute or chronic | Diagnosis | ICD-10-CM |
| J41.0 | Simple chronic bronchitis | Diagnosis | ICD-10-CM |
| J41.1 | Mucopurulent chronic bronchitis | Diagnosis | ICD-10-CM |
| J41.8 | Mixed simple and mucopurulent chronic bronchitis | Diagnosis | ICD-10-CM |
| J42 | Unspecified chronic bronchitis | Diagnosis | ICD-10-CM |
| J43 | Emphysema | Diagnosis | ICD-10-CM |
| J43.0 | Unilateral pulmonary emphysema [MacLeod's syndrome] | Diagnosis | ICD-10-CM |
| J43.1 | Panlobular emphysema | Diagnosis | ICD-10-CM |
| J43.2 | Centrilobular emphysema | Diagnosis | ICD-10-CM |
| J43.8 | Other emphysema | Diagnosis | ICD-10-CM |
| J43.9 | Emphysema, unspecified | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|-------|--|---------------|-----------|
| J44 | Other chronic obstructive pulmonary disease | Diagnosis | ICD-10-CM |
| J44.9 | Chronic obstructive pulmonary disease, unspecified | Diagnosis | ICD-10-CM |
| J47.0 | Bronchiectasis with acute lower respiratory infection | Diagnosis | ICD-10-CM |
| J47.1 | Bronchiectasis with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J47.9 | Bronchiectasis, uncomplicated | Diagnosis | ICD-10-CM |
| J60 | Coalworker's pneumoconiosis | Diagnosis | ICD-10-CM |
| J61 | Pneumoconiosis due to asbestos and other mineral fibers | Diagnosis | ICD-10-CM |
| J62 | Pneumoconiosis due to dust containing silica | Diagnosis | ICD-10-CM |
| J62.0 | Pneumoconiosis due to talc dust | Diagnosis | ICD-10-CM |
| J62.8 | Pneumoconiosis due to other dust containing silica | Diagnosis | ICD-10-CM |
| J63 | Pneumoconiosis due to other inorganic dusts | Diagnosis | ICD-10-CM |
| J63.0 | Aluminosis (of lung) | Diagnosis | ICD-10-CM |
| J63.1 | Bauxite fibrosis (of lung) | Diagnosis | ICD-10-CM |
| J63.2 | Berylliosis | Diagnosis | ICD-10-CM |
| J63.3 | Graphite fibrosis (of lung) | Diagnosis | ICD-10-CM |
| J63.4 | Siderosis | Diagnosis | ICD-10-CM |
| J63.5 | Stannosis | Diagnosis | ICD-10-CM |
| J63.6 | Pneumoconiosis due to other specified inorganic dusts | Diagnosis | ICD-10-CM |
| J64 | Unspecified pneumoconiosis | Diagnosis | ICD-10-CM |
| J65 | Pneumoconiosis associated with tuberculosis | Diagnosis | ICD-10-CM |
| J66.0 | Byssinosis | Diagnosis | ICD-10-CM |
| J66.1 | Flax-dressers' disease | Diagnosis | ICD-10-CM |
| J66.2 | Cannabinosis | Diagnosis | ICD-10-CM |
| J66.8 | Airway disease due to other specific organic dusts | Diagnosis | ICD-10-CM |
| J67.0 | Farmer's lung | Diagnosis | ICD-10-CM |
| J67.1 | Bagassosis | Diagnosis | ICD-10-CM |
| J67.2 | Bird fancier's lung | Diagnosis | ICD-10-CM |
| J67.3 | Suberosis | Diagnosis | ICD-10-CM |
| J67.4 | Maltworker's lung | Diagnosis | ICD-10-CM |
| J67.5 | Mushroom-worker's lung | Diagnosis | ICD-10-CM |
| J67.6 | Maple-bark-stripper's lung | Diagnosis | ICD-10-CM |
| J67.7 | Air conditioner and humidifier lung | Diagnosis | ICD-10-CM |
| J67.8 | Hypersensitivity pneumonitis due to other organic dusts | Diagnosis | ICD-10-CM |
| J67.9 | Hypersensitivity pneumonitis due to unspecified organic dust | Diagnosis | ICD-10-CM |
| J68.0 | Bronchitis and pneumonitis due to chemicals, gases, fumes and vapors | Diagnosis | ICD-10-CM |
| J68.1 | Pulmonary edema due to chemicals, gases, fumes and vapors | Diagnosis | ICD-10-CM |
| J68.2 | Upper respiratory inflammation due to chemicals, gases, fumes and vapors, not elsewhere classified | Diagnosis | ICD-10-CM |
| J68.3 | Other acute and subacute respiratory conditions due to chemicals, gases, fumes and vapors | Diagnosis | ICD-10-CM |
| J68.4 | Chronic respiratory conditions due to chemicals, gases, fumes and vapors | Diagnosis | ICD-10-CM |
| J68.8 | Other respiratory conditions due to chemicals, gases, fumes and vapors | Diagnosis | ICD-10-CM |
| J68.9 | Unspecified respiratory condition due to chemicals, gases, fumes and vapors | Diagnosis | ICD-10-CM |
| J69.0 | Pneumonitis due to inhalation of food and vomit | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| J69.1 | Pneumonitis due to inhalation of oils and essences | Diagnosis | ICD-10-CM |
| J69.8 | Pneumonitis due to inhalation of other solids and liquids | Diagnosis | ICD-10-CM |
| J70 | Respiratory conditions due to other external agents | Diagnosis | ICD-10-CM |
| J70.0 | Acute pulmonary manifestations due to radiation | Diagnosis | ICD-10-CM |
| J70.1 | Chronic and other pulmonary manifestations due to radiation | Diagnosis | ICD-10-CM |
| J70.2 | Acute drug-induced interstitial lung disorders | Diagnosis | ICD-10-CM |
| J70.3 | Chronic drug-induced interstitial lung disorders | Diagnosis | ICD-10-CM |
| J70.4 | Drug-induced interstitial lung disorders, unspecified | Diagnosis | ICD-10-CM |
| J70.5 | Respiratory conditions due to smoke inhalation | Diagnosis | ICD-10-CM |
| J70.8 | Respiratory conditions due to other specified external agents | Diagnosis | ICD-10-CM |
| J70.9 | Respiratory conditions due to unspecified external agent | Diagnosis | ICD-10-CM |
| J80 | Acute respiratory distress syndrome | Diagnosis | ICD-10-CM |
| J81.0 | Acute pulmonary edema | Diagnosis | ICD-10-CM |
| J81.1 | Chronic pulmonary edema | Diagnosis | ICD-10-CM |
| J82 | Pulmonary eosinophilia, not elsewhere classified | Diagnosis | ICD-10-CM |
| J82.8 | Pulmonary eosinophilia, not elsewhere classified | Diagnosis | ICD-10-CM |
| J82.89 | Other pulmonary eosinophilia, not elsewhere classified | Diagnosis | ICD-10-CM |
| J84 | Other interstitial pulmonary diseases | Diagnosis | ICD-10-CM |
| J84.0 | Alveolar and parieto-alveolar conditions | Diagnosis | ICD-10-CM |
| J84.01 | Alveolar proteinosis | Diagnosis | ICD-10-CM |
| J84.02 | Pulmonary alveolar microlithiasis | Diagnosis | ICD-10-CM |
| J84.03 | Idiopathic pulmonary hemosiderosis | Diagnosis | ICD-10-CM |
| J84.09 | Other alveolar and parieto-alveolar conditions | Diagnosis | ICD-10-CM |
| J84.1 | Other interstitial pulmonary diseases with fibrosis | Diagnosis | ICD-10-CM |
| J84.10 | Pulmonary fibrosis, unspecified | Diagnosis | ICD-10-CM |
| J84.111 | Idiopathic interstitial pneumonia, not otherwise specified | Diagnosis | ICD-10-CM |
| J84.112 | Idiopathic pulmonary fibrosis | Diagnosis | ICD-10-CM |
| J84.113 | Idiopathic non-specific interstitial pneumonitis | Diagnosis | ICD-10-CM |
| J84.114 | Acute interstitial pneumonitis | Diagnosis | ICD-10-CM |
| J84.115 | Respiratory bronchiolitis interstitial lung disease | Diagnosis | ICD-10-CM |
| J84.116 | Cryptogenic organizing pneumonia | Diagnosis | ICD-10-CM |
| J84.117 | Desquamative interstitial pneumonia | Diagnosis | ICD-10-CM |
| J84.17 | Other interstitial pulmonary diseases with fibrosis in diseases classified elsewhere | Diagnosis | ICD-10-CM |
| J84.170 | Interstitial lung disease with progressive fibrotic phenotype in diseases classified elsewhere | Diagnosis | ICD-10-CM |
| J84.178 | Other interstitial pulmonary diseases with fibrosis in diseases classified elsewhere | Diagnosis | ICD-10-CM |
| J84.2 | Lymphoid interstitial pneumonia | Diagnosis | ICD-10-CM |
| J84.8 | Other specified interstitial pulmonary diseases | Diagnosis | ICD-10-CM |
| J84.81 | Lymphangioliomyomatosis | Diagnosis | ICD-10-CM |
| J84.82 | Adult pulmonary Langerhans cell histiocytosis | Diagnosis | ICD-10-CM |
| J84.83 | Surfactant mutations of the lung | Diagnosis | ICD-10-CM |
| J84.84 | Other interstitial lung diseases of childhood | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| J84.841 | Neuroendocrine cell hyperplasia of infancy | Diagnosis | ICD-10-CM |
| J84.842 | Pulmonary interstitial glycogenosis | Diagnosis | ICD-10-CM |
| J84.843 | Alveolar capillary dysplasia with vein misalignment | Diagnosis | ICD-10-CM |
| J84.848 | Other interstitial lung diseases of childhood | Diagnosis | ICD-10-CM |
| J84.89 | Other specified interstitial pulmonary diseases | Diagnosis | ICD-10-CM |
| J84.9 | Interstitial pulmonary disease, unspecified | Diagnosis | ICD-10-CM |
| J85.0 | Gangrene and necrosis of lung | Diagnosis | ICD-10-CM |
| J85.1 | Abscess of lung with pneumonia | Diagnosis | ICD-10-CM |
| J85.2 | Abscess of lung without pneumonia | Diagnosis | ICD-10-CM |
| J85.3 | Abscess of mediastinum | Diagnosis | ICD-10-CM |
| J86.0 | Pyothorax with fistula | Diagnosis | ICD-10-CM |
| J86.9 | Pyothorax without fistula | Diagnosis | ICD-10-CM |
| J90 | Pleural effusion, not elsewhere classified | Diagnosis | ICD-10-CM |
| J91 | Pleural effusion in conditions classified elsewhere | Diagnosis | ICD-10-CM |
| J91.8 | Pleural effusion in other conditions classified elsewhere | Diagnosis | ICD-10-CM |
| J92.0 | Pleural plaque with presence of asbestos | Diagnosis | ICD-10-CM |
| J92.9 | Pleural plaque without asbestos | Diagnosis | ICD-10-CM |
| J93.0 | Spontaneous tension pneumothorax | Diagnosis | ICD-10-CM |
| J93.11 | Primary spontaneous pneumothorax | Diagnosis | ICD-10-CM |
| J93.12 | Secondary spontaneous pneumothorax | Diagnosis | ICD-10-CM |
| J93.81 | Chronic pneumothorax | Diagnosis | ICD-10-CM |
| J93.82 | Other air leak | Diagnosis | ICD-10-CM |
| J93.83 | Other pneumothorax | Diagnosis | ICD-10-CM |
| J93.9 | Pneumothorax, unspecified | Diagnosis | ICD-10-CM |
| J94.0 | Chylous effusion | Diagnosis | ICD-10-CM |
| J94.1 | Fibrothorax | Diagnosis | ICD-10-CM |
| J94.2 | Hemothorax | Diagnosis | ICD-10-CM |
| J94.8 | Other specified pleural conditions | Diagnosis | ICD-10-CM |
| J94.9 | Pleural condition, unspecified | Diagnosis | ICD-10-CM |
| J95.1 | Acute pulmonary insufficiency following thoracic surgery | Diagnosis | ICD-10-CM |
| J95.2 | Acute pulmonary insufficiency following nonthoracic surgery | Diagnosis | ICD-10-CM |
| J95.3 | Chronic pulmonary insufficiency following surgery | Diagnosis | ICD-10-CM |
| J95.821 | Acute postprocedural respiratory failure | Diagnosis | ICD-10-CM |
| J95.822 | Acute and chronic postprocedural respiratory failure | Diagnosis | ICD-10-CM |
| J95.850 | Mechanical complication of respirator | Diagnosis | ICD-10-CM |
| J96.00 | Acute respiratory failure, unspecified whether with hypoxia or hypercapnia | Diagnosis | ICD-10-CM |
| J96.01 | Acute respiratory failure with hypoxia | Diagnosis | ICD-10-CM |
| J96.02 | Acute respiratory failure with hypercapnia | Diagnosis | ICD-10-CM |
| J96.1 | Chronic respiratory failure | Diagnosis | ICD-10-CM |
| J96.10 | Chronic respiratory failure, unspecified whether with hypoxia or hypercapnia | Diagnosis | ICD-10-CM |
| J96.11 | Chronic respiratory failure with hypoxia | Diagnosis | ICD-10-CM |
| J96.12 | Chronic respiratory failure with hypercapnia | Diagnosis | ICD-10-CM |
| J96.20 | Acute and chronic respiratory failure, unspecified whether with hypoxia or hypercapnia | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| J96.21 | Acute and chronic respiratory failure with hypoxia | Diagnosis | ICD-10-CM |
| J96.22 | Acute and chronic respiratory failure with hypercapnia | Diagnosis | ICD-10-CM |
| J96.90 | Respiratory failure, unspecified, unspecified whether with hypoxia or hypercapnia | Diagnosis | ICD-10-CM |
| J96.91 | Respiratory failure, unspecified with hypoxia | Diagnosis | ICD-10-CM |
| J96.92 | Respiratory failure, unspecified with hypercapnia | Diagnosis | ICD-10-CM |
| J98.01 | Acute bronchospasm | Diagnosis | ICD-10-CM |
| J98.09 | Other diseases of bronchus, not elsewhere classified | Diagnosis | ICD-10-CM |
| J98.11 | Atelectasis | Diagnosis | ICD-10-CM |
| J98.19 | Other pulmonary collapse | Diagnosis | ICD-10-CM |
| J98.2 | Interstitial emphysema | Diagnosis | ICD-10-CM |
| J98.3 | Compensatory emphysema | Diagnosis | ICD-10-CM |
| J98.4 | Other disorders of lung | Diagnosis | ICD-10-CM |
| J98.51 | Mediastinitis | Diagnosis | ICD-10-CM |
| J98.59 | Other diseases of mediastinum, not elsewhere classified | Diagnosis | ICD-10-CM |
| J98.6 | Disorders of diaphragm | Diagnosis | ICD-10-CM |
| J98.8 | Other specified respiratory disorders | Diagnosis | ICD-10-CM |
| J98.9 | Respiratory disorder, unspecified | Diagnosis | ICD-10-CM |
| J99 | Respiratory disorders in diseases classified elsewhere | Diagnosis | ICD-10-CM |
| M32.13 | Lung involvement in systemic lupus erythematosus | Diagnosis | ICD-10-CM |
| M33.01 | Juvenile dermatomyositis with respiratory involvement | Diagnosis | ICD-10-CM |
| M33.11 | Other dermatomyositis with respiratory involvement | Diagnosis | ICD-10-CM |
| M33.21 | Polymyositis with respiratory involvement | Diagnosis | ICD-10-CM |
| M33.91 | Dermatopolymyositis, unspecified with respiratory involvement | Diagnosis | ICD-10-CM |
| M34.81 | Systemic sclerosis with lung involvement | Diagnosis | ICD-10-CM |
| M35.02 | Sjogren syndrome with lung involvement | Diagnosis | ICD-10-CM |
| P25 | Interstitial emphysema and related conditions originating in the perinatal period | Diagnosis | ICD-10-CM |
| P27 | Chronic respiratory disease originating in the perinatal period | Diagnosis | ICD-10-CM |
| P27.0 | Wilson-Mikity syndrome | Diagnosis | ICD-10-CM |
| P27.1 | Bronchopulmonary dysplasia originating in the perinatal period | Diagnosis | ICD-10-CM |
| P27.8 | Other chronic respiratory diseases originating in the perinatal period | Diagnosis | ICD-10-CM |
| P27.9 | Unspecified chronic respiratory disease originating in the perinatal period | Diagnosis | ICD-10-CM |
| R04.0 | Epistaxis | Diagnosis | ICD-10-CM |
| R04.1 | Hemorrhage from throat | Diagnosis | ICD-10-CM |
| R04.2 | Hemoptysis | Diagnosis | ICD-10-CM |
| R04.81 | Acute idiopathic pulmonary hemorrhage in infants | Diagnosis | ICD-10-CM |
| R04.89 | Hemorrhage from other sites in respiratory passages | Diagnosis | ICD-10-CM |
| R04.9 | Hemorrhage from respiratory passages, unspecified | Diagnosis | ICD-10-CM |
| R05 | Cough | Diagnosis | ICD-10-CM |
| R06.00 | Dyspnea, unspecified | Diagnosis | ICD-10-CM |
| R06.01 | Orthopnea | Diagnosis | ICD-10-CM |
| R06.02 | Shortness of breath | Diagnosis | ICD-10-CM |
| R06.03 | Acute respiratory distress | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| R06.09 | Other forms of dyspnea | Diagnosis | ICD-10-CM |
| R06.1 | Stridor | Diagnosis | ICD-10-CM |
| R06.2 | Wheezing | Diagnosis | ICD-10-CM |
| R06.3 | Periodic breathing | Diagnosis | ICD-10-CM |
| R06.4 | Hyperventilation | Diagnosis | ICD-10-CM |
| R06.5 | Mouth breathing | Diagnosis | ICD-10-CM |
| R06.6 | Hiccough | Diagnosis | ICD-10-CM |
| R06.7 | Sneezing | Diagnosis | ICD-10-CM |
| R06.81 | Apnea, not elsewhere classified | Diagnosis | ICD-10-CM |
| R06.82 | Tachypnea, not elsewhere classified | Diagnosis | ICD-10-CM |
| R06.83 | Snoring | Diagnosis | ICD-10-CM |
| R06.89 | Other abnormalities of breathing | Diagnosis | ICD-10-CM |
| R06.9 | Unspecified abnormalities of breathing | Diagnosis | ICD-10-CM |
| R07.0 | Pain in throat | Diagnosis | ICD-10-CM |
| R07.1 | Chest pain on breathing | Diagnosis | ICD-10-CM |
| R07.81 | Pleurodynia | Diagnosis | ICD-10-CM |
| R09.1 | Pleurisy | Diagnosis | ICD-10-CM |
| R09.2 | Respiratory arrest | Diagnosis | ICD-10-CM |
| R09.3 | Abnormal sputum | Diagnosis | ICD-10-CM |
| R09.81 | Nasal congestion | Diagnosis | ICD-10-CM |
| R09.82 | Postnasal drip | Diagnosis | ICD-10-CM |
| R09.89 | Other specified symptoms and signs involving the circulatory and respiratory systems | Diagnosis | ICD-10-CM |
| R19.6 | Halitosis | Diagnosis | ICD-10-CM |
| R22.2 | Localized swelling, mass and lump, trunk | Diagnosis | ICD-10-CM |
| R23.0 | Cyanosis | Diagnosis | ICD-10-CM |
| R47.89 | Other speech disturbances | Diagnosis | ICD-10-CM |
| R49.0 | Dysphonia | Diagnosis | ICD-10-CM |
| R49.1 | Aphonia | Diagnosis | ICD-10-CM |
| R49.21 | Hypernasality | Diagnosis | ICD-10-CM |
| R49.22 | Hyponasality | Diagnosis | ICD-10-CM |
| R49.8 | Other voice and resonance disorders | Diagnosis | ICD-10-CM |
| R49.9 | Unspecified voice and resonance disorder | Diagnosis | ICD-10-CM |
| R91.1 | Solitary pulmonary nodule | Diagnosis | ICD-10-CM |
| R91.8 | Other nonspecific abnormal finding of lung field | Diagnosis | ICD-10-CM |
| R94.2 | Abnormal results of pulmonary function studies | Diagnosis | ICD-10-CM |
| V12.6 | Personal history of diseases of respiratory system | Diagnosis | ICD-9-CM |
| V12.60 | Personal history, unspecified disease of respiratory system | Diagnosis | ICD-9-CM |
| V12.61 | Personal history, Pneumonia (recurrent) | Diagnosis | ICD-9-CM |
| V12.69 | Personal history, Other diseases of respiratory system | Diagnosis | ICD-9-CM |
| V41.4 | Problems with voice production | Diagnosis | ICD-9-CM |
| V42.6 | Lung replaced by transplant | Diagnosis | ICD-9-CM |
| V44.0 | Tracheostomy status | Diagnosis | ICD-9-CM |
| V46.1 | Dependence on Respirator [Ventilator] | Diagnosis | ICD-9-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|-----------------------|--|---------------|-----------|
| V46.11 | Dependence on respirator, status | Diagnosis | ICD-9-CM |
| V46.12 | Encounter for respirator dependence during power failure | Diagnosis | ICD-9-CM |
| V46.13 | Encounter for weaning from respirator [ventilator] | Diagnosis | ICD-9-CM |
| V46.14 | Mechanical complication of respirator [ventilator] | Diagnosis | ICD-9-CM |
| V46.2 | Dependence on machine for supplemental oxygen | Diagnosis | ICD-9-CM |
| V55.0 | Attention to tracheostomy | Diagnosis | ICD-9-CM |
| Z43.0 | Encounter for attention to tracheostomy | Diagnosis | ICD-10-CM |
| Z48.24 | Encounter for aftercare following lung transplant | Diagnosis | ICD-10-CM |
| Z48.280 | Encounter for aftercare following heart-lung transplant | Diagnosis | ICD-10-CM |
| Z87.01 | Personal history of pneumonia (recurrent) | Diagnosis | ICD-10-CM |
| Z87.09 | Personal history of other diseases of the respiratory system | Diagnosis | ICD-10-CM |
| Z93.0 | Tracheostomy status | Diagnosis | ICD-10-CM |
| Z94.2 | Lung transplant status | Diagnosis | ICD-10-CM |
| Z94.3 | Heart and lungs transplant status | Diagnosis | ICD-10-CM |
| Z99.11 | Dependence on respirator [ventilator] status | Diagnosis | ICD-10-CM |
| Z99.12 | Encounter for respirator [ventilator] dependence during power failure | Diagnosis | ICD-10-CM |
| Z99.81 | Dependence on supplemental oxygen | Diagnosis | ICD-10-CM |
| Self Harm - Poisoning | | | |
| T36.0X2 | Poisoning by penicillins, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.0X2A | Poisoning by penicillins, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.0X2D | Poisoning by penicillins, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.0X2S | Poisoning by penicillins, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.1X2 | Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.1X2A | Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.1X2D | Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.1X2S | Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.2X2 | Poisoning by chloramphenicol group, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.2X2A | Poisoning by chloramphenicol group, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.2X2D | Poisoning by chloramphenicol group, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.2X2S | Poisoning by chloramphenicol group, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.3X2 | Poisoning by macrolides, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.3X2A | Poisoning by macrolides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.3X2D | Poisoning by macrolides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.3X2S | Poisoning by macrolides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.4X2 | Poisoning by tetracyclines, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.4X2A | Poisoning by tetracyclines, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.4X2D | Poisoning by tetracyclines, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.4X2S | Poisoning by tetracyclines, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.5X2 | Poisoning by aminoglycosides, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T36.5X2A | Poisoning by aminoglycosides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.5X2D | Poisoning by aminoglycosides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.5X2S | Poisoning by aminoglycosides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.6X2 | Poisoning by rifampicins, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.6X2A | Poisoning by rifampicins, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.6X2D | Poisoning by rifampicins, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.6X2S | Poisoning by rifampicins, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.7X2 | Poisoning by antifungal antibiotics, systemically used, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.7X2A | Poisoning by antifungal antibiotics, systemically used, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.7X2D | Poisoning by antifungal antibiotics, systemically used, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.7X2S | Poisoning by antifungal antibiotics, systemically used, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.8X2 | Poisoning by other systemic antibiotics, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.8X2A | Poisoning by other systemic antibiotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.8X2D | Poisoning by other systemic antibiotics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.8X2S | Poisoning by other systemic antibiotics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T36.92 | Poisoning by unspecified systemic antibiotic, intentional self-harm | Diagnosis | ICD-10-CM |
| T36.92XA | Poisoning by unspecified systemic antibiotic, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T36.92XD | Poisoning by unspecified systemic antibiotic, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T36.92XS | Poisoning by unspecified systemic antibiotic, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.0X2 | Poisoning by sulfonamides, intentional self-harm | Diagnosis | ICD-10-CM |
| T37.0X2A | Poisoning by sulfonamides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.0X2D | Poisoning by sulfonamides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.0X2S | Poisoning by sulfonamides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.1X2 | Poisoning by antimycobacterial drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T37.1X2A | Poisoning by antimycobacterial drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.1X2D | Poisoning by antimycobacterial drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.1X2S | Poisoning by antimycobacterial drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.2X2 | Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm | Diagnosis | ICD-10-CM |
| T37.2X2A | Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.2X2D | Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.2X2S | Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.3X2 | Poisoning by other antiprotozoal drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T37.3X2A | Poisoning by other antiprotozoal drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T37.3X2D | Poisoning by other antiprotozoal drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.3X2S | Poisoning by other antiprotozoal drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.4X2 | Poisoning by anthelmintics, intentional self-harm | Diagnosis | ICD-10-CM |
| T37.4X2A | Poisoning by anthelmintics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.4X2D | Poisoning by anthelmintics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.4X2S | Poisoning by anthelmintics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.5X2 | Poisoning by antiviral drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T37.5X2A | Poisoning by antiviral drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.5X2D | Poisoning by antiviral drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.5X2S | Poisoning by antiviral drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.8X2 | Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm | Diagnosis | ICD-10-CM |
| T37.8X2A | Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.8X2D | Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.8X2S | Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T37.92 | Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm | Diagnosis | ICD-10-CM |
| T37.92XA | Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T37.92XD | Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T37.92XS | Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.0X2 | Poisoning by glucocorticoids and synthetic analogues, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.0X2A | Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.0X2D | Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.0X2S | Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.1X2 | Poisoning by thyroid hormones and substitutes, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.1X2A | Poisoning by thyroid hormones and substitutes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.1X2D | Poisoning by thyroid hormones and substitutes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.1X2S | Poisoning by thyroid hormones and substitutes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.2X2 | Poisoning by antithyroid drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.2X2A | Poisoning by antithyroid drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.2X2D | Poisoning by antithyroid drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.2X2S | Poisoning by antithyroid drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T38.3X2 | Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.3X2A | Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.3X2D | Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.3X2S | Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.4X2 | Poisoning by oral contraceptives, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.4X2A | Poisoning by oral contraceptives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.4X2D | Poisoning by oral contraceptives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.4X2S | Poisoning by oral contraceptives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.5X2 | Poisoning by other estrogens and progestogens, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.5X2A | Poisoning by other estrogens and progestogens, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.5X2D | Poisoning by other estrogens and progestogens, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.5X2S | Poisoning by other estrogens and progestogens, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.6X2 | Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.6X2A | Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.6X2D | Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.6X2S | Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.7X2 | Poisoning by androgens and anabolic congeners, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.7X2A | Poisoning by androgens and anabolic congeners, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.7X2D | Poisoning by androgens and anabolic congeners, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.7X2S | Poisoning by androgens and anabolic congeners, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.802 | Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.802A | Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.802D | Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.802S | Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.812 | Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.812A | Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T38.812D | Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.812S | Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.892 | Poisoning by other hormones and synthetic substitutes, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.892A | Poisoning by other hormones and synthetic substitutes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.892D | Poisoning by other hormones and synthetic substitutes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.892S | Poisoning by other hormones and synthetic substitutes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.902 | Poisoning by unspecified hormone antagonists, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.902A | Poisoning by unspecified hormone antagonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.902D | Poisoning by unspecified hormone antagonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.902S | Poisoning by unspecified hormone antagonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T38.992 | Poisoning by other hormone antagonists, intentional self-harm | Diagnosis | ICD-10-CM |
| T38.992A | Poisoning by other hormone antagonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T38.992D | Poisoning by other hormone antagonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T38.992S | Poisoning by other hormone antagonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.012 | Poisoning by aspirin, intentional self-harm | Diagnosis | ICD-10-CM |
| T39.012A | Poisoning by aspirin, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.012D | Poisoning by aspirin, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.012S | Poisoning by aspirin, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.092 | Poisoning by salicylates, intentional self-harm | Diagnosis | ICD-10-CM |
| T39.092A | Poisoning by salicylates, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.092D | Poisoning by salicylates, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.092S | Poisoning by salicylates, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.1X2 | Poisoning by 4-Aminophenol derivatives, intentional self-harm | Diagnosis | ICD-10-CM |
| T39.1X2A | Poisoning by 4-Aminophenol derivatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.1X2D | Poisoning by 4-Aminophenol derivatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.1X2S | Poisoning by 4-Aminophenol derivatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.2X2 | Poisoning by pyrazolone derivatives, intentional self-harm | Diagnosis | ICD-10-CM |
| T39.2X2A | Poisoning by pyrazolone derivatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.2X2D | Poisoning by pyrazolone derivatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.2X2S | Poisoning by pyrazolone derivatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.312 | Poisoning by propionic acid derivatives, intentional self-harm | Diagnosis | ICD-10-CM |
| T39.312A | Poisoning by propionic acid derivatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T39.312D | Poisoning by propionic acid derivatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.312S | Poisoning by propionic acid derivatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.392 | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm | Diagnosis | ICD-10-CM |
| T39.392A | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.392D | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.392S | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.4X2 | Poisoning by antirheumatics, not elsewhere classified, intentional self-harm | Diagnosis | ICD-10-CM |
| T39.4X2A | Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.4X2D | Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.4X2S | Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.8X2 | Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm | Diagnosis | ICD-10-CM |
| T39.8X2A | Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.8X2D | Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.8X2S | Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T39.92 | Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm | Diagnosis | ICD-10-CM |
| T39.92XA | Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T39.92XD | Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T39.92XS | Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.0X2 | Poisoning by opium, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.0X2A | Poisoning by opium, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.0X2D | Poisoning by opium, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.0X2S | Poisoning by opium, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.1X2 | Poisoning by heroin, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.1X2A | Poisoning by heroin, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.1X2D | Poisoning by heroin, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.1X2S | Poisoning by heroin, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.2X2 | Poisoning by other opioids, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.2X2A | Poisoning by other opioids, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T40.2X2D | Poisoning by other opioids, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.2X2S | Poisoning by other opioids, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.3X2 | Poisoning by methadone, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.3X2A | Poisoning by methadone, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.3X2D | Poisoning by methadone, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.3X2S | Poisoning by methadone, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.412 | Poisoning by fentanyl or fentanyl analogs, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.412A | Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.412D | Poisoning by fentanyl or fentanyl analogs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.412S | Poisoning by fentanyl or fentanyl analogs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.422 | Poisoning by tramadol, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.422A | Poisoning by tramadol, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.422D | Poisoning by tramadol, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.422S | Poisoning by tramadol, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.492 | Poisoning by other synthetic narcotics, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.492A | Poisoning by other synthetic narcotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.492D | Poisoning by other synthetic narcotics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.492S | Poisoning by other synthetic narcotics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.4X2 | Poisoning by other synthetic narcotics, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.4X2A | Poisoning by other synthetic narcotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.4X2D | Poisoning by other synthetic narcotics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.4X2S | Poisoning by other synthetic narcotics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.5X2 | Poisoning by cocaine, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.5X2A | Poisoning by cocaine, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.5X2D | Poisoning by cocaine, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.5X2S | Poisoning by cocaine, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.602 | Poisoning by unspecified narcotics, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.602A | Poisoning by unspecified narcotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.602D | Poisoning by unspecified narcotics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.602S | Poisoning by unspecified narcotics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.692 | Poisoning by other narcotics, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.692A | Poisoning by other narcotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.692D | Poisoning by other narcotics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.692S | Poisoning by other narcotics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.712 | Poisoning by cannabis, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.712A | Poisoning by cannabis, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.712D | Poisoning by cannabis, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.712S | Poisoning by cannabis, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.722 | Poisoning by synthetic cannabinoids, intentional self-harm | Diagnosis | ICD-10-CM |
| T40.722A | Poisoning by synthetic cannabinoids, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T40.722D | Poisoning by synthetic cannabinoids, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.722S | Poisoning by synthetic cannabinoids, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.7X2 | Poisoning by cannabis (derivatives), intentional self-harm | Diagnosis | ICD-10-CM |
| T40.7X2A | Poisoning by cannabis (derivatives), intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.7X2D | Poisoning by cannabis (derivatives), intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.7X2S | Poisoning by cannabis (derivatives), intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.8X2 | Poisoning by lysergide [LSD], intentional self-harm | Diagnosis | ICD-10-CM |
| T40.8X2A | Poisoning by lysergide [LSD], intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.8X2D | Poisoning by lysergide [LSD], intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.8X2S | Poisoning by lysergide [LSD], intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.902 | Poisoning by unspecified psychodysleptics [hallucinogens], intentional self- | Diagnosis | ICD-10-CM |
| T40.902A | Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.902D | Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.902S | Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T40.992 | Poisoning by other psychodysleptics [hallucinogens], intentional self-harm | Diagnosis | ICD-10-CM |
| T40.992A | Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.992D | Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T40.992S | Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.0X2 | Poisoning by inhaled anesthetics, intentional self-harm | Diagnosis | ICD-10-CM |
| T41.0X2A | Poisoning by inhaled anesthetics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.0X2D | Poisoning by inhaled anesthetics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.0X2S | Poisoning by inhaled anesthetics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.1X2 | Poisoning by intravenous anesthetics, intentional self-harm | Diagnosis | ICD-10-CM |
| T41.1X2A | Poisoning by intravenous anesthetics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.1X2D | Poisoning by intravenous anesthetics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.1X2S | Poisoning by intravenous anesthetics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.202 | Poisoning by unspecified general anesthetics, intentional self-harm | Diagnosis | ICD-10-CM |
| T41.202A | Poisoning by unspecified general anesthetics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.202D | Poisoning by unspecified general anesthetics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.202S | Poisoning by unspecified general anesthetics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.292 | Poisoning by other general anesthetics, intentional self-harm | Diagnosis | ICD-10-CM |
| T41.292A | Poisoning by other general anesthetics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T41.292D | Poisoning by other general anesthetics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.292S | Poisoning by other general anesthetics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.3X2 | Poisoning by local anesthetics, intentional self-harm | Diagnosis | ICD-10-CM |
| T41.3X2A | Poisoning by local anesthetics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.3X2D | Poisoning by local anesthetics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.3X2S | Poisoning by local anesthetics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.42 | Poisoning by unspecified anesthetic, intentional self-harm | Diagnosis | ICD-10-CM |
| T41.42XA | Poisoning by unspecified anesthetic, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.42XD | Poisoning by unspecified anesthetic, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.42XS | Poisoning by unspecified anesthetic, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T41.5X2 | Poisoning by therapeutic gases, intentional self-harm | Diagnosis | ICD-10-CM |
| T41.5X2A | Poisoning by therapeutic gases, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T41.5X2D | Poisoning by therapeutic gases, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T41.5X2S | Poisoning by therapeutic gases, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.0X2 | Poisoning by hydantoin derivatives, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.0X2A | Poisoning by hydantoin derivatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.0X2D | Poisoning by hydantoin derivatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.0X2S | Poisoning by hydantoin derivatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.1X2 | Poisoning by iminostilbenes, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.1X2A | Poisoning by iminostilbenes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.1X2D | Poisoning by iminostilbenes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.1X2S | Poisoning by iminostilbenes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.2X2 | Poisoning by succinimides and oxazolidinediones, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.2X2A | Poisoning by succinimides and oxazolidinediones, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.2X2D | Poisoning by succinimides and oxazolidinediones, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.2X2S | Poisoning by succinimides and oxazolidinediones, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.3X2 | Poisoning by barbiturates, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.3X2A | Poisoning by barbiturates, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.3X2D | Poisoning by barbiturates, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.3X2S | Poisoning by barbiturates, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.4X2 | Poisoning by benzodiazepines, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.4X2A | Poisoning by benzodiazepines, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.4X2D | Poisoning by benzodiazepines, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.4X2S | Poisoning by benzodiazepines, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.5X2 | Poisoning by mixed antiepileptics, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.5X2A | Poisoning by mixed antiepileptics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.5X2D | Poisoning by mixed antiepileptics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.5X2S | Poisoning by mixed antiepileptics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T42.6X2 | Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.6X2A | Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.6X2D | Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.6X2S | Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.72 | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.72XA | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.72XD | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.72XS | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T42.8X2 | Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm | Diagnosis | ICD-10-CM |
| T42.8X2A | Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T42.8X2D | Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T42.8X2S | Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.012 | Poisoning by tricyclic antidepressants, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.012A | Poisoning by tricyclic antidepressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.012D | Poisoning by tricyclic antidepressants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.012S | Poisoning by tricyclic antidepressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.022 | Poisoning by tetracyclic antidepressants, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.022A | Poisoning by tetracyclic antidepressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.022D | Poisoning by tetracyclic antidepressants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.022S | Poisoning by tetracyclic antidepressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.1X2 | Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.1X2A | Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.1X2D | Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.1X2S | Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.202 | Poisoning by unspecified antidepressants, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T43.202A | Poisoning by unspecified antidepressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.202D | Poisoning by unspecified antidepressants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.202S | Poisoning by unspecified antidepressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.212 | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.212A | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.212D | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.212S | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.222 | Poisoning by selective serotonin reuptake inhibitors, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.222A | Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.222D | Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.222S | Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.292 | Poisoning by other antidepressants, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.292A | Poisoning by other antidepressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.292D | Poisoning by other antidepressants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.292S | Poisoning by other antidepressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.3X2 | Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.3X2A | Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.3X2D | Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.3X2S | Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.4X2 | Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.4X2A | Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.4X2D | Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.4X2S | Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.502 | Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.502A | Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T43.502D | Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.502S | Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.592 | Poisoning by other antipsychotics and neuroleptics, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.592A | Poisoning by other antipsychotics and neuroleptics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.592D | Poisoning by other antipsychotics and neuroleptics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.592S | Poisoning by other antipsychotics and neuroleptics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.602 | Poisoning by unspecified psychostimulants, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.602A | Poisoning by unspecified psychostimulants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.602D | Poisoning by unspecified psychostimulants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.602S | Poisoning by unspecified psychostimulants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.612 | Poisoning by caffeine, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.612A | Poisoning by caffeine, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.612D | Poisoning by caffeine, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.612S | Poisoning by caffeine, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.622 | Poisoning by amphetamines, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.622A | Poisoning by amphetamines, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.622D | Poisoning by amphetamines, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.622S | Poisoning by amphetamines, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.632 | Poisoning by methylphenidate, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.632A | Poisoning by methylphenidate, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.632D | Poisoning by methylphenidate, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.632S | Poisoning by methylphenidate, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.642 | Poisoning by ecstasy, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.642A | Poisoning by ecstasy, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.642D | Poisoning by ecstasy, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.642S | Poisoning by ecstasy, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.692 | Poisoning by other psychostimulants, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.692A | Poisoning by other psychostimulants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.692D | Poisoning by other psychostimulants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.692S | Poisoning by other psychostimulants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.8X2 | Poisoning by other psychotropic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T43.8X2A | Poisoning by other psychotropic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.8X2D | Poisoning by other psychotropic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.8X2S | Poisoning by other psychotropic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T43.92 | Poisoning by unspecified psychotropic drug, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T43.92XA | Poisoning by unspecified psychotropic drug, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T43.92XD | Poisoning by unspecified psychotropic drug, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T43.92XS | Poisoning by unspecified psychotropic drug, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.0X2 | Poisoning by anticholinesterase agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.0X2A | Poisoning by anticholinesterase agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.0X2D | Poisoning by anticholinesterase agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.0X2S | Poisoning by anticholinesterase agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.1X2 | Poisoning by other parasympathomimetics [cholinergics], intentional self-harm | Diagnosis | ICD-10-CM |
| T44.1X2A | Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.1X2D | Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.1X2S | Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.2X2 | Poisoning by ganglionic blocking drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.2X2A | Poisoning by ganglionic blocking drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.2X2D | Poisoning by ganglionic blocking drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.2X2S | Poisoning by ganglionic blocking drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.3X2 | Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.3X2A | Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.3X2D | Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.3X2S | Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.4X2 | Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.4X2A | Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.4X2D | Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.4X2S | Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.5X2 | Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.5X2A | Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.5X2D | Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T44.5X2S | Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.6X2 | Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.6X2A | Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.6X2D | Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.6X2S | Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.7X2 | Poisoning by beta-adrenoreceptor antagonists, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.7X2A | Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.7X2D | Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.7X2S | Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.8X2 | Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.8X2A | Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.8X2D | Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.8X2S | Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.902 | Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.902A | Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.902D | Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.902S | Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T44.992 | Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm | Diagnosis | ICD-10-CM |
| T44.992A | Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T44.992D | Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T44.992S | Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.0X2 | Poisoning by antiallergic and antiemetic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.0X2A | Poisoning by antiallergic and antiemetic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.0X2D | Poisoning by antiallergic and antiemetic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.0X2S | Poisoning by antiallergic and antiemetic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T45.1X2 | Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.1X2A | Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.1X2D | Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.1X2S | Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.2X2 | Poisoning by vitamins, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.2X2A | Poisoning by vitamins, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.2X2D | Poisoning by vitamins, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.2X2S | Poisoning by vitamins, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.3X2 | Poisoning by enzymes, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.3X2A | Poisoning by enzymes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.3X2D | Poisoning by enzymes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.3X2S | Poisoning by enzymes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.4X2 | Poisoning by iron and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.4X2A | Poisoning by iron and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.4X2D | Poisoning by iron and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.4X2S | Poisoning by iron and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.512 | Poisoning by anticoagulants, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.512A | Poisoning by anticoagulants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.512D | Poisoning by anticoagulants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.512S | Poisoning by anticoagulants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.522 | Poisoning by antithrombotic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.522A | Poisoning by antithrombotic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.522D | Poisoning by antithrombotic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.522S | Poisoning by antithrombotic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.602 | Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.602A | Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.602D | Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.602S | Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.612 | Poisoning by thrombolytic drug, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.612A | Poisoning by thrombolytic drug, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.612D | Poisoning by thrombolytic drug, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.612S | Poisoning by thrombolytic drug, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.622 | Poisoning by hemostatic drug, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.622A | Poisoning by hemostatic drug, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.622D | Poisoning by hemostatic drug, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T45.622S | Poisoning by hemostatic drug, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.692 | Poisoning by other fibrinolysis-affecting drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.692A | Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.692D | Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.692S | Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.7X2 | Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.7X2A | Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.7X2D | Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.7X2S | Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.8X2 | Poisoning by other primarily systemic and hematological agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.8X2A | Poisoning by other primarily systemic and hematological agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.8X2D | Poisoning by other primarily systemic and hematological agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.8X2S | Poisoning by other primarily systemic and hematological agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T45.92 | Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm | Diagnosis | ICD-10-CM |
| T45.92XA | Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T45.92XD | Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T45.92XS | Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.0X2 | Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.0X2A | Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.0X2D | Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.0X2S | Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.1X2 | Poisoning by calcium-channel blockers, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.1X2A | Poisoning by calcium-channel blockers, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.1X2D | Poisoning by calcium-channel blockers, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.1X2S | Poisoning by calcium-channel blockers, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T46.2X2 | Poisoning by other antidysrhythmic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.2X2A | Poisoning by other antidysrhythmic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.2X2D | Poisoning by other antidysrhythmic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.2X2S | Poisoning by other antidysrhythmic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.3X2 | Poisoning by coronary vasodilators, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.3X2A | Poisoning by coronary vasodilators, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.3X2D | Poisoning by coronary vasodilators, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.3X2S | Poisoning by coronary vasodilators, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.4X2 | Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.4X2A | Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.4X2D | Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.4X2S | Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.5X2 | Poisoning by other antihypertensive drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.5X2A | Poisoning by other antihypertensive drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.5X2D | Poisoning by other antihypertensive drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.5X2S | Poisoning by other antihypertensive drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.6X2 | Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.6X2A | Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.6X2D | Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.6X2S | Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.7X2 | Poisoning by peripheral vasodilators, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.7X2A | Poisoning by peripheral vasodilators, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.7X2D | Poisoning by peripheral vasodilators, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.7X2S | Poisoning by peripheral vasodilators, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.8X2 | Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.8X2A | Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.8X2D | Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T46.8X2S | Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.902 | Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.902A | Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.902D | Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.902S | Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T46.992 | Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm | Diagnosis | ICD-10-CM |
| T46.992A | Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T46.992D | Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T46.992S | Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.0X2 | Poisoning by histamine H2-receptor blockers, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.0X2A | Poisoning by histamine H2-receptor blockers, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.0X2D | Poisoning by histamine H2-receptor blockers, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.0X2S | Poisoning by histamine H2-receptor blockers, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.1X2 | Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.1X2A | Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.1X2D | Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.1X2S | Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.2X2 | Poisoning by stimulant laxatives, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.2X2A | Poisoning by stimulant laxatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.2X2D | Poisoning by stimulant laxatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.2X2S | Poisoning by stimulant laxatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.3X2 | Poisoning by saline and osmotic laxatives, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.3X2A | Poisoning by saline and osmotic laxatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.3X2D | Poisoning by saline and osmotic laxatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.3X2S | Poisoning by saline and osmotic laxatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.4X2 | Poisoning by other laxatives, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.4X2A | Poisoning by other laxatives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T47.4X2D | Poisoning by other laxatives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.4X2S | Poisoning by other laxatives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.5X2 | Poisoning by digestants, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.5X2A | Poisoning by digestants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.5X2D | Poisoning by digestants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.5X2S | Poisoning by digestants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.6X2 | Poisoning by antidiarrheal drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.6X2A | Poisoning by antidiarrheal drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.6X2D | Poisoning by antidiarrheal drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.6X2S | Poisoning by antidiarrheal drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.7X2 | Poisoning by emetics, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.7X2A | Poisoning by emetics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.7X2D | Poisoning by emetics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.7X2S | Poisoning by emetics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.8X2 | Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.8X2A | Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.8X2D | Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.8X2S | Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T47.92 | Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm | Diagnosis | ICD-10-CM |
| T47.92XA | Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T47.92XD | Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T47.92XS | Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.0X2 | Poisoning by oxytocic drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.0X2A | Poisoning by oxytocic drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.0X2D | Poisoning by oxytocic drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.0X2S | Poisoning by oxytocic drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.1X2 | Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm | Diagnosis | ICD-10-CM |
| T48.1X2A | Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.1X2D | Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.1X2S | Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.202 | Poisoning by unspecified drugs acting on muscles, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T48.202A | Poisoning by unspecified drugs acting on muscles, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.202D | Poisoning by unspecified drugs acting on muscles, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.202S | Poisoning by unspecified drugs acting on muscles, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.292 | Poisoning by other drugs acting on muscles, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.292A | Poisoning by other drugs acting on muscles, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.292D | Poisoning by other drugs acting on muscles, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.292S | Poisoning by other drugs acting on muscles, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.3X2 | Poisoning by antitussives, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.3X2A | Poisoning by antitussives, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.3X2D | Poisoning by antitussives, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.3X2S | Poisoning by antitussives, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.4X2 | Poisoning by expectorants, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.4X2A | Poisoning by expectorants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.4X2D | Poisoning by expectorants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.4X2S | Poisoning by expectorants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.5X2 | Poisoning by other anti-common-cold drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.5X2A | Poisoning by other anti-common-cold drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.5X2D | Poisoning by other anti-common-cold drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.5X2S | Poisoning by other anti-common-cold drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.6X2 | Poisoning by antiasthmatics, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.6X2A | Poisoning by antiasthmatics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.6X2D | Poisoning by antiasthmatics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.6X2S | Poisoning by antiasthmatics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.902 | Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.902A | Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.902D | Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T48.902S | Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T48.992 | Poisoning by other agents primarily acting on the respiratory system, intentional self-harm | Diagnosis | ICD-10-CM |
| T48.992A | Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T48.992D | Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T48.992S | Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.0X2 | Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.0X2A | Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.0X2D | Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.0X2S | Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.1X2 | Poisoning by antipruritics, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.1X2A | Poisoning by antipruritics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.1X2D | Poisoning by antipruritics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.1X2S | Poisoning by antipruritics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.2X2 | Poisoning by local astringents and local detergents, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.2X2A | Poisoning by local astringents and local detergents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.2X2D | Poisoning by local astringents and local detergents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.2X2S | Poisoning by local astringents and local detergents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.3X2 | Poisoning by emollients, demulcents and protectants, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.3X2A | Poisoning by emollients, demulcents and protectants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.3X2D | Poisoning by emollients, demulcents and protectants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.3X2S | Poisoning by emollients, demulcents and protectants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.4X2 | Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.4X2A | Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.4X2D | Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.4X2S | Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.5X2 | Poisoning by ophthalmological drugs and preparations, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.5X2A | Poisoning by ophthalmological drugs and preparations, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.5X2D | Poisoning by ophthalmological drugs and preparations, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.5X2S | Poisoning by ophthalmological drugs and preparations, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T49.6X2 | Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.6X2A | Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.6X2D | Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.6X2S | Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.7X2 | Poisoning by dental drugs, topically applied, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.7X2A | Poisoning by dental drugs, topically applied, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.7X2D | Poisoning by dental drugs, topically applied, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.7X2S | Poisoning by dental drugs, topically applied, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.8X2 | Poisoning by other topical agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.8X2A | Poisoning by other topical agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.8X2D | Poisoning by other topical agents, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T49.8X2S | Poisoning by other topical agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T49.92 | Poisoning by unspecified topical agent, intentional self-harm | Diagnosis | ICD-10-CM |
| T49.92XA | Poisoning by unspecified topical agent, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T49.92XD | Poisoning by unspecified topical agent, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T49.92XS | Poisoning by unspecified topical agent, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.0X2 | Poisoning by mineralocorticoids and their antagonists, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.0X2A | Poisoning by mineralocorticoids and their antagonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.0X2D | Poisoning by mineralocorticoids and their antagonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.0X2S | Poisoning by mineralocorticoids and their antagonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.1X2 | Poisoning by loop [high-ceiling] diuretics, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.1X2A | Poisoning by loop [high-ceiling] diuretics, intentional self-harm, initial | Diagnosis | ICD-10-CM |
| T50.1X2D | Poisoning by loop [high-ceiling] diuretics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.1X2S | Poisoning by loop [high-ceiling] diuretics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.2X2 | Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.2X2A | Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.2X2D | Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.2X2S | Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T50.3X2 | Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.3X2A | Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.3X2D | Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.3X2S | Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.4X2 | Poisoning by drugs affecting uric acid metabolism, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.4X2A | Poisoning by drugs affecting uric acid metabolism, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.4X2D | Poisoning by drugs affecting uric acid metabolism, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.4X2S | Poisoning by drugs affecting uric acid metabolism, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.5X2 | Poisoning by appetite depressants, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.5X2A | Poisoning by appetite depressants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.5X2D | Poisoning by appetite depressants, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T50.5X2S | Poisoning by appetite depressants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.6X2 | Poisoning by antidotes and chelating agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.6X2A | Poisoning by antidotes and chelating agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.6X2D | Poisoning by antidotes and chelating agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.6X2S | Poisoning by antidotes and chelating agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.7X2 | Poisoning by analeptics and opioid receptor antagonists, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.7X2A | Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.7X2D | Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.7X2S | Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.8X2 | Poisoning by diagnostic agents, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.8X2A | Poisoning by diagnostic agents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.8X2D | Poisoning by diagnostic agents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.8X2S | Poisoning by diagnostic agents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.902 | Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.902A | Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.902D | Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.902S | Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T50.912 | Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.912A | Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.912D | Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.912S | Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.992 | Poisoning by other drugs, medicaments and biological substances, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.992A | Poisoning by other drugs, medicaments and biological substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.992D | Poisoning by other drugs, medicaments and biological substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.992S | Poisoning by other drugs, medicaments and biological substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.A12 | Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.A12A | Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.A12D | Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.A12S | Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.A22 | Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.A22A | Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.A22D | Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.A22S | Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.A92 | Poisoning by other bacterial vaccines, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.A92A | Poisoning by other bacterial vaccines, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.A92D | Poisoning by other bacterial vaccines, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.A92S | Poisoning by other bacterial vaccines, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.B12 | Poisoning by smallpox vaccines, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.B12A | Poisoning by smallpox vaccines, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.B12D | Poisoning by smallpox vaccines, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.B12S | Poisoning by smallpox vaccines, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.B92 | Poisoning by other viral vaccines, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.B92A | Poisoning by other viral vaccines, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.B92D | Poisoning by other viral vaccines, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--------------------------------|--|---------------|-----------|
| T50.B92S | Poisoning by other viral vaccines, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.Z12 | Poisoning by immunoglobulin, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.Z12A | Poisoning by immunoglobulin, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.Z12D | Poisoning by immunoglobulin, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.Z12S | Poisoning by immunoglobulin, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T50.Z92 | Poisoning by other vaccines and biological substances, intentional self-harm | Diagnosis | ICD-10-CM |
| T50.Z92A | Poisoning by other vaccines and biological substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T50.Z92D | Poisoning by other vaccines and biological substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T50.Z92S | Poisoning by other vaccines and biological substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| Self Harm - Suffocation | | | |
| T71.112 | Asphyxiation due to smothering under pillow, intentional self-harm | Diagnosis | ICD-10-CM |
| T71.112A | Asphyxiation due to smothering under pillow, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.112D | Asphyxiation due to smothering under pillow, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.112S | Asphyxiation due to smothering under pillow, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.122 | Asphyxiation due to plastic bag, intentional self-harm | Diagnosis | ICD-10-CM |
| T71.122A | Asphyxiation due to plastic bag, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.122D | Asphyxiation due to plastic bag, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.122S | Asphyxiation due to plastic bag, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.132 | Asphyxiation due to being trapped in bed linens, intentional self-harm | Diagnosis | ICD-10-CM |
| T71.132A | Asphyxiation due to being trapped in bed linens, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.132D | Asphyxiation due to being trapped in bed linens, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.132S | Asphyxiation due to being trapped in bed linens, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.152 | Asphyxiation due to smothering in furniture, intentional self-harm | Diagnosis | ICD-10-CM |
| T71.152A | Asphyxiation due to smothering in furniture, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.152D | Asphyxiation due to smothering in furniture, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.152S | Asphyxiation due to smothering in furniture, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.162 | Asphyxiation due to hanging, intentional self-harm | Diagnosis | ICD-10-CM |
| T71.162A | Asphyxiation due to hanging, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.162D | Asphyxiation due to hanging, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.162S | Asphyxiation due to hanging, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.192 | Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm | Diagnosis | ICD-10-CM |
| T71.192A | Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|-----------------------------|---|---------------|-----------|
| T71.192D | Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.192S | Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.222 | Asphyxiation due to being trapped in a car trunk, intentional self-harm | Diagnosis | ICD-10-CM |
| T71.222A | Asphyxiation due to being trapped in a car trunk, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.222D | Asphyxiation due to being trapped in a car trunk, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.222S | Asphyxiation due to being trapped in a car trunk, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T71.232 | Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm | Diagnosis | ICD-10-CM |
| T71.232A | Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T71.232D | Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T71.232S | Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| Suicide Attempt | | | |
| T14.91 | Suicide attempt | Diagnosis | ICD-10-CM |
| T14.91XA | Suicide attempt, initial encounter | Diagnosis | ICD-10-CM |
| T14.91XD | Suicide attempt, subsequent encounter | Diagnosis | ICD-10-CM |
| T14.91XS | Suicide attempt, sequela | Diagnosis | ICD-10-CM |
| Self-Harm - Toxicity | | | |
| T51.0X2 | Toxic effect of ethanol, intentional self-harm | Diagnosis | ICD-10-CM |
| T51.0X2A | Toxic effect of ethanol, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T51.0X2D | Toxic effect of ethanol, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T51.0X2S | Toxic effect of ethanol, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T51.1X2 | Toxic effect of methanol, intentional self-harm | Diagnosis | ICD-10-CM |
| T51.1X2A | Toxic effect of methanol, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T51.1X2D | Toxic effect of methanol, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T51.1X2S | Toxic effect of methanol, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T51.2X2 | Toxic effect of 2-Propanol, intentional self-harm | Diagnosis | ICD-10-CM |
| T51.2X2A | Toxic effect of 2-Propanol, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T51.2X2D | Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T51.2X2S | Toxic effect of 2-Propanol, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T51.3X2 | Toxic effect of fusel oil, intentional self-harm | Diagnosis | ICD-10-CM |
| T51.3X2A | Toxic effect of fusel oil, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T51.3X2D | Toxic effect of fusel oil, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T51.3X2S | Toxic effect of fusel oil, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T51.8X2 | Toxic effect of other alcohols, intentional self-harm | Diagnosis | ICD-10-CM |
| T51.8X2A | Toxic effect of other alcohols, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T51.8X2D | Toxic effect of other alcohols, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T51.8X2S | Toxic effect of other alcohols, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T51.92 | Toxic effect of unspecified alcohol, intentional self-harm | Diagnosis | ICD-10-CM |
| T51.92XA | Toxic effect of unspecified alcohol, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T51.92XD | Toxic effect of unspecified alcohol, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T51.92XS | Toxic effect of unspecified alcohol, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.0X2 | Toxic effect of petroleum products, intentional self-harm | Diagnosis | ICD-10-CM |
| T52.0X2A | Toxic effect of petroleum products, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.0X2D | Toxic effect of petroleum products, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T52.0X2S | Toxic effect of petroleum products, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.1X2 | Toxic effect of benzene, intentional self-harm | Diagnosis | ICD-10-CM |
| T52.1X2A | Toxic effect of benzene, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.1X2D | Toxic effect of benzene, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T52.1X2S | Toxic effect of benzene, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.2X2 | Toxic effect of homologues of benzene, intentional self-harm | Diagnosis | ICD-10-CM |
| T52.2X2A | Toxic effect of homologues of benzene, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.2X2D | Toxic effect of homologues of benzene, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T52.2X2S | Toxic effect of homologues of benzene, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.3X2 | Toxic effect of glycols, intentional self-harm | Diagnosis | ICD-10-CM |
| T52.3X2A | Toxic effect of glycols, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.3X2D | Toxic effect of glycols, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T52.3X2S | Toxic effect of glycols, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.4X2 | Toxic effect of ketones, intentional self-harm | Diagnosis | ICD-10-CM |
| T52.4X2A | Toxic effect of ketones, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.4X2D | Toxic effect of ketones, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T52.4X2S | Toxic effect of ketones, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.8X2 | Toxic effect of other organic solvents, intentional self-harm | Diagnosis | ICD-10-CM |
| T52.8X2A | Toxic effect of other organic solvents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.8X2D | Toxic effect of other organic solvents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T52.8X2S | Toxic effect of other organic solvents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T52.92 | Toxic effect of unspecified organic solvent, intentional self-harm | Diagnosis | ICD-10-CM |
| T52.92XA | Toxic effect of unspecified organic solvent, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T52.92XD | Toxic effect of unspecified organic solvent, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T52.92XS | Toxic effect of unspecified organic solvent, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.0X2 | Toxic effect of carbon tetrachloride, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.0X2A | Toxic effect of carbon tetrachloride, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.0X2D | Toxic effect of carbon tetrachloride, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.0X2S | Toxic effect of carbon tetrachloride, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.1X2 | Toxic effect of chloroform, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.1X2A | Toxic effect of chloroform, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.1X2D | Toxic effect of chloroform, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T53.1X2S | Toxic effect of chloroform, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.2X2 | Toxic effect of trichloroethylene, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.2X2A | Toxic effect of trichloroethylene, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.2X2D | Toxic effect of trichloroethylene, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.2X2S | Toxic effect of trichloroethylene, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.3X2 | Toxic effect of tetrachloroethylene, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.3X2A | Toxic effect of tetrachloroethylene, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.3X2D | Toxic effect of tetrachloroethylene, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T53.3X2S | Toxic effect of tetrachloroethylene, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.4X2 | Toxic effect of dichloromethane, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.4X2A | Toxic effect of dichloromethane, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.4X2D | Toxic effect of dichloromethane, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.4X2S | Toxic effect of dichloromethane, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.5X2 | Toxic effect of chlorofluorocarbons, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.5X2A | Toxic effect of chlorofluorocarbons, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.5X2D | Toxic effect of chlorofluorocarbons, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.5X2S | Toxic effect of chlorofluorocarbons, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.6X2 | Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.6X2A | Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.6X2D | Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.6X2S | Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.7X2 | Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.7X2A | Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.7X2D | Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.7X2S | Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T53.92 | Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm | Diagnosis | ICD-10-CM |
| T53.92XA | Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T53.92XD | Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T53.92XS | Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T54.0X2 | Toxic effect of phenol and phenol homologues, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T54.0X2A | Toxic effect of phenol and phenol homologues, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T54.0X2D | Toxic effect of phenol and phenol homologues, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T54.0X2S | Toxic effect of phenol and phenol homologues, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T54.1X2 | Toxic effect of other corrosive organic compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T54.1X2A | Toxic effect of other corrosive organic compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T54.1X2D | Toxic effect of other corrosive organic compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T54.1X2S | Toxic effect of other corrosive organic compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T54.2X2 | Toxic effect of corrosive acids and acid-like substances, intentional self-harm | Diagnosis | ICD-10-CM |
| T54.2X2A | Toxic effect of corrosive acids and acid-like substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T54.2X2D | Toxic effect of corrosive acids and acid-like substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T54.2X2S | Toxic effect of corrosive acids and acid-like substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T54.3X2 | Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm | Diagnosis | ICD-10-CM |
| T54.3X2A | Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T54.3X2D | Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T54.3X2S | Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T54.92 | Toxic effect of unspecified corrosive substance, intentional self-harm | Diagnosis | ICD-10-CM |
| T54.92XA | Toxic effect of unspecified corrosive substance, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T54.92XD | Toxic effect of unspecified corrosive substance, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T54.92XS | Toxic effect of unspecified corrosive substance, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T55.0X2 | Toxic effect of soaps, intentional self-harm | Diagnosis | ICD-10-CM |
| T55.0X2A | Toxic effect of soaps, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T55.0X2D | Toxic effect of soaps, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T55.0X2S | Toxic effect of soaps, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T55.1X2 | Toxic effect of detergents, intentional self-harm | Diagnosis | ICD-10-CM |
| T55.1X2A | Toxic effect of detergents, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T55.1X2D | Toxic effect of detergents, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T55.1X2S | Toxic effect of detergents, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.0X2 | Toxic effect of lead and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.0X2A | Toxic effect of lead and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.0X2D | Toxic effect of lead and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T56.0X2S | Toxic effect of lead and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.1X2 | Toxic effect of mercury and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.1X2A | Toxic effect of mercury and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.1X2D | Toxic effect of mercury and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.1X2S | Toxic effect of mercury and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.2X2 | Toxic effect of chromium and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.2X2A | Toxic effect of chromium and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.2X2D | Toxic effect of chromium and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.2X2S | Toxic effect of chromium and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.3X2 | Toxic effect of cadmium and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.3X2A | Toxic effect of cadmium and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.3X2D | Toxic effect of cadmium and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.3X2S | Toxic effect of cadmium and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.4X2 | Toxic effect of copper and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.4X2A | Toxic effect of copper and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.4X2D | Toxic effect of copper and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.4X2S | Toxic effect of copper and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.5X2 | Toxic effect of zinc and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.5X2A | Toxic effect of zinc and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.5X2D | Toxic effect of zinc and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.5X2S | Toxic effect of zinc and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.6X2 | Toxic effect of tin and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.6X2A | Toxic effect of tin and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.6X2D | Toxic effect of tin and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.6X2S | Toxic effect of tin and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.7X2 | Toxic effect of beryllium and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.7X2A | Toxic effect of beryllium and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.7X2D | Toxic effect of beryllium and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.7X2S | Toxic effect of beryllium and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.812 | Toxic effect of thallium, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.812A | Toxic effect of thallium, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.812D | Toxic effect of thallium, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T56.812S | Toxic effect of thallium, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.892 | Toxic effect of other metals, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.892A | Toxic effect of other metals, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.892D | Toxic effect of other metals, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.892S | Toxic effect of other metals, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T56.92 | Toxic effect of unspecified metal, intentional self-harm | Diagnosis | ICD-10-CM |
| T56.92XA | Toxic effect of unspecified metal, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T56.92XD | Toxic effect of unspecified metal, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T56.92XS | Toxic effect of unspecified metal, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T57.0X2 | Toxic effect of arsenic and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T57.0X2A | Toxic effect of arsenic and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T57.0X2D | Toxic effect of arsenic and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T57.0X2S | Toxic effect of arsenic and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T57.1X2 | Toxic effect of phosphorus and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T57.1X2A | Toxic effect of phosphorus and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T57.1X2D | Toxic effect of phosphorus and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T57.1X2S | Toxic effect of phosphorus and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T57.2X2 | Toxic effect of manganese and its compounds, intentional self-harm | Diagnosis | ICD-10-CM |
| T57.2X2A | Toxic effect of manganese and its compounds, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T57.2X2D | Toxic effect of manganese and its compounds, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T57.2X2S | Toxic effect of manganese and its compounds, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T57.3X2 | Toxic effect of hydrogen cyanide, intentional self-harm | Diagnosis | ICD-10-CM |
| T57.3X2A | Toxic effect of hydrogen cyanide, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T57.3X2D | Toxic effect of hydrogen cyanide, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T57.3X2S | Toxic effect of hydrogen cyanide, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T57.8X2 | Toxic effect of other specified inorganic substances, intentional self-harm | Diagnosis | ICD-10-CM |
| T57.8X2A | Toxic effect of other specified inorganic substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T57.8X2D | Toxic effect of other specified inorganic substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T57.8X2S | Toxic effect of other specified inorganic substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T57.92 | Toxic effect of unspecified inorganic substance, intentional self-harm | Diagnosis | ICD-10-CM |
| T57.92XA | Toxic effect of unspecified inorganic substance, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T57.92XD | Toxic effect of unspecified inorganic substance, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T57.92XS | Toxic effect of unspecified inorganic substance, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T58.02 | Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm | Diagnosis | ICD-10-CM |
| T58.02XA | Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T58.02XD | Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T58.02XS | Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T58.12 | Toxic effect of carbon monoxide from utility gas, intentional self-harm | Diagnosis | ICD-10-CM |
| T58.12XA | Toxic effect of carbon monoxide from utility gas, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T58.12XD | Toxic effect of carbon monoxide from utility gas, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T58.12XS | Toxic effect of carbon monoxide from utility gas, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T58.2X2 | Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm | Diagnosis | ICD-10-CM |
| T58.2X2A | Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T58.2X2D | Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T58.2X2S | Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T58.8X2 | Toxic effect of carbon monoxide from other source, intentional self-harm | Diagnosis | ICD-10-CM |
| T58.8X2A | Toxic effect of carbon monoxide from other source, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T58.8X2D | Toxic effect of carbon monoxide from other source, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T58.8X2S | Toxic effect of carbon monoxide from other source, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T58.92 | Toxic effect of carbon monoxide from unspecified source, intentional self-harm | Diagnosis | ICD-10-CM |
| T58.92XA | Toxic effect of carbon monoxide from unspecified source, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T58.92XD | Toxic effect of carbon monoxide from unspecified source, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T58.92XS | Toxic effect of carbon monoxide from unspecified source, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.0X2 | Toxic effect of nitrogen oxides, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.0X2A | Toxic effect of nitrogen oxides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.0X2D | Toxic effect of nitrogen oxides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.0X2S | Toxic effect of nitrogen oxides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.1X2 | Toxic effect of sulfur dioxide, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.1X2A | Toxic effect of sulfur dioxide, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.1X2D | Toxic effect of sulfur dioxide, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.1X2S | Toxic effect of sulfur dioxide, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T59.2X2 | Toxic effect of formaldehyde, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.2X2A | Toxic effect of formaldehyde, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.2X2D | Toxic effect of formaldehyde, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.2X2S | Toxic effect of formaldehyde, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.3X2 | Toxic effect of lacrimogenic gas, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.3X2A | Toxic effect of lacrimogenic gas, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.3X2D | Toxic effect of lacrimogenic gas, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.3X2S | Toxic effect of lacrimogenic gas, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.4X2 | Toxic effect of chlorine gas, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.4X2A | Toxic effect of chlorine gas, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.4X2D | Toxic effect of chlorine gas, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.4X2S | Toxic effect of chlorine gas, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.5X2 | Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.5X2A | Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.5X2D | Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.5X2S | Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.6X2 | Toxic effect of hydrogen sulfide, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.6X2A | Toxic effect of hydrogen sulfide, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.6X2D | Toxic effect of hydrogen sulfide, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.6X2S | Toxic effect of hydrogen sulfide, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.7X2 | Toxic effect of carbon dioxide, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.7X2A | Toxic effect of carbon dioxide, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.7X2D | Toxic effect of carbon dioxide, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.7X2S | Toxic effect of carbon dioxide, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.812 | Toxic effect of smoke, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.812A | Toxic effect of smoke, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.812D | Toxic effect of smoke, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.812S | Toxic effect of smoke, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.892 | Toxic effect of other specified gases, fumes and vapors, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.892A | Toxic effect of other specified gases, fumes and vapors, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.892D | Toxic effect of other specified gases, fumes and vapors, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.892S | Toxic effect of other specified gases, fumes and vapors, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T59.92 | Toxic effect of unspecified gases, fumes and vapors, intentional self-harm | Diagnosis | ICD-10-CM |
| T59.92XA | Toxic effect of unspecified gases, fumes and vapors, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T59.92XD | Toxic effect of unspecified gases, fumes and vapors, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T59.92XS | Toxic effect of unspecified gases, fumes and vapors, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T60.0X2 | Toxic effect of organophosphate and carbamate insecticides, intentional self-harm | Diagnosis | ICD-10-CM |
| T60.0X2A | Toxic effect of organophosphate and carbamate insecticides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.0X2D | Toxic effect of organophosphate and carbamate insecticides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.0X2S | Toxic effect of organophosphate and carbamate insecticides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.1X2 | Toxic effect of halogenated insecticides, intentional self-harm | Diagnosis | ICD-10-CM |
| T60.1X2A | Toxic effect of halogenated insecticides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.1X2D | Toxic effect of halogenated insecticides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.1X2S | Toxic effect of halogenated insecticides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.2X2 | Toxic effect of other insecticides, intentional self-harm | Diagnosis | ICD-10-CM |
| T60.2X2A | Toxic effect of other insecticides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.2X2D | Toxic effect of other insecticides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.2X2S | Toxic effect of other insecticides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.3X2 | Toxic effect of herbicides and fungicides, intentional self-harm | Diagnosis | ICD-10-CM |
| T60.3X2A | Toxic effect of herbicides and fungicides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.3X2D | Toxic effect of herbicides and fungicides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.3X2S | Toxic effect of herbicides and fungicides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.4X2 | Toxic effect of rodenticides, intentional self-harm | Diagnosis | ICD-10-CM |
| T60.4X2A | Toxic effect of rodenticides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.4X2D | Toxic effect of rodenticides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.4X2S | Toxic effect of rodenticides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.8X2 | Toxic effect of other pesticides, intentional self-harm | Diagnosis | ICD-10-CM |
| T60.8X2A | Toxic effect of other pesticides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.8X2D | Toxic effect of other pesticides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.8X2S | Toxic effect of other pesticides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T60.92 | Toxic effect of unspecified pesticide, intentional self-harm | Diagnosis | ICD-10-CM |
| T60.92XA | Toxic effect of unspecified pesticide, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T60.92XD | Toxic effect of unspecified pesticide, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T60.92XS | Toxic effect of unspecified pesticide, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T61.02 | Ciguatera fish poisoning, intentional self-harm | Diagnosis | ICD-10-CM |
| T61.02XA | Ciguatera fish poisoning, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T61.02XD | Ciguatera fish poisoning, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T61.02XS | Ciguatera fish poisoning, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T61.12 | Scombroid fish poisoning, intentional self-harm | Diagnosis | ICD-10-CM |
| T61.12XA | Scombroid fish poisoning, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T61.12XD | Scombroid fish poisoning, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T61.12XS | Scombroid fish poisoning, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T61.772 | Other fish poisoning, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T61.772A | Other fish poisoning, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T61.772D | Other fish poisoning, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T61.772S | Other fish poisoning, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T61.782 | Other shellfish poisoning, intentional self-harm | Diagnosis | ICD-10-CM |
| T61.782A | Other shellfish poisoning, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T61.782D | Other shellfish poisoning, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T61.782S | Other shellfish poisoning, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T61.8X2 | Toxic effect of other seafood, intentional self-harm | Diagnosis | ICD-10-CM |
| T61.8X2A | Toxic effect of other seafood, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T61.8X2D | Toxic effect of other seafood, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T61.8X2S | Toxic effect of other seafood, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T61.92 | Toxic effect of unspecified seafood, intentional self-harm | Diagnosis | ICD-10-CM |
| T61.92XA | Toxic effect of unspecified seafood, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T61.92XD | Toxic effect of unspecified seafood, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T61.92XS | Toxic effect of unspecified seafood, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T62.0X2 | Toxic effect of ingested mushrooms, intentional self-harm | Diagnosis | ICD-10-CM |
| T62.0X2A | Toxic effect of ingested mushrooms, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T62.0X2D | Toxic effect of ingested mushrooms, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T62.0X2S | Toxic effect of ingested mushrooms, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T62.1X2 | Toxic effect of ingested berries, intentional self-harm | Diagnosis | ICD-10-CM |
| T62.1X2A | Toxic effect of ingested berries, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T62.1X2D | Toxic effect of ingested berries, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T62.1X2S | Toxic effect of ingested berries, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T62.2X2 | Toxic effect of other ingested (parts of) plant(s), intentional self-harm | Diagnosis | ICD-10-CM |
| T62.2X2A | Toxic effect of other ingested (parts of) plant(s), intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T62.2X2D | Toxic effect of other ingested (parts of) plant(s), intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T62.2X2S | Toxic effect of other ingested (parts of) plant(s), intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T62.8X2 | Toxic effect of other specified noxious substances eaten as food, intentional self-harm | Diagnosis | ICD-10-CM |
| T62.8X2A | Toxic effect of other specified noxious substances eaten as food, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T62.8X2D | Toxic effect of other specified noxious substances eaten as food, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T62.8X2S | Toxic effect of other specified noxious substances eaten as food, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T62.92 | Toxic effect of unspecified noxious substance eaten as food, intentional self-harm | Diagnosis | ICD-10-CM |
| T62.92XA | Toxic effect of unspecified noxious substance eaten as food, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T62.92XD | Toxic effect of unspecified noxious substance eaten as food, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T62.92XS | Toxic effect of unspecified noxious substance eaten as food, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.002 | Toxic effect of unspecified snake venom, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.002A | Toxic effect of unspecified snake venom, intentional self-harm, initial | Diagnosis | ICD-10-CM |
| T63.002D | Toxic effect of unspecified snake venom, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.002S | Toxic effect of unspecified snake venom, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.012 | Toxic effect of rattlesnake venom, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.012A | Toxic effect of rattlesnake venom, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.012D | Toxic effect of rattlesnake venom, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T63.012S | Toxic effect of rattlesnake venom, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.022 | Toxic effect of coral snake venom, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.022A | Toxic effect of coral snake venom, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.022D | Toxic effect of coral snake venom, intentional self-harm, subsequent | Diagnosis | ICD-10-CM |
| T63.022S | Toxic effect of coral snake venom, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.032 | Toxic effect of taipan venom, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.032A | Toxic effect of taipan venom, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.032D | Toxic effect of taipan venom, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.032S | Toxic effect of taipan venom, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.042 | Toxic effect of cobra venom, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.042A | Toxic effect of cobra venom, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.042D | Toxic effect of cobra venom, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.042S | Toxic effect of cobra venom, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.062 | Toxic effect of venom of other North and South American snake, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.062A | Toxic effect of venom of other North and South American snake, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.062D | Toxic effect of venom of other North and South American snake, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.062S | Toxic effect of venom of other North and South American snake, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.072 | Toxic effect of venom of other Australian snake, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.072A | Toxic effect of venom of other Australian snake, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.072D | Toxic effect of venom of other Australian snake, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.072S | Toxic effect of venom of other Australian snake, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.082 | Toxic effect of venom of other African and Asian snake, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.082A | Toxic effect of venom of other African and Asian snake, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.082D | Toxic effect of venom of other African and Asian snake, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.082S | Toxic effect of venom of other African and Asian snake, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T63.092 | Toxic effect of venom of other snake, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.092A | Toxic effect of venom of other snake, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.092D | Toxic effect of venom of other snake, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.092S | Toxic effect of venom of other snake, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.112 | Toxic effect of venom of gila monster, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.112A | Toxic effect of venom of gila monster, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.112D | Toxic effect of venom of gila monster, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.112S | Toxic effect of venom of gila monster, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.122 | Toxic effect of venom of other venomous lizard, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.122A | Toxic effect of venom of other venomous lizard, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.122D | Toxic effect of venom of other venomous lizard, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.122S | Toxic effect of venom of other venomous lizard, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.192 | Toxic effect of venom of other reptiles, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.192A | Toxic effect of venom of other reptiles, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.192D | Toxic effect of venom of other reptiles, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.192S | Toxic effect of venom of other reptiles, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.2X2 | Toxic effect of venom of scorpion, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.2X2A | Toxic effect of venom of scorpion, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.2X2D | Toxic effect of venom of scorpion, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.2X2S | Toxic effect of venom of scorpion, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.302 | Toxic effect of unspecified spider venom, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.302A | Toxic effect of unspecified spider venom, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.302D | Toxic effect of unspecified spider venom, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.302S | Toxic effect of unspecified spider venom, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.312 | Toxic effect of venom of black widow spider, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.312A | Toxic effect of venom of black widow spider, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.312D | Toxic effect of venom of black widow spider, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.312S | Toxic effect of venom of black widow spider, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.322 | Toxic effect of venom of tarantula, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.322A | Toxic effect of venom of tarantula, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.322D | Toxic effect of venom of tarantula, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.322S | Toxic effect of venom of tarantula, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.332 | Toxic effect of venom of brown recluse spider, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.332A | Toxic effect of venom of brown recluse spider, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T63.332D | Toxic effect of venom of brown recluse spider, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.332S | Toxic effect of venom of brown recluse spider, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.392 | Toxic effect of venom of other spider, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.392A | Toxic effect of venom of other spider, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.392D | Toxic effect of venom of other spider, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.392S | Toxic effect of venom of other spider, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.412 | Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.412A | Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.412D | Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.412S | Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.422 | Toxic effect of venom of ants, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.422A | Toxic effect of venom of ants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.422D | Toxic effect of venom of ants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.422S | Toxic effect of venom of ants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.432 | Toxic effect of venom of caterpillars, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.432A | Toxic effect of venom of caterpillars, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.432D | Toxic effect of venom of caterpillars, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.432S | Toxic effect of venom of caterpillars, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.442 | Toxic effect of venom of bees, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.442A | Toxic effect of venom of bees, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.442D | Toxic effect of venom of bees, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.442S | Toxic effect of venom of bees, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.452 | Toxic effect of venom of hornets, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.452A | Toxic effect of venom of hornets, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.452D | Toxic effect of venom of hornets, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.452S | Toxic effect of venom of hornets, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.462 | Toxic effect of venom of wasps, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.462A | Toxic effect of venom of wasps, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.462D | Toxic effect of venom of wasps, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.462S | Toxic effect of venom of wasps, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.482 | Toxic effect of venom of other arthropod, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.482A | Toxic effect of venom of other arthropod, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.482D | Toxic effect of venom of other arthropod, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.482S | Toxic effect of venom of other arthropod, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.512 | Toxic effect of contact with stingray, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T63.512A | Toxic effect of contact with stingray, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.512D | Toxic effect of contact with stingray, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.512S | Toxic effect of contact with stingray, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.592 | Toxic effect of contact with other venomous fish, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.592A | Toxic effect of contact with other venomous fish, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.592D | Toxic effect of contact with other venomous fish, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.592S | Toxic effect of contact with other venomous fish, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.612 | Toxic effect of contact with Portuguese Man-o-war, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.612A | Toxic effect of contact with Portuguese Man-o-war, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.612D | Toxic effect of contact with Portuguese Man-o-war, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.612S | Toxic effect of contact with Portuguese Man-o-war, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.622 | Toxic effect of contact with other jellyfish, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.622A | Toxic effect of contact with other jellyfish, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.622D | Toxic effect of contact with other jellyfish, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.622S | Toxic effect of contact with other jellyfish, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.632 | Toxic effect of contact with sea anemone, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.632A | Toxic effect of contact with sea anemone, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.632D | Toxic effect of contact with sea anemone, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.632S | Toxic effect of contact with sea anemone, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.692 | Toxic effect of contact with other venomous marine animals, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.692A | Toxic effect of contact with other venomous marine animals, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.692D | Toxic effect of contact with other venomous marine animals, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.692S | Toxic effect of contact with other venomous marine animals, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.712 | Toxic effect of contact with venomous marine plant, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.712A | Toxic effect of contact with venomous marine plant, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.712D | Toxic effect of contact with venomous marine plant, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.712S | Toxic effect of contact with venomous marine plant, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| T63.792 | Toxic effect of contact with other venomous plant, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.792A | Toxic effect of contact with other venomous plant, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.792D | Toxic effect of contact with other venomous plant, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.792S | Toxic effect of contact with other venomous plant, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.812 | Toxic effect of contact with venomous frog, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.812A | Toxic effect of contact with venomous frog, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.812D | Toxic effect of contact with venomous frog, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.812S | Toxic effect of contact with venomous frog, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.822 | Toxic effect of contact with venomous toad, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.822A | Toxic effect of contact with venomous toad, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.822D | Toxic effect of contact with venomous toad, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.822S | Toxic effect of contact with venomous toad, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.832 | Toxic effect of contact with other venomous amphibian, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.832A | Toxic effect of contact with other venomous amphibian, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.832D | Toxic effect of contact with other venomous amphibian, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.832S | Toxic effect of contact with other venomous amphibian, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.892 | Toxic effect of contact with other venomous animals, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.892A | Toxic effect of contact with other venomous animals, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.892D | Toxic effect of contact with other venomous animals, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.892S | Toxic effect of contact with other venomous animals, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T63.92 | Toxic effect of contact with unspecified venomous animal, intentional self-harm | Diagnosis | ICD-10-CM |
| T63.92XA | Toxic effect of contact with unspecified venomous animal, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T63.92XD | Toxic effect of contact with unspecified venomous animal, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T63.92XS | Toxic effect of contact with unspecified venomous animal, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T64.02 | Toxic effect of aflatoxin, intentional self-harm | Diagnosis | ICD-10-CM |
| T64.02XA | Toxic effect of aflatoxin, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T64.02XD | Toxic effect of aflatoxin, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T64.02XS | Toxic effect of aflatoxin, intentional self-harm, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T64.82 | Toxic effect of other mycotoxin food contaminants, intentional self-harm | Diagnosis | ICD-10-CM |
| T64.82XA | Toxic effect of other mycotoxin food contaminants, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T64.82XD | Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T64.82XS | Toxic effect of other mycotoxin food contaminants, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.0X2 | Toxic effect of cyanides, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.0X2A | Toxic effect of cyanides, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.0X2D | Toxic effect of cyanides, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.0X2S | Toxic effect of cyanides, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.1X2 | Toxic effect of strychnine and its salts, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.1X2A | Toxic effect of strychnine and its salts, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.1X2D | Toxic effect of strychnine and its salts, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.1X2S | Toxic effect of strychnine and its salts, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.212 | Toxic effect of chewing tobacco, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.212A | Toxic effect of chewing tobacco, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.212D | Toxic effect of chewing tobacco, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.212S | Toxic effect of chewing tobacco, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.222 | Toxic effect of tobacco cigarettes, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.222A | Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.222D | Toxic effect of tobacco cigarettes, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.222S | Toxic effect of tobacco cigarettes, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.292 | Toxic effect of other tobacco and nicotine, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.292A | Toxic effect of other tobacco and nicotine, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.292D | Toxic effect of other tobacco and nicotine, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.292S | Toxic effect of other tobacco and nicotine, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.3X2 | Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.3X2A | Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.3X2D | Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.3X2S | Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.4X2 | Toxic effect of carbon disulfide, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.4X2A | Toxic effect of carbon disulfide, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.4X2D | Toxic effect of carbon disulfide, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.4X2S | Toxic effect of carbon disulfide, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.5X2 | Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|------------------------|--|---------------|-----------|
| T65.5X2A | Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.5X2D | Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.5X2S | Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.6X2 | Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.6X2A | Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.6X2D | Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.6X2S | Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.812 | Toxic effect of latex, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.812A | Toxic effect of latex, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.812D | Toxic effect of latex, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.812S | Toxic effect of latex, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.822 | Toxic effect of harmful algae and algae toxins, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.822A | Toxic effect of harmful algae and algae toxins, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.822D | Toxic effect of harmful algae and algae toxins, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.822S | Toxic effect of harmful algae and algae toxins, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.832 | Toxic effect of fiberglass, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.832A | Toxic effect of fiberglass, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.832D | Toxic effect of fiberglass, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.832S | Toxic effect of fiberglass, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.892 | Toxic effect of other specified substances, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.892A | Toxic effect of other specified substances, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.892D | Toxic effect of other specified substances, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.892S | Toxic effect of other specified substances, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| T65.92 | Toxic effect of unspecified substance, intentional self-harm | Diagnosis | ICD-10-CM |
| T65.92XA | Toxic effect of unspecified substance, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.92XD | Toxic effect of unspecified substance, intentional self-harm, subsequent encounter | Diagnosis | ICD-10-CM |
| T65.92XS | Toxic effect of unspecified substance, intentional self-harm, sequela | Diagnosis | ICD-10-CM |
| Other Self-Harm | | | |
| X71 | Intentional self-harm by drowning and submersion | Diagnosis | ICD-10-CM |
| X71.0 | Intentional self-harm by drowning and submersion while in bathtub | Diagnosis | ICD-10-CM |
| X71.0XXA | Intentional self-harm by drowning and submersion while in bathtub, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| X71.0XXD | Intentional self-harm by drowning and submersion while in bathtub, subsequent encounter | Diagnosis | ICD-10-CM |
| X71.0XXS | Intentional self-harm by drowning and submersion while in bathtub, sequela | Diagnosis | ICD-10-CM |
| X71.1 | Intentional self-harm by drowning and submersion while in swimming pool | Diagnosis | ICD-10-CM |
| X71.1XXA | Intentional self-harm by drowning and submersion while in swimming pool, initial encounter | Diagnosis | ICD-10-CM |
| X71.1XXD | Intentional self-harm by drowning and submersion while in swimming pool, subsequent encounter | Diagnosis | ICD-10-CM |
| X71.1XXS | Intentional self-harm by drowning and submersion while in swimming pool, sequela | Diagnosis | ICD-10-CM |
| X71.2 | Intentional self-harm by drowning and submersion after jump into swimming pool | Diagnosis | ICD-10-CM |
| X71.2XXA | Intentional self-harm by drowning and submersion after jump into swimming pool, initial encounter | Diagnosis | ICD-10-CM |
| X71.2XXD | Intentional self-harm by drowning and submersion after jump into swimming pool, subsequent encounter | Diagnosis | ICD-10-CM |
| X71.2XXS | Intentional self-harm by drowning and submersion after jump into swimming pool, sequela | Diagnosis | ICD-10-CM |
| X71.3 | Intentional self-harm by drowning and submersion in natural water | Diagnosis | ICD-10-CM |
| X71.3XXA | Intentional self-harm by drowning and submersion in natural water, initial encounter | Diagnosis | ICD-10-CM |
| X71.3XXD | Intentional self-harm by drowning and submersion in natural water, subsequent encounter | Diagnosis | ICD-10-CM |
| X71.3XXS | Intentional self-harm by drowning and submersion in natural water, sequela | Diagnosis | ICD-10-CM |
| X71.8 | Other intentional self-harm by drowning and submersion | Diagnosis | ICD-10-CM |
| X71.8XXA | Other intentional self-harm by drowning and submersion, initial encounter | Diagnosis | ICD-10-CM |
| X71.8XXD | Other intentional self-harm by drowning and submersion, subsequent encounter | Diagnosis | ICD-10-CM |
| X71.8XXS | Other intentional self-harm by drowning and submersion, sequela | Diagnosis | ICD-10-CM |
| X71.9 | Intentional self-harm by drowning and submersion, unspecified | Diagnosis | ICD-10-CM |
| X71.9XXA | Intentional self-harm by drowning and submersion, unspecified, initial encounter | Diagnosis | ICD-10-CM |
| X71.9XXD | Intentional self-harm by drowning and submersion, unspecified, subsequent encounter | Diagnosis | ICD-10-CM |
| X71.9XXS | Intentional self-harm by drowning and submersion, unspecified, sequela | Diagnosis | ICD-10-CM |
| X72 | Intentional self-harm by handgun discharge | Diagnosis | ICD-10-CM |
| X72.XXXA | Intentional self-harm by handgun discharge, initial encounter | Diagnosis | ICD-10-CM |
| X72.XXXD | Intentional self-harm by handgun discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X72.XXXS | Intentional self-harm by handgun discharge, sequela | Diagnosis | ICD-10-CM |
| X73 | Intentional self-harm by rifle, shotgun and larger firearm discharge | Diagnosis | ICD-10-CM |
| X73.0 | Intentional self-harm by shotgun discharge | Diagnosis | ICD-10-CM |
| X73.0XXA | Intentional self-harm by shotgun discharge, initial encounter | Diagnosis | ICD-10-CM |
| X73.0XXD | Intentional self-harm by shotgun discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X73.0XXS | Intentional self-harm by shotgun discharge, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| X73.1 | Intentional self-harm by hunting rifle discharge | Diagnosis | ICD-10-CM |
| X73.1XXA | Intentional self-harm by hunting rifle discharge, initial encounter | Diagnosis | ICD-10-CM |
| X73.1XXD | Intentional self-harm by hunting rifle discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X73.1XXS | Intentional self-harm by hunting rifle discharge, sequela | Diagnosis | ICD-10-CM |
| X73.2 | Intentional self-harm by machine gun discharge | Diagnosis | ICD-10-CM |
| X73.2XXA | Intentional self-harm by machine gun discharge, initial encounter | Diagnosis | ICD-10-CM |
| X73.2XXD | Intentional self-harm by machine gun discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X73.2XXS | Intentional self-harm by machine gun discharge, sequela | Diagnosis | ICD-10-CM |
| X73.8 | Intentional self-harm by other larger firearm discharge | Diagnosis | ICD-10-CM |
| X73.8XXA | Intentional self-harm by other larger firearm discharge, initial encounter | Diagnosis | ICD-10-CM |
| X73.8XXD | Intentional self-harm by other larger firearm discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X73.8XXS | Intentional self-harm by other larger firearm discharge, sequela | Diagnosis | ICD-10-CM |
| X73.9 | Intentional self-harm by unspecified larger firearm discharge | Diagnosis | ICD-10-CM |
| X73.9XXA | Intentional self-harm by unspecified larger firearm discharge, initial encounter | Diagnosis | ICD-10-CM |
| X73.9XXD | Intentional self-harm by unspecified larger firearm discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X73.9XXS | Intentional self-harm by unspecified larger firearm discharge, sequela | Diagnosis | ICD-10-CM |
| X74 | Intentional self-harm by other and unspecified firearm and gun discharge | Diagnosis | ICD-10-CM |
| X74.0 | Intentional self-harm by gas, air or spring-operated guns | Diagnosis | ICD-10-CM |
| X74.01 | Intentional self-harm by airgun | Diagnosis | ICD-10-CM |
| X74.01XA | Intentional self-harm by airgun, initial encounter | Diagnosis | ICD-10-CM |
| X74.01XD | Intentional self-harm by airgun, subsequent encounter | Diagnosis | ICD-10-CM |
| X74.01XS | Intentional self-harm by airgun, sequela | Diagnosis | ICD-10-CM |
| X74.02 | Intentional self-harm by paintball gun | Diagnosis | ICD-10-CM |
| X74.02XA | Intentional self-harm by paintball gun, initial encounter | Diagnosis | ICD-10-CM |
| X74.02XD | Intentional self-harm by paintball gun, subsequent encounter | Diagnosis | ICD-10-CM |
| X74.02XS | Intentional self-harm by paintball gun, sequela | Diagnosis | ICD-10-CM |
| X74.09 | Intentional self-harm by other gas, air or spring-operated gun | Diagnosis | ICD-10-CM |
| X74.09XA | Intentional self-harm by other gas, air or spring-operated gun, initial encounter | Diagnosis | ICD-10-CM |
| X74.09XD | Intentional self-harm by other gas, air or spring-operated gun, subsequent encounter | Diagnosis | ICD-10-CM |
| X74.09XS | Intentional self-harm by other gas, air or spring-operated gun, sequela | Diagnosis | ICD-10-CM |
| X74.8 | Intentional self-harm by other firearm discharge | Diagnosis | ICD-10-CM |
| X74.8XXA | Intentional self-harm by other firearm discharge, initial encounter | Diagnosis | ICD-10-CM |
| X74.8XXD | Intentional self-harm by other firearm discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X74.8XXS | Intentional self-harm by other firearm discharge, sequela | Diagnosis | ICD-10-CM |
| X74.9 | Intentional self-harm by unspecified firearm discharge | Diagnosis | ICD-10-CM |
| X74.9XXA | Intentional self-harm by unspecified firearm discharge, initial encounter | Diagnosis | ICD-10-CM |
| X74.9XXD | Intentional self-harm by unspecified firearm discharge, subsequent encounter | Diagnosis | ICD-10-CM |
| X74.9XXS | Intentional self-harm by unspecified firearm discharge, sequela | Diagnosis | ICD-10-CM |
| X75 | Intentional self-harm by explosive material | Diagnosis | ICD-10-CM |
| X75.XXXA | Intentional self-harm by explosive material, initial encounter | Diagnosis | ICD-10-CM |
| X75.XXXD | Intentional self-harm by explosive material, subsequent encounter | Diagnosis | ICD-10-CM |
| X75.XXXS | Intentional self-harm by explosive material, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| X76 | Intentional self-harm by smoke, fire and flames | Diagnosis | ICD-10-CM |
| X76.XXXA | Intentional self-harm by smoke, fire and flames, initial encounter | Diagnosis | ICD-10-CM |
| X76.XXXD | Intentional self-harm by smoke, fire and flames, subsequent encounter | Diagnosis | ICD-10-CM |
| X76.XXXS | Intentional self-harm by smoke, fire and flames, sequela | Diagnosis | ICD-10-CM |
| X77 | Intentional self-harm by steam, hot vapors and hot objects | Diagnosis | ICD-10-CM |
| X77.0 | Intentional self-harm by steam or hot vapors | Diagnosis | ICD-10-CM |
| X77.0XXA | Intentional self-harm by steam or hot vapors, initial encounter | Diagnosis | ICD-10-CM |
| X77.0XXD | Intentional self-harm by steam or hot vapors, subsequent encounter | Diagnosis | ICD-10-CM |
| X77.0XXS | Intentional self-harm by steam or hot vapors, sequela | Diagnosis | ICD-10-CM |
| X77.1 | Intentional self-harm by hot tap water | Diagnosis | ICD-10-CM |
| X77.1XXA | Intentional self-harm by hot tap water, initial encounter | Diagnosis | ICD-10-CM |
| X77.1XXD | Intentional self-harm by hot tap water, subsequent encounter | Diagnosis | ICD-10-CM |
| X77.1XXS | Intentional self-harm by hot tap water, sequela | Diagnosis | ICD-10-CM |
| X77.2 | Intentional self-harm by other hot fluids | Diagnosis | ICD-10-CM |
| X77.2XXA | Intentional self-harm by other hot fluids, initial encounter | Diagnosis | ICD-10-CM |
| X77.2XXD | Intentional self-harm by other hot fluids, subsequent encounter | Diagnosis | ICD-10-CM |
| X77.2XXS | Intentional self-harm by other hot fluids, sequela | Diagnosis | ICD-10-CM |
| X77.3 | Intentional self-harm by hot household appliances | Diagnosis | ICD-10-CM |
| X77.3XXA | Intentional self-harm by hot household appliances, initial encounter | Diagnosis | ICD-10-CM |
| X77.3XXD | Intentional self-harm by hot household appliances, subsequent encounter | Diagnosis | ICD-10-CM |
| X77.3XXS | Intentional self-harm by hot household appliances, sequela | Diagnosis | ICD-10-CM |
| X77.8 | Intentional self-harm by other hot objects | Diagnosis | ICD-10-CM |
| X77.8XXA | Intentional self-harm by other hot objects, initial encounter | Diagnosis | ICD-10-CM |
| X77.8XXD | Intentional self-harm by other hot objects, subsequent encounter | Diagnosis | ICD-10-CM |
| X77.8XXS | Intentional self-harm by other hot objects, sequela | Diagnosis | ICD-10-CM |
| X77.9 | Intentional self-harm by unspecified hot objects | Diagnosis | ICD-10-CM |
| X77.9XXA | Intentional self-harm by unspecified hot objects, initial encounter | Diagnosis | ICD-10-CM |
| X77.9XXD | Intentional self-harm by unspecified hot objects, subsequent encounter | Diagnosis | ICD-10-CM |
| X77.9XXS | Intentional self-harm by unspecified hot objects, sequela | Diagnosis | ICD-10-CM |
| X78 | Intentional self-harm by sharp object | Diagnosis | ICD-10-CM |
| X78.0 | Intentional self-harm by sharp glass | Diagnosis | ICD-10-CM |
| X78.0XXA | Intentional self-harm by sharp glass, initial encounter | Diagnosis | ICD-10-CM |
| X78.0XXD | Intentional self-harm by sharp glass, subsequent encounter | Diagnosis | ICD-10-CM |
| X78.0XXS | Intentional self-harm by sharp glass, sequela | Diagnosis | ICD-10-CM |
| X78.1 | Intentional self-harm by knife | Diagnosis | ICD-10-CM |
| X78.1XXA | Intentional self-harm by knife, initial encounter | Diagnosis | ICD-10-CM |
| X78.1XXD | Intentional self-harm by knife, subsequent encounter | Diagnosis | ICD-10-CM |
| X78.1XXS | Intentional self-harm by knife, sequela | Diagnosis | ICD-10-CM |
| X78.2 | Intentional self-harm by sword or dagger | Diagnosis | ICD-10-CM |
| X78.2XXA | Intentional self-harm by sword or dagger, initial encounter | Diagnosis | ICD-10-CM |
| X78.2XXD | Intentional self-harm by sword or dagger, subsequent encounter | Diagnosis | ICD-10-CM |
| X78.2XXS | Intentional self-harm by sword or dagger, sequela | Diagnosis | ICD-10-CM |
| X78.8 | Intentional self-harm by other sharp object | Diagnosis | ICD-10-CM |
| X78.8XXA | Intentional self-harm by other sharp object, initial encounter | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| X78.8XXD | Intentional self-harm by other sharp object, subsequent encounter | Diagnosis | ICD-10-CM |
| X78.8XXS | Intentional self-harm by other sharp object, sequela | Diagnosis | ICD-10-CM |
| X78.9 | Intentional self-harm by unspecified sharp object | Diagnosis | ICD-10-CM |
| X78.9XXA | Intentional self-harm by unspecified sharp object, initial encounter | Diagnosis | ICD-10-CM |
| X78.9XXD | Intentional self-harm by unspecified sharp object, subsequent encounter | Diagnosis | ICD-10-CM |
| X78.9XXS | Intentional self-harm by unspecified sharp object, sequela | Diagnosis | ICD-10-CM |
| X79 | Intentional self-harm by blunt object | Diagnosis | ICD-10-CM |
| X79.XXXA | Intentional self-harm by blunt object, initial encounter | Diagnosis | ICD-10-CM |
| X79.XXXD | Intentional self-harm by blunt object, subsequent encounter | Diagnosis | ICD-10-CM |
| X79.XXXS | Intentional self-harm by blunt object, sequela | Diagnosis | ICD-10-CM |
| X80 | Intentional self-harm by jumping from a high place | Diagnosis | ICD-10-CM |
| X80.XXXA | Intentional self-harm by jumping from a high place, initial encounter | Diagnosis | ICD-10-CM |
| X80.XXXD | Intentional self-harm by jumping from a high place, subsequent encounter | Diagnosis | ICD-10-CM |
| X80.XXXS | Intentional self-harm by jumping from a high place, sequela | Diagnosis | ICD-10-CM |
| X81 | Intentional self-harm by jumping or lying in front of moving object | Diagnosis | ICD-10-CM |
| X81.0 | Intentional self-harm by jumping or lying in front of motor vehicle | Diagnosis | ICD-10-CM |
| X81.0XXA | Intentional self-harm by jumping or lying in front of motor vehicle, initial encounter | Diagnosis | ICD-10-CM |
| X81.0XXD | Intentional self-harm by jumping or lying in front of motor vehicle, subsequent encounter | Diagnosis | ICD-10-CM |
| X81.0XXS | Intentional self-harm by jumping or lying in front of motor vehicle, sequela | Diagnosis | ICD-10-CM |
| X81.1 | Intentional self-harm by jumping or lying in front of (subway) train | Diagnosis | ICD-10-CM |
| X81.1XXA | Intentional self-harm by jumping or lying in front of (subway) train, initial encounter | Diagnosis | ICD-10-CM |
| X81.1XXD | Intentional self-harm by jumping or lying in front of (subway) train, subsequent encounter | Diagnosis | ICD-10-CM |
| X81.1XXS | Intentional self-harm by jumping or lying in front of (subway) train, sequela | Diagnosis | ICD-10-CM |
| X81.8 | Intentional self-harm by jumping or lying in front of other moving object | Diagnosis | ICD-10-CM |
| X81.8XXA | Intentional self-harm by jumping or lying in front of other moving object, initial encounter | Diagnosis | ICD-10-CM |
| X81.8XXD | Intentional self-harm by jumping or lying in front of other moving object, subsequent encounter | Diagnosis | ICD-10-CM |
| X81.8XXS | Intentional self-harm by jumping or lying in front of other moving object, sequela | Diagnosis | ICD-10-CM |
| X82 | Intentional self-harm by crashing of motor vehicle | Diagnosis | ICD-10-CM |
| X82.0 | Intentional collision of motor vehicle with other motor vehicle | Diagnosis | ICD-10-CM |
| X82.0XXA | Intentional collision of motor vehicle with other motor vehicle, initial encounter | Diagnosis | ICD-10-CM |
| X82.0XXD | Intentional collision of motor vehicle with other motor vehicle, subsequent encounter | Diagnosis | ICD-10-CM |
| X82.0XXS | Intentional collision of motor vehicle with other motor vehicle, sequela | Diagnosis | ICD-10-CM |
| X82.1 | Intentional collision of motor vehicle with train | Diagnosis | ICD-10-CM |
| X82.1XXA | Intentional collision of motor vehicle with train, initial encounter | Diagnosis | ICD-10-CM |
| X82.1XXD | Intentional collision of motor vehicle with train, subsequent encounter | Diagnosis | ICD-10-CM |
| X82.1XXS | Intentional collision of motor vehicle with train, sequela | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---|---|---------------|-----------|
| X82.2 | Intentional collision of motor vehicle with tree | Diagnosis | ICD-10-CM |
| X82.2XXA | Intentional collision of motor vehicle with tree, initial encounter | Diagnosis | ICD-10-CM |
| X82.2XXD | Intentional collision of motor vehicle with tree, subsequent encounter | Diagnosis | ICD-10-CM |
| X82.2XXS | Intentional collision of motor vehicle with tree, sequela | Diagnosis | ICD-10-CM |
| X82.8 | Other intentional self-harm by crashing of motor vehicle | Diagnosis | ICD-10-CM |
| X82.8XXA | Other intentional self-harm by crashing of motor vehicle, initial encounter | Diagnosis | ICD-10-CM |
| X82.8XXD | Other intentional self-harm by crashing of motor vehicle, subsequent | Diagnosis | ICD-10-CM |
| X82.8XXS | Other intentional self-harm by crashing of motor vehicle, sequela | Diagnosis | ICD-10-CM |
| X83 | Intentional self-harm by other specified means | Diagnosis | ICD-10-CM |
| X83.0 | Intentional self-harm by crashing of aircraft | Diagnosis | ICD-10-CM |
| X83.0XXA | Intentional self-harm by crashing of aircraft, initial encounter | Diagnosis | ICD-10-CM |
| X83.0XXD | Intentional self-harm by crashing of aircraft, subsequent encounter | Diagnosis | ICD-10-CM |
| X83.0XXS | Intentional self-harm by crashing of aircraft, sequela | Diagnosis | ICD-10-CM |
| X83.1 | Intentional self-harm by electrocution | Diagnosis | ICD-10-CM |
| X83.1XXA | Intentional self-harm by electrocution, initial encounter | Diagnosis | ICD-10-CM |
| X83.1XXD | Intentional self-harm by electrocution, subsequent encounter | Diagnosis | ICD-10-CM |
| X83.1XXS | Intentional self-harm by electrocution, sequela | Diagnosis | ICD-10-CM |
| X83.2 | Intentional self-harm by exposure to extremes of cold | Diagnosis | ICD-10-CM |
| X83.2XXA | Intentional self-harm by exposure to extremes of cold, initial encounter | Diagnosis | ICD-10-CM |
| X83.2XXD | Intentional self-harm by exposure to extremes of cold, subsequent encounter | Diagnosis | ICD-10-CM |
| X83.2XXS | Intentional self-harm by exposure to extremes of cold, sequela | Diagnosis | ICD-10-CM |
| X83.8 | Intentional self-harm by other specified means | Diagnosis | ICD-10-CM |
| X83.8XXA | Intentional self-harm by other specified means, initial encounter | Diagnosis | ICD-10-CM |
| X83.8XXD | Intentional self-harm by other specified means, subsequent encounter | Diagnosis | ICD-10-CM |
| X83.8XXS | Intentional self-harm by other specified means, sequela | Diagnosis | ICD-10-CM |
| Asthma Diagnosis - Component of Asthma Exacerbation Episode | | | |
| 493.0 | Extrinsic asthma | Diagnosis | ICD-9-CM |
| 493.00 | Extrinsic asthma, unspecified | Diagnosis | ICD-9-CM |
| 493.02 | Extrinsic asthma, with (acute) exacerbation | Diagnosis | ICD-9-CM |
| 493.1 | Intrinsic asthma | Diagnosis | ICD-9-CM |
| 493.10 | Intrinsic asthma, unspecified | Diagnosis | ICD-9-CM |
| 493.12 | Intrinsic asthma, with (acute) exacerbation | Diagnosis | ICD-9-CM |
| 493.20 | Chronic obstructive asthma, unspecified ICD-9-CM | Diagnosis | ICD-9-CM |
| 493.21 | Chronic obstructive asthma with status asthmaticus ICD-9-CM | Diagnosis | ICD-9-CM |
| 493.22 | Chronic obstructive asthma, with (acute) exacerbation ICD-9-CM | Diagnosis | ICD-9-CM |
| 493.8 | Other forms of asthma | Diagnosis | ICD-9-CM |
| 493.82 | Cough variant asthma | Diagnosis | ICD-9-CM |
| 493.9 | Unspecified asthma | Diagnosis | ICD-9-CM |
| 493.90 | Asthma, unspecified, unspecified status | Diagnosis | ICD-9-CM |
| 493.92 | Asthma, unspecified, with (acute) exacerbation | Diagnosis | ICD-9-CM |
| J45 | Asthma | Diagnosis | ICD-10-CM |
| J45.2 | Mild intermittent asthma | Diagnosis | ICD-10-CM |
| J45.20 | Mild intermittent asthma, uncomplicated | Diagnosis | ICD-10-CM |
| J45.21 | Mild intermittent asthma with (acute) exacerbation | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|---|--|---------------|-----------|
| J45.3 | Mild persistent asthma | Diagnosis | ICD-10-CM |
| J45.30 | Mild persistent asthma, uncomplicated | Diagnosis | ICD-10-CM |
| J45.31 | Mild persistent asthma with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J45.4 | Moderate persistent asthma | Diagnosis | ICD-10-CM |
| J45.40 | Moderate persistent asthma, uncomplicated | Diagnosis | ICD-10-CM |
| J45.41 | Moderate persistent asthma with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J45.5 | Severe persistent asthma | Diagnosis | ICD-10-CM |
| J45.50 | Severe persistent asthma, uncomplicated | Diagnosis | ICD-10-CM |
| J45.51 | Severe persistent asthma with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J45.9 | Other and unspecified asthma | Diagnosis | ICD-10-CM |
| J45.90 | Unspecified asthma | Diagnosis | ICD-10-CM |
| J45.901 | Unspecified asthma with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J45.909 | Unspecified asthma, uncomplicated | Diagnosis | ICD-10-CM |
| J45.99 | Other asthma | Diagnosis | ICD-10-CM |
| J45.991 | Cough variant asthma | Diagnosis | ICD-10-CM |
| J45.998 | Other asthma | Diagnosis | ICD-10-CM |
| Asthma Exacerbation - Component of Asthma Exacerbation Episode | | | |
| 493.01 | Extrinsic asthma with status asthmaticus | Diagnosis | ICD-9-CM |
| 493.02 | Extrinsic asthma, with (acute) exacerbation | Diagnosis | ICD-9-CM |
| 493.11 | Intrinsic asthma with status asthmaticus | Diagnosis | ICD-9-CM |
| 493.12 | Intrinsic asthma, with (acute) exacerbation | Diagnosis | ICD-9-CM |
| 493.91 | Asthma, unspecified with status asthmaticus | Diagnosis | ICD-9-CM |
| 493.92 | Asthma, unspecified, with (acute) exacerbation | Diagnosis | ICD-9-CM |
| J45.21 | Mild intermittent asthma with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J45.22 | Mild intermittent asthma with status asthmaticus | Diagnosis | ICD-10-CM |
| J45.31 | Mild persistent asthma with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J45.32 | Mild persistent asthma with status asthmaticus | Diagnosis | ICD-10-CM |
| J45.41 | Moderate persistent asthma with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J45.42 | Moderate persistent asthma with status asthmaticus | Diagnosis | ICD-10-CM |
| J45.51 | Severe persistent asthma with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J45.52 | Severe persistent asthma with status asthmaticus | Diagnosis | ICD-10-CM |
| J45.901 | Unspecified asthma with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J45.902 | Unspecified asthma with status asthmaticus | Diagnosis | ICD-10-CM |
| Respiratory Failure - Component of Asthma Exacerbation Episode | | | |
| 518.81 | Acute respiratory failure | Diagnosis | ICD-9-CM |
| 518.82 | Other pulmonary insufficiency, not elsewhere classified | Diagnosis | ICD-9-CM |
| 518.84 | Acute and chronic respiratory failure | Diagnosis | ICD-9-CM |
| 799.1 | Respiratory arrest | Diagnosis | ICD-9-CM |
| J80 | Acute respiratory distress syndrome | Diagnosis | ICD-10-CM |
| J96.0 | Acute respiratory failure | Diagnosis | ICD-10-CM |
| J96.00 | Acute respiratory failure, unspecified whether with hypoxia or hypercapnia | Diagnosis | ICD-10-CM |
| J96.01 | Acute respiratory failure with hypoxia | Diagnosis | ICD-10-CM |
| J96.02 | Acute respiratory failure with hypercapnia | Diagnosis | ICD-10-CM |

Appendix AD. List of Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|-------------|--|----------------------|------------------|
| J96.20 | Acute and chronic respiratory failure, unspecified whether with hypoxia or hypercapnia | Diagnosis | ICD-10-CM |
| J96.21 | Acute and chronic respiratory failure with hypoxia | Diagnosis | ICD-10-CM |
| J96.22 | Acute and chronic respiratory failure with hypercapnia | Diagnosis | ICD-10-CM |
| J96.90 | Respiratory failure, unspecified, unspecified whether with hypoxia or hypercapnia | Diagnosis | ICD-10-CM |
| J96.91 | Respiratory failure, unspecified with hypoxia | Diagnosis | ICD-10-CM |
| J96.92 | Respiratory failure, unspecified with hypercapnia | Diagnosis | ICD-10-CM |
| R09.2 | Respiratory arrest | Diagnosis | ICD-10-CM |

Appendix AE. List of Current Procedural Terminology, Fourth Edition (CPT-4) and Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|--|--|---------------|-----------|
| Oral Corticosteroid Dispensing | | | |
| J7506 | Prednisone, oral, per 5 mg | Procedure | HCPCS |
| J7509 | Methylprednisolone, oral, per 4 mg | Procedure | HCPCS |
| J7510 | Prednisolone, oral, per 5 mg | Procedure | HCPCS |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | Procedure | HCPCS |
| J8540 | Dexamethasone, oral, 0.25 mg | Procedure | HCPCS |
| S0173 | Dexamethasone, oral, 4 mg | Procedure | HCPCS |
| Oral Corticosteroid Dispensing - Component of Asthma Exacerbation Episode | | | |
| J7506 | Prednisone, oral, per 5 mg | Procedure | HCPCS |
| J7509 | Methylprednisolone, oral, per 4 mg | Procedure | HCPCS |
| J7510 | Prednisolone, oral, per 5 mg | Procedure | HCPCS |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | Procedure | HCPCS |
| J8540 | Dexamethasone, oral, 0.25 mg | Procedure | HCPCS |
| S0173 | Dexamethasone, oral, 4 mg | Procedure | HCPCS |
| Other Asthma Medication | | | |
| 80184 | Phenobarbital | Procedure | CPT-4 |
| 80198 | Theophylline | Procedure | CPT-4 |
| 82137 | Aminophylline | Procedure | CPT-4 |
| 84420 | Theophylline, Blood Or Saliva | Procedure | CPT-4 |
| J1180 | Injection, dyphylline, up to 500 mg | Procedure | HCPCS |
| J2560 | Injection, phenobarbital sodium, up to 120 mg | Procedure | HCPCS |
| J2810 | Injection, theophylline, per 40 mg | Procedure | HCPCS |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | Procedure | HCPCS |
| J7602 | Albuterol, all formulations including separated isomers, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 1 mg (Albuterol) or per 0.5 mg Levalbuterol) | Procedure | HCPCS |
| J7603 | Albuterol, all formulations including separated isomers, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose, per 1 mg (Albuterol) or per 0.5 mg Levalbuterol) | Procedure | HCPCS |
| J7607 | Levalbuterol, inhalation solution, compounded product, administered through DME, concentrated form, 0.5 mg | Procedure | HCPCS |
| J7609 | Albuterol, inhalation solution, compounded product, administered through DME, unit dose, 1 mg | Procedure | HCPCS |
| J7610 | Albuterol, inhalation solution, compounded product, administered through DME, concentrated form, 1 mg | Procedure | HCPCS |
| J7611 | Albuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, 1 mg | Procedure | HCPCS |
| J7612 | Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, 0.5 mg | Procedure | HCPCS |
| J7613 | Albuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose, 1 mg | Procedure | HCPCS |
| J7614 | Levalbuterol, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose, 0.5 mg | Procedure | HCPCS |
| J7615 | Levalbuterol, inhalation solution, compounded product, administered through DME, unit dose, 0.5 mg | Procedure | HCPCS |
| J7616 | Albuterol, up to 5 mg and ipratropium bromide, up to 1 mg, compounded inhalation solution, administered through DME | Procedure | HCPCS |
| J7617 | Levalbuterol, up to 2.5 mg and ipratropium bromide, up to 1 mg, compounded inhalation solution, administered through DME | Procedure | HCPCS |

Appendix AE. List of Current Procedural Terminology, Fourth Edition (CPT-4) and Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Covariates in this Request

| Code | Description | Code Category | Code Type |
|-------|--|---------------|-----------|
| J7618 | Albuterol, all formulations including separated isomers, inhalation solution administered through DME, concentrated form, per 1 mg (albuterol) or per 0.5 mg (levalbuterol) | Procedure | HCPCS |
| J7619 | Albuterol, all formulations including separated isomers, inhalation solution administered through DME, unit dose, per 1 mg (albuterol) or per 0.5 mg (levalbuterol) | Procedure | HCPCS |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, FDA-approved final product, noncompounded, administered through DME | Procedure | HCPCS |
| J7621 | Albuterol, all formulations, including separated isomers, up to 5 mg (albuterol) or 2.5 mg (levoalbuterol), and ipratropium bromide, up to 1 mg, compounded inhalation solution, administered through dme | Procedure | HCPCS |
| J7625 | Albuterol sulfate, 0.5%, per ml, inhalation solution administered through DME | Procedure | HCPCS |
| J7644 | Ipratropium bromide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, per mg | Procedure | HCPCS |
| J7645 | Ipratropium bromide, inhalation solution, compounded product, administered through DME, unit dose form, per mg | Procedure | HCPCS |
| J7667 | Metaproterenol sulfate, inhalation solution, compounded product, concentrated form, per 10 | Procedure | HCPCS |
| J7668 | Metaproterenol sulfate, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 10 mg | Procedure | HCPCS |
| J7669 | Metaproterenol sulfate, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, per 10 mg | Procedure | HCPCS |
| J7670 | Metaproterenol sulfate, inhalation solution, compounded product, administered through DME, unit dose form, per 10 mg | Procedure | HCPCS |
| J7672 | Metaproterenol sulfate, 0.6%, per 2.5 ml, inhalation solution administered through DME | Procedure | HCPCS |
| J7675 | Metaproterenol sulfate, 5.0%, per ml, inhalation solution administered through DME | Procedure | HCPCS |
| J7680 | Terbutaline sulfate, inhalation solution, compounded product, administered through DME, concentrated form, per mg | Procedure | HCPCS |
| J7681 | Terbutaline sulfate, inhalation solution, compounded product, administered through DME, unit dose form, per mg | Procedure | HCPCS |
| K0504 | Albuterol, inhalation solution administered through DME, concentrated form, per milligram | Procedure | HCPCS |
| K0505 | Albuterol, inhalation solution administered through DME, unit dose form, per milligram | Procedure | HCPCS |
| K0518 | Ipratropium bromide, inhalation solution administered through DME, unit dose form, per | Procedure | HCPCS |
| K0523 | Metaproterenol sulfate, inhalation solution administered through DME, concentrated form, per 10 milligrams | Procedure | HCPCS |
| K0524 | Metaproterenol sulfate, inhalation solution administered through DME, unit dose form, per 10 milligrams | Procedure | HCPCS |
| K0525 | Terbutaline sulfate, inhalation solution administered through DME, concentrated form, per | Procedure | HCPCS |
| K0526 | Terbutaline sulfate, inhalation solution administered through DME, unit dose form, per | Procedure | HCPCS |
| Q4093 | Albuterol, all formulations including separated isomers, inhalation solution, FDA-approved final product, non-compounded, administered through DME, concentrated form, per 1 mg (Albuterol) or per 0.5 mg (Levalbuterol) | Procedure | HCPCS |
| Q4094 | Albuterol, all formulations including separated isomers, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose, per 1 mg (Albuterol) or per 0.5 mg (Levalbuterol) | Procedure | HCPCS |

Appendix AF. Specifications Defining Parameters for Covariates in this Request

| Covariate | Table 1 | Propensity Score | Subgroup | Care Setting | Principal Diagnosis Position | Evaluation Period Start | Evaluation Period End | Dispensing Evaluation | Number of Instances the Covariate Should be Found in Evaluation Period |
|--|-------------------|----------------------------------|-------------------------|------------------------------|------------------------------|-------------------------|-----------------------|----------------------------|--|
| Combined Comorbidity Score | Yes | Yes | -- | Any | Any | -183 | 0 | N/A | 1 |
| Age | Yes (categorical) | Yes (continuous) | Yes (10-24, 25-54, 55+) | N/A | N/A | N/A | N/A | N/A | N/A |
| Sex | Yes | Yes | Yes | N/A | N/A | N/A | N/A | N/A | N/A |
| Year | Yes | Yes | -- | N/A | N/A | N/A | N/A | N/A | N/A |
| Pre/post boxed warning (March 2020) | Yes | Yes (but not subgroup PS models) | Yes | N/A | N/A | N/A | N/A | N/A | N/A |
| Pre boxed warning | Yes | No | -- | N/A | N/A | N/A | N/A | N/A | N/A |
| Post boxed warning | Yes | No | -- | N/A | N/A | N/A | N/A | N/A | N/A |
| 4-Level Seasonality | Yes (categorical) | Yes (categorical) | -- | N/A | N/A | N/A | N/A | N/A | N/A |
| Winter | Yes | Yes | -- | N/A | N/A | N/A | N/A | N/A | N/A |
| Spring | Yes | Yes | -- | N/A | N/A | N/A | N/A | N/A | N/A |
| Summer | Yes | Yes | -- | N/A | N/A | N/A | N/A | N/A | N/A |
| Fall | Yes | Yes | -- | N/A | N/A | N/A | N/A | N/A | N/A |
| Psychiatric history | Yes | Yes | Yes | Any | Any | -183 | 0 | Dispensing and days supply | 1 |
| Psychiatric drug dispensings | Yes | No | -- | Any | Any | -183 | 0 | Dispensing and days supply | 1 |
| Self harm encounter (Patrick algorithm for ICD-9 era) | Yes | No | -- | Any | Any | -183 | -1 | N/A | 1 |
| Encounter for any other psychiatric event (inpatient, outpatient, ER; including psychotherapy) | Yes | No | -- | Any | Any | -183 | 0 | N/A | 1 |
| Asthma Severity | | | | | | | | | |
| Asthma, Emergency encounter | Yes (continuous) | Yes (dichotomous) | -- | Emergency | N/A | -183 | 0 | N/A | 1 |
| Asthma, Inpatient encounter | Yes (continuous) | Yes (dichotomous) | -- | Inpatient | Primary | -183 | 0 ¹ | N/A | 1 |
| Asthma, Outpatient encounter | Yes (continuous) | Yes (dichotomous) | -- | Ambulatory, Other Ambulatory | N/A | -183 | 0 | N/A | 1 |
| Oral Corticosteroid Dispensing | Yes | Yes | -- | N/A | N/A | -183 | -1 | Dispensing and days supply | 1 |

Appendix AF. Specifications Defining Parameters for Covariates in this Request

| Covariate | Table 1 | Propensity Score | Subgroup | Care Setting | Principal Diagnosis Position | Evaluation Period Start | Evaluation Period End | Dispensing Evaluation | Number of Instances the Covariate Should be Found in Evaluation Period |
|--|------------------|------------------|----------|---|------------------------------|-------------------------|-----------------------|----------------------------|--|
| Use of other asthma medications (short-acting beta-agonists, anticholinergic agents, phosphodiesterase inhibitors) (dichotomous) | Yes | Yes | -- | N/A | N/A | -183 | 0 | Dispensing and days supply | 1 |
| Moderate asthma exacerbation event | Yes | No | -- | Ambulatory, Emergency, Other Ambulatory | No | -183 | -1 | Dispensing and days supply | 1 |
| Severe asthma exacerbation event | Yes | Yes | -- | Inpatient | No | -183 | -1 | Dispensing and days supply | 1 |
| Allergic Rhinitis | Yes | Yes | -- | Any | Any | -183 | 0 | N/A | 1 |
| Past Medical History | | | | | | | | | |
| Anxiety | Yes | Yes | -- | Any | Any | -183 | 0 | N/A | 1 |
| Depression | Yes | Yes | -- | Any | Any | -183 | 0 | N/A | 1 |
| Sleep disorder | Yes | Yes | -- | Any | Any | -183 | 0 | N/A | 1 |
| Substance Abuse | Yes | Yes | -- | Any | Any | -183 | 0 | N/A | 1 |
| Past History of Drug Use | | | | | | | | | |
| Analgesic opiates | Yes | Yes | -- | N/A | N/A | -183 | 0 | Dispensing and days supply | 1 |
| Antipsychotics | Yes | Yes | -- | N/A | N/A | -183 | 0 | Dispensing and days supply | 1 |
| Anxiolytics/hypnotics | Yes | Yes | -- | N/A | N/A | -183 | 0 | Dispensing and days supply | 1 |
| Lithium and other mood stabilizers | Yes | Yes | -- | N/A | N/A | -183 | 0 | Dispensing and days supply | 1 |
| Antidepressants | Yes | Yes | -- | N/A | N/A | -183 | 0 | Dispensing and days supply | 1 |
| Health Service Utilization Intensity | | | | | | | | | |
| Mean number of ambulatory encounters (continuous) | Yes (continuous) | Yes | | Ambulatory | N/A | -183 | 0 | N/A | N/A |
| Mean number of inpatient encounters (continuous) | Yes (continuous) | Yes | | Inpatient | N/A | -183 | 0 | N/A | N/A |
| Mean number of ED visits (continuous) | Yes (continuous) | Yes | | Emergency | N/A | -183 | 0 | N/A | N/A |
| Count of dispensings (continuous) | Yes (continuous) | Yes | | N/A | N/A | -183 | 0 | N/A | N/A |

Appendix AF. Specifications Defining Parameters for Covariates in this Request

| Covariate | Table 1 | Propensity Score | Subgroup | Care Setting | Principal Diagnosis Position | Evaluation Period Start | Evaluation Period End | Dispensing Evaluation | Number of Instances the Covariate Should be Found in Evaluation Period |
|--|------------------|------------------|----------|------------------------------|------------------------------|-------------------------|-----------------------|-----------------------|--|
| Count of unique generic names dispensed (continuous) | Yes (continuous) | Yes | | N/A | N/A | -183 | 0 | N/A | N/A |
| Count of unique class names dispensed (continuous) | Yes (continuous) | Yes | | N/A | N/A | -183 | 0 | N/A | N/A |
| Number of inpatient visits for respiratory disorders (continuous) | Yes (continuous) | Yes | -- | Inpatient | Any | -183 | 0 | N/A | 1 |
| Number of emergency dept visits for respiratory disorders | Yes (continuous) | Yes | -- | Emergency | Any | -183 | 0 | N/A | 1 |
| Number of outpatient visits for respiratory disorders (continuous) | Yes (continuous) | Yes | -- | Ambulatory, Other Ambulatory | Any | -183 | 0 | N/A | 1 |

¹ Evaluation on day 0 is limited to those members entering the cohort

For Self-harm, which is also an outcome, members are dropped for evidence of the outcome on the index date due to the blackout.

Appendix AG. Specifications Defining Parameters for Asthma Exacerbation Events in this Request

Asthma exacerbation episode definition

| Outcome | Description | Care setting | Episode gap | Episode extension |
|-----------------------------|--|---|-------------|-------------------|
| Severe exacerbation event | Asthma Exacerbation Codes in any position OR Asthma diagnosis in the primary position OR Acute respiratory failure diagnosis in the primary position + Asthma diagnosis in any position | Inpatient | 14 days | 14 days |
| Moderate exacerbation event | Asthma Exacerbation Codes AND Oral Corticosteroids (+/- 7 days) OR Asthma Diagnosis Codes AND Oral Corticosteroids (+/- 7 days) Events will be evaluated sequentially for patients in the cohort from their left censor date (earliest time frame of required data) to their right censor date. In this query, this will be [index dt – 183, end of available data]. Events will be processed and event dates assigned to the earlier of the paired RX and DX. A valid RX code can be assigned to be paired with one DX code alone. | Ambulatory, Emergency, Other Ambulatory | 14 days | 14 days |

Exacerbation episodes order of processing:

For every patient with qualifying index date, generate patient record of exacerbation episodes as follows:

Starting with leftmost censor date (183 days prior to 1st qualifying index) through available enrollment data, calculate exacerbation episodes by:

1. Find all evidence of serious exacerbations as defined by code lists, retaining admission date (ADATE) and discharge date (DDATE)
2. Find all evidence of moderate exacerbation events defined by code lists with required concomitant OCS/ABX medications, retaining ADATE and DDATE (which should be same for these events and is the FIRST of the RX/DX pair to occur)

This should result in various points-in-times (flags) for exacerbation events as described above.

3. Concatenate exacerbation episodes similarly to how treatment episodes are concatenated by a) dropping overlapping exacerbation events - i.e., no "stockpiling" equivalent, b) using gap parameter of 14 days to concatenate exacerbation events and c) adding final 14 day extension to last exacerbation event. These exacerbation episodes are formed from earliest to latest exacerbation using event date flags created in earlier steps. 14 day gap parameter looks ahead from DDATE.

If exacerbation episode has ANY serious exacerbation flag within it, assign episode as serious. Otherwise, assign as moderate.

Create standalone analytic dataset of PATID, exacerbation episode numbers, exacerbation episode start and end dates, exacerbation event dates (ADATE, DDATE) within episode, flag for serious or moderate exacerbations.

Appendix AH. Specifications Defining Parameters In this Request

We executed the Cohort Identification and Descriptive Analysis (CIDA) tool version 12.0.0 with additional programming, to investigate if there is an increased risk of intentional self-harm associated with montelukast compared to Inhaled Corticosteroids (ICS) in the Sentinel Distributed Database (SDD).

Query Period: 10/1/2015 - 6/30/2022
Coverage Requirement: Medical and Drug Coverage
Pre-index enrollment requirement: 183 days
Post-index enrollment requirement: None
Restrictions: Male and Female only
Age: 10-24, 25-54, 55+
Enrollment gap: 45 days
Envelope macro: On: Reclassify encounters during inpatient stay as inpatient
Never-exposed cohort: None
Additional Output (Dist of Index, MFU): Censoring
Freeze data: Yes

| | Comparison 1 | | Comparison 2 | |
|--|--|---|--|---|
| Logic | Composite Outcome | | Composite Outcome | |
| Group | Mont | ICS | Mont_sens | ICS_sens |
| Drug/Exposure | Montelukast | | ICS monotherapy | |
| Index Exposure/Comparator | First valid incident treatment episode during the query period | | First valid incident treatment episode during the query period | |
| Cohort Definition | | | | |
| Incidence Exposure washout period | -183 days | | -183 days | |
| Incident w/ Respect to: | Montelukast, ICS monotherapy, LABAs, ICS combination therapies, or other LTRAs | Montelukast, other LTRAs, ICS monotherapy, LABAs, ICS combination therapies | Montelukast, ICS monotherapy, LABAs, ICS combination therapies, or other LTRAs | Montelukast, other LTRAs, ICS monotherapy, LABAs, ICS combination therapies |
| Exclude evidence of days supply if exposure washout include dispensings | Washout lookback period should search for evidence of days supply | | Washout lookback period should search for evidence of days supply | |
| Stockpiling | Generic Name | | Generic Name | |
| Point Exposure | No | | No | |
| Treatment Episode Gap | 30 days Fixed | | 30 days Fixed | |
| Exposure Episode Extension | 30 days | | 30 days | |
| Incidence Criteria Care Setting/PDX | Any | | Any | |
| Create Baseline Table? | Yes | | Yes | |
| Inclusion/Exclusion Criteria | | | | |
| Criteria | Asthma with or without allergic rhinitis | | Asthma with or without allergic rhinitis | |

Appendix AH. Specifications Defining Parameters In this Request

| | Comparison 1 | | Comparison 2 | |
|---|-------------------|-------------|-------------------|-------------|
| Logic | Composite Outcome | | Composite Outcome | |
| Group | Mont | ICS | Mont_sens | ICS_sens |
| Type | Inclusion | | Inclusion | |
| Evaluation Window | -183, 0 | | -183, 0 | |
| Care Setting/PDX | Any | | Any | |
| Number of instances the criteria should be found in the evaluation period | 1 | | 1 | |
| Criteria | COPD | | COPD | |
| Type | Exclusion | | Exclusion | |
| Evaluation Window | -183, 0 | | -183, 0 | |
| Care Setting/PDX | Any | | Any | |
| Number of instances the criteria should be found in the evaluation period | 1 | | 1 | |
| Criteria | ICS Monotherapy | Montelukast | ICS Monotherapy | Montelukast |
| Type | Exclusion | | Exclusion | |
| Evaluation Window | 0,0 | | 0,1 | |
| Care Setting/PDX | Any | | Any | |
| Number of instances the criteria should be found in the evaluation period | 1 | | 1 | |
| At Risk Time | | | | |
| Minimum exposure episode duration | ---- | | ---- | |
| Maximum exposure episode duration | ---- | | ---- | |

Appendix AH. Specifications Defining Parameters In this Request

| | Comparison 1 | | Comparison 2 | |
|--------------------------------------|--|---|--|---|
| Logic | Composite Outcome | | Composite Outcome | |
| Group | Mont | ICS | Mont_sens | ICS_sens |
| Censoring Criteria | (1) Dispensing of ICS monotherapy, LABAs, ICS combination therapies, or another LTRA (2) Dispensing of oral corticosteroid (3) Asthma-related hospitalization in the primary position (4) Death (5) DP End Date (6) Query End Date (7) Disenrollment (8) Outcome (9) End of treatment episode (10) Hospitalization or Institutional Stay unrelated to the outcome | (1) Dispensing of montelukast, LABAs, ICS combination therapies, or LTRAs (2) Dispensing of oral corticosteroid (3) Asthma-related hospitalization in the primary position (4) Death (5) DP End Date (6) Query End Date (7) Disenrollment (8) Outcome (9) End of treatment episode (10) Hospitalization or Institutional Stay unrelated to the outcome | (1) Dispensing of ICS monotherapy, LABAs, ICS combination therapies, or another LTRA (2) Dispensing of oral corticosteroid (3) Asthma-related hospitalization in the primary position (4) Death (5) DP End Date (6) Query End Date (7) Disenrollment (8) Outcome (9) End of treatment episode (10) Hospitalization or Institutional Stay unrelated to the outcome | (1) Dispensing of montelukast, LABAs, ICS combination therapies, or LTRAs (2) Dispensing of oral corticosteroid (3) Asthma-related hospitalization in the primary position (4) Death (5) DP End Date (6) Query End Date (7) Disenrollment (8) Outcome (9) End of treatment episode (10) Hospitalization or Institutional Stay unrelated to the outcome |
| Blackout Period | 1 (no same day exposure outcome) | | 1 (no same day exposure outcome) | |
| Event/Outcome | | | | |
| Event/Outcome | Any Intentional Self-Harm Outcome (ICD-10) | | Any Intentional Self-Harm Outcome (ICD-10) | |
| Incident event washout period | 0 | | 0 | |
| Care Setting | Any | | Inpatient, Emergency Department | |
| Event de-duplication | De-duplicates occurrences of the same event group on the same day | | De-duplicates occurrences of the same event group on the same day | |
| Propensity Score Matching | | | | |
| Covariates | See covariates tab | | See covariates tab | |
| IP Weight | ATT | | ATT | |
| Truncate | 0, 2.5, 5.0 | | 0, 2.5, 5.0 | |
| Apply Firth Correction | No | | No | |

Appendix AH. Specifications Defining Parameters In this Request

| | Comparison 1 | | Comparison 2 | |
|--|---|---|---|---|
| Logic | Composite Outcome | | Composite Outcome | |
| Group | Mont | ICS | Mont_sens | ICS_sens |
| Additional Covariates to Adjust for in Cox Model | ----- | | ----- | |
| Subgroup Analysis | (1) Label change via dichotomous periods (2015-2020, 2021-forward) (2) Sex (Male and Female) (3) Age (12-24, 25-54, 55+) (4) History of psych disorder (y/n) | | (1) Label change via dichotomous periods (2015-2020, 2021-forward) (2) Sex (Male and Female) (3) Age (12-24, 25-54, 55+) (4) History of psych disorder (y/n) | |
| Re-estimate PS within subgroups | Yes | | Yes | |
| Effect Estimation | Risk set level | | Risk set level | |
| Kaplan Meier Plot | No | | No | |
| | Comparison 3 | | Comparison 4 | |
| Logic | Composite Outcome | | Composite Outcome | |
| Group | Mont_0gap | ICS_0gap | Mont_15gap | ICS_15gap |
| Drug/Exposure | | | | |
| Index Exposure/Comparator | Montelukast | ICS monotherapy | Montelukast | ICS monotherapy |
| Cohort Definition | First valid incident treatment episode during the query period | | First valid incident treatment episode during the query period | |
| Incidence Exposure washout period | -183 days | | -183 days | |
| Incident w/ Respect to: | Montelukast, ICS monotherapy, LABAs, ICS combination therapies, or other LTRAs | Montelukast, other LTRAs, ICS monotherapy, LABAs, ICS combination therapies | Montelukast, ICS monotherapy, LABAs, ICS combination therapies, or other LTRAs | Montelukast, other LTRAs, ICS monotherapy, LABAs, ICS combination therapies |
| Exclude evidence of days supply if exposure washout include dispensings | Washout lookback period should search for evidence of days supply | | Washout lookback period should search for evidence of days supply | |
| Stockpiling | Generic Name | | Generic Name | |
| Point Exposure | No | | No | |
| Treatment Episode Gap | 0 days Fixed | | 15 days Fixed | |
| Exposure Episode Extension | 0 days | | 15 days | |
| Incidence Criteria Care Setting/PDX | Any | | Any | |
| Create Baseline Table? | Yes | | Yes | |

Appendix AH. Specifications Defining Parameters In this Request

| | Comparison 3 | | Comparison 4 | |
|--|--|-------------|--|-------------|
| Logic | Composite Outcome | | Composite Outcome | |
| Group | Mont_0gap | ICS_0gap | Mont_15gap | ICS_15gap |
| Inclusion/Exclusion Criteria | | | | |
| Criteria | Asthma with or without allergic rhinitis | | Asthma with or without allergic rhinitis | |
| Type | Inclusion | | Inclusion | |
| Evaluation Window | -183, 0 | | -183, 0 | |
| Care Setting/PDX | Any | | Any | |
| Number of instances the criteria should be found in the evaluation period | 1 | | 1 | |
| Criteria | COPD | | COPD | |
| Type | Exclusion | | Exclusion | |
| Evaluation Window | -183, 0 | | -183, 0 | |
| Care Setting/PDX | Any | | Any | |
| Number of instances the criteria should be found in the evaluation period | 1 | | 1 | |
| Criteria | ICS Monotherapy | Montelukast | ICS Monotherapy | Montelukast |
| Type | Exclusion | | Exclusion | |
| Evaluation Window | 0,1 | | 0,1 | |
| Care Setting/PDX | Any | | Any | |
| Number of instances the criteria should be found in the evaluation period | 1 | | 1 | |
| At Risk Time | | | | |
| Minimum exposure episode duration | ---- | | ---- | |
| Maximum exposure episode duration | ---- | | ---- | |

Appendix AH. Specifications Defining Parameters In this Request


| | Comparison 3 | | Comparison 4 | |
|---|--|---|--|---|
| Logic | Composite Outcome | | Composite Outcome | |
| Group | Mont_Ogap | ICS_Ogap | Mont_15gap | ICS_15gap |
| Censoring Criteria | (1) Dispensing of ICS monotherapy, LABAs, ICS combination therapies, or another LTRA (2) Dispensing of oral corticosteroid (3) Asthma-related hospitalization in the primary position (4) Death (5) DP End Date (6) Query End Date (7) Disenrollment (8) Outcome (9) End of treatment episode (10) Hospitalization or Institutional Stay unrelated to the outcome | (1) Dispensing of montelukast, LABAs, ICS combination therapies, or LTRAs (2) Dispensing of oral corticosteroid (3) Asthma-related hospitalization in the primary position (4) Death (5) DP End Date (6) Query End Date (7) Disenrollment (8) Outcome (9) End of treatment episode (10) Hospitalization or Institutional Stay unrelated to the outcome | (1) Dispensing of ICS monotherapy, LABAs, ICS combination therapies, or another LTRA (2) Dispensing of oral corticosteroid (3) Asthma-related hospitalization in the primary position (4) Death (5) DP End Date (6) Query End Date (7) Disenrollment (8) Outcome (9) End of treatment episode (10) Hospitalization or Institutional Stay unrelated to the outcome | (1) Dispensing of montelukast, LABAs, ICS combination therapies, or LTRAs (2) Dispensing of oral corticosteroid (3) Asthma-related hospitalization in the primary position (4) Death (5) DP End Date (6) Query End Date (7) Disenrollment (8) Outcome (9) End of treatment episode (10) Hospitalization or Institutional Stay unrelated to the outcome |
| Blackout Period | 1 (no same day exposure outcome) | | 1 (no same day exposure outcome) | |
| Event/Outcome | Any Intentional Self-Harm Outcome (ICD-10) | | Any Intentional Self-Harm Outcome (ICD-10) | |
| Incident event washout period | 0 | | 0 | |
| Care Setting | Any | | Any | |
| Event de-duplication | De-duplicates occurrences of the same event group on the same day | | De-duplicates occurrences of the same event group on the same day | |
| Propensity Score Matching | | | | |
| Covariates | See covariates tab | | See covariates tab | |
| IP Weight | ATT | | ATT | |
| Truncate | 0, 2.5, 5.0 | | 0, 2.5, 5.0 | |
| Apply Firth Correction | No | | No | |
| Additional Covariates to Adjust for in Cox Model | ---- | | ---- | |

Appendix AH. Specifications Defining Parameters In this Request

| | Comparison 3 | | Comparison 4 | |
|--|---|----------|---|-----------|
| Logic | Composite Outcome | | Composite Outcome | |
| Group | Mont_0gap | ICS_0gap | Mont_15gap | ICS_15gap |
| Subgroup Analysis | (1) Label change via dichotomous periods (2015-2020, 2021-forward) (2) Sex (Male and Female) (3) Age (12-24, 25-54, 55+) (4) History of psych disorder (y/n) | | (1) Label change via dichotomous periods (2015-2020, 2021-forward) (2) Sex (Male and Female) (3) Age (12-24, 25-54, 55+) (4) History of psych disorder (y/n) | |
| Re-estimate PS within subgroups | Yes | | Yes | |
| Effect Estimation | Risk set level | | Risk set level | |
| Kaplan Meier Plot | No | | No | |

ICD-9-CM, HCPCS, and CPT codes are provided by Optum360. NDC codes are checked against First Data Bank's "National Drug Data File (NDDF®) Plus."

Appendix AI. Diagram Detailing the Design of this Request



***Covariates

Window I: Age, year, sex, pre- or post-March2020 (boxed warning), seasonality

Window II: Comorbidity score; psychiatric history; asthma severity; allergic rhinitis; Medical history: anxiety, depression, sleep disorder, substance abuse; health service utilization intensity; number of visits for respiratory disorders; Drug use: analgesic opiates, antipsychotics, anxiolytics/hypnotics, lithium, antidepressants